1	A 34-year-old lady developed a constellation of dermatitis, ENT1 fever ENT1END  lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral ENT2 sulphasalazine ENT2END for sero-negative rheumatoid arthritis
1	Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial ENT1 nephritis ENT1END and extensive bone marrow necrosis, with no evidence of malignancy. It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week ENT2 sulphasalazine ENT2END syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine
0	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral ENT1 sulphasalazine ENT1END  for sero-negative rheumatoid arthritis. Cervical and inguinal lymph node biopsies showed the features of severe necrotising ENT2 lymphadenitis ENT2END , associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction
1	A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by multi-organ failure and ENT1 sepsis  ENT1END  supervened. She subsequently died some 5 weeks after the commencement of her drug therapy.Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy. It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week ENT2 sulphasalazine ENT2END syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine
0	Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of ENT1 malignancy  ENT1END  It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week ENT2 sulphasalazine ENT2END syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine
0	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral ENT1 sulphasalazine ENT1END  for sero-negative rheumatoid arthritis. Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an adverse drug reaction.A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of ENT2 autoimmunity ENT2END ), and accompanied by multi-organ failure and sepsis, supervened
0	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral ENT1 sulphasalazine ENT1END  for sero-negative rheumatoid arthritis. Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis, associated with erythrophagocytosis and prominent eosinophilic infiltrates, without viral inclusion bodies, suggestive of an ENT2 adverse drug reaction ENT2END
0	Post-mortem examination showed evidence of ENT1 massive hepatocellular necrosis  ENT1END  acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy. It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week ENT2 sulphasalazine ENT2END syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine
0	Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive ENT1 bone marrow necrosis  ENT1END  with no evidence of malignancy. It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week ENT2 sulphasalazine ENT2END syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine
1	Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity ENT1 myocarditis  ENT1END  focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy. It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week ENT2 sulphasalazine ENT2END syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine
1	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and ENT1 hepatitis  ENT1END  beginning on the 17th day of a course of oral ENT2 sulphasalazine ENT2END for sero-negative rheumatoid arthritis
0	A week later, fulminant drug-induced hepatitis, associated with the presence of anti-nuclear autoantibodies (but not with other markers of autoimmunity), and accompanied by ENT1 multi-organ failure  ENT1END and sepsis, supervened. She subsequently died some 5 weeks after the commencement of her drug therapy.Post-mortem examination showed evidence of massive hepatocellular necrosis, acute hypersensitivity myocarditis, focal acute tubulo-interstitial nephritis and extensive bone marrow necrosis, with no evidence of malignancy. It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week ENT2 sulphasalazine ENT2END syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine
1	The 3-week ENT1 sulphasalazine ENT1END  syndrome strikes again.A 34-year-old lady developed a constellation of ENT2 dermatitis ENT2END , fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis
0	A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral ENT1 sulphasalazine ENT1END  for sero-negative ENT2 rheumatoid arthritis ENT2END
1	A 34-year-old lady developed a constellation of dermatitis, fever, ENT1 lymphadenopathy  ENT1END and hepatitis, beginning on the 17th day of a course of oral ENT2 sulphasalazine ENT2END for sero-negative rheumatoid arthritis
0	RESULTS: ENT1 CBDCA ENT1END administration induced dose-dependent peripheral neurotoxicity. ENT2 Pain ENT2END perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment
0	ENT1 Pain ENT1END  perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment. The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by ENT2 CDDP ENT2END , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons
0	ENT1 Pain ENT1END  perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment. The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons. Moreover, significant amounts of ENT2 platinum ENT2END were detected in the dorsal root ganglia and kidney after CBDCA treatment
1	RESULTS: ENT1 CBDCA ENT1END  administration induced dose-dependent ENT2 peripheral neurotoxicity ENT2END
1	BACKGROUND: The most striking of carboplatin's advantages (CBDCA) over cisplatin ( ENT1 CDDP ENT1END  is its markedly reduced rate of neurotoxic effects. However, the use of CBDCA higher-intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to ENT2 peripheral nervous system damage ENT2END
0	RESULTS: CBDCA administration induced dose-dependent ENT1 peripheral neurotoxicity  ENT1END . Pain perception and nerve conduction velocity in the tail were significantly impaired, particularly after the high-dose treatment. The dorsal root ganglia sensory neurons and, to a lesser extent, satellite cells showed the same changes as those induced by CDDP, mainly affecting the nucleus and nucleolus of ganglionic sensory neurons. Moreover, significant amounts of ENT2 platinum ENT2END were detected in the dorsal root ganglia and kidney after CBDCA treatment
0	CONCLUSIONS: ENT1 CBDCA ENT1END is ENT2 neurotoxic ENT2END in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism
0	CONCLUSIONS: CBDCA is neurotoxic in our model, and the type of pathological changes it induces are so closely similar to those caused by ENT1 CDDP ENT1END that it is probable that ENT2 neurotoxicity ENT2END is induced in the two drugs by the same mechanism
0	Moreover, significant amounts of ENT1 platinum  ENT1END  were detected in the dorsal root ganglia and kidney after CBDCA treatment. CONCLUSIONS: CBDCA is ENT2 neurotoxic ENT2END in our model, and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism
0	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic ENT1 epinephrine ENT1END  overdose.Catecholamine-induced ENT2 cardiomyopathy ENT2END due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon
0	ENT1 Catecholamine  ENT1END induced ENT2 cardiomyopathy ENT2END due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon
0	Severe reversible ENT1 left ventricular systolic and diastolic dysfunction  ENT1END  due to accidental iatrogenic ENT2 epinephrine ENT2END overdose
0	Severe reversible ENT1 left ventricular systolic and diastolic dysfunction  ENT1END  due to accidental iatrogenic epinephrine overdose ENT2 Catecholamine ENT2END -induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon
0	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic ENT1 epinephrine ENT1END ENT2 overdose ENT2END
0	Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine ENT1 overdose ENT1END ENT2 Catecholamine ENT2END -induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon
1	A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of ENT1 epinephrine ENT1END developed ENT2 myocardial stunning ENT2END that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis
0	Catecholamine-induced cardiomyopathy due to chronic excess of endogenous ENT1 catecholamines  ENT1END has been recognized for decades as a clinical phenomenon. In contrast, reports of myocardial dysfunction due to acute iatrogenic overdose are rare. A 35-year-old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed ENT2 myocardial stunning ENT2END that was characterized by severe hemodynamic compromise, profound, albeit transient, left ventricular systolic and diastolic dysfunction, and only modestly elevated biochemical markers of myocardial necrosis
0	BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of ENT1 heparin ENT1END induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB). In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation. The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe ENT2 intraoperative and postoperative bleeding ENT2END
1	The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe ENT1 intraoperative and postoperative bleeding ENT1END . STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for ENT2 argatroban ENT2END concentration using a modified ecarin clotting time (ECT) assay
0	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of ENT1 heparin  ENT1END -induced ENT2 thrombocytopenia ENT2END with thrombosis
0	In the following report, a 65-year-old critically ill patient with a suspected history of ENT1 HITT ENT1END was administered ENT2 argatroban ENT2END for anticoagulation on bypass during heart transplantation
0	BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of ENT1 heparin ENT1END -induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB). In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation. The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe ENT2 intraoperative and postoperative bleeding ENT2END
1	The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe ENT1 intraoperative and postoperative bleeding  ENT1END . STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for ENT2 argatroban ENT2END concentration using a modified ecarin clotting time (ECT) assay
0	Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of ENT1 heparin  ENT1END -induced thrombocytopenia with ENT2 thrombosis ENT2END
0	In the following report, a 65-year-old critically ill patient with a suspected history of ENT1 HITT  ENT1END was administered ENT2 argatroban ENT2END for anticoagulation on bypass during heart transplantation
0	BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of ENT1 heparin ENT1END -induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB). In the following report, a 65-year-old ENT2 critically ill ENT2END patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation
0	In the following report, a 65-year-old ENT1 critically ill  ENT1END  patient with a suspected history of HITT was administered ENT2 argatroban ENT2END for anticoagulation on bypass during heart transplantation
0	BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of ENT1 heparin ENT1END -induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB). In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation. The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding. STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay. RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with ENT2 hepatic impairment ENT2END ])
0	RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with ENT1 hepatic impairment ENT1END ]). CONCLUSIONS: Correlation of plasma ENT2 argatroban ENT2END concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended coagulopathy
0	BACKGROUND: Direct thrombin inhibitors (DTIs) provide an alternative method of anticoagulation for patients with a history of ENT1 heparin ENT1END -induced thrombocytopenia (HIT) or HIT with thrombosis (HITT) undergoing cardiopulmonary bypass (CPB). In the following report, a 65-year-old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation. The patient required massive transfusion support (55 units of red blood cells, 42 units of fresh-frozen plasma, 40 units of cryoprecipitate, 40 units of platelets, and three doses of recombinant Factor VIIa) for severe intraoperative and postoperative bleeding. STUDY DESIGN AND METHODS: Plasma samples from before and after CPB were analyzed postoperatively for argatroban concentration using a modified ecarin clotting time (ECT) assay. RESULTS: Unexpectedly high concentrations of argatroban were measured in these samples (range, 0-32 microg/mL), and a prolonged plasma argatroban half life (t(1/2)) of 514 minutes was observed (published elimination t(1/2) is 39-51 minutes [< or = 181 minutes with hepatic impairment]). CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient's extended ENT2 coagulopathy ENT2END
0	CONCLUSIONS: Correlation of plasma argatroban concentration versus the patient's coagulation variables and clinical course suggest that prolonged elevated levels of plasma ENT1 argatroban  ENT1END may have contributed to the patient's extended ENT2 coagulopathy ENT2END
1	Development of ENT1 clear cell adenocarcinoma  ENT1END  in ENT2 DES ENT2END -exposed offspring under observation
0	Two cases of clear cell adenocarcinoma of the vagina detected at follow-up in young women exposed in utero to ENT1 diethylstilbestrol ENT1END are reported. One patient, aged 23, had been followed for 2 years before ENT2 carcinoma ENT2END was diagnosed; the second patient, aged 22, had been seen on a regular basis for 5 years, 8 months
1	Development of clear cell adenocarcinoma in ENT1 DES ENT1END -exposed offspring under observation.Two cases of ENT2 clear cell adenocarcinoma of the vagina ENT2END detected at follow-up in young women exposed in utero to diethylstilbestrol are reported
0	Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving ENT1 penicillins ENT1END and first-generation cephalosporins. We describe a patient who developed ENT2 anemia ENT2END while receiving intravenous cefotetan
0	Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation ENT1 cephalosporins  ENT1END  We describe a patient who developed ENT2 anemia ENT2END while receiving intravenous cefotetan
0	We describe a patient who developed ENT1 anemia ENT1END  while receiving intravenous ENT2 cefotetan ENT2END
0	Immune ENT1 hemolytic anemia  ENT1END due to a drug-adsorption mechanism has been described primarily in patients receiving ENT2 penicillins ENT2END and first-generation cephalosporins
0	Immune ENT1 hemolytic anemia  ENT1END  due to a drug-adsorption mechanism has been described primarily in patients receiving penicillins and first-generation ENT2 cephalosporins ENT2END
1	ENT1 Cefotetan  ENT1END -induced immune ENT2 hemolytic anemia ENT2END
0	Immune hemolytic anemia due to a drug-adsorption mechanism has been described primarily in patients receiving ENT1 penicillins ENT1END  and first-generation cephalosporins. We describe a patient who developed anemia while receiving intravenous cefotetan. Cefotetan-dependent antibodies were detected in the patient's serum and in an eluate prepared from his red blood cells. The eluate also reacted weakly with red blood cells in the absence of cefotetan, suggesting the concomitant formation of warm-reactive autoantibodies. These observations, in conjunction with clinical and laboratory evidence of extravascular ENT2 hemolysis ENT2END , are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms
0	These observations, in conjunction with clinical and laboratory evidence of extravascular ENT1 hemolysis ENT1END , are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms. This case emphasizes the need for increased awareness of hemolytic reactions to all ENT2 cephalosporins ENT2END
0	The eluate also reacted weakly with red blood cells in the absence of ENT1 cefotetan  ENT1END  suggesting the concomitant formation of warm-reactive autoantibodies. These observations, in conjunction with clinical and laboratory evidence of extravascular ENT2 hemolysis ENT2END , are consistent with drug-induced hemolytic anemia, possibly involving both drug-adsorption and autoantibody formation mechanisms
0	Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and ENT1 testosterone ENT1END .More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with N-nitroso-N-methylurea (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the ENT2 tumor ENT2END -bearing rats manifested metastatic lesions
0	In L-W rats, ENT1 TP ENT1END acted as a ENT2 tumor ENT2END enhancement agent, with primary emphasis on the development of prostate cancer
0	More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas (PAs) following treatments with ENT1 N-nitroso-N-methylurea  ENT1END (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the ENT2 tumor ENT2END -bearing rats manifested metastatic lesions
0	Production of autochthonous ENT1 prostate cancer  ENT1END  in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and ENT2 testosterone ENT2END
1	Within the same timeframe, no L-W rat developed a similar palpable ENT1 PA ENT1END when treated only with ENT2 TP ENT2END
1	More than 50% of Lobund-Wistar (L-W) strain rats developed large, palpable prostate adenocarcinomas ( ENT1 PAs  ENT1END  following treatments with ENT2 N-nitroso-N-methylurea ENT2END (CAS: 684-93-5) and testosterone propionate [(TP) CAS: 57-85-2], and most of the tumor-bearing rats manifested metastatic lesions
0	It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT1 aggressiveness ENT1END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor. It may be concluded that, like other tricyclic ENT2 antidepressants ENT2END studied previously, TRI given repeatedly increases the responsiveness of brain dopamine D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists
0	The stereotypies induced by ENT1 d-amphetamine  ENT1END or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT2 aggressiveness ENT2END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	) does not antagonize the reserpine hypothermia in mice and does not potentiate the ENT1 5-hydroxytryptophan  ENT1END head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT2 aggressiveness ENT2END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	The stereotypies induced by d-amphetamine or apomorphine are not potentiated by ENT1 TRI  ENT1END  It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT2 aggressiveness ENT2END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	It increases the behaviour stimulation evoked by ENT1 phenylephrine  ENT1END (given intraventricularly) in rats, evaluated in the open field test as well as the ENT2 aggressiveness ENT2END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT1 aggressiveness ENT1END  evoked by ENT2 clonidine ENT2END in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT1 aggressiveness ENT1END  evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor. It may be concluded that, like other tricyclic antidepressants studied previously, TRI given repeatedly increases the responsiveness of brain ENT2 dopamine ENT2END D2 and D3 (locomotor activity but not stereotypy) as well as alpha1-adrenergic receptors to their agonists
0	The stereotypies induced by d-amphetamine or ENT1 apomorphine  ENT1END are not potentiated by TRI. It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT2 aggressiveness ENT2END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	) does not antagonize the ENT1 reserpine  ENT1END hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT2 aggressiveness ENT2END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, ENT1 quinpirole  ENT1END and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the ENT2 aggressiveness ENT2END evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various ENT1 antidepressants ENT1END  TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine ENT2 hypothermia ENT2END in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats
0	) does not antagonize the reserpine ENT1 hypothermia ENT1END  in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by ENT2 d-amphetamine ENT2END , quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and ENT1 5-hydroxytryptamine  ENT1END  nor does it induce beta-adrenergic down-regulation. The mechanism of its antidepressant activity is still unknown. The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants. TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine ENT2 hypothermia ENT2END in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats
0	Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of ENT1 noradrenaline  ENT1END and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation. The mechanism of its antidepressant activity is still unknown. The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants. TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine ENT2 hypothermia ENT2END in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats
0	) does not antagonize the reserpine ENT1 hypothermia  ENT1END  in mice and does not potentiate the ENT2 5-hydroxytryptophan ENT2END head twitches in rats
0	In the acute experiment ENT1 TRI  ENT1END (given i.p.) does not antagonize the reserpine ENT2 hypothermia ENT2END in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats
0	) does not antagonize the reserpine ENT1 hypothermia  ENT1END  in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by ENT2 phenylephrine ENT2END (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to ENT1 imipramine  ENT1END but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation. The mechanism of its antidepressant activity is still unknown. The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants. TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine ENT2 hypothermia ENT2END in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats
0	) does not antagonize the reserpine ENT1 hypothermia  ENT1END  in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by ENT2 clonidine ENT2END in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	) does not antagonize the reserpine ENT1 hypothermia  ENT1END  in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin ( ENT2 dopamine ENT2END D2 and D3 effects)
0	) does not antagonize the reserpine ENT1 hypothermia  ENT1END  in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or ENT2 apomorphine ENT2END are not potentiated by TRI
1	) does not antagonize the ENT1 reserpine ENT1END ENT2 hypothermia ENT2END in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats
0	) does not antagonize the reserpine ENT1 hypothermia  ENT1END  in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor hyperactivity induced by d-amphetamine, ENT2 quinpirole ENT2END and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various ENT1 antidepressants ENT1END . TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor ENT2 hyperactivity ENT2END induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
1	TRI given repeatedly to rats increases the locomotor ENT1 hyperactivity  ENT1END  induced by ENT2 d-amphetamine ENT2END , quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of noradrenaline and ENT1 5-hydroxytryptamine  ENT1END , nor does it induce beta-adrenergic down-regulation. The mechanism of its antidepressant activity is still unknown. The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants. TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor ENT2 hyperactivity ENT2END induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to imipramine but does not inhibit the reuptake of ENT1 noradrenaline  ENT1END  and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation. The mechanism of its antidepressant activity is still unknown. The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants. TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor ENT2 hyperactivity ENT2END induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	) does not antagonize the reserpine hypothermia in mice and does not potentiate the ENT1 5-hydroxytryptophan  ENT1END  head twitches in rats. TRI given repeatedly to rats increases the locomotor ENT2 hyperactivity ENT2END induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
1	ENT1 TRI  ENT1END given repeatedly to rats increases the locomotor ENT2 hyperactivity ENT2END induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	TRI given repeatedly to rats increases the locomotor ENT1 hyperactivity  ENT1END  induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by ENT2 phenylephrine ENT2END (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	Trimipramine (TRI), which shows a clinical antidepressant activity, is chemically related to ENT1 imipramine  ENT1END  but does not inhibit the reuptake of noradrenaline and 5-hydroxytryptamine, nor does it induce beta-adrenergic down-regulation. The mechanism of its antidepressant activity is still unknown. The aim of the present study was to find out whether TRI given repeatedly was able to induce adaptive changes in the dopaminergic and alpha1-adrenergic systems, demonstrated by us previously for various antidepressants. TRI was given to male Wistar rats and male Albino Swiss mice perorally twice daily for 14 days. In the acute experiment TRI (given i.p.) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor ENT2 hyperactivity ENT2END induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	TRI given repeatedly to rats increases the locomotor ENT1 hyperactivity  ENT1END  induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or apomorphine are not potentiated by TRI. It increases the behaviour stimulation evoked by phenylephrine (given intraventricularly) in rats, evaluated in the open field test as well as the aggressiveness evoked by ENT2 clonidine ENT2END in mice, both these effects being mediated by an alpha1-adrenergic receptor
0	TRI given repeatedly to rats increases the locomotor ENT1 hyperactivity ENT1END  induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin ENT2 dopamine ENT2END D2 and D3 effects)
0	TRI given repeatedly to rats increases the locomotor ENT1 hyperactivity  ENT1END  induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects). The stereotypies induced by d-amphetamine or ENT2 apomorphine ENT2END are not potentiated by TRI
0	) does not antagonize the ENT1 reserpine  ENT1END  hypothermia in mice and does not potentiate the 5-hydroxytryptophan head twitches in rats. TRI given repeatedly to rats increases the locomotor ENT2 hyperactivity ENT2END induced by d-amphetamine, quinpirole and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
1	TRI given repeatedly to rats increases the locomotor ENT1 hyperactivity  ENT1END  induced by d-amphetamine, ENT2 quinpirole ENT2END and (+)-7-hydroxy-dipropyloaminotetralin (dopamine D2 and D3 effects)
0	Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of ENT1 peripheral vascular disease ENT1END  Many of these patients are taking pentoxifylline (Trental), a ENT2 methylxanthine ENT2END derivative which may improve intermittent claudication
0	Dipyridamole- ENT1 thallium  ENT1END 201 imaging is often performed in patients unable to exercise because of ENT2 peripheral vascular disease ENT2END
0	ENT1 Dipyridamole  ENT1END thallium-201 imaging is often performed in patients unable to exercise because of ENT2 peripheral vascular disease ENT2END
0	Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of ENT1 peripheral vascular disease ENT1END . Many of these patients are taking ENT2 pentoxifylline ENT2END (Trental), a methylxanthine derivative which may improve intermittent claudication
0	Dipyridamole-thallium-201 imaging is often performed in patients unable to exercise because of ENT1 peripheral vascular disease ENT1END . Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve intermittent claudication. Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as ENT2 theophylline ENT2END and should be stopped prior to dipyridamole-thallium-201 imaging is unknown
0	Whether pentoxifylline inhibits dipyridamole-induced coronary ENT1 hyperemia ENT1END like other ENT2 methylxanthines ENT2END such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown
0	Pentoxifylline (Trental) does not inhibit dipyridamole-induced coronary ENT1 hyperemia  ENT1END : implications for dipyridamole ENT2 thallium ENT2END -201 myocardial imaging
1	Neither dose of pentoxifylline significantly decreased the ENT1 dipyridamole ENT1END induced ENT2 hyperemia ENT2END , while peak coronary blood flow was significantly lower after theophylline (p less than 0
0	Whether ENT1 pentoxifylline  ENT1END inhibits dipyridamole-induced coronary ENT2 hyperemia ENT2END like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown
0	Whether pentoxifylline inhibits dipyridamole-induced coronary ENT1 hyperemia  ENT1END  like other methylxanthines such as ENT2 theophylline ENT2END and should be stopped prior to dipyridamole-thallium-201 imaging is unknown
0	Many of these patients are taking pentoxifylline (Trental), a ENT1 methylxanthine ENT1END  derivative which may improve ENT2 intermittent claudication ENT2END
0	Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve ENT1 intermittent claudication  ENT1END . Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole- ENT2 thallium ENT2END -201 imaging is unknown
0	Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve ENT1 intermittent claudication ENT1END . Whether pentoxifylline inhibits ENT2 dipyridamole ENT2END -induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown
1	Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve ENT1 intermittent claudication  ENT1END . Whether ENT2 pentoxifylline ENT2END inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole-thallium-201 imaging is unknown
0	Many of these patients are taking pentoxifylline (Trental), a methylxanthine derivative which may improve ENT1 intermittent claudication  ENT1END . Whether pentoxifylline inhibits dipyridamole-induced coronary hyperemia like other methylxanthines such as ENT2 theophylline ENT2END and should be stopped prior to dipyridamole-thallium-201 imaging is unknown
0	The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of ENT1 arrhythmias ENT1END  This pharmacological profile is similar to those of mexiletine and ENT2 tocainide ENT2END , and all three drugs have central nervous system (CNS) stimulant action
1	The concentration for ENT1 adrenaline ENT1END induced ENT2 arrhythmia ENT2END was significantly higher than those for the other types of arrhythmias
0	The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of ENT1 arrhythmias ENT1END . This pharmacological profile is similar to those of ENT2 mexiletine ENT2END and tocainide, and all three drugs have central nervous system (CNS) stimulant action
1	Using two-stage coronary ligation-, ENT1 digitalis ENT1END , and adrenaline-induced canine ENT2 ventricular arrhythmias ENT2END , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined
0	Antiarrhythmic plasma concentrations of ENT1 cibenzoline  ENT1END  on canine ENT2 ventricular arrhythmias ENT2END
0	This pharmacological profile is similar to those of mexiletine and ENT1 tocainide ENT1END , and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak hypotensive and sinus node ENT2 depressive ENT2END effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	The concentration for ENT1 adrenaline  ENT1END -induced arrhythmia was significantly higher than those for the other types of arrhythmias. This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak hypotensive and sinus node ENT2 depressive ENT2END effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	This pharmacological profile is similar to those of ENT1 mexiletine  ENT1END  and tocainide, and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak hypotensive and sinus node ENT2 depressive ENT2END effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, ENT1 digitalis  ENT1END  and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7). The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias. This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak hypotensive and sinus node ENT2 depressive ENT2END effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	Because ENT1 cibenzoline  ENT1END had only weak hypotensive and sinus node ENT2 depressive ENT2END effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	This pharmacological profile is similar to those of mexiletine and ENT1 tocainide ENT1END , and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak ENT2 hypotensive ENT2END and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	The concentration for ENT1 adrenaline  ENT1END -induced arrhythmia was significantly higher than those for the other types of arrhythmias. This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak ENT2 hypotensive ENT2END and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	This pharmacological profile is similar to those of ENT1 mexiletine  ENT1END  and tocainide, and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak ENT2 hypotensive ENT2END and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	Cibenzoline suppressed all the arrhythmias, and the minimum effective plasma concentrations for arrhythmias induced by 24-h coronary ligation, 48-h coronary ligation, ENT1 digitalis  ENT1END , and adrenaline were 1.9 +/- 0.9 (by 8 mg/kg i.v.), 1.6 +/- 0.5 (by 8 mg/kg i.v.), 0.6 +/- 0.2 (by 2 mg/kg i.v.), and 3.5 +/- 1.3 (by 5 mg/kg i.v.) micrograms/ml, respectively (mean +/- SDM, n = 6-7). The concentration for adrenaline-induced arrhythmia was significantly higher than those for the other types of arrhythmias. This pharmacological profile is similar to those of mexiletine and tocainide, and all three drugs have central nervous system (CNS) stimulant action. Because cibenzoline had only weak ENT2 hypotensive ENT2END and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	Because ENT1 cibenzoline  ENT1END  had only weak ENT2 hypotensive ENT2END and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs, its clinical usefulness is expected
0	Syncope and ENT1 QT prolongation  ENT1END  among patients treated with methadone for ENT2 heroin ENT2END dependence in the city of Copenhagen
1	CONCLUSIONS: ENT1 Methadone ENT1END is associated with ENT2 QT prolongation ENT2END and higher reporting of syncope in a population of heroin addicts
0	Among the subjects treated with methadone, 28% men and 32% women had ENT1 prolonged QTc interval ENT1END  None of the subjects treated with ENT2 buprenorphine ENT2END had QTc interval >0
0	Prolongation of the QT interval in the ECG of patients with torsade de pointes ( ENT1 TdP ENT1END  has been reported in methadone users. As ENT2 heroin ENT2END addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone
0	Prolongation of the QT interval in the ECG of patients with torsade de pointes ( ENT1 TdP ENT1END ) has been reported in ENT2 methadone ENT2END users
0	As heroin addicts sometimes faint while using illicit drugs, doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of ENT1 TdP ENT1END in this special population, and the high mortality in this population may, in part, be caused by the proarrhythmic effect of methadone. METHODS: In this cross-sectional study interview, ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or ENT2 buprenorphine ENT2END on a daily basis
0	CONCLUSIONS: Methadone is associated with QT prolongation and higher reporting of ENT1 syncope ENT1END in a population of ENT2 heroin ENT2END addicts
1	4) times higher odds for ENT1 syncope  ENT1END  CONCLUSIONS: ENT2 Methadone ENT2END is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts
0	None of the subjects treated with ENT1 buprenorphine  ENT1END  had QTc interval >0.440 s((1/2)). A 50 mg higher methadone dose was associated with a 1.2 (95% CI 1.1 to 1.4) times higher odds for ENT2 syncope ENT2END
0	However, an unacceptable increase in disability from ENT1 Parkinsonism ENT1END with aggravation of end-of-dose akinesia led to its cessation in 14 patients. ENT2 Tiapride ENT2END had no effect on levodopa-induced early morning of "off-period" segmental dystonia
0	However, an unacceptable increase in disability from ENT1 Parkinsonism ENT1END  with aggravation of end-of-dose akinesia led to its cessation in 14 patients. Tiapride had no effect on levodopa-induced early morning of "off-period" segmental dystonia. These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of ENT2 dopamine ENT2END receptors
0	Tiapride, a substituted benzamide derivative closely related to ENT1 metoclopramide ENT1END  reduced levodopa-induced peak dose involuntary movements in 16 patients with ENT2 idiopathic Parkinson's disease ENT2END
0	Tiapride, a substituted ENT1 benzamide  ENT1END derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with ENT2 idiopathic Parkinson's disease ENT2END
0	Tiapride, a substituted benzamide derivative closely related to metoclopramide, reduced ENT1 levodopa  ENT1END induced peak dose involuntary movements in 16 patients with ENT2 idiopathic Parkinson's disease ENT2END
0	Tiapride in levodopa-induced ENT1 involuntary movements  ENT1END . ENT2 Tiapride ENT2END , a substituted benzamide derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease
0	These results fail to support the notion that levodopa-induced ENT1 dyskinesias  ENT1END are caused by overstimulation of a separate group of ENT2 dopamine ENT2END receptors
0	Tiapride, a substituted benzamide derivative closely related to ENT1 metoclopramide ENT1END , reduced levodopa-induced peak dose ENT2 involuntary movements ENT2END in 16 patients with idiopathic Parkinson's disease
0	Tiapride in levodopa-induced ENT1 involuntary movements  ENT1END .Tiapride, a substituted ENT2 benzamide ENT2END derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease
1	These results fail to support the notion that ENT1 levodopa  ENT1END induced ENT2 dyskinesias ENT2END are caused by overstimulation of a separate group of dopamine receptors
0	ENT1 Tiapride ENT1END  had no effect on levodopa-induced early morning of "off-period" segmental ENT2 dystonia ENT2END
0	Tiapride had no effect on levodopa-induced early morning of "off-period" segmental ENT1 dystonia  ENT1END . These results fail to support the notion that levodopa-induced dyskinesias are caused by overstimulation of a separate group of ENT2 dopamine ENT2END receptors
0	Tiapride, a substituted benzamide derivative closely related to ENT1 metoclopramide  ENT1END , reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease. However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients. Tiapride had no effect on levodopa-induced early morning of "off-period" segmental ENT2 dystonia ENT2END
0	Tiapride, a substituted ENT1 benzamide  ENT1END  derivative closely related to metoclopramide, reduced levodopa-induced peak dose involuntary movements in 16 patients with idiopathic Parkinson's disease. However, an unacceptable increase in disability from Parkinsonism with aggravation of end-of-dose akinesia led to its cessation in 14 patients. Tiapride had no effect on levodopa-induced early morning of "off-period" segmental ENT2 dystonia ENT2END
0	Tiapride had no effect on levodopa-induced early morning of "off-period" segmental ENT1 dystonia  ENT1END . These results fail to support the notion that ENT2 levodopa ENT2END -induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors
0	Our study group consisted of 74 HIV-positive homosexual men belonging to groups II B, III and IV C2 from the Centers for Disease Control (CDC) classification of ENT1 HIV disease ENT1END  Following a 3-week observation period, volunteers were treated with ENT2 zidovudine ENT2END 600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals
1	Following a 3-week observation period, volunteers were treated with ENT1 zidovudine ENT1END  600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly ENT2 nausea ENT2END (64%), fatigue (55%) and headache (49%)
1	Following a 3-week observation period, volunteers were treated with ENT1 zidovudine ENT1END  600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), ENT2 fatigue ENT2END (55%) and headache (49%)
1	Following a 3-week observation period, volunteers were treated with ENT1 zidovudine ENT1END  600 mg/day for 18 weeks, 900 mg/day for 9 weeks and 1200 mg/day for 9 weeks, followed by a washout period of 6 weeks after which they were re-started on 1200 mg/day or the highest tolerated dose at 8-hourly intervals. Subjects were randomly assigned to 4-hourly or 8-hourly regimens within CDC groups while taking 600 and 1200 mg/day. Clinical and laboratory evaluations were performed at 3-week intervals. Symptomatic adverse effects were present in 96% of subjects, most commonly nausea (64%), fatigue (55%) and ENT2 headache ENT2END (49%)
0	ENT1 Capsaicin ENT1END -induced muscle pain alters the excitability of the human jaw-stretch reflex.The pathophysiology of painful ENT2 temporomandibular disorders ENT2END is not fully understood, but evidence suggests that muscle pain modulates motor function in characteristic ways
0	ENT1 Capsaicin  ENT1END -induced ENT2 muscle pain ENT2END alters the excitability of the human jaw-stretch reflex
1	ENT1 Capsaicin ENT1END (10 micro g) was injected into the masseter muscle to induce ENT2 pain ENT2END in 11 healthy volunteers
0	RESULTS: As anticipated, ENT1 adriamycin ENT1END elicited ENT2 nephrotic ENT2END range proteinuria, renal interstitial damage and mild focal glomerulosclerosis
0	METHODS: Renal ACE activity ( ENT1 Hip-His-Leu  ENT1END cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats. After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v. n = 9]. Proteinuria was measured every 2 weeks. After 12 weeks, rats were sacrificed and their kidneys harvested. RESULTS: As anticipated, adriamycin elicited ENT2 nephrotic ENT2END range proteinuria, renal interstitial damage and mild focal glomerulosclerosis
0	RESULTS: As anticipated, ENT1 adriamycin ENT1END  elicited nephrotic range proteinuria, renal interstitial damage and mild ENT2 focal glomerulosclerosis ENT2END
0	METHODS: Renal ACE activity ( ENT1 Hip-His-Leu  ENT1END  cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats. After 1 week of recovery, proteinuria was induced by adriamycin [1.5 mg/kg intravenously (i.v.) n = 18; controls, saline i.v. n = 9]. Proteinuria was measured every 2 weeks. After 12 weeks, rats were sacrificed and their kidneys harvested. RESULTS: As anticipated, adriamycin elicited nephrotic range proteinuria, renal interstitial damage and mild ENT2 focal glomerulosclerosis ENT2END
0	Individual differences in renal ACE activity in healthy rats predict susceptibility to ENT1 adriamycin  ENT1END -induced ENT2 renal damage ENT2END
0	Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced ENT1 renal damage ENT1END .BACKGROUND: In man, differences in ENT2 angiotensin ENT2END -converting enzyme (ACE) levels, related to ACE (I/D) genotype, are associated with renal prognosis
0	Therefore, we studied the predictive effect of renal ACE activity for the severity of ENT1 renal damage ENT1END induced by a single injection of adriamycin in rats. METHODS: Renal ACE activity ENT2 Hip-His-Leu ENT2END cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats
1	Baseline renal ACE positively correlated with the relative rise in ENT1 proteinuria ENT1END after ENT2 adriamycin ENT2END (r = 0
0	BACKGROUND: In man, differences in ENT1 angiotensin ENT1END -converting enzyme (ACE) levels, related to ACE (I/D) genotype, are associated with renal prognosis. This raises the hypothesis that individual differences in renal ACE activity are involved in renal susceptibility to inflicted damage. Therefore, we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats. METHODS: Renal ACE activity (Hip-His-Leu cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats. After 1 week of recovery, ENT2 proteinuria ENT2END was induced by adriamycin [1
0	METHODS: Renal ACE activity ( ENT1 Hip-His-Leu  ENT1END  cleavage by cortical homogenates) was determined by renal biopsy in 27 adult male Wistar rats. After 1 week of recovery, ENT2 proteinuria ENT2END was induced by adriamycin [1
0	Intra-arterial ENT1 BCNU  ENT1END  chemotherapy for treatment of ENT2 malignant gliomas ENT2END of the central nervous system
0	Thirty-six patients were treated with ENT1 BCNU ENT1END every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area. Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the ENT2 tumor ENT2END without prior radiation therapy
0	The frequency of ENT1 visual loss ENT1END decreased after the concentration of the ENT2 ethanol ENT2END diluent was lowered
0	The catheterization procedure is safe, with no immediate complication in 111 infusions of ENT1 BCNU ENT1END  A delayed complication in nine patients has been unilateral ENT2 loss of vision ENT2END secondary to a retinal vasculitis
0	A delayed complication in nine patients has been unilateral loss of vision secondary to a ENT1 retinal vasculitis  ENT1END  The frequency of visual loss decreased after the concentration of the ENT2 ethanol ENT2END diluent was lowered
1	The catheterization procedure is safe, with no immediate complication in 111 infusions of ENT1 BCNU  ENT1END . A delayed complication in nine patients has been unilateral loss of vision secondary to a ENT2 retinal vasculitis ENT2END
0	Thirty-six patients were treated with ENT1 BCNU ENT1END  every 6 to 8 weeks, either by transfemoral catheterization of the internal carotid or vertebral artery or through a fully implantable intracarotid drug delivery system, beginning with a dose of 200 mg/sq m body surface area. Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy. After two to seven cycles of chemotherapy, nine patients showed a decrease in tumor size and surrounding ENT2 edema ENT2END on contrast-enhanced computerized tomography scans
0	Twenty-four patients with recurrent Grade I to IV ENT1 astrocytomas  ENT1END  whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial BCNU therapy. Seventeen of these had a response or were stable for a median of 20 weeks (range 6 to more than 66 weeks). The catheterization procedure is safe, with no immediate complication in 111 infusions of BCNU. A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis. The frequency of visual loss decreased after the concentration of the ENT2 ethanol ENT2END diluent was lowered
0	Twenty-four patients with recurrent Grade I to IV ENT1 astrocytomas ENT1END , whose resection and irradiation therapy had failed, received two to eight courses of intra-arterial ENT2 BCNU ENT2END therapy
0	A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and propranolol (20 mg tid) for treatment of ENT1 hyperthyroidism ENT1END  The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications. When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction. Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed. Over the following 9 days, the symptoms improved and plasma ENT2 bilirubin ENT2END levels were normal after 12 weeks without methimazole
0	A 43-year-old woman had severe jaundice and itching 1 month after receiving ENT1 methimazole  ENT1END (10 mg tid) and propranolol (20 mg tid) for treatment of ENT2 hyperthyroidism ENT2END
0	A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and ENT1 propranolol  ENT1END (20 mg tid) for treatment of ENT2 hyperthyroidism ENT2END
0	Over the following 9 days, the symptoms improved and plasma ENT1 bilirubin ENT1END  levels were normal after 12 weeks without methimazole. In rare cases within the first few weeks of therapy, this drug can cause severe and reversible ENT2 cholestatic jaundice ENT2END
1	Methimazole-induced ENT1 cholestatic jaundice  ENT1END . ENT2 Methimazole ENT2END is a widely used and generally well-tolerated antithyroid agent
0	Methimazole-induced ENT1 cholestatic jaundice  ENT1END .Methimazole is a widely used and generally well-tolerated antithyroid agent. A 43-year-old woman had severe jaundice and itching 1 month after receiving methimazole (10 mg tid) and ENT2 propranolol ENT2END (20 mg tid) for treatment of hyperthyroidism
0	Methimazole-induced ENT1 cholestasis  ENT1END was diagnosed, and propranolol therapy was resumed. Over the following 9 days, the symptoms improved and plasma ENT2 bilirubin ENT2END levels were normal after 12 weeks without methimazole
0	ENT1 Methimazole  ENT1END induced ENT2 cholestasis ENT2END was diagnosed, and propranolol therapy was resumed
0	Methimazole-induced ENT1 cholestasis ENT1END  was diagnosed, and ENT2 propranolol ENT2END therapy was resumed
0	When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and ENT1 hyperbilirubinemia  ENT1END  formed mainly of the conjugated fraction. Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed. Over the following 9 days, the symptoms improved and plasma ENT2 bilirubin ENT2END levels were normal after 12 weeks without methimazole
1	When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and ENT1 hyperbilirubinemia  ENT1END , formed mainly of the conjugated fraction. ENT2 Methimazole ENT2END -induced cholestasis was diagnosed, and propranolol therapy was resumed
0	When seen at the emergency department 2 weeks later, she still had severe icterus, pruritus, and ENT1 hyperbilirubinemia  ENT1END , formed mainly of the conjugated fraction. Methimazole-induced cholestasis was diagnosed, and ENT2 propranolol ENT2END therapy was resumed
0	When seen at the emergency department 2 weeks later, she still had severe ENT1 icterus  ENT1END  pruritus, and hyperbilirubinemia, formed mainly of the conjugated fraction. Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed. Over the following 9 days, the symptoms improved and plasma ENT2 bilirubin ENT2END levels were normal after 12 weeks without methimazole
0	A 43-year-old woman had severe ENT1 jaundice  ENT1END and itching 1 month after receiving ENT2 methimazole ENT2END (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism
0	A 43-year-old woman had severe ENT1 jaundice  ENT1END  and itching 1 month after receiving methimazole (10 mg tid) and ENT2 propranolol ENT2END (20 mg tid) for treatment of hyperthyroidism
0	When seen at the emergency department 2 weeks later, she still had severe icterus, ENT1 pruritus  ENT1END  and hyperbilirubinemia, formed mainly of the conjugated fraction. Methimazole-induced cholestasis was diagnosed, and propranolol therapy was resumed. Over the following 9 days, the symptoms improved and plasma ENT2 bilirubin ENT2END levels were normal after 12 weeks without methimazole
1	A 43-year-old woman had severe jaundice and ENT1 itching  ENT1END 1 month after receiving ENT2 methimazole ENT2END (10 mg tid) and propranolol (20 mg tid) for treatment of hyperthyroidism
0	A 43-year-old woman had severe jaundice and ENT1 itching  ENT1END  1 month after receiving methimazole (10 mg tid) and ENT2 propranolol ENT2END (20 mg tid) for treatment of hyperthyroidism
1	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with ENT1 PAN ENT1END induced ENT2 nephrotic syndrome ENT2END
0	ENT1 Nephrotic syndrome ENT1END is often accompanied by ENT2 sodium ENT2END retention and generalized edema
0	In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced ENT1 nephrotic syndrome  ENT1END . The decreased abundance of NHE3, BSC-1, TSC, and Na- ENT2 K ENT2END -ATPase may play a compensatory role to promote sodium excretion
0	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and ENT1 thiazide  ENT1END sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased. Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM. In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced ENT2 nephrotic syndrome ENT2END
0	In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)- ENT1 Cl  ENT1END -) cotransporter (TSC) were decreased. Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM. In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced ENT2 nephrotic syndrome ENT2END
0	In contrast, the protein abundances of Na(+)/ ENT1 H  ENT1END +) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased. Moreover, the abundance of the alpha(1)-subunit of the Na-K-ATPase was decreased in the cortex and ISOM, but it remained unchanged in the IM. In conclusion, the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2, connecting tubule, and collecting duct are likely to play a role in the sodium retention associated with PAN-induced ENT2 nephrotic syndrome ENT2END
1	After 7 days, ENT1 PAN ENT1END treatment induced significant proteinuria, ENT2 hypoalbuminemia ENT2END , decreased urinary sodium excretion, and extensive ascites
0	After 7 days, PAN treatment induced significant proteinuria, ENT1 hypoalbuminemia ENT1END , decreased urinary ENT2 sodium ENT2END excretion, and extensive ascites
0	After 7 days, PAN treatment induced significant proteinuria, ENT1 hypoalbuminemia  ENT1END , decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)- ENT2 K ENT2END (+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant proteinuria, ENT1 hypoalbuminemia  ENT1END , decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and ENT2 thiazide ENT2END -sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant proteinuria, ENT1 hypoalbuminemia  ENT1END , decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2 ENT2 Cl ENT2END (-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant proteinuria, ENT1 hypoalbuminemia  ENT1END , decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+) ENT2 H ENT2END (+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
1	After 7 days, ENT1 PAN ENT1END  treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ENT2 ascites ENT2END
0	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary ENT1 sodium  ENT1END  excretion, and extensive ENT2 ascites ENT2END
0	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ENT1 ascites  ENT1END . The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+) ENT2 K ENT2END (+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ENT1 ascites  ENT1END . The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and ENT2 thiazide ENT2END -sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ENT1 ascites  ENT1END . The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)- ENT2 Cl ENT2END (-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant proteinuria, hypoalbuminemia, decreased urinary sodium excretion, and extensive ENT1 ascites  ENT1END . The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+) ENT2 H ENT2END (+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	Increased expression and apical targeting of renal ENaC subunits in ENT1 puromycin aminonucleoside ENT1END -induced nephrotic syndrome in rats.Nephrotic syndrome is often accompanied by sodium retention and generalized ENT2 edema ENT2END
0	Nephrotic syndrome is often accompanied by ENT1 sodium  ENT1END  retention and generalized ENT2 edema ENT2END
1	After 7 days, ENT1 PAN ENT1END  treatment induced significant ENT2 proteinuria ENT2END , hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites
0	After 7 days, PAN treatment induced significant ENT1 proteinuria  ENT1END , hypoalbuminemia, decreased urinary ENT2 sodium ENT2END excretion, and extensive ascites
0	After 7 days, PAN treatment induced significant ENT1 proteinuria  ENT1END , hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+) ENT2 K ENT2END (+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant ENT1 proteinuria  ENT1END , hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and ENT2 thiazide ENT2END -sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant ENT1 proteinuria  ENT1END , hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+)/H(+) exchanger type 3 (NHE3), Na(+)-K(+)- ENT2 Cl ENT2END (-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	After 7 days, PAN treatment induced significant ENT1 proteinuria  ENT1END , hypoalbuminemia, decreased urinary sodium excretion, and extensive ascites. The protein abundance of alpha-ENaC and beta-ENaC was increased in the inner stripe of the outer medulla (ISOM) and in the inner medulla (IM) but was not altered in the cortex. gamma-ENaC abundance was increased in the cortex, ISOM, and IM. Immunoperoxidase brightfield- and laser-scanning confocal fluorescence microscopy demonstrated increased targeting of alpha-ENaC, beta-ENaC, and gamma-ENaC subunits to the apical plasma membrane in the distal convoluted tubule (DCT2), connecting tubule, and cortical and medullary collecting duct segments. Immunoelectron microscopy further revealed an increased labeling of alpha-ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN-treated rats, indicating enhanced apical targeting of alpha-ENaC subunits. In contrast, the protein abundances of Na(+) ENT2 H ENT2END (+) exchanger type 3 (NHE3), Na(+)-K(+)-2Cl(-) cotransporter (BSC-1), and thiazide-sensitive Na(+)-Cl(-) cotransporter (TSC) were decreased
0	05) occurred more frequently in patients who had a ENT1 morphine ENT1END infusion. There was also a higher incidence of ENT2 tachyarrhythmias ENT2END (P less than 0
0	25% ENT1 bupivacaine  ENT1END (mean 192 mg) in the 24-h period following upper abdominal surgery. Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion. There was also a higher incidence of ENT2 tachyarrhythmias ENT2END (P less than 0
0	Monitoring consisted of airflow detection by a ENT1 carbon dioxide  ENT1END analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion. There was also a higher incidence of ENT2 tachyarrhythmias ENT2END (P less than 0
1	ENT1 obstructive (P less than 0.05) and central apnoea  ENT1END (P less than 0.05) occurred more frequently in patients who had a ENT2 morphine ENT2END infusion
0	25% ENT1 bupivacaine  ENT1END  (mean 192 mg) in the 24-h period following upper abdominal surgery. Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both ENT2 obstructive (P less than 0.05) and central apnoea ENT2END (P less than 0
0	Monitoring consisted of airflow detection by a ENT1 carbon dioxide  ENT1END  analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both ENT2 obstructive (P less than 0.05) and central apnoea ENT2END (P less than 0
1	ENT1 obstructive (P less than 0.05) and central apnoea  ENT1END (P less than 0.05) occurred more frequently in patients who had a ENT2 morphine ENT2END infusion
0	25% ENT1 bupivacaine  ENT1END  (mean 192 mg) in the 24-h period following upper abdominal surgery. Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both ENT2 obstructive (P less than 0.05) and central apnoea ENT2END (P less than 0
0	Monitoring consisted of airflow detection by a ENT1 carbon dioxide  ENT1END  analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both ENT2 obstructive (P less than 0.05) and central apnoea ENT2END (P less than 0
0	The incidence of postoperative respiratory ENT1 apnoea ENT1END was compared between five patients receiving a continuous i.v. infusion of ENT2 morphine ENT2END (mean 73
0	The incidence of postoperative respiratory ENT1 apnoea  ENT1END  was compared between five patients receiving a continuous i.v. infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% ENT2 bupivacaine ENT2END (mean 192 mg) in the 24-h period following upper abdominal surgery
0	The incidence of postoperative respiratory ENT1 apnoea  ENT1END  was compared between five patients receiving a continuous i.v. infusion of morphine (mean 73.6 mg) and five patients receiving a continuous extradural infusion of 0.25% bupivacaine (mean 192 mg) in the 24-h period following upper abdominal surgery. Monitoring consisted of airflow detection by a ENT2 carbon dioxide ENT2END analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor
1	05) and ENT1 ventricular ectopic beats ENT1END (P less than 0.05) in the ENT2 morphine ENT2END infusion group
0	25% ENT1 bupivacaine  ENT1END  (mean 192 mg) in the 24-h period following upper abdominal surgery. Monitoring consisted of airflow detection by a carbon dioxide analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion. There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ENT2 ventricular ectopic beats ENT2END (P less than 0
0	Monitoring consisted of airflow detection by a ENT1 carbon dioxide  ENT1END  analyser, chest wall movement detected by pneumatic capsules, and continuous electrocardiograph recorded with a Holter ambulatory monitor. Both obstructive (P less than 0.05) and central apnoea (P less than 0.05) occurred more frequently in patients who had a morphine infusion. There was also a higher incidence of tachyarrhythmias (P less than 0.05) and ENT2 ventricular ectopic beats ENT2END (P less than 0
0	ENT1 Rabbit syndrome  ENT1END , ENT2 antidepressant ENT2END use, and cerebral perfusion SPECT scan findings
1	The ENT1 rabbit syndrome ENT1END is an extrapyramidal side effect associated with chronic neuroleptic therapy. Its occurrence in a patient being treated with ENT2 imipramine ENT2END is described, representing the first reported case of this syndrome in conjunction with antidepressants
0	Its occurrence in a patient being treated with imipramine is described, representing the first reported case of this syndrome in conjunction with ENT1 antidepressants ENT1END  Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the ENT2 movement disorder ENT2END was present, and a return to normal perfusion when the rabbit syndrome resolved
0	Its occurrence in a patient being treated with ENT1 imipramine  ENT1END  is described, representing the first reported case of this syndrome in conjunction with antidepressants. Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the ENT2 movement disorder ENT2END was present, and a return to normal perfusion when the rabbit syndrome resolved
0	In rats with immune experimental ENT1 glomerulonephritis ENT1END  5/6 rats given ENT2 DX ENT2END died within 7 days, in contrast to animals treated by DXNP, NP, or untreated, which all survived
0	Acute renal toxicity of doxorubicin (adriamycin)-loaded ENT1 cyanoacrylate ENT1END  nanoparticles.Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental ENT2 glomerulonephritis ENT2END
0	These results demonstrate that, in these experimental conditions, DXNP killed less animals than free ENT1 DX ENT1END  despite of an enhanced renal toxicity of the former. Both effects (better survival and ENT2 nephrosis ENT2END ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system, including mesangial cells
0	Acute ENT1 renal toxicity  ENT1END  of ENT2 doxorubicin ENT2END (adriamycin)-loaded cyanoacrylate nanoparticles
0	Acute ENT1 renal toxicity  ENT1END  of doxorubicin (adriamycin)-loaded ENT2 cyanoacrylate ENT2END nanoparticles
1	A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with ENT1 DX ENT1END  Free NP did not provoke any ENT2 proteinuria ENT2END
0	Acute renal toxicity of doxorubicin (adriamycin)-loaded ENT1 cyanoacrylate ENT1END  nanoparticles.Acute doxorubicin-loaded nanoparticle (DXNP) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis. In normal rats, 2/6 rats given free doxorubicin (DX) (5 mg/kg) died within one week, whereas all control animals and all rats having received free NP or DXNP survived. A 3 times higher ENT2 proteinuria ENT2END appeared in animals treated with DXNP than in those treated with DX
0	The occurrence of a myocardial infarction is reported after chemotherapy containing ENT1 etoposide ENT1END  in a man with no risk factors for ENT2 coronary heart disease ENT2END
1	ENT1 Etoposide  ENT1END -related ENT2 myocardial infarction ENT2END
0	Grade 3-4 adverse effects included myelosuppression, fatigue, ENT1 somnolence ENT1END depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent ENT2 thalidomide ENT2END in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide
0	Grade 3-4 adverse effects included myelosuppression, fatigue, ENT1 somnolence ENT1END /depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the ENT1 Cancer  ENT1END  and Leukemia Group B. ENT2 Thalidomide ENT2END is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma
1	Of concern was the occurrence of four ENT1 thromboembolic  ENT1END events. Our results failed to demonstrate an important response rate to single agent ENT2 thalidomide ENT2END in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide
0	Of concern was the occurrence of four ENT1 thromboembolic  ENT1END  events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, ENT1 neuropathy  ENT1END and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent ENT2 thalidomide ENT2END in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide
0	Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, ENT1 neuropathy  ENT1END  and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	ENT1 Thalidomide ENT1END  is an immunomodulatory agent with demonstrated activity in multiple myeloma, ENT2 mantle cell lymphoma ENT2END and lymphoplasmacytic lymphoma
0	Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/ ENT1 depressed mood  ENT1END  neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent ENT2 thalidomide ENT2END in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide
0	Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/ ENT1 depressed mood  ENT1END , neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	Thalidomide has limited single-agent activity in relapsed or refractory indolent ENT1 non-Hodgkin lymphomas  ENT1END : a phase II trial of the Cancer and Leukemia Group B ENT2 Thalidomide ENT2END is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma
0	ENT1 Thalidomide ENT1END  is an immunomodulatory agent with demonstrated activity in ENT2 multiple myeloma ENT2END , mantle cell lymphoma and lymphoplasmacytic lymphoma
0	Grade 3-4 adverse effects included ENT1 myelosuppression  ENT1END  fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent ENT2 thalidomide ENT2END in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide
0	Grade 3-4 adverse effects included ENT1 myelosuppression  ENT1END , fatigue, somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	Between July 2001 and April 2004, 24 patients with relapsed/refractory indolent ENT1 lymphomas ENT1END received ENT2 thalidomide ENT2END 200 mg daily with escalation by 100 mg daily every 1-2 weeks as tolerated, up to a maximum of 800 mg daily
0	Our results failed to demonstrate an important response rate to single agent thalidomide in indolent ENT1 lymphomas  ENT1END and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	Grade 3-4 adverse effects included myelosuppression, ENT1 fatigue  ENT1END  somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent ENT2 thalidomide ENT2END in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide
0	Grade 3-4 adverse effects included myelosuppression, ENT1 fatigue  ENT1END , somnolence/depressed mood, neuropathy and dyspnea. Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and ENT1 Leukemia  ENT1END  Group B ENT2 Thalidomide ENT2END is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma
0	Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and ENT1 dyspnea  ENT1END  Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent ENT2 thalidomide ENT2END in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, lenalidomide
0	Grade 3-4 adverse effects included myelosuppression, fatigue, somnolence/depressed mood, neuropathy and ENT1 dyspnea  ENT1END . Of concern was the occurrence of four thromboembolic events. Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent, ENT2 lenalidomide ENT2END
0	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and ENT1 blood coagulation ENT1END in vitro. In the in vivo study, the administration (50 mg/kg, i.p.) of TET and ENT2 FAN ENT2END in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i
0	Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a ENT1 bisbenzylisoquinoline  ENT1END structure. The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and ENT2 blood coagulation ENT2END in vitro
0	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and ENT1 blood coagulation ENT1END  in vitro. In the in vivo study, the administration (50 mg/kg, i.p.) of ENT2 TET ENT2END and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid (ASA, 50 mg/kg, i
0	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and ENT1 blood coagulation ENT1END  in vitro. In the in vivo study, the administration (50 mg/kg, i.p.) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while ENT2 acetylsalicylic acid ENT2END (ASA, 50 mg/kg, i
0	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( ENT1 EP  ENT1END  in mice, and platelet aggregation and ENT2 blood coagulation ENT2END in vitro
0	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human ENT1 platelet aggregation ENT1END .Tetrandrine (TET) and ENT2 fangchinoline ENT2END (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure
0	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human ENT1 platelet aggregation  ENT1END .Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a ENT2 bisbenzylisoquinoline ENT2END structure
0	Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human ENT1 platelet aggregation  ENT1END . ENT2 Tetrandrine ENT2END (TET) and fangchinoline (FAN) are two naturally occurring analogues with a bisbenzylisoquinoline structure
0	) of TET and FAN in mice showed the inhibition of thrombosis by 55% and 35%, respectively, while acetylsalicylic acid ( ENT1 ASA ENT1END  50 mg/kg, i.p.), a positive control, showed only 30% inhibition. In the vitro human ENT2 platelet aggregations ENT2END induced by the agonists used in tests, TET and FAN showed the inhibitions dose dependently
0	The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( ENT1 EP ENT1END ) in mice, and ENT2 platelet aggregation ENT2END and blood coagulation in vitro
0	The present study was undertaken to investigate the effects of TET and ENT1 FAN ENT1END on the experimental ENT2 thrombosis ENT2END induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro
0	Tetrandrine (TET) and fangchinoline (FAN) are two naturally occurring analogues with a ENT1 bisbenzylisoquinoline  ENT1END  structure. The present study was undertaken to investigate the effects of TET and FAN on the experimental ENT2 thrombosis ENT2END induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro
0	The present study was undertaken to investigate the effects of ENT1 TET  ENT1END and FAN on the experimental ENT2 thrombosis ENT2END induced by collagen plus epinephrine (EP) in mice, and platelet aggregation and blood coagulation in vitro
0	) of TET and FAN in mice showed the inhibition of ENT1 thrombosis  ENT1END by 55% and 35%, respectively, while ENT2 acetylsalicylic acid ENT2END (ASA, 50 mg/kg, i
1	The present study was undertaken to investigate the effects of TET and FAN on the experimental ENT1 thrombosis ENT1END  induced by collagen plus ENT2 epinephrine ENT2END (EP) in mice, and platelet aggregation and blood coagulation in vitro
0	At the time of admission, the patient was at high risk of ENT1 radiation injury ENT1END to the fetus, so a coronary angiogram was postponed until the second trimester. It showed normal coronary vessels. CONCLUSION: This appears to be the first reported case documenting a possible association between ENT2 CC ENT2END and myocardial infarction
1	Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with ENT1 CC ENT1END  Spontaneous coronary thrombosis or ENT2 thromboembolism ENT2END with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram
0	CONCLUSION: This appears to be the first reported case documenting a possible association between ENT1 CC ENT1END  and myocardial infarction. ENT2 Thrombosis ENT2END might be a rare but hazardous complication of CC
1	CONCLUSION: This appears to be the first reported case documenting a possible association between ENT1 CC ENT1END  and ENT2 myocardial infarction ENT2END
0	CASE: A 33-year-old woman with a 5-week gestation had recently received ENT1 CC ENT1END for ovulation induction and presented with ENT2 chest pain ENT2END
0	Thromboembolism is a rare but life-threatening complication that has been reported after ovulation induction with ENT1 CC ENT1END . Spontaneous ENT2 coronary thrombosis ENT2END or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction (MI) during pregnancy, with a subsequently normal coronary angiogram
0	001): decreases in LDL cholesterol (24% to 40%) and ENT1 triglycerides ENT1END (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%). Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL). Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose. ENT2 Myopathy ENT2END , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg)
0	Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL ENT1 cholesterol  ENT1END levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL). Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose. ENT2 Myopathy ENT2END , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg)
1	ENT1 Myopathy ENT1END , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of ENT2 lovastatin ENT2END (80 mg)
0	ENT1 Myopathy ENT1END , defined as muscle symptoms with ENT2 creatine ENT2END kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg)
0	OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate ENT1 hypercholesterolemia ENT1END  DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks. SETTING: Ambulatory patients recruited by 362 participating centers throughout the United States. PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers. MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and ENT2 triglycerides ENT2END ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study
0	OBJECTIVE: To evaluate the efficacy and safety of lovastatin in women with moderate ENT1 hypercholesterolemia ENT1END . DESIGN: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks. SETTING: Ambulatory patients recruited by 362 participating centers throughout the United States. PATIENTS: Women (n = 3390) from the total cohort of 8245 volunteers. MEASUREMENTS: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) ENT2 cholesterol ENT2END , and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study
0	OBJECTIVE: To evaluate the efficacy and safety of ENT1 lovastatin  ENT1END in women with moderate ENT2 hypercholesterolemia ENT2END
0	Myopathy, defined as muscle symptoms with ENT1 creatine ENT1END  kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg). Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin. CONCLUSION: Lovastatin is highly effective and generally well tolerated as therapy for primary ENT2 hypercholesterolemia ENT2END in women
1	Complete ENT1 heart block  ENT1END  following a single dose of ENT2 trazodone ENT2END
1	Photodistributed ENT1 nifedipine  ENT1END -induced facial ENT2 telangiectasia ENT2END
1	One commenced the closely related drug ENT1 amlodipine ENT1END 3 years later, with recurrence of ENT2 telangiectasia ENT2END
0	Five months after starting nifedipine ( ENT1 Adalat ENT1END , two patients developed photodistributed facial telangiectasia, which became more noticeable with time. Neither patient complained of photosensitivity or ENT2 flushing ENT2END
0	Neither patient complained of photosensitivity or ENT1 flushing  ENT1END . Both patients reported a significant cosmetic improvement after discontinuing the drug. One commenced the closely related drug ENT2 amlodipine ENT2END 3 years later, with recurrence of telangiectasia
1	ENT1 Cocaine  ENT1END  related ENT2 chest pain ENT2END : are we seeing the tip of an iceberg?The recreational use of cocaine is on the increase
0	Cholinergic ENT1 toxicity  ENT1END  resulting from ocular instillation of ENT2 echothiophate iodide ENT2END eye drops
0	A patient developed a severe cholinergic syndrome from the use of ENT1 echothiophate iodide ENT1END ophthalmic drops, presented with profound muscle weakness and was initially given the diagnosis of ENT2 myasthenia gravis ENT2END
1	A patient developed a severe cholinergic syndrome from the use of ENT1 echothiophate iodide ENT1END  ophthalmic drops, presented with profound ENT2 muscle weakness ENT2END and was initially given the diagnosis of myasthenia gravis
1	Less frequent toxic effects included thrombocytopenia, ENT1 anemia ENT1END  nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, ENT1 anemia ENT1END , nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, ENT1 anemia ENT1END , nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Less frequent toxic effects included thrombocytopenia, ENT1 anemia ENT1END , nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
1	Less frequent toxic effects included thrombocytopenia, anemia, ENT1 nausea  ENT1END  mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, ENT1 nausea  ENT1END , mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, ENT1 nausea  ENT1END , mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Less frequent toxic effects included thrombocytopenia, anemia, ENT1 nausea  ENT1END , mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin ( ENT1 Pirarubicin ENT1END  was done in 55 patients in good performance status with refractory ENT2 tumors ENT2END
1	Less frequent toxic effects included ENT1 thrombocytopenia  ENT1END  anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included ENT1 thrombocytopenia  ENT1END , anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included ENT1 thrombocytopenia  ENT1END , anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Less frequent toxic effects included ENT1 thrombocytopenia  ENT1END , anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
1	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild ENT1 alopecia  ENT1END  phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild ENT1 alopecia  ENT1END , phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild ENT1 alopecia  ENT1END , phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild ENT1 alopecia  ENT1END , phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	The dose-limiting toxic effect was transient noncumulative ENT1 granulocytopenia  ENT1END  Granulocyte nadir was on day 14 (range, 4-22). Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of ENT1 doxorubicin ENT1END was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, ENT2 leiomyosarcoma ENT2END , and basal cell carcinoma
0	ENT1 Adriamycinol  ENT1END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, ENT2 leiomyosarcoma ENT2END , and basal cell carcinoma
0	Urinary excretion of ENT1 Pirarubicin  ENT1END in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, ENT2 leiomyosarcoma ENT2END , and basal cell carcinoma
0	Adriamycinol, doxorubicin, ENT1 adriamycinone  ENT1END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, ENT2 leiomyosarcoma ENT2END , and basal cell carcinoma
0	Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of ENT1 doxorubicin ENT1END  was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in ENT2 mesothelioma ENT2END , leiomyosarcoma, and basal cell carcinoma
0	ENT1 Adriamycinol  ENT1END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in ENT2 mesothelioma ENT2END , leiomyosarcoma, and basal cell carcinoma
0	Urinary excretion of ENT1 Pirarubicin  ENT1END  in the first 24 hours was less than or equal to 10%. Activity was noted in ENT2 mesothelioma ENT2END , leiomyosarcoma, and basal cell carcinoma
0	Adriamycinol, doxorubicin, ENT1 adriamycinone  ENT1END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in ENT2 mesothelioma ENT2END , leiomyosarcoma, and basal cell carcinoma
0	A Phase I study of intravenous (IV) bolus 4'-0-tetrahydropyranyladriamycin ( ENT1 Pirarubicin ENT1END ) was done in 55 patients in good performance status with refractory tumors. Twenty-six had minimal prior therapy (good risk), 23 had extensive prior therapy (poor risk), and six had ENT2 renal and/or hepatic dysfunction ENT2END
0	Adriamycinol, doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of ENT1 doxorubicin ENT1END  was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and ENT2 basal cell carcinoma ENT2END
0	ENT1 Adriamycinol  ENT1END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and ENT2 basal cell carcinoma ENT2END
0	Urinary excretion of ENT1 Pirarubicin  ENT1END  in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and ENT2 basal cell carcinoma ENT2END
0	Adriamycinol, doxorubicin, ENT1 adriamycinone  ENT1END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites. Urinary excretion of Pirarubicin in the first 24 hours was less than or equal to 10%. Activity was noted in mesothelioma, leiomyosarcoma, and ENT2 basal cell carcinoma ENT2END
1	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, ENT1 phlebitis  ENT1END  and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, ENT1 phlebitis  ENT1END , and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, ENT1 phlebitis  ENT1END , and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, ENT1 phlebitis  ENT1END , and mucositis. Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
1	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and ENT1 mucositis  ENT1END  Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and ENT1 mucositis  ENT1END . Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and ENT1 mucositis  ENT1END . Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Less frequent toxic effects included thrombocytopenia, anemia, nausea, mild alopecia, phlebitis, and ENT1 mucositis  ENT1END . Myelosuppression was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	ENT1 Myelosuppression  ENT1END was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	ENT1 Myelosuppression  ENT1END  was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	ENT1 Myelosuppression  ENT1END  was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	ENT1 Myelosuppression  ENT1END  was more in patients with hepatic dysfunction. Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Myelosuppression was more in patients with ENT1 hepatic dysfunction  ENT1END  Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, ENT2 doxorubicin ENT2END , adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Myelosuppression was more in patients with ENT1 hepatic dysfunction  ENT1END . Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. ENT2 Adriamycinol ENT2END , doxorubicin, adriamycinone, and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Myelosuppression was more in patients with ENT1 hepatic dysfunction  ENT1END . Pharmacokinetic analyses in 21 patients revealed ENT2 Pirarubicin ENT2END plasma T 1/2 alpha (+/- SE) of 2
0	Myelosuppression was more in patients with ENT1 hepatic dysfunction  ENT1END . Pharmacokinetic analyses in 21 patients revealed Pirarubicin plasma T 1/2 alpha (+/- SE) of 2.5 +/- 0.85 minutes, T beta 1/2 of 25.6 +/- 6.5 minutes, and T 1/2 gamma of 23.6 +/- 7.6 hours. The area under the curve was 537 +/- 149 ng/ml x hours, volume of distribution (Vd) 3504 +/- 644 l/m2, and total clearance (ClT) was 204 + 39.3 l/hour/m2. Adriamycinol, doxorubicin, ENT2 adriamycinone ENT2END , and tetrahydropyranyladriamycinol were the metabolites detected in plasma and the amount of doxorubicin was less than or equal to 10% of the total metabolites
0	Diabetic rats progressively developed ENT1 albuminuria ENT1END reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002). At the same time, the number of heparan sulphate anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0.021) and by 26% (p<0.02), respectively. Number and total anionic site surface in the remaining part of the glomerular basement membrane (lamina densa and lamina rara interna) were not significantly changed. We conclude that in ENT2 streptozotocin ENT2END -diabetic rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane
0	The heparan sulphate specificity of the ENT1 cuprolinic blue  ENT1END staining was demonstrated by glycosaminoglycan-degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect. The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane. A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively). Diabetic rats progressively developed ENT2 albuminuria ENT2END reaching 40
0	The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by ENT1 glycosaminoglycan  ENT1END degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect. The majority of anionic sites (74% in diabetic and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane. A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna, and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane (p<0.001 and p<0.01 for diabetic and control rats, respectively). Diabetic rats progressively developed ENT2 albuminuria ENT2END reaching 40
0	Diabetic rats progressively developed ENT1 albuminuria ENT1END  reaching 40.3 (32.2-62.0) mg/24 h after 8 months in contrast to the control animals (0.8 (0.2-0.9) mg/24 h, p<0.002). At the same time, the number of ENT2 heparan sulphate ENT2END anionic sites and the total anionic site surface (number of anionic sites x mean anionic site surface) in the lamina rara externa of the glomerular basement membrane was reduced by 19% (p<0
1	Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with ENT1 streptozotocin  ENT1END -induced ENT2 diabetic nephropathy ENT2END
0	Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced ENT1 diabetic nephropathy ENT1END .Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye ENT2 cuprolinic blue ENT2END
0	Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced ENT1 diabetic nephropathy  ENT1END .Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue. Morphometric analysis at the ultrastructural level was performed using a computerized image processor. The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by ENT2 glycosaminoglycan ENT2END -degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect
0	Reduction of heparan sulphate-associated anionic sites in the glomerular basement membrane of rats with streptozotocin-induced ENT1 diabetic nephropathy  ENT1END . ENT2 Heparan sulphate ENT2END -associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye cuprolinic blue
0	We conclude that in ENT1 streptozotocin  ENT1END - ENT2 diabetic ENT2END rats with an increased urinary albumin excretion, a reduced heparan sulphate charge barrier/density is found at the lamina rara externa of the glomerular basement membrane
0	Heparan sulphate-associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of ENT1 diabetes  ENT1END by streptozotocin and in age- adn sex-matched control rats, employing the cationic dye ENT2 cuprolinic blue ENT2END
0	The heparan sulphate specificity of the cuprolinic blue staining was demonstrated by ENT1 glycosaminoglycan ENT1END -degrading enzymes, showing that pretreatment of the sections with heparitinase abolished all staining, whereas chondroitinase ABC had no effect. The majority of anionic sites (74% in ENT2 diabetic ENT2END and 81% in control rats) were found within the lamina rara externa of the glomerular basement membrane
0	We conclude that in streptozotocin- ENT1 diabetic ENT1END  rats with an increased urinary albumin excretion, a reduced ENT2 heparan sulphate ENT2END charge barrier/density is found at the lamina rara externa of the glomerular basement membrane
1	Ketanserin pretreatment reverses ENT1 alfentanil  ENT1END -induced ENT2 muscle rigidity ENT2END
0	ENT1 Chlordiazepoxide ENT1END at doses up to 10 mg/kg failed to significantly influence the ENT2 rigidity ENT2END produced by alfentanil
0	Systemic pretreatment with ketanserin, a relatively specific type-2 ENT1 serotonin ENT1END receptor antagonist, significantly attenuated the ENT2 muscle rigidity ENT2END produced in rats by the potent short-acting opiate agonist alfentanil
0	Despite the absence of ENT1 rigidity ENT1END  animals that received ENT2 ketanserin ENT2END (greater than 0
0	Rats that received ketanserin and ENT1 alfentanil ENT1END exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone. These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	ENT1 Chlordiazepoxide  ENT1END  at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil. Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone. Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone. These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	Pretreatment with type-2 ENT1 serotonin  ENT1END antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ENT1 ketanserin  ENT1END alone. These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	Rats that received ketanserin and ENT1 alfentanil ENT1END  exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone. These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	ENT1 Chlordiazepoxide  ENT1END  at doses up to 10 mg/kg failed to significantly influence the rigidity produced by alfentanil. Despite the absence of rigidity, animals that received ketanserin (greater than 0.31 mg/kg i.p.) followed by alfentanil were motionless, flaccid, and less responsive to external stimuli than were animals receiving alfentanil alone. Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ketanserin alone. These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	Pretreatment with type-2 ENT1 serotonin  ENT1END  antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60-min recording period than did animals that received ENT1 ketanserin  ENT1END  alone. These results, in combination with previous work, suggest that muscle rigidity, a clinically relevant side-effect of parenteral narcotic administration, may be partly mediated via serotonergic pathways. Pretreatment with type-2 serotonin antagonists may be clinically useful in attenuating opiate-induced rigidity, although further studies will be necessary to assess the interaction of possibly enhanced CNS, ENT2 cardiovascular, and respiratory depression ENT2END
0	05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/K+ ATPase and ENT1 Mg ENT1END 2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups. These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced ENT2 myocardial infarction ENT2END in rats
0	05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, ENT1 Na  ENT1END /K+ ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups. These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced ENT2 myocardial infarction ENT2END in rats
0	These findings indicate the synergistic protective effect of green tea and ENT1 vitamin E  ENT1END during ISO induced ENT2 myocardial infarction ENT2END in rats
0	These findings indicate the synergistic protective effect of ENT1 green tea  ENT1END and vitamin E during ISO induced ENT2 myocardial infarction ENT2END in rats
0	The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight, body weight, serum marker enzymes, lipid peroxidation, endogenous antioxidants and membrane bound ATPases in isoproterenol (ISO)-induced ENT1 myocardial infarction ENT1END in rats. Adult male albino rats, treated with ISO (200 mg/kg, s.c.) for 2 days at an interval of 24 h caused a significant (P<0.05) elevation of heart weight, serum marker enzymes, lipid peroxidation and ENT2 Ca ENT2END +2 ATPase level whereas there was a significant (P<0
0	05) decrease in heart weight, serum marker enzymes, lipid peroxidation, Ca+2 ATPase and a significant increase in the body weight, endogenous antioxidants, Na+/ ENT1 K  ENT1END  ATPase and Mg+2 ATPase when compared with ISO treated group and green tea or vitamin E alone treated groups. These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced ENT2 myocardial infarction ENT2END in rats
1	These findings indicate the synergistic protective effect of green tea and vitamin E during ENT1 ISO  ENT1END induced ENT2 myocardial infarction ENT2END in rats
1	Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and ENT1 doxorubicin  ENT1END -induced ENT2 cardiomyopathy ENT2END in beagle dogs
0	To examine a possibly deteriorating cardiotoxic effect of ENT1 SM-5887 ENT1END  low-grade ENT2 cardiomyopathy ENT2END was induced in dogs by four courses of doxorubicin (1
0	Chronic effects of a novel synthetic ENT1 anthracycline  ENT1END  derivative (SM-5887) on normal heart and doxorubicin-induced ENT2 cardiomyopathy ENT2END in beagle dogs
0	In conclusion, SM-5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on ENT1 doxorubicin ENT1END induced ENT2 cardiotoxicity ENT2END in dogs
0	To examine a possibly deteriorating ENT1 cardiotoxic  ENT1END effect of ENT2 SM-5887 ENT2END , low-grade cardiomyopathy was induced in dogs by four courses of doxorubicin (1
0	Chronic effects of a novel synthetic ENT1 anthracycline ENT1END  derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs.This study was designed to investigate the chronic ENT2 cardiotoxic ENT2END potential of SM-5887 and a possible deteriorating effect of SM-5887 on low-grade cardiotoxicity pre-induced by doxorubicin in beagle dogs
0	RESULTS: In most ENT1 glioma ENT1END patients, ENT2 mannitol ENT2END concentrations in white matter were 2 to 6 times higher than in plasma (mean 3
0	In meningioma and ENT1 metastases ENT1END patients plasma concentrations of ENT2 mannitol ENT2END were higher than white matter concentrations except in three cases with infiltration by neoplastic cells
1	AIM: Widespread use of ENT1 mannitol ENT1END to reduce brain edema and lower ENT2 elevated ICP ENT2END in brain tumor patients continues to be afflicted by the so-called rebound phenomenon
0	During resection, a sample of the surrounding ENT1 edematous ENT1END white matter was taken at the same time as a 10 ml venous blood sample. ENT2 Mannitol ENT2END concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al
0	AIM: Widespread use of ENT1 mannitol ENT1END  to reduce ENT2 brain edema ENT2END and lower elevated ICP in brain tumor patients continues to be afflicted by the so-called rebound phenomenon
0	In ENT1 meningioma  ENT1END and metastases patients plasma concentrations of ENT2 mannitol ENT2END were higher than white matter concentrations except in three cases with infiltration by neoplastic cells
0	As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 ENT1 brain tumor ENT1END patients. METHODS: ENT2 Mannitol ENT2END (18% solution; 1 g/kg) was administered as a bolus to patients (ten had malignant glioma, seven brain metastases and four meningioma) about 30 minutes before craniotomy
0	Significant obsessive-compulsive behavior ensued but diminished over several weeks when ENT1 methylphenidate ENT1END was replaced by fluvoxamine. The patient had no prior ENT2 psychiatric ENT2END history, but he had a sister with obsessive-compulsive disorder
0	Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by ENT1 fluvoxamine  ENT1END  The patient had no prior ENT2 psychiatric ENT2END history, but he had a sister with obsessive-compulsive disorder
0	An 82-year-old man with ENT1 treatment-resistant depression ENT1END and early Alzheimer's disease was started on ENT2 methylphenidate ENT2END
0	An 82-year-old man with ENT1 treatment-resistant depression  ENT1END  and early Alzheimer's disease was started on methylphenidate. Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by ENT2 fluvoxamine ENT2END
1	ENT1 Methylphenidate  ENT1END -induced ENT2 obsessive-compulsive symptoms ENT2END in an elderly man
0	Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by ENT1 fluvoxamine ENT1END . The patient had no prior psychiatric history, but he had a sister with ENT2 obsessive-compulsive disorder ENT2END
0	An 82-year-old man with treatment-resistant depression and early ENT1 Alzheimer's disease  ENT1END was started on ENT2 methylphenidate ENT2END
0	An 82-year-old man with treatment-resistant depression and early ENT1 Alzheimer's disease  ENT1END  was started on methylphenidate. Significant obsessive-compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by ENT2 fluvoxamine ENT2END
0	Two recently available immunosuppressive agents, mycophenolate mofetil and sirolimus ( ENT1 rapamycin ENT1END , have no ENT2 nephrotoxicity ENT2END
1	Calcineurin inhibitors, such as ENT1 cyclosporine ENT1END and tacrolimus, have been available for almost 20 years. Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic ENT2 nephrotoxicity ENT2END
0	Two recently available immunosuppressive agents, ENT1 mycophenolate mofetil  ENT1END and sirolimus (rapamycin), have no ENT2 nephrotoxicity ENT2END
1	Calcineurin inhibitors, such as cyclosporine and ENT1 tacrolimus  ENT1END  have been available for almost 20 years. Although these drugs are highly effective and represent the mainstay of transplant immunosuppression, they are associated with acute and chronic ENT2 nephrotoxicity ENT2END
1	Recurrent acute ENT1 interstitial nephritis  ENT1END  induced by ENT2 azithromycin ENT2END
0	A 14-year-old girl is reported with recurrent, ENT1 azithromycin ENT1END induced, acute interstitial nephritis. The second episode was more severe than the first; and although both were treated with intensive corticosteroid therapy, renal function remained impaired. Although most cases of antibiotic induced acute interstitial nephritis are benign and self-limited, some patients are at risk for permanent ENT2 renal injury ENT2END
0	In contrast, serotonin release from platelets does not provoke migraine, it may even counteract the ENT1 headache ENT1END and the concomitant ENT2 CGRP ENT2END release in this model
0	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate ENT1 headache ENT1END and the delayed genuine migraine attack provoked by ENT2 nitroglycerin ENT2END
0	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, ENT1 5-HT  ENT1END  content during the immediate ENT2 headache ENT2END and the delayed genuine migraine attack provoked by nitroglycerin
0	ENT1 NO  ENT1END -induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate ENT2 headache ENT2END and the delayed genuine migraine attack provoked by nitroglycerin
0	In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between ENT1 CGRP ENT1END and ENT2 migraine ENT2END
0	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine ENT1 migraine  ENT1END attack provoked by ENT2 nitroglycerin ENT2END
0	In conclusion, the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and ENT1 migraine ENT1END . In contrast, ENT2 serotonin ENT2END release from platelets does not provoke migraine, it may even counteract the headache and the concomitant CGRP release in this model
0	ENT1 NO  ENT1END -induced ENT2 migraine ENT2END attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release
0	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide ( ENT1 CGRP ENT1END  concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female ENT2 migraineurs (without aura) ENT2END and eight controls participated in the study
1	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by ENT1 nitroglycerin  ENT1END . Fifteen female ENT2 migraineurs (without aura) ENT2END and eight controls participated in the study
0	The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, ENT1 5-HT  ENT1END ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female ENT2 migraineurs (without aura) ENT2END and eight controls participated in the study
1	ENT1 NO  ENT1END -induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release.The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female ENT2 migraineurs (without aura) ENT2END and eight controls participated in the study
0	Combination of SCH 23390 with sulpiride did not induce ENT1 catalepsy ENT1END potentiation. 3. D-1 agonist ENT2 SKF 38393 ENT2END or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride
1	D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the ENT1 catalepsy ENT1END induced by ENT2 fluphenazine ENT2END , SCH 23390 or sulpiride
1	D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the ENT1 catalepsy ENT1END  induced by fluphenazine, ENT2 SCH 23390 ENT2END or sulpiride
0	The ENT1 catalepsy ENT1END induced by ENT2 dopamine ENT2END antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined
1	Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist ENT1 sulpiride ENT1END induced ENT2 catalepsy ENT2END
0	D-1 agonist SKF 38393 or D-2 agonist ENT1 quinpirole  ENT1END decreased the ENT2 catalepsy ENT2END induced by fluphenazine, SCH 23390 or sulpiride
0	ENT1 Steroid ENT1END treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for ENT2 corticosteroid glaucoma ENT2END and open angle glaucoma
0	CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the ENT1 dexamethasone  ENT1END treated eyes. Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for ENT2 corticosteroid glaucoma ENT2END and open angle glaucoma
0	CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ENT1 ocular hypertension  ENT1END in approximately 30% of the dexamethasone-treated eyes. ENT2 Steroid ENT2END treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma
1	In contrast, the ENT1 dexamethasone ENT1END treated ENT2 hypertensive eyes ENT2END had thickened trabecular beams, decreased intertrabecular spaces, thickened juxtacanalicular tissue, activated trabecular meshwork cells, and increased amounts of amorphogranular extracellular material, especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm
0	ENT1 Steroid ENT1END  treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and ENT2 open angle glaucoma ENT2END
0	CONCLUSION: Dexamethasone treatment of isolated, perfusion-cultured human eyes led to the generation of ocular hypertension in approximately 30% of the ENT1 dexamethasone  ENT1END -treated eyes. Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and ENT2 open angle glaucoma ENT2END
1	The influence of smoking during pregnancy on the developing cochlea has not been estimated, although ENT1 smoking ENT1END has been positively associated with ENT2 hearing loss ENT2END in adults
1	Treated rats were then evaluated for incidence, latency, and seizure pattern or for locomotor activity in animals without ENT1 seizures ENT1END  ENT2 BE ENT2END -Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine
1	Whereas ENT1 cocaine ENT1END induced ENT2 seizures ENT2END were best characterized as brief, generalized, and tonic and resulted in death, those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death
0	Whereas cocaine-induced seizures were best characterized as brief, generalized, and tonic and resulted in ENT1 death ENT1END  those induced by ENT2 BE ENT2END were prolonged, often multiple and mixed in type, and rarely resulted in death
0	Whereas ENT1 cocaine  ENT1END -induced seizures were best characterized as brief, generalized, and tonic and resulted in ENT2 death ENT2END , those induced by BE were prolonged, often multiple and mixed in type, and rarely resulted in death
0	Seizures induced by the cocaine metabolite ENT1 benzoylecgonine ENT1END  in rats.The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and ENT2 strokes ENT2END , can occur hours after exposure
0	The half-life (t1/2) of cocaine is relatively short, but some of the consequences of its use, such as seizures and ENT1 strokes ENT1END , can occur hours after exposure. This led us to hypothesize that a metabolite of ENT2 cocaine ENT2END may be responsible for some of those delayed sequelae
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, ENT1 lupus nephritis ENT1END  Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT2 cocaine ENT2END -related acute renal failure
0	Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute ENT1 interstitial nephritis  ENT1END  and acute tubular necrosis. RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens. These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT2 cocaine ENT2END -related acute renal failure
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT1 cocaine ENT1END -related acute renal failure. Mild PTCR in allografts without TG did not predict renal failure or significant ENT2 proteinuria ENT2END after follow-up periods of between 3 months and 1 year
0	In addition to renal allografts with TG, we also examined grafts with acute rejection, recurrent glomerulonephritis, ENT1 chronic allograft nephropathy  ENT1END and stable grafts ("protocol biopsies"). Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and acute tubular necrosis. RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens. These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT2 cocaine ENT2END -related acute renal failure
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT1 cocaine ENT1END -related acute renal failure. Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year. CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear. PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG. We suggest that repeated endothelial injury, including ENT2 immunologic injury ENT2END , may be the cause of this lesion both in allografts and native kidneys
0	These 13 included cases of malignant hypertension, ENT1 thrombotic microangiopathy  ENT1END  lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT2 cocaine ENT2END -related acute renal failure
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, ENT1 Henoch-Schonlein nephritis  ENT1END  crescentic glomerulonephritis, and ENT2 cocaine ENT2END -related acute renal failure
0	Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy, malignant hypertension, acute interstitial nephritis, and ENT1 acute tubular necrosis  ENT1END  RESULTS: We found PTCR in 14 of 15 cases of TG, in 7 transplant biopsy specimens without TG, and in 13 of 143 native kidney biopsy specimens. These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT2 cocaine ENT2END -related acute renal failure
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT1 cocaine ENT1END -related acute renal failure. Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year. CONCLUSIONS: We conclude that in transplants, there is a strong association between well-developed PTCR and TG, while the significance of mild PTCR and its predictive value in the absence of TG is unclear. PTCR also occurs in certain native kidney diseases, though the association is not as strong as that for TG. We suggest that repeated ENT2 endothelial injury ENT2END , including immunologic injury, may be the cause of this lesion both in allografts and native kidneys
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT1 cocaine ENT1END -related acute renal failure. Mild PTCR in allografts without ENT2 TG ENT2END did not predict renal failure or significant proteinuria after follow-up periods of between 3 months and 1 year
1	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT1 cocaine ENT1END -related ENT2 acute renal failure ENT2END
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic ENT1 glomerulonephritis  ENT1END  and ENT2 cocaine ENT2END -related acute renal failure
0	These 13 included cases of malignant hypertension, thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT1 cocaine ENT1END -related acute renal failure. Mild PTCR in allografts without TG did not predict ENT2 renal failure ENT2END or significant proteinuria after follow-up periods of between 3 months and 1 year
0	These 13 included cases of ENT1 malignant hypertension  ENT1END  thrombotic microangiopathy, lupus nephritis, Henoch-Schonlein nephritis, crescentic glomerulonephritis, and ENT2 cocaine ENT2END -related acute renal failure
1	In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of ENT1 cyclophosphamide ENT1END that causes ENT2 hemorrhagic cystitis ENT2END
0	Of 97 patients who received standard prophylaxis, 4 had symptomatic ENT1 hemorrhagic cystitis ENT1END  In contrast, two of four consecutive patients who received ENT2 mesna ENT2END uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks
1	In an attempt to obviate the inconvenience of bladder irrigation, we conducted a feasibility trial of uroprophylaxis with mesna, which neutralizes the hepatic metabolite of ENT1 cyclophosphamide ENT1END  that causes ENT2 hemorrhagic cystitis ENT2END
0	Of 97 patients who received standard prophylaxis, 4 had symptomatic ENT1 hemorrhagic cystitis  ENT1END  In contrast, two of four consecutive patients who received ENT2 mesna ENT2END uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks
1	ENT1 Chlorpropamide  ENT1END -induced ENT2 optic neuropathy ENT2END
0	A 65-year-old woman with ENT1 adult-onset diabetes ENT1END treated with ENT2 chlorpropamide ENT2END (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy
0	A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of ENT1 chlorpropamide ENT1END therapy. Visual loss occurs in ENT2 diabetics ENT2END for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy
0	A 65-year-old woman with adult-onset diabetes treated with chlorpropamide (Diabenese) had a toxic optic neuropathy that resolved with discontinuation of ENT1 chlorpropamide ENT1END  therapy. ENT2 Visual loss ENT2END occurs in diabetics for a variety of reasons, and accurate diagnosis is necessary to institute appropriate therapy
0	Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood ENT1 cancer  ENT1END . ENT2 Doxorubicin ENT2END is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy
0	To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using ENT1 dobutamine ENT1END infusion to differentiate asymptomatic long-term survivors of childhood ENT2 cancer ENT2END treated with doxorubicin from healthy control subjects
1	ENT1 Doxorubicin ENT1END  is an effective anticancer chemotherapeutic agent known to cause acute and chronic ENT2 cardiomyopathy ENT2END
0	Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic ENT1 cardiomyopathy  ENT1END . To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin, a cohort study was performed using ENT2 dobutamine ENT2END infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects
0	To develop a more sensitive echocardiographic screening test for ENT1 cardiac damage ENT1END due to ENT2 doxorubicin ENT2END , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects
0	To develop a more sensitive echocardiographic screening test for ENT1 cardiac damage  ENT1END  due to doxorubicin, a cohort study was performed using ENT2 dobutamine ENT2END infusion to differentiate asymptomatic long-term survivors of childhood cancer treated with doxorubicin from healthy control subjects
1	In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by ENT1 pilocarpine ENT1END in rats. BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of ENT2 status epilepticus ENT2END (SE)
0	In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of epilepsy induced by ENT1 pilocarpine ENT1END  in rats. BMCs obtained from green fluorescent protein (GFP) transgenic mice or rats were transplanted intravenously after induction of status epilepticus (SE). Spontaneous recurrent seizures (SRS) were monitored using Racine's ENT2 seizure ENT2END severity scale
1	In this study, we investigated the therapeutic potential of bone marrow mononuclear cells (BMCs) in a model of ENT1 epilepsy  ENT1END induced by ENT2 pilocarpine ENT2END in rats
0	Treatment of risperidone-induced hyperprolactinemia with a ENT1 dopamine ENT1END  agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children. Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature. These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth. We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth. METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline. RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) ENT2 bipolar disorder ENT2END or psychoses, with risperidone-induced elevations in serum prolactin levels (57
0	METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with ENT1 cabergoline  ENT1END  RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) ENT2 bipolar disorder ENT2END or psychoses, with risperidone-induced elevations in serum prolactin levels (57
0	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) ENT1 bipolar disorder ENT1END  or psychoses, with ENT2 risperidone ENT2END -induced elevations in serum prolactin levels (57
0	Treatment of risperidone-induced ENT1 hyperprolactinemia  ENT1END  with a ENT2 dopamine ENT2END agonist in children
0	We report the successful treatment of risperidone-induced ENT1 hyperprolactinemia ENT1END with ENT2 cabergoline ENT2END in youth
1	Treatment of ENT1 risperidone  ENT1END -induced ENT2 hyperprolactinemia ENT2END with a dopamine agonist in children
0	Treatment of risperidone-induced hyperprolactinemia with a ENT1 dopamine ENT1END  agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children. Chronically elevated prolactin levels in children with ENT2 prolactinomas ENT2END may be associated with arrested growth and development resulting in either delayed puberty or short stature
0	Chronically elevated prolactin levels in children with ENT1 prolactinomas  ENT1END  may be associated with arrested growth and development resulting in either delayed puberty or short stature. These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth. We report the successful treatment of risperidone-induced hyperprolactinemia with ENT2 cabergoline ENT2END in youth
0	BACKGROUND: ENT1 Risperidone  ENT1END  a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children. Chronically elevated prolactin levels in children with ENT2 prolactinomas ENT2END may be associated with arrested growth and development resulting in either delayed puberty or short stature
0	Treatment of risperidone-induced hyperprolactinemia with a ENT1 dopamine ENT1END  agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children. Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature. These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth. We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth. METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline. RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or ENT2 psychoses ENT2END , with risperidone-induced elevations in serum prolactin levels (57
0	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or ENT1 psychoses ENT1END , with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with ENT2 cabergoline ENT2END (mean dose 2
0	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or ENT1 psychoses  ENT1END , with ENT2 risperidone ENT2END -induced elevations in serum prolactin levels (57
0	Treatment of risperidone-induced hyperprolactinemia with a ENT1 dopamine ENT1END  agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children. Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature. These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth. We report the successful treatment of risperidone-induced hyperprolactinemia with cabergoline in youth. METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with cabergoline. RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of ENT2 Mental Disorders ENT2END (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57
0	METHODS: We undertook a retrospective case review of four children with risperidone-induced hyperprolactinemia treated with ENT1 cabergoline  ENT1END . RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of ENT2 Mental Disorders ENT2END (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57
0	RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of ENT1 Mental Disorders  ENT1END  (fourth edition) bipolar disorder or psychoses, with ENT2 risperidone ENT2END -induced elevations in serum prolactin levels (57
0	Treatment of risperidone-induced hyperprolactinemia with a ENT1 dopamine ENT1END  agonist in children.BACKGROUND: Risperidone, a potent antagonist of both serotonergic (5HT2A) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children. Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either ENT2 delayed puberty ENT2END or short stature
0	Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either ENT1 delayed puberty  ENT1END  or short stature. These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth. We report the successful treatment of risperidone-induced hyperprolactinemia with ENT2 cabergoline ENT2END in youth
0	Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either ENT1 delayed puberty ENT1END  or short stature. These possibilities stress the importance of developing a safe and effective approach to drug-induced hyperprolactinemia in youth. We report the successful treatment of ENT2 risperidone ENT2END -induced hyperprolactinemia with cabergoline in youth
0	Rizatriptan was also superior to ENT1 ergotamine ENT1END caffeine in the proportions of patients with no ENT2 nausea ENT2END , vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
1	The most common adverse events (incidence > or = 5% in one group) after ENT1 rizatriptan ENT1END and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), ENT2 nausea ENT2END (4
0	Rizatriptan was also superior to ergotamine/ ENT1 caffeine  ENT1END in the proportions of patients with no ENT2 nausea ENT2END , vomiting, phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
0	2% of patients who preferred ENT1 ergotamine ENT1END caffeine. The co-primary endpoint of being ENT2 pain ENT2END free at 2 h was also in favor of rizatriptan
0	Rizatriptan is a selective ENT1 5-HT  ENT1END 1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy. Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001). Faster relief of headache was the most important reason for preference, cited by 67.3% of patients preferring rizatriptan and 54.2% of patients who preferred ergotamine/caffeine. The co-primary endpoint of being ENT2 pain ENT2END free at 2 h was also in favor of rizatriptan
0	Almost 36% of patients taking ENT1 rizatriptan ENT1END were ENT2 pain ENT2END free at 2 h and had no recurrence or need for additional medication within 24 h, compared to 20% of patients on ergotamine/caffeine (p < or = 0
0	2% of patients who preferred ergotamine/ ENT1 caffeine  ENT1END  The co-primary endpoint of being ENT2 pain ENT2END free at 2 h was also in favor of rizatriptan
0	Rizatriptan was also superior to ENT1 ergotamine ENT1END /caffeine in the proportions of patients with no nausea, ENT2 vomiting ENT2END , phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
0	ENT1 Rizatriptan  ENT1END was also superior to ergotamine/caffeine in the proportions of patients with no nausea, ENT2 vomiting ENT2END , phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
0	Rizatriptan was also superior to ergotamine/ ENT1 caffeine  ENT1END  in the proportions of patients with no nausea, ENT2 vomiting ENT2END , phonophobia or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
0	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ENT1 ergotamine ENT1END caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and ENT2 somnolence ENT2END (5
0	The most common adverse events (incidence > or = 5% in one group) after ENT1 rizatriptan  ENT1END  and ergotamine/caffeine, respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and ENT2 somnolence ENT2END (5
0	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/ ENT1 caffeine  ENT1END  respectively, were dizziness (6.7 and 5.3%), nausea (4.2 and 8.5%) and ENT2 somnolence ENT2END (5
0	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ENT1 ergotamine  ENT1END /caffeine in ENT2 migraine ENT2END
0	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in ENT1 migraine  ENT1END .Rizatriptan is a selective ENT2 5-HT ENT2END (1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine
0	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in ENT1 migraine  ENT1END . ENT2 Rizatriptan ENT2END is a selective 5-HT(1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine
0	Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/ ENT1 caffeine  ENT1END  in ENT2 migraine ENT2END
0	Rizatriptan was also superior to ENT1 ergotamine ENT1END /caffeine in the proportions of patients with no nausea, vomiting, phonophobia or ENT2 photophobia ENT2END and for patients with normal function 2 h after drug intake (p < or = 0
0	ENT1 Rizatriptan  ENT1END  was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, phonophobia or ENT2 photophobia ENT2END and for patients with normal function 2 h after drug intake (p < or = 0
0	Rizatriptan was also superior to ergotamine/ ENT1 caffeine  ENT1END  in the proportions of patients with no nausea, vomiting, phonophobia or ENT2 photophobia ENT2END and for patients with normal function 2 h after drug intake (p < or = 0
0	ENT1 Headache ENT1END relief at 2 h was 75.9% for rizatriptan and 47.3% for ENT2 ergotamine ENT2END /caffeine (p < or = 0
0	Rizatriptan is a selective ENT1 5-HT ENT1END (1B/1D) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine. This randomized double- blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg/caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy. Of patients expressing a preference (89.1%), more than twice as many preferred rizatriptan to ergotamine/caffeine (69.9 vs. 30.1%, p < or = 0.001). Faster relief of ENT2 headache ENT2END was the most important reason for preference, cited by 67
0	ENT1 Headache ENT1END  relief at 2 h was 75.9% for ENT2 rizatriptan ENT2END and 47
0	1%), more than twice as many preferred rizatriptan to ergotamine/ ENT1 caffeine  ENT1END (69.9 vs. 30.1%, p < or = 0.001). Faster relief of ENT2 headache ENT2END was the most important reason for preference, cited by 67
0	Rizatriptan was also superior to ENT1 ergotamine ENT1END /caffeine in the proportions of patients with no nausea, vomiting, ENT2 phonophobia ENT2END or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
0	ENT1 Rizatriptan  ENT1END  was also superior to ergotamine/caffeine in the proportions of patients with no nausea, vomiting, ENT2 phonophobia ENT2END or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
0	Rizatriptan was also superior to ergotamine/ ENT1 caffeine  ENT1END  in the proportions of patients with no nausea, vomiting, ENT2 phonophobia ENT2END or photophobia and for patients with normal function 2 h after drug intake (p < or = 0
0	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ENT1 ergotamine ENT1END /caffeine, respectively, were ENT2 dizziness ENT2END (6
1	The most common adverse events (incidence > or = 5% in one group) after ENT1 rizatriptan  ENT1END  and ergotamine/caffeine, respectively, were ENT2 dizziness ENT2END (6
0	The most common adverse events (incidence > or = 5% in one group) after rizatriptan and ergotamine/ ENT1 caffeine  ENT1END , respectively, were ENT2 dizziness ENT2END (6
1	Rare serious complications may occur in some patients, including haemorrhagic ENT1 pancreatitis ENT1END  bone marrow suppression, ENT2 VPA ENT2END -induced hepatotoxicity and VPA-induced encephalopathy
0	The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased seizure frequency, with or without ENT1 hyperammonemia ENT1END  There is still no proof of causative effect of ENT2 VPA ENT2END in patients with encephalopathy, but only of an association with an assumed causal relation
1	The typical signs of ENT1 VPA ENT1END induced encephalopathy are ENT2 impaired consciousness ENT2END , sometimes marked EEG background slowing, increased seizure frequency, with or without hyperammonemia
0	The typical signs of VPA-induced encephalopathy are impaired consciousness, sometimes marked EEG background slowing, increased ENT1 seizure  ENT1END frequency, with or without hyperammonemia. There is still no proof of causative effect of ENT2 VPA ENT2END in patients with encephalopathy, but only of an association with an assumed causal relation
1	Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced hepatotoxicity and ENT1 VPA ENT1END induced ENT2 encephalopathy ENT2END
1	Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, ENT1 bone marrow suppression ENT1END ENT2 VPA ENT2END -induced hepatotoxicity and VPA-induced encephalopathy
1	Rare serious complications may occur in some patients, including haemorrhagic pancreatitis, bone marrow suppression, VPA-induced ENT1 hepatotoxicity  ENT1END and ENT2 VPA ENT2END -induced encephalopathy
0	Oral ENT1 diphenhydramine ENT1END and prednisone were ineffective in preventing the recurrence of the ENT2 allergic reaction ENT2END
0	Oral diphenhydramine and ENT1 prednisone  ENT1END were ineffective in preventing the recurrence of the ENT2 allergic reaction ENT2END
0	ENT1 Allergic reaction  ENT1END  to ENT2 5-fluorouracil ENT2END infusion
0	An ENT1 allergic reaction ENT1END consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and ENT2 cisplatin ENT2END -induced impaired renal function
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent ENT1 carcinoma of the oral cavity  ENT1END  cirrhosis, and cisplatin-induced impaired renal function. This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral ENT2 diphenhydramine ENT2END and prednisone were ineffective in preventing the recurrence of the allergic reaction
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent ENT1 carcinoma of the oral cavity  ENT1END , cirrhosis, and cisplatin-induced impaired renal function. This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral diphenhydramine and ENT2 prednisone ENT2END were ineffective in preventing the recurrence of the allergic reaction
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion ENT1 5-fluorouracil  ENT1END occurred in a patient with recurrent ENT2 carcinoma of the oral cavity ENT2END , cirrhosis, and cisplatin-induced impaired renal function
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent ENT1 carcinoma of the oral cavity  ENT1END , cirrhosis, and ENT2 cisplatin ENT2END -induced impaired renal function
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, ENT1 cirrhosis  ENT1END  and cisplatin-induced impaired renal function. This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral ENT2 diphenhydramine ENT2END and prednisone were ineffective in preventing the recurrence of the allergic reaction
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, ENT1 cirrhosis  ENT1END , and cisplatin-induced impaired renal function. This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral diphenhydramine and ENT2 prednisone ENT2END were ineffective in preventing the recurrence of the allergic reaction
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion ENT1 5-fluorouracil  ENT1END  occurred in a patient with recurrent carcinoma of the oral cavity, ENT2 cirrhosis ENT2END , and cisplatin-induced impaired renal function
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, ENT1 cirrhosis  ENT1END , and ENT2 cisplatin ENT2END -induced impaired renal function
0	An allergic reaction consisting of ENT1 angioneurotic edema  ENT1END secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function. This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral ENT2 diphenhydramine ENT2END and prednisone were ineffective in preventing the recurrence of the allergic reaction
0	An allergic reaction consisting of ENT1 angioneurotic edema  ENT1END  secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function. This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral diphenhydramine and ENT2 prednisone ENT2END were ineffective in preventing the recurrence of the allergic reaction
1	An allergic reaction consisting of ENT1 angioneurotic edema  ENT1END  secondary to continuous infusion ENT2 5-fluorouracil ENT2END occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced impaired renal function
0	An allergic reaction consisting of ENT1 angioneurotic edema  ENT1END  secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and ENT2 cisplatin ENT2END -induced impaired renal function
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced ENT1 impaired renal function  ENT1END  This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral ENT2 diphenhydramine ENT2END and prednisone were ineffective in preventing the recurrence of the allergic reaction
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced ENT1 impaired renal function  ENT1END . This reaction occurred during the sixth and seventh courses of infusional chemotherapy. Oral diphenhydramine and ENT2 prednisone ENT2END were ineffective in preventing the recurrence of the allergic reaction
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion ENT1 5-fluorouracil  ENT1END  occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and cisplatin-induced ENT2 impaired renal function ENT2END
0	An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5-fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity, cirrhosis, and ENT1 cisplatin  ENT1END -induced ENT2 impaired renal function ENT2END
0	Pseudo- ENT1 allergic reactions ENT1END  to corticosteroids: diagnosis and alternatives.Two patients treated with parenteral paramethasone (Triniol) and ENT2 dexamethasone ENT2END (Sedionbel) are described
0	To our knowledge, this is the first report of a pseudo- ENT1 allergy ENT1END caused by ENT2 paramethasone ENT2END
0	Pseudo- ENT1 allergic reactions  ENT1END  to ENT2 corticosteroids ENT2END : diagnosis and alternatives
1	Two patients treated with parenteral paramethasone (Triniol) and ENT1 dexamethasone ENT1END  (Sedionbel) are described. A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and ENT2 conjunctivitis ENT2END (patient 1)
1	Two patients treated with parenteral ENT1 paramethasone  ENT1END (Triniol) and dexamethasone (Sedionbel) are described. A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and ENT2 conjunctivitis ENT2END (patient 1)
0	Pseudo-allergic reactions to ENT1 corticosteroids  ENT1END : diagnosis and alternatives.Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described. A few minutes after administration of the drugs, they presented urticaria (patients 1 and 2) and ENT2 conjunctivitis ENT2END (patient 1)
1	Two patients treated with parenteral paramethasone (Triniol) and ENT1 dexamethasone ENT1END  (Sedionbel) are described. A few minutes after administration of the drugs, they presented ENT2 urticaria ENT2END (patients 1 and 2) and conjunctivitis (patient 1)
1	Two patients treated with parenteral ENT1 paramethasone  ENT1END  (Triniol) and dexamethasone (Sedionbel) are described. A few minutes after administration of the drugs, they presented ENT2 urticaria ENT2END (patients 1 and 2) and conjunctivitis (patient 1)
0	Pseudo-allergic reactions to ENT1 corticosteroids  ENT1END : diagnosis and alternatives.Two patients treated with parenteral paramethasone (Triniol) and dexamethasone (Sedionbel) are described. A few minutes after administration of the drugs, they presented ENT2 urticaria ENT2END (patients 1 and 2) and conjunctivitis (patient 1)
1	As a result, switching to tacrolimus has been reported to be a viable therapeutic option in the setting of ENT1 cyclosporine ENT1END induced ENT2 TMA ENT2END
1	With the more widespread application of tacrolimus in organ transplantation, ENT1 tacrolimus ENT1END associated ENT2 TMA ENT2END has also been recognized
1	BMT was used to treat severe ENT1 aplastic anemia ENT1END which was caused by gold in one case and ENT2 D-penicillamine ENT2END in the other
1	BMT was used to treat severe ENT1 aplastic anemia ENT1END  which was caused by ENT2 gold ENT2END in one case and D-penicillamine in the other
0	We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( ENT1 RA  ENT1END  by bone marrow transplantation (BMT) in 2 patients. BMT was used to treat severe aplastic anemia which was caused by gold in one case and ENT2 D-penicillamine ENT2END in the other
0	We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( ENT1 RA  ENT1END ) by bone marrow transplantation (BMT) in 2 patients. BMT was used to treat severe aplastic anemia which was caused by ENT2 gold ENT2END in one case and D-penicillamine in the other
0	BMT was used to treat severe aplastic anemia which was caused by gold in one case and ENT1 D-penicillamine ENT1END  in the other. In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent. Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available. This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive ENT2 synovitis ENT2END
0	BMT was used to treat severe aplastic anemia which was caused by ENT1 gold  ENT1END  in one case and D-penicillamine in the other. In the 8 and 6 years since the transplants (representing 8 and 4 years since cessation of all immunosuppressive therapy, respectively), the RA in each case has been completely quiescent. Although short term remission of severe RA following BMT has been reported, these are the first cases for which prolonged followup has been available. This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive ENT2 synovitis ENT2END
0	CONCLUSION: Pretreatment with ENT1 remifentanil ENT1END 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, ENT2 nausea ENT2END , or pruritus
0	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after ENT1 etomidate  ENT1END induction without side effects such as sedation, apnea, ENT2 nausea ENT2END , or pruritus
0	CONCLUSION: Pretreatment with ENT1 remifentanil ENT1END  1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or ENT2 pruritus ENT2END
0	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, apnea, nausea, or ENT1 pruritus ENT1END . Men experience increased incidence of myoclonus than women after ENT2 etomidate ENT2END administration
0	CONCLUSION: Pretreatment with ENT1 remifentanil ENT1END  1 microg/kg reduced ENT2 myoclonus ENT2END after etomidate induction without side effects such as sedation, apnea, nausea, or pruritus
1	Remifentanil pretreatment reduces ENT1 myoclonus  ENT1END  after ENT2 etomidate ENT2END
0	CONCLUSION: Pretreatment with ENT1 remifentanil ENT1END  1 microg/kg reduced myoclonus after etomidate induction without side effects such as sedation, ENT2 apnea ENT2END , nausea, or pruritus
0	CONCLUSION: Pretreatment with remifentanil 1 microg/kg reduced myoclonus after ENT1 etomidate  ENT1END  induction without side effects such as sedation, ENT2 apnea ENT2END , nausea, or pruritus
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of ENT2 prostaglandin E2 ENT2END -induced hyperalgesia
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia. The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by ENT2 naloxone ENT2END and prevented by co-injection of pertussis toxin
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia  ENT1END .The intradermal injection of mu ( ENT2 morphine ENT2END , Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia. The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin. Morphine did not, however, alter the hyperalgesia induced by 8-bromo cyclic adenosine monophosphate. We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the ENT2 cyclic adenosine monophosphate ENT2END second messenger system
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and ENT2 morphiceptin ENT2END ), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia  ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ( ENT2 [D-Pen2.5]-enkephalin ENT2END and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and ENT2 [D-Ser2]-[Leu]enkephalin-Thr ENT2END ) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia  ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa ( ENT2 trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide ENT2END ) and delta ([D-Pen2
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia ENT1END .The intradermal injection of mu (morphine, ENT2 Tyr-D-Ala-Gly-NMe-Phe-Gly-ol ENT2END and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2
0	Involvement of the mu-opiate receptor in peripheral ENT1 analgesia ENT1END .The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced hyperalgesia. The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by naloxone and prevented by co-injection of pertussis toxin. Morphine did not, however, alter the hyperalgesia induced by ENT2 8-bromo cyclic adenosine monophosphate ENT2END
1	Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of ENT1 prostaglandin E2 ENT1END -induced ENT2 hyperalgesia ENT2END
0	Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced ENT1 hyperalgesia  ENT1END . The analgesic effect of the mu-agonist morphine was dose-dependently antagonized by ENT2 naloxone ENT2END and prevented by co-injection of pertussis toxin
0	ENT1 Morphine ENT1END did not, however, alter the ENT2 hyperalgesia ENT2END induced by 8-bromo cyclic adenosine monophosphate
0	Morphine did not, however, alter the ENT1 hyperalgesia  ENT1END  induced by 8-bromo cyclic adenosine monophosphate. We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu-opioid receptor and that this action is mediated by inhibition of the ENT2 cyclic adenosine monophosphate ENT2END second messenger system
0	The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and ENT1 morphiceptin  ENT1END ), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced ENT2 hyperalgesia ENT2END
0	ENT1 [D-Pen2.5]-enkephalin  ENT1END  and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced ENT2 hyperalgesia ENT2END
0	5]-enkephalin and ENT1 [D-Ser2]-[Leu]enkephalin-Thr  ENT1END ) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced ENT2 hyperalgesia ENT2END
0	The intradermal injection of mu (morphine, Tyr-D-Ala-Gly-NMe-Phe-Gly-ol and morphiceptin), kappa ( ENT1 trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide  ENT1END ) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced ENT2 hyperalgesia ENT2END
0	The intradermal injection of mu (morphine, ENT1 Tyr-D-Ala-Gly-NMe-Phe-Gly-ol  ENT1END  and morphiceptin), kappa (trans-3,4-dichloro-N-methyl-N[2-(1-pyrrolidinyl) cyclohexyl]benzeneactemide) and delta ([D-Pen2.5]-enkephalin and [D-Ser2]-[Leu]enkephalin-Thr) selective opioid-agonists, by themselves, did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat. Intradermal injection of mu, but not delta or kappa opioid-agonists, however, produced dose-dependent inhibition of prostaglandin E2-induced ENT2 hyperalgesia ENT2END
1	Morphine did not, however, alter the ENT1 hyperalgesia  ENT1END  induced by ENT2 8-bromo cyclic adenosine monophosphate ENT2END
1	ENT1 Angioedema  ENT1END  due to ENT2 ACE inhibitors ENT2END : common and inadequately diagnosed
0	AZT has induced a ENT1 macrocytic anemia ENT1END in AIDS patients on long term AZT therapy. It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the ENT2 phosphate ENT2END hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation
1	ENT1 AZT  ENT1END has induced a ENT2 macrocytic anemia ENT2END in AIDS patients on long term AZT therapy
0	AZT has induced a ENT1 macrocytic anemia ENT1END  in AIDS patients on long term AZT therapy. It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of ENT2 thymidine ENT2END thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation
0	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the ENT1 phosphate ENT1END  hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation. CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such ENT2 thrombocytopenia ENT2END showed changes compatible with myelodysplastic syndrome (MDS)
1	5 mg/ml H2O for a group, another group removed from ENT1 AZT  ENT1END to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such ENT2 thrombocytopenia ENT2END showed changes compatible with myelodysplastic syndrome (MDS)
0	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of ENT1 thymidine  ENT1END  thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation. CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such ENT2 thrombocytopenia ENT2END showed changes compatible with myelodysplastic syndrome (MDS)
0	Lifetime treatment of mice with azidothymidine (AZT) produces ENT1 myelodysplasia  ENT1END .AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy. It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the ENT2 phosphate ENT2END hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation
1	Lifetime treatment of mice with azidothymidine (AZT) produces ENT1 myelodysplasia ENT1END ENT2 AZT ENT2END has induced a macrocytic anemia in AIDS patients on long term AZT therapy
0	Lifetime treatment of mice with azidothymidine (AZT) produces ENT1 myelodysplasia  ENT1END .AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy. It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of ENT2 thymidine ENT2END thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation
0	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the ENT1 phosphate ENT1END  hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation. CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS). A variety of histological patterns was observed. There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, ENT2 hemosiderosis ENT2END and a hypocellular marrow
0	There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, ENT1 hemosiderosis ENT1END  and a hypocellular marrow. Above mentioned ENT2 AZT ENT2END incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome
0	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of ENT1 thymidine  ENT1END  thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation. CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS). A variety of histological patterns was observed. There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, ENT2 hemosiderosis ENT2END and a hypocellular marrow
0	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the ENT1 phosphate ENT1END  hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation. CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS). A variety of histological patterns was observed. There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a ENT2 hyperplastic marrow ENT2END , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow
0	There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a hyperplastic marrow, dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a ENT1 hypocellular marrow  ENT1END  Above mentioned ENT2 AZT ENT2END incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells, which is known to be seen commonly in the myelodysplastic syndrome
0	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of ENT1 thymidine  ENT1END  thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation. CBA/Ca male mice started on AZT 0.75 mg/ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0.5 mg/ml H2O for a group, another group removed from AZT to see recovery, and third group remained on 0.75 mg. At 687 days mice that had been on 0.75 mg had average platelet counts of 2.5 x 10(6). Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome (MDS). A variety of histological patterns was observed. There were two cases of hypocellular myelodysplasia, two cases of hypersegmented myelodysplastic granulocytosis, two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei, one case of megakaryocytic myelosis associated with a ENT2 hyperplastic marrow ENT2END , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis, hemosiderosis and a hypocellular marrow
0	AZT has induced a macrocytic anemia in ENT1 AIDS  ENT1END patients on long term AZT therapy. It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the ENT2 phosphate ENT2END hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation
0	AZT has induced a macrocytic anemia in ENT1 AIDS ENT1END  patients on long term ENT2 AZT ENT2END therapy
0	AZT has induced a macrocytic anemia in ENT1 AIDS  ENT1END  patients on long term AZT therapy. It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of ENT2 thymidine ENT2END thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation
1	Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and ENT1 anemia ENT1END thrombocytopenia/emesis/rash (n = 1). All toxicities resolved after ENT2 cis-RA ENT2END was discontinued
1	Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/emesis/ ENT1 rash  ENT1END (n = 1). All toxicities resolved after ENT2 cis-RA ENT2END was discontinued
1	Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/thrombocytopenia/ ENT1 emesis  ENT1END rash (n = 1). All toxicities resolved after ENT2 cis-RA ENT2END was discontinued
1	Dose-limiting toxicities in six of nine patients at 200 mg/m2/d included hypercalcemia (n = 3), rash (n = 2), and anemia/ ENT1 thrombocytopenia  ENT1END emesis/rash (n = 1). All toxicities resolved after ENT2 cis-RA ENT2END was discontinued
0	All ENT1 toxicities  ENT1END resolved after ENT2 cis-RA ENT2END was discontinued
0	Phase I trial of ENT1 13-cis-retinoic acid  ENT1END  in children with ENT2 neuroblastoma ENT2END following bone marrow transplantation
0	Serum levels known to be effective against ENT1 neuroblastoma ENT1END in vitro were achieved at this dose. The DLT included hypercalcemia, and may be predicted by serum cis-RA levels. Monitoring of serum ENT2 calcium ENT2END and cis-RA levels is indicated in future trials
1	The DLT included ENT1 hypercalcemia ENT1END  and may be predicted by serum ENT2 cis-RA ENT2END levels
0	The DLT included ENT1 hypercalcemia  ENT1END , and may be predicted by serum cis-RA levels. Monitoring of serum ENT2 calcium ENT2END and cis-RA levels is indicated in future trials
0	All toxicities resolved after ENT1 cis-RA ENT1END  was discontinued. Three complete responses were observed in marrow ENT2 metastases ENT2END
0	Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during ENT1 amphotercin B ENT1END administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of ENT2 alcohol abuse ENT2END ; alcohol intake as well as withdrawal can also cause seizures
0	The patients concurrent medications included didanosine, ENT1 hydroxyzine  ENT1END  promethazine, hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of ENT2 alcohol abuse ENT2END ; alcohol intake as well as withdrawal can also cause seizures
0	Despite administration of phenytoin and ENT1 lorazepam  ENT1END  the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of ENT2 alcohol abuse ENT2END ; alcohol intake as well as withdrawal can also cause seizures
0	The patient had a history of ENT1 alcohol abuse ENT1END ; ENT2 alcohol ENT2END intake as well as withdrawal can also cause seizures
0	The patient had a history of ENT1 alcohol abuse ENT1END ; alcohol intake as well as withdrawal can also cause seizures. ENT2 Didanosine ENT2END also has a potential for inducing seizures
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, ENT1 hydrocortisone  ENT1END  and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of ENT2 alcohol abuse ENT2END ; alcohol intake as well as withdrawal can also cause seizures
0	Despite administration of ENT1 phenytoin  ENT1END and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of ENT2 alcohol abuse ENT2END ; alcohol intake as well as withdrawal can also cause seizures
0	The patients concurrent medications included didanosine, hydroxyzine, ENT1 promethazine  ENT1END  hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of ENT2 alcohol abuse ENT2END ; alcohol intake as well as withdrawal can also cause seizures
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and ENT1 prochlorperazine  ENT1END  Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of ENT2 alcohol abuse ENT2END ; alcohol intake as well as withdrawal can also cause seizures
1	ENT1 Amphotericin B  ENT1END -induced ENT2 seizures ENT2END in a patient with AIDS
0	The patients concurrent medications included didanosine, ENT1 hydroxyzine ENT1END , promethazine, hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the ENT2 seizures ENT2END persisted and occurred only during amphotercin B administration
0	Despite administration of phenytoin and ENT1 lorazepam  ENT1END , the ENT2 seizures ENT2END persisted and occurred only during amphotercin B administration
0	DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause ENT1 seizures  ENT1END  The patient had a history of alcohol abuse; ENT2 alcohol ENT2END intake as well as withdrawal can also cause seizures
0	The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause ENT1 seizures ENT1END ENT2 Didanosine ENT2END also has a potential for inducing seizures
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, ENT1 hydrocortisone  ENT1END , and prochlorperazine. Despite administration of phenytoin and lorazepam, the ENT2 seizures ENT2END persisted and occurred only during amphotercin B administration
0	Despite administration of ENT1 phenytoin  ENT1END  and lorazepam, the ENT2 seizures ENT2END persisted and occurred only during amphotercin B administration
0	The patients concurrent medications included didanosine, hydroxyzine, ENT1 promethazine  ENT1END , hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the ENT2 seizures ENT2END persisted and occurred only during amphotercin B administration
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and ENT1 prochlorperazine  ENT1END . Despite administration of phenytoin and lorazepam, the ENT2 seizures ENT2END persisted and occurred only during amphotercin B administration
0	Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during ENT1 amphotercin B ENT1END  administration. DISCUSSION: AIDS and ENT2 cryptococcal meningitis ENT2END , both of which the patient had, can potentially cause seizures
0	The patients concurrent medications included didanosine, ENT1 hydroxyzine  ENT1END , promethazine, hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and ENT2 cryptococcal meningitis ENT2END , both of which the patient had, can potentially cause seizures
0	Despite administration of phenytoin and ENT1 lorazepam  ENT1END , the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and ENT2 cryptococcal meningitis ENT2END , both of which the patient had, can potentially cause seizures
0	DISCUSSION: AIDS and ENT1 cryptococcal meningitis  ENT1END , both of which the patient had, can potentially cause seizures. The patient had a history of alcohol abuse; ENT2 alcohol ENT2END intake as well as withdrawal can also cause seizures
0	DISCUSSION: AIDS and ENT1 cryptococcal meningitis  ENT1END , both of which the patient had, can potentially cause seizures. The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures. ENT2 Didanosine ENT2END also has a potential for inducing seizures
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, ENT1 hydrocortisone  ENT1END , and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and ENT2 cryptococcal meningitis ENT2END , both of which the patient had, can potentially cause seizures
0	Despite administration of ENT1 phenytoin  ENT1END  and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and ENT2 cryptococcal meningitis ENT2END , both of which the patient had, can potentially cause seizures
0	The patients concurrent medications included didanosine, hydroxyzine, ENT1 promethazine  ENT1END , hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and ENT2 cryptococcal meningitis ENT2END , both of which the patient had, can potentially cause seizures
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and ENT1 prochlorperazine  ENT1END . Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and ENT2 cryptococcal meningitis ENT2END , both of which the patient had, can potentially cause seizures
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures ENT1END during intravenous infusion of ENT2 amphotericin B ENT2END , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures  ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, ENT2 hydroxyzine ENT2END , promethazine, hydrocortisone, and prochlorperazine
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures  ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine. Despite administration of phenytoin and ENT2 lorazepam ENT2END , the seizures persisted and occurred only during amphotercin B administration
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures  ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: AIDS and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of alcohol abuse; ENT2 alcohol ENT2END intake as well as withdrawal can also cause seizures
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included ENT2 didanosine ENT2END , hydroxyzine, promethazine, hydrocortisone, and prochlorperazine
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures  ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, hydroxyzine, promethazine, ENT2 hydrocortisone ENT2END , and prochlorperazine
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures  ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and prochlorperazine. Despite administration of ENT2 phenytoin ENT2END and lorazepam, the seizures persisted and occurred only during amphotercin B administration
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures  ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, hydroxyzine, ENT2 promethazine ENT2END , hydrocortisone, and prochlorperazine
0	CASE SUMMARY: A 46-year-old African-American man experienced recurrent ENT1 grand mal seizures  ENT1END  during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time. The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and ENT2 prochlorperazine ENT2END
0	OBJECTIVE: To report a case of multiple episodes of seizure activity in an ENT1 AIDS ENT1END patent following ENT2 amphotericin B ENT2END infusion
0	The patients concurrent medications included didanosine, ENT1 hydroxyzine ENT1END , promethazine, hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: ENT2 AIDS ENT2END and cryptococcal meningitis, both of which the patient had, can potentially cause seizures
0	Despite administration of phenytoin and ENT1 lorazepam  ENT1END , the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: ENT2 AIDS ENT2END and cryptococcal meningitis, both of which the patient had, can potentially cause seizures
0	DISCUSSION: ENT1 AIDS  ENT1END  and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of alcohol abuse; ENT2 alcohol ENT2END intake as well as withdrawal can also cause seizures
0	DISCUSSION: ENT1 AIDS  ENT1END  and cryptococcal meningitis, both of which the patient had, can potentially cause seizures. The patient had a history of alcohol abuse; alcohol intake as well as withdrawal can also cause seizures. ENT2 Didanosine ENT2END also has a potential for inducing seizures
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, ENT1 hydrocortisone  ENT1END , and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: ENT2 AIDS ENT2END and cryptococcal meningitis, both of which the patient had, can potentially cause seizures
0	Despite administration of ENT1 phenytoin  ENT1END  and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: ENT2 AIDS ENT2END and cryptococcal meningitis, both of which the patient had, can potentially cause seizures
0	The patients concurrent medications included didanosine, hydroxyzine, ENT1 promethazine  ENT1END , hydrocortisone, and prochlorperazine. Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: ENT2 AIDS ENT2END and cryptococcal meningitis, both of which the patient had, can potentially cause seizures
0	The patients concurrent medications included didanosine, hydroxyzine, promethazine, hydrocortisone, and ENT1 prochlorperazine  ENT1END . Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration. DISCUSSION: ENT2 AIDS ENT2END and cryptococcal meningitis, both of which the patient had, can potentially cause seizures
0	Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor ENT1 tariquidar ENT1END in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB. CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB. Because such a compensatory mechanism most likely occurs to reduce ENT2 injury to the brain ENT2END from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB
0	Experiments with systemic administration of the Pgp substrate ENT1 phenobarbital  ENT1END and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB. CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB. Because such a compensatory mechanism most likely occurs to reduce ENT2 injury to the brain ENT2END from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB
0	A comparable overexpression of Pgp in the BBB was obtained after ENT1 pilocarpine  ENT1END induced seizures in wild-type Wistar rats. Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB. CONCLUSIONS: The data on TR(-) rats indicate that Pgp plays an important role in the compensation of MRP2 deficiency in the BBB. Because such a compensatory mechanism most likely occurs to reduce ENT2 injury to the brain ENT2END from cytotoxic compounds, the present data substantiate the concept that MRP2 performs a protective role in the BBB
0	A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced ENT1 seizures  ENT1END in wild-type Wistar rats. Experiments with systemic administration of the Pgp substrate phenobarbital and the selective Pgp inhibitor ENT2 tariquidar ENT2END in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB
0	A comparable overexpression of Pgp in the BBB was obtained after pilocarpine-induced ENT1 seizures  ENT1END  in wild-type Wistar rats. Experiments with systemic administration of the Pgp substrate ENT2 phenobarbital ENT2END and the selective Pgp inhibitor tariquidar in TR(-) rats substantiated that Pgp is functional and compensates for the lack of MRP2 in the BBB
1	A comparable overexpression of Pgp in the BBB was obtained after ENT1 pilocarpine  ENT1END -induced ENT2 seizures ENT2END in wild-type Wistar rats
0	Upregulation of brain expression of P-glycoprotein in MRP2-deficient TR(-) rats resembles ENT1 seizure ENT1END -induced up-regulation of this drug efflux transporter in normal rats.PURPOSE: The multidrug resistance protein 2 (MRP2) is a drug efflux transporter that is expressed predominantly at the apical domain of hepatocytes but seems also to be expressed at the apical membrane of brain capillary endothelial cells that form the blood-brain barrier (BBB). MRP2 is absent in the transport-deficient (TR(-)) Wistar rat mutant, so that this rat strain was very helpful in defining substrates of MRP2 by comparing tissue concentrations or functional activities of compounds in MRP2-deficient rats with those in transport-competent Wistar rats. By using this strategy to study the involvement of MRP2 in brain access of antiepileptic drugs (AEDs), we recently reported that ENT2 phenytoin ENT2END is a substrate for MRP2 in the BBB
1	ENT1 Ranitidine  ENT1END -induced acute ENT2 interstitial nephritis ENT2END in a cadaveric renal allograft
1	Development of ENT1 apomorphine  ENT1END -induced ENT2 aggressive behavior ENT2END : comparison of adult male and female Wistar rats
1	These results indicate that noradrenergic neurons have an important role in the manifestation of ENT1 catalepsy ENT1END induced by ENT2 THC ENT2END , whereas dopaminergic neurons are important in catalepsy induced by haloperidol
0	On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with ENT1 desipramine  ENT1END and 6-OHDA but not in rats treated with 6-OHDA or in rats with lesions of the locus coeruleus. These results indicate that noradrenergic neurons have an important role in the manifestation of ENT2 catalepsy ENT2END induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol
1	These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC, whereas dopaminergic neurons are important in ENT1 catalepsy ENT1END induced by ENT2 haloperidol ENT2END
0	On the contrary, the cataleptogenic effect of haloperidol was significantly reduced in rats treated with desipramine and 6-OHDA but not in rats treated with ENT1 6-OHDA  ENT1END or in rats with lesions of the locus coeruleus. These results indicate that noradrenergic neurons have an important role in the manifestation of ENT2 catalepsy ENT2END induced by THC, whereas dopaminergic neurons are important in catalepsy induced by haloperidol
0	Three infants, born of two mothers with inflammatory bowel disease who received treatment with ENT1 sulphasalazine ENT1END throughout pregnancy, were found to have major ENT2 congenital anomalies ENT2END
0	Three infants, born of two mothers with inflammatory bowel disease who received treatment with ENT1 sulphasalazine ENT1END  throughout pregnancy, were found to have major congenital anomalies. In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ventricular septal defect. In the twin pregnancy, the mother had ENT2 Crohn's disease ENT2END
1	The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and ENT1 talipes equinovarus ENT1END  Despite reports to the contrary, it is suggested that ENT2 sulphasalazine ENT2END may be teratogenic
0	Three infants, born of two mothers with inflammatory bowel disease who received treatment with ENT1 sulphasalazine ENT1END  throughout pregnancy, were found to have major congenital anomalies. In the singleton pregnancy, the mother had ENT2 ulcerative colitis ENT2END , and the infant, a male, had coarctation of the aorta and a ventricular septal defect
1	The first twin, a female, had a left ENT1 Potter-type IIa polycystic kidney  ENT1END and a rudimentary left uterine cornu. The second twin, a male, had some features of Potter's facies, hypoplastic lungs, absent kidneys and ureters, and talipes equinovarus. Despite reports to the contrary, it is suggested that ENT2 sulphasalazine ENT2END may be teratogenic
0	Three infants, born of two mothers with ENT1 inflammatory bowel disease  ENT1END who received treatment with ENT2 sulphasalazine ENT2END throughout pregnancy, were found to have major congenital anomalies
1	Three infants, born of two mothers with inflammatory bowel disease who received treatment with ENT1 sulphasalazine ENT1END  throughout pregnancy, were found to have major congenital anomalies. In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had coarctation of the aorta and a ENT2 ventricular septal defect ENT2END
1	Three infants, born of two mothers with inflammatory bowel disease who received treatment with ENT1 sulphasalazine ENT1END  throughout pregnancy, were found to have major congenital anomalies. In the singleton pregnancy, the mother had ulcerative colitis, and the infant, a male, had ENT2 coarctation of the aorta ENT2END and a ventricular septal defect
0	DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed ENT1 myeloma ENT1END .A clinical trial was initiated to evaluate the recommended dose of ENT2 cyclophosphamide ENT2END in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma (MM)
0	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( ENT1 MM ENT1END . Thirty patients were treated with three 21-day cycles of ENT2 bortezomib ENT2END 1
0	DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/ ENT1 dexamethasone  ENT1END  for remission induction in patients with newly diagnosed ENT2 myeloma ENT2END
1	The most frequent adverse events were hematological and gastrointestinal toxicities as well as ENT1 neuropathy ENT1END  The results suggest that bortezomib in combination with ENT2 cyclophosphamide ENT2END at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were hematological and gastrointestinal toxicities as well as ENT1 neuropathy ENT1END . The results suggest that ENT2 bortezomib ENT2END in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were hematological and gastrointestinal toxicities as well as ENT1 neuropathy ENT1END . The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and ENT2 dexamethasone ENT2END is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were ENT1 hematological and gastrointestinal toxicities  ENT1END as well as neuropathy. The results suggest that bortezomib in combination with ENT2 cyclophosphamide ENT2END at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were ENT1 hematological and gastrointestinal toxicities  ENT1END  as well as neuropathy. The results suggest that ENT2 bortezomib ENT2END in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were ENT1 hematological and gastrointestinal toxicities  ENT1END  as well as neuropathy. The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and ENT2 dexamethasone ENT2END is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were ENT1 hematological and gastrointestinal toxicities  ENT1END as well as neuropathy. The results suggest that bortezomib in combination with ENT2 cyclophosphamide ENT2END at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were ENT1 hematological and gastrointestinal toxicities  ENT1END  as well as neuropathy. The results suggest that ENT2 bortezomib ENT2END in combination with cyclophosphamide at 900 mg/m(2) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
1	The most frequent adverse events were ENT1 hematological and gastrointestinal toxicities  ENT1END  as well as neuropathy. The results suggest that bortezomib in combination with cyclophosphamide at 900 mg/m(2) and ENT2 dexamethasone ENT2END is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of ENT1 arrhythmic ENT1END rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine. Moreover, M(3)-muscarinic ENT2 acetylcholine ENT2END receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine
1	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism, using both aconitine-induced rat and ENT1 ouabain ENT1END induced guinea pig ENT2 arrhythmia ENT2END models
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of ENT1 arrhythmic  ENT1END  rats and guinea pigs. [ ENT2 Ca ENT2END (2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine
0	The current data showed that ENT1 pilocarpine ENT1END significantly delayed onset of ENT2 arrhythmias ENT2END , decreased the time course of ventricular tachycardia and fibrillation, reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs
0	Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist 4-DAMP ( ENT1 4-diphenylacetoxy-N-methylpiperidine-methiodide ENT1END  partially abolished the beneficial effects of pilocarpine. These data suggest that pilocarpine produced antiarrhythmic actions on ENT2 arrhythmic ENT2END rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M(3)-mAChR
1	These data suggest that pilocarpine produced antiarrhythmic actions on ENT1 arrhythmic ENT1END  rat and guinea pig models induced by ENT2 aconitine ENT2END or ouabain via stimulating the cardiac M(3)-mAChR
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation  ENT1END  reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine. Moreover, M(3)-muscarinic ENT2 acetylcholine ENT2END receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ENT2 ouabain ENT2END was reduced in isolated myocytes pretreated with pilocarpine
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. ENT2 Ca ENT2END (2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine
0	The current data showed that ENT1 pilocarpine  ENT1END  significantly delayed onset of arrhythmias, decreased the time course of ENT2 ventricular tachycardia and fibrillation ENT2END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine. Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist ENT2 4-DAMP ENT2END (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by ENT2 aconitine ENT2END or ouabain was reduced in isolated myocytes pretreated with pilocarpine
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation  ENT1END  reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine. Moreover, M(3)-muscarinic ENT2 acetylcholine ENT2END receptor (mAChR) antagonist 4-DAMP (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation  ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ENT2 ouabain ENT2END was reduced in isolated myocytes pretreated with pilocarpine
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. ENT2 Ca ENT2END (2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine
0	The current data showed that ENT1 pilocarpine  ENT1END  significantly delayed onset of arrhythmias, decreased the time course of ENT2 ventricular tachycardia and fibrillation ENT2END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation  ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine. Moreover, M(3)-muscarinic acetylcholine receptor (mAChR) antagonist ENT2 4-DAMP ENT2END (4-diphenylacetoxy-N-methylpiperidine-methiodide) partially abolished the beneficial effects of pilocarpine
0	The current data showed that pilocarpine significantly delayed onset of arrhythmias, decreased the time course of ENT1 ventricular tachycardia and fibrillation  ENT1END , reduced arrhythmia score, and increased the survival time of arrhythmic rats and guinea pigs. [Ca(2+)](i) overload induced by ENT2 aconitine ENT2END or ouabain was reduced in isolated myocytes pretreated with pilocarpine
0	Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with ENT1 lamivudine ENT1END  monotherapy.Hepatitis B virus (HBV) infection, which causes ENT2 liver cirrhosis ENT2END and hepatocellular carcinoma, remains a major health problem in Asian countries
0	Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with ENT1 lamivudine  ENT1END  monotherapy. ENT2 Hepatitis B virus (HBV) infection ENT2END , which causes liver cirrhosis and hepatocellular carcinoma, remains a major health problem in Asian countries
0	Sustained clinical improvement of a patient with decompensated hepatitis B virus-related cirrhosis after treatment with ENT1 lamivudine ENT1END  monotherapy.Hepatitis B virus (HBV) infection, which causes liver cirrhosis and ENT2 hepatocellular carcinoma ENT2END , remains a major health problem in Asian countries
0	Sustained clinical improvement of a patient with decompensated hepatitis B virus-related ENT1 cirrhosis  ENT1END  after treatment with ENT2 lamivudine ENT2END monotherapy
0	Moreover, both ENT1 hepatitis B surface antigen and e antigen ENT1END were observed to have disappeared in this patient. The administration of lamivudine to patients with HBV-related ENT2 cirrhosis ENT2END , like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available
0	Moreover, both ENT1 hepatitis B surface antigen and e antigen  ENT1END were observed to have disappeared in this patient. The administration of lamivudine to patients with HBV-related ENT2 cirrhosis ENT2END , like our present case, should be considered as an initial medical therapeutic option, especially in countries where liver transplantation is not reliably available
0	Twenty-eight percent of patients showed increased proteinuria to the ENT1 nephrotic ENT1END range. Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis. These patients showed persistently good graft function. Serum creatinine values did not change significantly: 1.98 +/- 0.8 mg/dL before ENT2 SRL ENT2END therapy and 2
0	Twenty-eight percent of patients showed increased proteinuria to the ENT1 nephrotic ENT1END  range. Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and interstitial nephritis. These patients showed persistently good graft function. Serum ENT2 creatinine ENT2END values did not change significantly: 1
0	Biopsies performed in five patients revealed new pathological changes: One ENT1 membranoproliferative glomerulopathy  ENT1END and interstitial nephritis. These patients showed persistently good graft function. Serum creatinine values did not change significantly: 1.98 +/- 0.8 mg/dL before ENT2 SRL ENT2END therapy and 2
0	Biopsies performed in five patients revealed new pathological changes: One ENT1 membranoproliferative glomerulopathy  ENT1END  and interstitial nephritis. These patients showed persistently good graft function. Serum ENT2 creatinine ENT2END values did not change significantly: 1
0	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One ENT1 renal cell carsinom ENT1END  or BK virus nephropathy (n = 2). ENT2 SRL ENT2END was started at a mean of 78 +/- 42 (15 to 163) months after transplantation
1	We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased ENT1 proteinuria ENT1END after ENT2 SRL ENT2END conversion
0	Mean serum ENT1 creatinine ENT1END level before conversion was 2.21 mg/dL and thereafter, 4.93 mg/dL (P = .02). Heavy ENT2 proteinuria ENT2END was common after the use of SRL as rescue therapy for renal transplantation
0	The patient cohort (14 men, 11 women) was treated with ENT1 SRL ENT1END as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) ENT2 neoplasia ENT2END (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2)
0	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One ENT1 intestinal tumors  ENT1END  One renal cell carsinom) or BK virus nephropathy (n = 2). ENT2 SRL ENT2END was started at a mean of 78 +/- 42 (15 to 163) months after transplantation
0	The patient cohort (14 men, 11 women) was treated with ENT1 SRL ENT1END  as conversion therapy, due to ENT2 chronic allograft nephropathy ENT2END (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2)
0	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four ENT1 skin cancers  ENT1END  One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2). ENT2 SRL ENT2END was started at a mean of 78 +/- 42 (15 to 163) months after transplantation
0	The patient cohort (14 men, 11 women) was treated with SRL as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); Kaposi's sarcoma, Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus ENT1 nephropathy  ENT1END (n = 2). ENT2 SRL ENT2END was started at a mean of 78 +/- 42 (15 to 163) months after transplantation
0	Five patients displayed ENT1 CAN  ENT1END and Kaposi's sarcoma. Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01). Mean serum ENT2 creatinine ENT2END level before conversion was 2
0	The patient cohort (14 men, 11 women) was treated with ENT1 SRL ENT1END  as conversion therapy, due to chronic allograft nephropathy (CAN) (n = 15) neoplasia (n = 8); ENT2 Kaposi's sarcoma ENT2END , Four skin cancers, One intestinal tumors, One renal cell carsinom) or BK virus nephropathy (n = 2)
0	Five patients displayed CAN and ENT1 Kaposi's sarcoma  ENT1END  Mean urinary protein of patients who returned to dialysis was 1.26 (0.5 to 3.5) g/d before and 4.7 (3 to 12) g/d after conversion (P = .01). Mean serum ENT2 creatinine ENT2END level before conversion was 2
0	Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and ENT1 interstitial nephritis  ENT1END  These patients showed persistently good graft function. Serum creatinine values did not change significantly: 1.98 +/- 0.8 mg/dL before ENT2 SRL ENT2END therapy and 2
0	Biopsies performed in five patients revealed new pathological changes: One membranoproliferative glomerulopathy and ENT1 interstitial nephritis  ENT1END . These patients showed persistently good graft function. Serum ENT2 creatinine ENT2END values did not change significantly: 1
0	Value of ENT1 methylprednisolone  ENT1END  in prevention of the ENT2 arthralgia ENT2END -myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial
1	The safety and efficacy of total dose infusion (TDI) of ENT1 iron dextran ENT1END has been well documented. In 40% of treated patients, an ENT2 arthralgia ENT2END -myalgia syndrome develops
0	Value of ENT1 methylprednisolone  ENT1END  in prevention of the arthralgia ENT2 myalgia ENT2END syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial
0	Value of methylprednisolone in prevention of the arthralgia- ENT1 myalgia  ENT1END  syndrome associated with the total dose infusion of ENT2 iron dextran ENT2END : a double blind randomized trial
0	The concentrations of dopamine (DA), ENT1 serotonin ENT1END and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity. The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats. These changes were significantly attenuated by alpha-TC and DFO. This suggests that alpha-TC and DFO ameliorate the MA-induced ENT2 neuronal damage ENT2END by decreasing the level of oxidative stress
1	This suggests that alpha-TC and DFO ameliorate the ENT1 MA  ENT1END induced ENT2 neuronal damage ENT2END by decreasing the level of oxidative stress
0	This suggests that alpha-TC and ENT1 DFO  ENT1END ameliorate the MA-induced ENT2 neuronal damage ENT2END by decreasing the level of oxidative stress
0	The concentrations of dopamine ( ENT1 DA  ENT1END , serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity. The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA-treated rats. These changes were significantly attenuated by alpha-TC and DFO. This suggests that alpha-TC and DFO ameliorate the MA-induced ENT2 neuronal damage ENT2END by decreasing the level of oxidative stress
0	The level of lipid peroxidation was higher and the reduced ENT1 glutathione  ENT1END concentration was lower in the MA-treated rats. These changes were significantly attenuated by alpha-TC and DFO. This suggests that alpha-TC and DFO ameliorate the MA-induced ENT2 neuronal damage ENT2END by decreasing the level of oxidative stress
0	This suggests that ENT1 alpha-TC  ENT1END and DFO ameliorate the MA-induced ENT2 neuronal damage ENT2END by decreasing the level of oxidative stress
0	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an ENT1 iron ENT1END chelator, on the MA-induced neurotoxicity. Male rats were treated with MA (10 mg/kg, every 2 h for four injections). The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration. The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced ENT2 hyperthermia ENT2END as well as the alterations in the locomotor activity
0	The concentrations of dopamine (DA), ENT1 serotonin  ENT1END  and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced ENT2 hyperthermia ENT2END as well as the alterations in the locomotor activity
1	alpha-TC and DFO attenuated the ENT1 MA  ENT1END induced ENT2 hyperthermia ENT2END as well as the alterations in the locomotor activity
0	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive ENT1 oxygen  ENT1END species, and deferoxamine (DFO), an iron chelator, on the MA-induced neurotoxicity. Male rats were treated with MA (10 mg/kg, every 2 h for four injections). The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration. The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced ENT2 hyperthermia ENT2END as well as the alterations in the locomotor activity
0	alpha-TC and ENT1 DFO  ENT1END attenuated the MA-induced ENT2 hyperthermia ENT2END as well as the alterations in the locomotor activity
0	The concentrations of dopamine ( ENT1 DA  ENT1END ), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced ENT2 hyperthermia ENT2END as well as the alterations in the locomotor activity
0	alpha-TC and DFO attenuated the MA-induced ENT1 hyperthermia  ENT1END  as well as the alterations in the locomotor activity. The level of lipid peroxidation was higher and the reduced ENT2 glutathione ENT2END concentration was lower in the MA-treated rats
0	ENT1 alpha-TC  ENT1END and DFO attenuated the MA-induced ENT2 hyperthermia ENT2END as well as the alterations in the locomotor activity
0	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an ENT1 iron ENT1END  chelator, on the MA-induced ENT2 neurotoxicity ENT2END
0	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced ENT1 neurotoxicity  ENT1END . Male rats were treated with MA (10 mg/kg, every 2 h for four injections). The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration. The concentrations of dopamine (DA), ENT2 serotonin ENT2END and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment
0	Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced ENT1 neurotoxicity  ENT1END . ENT2 Methamphetamine ENT2END (MA)-induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals
0	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive ENT1 oxygen  ENT1END  species, and deferoxamine (DFO), an iron chelator, on the MA-induced ENT2 neurotoxicity ENT2END
0	Effect of alpha-tocopherol and ENT1 deferoxamine  ENT1END  on methamphetamine-induced ENT2 neurotoxicity ENT2END
0	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced ENT1 neurotoxicity ENT1END . Male rats were treated with MA (10 mg/kg, every 2 h for four injections). The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration. The concentrations of ENT2 dopamine ENT2END (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment
0	This study examined the effect of alpha-tocopherol (alpha-TC), a scavenger of reactive oxygen species, and deferoxamine (DFO), an iron chelator, on the MA-induced ENT1 neurotoxicity  ENT1END . Male rats were treated with MA (10 mg/kg, every 2 h for four injections). The rat received either alpha-TC (20 mg/kg) intraperitoneally for 3 days and 30 min prior to MA administration or DFO (50 mg/kg) subcutaneously 30 min before MA administration. The concentrations of dopamine (DA), serotonin and their metabolites decreased significantly after MA administration, which was inhibited by the alpha-TC and DFO pretreatment. alpha-TC and DFO attenuated the MA-induced hyperthermia as well as the alterations in the locomotor activity. The level of lipid peroxidation was higher and the reduced ENT2 glutathione ENT2END concentration was lower in the MA-treated rats
0	Effect of ENT1 alpha-tocopherol  ENT1END  and deferoxamine on methamphetamine-induced ENT2 neurotoxicity ENT2END
0	Ketoprofen but not ENT1 acetaminophen ENT1END impaired platelet function in patients with SAH. If ketoprofen is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for ENT2 hemorrhage ENT2END
0	If ENT1 ketoprofen  ENT1END is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for ENT2 hemorrhage ENT2END
0	In contrast, maximal platelet aggregation increased in the ENT1 acetaminophen ENT1END group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05). One patient in the ketoprofen group developed a postoperative intracranial ENT2 hematoma ENT2END
1	One patient in the ENT1 ketoprofen  ENT1END group developed a postoperative intracranial ENT2 hematoma ENT2END
0	Maximal platelet aggregation induced by 6 microM of ENT1 adenosine diphosphate  ENT1END decreased after administration of ketoprofen. Aggregation was lower (P < .05) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day. In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results (P < .05). One patient in the ketoprofen group developed a postoperative intracranial ENT2 hematoma ENT2END
0	Ketoprofen but not ENT1 acetaminophen ENT1END  impaired platelet function in patients with SAH. If ketoprofen is used before surgery on cerebral ENT2 artery aneurysms ENT2END , it may pose an additional risk factor for hemorrhage
0	If ENT1 ketoprofen  ENT1END  is used before surgery on cerebral ENT2 artery aneurysms ENT2END , it may pose an additional risk factor for hemorrhage
0	Ketoprofen but not ENT1 acetaminophen ENT1END  impaired platelet function in patients with ENT2 SAH ENT2END
0	Ketoprofen but not acetaminophen impaired platelet function in patients with ENT1 SAH  ENT1END . If ENT2 ketoprofen ENT2END is used before surgery on cerebral artery aneurysms, it may pose an additional risk factor for hemorrhage
0	Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of aneurysmal ENT1 SAH  ENT1END  Treatment was continued for 3 days postoperatively. Test blood samples were taken before treatment and surgery as well as on the first, third, and fifth postoperative mornings. Maximal platelet aggregation induced by 6 microM of ENT2 adenosine diphosphate ENT2END decreased after administration of ketoprofen
0	Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day ( ENT1 acetaminophen ENT1END group, n = 9) starting immediately after the diagnosis of ENT2 aneurysmal ENT2END SAH
0	Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day ( ENT1 ketoprofen  ENT1END group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of ENT2 aneurysmal ENT2END SAH
0	Patients with aneurysmal subarachnoid hemorrhage (SAH) were randomized to receive either ketoprofen, 100 mg, three times a day (ketoprofen group, n = 9) or a weak NSAID, acetaminophen, 1 g, three times a day (acetaminophen group, n = 9) starting immediately after the diagnosis of ENT1 aneurysmal  ENT1END  SAH. Treatment was continued for 3 days postoperatively. Test blood samples were taken before treatment and surgery as well as on the first, third, and fifth postoperative mornings. Maximal platelet aggregation induced by 6 microM of ENT2 adenosine diphosphate ENT2END decreased after administration of ketoprofen
0	In contrast, maximal ENT1 platelet aggregation  ENT1END increased in the ENT2 acetaminophen ENT2END group on the third postoperative day as compared with the pretreatment platelet aggregation results (P <
1	In contrast, maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment ENT1 platelet aggregation  ENT1END results (P < .05). One patient in the ENT2 ketoprofen ENT2END group developed a postoperative intracranial hematoma
0	Maximal ENT1 platelet aggregation  ENT1END induced by 6 microM of ENT2 adenosine diphosphate ENT2END decreased after administration of ketoprofen
0	Women who had endometrial cancer and had received ENT1 tamoxifen ENT1END had more ENT2 advanced disease ENT2END and poorer prognosis than those with endometrial cancer who had not received this treatment
1	We have investigated the association between ENT1 endometrial cancer ENT1END and ENT2 tamoxifen ENT2END use or other treatments in women treated for breast cancer in a case-control study
0	Women who receive ENT1 tamoxifen ENT1END for ENT2 breast cancer ENT2END should be offered gynaecological surveillance during and after treatment
1	Furthermore, transient ENT1 hemoglobinuria ENT1END was noted approximately 60 minutes postinjection of ENT2 WR242511 ENT2END (3
0	Using this rationale, the ENT1 8-aminoquinoline  ENT1END WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment. METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg. Health status and MHb levels were monitored following exposure. RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey. Furthermore, transient ENT2 hemoglobinuria ENT2END was noted approximately 60 minutes postinjection of WR242511 (3
0	It is concluded that ENT1 WR242511 ENT1END should not be pursued as a pretreatment for CN ENT2 poisoning ENT2END unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity
0	Although MHb formers are generally applied as treatments for CN ENT1 poisoning  ENT1END  it has been proposed that a stable, long-acting MHb former could serve as a CN pretreatment. Using this rationale, the ENT2 8-aminoquinoline ENT2END WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment
0	CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced ENT1 toxicity  ENT1END  It is concluded that ENT2 WR242511 ENT2END should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity
0	ENT1 Toxicity  ENT1END  in rhesus monkeys following administration of the ENT2 8-aminoquinoline ENT2END 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511)
0	RESULTS: The selected doses of ENT1 WR242511 ENT1END  which produced significant ENT2 methemoglobinemia ENT2END in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2
0	Using this rationale, the ENT1 8-aminoquinoline  ENT1END  WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment. METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg. Health status and MHb levels were monitored following exposure. RESULTS: The selected doses of WR242511, which produced significant ENT2 methemoglobinemia ENT2END in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2
1	Histopathology analyses in the 2 animals that died revealed ENT1 liver and kidney toxicity  ENT1END  with greater severity in the orally-treated animal. CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity. It is concluded that ENT2 WR242511 ENT2END should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity
1	Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of ENT1 WR242511 ENT1END  (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose. ENT2 Myoglobinuria ENT2END was also observed following the 7
0	Using this rationale, the ENT1 8-aminoquinoline  ENT1END  WR242511, a potent long-lasting MHb former in rodents and beagle dogs, was studied in the rhesus monkey for advanced development as a potential CN pretreatment. METHODS: In this study, WR242511 was administered intravenously (IV) in 2 female and 4 male rhesus monkeys in doses of 3.5 and/or 7.0 mg/kg; a single male also received WR242511 orally (PO) at 7.0 mg/kg. Health status and MHb levels were monitored following exposure. RESULTS: The selected doses of WR242511, which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere, produced very little MHb (mean < 2.0%) in the rhesus monkey. Furthermore, transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 (3.5 or 7.0 mg/kg), and 2 lethalities occurred (one IV and one PO) following the 7.0 mg/kg dose. ENT2 Myoglobinuria ENT2END was also observed following the 7
1	Histopathology analyses in the 2 animals that died revealed ENT1 liver and kidney toxicity  ENT1END  with greater severity in the orally-treated animal. CONCLUSIONS: These data demonstrate direct and/or indirect drug-induced toxicity. It is concluded that ENT2 WR242511 ENT2END should not be pursued as a pretreatment for CN poisoning unless the anti-CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity
0	These results suggested that ENT1 ammonia ENT1END blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol. The data suggest that ENT2 hyperammonemia ENT2END exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics
0	) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by ENT1 diazepam ENT1END  but NH4Ac treatment alone had no effect. Thus, ENT2 hyperammonemia ENT2END is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease
0	) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized ENT1 amphetamine  ENT1END induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol. The data suggest that ENT2 hyperammonemia ENT2END exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics
0	Modification of drug action by ENT1 hyperammonemia ENT1END .Pretreatment with ENT2 ammonium acetate ENT2END (NH4Ac) (6 mmol/kg s
0	Modification of drug action by ENT1 hyperammonemia ENT1END .Pretreatment with ammonium acetate (NH4Ac) (6 mmol/kg s.c.) approximately doubled the time ENT2 morphine ENT2END -treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect
0	) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of ENT1 metrazol  ENT1END  The data suggest that ENT2 hyperammonemia ENT2END exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics
0	The data suggest that ENT1 hyperammonemia ENT1END  exerts a ENT2 calcium ENT2END channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics
0	) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither ENT1 verapamil  ENT1END nor NH4Ac affected the convulsant action of metrazol. The data suggest that ENT2 hyperammonemia ENT2END exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics
0	Thus, ENT1 hyperammonemia ENT1END  is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease. Experiments in vitro showed that ENT2 acetylcholine ENT2END -induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0
0	Thus, ENT1 hyperammonemia ENT1END  is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease. Experiments in vitro showed that acetylcholine-induced ENT2 catecholamine ENT2END release from bovine adrenal medulla is depressed as much as 50% by 0
0	Thus, ENT1 hyperammonemia ENT1END  is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease. Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and ENT2 KCl ENT2END -induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac
0	Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by ENT1 acetaldehyde  ENT1END was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol. The data suggest that ENT2 hyperammonemia ENT2END exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics
0	These results suggested that ENT1 ammonia ENT1END  blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular ENT2 incoordination ENT2END and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
1	) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular ENT1 incoordination  ENT1END by ENT2 diazepam ENT2END , but NH4Ac treatment alone had no effect
0	) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular ENT1 incoordination  ENT1END  and antagonized ENT2 amphetamine ENT2END -induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
1	) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular ENT1 incoordination ENT1END  by diazepam, but ENT2 NH4Ac ENT2END treatment alone had no effect
0	) and NH4Ac pretreatment enhanced ENT1 morphine  ENT1END analgesia- and diazepam-induced muscular ENT2 incoordination ENT2END and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular ENT1 incoordination  ENT1END  and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of ENT2 metrazol ENT2END
0	Parallels in the actions of NH4Ac and the ENT1 calcium  ENT1END channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular ENT2 incoordination ENT2END and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular ENT1 incoordination  ENT1END  and antagonized amphetamine-induced motor activity, and neither ENT2 verapamil ENT2END nor NH4Ac affected the convulsant action of metrazol
0	) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular ENT1 incoordination  ENT1END  by diazepam, but NH4Ac treatment alone had no effect. Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease. Experiments in vitro showed that ENT2 acetylcholine ENT2END -induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0
0	) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular ENT1 incoordination  ENT1END  by diazepam, but NH4Ac treatment alone had no effect. Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease. Experiments in vitro showed that acetylcholine-induced ENT2 catecholamine ENT2END release from bovine adrenal medulla is depressed as much as 50% by 0
0	) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular ENT1 incoordination  ENT1END  by diazepam, but NH4Ac treatment alone had no effect. Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease. Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and ENT2 KCl ENT2END -induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac
0	Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by ENT1 acetaldehyde  ENT1END  was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular ENT2 incoordination ENT2END and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Addition of excess calcium reversed the ENT1 depression  ENT1END in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ENT2 ammonia ENT2END blocks calcium channels
0	Addition of excess calcium reversed the ENT1 depression ENT1END  in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and ENT2 diazepam ENT2END -induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Addition of excess calcium reversed the ENT1 depression  ENT1END  in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized ENT2 amphetamine ENT2END -induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM ENT1 NH4Ac  ENT1END  Addition of excess calcium reversed the ENT2 depression ENT2END in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac
0	Addition of excess calcium reversed the ENT1 depression  ENT1END  in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced ENT2 morphine ENT2END analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Addition of excess calcium reversed the ENT1 depression  ENT1END  in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of ENT2 metrazol ENT2END
0	Addition of excess ENT1 calcium  ENT1END reversed the ENT2 depression ENT2END in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac
0	Addition of excess calcium reversed the ENT1 depression ENT1END  in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker ENT2 verapamil ENT2END support this concept
0	Experiments in vitro showed that ENT1 acetylcholine  ENT1END -induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the ENT2 depression ENT2END in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac
0	Addition of excess calcium reversed the ENT1 depression ENT1END  in both tissues, but calcium-independent ENT2 catecholamine ENT2END release by acetaldehyde was not blocked by NH4Ac
0	3 mM NH4Ac and ENT1 KCl  ENT1END -induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the ENT2 depression ENT2END in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac
0	Addition of excess calcium reversed the ENT1 depression  ENT1END  in both tissues, but calcium-independent catecholamine release by ENT2 acetaldehyde ENT2END was not blocked by NH4Ac
0	These results suggested that ENT1 ammonia ENT1END  blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	) and NH4Ac pretreatment enhanced morphine ENT1 analgesia  ENT1END - and ENT2 diazepam ENT2END -induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	) and NH4Ac pretreatment enhanced morphine ENT1 analgesia  ENT1END - and diazepam-induced muscular incoordination and antagonized ENT2 amphetamine ENT2END -induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	) and ENT1 NH4Ac  ENT1END pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	) and NH4Ac pretreatment enhanced ENT1 morphine ENT1END ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	) and NH4Ac pretreatment enhanced morphine ENT1 analgesia  ENT1END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of ENT2 metrazol ENT2END
0	Parallels in the actions of NH4Ac and the ENT1 calcium  ENT1END  channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Both ENT1 verapamil  ENT1END (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Experiments in vitro showed that ENT1 acetylcholine  ENT1END -induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Addition of excess calcium reversed the depression in both tissues, but calcium-independent ENT1 catecholamine  ENT1END  release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	3 mM NH4Ac and ENT1 KCl  ENT1END -induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by ENT1 acetaldehyde  ENT1END  was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine ENT2 analgesia ENT2END - and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END  Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ENT2 ammonia ENT2END blocks calcium channels
0	) approximately doubled the time morphine-treated mice remained on a hot surface and similarly increased muscular incoordination by ENT1 diazepam  ENT1END , but NH4Ac treatment alone had no effect. Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT2 liver disease ENT2END
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized ENT2 amphetamine ENT2END -induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of metrazol
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease ENT1END . Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM ENT2 NH4Ac ENT2END and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac
0	) approximately doubled the time ENT1 morphine  ENT1END -treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam, but NH4Ac treatment alone had no effect. Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT2 liver disease ENT2END
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept. Both verapamil (10 mg/kg i.p.) and NH4Ac pretreatment enhanced morphine analgesia- and diazepam-induced muscular incoordination and antagonized amphetamine-induced motor activity, and neither verapamil nor NH4Ac affected the convulsant action of ENT2 metrazol ENT2END
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess ENT2 calcium ENT2END reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by acetaldehyde was not blocked by NH4Ac. These results suggested that ammonia blocks calcium channels. Parallels in the actions of NH4Ac and the calcium channel blocker ENT2 verapamil ENT2END support this concept
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that ENT2 acetylcholine ENT2END -induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that acetylcholine-induced ENT2 catecholamine ENT2END release from bovine adrenal medulla is depressed as much as 50% by 0
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and ENT2 KCl ENT2END -induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac
0	Thus, hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with ENT1 liver disease  ENT1END . Experiments in vitro showed that acetylcholine-induced catecholamine release from bovine adrenal medulla is depressed as much as 50% by 0.3 mM NH4Ac and KCl-induced contractions of guinea-pig ileum were inhibited 20% by 5 mM NH4Ac. Addition of excess calcium reversed the depression in both tissues, but calcium-independent catecholamine release by ENT2 acetaldehyde ENT2END was not blocked by NH4Ac
0	The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral bradykinesia, and ENT1 rigidity ENT1END were sustained in the 11 patients examined at two years. The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months. Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery. The complications of surgery were generally well tolerated, and there were no significant changes in the use of medication. CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces ENT2 levodopa ENT2END -induced dyskinesias and off-period disability
0	CONCLUSIONS: In late-stage ENT1 Parkinson's disease  ENT1END  pallidotomy significantly reduces ENT2 levodopa ENT2END -induced dyskinesias and off-period disability
1	CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces ENT1 levodopa ENT1END -induced ENT2 dyskinesias ENT2END and off-period disability
0	The improvements in dyskinesias and the total scores for off-period parkinsonism, contralateral ENT1 bradykinesia  ENT1END  and rigidity were sustained in the 11 patients examined at two years. The improvement in ipsilateral dyskinesias was lost after one year, and the improvements in postural stability and gait lasted only three to six months. Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery. The complications of surgery were generally well tolerated, and there were no significant changes in the use of medication. CONCLUSIONS: In late-stage Parkinson's disease, pallidotomy significantly reduces ENT2 levodopa ENT2END -induced dyskinesias and off-period disability
1	ENT1 Prostaglandin E2  ENT1END -induced ENT2 bladder hyperactivity ENT2END in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure
0	Prostanoids may, via release of ENT1 tachykinins ENT1END  contribute to both urge and ENT2 bladder hyperactivity ENT2END seen in inflammatory conditions of the lower urinary tract
0	Prostaglandin E2-induced ENT1 bladder hyperactivity ENT1END  in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure. The effect was attenuated by both the NK1 receptor selective antagonist ENT2 RP 67,580 ENT2END and the NK2 receptor selective antagonist SR 48,968, given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors
0	Prostaglandin E2-induced ENT1 bladder hyperactivity ENT1END  in normal, conscious rats: involvement of tachykinins?In normal conscious rats investigated by continuous cystometry, intravesically instilled prostaglandin (PG) E2 facilitated micturition and increased basal intravesical pressure. The effect was attenuated by both the NK1 receptor selective antagonist RP 67,580 and the NK2 receptor selective antagonist ENT2 SR 48,968 ENT2END , given intra-arterially, suggesting that it was mediated by stimulation of both NK1 and NK2 receptors
0	ENT1 Prostanoids  ENT1END may, via release of tachykinins, contribute to both urge and ENT2 bladder hyperactivity ENT2END seen in inflammatory conditions of the lower urinary tract
0	Design and analysis of the HYPREN-trial: safety of ENT1 enalapril  ENT1END  and prazosin in the initial treatment phase of patients with ENT2 congestive heart failure ENT2END
0	Design and analysis of the HYPREN-trial: safety of enalapril and ENT1 prazosin  ENT1END  in the initial treatment phase of patients with ENT2 congestive heart failure ENT2END
0	Design and analysis of the HYPREN-trial: safety of enalapril and prazosin in the initial treatment phase of patients with ENT1 congestive heart failure ENT1END .Since the introduction of ENT2 angiotensin converting enzyme (ACE) inhibitors ENT2END into the adjunctive treatment of patients with congestive heart failure, cases of severe hypotension, especially on the first day of treatment, have occasionally been reported
0	To assess the safety of the ACE inhibitor enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic ENT1 hypotension ENT1END on the first day of treatment. Trial medication was 2.5 mg ENT2 enalapril ENT2END or 0
1	Patients who received enalapril experienced clinically and statistically significantly less symptomatic ENT1 hypotension ENT1END (5.2%) than the patients who received ENT2 prazosin ENT2END (12
1	Since the introduction of angiotensin converting enzyme (ACE) inhibitors into the adjunctive treatment of patients with congestive heart failure, cases of severe ENT1 hypotension ENT1END  especially on the first day of treatment, have occasionally been reported. To assess the safety of the ENT2 ACE inhibitor ENT2END enalapril a multicenter, randomized, prazosin-controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment
0	Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent ENT1 thrombosis ENT1END or vessel rupture. We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a ENT2 paclitaxel ENT2END -eluting stent
1	ENT1 Coronary aneurysm  ENT1END  after implantation of a ENT2 paclitaxel ENT2END -eluting stent
0	We present a 43-year-old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a ENT1 paclitaxel ENT1END -eluting stent. The patient was asymptomatic and the ENT2 aneurysm ENT2END was detected in a routine control
0	Cocaine causes ENT1 memory and learning impairments ENT1END  in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood. Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms. Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats. NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as ENT2 GSH ENT2END concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased
0	Cocaine causes ENT1 memory and learning impairments  ENT1END  in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by ENT2 topiramate ENT2END
1	ENT1 Cocaine  ENT1END  causes ENT2 memory and learning impairments ENT2END in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate
0	Cocaine causes ENT1 memory and learning impairments ENT1END  in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood. Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms. Therefore NFkappaB activity, oxidative stress, neuronal ENT2 nitric oxide ENT2END synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats
0	Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug ENT1 toxicity  ENT1END and addiction mechanisms. Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats. NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as ENT2 GSH ENT2END concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased
0	Cocaine causes memory and learning impairments in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by ENT1 topiramate ENT1END .Different mechanisms have been suggested for cocaine ENT2 toxicity ENT2END including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood
0	Different mechanisms have been suggested for ENT1 cocaine ENT1END ENT2 toxicity ENT2END including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood
0	Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug ENT1 toxicity  ENT1END  and addiction mechanisms. Therefore NFkappaB activity, oxidative stress, neuronal ENT2 nitric oxide ENT2END synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats
0	Cocaine causes ENT1 memory and learning impairments  ENT1END  in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood. Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms. Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats. NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as ENT2 GSH ENT2END concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased
0	Cocaine causes ENT1 memory and learning impairments  ENT1END  in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by ENT2 topiramate ENT2END
1	ENT1 Cocaine  ENT1END  causes ENT2 memory and learning impairments ENT2END in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate
0	Cocaine causes ENT1 memory and learning impairments  ENT1END  in rats: involvement of nuclear factor kappa B and oxidative stress, and prevention by topiramate.Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced-behaviour is poorly understood. Nuclear factor kappa B (NFkappaB) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms. Therefore NFkappaB activity, oxidative stress, neuronal ENT2 nitric oxide ENT2END synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for cocaine addiction, were evaluated in an experimental model of cocaine administration in rats
0	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for ENT1 cocaine addiction  ENT1END  were evaluated in an experimental model of cocaine administration in rats. NFkappaB activity was decreased in the frontal cortex of cocaine treated rats, as well as ENT2 GSH ENT2END concentration and glutathione peroxidase activity in the hippocampus, whereas nNOS activity in the hippocampus was increased
0	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of ENT1 topiramate  ENT1END  a previously proposed therapy for ENT2 cocaine addiction ENT2END , were evaluated in an experimental model of cocaine administration in rats
0	Therefore NFkappaB activity, oxidative stress, neuronal nitric oxide synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for ENT1 cocaine addiction ENT1END , were evaluated in an experimental model of ENT2 cocaine ENT2END administration in rats
0	Therefore NFkappaB activity, oxidative stress, neuronal ENT1 nitric oxide  ENT1END  synthase (nNOS) activity, spatial learning and memory as well as the effect of topiramate, a previously proposed therapy for ENT2 cocaine addiction ENT2END , were evaluated in an experimental model of cocaine administration in rats
0	CaCl2 and ENT1 4-aminopyridine ENT1END failed to improve blood pressure. The incidence of ENT2 ventricular arrhythmias ENT2END (p = 0
1	In a second experiment, rats received tricyclic antidepressant ENT1 desipramine  ENT1END IP followed in 15 min by 4-aminopyridine or saline. RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ENT2 ventricular arrhythmias ENT2END (p = 0
1	The incidence of ENT1 ventricular arrhythmias ENT1END  (p = 0.004) and seizures (p = 0.03) in the ENT2 CaCl2 ENT2END group was higher than the other groups
0	RESULTS: ENT1 NaHCO3  ENT1END briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ENT2 ventricular arrhythmias ENT2END (p = 0
0	The incidence of ENT1 ventricular arrhythmias ENT1END  (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity. These findings do not support a role for ENT2 calcium ENT2END channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension
0	CONCLUSION: The administration of CaCl2 or ENT1 4-aminopyridine ENT1END did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	In a second experiment, rats received tricyclic antidepressant ENT1 desipramine  ENT1END  IP followed in 15 min by 4-aminopyridine or saline. RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	ENT1 CaCl2  ENT1END therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	RESULTS: ENT1 NaHCO3  ENT1END  briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	CaCl2 therapy may possibly worsen both ENT1 cardiovascular and central nervous system toxicity  ENT1END . These findings do not support a role for ENT2 calcium ENT2END channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension
0	RESULTS: NaHCO3 briefly (5 min) reversed ENT1 hypotension  ENT1END and QRS prolongation. CaCl2 and ENT2 4-aminopyridine ENT2END failed to improve blood pressure
1	Anesthetized rats received the tricyclic antidepressant ENT1 desipramine ENT1END IP to produce ENT2 hypotension ENT2END , QRS prolongation, and bradycardia
0	CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced ENT1 hypotension  ENT1END in rats. ENT2 CaCl2 ENT2END therapy may possibly worsen both cardiovascular and central nervous system toxicity
0	RESULTS: ENT1 NaHCO3  ENT1END  briefly (5 min) reversed ENT2 hypotension ENT2END and QRS prolongation
0	This study addressed the potential role of ENT1 calcium ENT1END channel blockade in tricyclic antidepressant-induced ENT2 hypotension ENT2END
0	Effect of calcium chloride and ENT1 4-aminopyridine  ENT1END  therapy on desipramine ENT2 toxicity ENT2END in rats
0	Effect of calcium chloride and 4-aminopyridine therapy on ENT1 desipramine ENT1END ENT2 toxicity ENT2END in rats
0	Effect of ENT1 calcium chloride  ENT1END  and 4-aminopyridine therapy on desipramine ENT2 toxicity ENT2END in rats
0	Effect of calcium chloride and 4-aminopyridine therapy on desipramine ENT1 toxicity ENT1END  in rats.BACKGROUND: Hypotension is a major contributor to mortality in tricyclic antidepressant overdose. Recent data suggest that tricyclic antidepressants inhibit ENT2 calcium ENT2END influx in some tissues
0	CONCLUSION: The administration of CaCl2 or ENT1 4-aminopyridine ENT1END  did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	In a second experiment, rats received tricyclic antidepressant ENT1 desipramine  ENT1END  IP followed in 15 min by 4-aminopyridine or saline. RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	ENT1 CaCl2  ENT1END  therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	RESULTS: ENT1 NaHCO3  ENT1END  briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ventricular arrhythmias (p = 0.004) and seizures (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both ENT2 cardiovascular and central nervous system toxicity ENT2END
0	CaCl2 therapy may possibly worsen both ENT1 cardiovascular and central nervous system toxicity  ENT1END . These findings do not support a role for ENT2 calcium ENT2END channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension
0	CaCl2 and ENT1 4-aminopyridine ENT1END  Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and ENT2 bradycardia ENT2END
1	Anesthetized rats received the tricyclic antidepressant ENT1 desipramine  ENT1END  IP to produce hypotension, QRS prolongation, and ENT2 bradycardia ENT2END
0	Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and ENT1 bradycardia ENT1END . Fifteen min later, animals received ENT2 CaCl2 ENT2END , NaHCO3, or saline
0	Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and ENT1 bradycardia ENT1END . Fifteen min later, animals received CaCl2, ENT2 NaHCO3 ENT2END , or saline
0	METHODS: Two interventions were studied that have been shown previously to improve blood pressure with ENT1 calcium  ENT1END channel blocker overdose. CaCl2 and 4-aminopyridine. Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and ENT2 bradycardia ENT2END
0	CaCl2 and ENT1 4-aminopyridine ENT1END  failed to improve blood pressure. The incidence of ventricular arrhythmias (p = 0.004) and ENT2 seizures ENT2END (p = 0
0	In a second experiment, rats received tricyclic antidepressant ENT1 desipramine  ENT1END  IP followed in 15 min by 4-aminopyridine or saline. RESULTS: NaHCO3 briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ventricular arrhythmias (p = 0.004) and ENT2 seizures ENT2END (p = 0
0	004) and ENT1 seizures  ENT1END  (p = 0.03) in the ENT2 CaCl2 ENT2END group was higher than the other groups
0	RESULTS: ENT1 NaHCO3  ENT1END  briefly (5 min) reversed hypotension and QRS prolongation. CaCl2 and 4-aminopyridine failed to improve blood pressure. The incidence of ventricular arrhythmias (p = 0.004) and ENT2 seizures ENT2END (p = 0
0	004) and ENT1 seizures  ENT1END  (p = 0.03) in the CaCl2 group was higher than the other groups. CONCLUSION: The administration of CaCl2 or 4-aminopyridine did not reverse tricyclic antidepressant-induced hypotension in rats. CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity. These findings do not support a role for ENT2 calcium ENT2END channel inhibition in the pathogenesis of tricyclic antidepressant-induced hypotension
0	METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker ENT1 overdose  ENT1END  CaCl2 and ENT2 4-aminopyridine ENT2END
0	METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker ENT1 overdose  ENT1END . CaCl2 and 4-aminopyridine. Anesthetized rats received the tricyclic antidepressant ENT2 desipramine ENT2END IP to produce hypotension, QRS prolongation, and bradycardia
0	METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker ENT1 overdose ENT1END . ENT2 CaCl2 ENT2END and 4-aminopyridine
0	METHODS: Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker ENT1 overdose  ENT1END . CaCl2 and 4-aminopyridine. Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension, QRS prolongation, and bradycardia. Fifteen min later, animals received CaCl2, ENT2 NaHCO3 ENT2END , or saline
0	METHODS: Two interventions were studied that have been shown previously to improve blood pressure with ENT1 calcium  ENT1END  channel blocker ENT2 overdose ENT2END
0	ENT1 Muscle rigidity ENT1END was induced by haloperidol (2.5 mg/kg i.p.). ENT2 5,7-dichlorokynurenic acid ENT2END (5,7-DCKA), a selective glycine site antagonist, injected in doses of 2
0	ENT1 Muscle rigidity ENT1END  was induced by haloperidol (2.5 mg/kg i.p.). 5,7-dichlorokynurenic acid (5,7-DCKA), a selective ENT2 glycine ENT2END site antagonist, injected in doses of 2
0	5 microl bilaterally, into the rostral region of the striatum, decreased both the haloperidol-induced ENT1 muscle rigidity ENT1END (MMG) and the enhanced electromyographic activity (EMG). 5,7-DCKA injected bilaterally in a dose of 4.5 microg/0.5 microl into the intermediate-caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone. The present results suggest that blockade of the glycine site of ENT2 NMDA ENT2END receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug
1	5 microl bilaterally, into the rostral region of the striatum, decreased both the ENT1 haloperidol  ENT1END induced ENT2 muscle rigidity ENT2END (MMG) and the enhanced electromyographic activity (EMG)
0	Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ENT1 ischemia ENT1END occurring four to twenty days after the initiation of ENT2 heparin ENT2END therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter
0	The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ENT1 ischemic ENT1END in origin, and might serve to warn the clinician of these complications. Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed. The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation. Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
1	Arterial thromboembolism is a recognized complication of systemic ENT1 heparin ENT1END therapy. Characteristic of the entity is ENT2 arterial occlusion ENT2END by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter
0	Characteristic of the entity is ENT1 arterial occlusion  ENT1END  by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter. The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications. Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed. The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation. Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
1	The common factor relating thromboembolism and ENT1 thrombocytopenia ENT1END is ENT2 heparin ENT2END -induced platelet aggregation
0	The common factor relating thromboembolism and ENT1 thrombocytopenia  ENT1END  is heparin-induced platelet aggregation. Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
0	The common factor relating ENT1 thromboembolism  ENT1END and thrombocytopenia is ENT2 heparin ENT2END -induced platelet aggregation
0	The common factor relating ENT1 thromboembolism  ENT1END  and thrombocytopenia is heparin-induced platelet aggregation. Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
0	Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of ENT1 heparin ENT1END  therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter. The clinically apparent occlusion may be preceded by ENT2 gastrointestinal and musculoskeletal symptoms ENT2END that appear to be ischemic in origin, and might serve to warn the clinician of these complications
0	The clinically apparent occlusion may be preceded by ENT1 gastrointestinal and musculoskeletal symptoms  ENT1END  that appear to be ischemic in origin, and might serve to warn the clinician of these complications. Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed. The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation. Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
0	Characteristic of the entity is arterial occlusion by platelet-fibrin ENT1 thrombi  ENT1END with distal ischemia occurring four to twenty days after the initiation of ENT2 heparin ENT2END therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter
0	Characteristic of the entity is arterial occlusion by platelet-fibrin ENT1 thrombi  ENT1END  with distal ischemia occurring four to twenty days after the initiation of heparin therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter. The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin, and might serve to warn the clinician of these complications. Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed. The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation. Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
0	Characteristic of the entity is arterial occlusion by platelet-fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of ENT1 heparin ENT1END  therapy, preceded by profound thrombocytopenia with platelet counts in the range of 30,000 to 40,000 per cubic millimeter. The clinically apparent occlusion may be preceded by ENT2 gastrointestinal and musculoskeletal symptoms ENT2END that appear to be ischemic in origin, and might serve to warn the clinician of these complications
0	The clinically apparent occlusion may be preceded by ENT1 gastrointestinal and musculoskeletal symptoms  ENT1END  that appear to be ischemic in origin, and might serve to warn the clinician of these complications. Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed. The common factor relating thromboembolism and thrombocytopenia is heparin-induced platelet aggregation. Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
0	The common factor relating thromboembolism and thrombocytopenia is ENT1 heparin ENT1END -induced ENT2 platelet aggregation ENT2END
0	The common factor relating thromboembolism and thrombocytopenia is heparin-induced ENT1 platelet aggregation  ENT1END . Appropriate treatment consists of discontinuation of heparin, and anticoagulation with ENT2 sodium warfarin ENT2END if necessary
0	BACKGROUND: A transient leukoencephalopathy mimicking ENT1 cerebrovascular accident ENT1END has been described as a complication of chemotherapy, most commonly in recipients of intrathecal ENT2 methotrexate ENT2END for childhood leukaemia
0	Patients with ENT1 cerebrovascular accidents ENT1END were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative ENT2 carmofur ENT2END , and capecitabine
0	Patients with ENT1 cerebrovascular accidents ENT1END  were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), ENT2 5-fluorouracil ENT2END and its derivative carmofur, and capecitabine
0	Patients with ENT1 cerebrovascular accidents ENT1END  were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and ENT2 capecitabine ENT2END
1	RESULTS: We identified 27 reports of toxic ENT1 leukoencephalopathy ENT1END in patients treated with ENT2 methotrexate ENT2END (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and capecitabine
1	RESULTS: We identified 27 reports of toxic ENT1 leukoencephalopathy  ENT1END  in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative ENT2 carmofur ENT2END , and capecitabine
1	RESULTS: We identified 27 reports of toxic ENT1 leukoencephalopathy  ENT1END  in patients treated with methotrexate (intrathecal, systemic), ENT2 5-fluorouracil ENT2END and its derivative carmofur, and capecitabine
1	RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and ENT1 capecitabine ENT1END . Diffusion weighted imaging (DWI) of all patients revealed well demarcated hyperintense ENT2 lesions within the subcortical white matter ENT2END of the cerebral hemispheres and the corpus callosum, corresponding to areas of decreased proton diffusion on apparent diffusion coefficient (ADC) maps (available in 21/27 patients)
0	BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal ENT1 methotrexate ENT1END  for childhood ENT2 leukaemia ENT2END
0	BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood ENT1 leukaemia  ENT1END . Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration. METHODS: We reviewed the medical literature for single reports and case series of patients presenting with stroke-like episodes while receiving systemic or intrathecal chemotherapy. We only included studies providing detailed neuroimaging data. Patients with cerebrovascular accidents were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative ENT2 carmofur ENT2END , and capecitabine
0	BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood ENT1 leukaemia  ENT1END . Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration. METHODS: We reviewed the medical literature for single reports and case series of patients presenting with stroke-like episodes while receiving systemic or intrathecal chemotherapy. We only included studies providing detailed neuroimaging data. Patients with cerebrovascular accidents were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), ENT2 5-fluorouracil ENT2END and its derivative carmofur, and capecitabine
0	BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal methotrexate for childhood ENT1 leukaemia  ENT1END . Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration. METHODS: We reviewed the medical literature for single reports and case series of patients presenting with stroke-like episodes while receiving systemic or intrathecal chemotherapy. We only included studies providing detailed neuroimaging data. Patients with cerebrovascular accidents were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and ENT2 capecitabine ENT2END
0	Delayed leukoencephalopathy with ENT1 stroke  ENT1END -like presentation in chemotherapy recipients.BACKGROUND: A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy, most commonly in recipients of intrathecal ENT2 methotrexate ENT2END for childhood leukaemia
0	METHODS: We reviewed the medical literature for single reports and case series of patients presenting with ENT1 stroke  ENT1END like episodes while receiving systemic or intrathecal chemotherapy. We only included studies providing detailed neuroimaging data. Patients with cerebrovascular accidents were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative ENT2 carmofur ENT2END , and capecitabine
0	METHODS: We reviewed the medical literature for single reports and case series of patients presenting with ENT1 stroke  ENT1END -like episodes while receiving systemic or intrathecal chemotherapy. We only included studies providing detailed neuroimaging data. Patients with cerebrovascular accidents were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), ENT2 5-fluorouracil ENT2END and its derivative carmofur, and capecitabine
0	METHODS: We reviewed the medical literature for single reports and case series of patients presenting with ENT1 stroke  ENT1END -like episodes while receiving systemic or intrathecal chemotherapy. We only included studies providing detailed neuroimaging data. Patients with cerebrovascular accidents were excluded. RESULTS: We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate (intrathecal, systemic), 5-fluorouracil and its derivative carmofur, and ENT2 capecitabine ENT2END
0	This was accounted for by a significant number of depressions occurring in ENT1 methyl dopa ENT1END treated patients with ENT2 psychiatric ENT2END histories
1	This was accounted for by a significant number of ENT1 depressions  ENT1END occurring in ENT2 methyl dopa ENT2END treated patients with psychiatric histories
0	ENT1 Hypertensive  ENT1END patients with psychiatric histories had a higher prevalence of depression than the comparison patients. This was accounted for by a significant number of depressions occurring in ENT2 methyl dopa ENT2END treated patients with psychiatric histories
0	A series of aryl-piperazine analogues of buspirone and other ENT1 5-hydroxytryptaminergic agonists ENT1END were tested for their ability to reverse haloperidol induced ENT2 catalepsy ENT2END
0	The novel anxiolytic drug, ENT1 buspirone ENT1END  reverses ENT2 catalepsy ENT2END induced by haloperidol
1	A series of aryl-piperazine analogues of buspirone and other 5-hydroxytryptaminergic agonists were tested for their ability to reverse ENT1 haloperidol  ENT1END induced ENT2 catalepsy ENT2END
0	Those drugs with strong affinity for 5-hydroxytryptamine1a receptors were able to reverse ENT1 catalepsy ENT1END  Drugs with affinity for other ENT2 5-HT ENT2END receptors or weak affinity were ineffective
0	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ENT1 ribavirin  ENT1END  for ENT2 chronic hepatitis C ENT2END
0	Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of ENT1 interferon  ENT1END  and ribavirin for ENT2 chronic hepatitis C ENT2END
0	METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed anemia with hemoglobin level <10 g/dl or ENT1 anemia ENT1END related signs during therapy. After that, these 37 patients were reduced one tablet of ENT2 ribavirin ENT2END (200 mg) per day
0	BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of ENT1 interferon ENT1END and ribavirin. Because of ribavirin-related hemolytic anemia, dose reduction is a common event in this therapy. In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy. METHODS: Thirty-seven of 160 patients who had HCV-genotype 1b, had high virus load, and received 24-week combination therapy developed ENT2 anemia ENT2END with hemoglobin level <10 g/dl or anemia-related signs during therapy
1	Because of ENT1 ribavirin ENT1END related ENT2 hemolytic anemia ENT2END , dose reduction is a common event in this therapy
1	BACKGROUND: Hemolytic anemia is one of the major adverse events of the combination therapy of ENT1 interferon  ENT1END  and ribavirin. Because of ribavirin-related ENT2 hemolytic anemia ENT2END , dose reduction is a common event in this therapy
0	Adequate timing of ENT1 ribavirin  ENT1END  reduction in patients with ENT2 hemolysis ENT2END during combination therapy of interferon and ribavirin for chronic hepatitis C
0	Adequate timing of ribavirin reduction in patients with ENT1 hemolysis  ENT1END  during combination therapy of ENT2 interferon ENT2END and ribavirin for chronic hepatitis C
0	1% tacrolimus ointment for ENT1 facial dermatitis ENT1END  Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis. Continuous topical use of immunomodulators such as tacrolimus or ENT2 pimecrolimus ENT2END should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported
0	1% ENT1 tacrolimus  ENT1END ointment for ENT2 facial dermatitis ENT2END
1	We describe herein 3 patients who developed rosacea-like dermatitis ENT1 eruptions  ENT1END while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis. Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis. Continuous topical use of immunomodulators such as tacrolimus or ENT2 pimecrolimus ENT2END should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported
0	We describe herein 3 patients who developed rosacea-like dermatitis ENT1 eruptions  ENT1END  while using 0.03% or 0.1% ENT2 tacrolimus ENT2END ointment for facial dermatitis
0	We describe herein 3 patients who developed ENT1 rosacea  ENT1END like dermatitis eruptions while using 0.03% or 0.1% tacrolimus ointment for facial dermatitis. Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis. Continuous topical use of immunomodulators such as tacrolimus or ENT2 pimecrolimus ENT2END should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported
0	We describe herein 3 patients who developed ENT1 rosacea  ENT1END -like dermatitis eruptions while using 0.03% or 0.1% ENT2 tacrolimus ENT2END ointment for facial dermatitis
1	Continuous topical use of immunomodulators such as tacrolimus or ENT1 pimecrolimus ENT1END  should be regarded as a potential cause of rosaceiform ENT2 dermatitis ENT2END , although many cases have not been reported
0	Rosaceiform ENT1 dermatitis  ENT1END  associated with topical ENT2 tacrolimus ENT2END treatment
1	Skin biopsy specimens showed ENT1 telangiectasia  ENT1END and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis. Continuous topical use of immunomodulators such as tacrolimus or ENT2 pimecrolimus ENT2END should be regarded as a potential cause of rosaceiform dermatitis, although many cases have not been reported
0	1% ENT1 tacrolimus  ENT1END  ointment for facial dermatitis. Skin biopsy specimens showed ENT2 telangiectasia ENT2END and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis
0	Levodopa-induced dyskinesias (LIDs) present a major problem for the long-term management of Parkinson's disease ( ENT1 PD ENT1END  patients. Due to the interdependence of risk factors in clinical populations, it is difficult to independently examine factors that may influence the development of LIDs. Using macaque monkeys with different types of ENT2 MPTP ENT2END -induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs
0	Development of ENT1 levodopa  ENT1END -induced dyskinesias in ENT2 parkinsonian ENT2END monkeys may depend upon rate of symptom onset and/or duration of symptoms
0	Using macaque monkeys with different types of MPTP-induced parkinsonism, the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of ENT1 LIDs ENT1END  Monkeys with acute (short-term) ENT2 MPTP ENT2END exposure, rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration
1	Development of ENT1 levodopa  ENT1END -induced ENT2 dyskinesias ENT2END in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms
1	Using macaque monkeys with different types of ENT1 MPTP ENT1END -induced ENT2 parkinsonism ENT2END , the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of levodopa therapy may be involved in the development of LIDs
0	Using macaque monkeys with different types of MPTP-induced ENT1 parkinsonism ENT1END , the current study evaluated the degree to which rate of symptom progression, symptom severity, and response to and duration of ENT2 levodopa ENT2END therapy may be involved in the development of LIDs
0	We have previously demonstrated that ritonavir treatment increases ENT1 atherosclerotic lesion ENT1END formation in male mice to a greater extent than in female mice. Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less ENT2 cholesteryl ester ENT2END accumulation
1	We have previously demonstrated that ENT1 ritonavir  ENT1END treatment increases ENT2 atherosclerotic lesion ENT2END formation in male mice to a greater extent than in female mice
0	We have previously demonstrated that ritonavir treatment increases ENT1 atherosclerotic lesion ENT1END  formation in male mice to a greater extent than in female mice. Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation. In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir. We have utilized the human monocyte cell line, THP-1 as a model to address this question. Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM ENT2 17beta-estradiol ENT2END (E2), 100 nM progesterone or vehicle (0
0	We have previously demonstrated that ritonavir treatment increases ENT1 atherosclerotic lesion ENT1END  formation in male mice to a greater extent than in female mice. Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation. In the present study, we have investigated the molecular mechanisms by which female hormones influence ENT2 cholesterol ENT2END metabolism in macrophages in response to the HIV protease inhibitor ritonavir
0	We have previously demonstrated that ritonavir treatment increases ENT1 atherosclerotic lesion ENT1END  formation in male mice to a greater extent than in female mice. Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation. In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir. We have utilized the human monocyte cell line, THP-1 as a model to address this question. Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM progesterone or vehicle (0.01% ENT2 ethanol ENT2END )
0	We have previously demonstrated that ritonavir treatment increases ENT1 atherosclerotic lesion ENT1END  formation in male mice to a greater extent than in female mice. Furthermore, peripheral blood monocytes isolated from ritonavir-treated females had less cholesteryl ester accumulation. In the present study, we have investigated the molecular mechanisms by which female hormones influence cholesterol metabolism in macrophages in response to the HIV protease inhibitor ritonavir. We have utilized the human monocyte cell line, THP-1 as a model to address this question. Briefly, cells were differentiated for 72 h with 100 nM PMA to obtain a macrophage-like phenotype in the presence or absence of 1 nM 17beta-estradiol (E2), 100 nM ENT2 progesterone ENT2END or vehicle (0
0	The association of ENT1 cocaine ENT1END and amphetamine use with hemorrhagic and ENT2 ischemic ENT2END stroke is based almost solely on data from case series
0	The association of cocaine and ENT1 amphetamine  ENT1END use with hemorrhagic and ENT2 ischemic ENT2END stroke is based almost solely on data from case series
1	ENT1 Stroke  ENT1END  and ENT2 cocaine ENT2END or amphetamine use
1	ENT1 Stroke  ENT1END  and cocaine or ENT2 amphetamine ENT2END use
0	We studied two groups of Parkinson's disease patients with (Parkinson's disease + LID, n = 23) and without ENT1 levodopa  ENT1END induced dyskinesias ( ENT2 Parkinson's disease ENT2END - LID, n = 10), and age-matched healthy controls
1	Force overflow and ENT1 levodopa  ENT1END -induced ENT2 dyskinesias ENT2END in Parkinson's disease
0	Because ENT1 carbamazepine ENT1END is widely used in the treatment of many neurologic and ENT2 psychiatric ENT2END conditions, the recognition of the latter syndrome has important implications for the use of this drug in elderly patients
1	A patient with sinus ENT1 bradycardia ENT1END and atrioventricular block, induced by ENT2 carbamazepine ENT2END , prompted an extensive literature review of all previously reported cases
1	One patient group developed ENT1 sinus tachycardias ENT1END in the setting of a massive ENT2 carbamazepine ENT2END overdose
1	A patient with sinus bradycardia and ENT1 atrioventricular block  ENT1END  induced by ENT2 carbamazepine ENT2END , prompted an extensive literature review of all previously reported cases
0	ENT1 Carbamazepine  ENT1END -induced ENT2 cardiac dysfunction ENT2END
0	One patient group developed sinus tachycardias in the setting of a massive ENT1 carbamazepine ENT1END  ENT2 overdose ENT2END
0	In contrast to controls, ENT1 methoctramine ENT1END increased -- instead of decreased -- the tonic responses at high frequencies. While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips. Thus, in ENT2 cystitis ENT2END substantial changes of the efferent functional responses occur
0	While contractions to carbachol and ENT1 ATP  ENT1END were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips. Thus, in ENT2 cystitis ENT2END substantial changes of the efferent functional responses occur
1	In vitro characterization of parasympathetic and sympathetic responses in ENT1 cyclophosphamide  ENT1END -induced ENT2 cystitis ENT2END in the rat
0	While contractions to ENT1 carbachol  ENT1END and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips. Thus, in ENT2 cystitis ENT2END substantial changes of the efferent functional responses occur
0	While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference ENT1 potassium  ENT1END response, isoprenaline-induced relaxations were smaller in inflamed strips. Thus, in ENT2 cystitis ENT2END substantial changes of the efferent functional responses occur
0	In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the ENT1 pirenzepine  ENT1END and 4-DAMP antagonism on the tonic component was much less efficient than in controls. In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies. While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips. Thus, in ENT2 cystitis ENT2END substantial changes of the efferent functional responses occur
0	Whether or not the neuronal transmission may be affected by ENT1 cystitis ENT1END was presently investigated. Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists. Generally, ENT2 atropine ENT2END reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations
0	While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, ENT1 isoprenaline  ENT1END induced relaxations were smaller in inflamed strips. Thus, in ENT2 cystitis ENT2END substantial changes of the efferent functional responses occur
0	Whether or not the neuronal transmission may be affected by ENT1 cystitis ENT1END  was presently investigated. Responses of urinary strip preparations from control and cyclophosphamide-pretreated rats to electrical field stimulation and to agonists were assessed in the absence and presence of muscarinic, adrenergic and purinergic receptor antagonists. Generally, atropine reduced contractions, but in contrast to controls, it also reduced responses to low electrical field stimulation intensity (1-5 Hz) in inflamed preparations. In both types, purinoceptor desensitization with ENT2 alpha,beta-methylene adenosine-5'-triphosphate ENT2END (alpha,beta-meATP) caused further reductions at low frequencies (<10 Hz)
0	In inflamed preparations, the muscarinic receptor antagonism on the phasic component of the electrical field stimulation-evoked contraction was decreased and the pirenzepine and ENT1 4-DAMP  ENT1END antagonism on the tonic component was much less efficient than in controls. In contrast to controls, methoctramine increased -- instead of decreased -- the tonic responses at high frequencies. While contractions to carbachol and ATP were the same in inflamed and in control strips when related to a reference potassium response, isoprenaline-induced relaxations were smaller in inflamed strips. Thus, in ENT2 cystitis ENT2END substantial changes of the efferent functional responses occur
1	A rechallenge with ENT1 androgen ENT1END produced symptoms of ENT2 obstructive sleep apnea ENT2END that abated upon withdrawal of the hormone
0	Previous reports have favored a role of ENT1 androgens ENT1END in the pathogenesis of ENT2 sleep apnea ENT2END
0	Twenty-three hours after heart transplantation, life-threatening acute ENT1 right heart failure ENT1END was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF). Increasing doses of catecholamines, sedatives, and muscle relaxants administered through a central venous catheter were ineffective. However, a bolus of ENT2 epinephrine ENT2END injected through an alternative catheter provoked a hypertensive crisis
0	Twenty-three hours after heart transplantation, life-threatening acute ENT1 right heart failure ENT1END  was diagnosed in a patient requiring continuous venovenous hemodiafiltration (CVVHDF). Increasing doses of ENT2 catecholamines ENT2END , sedatives, and muscle relaxants administered through a central venous catheter were ineffective
1	However, a bolus of ENT1 epinephrine ENT1END  injected through an alternative catheter provoked a ENT2 hypertensive ENT2END crisis
0	However, a bolus of epinephrine injected through an alternative catheter provoked a ENT1 hypertensive ENT1END  crisis. Thus, interference with the central venous infusion by the dialysis catheter was suspected. The catheters were changed, and hemodynamics stabilized at lower ENT2 catecholamine ENT2END doses
0	Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced ENT1 heart failure ENT1END .Activation of the nuclear enzyme ENT2 poly(ADP-ribose) ENT2END polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress
1	Activation of poly(ADP-ribose) polymerase contributes to development of ENT1 doxorubicin  ENT1END -induced ENT2 heart failure ENT2END
0	Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced ENT1 heart failure ENT1END .Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor ENT2 PJ34 ENT2END , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX
0	Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced ENT1 heart failure ENT1END .Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor ENT2 anthracycline ENT2END antibiotic
0	In addition PJ34 significantly reduced the DOX-induced increase in the serum ENT1 lactate ENT1END dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the ENT2 cardiotoxicity ENT2END of DOX
0	Activation of the nuclear enzyme ENT1 poly(ADP-ribose) ENT1END  polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the ENT2 cardiotoxicity ENT2END of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic
0	Thus, PARP activation contributes to the ENT1 cardiotoxicity ENT1END  of ENT2 DOX ENT2END
0	Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced ENT1 cardiotoxicity  ENT1END  Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor ENT2 PJ34 ENT2END , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX
0	Increased oxidative stress is a major factor implicated in the ENT1 cardiotoxicity  ENT1END  of doxorubicin (DOX), a widely used antitumor ENT2 anthracycline ENT2END antibiotic
0	In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and ENT1 creatine  ENT1END kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the ENT2 cardiotoxicity ENT2END of DOX
0	Treatment with a PJ34 significantly improved ENT1 cardiac dysfunction  ENT1END and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum ENT2 lactate ENT2END dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart
0	Activation of the nuclear enzyme ENT1 poly(ADP-ribose) ENT1END  polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of ENT2 cardiac dysfunction ENT2END induced by DOX
0	Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of ENT1 cardiac dysfunction ENT1END  induced by ENT2 DOX ENT2END
0	Treatment with a ENT1 PJ34  ENT1END significantly improved ENT2 cardiac dysfunction ENT2END and increased the survival of the animals
0	Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor ENT1 anthracycline  ENT1END  antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of ENT2 cardiac dysfunction ENT2END induced by DOX
0	Treatment with a PJ34 significantly improved ENT1 cardiac dysfunction  ENT1END  and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and ENT2 creatine ENT2END kinase activities but not metalloproteinase activation in the heart
0	In addition PJ34 significantly reduced the DOX-induced increase in the serum ENT1 lactate ENT1END  dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe ENT2 cardiac complications ENT2END associated with the DOX treatment
0	PARP inhibitors may exert protective effects against the development of severe ENT1 cardiac complications ENT1END  associated with the ENT2 DOX ENT2END treatment
0	In addition ENT1 PJ34  ENT1END significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe ENT2 cardiac complications ENT2END associated with the DOX treatment
0	In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and ENT1 creatine  ENT1END  kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe ENT2 cardiac complications ENT2END associated with the DOX treatment
0	ENT1 Pain  ENT1END  responses in ENT2 methadone ENT2END -maintained opioid abusers
0	By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory ( ENT1 ketorolac ENT1END 10 mg) analgesic agents. Results showed that MM individuals were significantly less tolerant of CP ENT2 pain ENT2END than control subjects, replicating previous work
0	By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) ENT1 pain  ENT1END was examined, both before and after oral administration of therapeutic doses of common opioid ( ENT2 hydromorphone ENT2END 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents
1	This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in ENT1 methadone ENT1END maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60). By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents. Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work. Analgesic effects were significant neither for medication nor group. These data indicate that MM opioid abusers represent a ENT2 pain-intolerant ENT2END subset of clinical patients
0	By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory ( ENT1 ketorolac  ENT1END  10 mg) analgesic agents. Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work. Analgesic effects were significant neither for medication nor group. These data indicate that MM opioid abusers represent a ENT2 pain-intolerant ENT2END subset of clinical patients
0	By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid ( ENT1 hydromorphone  ENT1END  2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents. Results showed that MM individuals were significantly less tolerant of CP pain than control subjects, replicating previous work. Analgesic effects were significant neither for medication nor group. These data indicate that MM opioid abusers represent a ENT2 pain-intolerant ENT2END subset of clinical patients
0	This study was designed to describe pain tolerance and analgesic response in a sample of ENT1 opioid addicts  ENT1END stabilized in ENT2 methadone ENT2END -maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60)
0	This study was designed to describe pain tolerance and analgesic response in a sample of ENT1 opioid addicts ENT1END  stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60). By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid (hydromorphone 2 mg) and nonsteroidal anti-inflammatory ENT2 ketorolac ENT2END 10 mg) analgesic agents
0	This study was designed to describe pain tolerance and analgesic response in a sample of ENT1 opioid addicts ENT1END  stabilized in methadone-maintenance (MM) treatment (n = 60) in comparison to matched nondependent control subjects (n = 60). By using a placebo-controlled, two-way factorial design, tolerance to cold-pressor (CP) pain was examined, both before and after oral administration of therapeutic doses of common opioid ENT2 hydromorphone ENT2END 2 mg) and nonsteroidal anti-inflammatory (ketorolac 10 mg) analgesic agents
0	ENT1 Pain ENT1END not responsive to ENT2 morphine ENT2END is often problematic
0	Ketamine, but not saline solution, significantly reduced the ENT1 pain ENT1END intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. Hallucinations occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of ENT2 diazepam ENT2END 1 mg intravenously
0	Animal and clinical studies have suggested that N-methyl-D-aspartate ( ENT1 NMDA ENT1END  antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult ENT2 pain ENT2END syndromes, such as neuropathic pain
0	ENT1 Ketamine ENT1END can improve morphine analgesia in difficult ENT2 pain ENT2END syndromes, such as neuropathic pain
0	Ketamine can improve ENT1 morphine ENT1END analgesia in difficult pain syndromes, such as ENT2 neuropathic pain ENT2END
0	These episodes reversed after the administration of ENT1 diazepam  ENT1END  1 mg intravenously. Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg. A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine. Ketamine can improve morphine analgesia in difficult pain syndromes, such as ENT2 neuropathic pain ENT2END
0	Animal and clinical studies have suggested that N-methyl-D-aspartate ( ENT1 NMDA ENT1END ) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as ENT2 neuropathic pain ENT2END
0	Animal and clinical studies have suggested that N-methyl-D-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as ENT1 neuropathic pain ENT1END . A slow bolus of subhypnotic doses of ENT2 ketamine ENT2END (0
0	50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by ENT1 morphine ENT1END in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and ENT2 vomiting ENT2END , drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	Pain intensity on a 0 to 10 numerical scale; nausea and ENT1 vomiting  ENT1END , drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180). Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. Hallucinations occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of ENT2 diazepam ENT2END 1 mg intravenously
0	Animal and clinical studies have suggested that N-methyl-D-aspartate ( ENT1 NMDA  ENT1END ) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and ENT2 vomiting ENT2END , drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	A slow bolus of subhypnotic doses of ENT1 ketamine  ENT1END  (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and ENT2 vomiting ENT2END , drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	Analgesic effect of intravenous ketamine in ENT1 cancer  ENT1END  patients on ENT2 morphine ENT2END therapy: a randomized, controlled, double-blind, crossover, double-dose study
0	50 mg/kg) was given to 10 ENT1 cancer  ENT1END patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180). Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. Hallucinations occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of ENT2 diazepam ENT2END 1 mg intravenously
0	Analgesic effect of intravenous ketamine in ENT1 cancer ENT1END  patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study.Pain not responsive to morphine is often problematic. Animal and clinical studies have suggested that ENT2 N-methyl-D-aspartate ENT2END (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain
0	Analgesic effect of intravenous ENT1 ketamine  ENT1END  in ENT2 cancer ENT2END patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study
0	50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by ENT1 morphine ENT1END  in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, ENT2 confusion ENT2END , and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, ENT1 confusion  ENT1END , and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180). Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. Hallucinations occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of ENT2 diazepam ENT2END 1 mg intravenously
0	Animal and clinical studies have suggested that N-methyl-D-aspartate ( ENT1 NMDA  ENT1END ) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, ENT2 confusion ENT2END , and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	A slow bolus of subhypnotic doses of ENT1 ketamine  ENT1END  (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, ENT2 confusion ENT2END , and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by ENT1 morphine ENT1END  in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; ENT2 nausea ENT2END and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	Pain intensity on a 0 to 10 numerical scale; ENT1 nausea  ENT1END  and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180). Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. Hallucinations occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of ENT2 diazepam ENT2END 1 mg intravenously
0	Animal and clinical studies have suggested that N-methyl-D-aspartate ( ENT1 NMDA  ENT1END ) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; ENT2 nausea ENT2END and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	A slow bolus of subhypnotic doses of ENT1 ketamine  ENT1END  (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; ENT2 nausea ENT2END and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by ENT1 morphine ENT1END  in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and ENT2 dry mouth ENT2END , using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and ENT1 dry mouth  ENT1END , using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180). Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. Hallucinations occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of ENT2 diazepam ENT2END 1 mg intravenously
0	Animal and clinical studies have suggested that N-methyl-D-aspartate ( ENT1 NMDA  ENT1END ) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and ENT2 dry mouth ENT2END , using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	A slow bolus of subhypnotic doses of ENT1 ketamine  ENT1END  (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and ENT2 dry mouth ENT2END , using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180)
0	ENT1 Hallucinations  ENT1END occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of diazepam 1 mg intravenously. Significant increases in drowsiness were reported in patients treated with ketamine in both groups and were more marked with ketamine 0.50 mg/kg. A significant difference in MMSE was observed at T30 in patients who received 0.50 mg/kg of ketamine. Ketamine can improve ENT2 morphine ENT2END analgesia in difficult pain syndromes, such as neuropathic pain
0	ENT1 Hallucinations  ENT1END  occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients. These episodes reversed after the administration of ENT2 diazepam ENT2END 1 mg intravenously
0	Animal and clinical studies have suggested that N-methyl-D-aspartate ( ENT1 NMDA  ENT1END ) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0-30); and arterial pressure were recorded before administration of drugs (T0) and after 30 minutes (T30), 60 minutes (T60), 120 minutes (T120), and 180 minutes (T180). Ketamine, but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. ENT2 Hallucinations ENT2END occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients
1	ENT1 Ketamine  ENT1END  but not saline solution, significantly reduced the pain intensity in almost all the patients at both doses. This effect was more relevant in patients treated with higher doses. ENT2 Hallucinations ENT2END occurred in 4 patients, and an unpleasant sensation ("empty head") was also reported by 2 patients
0	Fusidic acid is an antibiotic with T-cell specific immunosuppressive effects similar to those of ENT1 cyclosporin ENT1END  Because of the need for the development of new treatments for ENT2 Crohn's disease ENT2END , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active, therapy-resistant patients
0	Treatment of ENT1 Crohn's disease  ENT1END  with ENT2 fusidic acid ENT2END : an antibiotic with immunosuppressive properties similar to cyclosporin
1	Five of 8 patients (63%) improved during ENT1 fusidic acid ENT1END treatment: 3 at two weeks and 2 after four weeks. There were no serious clinical side effects, but dose reduction was required in two patients because of ENT2 nausea ENT2END
0	Because there seems to exist a scientific rationale for the use of ENT1 fusidic acid ENT1END at the cytokine level in ENT2 inflammatory bowel disease ENT2END , we suggest that the role of this treatment should be further investigated
0	ENT1 glycopyrrolate  ENT1END  and atropine in the prevention of bradycardia and ENT2 arrhythmias ENT2END following repeated doses of suxamethonium in children
0	glycopyrrolate and atropine in the prevention of bradycardia and ENT1 arrhythmias  ENT1END  following repeated doses of ENT2 suxamethonium ENT2END in children
0	glycopyrrolate and ENT1 atropine  ENT1END  in the prevention of bradycardia and ENT2 arrhythmias ENT2END following repeated doses of suxamethonium in children
0	A control group was included for comparison with the lower dose range of ENT1 glycopyrrolate ENT1END and atropine. A frequency of ENT2 bradycardia ENT2END of 50% was noted in the control group, but this was not significantly different from the frequency with the active drugs
1	immediately before the induction of anaesthesia, to prevent arrhythmia and ENT1 bradycardia ENT1END following repeated doses of ENT2 suxamethonium ENT2END in children, was studied
0	A control group was included for comparison with the lower dose range of glycopyrrolate and ENT1 atropine  ENT1END  A frequency of ENT2 bradycardia ENT2END of 50% was noted in the control group, but this was not significantly different from the frequency with the active drugs
0	We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with ENT1 human immunodeficiency virus infection ENT1END  One of the twins developed complete heart block and dilated cardiomyopathy related to ENT2 lopinavir/ritonavir ENT2END therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia
1	One of the twins developed complete heart block and ENT1 dilated cardiomyopathy  ENT1END related to ENT2 lopinavir/ritonavir ENT2END therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia
0	Twin preterm neonates with ENT1 cardiac toxicity  ENT1END  related to ENT2 lopinavir/ritonavir ENT2END therapy
1	One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir/ritonavir therapy, a boosted protease-inhibitor agent, while the other twin developed mild ENT1 bradycardia ENT1END  We recommend caution in the use of ENT2 lopinavir/ritonavir ENT2END in the immediate neonatal period
1	One of the twins developed complete ENT1 heart block  ENT1END and dilated cardiomyopathy related to ENT2 lopinavir/ritonavir ENT2END therapy, a boosted protease-inhibitor agent, while the other twin developed mild bradycardia
0	The likely frequency of hepatotoxicity with ENT1 sulfasalazine ENT1END was estimated by making a series of conservative assumptions. RESULTS: Ten cases were identified: eight occurred during surveillance. Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant. All but one event occurred within 6 weeks of treatment. Seven patients had a ENT2 skin rash ENT2END , three eosinophilia and one interstitial nephritis
0	Seven patients had a skin rash, three eosinophilia and one ENT1 interstitial nephritis ENT1END  Five patients were of Black British of African or Caribbean descent. Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six. Drug-related hepatotoxicity was judged probable or highly probable in 8 patients. The likely frequency of serious hepatotoxicity with ENT2 sulfasalazine ENT2END was estimated at 0
0	The likely frequency of hepatotoxicity with ENT1 sulfasalazine ENT1END  was estimated by making a series of conservative assumptions. RESULTS: Ten cases were identified: eight occurred during surveillance. Eight patients were hospitalised, two in ENT2 hepatic failure ENT2END - one died after a liver transplant
0	Hepatotoxicity associated with ENT1 sulfasalazine  ENT1END  in inflammatory ENT2 arthritis ENT2END : A case series from a local surveillance of serious adverse events
0	The likely frequency of hepatotoxicity with ENT1 sulfasalazine ENT1END  was estimated by making a series of conservative assumptions. RESULTS: Ten cases were identified: eight occurred during surveillance. Eight patients were hospitalised, two in hepatic failure - one died after a liver transplant. All but one event occurred within 6 weeks of treatment. Seven patients had a skin rash, three ENT2 eosinophilia ENT2END and one interstitial nephritis
1	Patients', who had ENT1 hepatotoxicity ENT1END on ENT2 sulfasalazine ENT2END and met a definition of a serious ADR, were identified
0	In contrast with the literature, serum levels of angiogenesis factors did not change significantly by ENT1 pegylated interferon ENT1END and ribavirin therapy. We found no correlation of angiogenesis soluble markers with either hemoglobin or haptoglobin. CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced ENT2 anemia ENT2END in patients with hepatitis C and we could not find any relation
0	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and ENT1 sorafenib ENT1END have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against ENT2 anemia ENT2END
0	CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ENT1 ribavirin  ENT1END induced ENT2 anemia ENT2END in patients with hepatitis C and we could not find any relation
0	We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against ENT1 anemia ENT1END . METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by ENT2 pegylated interferon alpha 2a ENT2END and ribavirin
0	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as ENT1 sunitinib  ENT1END and sorafenib have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against ENT2 anemia ENT2END
0	In contrast with the literature, serum levels of angiogenesis factors did not change significantly by ENT1 pegylated interferon ENT1END  and ribavirin therapy. We found no correlation of angiogenesis soluble markers with either hemoglobin or haptoglobin. CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with ENT2 hepatitis C ENT2END and we could not find any relation
0	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and ENT1 sorafenib ENT1END  have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients ENT2 chronically infected with hepatitis C virus ENT2END were treated by pegylated interferon alpha 2a and ribavirin
0	CONCLUSION: This is the first study in the literature investigating a link between angiogenesis soluble markers and ENT1 ribavirin  ENT1END  induced anemia in patients with ENT2 hepatitis C ENT2END and we could not find any relation
0	METHODS: Fourteen patients ENT1 chronically infected with hepatitis C virus  ENT1END  were treated by ENT2 pegylated interferon alpha 2a ENT2END and ribavirin
0	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as ENT1 sunitinib  ENT1END  and sorafenib have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients ENT2 chronically infected with hepatitis C virus ENT2END were treated by pegylated interferon alpha 2a and ribavirin
0	Can angiogenesis be a target of treatment for ribavirin associated ENT1 hemolytic anemia  ENT1END ?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and ENT2 sorafenib ENT2END have been found to cause acute hemolysis
0	Can angiogenesis be a target of treatment for ENT1 ribavirin  ENT1END  associated ENT2 hemolytic anemia ENT2END ?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis
0	Can angiogenesis be a target of treatment for ribavirin associated ENT1 hemolytic anemia  ENT1END ?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis. We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by ENT2 pegylated interferon alpha 2a ENT2END and ribavirin
0	Can angiogenesis be a target of treatment for ribavirin associated ENT1 hemolytic anemia  ENT1END ?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as ENT2 sunitinib ENT2END and sorafenib have been found to cause acute hemolysis
1	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and ENT1 sorafenib ENT1END  have been found to cause acute ENT2 hemolysis ENT2END
0	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ENT1 ribavirin  ENT1END has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute ENT2 hemolysis ENT2END
0	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute ENT1 hemolysis  ENT1END . We aimed to investigate whether there is a relation between hemoglobin, haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia. METHODS: Fourteen patients chronically infected with hepatitis C virus were treated by ENT2 pegylated interferon alpha 2a ENT2END and ribavirin
1	Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia?BACKGROUND/AIMS: Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as ENT1 sunitinib  ENT1END  and sorafenib have been found to cause acute ENT2 hemolysis ENT2END
0	Diltiazem was used as a comparison drug and autonomic blockade with atropine and ENT1 nadolol ENT1END was applied in some experiments. Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during ENT2 AF ENT2END
0	METHODS: To evaluate the potential mechanisms of ENT1 AF  ENT1END promotion by Ca(2+) channel blockers, we administered verapamil to morphine- ENT2 chloralose ENT2END anesthetized dogs
0	METHODS: To evaluate the potential mechanisms of ENT1 AF ENT1END  promotion by Ca(2+) channel blockers, we administered verapamil to ENT2 morphine ENT2END -chloralose anesthetized dogs
0	METHODS: To evaluate the potential mechanisms of ENT1 AF ENT1END  promotion by ENT2 Ca ENT2END (2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs
1	RESULTS: ENT1 Verapamil ENT1END caused ENT2 AF ENT2END promotion in six dogs, increasing mean duration of AF induced by burst pacing, from 8+/-4 s (mean+/-S
0	Diltiazem was used as a comparison drug and autonomic blockade with ENT1 atropine  ENT1END and nadolol was applied in some experiments. Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during ENT2 AF ENT2END
0	ENT1 Diltiazem ENT1END did not affect ERP, ENT2 AF ENT2END cycle length or AF duration, but produced conduction acceleration similar to that caused by verapamil (n=5)
0	BACKGROUND: ENT1 Atrial tachycardia  ENT1END induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current. There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition. METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs. Diltiazem was used as a comparison drug and autonomic blockade with atropine and ENT2 nadolol ENT2END was applied in some experiments
0	BACKGROUND: ENT1 Atrial tachycardia  ENT1END -induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current. There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition. METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine ENT2 chloralose ENT2END anesthetized dogs
0	BACKGROUND: ENT1 Atrial tachycardia  ENT1END -induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current. There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition. METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to ENT2 morphine ENT2END -chloralose anesthetized dogs
0	BACKGROUND: ENT1 Atrial tachycardia ENT1END -induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type ENT2 Ca ENT2END (2+) current
0	Effects of ENT1 verapamil  ENT1END  on atrial fibrillation and its electrophysiological determinants in dogs.BACKGROUND: ENT2 Atrial tachycardia ENT2END -induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current
0	BACKGROUND: ENT1 Atrial tachycardia  ENT1END -induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current. There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition. METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs. Diltiazem was used as a comparison drug and autonomic blockade with ENT2 atropine ENT2END and nadolol was applied in some experiments
0	BACKGROUND: ENT1 Atrial tachycardia ENT1END -induced remodeling promotes the occurrence and maintenance of atrial fibrillation (AF) and decreases L-type Ca(2+) current. There is also a clinical suggestion that acute L-type Ca(2) channel blockade can promote AF, consistent with an AF promoting effect of Ca(2+) channel inhibition. METHODS: To evaluate the potential mechanisms of AF promotion by Ca(2+) channel blockers, we administered verapamil to morphine-chloralose anesthetized dogs. ENT2 Diltiazem ENT2END was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments
0	In the absence of caffeine, ENT1 acetaminophen ENT1END (up to 300 mg/kg) did not modify the ENT2 seizures ENT2END induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS)
0	In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the ENT1 seizures ENT1END  induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS). Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive ENT2 adenosine ENT2END into ATP in slices of rat cerebral cortex
0	In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the ENT1 seizures ENT1END  induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS). Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ENT2 ATP ENT2END in slices of rat cerebral cortex
1	In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the ENT1 seizures ENT1END  induced by maximal electroshock and did not alter the convulsant dose of ENT2 pentylenetetrezol ENT2END in mice (tests performed by the Anticonvulsant Screening Project of NINCDS)
1	The frequency of sound-induced ENT1 seizures ENT1END after 12.5 or 25 mg/kg ENT2 caffeine ENT2END was reduced from 50 to 5% by acetaminophen
0	Reduction in caffeine ENT1 toxicity  ENT1END  by ENT2 acetaminophen ENT2END
0	Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS ENT1 toxicity  ENT1END of caffeine. Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP). The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen. In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS). Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive ENT2 adenosine ENT2END into ATP in slices of rat cerebral cortex
0	Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS ENT1 toxicity  ENT1END  of caffeine. Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP). The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen. In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice (tests performed by the Anticonvulsant Screening Project of NINCDS). Acetaminophen (up to 150 micrograms/mL) did not retard the incorporation of radioactive adenosine into ENT2 ATP ENT2END in slices of rat cerebral cortex
0	Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS, attention was focused on the possibility that the presence of acetaminophen (52 micrograms/mL) reduced the CNS ENT1 toxicity  ENT1END  of caffeine. Studies in DBA/2J mice showed that: 1) pretreatment with acetaminophen (100 mg/kg) increased the interval between the administration of caffeine (300 to 450 mg/kg IP) and the onset of fatal convulsions by a factor of about two; and 2) pretreatment with acetaminophen (75 mg/kg) reduced the incidence of audiogenic seizures produced in the presence of caffeine (12.5 to 75 mg/kg IP). The frequency of sound-induced seizures after 12.5 or 25 mg/kg caffeine was reduced from 50 to 5% by acetaminophen. In the absence of caffeine, acetaminophen (up to 300 mg/kg) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of ENT2 pentylenetetrezol ENT2END in mice (tests performed by the Anticonvulsant Screening Project of NINCDS)
0	Reduction in ENT1 caffeine ENT1END ENT2 toxicity ENT2END by acetaminophen
0	The later enhancement was attenuated after intra-accumbens shell treatment with ENT1 GR 55562 ENT1END (1 microg/side). Our findings indicate that cocaine induced ENT2 hyperlocomotion ENT2END is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively
1	1-10 microg/side), administered intra-accumbens shell prior to cocaine, dose-dependently attenuated the psychostimulant-induced ENT1 locomotor hyperactivity ENT1END  Such attenuation was not found in animals which had been injected with GR 55562 into the accumbens core. When injected into the accumbens shell (but not the core) before cocaine, ENT2 CP 93129 ENT2END (0
1	Our findings indicate that ENT1 cocaine  ENT1END induced ENT2 hyperlocomotion ENT2END is modified by 5-HT1B receptor ligands microinjected into the accumbens shell, but not core, this modification consisting in inhibitory and facilitatory effects of the 5-HT1B receptor antagonist (GR 55562) and agonist (CP 93129), respectively
0	ENT1 Atorva ENT1END reversed dex-induced ENT2 hypertension ENT2END (129 +/- 0
0	Atorva reversed dex-induced ENT1 hypertension ENT1END  (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001). Plasma ENT2 nitrate ENT2END /nitrite (NOx) was decreased in dex-treated rats compared to saline-treated rats (11
1	Atorva reversed ENT1 dex  ENT1END induced ENT2 hypertension ENT2END (129 +/- 0
0	Atorva reversed dex-induced ENT1 hypertension ENT1END  (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma ENT2 superoxide ENT2END (7931 +/- 392
0	Atorva reversed dex-induced ENT1 hypertension  ENT1END  (129 +/- 0.6 mmHg, vs. 135 +/- 0.6 mmHg P' < 0.05) and decreased plasma superoxide (7931 +/- 392.8 dex, 1187 +/- 441.2 atorva + dex, P < 0.0001). Plasma nitrate/ ENT2 nitrite ENT2END (NOx) was decreased in dex-treated rats compared to saline-treated rats (11
0	Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced ENT1 nephropathy ENT1END  in patients with chronic kidney disease.BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions. Serum ENT2 creatinine ENT2END (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications
0	In 414 patients, contrast volume, presence of diabetes mellitus, use of ENT1 N-acetylcysteine ENT1END  mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups. SCr increases > or = 0.5 mg/dL occurred in 4.4% (9 of 204 patients) after iopamidol and 6.7% (14 of 210 patients) after iodixanol (P=0.39), whereas rates of SCr increases > or = 25% were 9.8% and 12.4%, respectively (P=0.44). In patients with diabetes, SCr increases > or = 0.5 mg/dL were 5.1% (4 of 78 patients) with iopamidol and 13.0% (12 of 92 patients) with iodixanol (P=0.11), whereas SCr increases > or = 25% were 10.3% and 15.2%, respectively (P=0.37). Mean post-SCr increases were significantly less with iopamidol (all patients: 0.07 versus 0.12 mg/dL, 6.2 versus 10.6 micromol/L, P=0.03; patients with diabetes: 0.07 versus 0.16 mg/dL, 6.2 versus 14.1 micromol/L, P=0.01). CONCLUSIONS: The rate of contrast-induced ENT2 nephropathy ENT2END , defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or iodixanol to high-risk patients, with or without diabetes mellitus
1	CONCLUSIONS: The rate of contrast-induced ENT1 nephropathy ENT1END , defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or ENT2 iodixanol ENT2END to high-risk patients, with or without diabetes mellitus
1	CONCLUSIONS: The rate of contrast-induced ENT1 nephropathy ENT1END , defined by multiple end points, is not statistically different after the intraarterial administration of ENT2 iopamidol ENT2END or iodixanol to high-risk patients, with or without diabetes mellitus
1	Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced ENT1 nephropathy ENT1END  in patients with chronic kidney disease.BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality ENT2 contrast medium ENT2END iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients
0	METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with ENT1 chronic kidney disease  ENT1END (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions. Serum ENT2 creatinine ENT2END (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications
0	METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with ENT1 chronic kidney disease  ENT1END  (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions. Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications. The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline. Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr. In 414 patients, contrast volume, presence of diabetes mellitus, use of ENT2 N-acetylcysteine ENT2END , mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups
0	METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and ENT1 iodixanol  ENT1END in patients with ENT2 chronic kidney disease ENT2END (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions
0	METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of ENT1 iopamidol  ENT1END and iodixanol in patients with ENT2 chronic kidney disease ENT2END (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions
0	Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with ENT1 chronic kidney disease  ENT1END .BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality ENT2 contrast medium ENT2END iopamidol with that of the iso-osmolality contrast medium iodixanol in high-risk patients
0	Serum ENT1 creatinine ENT1END  (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications. The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline. Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr. In 414 patients, contrast volume, presence of ENT2 diabetes mellitus ENT2END , use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups
0	In 414 patients, contrast volume, presence of ENT1 diabetes mellitus  ENT1END , use of ENT2 N-acetylcysteine ENT2END , mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups
0	CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of iopamidol or ENT1 iodixanol ENT1END  to high-risk patients, with or without ENT2 diabetes mellitus ENT2END
0	CONCLUSIONS: The rate of contrast-induced nephropathy, defined by multiple end points, is not statistically different after the intraarterial administration of ENT1 iopamidol  ENT1END  or iodixanol to high-risk patients, with or without ENT2 diabetes mellitus ENT2END
0	BACKGROUND: No direct comparisons exist of the renal tolerability of the low-osmolality contrast medium iopamidol with that of the iso-osmolality ENT1 contrast medium  ENT1END iodixanol in high-risk patients. METHODS AND RESULTS: The present study is a multicenter, randomized, double-blind comparison of iopamidol and iodixanol in patients with chronic kidney disease (estimated glomerular filtration rate, 20 to 59 mL/min) who underwent cardiac angiography or percutaneous coronary interventions. Serum creatinine (SCr) levels and estimated glomerular filtration rate were assessed at baseline and 2 to 5 days after receiving medications. The primary outcome was a postdose SCr increase > or = 0.5 mg/dL (44.2 micromol/L) over baseline. Secondary outcomes were a postdose SCr increase > or = 25%, a postdose estimated glomerular filtration rate decrease of > or = 25%, and the mean peak change in SCr. In 414 patients, contrast volume, presence of ENT2 diabetes mellitus ENT2END , use of N-acetylcysteine, mean baseline SCr, and estimated glomerular filtration rate were comparable in the 2 groups
1	The third patient had acute ENT1 amphetamine ENT1END induced ENT2 chorea ENT2END after prolonged oral contraception
1	ENT1 Chorea  ENT1END  associated with ENT2 oral contraception ENT2END
0	The third patient had acute ENT1 amphetamine ENT1END -induced chorea after prolonged oral contraception. Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or ENT2 rheumatic fever ENT2END
0	The third patient had acute amphetamine-induced chorea after prolonged ENT1 oral contraception  ENT1END  Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or ENT2 rheumatic fever ENT2END
0	Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of ENT1 telmisartan  ENT1END  and amlodipine versus amlodipine monotherapy in Indian adults with stage II ENT2 hypertension ENT2END
0	Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus ENT1 amlodipine  ENT1END  monotherapy in Indian adults with stage II ENT2 hypertension ENT2END
0	The novel immunosuppressive (IS) drug sirolmus (Srl) lacks ENT1 nephrotoxic ENT1END effects; however, proteinuria associated with Srl has been reported following renal transplantation. In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown. In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS. Concomitant IS consisted of mycophenolate mofetil +/- ENT2 steroids ENT2END
0	Srl should be used with ACEi/ ENT1 ARB ENT1END therapy and patients monitored for proteinuria and increased ENT2 renal dysfunction ENT2END
0	Srl should be used with ENT1 ACEi  ENT1END ARB therapy and patients monitored for proteinuria and increased ENT2 renal dysfunction ENT2END
0	The novel immunosuppressive (IS) drug sirolmus ( ENT1 Srl  ENT1END  lacks ENT2 nephrotoxic ENT2END effects; however, proteinuria associated with Srl has been reported following renal transplantation
0	The novel immunosuppressive (IS) drug sirolmus (Srl) lacks ENT1 nephrotoxic ENT1END  effects; however, proteinuria associated with Srl has been reported following renal transplantation. In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown. In this study, long-term cardiac transplant patients were switched from ENT2 cyclosporine ENT2END to Srl-based IS
0	The novel immunosuppressive (IS) drug sirolmus (Srl) lacks ENT1 nephrotoxic ENT1END  effects; however, proteinuria associated with Srl has been reported following renal transplantation. In cardiac transplantation, the incidence of proteinuria associated with Srl is unknown. In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS. Concomitant IS consisted of ENT2 mycophenolate mofetil ENT2END +/- steroids
0	In cardiac transplantation, the incidence of ENT1 proteinuria  ENT1END associated with Srl is unknown. In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS. Concomitant IS consisted of mycophenolate mofetil +/- ENT2 steroids ENT2END
0	ACE inhibitor and angiotensin-releasing blocker ( ENT1 ARB ENT1END  therapy reduced ENT2 proteinuria ENT2END development
0	Srl should be used with ENT1 ACEi ENT1END /ARB therapy and patients monitored for ENT2 proteinuria ENT2END and increased renal dysfunction
1	The novel immunosuppressive (IS) drug sirolmus (Srl) lacks nephrotoxic effects; however, ENT1 proteinuria ENT1END associated with ENT2 Srl ENT2END has been reported following renal transplantation
0	In cardiac transplantation, the incidence of ENT1 proteinuria  ENT1END  associated with Srl is unknown. In this study, long-term cardiac transplant patients were switched from ENT2 cyclosporine ENT2END to Srl-based IS
0	In cardiac transplantation, the incidence of ENT1 proteinuria  ENT1END  associated with Srl is unknown. In this study, long-term cardiac transplant patients were switched from cyclosporine to Srl-based IS. Concomitant IS consisted of ENT2 mycophenolate mofetil ENT2END +/- steroids
1	Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of ENT1 hypaque 76 ENT1END  The subjects were ten patients found to have normal left ventricles and coronary arteries. Significant ENT2 QTC prolongation ENT2END occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output
1	Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one, three, five and ten minutes after injection of ENT1 hypaque 76 ENT1END . The subjects were ten patients found to have normal left ventricles and coronary arteries. Significant QTC prolongation occurred in 30 seconds to one minute in association with marked ENT2 hypotension ENT2END and elevation of cardiac output
1	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of renal disease developed ENT1 seizures ENT1END while receiving maximum doses of ENT2 imipenem/cilastatin ENT2END
0	All ENT1 seizures ENT1END were controlled with therapeutic doses of ENT2 phenytoin ENT2END
0	Both patients had received maximum doses of other ENT1 beta-lactam ENT1END antibiotics without evidence of ENT2 seizure ENT2END activity
0	ENT1 Seizure  ENT1END  activity with ENT2 imipenem ENT2END therapy: incidence and risk factors
0	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of ENT1 renal disease  ENT1END developed seizures while receiving maximum doses of ENT2 imipenem/cilastatin ENT2END
0	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of ENT1 renal disease  ENT1END  developed seizures while receiving maximum doses of imipenem/cilastatin. Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents. All seizures were controlled with therapeutic doses of ENT2 phenytoin ENT2END
0	Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of ENT1 renal disease  ENT1END  developed seizures while receiving maximum doses of imipenem/cilastatin. Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents. All seizures were controlled with therapeutic doses of phenytoin. Both patients had received maximum doses of other ENT2 beta-lactam ENT2END antibiotics without evidence of seizure activity
0	Seizure activity with ENT1 imipenem  ENT1END  therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or head trauma and no evidence of ENT2 renal disease ENT2END developed seizures while receiving maximum doses of imipenem/cilastatin
0	Two elderly patients with a history of either cerebral vascular accident (CVA) or ENT1 head trauma  ENT1END and no evidence of renal disease developed seizures while receiving maximum doses of ENT2 imipenem/cilastatin ENT2END
0	Two elderly patients with a history of either cerebral vascular accident (CVA) or ENT1 head trauma  ENT1END  and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin. Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents. All seizures were controlled with therapeutic doses of ENT2 phenytoin ENT2END
0	Two elderly patients with a history of either cerebral vascular accident (CVA) or ENT1 head trauma  ENT1END  and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin. Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents. All seizures were controlled with therapeutic doses of phenytoin. Both patients had received maximum doses of other ENT2 beta-lactam ENT2END antibiotics without evidence of seizure activity
0	Seizure activity with ENT1 imipenem  ENT1END  therapy: incidence and risk factors.Two elderly patients with a history of either cerebral vascular accident (CVA) or ENT2 head trauma ENT2END and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin
0	Two elderly patients with a history of either cerebral vascular accident ( ENT1 CVA  ENT1END  or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of ENT2 imipenem/cilastatin ENT2END
0	Two elderly patients with a history of either cerebral vascular accident ( ENT1 CVA  ENT1END ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin. Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents. All seizures were controlled with therapeutic doses of ENT2 phenytoin ENT2END
0	Two elderly patients with a history of either cerebral vascular accident ( ENT1 CVA  ENT1END ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin. Neither patient had reported previous seizures or seizure-like activity nor was receiving anticonvulsant agents. All seizures were controlled with therapeutic doses of phenytoin. Both patients had received maximum doses of other ENT2 beta-lactam ENT2END antibiotics without evidence of seizure activity
0	Seizure activity with ENT1 imipenem ENT1END  therapy: incidence and risk factors.Two elderly patients with a history of either ENT2 cerebral vascular accident ENT2END (CVA) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem/cilastatin
1	Prenatal ENT1 dexamethasone  ENT1END  programs ENT2 hypertension ENT2END and renal injury in the rat
0	Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with ENT1 glomerulosclerosis ENT1END than control rats. This study shows that prenatal ENT2 dexamethasone ENT2END in rats results in a reduction in glomerular number, glomerulosclerosis, and hypertension when administered at specific points during gestation
1	Prenatal ENT1 dexamethasone  ENT1END  programs hypertension and ENT2 renal injury ENT2END in the rat
1	The ENT1 MFL regimen ENT1END achieves little palliative benefit and induces severe toxicity at a fairly high rate. Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with ENT2 impaired heart function ENT2END requires careful attention
0	Major toxicities were ENT1 cardiotoxicity  ENT1END and leukopenia. Eight patients were dead in the last follow-up; two of them died of treatment-related toxicity. The ENT2 MFL regimen ENT2END achieves little palliative benefit and induces severe toxicity at a fairly high rate
0	Eight patients were dead in the last follow-up; two of them died of treatment-related ENT1 toxicity  ENT1END  The ENT2 MFL regimen ENT2END achieves little palliative benefit and induces severe toxicity at a fairly high rate
0	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose ENT1 5-FU  ENT1END  and leucovorin (MFL): low palliative benefit and high treatment-related ENT2 toxicity ENT2END
0	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related ENT1 toxicity ENT1END .For previously treated advanced breast cancer, there is no standard second-line therapy. Combination chemotherapy with ENT2 mitoxantrone ENT2END , high-dose 5-fluorouracil (5-FU) and leucovorin (MFL regimen) had been reported as an effective and well tolerated regimen
0	Treatment of previously treated metastatic breast cancer by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and ENT1 leucovorin  ENT1END  (MFL): low palliative benefit and high treatment-related ENT2 toxicity ENT2END
1	Major toxicities were cardiotoxicity and ENT1 leukopenia  ENT1END  Eight patients were dead in the last follow-up; two of them died of treatment-related toxicity. The ENT2 MFL regimen ENT2END achieves little palliative benefit and induces severe toxicity at a fairly high rate
0	Treatment of previously treated metastatic ENT1 breast cancer ENT1END  by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and leucovorin ENT2 MFL ENT2END ): low palliative benefit and high treatment-related toxicity
0	Treatment of previously treated metastatic ENT1 breast cancer  ENT1END  by mitoxantrone and 48-hour continuous infusion of high-dose ENT2 5-FU ENT2END and leucovorin (MFL): low palliative benefit and high treatment-related toxicity
0	Treatment of previously treated metastatic ENT1 breast cancer  ENT1END  by ENT2 mitoxantrone ENT2END and 48-hour continuous infusion of high-dose 5-FU and leucovorin (MFL): low palliative benefit and high treatment-related toxicity
0	Treatment of previously treated metastatic ENT1 breast cancer  ENT1END  by mitoxantrone and 48-hour continuous infusion of high-dose 5-FU and ENT2 leucovorin ENT2END (MFL): low palliative benefit and high treatment-related toxicity
0	From October 1993 to November 1995, we treated 13 patients with previously chemotherapy-treated metastatic ENT1 breast cancer ENT1END by mitoxantrone, 12 mg/m2, on day 1 and continuous infusion of 5-FU, 3000 mg/m2, together with leucovorin, 300 mg/m2, for 48 h from day 1 to 2. Each course of chemotherapy was given every 4 weeks. Most of these patients had more than two metastatic sites, with lung metastasis predominant. Seven patients had been treated with ENT2 anthracycline ENT2END
0	), enhanced the later (60-120 min) ENT1 nicotine ENT1END induced hyperactivity, and raised spontaneous nocturnal activity. Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region. We conclude that the interpeduncular nucleus mediates nicotinic ENT2 depression ENT2END of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain
0	Partial lesions were made with ENT1 kainic acid  ENT1END in the interpeduncular nucleus of the ventral midbrain of the rat. Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity. Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region. We conclude that the interpeduncular nucleus mediates nicotinic ENT2 depression ENT2END of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain
0	025), but not for ENT1 tyrosine  ENT1END hydroxylase in the surrounding catecholaminergic A10 region. We conclude that the interpeduncular nucleus mediates nicotinic ENT2 depression ENT2END of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain
0	Lesions reduced the extent of immunohistological staining for ENT1 choline  ENT1END acetyltransferase in the interpeduncular nucleus (p <0.025), but not for tyrosine hydroxylase in the surrounding catecholaminergic A10 region. We conclude that the interpeduncular nucleus mediates nicotinic ENT2 depression ENT2END of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain
1	), enhanced the later (60-120 min) ENT1 nicotine ENT1END -induced ENT2 hyperactivity ENT2END , and raised spontaneous nocturnal activity
0	Partial lesions were made with ENT1 kainic acid  ENT1END  in the interpeduncular nucleus of the ventral midbrain of the rat. Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field locomotor hypoactivity caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced ENT2 hyperactivity ENT2END , and raised spontaneous nocturnal activity
0	), enhanced the later (60-120 min) nicotine-induced ENT1 hyperactivity  ENT1END , and raised spontaneous nocturnal activity. Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for ENT2 tyrosine ENT2END hydroxylase in the surrounding catecholaminergic A10 region
0	), enhanced the later (60-120 min) nicotine-induced ENT1 hyperactivity  ENT1END , and raised spontaneous nocturnal activity. Lesions reduced the extent of immunohistological staining for ENT2 choline ENT2END acetyltransferase in the interpeduncular nucleus (p <0
0	25) blunted the early (<60 min) free-field ENT1 locomotor hypoactivity ENT1END caused by ENT2 nicotine ENT2END (0
0	Partial lesions were made with ENT1 kainic acid  ENT1END  in the interpeduncular nucleus of the ventral midbrain of the rat. Compared with sham-operated controls, lesions significantly (p < 0.25) blunted the early (<60 min) free-field ENT2 locomotor hypoactivity ENT2END caused by nicotine (0
0	25) blunted the early (<60 min) free-field ENT1 locomotor hypoactivity  ENT1END  caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity. Lesions reduced the extent of immunohistological staining for choline acetyltransferase in the interpeduncular nucleus (p <0.025), but not for ENT2 tyrosine ENT2END hydroxylase in the surrounding catecholaminergic A10 region
0	25) blunted the early (<60 min) free-field ENT1 locomotor hypoactivity  ENT1END  caused by nicotine (0.5 mg kg(-1), i.m.), enhanced the later (60-120 min) nicotine-induced hyperactivity, and raised spontaneous nocturnal activity. Lesions reduced the extent of immunohistological staining for ENT2 choline ENT2END acetyltransferase in the interpeduncular nucleus (p <0
1	0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, ENT1 weight loss ENT1END and ataxia. Side-effects tended to diminish during treatment but remained significant at week 8. Despite this, the drop-out rate was low. CONCLUSIONS: ENT2 Alprazolam ENT2END caused side-effects and adverse effects during treatment but many patients were willing to accept these
0	Compared with placebo subjects, ENT1 alprazolam ENT1END patients developed more adverse reactions (21% v. 0%) of depression, enuresis, disinhibition and ENT2 aggression ENT2END ; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia
1	Compared with placebo subjects, ENT1 alprazolam ENT1END  patients developed more adverse reactions (21% v. 0%) of depression, ENT2 enuresis ENT2END , disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia
1	0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ENT1 ataxia  ENT1END  Side-effects tended to diminish during treatment but remained significant at week 8. Despite this, the drop-out rate was low. CONCLUSIONS: ENT2 Alprazolam ENT2END caused side-effects and adverse effects during treatment but many patients were willing to accept these
0	The efficacy of ENT1 alprazolam ENT1END and placebo in ENT2 panic disorder ENT2END with agoraphobia, and the side-effect and adverse effect profiles of both drug groups were measured
0	Controlled study in agoraphobia with ENT1 panic disorder ENT1END .BACKGROUND: The widespread use of ENT2 benzodiazepines ENT2END has led to increasing recognition of their unwanted effects
0	METHOD: In London and Toronto 154 patients who met DSM-III criteria for panic disorder with ENT1 agoraphobia ENT1END were randomised to ENT2 alprazolam ENT2END or placebo
0	Controlled study in ENT1 agoraphobia  ENT1END  with panic disorder.BACKGROUND: The widespread use of ENT2 benzodiazepines ENT2END has led to increasing recognition of their unwanted effects
1	0%) of depression, enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, ENT1 impaired memory  ENT1END  weight loss and ataxia. Side-effects tended to diminish during treatment but remained significant at week 8. Despite this, the drop-out rate was low. CONCLUSIONS: ENT2 Alprazolam ENT2END caused side-effects and adverse effects during treatment but many patients were willing to accept these
1	Compared with placebo subjects, ENT1 alprazolam ENT1END  patients developed more adverse reactions (21% v. 0%) of ENT2 depression ENT2END , enuresis, disinhibition and aggression; and more side-effects, particularly sedation, irritability, impaired memory, weight loss and ataxia
1	ENT1 Levodopa  ENT1END -induced oromandibular ENT2 dystonia ENT2END in progressive supranuclear palsy
0	In this report we describe an unusual case of reversible ENT1 levodopa ENT1END induced ENT2 Oromandibular dystonia ENT2END (OMD) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP, and discuss the possible underlying pathophysiology
0	ENT1 Levodopa ENT1END induced dyskinesias have been reported in Parkinson's disease and ENT2 multiple system atrophy ENT2END
0	ENT1 Levodopa ENT1END -induced ENT2 dyskinesias ENT2END have been reported in Parkinson's disease and multiple system atrophy
0	Levodopa-induced oromandibular dystonia in ENT1 progressive supranuclear palsy ENT1END ENT2 Levodopa ENT2END -induced dyskinesias have been reported in Parkinson's disease and multiple system atrophy
0	ENT1 Levodopa ENT1END -induced dyskinesias have been reported in ENT2 Parkinson's disease ENT2END and multiple system atrophy
0	A warfarin-drug interaction could have contributed to the ENT1 haemorrhage ENT1END in 24 (41%) of the ENT2 warfarin ENT2END patients and in 7 of these (12%) the bleeding complication was considered being possible to avoid
1	PURPOSE: To evaluate the frequency, severity and preventability of ENT1 warfarin ENT1END induced ENT2 cerebral haemorrhages ENT2END due to warfarin and warfarin-drug interactions in patients living in the county of Osterg  tland, Sweden
0	Iron accumulation is considered to be involved in the pathogenesis of ENT1 Parkinson's disease ENT1END  To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals. The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN. As a result, ENT2 dopamine ENT2END release and content, as well as its metabolites contents were decreased in caudate putamen
0	Iron accumulation is considered to be involved in the pathogenesis of ENT1 Parkinson's disease ENT1END . To demonstrate the relationship between peripheral ENT2 iron ENT2END overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals
0	Iron accumulation is considered to be involved in the pathogenesis of ENT1 Parkinson's disease ENT1END . To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, ENT2 tyrosine ENT2END hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals
0	Peripheral ENT1 iron dextran  ENT1END  induced degeneration of dopaminergic neurons in rat substantia nigra.Iron accumulation is considered to be involved in the pathogenesis of ENT2 Parkinson's disease ENT2END
0	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, tyrosine hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the ENT1 degeneration of dopaminergic neurons  ENT1END and increased iron content in the SN of iron dextran overloaded animals. The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH-immunoreactive neurons in the SN. As a result, ENT2 dopamine ENT2END release and content, as well as its metabolites contents were decreased in caudate putamen
0	These results suggest that peripheral iron dextran can increase the iron level in the SN, where excessive ENT1 iron ENT1END causes the ENT2 degeneration of dopaminergic neurons ENT2END
0	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra (SN), in the present study we used fast cyclic voltammetry, ENT1 tyrosine  ENT1END  hydroxylase (TH) immunohistochemistry, Perls' iron staining, and high performance liquid chromatography-electrochemical detection to study the ENT2 degeneration of dopaminergic neurons ENT2END and increased iron content in the SN of iron dextran overloaded animals
1	Peripheral ENT1 iron dextran  ENT1END  induced ENT2 degeneration of dopaminergic neurons ENT2END in rat substantia nigra
0	ENT1 Sodium chloride ENT1END solution (0.9%) or noradrenaline in doses of 4, 12 and 36 micrograms h-1 kg-1 was infused for five consecutive days, either intrarenally (by a new technique) or intravenously into rats with one kidney removed. Intrarenal infusion of noradrenaline caused ENT2 hypertension ENT2END at doses which did not do so when infused intravenously
1	Intrarenal infusion of ENT1 noradrenaline  ENT1END caused ENT2 hypertension ENT2END at doses which did not do so when infused intravenously
0	For each of the three tested calcium channel blockers ( ENT1 diltiazem ENT1END  verapamil and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p. dose of bupivacaine. The convulsant activity, the time of latency to convulse and the mortality rate were assessed in each group. The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers. The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced ENT2 convulsions ENT2END ; this effect was less pronounced with bepridil
0	For each of the three tested calcium channel blockers (diltiazem, ENT1 verapamil  ENT1END and bepridil) 6 groups of mice were treated by two different doses, i.e. 2 and 10 mg/kg/i.p., or an equal volume of saline for the control group (n = 20); 15 minutes later, all the animals were injected with a single 50 mg/kg/i.p. dose of bupivacaine. The convulsant activity, the time of latency to convulse and the mortality rate were assessed in each group. The local anesthetic-induced mortality was significantly increased by the three different calcium channel blockers. The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced ENT2 convulsions ENT2END ; this effect was less pronounced with bepridil
1	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain ENT1 bupivacaine  ENT1END induced ENT2 convulsions ENT2END ; this effect was less pronounced with bepridil
0	The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine-induced ENT1 convulsions ENT1END ; this effect was less pronounced with ENT2 bepridil ENT2END
0	The convulsant activity of bupivacaine was not significantly modified but ENT1 calcium  ENT1END channel blockers decreased the time of latency to obtain bupivacaine-induced ENT2 convulsions ENT2END ; this effect was less pronounced with bepridil
0	The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute ENT1 toxicity ENT1END  For each of the three tested calcium channel blockers ENT2 diltiazem ENT2END , verapamil and bepridil) 6 groups of mice were treated by two different doses, i
0	The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute ENT1 toxicity  ENT1END . For each of the three tested calcium channel blockers (diltiazem, ENT2 verapamil ENT2END and bepridil) 6 groups of mice were treated by two different doses, i
0	Effects of calcium channel blockers on ENT1 bupivacaine  ENT1END -induced ENT2 toxicity ENT2END
0	The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute ENT1 toxicity ENT1END . For each of the three tested calcium channel blockers (diltiazem, verapamil and ENT2 bepridil ENT2END ) 6 groups of mice were treated by two different doses, i
0	The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine-induced acute ENT1 toxicity ENT1END . For each of the three tested ENT2 calcium ENT2END channel blockers (diltiazem, verapamil and bepridil) 6 groups of mice were treated by two different doses, i
0	OUTCOME MEASURES: Pupil size at time points after administration of ENT1 tropicamide ENT1END and pilocarpine; scopolamine-induced ENT2 impairment in word recall ENT2END
0	OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and ENT1 pilocarpine  ENT1END  scopolamine-induced ENT2 impairment in word recall ENT2END
1	OUTCOME MEASURES: Pupil size at time points after administration of tropicamide and pilocarpine; ENT1 scopolamine  ENT1END induced ENT2 impairment in word recall ENT2END
0	OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as ENT1 Alzheimer's disease ENT1END  yet correlations between central and peripheral responses have not been properly studied. This study assessed the effect of normal aging on (1) the ENT2 tropicamide ENT2END -induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine
0	OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as ENT1 Alzheimer's disease ENT1END , yet correlations between central and peripheral responses have not been properly studied. This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with ENT2 pilocarpine ENT2END
0	OBJECTIVE: The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as ENT1 Alzheimer's disease ENT1END , yet correlations between central and peripheral responses have not been properly studied. This study assessed the effect of normal aging on (1) the tropicamide-induced increase in pupil diameter, and (2) the reversal of this effect with pilocarpine. ENT2 Scopolamine ENT2END was used as a positive control to detect age-dependent changes in central cholinergic functioning in the elderly
1	In the present work we assessed the effect of treatment of rats with gum Arabic on ENT1 acute renal failure ENT1END induced by ENT2 gentamicin ENT2END (GM) nephrotoxicity
1	In the present work we assessed the effect of treatment of rats with ENT1 gum Arabic  ENT1END on ENT2 acute renal failure ENT2END induced by gentamicin (GM) nephrotoxicity
0	In the present work we assessed the effect of treatment of rats with gum Arabic on ENT1 acute renal failure ENT1END  induced by gentamicin (GM) nephrotoxicity. Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period). Nephrotoxicity was assessed by measuring the concentrations of ENT2 creatinine ENT2END and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections
0	In the present work we assessed the effect of treatment of rats with gum Arabic on ENT1 acute renal failure ENT1END  induced by gentamicin (GM) nephrotoxicity. Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period). Nephrotoxicity was assessed by measuring the concentrations of creatinine and ENT2 urea ENT2END in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections
0	In the present work we assessed the effect of treatment of rats with gum Arabic on ENT1 acute renal failure ENT1END  induced by gentamicin (GM) nephrotoxicity. Rats were treated with the vehicle (2 mL/kg of distilled water and 5% w/v cellulose, 10 days), gum Arabic (2 mL/kg of a 10% w/v aqueous suspension of gum Arabic powder, orally for 10 days), or gum Arabic concomitantly with GM (80mg/kg/day intramuscularly, during the last six days of the treatment period). Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced ENT2 glutathione ENT2END (GSH) in the kidney cortex, and by light microscopic examination of kidney sections
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The ENT1 GM ENT1END induced proximal ENT2 tubular necrosis ENT2END appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal ENT1 tubular necrosis ENT1END  appeared to be slightly less severe in rats given GM together with ENT2 gum Arabic ENT2END than in those given GM and cellulose
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased ENT1 creatinine  ENT1END and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal ENT2 tubular necrosis ENT2END appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and ENT1 urea  ENT1END by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal ENT2 tubular necrosis ENT2END appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical ENT1 GSH  ENT1END by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal ENT2 tubular necrosis ENT2END appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose
0	It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of ENT1 GM ENT1END ENT2 nephrotoxicity ENT2END
0	The effect of treatment with ENT1 gum Arabic  ENT1END  on gentamicin ENT2 nephrotoxicity ENT2END in rats: a preliminary study
0	ENT1 Nephrotoxicity  ENT1END was assessed by measuring the concentrations of ENT2 creatinine ENT2END and urea in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections
0	ENT1 Nephrotoxicity  ENT1END  was assessed by measuring the concentrations of creatinine and ENT2 urea ENT2END in the plasma and reduced glutathione (GSH) in the kidney cortex, and by light microscopic examination of kidney sections
0	ENT1 Nephrotoxicity  ENT1END  was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced ENT2 glutathione ENT2END (GSH) in the kidney cortex, and by light microscopic examination of kidney sections
0	It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of ENT1 GM ENT1END  nephrotoxicity. Further work is warranted on the effect of the treatments on renal functional aspects in models of ENT2 chronic renal failure ENT2END , and on the mechanism(s) involved
0	It could be inferred that ENT1 gum Arabic  ENT1END treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity. Further work is warranted on the effect of the treatments on renal functional aspects in models of ENT2 chronic renal failure ENT2END , and on the mechanism(s) involved
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased ENT1 creatinine  ENT1END  and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose. It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity. Further work is warranted on the effect of the treatments on renal functional aspects in models of ENT2 chronic renal failure ENT2END , and on the mechanism(s) involved
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and ENT1 urea  ENT1END  by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical GSH by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose. It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity. Further work is warranted on the effect of the treatments on renal functional aspects in models of ENT2 chronic renal failure ENT2END , and on the mechanism(s) involved
0	The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239%, respectively (compared to 432 and 346%, respectively, in rats treated with cellulose and GM), and decreased that of cortical ENT1 GSH  ENT1END  by 21% (compared to 27% in the cellulose plus GM group) The GM-induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose. It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity. Further work is warranted on the effect of the treatments on renal functional aspects in models of ENT2 chronic renal failure ENT2END , and on the mechanism(s) involved
0	Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced ENT1 cholestasis ENT1END  in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats. Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment. During [24-14C]sodium deoxycholate infusion, [14C]biliary bile acid secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats. Ethinyl estradiol-treated animals excreted significantly less 14C as ENT2 taurocholic acid ENT2END than did control animals, consistent with an impairment of 7alpha-hydroxylation of taurodeoxycholic acid
0	Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced ENT1 cholestasis ENT1END  in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats. Control rats were found to have a lower capacity to transport deoxycholic acid than ENT2 taurodeoxycholic acid ENT2END , and both were decreased by ethinyl estradiol treatment
1	Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ENT1 ethinyl estradiol  ENT1END -induced ENT2 cholestasis ENT2END in rats
0	Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced ENT1 cholestasis  ENT1END  in rats. ENT2 Deoxycholic acid ENT2END conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats
0	Increased sulfation and decreased 7alpha-hydroxylation of deoxycholic acid in ethinyl estradiol-induced ENT1 cholestasis ENT1END  in rats.Deoxycholic acid conjugation, transport capacity, and metabolism were compared in control and ethinyl estradiol-treated rats. Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid, and both were decreased by ethinyl estradiol treatment. During [24-14C]sodium deoxycholate infusion, [14C]biliary ENT2 bile acid ENT2END secretion increased, but bile flow did not change significantly in either control or ethinyl estradiol-treated rats
0	The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating ENT1 anxiety ENT1END scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall. The tests were performed preoperatively and 2 days postoperatively. There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value. The results indicate that hypotension induced by labetalol with ENT2 isoflurane ENT2END has no significant harmful effects on mental functions compared to normotensive anaesthesia
0	The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating ENT1 anxiety ENT1END  scale and self-rating depression scale) and two-part memory test battery with immediate and delayed recall. The tests were performed preoperatively and 2 days postoperatively. There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value. The results indicate that hypotension induced by ENT2 labetalol ENT2END with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia
0	The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating ENT1 depression  ENT1END scale) and two-part memory test battery with immediate and delayed recall. The tests were performed preoperatively and 2 days postoperatively. There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value. The results indicate that hypotension induced by labetalol with ENT2 isoflurane ENT2END has no significant harmful effects on mental functions compared to normotensive anaesthesia
0	The following psychological tests were performed: four subtests of the Wechsler Adult Intelligence Scale (similarities, digit span, vocabulary and digit symbol), Trail-Making tests A and B, Zung tests (self-rating anxiety scale and self-rating ENT1 depression  ENT1END  scale) and two-part memory test battery with immediate and delayed recall. The tests were performed preoperatively and 2 days postoperatively. There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value. The results indicate that hypotension induced by ENT2 labetalol ENT2END with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia
1	Twenty-four patients were anaesthetized for middle-ear surgery with deliberate hypotension induced by labetalol with ENT1 isoflurane  ENT1END ( ENT2 hypotensive ENT2END group)
1	Effects of deliberate ENT1 hypotension  ENT1END  induced by ENT2 labetalol ENT2END with isoflurane on neuropsychological function
0	Apomorphine, a nonselective ENT1 dopamine agonist ENT1END  was selected due to its biphasic behavioral effects, its ability to induce ENT2 hypothermia ENT2END , and to produce distinct changes to dopamine turnover in the rodent brain
0	Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced ENT1 hypothermia ENT1END  In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage. Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both. By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box. Dopamine turnover ratios (DOPAC:DA and ENT2 HVA ENT2END :DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts
0	Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce ENT1 hypothermia ENT1END , and to produce distinct changes to ENT2 dopamine ENT2END turnover in the rodent brain
0	Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced ENT1 hypothermia  ENT1END . In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage. Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both. By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box. Dopamine turnover ratios ( ENT2 DOPAC ENT2END :DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts
1	Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced ENT1 hypothermia ENT1END . In mice, ENT2 apomorphine ENT2END produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage
0	Apomorphine, a nonselective ENT1 dopamine agonist ENT1END , was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to dopamine turnover in the rodent brain. From such experiments there is evidence that characterization and detection of apomorphine-induced activity in rodents critically depends upon the test conditions employed. In rats, detection of apomorphine-induced ENT2 hyperactivity ENT2END was facilitated by a period of acclimatization to the test conditions
0	In rats, detection of apomorphine-induced ENT1 hyperactivity  ENT1END  was facilitated by a period of acclimatization to the test conditions. Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia. In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage. Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both. By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box. Dopamine turnover ratios (DOPAC:DA and ENT2 HVA ENT2END :DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts
0	Apomorphine, a nonselective dopamine agonist, was selected due to its biphasic behavioral effects, its ability to induce hypothermia, and to produce distinct changes to ENT1 dopamine  ENT1END  turnover in the rodent brain. From such experiments there is evidence that characterization and detection of apomorphine-induced activity in rodents critically depends upon the test conditions employed. In rats, detection of apomorphine-induced ENT2 hyperactivity ENT2END was facilitated by a period of acclimatization to the test conditions
0	In rats, detection of apomorphine-induced ENT1 hyperactivity ENT1END  was facilitated by a period of acclimatization to the test conditions. Moreover, test conditions can impact upon other physiological responses to apomorphine such as drug-induced hypothermia. In mice, apomorphine produced qualitatively different responses under novel conditions when compared to those behaviors elicited in the home test cage. Drug-induced gross activity counts were increased in the novel exploratory box only, while measures of stereotypic behavior were similar in both. By contrast, apomorphine-induced locomotion was more prominent in the novel exploratory box. Dopamine turnover ratios ENT2 DOPAC ENT2END :DA and HVA:DA) were found to be lower in those animals exposed to the exploratory box when compared to their home cage counterparts
1	In rats, detection of ENT1 apomorphine  ENT1END induced ENT2 hyperactivity ENT2END was facilitated by a period of acclimatization to the test conditions
0	The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and ENT1 bromocriptine ENT1END  It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from ENT2 neuroleptic malignant syndrome ENT2END
0	ENT1 Neuroleptic malignant syndrome ENT1END is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia. Risperidone, a benzisoxazole derivative antipsychotic, has high ENT2 serotonin ENT2END 5-HT2 receptor blockade and dose-related D2 receptor blockade
0	ENT1 Neuroleptic malignant syndrome ENT1END  is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia. Risperidone, a ENT2 benzisoxazole ENT2END derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade
0	A 73-year-old woman developed ENT1 neuroleptic malignant syndrome ENT1END after monotherapy with risperidone. The syndrome reversed after discontinuing risperidone and starting treatment with ENT2 dantrolene ENT2END and bromocriptine
1	Neuroleptic malignant syndrome with ENT1 risperidone ENT1END ENT2 Neuroleptic malignant syndrome ENT2END is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia
0	ENT1 Neuroleptic malignant syndrome ENT1END  is thought to be a result of ENT2 dopamine ENT2END D2 receptor blockade in the striatum of the basal ganglia
0	With this low frequency of ENT1 extrapyramidal symptoms  ENT1END  it was thought the frequency of neuroleptic malignant syndrome might also be lowered. A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone. The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and ENT2 bromocriptine ENT2END
0	Risperidone, a benzisoxazole derivative antipsychotic, has high ENT1 serotonin ENT1END  5-HT2 receptor blockade and dose-related D2 receptor blockade. The high ratio is believed to impart the low frequency of ENT2 extrapyramidal symptoms ENT2END with risperidone at low dosages
0	Risperidone, a ENT1 benzisoxazole  ENT1END  derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade. The high ratio is believed to impart the low frequency of ENT2 extrapyramidal symptoms ENT2END with risperidone at low dosages
0	With this low frequency of ENT1 extrapyramidal symptoms  ENT1END , it was thought the frequency of neuroleptic malignant syndrome might also be lowered. A 73-year-old woman developed neuroleptic malignant syndrome after monotherapy with risperidone. The syndrome reversed after discontinuing risperidone and starting treatment with ENT2 dantrolene ENT2END and bromocriptine
0	The high ratio is believed to impart the low frequency of ENT1 extrapyramidal symptoms ENT1END  with ENT2 risperidone ENT2END at low dosages
0	Neuroleptic malignant syndrome is thought to be a result of ENT1 dopamine  ENT1END  D2 receptor blockade in the striatum of the basal ganglia. Risperidone, a benzisoxazole derivative antipsychotic, has high serotonin 5-HT2 receptor blockade and dose-related D2 receptor blockade. The high ratio is believed to impart the low frequency of ENT2 extrapyramidal symptoms ENT2END with risperidone at low dosages
0	Cocaine-induced ENT1 anxiety ENT1END was also attenuated in Dbh +/- mice following administration of ENT2 disulfiram ENT2END , a dopamine beta-hydroxylase (DBH) inhibitor
0	ENT1 Norepinephrine  ENT1END  signaling through beta-adrenergic receptors is critical for expression of cocaine-induced ENT2 anxiety ENT2END
1	Norepinephrine signaling through beta-adrenergic receptors is critical for expression of ENT1 cocaine  ENT1END -induced ENT2 anxiety ENT2END
0	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced ENT1 anxiety ENT1END like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist ENT2 prazosin ENT2END and the alpha(2) antagonist yohimbine had no effect
0	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist propranolol blocked cocaine-induced ENT1 anxiety ENT1END -like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist ENT2 yohimbine ENT2END had no effect
0	While the mechanisms underlying cocaine's rewarding effects have been studied extensively, less attention has been paid to the unpleasant behavioral states induced by cocaine, such as ENT1 anxiety ENT1END  METHODS: In this study, we evaluated the performance of ENT2 dopamine ENT2END beta-hydroxylase knockout (Dbh -/-) mice, which lack norepinephrine (NE), in the elevated plus maze (EPM) to examine the contribution of noradrenergic signaling to cocaine-induced anxiety
0	In experiments using specific adrenergic antagonists, we found that pretreatment with the beta-adrenergic receptor antagonist ENT1 propranolol  ENT1END blocked cocaine-induced ENT2 anxiety ENT2END -like behavior in Dbh +/- and wild-type C57BL6/J mice, while the alpha(1) antagonist prazosin and the alpha(2) antagonist yohimbine had no effect
0	Although the AE RBCs from an individual not taking dapsone had increased incubated Heinz body formation, the GSH content and ENT1 GSH ENT1END stability were normal. The pentose phosphate shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs. Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals. Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an ENT2 infection ENT2END is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E
0	Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since ENT1 dapsone  ENT1END does not cause hemolytic anemia at this dose in hematologically normal individuals. Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an ENT2 infection ENT2END is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E
0	The ENT1 pentose phosphate  ENT1END shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs. Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals. Given the influx of Southeast Asians into the United States, oxidant medications should be used with caution, especially if an ENT2 infection ENT2END is present, in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E
0	A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body ENT1 hemolytic anemia ENT1END while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis. Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced ENT2 glutathione ENT2END (GSH), and decreased GSH stability
1	Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since ENT1 dapsone ENT1END  does not cause ENT2 hemolytic anemia ENT2END at this dose in hematologically normal individuals
0	The ENT1 pentose phosphate  ENT1END  shunt activity of the non-dapsone-exposed AE RBCs was decreased compared to normal RBCs. Thus, AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo, since dapsone does not cause ENT2 hemolytic anemia ENT2END at this dose in hematologically normal individuals
0	A Cambodian woman with hemoglobin E trait (AE) and ENT1 leprosy  ENT1END developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis. Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced ENT2 glutathione ENT2END (GSH), and decreased GSH stability
0	A Cambodian woman with hemoglobin E trait (AE) and ENT1 leprosy ENT1END  developed a Heinz body hemolytic anemia while taking a dose of ENT2 dapsone ENT2END (50 mg/day) not usually associated with clinical hemolysis
0	A Cambodian woman with hemoglobin E trait (AE) and ENT1 leprosy ENT1END  developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical hemolysis. Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability. The ENT2 pentose phosphate ENT2END shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs
0	A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical ENT1 hemolysis  ENT1END  Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced ENT2 glutathione ENT2END (GSH), and decreased GSH stability
0	A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of ENT1 dapsone  ENT1END  (50 mg/day) not usually associated with clinical ENT2 hemolysis ENT2END
0	A Cambodian woman with hemoglobin E trait (AE) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone (50 mg/day) not usually associated with clinical ENT1 hemolysis  ENT1END . Her red blood cells (RBCs) had increased incubated Heinz body formation, decreased reduced glutathione (GSH), and decreased GSH stability. The ENT2 pentose phosphate ENT2END shunt activity of the dapsone-exposed AE RBCs was increased compared to normal RBCs
0	Renal failure was associated with ENT1 weight loss ENT1END in the ENT2 furosemide ENT2END -treated group
0	005 by ANOVA), with a rise in serum ENT1 creatinine  ENT1END from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l). Renal failure was associated with ENT2 weight loss ENT2END in the furosemide-treated group
1	ENT1 Renal function significantly deteriorated ENT1END in the group pretreated with ENT2 furosemide ENT2END (p < 0
0	ENT1 Renal function significantly deteriorated  ENT1END  in the group pretreated with furosemide (p < 0.005 by ANOVA), with a rise in serum ENT2 creatinine ENT2END from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l)
0	Potential deleterious effect of ENT1 furosemide  ENT1END  in radiocontrast ENT2 nephropathy ENT2END
0	005 by ANOVA), with a rise in serum ENT1 creatinine ENT1END  from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l). Renal failure was associated with weight loss in the furosemide-treated group. Furosemide may be deleterious in the prevention of radiocontrast ENT2 nephropathy ENT2END
0	ENT1 Renal failure  ENT1END was associated with weight loss in the ENT2 furosemide ENT2END -treated group
0	005 by ANOVA), with a rise in serum ENT1 creatinine  ENT1END  from 145 +/- 13 to 182 +/- 16 mumol/l at 24 h, while no change occurred in the control group (from 141 +/- 6 to 142 +/- 7 mumol/l). ENT2 Renal failure ENT2END was associated with weight loss in the furosemide-treated group
0	The findings suggest that ENT1 NIK-247 ENT1END may be a useful drug for the treatment of ENT2 Alzheimer's disease ENT2END
0	) improves ENT1 scopolamine  ENT1END induced amnesia but does not affect spontaneous movement. The findings suggest that NIK-247 may be a useful drug for the treatment of ENT2 Alzheimer's disease ENT2END
1	Effects of NIK-247 on cholinesterase and scopolamine-induced ENT1 amnesia ENT1END .The effects of ENT2 NIK-247 ENT2END on cholinesterase, scopolamine-induced amnesia and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and E-2020
1	The effects of NIK-247 on cholinesterase, scopolamine-induced ENT1 amnesia ENT1END and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors tacrine and ENT2 E-2020 ENT2END
1	The effects of NIK-247 on cholinesterase, scopolamine-induced ENT1 amnesia ENT1END  and spontaneous movement were examined and compared with those of the well-known cholinesterase inhibitors ENT2 tacrine ENT2END and E-2020
1	Effects of NIK-247 on cholinesterase and ENT1 scopolamine  ENT1END -induced ENT2 amnesia ENT2END
0	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a ENT1 hypotensive ENT1END mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
1	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT1 levodopa  ENT1END and a ENT2 hypotensive ENT2END mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	7%) and ENT1 septicaemia  ENT1END (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	7%) and ENT1 septicaemia  ENT1END  (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	1%), malignant ENT1 neoplasms  ENT1END (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	1%), malignant ENT1 neoplasms  ENT1END  (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	The low incidence of cerebral haemorrhage as a cause of ENT1 death  ENT1END in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	The low incidence of cerebral haemorrhage as a cause of ENT1 death  ENT1END  in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	The leading causes of death were pneumonia and ENT1 bronchitis  ENT1END (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	The leading causes of death were pneumonia and ENT1 bronchitis  ENT1END  (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	1%), ENT1 cerebral infarction  ENT1END (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	1%), ENT1 cerebral infarction  ENT1END  (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT1 noradrenaline ENT1END  levels in the ENT2 parkinsonian ENT2END brain
0	The low incidence of cerebral haemorrhage as a cause of death in patients with ENT1 Parkinson's disease  ENT1END may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	6%), ENT1 heart diseases  ENT1END (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	6%), ENT1 heart diseases  ENT1END  (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	The leading causes of death were ENT1 pneumonia  ENT1END and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	The leading causes of death were ENT1 pneumonia  ENT1END  and bronchitis (44.1%), malignant neoplasms (11.6%), heart diseases (4.1%), cerebral infarction (3.7%) and septicaemia (3.3%). Cerebral haemorrhage was the 11th most frequent cause of death, accounting for only 0.8% of deaths among the patients, whereas it was the 5th most common cause of death among the Japanese general population in 1985. The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	The low incidence of ENT1 cerebral haemorrhage  ENT1END as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced ENT2 noradrenaline ENT2END levels in the parkinsonian brain
0	The low incidence of ENT1 cerebral haemorrhage  ENT1END  as a cause of death in patients with Parkinson's disease may reflect the hypotensive effect of ENT2 levodopa ENT2END and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain
0	Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or ENT1 cancer of the renal pelvis, ureter or bladder ENT1END associated with consumption of either phenacetin or ENT2 paracetamol ENT2END was calculated from data acquired by questionnaire from 381 cases and 808 controls
1	The risk of renal papillary necrosis was increased nearly 20-fold by consumption of ENT1 phenacetin ENT1END  which also increased the risk for ENT2 cancer of the renal pelvis and bladder ENT2END but not for ureteric cancer
0	Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or ENT1 cancer of the renal pelvis, ureter or bladder  ENT1END associated with consumption of either phenacetin or ENT2 paracetamol ENT2END was calculated from data acquired by questionnaire from 381 cases and 808 controls
0	Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or ENT1 cancer of the renal pelvis, ureter or bladder ENT1END  associated with consumption of either ENT2 phenacetin ENT2END or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls
0	By contrast, we were unable to substantiate an increased risk from ENT1 paracetamol ENT1END consumption for renal papillary necrosis or any of these ENT2 cancers ENT2END although there was a suggestion of an association with cancer of the ureter
0	The risk of renal papillary necrosis was increased nearly 20-fold by consumption of ENT1 phenacetin  ENT1END , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer. By contrast, we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these ENT2 cancers ENT2END although there was a suggestion of an association with cancer of the ureter
0	Does ENT1 paracetamol  ENT1END  cause ENT2 urothelial cancer ENT2END or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls
0	Does paracetamol cause ENT1 urothelial cancer  ENT1END  or renal papillary necrosis?The risk of developing renal papillary necrosis or cancer of the renal pelvis, ureter or bladder associated with consumption of either ENT2 phenacetin ENT2END or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls
0	Does paracetamol cause urothelial cancer or renal papillary necrosis?The risk of developing renal papillary necrosis or ENT1 cancer of the renal pelvis, ureter or bladder  ENT1END associated with consumption of either phenacetin or ENT2 paracetamol ENT2END was calculated from data acquired by questionnaire from 381 cases and 808 controls
1	The risk of renal papillary necrosis was increased nearly 20-fold by consumption of ENT1 phenacetin ENT1END , which also increased the risk for ENT2 cancer of the renal pelvis and bladder ENT2END but not for ureteric cancer
0	By contrast, we were unable to substantiate an increased risk from ENT1 paracetamol ENT1END  consumption for ENT2 renal papillary necrosis ENT2END or any of these cancers although there was a suggestion of an association with cancer of the ureter
1	The risk of ENT1 renal papillary necrosis  ENT1END was increased nearly 20-fold by consumption of ENT2 phenacetin ENT2END , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer
0	The pathogenesis of 5-fluorouracil ENT1 neurotoxicity ENT1END may be due to a Krebs cycle blockade by fluoroacetate and ENT2 fluorocitrate ENT2END , thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating ENT1 cisplatinum ENT1END  etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, ENT2 neurotoxicity ENT2END due to high-dose 5-fluorouracil was highly suspected
0	Because ENT1 folinic acid  ENT1END was unlikely to be associated with this condition, ENT2 neurotoxicity ENT2END due to high-dose 5-fluorouracil was highly suspected
0	The pathogenesis of ENT1 5-fluorouracil ENT1END ENT2 neurotoxicity ENT2END may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	The pathogenesis of 5-fluorouracil ENT1 neurotoxicity ENT1END  may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, ENT2 thiamine ENT2END deficiency, or dihydrouracil dehydrogenase deficiency
0	The pathogenesis of 5-fluorouracil ENT1 neurotoxicity ENT1END  may be due to a Krebs cycle blockade by ENT2 fluoroacetate ENT2END and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	The pathogenesis of 5-fluorouracil ENT1 neurotoxicity ENT1END  may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or ENT2 dihydrouracil ENT2END dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, ENT1 etoposide  ENT1END  high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, ENT2 neurotoxicity ENT2END due to high-dose 5-fluorouracil was highly suspected
0	He developed acute neurologic symptoms of mental confusion, disorientation and ENT1 irritability  ENT1END  and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and ENT2 fluorocitrate ENT2END , thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating ENT1 cisplatinum  ENT1END , etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and ENT2 irritability ENT2END , and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and ENT1 folinic acid  ENT1END for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and ENT2 irritability ENT2END , and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion
0	He developed acute neurologic symptoms of mental confusion, disorientation and ENT1 irritability ENT1END , and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of ENT2 5-fluorouracil ENT2END and folinic acid infusion
0	He developed acute neurologic symptoms of mental confusion, disorientation and ENT1 irritability  ENT1END , and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, ENT2 thiamine ENT2END deficiency, or dihydrouracil dehydrogenase deficiency
0	He developed acute neurologic symptoms of mental confusion, disorientation and ENT1 irritability  ENT1END , and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by ENT2 fluoroacetate ENT2END and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	He developed acute neurologic symptoms of mental confusion, disorientation and ENT1 irritability  ENT1END , and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or ENT2 dihydrouracil ENT2END dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, ENT1 etoposide  ENT1END , high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and ENT2 irritability ENT2END , and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion
0	He developed acute neurologic symptoms of mental confusion, ENT1 disorientation  ENT1END and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and ENT2 fluorocitrate ENT2END , thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	Acute ENT1 confusion  ENT1END  induced by a high-dose infusion of 5-fluorouracil and folinic acid.A 61-year-old man was treated with combination chemotherapy incorporating ENT2 cisplatinum ENT2END , etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma
1	Acute ENT1 confusion  ENT1END  induced by a high-dose infusion of 5-fluorouracil and ENT2 folinic acid ENT2END
1	Acute ENT1 confusion  ENT1END  induced by a high-dose infusion of ENT2 5-fluorouracil ENT2END and folinic acid
0	He developed acute neurologic symptoms of mental confusion, ENT1 disorientation  ENT1END  and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, ENT2 thiamine ENT2END deficiency, or dihydrouracil dehydrogenase deficiency
0	He developed acute neurologic symptoms of mental confusion, ENT1 disorientation  ENT1END  and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by ENT2 fluoroacetate ENT2END and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	He developed acute neurologic symptoms of mental confusion, ENT1 disorientation  ENT1END  and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or ENT2 dihydrouracil ENT2END dehydrogenase deficiency
0	Acute ENT1 confusion  ENT1END  induced by a high-dose infusion of 5-fluorouracil and folinic acid.A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, ENT2 etoposide ENT2END , high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma
0	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and ENT1 fluorocitrate ENT1END , thiamine deficiency, or dihydrouracil dehydrogenase deficiency. High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	A 61-year-old man was treated with combination chemotherapy incorporating ENT1 cisplatinum  ENT1END , etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency. High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	High-dose 5-fluorouracil/ ENT1 folinic acid  ENT1END infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	High-dose ENT1 5-fluorouracil  ENT1END folinic acid infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, ENT1 thiamine  ENT1END  deficiency, or dihydrouracil dehydrogenase deficiency. High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by ENT1 fluoroacetate  ENT1END  and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency. High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or ENT1 dihydrouracil  ENT1END  dehydrogenase deficiency. High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, ENT1 etoposide  ENT1END , high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency. High-dose 5-fluorouracil/folinic acid infusion therapy has recently become a popular regimen for various ENT2 cancers ENT2END
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable ENT1 gastric adenocarcinoma  ENT1END  He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and ENT2 fluorocitrate ENT2END , thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating ENT1 cisplatinum  ENT1END , etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable ENT2 gastric adenocarcinoma ENT2END
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and ENT1 folinic acid  ENT1END  for an inoperable ENT2 gastric adenocarcinoma ENT2END
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose ENT1 5-fluorouracil  ENT1END (2,250 mg/m2/24 hours) and folinic acid for an inoperable ENT2 gastric adenocarcinoma ENT2END
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable ENT1 gastric adenocarcinoma  ENT1END . He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, ENT2 thiamine ENT2END deficiency, or dihydrouracil dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable ENT1 gastric adenocarcinoma  ENT1END . He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by ENT2 fluoroacetate ENT2END and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable ENT1 gastric adenocarcinoma  ENT1END . He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep coma, lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or ENT2 dihydrouracil ENT2END dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, ENT1 etoposide  ENT1END , high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable ENT2 gastric adenocarcinoma ENT2END
0	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT1 coma  ENT1END  lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and ENT2 fluorocitrate ENT2END , thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating ENT1 cisplatinum  ENT1END , etoposide, high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT2 coma ENT2END , lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion
1	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT1 coma ENT1END , lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and ENT2 folinic acid ENT2END infusion
1	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT1 coma  ENT1END , lasting for approximately 40 hours during the first dose (day 2) of ENT2 5-fluorouracil ENT2END and folinic acid infusion
0	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT1 coma  ENT1END , lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, ENT2 thiamine ENT2END deficiency, or dihydrouracil dehydrogenase deficiency
0	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT1 coma  ENT1END , lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by ENT2 fluoroacetate ENT2END and fluorocitrate, thiamine deficiency, or dihydrouracil dehydrogenase deficiency
0	He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT1 coma  ENT1END , lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion. This complication reappeared on day 25 during the second dose of 5-fluorouracil and folinic acid, which were then the only drugs given. Because folinic acid was unlikely to be associated with this condition, neurotoxicity due to high-dose 5-fluorouracil was highly suspected. The pathogenesis of 5-fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate, thiamine deficiency, or ENT2 dihydrouracil ENT2END dehydrogenase deficiency
0	A 61-year-old man was treated with combination chemotherapy incorporating cisplatinum, ENT1 etoposide  ENT1END , high-dose 5-fluorouracil (2,250 mg/m2/24 hours) and folinic acid for an inoperable gastric adenocarcinoma. He developed acute neurologic symptoms of mental confusion, disorientation and irritability, and then lapsed into a deep ENT2 coma ENT2END , lasting for approximately 40 hours during the first dose (day 2) of 5-fluorouracil and folinic acid infusion
1	RESULTS: The results indicate that ENT1 ciprofloxacin ENT1END  and norfloxacin-treated rats showed ENT2 anxious behaviour ENT2END in comparison to control rats in all the parameters studied
1	RESULTS: The results indicate that ciprofloxacin- and ENT1 norfloxacin  ENT1END treated rats showed ENT2 anxious behaviour ENT2END in comparison to control rats in all the parameters studied
0	INTRODUCTION: The possible anxiogenic effects of ENT1 fluoroquinolones  ENT1END  namely ciprofloxacin and norfloxacin, were investigated in adult Charles Foster albino rats of either sex, weighing 150-200 g. METHODS: The drugs were given orally, in doses of 50 mg/kg for five consecutive days and the experiments were performed on the fifth day. The tests included open-field exploratory behaviour, elevated plus maze and elevated zero maze, social interaction and novelty-suppressed feeding latency behaviour. RESULTS: The results indicate that ciprofloxacin- and norfloxacin-treated rats showed ENT2 anxious behaviour ENT2END in comparison to control rats in all the parameters studied
0	The effects of REM sleep deprivation (REMD) on apomorphine-induced ENT1 aggressiveness ENT1END and ENT2 quipazine ENT2END -induced head twitches in rats were determined
1	The effects of REM sleep deprivation (REMD) on ENT1 apomorphine  ENT1END induced ENT2 aggressiveness ENT2END and quipazine-induced head twitches in rats were determined
0	Forty-eight hr of REMD increased apomorphine-induced aggressiveness, and reduced (immediately after completing of REMD) or increased (96 hr after completing of ENT1 REMD ENT1END  ENT2 quipazine ENT2END -induced head twitches
0	The effects of REM sleep deprivation ( ENT1 REMD  ENT1END  on ENT2 apomorphine ENT2END -induced aggressiveness and quipazine-induced head twitches in rats were determined
1	The effects of REM sleep deprivation (REMD) on apomorphine-induced aggressiveness and ENT1 quipazine ENT1END -induced ENT2 head twitches ENT2END in rats were determined
0	The effects of REM sleep deprivation (REMD) on ENT1 apomorphine  ENT1END -induced aggressiveness and quipazine-induced ENT2 head twitches ENT2END in rats were determined
0	Enhanced heart magnetic resonance imaging also showed ENT1 subendocardial infarction ENT1END  However, there was no stenosis in coronary arteries on angiography. Coronary artery spasm was induced by a provocative test. Cessation of sorafenib and administration of Ca-channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib. Addition of oral ENT2 nicorandil ENT2END reduced his symptoms and maintained stable angina status
0	Enhanced heart magnetic resonance imaging also showed ENT1 subendocardial infarction ENT1END . However, there was no stenosis in coronary arteries on angiography. Coronary artery spasm was induced by a provocative test. Cessation of sorafenib and administration of Ca-channel blocker and ENT2 nitrates ENT2END ameliorated his symptoms, but relapse occurred after resumption of sorafenib
0	ENT1 Sorafenib  ENT1END -induced acute ENT2 myocardial infarction ENT2END due to coronary artery spasm
0	Enhanced heart magnetic resonance imaging also showed ENT1 subendocardial infarction ENT1END . However, there was no stenosis in coronary arteries on angiography. Coronary artery spasm was induced by a provocative test. Cessation of sorafenib and administration of ENT2 Ca ENT2END -channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib
0	Addition of oral ENT1 nicorandil ENT1END  reduced his symptoms and maintained ENT2 stable angina ENT2END status
0	Cessation of sorafenib and administration of Ca-channel blocker and ENT1 nitrates  ENT1END  ameliorated his symptoms, but relapse occurred after resumption of sorafenib. Addition of oral nicorandil reduced his symptoms and maintained ENT2 stable angina ENT2END status
0	Addition of oral nicorandil reduced his symptoms and maintained ENT1 stable angina ENT1END  status. We report the first case of ENT2 sorafenib ENT2END -induced coronary artery spasm
0	Cessation of sorafenib and administration of ENT1 Ca  ENT1END -channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib. Addition of oral nicorandil reduced his symptoms and maintained ENT2 stable angina ENT2END status
0	A 65-year-old man with advanced ENT1 renal cell carcinoma ENT1END was admitted due to continuing chest pain at rest. Two weeks before his admission, ENT2 sorafenib ENT2END had been started
0	Addition of oral ENT1 nicorandil ENT1END  reduced his symptoms and maintained stable angina status. We report the first case of sorafenib-induced ENT2 coronary artery spasm ENT2END
0	ENT1 Coronary artery spasm  ENT1END was induced by a provocative test. Cessation of sorafenib and administration of Ca-channel blocker and ENT2 nitrates ENT2END ameliorated his symptoms, but relapse occurred after resumption of sorafenib
1	We report the first case of sorafenib-induced ENT1 coronary artery spasm ENT1END . ENT2 Sorafenib ENT2END is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival
0	ENT1 Coronary artery spasm  ENT1END  was induced by a provocative test. Cessation of sorafenib and administration of ENT2 Ca ENT2END -channel blocker and nitrates ameliorated his symptoms, but relapse occurred after resumption of sorafenib
0	A 65-year-old man with advanced renal cell carcinoma was admitted due to continuing ENT1 chest pain  ENT1END at rest. Two weeks before his admission, ENT2 sorafenib ENT2END had been started
1	Dexamethasone ( ENT1 Dex ENT1END -induced ENT2 hypertension ENT2END is characterized by endothelial dysfunction associated with nitric oxide (NO) deficiency and increased superoxide (O2-) production
0	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of ENT1 NO ENT1END and reduced O2- production in various forms of ENT2 hypertension ENT2END
0	Anti-oxidant effects of ENT1 atorvastatin  ENT1END  in dexamethasone-induced ENT2 hypertension ENT2END in the rat
0	Atorvastatin (Ato) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced ENT1 O2-  ENT1END production in various forms of ENT2 hypertension ENT2END
0	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ENT1 ADP ENT1END O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and ENT2 myocardial injury ENT2END and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, ENT1 aspartate  ENT1END transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and ENT2 myocardial injury ENT2END and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of ENT1 lactate  ENT1END dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and ENT2 myocardial injury ENT2END and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and ENT1 malondialdehyde  ENT1END and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and ENT2 myocardial injury ENT2END and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, ENT1 creatine  ENT1END kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and ENT2 myocardial injury ENT2END and improved mitochondrial respiratory function
0	The protective role of salvianolic acid A against ENT1 isoproterenol ENT1END induced ENT2 myocardial damage ENT2END was further confirmed by histopathological examination
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and ENT1 glutathione  ENT1END peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and ENT2 myocardial injury ENT2END and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of ENT1 superoxide  ENT1END dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and ENT2 myocardial injury ENT2END and improved mitochondrial respiratory function
0	The protective role of ENT1 salvianolic acid A  ENT1END against isoproterenol-induced ENT2 myocardial damage ENT2END was further confirmed by histopathological examination
0	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ENT1 ADP ENT1END /O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function. The protective role of salvianolic acid A against isoproterenol-induced myocardial damage was further confirmed by histopathological examination. The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol-induced ENT2 myocardial infarction ENT2END
0	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced ENT1 myocardial infarction  ENT1END in rats. Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously. Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured. Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed. Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, ENT2 aspartate ENT2END transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart
0	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced ENT1 myocardial infarction  ENT1END  in rats. Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously. Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured. Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed. Isoproterenol-treated rats showed significant increases in the levels of ENT2 lactate ENT2END dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart
0	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced ENT1 myocardial infarction  ENT1END  in rats. Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously. Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured. Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed. Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and ENT2 malondialdehyde ENT2END and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart
0	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced ENT1 myocardial infarction  ENT1END  in rats. Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously. Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured. Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed. Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, ENT2 creatine ENT2END kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart
1	Cardioprotective effect of salvianolic acid A on ENT1 isoproterenol  ENT1END -induced ENT2 myocardial infarction ENT2END in rats
0	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced ENT1 myocardial infarction  ENT1END  in rats. Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously. Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured. Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed. Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and ENT2 glutathione ENT2END peroxidase in serum and heart
0	The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol-induced ENT1 myocardial infarction  ENT1END  in rats. Hemodynamic parameters and lead II electrocardiograph were monitored and recorded continuously. Cardiac marker enzymes and antioxidative parameters in serum and heart tissues were measured. Assay for mitochondrial respiratory function and histopathological examination of heart tissues were performed. Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of ENT2 superoxide ENT2END dismutase, catalase and glutathione peroxidase in serum and heart
0	Cardioprotective effect of ENT1 salvianolic acid A  ENT1END  on isoproterenol-induced ENT2 myocardial infarction ENT2END in rats
0	In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ENT1 ADP ENT1END /O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, ENT1 aspartate  ENT1END  transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of ENT1 lactate  ENT1END  dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and ENT1 malondialdehyde  ENT1END  and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, ENT1 creatine  ENT1END  kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Administration of salvianolic acid A for a period of 8 days significantly attenuated ENT1 isoproterenol  ENT1END induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and ENT1 glutathione  ENT1END  peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of ENT1 superoxide  ENT1END  dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	Administration of ENT1 salvianolic acid A  ENT1END for a period of 8 days significantly attenuated isoproterenol-induced ENT2 cardiac dysfunction ENT2END and myocardial injury and improved mitochondrial respiratory function
0	In addition, mitochondrial ENT1 respiratory dysfunction  ENT1END characterized by decreased respiratory control ratio and ENT2 ADP ENT2END /O was observed in isoproterenol-treated rats
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, ENT1 aspartate  ENT1END  transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial ENT2 respiratory dysfunction ENT2END characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats
0	Isoproterenol-treated rats showed significant increases in the levels of ENT1 lactate  ENT1END  dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial ENT2 respiratory dysfunction ENT2END characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and ENT1 malondialdehyde  ENT1END  and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial ENT2 respiratory dysfunction ENT2END characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, ENT1 creatine  ENT1END  kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial ENT2 respiratory dysfunction ENT2END characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats
0	In addition, mitochondrial ENT1 respiratory dysfunction ENT1END  characterized by decreased respiratory control ratio and ADP/O was observed in ENT2 isoproterenol ENT2END -treated rats
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of superoxide dismutase, catalase and ENT1 glutathione  ENT1END  peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial ENT2 respiratory dysfunction ENT2END characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats
0	Isoproterenol-treated rats showed significant increases in the levels of lactate dehydrogenase, aspartate transaminase, creatine kinase and malondialdehyde and significant decreases in the activities of ENT1 superoxide  ENT1END  dismutase, catalase and glutathione peroxidase in serum and heart. These rats also showed declines in left ventricular systolic pressure, maximum and minimum rate of developed left ventricular pressure, and elevation of left ventricular end-diastolic pressure and ST-segment. In addition, mitochondrial ENT2 respiratory dysfunction ENT2END characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats
0	In addition, mitochondrial ENT1 respiratory dysfunction  ENT1END  characterized by decreased respiratory control ratio and ADP/O was observed in isoproterenol-treated rats. Administration of ENT2 salvianolic acid A ENT2END for a period of 8 days significantly attenuated isoproterenol-induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function
1	Reduction in injection ENT1 pain  ENT1END  using buffered ENT2 lidocaine ENT2END as a local anesthetic before cardiac catheterization
1	8), and ENT1 headache ENT1END (8.7% and 9.9%; 95% Cl, -5.0 to 2.6). Serious adverse events were reported in 11 and 13 patients in the respective groups. Fewer than 6% of patients in either group were considered by the investigator to have a worsening of their overall disease condition during the study. The majority of patients (>60%) experienced no change in their disease status from baseline. CONCLUSION: The 4-mg ENT2 nicotine ENT2END lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions
0	METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, ENT1 hypertension ENT1END not controlled by medication, and/or diabetes mellitus. Patients were randomized in a 1:1 ratio to receive the 4-mg ENT2 nicotine ENT2END lozenge or 4-mg nicotine gum
0	METHODS: This was a multicenter, randomized, open-label study in adult smokers with heart disease, hypertension not controlled by medication, and/or ENT1 diabetes mellitus  ENT1END  Patients were randomized in a 1:1 ratio to receive the 4-mg ENT2 nicotine ENT2END lozenge or 4-mg nicotine gum
1	The most common adverse events were ENT1 nausea  ENT1END (17.2% and 16.1%; 95% CI, -3.7 to 6.0), hiccups (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6). Serious adverse events were reported in 11 and 13 patients in the respective groups. Fewer than 6% of patients in either group were considered by the investigator to have a worsening of their overall disease condition during the study. The majority of patients (>60%) experienced no change in their disease status from baseline. CONCLUSION: The 4-mg ENT2 nicotine ENT2END lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions
1	0), ENT1 hiccups  ENT1END (10.7% and 6.6%; 95% CI, 0.5 to 7.8), and headache (8.7% and 9.9%; 95% Cl, -5.0 to 2.6). Serious adverse events were reported in 11 and 13 patients in the respective groups. Fewer than 6% of patients in either group were considered by the investigator to have a worsening of their overall disease condition during the study. The majority of patients (>60%) experienced no change in their disease status from baseline. CONCLUSION: The 4-mg ENT2 nicotine ENT2END lozenge and 4-mg nicotine gum had comparable safety profiles in these patients with label-restricted medical conditions
0	METHODS: This was a multicenter, randomized, open-label study in adult smokers with ENT1 heart disease  ENT1END  hypertension not controlled by medication, and/or diabetes mellitus. Patients were randomized in a 1:1 ratio to receive the 4-mg ENT2 nicotine ENT2END lozenge or 4-mg nicotine gum
0	We prospectively compared the efficacy and safety of netilmicin sulfate or ENT1 tobramycin sulfate ENT1END in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe ENT2 infections ENT2END
0	We prospectively compared the efficacy and safety of ENT1 netilmicin sulfate  ENT1END or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe ENT2 infections ENT2END
0	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with ENT1 piperacillin sodium  ENT1END in 118 immunocompromised patients with presumed severe ENT2 infections ENT2END
0	Relative efficacy and ENT1 toxicity  ENT1END  of netilmicin and ENT2 tobramycin ENT2END in oncology patients
0	Relative efficacy and ENT1 toxicity  ENT1END  of ENT2 netilmicin ENT2END and tobramycin in oncology patients
0	Relative efficacy and ENT1 toxicity  ENT1END  of netilmicin and tobramycin in oncology patients.We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with ENT2 piperacillin sodium ENT2END in 118 immunocompromised patients with presumed severe infections
0	We conclude that ENT1 aminoglycoside ENT1END associated ENT2 ototoxicity ENT2END was less severe and more often reversible with netilmicin than with tobramycin
1	Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and ENT1 tobramycin ENT1END (17% vs 11%). ENT2 Ototoxicity ENT2END occurred in four (9
1	Nephrotoxicity occurred in a similar proportion in patients treated with ENT1 netilmicin  ENT1END and tobramycin (17% vs 11%). ENT2 Ototoxicity ENT2END occurred in four (9
1	ENT1 Ototoxicity ENT1END  occurred in four (9.5%) of 42 netilmicin and ENT2 piperacillin ENT2END and in 12 (22%) of 54 tobramycin and piperacillin-treated patients
0	ENT1 Nephrotoxicity  ENT1END occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%). Ototoxicity occurred in four (9.5%) of 42 netilmicin and piperacillin and in 12 (22%) of 54 tobramycin and piperacillin-treated patients. Of those evaluated with posttherapy audiograms, three of four netilmicin and piperacillin-treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin-treated patients. The number of greater than or equal to 15-dB increases in auditory threshold as a proportion of total greater than or equal to 15-dB changes (increases and decreases) was significantly lower in netilmicin and piperacillin- vs tobramycin and piperacillin-treated patients (18 of 78 vs 67 of 115). We conclude that ENT2 aminoglycoside ENT2END -associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin
1	ENT1 Nephrotoxicity  ENT1END  occurred in a similar proportion in patients treated with netilmicin and ENT2 tobramycin ENT2END (17% vs 11%)
1	ENT1 Nephrotoxicity  ENT1END  occurred in a similar proportion in patients treated with ENT2 netilmicin ENT2END and tobramycin (17% vs 11%)
1	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with ENT1 piperacillin sodium  ENT1END  in 118 immunocompromised patients with presumed severe infections. The two treatment regimens were equally efficacious. ENT2 Nephrotoxicity ENT2END occurred in a similar proportion in patients treated with netilmicin and tobramycin (17% vs 11%)
0	Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous ENT1 morphine ENT1END .Eight ENT2 cancer ENT2END patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia
1	Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous ENT1 morphine ENT1END developed hyperalgesia. All cases were retrospectively sampled from three different hospitals in Copenhagen. Five patients developed universal hyperalgesia and ENT2 hyperesthesia ENT2END which in 2 cases were accompanied by myoclonus
1	Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous ENT1 morphine ENT1END  developed ENT2 hyperalgesia ENT2END
1	In 3 patients a pre-existing ENT1 neuralgia ENT1END increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously. Although only few clinical descriptions of the relationship between hyperalgesia/myoclonus and high doses of ENT2 morphine ENT2END are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome
1	Although only few clinical descriptions of the relationship between hyperalgesia/ ENT1 myoclonus  ENT1END and high doses of ENT2 morphine ENT2END are available, experimental support from animal studies indicates that morphine, or its metabolites, plays a causative role for the observed behavioural syndrome
0	Complications were observed in two patients: one had a left ENT1 homonymous hemianopsia ENT1END after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with ENT2 Valproate ENT2END 1000 mg/day
0	ENT1 Levodopa  ENT1END equivalent daily intake was significantly reduced in the STN group. Changes in UPDRS, Hoehn _ Yahr and Schwab England ADL scores were similar in both groups. Cognitive functions were unchanged in both groups. Complications were observed in two patients: one had a left ENT2 homonymous hemianopsia ENT2END after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg/day
0	Complications were observed in two patients: one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with ENT1 Valproate ENT1END  1000 mg/day. The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced ENT2 PD ENT2END refractory to medical treatment
0	There was statistically significant improvement in all contralateral major ENT1 parkinsonian  ENT1END motor signs in all patients followed for 6 months. ENT2 Levodopa ENT2END equivalent daily intake was significantly reduced in the STN group
1	5 years), disabling motor fluctuations (Hoehn _ Yahr stage 3-5 in off-drug phases) and ENT1 levodopa ENT1END induced ENT2 dyskinesias ENT2END were selected
0	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose ENT1 salicylates ENT1END and gold salts, developed ENT2 renal papillary necrosis ENT2END (RPN) 4 months after institution of naproxen therapy
1	ENT1 Renal papillary necrosis  ENT1END  due to ENT2 naproxen ENT2END
0	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and ENT1 gold  ENT1END salts, developed ENT2 renal papillary necrosis ENT2END (RPN) 4 months after institution of naproxen therapy
0	No other factor predisposing to ENT1 RPN ENT1END could be discovered. ENT2 Sulindac ENT2END was substituted for naproxen and no further adverse renal effects occurred over the next 12 months
0	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, ENT1 fenoprofen calcium  ENT1END  high dose salicylates and gold salts, developed ENT2 renal papillary necrosis ENT2END (RPN) 4 months after institution of naproxen therapy
0	A 31-year-old man with ENT1 rheumatoid arthritis  ENT1END  who had previously been treated with sulindac, fenoprofen calcium, high dose ENT2 salicylates ENT2END and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy
0	Renal papillary necrosis due to ENT1 naproxen  ENT1END .A 31-year-old man with ENT2 rheumatoid arthritis ENT2END , who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy
0	A 31-year-old man with ENT1 rheumatoid arthritis  ENT1END , who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and ENT2 gold ENT2END salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy
0	A 31-year-old man with ENT1 rheumatoid arthritis ENT1END , who had previously been treated with ENT2 sulindac ENT2END , fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy
0	A 31-year-old man with ENT1 rheumatoid arthritis  ENT1END , who had previously been treated with sulindac, ENT2 fenoprofen calcium ENT2END , high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy
0	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose ENT1 salicylates ENT1END  and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy. No other factor predisposing to RPN could be discovered. Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months. We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced ENT2 renal toxicity ENT2END from other antiinflammatory agents
0	Sulindac was substituted for ENT1 naproxen  ENT1END and no further adverse renal effects occurred over the next 12 months. We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced ENT2 renal toxicity ENT2END from other antiinflammatory agents
0	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and ENT1 gold  ENT1END  salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy. No other factor predisposing to RPN could be discovered. Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months. We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced ENT2 renal toxicity ENT2END from other antiinflammatory agents
0	We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of ENT1 sulindac  ENT1END in patients who have experienced ENT2 renal toxicity ENT2END from other antiinflammatory agents
0	A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, ENT1 fenoprofen calcium  ENT1END , high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy. No other factor predisposing to RPN could be discovered. Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months. We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced ENT2 renal toxicity ENT2END from other antiinflammatory agents
0	ENT1 Thyroxine ENT1END  abuse: an unusual case of thyrotoxicosis in pregnancy.Eating disorders and the associated behavioural problems and ENT2 drug abuse ENT2END are uncommon in pregnancy
0	ENT1 Thyroxine  ENT1END  abuse: an unusual case of thyrotoxicosis in pregnancy. ENT2 Eating disorders ENT2END and the associated behavioural problems and drug abuse are uncommon in pregnancy
1	In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for ENT1 thyrotoxicosis ENT1END remains obscure, ENT2 thyroxine ENT2END abuse should be considered and explored
0	Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate (OSCS) derivative that could elicit a ENT1 hypotensive ENT1END response in pigs following a single high-dose infusion. Using both contaminated ENT2 heparin ENT2END products and the synthetically produced derivative, we showed that the OSCS produces dose-dependent hypotension in pigs
1	Recently, a number of commercial lots of heparin products were found to be contaminated with an oversulfated ENT1 chondroitin sulfate  ENT1END (OSCS) derivative that could elicit a ENT2 hypotensive ENT2END response in pigs following a single high-dose infusion
0	Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ENT1 ventricular arrhythmias ENT1END  left ventricular dilation, decreased shortening fraction, or decreased ejection fraction. The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05). No correlation could be demonstrated between cumulative dose of ENT2 doxorubicin ENT2END and cardiac status, except for heart rate variability
0	Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to ENT1 Rosen's T5 or T10 protocol  ENT1END  both including doxorubicin. Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment. Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360). The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography. Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ENT2 ventricular arrhythmias ENT2END , left ventricular dilation, decreased shortening fraction, or decreased ejection fraction
0	Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ENT1 ventricular dilation  ENT1END  decreased shortening fraction, or decreased ejection fraction. The incidence of cardiac abnormalities increased with length of follow-up (P< or = .05). No correlation could be demonstrated between cumulative dose of ENT2 doxorubicin ENT2END and cardiac status, except for heart rate variability
0	Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to ENT1 Rosen's T5 or T10 protocol  ENT1END , both including doxorubicin. Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment. Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360). The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography. Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ENT2 ventricular dilation ENT2END , decreased shortening fraction, or decreased ejection fraction
0	The incidence of ENT1 doxorubicin ENT1END induced ENT2 cardiotoxicity ENT2END is high and increases with follow-up, irrespective of cumulative dose
0	Late ENT1 cardiotoxicity  ENT1END  after treatment for a malignant bone tumor.Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to ENT2 Rosen's T5 or T10 protocol ENT2END , both including doxorubicin
1	The incidence of ENT1 cardiac abnormalities  ENT1END increased with length of follow-up (P< or = .05). No correlation could be demonstrated between cumulative dose of ENT2 doxorubicin ENT2END and cardiac status, except for heart rate variability
0	Cardiac function was assessed in long-term survivors of malignant bone tumors who were treated according to ENT1 Rosen's T5 or T10 protocol  ENT1END , both including doxorubicin. Thirty-one patients, age 10-45 years (median age 17.8 years) were evaluated 2.3-14.1 years (median 8.9 years) following completion of treatment. Cumulative doses of doxorubicin were 225-550 mg/m2 (median dose 360). The evaluation consisted of a history, physical examination, electrocardiogram (ECG), signal averaged ECG, 24-hour ambulatory ECG, echocardiography and radionuclide angiography. Eighteen of 31 (58%) patients showed cardiac toxicity, defined as having one or more of the following abnormalities: late potentials, complex ventricular arrhythmias, left ventricular dilation, decreased shortening fraction, or decreased ejection fraction. The incidence of ENT2 cardiac abnormalities ENT2END increased with length of follow-up (P< or =
0	Cardiac function was assessed in long-term survivors of malignant ENT1 bone tumors ENT1END who were treated according to Rosen's T5 or T10 protocol, both including ENT2 doxorubicin ENT2END
0	Cardiac function was assessed in long-term survivors of malignant ENT1 bone tumors  ENT1END  who were treated according to ENT2 Rosen's T5 or T10 protocol ENT2END , both including doxorubicin
0	We suggest that our patient's tubular dysfunction and myopathy may have resulted from ENT1 mitochondrial dysfunction ENT1END which is triggered by tacrolimus and augmented by ENT2 lamivudine ENT2END
0	We suggest that our patient's tubular dysfunction and myopathy may have resulted from ENT1 mitochondrial dysfunction ENT1END  which is triggered by ENT2 tacrolimus ENT2END and augmented by lamivudine
0	Tacrolimus, MMF, and ENT1 steroids ENT1END were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse. Proximal muscle weakness has developed during her follow-up. Fanconi syndrome, as well as myopathy, is well recognized in patients with ENT2 mitochondrial disorders ENT2END and caused by depletion of mtDNA
0	Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT1 sirolimus  ENT1END  acidosis, and electrolyte imbalance got worse. Proximal muscle weakness has developed during her follow-up. Fanconi syndrome, as well as myopathy, is well recognized in patients with ENT2 mitochondrial disorders ENT2END and caused by depletion of mtDNA
0	ENT1 Lamivudine ENT1END was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, ENT2 glycosuria ENT2END , and aminoaciduria
0	Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, ENT1 glycosuria ENT1END , and aminoaciduria. Although ENT2 tacrolimus ENT2END was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse
0	Tacrolimus, MMF, and ENT1 steroids  ENT1END  were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, ENT2 glycosuria ENT2END , and aminoaciduria
0	Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, ENT1 glycosuria  ENT1END , and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT2 sirolimus ENT2END , acidosis, and electrolyte imbalance got worse
0	ENT1 Lamivudine ENT1END  was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe ENT2 metabolic acidosis ENT2END , hypophosphatemia, glycosuria, and aminoaciduria
0	Although ENT1 tacrolimus ENT1END  was suspected to be the cause of late post-transplant renal ENT2 acidosis ENT2END and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse
0	Tacrolimus, MMF, and ENT1 steroids  ENT1END  were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe ENT2 metabolic acidosis ENT2END , hypophosphatemia, glycosuria, and aminoaciduria
0	Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT1 sirolimus ENT1END , ENT2 acidosis ENT2END , and electrolyte imbalance got worse
0	ENT1 Lamivudine ENT1END  was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and ENT2 aminoaciduria ENT2END
0	Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and ENT1 aminoaciduria  ENT1END . Although ENT2 tacrolimus ENT2END was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse
0	Tacrolimus, MMF, and ENT1 steroids  ENT1END  were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and ENT2 aminoaciduria ENT2END
0	Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and ENT1 aminoaciduria  ENT1END . Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT2 sirolimus ENT2END , acidosis, and electrolyte imbalance got worse
0	Renal Fanconi syndrome and myopathy after liver transplantation: drug-related ENT1 mitochondrial cytopathy  ENT1END ?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children. However, combinations of different therapeutic regimens require consideration of potential adverse reactions. We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease. Tacrolimus, MMF, and steroids were given as immunosuppressant. ENT2 Lamivudine ENT2END was added because of de nova hepatitis B infection during her follow-up
0	Renal Fanconi syndrome and myopathy after liver transplantation: drug-related ENT1 mitochondrial cytopathy ENT1END ?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children. However, combinations of different therapeutic regimens require consideration of potential adverse reactions. We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease. ENT2 Tacrolimus ENT2END , MMF, and steroids were given as immunosuppressant
0	Renal Fanconi syndrome and myopathy after liver transplantation: drug-related ENT1 mitochondrial cytopathy  ENT1END ?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children. However, combinations of different therapeutic regimens require consideration of potential adverse reactions. We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease. Tacrolimus, MMF, and ENT2 steroids ENT2END were given as immunosuppressant
0	Proximal ENT1 muscle weakness  ENT1END has developed during her follow-up. Fanconi syndrome, as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA. We suggest that our patient's tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by ENT2 lamivudine ENT2END
0	Although ENT1 tacrolimus  ENT1END  was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse. Proximal ENT2 muscle weakness ENT2END has developed during her follow-up
0	Tacrolimus, MMF, and ENT1 steroids  ENT1END  were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse. Proximal ENT2 muscle weakness ENT2END has developed during her follow-up
0	Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT1 sirolimus  ENT1END , acidosis, and electrolyte imbalance got worse. Proximal ENT2 muscle weakness ENT2END has developed during her follow-up
0	ENT1 Lamivudine ENT1END  was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, ENT2 hypophosphatemia ENT2END , glycosuria, and aminoaciduria
0	Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, ENT1 hypophosphatemia  ENT1END , glycosuria, and aminoaciduria. Although ENT2 tacrolimus ENT2END was suspected to be the cause of late post-transplant renal acidosis and was replaced by sirolimus, acidosis, and electrolyte imbalance got worse
0	Tacrolimus, MMF, and ENT1 steroids  ENT1END  were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, ENT2 hypophosphatemia ENT2END , glycosuria, and aminoaciduria
0	Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, ENT1 hypophosphatemia  ENT1END , glycosuria, and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT2 sirolimus ENT2END , acidosis, and electrolyte imbalance got worse
0	We describe a 15-yr-old girl who had orthotopic liver transplantation because of ENT1 Wilson's disease  ENT1END  Tacrolimus, MMF, and steroids were given as immunosuppressant. ENT2 Lamivudine ENT2END was added because of de nova hepatitis B infection during her follow-up
0	We describe a 15-yr-old girl who had orthotopic liver transplantation because of ENT1 Wilson's disease  ENT1END . ENT2 Tacrolimus ENT2END , MMF, and steroids were given as immunosuppressant
0	We describe a 15-yr-old girl who had orthotopic liver transplantation because of ENT1 Wilson's disease  ENT1END . Tacrolimus, MMF, and ENT2 steroids ENT2END were given as immunosuppressant
0	We describe a 15-yr-old girl who had orthotopic liver transplantation because of ENT1 Wilson's disease  ENT1END . Tacrolimus, MMF, and steroids were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT2 sirolimus ENT2END , acidosis, and electrolyte imbalance got worse
1	We suggest that our patient's tubular dysfunction and ENT1 myopathy  ENT1END may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by ENT2 lamivudine ENT2END
1	We suggest that our patient's tubular dysfunction and ENT1 myopathy  ENT1END  may have resulted from mitochondrial dysfunction which is triggered by ENT2 tacrolimus ENT2END and augmented by lamivudine
0	Renal Fanconi syndrome and ENT1 myopathy  ENT1END  after liver transplantation: drug-related mitochondrial cytopathy?Advances in the field of transplantation provide a better quality of life and allow more favorable conditions for growth and development in children. However, combinations of different therapeutic regimens require consideration of potential adverse reactions. We describe a 15-yr-old girl who had orthotopic liver transplantation because of Wilson's disease. Tacrolimus, MMF, and ENT2 steroids ENT2END were given as immunosuppressant
0	Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT1 sirolimus ENT1END , acidosis, and electrolyte imbalance got worse. Proximal muscle weakness has developed during her follow-up. Fanconi syndrome, as well as ENT2 myopathy ENT2END , is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA
1	We suggest that our patient's ENT1 tubular dysfunction  ENT1END and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by ENT2 lamivudine ENT2END
1	We suggest that our patient's ENT1 tubular dysfunction  ENT1END  and myopathy may have resulted from mitochondrial dysfunction which is triggered by ENT2 tacrolimus ENT2END and augmented by lamivudine
0	Tacrolimus, MMF, and ENT1 steroids ENT1END  were given as immunosuppressant. Lamivudine was added because of de nova hepatitis B infection during her follow-up. Three yr after transplantation she developed ENT2 renal Fanconi syndrome ENT2END with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria
0	Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT1 sirolimus ENT1END , acidosis, and electrolyte imbalance got worse. Proximal muscle weakness has developed during her follow-up. ENT2 Fanconi syndrome ENT2END , as well as myopathy, is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA
0	ENT1 Lamivudine ENT1END  was added because of de nova ENT2 hepatitis B infection ENT2END during her follow-up
0	ENT1 Tacrolimus  ENT1END , MMF, and steroids were given as immunosuppressant. Lamivudine was added because of de nova ENT2 hepatitis B infection ENT2END during her follow-up
0	Tacrolimus, MMF, and ENT1 steroids  ENT1END  were given as immunosuppressant. Lamivudine was added because of de nova ENT2 hepatitis B infection ENT2END during her follow-up
0	Lamivudine was added because of de nova ENT1 hepatitis B infection  ENT1END  during her follow-up. Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis, hypophosphatemia, glycosuria, and aminoaciduria. Although tacrolimus was suspected to be the cause of late post-transplant renal acidosis and was replaced by ENT2 sirolimus ENT2END , acidosis, and electrolyte imbalance got worse
1	Reserpine- and ENT1 haloperidol ENT1END induced ENT2 orofacial dyskinesia ENT2END are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress
1	Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit ENT1 orofacial dyskinesia  ENT1END  in rats. ENT2 Reserpine ENT2END - and haloperidol-induced orofacial dyskinesia are putative animal models of tardive dyskinesia (TD) whose pathophysiology has been related to free radical generation and oxidative stress
0	Acute reserpine and subchronic haloperidol treatments change synaptosomal brain ENT1 glutamate  ENT1END  uptake and elicit ENT2 orofacial dyskinesia ENT2END in rats
0	4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect ENT1 bilirubin ENT1END  After she discontinued the omeprazole, her hemoglobin and hematocrit gradually returned to normal. The mechanism by which omeprazole caused the patient's ENT2 hemolytic anemia ENT2END is uncertain, but physicians should be alerted to this possible adverse effect
1	We report the first case of a serious short-term adverse reaction with the use of ENT1 omeprazole ENT1END  ENT2 hemolytic anemia ENT2END
0	It has been shown to be extremely effective in the treatment of ENT1 peptic ulcer disease  ENT1END  reflux esophagitis, and the Zollinger-Ellison syndrome. Although clinical experience with omeprazole is still limited, many controlled studies have established the short-term safety of this drug. We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia. The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole. Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect ENT2 bilirubin ENT2END
0	It has been shown to be extremely effective in the treatment of ENT1 peptic ulcer disease ENT1END , reflux esophagitis, and the Zollinger-Ellison syndrome. Although clinical experience with ENT2 omeprazole ENT2END is still limited, many controlled studies have established the short-term safety of this drug
0	It has been shown to be extremely effective in the treatment of peptic ulcer disease, ENT1 reflux esophagitis  ENT1END  and the Zollinger-Ellison syndrome. Although clinical experience with omeprazole is still limited, many controlled studies have established the short-term safety of this drug. We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia. The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole. Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect ENT2 bilirubin ENT2END
0	It has been shown to be extremely effective in the treatment of peptic ulcer disease, ENT1 reflux esophagitis  ENT1END , and the Zollinger-Ellison syndrome. Although clinical experience with ENT2 omeprazole ENT2END is still limited, many controlled studies have established the short-term safety of this drug
0	The patient developed weakness, ENT1 lethargy  ENT1END  and shortness of breath 2 days after starting therapy with omeprazole. Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect ENT2 bilirubin ENT2END
1	We report the first case of a serious short-term adverse reaction with the use of ENT1 omeprazole  ENT1END : hemolytic anemia. The patient developed weakness, ENT2 lethargy ENT2END , and shortness of breath 2 days after starting therapy with omeprazole
0	It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the ENT1 Zollinger-Ellison syndrome  ENT1END  Although clinical experience with omeprazole is still limited, many controlled studies have established the short-term safety of this drug. We report the first case of a serious short-term adverse reaction with the use of omeprazole: hemolytic anemia. The patient developed weakness, lethargy, and shortness of breath 2 days after starting therapy with omeprazole. Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect ENT2 bilirubin ENT2END
0	It has been shown to be extremely effective in the treatment of peptic ulcer disease, reflux esophagitis, and the ENT1 Zollinger-Ellison syndrome  ENT1END . Although clinical experience with ENT2 omeprazole ENT2END is still limited, many controlled studies have established the short-term safety of this drug
0	The patient developed weakness, lethargy, and ENT1 shortness of breath  ENT1END 2 days after starting therapy with omeprazole. Two weeks after the initiation of therapy, her hematocrit had decreased from 44.1% to 20.4%, and she had a positive direct Coombs antiglobulin test and an elevated indirect ENT2 bilirubin ENT2END
1	The patient developed weakness, lethargy, and ENT1 shortness of breath ENT1END  2 days after starting therapy with ENT2 omeprazole ENT2END
0	These findings suggest that thrombin plays an important role in the pathogenesis of ENT1 puromycin aminonucleoside ENT1END induced ENT2 nephrotic syndrome ENT2END
0	ENT1 Puromycin aminonucleoside ENT1END induced renal dysfunction and ENT2 hyperlipidemia ENT2END were also suppressed
0	ENT1 Puromycin aminonucleoside ENT1END -induced ENT2 renal dysfunction ENT2END and hyperlipidemia were also suppressed
1	Protective effects of antithrombin on ENT1 puromycin aminonucleoside ENT1END ENT2 nephrosis ENT2END in rats
0	Treatment with antithrombin attenuated the puromycin aminonucleoside-induced ENT1 hematological abnormalities ENT1END ENT2 Puromycin aminonucleoside ENT2END -induced renal dysfunction and hyperlipidemia were also suppressed
0	Few days later, the patient used another 200 mg ENT1 ketoconazole ENT1END tablet, and within an hour experienced a similar clinical picture, which resolved again spontaneously within hours. Laboratory evaluations, including head CT scan, were normal. This case illustrates the need for close vigilance in ENT2 adverse drug reactions ENT2END , particularly in the elderly
0	ENT1 Ketoconazole  ENT1END -induced ENT2 neurologic sequelae ENT2END
1	ENT1 Ketoconazole ENT1END -induced neurologic sequelae.A 77-y-old patient developed ENT2 weakness of extremities ENT2END , legs paralysis, dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life
1	A 77-y-old patient developed weakness of extremities, legs paralysis, ENT1 dysarthria ENT1END and tremor 1 h after ingestion of 200 mg ENT2 ketoconazole ENT2END for the first time in his life
1	A 77-y-old patient developed weakness of extremities, legs paralysis, dysarthria and ENT1 tremor  ENT1END 1 h after ingestion of 200 mg ENT2 ketoconazole ENT2END for the first time in his life
1	A 77-y-old patient developed weakness of extremities, ENT1 legs paralysis  ENT1END  dysarthria and tremor 1 h after ingestion of 200 mg ENT2 ketoconazole ENT2END for the first time in his life
1	ENT1 Quinidine phenylethylbarbiturate  ENT1END -induced fulminant ENT2 hepatitis ENT2END in a pregnant woman
0	ENT1 Quinidine ENT1END itself or phenylethylbarbiturate may be responsible for fulminant ENT2 hepatitis ENT2END in this patient
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and ENT1 vancomycin ENT1END for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis. CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ENT2 ischaemia ENT2END
1	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with ENT1 amikacin  ENT1END and vancomycin for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis. CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ENT2 ischaemia ENT2END
0	Fundus ENT1 fluorescein  ENT1END angiography confirmed macular capillary closure and telangiectasis. CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ENT2 ischaemia ENT2END
0	BACKGROUND: Although intravitreal ENT1 aminoglycosides  ENT1END have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery. METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis. CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ENT2 ischaemia ENT2END
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and ENT1 vancomycin ENT1END  for alpha-haemolytic streptococcal endophthalmitis. RESULTS: ENT2 Endophthalmitis ENT2END resolved with improvement in visual acuity to 6/24 at three months
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with ENT1 amikacin  ENT1END  and vancomycin for alpha-haemolytic streptococcal endophthalmitis. RESULTS: ENT2 Endophthalmitis ENT2END resolved with improvement in visual acuity to 6/24 at three months
0	RESULTS: ENT1 Endophthalmitis  ENT1END  resolved with improvement in visual acuity to 6/24 at three months. Fundus ENT2 fluorescein ENT2END angiography confirmed macular capillary closure and telangiectasis
0	BACKGROUND: Although intravitreal ENT1 aminoglycosides ENT1END  have substantially improved visual prognosis in ENT2 endophthalmitis ENT2END , macular infarction may impair full visual recovery
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and ENT1 vancomycin ENT1END  for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus fluorescein angiography confirmed macular capillary closure and ENT2 telangiectasis ENT2END
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with ENT1 amikacin  ENT1END  and vancomycin for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus fluorescein angiography confirmed macular capillary closure and ENT2 telangiectasis ENT2END
0	Fundus ENT1 fluorescein  ENT1END  angiography confirmed macular capillary closure and ENT2 telangiectasis ENT2END
0	BACKGROUND: Although intravitreal ENT1 aminoglycosides  ENT1END  have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery. METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus fluorescein angiography confirmed macular capillary closure and ENT2 telangiectasis ENT2END
0	Macula ENT1 toxicity  ENT1END  after intravitreal amikacin.BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery. METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and ENT2 vancomycin ENT2END for alpha-haemolytic streptococcal endophthalmitis
0	Macula ENT1 toxicity  ENT1END  after intravitreal ENT2 amikacin ENT2END
0	Macula ENT1 toxicity  ENT1END  after intravitreal amikacin.BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery. METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus ENT2 fluorescein ENT2END angiography confirmed macular capillary closure and telangiectasis
0	Macula ENT1 toxicity  ENT1END  after intravitreal amikacin.BACKGROUND: Although intravitreal ENT2 aminoglycosides ENT2END have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery
0	BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular ENT1 infarction  ENT1END may impair full visual recovery. METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and ENT2 vancomycin ENT2END for alpha-haemolytic streptococcal endophthalmitis
0	BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular ENT1 infarction ENT1END  may impair full visual recovery. METHODS: We present a case of presumed ENT2 amikacin ENT2END retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis
0	BACKGROUND: Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis, macular ENT1 infarction  ENT1END  may impair full visual recovery. METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis. RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus ENT2 fluorescein ENT2END angiography confirmed macular capillary closure and telangiectasis
0	BACKGROUND: Although intravitreal ENT1 aminoglycosides  ENT1END  have substantially improved visual prognosis in endophthalmitis, macular ENT2 infarction ENT2END may impair full visual recovery
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and ENT1 vancomycin ENT1END  for alpha-haemolytic ENT2 streptococcal endophthalmitis ENT2END
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with ENT1 amikacin  ENT1END  and vancomycin for alpha-haemolytic ENT2 streptococcal endophthalmitis ENT2END
0	METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic ENT1 streptococcal endophthalmitis  ENT1END . RESULTS: Endophthalmitis resolved with improvement in visual acuity to 6/24 at three months. Fundus ENT2 fluorescein ENT2END angiography confirmed macular capillary closure and telangiectasis
0	BACKGROUND: Although intravitreal ENT1 aminoglycosides  ENT1END  have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery. METHODS: We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha-haemolytic ENT2 streptococcal endophthalmitis ENT2END
0	METHODS: We present a case of presumed amikacin ENT1 retinal toxicity  ENT1END following treatment with amikacin and ENT2 vancomycin ENT2END for alpha-haemolytic streptococcal endophthalmitis
1	METHODS: We present a case of presumed ENT1 amikacin ENT1END ENT2 retinal toxicity ENT2END following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis
0	Fundus ENT1 fluorescein ENT1END  angiography confirmed macular capillary closure and telangiectasis. CONCLUSIONS: Currently accepted intravitreal antibiotic regimens may cause ENT2 retinal toxicity ENT2END and macular ischaemia
0	BACKGROUND: Although intravitreal ENT1 aminoglycosides  ENT1END  have substantially improved visual prognosis in endophthalmitis, macular infarction may impair full visual recovery. METHODS: We present a case of presumed amikacin ENT2 retinal toxicity ENT2END following treatment with amikacin and vancomycin for alpha-haemolytic streptococcal endophthalmitis
1	ENT1 Acute renal failure  ENT1END  subsequent to the administration of ENT2 rifampicin ENT2END
0	The patients had developed transient renal failure after the intermittent administration of ENT1 rifampicin  ENT1END  The stage of olig- ENT2 anuria ENT2END lasted for 1-3 weeks, and five of the patients were treated by hemodialysis
0	The patients had developed transient ENT1 renal failure  ENT1END after the intermittent administration of ENT2 rifampicin ENT2END
1	It is well known that ENT1 ceftriaxone ENT1END leads to ENT2 pseudolithiasis ENT2END in some patients
0	It is well known that ENT1 ceftriaxone ENT1END  leads to pseudolithiasis in some patients. Clinical and experimental studies also suggest that situations causing ENT2 gallbladder dysfunction ENT2END , such as fasting, may have a role for the development of pseudolithiasis
0	Chronic oral CBZ inhibited the development of both lidocaine- and cocaine-induced seizures, but had little effect on the fully developed local anesthetic ENT1 seizures ENT1END  Chronic ENT2 CBZ ENT2END also decreased the incidence of seizure-related mortality in the cocaine-injected rats
1	injection of CBZ (15 mg/kg) also was without effect on the development of ENT1 lidocaine ENT1END  or cocaine-kindled ENT2 seizures ENT2END
1	Chronic oral CBZ inhibited the development of both lidocaine- and ENT1 cocaine ENT1END induced ENT2 seizures ENT2END , but had little effect on the fully developed local anesthetic seizures
0	A total of 38 consecutive patients who presented to our clinic with ENT1 impotence ENT1END received 0.2 ml. of a combination of 3 drugs: 6 mg. ENT2 papaverine ENT2END , 100 micrograms
0	A total of 38 consecutive patients who presented to our clinic with ENT1 impotence ENT1END  received 0.2 ml. of a combination of 3 drugs: 6 mg. papaverine, 100 micrograms. phentolamine and 10 micrograms. ENT2 prostaglandin E1 ENT2END with (pH 7
0	ENT1 Sodium bicarbonate  ENT1END  alleviates penile pain induced by intracavernous injections for ENT2 erectile dysfunction ENT2END
0	A total of 38 consecutive patients who presented to our clinic with ENT1 impotence ENT1END  received 0.2 ml. of a combination of 3 drugs: 6 mg. papaverine, 100 micrograms. ENT2 phentolamine ENT2END and 10 micrograms
0	ENT1 papaverine ENT1END , 100 micrograms. phentolamine and 10 micrograms. prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.). Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of ENT2 penile pain ENT2END due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain
1	ENT1 prostaglandin E1  ENT1END  with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.). Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of ENT2 penile pain ENT2END due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain
0	ENT1 Sodium bicarbonate  ENT1END  alleviates ENT2 penile pain ENT2END induced by intracavernous injections for erectile dysfunction
1	ENT1 phentolamine  ENT1END  and 10 micrograms. prostaglandin E1 with (pH 7.05) or without (pH 4.17) the addition of sodium bicarbonate (0.03 mEq.). Of the 19 patients without sodium bicarbonate added to the medication 11 (58%) complained of ENT2 penile pain ENT2END due to the medication, while only 1 of the 19 men (5%) who received sodium bicarbonate complained of penile pain
1	We report the case of a 62-year-old man who was administered sodium valproate (VPA) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( ENT1 SIADH ENT1END . He had been taking ENT2 VPA ENT2END for treatment of idiopathic generalized tonic-clonic convulsions since he was 56 years old
0	After substituting VPA with ENT1 zonisamide ENT1END  the serum sodium level returned to normal. We consider this episode of ENT2 SIADH ENT2END to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA
0	After substituting VPA with zonisamide, the serum ENT1 sodium  ENT1END level returned to normal. We consider this episode of ENT2 SIADH ENT2END to be the result of a combination of factors including a weakness of the central nervous system and the long-term administration of VPA
0	He had been taking ENT1 VPA ENT1END  for treatment of idiopathic generalized ENT2 tonic-clonic convulsions ENT2END since he was 56 years old
0	He had been taking VPA for treatment of idiopathic generalized ENT1 tonic-clonic convulsions  ENT1END  since he was 56 years old. After substituting VPA with ENT2 zonisamide ENT2END , the serum sodium level returned to normal
0	He had been taking VPA for treatment of idiopathic generalized ENT1 tonic-clonic convulsions  ENT1END  since he was 56 years old. After substituting VPA with zonisamide, the serum ENT2 sodium ENT2END level returned to normal
0	We consider this episode of SIADH to be the result of a combination of factors including a ENT1 weakness of the central nervous system ENT1END and the long-term administration of ENT2 VPA ENT2END
0	After substituting VPA with ENT1 zonisamide  ENT1END , the serum sodium level returned to normal. We consider this episode of SIADH to be the result of a combination of factors including a ENT2 weakness of the central nervous system ENT2END and the long-term administration of VPA
0	After substituting VPA with zonisamide, the serum ENT1 sodium  ENT1END  level returned to normal. We consider this episode of SIADH to be the result of a combination of factors including a ENT2 weakness of the central nervous system ENT2END and the long-term administration of VPA
0	Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of BN 52021, a specific antagonist of PAF, against ENT1 bupivacaine ENT1END induced ENT2 cardiovascular toxicity ENT2END
0	Protective effect of a specific platelet-activating factor antagonist, ENT1 BN 52021  ENT1END , on bupivacaine-induced ENT2 cardiovascular impairments ENT2END in rats
0	Thus, consistent with its direct effect on heart, PAF appears to be implicated in ENT1 bupivacaine ENT1END induced ENT2 cardiovascular alterations ENT2END
0	Since the administration of BN 52021, at all doses studied, did not alter MBP and HR at the doses used, the bulk of these results clearly demonstrate a protective action of ENT1 BN 52021  ENT1END  a specific antagonist of PAF, against bupivacaine-induced cardiovascular toxicity. Thus, consistent with its direct effect on heart, PAF appears to be implicated in bupivacaine-induced ENT2 cardiovascular alterations ENT2END
1	) was injected immediately after ENT1 bupivacaine ENT1END (2 mg/kg), a partial reversion of the ENT2 decrease of MBP and HR ENT2END was observed, whereas the dose of 10 mg/kg was ineffective
0	) suppressed both the ENT1 decrease of MBP and HR ENT1END  In contrast, doses of 1 mg/kg ENT2 BN 52021 ENT2END given 30 min before or 10 mg/kg administered 5 min before i
1	) was injected immediately after ENT1 bupivacaine ENT1END  (2 mg/kg), a partial reversion of the ENT2 decrease of MBP and HR ENT2END was observed, whereas the dose of 10 mg/kg was ineffective
0	) suppressed both the ENT1 decrease of MBP and HR  ENT1END  In contrast, doses of 1 mg/kg ENT2 BN 52021 ENT2END given 30 min before or 10 mg/kg administered 5 min before i
0	Ciprofloxacin-induced nephrotoxicity in patients with ENT1 cancer ENT1END .Nephrotoxicity associated with ENT2 ciprofloxacin ENT2END is uncommon
0	Five patients with ENT1 cancer ENT1END who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed. Other than elevation of serum ENT2 creatinine ENT2END levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present
1	An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ENT1 ciprofloxacin ENT1END induced ENT2 acute renal failure ENT2END
0	Five patients with cancer who developed ENT1 acute renal failure  ENT1END that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed. Other than elevation of serum ENT2 creatinine ENT2END levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present
0	ENT1 Ciprofloxacin  ENT1END -induced ENT2 nephrotoxicity ENT2END in patients with cancer
0	ENT1 Nephrotoxicity  ENT1END associated with ciprofloxacin is uncommon. Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed. Other than elevation of serum ENT2 creatinine ENT2END levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present
0	Five patients with cancer who developed acute renal failure that followed treatment with ENT1 ciprofloxacin ENT1END are described and an additional 15 cases reported in the literature are reviewed. Other than elevation of serum creatinine levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present. Allergic ENT2 interstitial nephritis ENT2END is believed to be the underlying pathological-process
0	Other than elevation of serum ENT1 creatinine  ENT1END  levels, characteristic clinical manifestations and abnormal laboratory findings are not frequently present. Allergic ENT2 interstitial nephritis ENT2END is believed to be the underlying pathological-process
0	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine- ENT1 methionine ENT1END aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 ENT2 HBV-HIV co-infected ENT2END patients
0	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate- ENT1 aspartate  ENT1END (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 ENT2 HBV-HIV co-infected ENT2END patients
0	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the ENT1 tyrosine  ENT1END methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic hepatitis B patients and 10 of 20 ENT2 HBV-HIV co-infected ENT2END patients
0	To the best of our knowledge, this constitutes the first report of HBV lamivudine-resistant strains in therapy- ENT1 na ENT1END  ve ENT2 HBV-HIV co-infected ENT2END patients
0	To the best of our knowledge, this constitutes the first report of HBV ENT1 lamivudine  ENT1END resistant strains in therapy-na  ve ENT2 HBV-HIV co-infected ENT2END patients
0	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 ENT1 HBV-HIV co-infected  ENT1END patients. The latter group was further sub-divided into 13 occult HBV ( ENT2 HBsAg ENT2END -negative) and 7 overt HBV (HBsAg- positive) patients
0	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine- ENT1 methionine ENT1END -aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic ENT2 hepatitis B ENT2END patients and 10 of 20 HBV-HIV co-infected patients
0	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the tyrosine-methionine-aspartate- ENT1 aspartate  ENT1END  (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic ENT2 hepatitis B ENT2END patients and 10 of 20 HBV-HIV co-infected patients
0	Serum samples were PCR amplified with HBV reverse transcriptase (RT) primers, followed by direct sequencing across the ENT1 tyrosine  ENT1END -methionine-aspartate-aspartate (YMDD) motif of the major catalytic region in the C domain of the HBV RT enzyme. HBV viral load was performed with Amplicor HBV Monitor test v2.0 (Roche Diagnostics, Penzberg, Germany). HBV lamivudine-resistant strains were detected in 3 of 15 mono-infected chronic ENT2 hepatitis B ENT2END patients and 10 of 20 HBV-HIV co-infected patients
0	Thirty-five lamivudine- ENT1 na ENT1END  ve ENT2 HBV infected ENT2END patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients
0	Thirty-five ENT1 lamivudine  ENT1END na  ve ENT2 HBV infected ENT2END patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 HBV-HIV co-infected patients
1	Thirty-five lamivudine-na  ve HBV infected patients with or without HIV co-infection were studied: 15 chronic HBV mono-infected patients and 20 ENT1 HBV-HIV co-infected ENT1END patients. The latter group was further sub-divided into 13 occult HBV ENT2 HBsAg ENT2END -negative) and 7 overt HBV (HBsAg- positive) patients
0	Patients aged 18 years or older treated with ENT1 prochlorperazine ENT1END for ENT2 headache ENT2END , nausea, or vomiting were eligible for inclusion
0	Patients aged 18 years or older treated with ENT1 prochlorperazine ENT1END  for headache, ENT2 nausea ENT2END , or vomiting were eligible for inclusion
0	Study participants were randomized to receive 10 mg of ENT1 prochlorperazine ENT1END administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group). The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration. Akathisia was defined as either a spontaneous report of restlessness or ENT2 agitation ENT2END or a change of 2 or more in the patient-reported akathisia rating scale and a change of at least 1 in the investigator-observed akathisia rating scale
0	Patients aged 18 years or older treated with ENT1 prochlorperazine ENT1END  for headache, nausea, or ENT2 vomiting ENT2END were eligible for inclusion
1	CONCLUSION: A 50% reduction in the incidence of ENT1 akathisia ENT1END when ENT2 prochlorperazine ENT2END was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected
0	The patient's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking ENT1 verapamil ENT1END  Her incontinence resolved with the change of medication. The restoration of continence was accompanied by a substantial rise in maximum urethral pressure, maximum urethral closure pressure, and functional urethral length. Patients who present with ENT2 stress incontinence ENT2END while taking prazosin should change their antihypertensive medication before considering surgery, because their incontinence may resolve spontaneously with a change in drug therapy
1	ENT1 Prazosin  ENT1END -induced ENT2 stress incontinence ENT2END
0	The patient's clinical course is described and correlated with initial urodynamic studies while on prazosin and subsequent studies while taking ENT1 verapamil ENT1END . Her ENT2 incontinence ENT2END resolved with the change of medication
0	The patient's clinical course is described and correlated with initial urodynamic studies while on ENT1 prazosin  ENT1END and subsequent studies while taking verapamil. Her ENT2 incontinence ENT2END resolved with the change of medication
1	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe ENT1 headache ENT1END and vomiting 2 hours after the first doses of amisulpride 100 mg and ENT2 tiapride ENT2END 100 mg
0	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe ENT1 headache ENT1END  and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and ENT2 verapamil ENT2END treatment
0	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe ENT1 headache ENT1END  and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent ENT2 nicardipine ENT2END and verapamil treatment
0	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe ENT1 headache ENT1END  and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment. Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma. DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted ENT2 benzamide ENT2END drugs, but the underlying mechanism is unknown
1	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe ENT1 headache ENT1END  and vomiting 2 hours after the first doses of ENT2 amisulpride ENT2END 100 mg and tiapride 100 mg
1	CONCLUSIONS: As of March 24, 2005, this is the first reported case of amisulpride- and ENT1 tiapride ENT1END induced ENT2 hypertensive ENT2END crisis in a patient with pheochromocytoma
0	CASE SUMMARY: A 42-year-old white man developed acute ENT1 hypertension  ENT1END with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and ENT2 verapamil ENT2END treatment
0	CASE SUMMARY: A 42-year-old white man developed acute ENT1 hypertension  ENT1END  with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent ENT2 nicardipine ENT2END and verapamil treatment
0	DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted ENT1 benzamide ENT1END  drugs, but the underlying mechanism is unknown. In our case, use of the Naranjo probability scale indicated a possible relationship between the ENT2 hypertensive ENT2END crisis and amisulpride and tiapride therapy
1	In our case, use of the Naranjo probability scale indicated a possible relationship between the ENT1 hypertensive ENT1END  crisis and ENT2 amisulpride ENT2END and tiapride therapy
1	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and ENT1 vomiting  ENT1END 2 hours after the first doses of amisulpride 100 mg and ENT2 tiapride ENT2END 100 mg
0	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and ENT1 vomiting  ENT1END  2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and ENT2 verapamil ENT2END treatment
0	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and ENT1 vomiting  ENT1END  2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent ENT2 nicardipine ENT2END and verapamil treatment
0	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and ENT1 vomiting  ENT1END  2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg. Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and verapamil treatment. Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of pheochromocytoma. DISCUSSION: Drug-induced symptoms of pheochromocytoma are often associated with the use of substituted ENT2 benzamide ENT2END drugs, but the underlying mechanism is unknown
1	CASE SUMMARY: A 42-year-old white man developed acute hypertension with severe headache and ENT1 vomiting  ENT1END  2 hours after the first doses of ENT2 amisulpride ENT2END 100 mg and tiapride 100 mg
0	ENT1 Pheochromocytoma  ENT1END  unmasked by amisulpride and ENT2 tiapride ENT2END
0	Both drugs were immediately discontinued, and the patient recovered after subsequent nicardipine and ENT1 verapamil ENT1END  treatment. Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of ENT2 pheochromocytoma ENT2END
0	Both drugs were immediately discontinued, and the patient recovered after subsequent ENT1 nicardipine  ENT1END  and verapamil treatment. Abdominal ultrasound showed an adrenal mass, and postoperative histologic examination confirmed the diagnosis of ENT2 pheochromocytoma ENT2END
0	DISCUSSION: Drug-induced symptoms of ENT1 pheochromocytoma  ENT1END are often associated with the use of substituted ENT2 benzamide ENT2END drugs, but the underlying mechanism is unknown
0	ENT1 Pheochromocytoma  ENT1END  unmasked by ENT2 amisulpride ENT2END and tiapride
0	Long-term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT, ENT1 lactic acid ENT1END dehydrogenase, and alkaline phosphatase. Liver biopsy showed active ENT2 hepatitis ENT2END
1	ENT1 Quinidine ENT1END ENT2 hepatitis ENT2END
0	Recommendations to avoid potential ENT1 cranial nerve deficits ENT1END from ENT2 papaverine ENT2END are provided
1	The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible ENT1 adverse effect on the proximal eighth nerve  ENT1END  Recommendations to avoid potential cranial nerve deficits from ENT2 papaverine ENT2END are provided
0	METHODS: We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical ENT1 papaverine ENT1END for ENT2 vasospasm ENT2END
1	One patient showed no recovery of later waves and a delayed profound ENT1 sensorineural hearing loss  ENT1END  The average recovery time of BAEP waveforms to pre- ENT2 papaverine ENT2END baseline values was 39 min
0	A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion ENT1 cimetidine ENT1END 50 mg/hour. The ENT2 arrhythmias ENT2END were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ranitidine treatment
0	The ENT1 arrhythmias ENT1END  were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ENT2 ranitidine ENT2END treatment
1	ENT1 Sinus arrest  ENT1END  associated with continuous-infusion ENT2 cimetidine ENT2END
0	The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ENT1 ranitidine ENT1END  treatment. This is the first reported case of ENT2 sinus arrest ENT2END associated with continuous-infusion cimetidine
0	A 40-year-old man with leukemia and no history of ENT1 cardiac disease  ENT1END developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion ENT2 cimetidine ENT2END 50 mg/hour
0	A 40-year-old man with leukemia and no history of ENT1 cardiac disease  ENT1END  developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour. The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ENT2 ranitidine ENT2END treatment
0	The administration of intermittent intravenous infusions of ENT1 cimetidine ENT1END is infrequently associated with the development of bradyarrhythmias. A 40-year-old man with ENT2 leukemia ENT2END and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour
0	A 40-year-old man with ENT1 leukemia  ENT1END  and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour. The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ENT2 ranitidine ENT2END treatment
1	The administration of intermittent intravenous infusions of ENT1 cimetidine ENT1END  is infrequently associated with the development of ENT2 bradyarrhythmias ENT2END
0	The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of ENT1 bradyarrhythmias  ENT1END . A 40-year-old man with leukemia and no history of cardiac disease developed recurrent, brief episodes of apparent sinus arrest while receiving continuous-infusion cimetidine 50 mg/hour. The arrhythmias were temporally related to cimetidine administration, disappeared after dechallenge, and did not recur during ENT2 ranitidine ENT2END treatment
1	The role of nicotine in smoking-related ENT1 cardiovascular disease  ENT1END . ENT2 Nicotine ENT2END activates the sympathetic nervous system and in this way could contribute to cardiovascular disease
0	Nicotine activates the sympathetic nervous system and in this way could contribute to ENT1 cardiovascular disease ENT1END  Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis, but evidence among humans is too inadequate to be definitive about such an effect. Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of ENT2 carbon monoxide ENT2END
1	Animal studies and mechanistic studies indicate that ENT1 nicotine ENT1END could play a role in accelerating ENT2 atherosclerosis ENT2END , but evidence among humans is too inadequate to be definitive about such an effect
0	Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating ENT1 atherosclerosis  ENT1END , but evidence among humans is too inadequate to be definitive about such an effect. Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of ENT2 carbon monoxide ENT2END
0	ENT1 Nicotine ENT1END does not appear to enhance ENT2 thrombosis ENT2END among humans
0	Almost certainly, nicotine via its hemodynamic effects contributes to acute cardiovascular events, although current evidence suggests that the effects of nicotine are much less important than are the prothrombotic effects of cigarette smoking or the effects of ENT1 carbon monoxide  ENT1END . Nicotine does not appear to enhance ENT2 thrombosis ENT2END among humans
0	The present study was designed to investigate the hypothesis that calcium channel blockers in general induce ENT1 cardiovascular malformations ENT1END indicating a pharmacologic class effect. We studied three calcium channel blockers of different structure, nifedipine, ENT2 diltiazem ENT2END , and verapamil, along with the new agent
1	Preclinical toxicologic investigation suggested that a new calcium channel blocker, ENT1 Ro 40-5967 ENT1END  induced ENT2 cardiovascular alterations ENT2END in rat fetuses exposed to this agent during organogenesis
1	A low incidence of ENT1 cardiovascular malformations ENT1END was observed after exposure to each of the four calcium channel blockers, but this incidence was statistically significant only for ENT2 verapamil ENT2END and nifedipine
1	The present study was designed to investigate the hypothesis that calcium channel blockers in general induce ENT1 cardiovascular malformations ENT1END  indicating a pharmacologic class effect. We studied three calcium channel blockers of different structure, ENT2 nifedipine ENT2END , diltiazem, and verapamil, along with the new agent
0	ENT1 Cardiovascular alterations  ENT1END  in rat fetuses exposed to ENT2 calcium ENT2END channel blockers
0	Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a ENT1 dopamine ENT1END agonist. Other possible adverse effects--such as gastrointestinal disorders, ENT2 orthostatic hypotension ENT2END , levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate ENT1 carbidopa  ENT1END levodopa to the point of "normality," which can lead to toxicity. The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist. Other possible adverse effects--such as gastrointestinal disorders, ENT2 orthostatic hypotension ENT2END , levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
1	Other possible adverse effects--such as gastrointestinal disorders, ENT1 orthostatic hypotension ENT1END , ENT2 levodopa ENT2END -induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a ENT1 dopamine ENT1END  agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced ENT2 psychosis ENT2END , sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate ENT1 carbidopa  ENT1END -levodopa to the point of "normality," which can lead to toxicity. The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced ENT2 psychosis ENT2END , sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, ENT1 levodopa  ENT1END -induced ENT2 psychosis ENT2END , sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a ENT1 dopamine ENT1END  agonist. Other possible adverse effects--such as ENT2 gastrointestinal disorders ENT2END , orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate ENT1 carbidopa  ENT1END -levodopa to the point of "normality," which can lead to toxicity. The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist. Other possible adverse effects--such as ENT2 gastrointestinal disorders ENT2END , orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
1	Other possible adverse effects--such as ENT1 gastrointestinal disorders  ENT1END , orthostatic hypotension, ENT2 levodopa ENT2END -induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a ENT1 dopamine ENT1END  agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, ENT2 sleep disturbances ENT2END or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate ENT1 carbidopa  ENT1END -levodopa to the point of "normality," which can lead to toxicity. The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, ENT2 sleep disturbances ENT2END or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, ENT1 levodopa  ENT1END -induced psychosis, ENT2 sleep disturbances ENT2END or parasomnias, or drug interactions--also require carefully monitored individual treatment
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa-levodopa to the point of "normality," which can lead to ENT1 toxicity  ENT1END  The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a ENT2 dopamine ENT2END agonist
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate ENT1 carbidopa  ENT1END -levodopa to the point of "normality," which can lead to ENT2 toxicity ENT2END
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate carbidopa- ENT1 levodopa  ENT1END to the point of "normality," which can lead to ENT2 toxicity ENT2END
0	Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a ENT1 dopamine ENT1END  agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or ENT2 parasomnias ENT2END , or drug interactions--also require carefully monitored individual treatment
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate ENT1 carbidopa  ENT1END -levodopa to the point of "normality," which can lead to toxicity. The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or ENT2 parasomnias ENT2END , or drug interactions--also require carefully monitored individual treatment
1	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, ENT1 levodopa  ENT1END -induced psychosis, sleep disturbances or ENT2 parasomnias ENT2END , or drug interactions--also require carefully monitored individual treatment
0	Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a ENT1 dopamine ENT1END  agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment. Nonpharmacologic concerns can help the ENT2 Parkinson's disease ENT2END patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups
0	While there is no single correct starting dose for levodopa therapy, many individuals can be started on either the 25/100 or controlled-release formula, following the general rule not to attempt to titrate ENT1 carbidopa  ENT1END -levodopa to the point of "normality," which can lead to toxicity. The physician should also determine the proper use of any adjunctive medications; such combined therapy has become the standard approach to treatment. Following the initial period of therapy, emerging difficulties require a reassessment of therapeutic approaches, such as dosage adjustment or introduction of a dopamine agonist. Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, levodopa-induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment. Nonpharmacologic concerns can help the ENT2 Parkinson's disease ENT2END patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups
0	Other possible adverse effects--such as gastrointestinal disorders, orthostatic hypotension, ENT1 levodopa  ENT1END -induced psychosis, sleep disturbances or parasomnias, or drug interactions--also require carefully monitored individual treatment. Nonpharmacologic concerns can help the ENT2 Parkinson's disease ENT2END patient achieve and maintain optimal functioning, including daily exercise, physical therapy, and involvement with support groups
0	Delayed asystolic ENT1 cardiac arrest ENT1END  after diltiazem overdose; resuscitation with high dose intravenous calcium.A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, ENT2 aspirin ENT2END , isosorbide nitrate, and alcohol
0	Delayed asystolic ENT1 cardiac arrest ENT1END  after diltiazem overdose; resuscitation with high dose intravenous calcium.A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide ENT2 nitrate ENT2END , and alcohol
0	The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became ENT1 asystolic ENT1END  He was resuscitated with high dose (13.5 g) intravenous calcium and ENT2 adrenaline ENT2END (epinephrine)
0	The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became ENT1 asystolic ENT1END . He was resuscitated with high dose (13.5 g) intravenous ENT2 calcium ENT2END and adrenaline (epinephrine)
0	Delayed asystolic ENT1 cardiac arrest ENT1END  after diltiazem overdose; resuscitation with high dose intravenous calcium.A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, ENT2 paracetamol ENT2END , aspirin, isosorbide nitrate, and alcohol
0	Delayed asystolic ENT1 cardiac arrest ENT1END  after diltiazem overdose; resuscitation with high dose intravenous calcium.A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, ENT2 isosorbide ENT2END nitrate, and alcohol
1	Delayed asystolic ENT1 cardiac arrest  ENT1END  after ENT2 diltiazem ENT2END overdose; resuscitation with high dose intravenous calcium
0	Delayed asystolic ENT1 cardiac arrest ENT1END  after diltiazem overdose; resuscitation with high dose intravenous calcium.A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and ENT2 alcohol ENT2END
0	6 g of diltiazem, paracetamol, ENT1 aspirin ENT1END , isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild ENT2 hypotension ENT2END and was treated with activated charcoal and intravenous fluids
0	6 g of diltiazem, paracetamol, aspirin, isosorbide ENT1 nitrate  ENT1END , and alcohol. He initially presented to hospital after six hours with mild ENT2 hypotension ENT2END and was treated with activated charcoal and intravenous fluids
0	He initially presented to hospital after six hours with mild ENT1 hypotension  ENT1END  and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised tonic-clonic seizures. The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic. He was resuscitated with high dose (13.5 g) intravenous calcium and ENT2 adrenaline ENT2END (epinephrine)
0	Delayed asystolic cardiac arrest after diltiazem overdose; resuscitation with high dose intravenous ENT1 calcium  ENT1END .A 51 year old man took a mixed overdose including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild ENT2 hypotension ENT2END and was treated with activated charcoal and intravenous fluids
0	6 g of diltiazem, ENT1 paracetamol  ENT1END , aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild ENT2 hypotension ENT2END and was treated with activated charcoal and intravenous fluids
0	6 g of diltiazem, paracetamol, aspirin, ENT1 isosorbide  ENT1END  nitrate, and alcohol. He initially presented to hospital after six hours with mild ENT2 hypotension ENT2END and was treated with activated charcoal and intravenous fluids
1	6 g of ENT1 diltiazem  ENT1END  paracetamol, aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild ENT2 hypotension ENT2END and was treated with activated charcoal and intravenous fluids
0	6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and ENT1 alcohol  ENT1END . He initially presented to hospital after six hours with mild ENT2 hypotension ENT2END and was treated with activated charcoal and intravenous fluids
0	5 g) intravenous calcium and adrenaline ( ENT1 epinephrine ENT1END . He required inotropic support and temporary pacing over the next 48 hours. This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose, particularly with the onset of asystole. It should be considered early in cases of cardiac arrest after diltiazem overdose. The case also highlights the problems with delayed ENT2 toxicity ENT2END when whole bowel irrigation is not administered
0	This case suggests there is a role for aggressive high dose intravenous ENT1 calcium  ENT1END therapy in severe diltiazem overdose, particularly with the onset of asystole. It should be considered early in cases of cardiac arrest after diltiazem overdose. The case also highlights the problems with delayed ENT2 toxicity ENT2END when whole bowel irrigation is not administered
0	It should be considered early in cases of cardiac arrest after ENT1 diltiazem  ENT1END overdose. The case also highlights the problems with delayed ENT2 toxicity ENT2END when whole bowel irrigation is not administered
0	6 g of diltiazem, paracetamol, ENT1 aspirin ENT1END , isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised tonic-clonic seizures. The patient remained unresponsive with junctional ENT2 bradycardia ENT2END , unrecordable blood pressure, and then became asystolic
0	6 g of diltiazem, paracetamol, aspirin, isosorbide ENT1 nitrate  ENT1END , and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised tonic-clonic seizures. The patient remained unresponsive with junctional ENT2 bradycardia ENT2END , unrecordable blood pressure, and then became asystolic
0	The patient remained unresponsive with junctional ENT1 bradycardia  ENT1END , unrecordable blood pressure, and then became asystolic. He was resuscitated with high dose (13.5 g) intravenous calcium and ENT2 adrenaline ENT2END (epinephrine)
0	The patient remained unresponsive with junctional ENT1 bradycardia  ENT1END , unrecordable blood pressure, and then became asystolic. He was resuscitated with high dose (13.5 g) intravenous ENT2 calcium ENT2END and adrenaline (epinephrine)
0	6 g of diltiazem, ENT1 paracetamol  ENT1END , aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised tonic-clonic seizures. The patient remained unresponsive with junctional ENT2 bradycardia ENT2END , unrecordable blood pressure, and then became asystolic
0	6 g of diltiazem, paracetamol, aspirin, ENT1 isosorbide  ENT1END  nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised tonic-clonic seizures. The patient remained unresponsive with junctional ENT2 bradycardia ENT2END , unrecordable blood pressure, and then became asystolic
1	6 g of ENT1 diltiazem  ENT1END , paracetamol, aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised tonic-clonic seizures. The patient remained unresponsive with junctional ENT2 bradycardia ENT2END , unrecordable blood pressure, and then became asystolic
0	6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and ENT1 alcohol  ENT1END . He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised tonic-clonic seizures. The patient remained unresponsive with junctional ENT2 bradycardia ENT2END , unrecordable blood pressure, and then became asystolic
0	A 51 year old man took a mixed ENT1 overdose  ENT1END including 1.8-3.6 g of diltiazem, paracetamol, ENT2 aspirin ENT2END , isosorbide nitrate, and alcohol
0	A 51 year old man took a mixed ENT1 overdose  ENT1END  including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide ENT2 nitrate ENT2END , and alcohol
0	5 g) intravenous calcium and adrenaline ( ENT1 epinephrine ENT1END ). He required inotropic support and temporary pacing over the next 48 hours. This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem ENT2 overdose ENT2END , particularly with the onset of asystole
0	This case suggests there is a role for aggressive high dose intravenous ENT1 calcium  ENT1END  therapy in severe diltiazem ENT2 overdose ENT2END , particularly with the onset of asystole
0	A 51 year old man took a mixed ENT1 overdose  ENT1END  including 1.8-3.6 g of diltiazem, ENT2 paracetamol ENT2END , aspirin, isosorbide nitrate, and alcohol
0	A 51 year old man took a mixed ENT1 overdose  ENT1END  including 1.8-3.6 g of diltiazem, paracetamol, aspirin, ENT2 isosorbide ENT2END nitrate, and alcohol
1	Delayed asystolic cardiac arrest after ENT1 diltiazem ENT1END ENT2 overdose ENT2END ; resuscitation with high dose intravenous calcium
0	A 51 year old man took a mixed ENT1 overdose  ENT1END  including 1.8-3.6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and ENT2 alcohol ENT2END
0	6 g of diltiazem, paracetamol, ENT1 aspirin ENT1END , isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised ENT2 tonic-clonic seizures ENT2END
0	6 g of diltiazem, paracetamol, aspirin, isosorbide ENT1 nitrate  ENT1END , and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised ENT2 tonic-clonic seizures ENT2END
0	Eighteen hours after the overdose he had two generalised ENT1 tonic-clonic seizures  ENT1END . The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic. He was resuscitated with high dose (13.5 g) intravenous calcium and ENT2 adrenaline ENT2END (epinephrine)
0	Eighteen hours after the overdose he had two generalised ENT1 tonic-clonic seizures  ENT1END . The patient remained unresponsive with junctional bradycardia, unrecordable blood pressure, and then became asystolic. He was resuscitated with high dose (13.5 g) intravenous ENT2 calcium ENT2END and adrenaline (epinephrine)
0	6 g of diltiazem, ENT1 paracetamol  ENT1END , aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised ENT2 tonic-clonic seizures ENT2END
0	6 g of diltiazem, paracetamol, aspirin, ENT1 isosorbide  ENT1END  nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised ENT2 tonic-clonic seizures ENT2END
0	6 g of ENT1 diltiazem  ENT1END , paracetamol, aspirin, isosorbide nitrate, and alcohol. He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised ENT2 tonic-clonic seizures ENT2END
0	6 g of diltiazem, paracetamol, aspirin, isosorbide nitrate, and ENT1 alcohol  ENT1END . He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids. Eighteen hours after the overdose he had two generalised ENT2 tonic-clonic seizures ENT2END
1	The goal of the study was to deliver a dose rate and total cumulative dose of ENT1 ifosfamide ENT1END that would be comparable to standard bolus or short-term infusions administered with Mesna. Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), ENT2 nausea ENT2END (1), and Grade 2 leukopenia (1)
0	The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with ENT1 Mesna  ENT1END  Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), ENT2 nausea ENT2END (1), and Grade 2 leukopenia (1)
1	The goal of the study was to deliver a dose rate and total cumulative dose of ENT1 ifosfamide ENT1END  that would be comparable to standard bolus or short-term infusions administered with Mesna. Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic toxicity; ENT2 confusion ENT2END (1), nausea (1), and Grade 2 leukopenia (1)
0	The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with ENT1 Mesna  ENT1END . Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic toxicity; ENT2 confusion ENT2END (1), nausea (1), and Grade 2 leukopenia (1)
1	The goal of the study was to deliver a dose rate and total cumulative dose of ENT1 ifosfamide ENT1END  that would be comparable to standard bolus or short-term infusions administered with Mesna. Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 ENT2 leukopenia ENT2END (1)
0	The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with ENT1 Mesna  ENT1END . Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic toxicity; confusion (1), nausea (1), and Grade 2 ENT2 leukopenia ENT2END (1)
0	The goal of the study was to deliver a dose rate and total cumulative dose of ENT1 ifosfamide ENT1END  that would be comparable to standard bolus or short-term infusions administered with Mesna. Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic ENT2 toxicity ENT2END ; confusion (1), nausea (1), and Grade 2 leukopenia (1)
0	The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short-term infusions administered with ENT1 Mesna  ENT1END . Dose escalations proceeded from 200 to 300, 400, 450, 500, and 550 mg/m2/d. Four patients developed transient microscopic hematuria at 400, 450, and 500 mg/m2/d. There were no instances of macroscopic hematuria. At 550 mg/m2/d, three patients experienced nonurologic ENT2 toxicity ENT2END ; confusion (1), nausea (1), and Grade 2 leukopenia (1)
1	The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding Mesna to the infusate in patients with persistent ENT1 hematuria ENT1END  The protracted infusion schedule for ENT2 ifosfamide ENT2END permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to  890 per cycle
0	The frequency and predictability of hematuria are not precise, and at least daily monitoring by urine Hematest is essential, adding ENT1 Mesna  ENT1END to the infusate in patients with persistent ENT2 hematuria ENT2END
0	The ENT1 deformations ENT1END caused by both coniine and ENT2 nicotine ENT2END sulfate were excessive flexion or extension of one or more toes
0	The ENT1 deformations ENT1END  caused by both ENT2 coniine ENT2END and nicotine sulfate were excessive flexion or extension of one or more toes
1	95% of a 5-min interval, and no movement was observed for ENT1 nicotine ENT1END sulfate treated chicks. In summary, the chick embryo provides a reliable and simple experimental animal model of coniine-induced ENT2 arthrogryposis ENT2END
1	In summary, the chick embryo provides a reliable and simple experimental animal model of ENT1 coniine  ENT1END induced ENT2 arthrogryposis ENT2END
1	No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive ENT1 cranial hemorrhage ENT1END occurred in all ENT2 nicotine ENT2END sulfate-treated chicks
0	No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group; however, extensive ENT1 cranial hemorrhage ENT1END  occurred in all nicotine sulfate-treated chicks. There was a statistically significant (P < or = 0.01) decrease in movement in ENT2 coniine ENT2END and nicotine sulfate treated chicks as determined by ultrasound
0	INTERPRETATION: Repeated exposure of human beings to ENT1 HCFCs 123 and 124 ENT1END can result in serious ENT2 liver injury ENT2END in a large proportion of the exposed population
0	Although the exact mechanism of ENT1 hepatotoxicity ENT1END of these agents is not known, the results suggest that ENT2 trifluoroacetyl ENT2END -altered liver proteins are involved
0	Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the ENT1 hepatotoxicity ENT1END of ENT2 halothane ENT2END
0	INTERPRETATION: Repeated exposure of human beings to ENT1 HCFCs 123 and 124  ENT1END can result in serious ENT2 liver injury ENT2END in a large proportion of the exposed population
0	BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ENT1 ozone ENT1END depleting chlorofluorocarbons (CFCs). Limited studies in animals indicate potential ENT2 hepatotoxicity ENT2END of some of these compounds
0	BACKGROUND: Hydrochlorofluorocarbons (HCFCs) are used increasingly in industry as substitutes for ozone-depleting chlorofluorocarbons ( ENT1 CFCs  ENT1END . Limited studies in animals indicate potential ENT2 hepatotoxicity ENT2END of some of these compounds
0	FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging ENT1 necrosis  ENT1END . Trifluoroacetyl-adducted proteins were detected in surviving hepatocytes. Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers. INTERPRETATION: Repeated exposure of human beings to ENT2 HCFCs 123 and 124 ENT2END can result in serious liver injury in a large proportion of the exposed population
0	FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging ENT1 necrosis ENT1END ). ENT2 Trifluoroacetyl ENT2END -adducted proteins were detected in surviving hepatocytes
0	Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of ENT1 halothane ENT1END . We aimed to test whether HCFCs 123 and 124 can result in serious liver disease. METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of trifluoroacetyl protein adducts were done. The serum of six affected workers and five controls was tested for autoantibodies that react with human liver cytochrome-P450 2E1 (P450 2E1) and P58 protein disulphide isomerase isoform (P58). FINDINGS: The liver biopsy sample showed hepatocellular ENT2 necrosis ENT2END which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging necrosis)
0	FINDINGS: The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas (bridging ENT1 necrosis  ENT1END ). Trifluoroacetyl-adducted proteins were detected in surviving hepatocytes. Autoantibodies against P450 2E1 or P58, previously associated with halothane hepatitis, were detected in the serum of five affected workers. INTERPRETATION: Repeated exposure of human beings to ENT2 HCFCs 123 and 124 ENT2END can result in serious liver injury in a large proportion of the exposed population
1	We aimed to test whether ENT1 HCFCs 123 and 124 ENT1END can result in serious ENT2 liver disease ENT2END
0	We aimed to test whether HCFCs 123 and 124 can result in serious ENT1 liver disease ENT1END . METHODS: For one severely affected worker liver biopsy and immunohistochemical stainings for the presence of ENT2 trifluoroacetyl ENT2END protein adducts were done
0	Both compounds are metabolised in the same way as 1-bromo-1-chloro-2,2,2-trifluoroethane (halothane) to form reactive trifluoroacetyl halide intermediates, which have been implicated in the hepatotoxicity of ENT1 halothane  ENT1END . We aimed to test whether HCFCs 123 and 124 can result in serious ENT2 liver disease ENT2END
1	We aimed to test whether ENT1 HCFCs 123 and 124  ENT1END can result in serious ENT2 liver disease ENT2END
0	Epidemic of ENT1 liver disease  ENT1END  caused by hydrochlorofluorocarbons used as ENT2 ozone ENT2END -sparing substitutes of chlorofluorocarbons
0	Epidemic of ENT1 liver disease  ENT1END  caused by hydrochlorofluorocarbons used as ozone-sparing substitutes of ENT2 chlorofluorocarbons ENT2END
0	Autoantibodies against P450 2E1 or P58, previously associated with ENT1 halothane hepatitis  ENT1END  were detected in the serum of five affected workers. INTERPRETATION: Repeated exposure of human beings to ENT2 HCFCs 123 and 124 ENT2END can result in serious liver injury in a large proportion of the exposed population
0	ENT1 Trifluoroacetyl  ENT1END -adducted proteins were detected in surviving hepatocytes. Autoantibodies against P450 2E1 or P58, previously associated with ENT2 halothane hepatitis ENT2END , were detected in the serum of five affected workers
0	Autoantibodies against P450 2E1 or P58, previously associated with ENT1 halothane hepatitis  ENT1END , were detected in the serum of five affected workers. INTERPRETATION: Repeated exposure of human beings to ENT2 HCFCs 123 and 124 ENT2END can result in serious liver injury in a large proportion of the exposed population
1	The present report describes a case of cardiac arrest and subsequent death as a result of ENT1 hyperkalaemia ENT1END following the use of ENT2 suxamethonium ENT2END in a 23-year-old Malawian woman
0	The serum level of ENT1 potassium ENT1END was observed to be 8.4 mequiv L-1. Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for ENT2 hyperkalaemia ENT2END following the administration of suxamethonium
0	ENT1 Suxamethonium  ENT1END -induced cardiac arrest and ENT2 death ENT2END following 5 days of immobilization
0	The serum level of ENT1 potassium ENT1END  was observed to be 8.4 mequiv L-1. Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium. It is postulated that her ENT2 death ENT2END was caused by hypersensitivity to suxamethonium, associated with her 5-day immobilization
1	Forty seconds after injection of ENT1 suxamethonium ENT1END  ENT2 bradycardia ENT2END and cardiac arrest occurred
0	Forty seconds after injection of suxamethonium, ENT1 bradycardia  ENT1END  and cardiac arrest occurred. Attempts to resuscitate the patient were not successful. The serum level of ENT2 potassium ENT2END was observed to be 8
1	It is postulated that her death was caused by ENT1 hypersensitivity ENT1END to ENT2 suxamethonium ENT2END , associated with her 5-day immobilization
0	The serum level of ENT1 potassium  ENT1END  was observed to be 8.4 mequiv L-1. Apart from the reduction in the patient's level of consciousness, there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium. It is postulated that her death was caused by ENT2 hypersensitivity ENT2END to suxamethonium, associated with her 5-day immobilization
1	ENT1 Suxamethonium  ENT1END -induced ENT2 cardiac arrest ENT2END and death following 5 days of immobilization
0	Forty seconds after injection of suxamethonium, bradycardia and ENT1 cardiac arrest  ENT1END occurred. Attempts to resuscitate the patient were not successful. The serum level of ENT2 potassium ENT2END was observed to be 8
0	The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of ENT1 suxamethonium ENT1END  in a 23-year-old Malawian woman. Five days after the onset of the symptoms of ENT2 meningitis ENT2END , the patient aspirated stomach contents and needed endotracheal intubation
0	Five days after the onset of the symptoms of ENT1 meningitis  ENT1END , the patient aspirated stomach contents and needed endotracheal intubation. Forty seconds after injection of suxamethonium, bradycardia and cardiac arrest occurred. Attempts to resuscitate the patient were not successful. The serum level of ENT2 potassium ENT2END was observed to be 8
1	ENT1 Suxamethonium  ENT1END  infusion rate and observed ENT2 fasciculations ENT2END
0	The infusion was discontinued either when there was no muscular response to ENT1 tetanic ENT1END stimulation of the ulnar nerve or when ENT2 Sch ENT2END 120 mg was exceeded
0	Its role in the therapy of glomerulonephritis, autoimmunity, ENT1 cystic renal diseases ENT1END and renal cancer is under investigation. Because ENT2 sirolimus ENT2END does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'
1	ENT1 Sirolimus  ENT1END -associated ENT2 proteinuria ENT2END and renal dysfunction
0	Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of ENT1 proteinuria ENT1END and renal function, use of ENT2 angiotensin ENT2END -converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed
0	Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or ENT1 angiotensin II ENT1END receptor blockers if ENT2 proteinuria ENT2END occurs and withdrawal if needed
0	Its role in the therapy of glomerulonephritis, ENT1 autoimmunity  ENT1END  cystic renal diseases and renal cancer is under investigation. Because ENT2 sirolimus ENT2END does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'
0	A common risk factor appears to be presence of pre-existing ENT1 chronic renal damage ENT1END  The mechanisms of ENT2 sirolimus ENT2END -associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal
0	A common risk factor appears to be presence of pre-existing ENT1 chronic renal damage  ENT1END . The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal. It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive. The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes. Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of ENT2 angiotensin ENT2END -converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed
0	A common risk factor appears to be presence of pre-existing ENT1 chronic renal damage  ENT1END . The mechanisms of sirolimus-associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal. It has also been suggested that sirolimus directly causes increased glomerular permeability/injury, but evidence for this mechanism is currently inconclusive. The acute renal dysfunction associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes. Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or ENT2 angiotensin II ENT2END receptor blockers if proteinuria occurs and withdrawal if needed
0	Its role in the therapy of glomerulonephritis, autoimmunity, cystic renal diseases and ENT1 renal cancer  ENT1END is under investigation. Because ENT2 sirolimus ENT2END does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'
1	Sirolimus-associated proteinuria and ENT1 renal dysfunction  ENT1END . ENT2 Sirolimus ENT2END is a novel immunosuppressant with potent antiproliferative actions through its ability to inhibit the raptor-containing mammalian target of rapamycin protein kinase
0	The ENT1 acute renal dysfunction ENT1END associated with ENT2 sirolimus ENT2END (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes
0	The ENT1 acute renal dysfunction  ENT1END  associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes. Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of ENT2 angiotensin ENT2END -converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed
0	The ENT1 acute renal dysfunction  ENT1END  associated with sirolimus (such as in delayed graft function) may be due to suppression of compensatory renal cell proliferation and survival/repair processes. Although these adverse effects occur in some patients, their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney, the use of sirolimus in appropriate patient populations, close monitoring of proteinuria and renal function, use of angiotensin-converting enzyme inhibitors or ENT2 angiotensin II ENT2END receptor blockers if proteinuria occurs and withdrawal if needed
0	Its role in the therapy of ENT1 glomerulonephritis  ENT1END  autoimmunity, cystic renal diseases and renal cancer is under investigation. Because ENT2 sirolimus ENT2END does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors, it has been designated a 'non-nephrotoxic drug'
0	9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of MPTP-induced ENT1 neurodegeneration ENT1END of ENT2 DA ENT2END neurons
1	9 (2006), 917] recently identified the microglial-specific fractalkine receptor (CX3CR1) as an important mediator of ENT1 MPTP  ENT1END induced ENT2 neurodegeneration ENT2END of DA neurons
1	Because the ENT1 CNS damage ENT1END caused by ENT2 METH ENT2END and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity, we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation
0	Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein (eGFP) were treated with METH and examined for striatal ENT1 neurotoxicity ENT1END  METH depleted ENT2 DA ENT2END , caused microglial activation, and increased body temperature in CX3CR1 knockout mice to the same extent and over the same time course seen in wild-type controls
0	Because the CNS damage caused by METH and ENT1 MPTP ENT1END is highly selective for the DA neuronal system in mouse models of ENT2 neurotoxicity ENT2END , we hypothesized that the CX3CR1 plays a role in METH-induced neurotoxicity and microglial activation
0	We conclude from these studies that CX3CR1 signaling does not modulate ENT1 METH ENT1END ENT2 neurotoxicity ENT2END or microglial activation
0	In 7 of the 28 patients there was a striking temporal association between the initiation of ENT1 sirolimus ENT1END and the development of ENT2 nephrotic ENT2END -range proteinuria
0	In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein: ENT1 creatinine  ENT1END ratios, an estimate of grams of proteinuria/day. Laboratory results were compared between prior, during and following sirolimus use. RESULTS: Twenty-eight patients (24%) developed increased proteinuria from baseline during their post-transplantation course. In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive. In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of ENT2 nephrotic ENT2END -range proteinuria
0	BACKGROUND: ENT1 Sirolimus ENT1END is the latest immunosuppressive agent used to prevent rejection, and may have less ENT2 nephrotoxicity ENT2END than calcineurin inhibitor (CNI)-based regimens
0	BACKGROUND: Sirolimus is the latest immunosuppressive agent used to prevent rejection, and may have less ENT1 nephrotoxicity  ENT1END  than calcineurin inhibitor (CNI)-based regimens. To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus. We have encountered several patients who developed substantial proteinuria associated with sirolimus use. In each patient, the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria. METHODS: We analyzed the clinical and laboratory information available for all 119 patients transplanted at the Washington Hospital Center between 1999-2003 for whom sirolimus was a component of their immunosuppressant regimen. In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein ENT2 creatinine ENT2END ratios, an estimate of grams of proteinuria/day
1	In each patient, the close temporal association between the commencement of sirolimus therapy and ENT1 proteinuria ENT1END implicated ENT2 sirolimus ENT2END as the most likely etiology of the proteinuria
0	In these patients, the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein: ENT1 creatinine ENT1END  ratios, an estimate of grams of ENT2 proteinuria ENT2END /day
1	ENT1 Clomipramine  ENT1END -induced ENT2 sleep disturbance ENT2END does not impair its prolactin-releasing action
0	The possible role of low pH as well as total volume as potential factors in causing ENT1 neurotoxicity ENT1END was evaluated. The 65 dogs in the study received injections in the subarachnoid space as follows: 6 to 8 ml of ENT2 bupivacaine ENT2END (N = 15), 2-chloroprocaine-CE (N = 20), low pH normal saline (pH 3
0	The purpose of this study was to evaluate the neurologic consequences of deliberate subarachnoid injection of large volumes of ENT1 2-chloroprocaine-CE  ENT1END in experimental animals. The possible role of low pH as well as total volume as potential factors in causing ENT2 neurotoxicity ENT2END was evaluated
0	Of the 15 spinal cords of the animals that received 2-chloroprocaine-CE, 13 showed ENT1 subpial necrosis ENT1END  the nerve roots and subarachnoid vessels were normal. The spinal cords of the animals that received ENT2 bupivacaine ENT2END , low pH normal saline (pH 3
1	Of the 15 spinal cords of the animals that received ENT1 2-chloroprocaine-CE  ENT1END  13 showed ENT2 subpial necrosis ENT2END ; the nerve roots and subarachnoid vessels were normal
0	Of the 20 animals that received subarachnoid injection of 2-chloroprocaine-CE seven (35%) developed hind-limb ENT1 paralysis ENT1END  None of the animals that received ENT2 bupivacaine ENT2END , normal saline, or normal saline titrated to a pH 3
1	Of the 20 animals that received subarachnoid injection of ENT1 2-chloroprocaine-CE  ENT1END seven (35%) developed hind-limb ENT2 paralysis ENT2END
1	We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L-dopa medication, the first one without ENT1 L-dopa ENT1END induced ENT2 dyskinesia ENT2END (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects
0	We have studied the regional cerebral blood flow (rCBF) changes induced by the execution of a finger-to-thumb opposition motor task in the supplementary and primary motor cortex of two groups of ENT1 parkinsonian ENT1END patients on ENT2 L-dopa ENT2END medication, the first one without L-dopa induced dyskinesia (n = 23) and the other with moderate peak-dose dyskinesia (n = 15), and of a group of 14 normal subjects
0	These results are compatible with the hypothesis that an ENT1 hyperkinetic ENT1END abnormal involuntary movement, like ENT2 L-dopa ENT2END -induced peak dose dyskinesia, is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop
0	The aim of the study was to examine the influence of ENT1 hyperprolactinemia ENT1END  induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe. The study was performed on sexually mature male rats. Serum concentrations of prolactin (PRL) and ENT2 testosterone ENT2END (T) were measured
1	Aging process of epithelial cells of the rat prostate lateral lobe in experimental ENT1 hyperprolactinemia  ENT1END  induced by ENT2 haloperidol ENT2END
0	The aim of the study was to examine the influence of ENT1 hyperprolactinemia  ENT1END , induced by haloperidol (HAL) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe. The study was performed on sexually mature male rats. Serum concentrations of prolactin ( ENT2 PRL ENT2END ) and testosterone (T) were measured
0	In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas ENT1 T ENT1END concentration was almost twice lower than that in the control group. Light microscopy visualized the following: hypertrophy and epithelium ENT2 hyperplasia ENT2END of the glandular ducts, associated with increased PCNA expression
0	In rats of the experimental group, the mean concentration of: ENT1 PRL  ENT1END was more than twice higher, whereas T concentration was almost twice lower than that in the control group. Light microscopy visualized the following: hypertrophy and epithelium ENT2 hyperplasia ENT2END of the glandular ducts, associated with increased PCNA expression
0	In rats of the experimental group, the mean concentration of: PRL was more than twice higher, whereas ENT1 T ENT1END  concentration was almost twice lower than that in the control group. Light microscopy visualized the following: ENT2 hypertrophy ENT2END and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression
0	In rats of the experimental group, the mean concentration of: ENT1 PRL  ENT1END  was more than twice higher, whereas T concentration was almost twice lower than that in the control group. Light microscopy visualized the following: ENT2 hypertrophy ENT2END and epithelium hyperplasia of the glandular ducts, associated with increased PCNA expression
1	No hepatic preneoplastic nodules or ENT1 hepatocellular carcinomas ENT1END developed in rats fed the plain ENT2 choline ENT2END -supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital
0	06% ENT1 phenobarbital  ENT1END  No hepatic preneoplastic nodules or ENT2 hepatocellular carcinomas ENT2END developed in rats fed the plain choline-supplemented diet, while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital
0	A hemodynamic, volumetric, and metabolic study in patients without ENT1 heart failure ENT1END .The effects of ENT2 digitalis glycosides ENT2END on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man
0	A hemodynamic, volumetric, and metabolic study in patients without ENT1 heart failure ENT1END .The effects of digitalis glycosides on myocardial ENT2 oxygen ENT2END supply and demand are of particular interest in the presence of obstructive coronary artery disease, but have not been measured previously in man
0	We conclude that in patients with chronic coronary artery disease who are not in clinical ENT1 congestive heart failure ENT1END left ventricular end-diastolic volume falls after ENT2 ouabain ENT2END administration even when it is initially normal
0	The effects of ENT1 digitalis glycosides ENT1END  on myocardial oxygen supply and demand are of particular interest in the presence of obstructive ENT2 coronary artery disease ENT2END , but have not been measured previously in man
0	Effects of ouabain on myocardial ENT1 oxygen  ENT1END  supply and demand in patients with chronic ENT2 coronary artery disease ENT2END
0	Effects of ENT1 ouabain  ENT1END  on myocardial oxygen supply and demand in patients with chronic ENT2 coronary artery disease ENT2END
0	We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure ENT1 left ventricular end-diastolic volume falls ENT1END after ouabain administration even when it is initially normal. Though this fall would be associated with a decrease in wall tension, and, therefore, of myocardial ENT2 oxygen ENT2END consumption, it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption
1	We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure ENT1 left ventricular end-diastolic volume falls  ENT1END  after ENT2 ouabain ENT2END administration even when it is initially normal
0	In addition, the disrupted prepulse inhibition induced by ENT1 d-amphetamine ENT1END or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders. The symptoms of methamphetamine (METH)-induced psychosis are similar to those of ENT2 paranoid type schizophrenia ENT2END
0	The symptoms of methamphetamine (METH)-induced psychosis are similar to those of ENT1 paranoid type schizophrenia ENT1END . Therefore, we conducted an analysis of the association of the ENT2 5-HT ENT2END 6 gene (HTR6) with METH-induced psychosis
0	The symptoms of methamphetamine ( ENT1 METH  ENT1END -induced psychosis are similar to those of ENT2 paranoid type schizophrenia ENT2END
0	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as ENT1 clozapine  ENT1END and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist. In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders. The symptoms of methamphetamine (METH)-induced psychosis are similar to those of ENT2 paranoid type schizophrenia ENT2END
0	In addition, the disrupted prepulse inhibition induced by d-amphetamine or ENT1 phencyclidine  ENT1END was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders. The symptoms of methamphetamine (METH)-induced psychosis are similar to those of ENT2 paranoid type schizophrenia ENT2END
0	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and ENT1 olanzapine  ENT1END  and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist. In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders. The symptoms of methamphetamine (METH)-induced psychosis are similar to those of ENT2 paranoid type schizophrenia ENT2END
0	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and ENT1 d-amphetamine ENT1END induced ENT2 hyperactivity ENT2END in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced ENT1 hyperactivity ENT1END  in rats is corrected with the use of a selective ENT2 5-HT ENT2END 6 receptor antagonist
0	Serotonin 6 receptor gene is associated with ENT1 methamphetamine  ENT1END -induced psychosis in a Japanese population.BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced ENT2 hyperactivity ENT2END in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as ENT1 clozapine  ENT1END  and olanzapine, and d-amphetamine-induced ENT2 hyperactivity ENT2END in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced ENT1 hyperactivity  ENT1END  in rats is corrected with the use of a selective 5-HT6 receptor antagonist. In addition, the disrupted prepulse inhibition induced by d-amphetamine or ENT2 phencyclidine ENT2END was restored by 5-HT6 receptor antagonist in an animal study using rats
0	The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and ENT1 olanzapine  ENT1END , and d-amphetamine-induced ENT2 hyperactivity ENT2END in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for ENT1 psychotic disorders  ENT1END such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and ENT2 d-amphetamine ENT2END -induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	Therefore, we conducted an analysis of the association of the ENT1 5-HT ENT1END 6 gene (HTR6) with METH-induced ENT2 psychosis ENT2END
1	Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with ENT1 METH  ENT1END induced ENT2 psychosis ENT2END
0	BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for ENT1 psychotic disorders  ENT1END  such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as ENT2 clozapine ENT2END and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	In addition, the disrupted prepulse inhibition induced by d-amphetamine or ENT1 phencyclidine ENT1END  was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of ENT2 psychotic disorders ENT2END
0	BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for ENT1 psychotic disorders  ENT1END  such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and ENT2 olanzapine ENT2END , and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as ENT1 schizophrenia  ENT1END  The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and ENT2 d-amphetamine ENT2END -induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as ENT1 schizophrenia ENT1END . The ENT2 serotonin ENT2END 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	These animal models were considered to reflect the positive symptoms of ENT1 schizophrenia ENT1END  and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders. The symptoms of ENT2 methamphetamine ENT2END (METH)-induced psychosis are similar to those of paranoid type schizophrenia
0	BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as ENT1 schizophrenia  ENT1END . The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as ENT2 clozapine ENT2END and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist
0	In addition, the disrupted prepulse inhibition induced by d-amphetamine or ENT1 phencyclidine  ENT1END  was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of ENT2 schizophrenia ENT2END , and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders
0	BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as ENT1 schizophrenia  ENT1END . The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and ENT2 olanzapine ENT2END , and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist
1	Side effects attributable to ENT1 mazindol ENT1END included decreased appetite (36%), ENT2 dry mouth ENT2END (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients
0	Randomized, double-blind trial of ENT1 mazindol  ENT1END  in ENT2 Duchenne dystrophy ENT2END
0	90 to detect a slowing to 25% of the expected rate of progression of ENT1 weakness ENT1END at P less than 0.05. ENT2 Mazindol ENT2END did not benefit strength at any point in the study
1	Side effects attributable to mazindol included decreased appetite (36%), dry mouth (10%), behavioral change (22%), and ENT1 gastrointestinal symptoms ENT1END (18%); ENT2 mazindol ENT2END dosage was reduced in 43% of patients
1	Side effects attributable to ENT1 mazindol ENT1END  included ENT2 decreased appetite ENT2END (36%), dry mouth (10%), behavioral change (22%), and gastrointestinal symptoms (18%); mazindol dosage was reduced in 43% of patients
1	Also recorded were one case of ENT1 pain ENT1END of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to ENT2 indocyanine green ENT2END with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography
0	Also recorded were one case of ENT1 pain ENT1END  of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to ENT2 fluorescein sodium ENT2END indicated that indocyanine green is a safe as fluorescein for use in angiography
1	The dosage of ENT1 indocyanine green ENT1END used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, ENT2 exanthema ENT2END , urtication, itchiness, and urgency to defecate, and did not require treatment
0	34%), ten of which were mild reactions such as nausea, ENT1 exanthema  ENT1END , urtication, itchiness, and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to ENT2 fluorescein sodium ENT2END indicated that indocyanine green is a safe as fluorescein for use in angiography
1	The two ENT1 hypotensive  ENT1END patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to ENT2 indocyanine green ENT2END with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography
0	The two ENT1 hypotensive  ENT1END  patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to ENT2 fluorescein sodium ENT2END indicated that indocyanine green is a safe as fluorescein for use in angiography
1	The dosage of ENT1 indocyanine green ENT1END  used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, ENT2 urtication ENT2END , itchiness, and urgency to defecate, and did not require treatment
0	34%), ten of which were mild reactions such as nausea, exanthema, ENT1 urtication  ENT1END , itchiness, and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to ENT2 fluorescein sodium ENT2END indicated that indocyanine green is a safe as fluorescein for use in angiography
1	The dosage of ENT1 indocyanine green ENT1END  used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as ENT2 nausea ENT2END , exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment
0	34%), ten of which were mild reactions such as ENT1 nausea  ENT1END , exanthema, urtication, itchiness, and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to ENT2 fluorescein sodium ENT2END indicated that indocyanine green is a safe as fluorescein for use in angiography
1	The two hypotensive patients required treatment for ENT1 shock  ENT1END  CONCLUSIONS: A comparison of frequency of adverse reactions to ENT2 indocyanine green ENT2END with the previously reported frequency of such reactions to fluorescein sodium indicated that indocyanine green is a safe as fluorescein for use in angiography
0	The two hypotensive patients required treatment for ENT1 shock  ENT1END . CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to ENT2 fluorescein sodium ENT2END indicated that indocyanine green is a safe as fluorescein for use in angiography
1	The dosage of ENT1 indocyanine green ENT1END  used for angiography varied from 25 to 75 mg, depending upon the institution. There were 13 cases of adverse reactions (0.34%), ten of which were mild reactions such as nausea, exanthema, urtication, ENT2 itchiness ENT2END , and urgency to defecate, and did not require treatment
0	34%), ten of which were mild reactions such as nausea, exanthema, urtication, ENT1 itchiness  ENT1END , and urgency to defecate, and did not require treatment. Also recorded were one case of pain of the vein, which required treatment, and two cases of hypotension. The two hypotensive patients required treatment for shock. CONCLUSIONS: A comparison of frequency of adverse reactions to indocyanine green with the previously reported frequency of such reactions to ENT2 fluorescein sodium ENT2END indicated that indocyanine green is a safe as fluorescein for use in angiography
0	Management strategies for ENT1 ribavirin  ENT1END -induced hemolytic anemia in the treatment of ENT2 hepatitis C ENT2END : clinical and economic implications
0	Management strategies for ribavirin-induced hemolytic anemia in the treatment of ENT1 hepatitis C ENT1END : clinical and economic implications.OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with ENT2 interferon-alpha ENT2END monotherapy in the treatment of chronic hepatitis C (CHC)
0	OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ ENT1 ribavirin ENT1END compared with interferon-alpha monotherapy in the treatment of ENT2 chronic hepatitis C ENT2END (CHC)
0	OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with ENT1 interferon-alpha  ENT1END  monotherapy in the treatment of ENT2 chronic hepatitis C ENT2END (CHC)
1	Management strategies for ENT1 ribavirin  ENT1END -induced ENT2 hemolytic anemia ENT2END in the treatment of hepatitis C: clinical and economic implications
1	OBJECTIVES: Recently published studies have demonstrated increased efficacy and cost-effectiveness of combination therapy with interferon and alpha-2b/ribavirin compared with ENT1 interferon-alpha ENT1END  monotherapy in the treatment of chronic hepatitis C (CHC). Combination therapy is associated with a clinically important adverse effect: ribavirin-induced ENT2 hemolytic anemia ENT2END (RIHA)
0	A common side effect associated with ENT1 succinylcholine ENT1END is postoperative myalgia. The pathogenesis of this myalgia is still unclear; ENT2 inflammation ENT2END has been suggested but without convincing evidence
0	Furthermore, there was no significant relationship between postoperative myalgia and time course of interleukin-6 concentrations, a marker of ENT1 inflammation ENT1END  Pretreatment with ENT2 dexamethasone ENT2END is not justified to prevent postoperative myalgia after succinylcholine
1	The incidence and severity of ENT1 succinylcholine ENT1END associated ENT2 myalgia ENT2END was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine (n = 32 for each)
0	Incidence and severity of myalgia did not differ significantly between the two groups: 15 patients in the ENT1 dexamethasone ENT1END group complained of ENT2 myalgia ENT2END compared with 18 patients in the saline group, and severe myalgia was reported by five patients and three patients, respectively (not significant)
1	A common side effect associated with ENT1 succinylcholine ENT1END  is ENT2 postoperative myalgia ENT2END
0	Pretreatment with ENT1 dexamethasone ENT1END  is not justified to prevent ENT2 postoperative myalgia ENT2END after succinylcholine
1	8%]) receiving ENT1 fenfluramine ENT1END phentermine developed valvular heart disease. One had baseline bicuspid aortic valve and mild ENT2 aortic regurgitation ENT2END that progressed to moderate regurgitation
0	PATIENTS: 46 patients who used fenfluramine or ENT1 dexfenfluramine ENT1END for 14 days or more and had echocardiograms obtained before therapy. MEASUREMENTS: Follow-up echocardiography. The primary outcome was new or worsening valvulopathy, defined as progression of either ENT2 aortic or mitral regurgitation ENT2END by at least one degree of severity and disease that met U
1	8%]) receiving fenfluramine- ENT1 phentermine  ENT1END developed valvular heart disease. One had baseline bicuspid aortic valve and mild ENT2 aortic regurgitation ENT2END that progressed to moderate regurgitation
0	8%]) receiving ENT1 fenfluramine ENT1END -phentermine developed valvular heart disease. One had baseline ENT2 bicuspid aortic valve ENT2END and mild aortic regurgitation that progressed to moderate regurgitation
0	PATIENTS: 46 patients who used fenfluramine or ENT1 dexfenfluramine  ENT1END  for 14 days or more and had echocardiograms obtained before therapy. MEASUREMENTS: Follow-up echocardiography. The primary outcome was new or worsening valvulopathy, defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U.S. Food and Drug Administration criteria (at least mild aortic regurgitation or moderate mitral regurgitation). RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine-phentermine developed valvular heart disease. One had baseline ENT2 bicuspid aortic valve ENT2END and mild aortic regurgitation that progressed to moderate regurgitation
0	8%]) receiving fenfluramine- ENT1 phentermine  ENT1END  developed valvular heart disease. One had baseline ENT2 bicuspid aortic valve ENT2END and mild aortic regurgitation that progressed to moderate regurgitation
0	Food and Drug Administration criteria (at least mild aortic regurgitation or moderate ENT1 mitral regurgitation  ENT1END . RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving ENT2 fenfluramine ENT2END -phentermine developed valvular heart disease
0	PATIENTS: 46 patients who used fenfluramine or ENT1 dexfenfluramine ENT1END  for 14 days or more and had echocardiograms obtained before therapy. MEASUREMENTS: Follow-up echocardiography. The primary outcome was new or worsening valvulopathy, defined as progression of either ENT2 aortic or mitral regurgitation ENT2END by at least one degree of severity and disease that met U
0	Food and Drug Administration criteria (at least mild aortic regurgitation or moderate ENT1 mitral regurgitation  ENT1END ). RESULTS: Two patients (4.3% [95% CI, 0.6% to 14.8%]) receiving fenfluramine ENT2 phentermine ENT2END developed valvular heart disease
0	Risk for ENT1 valvular heart disease  ENT1END  among users of ENT2 fenfluramine ENT2END and dexfenfluramine who underwent echocardiography before use of medication
0	BACKGROUND: Because uncontrolled echocardiographic surveys suggested that up to 30% to 38% of users of fenfluramine and ENT1 dexfenfluramine ENT1END had ENT2 valvular disease ENT2END , these drugs were withdrawn from the market
0	8%]) receiving fenfluramine- ENT1 phentermine ENT1END  developed ENT2 valvular heart disease ENT2END
0	All cases sustained permanent ENT1 neurological deficits ENT1END  We recommend that hyperbaric ENT2 lignocaine ENT2END should be administered in concentrations not greater than 2% and at a total dose preferably not exceeding 60 mg
0	Three of the cases were most likely caused by direct ENT1 neurotoxicity ENT1END of hyperbaric 5% ENT2 lignocaine ENT2END
1	Cauda equina syndrome after spinal anaesthesia with hyperbaric 5% ENT1 lignocaine  ENT1END : a review of six cases of ENT2 cauda equina syndrome ENT2END reported to the Swedish Pharmaceutical Insurance 1993-1997
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), ENT2 hemolytic anemia ENT2END (1), and pruritus (1)
1	Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), ENT1 hemolytic anemia ENT1END  (1), and pruritus (1). All early-conversion patients showed improvement/resolution of symptoms. Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted. The overall rejection rate was 30%. Sixty-two patients (88.6%) are alive with functioning grafts 686 +/- 362 days (range, 154-1433 days) after conversion. When ENT2 tacrolimus ENT2END side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were ENT2 neurotoxicity ENT2END (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
1	We recorded indication for conversion, whether conversion was early or late after transplantation, ENT1 tacrolimus  ENT1END dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were ENT2 neurotoxicity ENT2END (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and ENT2 pruritus ENT2END (1)
1	Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and ENT1 pruritus  ENT1END  (1). All early-conversion patients showed improvement/resolution of symptoms. Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted. The overall rejection rate was 30%. Sixty-two patients (88.6%) are alive with functioning grafts 686 +/- 362 days (range, 154-1433 days) after conversion. When ENT2 tacrolimus ENT2END side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), ENT2 (insulin-dependent) diabetes mellitus ENT2END (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
1	We recorded indication for conversion, whether conversion was early or late after transplantation, ENT1 tacrolimus  ENT1END  dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), ENT2 (insulin-dependent) diabetes mellitus ENT2END (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and ENT2 cardiomyopathy ENT2END (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
1	We recorded indication for conversion, whether conversion was early or late after transplantation, ENT1 tacrolimus  ENT1END  dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and ENT2 cardiomyopathy ENT2END (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), ENT2 nephrotoxicity ENT2END (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
1	We recorded indication for conversion, whether conversion was early or late after transplantation, ENT1 tacrolimus  ENT1END  dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), ENT2 nephrotoxicity ENT2END (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), ENT2 gastrointestinal (GI) toxicity ENT2END (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
1	We recorded indication for conversion, whether conversion was early or late after transplantation, ENT1 tacrolimus  ENT1END  dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), ENT2 gastrointestinal (GI) toxicity ENT2END (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), ENT2 hepatotoxicity ENT2END (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
1	We recorded indication for conversion, whether conversion was early or late after transplantation, ENT1 tacrolimus  ENT1END  dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), ENT2 hepatotoxicity ENT2END (6), post-transplant lmphoproliferate disease (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
0	When tacrolimus side effects persist despite dose reduction, conversion to ENT1 cyclosporine ENT1END -based immunosuppression (CyA) is necessary. We characterized tacrolimus side effects that warranted discontinuation of the drug, and outcomes after conversion. Of 388 liver recipients who received tacrolimus as primary immunosuppression, 70 required conversion to CyA. We recorded indication for conversion, whether conversion was early or late after transplantation, tacrolimus dose and trough blood level at conversion, and incidence of rejection after conversion. Conversion was early in 29 patients (41.4%) and late in 41 (58.6%). Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), ENT2 post-transplant lmphoproliferate disease ENT2END (PTLD) (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1)
1	Indications for early conversion were neurotoxicity (20), (insulin-dependent) diabetes mellitus (IDDM) (5), nephrotoxicity (3), gastrointestinal (GI) toxicity (6), and cardiomyopathy (1), and for late conversion were neurotoxicity (15), IDDM (12), nephrotoxicity (3), GI toxicity (5), hepatotoxicity (6), post-transplant lmphoproliferate disease ( ENT1 PTLD  ENT1END  (2), cardiomyopathy (1), hemolytic anemia (1), and pruritus (1). All early-conversion patients showed improvement/resolution of symptoms. Among late-conversion patients, 37 (90.2%) had improvement/resolution; in 4 (9.8%), adverse effects persisted. The overall rejection rate was 30%. Sixty-two patients (88.6%) are alive with functioning grafts 686 +/- 362 days (range, 154-1433 days) after conversion. When ENT2 tacrolimus ENT2END side effects are unresponsive to dose reduction, conversion to CyA can be accomplished safely, with no increased risk of rejection and excellent long-term outcome
0	In early clinical studies with ENT1 CB 3717 ENT1END  activity has been seen in breast cancer, ENT2 ovarian cancer ENT2END , hepatoma, and mesothelioma
0	As inhibitors of isolated L1210 TS, CB 3717 di-, tri-, tetra- and pentaglutamate are 26-, 87-, 119- and 114-fold more potent than CB 3717, respectively, and their formation may, therefore, be an important determinant of ENT1 CB 3717 ENT1END ENT2 cytotoxicity ENT2END
0	In early clinical studies with ENT1 CB 3717 ENT1END , activity has been seen in ENT2 breast cancer ENT2END , ovarian cancer, hepatoma, and mesothelioma
0	In early clinical studies with ENT1 CB 3717 ENT1END , activity has been seen in breast cancer, ovarian cancer, hepatoma, and ENT2 mesothelioma ENT2END
1	In an attempt to overcome this problem, a clinical trial of ENT1 CB 3717 ENT1END administered with alkaline diuresis is under way. Preliminary results at 400 and 500 mg/m2 suggest that a reduction in ENT2 nephrotoxicity ENT2END may have been achieved with only 1 instance of renal toxicity in 10 patients
0	In early clinical studies with ENT1 CB 3717 ENT1END , activity has been seen in breast cancer, ovarian cancer, ENT2 hepatoma ENT2END , and mesothelioma
1	In early clinical studies with ENT1 CB 3717 ENT1END , activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma. Toxicities included ENT2 hepatotoxicity ENT2END , malaise, and dose-limiting nephrotoxicity
1	In early clinical studies with ENT1 CB 3717 ENT1END , activity has been seen in breast cancer, ovarian cancer, hepatoma, and mesothelioma. Toxicities included hepatotoxicity, ENT2 malaise ENT2END , and dose-limiting nephrotoxicity
0	Risperidone-associated, benign transient ENT1 visual disturbances  ENT1END  in schizophrenic patients with a past history of ENT2 LSD ENT2END abuse
1	They both reported short episodes of transient visual disturbances, which appeared immediately after starting treatment with ENT1 risperidone ENT1END  This imagery resembled ENT2 visual disturbances ENT2END previously experienced as "flashbacks" related to prior LSD consumption
0	Two schizophrenic patients, who had a prior history of ENT1 LSD ENT1END abuse and who had previously developed ENT2 EPS ENT2END with classic antipsychotics, were successfully treated with risperidone
0	Two schizophrenic patients, who had a prior history of LSD abuse and who had previously developed ENT1 EPS ENT1END  with classic antipsychotics, were successfully treated with ENT2 risperidone ENT2END
0	Risperidone-associated, benign transient visual disturbances in schizophrenic patients with a past history of ENT1 LSD ENT1END  abuse.Two ENT2 schizophrenic ENT2END patients, who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics, were successfully treated with risperidone
0	ENT1 Risperidone  ENT1END -associated, benign transient visual disturbances in ENT2 schizophrenic ENT2END patients with a past history of LSD abuse
0	METHODS: We present the first case report of a woman with ENT1 hyperthyroidism ENT1END treated with propylthiouracil in whom a syndrome of pericarditis, fever, and glomerulonephritis developed. Serologic testing and immunologic studies were done, and a pericardial biopsy was performed. RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy. Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO). Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of ENT2 prednisone ENT2END , which alleviated her symptoms
0	METHODS: We present the first case report of a woman with ENT1 hyperthyroidism ENT1END  treated with ENT2 propylthiouracil ENT2END in whom a syndrome of pericarditis, fever, and glomerulonephritis developed
0	RESULTS: A 25-year-old woman with Graves' disease had a ENT1 febrile illness  ENT1END and evidence of pericarditis, which was confirmed by biopsy. Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO). Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of ENT2 prednisone ENT2END , which alleviated her symptoms
1	METHODS: We present the first case report of a woman with hyperthyroidism treated with ENT1 propylthiouracil ENT1END  in whom a syndrome of pericarditis, ENT2 fever ENT2END , and glomerulonephritis developed
0	RESULTS: A 25-year-old woman with ENT1 Graves' disease  ENT1END had a febrile illness and evidence of pericarditis, which was confirmed by biopsy. Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO). Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of ENT2 prednisone ENT2END , which alleviated her symptoms
0	METHODS: We present the first case report of a woman with hyperthyroidism treated with ENT1 propylthiouracil  ENT1END  in whom a syndrome of pericarditis, fever, and glomerulonephritis developed. Serologic testing and immunologic studies were done, and a pericardial biopsy was performed. RESULTS: A 25-year-old woman with ENT2 Graves' disease ENT2END had a febrile illness and evidence of pericarditis, which was confirmed by biopsy
0	Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of ENT1 prednisone ENT1END , which alleviated her symptoms. A literature review revealed no prior reports of pericarditis in anti-MPO pANCA-positive ENT2 vasculitis ENT2END associated with propylthio- uracil therapy
0	OBJECTIVE: To describe a case of ENT1 propylthiouracil ENT1END induced ENT2 vasculitis ENT2END manifesting with pericarditis
0	Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of ENT1 prednisone ENT1END , which alleviated her symptoms. A literature review revealed no prior reports of ENT2 pericarditis ENT2END in anti-MPO pANCA-positive vasculitis associated with propylthio- uracil therapy
1	METHODS: We present the first case report of a woman with hyperthyroidism treated with ENT1 propylthiouracil ENT1END  in whom a syndrome of ENT2 pericarditis ENT2END , fever, and glomerulonephritis developed
0	METHODS: We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis, fever, and ENT1 glomerulonephritis  ENT1END developed. Serologic testing and immunologic studies were done, and a pericardial biopsy was performed. RESULTS: A 25-year-old woman with Graves' disease had a febrile illness and evidence of pericarditis, which was confirmed by biopsy. Serologic evaluation revealed the presence of perinuclear-staining antineutrophil cytoplasmic autoantibodies (pANCA) against myeloperoxidase (MPO). Propylthiouracil therapy was withdrawn, and she was treated with a 1-month course of ENT2 prednisone ENT2END , which alleviated her symptoms
1	METHODS: We present the first case report of a woman with hyperthyroidism treated with ENT1 propylthiouracil  ENT1END  in whom a syndrome of pericarditis, fever, and ENT2 glomerulonephritis ENT2END developed
1	Butyrylcholinesterase gene mutations in patients with prolonged ENT1 apnea  ENT1END  after ENT2 succinylcholine ENT2END for electroconvulsive therapy
1	We think that even these lower dosages of ENT1 cyclosporine ENT1END can cause chronic ENT2 nephrotoxicity ENT2END and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect
0	Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum ENT1 creatinine ENT1END levels. Group II also showed a significant decrease of chronic ENT2 nephrotoxicity ENT2END secondary to long-term therapy with cyclosporine
0	Group II showed a better perioperative renal function as determined by serum blood ENT1 urea nitrogen  ENT1END and serum creatinine levels. Group II also showed a significant decrease of chronic ENT2 nephrotoxicity ENT2END secondary to long-term therapy with cyclosporine
0	In group II, cyclosporine was started only after the procedure at a lower dosage and was complemented by ENT1 azathioprine  ENT1END  which was used for the first postoperative week. Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels. Group II also showed a significant decrease of chronic ENT2 nephrotoxicity ENT2END secondary to long-term therapy with cyclosporine
0	Time dependence of plasma malondialdehyde, oxypurines, and ENT1 nucleosides  ENT1END  during incomplete ENT2 cerebral ischemia ENT2END in the rat
1	Time dependence of plasma ENT1 malondialdehyde  ENT1END , oxypurines, and nucleosides during incomplete ENT2 cerebral ischemia ENT2END in the rat
0	of the ENT1 hypotensive ENT1END drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher. The present data indicate that the determination of malondialdehyde, oxypurines, and ENT2 nucleosides ENT2END in peripheral blood, may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena
0	of the ENT1 hypotensive ENT1END  drug ENT2 nitroprusside ENT2END at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher
0	of the ENT1 hypotensive ENT1END  drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group ENT2 malondialdehyde ENT2END was significantly higher
0	of the cyclooxygenase inhibitor ENT1 acetylsalicylate  ENT1END intravenously immediately before ischemia, the other receiving 650 micrograms/kg b.w. of the ENT2 hypotensive ENT2END drug nitroprusside at a flow rate of 103 microliters/min intravenously during ischemia, although in this latter group malondialdehyde was significantly higher
0	Plasma extracts were analyzed by a highly sensitive high-performance liquid chromatographic method for the direct determination of malondialdehyde, oxypurines, and ENT1 nucleosides ENT1END  During ENT2 ischemia ENT2END , a time-dependent increase of plasma oxypurines and nucleosides was observed
0	of the hypotensive drug ENT1 nitroprusside ENT1END  at a flow rate of 103 microliters/min intravenously during ENT2 ischemia ENT2END , although in this latter group malondialdehyde was significantly higher
0	of the hypotensive drug nitroprusside at a flow rate of 103 microliters/min intravenously during ENT1 ischemia  ENT1END , although in this latter group ENT2 malondialdehyde ENT2END was significantly higher
0	of the cyclooxygenase inhibitor ENT1 acetylsalicylate ENT1END  intravenously immediately before ENT2 ischemia ENT2END , the other receiving 650 micrograms/kg b
0	Concentration of ENT1 dopamine ENT1END and its metabolites were decreased in the striatum of substantia nigra lesioned rats. Lesions of the substantia nigra are therefore associated with ENT2 erectile dysfunction ENT2END in rats and may serve as a model to study erectile dysfunction in Parkinson's disease
0	ENT1 Erectile dysfunction ENT1END  occurs following substantia nigra lesions in the rat.Erectile function was assessed 6 weeks following uni- and bilateral injections of 6-hydroxydopamine in the substantia nigra nucleus of the brain. Behavioral ENT2 apomorphine ENT2END -induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals
1	ENT1 Erectile dysfunction ENT1END  occurs following substantia nigra lesions in the rat.Erectile function was assessed 6 weeks following uni- and bilateral injections of ENT2 6-hydroxydopamine ENT2END in the substantia nigra nucleus of the brain
0	Concentration of ENT1 dopamine ENT1END  and its metabolites were decreased in the striatum of substantia nigra lesioned rats. Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in ENT2 Parkinson's disease ENT2END
0	Behavioral ENT1 apomorphine  ENT1END -induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals. Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals. Lesions of the substantia nigra were confirmed by histology. Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats. Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in ENT2 Parkinson's disease ENT2END
0	Erectile function was assessed 6 weeks following uni- and bilateral injections of ENT1 6-hydroxydopamine  ENT1END  in the substantia nigra nucleus of the brain. Behavioral apomorphine-induced penile erections were reduced (5/8) and increased (3/8) in uni- and bilateral lesioned animals. Intracavernous pressures, following electrical stimulation of the cavernous nerve, decreased in lesioned animals. Lesions of the substantia nigra were confirmed by histology. Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats. Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in ENT2 Parkinson's disease ENT2END
1	All infants who were born to ENT1 hepatitis B surface antigen ENT1END positive mothers also received ENT2 hepatitis B ENT2END immune globulin
0	Assessment was done on the following: prenatal screening for hepatitis B and rubella, administration of the hepatitis B vaccine birth dose to all infants, administration of hepatitis B immune globulin to infants who were born to ENT1 hepatitis B surface antigen ENT1END positive mothers, ENT2 rubella ENT2END immunity, and administration of in-hospital postpartum rubella vaccine to rubella nonimmune women
0	RESULTS: He was treated with intravenous administration of corticosteroids and ENT1 glycerin ENT1END for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ENT2 ocular pain ENT2END diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks
1	CASE: A 58-year-old man received an intracarotid injection of ENT1 carboplatin ENT1END for recurrent glioblastomas in his left temporal lobe. He complained of ENT2 pain and visual disturbance in the ipsilateral eye ENT2END 30 h after the injection
0	Generally, carboplatin is said to have milder side effects than ENT1 cisplatin  ENT1END  whose ocular and orbital toxicity are well known. However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported. CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of ENT2 pain and visual disturbance in the ipsilateral eye ENT2END 30 h after the injection
0	RESULTS: He was treated with intravenous administration of corticosteroids and ENT1 glycerin ENT1END  for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable ENT2 papilledema ENT2END and exudative retinal detachment continued for 3 weeks
1	Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable ENT1 papilledema ENT1END  and exudative retinal detachment continued for 3 weeks. Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost. CONCLUSION: When performing intracarotid injection of ENT2 carboplatin ENT2END , we must be aware of its potentially blinding ocular toxicity
0	Various ocular symptoms and findings caused by carboplatin ENT1 toxicity  ENT1END were seen. RESULTS: He was treated with intravenous administration of corticosteroids and ENT2 glycerin ENT2END for 6 days after the injection
0	Various ocular symptoms and findings caused by ENT1 carboplatin ENT1END ENT2 toxicity ENT2END were seen
0	Generally, carboplatin is said to have milder side effects than ENT1 cisplatin  ENT1END , whose ocular and orbital toxicity are well known. However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported. CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection. Various ocular symptoms and findings caused by carboplatin ENT2 toxicity ENT2END were seen
0	RESULTS: He was treated with intravenous administration of corticosteroids and ENT1 glycerin ENT1END  for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure ENT2 glaucoma ENT2END decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks
0	Various ocular symptoms and findings caused by ENT1 carboplatin  ENT1END  toxicity were seen. RESULTS: He was treated with intravenous administration of corticosteroids and glycerin for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure ENT2 glaucoma ENT2END decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks
0	Severe ocular and orbital toxicity after intracarotid injection of ENT1 carboplatin ENT1END  for recurrent glioblastomas.BACKGROUND: Glioblastoma is a ENT2 malignant tumor ENT2END that occurs in the cerebrum during adulthood
0	BACKGROUND: Glioblastoma is a ENT1 malignant tumor  ENT1END  that occurs in the cerebrum during adulthood. With current treatment regimens including combined surgery, radiation and chemotherapy, the average life expectancy of the patients is limited to approximately 1 year. Therefore, patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen. Generally, carboplatin is said to have milder side effects than ENT2 cisplatin ENT2END , whose ocular and orbital toxicity are well known
0	However, we experienced a case of severe ENT1 ocular and orbital toxicity  ENT1END after intracarotid injection of carboplatin, which is infrequently reported. CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection. Various ocular symptoms and findings caused by carboplatin toxicity were seen. RESULTS: He was treated with intravenous administration of corticosteroids and ENT2 glycerin ENT2END for 6 days after the injection
0	Severe ENT1 ocular and orbital toxicity  ENT1END  after intracarotid injection of ENT2 carboplatin ENT2END for recurrent glioblastomas
0	Generally, carboplatin is said to have milder side effects than ENT1 cisplatin ENT1END , whose ENT2 ocular and orbital toxicity ENT2END are well known
0	CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent ENT1 glioblastomas  ENT1END in his left temporal lobe. He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection. Various ocular symptoms and findings caused by carboplatin toxicity were seen. RESULTS: He was treated with intravenous administration of corticosteroids and ENT2 glycerin ENT2END for 6 days after the injection
0	Severe ocular and orbital toxicity after intracarotid injection of ENT1 carboplatin  ENT1END  for recurrent ENT2 glioblastomas ENT2END
0	Therefore, patients with ENT1 glioblastoma  ENT1END sometimes have intracarotid injection of carcinostatics added to the treatment regimen. Generally, carboplatin is said to have milder side effects than ENT2 cisplatin ENT2END , whose ocular and orbital toxicity are well known
0	RESULTS: He was treated with intravenous administration of corticosteroids and ENT1 glycerin ENT1END  for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks. Finally, 6 weeks later, diffuse ENT2 chorioretinal atrophy ENT2END with optic atrophy occurred and the vision in his left eye was lost
0	Finally, 6 weeks later, diffuse ENT1 chorioretinal atrophy  ENT1END  with optic atrophy occurred and the vision in his left eye was lost. CONCLUSION: When performing intracarotid injection of ENT2 carboplatin ENT2END , we must be aware of its potentially blinding ocular toxicity
0	He complained of ENT1 pain and visual disturbance in the ipsilateral eye  ENT1END 30 h after the injection. Various ocular symptoms and findings caused by carboplatin toxicity were seen. RESULTS: He was treated with intravenous administration of corticosteroids and ENT2 glycerin ENT2END for 6 days after the injection
1	CASE: A 58-year-old man received an intracarotid injection of ENT1 carboplatin  ENT1END  for recurrent glioblastomas in his left temporal lobe. He complained of ENT2 pain and visual disturbance in the ipsilateral eye ENT2END 30 h after the injection
0	Generally, carboplatin is said to have milder side effects than ENT1 cisplatin  ENT1END , whose ocular and orbital toxicity are well known. However, we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin, which is infrequently reported. CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of ENT2 pain and visual disturbance in the ipsilateral eye ENT2END 30 h after the injection
0	RESULTS: He was treated with intravenous administration of corticosteroids and ENT1 glycerin ENT1END  for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative ENT2 retinal detachment ENT2END continued for 3 weeks
1	Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative ENT1 retinal detachment  ENT1END  continued for 3 weeks. Finally, 6 weeks later, diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost. CONCLUSION: When performing intracarotid injection of ENT2 carboplatin ENT2END , we must be aware of its potentially blinding ocular toxicity
0	RESULTS: He was treated with intravenous administration of corticosteroids and ENT1 glycerin ENT1END  for 6 days after the injection. Although the intraocular pressure elevation caused by secondary acute angle-closure glaucoma decreased and ocular pain diminished, inexorable papilledema and exudative retinal detachment continued for 3 weeks. Finally, 6 weeks later, diffuse chorioretinal atrophy with ENT2 optic atrophy ENT2END occurred and the vision in his left eye was lost
1	Finally, 6 weeks later, diffuse chorioretinal atrophy with ENT1 optic atrophy  ENT1END  occurred and the vision in his left eye was lost. CONCLUSION: When performing intracarotid injection of ENT2 carboplatin ENT2END , we must be aware of its potentially blinding ocular toxicity
0	However, we experienced a case of severe ENT1 ocular and orbital toxicity  ENT1END after intracarotid injection of carboplatin, which is infrequently reported. CASE: A 58-year-old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe. He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection. Various ocular symptoms and findings caused by carboplatin toxicity were seen. RESULTS: He was treated with intravenous administration of corticosteroids and ENT2 glycerin ENT2END for 6 days after the injection
1	Severe ENT1 ocular and orbital toxicity  ENT1END  after intracarotid injection of ENT2 carboplatin ENT2END for recurrent glioblastomas
0	Generally, carboplatin is said to have milder side effects than ENT1 cisplatin ENT1END , whose ENT2 ocular and orbital toxicity ENT2END are well known
0	This case study reveals an unusual finding of rapidly proliferative crescentic ENT1 glomerulonephritis ENT1END in a patient treated with rifampin who had no other identifiable causes for developing this disease. This patient underwent a 10-month regimen of rifampin and ENT2 isoniazid ENT2END for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy
1	This case study reveals an unusual finding of rapidly proliferative crescentic ENT1 glomerulonephritis ENT1END  in a patient treated with ENT2 rifampin ENT2END who had no other identifiable causes for developing this disease
0	This patient underwent a 10-month regimen of rifampin and ENT1 isoniazid ENT1END  for ENT2 pulmonary tuberculosis ENT2END and was discovered to have developed signs of severe renal failure five weeks after completion of therapy
0	Crescentic fibrillary glomerulonephritis associated with intermittent ENT1 rifampin  ENT1END  therapy for ENT2 pulmonary tuberculosis ENT2END
0	This patient underwent a 10-month regimen of rifampin and ENT1 isoniazid ENT1END  for pulmonary tuberculosis and was discovered to have developed signs of severe ENT2 renal failure ENT2END five weeks after completion of therapy
1	This patient underwent a 10-month regimen of ENT1 rifampin  ENT1END and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe ENT2 renal failure ENT2END five weeks after completion of therapy
0	In patients premedicated with scopolamine + morphine (+5 mg ENT1 nitrazepam ENT1END the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although ENT2 apnoea ENT2END occurred less often in the midazolam group it lasted longer
1	Somewhat fewer cardiovascular and local sequelae were found in the ENT1 midazolam  ENT1END group, but, although ENT2 apnoea ENT2END occurred less often in the midazolam group it lasted longer
1	Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although ENT1 apnoea ENT1END  occurred less often in the midazolam group it lasted longer. On the whole, the differences between midazolam and ENT2 thiopentone ENT2END had no apparent clinical consequences
0	In patients premedicated with scopolamine + ENT1 morphine  ENT1END (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although ENT2 apnoea ENT2END occurred less often in the midazolam group it lasted longer
0	In patients premedicated with ENT1 scopolamine  ENT1END + morphine (+5 mg nitrazepam the evening before surgery), the sleep-inducing effect of midazolam 0.15 mg/kg i.v. was clearly slower in onset than that of thiopentone 4.67 mg/kg i.v. Somewhat fewer cardiovascular and local sequelae were found in the midazolam group, but, although ENT2 apnoea ENT2END occurred less often in the midazolam group it lasted longer
0	However, only secretory granules showed the positive reaction products for prolactin 6 h after ENT1 bromocriptine ENT1END treatment of the ENT2 adenoma ENT2END cells
0	To clarify the effects of ENT1 bromocriptine ENT1END on ENT2 prolactinoma ENT2END cells in vivo, immunohistochemical, ultrastructural and morphometrical analyses were applied to estrogen-induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine (3 mg/kg of body weight)
1	Immunohistochemical, electron microscopic and morphometric studies of ENT1 estrogen  ENT1END -induced rat ENT2 prolactinomas ENT2END after bromocriptine treatment
0	Shortly after treatment their tests normalized and during follow-up period none of the patients had ENT1 abnormal liver function ENT1END tests. In four patients HBV DNA levels were higher than normal at baseline. Two of these normalized and the others increased later. In three additional patients, HBV DNA levels were increased during follow-up. None of the patients had significant clinical sings of HBV activation. ENT2 Lamivudine ENT2END was well tolerated and was continued in all patients
0	From June 2004 to October 2006, 11 ENT1 HBs Ag  ENT1END positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed. Liver function tests, hepatitis B virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records. Eleven patients (six male) with median age 47 years (range 27-73), median disease duration 50 months (range 9-178) and median follow-up period of patients 13.8 months (range 5-27) were enrolled in this study. Lamivudine therapy was started 3-7 days prior to immunosuppressive therapy in all patients. Baseline, liver function tests were elevated in two patients (fourth patient: ALT:122 IU/l, AST:111 IU/l, tenth patient:ALT:294 IU/l, AST:274 IU/l, with minimal changes in the liver biopsy in both). Shortly after treatment their tests normalized and during follow-up period none of the patients had ENT2 abnormal liver function ENT2END tests
0	Prophylactic use of ENT1 lamivudine  ENT1END  with chronic immunosuppressive therapy for ENT2 rheumatologic disorders ENT2END
0	The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( ENT1 HBs Ag ENT1END  positive patients with ENT2 rheumatologic disease ENT2END
0	From June 2004 to October 2006, 11 HBs Ag positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic ENT1 lamivudine ENT1END therapies, were retrospectively assessed. Liver function tests, ENT2 hepatitis B ENT2END virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records
1	From June 2004 to October 2006, 11 ENT1 HBs Ag  ENT1END  positive patients with rheumatologic diseases, who were on both immunosuppressive and prophylactic lamivudine therapies, were retrospectively assessed. Liver function tests, ENT2 hepatitis B ENT2END virus (HBV) serologic markers, and HBV DNA levels of the patients during follow-up were obtained from hospital file records
0	Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), ENT1 focal segmental glomerulosclerosis ENT1END (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies). The serum ENT2 creatinine ENT2END levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0
1	Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), ENT1 focal segmental glomerulosclerosis ENT1END  (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies). The serum creatinine levels of patients in the mild-type chronic ENT2 FK506 ENT2END nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0
0	RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent ENT1 IgA nephropathy  ENT1END (n =5), normal findings (n =2), minimal-type chronic FK506 nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11). Of the nonepisode biopsies, 7 and 4 biopsies showed minimal-type and mild-type chronic FK506 nephropathy, respectively. Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of interstitial fibrosis (11 biopsies). The serum ENT2 creatinine ENT2END levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0
0	RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent ENT1 IgA nephropathy ENT1END  (n =5), normal findings (n =2), minimal-type chronic ENT2 FK506 ENT2END nephropathy (n = 9), and mild-type FK506 nephropathy (n = 11)
0	The serum ENT1 creatinine ENT1END  levels of patients in the mild-type chronic FK506 ENT2 nephropathy ENT2END group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0
0	RESULTS: The main pathologic diagnoses (some overlap) were acute rejection (AR; n = 4), chronic rejection (CR; n=5), AR+CR (n =4), recurrent IgA nephropathy (n =5), normal findings (n =2), minimal-type chronic ENT1 FK506 ENT1END  ENT2 nephropathy ENT2END (n = 9), and mild-type FK506 nephropathy (n = 11)
0	Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of ENT1 interstitial fibrosis  ENT1END (11 biopsies). The serum ENT2 creatinine ENT2END levels of patients in the mild-type chronic FK506 nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0
0	Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization (5 biopsies), arteriolopathy (angiodegeneration of the arteriolar wall; 20 biopsies), focal segmental glomerulosclerosis (4 biopsies) and the striped form of ENT1 interstitial fibrosis  ENT1END  (11 biopsies). The serum creatinine levels of patients in the mild-type chronic ENT2 FK506 ENT2END nephropathy group, which included 7 episode biopsies, were statistically higher than those in the minimum-type chronic FK506-nephropathy group (P< 0
1	In summary, ENT1 suprofen ENT1END causes ENT2 acute declines in renal function ENT2END , most likely by directly altering the intrarenal distribution of uric acid
0	Although suprofen has been associated with the development of ENT1 acute renal failure ENT1END in greater than 100 subjects, the mechanism of damage remains unclear. The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid. There were no significant differences in renal sodium excretion, ENT2 oxygen ENT2END consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups
0	In summary, suprofen causes ENT1 acute declines in renal function ENT1END , most likely by directly altering the intrarenal distribution of ENT2 uric acid ENT2END
0	Although suprofen has been associated with the development of ENT1 acute renal failure ENT1END  in greater than 100 subjects, the mechanism of damage remains unclear. The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid. There were no significant differences in renal ENT2 sodium ENT2END excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups
0	The direct ENT1 nephrotoxic ENT1END effects of a single dose of 15 mg of ENT2 suprofen ENT2END were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid
0	The direct ENT1 nephrotoxic  ENT1END  effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid. There were no significant differences in renal sodium excretion, ENT2 oxygen ENT2END consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups
0	The direct ENT1 nephrotoxic ENT1END  effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of ENT2 uric acid ENT2END
0	The direct ENT1 nephrotoxic  ENT1END  effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell-free buffer with or without the addition of 5 mg/dL of uric acid. There were no significant differences in renal ENT2 sodium ENT2END excretion, oxygen consumption, or urinary flow rates in kidneys perfused with suprofen compared with the drug-free control groups
0	In ENT1 DEN ENT1END + PB treated rats, the survival was prolonged and the ENT2 tumor ENT2END incidence decreased as compared with the results obtained by DEN alone
0	In DEN + ENT1 PB  ENT1END treated rats, the survival was prolonged and the ENT2 tumor ENT2END incidence decreased as compared with the results obtained by DEN alone
0	It is concluded that PB, which promotes ENT1 carcinogenesis ENT1END when administered after the ENT2 DEN ENT2END treatment, reduces the carcinogen effect when given simultaneously with DEN
0	Anti- ENT1 carcinogenic  ENT1END  action of ENT2 phenobarbital ENT2END given simultaneously with diethylnitrosamine in the rat
1	After the end of the treatment, the number and the size of induced PAS positive ENT1 preneoplastic foci ENT1END was significantly reduced when PB was given simultaneously with ENT2 DEN ENT2END for 4 and 6 weeks
0	After the end of the treatment, the number and the size of induced PAS positive ENT1 preneoplastic foci ENT1END  was significantly reduced when ENT2 PB ENT2END was given simultaneously with DEN for 4 and 6 weeks
0	Repetitive transcranial magnetic stimulation for ENT1 levodopa  ENT1END -induced dyskinesias in ENT2 Parkinson's disease ENT2END
1	Repetitive transcranial magnetic stimulation for ENT1 levodopa  ENT1END -induced ENT2 dyskinesias ENT2END in Parkinson's disease
0	Repetitive transcranial magnetic stimulation for ENT1 levodopa ENT1END -induced dyskinesias in Parkinson's disease.In a placebo-controlled, single-blinded, crossover study, we assessed the effect of "real" repetitive transcranial magnetic stimulation (rTMS) versus "sham" rTMS (placebo) on peak dose dyskinesias in patients with Parkinson's disease (PD). Ten patients with PD and prominent dyskinesias had rTMS (1,800 pulses; 1 Hz rate) delivered over the motor cortex for 4 consecutive days twice, once real stimuli and once sham stimulation were used; evaluations were done at the baseline and 1 day after the end of each of the treatment series. Direct comparison between sham and real rTMS effects showed no significant difference in clinician-assessed dyskinesia severity. However, comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo. The major effect was on ENT2 dystonia ENT2END subscore
1	Adverse reactions possibly attributable to ENT1 didanosine ENT1END were common. The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals. Peripheral neuropathy occurred in 12 patients and ENT2 pancreatitis ENT2END in six
1	Seven patients developed ENT1 glucose tolerance curves ENT1END characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing ENT2 didanosine ENT2END
0	The use and toxicity of didanosine ( ENT1 ddI  ENT1END ) in ENT2 HIV antibody-positive ENT2END individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12
0	The use and toxicity of didanosine (ddI) in ENT1 HIV antibody-positive  ENT1END  individuals intolerant to ENT2 zidovudine ENT2END (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12
1	Adverse reactions possibly attributable to ENT1 didanosine ENT1END  were common. The most common side-effect was diarrhoea, which resulted in cessation of therapy in 19 individuals. ENT2 Peripheral neuropathy ENT2END occurred in 12 patients and pancreatitis in six
0	The use and ENT1 toxicity  ENT1END  of ENT2 didanosine ENT2END (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12
0	The use and ENT1 toxicity  ENT1END  of didanosine (ddI) in HIV antibody-positive individuals intolerant to ENT2 zidovudine ENT2END (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine (ddI) to a maximum dose of 12
0	Thirteen patients developed a raised serum amylase without ENT1 abdominal pain  ENT1END  Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild, did not require treatment and returned to normal on ceasing ENT2 didanosine ENT2END
0	Seven patients developed glucose tolerance curves characteristic of ENT1 diabetes  ENT1END but these were mild, did not require treatment and returned to normal on ceasing ENT2 didanosine ENT2END
0	The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine ( ENT1 ddI ENT1END  to a maximum dose of 12.5 mg/kg/day. Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life. Seventy patients developed major ENT2 opportunistic infections ENT2END whilst on therapy; this was the first AIDS diagnosis in 17
0	The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine ( ENT1 AZT  ENT1END  received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day. Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life. Seventy patients developed major ENT2 opportunistic infections ENT2END whilst on therapy; this was the first AIDS diagnosis in 17
1	Adverse reactions possibly attributable to ENT1 didanosine ENT1END  were common. The most common side-effect was ENT2 diarrhoea ENT2END , which resulted in cessation of therapy in 19 individuals
0	The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine (AZT) received didanosine ( ENT1 ddI ENT1END ) to a maximum dose of 12.5 mg/kg/day. Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life. Seventy patients developed major opportunistic infections whilst on therapy; this was the first ENT2 AIDS ENT2END diagnosis in 17
0	The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT)One hundred and fifty-one patients intolerant to zidovudine ( ENT1 AZT  ENT1END ) received didanosine (ddI) to a maximum dose of 12.5 mg/kg/day. Patient response was assessed using changes in CD4+ lymphocyte subset count, HIV p24 antigen, weight, and quality of life. Seventy patients developed major opportunistic infections whilst on therapy; this was the first ENT2 AIDS ENT2END diagnosis in 17
1	We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, ENT1 hyponatremia ENT1END  and renal failure. This is the first report of such an unusual reaction to ENT2 carbamazepine ENT2END
1	Hypersensitivity to carbamazepine presenting with a leukemoid reaction, eosinophilia, erythroderma, and ENT1 renal failure ENT1END .We report a patient in whom hypersensitivity to ENT2 carbamazepine ENT2END presented with generalized erythroderma, a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure
1	Hypersensitivity to ENT1 carbamazepine  ENT1END  presenting with a ENT2 leukemoid reaction ENT2END , eosinophilia, erythroderma, and renal failure
1	ENT1 Hypersensitivity  ENT1END  to ENT2 carbamazepine ENT2END presenting with a leukemoid reaction, eosinophilia, erythroderma, and renal failure
1	We report a patient in whom hypersensitivity to ENT1 carbamazepine ENT1END  presented with generalized ENT2 erythroderma ENT2END , a severe leukemoid reaction, eosinophilia, hyponatremia, and renal failure
0	Hypersensitivity to ENT1 carbamazepine  ENT1END  presenting with a leukemoid reaction, ENT2 eosinophilia ENT2END , erythroderma, and renal failure
1	Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in ENT1 adriamycin ENT1END ENT2 cardiomyopathy ENT2END
0	Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced ENT1 cardiomyopathy  ENT1END  with ENT2 iodine-125-metaiodobenzylguanidine ENT2END
0	Detection of abnormal cardiac adrenergic neuron activity in adriamycin-induced ENT1 cardiomyopathy ENT1END  with iodine-125-metaiodobenzylguanidine.Radiolabeled metaiodobenzylguanidine (MIBG), an analog of ENT2 norepinephrine ENT2END (NE), serves as an index of adrenergic neuron integrity and function
0	Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in ENT1 adriamycin ENT1END  cardiomyopathy. The degree of ENT2 vacuolar degeneration of myocardial cells ENT2END was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week)
0	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment (scattered or focal ENT1 vacuolar degeneration ENT1END  indicates that ENT2 MIBG ENT2END scintigraphy may be a useful method for detection of adriamycin-induced cardiomyopathy
0	Radiolabeled metaiodobenzylguanidine (MIBG), an analog of norepinephrine ( ENT1 NE  ENT1END , serves as an index of adrenergic neuron integrity and function. Using a rat model of adriamycin-induced cardiomyopathy, we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose-dependently in adriamycin cardiomyopathy. The degree of ENT2 vacuolar degeneration of myocardial cells ENT2END was analyzed in relation to the duration of adriamycin treatment (2 mg/kg, once a week)
1	Whether the vasoconstrictive actions of ENT1 caffeine ENT1END are enhanced in ENT2 hypertensive ENT2END persons has not been demonstrated
0	Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled ENT1 dextran ENT1END before and during phenylephrine-induced acute ENT2 hypertension ENT2END in rats treated with vehicle and Hoe-140 (0
0	Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during phenylephrine-induced acute ENT1 hypertension ENT1END  in rats treated with vehicle and ENT2 Hoe-140 ENT2END (0
1	Permeability of the blood-brain barrier was quantitated by clearance of fluorescent-labeled dextran before and during ENT1 phenylephrine  ENT1END induced acute ENT2 hypertension ENT2END in rats treated with vehicle and Hoe-140 (0
0	These findings suggest that disruption of the blood-brain barrier during acute ENT1 hypertension ENT1END is not related to the synthesis/release of ENT2 bradykinin ENT2END to activate B2 receptors
1	ENT1 Fucoidan ENT1END treated rats exhibited evidence of ENT2 impaired blood clotting ENT2END and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days
0	ENT1 Fucoidan ENT1END -treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days. They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test. Acute white matter edema and eventual ENT2 neuronal loss ENT2END in the striatum adjacent to the hematoma did not differ between the two groups
0	Intracerebral hemorrhage is associated with more ENT1 inflammation ENT1END than ischemic stroke. We tested the sulfated polysaccharide ENT2 fucoidan ENT2END , which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus
0	Rats were treated with seven day intravenous infusion of ENT1 fucoidan ENT1END (30 micrograms h-1) or vehicle. The ENT2 hematoma ENT2END was assessed in vivo by magnetic resonance imaging
1	ENT1 Fucoidan ENT1END -treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days. They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test. Acute ENT2 white matter edema ENT2END and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups
0	Intracerebral hemorrhage is associated with more inflammation than ENT1 ischemic stroke  ENT1END  We tested the sulfated polysaccharide ENT2 fucoidan ENT2END , which has been reported to reduce inflammatory brain damage, in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus
0	We tested the sulfated polysaccharide ENT1 fucoidan ENT1END , which has been reported to reduce inflammatory ENT2 brain damage ENT2END , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus
0	ENT1 Fucoidan ENT1END -treated rats exhibited evidence of impaired blood clotting and hemodilution, had larger hematomas, and tended to have less inflammation in the vicinity of the hematoma after three days. They showed significantly more rapid improvement of motor function in the first week following ENT2 hemorrhage ENT2END and better memory retention in the passive avoidance test
0	Effect of ENT1 fucoidan  ENT1END  treatment on collagenase-induced ENT2 intracerebral hemorrhage ENT2END in rats
0	Through linkage with the Swedish ENT1 Cancer ENT1END Register, all subjects in this cohort diagnosed with bladder cancer were identified. Nested within the cohort, a matched case-control study was performed to estimate the association between ENT2 cyclophosphamide ENT2END and bladder cancer using odds ratios (ORs) as relative risk
0	OBJECTIVE: To assess and characterise the risk of bladder cancer, and its relation to ENT1 cyclophosphamide ENT1END  in patients with ENT2 Wegener's granulomatosis ENT2END
1	Nested within the cohort, a matched case-control study was performed to estimate the association between ENT1 cyclophosphamide ENT1END  and ENT2 bladder cancer ENT2END using odds ratios (ORs) as relative risk
1	Sodium status influences chronic ENT1 amphotericin B ENT1END ENT2 nephrotoxicity ENT2END in rats
0	The ENT1 nephrotoxic ENT1END potential of amphotericin B (5 mg/kg per day intraperitoneally for 3 weeks) has been investigated in salt-depleted, normal-salt, and salt-loaded rats. In salt-depleted rats, amphotericin B decreased ENT2 creatinine ENT2END clearance linearly with time, with an 85% reduction by week 3
0	ENT1 Sodium  ENT1END  status influences chronic amphotericin B ENT2 nephrotoxicity ENT2END in rats
0	Flestolol produced a dose-dependent attenuation of isoproterenol-induced ENT1 tachycardia ENT1END  Electrophysiologic and hemodynamic effects of ENT2 flestolol ENT2END are similar to those of other beta blockers
1	Flestolol produced a dose-dependent attenuation of ENT1 isoproterenol  ENT1END induced ENT2 tachycardia ENT2END
0	In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling ENT1 chest pain ENT1END  It is concluded that ENT2 flestolol ENT2END is a potent, well-tolerated, ultra-short-acting beta-adrenergic blocking agent
0	Flestolol produced a dose-dependent attenuation of ENT1 isoproterenol  ENT1END -induced tachycardia. Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers. In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life. Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia. In patients with unstable angina, flestolol infusion was found to be safe and effective in controlling ENT2 chest pain ENT2END
0	Flestolol effectively reduced heart rate in patients with ENT1 supraventricular tachyarrhythmia ENT1END  In patients with unstable angina, ENT2 flestolol ENT2END infusion was found to be safe and effective in controlling chest pain
0	Flestolol produced a dose-dependent attenuation of ENT1 isoproterenol  ENT1END -induced tachycardia. Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers. In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life. Flestolol effectively reduced heart rate in patients with ENT2 supraventricular tachyarrhythmia ENT2END
0	In patients with ENT1 unstable angina ENT1END ENT2 flestolol ENT2END infusion was found to be safe and effective in controlling chest pain
0	Flestolol produced a dose-dependent attenuation of ENT1 isoproterenol  ENT1END -induced tachycardia. Electrophysiologic and hemodynamic effects of flestolol are similar to those of other beta blockers. In contrast with other beta blockers, flestolol-induced effects reverse rapidly (within 30 minutes) following discontinuation because of its short half-life. Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia. In patients with ENT2 unstable angina ENT2END , flestolol infusion was found to be safe and effective in controlling chest pain
0	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of ENT1 doxorubicin ENT1END based chemotherapy in the same patient. Atrial fibrillation or other ENT2 cardiac arrhythmias ENT2END are unusual complications in patients treated with chemotherapy
0	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of ENT1 doxorubicin ENT1END -based chemotherapy in the same patient. Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy. The ENT2 cardiac toxicity ENT2END intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient
0	The authors describe the unusual association between diffuse B-cell gastric lymphoma and ENT1 myotonic dystrophy  ENT1END  the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of ENT2 doxorubicin ENT2END -based chemotherapy in the same patient
1	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden ENT1 atrial fibrillation  ENT1END following one cycle of ENT2 doxorubicin ENT2END -based chemotherapy in the same patient
0	The authors describe the unusual association between diffuse B-cell gastric lymphoma and myotonic dystrophy, the most common form of adult ENT1 muscular dystrophy  ENT1END  and sudden atrial fibrillation following one cycle of ENT2 doxorubicin ENT2END -based chemotherapy in the same patient
0	The authors describe the unusual association between diffuse B-cell ENT1 gastric lymphoma  ENT1END and myotonic dystrophy, the most common form of adult muscular dystrophy, and sudden atrial fibrillation following one cycle of ENT2 doxorubicin ENT2END -based chemotherapy in the same patient
0	Seventy-five ENT1 human immunodeficiency virus (HIV)-infected ENT1END patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37). Finally, 15 patients were excluded from the study (noncompliance 14, death 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis. No significant differences between groups were found at enrollment. During the study, vitamin B12 and ENT2 folate ENT2END levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months
0	A prospective, randomized study was conducted to evaluate the role of ENT1 vitamin B12  ENT1END and folinic acid supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression. Seventy-five ENT2 human immunodeficiency virus (HIV)-infected ENT2END patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37)
0	A prospective, randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( ENT1 ZDV  ENT1END -induced bone marrow suppression. Seventy-five ENT2 human immunodeficiency virus (HIV)-infected ENT2END patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37)
0	A prospective, randomized study was conducted to evaluate the role of vitamin B12 and ENT1 folinic acid  ENT1END supplementation in preventing zidovudine (ZDV)-induced bone marrow suppression. Seventy-five ENT2 human immunodeficiency virus (HIV)-infected ENT2END patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37)
0	There was no correlation between vitamin B12 or ENT1 folate ENT1END levels and development of ENT2 myelosuppression ENT2END
0	There was no correlation between vitamin B12 or folate levels and development of ENT1 myelosuppression ENT1END . ENT2 Vitamin B12 ENT2END and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded
1	Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ENT1 ZDV ENT1END induced ENT2 myelotoxicity ENT2END in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded
0	There was no correlation between vitamin B12 or folate levels and development of ENT1 myelosuppression ENT1END . Vitamin B12 and ENT2 folinic acid ENT2END supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV-induced myelotoxicity in the overall treated population, although a beneficial effect in certain subgroups of patients cannot be excluded
0	Severe hematologic ENT1 toxicity  ENT1END (neutrophil count < 1000/mm3 and/or hemoglobin < 8 g/dl) occurred in 4 patients assigned to group I and 7 assigned to group II. There was no correlation between vitamin B12 or ENT2 folate ENT2END levels and development of myelosuppression
0	Study of the role of ENT1 vitamin B12  ENT1END  and folinic acid supplementation in preventing hematologic ENT2 toxicity ENT2END of zidovudine
0	Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic ENT1 toxicity  ENT1END  of ENT2 zidovudine ENT2END
0	Study of the role of vitamin B12 and ENT1 folinic acid  ENT1END  supplementation in preventing hematologic ENT2 toxicity ENT2END of zidovudine
0	Finally, 15 patients were excluded from the study (noncompliance 14, ENT1 death  ENT1END 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis. No significant differences between groups were found at enrollment. During the study, vitamin B12 and ENT2 folate ENT2END levels were significantly higher in group II patients; however, no differences in hemoglobin, hematocrit, mean corpuscular volume, and white-cell, neutrophil and platelet counts were observed between groups at 3, 6, 9 and 12 months
0	Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular ENT1 vitamin B12  ENT1END (1000 micrograms monthly) (group II, n = 37). Finally, 15 patients were excluded from the study (noncompliance 14, ENT2 death ENT2END 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis
0	Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ENT1 ZDV  ENT1END (500 mg daily) alone (group I, n = 38) or in combination with folinic acid (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37). Finally, 15 patients were excluded from the study (noncompliance 14, ENT2 death ENT2END 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis
0	Seventy-five human immunodeficiency virus (HIV)-infected patients with CD4+ cell counts < 500/mm3 were randomized to receive either ZDV (500 mg daily) alone (group I, n = 38) or in combination with ENT1 folinic acid  ENT1END (15 mg daily) and intramascular vitamin B12 (1000 micrograms monthly) (group II, n = 37). Finally, 15 patients were excluded from the study (noncompliance 14, ENT2 death ENT2END 1); thus, 60 patients (31 in group I and 29 in group II) were eligible for analysis
1	When given intraperitoneally, bupivacaine thus was only about twice as toxic as ENT1 lidocaine ENT1END and four times as toxic as chloroprocaine. ENT2 Convulsions ENT2END always preceded death, except after precipitous cardiopulmonary arrest from extreme doses
1	A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of ENT1 bupivacaine ENT1END induced ENT2 seizures ENT2END , in 57% of the chloroprocaine group, and in 6% of the lidocaine group
1	When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as ENT1 chloroprocaine ENT1END ENT2 Convulsions ENT2END always preceded death, except after precipitous cardiopulmonary arrest from extreme doses
0	When given intraperitoneally, bupivacaine thus was only about twice as toxic as ENT1 lidocaine ENT1END  and four times as toxic as chloroprocaine. Convulsions always preceded death, except after precipitous ENT2 cardiopulmonary arrest ENT2END from extreme doses
0	Convulsions always preceded death, except after precipitous ENT1 cardiopulmonary arrest  ENT1END  from extreme doses. A CD50 dose of local anesthetic (causing convulsions in 50% of mice) was fatal in 90% of ENT2 bupivacaine ENT2END -induced seizures, in 57% of the chloroprocaine group, and in 6% of the lidocaine group
0	When given intraperitoneally, bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as ENT1 chloroprocaine  ENT1END . Convulsions always preceded death, except after precipitous ENT2 cardiopulmonary arrest ENT2END from extreme doses
0	DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with ENT1 hiccups  ENT1END  Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines ( ENT2 midazolam ENT2END ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with ENT1 hiccups  ENT1END . Corticosteroids ( ENT2 dexamethasone ENT2END and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with ENT1 hiccups ENT1END . Corticosteroids (dexamethasone and methylprednisolone), ENT2 benzodiazepines ENT2END (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with ENT1 hiccups ENT1END . Corticosteroids (dexamethasone and ENT2 methylprednisolone ENT2END ), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	Few cases of drug-induced ENT1 hiccups ENT1END have been reported related to ENT2 macrolide ENT2END antimicrobials
1	Discontinuation of azithromycin and therapy with ENT1 baclofen ENT1END finally resolved ENT2 hiccups ENT2END
1	Possible ENT1 azithromycin  ENT1END -associated ENT2 hiccups ENT2END
0	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of ENT1 pharyngitis ENT1END  Hiccups were persistent and exhausting. Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups. No organic cause of hiccups was identified despite extensive investigation. DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), benzodiazepines ENT2 midazolam ENT2END ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of ENT1 pharyngitis ENT1END . Hiccups were persistent and exhausting. Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups. No organic cause of hiccups was identified despite extensive investigation. DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids ENT2 dexamethasone ENT2END and methylprednisolone), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of ENT1 pharyngitis  ENT1END . Hiccups were persistent and exhausting. Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups. No organic cause of hiccups was identified despite extensive investigation. DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and methylprednisolone), ENT2 benzodiazepines ENT2END (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of ENT1 pharyngitis  ENT1END . Hiccups were persistent and exhausting. Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups. No organic cause of hiccups was identified despite extensive investigation. DISCUSSION: Pharmacotherapeutic agents have been uncommonly associated with hiccups. Corticosteroids (dexamethasone and ENT2 methylprednisolone ENT2END ), benzodiazepines (midazolam) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups
0	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning azithromycin for the treatment of ENT1 pharyngitis  ENT1END . Hiccups were persistent and exhausting. Discontinuation of azithromycin and therapy with ENT2 baclofen ENT2END finally resolved hiccups
0	CASE SUMMARY: A 76-year-old man presented with persistent hiccups after beginning ENT1 azithromycin  ENT1END for the treatment of ENT2 pharyngitis ENT2END
1	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, ENT1 diltiazem ENT1END , and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. AV block, severe ENT2 hypotension ENT2END , and impairment of ventricular function
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, ENT1 propafenone  ENT1END , diltiazem, and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. AV block, severe ENT2 hypotension ENT2END , and impairment of ventricular function
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and ENT1 sparteine  ENT1END .A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. AV block, severe ENT2 hypotension ENT2END , and impairment of ventricular function
1	AV block, severe ENT1 hypotension ENT1END , and impairment of ventricular function. One week prior to admission a therapy with standard doses of ENT2 metoprolol ENT2END (100 mg t
0	Three months later the patient was exposed to a single dose of metoprolol, ENT1 diltiazem ENT1END  propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism). It was found that he was a poor metabolizer of all four drugs, indicating that their metabolism is under the same genetic control. Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience ENT2 adverse drug reactions ENT2END when treated with standard doses of one of these drugs alone
0	Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/ ENT1 debrisoquine  ENT1END polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience ENT2 adverse drug reactions ENT2END when treated with standard doses of one of these drugs alone
0	Three months later the patient was exposed to a single dose of metoprolol, diltiazem, ENT1 propafenone  ENT1END (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism). It was found that he was a poor metabolizer of all four drugs, indicating that their metabolism is under the same genetic control. Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience ENT2 adverse drug reactions ENT2END when treated with standard doses of one of these drugs alone
0	Therefore, patients belonging to the poor-metabolizer phenotype of ENT1 sparteine  ENT1END debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience ENT2 adverse drug reactions ENT2END when treated with standard doses of one of these drugs alone
0	Three months later the patient was exposed to a single dose of ENT1 metoprolol  ENT1END  diltiazem, propafenone (since he had received this drug in the past), and sparteine (as a probe for the debrisoquine/sparteine type polymorphism of oxidative drug metabolism). It was found that he was a poor metabolizer of all four drugs, indicating that their metabolism is under the same genetic control. Therefore, patients belonging to the poor-metabolizer phenotype of sparteine/debrisoquine polymorphism in drug metabolism, which constitutes 6.4% of the German population, may experience ENT2 adverse drug reactions ENT2END when treated with standard doses of one of these drugs alone
1	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, ENT1 diltiazem ENT1END , and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. ENT2 AV block ENT2END , severe hypotension, and impairment of ventricular function
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, ENT1 propafenone  ENT1END , diltiazem, and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. ENT2 AV block ENT2END , severe hypotension, and impairment of ventricular function
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and ENT1 sparteine  ENT1END .A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. ENT2 AV block ENT2END , severe hypotension, and impairment of ventricular function
1	ENT1 AV block  ENT1END , severe hypotension, and impairment of ventricular function. One week prior to admission a therapy with standard doses of ENT2 metoprolol ENT2END (100 mg t
1	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, ENT1 diltiazem ENT1END , and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. AV block, severe hypotension, and ENT2 impairment of ventricular function ENT2END
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, ENT1 propafenone  ENT1END , diltiazem, and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. AV block, severe hypotension, and ENT2 impairment of ventricular function ENT2END
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and ENT1 sparteine  ENT1END .A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in shock with III. AV block, severe hypotension, and ENT2 impairment of ventricular function ENT2END
1	AV block, severe hypotension, and ENT1 impairment of ventricular function  ENT1END . One week prior to admission a therapy with standard doses of ENT2 metoprolol ENT2END (100 mg t
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, ENT1 diltiazem ENT1END , and sparteine.A 47-year-old patient suffering from ENT2 coronary artery disease ENT2END was admitted to the CCU in shock with III
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, ENT1 propafenone  ENT1END , diltiazem, and sparteine.A 47-year-old patient suffering from ENT2 coronary artery disease ENT2END was admitted to the CCU in shock with III
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and ENT1 sparteine  ENT1END .A 47-year-old patient suffering from ENT2 coronary artery disease ENT2END was admitted to the CCU in shock with III
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of ENT1 metoprolol  ENT1END , propafenone, diltiazem, and sparteine.A 47-year-old patient suffering from ENT2 coronary artery disease ENT2END was admitted to the CCU in shock with III
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, ENT1 diltiazem ENT1END , and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in ENT2 shock ENT2END with III
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, ENT1 propafenone  ENT1END , diltiazem, and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in ENT2 shock ENT2END with III
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and ENT1 sparteine  ENT1END .A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in ENT2 shock ENT2END with III
0	Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of ENT1 metoprolol  ENT1END , propafenone, diltiazem, and sparteine.A 47-year-old patient suffering from coronary artery disease was admitted to the CCU in ENT2 shock ENT2END with III
1	A case of metabolic acidosis, ENT1 acute renal failure and hepatic failure ENT1END following ENT2 paracetamol ENT2END ingestion is presented
1	A case of metabolic acidosis, ENT1 acute renal failure and hepatic failure  ENT1END following ENT2 paracetamol ENT2END ingestion is presented
1	ENT1 Paracetamol  ENT1END -associated coma, ENT2 metabolic acidosis ENT2END , renal and hepatic failure
0	ENT1 Paracetamol  ENT1END -associated ENT2 coma ENT2END , metabolic acidosis, renal and hepatic failure
0	ENT1 Paracetamol  ENT1END -associated coma, metabolic acidosis, ENT2 renal and hepatic failure ENT2END
1	RESULTS: Nine of 30 patients receiving lidocaine experienced ENT1 TNSs ENT1END  1 of 30 patients receiving ENT2 prilocaine ENT2END (P = 0
1	RESULTS: Nine of 30 patients receiving ENT1 lidocaine  ENT1END experienced ENT2 TNSs ENT2END , 1 of 30 patients receiving prilocaine (P = 0
0	03) had them, and none of 30 patients receiving ENT1 bupivacaine ENT1END had ENT2 TNSs ENT2END
0	Accordingly, the present, prospective double-blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of ENT1 TNSs ENT1END  METHODS: Ninety patients classified as American Society of Anesthesiologists physical status I or II who were scheduled for short gynecologic procedures under spinal anesthesia were randomly allocated to receive 2.5 ml 2% lidocaine in 7.5% ENT2 glucose ENT2END , 2% prilocaine in 7
0	The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of ENT1 PD ENT1END  Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses ENT2 haloperidol ENT2END -induced catalepsy in rats
0	In a more complex task commonly used to evaluate major akinetic symptoms of ENT1 PD ENT1END patients, 5 mg/kg ENT2 AMN082 ENT2END reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats
0	Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of ENT1 Parkinson's disease ENT1END .Metabotropic ENT2 glutamate ENT2END (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD)
0	) have no effect on the same models of ENT1 PD ENT1END  Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced ENT2 dopamine ENT2END activity
0	5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine ( ENT1 6-OHDA  ENT1END -lesioned rats. In a more complex task commonly used to evaluate major akinetic symptoms of ENT2 PD ENT2END patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats
0	5 and 5 mg/kg) reduces ENT1 apomorphine  ENT1END induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats. In a more complex task commonly used to evaluate major akinetic symptoms of ENT2 PD ENT2END patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats
0	In a more complex task commonly used to evaluate major ENT1 akinetic ENT1END symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats. In addition, AMN082 reduces the duration of ENT2 haloperidol ENT2END -induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice
0	In a more complex task commonly used to evaluate major ENT1 akinetic  ENT1END  symptoms of PD patients, 5 mg/kg ENT2 AMN082 ENT2END reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats
0	Metabotropic ENT1 glutamate  ENT1END  (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD). Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known. The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD. Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced catalepsy in rats. AMN082 (2.5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats. In a more complex task commonly used to evaluate major ENT2 akinetic ENT2END symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats
0	In a more complex task commonly used to evaluate major ENT1 akinetic  ENT1END  symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats. In addition, AMN082 reduces the duration of haloperidol-induced catalepsy in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice. Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD. Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced ENT2 dopamine ENT2END activity
0	5 and 5 mg/kg) reduces apomorphine-induced rotations in unilateral 6-hydroxydopamine ( ENT1 6-OHDA  ENT1END )-lesioned rats. In a more complex task commonly used to evaluate major ENT2 akinetic ENT2END symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats
0	5 and 5 mg/kg) reduces ENT1 apomorphine  ENT1END -induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats. In a more complex task commonly used to evaluate major ENT2 akinetic ENT2END symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6-OHDA-lesioned rats
1	5 nmol) of AMN082 reverses ENT1 haloperidol ENT1END -induced ENT2 catalepsy ENT2END in rats
0	5 nmol) of AMN082 reverses haloperidol-induced ENT1 catalepsy ENT1END  in rats. ENT2 AMN082 ENT2END (2
0	Metabotropic ENT1 glutamate  ENT1END  (mGlu) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson's disease (PD). Among the eight mGlu receptor subtypes, mGlu7 receptor is prominently expressed in the basal ganglia, but its role in restoring motor function in animal models of PD is not known. The effects of N,N'-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), the first selective allosteric activator of mGlu7 receptors, were thus tested in different rodent models of PD. Here, we show that oral (5 mg/kg) or intrastriatal administration (0.1 and 0.5 nmol) of AMN082 reverses haloperidol-induced ENT2 catalepsy ENT2END in rats
0	In addition, AMN082 reduces the duration of haloperidol-induced ENT1 catalepsy  ENT1END in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice. Higher doses of AMN082 (10 and 20 mg/kg p.o.) have no effect on the same models of PD. Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced ENT2 dopamine ENT2END activity
0	In a more complex task commonly used to evaluate major akinetic symptoms of PD patients, 5 mg/kg AMN082 reverses the increased reaction time to respond to a cue of bilateral ENT1 6-OHDA  ENT1END lesioned rats. In addition, AMN082 reduces the duration of haloperidol-induced ENT2 catalepsy ENT2END in a mGlu7 receptor-dependent manner in wild-type but not mGlu7 receptor knockout mice
0	5 nmol) of AMN082 reverses haloperidol-induced ENT1 catalepsy  ENT1END  in rats. AMN082 (2.5 and 5 mg/kg) reduces ENT2 apomorphine ENT2END -induced rotations in unilateral 6-hydroxydopamine (6-OHDA)-lesioned rats
0	However, there are two case reports that show ENT1 tic-like symptoms ENT1END  including motor and phonic variants, occurring during treatment with quetiapine or ENT2 clozapine ENT2END
0	However, there are two case reports that show ENT1 tic-like symptoms ENT1END , including motor and phonic variants, occurring during treatment with ENT2 quetiapine ENT2END or clozapine
0	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, ENT1 olanzapine  ENT1END and ziprasidone. However, there are two case reports that show ENT2 tic-like symptoms ENT2END , including motor and phonic variants, occurring during treatment with quetiapine or clozapine
0	ENT1 Tic disorders ENT1END can be effectively treated by atypical antipsychotics such as ENT2 risperidone ENT2END , olanzapine and ziprasidone
0	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ENT1 ziprasidone  ENT1END  However, there are two case reports that show ENT2 tic-like symptoms ENT2END , including motor and phonic variants, occurring during treatment with quetiapine or clozapine
1	ENT1 Amisulpride  ENT1END  related ENT2 tic-like symptoms ENT2END in an adolescent schizophrenic
0	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or ENT1 clozapine ENT1END . We present a 15-year-old girl schizophrenic who developed frequent ENT2 involuntary eye-blinking movements ENT2END after 5 months of amisulpride treatment (1000 mg per day)
0	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with ENT1 quetiapine  ENT1END  or clozapine. We present a 15-year-old girl schizophrenic who developed frequent ENT2 involuntary eye-blinking movements ENT2END after 5 months of amisulpride treatment (1000 mg per day)
0	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, ENT1 olanzapine  ENT1END  and ziprasidone. However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed frequent ENT2 involuntary eye-blinking movements ENT2END after 5 months of amisulpride treatment (1000 mg per day)
0	Tic disorders can be effectively treated by atypical antipsychotics such as ENT1 risperidone  ENT1END , olanzapine and ziprasidone. However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed frequent ENT2 involuntary eye-blinking movements ENT2END after 5 months of amisulpride treatment (1000 mg per day)
0	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ENT1 ziprasidone  ENT1END . However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed frequent ENT2 involuntary eye-blinking movements ENT2END after 5 months of amisulpride treatment (1000 mg per day)
0	We present a 15-year-old girl schizophrenic who developed frequent ENT1 involuntary eye-blinking movements ENT1END  after 5 months of ENT2 amisulpride ENT2END treatment (1000 mg per day)
0	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or ENT1 clozapine ENT1END . We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day). The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day. However, her ENT2 psychosis ENT2END recurred after the dose reduction
0	However, her ENT1 psychosis ENT1END  recurred after the dose reduction. We then placed her on an additional 100 mg per day of ENT2 quetiapine ENT2END
0	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, ENT1 olanzapine  ENT1END  and ziprasidone. However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day). The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day. However, her ENT2 psychosis ENT2END recurred after the dose reduction
0	Tic disorders can be effectively treated by atypical antipsychotics such as ENT1 risperidone  ENT1END , olanzapine and ziprasidone. However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day). The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day. However, her ENT2 psychosis ENT2END recurred after the dose reduction
0	Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ENT1 ziprasidone  ENT1END . However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or clozapine. We present a 15-year-old girl schizophrenic who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day). The tic-like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day. However, her ENT2 psychosis ENT2END recurred after the dose reduction
0	The tic-like symptoms resolved completely after we reduced the dose of ENT1 amisulpride  ENT1END down to 800 mg per day. However, her ENT2 psychosis ENT2END recurred after the dose reduction
0	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with quetiapine or ENT1 clozapine ENT1END . We present a 15-year-old girl ENT2 schizophrenic ENT2END who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day)
0	However, there are two case reports that show tic-like symptoms, including motor and phonic variants, occurring during treatment with ENT1 quetiapine  ENT1END  or clozapine. We present a 15-year-old girl ENT2 schizophrenic ENT2END who developed frequent involuntary eye-blinking movements after 5 months of amisulpride treatment (1000 mg per day)
0	Amisulpride related tic-like symptoms in an adolescent ENT1 schizophrenic  ENT1END .Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, ENT2 olanzapine ENT2END and ziprasidone
0	Amisulpride related tic-like symptoms in an adolescent ENT1 schizophrenic  ENT1END .Tic disorders can be effectively treated by atypical antipsychotics such as ENT2 risperidone ENT2END , olanzapine and ziprasidone
0	Amisulpride related tic-like symptoms in an adolescent ENT1 schizophrenic  ENT1END .Tic disorders can be effectively treated by atypical antipsychotics such as risperidone, olanzapine and ENT2 ziprasidone ENT2END
0	ENT1 Amisulpride  ENT1END  related tic-like symptoms in an adolescent ENT2 schizophrenic ENT2END
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular ENT1 irritability ENT1END  or headaches. The ENT2 oxytocin ENT2END should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular ENT1 irritability ENT1END , or headaches. The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent ENT2 dextrose ENT2END and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular ENT1 irritability ENT1END , or headaches. The oxytocin should be given only in Ringers ENT2 lactate ENT2END or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
1	ENT1 Water intoxication  ENT1END  associated with ENT2 oxytocin ENT2END administration during saline-induced abortion
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of ENT1 water intoxication  ENT1END and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches. The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent ENT2 dextrose ENT2END and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of ENT1 water intoxication  ENT1END  and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches. The oxytocin should be given only in Ringers ENT2 lactate ENT2END or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
0	Water intoxication associated with ENT1 oxytocin  ENT1END  administration during saline-induced ENT2 abortion ENT2END
0	Oxytocin administration during midtrimester-induced ENT1 abortions  ENT1END is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches. The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent ENT2 dextrose ENT2END and water solutions
0	Oxytocin administration during midtrimester-induced ENT1 abortions  ENT1END  is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or headaches. The oxytocin should be given only in Ringers ENT2 lactate ENT2END or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or ENT1 headaches  ENT1END  The ENT2 oxytocin ENT2END should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or ENT1 headaches  ENT1END . The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent ENT2 dextrose ENT2END and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia, muscular irritability, or ENT1 headaches  ENT1END . The oxytocin should be given only in Ringers ENT2 lactate ENT2END or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as ENT1 asthenia  ENT1END  muscular irritability, or headaches. The ENT2 oxytocin ENT2END should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as ENT1 asthenia  ENT1END , muscular irritability, or headaches. The oxytocin should be given only in Ringers lactate or, alternately, in Ringers lactate and a 5 per cent ENT2 dextrose ENT2END and water solutions
0	Oxytocin administration during midtrimester-induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff, aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as ENT1 asthenia  ENT1END , muscular irritability, or headaches. The oxytocin should be given only in Ringers ENT2 lactate ENT2END or, alternately, in Ringers lactate and a 5 per cent dextrose and water solutions
0	INTRODUCTION: Cocaine use has been associated with neurovascular complications, including arterial vasoconstriction and ENT1 vasculitis ENT1END  However, there are few studies of angiographic effects of ENT2 cocaine ENT2END on human cerebral arteries
1	CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal ENT1 SAH ENT1END associated with ENT2 cocaine ENT2END use
0	INTRODUCTION: ENT1 Cocaine ENT1END use has been associated with ENT2 neurovascular complications ENT2END , including arterial vasoconstriction and vasculitis
1	CONCLUSION: No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after ENT1 aneurysmal  ENT1END SAH associated with ENT2 cocaine ENT2END use
1	In this study we postulated that during ENT1 acute renal failure ENT1END induced by ENT2 gentamicin ENT2END the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels
0	In this study we postulated that during ENT1 acute renal failure ENT1END  induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels. The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper. Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals. The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and ENT2 creatinine ENT2END and higher level of potassium
0	In this study we postulated that during ENT1 acute renal failure ENT1END  induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels. The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper. Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals. The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood ENT2 urea ENT2END and creatinine and higher level of potassium
0	In this study we postulated that during ENT1 acute renal failure ENT1END  induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels. The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper. Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals. The beneficial effects of vitamin C administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of ENT2 potassium ENT2END
0	In this study we postulated that during ENT1 acute renal failure ENT1END  induced by gentamicin the transient or dynamic response of blood vessels could be affected, and that antioxidants can prevent the changes in dynamic responses of blood vessels. The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered, but also dynamics of this response, was used in this paper. Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin-treated animals. The beneficial effects of ENT2 vitamin C ENT2END administration to gentamicin-treated animals are also confirmed through: lower level of blood urea and creatinine and higher level of potassium
0	Melatonin pre-treatment affected in a dual manner ENT1 barbiturate ENT1END ENT2 narcosis ENT2END , however, no dose-effect correlation was found
1	Melatonin affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced ENT1 narcosis ENT1END  ENT2 Sodium thiopenthal ENT2END was administered intraperitoneally into male rats pre-treated with melatonin (0
1	5 and 5 mg/kg influenced the duration but not the latency of ketamine- or ENT1 diazepam ENT1END induced ENT2 narcosis ENT2END
1	Dual effects of melatonin on barbiturate-induced ENT1 narcosis  ENT1END  in rats. ENT2 Melatonin ENT2END affects the circadian sleep/wake cycle, but it is not clear whether it may influence drug-induced narcosis
1	5 and 5 mg/kg influenced the duration but not the latency of ENT1 ketamine  ENT1END  or diazepam-induced ENT2 narcosis ENT2END
0	Morphine dose-dependently reversed these ENT1 behavioral disorders ENT1END  A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by ENT2 CP ENT2END 200 mg
0	ENT1 Morphine  ENT1END dose-dependently reversed these ENT2 behavioral disorders ENT2END
0	by the intravesical route, and ENT1 acrolein  ENT1END at doses of 0.5 mg. by the intravesical route and of 5 mg./kg. i.v. RESULTS: CP dose-relatedly induced marked behavioral modifications in male rats: breathing rate decrease, closing of the eyes and occurrence of specific postures. Morphine dose-dependently reversed these ENT2 behavioral disorders ENT2END
0	Morphine dose-dependently reversed these ENT1 behavioral disorders ENT1END . A dose of 0.5 mg./kg. produced a reduction of almost 50% of the behavioral score induced by CP 200 mg./kg. This effect was completely prevented by pretreatment with ENT2 naloxone ENT2END
0	At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer ENT1 edema ENT1END  were observed. In female rats, ENT2 CP ENT2END 200 mg
0	At the time of administration of ENT1 morphine  ENT1END  histological modifications of the bladder wall, such as chorionic and muscle layer ENT2 edema ENT2END , were observed
0	At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer ENT1 edema ENT1END , were observed. In female rats, CP 200 mg./kg. i.p. produced the same marked behavioral modifications as those observed in male rats. Administered at the dose of 20 mg. intravesically, CP did not produce any behavioral effects, whereas ENT2 acrolein ENT2END at 0
0	This effect was completely prevented by pretreatment with ENT1 naloxone  ENT1END . At the time of administration of morphine, histological modifications of the bladder wall, such as chorionic and muscle layer ENT2 edema ENT2END , were observed
0	PURPOSE: To develop a model of ENT1 visceral pain ENT1END in rats using a behavioral approach. ENT2 Cyclophosphamide ENT2END (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis
0	PURPOSE: To develop a model of ENT1 visceral pain ENT1END  in rats using a behavioral approach. Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce cystitis. MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg. i.p. to male rats, and their behavior observed and scored. The effects of ENT2 morphine ENT2END (0
0	PURPOSE: To develop a model of ENT1 visceral pain ENT1END  in rats using a behavioral approach. Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite ENT2 acrolein ENT2END , was used to induce cystitis
1	CONCLUSIONS: Overall, these results indicate that this experimental model of ENT1 CP ENT1END induced ENT2 cystitis ENT2END may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them
0	Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce ENT1 cystitis  ENT1END  MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg. i.p. to male rats, and their behavior observed and scored. The effects of ENT2 morphine ENT2END (0
0	Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite ENT1 acrolein  ENT1END , was used to induce ENT2 cystitis ENT2END
0	Cyclophosphamide (CP), an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein, was used to induce ENT1 cystitis ENT1END . MATERIALS AND METHODS: CP was administered at doses of 50, 100 and 200 mg./kg. i.p. to male rats, and their behavior observed and scored. The effects of morphine (0.5 to 4 mg./kg. i.v.) on CP-induced behavioral modifications were tested administered alone and after ENT2 naloxone ENT2END (1 mg
1	CONCLUSIONS: Overall, these results indicate that this experimental model of ENT1 CP ENT1END -induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these ENT2 painful syndromes ENT2END and thus a better therapeutic approach to them
1	Conversely, ENT1 acrolein  ENT1END 5 mg./kg. i.v. did not produce any behavioral effects at all. CONCLUSIONS: Overall, these results indicate that this experimental model of CP-induced cystitis may be an interesting new behavioral model of inflammatory visceral pain, allowing a better understanding of these ENT2 painful syndromes ENT2END and thus a better therapeutic approach to them
0	kg(-1) ENT1 thiopental ENT1END iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation. Following administration of these agents, the presence, and degree of ENT2 fasciculation ENT2END were assessed visually on a four point scale by one investigator who was blinded to the drug administered
0	A correlation was not found between the incidence of myalgia and the occurrence of ENT1 muscle fasciculation ENT1END  The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups. In conclusion, where succinylcholine is used, ENT2 lidocaine ENT2END is proven to be the useful pretreatment agent for the reduction of postoperative myalgia
1	followed by ENT1 succinylcholine  ENT1END (Group PS, LS) or rocuronium (Group PR) for tracheal intubation. Following administration of these agents, the presence, and degree of ENT2 fasciculation ENT2END were assessed visually on a four point scale by one investigator who was blinded to the drug administered
0	followed by succinylcholine (Group PS, LS) or ENT1 rocuronium  ENT1END (Group PR) for tracheal intubation. Following administration of these agents, the presence, and degree of ENT2 fasciculation ENT2END were assessed visually on a four point scale by one investigator who was blinded to the drug administered
0	ENT1 Morphine  ENT1END 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry. Anesthesia was induced with 5 mg.kg(-1) thiopental iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation. Following administration of these agents, the presence, and degree of ENT2 fasciculation ENT2END were assessed visually on a four point scale by one investigator who was blinded to the drug administered
0	kg(-1) ENT1 thiopental ENT1END  iv. followed by succinylcholine (Group PS, LS) or rocuronium (Group PR) for tracheal intubation. Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered. The blood pressure and heart rate of each patient were monitored on nine occasions. Twenty-four hours later, any ENT2 myalgia ENT2END experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management
0	Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of ENT1 lidocaine ENT1END pretreatment on reduction of succinylcholine-induced ENT2 myalgia ENT2END in patients undergoing general anesthesia for gynecological surgery
0	Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of ENT1 succinylcholine  ENT1END induced ENT2 myalgia ENT2END in patients undergoing general anesthesia for gynecological surgery
0	followed by succinylcholine (Group PS, LS) or ENT1 rocuronium  ENT1END  (Group PR) for tracheal intubation. Following administration of these agents, the presence, and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered. The blood pressure and heart rate of each patient were monitored on nine occasions. Twenty-four hours later, any ENT2 myalgia ENT2END experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management
0	Can lidocaine reduce succinylcholine induced postoperative myalgia?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced ENT1 myalgia  ENT1END  in patients undergoing general anesthesia for gynecological surgery. One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner. Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1). ENT2 Morphine ENT2END 0
0	Can lidocaine reduce succinylcholine induced ENT1 postoperative myalgia  ENT1END ?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery. One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner. Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1). Morphine 0.1 mg x kg(-1) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor, ECG and pulse oximetry. Anesthesia was induced with 5 mg.kg(-1) ENT2 thiopental ENT2END iv
0	Can ENT1 lidocaine  ENT1END  reduce succinylcholine induced ENT2 postoperative myalgia ENT2END ?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery
1	Can lidocaine reduce ENT1 succinylcholine  ENT1END  induced ENT2 postoperative myalgia ENT2END ?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery
0	Can lidocaine reduce succinylcholine induced ENT1 postoperative myalgia ENT1END ?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery. One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner. Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and ENT2 rocuronium ENT2END 0
0	Can lidocaine reduce succinylcholine induced ENT1 postoperative myalgia  ENT1END ?This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine-induced myalgia in patients undergoing general anesthesia for gynecological surgery. One hundred and thirty-five patients were assigned to one of three groups in a prospective, double blind, randomized manner. Group PS, the control group, received normal saline and succinylcholine 1.5 mg x kg(-1); Group LS, lidocaine 1.5 mg x kg(-1) and succinylcholine 1.5 mg x kg(-1); Group PR, normal saline and rocuronium 0.6 mg x kg(-1). ENT2 Morphine ENT2END 0
1	ENT1 Infarcts in substantia nigra pars reticulata ENT1END were evoked by prolonged ENT2 pilocarpine ENT2END -induced status epilepticus
0	Focal injury in the cortex was produced by infusion of ENT1 lactate  ENT1END at acid pH or by stab caused by needle insertion. ENT2 Infarcts in substantia nigra pars reticulata ENT2END were evoked by prolonged pilocarpine-induced status epilepticus
1	Infarcts in substantia nigra pars reticulata were evoked by prolonged ENT1 pilocarpine ENT1END -induced ENT2 status epilepticus ENT2END
0	Focal injury in the cortex was produced by infusion of ENT1 lactate  ENT1END  at acid pH or by stab caused by needle insertion. Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced ENT2 status epilepticus ENT2END
1	Focal ENT1 injury in the cortex  ENT1END was produced by infusion of lactate at acid pH or by stab caused by needle insertion. Infarcts in substantia nigra pars reticulata were evoked by prolonged ENT2 pilocarpine ENT2END -induced status epilepticus
0	Focal ENT1 injury in the cortex  ENT1END  was produced by infusion of ENT2 lactate ENT2END at acid pH or by stab caused by needle insertion
0	Infarcts in substantia nigra pars reticulata were evoked by prolonged ENT1 pilocarpine ENT1END -induced status epilepticus. Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions. Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state. These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental ENT2 traumatic ENT2END or ischemic lesions
0	Focal injury in the cortex was produced by infusion of ENT1 lactate  ENT1END  at acid pH or by stab caused by needle insertion. Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine-induced status epilepticus. Immunohistochemical staining for NFs showed characteristic terminal clubs of axons in the borderzone of lesions. Differences in the labelling pattern occurred with different antibodies which apparently depended on molecular weight class of NFs and phosphorylation state. These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental ENT2 traumatic ENT2END or ischemic lesions
0	Intracavitary chemotherapy ( ENT1 paclitaxel  ENT1END /carboplatin liquid crystalline cubic phases) for recurrent ENT2 glioblastoma ENT2END -- clinical observations
0	Intracavitary chemotherapy (paclitaxel/ ENT1 carboplatin  ENT1END  liquid crystalline cubic phases) for recurrent ENT2 glioblastoma ENT2END -- clinical observations
1	Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema, while the remaining patients received only a total of 15 mg ENT1 paclitaxel ENT1END  In the latter group, ENT2 brain edema ENT2END was markedly reduced and dealt medically
0	A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re-resection and received an intracavitary application of paclitaxel and ENT1 carboplatin ENT1END cubic phases in different dosages. Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe ENT2 brain edema ENT2END , while the remaining patients received only a total of 15 mg paclitaxel
0	Intracavitary chemotherapy ( ENT1 paclitaxel ENT1END /carboplatin liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.Human malignant ENT2 brain tumors ENT2END have a poor prognosis in spite of surgery and radiation therapy
0	Intracavitary chemotherapy (paclitaxel/ ENT1 carboplatin  ENT1END  liquid crystalline cubic phases) for recurrent glioblastoma -- clinical observations.Human malignant ENT2 brain tumors ENT2END have a poor prognosis in spite of surgery and radiation therapy
0	CASE SUMMARY: A 13-year-old boy was treated with ENT1 ampicillin ENT1END and gentamicin because of suspected ENT2 septicemia ENT2END
0	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and ENT1 gentamicin  ENT1END because of suspected ENT2 septicemia ENT2END
0	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and gentamicin because of suspected ENT1 septicemia ENT1END . Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred. The patient was treated with ENT2 methylprednisolone ENT2END and gradually improved
1	Erythema multiforme and hypersensitivity myocarditis caused by ENT1 ampicillin ENT1END .OBJECTIVE: To report a case of ENT2 erythema multiforme ENT2END and hypersensitivity myocarditis caused by ampicillin
0	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and ENT1 gentamicin ENT1END  because of suspected septicemia. Medications were discontinued when ENT2 erythema multiforme ENT2END and congestive heart failure caused by myocarditis occurred
0	DISCUSSION: After most infections causing ENT1 erythema multiforme ENT1END and myocarditis were ruled out, a drug-induced allergic reaction was suspected. Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin. CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to ENT2 penicillins ENT2END
0	Medications were discontinued when ENT1 erythema multiforme  ENT1END  and congestive heart failure caused by myocarditis occurred. The patient was treated with ENT2 methylprednisolone ENT2END and gradually improved
0	Macrophage-migration inhibition (MIF) test with ENT1 ampicillin ENT1END was positive. DISCUSSION: After most ENT2 infections ENT2END causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected
0	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and ENT1 gentamicin  ENT1END  because of suspected septicemia. Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred. The patient was treated with methylprednisolone and gradually improved. Macrophage-migration inhibition (MIF) test with ampicillin was positive. DISCUSSION: After most ENT2 infections ENT2END causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected
0	DISCUSSION: After most ENT1 infections  ENT1END  causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected. Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin. CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to ENT2 penicillins ENT2END
0	The patient was treated with ENT1 methylprednisolone  ENT1END  and gradually improved. Macrophage-migration inhibition (MIF) test with ampicillin was positive. DISCUSSION: After most ENT2 infections ENT2END causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected
1	Erythema multiforme and ENT1 hypersensitivity myocarditis  ENT1END  caused by ENT2 ampicillin ENT2END
0	OBJECTIVE: To report a case of erythema multiforme and ENT1 hypersensitivity myocarditis  ENT1END caused by ampicillin. CASE SUMMARY: A 13-year-old boy was treated with ampicillin and ENT2 gentamicin ENT2END because of suspected septicemia
0	CONCLUSIONS: ENT1 Hypersensitivity myocarditis  ENT1END is a rare and dangerous manifestation of allergy to ENT2 penicillins ENT2END
0	Medications were discontinued when erythema multiforme and congestive heart failure caused by ENT1 myocarditis  ENT1END occurred. The patient was treated with ENT2 methylprednisolone ENT2END and gradually improved
0	CASE SUMMARY: A 13-year-old boy was treated with ENT1 ampicillin ENT1END  and gentamicin because of suspected septicemia. Medications were discontinued when erythema multiforme and ENT2 congestive heart failure ENT2END caused by myocarditis occurred
0	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and ENT1 gentamicin  ENT1END  because of suspected septicemia. Medications were discontinued when erythema multiforme and ENT2 congestive heart failure ENT2END caused by myocarditis occurred
0	Medications were discontinued when erythema multiforme and ENT1 congestive heart failure  ENT1END  caused by myocarditis occurred. The patient was treated with methylprednisolone and gradually improved. Macrophage-migration inhibition (MIF) test with ampicillin was positive. DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a drug-induced allergic reaction was suspected. Positive MIF test for ampicillin showed sensitization of the patient's lymphocytes to ampicillin. CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to ENT2 penicillins ENT2END
0	Medications were discontinued when erythema multiforme and ENT1 congestive heart failure  ENT1END  caused by myocarditis occurred. The patient was treated with ENT2 methylprednisolone ENT2END and gradually improved
1	DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a ENT1 drug-induced allergic reaction ENT1END was suspected. Positive MIF test for ENT2 ampicillin ENT2END showed sensitization of the patient's lymphocytes to ampicillin
0	CASE SUMMARY: A 13-year-old boy was treated with ampicillin and ENT1 gentamicin  ENT1END  because of suspected septicemia. Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred. The patient was treated with methylprednisolone and gradually improved. Macrophage-migration inhibition (MIF) test with ampicillin was positive. DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a ENT2 drug-induced allergic reaction ENT2END was suspected
0	CONCLUSIONS: Hypersensitivity myocarditis is a rare and dangerous manifestation of ENT1 allergy  ENT1END to ENT2 penicillins ENT2END
0	The patient was treated with ENT1 methylprednisolone  ENT1END  and gradually improved. Macrophage-migration inhibition (MIF) test with ampicillin was positive. DISCUSSION: After most infections causing erythema multiforme and myocarditis were ruled out, a ENT2 drug-induced allergic reaction ENT2END was suspected
0	The beta adrenergic blocking drug, timolol, tended to correct the ENT1 hypokalemia ENT1END of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant. Timolol also reduced the rise in plasma ENT2 aldosterone ENT2END and urine potassium excretion following bendrofluazide and increased the urine sodium/potassium ratio
1	Amelioration of ENT1 bendrofluazide  ENT1END -induced ENT2 hypokalemia ENT2END by timolol
0	The beta adrenergic blocking drug, timolol, tended to correct the ENT1 hypokalemia ENT1END  of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant. Timolol also reduced the rise in plasma aldosterone and urine ENT2 potassium ENT2END excretion following bendrofluazide and increased the urine sodium/potassium ratio
0	Amelioration of bendrofluazide-induced ENT1 hypokalemia  ENT1END  by ENT2 timolol ENT2END
0	The beta adrenergic blocking drug, timolol, tended to correct the ENT1 hypokalemia ENT1END  of short-term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant. Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine ENT2 sodium ENT2END /potassium ratio
0	Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ATP, and ENT1 bethanechol ENT1END  4. ENT2 Diabetes ENT2END of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study
1	The effects of insulin treatment on in vivo and in vitro urinary bladder function in ENT1 streptozotocin ENT1END ENT2 diabetic ENT2END rats were investigated
0	Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation, ENT1 ATP  ENT1END  and bethanechol. 4. ENT2 Diabetes ENT2END of 4 months duration also resulted in decreases in body weight, and increases in fluid consumption, urine volume, frequency of micturition, and average volume per micturition, effects which were reversed by insulin treatment for the final 2 months of the study
1	Thirty-four patients with juvenile rheumatoid arthritis, who were treated with ENT1 flurbiprofen ENT1END at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment. Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee. The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients. One patient was prematurely discontinued from the study for severe headache and ENT2 abdominal pain ENT2END
1	Thirty-four patients with juvenile rheumatoid arthritis, who were treated with ENT1 flurbiprofen ENT1END  at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment. Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee. The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of gastrointestinal (GI) bleeding in these patients. One patient was prematurely discontinued from the study for severe ENT2 headache ENT2END and abdominal pain
0	Thirty-four patients with juvenile rheumatoid arthritis, who were treated with ENT1 flurbiprofen ENT1END  at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 ENT2 arthritis ENT2END indices after 12 weeks of treatment
0	Thirty-four patients with juvenile rheumatoid arthritis, who were treated with ENT1 flurbiprofen ENT1END  at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment. Improvements were seen in the number of tender joints, the severity of ENT2 swelling ENT2END and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee
0	ENT1 Flurbiprofen  ENT1END  in the treatment of ENT2 juvenile rheumatoid arthritis ENT2END
1	Thirty-four patients with juvenile rheumatoid arthritis, who were treated with ENT1 flurbiprofen ENT1END  at a maximum dose of 4 mg/kg/day, had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment. Improvements were seen in the number of tender joints, the severity of swelling and tenderness, the time of walk 50 feet, the duration of morning stiffness and the circumference of the left knee. The most frequently observed side effect was fecal occult blood (25% of patients); however, there was no other evidence of ENT2 gastrointestinal (GI) bleeding ENT2END in these patients
1	Remodelling of nerve structure in experimental ENT1 isoniazid ENT1END ENT2 neuropathy ENT2END in the rat
1	ENT1 Acute experimental models of renal damage ENT1END to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and ENT2 2-bromoethylamine ENT2END (BEA), respectively
1	ENT1 Acute experimental models of renal damage ENT1END  to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), ENT2 puromycin aminonucleoside ENT2END (PAN), and 2-bromoethylamine (BEA), respectively
1	ENT1 Acute experimental models of renal damage ENT1END  to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of ENT2 hexachloro-1:3-butadiene ENT2END (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine (BEA), respectively
0	Acute experimental models of renal damage to the proximal tubular, glomerular, and papillary regions of the rat were produced by administration of hexachloro-1:3-butadiene (HCBD), puromycin aminonucleoside (PAN), and 2-bromoethylamine ( ENT1 BEA ENT1END , respectively. Several routine indicators of ENT2 nephrotoxicity ENT2END , the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of protein excretion were determined on urine samples
0	Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from ENT1 glomerular damage ENT1END produced by ENT2 PAN ENT2END
0	Tubular damage produced by ENT1 HCBD  ENT1END or BEA was discriminated both quantitatively and qualitatively from ENT2 glomerular damage ENT2END produced by PAN
0	Alkaline phosphatase and ENT1 glucose ENT1END were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage. It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of ENT2 renal damage ENT2END
0	Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of ENT1 protein excretion ENT1END were determined on urine samples. Tubular damage produced by HCBD or ENT2 BEA ENT2END was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN
1	Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by ENT1 PAN ENT1END . The latter was characterized by a pronounced increase in ENT2 protein excretion ENT2END , especially proteins with molecular weight greater than 40,000 Da
0	Several routine indicators of nephrotoxicity, the enzymes alkaline phosphatase and N-acetyl-beta-glucosaminidase, and the molecular weight of ENT1 protein excretion  ENT1END  were determined on urine samples. Tubular damage produced by ENT2 HCBD ENT2END or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN
0	In contrast, protein excretion in tubular damage was raised only slightly and characterized by ENT1 excretion of proteins  ENT1END of a wide range of molecular weights. Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis (volume and specific gravity) and by measurement of the two urinary enzymes. Alkaline phosphatase and ENT2 glucose ENT2END were markedly and transiently elevated in proximal tubular damage and N-acetyl-beta-glucosaminidase showed a sustained elevation in papillary damage
0	The rise in resting blood pressure with ENT1 hydrocortisone ENT1END is associated with an ENT2 increased cardiac output ENT2END (presumably due to increased blood volume)
0	Measurement of resting norepinephrine spillover rate to plasma and ENT1 norepinephrine  ENT1END uptake indicated that overall resting sympathetic nervous system activity was not increased. The rise in resting blood pressure with hydrocortisone is associated with an ENT2 increased cardiac output ENT2END (presumably due to increased blood volume)
1	ENT1 Hydrocortisone  ENT1END -induced ENT2 hypertension ENT2END in humans: pressor responsiveness and sympathetic function
0	Measurement of resting norepinephrine spillover rate to plasma and ENT1 norepinephrine ENT1END  uptake indicated that overall resting sympathetic nervous system activity was not increased. The ENT2 rise in resting blood pressure ENT2END with hydrocortisone is associated with an increased cardiac output (presumably due to increased blood volume)
0	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT1 furosemide ENT1END was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were ENT2 hyperhidrosis ENT2END , hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation
0	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline ( ENT1 epinephrine  ENT1END , atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were ENT2 hyperhidrosis ENT2END , hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation
0	Further signs were ENT1 hyperhidrosis ENT1END , hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
1	ENT1 Carbachol  ENT1END concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry. RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were ENT2 hyperhidrosis ENT2END , hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation
0	Further signs were ENT1 hyperhidrosis ENT1END , hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of ENT2 atropine ENT2END (up to 50 mg per 24 hours), adrenaline and dopamine were necessary
0	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT1 furosemide ENT1END  was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary. The patient was extubated 1 week later. However, increased ENT2 dyspnoea ENT2END and bronchospasm necessitated reintubation
0	High doses of atropine (up to 50 mg per 24 hours), ENT1 adrenaline  ENT1END and dopamine were necessary. The patient was extubated 1 week later. However, increased ENT2 dyspnoea ENT2END and bronchospasm necessitated reintubation
0	High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT1 dopamine  ENT1END  were necessary. The patient was extubated 1 week later. However, increased ENT2 dyspnoea ENT2END and bronchospasm necessitated reintubation
0	However, increased ENT1 dyspnoea ENT1END  and bronchospasm necessitated reintubation. Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction. One week later, the patient was again extubated and 3 days later was transferred to a peripheral ward. On the next day he died, probably as a result of heart failure. Serum samples from the first and second days contained 3.6 and 1.9 mg/l ENT2 carbachol ENT2END , respectively
0	High doses of ENT1 atropine  ENT1END  (up to 50 mg per 24 hours), adrenaline and dopamine were necessary. The patient was extubated 1 week later. However, increased ENT2 dyspnoea ENT2END and bronchospasm necessitated reintubation
0	RESULTS: Minutes after oral administration, the patient developed nausea, sweating and ENT1 hypotension  ENT1END  and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT2 furosemide ENT2END was successful
0	RESULTS: Minutes after oral administration, the patient developed nausea, sweating and ENT1 hypotension ENT1END , and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with ENT2 adrenaline ENT2END (epinephrine), atropine and furosemide was successful
0	RESULTS: Minutes after oral administration, the patient developed nausea, sweating and ENT1 hypotension  ENT1END , and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
1	ENT1 Carbachol  ENT1END  concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry. RESULTS: Minutes after oral administration, the patient developed nausea, sweating and ENT2 hypotension ENT2END , and finally collapsed
0	RESULTS: Minutes after oral administration, the patient developed nausea, sweating and ENT1 hypotension ENT1END , and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), ENT2 atropine ENT2END and furosemide was successful
0	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT1 furosemide ENT1END  was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and ENT2 bronchospasm ENT2END necessitated reintubation
0	High doses of atropine (up to 50 mg per 24 hours), ENT1 adrenaline  ENT1END  and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and ENT2 bronchospasm ENT2END necessitated reintubation
0	High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT1 dopamine  ENT1END  were necessary. The patient was extubated 1 week later. However, increased dyspnoea and ENT2 bronchospasm ENT2END necessitated reintubation
0	However, increased dyspnoea and ENT1 bronchospasm  ENT1END  necessitated reintubation. Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction. One week later, the patient was again extubated and 3 days later was transferred to a peripheral ward. On the next day he died, probably as a result of heart failure. Serum samples from the first and second days contained 3.6 and 1.9 mg/l ENT2 carbachol ENT2END , respectively
0	High doses of ENT1 atropine  ENT1END  (up to 50 mg per 24 hours), adrenaline and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and ENT2 bronchospasm ENT2END necessitated reintubation
0	INTRODUCTION: Intoxications with ENT1 carbachol ENT1END  a muscarinic cholinergic receptor agonist are rare. We report an interesting case investigating a (near) fatal ENT2 poisoning ENT2END
0	The analysed ENT1 carbachol ENT1END concentration exceeded the supposed serum level resulting from a therapeutic dose by a factor of 130 to 260. Especially in old patients, intensivists should consider intoxications (with cholinergics) as a cause of ENT2 acute cardiovascular failure ENT2END
0	ENT1 Bradycardia  ENT1END  cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT2 furosemide ENT2END was successful
0	ENT1 Bradycardia  ENT1END , cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with ENT2 adrenaline ENT2END (epinephrine), atropine and furosemide was successful
0	ENT1 Bradycardia  ENT1END , cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
1	ENT1 Carbachol  ENT1END  concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry. RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed. ENT2 Bradycardia ENT2END , cholinergic symptoms and asystole occurred
0	ENT1 Bradycardia  ENT1END , cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), ENT2 atropine ENT2END and furosemide was successful
0	RESULTS: Minutes after oral administration, the patient developed ENT1 nausea  ENT1END  sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT2 furosemide ENT2END was successful
0	RESULTS: Minutes after oral administration, the patient developed ENT1 nausea  ENT1END , sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with ENT2 adrenaline ENT2END (epinephrine), atropine and furosemide was successful
0	RESULTS: Minutes after oral administration, the patient developed ENT1 nausea  ENT1END , sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
1	ENT1 Carbachol  ENT1END  concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry. RESULTS: Minutes after oral administration, the patient developed ENT2 nausea ENT2END , sweating and hypotension, and finally collapsed
0	RESULTS: Minutes after oral administration, the patient developed ENT1 nausea  ENT1END , sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), ENT2 atropine ENT2END and furosemide was successful
0	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT1 furosemide ENT1END  was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, ENT2 hypersalivation ENT2END , bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation
0	Further signs were hyperhidrosis, ENT1 hypersalivation  ENT1END , bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), ENT2 adrenaline ENT2END and dopamine were necessary
0	Further signs were hyperhidrosis, ENT1 hypersalivation  ENT1END , bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
1	ENT1 Carbachol  ENT1END  concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry. RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, ENT2 hypersalivation ENT2END , bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation
0	Further signs were hyperhidrosis, ENT1 hypersalivation  ENT1END , bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of ENT2 atropine ENT2END (up to 50 mg per 24 hours), adrenaline and dopamine were necessary
0	High doses of atropine (up to 50 mg per 24 hours), ENT1 adrenaline ENT1END  and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. ENT2 Respiratory insufficiency ENT2END was further worsened by Proteus mirabilis infection and severe bronchoconstriction
0	High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT1 dopamine  ENT1END  were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. ENT2 Respiratory insufficiency ENT2END was further worsened by Proteus mirabilis infection and severe bronchoconstriction
0	ENT1 Respiratory insufficiency  ENT1END  was further worsened by Proteus mirabilis infection and severe bronchoconstriction. One week later, the patient was again extubated and 3 days later was transferred to a peripheral ward. On the next day he died, probably as a result of heart failure. Serum samples from the first and second days contained 3.6 and 1.9 mg/l ENT2 carbachol ENT2END , respectively
0	High doses of ENT1 atropine  ENT1END  (up to 50 mg per 24 hours), adrenaline and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. ENT2 Respiratory insufficiency ENT2END was further worsened by Proteus mirabilis infection and severe bronchoconstriction
0	METHODS: The son of an 84-year-old male discovered a newspaper report stating clinical success with plant extracts in ENT1 Alzheimer's disease  ENT1END  The mode of action was said to be comparable to that of the synthetic compound ' ENT2 carbamylcholin ENT2END '; that is, carbachol
0	High doses of atropine (up to 50 mg per 24 hours), ENT1 adrenaline ENT1END  and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. Respiratory insufficiency was further worsened by ENT2 Proteus mirabilis infection ENT2END and severe bronchoconstriction
0	High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT1 dopamine  ENT1END  were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. Respiratory insufficiency was further worsened by ENT2 Proteus mirabilis infection ENT2END and severe bronchoconstriction
0	Respiratory insufficiency was further worsened by ENT1 Proteus mirabilis infection  ENT1END  and severe bronchoconstriction. One week later, the patient was again extubated and 3 days later was transferred to a peripheral ward. On the next day he died, probably as a result of heart failure. Serum samples from the first and second days contained 3.6 and 1.9 mg/l ENT2 carbachol ENT2END , respectively
0	High doses of ENT1 atropine  ENT1END  (up to 50 mg per 24 hours), adrenaline and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. Respiratory insufficiency was further worsened by ENT2 Proteus mirabilis infection ENT2END and severe bronchoconstriction
0	High doses of atropine (up to 50 mg per 24 hours), ENT1 adrenaline ENT1END  and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction. One week later, the patient was again extubated and 3 days later was transferred to a peripheral ward. On the next day he died, probably as a result of ENT2 heart failure ENT2END
0	High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT1 dopamine  ENT1END  were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction. One week later, the patient was again extubated and 3 days later was transferred to a peripheral ward. On the next day he died, probably as a result of ENT2 heart failure ENT2END
1	On the next day he died, probably as a result of ENT1 heart failure  ENT1END . Serum samples from the first and second days contained 3.6 and 1.9 mg/l ENT2 carbachol ENT2END , respectively
0	High doses of ENT1 atropine  ENT1END  (up to 50 mg per 24 hours), adrenaline and dopamine were necessary. The patient was extubated 1 week later. However, increased dyspnoea and bronchospasm necessitated reintubation. Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction. One week later, the patient was again extubated and 3 days later was transferred to a peripheral ward. On the next day he died, probably as a result of ENT2 heart failure ENT2END
0	Bradycardia, cholinergic symptoms and ENT1 asystole  ENT1END occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT2 furosemide ENT2END was successful
0	Bradycardia, cholinergic symptoms and ENT1 asystole  ENT1END  occurred. Initial cardiopulmonary resuscitation and immediate treatment with ENT2 adrenaline ENT2END (epinephrine), atropine and furosemide was successful
0	Bradycardia, cholinergic symptoms and ENT1 asystole  ENT1END  occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
1	ENT1 Carbachol  ENT1END  concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry. RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and ENT2 asystole ENT2END occurred
0	Bradycardia, cholinergic symptoms and ENT1 asystole  ENT1END  occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), ENT2 atropine ENT2END and furosemide was successful
0	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT1 furosemide ENT1END  was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe ENT2 miosis ENT2END ; the electrocardiographic finding was atrio-ventricular dissociation
0	Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe ENT1 miosis  ENT1END ; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), ENT2 adrenaline ENT2END and dopamine were necessary
0	Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe ENT1 miosis  ENT1END ; the electrocardiographic finding was atrio-ventricular dissociation. High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
1	ENT1 Carbachol  ENT1END  concentrations in serum and urine on day 1 and 2 of hospital admission were analysed by HPLC-mass spectrometry. RESULTS: Minutes after oral administration, the patient developed nausea, sweating and hypotension, and finally collapsed. Bradycardia, cholinergic symptoms and asystole occurred. Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and furosemide was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe ENT2 miosis ENT2END ; the electrocardiographic finding was atrio-ventricular dissociation
0	Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe ENT1 miosis  ENT1END ; the electrocardiographic finding was atrio-ventricular dissociation. High doses of ENT2 atropine ENT2END (up to 50 mg per 24 hours), adrenaline and dopamine were necessary
0	Initial cardiopulmonary resuscitation and immediate treatment with adrenaline (epinephrine), atropine and ENT1 furosemide ENT1END  was successful. On hospital admission, blood pressure of the intubated, bradyarrhythmic patient was 100/65 mmHg. Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was ENT2 atrio-ventricular dissociation ENT2END
0	Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was ENT1 atrio-ventricular dissociation  ENT1END . High doses of atropine (up to 50 mg per 24 hours), ENT2 adrenaline ENT2END and dopamine were necessary
0	Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was ENT1 atrio-ventricular dissociation  ENT1END . High doses of atropine (up to 50 mg per 24 hours), adrenaline and ENT2 dopamine ENT2END were necessary
0	Further signs were hyperhidrosis, hypersalivation, bronchorrhoea, and severe miosis; the electrocardiographic finding was ENT1 atrio-ventricular dissociation  ENT1END . High doses of ENT2 atropine ENT2END (up to 50 mg per 24 hours), adrenaline and dopamine were necessary
0	Pseudoacromegaly induced by the long-term use of ENT1 minoxidil ENT1END .Acromegaly is an ENT2 endocrine disorder ENT2END caused by chronic excessive growth hormone secretion from the anterior pituitary gland
0	Pseudoacromegaly induced by the long-term use of ENT1 minoxidil ENT1END .Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland. Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue ENT2 hypertrophy ENT2END , including the thickening of the skin, coarsening of facial features, and cutis verticis gyrata
0	This is the first case report of ENT1 pseudoacromegaly ENT1END as a side effect of ENT2 minoxidil ENT2END use
0	Significant disfiguring changes occur as a result of bone, cartilage, and soft tissue hypertrophy, including the thickening of the skin, coarsening of facial features, and ENT1 cutis verticis gyrata ENT1END  Pseudoacromegaly, on the other hand, is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin-like growth factor levels. We present a patient with pseudoacromegaly that resulted from the long-term use of ENT2 minoxidil ENT2END at an unusually high dose
1	Pseudoacromegaly induced by the long-term use of ENT1 minoxidil  ENT1END . ENT2 Acromegaly ENT2END is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland
0	METHODS: Patients with a clinical diagnosis of ENT1 ischemic stroke ENT1END (within 24 hours) were consecutively allocated to receive placebo (n=100), 1 mg/h (low-dose) ENT2 nimodipine ENT2END (n=101), or 2 mg/h (high-dose) nimodipine (n=94)
0	74) and ENT1 death ENT1END alone (n/N=9/26, OR 4.336, 95% CI 1.131 16.619) compared with all placebo patients (n/N=62/92 and 14/92, respectively). There was no correlation between SBP change and outcome. CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose ENT2 nimodipine ENT2END after acute stroke
1	BACKGROUND AND PURPOSE: The Intravenous Nimodipine West European Stroke Trial (INWEST) found a correlation between ENT1 nimodipine ENT1END induced ENT2 reduction in blood pressure ENT2END (BP) and an unfavorable outcome in acute stroke
0	CONCLUSIONS: DBP, but not SBP, reduction was associated with neurological worsening after the intravenous administration of high-dose ENT1 nimodipine ENT1END  after ENT2 acute stroke ENT2END
0	The data extend the findings of other investigators, further establishing the ENT1 DES ENT1END induced ENT2 tumor ENT2END as a model for study of PRL cellular control mechanisms
0	ENT1 Pituitary tumors ENT1END were induced in F344 female rats by chronic treatment with diethylstilbestrol (DES, 8-10 mg) implanted subcutaneously in silastic capsules. Over a range of 1-150 days of DES treatment, pairs of control and DES-treated rats were sacrificed, and their pituitaries dissociated enzymatically into single-cell preparations. The cell populations were examined regarding total cell recovery correlated with gland weight, intracellular prolactin (PRL) content and subsequent release in primary culture, immunocytochemical PRL staining, density and/or size alterations via separation on Ficoll-Hypaque and by unit gravity sedimentation, and cell cycle analysis, after ENT2 acriflavine ENT2END DNA staining, by laser flow cytometry
1	ENT1 Pituitary tumors ENT1END  were induced in F344 female rats by chronic treatment with ENT2 diethylstilbestrol ENT2END (DES, 8-10 mg) implanted subcutaneously in silastic capsules
0	Characterization of ENT1 estrogen  ENT1END -induced ENT2 adenohypophyseal tumors ENT2END in the Fischer 344 rat
0	VPU was more potent than VPA, exhibiting the median effective dose (ED(50)) of 49 mg/kg in protecting rats against pilocarpine-induced ENT1 seizure ENT1END whereas the corresponding value for ENT2 VPA ENT2END was 322 mg/kg
0	Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in glutamate and ENT1 aspartate ENT1END should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced ENT2 seizure ENT2END in experimental animals
0	In addition, a statistically significant reduction was also observed on the level of GABA and ENT1 glycine ENT1END but less than a drastic reduction of glutamate and aspartate level. Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced ENT2 seizure ENT2END it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate
0	Based on the finding that ENT1 VPU  ENT1END and VPA could protect the animals against pilocarpine-induced ENT2 seizure ENT2END it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate
0	In addition, a statistically significant reduction was also observed on the level of ENT1 GABA  ENT1END and glycine but less than a drastic reduction of glutamate and aspartate level. Based on the finding that VPU and VPA could protect the animals against pilocarpine-induced ENT2 seizure ENT2END it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate
0	Acute effects of N-(2-propylpentanoyl)urea on hippocampal ENT1 amino acid  ENT1END  neurotransmitters in pilocarpine-induced ENT2 seizure ENT2END in rats
1	Acute effects of N-(2-propylpentanoyl)urea on hippocampal amino acid neurotransmitters in ENT1 pilocarpine  ENT1END -induced ENT2 seizure ENT2END in rats
0	Therefore, like VPA, the finding that VPU could drastically reduce pilocarpine-induced increases in ENT1 glutamate  ENT1END and aspartate should account, at least partly, for its anticonvulsant activity observed in pilocarpine-induced ENT2 seizure ENT2END in experimental animals
0	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected ENT1 infections ENT1END  Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population. To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center. Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin. The occurrence of nephrotoxicity by means of an increase in serum ENT2 creatinine ENT2END and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed
0	ENT1 Amikacin  ENT1END is an aminoglycoside commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected ENT2 infections ENT2END
0	Amikacin is an ENT1 aminoglycoside  ENT1END commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected ENT2 infections ENT2END
0	Forty patients with a diagnosis consistent with a ENT1 hematologic/oncologic disorder  ENT1END that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin. The occurrence of nephrotoxicity by means of an increase in serum ENT2 creatinine ENT2END and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed
0	Forty patients with a diagnosis consistent with a ENT1 hematologic/oncologic disorder ENT1END  that required treatment with an aminoglycoside were randomized to either conventional or extended-interval ENT2 amikacin ENT2END
0	Forty patients with a diagnosis consistent with a ENT1 hematologic/oncologic disorder ENT1END  that required treatment with an ENT2 aminoglycoside ENT2END were randomized to either conventional or extended-interval amikacin
0	The occurrence of ENT1 nephrotoxicity  ENT1END by means of an increase in serum ENT2 creatinine ENT2END and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed
1	An evaluation of ENT1 amikacin ENT1END ENT2 nephrotoxicity ENT2END in the hematology/oncology population
0	An evaluation of amikacin ENT1 nephrotoxicity  ENT1END  in the hematology/oncology population.Amikacin is an ENT2 aminoglycoside ENT2END commonly used to provide empirical double gram-negative treatment for febrile neutropenia and other suspected infections
0	Amikacin is an aminoglycoside commonly used to provide empirical double gram-negative treatment for ENT1 febrile neutropenia  ENT1END and other suspected infections. Strategies of extended-interval and conventional dosing have been utilized extensively in the general medical population; however, data are lacking to support a dosing strategy in the hematology/oncology population. To evaluate amikacin-associated nephrotoxicity in an adult hematology/oncology population, a prospective, randomized, open-label trial was conducted at a university-affiliated medical center. Forty patients with a diagnosis consistent with a hematologic/oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin. The occurrence of nephrotoxicity by means of an increase in serum ENT2 creatinine ENT2END and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed
0	ENT1 Amikacin  ENT1END  is an aminoglycoside commonly used to provide empirical double gram-negative treatment for ENT2 febrile neutropenia ENT2END and other suspected infections
0	Amikacin is an ENT1 aminoglycoside  ENT1END  commonly used to provide empirical double gram-negative treatment for ENT2 febrile neutropenia ENT2END and other suspected infections
0	Forty patients with a diagnosis consistent with a ENT1 hematologic/oncologic disorder  ENT1END that required treatment with an aminoglycoside were randomized to either conventional or extended-interval amikacin. The occurrence of nephrotoxicity by means of an increase in serum ENT2 creatinine ENT2END and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed
0	Forty patients with a diagnosis consistent with a ENT1 hematologic/oncologic disorder  ENT1END  that required treatment with an aminoglycoside were randomized to either conventional or extended-interval ENT2 amikacin ENT2END
0	Forty patients with a diagnosis consistent with a ENT1 hematologic/oncologic disorder  ENT1END  that required treatment with an ENT2 aminoglycoside ENT2END were randomized to either conventional or extended-interval amikacin
1	There was only one case of ENT1 dementia ENT1END possibly due to ENT2 cimetidine ENT2END (with a drug level of 1
0	The ratio of cimetidine clearance to ENT1 creatinine  ENT1END clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine. Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process. There was only one case of ENT2 dementia ENT2END possibly due to cimetidine (with a drug level of 1
0	9 microgram/ml 6 hr after a dose) in a group of 13 patients without ENT1 liver or kidney disease ENT1END who had ENT2 cimetidine ENT2END levels above 1
0	The ratio of cimetidine clearance to ENT1 creatinine  ENT1END  clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine. Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process. There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without ENT2 liver or kidney disease ENT2END who had cimetidine levels above 1
0	9 microgram/ml 6 hr after a dose) in a group of 13 patients without ENT1 liver or kidney disease  ENT1END who had ENT2 cimetidine ENT2END levels above 1
0	The ratio of cimetidine clearance to ENT1 creatinine  ENT1END  clearance (Rc) averaged 4.8 +/- 2.0, indicating net tubular secretion for cimetidine. Rc seemed to be independent of age and decreased with increasing serum concentration of cimetidine, suggesting that secretion of cimetidine is a saturable process. There was only one case of dementia possibly due to cimetidine (with a drug level of 1.9 microgram/ml 6 hr after a dose) in a group of 13 patients without ENT2 liver or kidney disease ENT2END who had cimetidine levels above 1
0	The morphine-induced ENT1 hyperactivity ENT1END was potentiated by scopolamine and attenuated by physostigmine. In contrast, both ENT2 methscopolamine ENT2END and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the hyperactivity produced by morphine
0	The morphine-induced ENT1 hyperactivity ENT1END  was potentiated by scopolamine and attenuated by ENT2 physostigmine ENT2END
0	In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the ENT1 hyperactivity ENT1END produced by morphine. Pretreatment of mice with alpha-methyltyrosine (20 mg/kg i.p., one hour), an inhibitor of ENT2 tyrosine ENT2END hydroxylase, significantly decreased the activity-increasing effects of morphine
0	, 24 hr), a ENT1 serotonin ENT1END depletor, caused no significant change in the ENT2 hyperactivity ENT2END
0	In contrast, both methscopolamine and neostigmine, which do not penetrate the blood-brain barrier, had no effect on the ENT1 hyperactivity ENT1END  produced by morphine. Pretreatment of mice with ENT2 alpha-methyltyrosine ENT2END (20 mg/kg i
1	The ENT1 morphine  ENT1END induced ENT2 hyperactivity ENT2END was potentiated by scopolamine and attenuated by physostigmine
0	In contrast, both methscopolamine and ENT1 neostigmine  ENT1END  which do not penetrate the blood-brain barrier, had no effect on the ENT2 hyperactivity ENT2END produced by morphine
1	The morphine-induced ENT1 hyperactivity ENT1END  was potentiated by ENT2 scopolamine ENT2END and attenuated by physostigmine
0	, 24 hr), a serotonin depletor, caused no significant change in the ENT1 hyperactivity ENT1END . The study suggests that the activity-increasing effects of morphine are mediated by the release of catecholamines from adrenergic neurons in the brain. And the results are consistent with the hypothesis that morphine acts by retarding the release of ENT2 acetylcholine ENT2END at some central cholinergic synapses
0	, 24 hr), a serotonin depletor, caused no significant change in the ENT1 hyperactivity ENT1END . The study suggests that the activity-increasing effects of morphine are mediated by the release of ENT2 catecholamines ENT2END from adrenergic neurons in the brain
0	On the other hand, pretreatment with ENT1 p-chlorophenylalamine  ENT1END (3 X 320 mg/kg i.p., 24 hr), a serotonin depletor, caused no significant change in the ENT2 hyperactivity ENT2END
0	Total cumulative doses were 36 or 60 g/m2 of ENT1 ifosfamide ENT1END (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, ENT2 proteinuria ENT2END , aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, ENT1 proteinuria ENT1END , aminoaciduria, urinary pH, osmolarity, ENT2 creatinine ENT2END clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, ENT1 proteinuria ENT1END , aminoaciduria, urinary pH, osmolarity, creatinine clearance, ENT2 phosphate ENT2END tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	None of them had received ENT1 cisplatin  ENT1END chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, ENT2 proteinuria ENT2END , aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [ ENT1 IVA  ENT1END ). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, ENT2 proteinuria ENT2END , aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ENT1 ifosfamide ENT1END in the treatment of ENT2 mesenchymal tumors ENT2END in children
0	The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology ENT1 Malignant Mesenchymal Tumor  ENT1END Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment. Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, ENT2 creatinine ENT2END clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low ENT1 phosphate  ENT1END reabsorption. The remaining seven patients had isolated beta 2 microglobulinuria. Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement. This low percentage (5%) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of ENT2 mesenchymal tumors ENT2END in children
0	The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology ENT1 Malignant Mesenchymal Tumor  ENT1END  Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment. Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]). None of them had received ENT2 cisplatin ENT2END chemotherapy
0	The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology ENT1 Malignant Mesenchymal Tumor ENT1END  Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment. Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ENT2 ifosfamide, vincristine, and dactinomycin ENT2END [IVA])
0	Severe ENT1 toxicity ENT1END was correlated with the higher cumulative dose of 60 g/m2 of ENT2 ifosfamide ENT2END , a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, ENT1 creatinine ENT1END  clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria. Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities. Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major ENT2 toxicity ENT2END resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption
0	Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low ENT1 phosphate  ENT1END  reabsorption. The remaining seven patients had isolated beta 2 microglobulinuria. Severe ENT2 toxicity ENT2END was correlated with the higher cumulative dose of 60 g/m2 of ifosfamide, a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement
0	None of them had received ENT1 cisplatin  ENT1END  chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria. Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities. Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major ENT2 toxicity ENT2END resulting in Fanconi's syndrome (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption
0	Total cumulative doses were 36 or 60 g/m2 of ENT1 ifosfamide ENT1END  (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, ENT2 glucosuria ENT2END , proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Renal function was investigated by measuring plasma and urinary electrolytes, ENT1 glucosuria  ENT1END , proteinuria, aminoaciduria, urinary pH, osmolarity, ENT2 creatinine ENT2END clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Renal function was investigated by measuring plasma and urinary electrolytes, ENT1 glucosuria  ENT1END , proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, ENT2 phosphate ENT2END tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	None of them had received ENT1 cisplatin  ENT1END  chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, ENT2 glucosuria ENT2END , proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [ ENT1 IVA  ENT1END ]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, ENT2 glucosuria ENT2END , proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ENT1 ifosfamide ENT1END , a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic ENT2 tumor ENT2END involvement
0	The most common primary ENT1 tumor  ENT1END site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, ENT2 creatinine ENT2END clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	The most common primary ENT1 tumor  ENT1END  site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, ENT2 phosphate ENT2END tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	None of them had received ENT1 cisplatin  ENT1END  chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary ENT2 tumor ENT2END site was the head and neck
0	Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [ ENT1 IVA  ENT1END ]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary ENT2 tumor ENT2END site was the head and neck
1	Long-term follow-up of ENT1 ifosfamide ENT1END ENT2 renal toxicity ENT2END in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, ENT1 creatinine ENT1END  clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria. Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had ENT2 renal abnormalities ENT2END
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, ENT1 phosphate  ENT1END  tubular reabsorption, beta 2 microglobulinuria, and lysozymuria. Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had ENT2 renal abnormalities ENT2END
0	None of them had received ENT1 cisplatin  ENT1END  chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria. Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had ENT2 renal abnormalities ENT2END
0	Long-term follow-up of ifosfamide ENT1 renal toxicity  ENT1END  in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report.The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol (International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [SIOP MMT 84]) were studied 1 year after the completion of treatment. Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ENT2 ifosfamide, vincristine, and dactinomycin ENT2END [IVA])
1	Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome ( ENT1 TDFS  ENT1END ; and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption. The remaining seven patients had isolated beta 2 microglobulinuria. Severe toxicity was correlated with the higher cumulative dose of 60 g/m2 of ENT2 ifosfamide ENT2END , a younger age (less than 2 1/2 years old), and a predominance of vesicoprostatic tumor involvement
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, ENT1 creatinine ENT1END  clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria. Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities. Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in ENT2 Fanconi's syndrome ENT2END (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption
0	Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in Fanconi's syndrome ( ENT1 TDFS  ENT1END ); and the second group included five patients with elevated beta 2 microglobulinuria and low ENT2 phosphate ENT2END reabsorption
0	None of them had received ENT1 cisplatin  ENT1END  chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, aminoaciduria, urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria. Fifty-eight patients (78%) had normal renal tests, whereas 16 patients (22%) had renal abnormalities. Two subsets of patients were identified from this latter group: the first included four patients (5% of the total population) who developed major toxicity resulting in ENT2 Fanconi's syndrome ENT2END (TDFS); and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption
0	Total cumulative doses were 36 or 60 g/m2 of ENT1 ifosfamide ENT1END  (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [IVA]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, ENT2 aminoaciduria ENT2END , urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, ENT1 aminoaciduria  ENT1END , urinary pH, osmolarity, ENT2 creatinine ENT2END clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, ENT1 aminoaciduria  ENT1END , urinary pH, osmolarity, creatinine clearance, ENT2 phosphate ENT2END tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	None of them had received ENT1 cisplatin  ENT1END  chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, ENT2 aminoaciduria ENT2END , urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	Total cumulative doses were 36 or 60 g/m2 of ifosfamide (six or 10 cycles of ifosfamide, vincristine, and dactinomycin [ ENT1 IVA  ENT1END ]). None of them had received cisplatin chemotherapy. Ages ranged from 4 months to 17 years; 58 patients were males and 42 females. The most common primary tumor site was the head and neck. Renal function was investigated by measuring plasma and urinary electrolytes, glucosuria, proteinuria, ENT2 aminoaciduria ENT2END , urinary pH, osmolarity, creatinine clearance, phosphate tubular reabsorption, beta 2 microglobulinuria, and lysozymuria
0	In a phase I study to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin administered every 21 days to women with advanced ENT1 ovarian cancer ENT1END  ENT2 paclitaxel ENT2END doses were escalated as follows: level 1, 135 mg/m2; level 2, 160 mg/m2; level 3, 185 mg/m2; and level 4,210 mg/m2
0	Paclitaxel combined with ENT1 carboplatin  ENT1END  in the first-line treatment of advanced ENT2 ovarian cancer ENT2END
1	ENT1 Neurotoxicity ENT1END was largely moderate. So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients. No patient had disease progression. We conclude that the combination of ENT2 paclitaxel ENT2END 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting
1	ENT1 Neurotoxicity ENT1END  was largely moderate. So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients. No patient had disease progression. We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of ENT2 carboplatin ENT2END at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting
1	The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and ENT1 thrombocytopenia  ENT1END . Neurotoxicity was largely moderate. So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients. No patient had disease progression. We conclude that the combination of ENT2 paclitaxel ENT2END 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting
1	The dose-limiting toxicity of the combination was myelosuppression (leukopenia, granulocytopenia, and ENT1 thrombocytopenia  ENT1END ). Neurotoxicity was largely moderate. So far, 14 patients are evaluable for response; of these, eight (57%) showed objective (complete or partial) response and disease stabilized in six patients. No patient had disease progression. We conclude that the combination of paclitaxel 185 mg/m2 administered as a 3-hour infusion followed immediately by a 1-hour infusion of ENT2 carboplatin ENT2END at an AUC of 6 can be administered safely in a 21-day schedule in the outpatient setting
0	5, respectively, combined with a fixed ENT1 paclitaxel ENT1END dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting ENT2 toxicity ENT2END of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia)
0	In levels 5 and 6 the ENT1 carboplatin  ENT1END dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting ENT2 toxicity ENT2END of the combination was myelosuppression (leukopenia, granulocytopenia, and thrombocytopenia)
1	5, respectively, combined with a fixed ENT1 paclitaxel ENT1END  dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was myelosuppression (leukopenia, ENT2 granulocytopenia ENT2END , and thrombocytopenia)
1	In levels 5 and 6 the ENT1 carboplatin  ENT1END  dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was myelosuppression (leukopenia, ENT2 granulocytopenia ENT2END , and thrombocytopenia)
0	5, respectively, combined with a fixed ENT1 paclitaxel ENT1END  dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was ENT2 myelosuppression ENT2END (leukopenia, granulocytopenia, and thrombocytopenia)
0	In levels 5 and 6 the ENT1 carboplatin  ENT1END  dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was ENT2 myelosuppression ENT2END (leukopenia, granulocytopenia, and thrombocytopenia)
1	5, respectively, combined with a fixed ENT1 paclitaxel  ENT1END  dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was myelosuppression ( ENT2 leukopenia ENT2END , granulocytopenia, and thrombocytopenia)
1	In levels 5 and 6 the ENT1 carboplatin ENT1END  dose was targeted at AUCs of 6 and 7.5, respectively, combined with a fixed paclitaxel dose of 185 mg/m2. To date, 30 previously untreated patients, all with a good performance status (Eastern Cooperative Oncology Group 0 to 2) have been entered into this ongoing study. The dose-limiting toxicity of the combination was myelosuppression ENT2 leukopenia ENT2END , granulocytopenia, and thrombocytopenia)
0	Pallidal stimulation improves bradykinesia and ENT1 rigidity ENT1END to a minor extent; however, its strength seems to be in improving ENT2 levodopa ENT2END -induced dyskinesias
0	According to the literature pallidotomy improves the "on" symptoms of ENT1 PD  ENT1END  such as dyskinesias, as well as the "off" symptoms, such as rigidity, bradykinesia, and on-off fluctuations. Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving ENT2 levodopa ENT2END -induced dyskinesias
1	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving ENT1 levodopa ENT1END -induced ENT2 dyskinesias ENT2END
0	Pallidal stimulation improves bradykinesia and rigidity to a minor extent; however, its strength seems to be in improving ENT1 levodopa ENT1END -induced dyskinesias. Stimulation often produces an improvement in the ENT2 hyper- or dyskinetic ENT2END upper limbs, but increases the "freezing" phenomenon in the lower limbs at the same time
0	Pallidal stimulation improves ENT1 bradykinesia  ENT1END and rigidity to a minor extent; however, its strength seems to be in improving ENT2 levodopa ENT2END -induced dyskinesias
0	Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced ENT1 Parkinson disease ENT1END  the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous ENT2 apomorphine ENT2END infusion
0	rTMS of supplementary motor area modulates therapy-induced dyskinesias in ENT1 Parkinson disease ENT1END .The neural mechanisms and circuitry involved in ENT2 levodopa ENT2END -induced dyskinesia are unclear
0	Using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area (SMA) in a group of patients with advanced Parkinson disease, the authors investigated whether modulation of SMA excitability may result in a modification of a ENT1 dyskinetic  ENT1END state induced by continuous ENT2 apomorphine ENT2END infusion
1	The neural mechanisms and circuitry involved in ENT1 levodopa ENT1END -induced ENT2 dyskinesia ENT2END are unclear
0	Thus, while whole body ENT1 hyperthermia ENT1END enhances ENT2 Adriamycin ENT2END -mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded
0	Effect of ENT1 adriamycin  ENT1END  combined with whole body hyperthermia on ENT2 tumor ENT2END and normal tissues
0	, leukopenia and ENT1 thrombocytopenia ENT1END  and late normal tissue toxicities (i.e., myocardial and kidney injury) were evaluated by functional/physiological assays and by morphological techniques. Whole body hyperthermia (120 min at 41.5 degrees C) enhanced both ENT2 Adriamycin ENT2END -mediated antitumor activity and toxic side effects
0	Thus, while whole body hyperthermia enhances ENT1 Adriamycin ENT1END -mediated antitumor effect, normal tissue ENT2 toxicity ENT2END is also increased, and the potential therapeutic gain of the combined modality treatment is eroded
0	3, whereas those estimated for "late" damage (based on morphological ENT1 cardiac and renal lesions  ENT1END  varied between 2.4 and 4.3. Thus, while whole body hyperthermia enhances ENT2 Adriamycin ENT2END -mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded
0	Thermal enhancement of ENT1 Adriamycin ENT1END mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model. Antitumor activity was studied using a tumor growth delay assay. Acute normal tissue toxicities (i.e., ENT2 leukopenia ENT2END and thrombocytopenia) and late normal tissue toxicities (i
1	3, whereas those estimated for "late" damage (based on morphological ENT1 cardiac and renal lesions  ENT1END  varied between 2.4 and 4.3. Thus, while whole body hyperthermia enhances ENT2 Adriamycin ENT2END -mediated antitumor effect, normal tissue toxicity is also increased, and the potential therapeutic gain of the combined modality treatment is eroded
0	Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with ENT1 diethylstilbestrol ENT1END for 13 years. Angiosarcoma was also present within pulmonary and renal arteries. The possibility that the intraarterial lesions might represent independent primary ENT2 tumors ENT2END is considered
1	Angiosarcoma of the liver associated with ENT1 diethylstilbestrol  ENT1END . ENT2 Angiosarcoma of the liver ENT2END occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years
0	Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated ENT1 adenocarcinoma of the liver  ENT1END with ENT2 diethylstilbestrol ENT2END for 13 years
0	Angiosarcoma of the liver occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with ENT1 diethylstilbestrol ENT1END  for 13 years. Angiosarcoma was also present within pulmonary and renal arteries. The possibility that the ENT2 intraarterial lesions ENT2END might represent independent primary tumors is considered
1	Angiosarcoma of the liver associated with ENT1 diethylstilbestrol  ENT1END . ENT2 Angiosarcoma of the liver ENT2END occurred in a 76-year-old man who had been treated for a well-differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years
1	8%) due to ENT1 hypoxia ENT1END caused by ENT2 MZ ENT2END use
0	The mean doses of MZ and ENT1 FL ENT1END were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively. The duration of the examination and the mean ejection fraction (EF) were 16.4+/-6.1 minutes and 60+/-9%, respectively. Mild ENT2 hypoxia ENT2END (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5
0	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation ( ENT1 MR ENT1END  and the ENT2 MZ ENT2END dose
0	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy (MP), duration of the test, mitral regurgitation ( ENT1 MR  ENT1END ) and the MZ dose. RESULTS: All patients (65+/-16 yrs; 58% males) finished the examination. The mean doses of MZ and ENT2 FL ENT2END were 4
0	Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper ENT1 airway obstruction  ENT1END by probe introduction and 8 (5.8%) due to hypoxia caused by ENT2 MZ ENT2END use
0	The mean doses of MZ and ENT1 FL  ENT1END  were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively. The duration of the examination and the mean ejection fraction (EF) were 16.4+/-6.1 minutes and 60+/-9%, respectively. Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper ENT2 airway obstruction ENT2END by probe introduction and 8 (5
0	8%) due to hypoxia caused by ENT1 MZ ENT1END  use. Transient ENT2 hypotension ENT2END (SAP<90mmHg) occurred in 1 patient (0
0	The mean doses of MZ and ENT1 FL  ENT1END  were 4.3+/-1.9 mg and 0.28+/-0.2 mg, respectively. The duration of the examination and the mean ejection fraction (EF) were 16.4+/-6.1 minutes and 60+/-9%, respectively. Mild hypoxia (SO2<90%) was the most common event (11 patients); 3 patients (2%) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 (5.8%) due to hypoxia caused by MZ use. Transient ENT2 hypotension ENT2END (SAP<90mmHg) occurred in 1 patient (0
0	The multivariate analysis showed that severe MR, ENT1 MP ENT1END (EF<45%) and high doses of ENT2 MZ ENT2END (>5mg) were associated with events (p<0
0	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, stroke, myocardiopathy ( ENT1 MP  ENT1END , duration of the test, mitral regurgitation (MR) and the MZ dose. RESULTS: All patients (65+/-16 yrs; 58% males) finished the examination. The mean doses of MZ and ENT2 FL ENT2END were 4
0	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, ENT1 stroke  ENT1END  myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the ENT2 MZ ENT2END dose
0	Uni- and multivariate analyses were used to test the influence of the clinical variables: age, sex, ENT1 stroke  ENT1END , myocardiopathy (MP), duration of the test, mitral regurgitation (MR) and the MZ dose. RESULTS: All patients (65+/-16 yrs; 58% males) finished the examination. The mean doses of MZ and ENT2 FL ENT2END were 4
1	ENT1 Levodopa  ENT1END -induced ENT2 dyskinesia ENT2END and thalamotomy
0	ENT1 Levodopa ENT1END induced dyskinesia of the limbs in thirteen cases of ENT2 Parkinsonism ENT2END , which was choreic, ballistic or dystonic in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus
0	Control of ENT1 levodopa ENT1END induced dyskinesias by ENT2 thalamic lesions ENT2END in the course of routine treatment of Parkinsonism is discussed
0	ENT1 Levodopa ENT1END -induced dyskinesia of the limbs in thirteen cases of Parkinsonism, which was choreic, ballistic or ENT2 dystonic ENT2END in type, was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus, but much less by the ventralis intermedius nucleus
0	The effect of ENT1 PDTC ENT1END on ENT2 status epilepticus ENT2END -associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model
0	Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine ENT1 status epilepticus ENT1END  model.Pyrrolidine dithiocarbamate (PDTC) has a dual mechanism of action as an antioxidant and an inhibitor of the transcription factor kappa-beta. Both, production of reactive ENT2 oxygen ENT2END species as well as activation of NF-kappaB have been implicated in severe neuronal damage in different sub-regions of the hippocampus as well as in the surrounding cortices
1	Pyrrolidine dithiocarbamate protects the piriform cortex in the ENT1 pilocarpine ENT1END ENT2 status epilepticus ENT2END model
0	These data might indicate that the generation of reactive oxygen species and activation of NF-kappaB plays a more central role in ENT1 seizure ENT1END associated neuronal damage in the temporal cortex as compared to the hippocampal hilus. However, future investigations are necessary to exactly analyze the biochemical mechanisms by which ENT2 PDTC ENT2END exerted its beneficial effects in the piriform cortex
0	These data might indicate that the generation of reactive ENT1 oxygen  ENT1END species and activation of NF-kappaB plays a more central role in ENT2 seizure ENT2END -associated neuronal damage in the temporal cortex as compared to the hippocampal hilus
0	In conclusion, the NF-kappaB inhibitor and antioxidant ENT1 PDTC ENT1END protected the piriform cortex, whereas it did not affect hilar ENT2 neuronal loss ENT2END
0	In conclusion, the NF-kappaB inhibitor and antioxidant PDTC protected the piriform cortex, whereas it did not affect hilar ENT1 neuronal loss  ENT1END . These data might indicate that the generation of reactive ENT2 oxygen ENT2END species and activation of NF-kappaB plays a more central role in seizure-associated neuronal damage in the temporal cortex as compared to the hippocampal hilus
1	Both, production of reactive oxygen species as well as activation of NF-kappaB have been implicated in severe ENT1 neuronal damage ENT1END in different sub-regions of the hippocampus as well as in the surrounding cortices. The effect of PDTC on status epilepticus-associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated ENT2 pilocarpine ENT2END model
1	The time course and concentration-effect relationship of ENT1 terbutaline ENT1END induced ENT2 hypokalemia ENT2END was studied, using computer-aided pharmacokinetic-dynamic modeling
0	In spite of higher terbutaline concentrations after ENT1 oxprenolol ENT1END pretreatment, the ENT2 hypokalemia ENT2END was almost completely antagonized by the beta 2-blocking action
0	The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and ENT1 potassium  ENT1END effects. Oxprenolol caused decreases of 65% and 56% of terbutaline volume of distribution and clearance, respectively, and an increase of 130% of its AUC. In spite of higher terbutaline concentrations after oxprenolol pretreatment, the ENT2 hypokalemia ENT2END was almost completely antagonized by the beta 2-blocking action
0	Attenuation of the lithium-induced ENT1 diabetes-insipidus-like syndrome ENT1END  by amiloride in rats.The effect of amiloride on lithium-induced polydipsia and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with ENT2 LiCl ENT2END
0	Attenuation of the lithium-induced ENT1 diabetes-insipidus-like syndrome  ENT1END  by ENT2 amiloride ENT2END in rats
0	In all the experiments, the attenuation of the lithium-induced ENT1 diabetes-insipidus-like syndrome ENT1END by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma ENT2 potassium ENT2END level
1	Attenuation of the ENT1 lithium  ENT1END -induced ENT2 diabetes-insipidus-like syndrome ENT2END by amiloride in rats
0	The effect of amiloride on lithium-induced polydipsia and ENT1 polyuria  ENT1END and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with ENT2 LiCl ENT2END
0	The effect of ENT1 amiloride  ENT1END on lithium-induced polydipsia and ENT2 polyuria ENT2END and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl
0	In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma ENT1 potassium ENT1END  level. It is concluded that acute amiloride administration to lithium-treated patients suffering from polydipsia and ENT2 polyuria ENT2END might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous
0	The effect of amiloride on lithium-induced polydipsia and ENT1 polyuria ENT1END  and on the ENT2 lithium ENT2END concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl
0	The effect of amiloride on lithium-induced ENT1 polydipsia  ENT1END and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with ENT2 LiCl ENT2END
0	The effect of ENT1 amiloride  ENT1END  on lithium-induced ENT2 polydipsia ENT2END and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl
0	In all the experiments, the attenuation of the lithium-induced diabetes-insipidus-like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma ENT1 potassium ENT1END  level. It is concluded that acute amiloride administration to lithium-treated patients suffering from ENT2 polydipsia ENT2END and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous
0	The effect of amiloride on ENT1 lithium  ENT1END induced ENT2 polydipsia ENT2END and polyuria and on the lithium concentration in the plasma, brain, kidney, thyroid and red blood cells was investigated in rats, chronically treated with LiCl
0	Such an induced ENT1 muscular rigidity ENT1END by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, ENT2 prazosin ENT2END
1	It is speculated that the induction of ENT1 muscular rigidity ENT1END by ENT2 fentanyl ENT2END may involve the coerulospinal noradrenergic fibers to the spinal motoneurons
0	Under proper control of respiration, body temperature and end-tidal ENT1 CO2  ENT1END  intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles. Such an induced ENT2 muscular rigidity ENT2END by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin
0	We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon, using male Sprague-Dawley rats anesthetized with ENT1 ketamine  ENT1END  Under proper control of respiration, body temperature and end-tidal CO2, intravenous administration of fentanyl (50 or 100 micrograms/kg) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles. Such an induced ENT2 muscular rigidity ENT2END by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha-adrenoceptor blocker, prazosin
0	MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with ENT1 cyclophosphamide ENT1END associated bladder cancer were reviewed. RESULTS: All ENT2 tumors ENT2END were grade 3 or 4 transitional cell carcinoma
1	CONCLUSIONS: ENT1 Cyclophosphamide ENT1END associated ENT2 bladder tumor ENT2END is an aggressive disease
0	MATERIALS AND METHODS: The medical records of 6 men and 6 women (mean age 55 years) with ENT1 cyclophosphamide ENT1END  associated bladder cancer were reviewed. RESULTS: All tumors were grade 3 or 4 transitional cell ENT2 carcinoma ENT2END
0	PURPOSE: We gained knowledge of the etiology, treatment and prevention of ENT1 cyclophosphamide ENT1END associated ENT2 urothelial cancer ENT2END
0	Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn ENT1 calculus ENT1END in another, permitting continued treatment. Renal function remained normal in all patients. Nephrolithiasis is a complication of ENT2 acetazolamide ENT2END but does not preclude its use
0	We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic paralysis and ENT1 myotonia ENT1END  Three patients on ENT2 acetazolamide ENT2END (15%) developed renal calculi
0	ENT1 Acetazolamide  ENT1END -induced ENT2 nephrolithiasis ENT2END : implications for treatment of neuromuscular disorders
1	Three patients on ENT1 acetazolamide ENT1END  (15%) developed ENT2 renal calculi ENT2END
0	ENT1 Acetazolamide  ENT1END -induced nephrolithiasis: implications for treatment of ENT2 neuromuscular disorders ENT2END
0	We studied 20 patients receiving long-term carbonic anhydrase inhibitor treatment for periodic ENT1 paralysis  ENT1END and myotonia. Three patients on ENT2 acetazolamide ENT2END (15%) developed renal calculi
1	Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the adrenaline-induced reflex ENT1 bradycardia ENT1END  However, the ENT2 diazepam ENT2END enhancement of adrenaline-induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex)
0	The data indicate that diazepam acts through the ENT1 benzodiazepine ENT1END GABA-chloride channel macromolecular complex within the central nervous system to facilitate reflex ENT2 bradycardia ENT2END mediated through baroreceptor reflexes in response to an acute increase in arterial pressure
0	The data indicate that diazepam acts through the benzodiazepine-GABA- ENT1 chloride  ENT1END channel macromolecular complex within the central nervous system to facilitate reflex ENT2 bradycardia ENT2END mediated through baroreceptor reflexes in response to an acute increase in arterial pressure
1	Intravenous pretreatment of the rats with diazepam, although causing no change in the adrenaline-induced pressor effect, did enhance the ENT1 adrenaline  ENT1END induced reflex ENT2 bradycardia ENT2END
0	The data indicate that diazepam acts through the benzodiazepine- ENT1 GABA  ENT1END chloride channel macromolecular complex within the central nervous system to facilitate reflex ENT2 bradycardia ENT2END mediated through baroreceptor reflexes in response to an acute increase in arterial pressure
0	However, the diazepam enhancement of adrenaline-induced reflex ENT1 bradycardia ENT1END was antagonized by pretreatment of rats with an intravenous dose of ENT2 picrotoxin ENT2END (an agent blocks chloride channels by binding to sites associated with the benzodiazepine-GABA-chloride channel macromolecular complex)
1	Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after ENT1 vincristine ENT1END treatment. Twenty-seven patients reported ENT2 neuropathic symptoms ENT2END
0	It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of ENT1 vincristine ENT1END ENT2 neuropathy ENT2END are reversible for a great deal and prognosis is fairly good
0	Forty patients with ENT1 Non-Hodgkin's Lymphoma ENT1END treated with ENT2 vincristine ENT2END between 1984 and 1990 (cumulative dose 12 mg in 18-24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system
0	This report summarizes our experience in switching ENT1 bipolar ENT1END patients from lithium to ENT2 divalproex sodium ENT2END to alleviate such cognitive and functional impairments
0	CONCLUSION: In this preliminary report, divalproex sodium was a superior alternative to ENT1 lithium ENT1END in ENT2 bipolar ENT2END patients experiencing cognitive deficits, loss of creativity, and functional impairments
0	Although much has been written about the management of the more common adverse effects of lithium, such as ENT1 polyuria  ENT1END and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied. This report summarizes our experience in switching bipolar patients from lithium to ENT2 divalproex sodium ENT2END to alleviate such cognitive and functional impairments
0	Although much has been written about the management of the more common adverse effects of ENT1 lithium  ENT1END  such as ENT2 polyuria ENT2END and tremor, more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied
0	This report summarizes our experience in switching bipolar patients from lithium to ENT1 divalproex sodium ENT1END  to alleviate such ENT2 cognitive and functional impairments ENT2END
1	ENT1 Lithium  ENT1END -associated ENT2 cognitive and functional deficits ENT2END reduced by a switch to divalproex sodium: a case series
0	Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and ENT1 tremor  ENT1END  more subtle lithium side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied. This report summarizes our experience in switching bipolar patients from lithium to ENT2 divalproex sodium ENT2END to alleviate such cognitive and functional impairments
0	Although much has been written about the management of the more common adverse effects of lithium, such as polyuria and ENT1 tremor ENT1END , more subtle ENT2 lithium ENT2END side effects such as cognitive deficits, loss of creativity, and functional impairments remain understudied
1	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for ENT1 nicotine  ENT1END -induced ENT2 seizures ENT2END and hypolocomotion in mice
0	The alpha3 and beta4 nicotinic ENT1 acetylcholine  ENT1END  receptor subunits are necessary for nicotine-induced ENT2 seizures ENT2END and hypolocomotion in mice
0	Binding of ENT1 nicotine ENT1END to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and ENT2 death ENT2END
0	Binding of nicotine to nicotinic ENT1 acetylcholine  ENT1END receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and ENT2 death ENT2END
0	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and ENT1 hypolocomotion  ENT1END  in mice.Binding of ENT2 nicotine ENT2END to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death
0	The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine-induced seizures and ENT1 hypolocomotion  ENT1END  in mice.Binding of nicotine to nicotinic ENT2 acetylcholine ENT2END receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and tremors, to seizures and death
0	Binding of ENT1 nicotine ENT1END  to nicotinic acetylcholine receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and ENT2 tremors ENT2END , to seizures and death
0	Binding of nicotine to nicotinic ENT1 acetylcholine  ENT1END  receptors (nAChRs) elicits a series of dose-dependent behaviors that go from altered exploration, sedation, and ENT2 tremors ENT2END , to seizures and death
0	CY caused ENT1 hemorrhagic cystitis ENT1END in 40% of rats, but it did not cause this complication when combined with 5-FU and ENT2 MTX ENT2END
0	CY caused ENT1 hemorrhagic cystitis ENT1END  in 40% of rats, but it did not cause this complication when combined with ENT2 5-FU ENT2END and MTX
0	CY caused ENT1 hemorrhagic cystitis ENT1END  in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX. Histologic changes were found in rat kidneys after administration of MTX, CY and ENT2 NG ENT2END , while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls
0	0343) in creatinine clearance was found, but ENT1 creatinine  ENT1END concentration did not increase significantly compared to controls. CY caused ENT2 hemorrhagic cystitis ENT2END in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX
1	ENT1 CY  ENT1END caused ENT2 hemorrhagic cystitis ENT2END in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX
0	Our studies indicate that ENT1 nephrotoxicity ENT1END of ENT2 MTX ENT2END + 5-FU + CY administered jointly is lower than in monotherapy
0	Our studies indicate that ENT1 nephrotoxicity ENT1END  of MTX + ENT2 5-FU ENT2END + CY administered jointly is lower than in monotherapy
0	The ENT1 nephrotoxic ENT1END action of anticancer drugs such as ENT2 nitrogranulogen ENT2END (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats
0	The ENT1 nephrotoxic ENT1END  action of anticancer drugs such as nitrogranulogen (NG), methotrexate (MTX), 5-fluorouracil (5-FU) and cyclophosphamide (CY) administered alone or in combination [MTX + 5-FU + CY (CMF)] was evaluated in experiments on Wistar rats. After drug administration, ENT2 creatinine ENT2END concentrations in the plasma and in the urine of the rats were determined, as well as creatinine clearance
0	Our studies indicate that ENT1 nephrotoxicity ENT1END  of MTX + 5-FU + ENT2 CY ENT2END administered jointly is lower than in monotherapy
0	CY caused ENT1 hemorrhagic cystitis  ENT1END in 40% of rats, but it did not cause this complication when combined with 5-FU and ENT2 MTX ENT2END
0	CY caused ENT1 hemorrhagic cystitis  ENT1END  in 40% of rats, but it did not cause this complication when combined with ENT2 5-FU ENT2END and MTX
0	CY caused ENT1 hemorrhagic cystitis  ENT1END  in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX. Histologic changes were found in rat kidneys after administration of MTX, CY and ENT2 NG ENT2END , while no such change was observed after 5-FU and joint administration of MTX + 5-FU + CY compared to controls
0	0343) in creatinine clearance was found, but ENT1 creatinine  ENT1END  concentration did not increase significantly compared to controls. CY caused ENT2 hemorrhagic cystitis ENT2END in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX
1	ENT1 CY  ENT1END  caused ENT2 hemorrhagic cystitis ENT2END in 40% of rats, but it did not cause this complication when combined with 5-FU and MTX
0	Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by ENT1 clonidine ENT1END .BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including ENT2 arrhythmia ENT2END , coronary heart disease, and chronic heart failure
0	Direct inhibition of cardiac hyperpolarization-activated ENT1 cyclic nucleotide  ENT1END -gated pacemaker channels by clonidine.BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including ENT2 arrhythmia ENT2END , coronary heart disease, and chronic heart failure
0	Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by ENT1 clonidine ENT1END .BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of ENT2 cardiovascular disease ENT2END , including arrhythmia, coronary heart disease, and chronic heart failure
0	Direct inhibition of cardiac hyperpolarization-activated ENT1 cyclic nucleotide  ENT1END -gated pacemaker channels by clonidine.BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of ENT2 cardiovascular disease ENT2END , including arrhythmia, coronary heart disease, and chronic heart failure
0	BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic ENT1 heart failure ENT1END  Activation of presynaptic alpha2-adrenoceptors is the most widely accepted mechanism of action of the antisympathetic drug ENT2 clonidine ENT2END ; however, other target proteins have been postulated to contribute to the in vivo actions of clonidine
0	Direct inhibition of cardiac hyperpolarization-activated ENT1 cyclic nucleotide  ENT1END -gated pacemaker channels by clonidine.BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, coronary heart disease, and chronic ENT2 heart failure ENT2END
0	Direct inhibition of cardiac hyperpolarization-activated cyclic nucleotide-gated pacemaker channels by ENT1 clonidine ENT1END .BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, ENT2 coronary heart disease ENT2END , and chronic heart failure
0	Direct inhibition of cardiac hyperpolarization-activated ENT1 cyclic nucleotide  ENT1END -gated pacemaker channels by clonidine.BACKGROUND: Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease, including arrhythmia, ENT2 coronary heart disease ENT2END , and chronic heart failure
1	ENT1 Clonidine ENT1END induced ENT2 bradycardia ENT2END in conscious alpha2ABC-/- mice was 32
0	Clonidine-induced ENT1 bradycardia ENT1END  in conscious alpha2ABC-/- mice was 32.3% (10 microg/kg) and 26.6% (100 microg/kg) of the effect in wild-type mice. A similar bradycardic effect of clonidine was observed in isolated spontaneously beating right atria from alpha2ABC-knockout and wild-type mice. Clonidine inhibited the native pacemaker current (I(f)) in isolated sinoatrial node pacemaker cells and the I(f)-generating hyperpolarization-activated ENT2 cyclic nucleotide ENT2END -gated (HCN) 2 and HCN4 channels in transfected HEK293 cells
0	ENT1 Antituberculosis ENT1END therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia. Prospective studies on ATT-ALF are lacking. The current study prospectively evaluated the magnitude, clinical course, outcome, and prognostic factors in ATT-ALF. From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients. Another 15 (1.2%) had ATT and simultaneous hepatitis virus infection. In 44 (62.8%) patients, ATT was prescribed empirically without definitive evidence of ENT2 tuberculosis ENT2END
0	ENT1 Gastrointestinal bleed ENT1END  seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively. Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes. The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment. In multivariate analysis, three factors independently predicted mortality: serum ENT2 bilirubin ENT2END (>or=10
0	Gastrointestinal bleed, seizures, ENT1 infection  ENT1END  and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively. Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes. The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment. In multivariate analysis, three factors independently predicted mortality: serum ENT2 bilirubin ENT2END (>or=10
0	Gastrointestinal bleed, ENT1 seizures  ENT1END  infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively. Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes. The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment. In multivariate analysis, three factors independently predicted mortality: serum ENT2 bilirubin ENT2END (>or=10
0	Compared with ENT1 hepatitis E  ENT1END virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes. The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment. In multivariate analysis, three factors independently predicted mortality: serum ENT2 bilirubin ENT2END (>or=10
0	At presentation, advanced encephalopathy and ENT1 cerebral edema  ENT1END were present in 51 (76%) and 29 (41.4%) patients, respectively. Gastrointestinal bleed, seizures, infection, and acute renal failure were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively. Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes. The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment. In multivariate analysis, three factors independently predicted mortality: serum ENT2 bilirubin ENT2END (>or=10
0	In multivariate analysis, three factors independently predicted mortality: serum ENT1 bilirubin ENT1END  (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV ENT2 encephalopathy ENT2END at presentation
0	Gastrointestinal bleed, seizures, infection, and ENT1 acute renal failure  ENT1END were documented in seven (10%), five (7.1%), 26 (37.1%), and seven (10%) patients, respectively. Compared with hepatitis E virus (HEV) and non-A non-E-induced ALF, ATT-ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes. The mortality rate among patients with ATT-ALF was high (67.1%, n = 47), and only 23 (32.9%) patients recovered with medical treatment. In multivariate analysis, three factors independently predicted mortality: serum ENT2 bilirubin ENT2END (>or=10
0	ENT1 Antituberculosis ENT1END  therapy (ATT)-associated acute liver failure (ATT-ALF) is the commonest drug-induced ALF in South Asia. Prospective studies on ATT-ALF are lacking. The current study prospectively evaluated the magnitude, clinical course, outcome, and prognostic factors in ATT-ALF. From January 1986 to January 2009, 1223 consecutive ALF patients were evaluated: ATT alone was the cause in 70 (5.7%) patients. Another 15 (1.2%) had ATT and simultaneous ENT2 hepatitis virus infection ENT2END
1	ENT1 Antituberculosis  ENT1END  therapy-induced ENT2 acute liver failure ENT2END : magnitude, profile, prognosis, and predictors of outcome
0	In multivariate analysis, three factors independently predicted mortality: serum ENT1 bilirubin  ENT1END  (>or=10.8 mg/dL), prothrombin time (PT) prolongation (>or=26 seconds), and grade III/IV encephalopathy at presentation. CONCLUSION: ATT- ENT2 ALF ENT2END constituted 5
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine ( ENT1 purine ENT1END analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and ENT1 methotrexate  ENT1END (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	Cyclophosphamide therapy increases the risk of ENT1 carcinoma of the bladder ENT1END . There have been several long-term studies of patients with rheumatoid arthritis treated with ENT2 azathioprine ENT2END and cyclophosphamide and the incidence of most of the common cancers is not increased
0	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both ENT1 alkylating agents  ENT1END and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
1	ENT1 Cyclophosphamide  ENT1END therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate ( ENT1 folic acid  ENT1END analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	The drugs commonly used are cyclophosphamide and ENT1 chlorambucil  ENT1END (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine ( ENT1 purine ENT1END  analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce ENT2 synovitis ENT2END , but disease activity almost always recurs after therapy is stopped
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and ENT1 methotrexate  ENT1END  (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce ENT2 synovitis ENT2END , but disease activity almost always recurs after therapy is stopped
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), ENT1 azathioprine  ENT1END (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce ENT2 synovitis ENT2END , but disease activity almost always recurs after therapy is stopped
0	The drugs commonly used are cyclophosphamide and chlorambucil ( ENT1 alkylating agents  ENT1END , azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce ENT2 synovitis ENT2END , but disease activity almost always recurs after therapy is stopped
0	The drugs commonly used are ENT1 cyclophosphamide  ENT1END and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce ENT2 synovitis ENT2END , but disease activity almost always recurs after therapy is stopped
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate ( ENT1 folic acid  ENT1END  analogue). There is evidence that all four immunosuppressive drugs can reduce ENT2 synovitis ENT2END , but disease activity almost always recurs after therapy is stopped
0	The drugs commonly used are cyclophosphamide and ENT1 chlorambucil  ENT1END  (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce ENT2 synovitis ENT2END , but disease activity almost always recurs after therapy is stopped
0	Incidence of ENT1 neoplasms ENT1END  in patients with rheumatoid arthritis exposed to different treatment regimens.Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis. The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine ENT2 purine ENT2END analogue), and methotrexate (folic acid analogue)
0	Incidence of ENT1 neoplasms  ENT1END  in patients with rheumatoid arthritis exposed to different treatment regimens.Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis. The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and ENT2 methotrexate ENT2END (folic acid analogue)
0	There have been several long-term studies of patients with rheumatoid arthritis treated with ENT1 azathioprine ENT1END  and cyclophosphamide and the incidence of most of the common ENT2 cancers ENT2END is not increased
0	Data on the possible increased risk of ENT1 malignancy ENT1END in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly ENT2 alkylating agents ENT2END , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life-threatening complications
0	There have been several long-term studies of patients with rheumatoid arthritis treated with azathioprine and ENT1 cyclophosphamide  ENT1END and the incidence of most of the common ENT2 cancers ENT2END is not increased
0	Incidence of ENT1 neoplasms ENT1END  in patients with rheumatoid arthritis exposed to different treatment regimens.Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis. The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate ENT2 folic acid ENT2END analogue)
0	Incidence of ENT1 neoplasms  ENT1END  in patients with rheumatoid arthritis exposed to different treatment regimens.Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis. The drugs commonly used are cyclophosphamide and ENT2 chlorambucil ENT2END (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue)
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine ( ENT1 purine ENT1END  analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of ENT2 non-Hodgkin's lymphoma ENT2END
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and ENT1 methotrexate  ENT1END  (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of ENT2 non-Hodgkin's lymphoma ENT2END
1	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and ENT1 azathioprine  ENT1END are associated with the development of ENT2 non-Hodgkin's lymphoma ENT2END
1	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both ENT1 alkylating agents  ENT1END  and azathioprine are associated with the development of ENT2 non-Hodgkin's lymphoma ENT2END
0	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of ENT1 non-Hodgkin's lymphoma  ENT1END . ENT2 Cyclophosphamide ENT2END therapy increases the risk of carcinoma of the bladder
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate ( ENT1 folic acid  ENT1END  analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of ENT2 non-Hodgkin's lymphoma ENT2END
0	The drugs commonly used are cyclophosphamide and ENT1 chlorambucil  ENT1END  (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of ENT2 non-Hodgkin's lymphoma ENT2END
0	Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe ENT1 rheumatoid arthritis ENT1END  The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine ENT2 purine ENT2END analogue), and methotrexate (folic acid analogue)
0	Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe ENT1 rheumatoid arthritis  ENT1END . The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and ENT2 methotrexate ENT2END (folic acid analogue)
0	There have been several long-term studies of patients with ENT1 rheumatoid arthritis  ENT1END treated with ENT2 azathioprine ENT2END and cyclophosphamide and the incidence of most of the common cancers is not increased
0	Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected, and until further information is available, the use of immunosuppressive drugs, particularly ENT1 alkylating agents ENT1END , in the treatment of ENT2 rheumatoid arthritis ENT2END should be reserved for patients with severe progressive disease or life-threatening complications
0	Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe ENT1 rheumatoid arthritis  ENT1END . The drugs commonly used are ENT2 cyclophosphamide ENT2END and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue)
0	Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe ENT1 rheumatoid arthritis ENT1END . The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate ENT2 folic acid ENT2END analogue)
0	Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe ENT1 rheumatoid arthritis  ENT1END . The drugs commonly used are cyclophosphamide and ENT2 chlorambucil ENT2END (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue)
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine ( ENT1 purine ENT1END  analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of ENT2 acute nonlymphocytic leukemia ENT2END , and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and ENT1 methotrexate  ENT1END  (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of ENT2 acute nonlymphocytic leukemia ENT2END , and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma
0	Patients treated with alkylating agents have an increased risk of development of ENT1 acute nonlymphocytic leukemia  ENT1END , and both alkylating agents and ENT2 azathioprine ENT2END are associated with the development of non-Hodgkin's lymphoma
1	Patients treated with alkylating agents have an increased risk of development of ENT1 acute nonlymphocytic leukemia  ENT1END , and both ENT2 alkylating agents ENT2END and azathioprine are associated with the development of non-Hodgkin's lymphoma
0	Patients treated with alkylating agents have an increased risk of development of ENT1 acute nonlymphocytic leukemia  ENT1END , and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. ENT2 Cyclophosphamide ENT2END therapy increases the risk of carcinoma of the bladder
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate ( ENT1 folic acid  ENT1END  analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of ENT2 acute nonlymphocytic leukemia ENT2END , and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma
0	The drugs commonly used are cyclophosphamide and ENT1 chlorambucil  ENT1END  (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of ENT2 acute nonlymphocytic leukemia ENT2END , and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine ( ENT1 purine ENT1END  analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and ENT1 methotrexate  ENT1END  (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	Cyclophosphamide therapy increases the risk of ENT1 carcinoma of the bladder  ENT1END . There have been several long-term studies of patients with rheumatoid arthritis treated with ENT2 azathioprine ENT2END and cyclophosphamide and the incidence of most of the common cancers is not increased
0	Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both ENT1 alkylating agents  ENT1END  and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
1	ENT1 Cyclophosphamide  ENT1END  therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	The drugs commonly used are cyclophosphamide and chlorambucil (alkylating agents), azathioprine (purine analogue), and methotrexate ( ENT1 folic acid  ENT1END  analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
0	The drugs commonly used are cyclophosphamide and ENT1 chlorambucil  ENT1END  (alkylating agents), azathioprine (purine analogue), and methotrexate (folic acid analogue). There is evidence that all four immunosuppressive drugs can reduce synovitis, but disease activity almost always recurs after therapy is stopped. Since adverse reactions are frequent, less than 50 percent of patients are able to continue a particular drug for more than one year. Since it takes three to 12 months to achieve maximal effects, those patients who are unable to continue the drug receive little benefit from it. Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia, and both alkylating agents and azathioprine are associated with the development of non-Hodgkin's lymphoma. Cyclophosphamide therapy increases the risk of ENT2 carcinoma of the bladder ENT2END
1	ENT1 Haemolytic-uraemic syndrome  ENT1END  after treatment with ENT2 metronidazole ENT2END
0	Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral ENT1 dopamine ENT1END agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and ENT2 psychiatric ENT2END complications play a lesser role
0	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting ENT1 levodopa  ENT1END induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and ENT2 psychiatric ENT2END complications play a lesser role
0	The main side effects of subcutaneous ENT1 apomorphine  ENT1END treatment are related to cutaneous tolerability problems, whereas sedation and ENT2 psychiatric ENT2END complications play a lesser role
0	Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral ENT1 dopamine ENT1END  agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating ENT2 Parkinson's disease ENT2END , this approach seems to deserve more widespread clinical use
0	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting ENT1 levodopa  ENT1END -induced dyskinesias. The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role. Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating ENT2 Parkinson's disease ENT2END , this approach seems to deserve more widespread clinical use
0	Apomorphine: an underutilized therapy for ENT1 Parkinson's disease  ENT1END . ENT2 Apomorphine ENT2END was the first dopaminergic drug ever used to treat symptoms of Parkinson's disease
0	Continuous subcutaneous apomorphine infusions can reduce daily off-time by more than 50% in this group of patients, which appears to be a stronger effect than that generally seen with add-on therapy with oral ENT1 dopamine ENT1END  agonists or COMT inhibitors. Extended follow-up studies of up to 8 years have demonstrated long-term persistence of apomorphine efficacy. In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced ENT2 dyskinesias ENT2END
1	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting ENT1 levodopa  ENT1END -induced ENT2 dyskinesias ENT2END
0	In addition, there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa-induced ENT1 dyskinesias  ENT1END . The main side effects of subcutaneous ENT2 apomorphine ENT2END treatment are related to cutaneous tolerability problems, whereas sedation and psychiatric complications play a lesser role
0	High doses of ENT1 isoniazid ENT1END increase hypotension induced by vasodilators and change the accompanying reflex ENT2 tachycardia ENT2END to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA)
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, ENT2 labetalol ENT2END and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with ENT2 chloralose ENT2END -urethane
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol. Enhancement was not observed in rats pretreated with ENT2 methylatropine ENT2END or previously vagotomised
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or ENT2 carbachol ENT2END
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia  ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose- ENT2 urethane ENT2END
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after ENT2 hexamethonium ENT2END or carbachol
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after ENT2 clonidine ENT2END , but not after hexamethonium or carbachol
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, ENT2 pindolol ENT2END , labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain ENT2 gamma-aminobutyric acid ENT2END (GABA)
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and ENT2 atenolol ENT2END , as well as after clonidine, but not after hexamethonium or carbachol
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex ENT1 tachycardia ENT1END  to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after ENT2 propranolol ENT2END , pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
1	High doses of ENT1 isoniazid ENT1END  increase ENT2 hypotension ENT2END induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA)
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, ENT2 labetalol ENT2END and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with ENT2 chloralose ENT2END -urethane
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol. Enhancement was not observed in rats pretreated with ENT2 methylatropine ENT2END or previously vagotomised
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or ENT2 carbachol ENT2END
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose ENT2 urethane ENT2END
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after ENT2 hexamethonium ENT2END or carbachol
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and atenolol, as well as after ENT2 clonidine ENT2END , but not after hexamethonium or carbachol
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, ENT2 pindolol ENT2END , labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain ENT2 gamma-aminobutyric acid ENT2END (GABA)
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after propranolol, pindolol, labetalol and ENT2 atenolol ENT2END , as well as after clonidine, but not after hexamethonium or carbachol
0	High doses of isoniazid increase ENT1 hypotension  ENT1END  induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid (GABA). In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane. Isoniazid significantly increased bradycardia after ENT2 propranolol ENT2END , pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
1	In the present study, the possible enhancement by ENT1 isoniazid ENT1END of ENT2 bradycardia ENT2END induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END after propranolol, pindolol, ENT2 labetalol ENT2END and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with ENT1 chloralose  ENT1END -urethane. Isoniazid significantly increased ENT2 bradycardia ENT2END after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END  after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol. Enhancement was not observed in rats pretreated with ENT2 methylatropine ENT2END or previously vagotomised
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END  after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or ENT2 carbachol ENT2END
0	In the present study, the possible enhancement by isoniazid of bradycardia induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose- ENT1 urethane  ENT1END . Isoniazid significantly increased ENT2 bradycardia ENT2END after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END  after propranolol, pindolol, labetalol and atenolol, as well as after clonidine, but not after ENT2 hexamethonium ENT2END or carbachol
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END  after propranolol, pindolol, labetalol and atenolol, as well as after ENT2 clonidine ENT2END , but not after hexamethonium or carbachol
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END  after propranolol, ENT2 pindolol ENT2END , labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia, an interaction attributed to decreased synthesis of brain gamma-aminobutyric acid ( ENT1 GABA  ENT1END . In the present study, the possible enhancement by isoniazid of ENT2 bradycardia ENT2END induced by beta-adrenoceptor antagonists was determined in rats anaesthetised with chloralose-urethane
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END  after propranolol, pindolol, labetalol and ENT2 atenolol ENT2END , as well as after clonidine, but not after hexamethonium or carbachol
0	Isoniazid significantly increased ENT1 bradycardia  ENT1END  after ENT2 propranolol ENT2END , pindolol, labetalol and atenolol, as well as after clonidine, but not after hexamethonium or carbachol
0	When hippocampal ACh was measured during testing for handling-induced ENT1 convulsions ENT1END  extracellular ENT2 ACh ENT2END was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice
1	RESULTS: Sensitivity to several ENT1 convulsion ENT1END endpoints induced by nicotine, ENT2 carbachol ENT2END , and neostigmine were significantly greater in WSR versus WSP mice
0	METHODS: Cholinergic convulsant sensitivity was examined in ENT1 alcohol ENT1END na  ve Withdrawal ENT2 Seizure ENT2END -Prone (WSP) and-Resistant (WSR) mice
0	ENT1 Potassium ENT1END was applied by reverse dialysis twice, separated by 75 min. Hippocampal ACh also was measured during testing for handling-induced ENT2 convulsions ENT2END
1	RESULTS: Sensitivity to several ENT1 convulsion ENT1END  endpoints induced by ENT2 nicotine ENT2END , carbachol, and neostigmine were significantly greater in WSR versus WSP mice
0	However, the increase in release of ACh produced by the first application of ENT1 KCl  ENT1END was 2-fold higher in WSP versus WSR mice. When hippocampal ACh was measured during testing for handling-induced ENT2 convulsions ENT2END , extracellular ACh was significantly elevated (192%) in WSP mice, but was nonsignificantly elevated (59%) in WSR mice
1	RESULTS: Sensitivity to several ENT1 convulsion ENT1END  endpoints induced by nicotine, carbachol, and ENT2 neostigmine ENT2END were significantly greater in WSR versus WSP mice
0	Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of ENT1 tremor ENT1END and clonus were recorded and converted to threshold dose. We also used microdialysis to measure basal and potassium-stimulated ENT2 acetylcholine ENT2END (ACh) release in the CA1 region of the hippocampus
0	Animals were administered nicotine, ENT1 carbachol  ENT1END  or neostigmine via timed tail vein infusion, and the latencies to onset of ENT2 tremor ENT2END and clonus were recorded and converted to threshold dose
0	METHODS: Cholinergic convulsant sensitivity was examined in ENT1 alcohol  ENT1END -na  ve Withdrawal Seizure-Prone (WSP) and-Resistant (WSR) mice. Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of ENT2 tremor ENT2END and clonus were recorded and converted to threshold dose
0	Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of ENT1 tremor ENT1END  and clonus were recorded and converted to threshold dose. We also used microdialysis to measure basal and ENT2 potassium ENT2END -stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus
0	Animals were administered ENT1 nicotine  ENT1END  carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of ENT2 tremor ENT2END and clonus were recorded and converted to threshold dose
0	Animals were administered nicotine, carbachol, or neostigmine via timed tail vein infusion, and the latencies to onset of ENT1 tremor ENT1END  and clonus were recorded and converted to threshold dose. We also used microdialysis to measure basal and potassium-stimulated acetylcholine (ACh) release in the CA1 region of the hippocampus. Potassium was applied by reverse dialysis twice, separated by 75 min. Hippocampal ACh also was measured during testing for handling-induced convulsions. RESULTS: Sensitivity to several convulsion endpoints induced by nicotine, carbachol, and neostigmine were significantly greater in WSR versus WSP mice. In microdialysis experiments, the lines did not differ in basal release of ACh, and 50 mM ENT2 KCl ENT2END increased ACh output in both lines of mice
0	Animals were administered nicotine, carbachol, or ENT1 neostigmine  ENT1END via timed tail vein infusion, and the latencies to onset of ENT2 tremor ENT2END and clonus were recorded and converted to threshold dose
0	Hepatitis B immune globulin (HBIG) and immune serum globulin (ISG) were examined in a randomized, double-blind trial to assess their relative efficacies in preventing type B hepatitis after needle-stick exposure to hepatitis B surface antigen ( ENT1 HBsAG ENT1END -positive donors. Clinical ENT2 hepatitis ENT2END developed in 1
0	Clinical ENT1 hepatitis  ENT1END  developed in 1.4% of HBIG and in 5.9% of ISG recipients (P = 0.016), and seroconversion (anti-HBs) occurred in 5.6% and 20.7% of them respectively (P less than 0.001). Mild and transient side-effects were noted in 3.0% of ISG and in 3.2% of HBIG recipients. Available donor sera were examined for DNA polymerase (DNAP) and e antigen and antibody ( ENT2 HBeAg ENT2END ; anti-HBE)
0	Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of ENT1 HBsAg ENT1END positive donors. ENT2 Hepatitis B ENT2END immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups
1	Both DNAP and ENT1 HBeAg  ENT1END showed a highly statistically significant correlation with the infectivity of HBsAg-positive donors. ENT2 Hepatitis B ENT2END immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high-risk subgroups
1	Pretreatment with naloxazone significantly blocked ENT1 morphine ENT1END analgesia, catalepsy and ENT2 hypothermia ENT2END at a dose which completely eliminated high-affinity binding in brain membranes
0	Pretreatment with ENT1 naloxazone  ENT1END significantly blocked morphine analgesia, catalepsy and ENT2 hypothermia ENT2END at a dose which completely eliminated high-affinity binding in brain membranes
0	Pretreatment with naloxazone significantly blocked ENT1 morphine ENT1END  ENT2 analgesia ENT2END , catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes
0	Pretreatment with ENT1 naloxazone  ENT1END  significantly blocked morphine ENT2 analgesia ENT2END , catalepsy and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes
1	Moreover, naloxazone significantly attenuated the ENT1 morphine ENT1END induced ENT2 hypotension ENT2END and respiratory depression, whereas morphine-induced bradycardia was less affected
0	Moreover, ENT1 naloxazone  ENT1END significantly attenuated the morphine-induced ENT2 hypotension ENT2END and respiratory depression, whereas morphine-induced bradycardia was less affected
1	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and respiratory depression, whereas ENT1 morphine ENT1END induced ENT2 bradycardia ENT2END was less affected
0	Moreover, ENT1 naloxazone  ENT1END  significantly attenuated the morphine-induced hypotension and respiratory depression, whereas morphine-induced ENT2 bradycardia ENT2END was less affected
0	Moreover, naloxazone significantly attenuated the morphine-induced hypotension and ENT1 respiratory depression  ENT1END  whereas ENT2 morphine ENT2END -induced bradycardia was less affected
0	Moreover, ENT1 naloxazone  ENT1END  significantly attenuated the morphine-induced hypotension and ENT2 respiratory depression ENT2END , whereas morphine-induced bradycardia was less affected
1	Pretreatment with naloxazone significantly blocked ENT1 morphine ENT1END  analgesia, ENT2 catalepsy ENT2END and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes
0	Pretreatment with ENT1 naloxazone  ENT1END  significantly blocked morphine analgesia, ENT2 catalepsy ENT2END and hypothermia at a dose which completely eliminated high-affinity binding in brain membranes
0	Ototoxicity appeared closely related to a prolonged administration and higher total dose of ENT1 ototoxic ENT1END drugs, particularly aminoglycosides and ENT2 furosemide ENT2END
0	Ototoxicity appeared closely related to a prolonged administration and higher total dose of ENT1 ototoxic ENT1END  drugs, particularly ENT2 aminoglycosides ENT2END and furosemide
1	46%) developed severe progressive and bilateral ENT1 sensorineural hearing loss  ENT1END  Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications. Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications. Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and ENT2 furosemide ENT2END
1	46%) developed severe progressive and bilateral ENT1 sensorineural hearing loss  ENT1END . Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications. Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications. Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly ENT2 aminoglycosides ENT2END and furosemide
0	Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly aminoglycosides and ENT1 furosemide ENT1END . Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as ENT2 hearing loss ENT2END is of delayed onset and in most cases bilateral and severe
0	Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs, particularly ENT1 aminoglycosides  ENT1END  and furosemide. Finally, we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as ENT2 hearing loss ENT2END is of delayed onset and in most cases bilateral and severe
0	ENT1 Gentamicin sulfate ENT1END and tobramycin sulfate continue to demonstrate ENT2 ototoxicity ENT2END and nephrotoxicity in both animal and clinical studies
0	2 million people in this country receive ENT1 aminoglycoside  ENT1END antibiotics annually. Gentamicin sulfate and tobramycin sulfate continue to demonstrate ENT2 ototoxicity ENT2END and nephrotoxicity in both animal and clinical studies
0	Gentamicin sulfate and ENT1 tobramycin sulfate  ENT1END continue to demonstrate ENT2 ototoxicity ENT2END and nephrotoxicity in both animal and clinical studies
0	Clinical ENT1 nephrotoxicity  ENT1END  of tobramycin and ENT2 gentamicin ENT2END
0	Clinical ENT1 nephrotoxicity  ENT1END  of tobramycin and gentamicin. A prospective study.Nearly 3.2 million people in this country receive ENT2 aminoglycoside ENT2END antibiotics annually
0	Clinical ENT1 nephrotoxicity  ENT1END  of ENT2 tobramycin ENT2END and gentamicin
1	2%) of the gentamicin-treated patients had ENT1 renal failure ENT1END  Thus, ENT2 gentamicin ENT2END was associated with renal failure more than three times as often as was tobramycin
0	In this study, 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg/kg/day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of ENT1 aminoglycoside ENT1END related ENT2 renal failure ENT2END , defined as at least a one-third reduction in renal function
1	Thus, gentamicin was associated with ENT1 renal failure ENT1END more than three times as often as was ENT2 tobramycin ENT2END
1	Neonatal pyridoxine responsive ENT1 convulsions  ENT1END  due to ENT2 isoniazid ENT2END therapy
0	Neonatal ENT1 pyridoxine  ENT1END  responsive ENT2 convulsions ENT2END due to isoniazid therapy
0	A 17-day-old infant on ENT1 isoniazid ENT1END therapy 13 mg/kg daily from birth because of maternal ENT2 tuberculosis ENT2END was admitted after 4 days of clonic fits
0	Neonatal ENT1 pyridoxine  ENT1END  responsive convulsions due to isoniazid therapy.A 17-day-old infant on isoniazid therapy 13 mg/kg daily from birth because of maternal ENT2 tuberculosis ENT2END was admitted after 4 days of clonic fits
0	Consequently, ENT1 carmofur ENT1END induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state. It may be attributed to the ENT2 structural damage to the frontal lobe ENT2END
1	Organic mental disorder was observed in a 29-year-old female in the prognostic period after the onset of ENT1 carmofur ENT1END induced ENT2 leukoencephalopathy ENT2END
0	Consequently, ENT1 carmofur ENT1END -induced leukoencephalopathy may uncommonly result in ENT2 organic personality syndrome ENT2END in the residual state
1	ENT1 Carmofur  ENT1END -induced ENT2 organic mental disorders ENT2END
0	Absence of effect of ENT1 sertraline  ENT1END  on time-based sensitization of ENT2 cognitive impairment ENT2END with haloperidol
1	Absence of effect of sertraline on time-based sensitization of ENT1 cognitive impairment  ENT1END  with ENT2 haloperidol ENT2END
0	ENT1 Cardiac toxicity ENT1END  observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens. In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, ENT2 thiotepa ENT2END , and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	Incidence of transient ENT1 cyclophosphamide ENT1END related ENT2 cardiac toxicity ENT2END (10%) is comparable to previous recorded literature
0	ENT1 Cardiac toxicity ENT1END  observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens. In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and ENT2 carboplatin ENT2END in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of ENT1 anthracyclines  ENT1END  and left-sided chest irradiation. RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%. Incidence of transient cyclophosphamide-related ENT2 cardiac toxicity ENT2END (10%) is comparable to previous recorded literature
0	ENT1 Cardiac toxicity ENT1END  observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens. In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, ENT2 melphalan ENT2END and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	ENT1 Cardiac toxicity ENT1END  observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.INTRODUCTION: Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens. In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy. STUDY DESIGN: We combined ENT2 paclitaxel ENT2END , melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting ENT1 toxicity  ENT1END is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, ENT2 thiotepa ENT2END , and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting ENT1 toxicity ENT1END  is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, melphalan and high-dose ENT2 cyclophosphamide ENT2END , thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting ENT1 toxicity  ENT1END  is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and ENT2 carboplatin ENT2END in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting ENT1 toxicity  ENT1END  is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of ENT2 anthracyclines ENT2END , and left-sided chest irradiation
0	In high doses, its nonhematological dose-limiting ENT1 toxicity  ENT1END  is cardiomyopathy. STUDY DESIGN: We combined paclitaxel, ENT2 melphalan ENT2END and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting ENT1 toxicity  ENT1END  is cardiomyopathy. STUDY DESIGN: We combined ENT2 paclitaxel ENT2END , melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, ENT1 thiotepa ENT1END , and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, ENT2 hypertension ENT2END , prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
0	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, ENT1 hypertension ENT1END , prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation. RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional ENT2 cyclophosphamide ENT2END with a median percent decline in ejection fraction of 31%
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and ENT1 carboplatin  ENT1END  in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, ENT2 hypertension ENT2END , prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
0	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, ENT1 hypertension  ENT1END , prior cardiac history, smoking, diabetes mellitus, prior use of ENT2 anthracyclines ENT2END , and left-sided chest irradiation
0	STUDY DESIGN: We combined paclitaxel, ENT1 melphalan  ENT1END  and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, ENT2 hypertension ENT2END , prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
0	STUDY DESIGN: We combined ENT1 paclitaxel  ENT1END , melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, ENT2 hypertension ENT2END , prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, ENT1 thiotepa ENT1END , and carboplatin in a triple sequential high-dose regimen for patients with metastatic ENT2 breast cancer ENT2END
0	Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic ENT1 breast cancer ENT1END .INTRODUCTION: ENT2 Cyclophosphamide ENT2END is an alkylating agent given frequently as a component of many conditioning regimens
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and ENT1 carboplatin  ENT1END  in a triple sequential high-dose regimen for patients with metastatic ENT2 breast cancer ENT2END
0	Analysis was performed on 61 women with chemotherapy-responsive metastatic ENT1 breast cancer  ENT1END receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of ENT2 anthracyclines ENT2END , and left-sided chest irradiation
0	STUDY DESIGN: We combined paclitaxel, ENT1 melphalan  ENT1END  and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic ENT2 breast cancer ENT2END
0	STUDY DESIGN: We combined ENT1 paclitaxel  ENT1END , melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic ENT2 breast cancer ENT2END
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, ENT1 thiotepa ENT1END , and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, ENT2 diabetes mellitus ENT2END , prior use of anthracyclines, and left-sided chest irradiation
0	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, ENT1 diabetes mellitus  ENT1END , prior use of anthracyclines, and left-sided chest irradiation. RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 CHF following infusional ENT2 cyclophosphamide ENT2END with a median percent decline in ejection fraction of 31%
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and ENT1 carboplatin  ENT1END  in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, ENT2 diabetes mellitus ENT2END , prior use of anthracyclines, and left-sided chest irradiation
0	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, ENT1 diabetes mellitus  ENT1END , prior use of ENT2 anthracyclines ENT2END , and left-sided chest irradiation
0	STUDY DESIGN: We combined paclitaxel, ENT1 melphalan  ENT1END  and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, ENT2 diabetes mellitus ENT2END , prior use of anthracyclines, and left-sided chest irradiation
0	STUDY DESIGN: We combined ENT1 paclitaxel  ENT1END , melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, ENT2 diabetes mellitus ENT2END , prior use of anthracyclines, and left-sided chest irradiation
0	In high doses, its nonhematological dose-limiting toxicity is ENT1 cardiomyopathy  ENT1END  STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, ENT2 thiotepa ENT2END , and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting toxicity is ENT1 cardiomyopathy  ENT1END . STUDY DESIGN: We combined paclitaxel, melphalan and high-dose ENT2 cyclophosphamide ENT2END , thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting toxicity is ENT1 cardiomyopathy  ENT1END . STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and ENT2 carboplatin ENT2END in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting toxicity is ENT1 cardiomyopathy  ENT1END . STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of ENT2 anthracyclines ENT2END , and left-sided chest irradiation
0	In high doses, its nonhematological dose-limiting toxicity is ENT1 cardiomyopathy  ENT1END . STUDY DESIGN: We combined paclitaxel, ENT2 melphalan ENT2END and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	In high doses, its nonhematological dose-limiting toxicity is ENT1 cardiomyopathy  ENT1END . STUDY DESIGN: We combined ENT2 paclitaxel ENT2END , melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, ENT1 thiotepa ENT1END , and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant ENT2 congestive heart failure ENT2END (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
1	Routine EKG monitoring during infusional ENT1 cyclophosphamide ENT1END did not predict ENT2 CHF ENT2END development
0	STUDY DESIGN: We combined paclitaxel, melphalan and high-dose cyclophosphamide, thiotepa, and ENT1 carboplatin  ENT1END  in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant ENT2 congestive heart failure ENT2END (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
0	Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant congestive heart failure (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of ENT1 anthracyclines ENT1END , and left-sided chest irradiation. RESULTS: Six of 61 women (10%) developed clinically reversible grade 3 ENT2 CHF ENT2END following infusional cyclophosphamide with a median percent decline in ejection fraction of 31%
0	STUDY DESIGN: We combined paclitaxel, ENT1 melphalan  ENT1END  and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant ENT2 congestive heart failure ENT2END (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
0	STUDY DESIGN: We combined ENT1 paclitaxel  ENT1END , melphalan and high-dose cyclophosphamide, thiotepa, and carboplatin in a triple sequential high-dose regimen for patients with metastatic breast cancer. Analysis was performed on 61 women with chemotherapy-responsive metastatic breast cancer receiving 96-h infusional cyclophosphamide as part of a triple sequential high-dose regimen to assess association between presence of peritransplant ENT2 congestive heart failure ENT2END (CHF) and the following pretreatment characteristics: presence of electrocardiogram (EKG) abnormalities, age, hypertension, prior cardiac history, smoking, diabetes mellitus, prior use of anthracyclines, and left-sided chest irradiation
0	0%) showed lower than normal ADC value and showed incomplete resolution with ENT1 cortical laminar necrosis ENT1END  Diffusion-weighted imaging may be useful in predicting the outcomes of the lesions of ENT2 tacrolimus ENT2END -induced neurotoxicity
0	Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving ENT1 tacrolimus ENT1END who developed ENT2 neurologic complications ENT2END
0	Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving ENT1 tacrolimus ENT1END  who developed neurologic complications. In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later. Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions. Of the 14 patients, 5 (35.7%) had white matter abnormalities, 1 (7.1%) had ENT2 putaminal hemorrhage ENT2END , and 8 (57
1	Brain MR studies, including DW imaging, were prospectively performed in 14 organ transplant patients receiving ENT1 tacrolimus ENT1END  who developed neurologic complications. In each patient who had abnormalities on the initial MR study, a follow-up MR study was performed 1 month later. Apparent diffusion coefficient (ADC) values on the initial MR study were correlated with reversibility of the lesions. Of the 14 patients, 5 (35.7%) had ENT2 white matter abnormalities ENT2END , 1 (7
0	MR imaging with quantitative diffusion mapping of ENT1 tacrolimus  ENT1END -induced ENT2 neurotoxicity ENT2END in organ transplant patients
0	Two ENT1 pituitary tumors ENT1END were discovered after ENT2 testosterone ENT2END determination
0	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and ENT1 bromocriptine  ENT1END for hyperprolactinemia. RESULTS: Testosterone was less than 3 ng./ml. in 107 patients but normal in 40% at repeat determination. The prevalence of repeatedly low testosterone increased with age (4% before age 50 years and 9% 50 years or older). Two ENT2 pituitary tumors ENT2END were discovered after testosterone determination
0	Endocrine therapy consisted of ENT1 testosterone heptylate  ENT1END or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia. RESULTS: Testosterone was less than 3 ng./ml. in 107 patients but normal in 40% at repeat determination. The prevalence of repeatedly low testosterone increased with age (4% before age 50 years and 9% 50 years or older). Two ENT2 pituitary tumors ENT2END were discovered after testosterone determination
0	Most of the other low ENT1 testosterone ENT1END levels seemed to result from nonorganic ENT2 hypothalamic dysfunction ENT2END because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%)
0	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and ENT1 bromocriptine  ENT1END  for hyperprolactinemia. RESULTS: Testosterone was less than 3 ng./ml. in 107 patients but normal in 40% at repeat determination. The prevalence of repeatedly low testosterone increased with age (4% before age 50 years and 9% 50 years or older). Two pituitary tumors were discovered after testosterone determination. Most of the other low testosterone levels seemed to result from nonorganic ENT2 hypothalamic dysfunction ENT2END because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%)
0	Endocrine therapy consisted of ENT1 testosterone heptylate  ENT1END  or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia. RESULTS: Testosterone was less than 3 ng./ml. in 107 patients but normal in 40% at repeat determination. The prevalence of repeatedly low testosterone increased with age (4% before age 50 years and 9% 50 years or older). Two pituitary tumors were discovered after testosterone determination. Most of the other low testosterone levels seemed to result from nonorganic ENT2 hypothalamic dysfunction ENT2END because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%)
1	Determining ENT1 testosterone ENT1END only in cases of ENT2 low sexual desire ENT2END or abnormal physical examination would have missed 40% of the cases with low testosterone, including 37% of those subsequently improved by androgen therapy
0	Main clinical criteria tested regarding efficiency in hormone determination were ENT1 low sexual desire  ENT1END  small testes and gynecomastia. Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and ENT2 bromocriptine ENT2END for hyperprolactinemia
0	Main clinical criteria tested regarding efficiency in hormone determination were ENT1 low sexual desire  ENT1END , small testes and gynecomastia. Endocrine therapy consisted of ENT2 testosterone heptylate ENT2END or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia
0	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for ENT1 hypogonadism ENT1END and bromocriptine for hyperprolactinemia. RESULTS: ENT2 Testosterone ENT2END was less than 3 ng
0	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for ENT1 hypogonadism  ENT1END  and ENT2 bromocriptine ENT2END for hyperprolactinemia
0	Endocrine therapy consisted of ENT1 testosterone heptylate  ENT1END  or human chorionic gonadotropin for ENT2 hypogonadism ENT2END and bromocriptine for hyperprolactinemia
0	Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40% of the cases with low ENT1 testosterone ENT1END  including 37% of those subsequently improved by androgen therapy. Prolactin exceeded 20 ng./ml. in 5 men and was normal in 2 at repeat determination. Only 1 ENT2 prolactinoma ENT2END was discovered
0	86% of 1,821 patients, ENT1 prolactinomas ENT1END in 7, 0.38%). ENT2 Bromocriptine ENT2END was definitely effective in cases with prolactin greater than 35 ng
0	Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, ENT1 gynecomastia ENT1END or ENT2 testosterone ENT2END less than 4 ng
0	Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and ENT1 gynecomastia  ENT1END  Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and ENT2 bromocriptine ENT2END for hyperprolactinemia
0	Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and ENT1 gynecomastia  ENT1END . Endocrine therapy consisted of ENT2 testosterone heptylate ENT2END or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia
0	CONCLUSIONS: Low prevalences and effects of low ENT1 testosterone ENT1END and high prolactin in ENT2 erectile dysfunction ENT2END cannot justify their routine determination
0	Prolactin results were compared with those of a previous personal cohort of 1,340 patients with ENT1 erectile dysfunction  ENT1END and systematic prolactin determination. Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia. Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and ENT2 bromocriptine ENT2END for hyperprolactinemia
0	Prolactin results were compared with those of a previous personal cohort of 1,340 patients with ENT1 erectile dysfunction  ENT1END  and systematic prolactin determination. Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire, small testes and gynecomastia. Endocrine therapy consisted of ENT2 testosterone heptylate ENT2END or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia
0	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for ENT1 hyperprolactinemia  ENT1END  RESULTS: ENT2 Testosterone ENT2END was less than 3 ng
0	Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and ENT1 bromocriptine  ENT1END  for ENT2 hyperprolactinemia ENT2END
0	Endocrine therapy consisted of ENT1 testosterone heptylate  ENT1END  or human chorionic gonadotropin for hypogonadism and bromocriptine for ENT2 hyperprolactinemia ENT2END
0	Side effects of ENT1 yohimbine ENT1END included excessive sweating, increased ENT2 anxiety ENT2END , and a wound-up feeling in some patients
0	A single case report suggests that yohimbine may be used to treat the sexual side effects of ENT1 clomipramine ENT1END  This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers. METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, ENT2 anxiety ENT2END , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p
0	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, ENT1 anxiety ENT1END , or affective disorders who suffered sexual side effects after treatment with ENT2 serotonin ENT2END reuptake blockers were given yohimbine on a p
0	METHOD: Six patients with either obsessive compulsive disorder, ENT1 trichotillomania ENT1END  anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given ENT2 yohimbine ENT2END on a p
0	A single case report suggests that yohimbine may be used to treat the sexual side effects of ENT1 clomipramine  ENT1END . This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers. METHOD: Six patients with either obsessive compulsive disorder, ENT2 trichotillomania ENT2END , anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p
0	This study evaluated yohimbine as a treatment for the sexual side effects caused by ENT1 serotonin  ENT1END reuptake blockers. METHOD: Six patients with either obsessive compulsive disorder, ENT2 trichotillomania ENT2END , anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p
0	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or ENT1 affective disorders  ENT1END who suffered sexual side effects after treatment with serotonin reuptake blockers were given ENT2 yohimbine ENT2END on a p
0	A single case report suggests that yohimbine may be used to treat the sexual side effects of ENT1 clomipramine  ENT1END . This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers. METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or ENT2 affective disorders ENT2END who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p
0	METHOD: Six patients with either obsessive compulsive disorder, trichotillomania, anxiety, or ENT1 affective disorders  ENT1END  who suffered sexual side effects after treatment with ENT2 serotonin ENT2END reuptake blockers were given yohimbine on a p
0	ENT1 Yohimbine  ENT1END  treatment of ENT2 sexual side effects ENT2END induced by serotonin reuptake blockers
1	A single case report suggests that yohimbine may be used to treat the ENT1 sexual side effects  ENT1END of ENT2 clomipramine ENT2END
0	This study evaluated yohimbine as a treatment for the ENT1 sexual side effects  ENT1END caused by ENT2 serotonin ENT2END reuptake blockers
0	BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of ENT1 male impotence ENT1END  A single case report suggests that ENT2 yohimbine ENT2END may be used to treat the sexual side effects of clomipramine
0	BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of ENT1 male impotence  ENT1END . A single case report suggests that yohimbine may be used to treat the sexual side effects of ENT2 clomipramine ENT2END
0	Yohimbine treatment of sexual side effects induced by ENT1 serotonin  ENT1END  reuptake blockers.BACKGROUND: Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of ENT2 male impotence ENT2END
0	This study evaluated ENT1 yohimbine ENT1END as a treatment for the sexual side effects caused by serotonin reuptake blockers. METHOD: Six patients with either ENT2 obsessive compulsive disorder ENT2END , trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p
0	A single case report suggests that yohimbine may be used to treat the sexual side effects of ENT1 clomipramine  ENT1END . This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers. METHOD: Six patients with either ENT2 obsessive compulsive disorder ENT2END , trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p
0	This study evaluated yohimbine as a treatment for the sexual side effects caused by ENT1 serotonin  ENT1END  reuptake blockers. METHOD: Six patients with either ENT2 obsessive compulsive disorder ENT2END , trichotillomania, anxiety, or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p
1	ENT1 Hypersensitivity  ENT1END  immune reaction as a mechanism for ENT2 dilevalol ENT2END -associated hepatitis
1	OBJECTIVE: To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of ENT1 dilevalol ENT1END induced ENT2 liver injury ENT2END
0	Massive cerebral edema associated with fulminant hepatic failure in ENT1 acetaminophen ENT1END ENT2 overdose ENT2END : possible role of cranial decompression
1	Massive ENT1 cerebral edema  ENT1END  associated with fulminant hepatic failure in ENT2 acetaminophen ENT2END overdose: possible role of cranial decompression
1	Massive cerebral edema associated with fulminant ENT1 hepatic failure  ENT1END  in ENT2 acetaminophen ENT2END overdose: possible role of cranial decompression
1	The mechanism of ENT1 isoproterenol ENT1END induced ENT2 myocardial damage ENT2END is unknown, but a mismatch of oxygen supply vs
0	The mechanism of isoproterenol-induced ENT1 myocardial damage ENT1END  is unknown, but a mismatch of ENT2 oxygen ENT2END supply vs
1	These changes, related to ENT1 ischaemic injury ENT1END  explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by ENT2 isoproterenol ENT2END
0	The mechanism of ENT1 isoproterenol ENT1END -induced myocardial damage is unknown, but a mismatch of oxygen supply vs. demand following coronary ENT2 hypotension ENT2END and myocardial hyperactivity is the best explanation for the complex morphological alterations observed
0	The mechanism of isoproterenol-induced myocardial damage is unknown, but a mismatch of ENT1 oxygen  ENT1END  supply vs. demand following coronary ENT2 hypotension ENT2END and myocardial hyperactivity is the best explanation for the complex morphological alterations observed
0	We observed the exencephaly induced by ENT1 5-azacytidine ENT1END at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5. We confirmed several cases of transformation from exencephaly to anencephaly. However, in many cases, the exencephalic brain tissue was preserved with more or less reduction during this period. To analyze the transformation patterns, we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13.5 and E18.5. It was found that the transformation of exencephalic tissue was not simply size-dependent, and all cases of anencephaly at E18.5 resulted from embryos with a large amount of exencephalic tissue at E13.5. Microscopic observation showed the configuration of exencephaly at E13.5, frequent ENT2 hemorrhaging ENT2END and detachment of the neural plate from surface ectoderm in the exencephalic head at E15
1	We observed the exencephaly induced by ENT1 5-azacytidine ENT1END  at embryonic day 13.5 (E13.5), let the embryos develop exo utero until E18.5, and re-observed the same embryos at E18.5. We confirmed several cases of transformation from exencephaly to ENT2 anencephaly ENT2END
0	We observed the ENT1 exencephaly  ENT1END induced by ENT2 5-azacytidine ENT2END at embryonic day 13
0	METHODS: A review of admissions during a 6-year period revealed 14 patients with ENT1 cocaine ENT1END related aneurysms. This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse. Age at presentation, time of ictus after intoxication, Hunt and Hess grade of ENT2 subarachnoid hemorrhage ENT2END , size of the aneurysm, location of the aneurysm, and the Glasgow Outcome Scale score were assessed and compared
0	METHODS: A review of admissions during a 6-year period revealed 14 patients with ENT1 cocaine ENT1END -related ENT2 aneurysms ENT2END
1	CONCLUSION: ENT1 Cocaine ENT1END use predisposed ENT2 aneurysmal rupture ENT2END at a significantly earlier age and in much smaller aneurysms
0	METHODS: A review of admissions during a 6-year period revealed 14 patients with ENT1 cocaine ENT1END -related aneurysms. This group was compared with a control group of 135 patients with ruptured aneurysms and no history of ENT2 cocaine abuse ENT2END
0	ENT1 Intracranial aneurysms  ENT1END  and cocaine abuse: analysis of prognostic indicators.OBJECTIVE: The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor. However, no study in the literature has reported the use of a statistical model to analyze the variables that influence outcome. METHODS: A review of admissions during a 6-year period revealed 14 patients with ENT2 cocaine ENT2END -related aneurysms
0	Severe cardiovascular complications occurred in eight of 160 patients treated with ENT1 terbutaline ENT1END for ENT2 preterm labor ENT2END
1	ENT1 Cardiovascular complications  ENT1END  associated with ENT2 terbutaline ENT2END treatment for preterm labor
0	Phenobarbitone-induced enlargement of the liver in the rat: its relationship to ENT1 carbon tetrachloride  ENT1END -induced ENT2 cirrhosis ENT2END
0	ENT1 Phenobarbitone  ENT1END -induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced ENT2 cirrhosis ENT2END
0	Phenobarbitone-induced enlargement of the liver in the rat: its relationship to ENT1 carbon tetrachloride ENT1END -induced cirrhosis.The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ENT2 ascites ENT2END greater than 30 ml, plasma albumin less than 2
0	The yield of severe cirrhosis of the liver (defined as a shrunken finely nodular liver with micronodular histology, ENT1 ascites ENT1END  greater than 30 ml, plasma albumin less than 2.2 g/dl, splenomegaly 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the ENT2 phenobarbitone ENT2END -primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver
1	Phenobarbitone-induced enlargement of the liver in the rat: its relationship to ENT1 carbon tetrachloride ENT1END -induced cirrhosis.The yield of severe ENT2 cirrhosis of the liver ENT2END (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2
1	ENT1 Phenobarbitone  ENT1END -induced enlargement of the liver in the rat: its relationship to carbon tetrachloride-induced cirrhosis.The yield of severe ENT2 cirrhosis of the liver ENT2END (defined as a shrunken finely nodular liver with micronodular histology, ascites greater than 30 ml, plasma albumin less than 2
0	2 g/dl, splenomegaly 2-3 times normal, and testicular ENT1 atrophy ENT1END approximately half normal weight) after 12 doses of ENT2 carbon tetrachloride ENT2END given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver
0	2 g/dl, splenomegaly 2-3 times normal, and testicular ENT1 atrophy  ENT1END  approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the ENT2 phenobarbitone ENT2END -primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver
0	Phenobarbitone-induced ENT1 enlargement of the liver  ENT1END  in the rat: its relationship to ENT2 carbon tetrachloride ENT2END -induced cirrhosis
1	ENT1 Phenobarbitone  ENT1END -induced ENT2 enlargement of the liver ENT2END in the rat: its relationship to carbon tetrachloride-induced cirrhosis
0	2 g/dl, ENT1 splenomegaly  ENT1END 2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of ENT2 carbon tetrachloride ENT2END given intragastrically in the phenobarbitone-primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver
0	2 g/dl, ENT1 splenomegaly  ENT1END  2-3 times normal, and testicular atrophy approximately half normal weight) after 12 doses of carbon tetrachloride given intragastrically in the ENT2 phenobarbitone ENT2END -primed rat was increased from 25% to 56% by giving the initial "calibrating" dose of carbon tetrachloride at the peak of the phenobarbitone-induced enlargement of the liver
1	Intracranial pressure increases during ENT1 alfentanil  ENT1END -induced ENT2 rigidity ENT2END
0	Following instrumentation, halothane was discontinued and alfentanil (125 mu/kg) administered iv during emergence from ENT1 halothane ENT1END anesthesia. In the five rats that developed ENT2 somatic rigidity ENT2END , ICP and CVP increased significantly above baseline (delta ICP 7
0	These variables returned to baseline when ENT1 rigidity ENT1END was abolished with ENT2 metocurine ENT2END
1	Dimensions of the ENT1 bruising ENT1END on the ENT2 heparin ENT2END applied areas were measured using transparent millimetric measuring paper
1	A study on the effect of the duration of subcutaneous ENT1 heparin  ENT1END  injection on bruising and ENT2 pain ENT2END
0	Carbamazepine and vigabatrin are contraindicated in typical ENT1 absence seizures ENT1END  Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on. Vigabatrin was also used in the treatment of two children. Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine. Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment. Optimal control of the absences was achieved with ENT2 sodium valproate ENT2END , lamotrigine, or ethosuximide alone or in combination
1	Inappropriate use of carbamazepine and vigabatrin in typical ENT1 absence seizures  ENT1END . ENT2 Carbamazepine ENT2END and vigabatrin are contraindicated in typical absence seizures
0	Carbamazepine and vigabatrin are contraindicated in typical ENT1 absence seizures ENT1END . Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on. Vigabatrin was also used in the treatment of two children. Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine. Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment. Optimal control of the absences was achieved with sodium valproate, ENT2 lamotrigine ENT2END , or ethosuximide alone or in combination
0	Carbamazepine and vigabatrin are contraindicated in typical ENT1 absence seizures ENT1END . Of 18 consecutive referrals of children with resistant typical absences only, eight were erroneously treated with carbamazepine either as monotherapy or as an add-on. Vigabatrin was also used in the treatment of two children. Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks, which resolved on withdrawal of carbamazepine. Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment. Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ENT2 ethosuximide ENT2END alone or in combination
1	Inappropriate use of carbamazepine and ENT1 vigabatrin  ENT1END  in typical ENT2 absence seizures ENT2END
0	Frequency of absences increased in four children treated with carbamazepine and two of these developed ENT1 myoclonic jerks  ENT1END  which resolved on withdrawal of carbamazepine. Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment. Optimal control of the absences was achieved with ENT2 sodium valproate ENT2END , lamotrigine, or ethosuximide alone or in combination
1	Frequency of absences increased in four children treated with ENT1 carbamazepine  ENT1END and two of these developed ENT2 myoclonic jerks ENT2END , which resolved on withdrawal of carbamazepine
0	Frequency of absences increased in four children treated with carbamazepine and two of these developed ENT1 myoclonic jerks  ENT1END , which resolved on withdrawal of carbamazepine. Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment. Optimal control of the absences was achieved with sodium valproate, ENT2 lamotrigine ENT2END , or ethosuximide alone or in combination
0	Frequency of absences increased in four children treated with carbamazepine and two of these developed ENT1 myoclonic jerks  ENT1END , which resolved on withdrawal of carbamazepine. Absences were aggravated in both cases where vigabatrin was added on to concurrent treatment. Optimal control of the absences was achieved with sodium valproate, lamotrigine, or ENT2 ethosuximide ENT2END alone or in combination
0	Frequency of absences increased in four children treated with carbamazepine and two of these developed ENT1 myoclonic jerks ENT1END , which resolved on withdrawal of carbamazepine. Absences were aggravated in both cases where ENT2 vigabatrin ENT2END was added on to concurrent treatment
1	Metabolic involvement in ENT1 adriamycin ENT1END ENT2 cardiotoxicity ENT2END
0	The ENT1 cardiotoxic ENT1END effects of adriamycin were studied in mammalian myocardial cells in culture as a model system. Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture. A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells. The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged. Such disparity suggests an inhibition of creatine phosphokinase. The addition of 1 mM adenosine to the myocardial cell cultures markedly increases the ENT2 ATP ENT2END concentration through a pathway reportedly leading to a compartmentalized ATP pool
0	The ENT1 cardiotoxic ENT1END  effects of adriamycin were studied in mammalian myocardial cells in culture as a model system. Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture. A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells. The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged. Such disparity suggests an inhibition of creatine phosphokinase. The addition of 1 mM ENT2 adenosine ENT2END to the myocardial cell cultures markedly increases the ATP concentration through a pathway reportedly leading to a compartmentalized ATP pool
0	The ENT1 cardiotoxic ENT1END  effects of adriamycin were studied in mammalian myocardial cells in culture as a model system. Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture. A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and ENT2 phosphorylcreatine ENT2END mole fraction were determined in the adriamycin-treated cells
0	The ENT1 cardiotoxic ENT1END  effects of adriamycin were studied in mammalian myocardial cells in culture as a model system. Adriamycin inhibited cell growth and the rhythmic contractions characteristic of myocardial cells in culture. A possible involvement of energy metabolism was suggested previously, and in this study the adenylate energy charge and phosphorylcreatine mole fraction were determined in the adriamycin-treated cells. The adenylate energy charge was found to be significantly decreased, while the phophorylcreatine mole fraction was unchanged. Such disparity suggests an inhibition of ENT2 creatine ENT2END phosphokinase
0	Bladder retention of urine as a result of continuous intravenous infusion of ENT1 fentanyl ENT1END : 2 case reports.Sedation has been commonly used in the neonate to decrease the stress and ENT2 pain ENT2END from the noxious stimuli and invasive procedures in the neonatal intensive care unit, as well as to facilitate synchrony between ventilator and spontaneous breaths
0	Here, 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking ENT1 hydronephrosis ENT1END as a result of continuous infusion of ENT2 fentanyl ENT2END are reported
1	Various reported side effects of ENT1 fentanyl ENT1END administration include chest wall rigidity, ENT2 hypotension ENT2END , respiratory depression, and bradycardia
1	Here, 2 cases of ENT1 urinary bladder retention  ENT1END leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of ENT2 fentanyl ENT2END are reported
1	Various reported side effects of ENT1 fentanyl ENT1END  administration include chest wall rigidity, hypotension, respiratory depression, and ENT2 bradycardia ENT2END
1	Various reported side effects of ENT1 fentanyl ENT1END  administration include chest wall rigidity, hypotension, ENT2 respiratory depression ENT2END , and bradycardia
0	Various reported side effects of ENT1 fentanyl ENT1END  administration include ENT2 chest wall rigidity ENT2END , hypotension, respiratory depression, and bradycardia
1	Bladder ENT1 retention of urine  ENT1END  as a result of continuous intravenous infusion of ENT2 fentanyl ENT2END : 2 case reports
1	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, ENT1 lamivudine ENT1END  and indinavir or vehicle control for 10 days or 35 days. At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of ENT2 CM ENT2END (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA
1	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and ENT1 indinavir  ENT1END or vehicle control for 10 days or 35 days. At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of ENT2 CM ENT2END (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA
1	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of ENT1 zidovudine  ENT1END  lamivudine, and indinavir or vehicle control for 10 days or 35 days. At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of ENT2 CM ENT2END (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic calcium ATPase [SERCA2]), and determination of plasma LA
0	Results show that cumulative HAART caused mitochondrial ENT1 CM ENT1END with elevated ENT2 LA ENT2END in AIDS transgenic mice
0	At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of ENT1 CM ENT1END  (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic ENT2 calcium ENT2END ATPase [SERCA2]), and determination of plasma LA
0	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of ENT1 mitochondrial dysfunction  ENT1END  To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, ENT2 lamivudine ENT2END , and indinavir or vehicle control for 10 days or 35 days
0	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of ENT1 mitochondrial dysfunction  ENT1END . To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and ENT2 indinavir ENT2END or vehicle control for 10 days or 35 days
0	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of ENT1 mitochondrial dysfunction  ENT1END . To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of ENT2 zidovudine ENT2END , lamivudine, and indinavir or vehicle control for 10 days or 35 days
0	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate ( ENT1 LA  ENT1END  in AIDS through mechanisms of ENT2 mitochondrial dysfunction ENT2END
0	Highly active antiretroviral therapy (HAART) is implicated in cardiomyopathy (CM) and in elevated plasma lactate (LA) in AIDS through mechanisms of ENT1 mitochondrial dysfunction  ENT1END . To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic AIDS mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days. At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic ENT2 calcium ENT2END ATPase [SERCA2]), and determination of plasma LA
0	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic ENT1 AIDS  ENT1END mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, ENT2 lamivudine ENT2END , and indinavir or vehicle control for 10 days or 35 days
0	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic ENT1 AIDS  ENT1END  mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and ENT2 indinavir ENT2END or vehicle control for 10 days or 35 days
0	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic ENT1 AIDS  ENT1END  mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of ENT2 zidovudine ENT2END , lamivudine, and indinavir or vehicle control for 10 days or 35 days
0	Results show that cumulative HAART caused mitochondrial CM with elevated ENT1 LA ENT1END  in ENT2 AIDS ENT2END transgenic mice
0	To determine mitochondrial events from HAART in vivo, 8-week-old hemizygous transgenic ENT1 AIDS  ENT1END  mice (NL4-3Delta gag/pol; TG) and wild-type FVB/n littermates were treated with the HAART combination of zidovudine, lamivudine, and indinavir or vehicle control for 10 days or 35 days. At termination of the experiments, mice underwent echocardiography, quantitation of abundance of molecular markers of CM (ventricular mRNA encoding atrial natriuretic factor [ANF] and sarcoplasmic ENT2 calcium ENT2END ATPase [SERCA2]), and determination of plasma LA
0	No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H- ENT1 MK-801 ENT1END binding in cortex. This animal model may be useful to explore the mechanisms by which prenatal ENT2 nutritional deficiency ENT2END enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse
0	PD female rats also showed increased (3)H- ENT1 haloperidol  ENT1END binding and decreased dopamine transporter binding in striatum. No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex. This animal model may be useful to explore the mechanisms by which prenatal ENT2 nutritional deficiency ENT2END enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse
0	PD female rats also showed increased (3)H-haloperidol binding and decreased ENT1 dopamine  ENT1END transporter binding in striatum. No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H-MK-801 binding in cortex. This animal model may be useful to explore the mechanisms by which prenatal ENT2 nutritional deficiency ENT2END enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse
0	No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3) ENT1 H  ENT1END MK-801 binding in cortex. This animal model may be useful to explore the mechanisms by which prenatal ENT2 nutritional deficiency ENT2END enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse
0	No changes in haloperidol-induced ENT1 catalepsy ENT1END or ENT2 MK-801 ENT2END -induced locomotion were seen following PD
1	No changes in ENT1 haloperidol  ENT1END induced ENT2 catalepsy ENT2END or MK-801-induced locomotion were seen following PD
0	We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to ENT1 amphetamine  ENT1END in adulthood. These differences were not observed during puberty. No changes in haloperidol-induced ENT2 catalepsy ENT2END or MK-801-induced locomotion were seen following PD
0	No changes in haloperidol-induced ENT1 catalepsy  ENT1END  or MK-801-induced locomotion were seen following PD. In addition, PD female rats showed increased (3)H-MK-801 binding in the striatum and hippocampus, but not in the cortex. PD female rats also showed increased (3)H-haloperidol binding and decreased ENT2 dopamine ENT2END transporter binding in striatum
0	No changes in haloperidol-induced ENT1 catalepsy  ENT1END  or MK-801-induced locomotion were seen following PD. In addition, PD female rats showed increased (3) ENT2 H ENT2END -MK-801 binding in the striatum and hippocampus, but not in the cortex
0	We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to ENT1 apomorphine  ENT1END and an increased locomotor response to amphetamine in adulthood. These differences were not observed during puberty. No changes in haloperidol-induced ENT2 catalepsy ENT2END or MK-801-induced locomotion were seen following PD
0	No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3)H- ENT1 MK-801 ENT1END  binding in cortex. This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for ENT2 schizophrenia ENT2END in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse
0	The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to ENT1 schizophrenia  ENT1END  We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to amphetamine in adulthood. These differences were not observed during puberty. No changes in ENT2 haloperidol ENT2END -induced catalepsy or MK-801-induced locomotion were seen following PD
0	The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to ENT1 schizophrenia  ENT1END . We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to apomorphine and an increased locomotor response to ENT2 amphetamine ENT2END in adulthood
0	Prenatal protein deprivation alters ENT1 dopamine ENT1END -mediated behaviors and dopaminergic and glutamatergic receptor binding.Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of ENT2 schizophrenia ENT2END
0	No statistically significant changes in behavior or receptor binding were found in PD males with the exception of increased (3) ENT1 H  ENT1END -MK-801 binding in cortex. This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for ENT2 schizophrenia ENT2END in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse
0	The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to ENT1 schizophrenia  ENT1END . We report that prenatally protein deprived (PD) female rats showed an increased stereotypic response to ENT2 apomorphine ENT2END and an increased locomotor response to amphetamine in adulthood
1	Reversible ENT1 myocardial hypertrophy  ENT1END  induced by ENT2 tacrolimus ENT2END in a pediatric heart transplant recipient: case report
0	However, adverse effects include ENT1 cardiac toxicity ENT1END  Herein we describe transient myocardial hypertrophy induced by ENT2 tacrolimus ENT2END after heart transplantation
0	Initially, allograft rejection was feared; however, myocardial biopsy samples revealed only interstitial ENT1 edema ENT1END and mild myocardial hypertrophy; neither cellular nor humoral rejection was detected. The blood ENT2 tacrolimus ENT2END concentration was higher than usual at that time; thus, tacrolimus dosage was reduced
0	Herein we describe transient myocardial hypertrophy induced by ENT1 tacrolimus ENT1END  after heart transplantation. The ENT2 hypertrophy ENT2END caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography
1	Abnormal movements and ENT1 deafness ENT1END occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to ENT2 streptomycin ENT2END than the site (vestibular or central) responsible for the dyskinesias
1	Abnormal movements and deafness occurred only in rats treated during the preweaning period; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11-17 and 5 to 11 days of age, respectively, indicating that the cochlea is more sensitive to ENT1 streptomycin ENT1END  than the site (vestibular or central) responsible for the ENT2 dyskinesias ENT2END
0	Age-dependent sensitivity of the rat to ENT1 neurotoxic  ENT1END  effects of ENT2 streptomycin ENT2END
0	METHODS: Forty-three Caucasian patients with primary open-angle glaucoma or ENT1 ocular hypertension ENT1END with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), ENT2 timolol ENT2END solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening)
1	CONCLUSIONS: Both timolol solution and ENT1 timolol ENT1END gellan decrease the mean 24-hour heart rate compared with placebo. This response was most pronounced during the active daytime period. These data quantify the modest ENT2 bradycardia ENT2END associated with ophthalmic beta-blocker therapy in a typical patient population on therapy for glaucoma
0	5% timolol suspension that forms a gel on application to the conjunctiva ( ENT1 timolol ENT1END gellan) on the 24-hour heart rate in patients currently being treated for ENT2 glaucoma ENT2END to quantify the reduction in mean heart rate
0	5% timolol suspension that forms a gel on application to the conjunctiva ( ENT1 timolol ENT1END  gellan) on the 24-hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate. METHODS: Forty-three Caucasian patients with primary ENT2 open-angle glaucoma ENT2END or ocular hypertension with a mean (+/-SD) age of 63 (+/-8) years were randomized and crossed over in a double-masked manner to 14 days of treatment with placebo (morning and evening in both eyes), timolol solution (morning and evening in both eyes), or timolol gellan (morning in both eyes with placebo in the evening)
0	METHODS: We used computerized pharmacy records to identify all adult ENT1 psychiatric ENT1END inpatients treated with ENT2 clozapine ENT2END (1995-96), reviewed their medical records to score incidence and severity of delirium, and tested associations with potential risk factors
1	ENT1 Delirium  ENT1END  during ENT2 clozapine ENT2END treatment: incidence and associated risk factors
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and ENT1 hyperthermia ENT1END  The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT2 norepinephrine ENT2END
1	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and ENT1 hyperthermia ENT1END . The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. ENT2 Venlafaxine ENT2END is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of ENT1 serotonin  ENT1END excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and ENT2 hyperthermia ENT2END
1	Serotonin syndrome from venlafaxine- ENT1 tranylcypromine  ENT1END  interaction.Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and ENT2 hyperthermia ENT2END
0	After 180 mg of ENT1 diazepam ENT1END i.v. he remained tremulous with muscle rigidity and clenched jaws. He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity. His subsequent course was remarkable for non-immune ENT2 thrombocytopenia ENT2END which resolved
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, ENT1 confusion  ENT1END  agitation and hyperthermia. The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT2 norepinephrine ENT2END
1	Serotonin syndrome from ENT1 venlafaxine  ENT1END -tranylcypromine interaction.Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, ENT2 confusion ENT2END , agitation and hyperthermia
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of ENT1 serotonin  ENT1END  excess that consists of shivering, muscle rigidity, salivation, ENT2 confusion ENT2END , agitation and hyperthermia
1	Serotonin syndrome from venlafaxine- ENT1 tranylcypromine  ENT1END  interaction.Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, ENT2 confusion ENT2END , agitation and hyperthermia
0	After 180 mg of ENT1 diazepam ENT1END  i.v. he remained tremulous with muscle rigidity and clenched jaws. He was intubated for airway protection and because of hypoventilation, and was paralyzed to control muscle rigidity. His subsequent course was remarkable for non-immune thrombocytopenia which resolved. The patient's maximal temperature was 101.2 F and his CPK remained < 500 units/L with no other evidence of ENT2 rhabdomyolysis ENT2END
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, ENT1 agitation  ENT1END and hyperthermia. The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT2 norepinephrine ENT2END
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, ENT1 agitation  ENT1END  and hyperthermia. The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. ENT2 Venlafaxine ENT2END is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of ENT1 serotonin  ENT1END  excess that consists of shivering, muscle rigidity, salivation, confusion, ENT2 agitation ENT2END and hyperthermia
0	Serotonin syndrome from venlafaxine- ENT1 tranylcypromine  ENT1END  interaction.Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, ENT2 agitation ENT2END and hyperthermia
0	After 180 mg of ENT1 diazepam ENT1END  i.v. he remained tremulous with muscle rigidity and clenched jaws. He was intubated for airway protection and because of ENT2 hypoventilation ENT2END , and was paralyzed to control muscle rigidity
0	He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, ENT1 salivation  ENT1END and diaphoresis. His pupils were 7 mm and sluggishly reactive to light. Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of ENT2 diazepam ENT2END i
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, ENT1 salivation  ENT1END  confusion, agitation and hyperthermia. The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT2 norepinephrine ENT2END
1	Serotonin syndrome from ENT1 venlafaxine  ENT1END -tranylcypromine interaction.Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, ENT2 salivation ENT2END , confusion, agitation and hyperthermia
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of ENT1 serotonin  ENT1END  excess that consists of shivering, muscle rigidity, ENT2 salivation ENT2END , confusion, agitation and hyperthermia
1	Serotonin syndrome from venlafaxine- ENT1 tranylcypromine  ENT1END  interaction.Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, ENT2 salivation ENT2END , confusion, agitation and hyperthermia
0	He was brought directly to a hospital where he was found to be agitated and confused with shivering, ENT1 myoclonic jerks  ENT1END  rigidity, salivation and diaphoresis. His pupils were 7 mm and sluggishly reactive to light. Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of ENT2 diazepam ENT2END i
0	Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT1 norepinephrine  ENT1END . We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression. He had been well until the morning of presentation when he took 1/2 tab of venlafaxine. Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity. He was brought directly to a hospital where he was found to be agitated and confused with shivering, ENT2 myoclonic jerks ENT2END , rigidity, salivation and diaphoresis
1	He had been well until the morning of presentation when he took 1/2 tab of ENT1 venlafaxine  ENT1END  Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity. He was brought directly to a hospital where he was found to be agitated and confused with shivering, ENT2 myoclonic jerks ENT2END , rigidity, salivation and diaphoresis
0	Venlafaxine is a new antidepressant agent that inhibits the reuptake of ENT1 serotonin  ENT1END and norepinephrine. We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression. He had been well until the morning of presentation when he took 1/2 tab of venlafaxine. Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity. He was brought directly to a hospital where he was found to be agitated and confused with shivering, ENT2 myoclonic jerks ENT2END , rigidity, salivation and diaphoresis
1	We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking ENT1 tranylcypromine  ENT1END for depression. He had been well until the morning of presentation when he took 1/2 tab of venlafaxine. Within 2 h he became confused with jerking movements of his extremities, tremors and rigidity. He was brought directly to a hospital where he was found to be agitated and confused with shivering, ENT2 myoclonic jerks ENT2END , rigidity, salivation and diaphoresis
0	After 180 mg of ENT1 diazepam ENT1END  i.v. he remained tremulous with ENT2 muscle rigidity ENT2END and clenched jaws
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, ENT1 muscle rigidity  ENT1END  salivation, confusion, agitation and hyperthermia. The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor (MAOI) and a specific serotonin reuptake inhibitor. Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT2 norepinephrine ENT2END
1	He had been well until the morning of presentation when he took 1/2 tab of ENT1 venlafaxine ENT1END . Within 2 h he became confused with jerking movements of his extremities, tremors and ENT2 rigidity ENT2END
0	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of ENT1 serotonin  ENT1END  excess that consists of shivering, ENT2 muscle rigidity ENT2END , salivation, confusion, agitation and hyperthermia
1	Serotonin syndrome from venlafaxine- ENT1 tranylcypromine  ENT1END  interaction.Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, ENT2 muscle rigidity ENT2END , salivation, confusion, agitation and hyperthermia
0	Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT1 norepinephrine ENT1END . We report a venlafaxine-MAOI interaction that resulted in the ENT2 serotonin syndrome ENT2END in a 23-y-old male who was taking tranylcypromine for depression
1	ENT1 Serotonin syndrome  ENT1END  from ENT2 venlafaxine ENT2END -tranylcypromine interaction
0	ENT1 Serotonin syndrome ENT1END  from venlafaxine-tranylcypromine interaction.Excessive stimulation of ENT2 serotonin ENT2END 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering, muscle rigidity, salivation, confusion, agitation and hyperthermia
1	ENT1 Serotonin syndrome  ENT1END  from venlafaxine ENT2 tranylcypromine ENT2END interaction
0	Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT1 norepinephrine ENT1END . We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for ENT2 depression ENT2END
0	We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for ENT1 depression  ENT1END . He had been well until the morning of presentation when he took 1/2 tab of ENT2 venlafaxine ENT2END
0	Venlafaxine is a new antidepressant agent that inhibits the reuptake of ENT1 serotonin  ENT1END  and norepinephrine. We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for ENT2 depression ENT2END
0	We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking ENT1 tranylcypromine  ENT1END  for ENT2 depression ENT2END
0	Within 2 h he became confused with jerking movements of his extremities, ENT1 tremors  ENT1END and rigidity. He was brought directly to a hospital where he was found to be agitated and confused with shivering, myoclonic jerks, rigidity, salivation and diaphoresis. His pupils were 7 mm and sluggishly reactive to light. Vital signs were: blood pressure 120/67 mm Hg, heart rate 127/min, respiratory rate 28/min, and temperature 97 F. After 180 mg of ENT2 diazepam ENT2END i
0	Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and ENT1 norepinephrine  ENT1END . We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression. He had been well until the morning of presentation when he took 1/2 tab of venlafaxine. Within 2 h he became confused with jerking movements of his extremities, ENT2 tremors ENT2END and rigidity
1	He had been well until the morning of presentation when he took 1/2 tab of ENT1 venlafaxine  ENT1END . Within 2 h he became confused with jerking movements of his extremities, ENT2 tremors ENT2END and rigidity
0	Venlafaxine is a new antidepressant agent that inhibits the reuptake of ENT1 serotonin  ENT1END  and norepinephrine. We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking tranylcypromine for depression. He had been well until the morning of presentation when he took 1/2 tab of venlafaxine. Within 2 h he became confused with jerking movements of his extremities, ENT2 tremors ENT2END and rigidity
1	We report a venlafaxine-MAOI interaction that resulted in the serotonin syndrome in a 23-y-old male who was taking ENT1 tranylcypromine  ENT1END  for depression. He had been well until the morning of presentation when he took 1/2 tab of venlafaxine. Within 2 h he became confused with jerking movements of his extremities, ENT2 tremors ENT2END and rigidity
0	After 180 mg of ENT1 diazepam ENT1END  i.v. he remained tremulous with muscle rigidity and clenched jaws. He was intubated for airway protection and because of hypoventilation, and was ENT2 paralyzed ENT2END to control muscle rigidity
0	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after ENT1 cocaine ENT1END use is frequently associated with ENT2 intracranial aneurysms ENT2END and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction
1	Cerebral infarction occurred in 10 patients (22%), intracerebral hemorrhage in 22 (49%), and ENT1 subarachnoid hemorrhage ENT1END in 13 (29%). These data indicate that (1) the apparent incidence of stroke related to ENT2 cocaine ENT2END use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction
0	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) ENT1 stroke  ENT1END after ENT2 cocaine ENT2END use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction
1	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in ENT1 cocaine ENT1END associated stroke, the frequency of intracranial hemorrhage exceeds that of ENT2 cerebral infarction ENT2END
0	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in ENT1 cocaine ENT1END -associated stroke, the frequency of ENT2 intracranial hemorrhage ENT2END exceeds that of cerebral infarction
0	Stroke followed ENT1 cocaine ENT1END use by inhalation, intranasal, intravenous, and intramuscular routes. Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy; ENT2 cerebral vasculitis ENT2END was present in two patients
0	These data indicate that (1) the apparent incidence of stroke related to cocaine use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and ENT1 arteriovenous malformations  ENT1END  and (5) in ENT2 cocaine ENT2END -associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction
1	Cerebral infarction occurred in 10 patients (22%), ENT1 intracerebral hemorrhage  ENT1END in 22 (49%), and subarachnoid hemorrhage in 13 (29%). These data indicate that (1) the apparent incidence of stroke related to ENT2 cocaine ENT2END use is increasing; (2) cocaine-associated stroke occurs primarily in young adults; (3) stroke may follow any route of cocaine administration; (4) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations; and (5) in cocaine-associated stroke, the frequency of intracranial hemorrhage exceeds that of cerebral infarction
1	Transketolase abnormality in ENT1 tolazamide  ENT1END -induced ENT2 Wernicke's encephalopathy ENT2END
0	Transketolase abnormality in tolazamide-induced ENT1 Wernicke's encephalopathy ENT1END .We studied a ENT2 thiamine ENT2END -dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome
0	We found that the above-mentioned patient and one of the diabetic kindreds with no history of ENT1 Wernicke's encephalopathy ENT1END had abnormal transketolase as determined by its Km for ENT2 TPP ENT2END
0	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a ENT1 diabetic ENT1END patient who developed Wernicke's encephalopathy when treated with ENT2 tolazamide ENT2END , in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome
0	We studied a ENT1 thiamine  ENT1END -dependent enzyme, transketolase, from fibroblasts of a ENT2 diabetic ENT2END patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic Wernicke-Korsakoff syndrome
0	We found that the above-mentioned patient and one of the ENT1 diabetic  ENT1END kindreds with no history of Wernicke's encephalopathy had abnormal transketolase as determined by its Km for ENT2 TPP ENT2END
0	These data suggest a similarity between postalcoholic ENT1 Wernicke-Korsakoff syndrome ENT1END and the patient with ENT2 tolazamide ENT2END -induced Wernicke's encephalopathy from the standpoint of transketolase abnormality
0	We studied a ENT1 thiamine ENT1END -dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate (TPP)], as previously reported in postalcoholic ENT2 Wernicke-Korsakoff syndrome ENT2END
0	We studied a thiamine-dependent enzyme, transketolase, from fibroblasts of a diabetic patient who developed Wernicke's encephalopathy when treated with tolazamide, in order to delineate if this patient also had transketolase abnormality [high Km for thiamine pyrophosphate ( ENT1 TPP  ENT1END ], as previously reported in postalcoholic ENT2 Wernicke-Korsakoff syndrome ENT2END
0	Under ENT1 isoflurane ENT1END anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded. In the control group (n = 7), the mean arterial pressure (MAP) was not manipulated. In the hypertensive group (n = 7), the MAP was elevated by 25-30 mm Hg beginning 2 h after MCAO. Four hours after MCAO, the rats were killed and the brains harvested. The brains were sectioned along coronal planes spanning the distribution of ENT2 ischemia ENT2END produced by MCAO
0	The extent of neuronal injury was determined by ENT1 2,3,5-triphenyltetrazolium ENT1END staining. In the ENT2 ischemic ENT2END core, there was no difference in SG in the subcortex and cortex in the two groups
0	The data indicate that ENT1 phenylephrine ENT1END induced hypertension instituted 2 h after MCAO does not aggravate edema in the ENT2 ischemic ENT2END core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction
0	Under ENT1 isoflurane ENT1END  anesthesia, the MCA of 14 spontaneously ENT2 hypertensive ENT2END rats was occluded
0	The extent of neuronal injury was determined by ENT1 2,3,5-triphenyltetrazolium ENT1END  staining. In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups. In the periphery of the ischemic territory, SG in the cortex was greater (less edema accumulation) in the ENT2 hypertensive ENT2END group (1
1	The data indicate that ENT1 phenylephrine ENT1END -induced ENT2 hypertension ENT2END instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction
0	The extent of ENT1 neuronal injury  ENT1END was determined by ENT2 2,3,5-triphenyltetrazolium ENT2END staining
0	The data indicate that ENT1 phenylephrine ENT1END -induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical ENT2 neuronal dysfunction ENT2END
0	The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion ( ENT1 MCAO  ENT1END  on brain edema formation and histochemical injury was studied. Under ENT2 isoflurane ENT2END anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded
0	The brains were sectioned along coronal planes spanning the distribution of ischemia produced by ENT1 MCAO  ENT1END  Specific gravity (SG) was determined in the subcortex and in two sites in the cortex (core and periphery of the ischemic territory). The extent of neuronal injury was determined by ENT2 2,3,5-triphenyltetrazolium ENT2END staining
0	The data indicate that ENT1 phenylephrine ENT1END -induced hypertension instituted 2 h after ENT2 MCAO ENT2END does not aggravate edema in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction
0	The extent of neuronal injury was determined by ENT1 2,3,5-triphenyltetrazolium ENT1END  staining. In the ischemic core, there was no difference in SG in the subcortex and cortex in the two groups. In the periphery of the ischemic territory, SG in the cortex was greater (less ENT2 edema ENT2END accumulation) in the hypertensive group (1
0	The data indicate that ENT1 phenylephrine ENT1END -induced hypertension instituted 2 h after MCAO does not aggravate ENT2 edema ENT2END in the ischemic core, that it improves edema in the periphery of the ischemic territory, and that it reduces the area of histochemical neuronal dysfunction
0	The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on ENT1 brain edema  ENT1END formation and histochemical injury was studied. Under ENT2 isoflurane ENT2END anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded
0	Delayed institution of hypertension during focal ENT1 cerebral ischemia  ENT1END : effect on brain edema.The effect of induced hypertension instituted after a 2-h delay following middle cerebral artery occlusion (MCAO) on brain edema formation and histochemical injury was studied. Under ENT2 isoflurane ENT2END anesthesia, the MCA of 14 spontaneously hypertensive rats was occluded
0	Thus the migraine-inducing effect of ENT1 nitroglycerin ENT1END seems to depend on direct stimulation of the habitual site of ENT2 pain ENT2END , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis
1	Thus the ENT1 migraine  ENT1END inducing effect of ENT2 nitroglycerin ENT2END seems to depend on direct stimulation of the habitual site of pain, suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis
0	Serial electrocardiographic monitoring may be considered when ENT1 fluconazole ENT1END is administered in patients who are at risk for ENT2 ventricular arrhythmias ENT2END
0	The possible mechanism is depression of rapidly activating delayed rectifier ENT1 potassium  ENT1END currents. In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology. CONCLUSIONS: Clinicians should be aware that fluconazole, even at low doses, may cause prolongation of the QT interval, leading to TDP. Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ENT2 ventricular arrhythmias ENT2END
0	CONCLUSIONS: Clinicians should be aware that ENT1 fluconazole ENT1END  even at low doses, may cause ENT2 prolongation of the QT interval ENT2END , leading to TDP
0	The possible mechanism is depression of rapidly activating delayed rectifier ENT1 potassium ENT1END  currents. In our patient, there was no other etiology identified that could explain ENT2 QT prolongation ENT2END or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology
0	The TDP resolved when ENT1 fluconazole ENT1END was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ENT2 ventricular tachycardia ENT2END (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP
0	The possible mechanism is depression of rapidly activating delayed rectifier ENT1 potassium ENT1END  currents. In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of ENT2 NSVT ENT2END and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology
0	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral ENT1 fluconazole ENT1END The patient had no other risk factors for TDP, including coronary artery disease, ENT2 cardiomyopathy ENT2END , congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP
0	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, ENT1 cardiomyopathy  ENT1END , congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP. The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP. The possible mechanism is depression of rapidly activating delayed rectifier ENT2 potassium ENT2END currents
0	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, ENT1 congestive heart failure ENT1END  and electrolyte abnormalities There was a temporal association between the initiation of ENT2 fluconazole ENT2END and TDP
0	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, ENT1 congestive heart failure  ENT1END , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP. The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP. The possible mechanism is depression of rapidly activating delayed rectifier ENT2 potassium ENT2END currents
0	The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of ENT1 fluconazole ENT1END and the development of TDP. The possible mechanism is ENT2 depression ENT2END of rapidly activating delayed rectifier potassium currents
0	The possible mechanism is ENT1 depression  ENT1END  of rapidly activating delayed rectifier ENT2 potassium ENT2END currents
0	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral ENT1 fluconazole ENT1END  The patient had no other risk factors for TDP, including ENT2 coronary artery disease ENT2END , cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP
0	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including ENT1 coronary artery disease  ENT1END , cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP. The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP. The possible mechanism is depression of rapidly activating delayed rectifier ENT2 potassium ENT2END currents
1	CASE SUMMARY: A 68-year-old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP, including coronary artery disease, cardiomyopathy, congestive heart failure, and electrolyte abnormalities There was a temporal association between the initiation of ENT1 fluconazole ENT1END  and ENT2 TDP ENT2END
0	The TDP resolved when fluconazole was discontinued; however, the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of ENT1 TDP  ENT1END  The possible mechanism is depression of rapidly activating delayed rectifier ENT2 potassium ENT2END currents
0	The TDP resolved when ENT1 fluconazole ENT1END  was discontinued; however, the patient continued to have ENT2 premature ventricular contractions ENT2END and nonsustained ventricular tachycardia (NSVT) until six days after drug cessation DISCUSSION: Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP
0	The possible mechanism is depression of rapidly activating delayed rectifier ENT1 potassium ENT1END  currents. In our patient, there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and ENT2 premature ventricular contractions ENT2END followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology
0	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by ENT1 weight gain ENT1END over 8 weeks of treatment. The ENT2 CBZ ENT2END levels measured in plasma and brain of these animals, however, were below those normally considered protective
0	In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited ENT1 weight gain ENT1END  Seizures induced by ENT2 hexafluorodiethyl ether ENT2END (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES)
0	In the course of developing this model, a common vehicle, ENT1 propylene glycol  ENT1END  by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited ENT2 weight gain ENT2END
0	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against HFDE-induced seizures and was minimally toxic as measured by ENT1 weight gain ENT1END  over 8 weeks of treatment. The CBZ levels measured in plasma and brain of these animals, however, were below those normally considered protective. This treatment with CBZ had no apparent adverse effect on ENT2 folate ENT2END concentrations in the rat, and, indeed, the folate concentration increased in liver after 6 weeks of treatment and in plasma at 8 weeks of treatment
0	Seizures induced by hexafluorodiethyl ether (HFDE) were also found to be a more sensitive measure of protection by ENT1 CBZ ENT1END than ENT2 seizures ENT2END induced by maximal electroshock (MES)
1	Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg/kg was continuously protective against ENT1 HFDE ENT1END induced ENT2 seizures ENT2END and was minimally toxic as measured by weight gain over 8 weeks of treatment
0	In the course of developing this model, a common vehicle, ENT1 propylene glycol ENT1END , by itself in high doses, was found to exhibit protective properties against induced ENT2 seizures ENT2END and inhibited weight gain
0	A rat model was developed to examine the effects of chronic CBZ treatment on ENT1 folate  ENT1END concentrations in the rat. In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced ENT2 seizures ENT2END and inhibited weight gain
0	Chronic ENT1 carbamazepine  ENT1END  treatment in the rat: efficacy, ENT2 toxicity ENT2END , and effect on plasma and tissue folate concentrations
0	Chronic carbamazepine treatment in the rat: efficacy, ENT1 toxicity  ENT1END , and effect on plasma and tissue folate concentrations.Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy. Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies. A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat. In the course of developing this model, a common vehicle, propylene glycol, by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain. Seizures induced by ENT2 hexafluorodiethyl ether ENT2END (HFDE) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock (MES)
0	Chronic carbamazepine treatment in the rat: efficacy, ENT1 toxicity  ENT1END , and effect on plasma and tissue folate concentrations.Folate depletion has often been a problem in chronic antiepileptic drug (AED) therapy. Carbamazepine (CBZ), a commonly used AED, has been implicated in some clinical studies. A rat model was developed to examine the effects of chronic CBZ treatment on folate concentrations in the rat. In the course of developing this model, a common vehicle, ENT2 propylene glycol ENT2END , by itself in high doses, was found to exhibit protective properties against induced seizures and inhibited weight gain
0	Chronic carbamazepine treatment in the rat: efficacy, ENT1 toxicity  ENT1END , and effect on plasma and tissue ENT2 folate ENT2END concentrations
0	Severe and long lasting cholestasis after high-dose ENT1 co-trimoxazole  ENT1END  treatment for Pneumocystis pneumonia in ENT2 HIV-infected ENT2END patients--a report of two cases
1	Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe ENT1 intrahepatic cholestasis ENT1END  and in one patient lesions mimicking liver abscess formation on radiologic exams, during ENT2 co-trimoxazole ENT2END treatment for PCP
0	Severe and long lasting ENT1 cholestasis  ENT1END  after high-dose ENT2 co-trimoxazole ENT2END treatment for Pneumocystis pneumonia in HIV-infected patients--a report of two cases
0	Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking ENT1 liver abscess  ENT1END formation on radiologic exams, during ENT2 co-trimoxazole ENT2END treatment for PCP
0	Here, we report two cases of severely immunocompromised HIV-infected patients who developed severe intrahepatic cholestasis, and in one patient lesions mimicking liver abscess formation on radiologic exams, during ENT1 co-trimoxazole ENT1END  treatment for ENT2 PCP ENT2END
0	Pneumocystis pneumonia (PCP), a common ENT1 opportunistic infection ENT1END in HIV-infected individuals, is generally treated with high doses of ENT2 co-trimoxazole ENT2END
1	This was their first day of ENT1 pemoline ENT1END therapy. The ENT2 choreoathetoid ENT2END movements began 45 min to 1 h after ingestion
0	The children had a medical history significant for attention deficit disorder previously treated with ENT1 methylphenidate  ENT1END without success. This was their first day of pemoline therapy. The ENT2 choreoathetoid ENT2END movements began 45 min to 1 h after ingestion
0	Pemoline induced acute ENT1 choreoathetosis ENT1END : case report and review of the literature.BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from ENT2 amphetamines ENT2END and used in the treatment of attention deficit disorder
0	The children received gastrointestinal decontamination and high doses of intravenous ENT1 benzodiazepines ENT1END in an attempt to control the ENT2 choreoathetoid ENT2END movements
0	Pemoline induced acute ENT1 choreoathetosis ENT1END : case report and review of the literature.BACKGROUND: Pemoline is an ENT2 oxazolidine ENT2END derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder
1	The possibility of choreoathetoid movements should be considered in patients presenting after ENT1 pemoline ENT1END ENT2 overdose ENT2END
0	The children received gastrointestinal decontamination and high doses of intravenous ENT1 benzodiazepines  ENT1END  in an attempt to control the choreoathetoid movements. Despite treatment, the children continued to have choreoathetosis for approximately 24 hours. Forty-eight hours after admission, the children appeared to be at their baseline and were discharged home. CONCLUSION: Pemoline associated movement disorder has been rarely reported in the acute toxicology literature. The possibility of choreoathetoid movements should be considered in patients presenting after pemoline ENT2 overdose ENT2END
1	This was their first day of ENT1 pemoline ENT1END  therapy. The ENT2 choreoathetoid ENT2END movements began 45 min to 1 h after ingestion
0	The children had a medical history significant for attention deficit disorder previously treated with ENT1 methylphenidate  ENT1END  without success. This was their first day of pemoline therapy. The ENT2 choreoathetoid ENT2END movements began 45 min to 1 h after ingestion
0	Pemoline induced acute ENT1 choreoathetosis  ENT1END : case report and review of the literature.BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from ENT2 amphetamines ENT2END and used in the treatment of attention deficit disorder
0	The children received gastrointestinal decontamination and high doses of intravenous ENT1 benzodiazepines ENT1END  in an attempt to control the ENT2 choreoathetoid ENT2END movements
0	Pemoline induced acute ENT1 choreoathetosis  ENT1END : case report and review of the literature.BACKGROUND: Pemoline is an ENT2 oxazolidine ENT2END derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder
0	BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of ENT1 attention deficit disorder ENT1END  ENT2 Pemoline ENT2END has not been commonly associated in the literature as a cause of acute movement disorders
0	The children had a medical history significant for ENT1 attention deficit disorder  ENT1END previously treated with ENT2 methylphenidate ENT2END without success
0	BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from ENT1 amphetamines  ENT1END  and used in the treatment of ENT2 attention deficit disorder ENT2END
0	The children had a medical history significant for ENT1 attention deficit disorder  ENT1END  previously treated with methylphenidate without success. This was their first day of pemoline therapy. The choreoathetoid movements began 45 min to 1 h after ingestion. The children gave no history of prior movement disorders and there was no family history of movement disorders. The children received gastrointestinal decontamination and high doses of intravenous ENT2 benzodiazepines ENT2END in an attempt to control the choreoathetoid movements
0	BACKGROUND: Pemoline is an ENT1 oxazolidine  ENT1END  derivative that is structurally different from amphetamines and used in the treatment of ENT2 attention deficit disorder ENT2END
0	CONCLUSION: ENT1 Pemoline ENT1END associated ENT2 movement disorder ENT2END has been rarely reported in the acute toxicology literature
0	The children had a medical history significant for attention deficit disorder previously treated with ENT1 methylphenidate ENT1END  without success. This was their first day of pemoline therapy. The choreoathetoid movements began 45 min to 1 h after ingestion. The children gave no history of prior ENT2 movement disorders ENT2END and there was no family history of movement disorders
0	BACKGROUND: Pemoline is an oxazolidine derivative that is structurally different from ENT1 amphetamines ENT1END  and used in the treatment of attention deficit disorder. Pemoline has not been commonly associated in the literature as a cause of acute ENT2 movement disorders ENT2END
0	The children gave no history of prior movement disorders and there was no family history of ENT1 movement disorders  ENT1END  The children received gastrointestinal decontamination and high doses of intravenous ENT2 benzodiazepines ENT2END in an attempt to control the choreoathetoid movements
0	BACKGROUND: Pemoline is an ENT1 oxazolidine  ENT1END  derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder. Pemoline has not been commonly associated in the literature as a cause of acute ENT2 movement disorders ENT2END
0	The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on ENT1 parkinsonian ENT1END 'off' signs and ENT2 levodopa ENT2END -induced dyskinesias (LID)
1	The objective of this study was to explore the functional anatomy of the globus pallidus internus (GPi) by studying the effects of unilateral pallidotomy on parkinsonian 'off' signs and ENT1 levodopa ENT1END -induced ENT2 dyskinesias ENT2END (LID)
1	ENT1 Ethambutol  ENT1END -associated ENT2 optic neuropathy ENT2END
0	We report 3 cases which presented with ENT1 bitemporal hemianopia ENT1END  CLINICAL PICTURE: Three patients with ENT2 ethambutol ENT2END -associated toxic optic neuropathy are described
0	INTRODUCTION: ENT1 Ethambutol ENT1END is used in the treatment of ENT2 tuberculosis ENT2END , which is still prevalent in Southeast Asia, and can be associated with permanent visual loss
1	OUTCOME: All 3 patients had some permanent ENT1 loss of visual function ENT1END  CONCLUSIONS: ENT2 Ethambutol ENT2END usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow-up
1	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with ENT1 cinacalcet  ENT1END (33 versus 86%), the most frequent of which ( ENT2 nausea ENT2END and headache) have been reported for patients treated with either desipramine or cinacalcet
1	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving ENT1 desipramine ENT1END with cinacalcet (33 versus 86%), the most frequent of which ENT2 nausea ENT2END and headache) have been reported for patients treated with either desipramine or cinacalcet
1	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with ENT1 cinacalcet ENT1END  (33 versus 86%), the most frequent of which (nausea and ENT2 headache ENT2END ) have been reported for patients treated with either desipramine or cinacalcet
1	Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet (33 versus 86%), the most frequent of which (nausea and ENT1 headache ENT1END ) have been reported for patients treated with either ENT2 desipramine ENT2END or cinacalcet
1	However, compression neuropathy due to fibrotic muscle affected by ENT1 pentazocine ENT1END induced ENT2 myopathy ENT2END has not previously been reported
1	ENT1 Compression neuropathy of the radial nerve  ENT1END  due to ENT2 pentazocine ENT2END -induced fibrous myopathy
1	Compression neuropathy of the radial nerve due to ENT1 pentazocine  ENT1END -induced ENT2 fibrous myopathy ENT2END
1	ENT1 Compression neuropathy of the radial nerve  ENT1END  due to ENT2 pentazocine ENT2END -induced fibrous myopathy
0	In Australia, the pediatric usage of aspirin has been extremely low for the past 25 years (less than 1% of total dosage units sold), with paracetamol ( ENT1 acetaminophen ENT1END  dominating the pediatric analgesic and antipyretic market. ENT2 Reye syndrome ENT2END may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion, since there were no cases found at The Children's Hospital in 1983, 1984, or 1985
0	Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of ENT1 Reye syndrome ENT1END  Aspirin or ENT2 salicylate ENT2END ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%)
1	Of these, 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of ENT1 Reye syndrome ENT1END . ENT2 Aspirin ENT2END or salicylate ingestion had occurred in only one of the 20 cases (5%), and paracetamol (acetaminophen) had been administered in only six of the cases (30%)
1	High-dose ENT1 testosterone  ENT1END  is associated with ENT2 atherosclerosis ENT2END in postmenopausal women
0	METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy ( ENT1 estradiol- and testosterone esters ENT1END  and aortic ENT2 atherosclerosis ENT2END
0	The association remained after additional adjustment for diabetes, cholesterol level, systolic blood pressure, or ENT1 alcohol ENT1END use. No association was found for hormone use less than 1 year. CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect ENT2 atherosclerosis ENT2END in postmenopausal women and indicate that androgen replacement in these women may not be harmless
0	The association remained after additional adjustment for diabetes, ENT1 cholesterol  ENT1END level, systolic blood pressure, or alcohol use. No association was found for hormone use less than 1 year. CONCLUSION: Our results suggest that high-dose testosterone therapy may adversely affect ENT2 atherosclerosis ENT2END in postmenopausal women and indicate that androgen replacement in these women may not be harmless
0	METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose ENT1 estrogen  ENT1END testosterone therapy (estradiol- and testosterone esters) and aortic ENT2 atherosclerosis ENT2END
0	The association remained after additional adjustment for ENT1 diabetes ENT1END  cholesterol level, systolic blood pressure, or alcohol use. No association was found for hormone use less than 1 year. CONCLUSION: Our results suggest that high-dose ENT2 testosterone ENT2END therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless
0	METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose estrogen-testosterone therapy ( ENT1 estradiol- and testosterone esters  ENT1END ) and aortic atherosclerosis. Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis. Hormone therapy users were compared with never users. RESULTS: Intramuscular hormone therapy use for 1 year or longer was reported by 25 women. In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index). The association remained after additional adjustment for ENT2 diabetes ENT2END , cholesterol level, systolic blood pressure, or alcohol use
0	The association remained after additional adjustment for ENT1 diabetes  ENT1END , cholesterol level, systolic blood pressure, or ENT2 alcohol ENT2END use
0	The association remained after additional adjustment for ENT1 diabetes  ENT1END , ENT2 cholesterol ENT2END level, systolic blood pressure, or alcohol use
0	METHODS: In a population-based study in 513 naturally postmenopausal women aged 54-67 years, we studied the association between self-reported intramuscularly administered high-dose ENT1 estrogen  ENT1END -testosterone therapy (estradiol- and testosterone esters) and aortic atherosclerosis. Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta, which have been shown to reflect intima atherosclerosis. Hormone therapy users were compared with never users. RESULTS: Intramuscular hormone therapy use for 1 year or longer was reported by 25 women. In almost half of these women severe atherosclerosis of the aorta was present (n=11), while in women without hormone use severe atherosclerosis of the aorta was present in less than 20% (OR 3.1; 95% CI, 1.1-8.5, adjusted for age, years since menopause, smoking, and body mass index). The association remained after additional adjustment for ENT2 diabetes ENT2END , cholesterol level, systolic blood pressure, or alcohol use
0	ENT1 Isoniazid ENT1END was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of ENT2 cranial neuropathy ENT2END although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	Peripheral neuropathy due to nutritional deficiency of ENT1 thiamine  ENT1END and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of ENT2 cranial neuropathy ENT2END although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	Peripheral neuropathy due to nutritional deficiency of thiamine and ENT1 riboflavin  ENT1END was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of ENT2 cranial neuropathy ENT2END although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	ENT1 Isoniazid ENT1END  was the most frequent agent in drug-induced neuropathy. ENT2 Migraine ENT2END (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	Peripheral neuropathy due to nutritional deficiency of ENT1 thiamine  ENT1END  and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. ENT2 Migraine ENT2END (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	Peripheral neuropathy due to nutritional deficiency of thiamine and ENT1 riboflavin  ENT1END  was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. ENT2 Migraine ENT2END (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	Diabetes mellitus was the major cause of ENT1 autonomic neuropathy ENT1END ENT2 Isoniazid ENT2END was the most frequent agent in drug-induced neuropathy
0	Peripheral neuropathy due to nutritional deficiency of ENT1 thiamine  ENT1END  and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of ENT2 autonomic neuropathy ENT2END
0	Peripheral neuropathy due to nutritional deficiency of thiamine and ENT1 riboflavin  ENT1END  was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of ENT2 autonomic neuropathy ENT2END
0	ENT1 Diabetes mellitus  ENT1END was the major cause of autonomic neuropathy. ENT2 Isoniazid ENT2END was the most frequent agent in drug-induced neuropathy
0	Peripheral neuropathy due to nutritional deficiency of ENT1 thiamine  ENT1END  and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. ENT2 Diabetes mellitus ENT2END was the major cause of autonomic neuropathy
0	Peripheral neuropathy due to nutritional deficiency of thiamine and ENT1 riboflavin  ENT1END  was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. ENT2 Diabetes mellitus ENT2END was the major cause of autonomic neuropathy
0	ENT1 Isoniazid ENT1END  was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of cranial neuropathy although ENT2 malignancies ENT2END arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	Peripheral neuropathy due to nutritional deficiency of ENT1 thiamine  ENT1END  and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of cranial neuropathy although ENT2 malignancies ENT2END arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	Peripheral neuropathy due to nutritional deficiency of thiamine and ENT1 riboflavin  ENT1END  was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of cranial neuropathy although ENT2 malignancies ENT2END arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%)
0	ENT1 Guillain-Barr   syndrome  ENT1END was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy. Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. ENT2 Isoniazid ENT2END was the most frequent agent in drug-induced neuropathy
0	ENT1 Guillain-Barr   syndrome  ENT1END  was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy. Peripheral neuropathy due to nutritional deficiency of ENT2 thiamine ENT2END and riboflavin was common (10
0	ENT1 Guillain-Barr   syndrome  ENT1END  was the commonest identifiable cause (15.6%), accounting for half of the cases with motor neuropathy. Peripheral neuropathy due to nutritional deficiency of thiamine and ENT2 riboflavin ENT2END was common (10
0	ENT1 Isoniazid ENT1END  was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%). In 26.5% of all the cases, the aetiology of the neuropathy was undetermined. Heredofamilial and ENT2 connective tissue disorders ENT2END were rare
0	Peripheral neuropathy due to nutritional deficiency of ENT1 thiamine  ENT1END  and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%). In 26.5% of all the cases, the aetiology of the neuropathy was undetermined. Heredofamilial and ENT2 connective tissue disorders ENT2END were rare
0	Peripheral neuropathy due to nutritional deficiency of thiamine and ENT1 riboflavin  ENT1END  was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. Isoniazid was the most frequent agent in drug-induced neuropathy. Migraine (20%) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent (26%). In 26.5% of all the cases, the aetiology of the neuropathy was undetermined. Heredofamilial and ENT2 connective tissue disorders ENT2END were rare
1	1%) and presented mainly as sensory and ENT1 sensori-motor neuropathy  ENT1END  Diabetes mellitus was the major cause of autonomic neuropathy. ENT2 Isoniazid ENT2END was the most frequent agent in drug-induced neuropathy
1	ENT1 Peripheral neuropathy  ENT1END due to nutritional deficiency of ENT2 thiamine ENT2END and riboflavin was common (10
1	ENT1 Peripheral neuropathy  ENT1END  due to nutritional deficiency of thiamine and ENT2 riboflavin ENT2END was common (10
0	Peripheral neuropathy due to ENT1 nutritional deficiency  ENT1END of thiamine and riboflavin was common (10.1%) and presented mainly as sensory and sensori-motor neuropathy. Diabetes mellitus was the major cause of autonomic neuropathy. ENT2 Isoniazid ENT2END was the most frequent agent in drug-induced neuropathy
0	Peripheral neuropathy due to ENT1 nutritional deficiency  ENT1END  of ENT2 thiamine ENT2END and riboflavin was common (10
0	Peripheral neuropathy due to ENT1 nutritional deficiency  ENT1END  of thiamine and ENT2 riboflavin ENT2END was common (10
0	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to ENT1 paclitaxel ENT1END and cisplatin, two widely used and highly effective chemotherapeutic drugs. This approach allowed investigating the efficacy of alpha-lipoic acid in preventing ENT2 axonal damage ENT2END and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid
0	This approach allowed investigating the efficacy of ENT1 alpha-lipoic acid  ENT1END in preventing ENT2 axonal damage ENT2END and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid
0	We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and ENT1 cisplatin  ENT1END  two widely used and highly effective chemotherapeutic drugs. This approach allowed investigating the efficacy of alpha-lipoic acid in preventing ENT2 axonal damage ENT2END and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha-lipoic acid
0	Our results demonstrate that both cisplatin and ENT1 paclitaxel ENT1END cause early ENT2 mitochondrial impairment ENT2END with loss of membrane potential and induction of autophagic vacuoles in neurons
0	ENT1 Alpha-lipoic acid  ENT1END  prevents ENT2 mitochondrial damage ENT2END and neurotoxicity in experimental chemotherapy neuropathy
0	Our results demonstrate that both ENT1 cisplatin  ENT1END and paclitaxel cause early ENT2 mitochondrial impairment ENT2END with loss of membrane potential and induction of autophagic vacuoles in neurons
1	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in ENT1 toxic neurodegenerative cascade  ENT1END  and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection. We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to ENT2 paclitaxel ENT2END and cisplatin, two widely used and highly effective chemotherapeutic drugs
0	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in ENT1 toxic neurodegenerative cascade ENT1END , and if neuroprotective effects of ENT2 alpha-lipoic acid ENT2END depend on mitochondria protection
1	The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in ENT1 toxic neurodegenerative cascade  ENT1END , and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection. We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and ENT2 cisplatin ENT2END , two widely used and highly effective chemotherapeutic drugs
1	We used an in vitro model of chemotherapy induced ENT1 peripheral neuropathy  ENT1END that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to ENT2 paclitaxel ENT2END and cisplatin, two widely used and highly effective chemotherapeutic drugs
0	These findings suggest that ENT1 alpha-lipoic acid ENT1END might reduce the risk of developing ENT2 peripheral nerve toxicity ENT2END in patients undergoing chemotherapy and encourage further confirmatory clinical trials
1	We used an in vitro model of chemotherapy induced ENT1 peripheral neuropathy  ENT1END  that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and ENT2 cisplatin ENT2END , two widely used and highly effective chemotherapeutic drugs
0	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy ENT1 neuropathy  ENT1END .The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection. We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to ENT2 paclitaxel ENT2END and cisplatin, two widely used and highly effective chemotherapeutic drugs
0	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy ENT1 neuropathy ENT1END .The study investigates if ENT2 alpha-lipoic acid ENT2END is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection
0	Alpha-lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy ENT1 neuropathy  ENT1END .The study investigates if alpha-lipoic acid is neuroprotective against chemotherapy induced neurotoxicity, if mitochondrial damage plays a critical role in toxic neurodegenerative cascade, and if neuroprotective effects of alpha-lipoic acid depend on mitochondria protection. We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion (DRG) sensory neurons to paclitaxel and ENT2 cisplatin ENT2END , two widely used and highly effective chemotherapeutic drugs
0	In conclusion mitochondrial toxicity is an early common event both in ENT1 paclitaxel ENT1END and cisplatin induced ENT2 neurotoxicity ENT2END
0	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced ENT1 neurotoxicity ENT1END . ENT2 Alpha-lipoic acid ENT2END protects sensory neurons through its anti-oxidant and mitochondrial regulatory functions, possibly inducing the expression of frataxin
0	In conclusion mitochondrial toxicity is an early common event both in paclitaxel and ENT1 cisplatin  ENT1END induced ENT2 neurotoxicity ENT2END
1	We wanted to study whether ENT1 tAMCA ENT1END retains its ENT2 convulsive ENT2END action if incorporated into a FS
0	However, ENT1 tAMCA ENT1END has been shown to cause ENT2 epileptic seizures ENT2END
0	In spontaneously ENT1 hypertensive ENT1END  stroke-prone rats, microinjection of ENT2 methyldopa ENT2END into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly
0	In spontaneously ENT1 hypertensive ENT1END , stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin ENT2 5,7-dihydroxytryptamine ENT2END (5,7-DHT) injected intracerebroventricularly
0	The present experiments were designed to investigate the role of the midline cells of the B3 ENT1 serotonin  ENT1END neurons in the medulla, coinciding with the raphe magnus. In spontaneously ENT2 hypertensive ENT2END , stroke-prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly
1	It is concluded therefore that, unlike the ventrolateral B3 cells which mediate a ENT1 methyldopa ENT1END induced ENT2 hypotension ENT2END via descending projections, the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa, either by way of an ascending projection which does not pass through the median forebrain bundle, or through a projection restricted to the caudal brainstem
0	However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this ENT1 hypotension ENT1END  Further, ENT2 5,7-DHT ENT2END lesion of serotonin nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection
0	However, intraspinal injection of 5,7-DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this ENT1 hypotension ENT1END . Further, 5,7-DHT lesion of ENT2 serotonin ENT2END nerves travelling in the median forebrain bundle, one of the main ascending pathways from the B3 serotonin cells, did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection
0	In spontaneously hypertensive, ENT1 stroke  ENT1END prone rats, microinjection of ENT2 methyldopa ENT2END into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly
0	In spontaneously hypertensive, ENT1 stroke  ENT1END -prone rats, microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin ENT2 5,7-dihydroxytryptamine ENT2END (5,7-DHT) injected intracerebroventricularly
0	In spontaneously hypertensive, ENT1 stroke ENT1END -prone rats, microinjection of methyldopa into the area of the midline B3 ENT2 serotonin ENT2END cell group in the ventral medulla caused a potent hypotension of 30-40 mm Hg, which was maximal 2-3 h after administration and was abolished by the serotonin neurotoxin 5,7-dihydroxytryptamine (5,7-DHT) injected intracerebroventricularly
1	After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for ENT1 paclitaxel ENT1END (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%). World Health Organization Grade 3-4 neutropenia and ENT2 thrombocytopenia ENT2END occurred in 39
1	3%), 117 mg/m(2) for ENT1 cisplatin  ENT1END (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%). World Health Organization Grade 3-4 neutropenia and ENT2 thrombocytopenia ENT2END occurred in 39
1	3%), and 1378 mg/m(2) for ENT1 gemcitabine  ENT1END (86.2%). World Health Organization Grade 3-4 neutropenia and ENT2 thrombocytopenia ENT2END occurred in 39
0	METHODS: The objective of this study was to determine the feasibility, response rate, and ENT1 toxicity ENT1END of a ENT2 paclitaxel ENT2END , cisplatin, and gemcitabine combination to treat metastatic NSCLC
0	METHODS: The objective of this study was to determine the feasibility, response rate, and ENT1 toxicity ENT1END  of a paclitaxel, ENT2 cisplatin ENT2END , and gemcitabine combination to treat metastatic NSCLC
0	METHODS: The objective of this study was to determine the feasibility, response rate, and ENT1 toxicity ENT1END  of a paclitaxel, cisplatin, and ENT2 gemcitabine ENT2END combination to treat metastatic NSCLC
0	There was one treatment-related ENT1 death ENT1END  Nonhematologic toxicities were mild. After a median follow-up of 22 months, the median progression free survival rate was 7 months, and the median survival time was 16 months. CONCLUSIONS: The combination of ENT2 paclitaxel ENT2END , cisplatin, and gemcitabine is well tolerated and shows high activity in metastatic NSCLC
0	3%), 117 mg/m(2) for ENT1 cisplatin  ENT1END  (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%). World Health Organization Grade 3-4 neutropenia and thrombocytopenia occurred in 39.9% and 11.4% of patients, respectively. There was one treatment-related ENT2 death ENT2END
0	3%), and 1378 mg/m(2) for ENT1 gemcitabine  ENT1END  (86.2%). World Health Organization Grade 3-4 neutropenia and thrombocytopenia occurred in 39.9% and 11.4% of patients, respectively. There was one treatment-related ENT2 death ENT2END
1	After 154 courses of therapy, the median dose intensity was 131 mg/m(2) for ENT1 paclitaxel ENT1END  (97.3%), 117 mg/m(2) for cisplatin (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%). World Health Organization Grade 3-4 ENT2 neutropenia ENT2END and thrombocytopenia occurred in 39
1	3%), 117 mg/m(2) for ENT1 cisplatin  ENT1END  (97.3%), and 1378 mg/m(2) for gemcitabine (86.2%). World Health Organization Grade 3-4 ENT2 neutropenia ENT2END and thrombocytopenia occurred in 39
1	3%), and 1378 mg/m(2) for ENT1 gemcitabine  ENT1END  (86.2%). World Health Organization Grade 3-4 ENT2 neutropenia ENT2END and thrombocytopenia occurred in 39
0	METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a ENT1 paclitaxel ENT1END , cisplatin, and gemcitabine combination to treat metastatic ENT2 NSCLC ENT2END
0	Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic ENT1 nonsmall cell lung carcinoma ENT1END .BACKGROUND: ENT2 Cisplatin ENT2END -based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma (NSCLC)
0	METHODS: The objective of this study was to determine the feasibility, response rate, and toxicity of a paclitaxel, cisplatin, and ENT1 gemcitabine  ENT1END  combination to treat metastatic ENT2 NSCLC ENT2END
0	OBJECTIVE: The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with ENT1 beta-thalassemia ENT1END major. METHODS: One hundred and four (104) patients aged 6-35 years (mean 17,2 years) participated in the study. All patients were on a regular transfusion-chelation program maintaining a mean hemoglobin level of 9.5 gr/dl. Subjects were receiving ENT2 desferrioxamine ENT2END (DFO) chelation treatment with a mean daily dose of 50-60 mg/kg, 5-6 days a week during the first six years of the study, which was then reduced to 40-50 mg/kg for the following eight years
1	Subjects with ENT1 SNHL ENT1END were submitted to ENT2 DFO ENT2END reduction or temporary withdrawal
0	No ENT1 ototoxic ENT1END factor, other than ENT2 DFO ENT2END , was present in any of the patients
0	CONCLUSION: The findings are indicative of ENT1 DFO ENT1END s contributing role in the development of ENT2 hearing impairment ENT2END
0	CONCLUSION: The findings are indicative of ENT1 DFO ENT1END 's contributing role in the development of hearing impairment. Regular audiologic evaluation is imperative in all ENT2 thalassemic ENT2END patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment
0	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of ENT1 anaemia ENT1END observed when compared with ENT2 phenylhydrazine ENT2END (PHZ) treated mice
1	We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if ENT1 AZT ENT1END induced ENT2 anaemia ENT2END is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)
0	The numbers of BFU-e and the percentage of bone marrow erythroblasts observed were comparable in AZT and ENT1 PHZ ENT1END treated mice with similar degrees of anaemia. However, ENT2 reticulocytosis ENT2END was inappropriate for the degree of anaemia observed in AZT treated infected mice
0	However, ENT1 reticulocytosis ENT1END  was inappropriate for the degree of anaemia observed in ENT2 AZT ENT2END treated infected mice
0	Sensitivity of erythroid progenitor colonies to erythropoietin in ENT1 azidothymidine  ENT1END  treated ENT2 immunodeficient ENT2END mice
0	The anaemia induced by 3'-azido-3'dideoxythymidine ( ENT1 AZT ENT1END  is poorly understood. We have used a murine model of AIDS, ENT2 infection ENT2END of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)
0	We have used a murine model of AIDS, infection of female C57BL/6 mice with LP-BM5 murine ENT1 leukaemia  ENT1END (MuLV) virus, to determine if ENT2 AZT ENT2END -induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)
0	The anaemia induced by 3'-azido-3'dideoxythymidine ( ENT1 AZT ENT1END ) is poorly understood. We have used a murine model of ENT2 AIDS ENT2END , infection of female C57BL/6 mice with LP-BM5 murine leukaemia (MuLV) virus, to determine if AZT-induced anaemia is due, in part, to decreased responsiveness of erythropoietic precursors (BFU-e) to erythropoietin (EPO)
1	The effects of exercise on the severity of ENT1 isoproterenol ENT1END induced ENT2 myocardial infarction ENT2END were studied in female albino rats of 20,40,60 and 80 weeks of age
0	The occurrence of ENT1 infarcts  ENT1END were confirmed by histological methods. Elevations in the serum GOT and GPT were maximum in the sedentary- ENT2 isoproterenols ENT2END and minimum in the exercise-controls
1	Ammonia ( ENT1 NH3 ENT1END  was higher in patients who, during continuous therapy, complained of ENT2 drowsiness ENT2END (7 patients) than in those who were symptom-free (17 patients), although VPA plasma levels were similar in both groups
1	Ammonia (NH3) was higher in patients who, during continuous therapy, complained of ENT1 drowsiness ENT1END  (7 patients) than in those who were symptom-free (17 patients), although ENT2 VPA ENT2END plasma levels were similar in both groups
0	Acute changes of blood ENT1 ammonia ENT1END  may predict short-term adverse effects of valproic acid.Valproic acid (VPA) was given to 24 ENT2 epileptic ENT2END patients who were already being treated with other antiepileptic drugs
0	Valproic acid ( ENT1 VPA  ENT1END  was given to 24 ENT2 epileptic ENT2END patients who were already being treated with other antiepileptic drugs
0	This case report describes a generalized seizure associated with sustained-release ENT1 bupropion ENT1END use and ENT2 sleep deprivation ENT2END
1	We suggest that sleep deprivation may add to the risk of ENT1 bupropion ENT1END associated ENT2 seizures ENT2END
1	Mitochondrial injury may be involved in the progression of ENT1 heart failure ENT1END caused by ENT2 adriamycin ENT2END via the autophagy pathway
0	METHODS: 3-methyladenine (3MA), a specific inhibitor on autophagy was used in a ENT1 heart failure  ENT1END model of rats induced by adriamycin. Neonatal cardiomyocytes were isolated from Sprague-Dawley rat hearts and randomly divided into controls, an adriamycin-treated group, and a 3MA plus adriamycin-treated group. We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+- ENT2 K ENT2END + ATPase activity in vivo
0	The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin, so that we can develop a novel treatment strategy for ENT1 heart failure ENT1END  METHODS: ENT2 3-methyladenine ENT2END (3MA), a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin
0	ENT1 Adriamycin  ENT1END -induced autophagic cardiomyocyte ENT2 death ENT2END plays a pathogenic role in a rat model of heart failure
0	We then examined the morphology, expression of beclin 1 gene, mitochondrial permeability transition (MPT), and Na+- ENT1 K ENT1END + ATPase activity in vivo. We also assessed cell viability, mitochondrial membrane potential changes and counted autophagic vacuoles in cultured cardiomyocytes. In addition, we analyzed the expression of autophagy associated gene, beclin 1 using RT-PCR and Western blotting in an animal model. RESULTS: 3MA significantly improved cardiac function and reduced mitochondrial injury. Furthermore, adriamycin induced the formation of autophagic vacuoles, and 3MA strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles. CONCLUSION: Autophagic cardiomyocyte ENT2 death ENT2END plays an important role in the pathogenesis of heart failure in rats induced by adriamycin
0	Furthermore, adriamycin induced the formation of autophagic vacuoles, and ENT1 3MA  ENT1END strongly downregulated the expression of beclin 1 in adriamycin-induced failing heart and inhibited the formation of autophagic vacuoles. CONCLUSION: Autophagic cardiomyocyte ENT2 death ENT2END plays an important role in the pathogenesis of heart failure in rats induced by adriamycin
0	There was no evidence of ENT1 cardiotoxicity ENT1END  In this small patient sample, liposomal ENT2 daunorubicin ENT2END was an effective and well tolerated agent in the treatment of Kaposi's sarcoma
0	The main problem encountered was haematological ENT1 toxicity  ENT1END  with three subjects experiencing severe neutropenia (neutrophil count < 0.5 x 10(9)/l). There was no evidence of cardiotoxicity. In this small patient sample, liposomal ENT2 daunorubicin ENT2END was an effective and well tolerated agent in the treatment of Kaposi's sarcoma
0	We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal ENT1 daunorubicin ENT1END (DaunoXome) in the treatment of AIDS related Kaposi's sarcoma. Eleven homosexual men with advanced Kaposi's sarcoma were entered in the trial. Changes in size, colour and associated ENT2 oedema ENT2END of selected 'target' lesions were measured
0	Liposomal ENT1 daunorubicin  ENT1END  in advanced ENT2 Kaposi's sarcoma ENT2END : a phase II study
1	The main problem encountered was haematological toxicity, with three subjects experiencing severe ENT1 neutropenia  ENT1END (neutrophil count < 0.5 x 10(9)/l). There was no evidence of cardiotoxicity. In this small patient sample, liposomal ENT2 daunorubicin ENT2END was an effective and well tolerated agent in the treatment of Kaposi's sarcoma
0	We report a non-randomized Phase II clinical trial to assess the efficacy and safety of liposomal ENT1 daunorubicin ENT1END  (DaunoXome) in the treatment of ENT2 AIDS ENT2END related Kaposi's sarcoma
1	ENT1 Nicotine  ENT1END -induced ENT2 nystagmus ENT2END correlates with midpontine activation
0	ENT1 NIN ENT1END correlated with blood ENT2 oxygen ENT2END level-dependent (BOLD) activity levels in a midpontine site in the posterior basis pontis
0	Allergic manifestations such as ENT1 rash ENT1END and eosinophilia were rare. Hepatitis was usually reversible when treatment was stopped, with the results of liver function tests returning to normal after an average of 3.1 months. In two of the three deaths probably associated with ENT2 ketoconazole ENT2END treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis
0	In two of the three ENT1 deaths  ENT1END probably associated with ENT2 ketoconazole ENT2END treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis
1	In contrast, the results of histological examination of the liver often showed evidence of ENT1 cholestasis  ENT1END  The characteristics of the 48 patients in the possible cases were similar. Allergic manifestations such as rash and eosinophilia were rare. Hepatitis was usually reversible when treatment was stopped, with the results of liver function tests returning to normal after an average of 3.1 months. In two of the three deaths probably associated with ENT2 ketoconazole ENT2END treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis
0	Allergic manifestations such as rash and ENT1 eosinophilia  ENT1END were rare. Hepatitis was usually reversible when treatment was stopped, with the results of liver function tests returning to normal after an average of 3.1 months. In two of the three deaths probably associated with ENT2 ketoconazole ENT2END treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis
1	Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ENT1 ketoconazole ENT1END to prevent possible serious ENT2 hepatic injury ENT2END
1	In two of the three deaths probably associated with ENT1 ketoconazole ENT1END  treatment the drug had been continued after the onset of ENT2 jaundice ENT2END and other symptoms of hepatitis
0	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine-induced ENT1 myocardial ischemia ENT1END .STUDY OBJECTIVE: To determine the effect of metoprolol on dobutamine stress testing with ENT2 technetium-99m sestamibi ENT2END single-photon emission computed tomography imaging and ST-segment monitoring, and to assess the impact of intravenous glucagon on metoprolol's effects
1	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on ENT1 dobutamine  ENT1END -induced ENT2 myocardial ischemia ENT2END
0	Effect of intravenous metoprolol or intravenous ENT1 metoprolol  ENT1END  plus glucagon on dobutamine-induced ENT2 myocardial ischemia ENT2END
0	The animals that had experienced cyclic sucrose and chow were ENT1 hyperactive ENT1END in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection). These results suggest that a diet comprised of alternating deprivation and access to a sugar solution and chow produces bingeing on sugar that leads to a long lasting state of increased sensitivity to amphetamine, possibly due to a lasting alteration in the ENT2 dopamine ENT2END system
1	The animals that had experienced cyclic ENT1 sucrose  ENT1END and chow were ENT2 hyperactive ENT2END in response to amphetamine compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection)
1	The animals that had experienced cyclic sucrose and chow were ENT1 hyperactive ENT1END  in response to ENT2 amphetamine ENT2END compared with four control groups (ad libitum 10% sucrose and chow followed by amphetamine injection, cyclic chow followed by amphetamine injection, ad libitum chow with amphetamine, or cyclic 10% sucrose and chow with a saline injection)
0	Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to ENT1 drug dependency ENT1END  The present study examined whether female rats on various regimens of sugar access would show behavioral cross-sensitization to a low dose of amphetamine. After a 30-min baseline measure of locomotor activity (day 0), animals were maintained on a cyclic diet of 12-h deprivation followed by 12-h access to 10% ENT2 sucrose ENT2END solution and chow pellets (12 h access starting 4 h after onset of the dark period) for 21 days
0	A diet promoting ENT1 sugar dependency  ENT1END  causes behavioral cross-sensitization to a low dose of ENT2 amphetamine ENT2END
1	In all subjects with history of ENT1 EMB ENT1END induced ENT2 optic neuropathy ENT2END , there was a mean loss of 72% nerve fiber layer thickness in the temporal quadrant (patient A, with eventual recovery of visual acuity and fields, 58% loss; patient B, with intermediate visual deficits, 68% loss; patient C, with chronic visual deficits, 90% loss), with an average mean optic nerve thickness of 26+/-16 microm
0	Additionally, in terms of management of EMB-induced optic neuropathy, it is important to properly manage ENT1 ethambutol ENT1END dosing in patients with ENT2 renal impairment ENT2END and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached
0	Ethambutol is an antimycobacterial agent often used to treat ENT1 tuberculosis ENT1END  A serious complication of ENT2 ethambutol ENT2END is an optic neuropathy that impairs visual acuity, contrast sensitivity, and color vision
1	METHODS: Three subjects with a history of ethambutol ( ENT1 EMB ENT1END -induced optic neuropathy of short-, intermediate-, and long-term ENT2 visual deficits ENT2END were administered a full neuro-ophthalmologic examination including visual acuity, color vision, contrast sensitivity, and fundus examination
0	PURPOSE: To map and identify the pattern, in vivo, of ENT1 axonal degeneration ENT1END in ENT2 ethambutol ENT2END -induced optic neuropathy using optical coherence tomography (OCT)
0	All patients with seizures did not have permanent ENT1 neurological abnormalities ENT1END  All 24 patients with seizures received high doses of ENT2 TXA ENT2END intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69
1	The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between ENT1 TXA ENT1END usage and ENT2 seizures ENT2END after cardiac surgery
0	RESULTS: Twenty-one of the 24 patients did not have evidence of new cerebral ischemic injury, but seizures were likely due to ENT1 ischemic brain injury  ENT1END in 3 patients. All patients with seizures did not have permanent neurological abnormalities. All 24 patients with seizures received high doses of ENT2 TXA ENT2END intraoperatively ranging from 61 to 259 mg/kg, had a mean age of 69
0	No evidence of ENT1 brain ischemic ENT1END  metabolic, or hyperthermia-induced causes for their seizures was apparent. CONCLUSION: Our results suggest that use of high-dose ENT2 TXA ENT2END in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients
0	No evidence of brain ischemic, metabolic, or ENT1 hyperthermia  ENT1END induced causes for their seizures was apparent. CONCLUSION: Our results suggest that use of high-dose ENT2 TXA ENT2END in older patients in conjunction with cardiopulmonary bypass and open-chamber cardiac surgery is associated with clinical seizures in susceptible patients
0	A case of massive rhabdomyolysis following ENT1 molindone ENT1END  administration.Rhabdomyolysis is a potentially lethal syndrome that ENT2 psychiatric ENT2END patients seem predisposed to develop
1	The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent ENT1 acute renal failure ENT1END following ENT2 molindone ENT2END administration
1	A case of massive ENT1 rhabdomyolysis  ENT1END  following ENT2 molindone ENT2END administration
0	The case of a ENT1 schizophrenic  ENT1END patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following ENT2 molindone ENT2END administration
0	PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of ENT1 methylprednisolone ENT1END and gentamicin into the posterior sub-Tenon's space at the end of routine ENT2 cataract ENT2END surgery
0	PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and ENT1 gentamicin  ENT1END into the posterior sub-Tenon's space at the end of routine ENT2 cataract ENT2END surgery
0	PURPOSE: To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub-Tenon's space at the end of routine ENT1 cataract ENT1END  surgery. SETTING: St. Luke's Hospital, Gwardamangia, Malta. METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain ENT2 lignocaine ENT2END
1	RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, ENT1 headache ENT1END  or both; 1 patient in Group B developed symptoms. CONCLUSIONS: The administration of ENT2 methylprednisolone ENT2END and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache
1	RESULTS: Sixty percent in Group A developed postoperative emetic symptoms, ENT1 headache ENT1END , or both; 1 patient in Group B developed symptoms. CONCLUSIONS: The administration of methylprednisolone and ENT2 gentamicin ENT2END in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache
0	METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain ENT1 lignocaine ENT1END . At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space. Postoperatively, all patients were assessed for symptoms of nausea, vomiting, and ENT2 headache ENT2END
1	RESULTS: Sixty percent in Group A developed ENT1 postoperative emetic symptoms  ENT1END  headache, or both; 1 patient in Group B developed symptoms. CONCLUSIONS: The administration of ENT2 methylprednisolone ENT2END and gentamicin in the posterior sub-Tenon's space was related to a high incidence of side effects including nausea, vomiting, and headache
1	CONCLUSIONS: The administration of methylprednisolone and ENT1 gentamicin ENT1END  in the posterior sub-Tenon's space was related to a high incidence of side effects including ENT2 nausea, vomiting ENT2END , and headache
0	METHODS: A double-blind double-armed prospective study comprised 40 patients who had uneventful sutureless phacoemulsification under sub-Tenon's local infiltration of 3 mL of plain ENT1 lignocaine ENT1END . At the end of the procedure, Group A (n = 20) had 20 mg/0.5 mL of methylprednisolone and 10 mg/0.5 mL of gentamicin injected into the posterior sub-Tenon's space and Group B (n = 20) had the same combination injected into the anterior sub-Tenon's space. Postoperatively, all patients were assessed for symptoms of ENT2 nausea, vomiting ENT2END , and headache
1	In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound ENT1 hypoxia ENT1END and cyanosis. This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a ENT2 propafenone ENT2END overdose
0	Transient platypnea-orthodeoxia-like syndrome induced by ENT1 propafenone  ENT1END  overdose in a young woman with ENT2 Ebstein's anomaly ENT2END
0	This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a ENT1 propafenone ENT1END  overdose. This drug caused biventricular dysfunction, due to its negative inotropic effect, and ENT2 hypotension ENT2END , due to its peripheral vasodilatory effect
0	This shunt of blood via a ENT1 patent foramen ovale  ENT1END occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a ENT2 propafenone ENT2END overdose
1	In this report we describe the case of a 37-year-old white woman with Ebstein's anomaly, who developed a rare syndrome called platypnea-orthodeoxia, characterized by massive right-to-left interatrial shunting with transient profound hypoxia and ENT1 cyanosis  ENT1END  This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a ENT2 propafenone ENT2END overdose
1	This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure, and was probably precipitated by a ENT1 propafenone ENT1END  overdose. This drug caused ENT2 biventricular dysfunction ENT2END , due to its negative inotropic effect, and hypotension, due to its peripheral vasodilatory effect
0	Transient platypnea-orthodeoxia-like syndrome induced by ENT1 propafenone ENT1END ENT2 overdose ENT2END in a young woman with Ebstein's anomaly
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT1 bleomycin ENT1END  and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy. Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the ENT2 anemia ENT2END and thrombocytopenia to drug-induced bone marrow suppression
0	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to ENT1 cisplatin  ENT1END nephrotoxicity and the ENT2 anemia ENT2END and thrombocytopenia to drug-induced bone marrow suppression
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT1 vinca alkaloid  ENT1END  One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy. Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the ENT2 anemia ENT2END and thrombocytopenia to drug-induced bone marrow suppression
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, ENT1 microangiopathic hemolytic anemia  ENT1END  and usually thrombocytopenia) after treatment with cisplatin, ENT2 bleomycin ENT2END , and a vinca alkaloid
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, ENT1 microangiopathic hemolytic anemia ENT1END , and usually thrombocytopenia) after treatment with ENT2 cisplatin ENT2END , bleomycin, and a vinca alkaloid
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, ENT1 microangiopathic hemolytic anemia  ENT1END , and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT2 vinca alkaloid ENT2END
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT1 bleomycin ENT1END , and a vinca alkaloid. One patient had ENT2 thrombotic thrombocytopenic purpura ENT2END , three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with ENT1 cisplatin  ENT1END , bleomycin, and a vinca alkaloid. One patient had ENT2 thrombotic thrombocytopenic purpura ENT2END , three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT1 vinca alkaloid  ENT1END . One patient had ENT2 thrombotic thrombocytopenic purpura ENT2END , three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT1 bleomycin ENT1END , and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was ENT2 tumor ENT2END -free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy
0	Because each patient was tumor-free or had only a small ENT1 tumor  ENT1END at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy. Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to ENT2 cisplatin ENT2END nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT1 vinca alkaloid  ENT1END . One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was ENT2 tumor ENT2END -free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually ENT1 thrombocytopenia  ENT1END  after treatment with cisplatin, ENT2 bleomycin ENT2END , and a vinca alkaloid
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually ENT1 thrombocytopenia  ENT1END ) after treatment with ENT2 cisplatin ENT2END , bleomycin, and a vinca alkaloid
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually ENT1 thrombocytopenia  ENT1END ) after treatment with cisplatin, bleomycin, and a ENT2 vinca alkaloid ENT2END
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT1 bleomycin ENT1END , and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of ENT2 intravascular coagulation ENT2END , primarily affecting the small arteries, arterioles, and glomeruli
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with ENT1 cisplatin  ENT1END , bleomycin, and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of ENT2 intravascular coagulation ENT2END , primarily affecting the small arteries, arterioles, and glomeruli
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT1 vinca alkaloid  ENT1END . One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of ENT2 intravascular coagulation ENT2END , primarily affecting the small arteries, arterioles, and glomeruli
0	Five patients with carcinoma developed ENT1 thrombotic microangiopathy  ENT1END (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT2 bleomycin ENT2END , and a vinca alkaloid
0	Five patients with carcinoma developed ENT1 thrombotic microangiopathy  ENT1END  (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with ENT2 cisplatin ENT2END , bleomycin, and a vinca alkaloid
0	Five patients with carcinoma developed ENT1 thrombotic microangiopathy  ENT1END  (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT2 vinca alkaloid ENT2END
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by ENT1 renal insufficiency  ENT1END  microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT2 bleomycin ENT2END , and a vinca alkaloid
0	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because ENT1 renal failure  ENT1END may be ascribed to ENT2 cisplatin ENT2END nephrotoxicity and the anemia and thrombocytopenia to drug-induced bone marrow suppression
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by ENT1 renal insufficiency  ENT1END , microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT2 vinca alkaloid ENT2END
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT1 bleomycin ENT1END , and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy. Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin ENT2 nephrotoxicity ENT2END and the anemia and thrombocytopenia to drug-induced bone marrow suppression
1	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to ENT1 cisplatin ENT1END ENT2 nephrotoxicity ENT2END and the anemia and thrombocytopenia to drug-induced bone marrow suppression
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT1 vinca alkaloid  ENT1END . One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy. Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin ENT2 nephrotoxicity ENT2END and the anemia and thrombocytopenia to drug-induced bone marrow suppression
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT1 bleomycin ENT1END , and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy. Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced ENT2 bone marrow suppression ENT2END
0	Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to ENT1 cisplatin  ENT1END  nephrotoxicity and the anemia and thrombocytopenia to drug-induced ENT2 bone marrow suppression ENT2END
0	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT1 vinca alkaloid  ENT1END . One patient had thrombotic thrombocytopenic purpura, three the hemolytic-uremic syndrome, and one an apparent forme fruste of one of these disorders. Histologic examination of the renal tissue showed evidence of intravascular coagulation, primarily affecting the small arteries, arterioles, and glomeruli. Because each patient was tumor-free or had only a small tumor at the onset of this syndrome, the thrombotic microangiopathy may have been induced by chemotherapy. Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined, because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug-induced ENT2 bone marrow suppression ENT2END
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT1 bleomycin ENT1END , and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the ENT2 hemolytic-uremic syndrome ENT2END , and one an apparent forme fruste of one of these disorders
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with ENT1 cisplatin  ENT1END , bleomycin, and a vinca alkaloid. One patient had thrombotic thrombocytopenic purpura, three the ENT2 hemolytic-uremic syndrome ENT2END , and one an apparent forme fruste of one of these disorders
1	Five patients with carcinoma developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT1 vinca alkaloid  ENT1END . One patient had thrombotic thrombocytopenic purpura, three the ENT2 hemolytic-uremic syndrome ENT2END , and one an apparent forme fruste of one of these disorders
0	Five patients with ENT1 carcinoma  ENT1END developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, ENT2 bleomycin ENT2END , and a vinca alkaloid
0	Five patients with ENT1 carcinoma  ENT1END  developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with ENT2 cisplatin ENT2END , bleomycin, and a vinca alkaloid
0	Five patients with ENT1 carcinoma  ENT1END  developed thrombotic microangiopathy (characterized by renal insufficiency, microangiopathic hemolytic anemia, and usually thrombocytopenia) after treatment with cisplatin, bleomycin, and a ENT2 vinca alkaloid ENT2END
0	Recombinant human erythropoietin has been used to manage ribavirin-associated ENT1 anemia ENT1END but has other potential disadvantages. ENT2 Viramidine ENT2END , a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C
0	Although ENT1 ribavirin ENT1END associated ENT2 anemia ENT2END can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates
0	Definition and management of ENT1 anemia ENT1END  in patients infected with hepatitis C virus.Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated ENT2 interferon ENT2END and ribavirin
0	Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid ENT1 renal or cardiovascular disorders  ENT1END  In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life. Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates. Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages. ENT2 Viramidine ENT2END , a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C
0	Hemoglobin concentrations decrease mainly as a result of ENT1 ribavirin  ENT1END induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid ENT2 renal or cardiovascular disorders ENT2END
0	The current best treatment for HCV infection is combination therapy with pegylated ENT1 interferon  ENT1END  and ribavirin. Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia. Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid ENT2 renal or cardiovascular disorders ENT2END
0	ENT1 Viramidine ENT1END , a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of ENT2 hemolytic anemia ENT2END in patients with chronic hepatitis C
1	Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ENT1 ribavirin  ENT1END while decreasing the risk of ENT2 hemolytic anemia ENT2END in patients with chronic hepatitis C
1	The current best treatment for HCV infection is combination therapy with pegylated ENT1 interferon ENT1END  and ribavirin. Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting ENT2 hemolytic anemia ENT2END
0	Chronic infection with hepatitis C virus (HCV) can progress to ENT1 cirrhosis ENT1END  hepatocellular carcinoma, and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated interferon and ENT2 ribavirin ENT2END
0	Chronic infection with hepatitis C virus (HCV) can progress to ENT1 cirrhosis  ENT1END , hepatocellular carcinoma, and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated ENT2 interferon ENT2END and ribavirin
0	Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and ENT1 end-stage liver disease  ENT1END  The current best treatment for HCV infection is combination therapy with pegylated interferon and ENT2 ribavirin ENT2END
0	Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, hepatocellular carcinoma, and ENT1 end-stage liver disease  ENT1END . The current best treatment for HCV infection is combination therapy with pegylated ENT2 interferon ENT2END and ribavirin
0	ENT1 Viramidine ENT1END , a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with ENT2 chronic hepatitis C ENT2END
0	Viramidine, a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ENT1 ribavirin  ENT1END  while decreasing the risk of hemolytic anemia in patients with ENT2 chronic hepatitis C ENT2END
0	ENT1 Chronic infection with hepatitis C virus  ENT1END (HCV) can progress to cirrhosis, hepatocellular carcinoma, and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated ENT2 interferon ENT2END and ribavirin
0	Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid ENT1 renal or cardiovascular disorders  ENT1END  In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life. Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates. Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages. ENT2 Viramidine ENT2END , a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C
0	Hemoglobin concentrations decrease mainly as a result of ENT1 ribavirin  ENT1END -induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid ENT2 renal or cardiovascular disorders ENT2END
0	The current best treatment for HCV infection is combination therapy with pegylated ENT1 interferon  ENT1END  and ribavirin. Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia. Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with HCV infection, especially those who have comorbid ENT2 renal or cardiovascular disorders ENT2END
0	Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, ENT1 hepatocellular carcinoma  ENT1END  and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated interferon and ENT2 ribavirin ENT2END
0	Chronic infection with hepatitis C virus (HCV) can progress to cirrhosis, ENT1 hepatocellular carcinoma  ENT1END , and end-stage liver disease. The current best treatment for HCV infection is combination therapy with pegylated ENT2 interferon ENT2END and ribavirin
0	Hemoglobin concentrations decrease mainly as a result of ribavirin-induced hemolysis, and this anemia can be problematic in patients with ENT1 HCV infection  ENT1END  especially those who have comorbid renal or cardiovascular disorders. In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life. Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates. Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages. ENT2 Viramidine ENT2END , a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C
0	The current best treatment for ENT1 HCV infection  ENT1END is combination therapy with pegylated interferon and ENT2 ribavirin ENT2END
0	The current best treatment for ENT1 HCV infection  ENT1END  is combination therapy with pegylated ENT2 interferon ENT2END and ribavirin
0	Hemoglobin concentrations decrease mainly as a result of ribavirin-induced ENT1 hemolysis  ENT1END  and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders. In general, anemia can increase the risk of morbidity and mortality, and may have negative effects on cerebral function and quality of life. Although ribavirin-associated anemia can be reversed by dose reduction or discontinuation, this approach compromises outcomes by significantly decreasing SVR rates. Recombinant human erythropoietin has been used to manage ribavirin-associated anemia but has other potential disadvantages. ENT2 Viramidine ENT2END , a liver-targeting prodrug of ribavirin, has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C
0	Hemoglobin concentrations decrease mainly as a result of ENT1 ribavirin  ENT1END -induced ENT2 hemolysis ENT2END , and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders
0	The current best treatment for HCV infection is combination therapy with pegylated ENT1 interferon  ENT1END  and ribavirin. Although this regimen produces sustained virologic responses (SVRs) in approximately 50% of patients, it can be associated with a potentially dose-limiting hemolytic anemia. Hemoglobin concentrations decrease mainly as a result of ribavirin-induced ENT2 hemolysis ENT2END , and this anemia can be problematic in patients with HCV infection, especially those who have comorbid renal or cardiovascular disorders
0	The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without ENT1 angina pectoris ENT1END (control group). ENT2 Methylergonovine ENT2END was administered continuously at a rate of 10 micrograms/min up to 50 micrograms
0	These results suggest that spasm provocation tests, which use an intracoronary injection of a relatively low dose of ENT1 methylergonovine ENT1END  have a high sensitivity in ENT2 variant angina ENT2END and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries
0	The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical ENT1 chest pain  ENT1END and in others without angina pectoris (control group). ENT2 Methylergonovine ENT2END was administered continuously at a rate of 10 micrograms/min up to 50 micrograms
1	ENT1 Methylergonovine ENT1END  was administered continuously at a rate of 10 micrograms/min up to 50 micrograms. In all patients with variant angina, ENT2 coronary spasm ENT2END was provoked at a mean dose of 28 +/- 13 micrograms (mean +/- SD)
0	These results suggest that ENT1 spasm  ENT1END provocation tests, which use an intracoronary injection of a relatively low dose of ENT2 methylergonovine ENT2END , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries
0	Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and ENT1 angina ENT1END  However, the mechanisms of myocardial ischemia induced by ENT2 epinephrine ENT2END were significantly different from those of exercise
0	Objective signs of ischemia and factors increasing myocardial ENT1 oxygen  ENT1END consumption were compared during epinephrine infusion and supine bicycle exercise. Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and ENT2 angina ENT2END
0	Exercise-induced myocardial ischemia was marked predominantly by increased heart rate and rate-pressure product with a minor contribution of end-diastolic volume, while ENT1 epinephrine ENT1END induced ENT2 ischemia ENT2END was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate-pressure product
0	Objective signs of ENT1 ischemia  ENT1END and factors increasing myocardial ENT2 oxygen ENT2END consumption were compared during epinephrine infusion and supine bicycle exercise
0	Both ENT1 epinephrine ENT1END and exercise produced myocardial ischemia as evidenced by ST segment ENT2 depression ENT2END and angina
0	Objective signs of ischemia and factors increasing myocardial ENT1 oxygen  ENT1END  consumption were compared during epinephrine infusion and supine bicycle exercise. Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment ENT2 depression ENT2END and angina
0	The role of ENT1 epinephrine ENT1END in eliciting myocardial ischemia was examined in patients with ENT2 coronary artery disease ENT2END
0	The role of epinephrine in eliciting myocardial ischemia was examined in patients with ENT1 coronary artery disease  ENT1END . Objective signs of ischemia and factors increasing myocardial ENT2 oxygen ENT2END consumption were compared during epinephrine infusion and supine bicycle exercise
1	Mechanisms of ENT1 myocardial ischemia  ENT1END  induced by ENT2 epinephrine ENT2END : comparison with exercise-induced ischemia
0	The role of epinephrine in eliciting ENT1 myocardial ischemia  ENT1END was examined in patients with coronary artery disease. Objective signs of ischemia and factors increasing myocardial ENT2 oxygen ENT2END consumption were compared during epinephrine infusion and supine bicycle exercise
1	The incidence of cardiotoxicity was not higher in patients with signs of ENT1 cardiovascular disease ENT1END than in those without in the pre-treatment evaluation. The most common signs of cardiotoxicity were chest pain, ST-T wave changes and atrial fibrillation. This was followed by ventricular fibrillation in one patient and sudden death in another. It is concluded that patients on ENT2 5-FU ENT2END treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed
1	In the present study, ENT1 cis-platin ENT1END (80-120 mg/m2BSA) and 5-FU (1000 mg/m2BSA daily as a continuous infusion during 5 days) were given to 76 patients before radiotherapy and surgery. The aim of the study was to clarify the incidence and severity of adverse cardiac effects to this treatment. Before treatment all patients had a cardiac evaluation and during treatment serial ECG recordings were performed. In the pre-treatment evaluation, signs of ENT2 cardiovascular disease ENT2END were found in 33 patients (43%)
0	The most common signs of ENT1 cardiotoxicity  ENT1END were chest pain, ST-T wave changes and atrial fibrillation. This was followed by ventricular fibrillation in one patient and sudden death in another. It is concluded that patients on ENT2 5-FU ENT2END treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed
0	This was followed by ventricular fibrillation in one patient and ENT1 sudden death  ENT1END in another. It is concluded that patients on ENT2 5-FU ENT2END treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed
1	This was followed by ENT1 ventricular fibrillation  ENT1END in one patient and sudden death in another. It is concluded that patients on ENT2 5-FU ENT2END treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed
0	It is concluded that patients on ENT1 5-FU ENT1END  treatment should be under close supervision and that the treatment should be discontinued if chest pain or ENT2 tachyarrhythmia ENT2END is observed
1	The most common signs of cardiotoxicity were chest pain, ST-T wave changes and ENT1 atrial fibrillation  ENT1END  This was followed by ventricular fibrillation in one patient and sudden death in another. It is concluded that patients on ENT2 5-FU ENT2END treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed
1	It is concluded that patients on ENT1 5-FU ENT1END  treatment should be under close supervision and that the treatment should be discontinued if ENT2 chest pain ENT2END or tachyarrhythmia is observed
0	Adverse cardiac effects during induction chemotherapy treatment with cis-platin and ENT1 5-fluorouracil ENT1END .Survival for patients with advanced ENT2 head and neck carcinoma ENT2END and esophageal carcinoma is poor with radiotherapy and/or surgery
0	Adverse cardiac effects during induction chemotherapy treatment with ENT1 cis-platin  ENT1END  and 5-fluorouracil.Survival for patients with advanced ENT2 head and neck carcinoma ENT2END and esophageal carcinoma is poor with radiotherapy and/or surgery
0	Adverse cardiac effects during induction chemotherapy treatment with cis-platin and ENT1 5-fluorouracil ENT1END .Survival for patients with advanced head and neck carcinoma and ENT2 esophageal carcinoma ENT2END is poor with radiotherapy and/or surgery
0	Adverse cardiac effects during induction chemotherapy treatment with ENT1 cis-platin  ENT1END  and 5-fluorouracil.Survival for patients with advanced head and neck carcinoma and ENT2 esophageal carcinoma ENT2END is poor with radiotherapy and/or surgery
0	The ECG showed a junctional rhythm without ENT1 ventricular arrhythmia ENT1END  This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous ENT2 methylprednisolone ENT2END (IVMP)
0	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose ENT1 methylprednisolone ENT1END in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode. There was a history of ENT2 ischemic ENT2END cardiac disease 9 years earlier
0	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose ENT1 methylprednisolone ENT1END  in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode. There was a history of ischemic cardiac disease 9 years earlier. The patient was admitted with a ENT2 pulmonary-renal syndrome ENT2END with hemoptysis, rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit
1	Hypotension, bradycardia, and asystole after high-dose intravenous ENT1 methylprednisolone ENT1END  in a monitored patient.We report a case of ENT2 hypotension ENT2END , bradycardia, and asystole after intravenous administration of high-dose methylprednisolone in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode
0	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose ENT1 methylprednisolone ENT1END  in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode. There was a history of ischemic cardiac disease 9 years earlier. The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive renal failure, and ENT2 hypoxemia ENT2END that required mechanical ventilation in the intensive care unit
0	This study reviews the current proposed mechanisms of ENT1 sudden death  ENT1END after a high dose of intravenous ENT2 methylprednisolone ENT2END (IVMP)
1	Hypotension, ENT1 bradycardia  ENT1END , and asystole after high-dose intravenous ENT2 methylprednisolone ENT2END in a monitored patient
0	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose ENT1 methylprednisolone ENT1END  in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode. There was a history of ischemic cardiac disease 9 years earlier. The patient was admitted with a pulmonary-renal syndrome with ENT2 hemoptysis ENT2END , rapidly progressive renal failure, and hypoxemia that required mechanical ventilation in the intensive care unit
0	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose ENT1 methylprednisolone ENT1END  in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode. There was a history of ischemic cardiac disease 9 years earlier. The patient was admitted with a pulmonary-renal syndrome with hemoptysis, rapidly progressive ENT2 renal failure ENT2END , and hypoxemia that required mechanical ventilation in the intensive care unit
0	We report a case of hypotension, bradycardia, and asystole after intravenous administration of high-dose ENT1 methylprednisolone ENT1END  in a 73-year-old patient who underwent electrocardiographic (ECG) monitoring throughout the episode. There was a history of ischemic ENT2 cardiac disease ENT2END 9 years earlier
1	Hypotension, bradycardia, and ENT1 asystole  ENT1END  after high-dose intravenous ENT2 methylprednisolone ENT2END in a monitored patient
0	ENT1 Pyrazinamide ENT1END can have adverse effects such as ENT2 hepatic toxicity ENT2END , hyperuricemia or digestive disorders
1	Recurrent ENT1 dysosmia  ENT1END  induced by ENT2 pyrazinamide ENT2END
0	ENT1 Pyrazinamide ENT1END  can have adverse effects such as hepatic toxicity, ENT2 hyperuricemia ENT2END or digestive disorders
1	Pharmacokinetic and clinical studies in patients with cimetidine-associated mental ENT1 confusion ENT1END .15 cases of ENT2 cimetidine ENT2END -associated mental confusion have been reported
0	changes are due to blockade of ENT1 histamine ENT1END H2-receptors in the central nervous system. Patients likely to have both raised trough-concentrations and mental ENT2 confusion ENT2END are those with both severe renal and hepatic dysfunction
0	These 6 patients had both ENT1 renal and liver dysfunction ENT1END (P less than 0.05), as well as ENT2 cimetidine ENT2END trough-concentrations of more than 1
0	changes are due to blockade of ENT1 histamine ENT1END  H2-receptors in the central nervous system. Patients likely to have both raised trough-concentrations and mental confusion are those with both severe ENT2 renal and hepatic dysfunction ENT2END
0	These 6 patients had both ENT1 renal and liver dysfunction  ENT1END (P less than 0.05), as well as ENT2 cimetidine ENT2END trough-concentrations of more than 1
0	changes are due to blockade of ENT1 histamine ENT1END  H2-receptors in the central nervous system. Patients likely to have both raised trough-concentrations and mental confusion are those with both severe ENT2 renal and hepatic dysfunction ENT2END
0	The selective 5-HT6 receptor antagonist ENT1 Ro4368554  ENT1END  restores memory performance in cholinergic and serotonergic models of ENT2 memory deficiency ENT2END in the rat
0	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of ENT1 memory deficiency ENT1END  in the rat.Antagonists at serotonin type 6 (5-HT(6)) receptors show activity in models of learning and memory. Although the underlying mechanism(s) are not well understood, these effects may involve an increase in ENT2 acetylcholine ENT2END (ACh) levels
0	The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of ENT1 memory deficiency ENT1END  in the rat.Antagonists at ENT2 serotonin ENT2END type 6 (5-HT(6)) receptors show activity in models of learning and memory
1	, respectively) reversed ENT1 memory deficits ENT1END induced by ENT2 scopolamine ENT2END and TRP depletion (10 mg/kg, i
0	, respectively) reversed ENT1 memory deficits ENT1END  induced by scopolamine and ENT2 TRP ENT2END depletion (10 mg/kg, i
0	)) and ENT1 metrifonate  ENT1END (10 mg/kg, p.o., respectively) reversed ENT2 memory deficits ENT2END induced by scopolamine and TRP depletion (10 mg/kg, i
1	The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear ENT1 hearing loss ENT1END  Under anesthesia, the superior temporal gyrus of adult macaque monkeys was exposed, and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques. Following recovery, the monkeys were selectively deafened for high frequencies using ENT2 kanamycin ENT2END and furosemide
1	The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear ENT1 hearing loss ENT1END . Under anesthesia, the superior temporal gyrus of adult macaque monkeys was exposed, and the tonotopic organization of A1 was mapped using conventional microelectrode recording techniques. Following recovery, the monkeys were selectively deafened for high frequencies using kanamycin and ENT2 furosemide ENT2END
0	In two patients, the ENT1 arrhythmia ENT1END degenerated into irreversible ventricular fibrillation and both patients died. In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of ENT2 procainamide ENT2END therapy, polymorphous ventricular tachycardia did not reoccur
0	In two patients, the arrhythmia degenerated into irreversible ENT1 ventricular fibrillation  ENT1END and both patients died. In the seventh patient, a permanent ventricular pacemaker was inserted and, despite continuation of ENT2 procainamide ENT2END therapy, polymorphous ventricular tachycardia did not reoccur
0	These seven cases demonstrate that ENT1 procainamide ENT1END can produce an acquired ENT2 prolonged Q-T syndrome ENT2END with polymorphous ventricular tachycardia
0	In the remaining three patients, ENT1 procainamide ENT1END was administered orally for treatment of chronic premature ventricular contractions or atrial flutter. These patients had Q-T prolongation and recurrent ENT2 syncope ENT2END due to polymorphous ventricular tachycardia
0	In the remaining three patients, ENT1 procainamide ENT1END  was administered orally for treatment of chronic premature ventricular contractions or ENT2 atrial flutter ENT2END
1	Procainamide-induced polymorphous ENT1 ventricular tachycardia ENT1END .Seven cases of ENT2 procainamide ENT2END -induced polymorphous ventricular tachycardia are presented
0	In the remaining three patients, ENT1 procainamide ENT1END  was administered orally for treatment of chronic ENT2 premature ventricular contractions ENT2END or atrial flutter
1	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm ( ENT1 TAA ENT1END  by ENT2 calcium chloride ENT2END (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation
0	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in ENT1 TAA  ENT1END formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline ( ENT2 NaCl ENT2END )
0	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride ( ENT1 CaCl(2) ENT1END -induced ENT2 arterial injury ENT2END and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation
0	PURPOSE: This study was designed to establish a rat model of thoracic aortic aneurysm (TAA) by calcium chloride (CaCl(2))-induced ENT1 arterial injury ENT1END  and to explore the potential role of a disintegrin and metalloproteinase (ADAM), matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in TAA formation. METHODS: Thoracic aorta of male Sprague-Dawley rats was exposed to 0.5M CaCl(2) or normal saline ENT2 NaCl ENT2END )
1	In this report, we describe a case of ENT1 ciprofloxacin ENT1END induced interstitial nephritis and autoimmune hemolytic anemia. ENT2 Hemolytic anemia ENT2END improved after stopping the drug and initiation of steroid therapy
0	ENT1 Hemolytic anemia ENT1END  improved after stopping the drug and initiation of ENT2 steroid ENT2END therapy
0	Ciprofloxacin-induced acute interstitial nephritis and ENT1 autoimmune hemolytic anemia  ENT1END . ENT2 Ciprofloxacin ENT2END has been associated with several side effects including interstitial nephritis and hemolytic anemia
0	In this report, we describe a case of ciprofloxacin-induced interstitial nephritis and ENT1 autoimmune hemolytic anemia  ENT1END  Hemolytic anemia improved after stopping the drug and initiation of ENT2 steroid ENT2END therapy
1	In this report, we describe a case of ENT1 ciprofloxacin ENT1END -induced ENT2 interstitial nephritis ENT2END and autoimmune hemolytic anemia
0	Hemolytic anemia improved after stopping the drug and initiation of ENT1 steroid ENT1END  therapy. Unfortunately, acute ENT2 interstitial nephritis ENT2END was irreversible and the patient developed end-stage renal disease
1	In this report, we describe a case of ENT1 ciprofloxacin ENT1END -induced interstitial nephritis and autoimmune hemolytic anemia. Hemolytic anemia improved after stopping the drug and initiation of steroid therapy. Unfortunately, acute interstitial nephritis was irreversible and the patient developed ENT2 end-stage renal disease ENT2END
0	Hemolytic anemia improved after stopping the drug and initiation of ENT1 steroid  ENT1END  therapy. Unfortunately, acute interstitial nephritis was irreversible and the patient developed ENT2 end-stage renal disease ENT2END
0	Erythropoietin restores the ENT1 anemia  ENT1END -induced reduction in ENT2 cyclophosphamide ENT2END cytotoxicity in rat tumors
1	ENT1 Anemia ENT1END was induced using a single dose of ENT2 carboplatin ENT2END (50 mg/kg i
0	These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of ENT1 anemia ENT1END by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved ENT2 oxygen ENT2END supply to tumor tissue
0	These results suggest that chemotherapy-induced anemia reduces cytotoxicity of ENT1 cyclophosphamide ENT1END in ENT2 tumors ENT2END , whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved oxygen supply to tumor tissue
0	Four days after ENT1 carboplatin ENT1END treatment, ENT2 tumors ENT2END (DS-sarcoma of the rat) were implanted s
0	These results suggest that chemotherapy-induced anemia reduces cytotoxicity of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved ENT1 oxygen ENT1END  supply to ENT2 tumor ENT2END tissue
0	Erythropoietin restores the anemia-induced reduction in ENT1 cyclophosphamide ENT1END ENT2 cytotoxicity ENT2END in rat tumors
0	The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin (rHuEPO) treatment on the ENT1 cytotoxicity  ENT1END of cyclophosphamide in solid experimental tumors. Anemia was induced using a single dose of ENT2 carboplatin ENT2END (50 mg/kg i
0	These results suggest that chemotherapy-induced anemia reduces ENT1 cytotoxicity  ENT1END of cyclophosphamide in tumors, whereas correction of anemia by rHuEPO treatment (epoetin alpha) increases the sensitivity, probably as a result of an improved ENT2 oxygen ENT2END supply to tumor tissue
0	Four days after carboplatin treatment, tumors (DS- ENT1 sarcoma ENT1END of the rat) were implanted s.c. onto the hind food dorsum. Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se. When tumors were treated with a single dose of ENT2 cyclophosphamide ENT2END (60 mg/kg i
0	Four days after ENT1 carboplatin  ENT1END  treatment, tumors (DS ENT2 sarcoma ENT2END of the rat) were implanted s
0	Young women on replacement ENT1 estrogens ENT1END for ovarian failure after ENT2 cancer ENT2END therapy may also have increased risk of endometrial carcinoma and should be examined periodically
1	She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease, and received exogenous ENT1 estrogens ENT1END  a treatment implicated in the development of ENT2 endometrial cancer ENT2END in menopausal women
0	She had ovarian failure after abdominal irradiation and chemotherapy for ENT1 Hodgkin disease  ENT1END  and received exogenous ENT2 estrogens ENT2END , a treatment implicated in the development of endometrial cancer in menopausal women
0	Young women on replacement ENT1 estrogens ENT1END  for ENT2 ovarian failure ENT2END after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically
0	Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of ENT1 methotrexate ENT1END  Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence. Marital unhappiness, as indicated by AMHS scores, was not associated with arthritis but was associated with ENT2 sexual dysfunction ENT2END , sexual dissatisfaction and being female
1	Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of ENT1 methotrexate ENT1END . Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with ENT2 impotence ENT2END
0	The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, ENT1 osteoarthritis  ENT1END and spondyloarthropathy, 130 of whom were pair-matched to controls. Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS). Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions. Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of ENT2 methotrexate ENT2END
0	Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of ENT1 methotrexate ENT1END . Depressed mood was more common among patients and was associated with certain sexual difficulties, but not with impotence. Marital unhappiness, as indicated by AMHS scores, was not associated with ENT2 arthritis ENT2END but was associated with sexual dysfunction, sexual dissatisfaction and being female
0	The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis, osteoarthritis and ENT1 spondyloarthropathy  ENT1END  130 of whom were pair-matched to controls. Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS). Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions. Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of ENT2 methotrexate ENT2END
0	Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of ENT1 methotrexate ENT1END . ENT2 Depressed mood ENT2END was more common among patients and was associated with certain sexual difficulties, but not with impotence
0	The relationship of arthritis and sexual dysfunction was investigated among 169 patients with ENT1 rheumatoid arthritis  ENT1END  osteoarthritis and spondyloarthropathy, 130 of whom were pair-matched to controls. Assessments of marital happiness and depressed mood were also made using the CES-D and the Azrin Marital Happiness Scale (AMHS). Sexual dysfunctions were found to be common among patients and controls, the majority in both groups reporting one or more dysfunctions. Impotence was more common among male patients than controls and was found to be associated with co-morbidity and the taking of ENT2 methotrexate ENT2END
0	ENT1 Neuroinflammation  ENT1END  and behavioral abnormalities after neonatal ENT2 terbutaline ENT2END treatment in rats: implications for autism
0	ENT1 Terbutaline ENT1END  a beta2-adrenoceptor agonist used to arrest ENT2 preterm labor ENT2END , has been associated with increased concordance for autism in dizygotic twins
0	Neuroinflammation and ENT1 behavioral abnormalities  ENT1END  after neonatal ENT2 terbutaline ENT2END treatment in rats: implications for autism
0	Neuroinflammation and behavioral abnormalities after neonatal ENT1 terbutaline ENT1END  treatment in rats: implications for autism.Autism is a ENT2 neurodevelopmental disorder ENT2END presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors
1	In addition to genetic influences, recent studies suggest that prenatal drug or chemical exposures are risk factors for ENT1 autism ENT1END ENT2 Terbutaline ENT2END , a beta2-adrenoceptor agonist used to arrest preterm labor, has been associated with increased concordance for autism in dizygotic twins
0	In behavioral tests, animals treated with ENT1 terbutaline ENT1END on PN 2 to 5 showed consistent patterns of hyper-reactivity to novelty and aversive stimuli when assessed in a novel open field, as well as in the acoustic startle response test. Our findings indicate that beta2-adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities, similar to those described in autism. This study provides a useful animal model for understanding the neuropathological processes underlying ENT2 autism spectrum disorders ENT2END
0	Neuroinflammation and behavioral abnormalities after neonatal ENT1 terbutaline ENT1END  treatment in rats: implications for autism.Autism is a neurodevelopmental disorder presenting before 3 years of age with ENT2 deficits in communication and social skills ENT2END and repetitive behaviors
0	Here, we describe a case of severe masseter muscle rigidity ( ENT1 jaw of steel ENT1END  after succinylcholine (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body. Anesthesia was continued uneventfully with ENT2 propofol ENT2END infusion while all facilities were available to detect and treat malignant hyperthermia
1	Here, we describe a case of severe masseter muscle rigidity ( ENT1 jaw of steel ENT1END ) after ENT2 succinylcholine ENT2END (Sch) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body
0	Anesthesia was continued uneventfully with ENT1 propofol ENT1END  infusion while all facilities were available to detect and treat ENT2 malignant hyperthermia ENT2END
0	ENT1 Succinylcholine ENT1END -induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body.Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of ENT2 malignant hyperthermia ENT2END
1	Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior, partner preference, or ENT1 aggression ENT1END  ENT2 T ENT2END alone had no effect on locomotion, irritability, or sexual behavior but increased partner preference and aggression
0	Animals were tested for ENT1 aggression ENT1END in their home cage, both with and without physical provocation (mild tail pinch). Brain levels of 5-HT and its metabolite, ENT2 5-hydroxyindoleacetic acid ENT2END (5-HIAA), were determined using HPLC
0	The goal of this study was to assess the interactive effects of chronic anabolic androgenic ENT1 steroid ENT1END (AAS) exposure and brain serotonin (5-hydroxytryptamine, 5-HT) depletion on behavior of pubertal male rats. Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received saline. At puberty (P40), half the PCPA-treated rats and half the saline-treated rats began treatment with testosterone (T, 5 mg/kg, 5 days/week). Behavioral measures included locomotion, ENT2 irritability ENT2END , copulation, partner preference, and aggression
0	Based on these data, it can be speculated that pubertal AAS users with low central ENT1 5-HT ENT1END may be especially prone to exhibit ENT2 aggressive behavior ENT2END
0	OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced myocardial ischemia, using Tc99m-Sestamibi single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ENT1 ischemia ENT1END  METHODS: The study group comprised 40 patients undergoing ENT2 Sestamibi ENT2END -SPECT/dobutamine stress test
0	Simultaneous measurements of ECG and brachial artery dP/dtejc were performed at each ENT1 dobutamine ENT1END level. In 19 of the 40 patients perfusion defects compatible with ENT2 ischemia ENT2END were detected on SPECT
0	OBJECTIVES: To assess the added diagnostic value of a new cardiac performance index (dP/dtejc) measurement, based on brachial artery flow changes, as compared to standard 12-lead ECG, for detecting dobutamine-induced ENT1 myocardial ischemia ENT1END  using ENT2 Tc99m-Sestamibi ENT2END single-photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia
1	Assessment of a new non-invasive index of cardiac performance for detection of ENT1 dobutamine  ENT1END -induced ENT2 myocardial ischemia ENT2END
0	Visual hallucinations are a rare event in chronic renal failure and not related to ENT1 uremia ENT1END per se. Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, clarithromycin. We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD). The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying ENT2 aluminum ENT2END intoxication, may have facilitated the appearance of this neurotoxic side effect
0	Visual hallucinations are a rare event in chronic renal failure and not related to ENT1 uremia ENT1END  per se. Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic, ENT2 clarithromycin ENT2END
0	Visual hallucinations are a rare event in chronic renal failure and not related to ENT1 uremia ENT1END  per se. Unreported in the literature is visual hallucinations occurring in association with the new ENT2 macrolide ENT2END antibiotic, clarithromycin
0	Unreported in the literature is ENT1 visual hallucinations  ENT1END occurring in association with the new macrolide antibiotic, clarithromycin. We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD). The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying ENT2 aluminum ENT2END intoxication, may have facilitated the appearance of this neurotoxic side effect
1	ENT1 Clarithromycin  ENT1END -associated ENT2 visual hallucinations ENT2END in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis
0	Unreported in the literature is ENT1 visual hallucinations  ENT1END  occurring in association with the new ENT2 macrolide ENT2END antibiotic, clarithromycin
0	The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying ENT1 aluminum ENT1END  intoxication, may have facilitated the appearance of this ENT2 neurotoxic ENT2END side effect
0	The combination of a relatively high dose of ENT1 clarithromycin  ENT1END in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this ENT2 neurotoxic ENT2END side effect
0	Unreported in the literature is visual hallucinations occurring in association with the new ENT1 macrolide  ENT1END  antibiotic, clarithromycin. We describe such a case in a patient with end-stage renal disease (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD). The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this ENT2 neurotoxic ENT2END side effect
0	The combination of a relatively high dose of clarithromycin in face of ENT1 chronic renal failure  ENT1END in a functionally anephric patient, with underlying ENT2 aluminum ENT2END intoxication, may have facilitated the appearance of this neurotoxic side effect
0	The combination of a relatively high dose of ENT1 clarithromycin  ENT1END  in face of ENT2 chronic renal failure ENT2END in a functionally anephric patient, with underlying aluminum intoxication, may have facilitated the appearance of this neurotoxic side effect
0	Unreported in the literature is visual hallucinations occurring in association with the new ENT1 macrolide ENT1END  antibiotic, clarithromycin. We describe such a case in a patient with ENT2 end-stage renal disease ENT2END (ESRD) maintained on continuous ambulatory peritoneal dialysis (CAPD)
1	Complete ENT1 atrioventricular block  ENT1END  secondary to ENT2 lithium ENT2END therapy
1	Complete atrioventricular block secondary to ENT1 lithium  ENT1END  therapy. ENT2 Sinus node dysfunction ENT2END has been reported most frequently among the adverse cardiovascular effects of lithium
0	Serum lithium levels remained under or within the therapeutic range during the ENT1 syncopal attacks ENT1END  ENT2 Lithium ENT2END should be used with extreme caution, especially in patients with mild disturbance of AV conduction
1	While the use of MDMA in quantities that may be considered "moderate" is not associated with ENT1 impaired memory functioning ENT1END  heavy use of ENT2 MDMA ENT2END use may lead to long lasting memory impairments
0	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of ENT1 MDMA ENT1END induced 5-HT ENT2 neurotoxic lesions ENT2END on functions in which 5-HT is involved, such as cognitive function
0	Although 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) has been shown to damage brain serotonin (5-HT) neurons in animals and possibly humans, little is known about the long-term consequences of MDMA-induced ENT1 5-HT ENT1END ENT2 neurotoxic lesions ENT2END on functions in which 5-HT is involved, such as cognitive function
0	In recent years working ENT1 memory deficits ENT1END have been reported in users of ENT2 MDMA ENT2END (3,4-methylenedioxymethamphetamine, ecstasy)
1	MDMA polydrug users show process-specific central executive impairments coupled with ENT1 impaired social and emotional judgement processes  ENT1END .In recent years working memory deficits have been reported in users of ENT2 MDMA ENT2END (3,4-methylenedioxymethamphetamine, ecstasy)
1	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine- ENT1 morphine ENT1END induced ENT2 sphincter of Oddi spasm ENT2END was evaluated in nine female patients with sphincter of Oddi dyskinesia
1	Effect of glyceryl trinitrate on the ENT1 sphincter of Oddi spasm  ENT1END  evoked by ENT2 prostigmine ENT2END -morphine administration
0	Effect of ENT1 glyceryl trinitrate  ENT1END  on the ENT2 sphincter of Oddi spasm ENT2END evoked by prostigmine-morphine administration
1	OBJECTIVE: In this study the effect of glyceryl trinitrate on the prostigmine- ENT1 morphine ENT1END -induced ENT2 sphincter of Oddi spasm ENT2END was evaluated in nine female patients with sphincter of Oddi dyskinesia
1	Effect of glyceryl trinitrate on the ENT1 sphincter of Oddi spasm  ENT1END  evoked by ENT2 prostigmine ENT2END -morphine administration
0	Effect of ENT1 glyceryl trinitrate  ENT1END  on the ENT2 sphincter of Oddi spasm ENT2END evoked by prostigmine-morphine administration
0	Forty-three ENT1 ovarian cancer ENT1END patients were available for analysis following six cycles of the same ENT2 PAC ENT2END -containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P)
0	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related ENT1 amino acid  ENT1END glutamine were claimed to ameliorate PAC neurotoxicity. This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study. Forty-three ENT2 ovarian cancer ENT2END patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P)
0	Forty-three ENT1 ovarian cancer ENT1END  patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by ENT2 glutamate ENT2END all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P)
0	However, this difference reached statistical significance only with regard to reported ENT1 pain ENT1END sensation (P = 0.011). Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%). This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of ENT2 PAC ENT2END
0	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related ENT1 amino acid  ENT1END  glutamine were claimed to ameliorate PAC neurotoxicity. This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC-induced peripheral neuropathy in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study. Forty-three ovarian cancer patients were available for analysis following six cycles of the same PAC-containing regimen: 23 had been supplemented by glutamate all along the treatment period, at a daily dose of three times 500 mg (group G), and 20 had received a placebo (group P). Patients were evaluated by neurological examinations, questionnaires and sensory-motor nerve conduction studies. There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G. However, this difference reached statistical significance only with regard to reported ENT2 pain ENT2END sensation (P = 0
0	However, this difference reached statistical significance only with regard to reported ENT1 pain ENT1END  sensation (P = 0.011). Also the frequency of abnormal electro-diagnostic findings showed similarity between the two groups (G: 7/23 = 30.4%; P: 6/20 = 30%). This pilot study leads to the conclusion that ENT2 glutamate ENT2END supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC
1	This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against ENT1 peripheral neurotoxicity  ENT1END of ENT2 PAC ENT2END
0	Toxic ENT1 peripheral neuropathy  ENT1END is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related ENT2 amino acid ENT2END glutamine were claimed to ameliorate PAC neurotoxicity
0	This pilot trial aimed to evaluate the role of ENT1 glutamate ENT1END supplementation for preventing PAC-induced ENT2 peripheral neuropathy ENT2END in a randomized, placebo-controlled, double-blinded clinical and electro-diagnostic study
0	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid glutamine were claimed to ameliorate ENT1 PAC ENT1END ENT2 neurotoxicity ENT2END
0	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related ENT1 amino acid  ENT1END  glutamine were claimed to ameliorate PAC ENT2 neurotoxicity ENT2END
0	Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel (PAC), although glutamate and its closely related amino acid ENT1 glutamine  ENT1END were claimed to ameliorate PAC ENT2 neurotoxicity ENT2END
1	Two patients developed acute tubular necrosis, characterized clinically by acute ENT1 oliguric renal failure ENT1END  while they were receiving a combination of cephalothin sodium and ENT2 gentamicin sulfate ENT2END therapy
1	Two patients developed acute tubular necrosis, characterized clinically by acute ENT1 oliguric renal failure ENT1END , while they were receiving a combination of ENT2 cephalothin sodium ENT2END and gentamicin sulfate therapy
1	Nephrotoxicity of combined cephalothin- ENT1 gentamicin ENT1END  regimen.Two patients developed ENT2 acute tubular necrosis ENT2END , characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy
1	Nephrotoxicity of combined ENT1 cephalothin  ENT1END -gentamicin regimen.Two patients developed ENT2 acute tubular necrosis ENT2END , characterized clinically by acute oliguric renal failure, while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy
0	ENT1 Nephrotoxicity  ENT1END  of combined cephalothin ENT2 gentamicin ENT2END regimen
0	ENT1 Nephrotoxicity  ENT1END  of combined ENT2 cephalothin ENT2END -gentamicin regimen
0	Two patients developed acute tubular necrosis, characterized clinically by acute ENT1 oliguric renal failure  ENT1END  while they were receiving a combination of cephalothin sodium and ENT2 gentamicin sulfate ENT2END therapy
0	Two patients developed acute tubular necrosis, characterized clinically by acute ENT1 oliguric renal failure  ENT1END , while they were receiving a combination of ENT2 cephalothin sodium ENT2END and gentamicin sulfate therapy
1	Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ENT1 ouabain ENT1END ENT2 arrhythmia ENT2END in dogs and cats
0	The compound ENT1 GYKI-41 099  ENT1END  as a beta-adrenergic antagonist, is 3-8 times more potent than propranolol in vitro and in vivo. Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain ENT2 arrhythmia ENT2END in dogs and cats
0	Its antiarrhythmic effectiveness surpasses that of propranolol and ENT1 pindolol  ENT1END inhibiting the ouabain ENT2 arrhythmia ENT2END in dogs and cats
0	Its antiarrhythmic effectiveness surpasses that of ENT1 propranolol  ENT1END and pindolol inhibiting the ouabain ENT2 arrhythmia ENT2END in dogs and cats
0	Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one ENT1 infectious mononucleosis ENT1END with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans. There were no deaths. ENT2 RAPA ENT2END was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one
0	Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one ENT1 infectious mononucleosis ENT1END  with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans. There were no deaths. RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one. RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients. CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable ENT2 CsA ENT2END withdrawal
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or ENT1 Tac  ENT1END toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1. Follow-up is 7 to 24 months. RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one ENT2 infectious mononucleosis ENT2END with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans
0	RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT1 creatinine  ENT1END [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one ENT2 infectious mononucleosis ENT2END with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans
0	Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had ENT1 bronchiolitis obliterans  ENT1END  There were no deaths. ENT2 RAPA ENT2END was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one
0	Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had ENT1 bronchiolitis obliterans  ENT1END . There were no deaths. RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral aphtous ulcers in one. RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients. CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable ENT2 CsA ENT2END withdrawal
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or ENT1 Tac  ENT1END  toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1. Follow-up is 7 to 24 months. RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had ENT2 bronchiolitis obliterans ENT2END
0	RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT1 creatinine  ENT1END  [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had ENT2 bronchiolitis obliterans ENT2END
0	RAPA was discontinued in four patients, because of pneumonia in two, ENT1 PTLD ENT1END in one, and oral aphtous ulcers in one. ENT2 RAPA ENT2END levels were high (>15 ng/ml) in 7 of 13 (54%) patients
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute ENT1 CsA ENT1END or Tac toxicity (3), severe facial dysmorphism (2), ENT2 posttransplant lymphoproliferative disorder ENT2END (PTLD) in remission (2), and hepatotoxicity in 1
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or ENT1 Tac  ENT1END  toxicity (3), severe facial dysmorphism (2), ENT2 posttransplant lymphoproliferative disorder ENT2END (PTLD) in remission (2), and hepatotoxicity in 1
0	RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT1 creatinine ENT1END  [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of ENT2 PTLD ENT2END was observed
0	BACKGROUND: The aim of this study is to evaluate the effects of ENT1 RAPA ENT1END conversion in patients undergoing cyclosporine (CsA) or tacrolimus (Tac) ENT2 toxicity ENT2END
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute ENT1 CsA ENT1END  or Tac ENT2 toxicity ENT2END (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or ENT1 Tac ENT1END ENT2 toxicity ENT2END (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac ENT1 toxicity  ENT1END  (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1. Follow-up is 7 to 24 months. RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT2 creatinine ENT2END [233+/-34 to 210+/-56 micromol/liter (P<0
0	RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral ENT1 aphtous ulcers  ENT1END in one. ENT2 RAPA ENT2END levels were high (>15 ng/ml) in 7 of 13 (54%) patients
0	RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral ENT1 aphtous ulcers  ENT1END  in one. RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients. CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable ENT2 CsA ENT2END withdrawal
0	RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT1 creatinine  ENT1END  [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed pneumonia (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans. There were no deaths. RAPA was discontinued in four patients, because of pneumonia in two, PTLD in one, and oral ENT2 aphtous ulcers ENT2END in one
0	However, when converting patients to ENT1 RAPA ENT1END drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and ENT2 Pneumocystis carinii pneumonia ENT2END prophylaxis should be given
0	CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable ENT1 CsA  ENT1END  withdrawal. However, when converting patients to RAPA drug levels should be monitored to avoid over-immunosuppression and adequate antiviral and ENT2 Pneumocystis carinii pneumonia ENT2END prophylaxis should be given
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or ENT1 Tac ENT1END  toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1. Follow-up is 7 to 24 months. RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed pneumonia (two ENT2 Pneumocystis carinii pneumonia ENT2END , one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans
0	RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT1 creatinine  ENT1END  [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed pneumonia (two ENT2 Pneumocystis carinii pneumonia ENT2END , one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans
0	METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin ( ENT1 RAPA ENT1END  (5 mg/day) 0 to 204 months posttransplant. Drug monitoring was not initially used to adjust doses. The indications for switch were chronic CsA or Tac ENT2 nephrotoxicity ENT2END (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1
1	The indications for switch were chronic ENT1 CsA  ENT1END or Tac ENT2 nephrotoxicity ENT2END (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1
1	The indications for switch were chronic CsA or ENT1 Tac ENT1END ENT2 nephrotoxicity ENT2END (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1
0	RESULTS: In the 12 patients switched because of chronic ENT1 nephrotoxicity  ENT1END there was a significant decrease in serum ENT2 creatinine ENT2END [233+/-34 to 210+/-56 micromol/liter (P<0
0	METHODS: Twenty renal transplant recipients were switched to fixed dose rapamycin ( ENT1 RAPA ENT1END ) (5 mg/day) 0 to 204 months posttransplant. Drug monitoring was not initially used to adjust doses. The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and ENT2 hepatotoxicity ENT2END in 1
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute ENT1 CsA  ENT1END  or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and ENT2 hepatotoxicity ENT2END in 1
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or ENT1 Tac  ENT1END  toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and ENT2 hepatotoxicity ENT2END in 1
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or Tac toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and ENT1 hepatotoxicity  ENT1END  in 1. Follow-up is 7 to 24 months. RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT2 creatinine ENT2END [233+/-34 to 210+/-56 micromol/liter (P<0
0	ENT1 RAPA ENT1END  was discontinued in four patients, because of ENT2 pneumonia ENT2END in two, PTLD in one, and oral aphtous ulcers in one
0	RAPA was discontinued in four patients, because of ENT1 pneumonia  ENT1END  in two, PTLD in one, and oral aphtous ulcers in one. RAPA levels were high (>15 ng/ml) in 7 of 13 (54%) patients. CONCLUSIONS: RAPA conversion provides adequate immunosuppression to enable ENT2 CsA ENT2END withdrawal
0	The indications for switch were chronic CsA or Tac nephrotoxicity (12), acute CsA or ENT1 Tac ENT1END  toxicity (3), severe facial dysmorphism (2), posttransplant lymphoproliferative disorder (PTLD) in remission (2), and hepatotoxicity in 1. Follow-up is 7 to 24 months. RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed ENT2 pneumonia ENT2END (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans
0	RESULTS: In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum ENT1 creatinine  ENT1END  [233+/-34 to 210+/-56 micromol/liter (P<0.05) at 6 months]. Facial dysmorphism improved in two patients. No relapse of PTLD was observed. Five patients developed ENT2 pneumonia ENT2END (two Pneumocystis carinii pneumonia, one infectious mononucleosis with polyclonal PTLD lung infiltrate) and two had bronchiolitis obliterans
0	This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, ENT1 testosterone ENT1END  and LH. The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the ENT2 rheumatic heart disease ENT2END patients
0	This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of ENT1 estradiol  ENT1END  testosterone, and LH. The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the ENT2 rheumatic heart disease ENT2END patients
0	The patients of the study and control group (without ENT1 digoxin  ENT1END  were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the ENT2 rheumatic heart disease ENT2END patients
0	Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum ENT1 estrogen  ENT1END and decreased levels of plasma testosterone and luteinizing hormone (LH). This study was undertaken to investigate the links between the long-term administration of digoxin therapy and sexual behavior, and the effect of digoxin on plasma levels of estradiol, testosterone, and LH. The patients of the study and control group (without digoxin) were of similar cardiac functional capacity and age (25-40 years) and were randomly selected from the ENT2 rheumatic heart disease ENT2END patients
0	The findings support the reports concerning digoxin effect on plasma estradiol, ENT1 testosterone ENT1END  and LH. The differences in the means were significant. Tests used to evaluate the changes in sexual behavior showed a significant ENT2 decrease in sexual desire ENT2END , sexual excitement phase (erection), and frequency of sexual relations in the study group
0	The findings support the reports concerning digoxin effect on plasma ENT1 estradiol  ENT1END  testosterone, and LH. The differences in the means were significant. Tests used to evaluate the changes in sexual behavior showed a significant ENT2 decrease in sexual desire ENT2END , sexual excitement phase (erection), and frequency of sexual relations in the study group
1	Subjective assessment of ENT1 sexual dysfunction  ENT1END  of patients on long-term administration of ENT2 digoxin ENT2END
0	Subjective assessment of ENT1 sexual dysfunction  ENT1END  of patients on long-term administration of digoxin.Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum ENT2 estrogen ENT2END and decreased levels of plasma testosterone and luteinizing hormone (LH)
1	METHODS: This prospective study evaluated consecutive eligible ENT1 seizure ENT1END patients who had a plasma sample collected as part of their clinical evaluation. Plasma was tested for amphetamine and the cocaine metabolite ENT2 benzoylecgonine ENT2END using enzyme-mediated immunoassay methodology
0	CONCLUSIONS: During this study period, routine plasma screening for ENT1 cocaine ENT1END and amphetamines in adult ENT2 seizure ENT2END patients had a low yield
0	CONCLUSIONS: During this study period, routine plasma screening for cocaine and ENT1 amphetamines  ENT1END in adult ENT2 seizure ENT2END patients had a low yield
0	OBJECTIVE: The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or ENT1 amphetamine ENT1END in adult emergency department ENT2 seizure ENT2END patients
0	Patient demographics, history of underlying drug or ENT1 alcohol ENT1END related ENT2 seizure ENT2END disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers
0	5%) plasma samples were positive by immunoassay testing for ENT1 benzoylecgonine ENT1END and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine. Positive test results were more common in patient visits where there was a history or suspicion of ENT2 cocaine or amphetamine abuse ENT2END (p < 0
0	Positive test results were more common in patient visits where there was a history or suspicion of ENT1 cocaine or amphetamine abuse  ENT1END  (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for ENT2 cocaine ENT2END and amphetamines in adult seizure patients had a low yield
0	Positive test results were more common in patient visits where there was a history or suspicion of ENT1 cocaine or amphetamine abuse  ENT1END  (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for cocaine and ENT2 amphetamines ENT2END in adult seizure patients had a low yield
0	2%) were positive for ENT1 amphetamine  ENT1END  Positive test results were more common in patient visits where there was a history or suspicion of ENT2 cocaine or amphetamine abuse ENT2END (p < 0
0	Patient demographics, history of underlying drug or ENT1 alcohol ENT1END -related seizure disorder, estimated time from seizure to sample collection, history or suspicion of ENT2 cocaine or amphetamine abuse ENT2END , results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers
0	5%) plasma samples were positive by immunoassay testing for ENT1 benzoylecgonine ENT1END  and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine. Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield. As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of ENT2 drug abuse ENT2END in this population
0	CONCLUSIONS: During this study period, routine plasma screening for ENT1 cocaine  ENT1END  and amphetamines in adult seizure patients had a low yield. As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of ENT2 drug abuse ENT2END in this population
0	CONCLUSIONS: During this study period, routine plasma screening for cocaine and ENT1 amphetamines  ENT1END  in adult seizure patients had a low yield. As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of ENT2 drug abuse ENT2END in this population
0	2%) were positive for ENT1 amphetamine  ENT1END . Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield. As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of ENT2 drug abuse ENT2END in this population
0	Patient demographics, history of underlying drug or ENT1 alcohol  ENT1END -related seizure disorder, estimated time from seizure to sample collection, history or suspicion of cocaine or amphetamine abuse, results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers. RESULTS: Fourteen of 248 (5.6%, 95% CI 2.7%-8.5%) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine. Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield. As a result, routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of ENT2 drug abuse ENT2END in this population
0	5%) plasma samples were positive by immunoassay testing for ENT1 benzoylecgonine ENT1END  and no samples (0%, 95% CI 0-1.2%) were positive for amphetamine. Positive test results were more common in patient visits where there was a history or suspicion of ENT2 cocaine or amphetamine abuse ENT2END (p < 0
0	Positive test results were more common in patient visits where there was a history or suspicion of ENT1 cocaine or amphetamine abuse  ENT1END  (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for ENT2 cocaine ENT2END and amphetamines in adult seizure patients had a low yield
0	Positive test results were more common in patient visits where there was a history or suspicion of ENT1 cocaine or amphetamine abuse  ENT1END  (p < 0.0005). CONCLUSIONS: During this study period, routine plasma screening for cocaine and ENT2 amphetamines ENT2END in adult seizure patients had a low yield
0	2%) were positive for ENT1 amphetamine  ENT1END . Positive test results were more common in patient visits where there was a history or suspicion of ENT2 cocaine or amphetamine abuse ENT2END (p < 0
0	Patient demographics, history of underlying drug or ENT1 alcohol ENT1END -related seizure disorder, estimated time from seizure to sample collection, history or suspicion of ENT2 cocaine or amphetamine abuse ENT2END , results of clinical urine testing for drugs of abuse, and assay results were recorded without patient identifiers
1	Twelve patients with liver disease related to ENT1 methyldopa ENT1END were seen between 1967 and 1977. Illness occurred within 1--9 weeks of commencement of therapy in 9 patients, the remaining 3 patients having received the drug for 13 months, 15 months and 7 years before experiencing symptoms. Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, ENT2 anorexia ENT2END , nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients
1	Twelve patients with liver disease related to ENT1 methyldopa ENT1END  were seen between 1967 and 1977. Illness occurred within 1--9 weeks of commencement of therapy in 9 patients, the remaining 3 patients having received the drug for 13 months, 15 months and 7 years before experiencing symptoms. Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and ENT2 vomiting ENT2END , and associated with upper abdominal pain, was an invariable finding in all patients
0	One patient died, having presented in ENT1 hepatic failure ENT1END  and another, who had been taking ENT2 methyldopa ENT2END for 7 years, showed slower clinical and biochemical resolution over a period of several months
1	Twelve patients with liver disease related to ENT1 methyldopa ENT1END  were seen between 1967 and 1977. Illness occurred within 1--9 weeks of commencement of therapy in 9 patients, the remaining 3 patients having received the drug for 13 months, 15 months and 7 years before experiencing symptoms. Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper ENT2 abdominal pain ENT2END , was an invariable finding in all patients
1	Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated ENT1 cholestasis  ENT1END  The drug was withdrawn on presentation to hospital in 11 patients, with rapid clinical improvement in 9. One patient died, having presented in hepatic failure, and another, who had been taking ENT2 methyldopa ENT2END for 7 years, showed slower clinical and biochemical resolution over a period of several months
1	Twelve patients with liver disease related to ENT1 methyldopa ENT1END  were seen between 1967 and 1977. Illness occurred within 1--9 weeks of commencement of therapy in 9 patients, the remaining 3 patients having received the drug for 13 months, 15 months and 7 years before experiencing symptoms. Jaundice with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, ENT2 nausea ENT2END and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients
1	Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular ENT1 necrosis  ENT1END to massive hepatic necrosis. Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis. The drug was withdrawn on presentation to hospital in 11 patients, with rapid clinical improvement in 9. One patient died, having presented in hepatic failure, and another, who had been taking ENT2 methyldopa ENT2END for 7 years, showed slower clinical and biochemical resolution over a period of several months
0	In this latter patient, and in 2 others, the causal relationship between ENT1 methyldopa ENT1END and ENT2 hepatic dysfunction ENT2END was proved with the recurrence of hepatitis within 2 weeks of re-exposure to the drug
1	Twelve patients with liver disease related to ENT1 methyldopa ENT1END  were seen between 1967 and 1977. Illness occurred within 1--9 weeks of commencement of therapy in 9 patients, the remaining 3 patients having received the drug for 13 months, 15 months and 7 years before experiencing symptoms. Jaundice with tender ENT2 hepatomegaly ENT2END , usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients
1	The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of ENT1 methyldopa ENT1END induced ENT2 hepatitis ENT2END
1	Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from ENT1 fatty change  ENT1END and focal hepatocellular necrosis to massive hepatic necrosis. Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis. The drug was withdrawn on presentation to hospital in 11 patients, with rapid clinical improvement in 9. One patient died, having presented in hepatic failure, and another, who had been taking ENT2 methyldopa ENT2END for 7 years, showed slower clinical and biochemical resolution over a period of several months
1	Twelve patients with liver disease related to ENT1 methyldopa ENT1END  were seen between 1967 and 1977. Illness occurred within 1--9 weeks of commencement of therapy in 9 patients, the remaining 3 patients having received the drug for 13 months, 15 months and 7 years before experiencing symptoms. ENT2 Jaundice ENT2END with tender hepatomegaly, usually preceded by symptoms of malaise, anorexia, nausea and vomiting, and associated with upper abdominal pain, was an invariable finding in all patients
0	The remaining patient in the series developed ENT1 fulminant hepatitis  ENT1END when the drug was accidentally recommenced 1 year after a prior episode of ENT2 methyldopa ENT2END -induced hepatitis
0	Most patients showed moderate to severe acute hepatitis or ENT1 chronic active hepatitis  ENT1END with associated cholestasis. The drug was withdrawn on presentation to hospital in 11 patients, with rapid clinical improvement in 9. One patient died, having presented in hepatic failure, and another, who had been taking ENT2 methyldopa ENT2END for 7 years, showed slower clinical and biochemical resolution over a period of several months
0	Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury, the spectrum of which ranged from fatty change and focal hepatocellular necrosis to ENT1 massive hepatic necrosis  ENT1END  Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis. The drug was withdrawn on presentation to hospital in 11 patients, with rapid clinical improvement in 9. One patient died, having presented in hepatic failure, and another, who had been taking ENT2 methyldopa ENT2END for 7 years, showed slower clinical and biochemical resolution over a period of several months
0	Tetany and rhabdomyolysis due to surreptitious ENT1 furosemide ENT1END --importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and ENT2 hypomagnesemia ENT2END
0	While severe hypokalemia may cause muscle weakness, severe ENT1 hypomagnesemia ENT1END is associated with muscle spasms and tetany which cannot be corrected by ENT2 potassium ENT2END and calcium supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of ENT1 magnesium  ENT1END  supplementation.Diuretics may induce hypokalemia, hypocalcemia and ENT2 hypomagnesemia ENT2END
0	While severe hypokalemia may cause muscle weakness, severe ENT1 hypomagnesemia ENT1END  is associated with muscle spasms and tetany which cannot be corrected by potassium and ENT2 calcium ENT2END supplementation alone (1,2)
1	ENT1 Tetany  ENT1END  and rhabdomyolysis due to surreptitious ENT2 furosemide ENT2END --importance of magnesium supplementation
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and ENT1 tetany  ENT1END which cannot be corrected by ENT2 potassium ENT2END and calcium supplementation alone (1,2)
0	ENT1 Tetany  ENT1END  and rhabdomyolysis due to surreptitious furosemide--importance of ENT2 magnesium ENT2END supplementation
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and ENT1 tetany  ENT1END  which cannot be corrected by potassium and ENT2 calcium ENT2END supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious ENT1 furosemide ENT1END --importance of magnesium supplementation.Diuretics may induce ENT2 hypokalemia ENT2END , hypocalcemia and hypomagnesemia
0	While severe ENT1 hypokalemia  ENT1END may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by ENT2 potassium ENT2END and calcium supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of ENT1 magnesium  ENT1END  supplementation.Diuretics may induce ENT2 hypokalemia ENT2END , hypocalcemia and hypomagnesemia
0	While severe ENT1 hypokalemia  ENT1END  may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and ENT2 calcium ENT2END supplementation alone (1,2)
1	Tetany and ENT1 rhabdomyolysis  ENT1END  due to surreptitious ENT2 furosemide ENT2END --importance of magnesium supplementation
0	Tetany and ENT1 rhabdomyolysis  ENT1END  due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by ENT2 potassium ENT2END and calcium supplementation alone (1,2)
0	Tetany and ENT1 rhabdomyolysis  ENT1END  due to surreptitious furosemide--importance of ENT2 magnesium ENT2END supplementation
0	Tetany and ENT1 rhabdomyolysis  ENT1END  due to surreptitious furosemide--importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and ENT2 calcium ENT2END supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious ENT1 furosemide ENT1END --importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with ENT2 muscle spasms ENT2END and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2)
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with ENT1 muscle spasms  ENT1END  and tetany which cannot be corrected by ENT2 potassium ENT2END and calcium supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of ENT1 magnesium  ENT1END  supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with ENT2 muscle spasms ENT2END and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2)
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with ENT1 muscle spasms  ENT1END  and tetany which cannot be corrected by potassium and ENT2 calcium ENT2END supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious ENT1 furosemide ENT1END --importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause ENT2 muscle weakness ENT2END , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2)
0	While severe hypokalemia may cause ENT1 muscle weakness  ENT1END , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by ENT2 potassium ENT2END and calcium supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious furosemide--importance of ENT1 magnesium  ENT1END  supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause ENT2 muscle weakness ENT2END , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2)
0	While severe hypokalemia may cause ENT1 muscle weakness  ENT1END , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and ENT2 calcium ENT2END supplementation alone (1,2)
0	Tetany and rhabdomyolysis due to surreptitious ENT1 furosemide ENT1END --importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2). Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or ENT2 edematous ENT2END
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by ENT1 potassium  ENT1END  and calcium supplementation alone (1,2). Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or ENT2 edematous ENT2END
0	Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or ENT1 edematous ENT1END . Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of ENT2 magnesium ENT2END depletion were not noted in these patients
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and ENT1 calcium  ENT1END  supplementation alone (1,2). Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are obese or ENT2 edematous ENT2END
0	Tetany and rhabdomyolysis due to surreptitious ENT1 furosemide ENT1END --importance of magnesium supplementation.Diuretics may induce hypokalemia, hypocalcemia and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone (1,2). Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are ENT2 obese ENT2END or edematous
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by ENT1 potassium  ENT1END  and calcium supplementation alone (1,2). Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are ENT2 obese ENT2END or edematous
0	Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are ENT1 obese  ENT1END  or edematous. Symptomatic hypokalemia has been reported in such patients (3-7) and in one case hypocalcemia was observed (8), but the effects of ENT2 magnesium ENT2END depletion were not noted in these patients
0	While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and ENT1 calcium  ENT1END  supplementation alone (1,2). Surreptitious diuretic ingestion has been described, mainly in women who are concerned that they are ENT2 obese ENT2END or edematous
0	Tetany and rhabdomyolysis due to surreptitious ENT1 furosemide ENT1END --importance of magnesium supplementation.Diuretics may induce hypokalemia, ENT2 hypocalcemia ENT2END and hypomagnesemia
0	Diuretics may induce hypokalemia, ENT1 hypocalcemia  ENT1END  and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by ENT2 potassium ENT2END and calcium supplementation alone (1,2)
0	Symptomatic hypokalemia has been reported in such patients (3-7) and in one case ENT1 hypocalcemia  ENT1END was observed (8), but the effects of ENT2 magnesium ENT2END depletion were not noted in these patients
0	Diuretics may induce hypokalemia, ENT1 hypocalcemia  ENT1END  and hypomagnesemia. While severe hypokalemia may cause muscle weakness, severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and ENT2 calcium ENT2END supplementation alone (1,2)
1	Two halogenated anesthetics, ENT1 enflurane ENT1END and isoflurane, have been associated with an allergic-type ENT2 hepatic injury ENT2END both alone and following previous exposure to halothane
0	An antibody response to a protein-bound biotransformation product ( ENT1 trifluoroacetyl ENT1END adduct) has been detected on halothane ENT2 hepatitis ENT2END patients
1	ENT1 Halothane ENT1END ENT2 hepatitis ENT2END appears to involve an aberrant immune response
1	Two halogenated anesthetics, enflurane and ENT1 isoflurane  ENT1END  have been associated with an allergic-type ENT2 hepatic injury ENT2END both alone and following previous exposure to halothane
0	This study was performed to determine cross-reactivity between ENT1 enflurane ENT1END and isoflurane with the ENT2 hypersensitivity ENT2END induced by halothane
0	An antibody response to a protein-bound biotransformation product ( ENT1 trifluoroacetyl  ENT1END  adduct) has been detected on halothane hepatitis patients. This study was performed to determine cross-reactivity between enflurane and isoflurane with the ENT2 hypersensitivity ENT2END induced by halothane
0	This study was performed to determine cross-reactivity between enflurane and isoflurane with the ENT1 hypersensitivity ENT1END  induced by ENT2 halothane ENT2END
0	This study was performed to determine cross-reactivity between enflurane and ENT1 isoflurane  ENT1END with the ENT2 hypersensitivity ENT2END induced by halothane
0	RESULTS: ENT1 Adenosine ENT1END produced no effect on ENT2 pain ENT2END report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h
0	Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal ENT1 capsaicin  ENT1END injection were determined. RESULTS: Adenosine produced no effect on ENT2 pain ENT2END report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h
0	The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic ENT1 neuropathic pain ENT1END and is not due to prolonged residence of ENT2 adenosine ENT2END in cerebrospinal fluid
0	CONCLUSIONS: These results show selective inhibition by intrathecal adenosine of hypersensitivity, presumed to reflect central sensitization in humans after peripheral ENT1 capsaicin  ENT1END injection. The long-lasting effect is consistent with that observed in preliminary reports of patients with chronic ENT2 neuropathic pain ENT2END and is not due to prolonged residence of adenosine in cerebrospinal fluid
0	BACKGROUND: Preclinical studies of intrathecal ENT1 adenosine ENT1END suggest it may be effective in the treatment of ENT2 acute and chronic pain ENT2END in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation
0	BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of ENT1 acute and chronic pain ENT1END  in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation. The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and ENT2 capsaicin ENT2END -evoked mechanical hypersensitivity
0	BACKGROUND: Preclinical studies of intrathecal ENT1 adenosine ENT1END  suggest it may be effective in the treatment of ENT2 acute and chronic pain ENT2END in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation
0	BACKGROUND: Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of ENT1 acute and chronic pain  ENT1END  in humans, and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation. The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and ENT2 capsaicin ENT2END -evoked mechanical hypersensitivity
0	Cerebrospinal fluid was obtained for pharmacokinetic analysis, and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and ENT1 allodynia  ENT1END after intradermal capsaicin injection were determined. RESULTS: ENT2 Adenosine ENT2END produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h
1	RESULTS: Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and ENT1 allodynia ENT1END from intradermal ENT2 capsaicin ENT2END injection for at least 24 h
0	CONCLUSIONS: These results show selective inhibition by intrathecal ENT1 adenosine ENT1END of ENT2 hypersensitivity ENT2END , presumed to reflect central sensitization in humans after peripheral capsaicin injection
0	The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US, using both acute noxious stimulation and ENT1 capsaicin ENT1END -evoked mechanical ENT2 hypersensitivity ENT2END
1	ENT1 CCNU ENT1END was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced ENT2 anaemia ENT2END and 14
0	2% experienced ENT1 anaemia ENT1END  and 14.2% experienced thrombocytopenia. Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
1	ENT1 CCNU ENT1END  was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced ENT2 neutropenia ENT2END , 34
0	9% of dogs experienced ENT1 neutropenia  ENT1END , 34.2% experienced anaemia and 14.2% experienced thrombocytopenia. Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
1	8% of dogs, the most common sign of which was ENT1 vomiting ENT1END (24.3%). Potential renal toxicity and elevated alanine transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively. The incidence of hepatic failure was 1.2%. CONCLUSIONS: ENT2 CCNU ENT2END -associated toxicity in dogs is common, but is usually not life threatening
0	8% of dogs, the most common sign of which was ENT1 vomiting  ENT1END  (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
1	The incidence of ENT1 hepatic failure  ENT1END was 1.2%. CONCLUSIONS: ENT2 CCNU ENT2END -associated toxicity in dogs is common, but is usually not life threatening
0	Potential renal toxicity and elevated ENT1 alanine  ENT1END  transaminase (ALT) concentration were reported in 12.2% and 48.8% of dogs, respectively. The incidence of ENT2 hepatic failure ENT2END was 1
1	ENT1 CCNU ENT1END  was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced ENT2 thrombocytopenia ENT2END
0	2% experienced ENT1 thrombocytopenia  ENT1END . Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
0	RESULTS: Of the 206 dogs treated with CCNU, 185 met the inclusion criteria for at least one class of ENT1 toxicity ENT1END ENT2 CCNU ENT2END was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma
0	Potential renal ENT1 toxicity  ENT1END and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
0	OBJECTIVE: To describe the incidence of ENT1 haematological, renal, hepatic and gastrointestinal toxicities ENT1END in tumour-bearing dogs receiving ENT2 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea ENT2END (CCNU)
1	OBJECTIVE: To describe the incidence of ENT1 haematological, renal, hepatic and gastrointestinal toxicities  ENT1END in tumour-bearing dogs receiving ENT2 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea ENT2END (CCNU)
1	OBJECTIVE: To describe the incidence of ENT1 haematological, renal, hepatic and gastrointestinal toxicities  ENT1END in tumour-bearing dogs receiving ENT2 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea ENT2END (CCNU)
0	ENT1 Gastrointestinal toxicosis  ENT1END was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
0	ENT1 CCNU ENT1END  was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, ENT2 histiocytic tumours ENT2END and epitheliotropic lymphoma
0	CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, ENT1 histiocytic tumours  ENT1END  and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia. Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
0	OBJECTIVE: To describe the incidence of ENT1 haematological, renal, hepatic and gastrointestinal toxicities  ENT1END in tumour-bearing dogs receiving ENT2 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea ENT2END (CCNU)
0	ENT1 CCNU ENT1END  was used most commonly in the treatment of ENT2 lymphoma ENT2END , mast cell tumour, brain tumour, histiocytic tumours and epitheliotropic lymphoma
0	CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, brain tumour, histiocytic tumours and ENT1 epitheliotropic lymphoma  ENT1END  Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia. Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
0	ENT1 CCNU ENT1END  was used most commonly in the treatment of lymphoma, mast cell tumour, ENT2 brain tumour ENT2END , histiocytic tumours and epitheliotropic lymphoma
0	CCNU was used most commonly in the treatment of lymphoma, mast cell tumour, ENT1 brain tumour  ENT1END , histiocytic tumours and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia. Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
0	ENT1 CCNU ENT1END  was used most commonly in the treatment of lymphoma, ENT2 mast cell tumour ENT2END , brain tumour, histiocytic tumours and epitheliotropic lymphoma
0	CCNU was used most commonly in the treatment of lymphoma, ENT1 mast cell tumour  ENT1END , brain tumour, histiocytic tumours and epitheliotropic lymphoma. Throughout treatment, 56.9% of dogs experienced neutropenia, 34.2% experienced anaemia and 14.2% experienced thrombocytopenia. Gastrointestinal toxicosis was detected in 37.8% of dogs, the most common sign of which was vomiting (24.3%). Potential renal toxicity and elevated ENT2 alanine ENT2END transaminase (ALT) concentration were reported in 12
0	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/ ENT1 EE ENT1END in women with acne, hirsutism or ENT2 PCOS ENT2END although residual confounding by indication cannot be excluded
0	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of ENT1 CPA  ENT1END EE in women with acne, hirsutism or ENT2 PCOS ENT2END although residual confounding by indication cannot be excluded
0	BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( ENT1 PCOS ENT1END . Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined ENT2 oral contraceptives ENT2END (COCs)
0	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/ ENT1 EE ENT1END  in women with acne, ENT2 hirsutism ENT2END or PCOS although residual confounding by indication cannot be excluded
0	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of ENT1 CPA  ENT1END /EE in women with acne, ENT2 hirsutism ENT2END or PCOS although residual confounding by indication cannot be excluded
0	BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with acne and ENT1 hirsutism  ENT1END and is also a treatment option for polycystic ovary syndrome (PCOS). Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined ENT2 oral contraceptives ENT2END (COCs)
0	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of CPA/ ENT1 EE ENT1END  in women with ENT2 acne ENT2END , hirsutism or PCOS although residual confounding by indication cannot be excluded
0	CONCLUSIONS: We have demonstrated an increased risk of VTE associated with the use of ENT1 CPA  ENT1END /EE in women with ENT2 acne ENT2END , hirsutism or PCOS although residual confounding by indication cannot be excluded
0	BACKGROUND: Cyproterone acetate combined with ethinyl estradiol (CPA/EE) is licensed in the UK for the treatment of women with ENT1 acne  ENT1END and hirsutism and is also a treatment option for polycystic ovary syndrome (PCOS). Previous studies have demonstrated an increased risk of venous thromboembolism (VTE) associated with CPA/EE compared with conventional combined ENT2 oral contraceptives ENT2END (COCs)
1	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of ENT1 VTE  ENT1END associated with CPA/ ENT2 EE ENT2END
1	METHODS: Using the General Practice Research Database we conducted a cohort analysis and case-control study nested within a population of women aged between 15 and 39 years with acne, hirsutism or PCOS to estimate the risk of ENT1 VTE ENT1END  associated with ENT2 CPA ENT2END /EE
0	Previous studies have demonstrated an increased risk of venous thromboembolism ( ENT1 VTE  ENT1END  associated with CPA/EE compared with conventional combined ENT2 oral contraceptives ENT2END (COCs)
0	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced ENT1 sensorineural hearing loss ENT1END  In this experimental study we used 30 Sprague-Dawley rats, 27 of which had ENT2 gentamicin ENT2END instilled into the middle ear
0	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of ENT1 NO  ENT1END inhibitors for the prevention of aminoglycoside-induced ENT2 sensorineural hearing loss ENT2END
0	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced ENT1 sensorineural hearing loss ENT1END . In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear. The otoprotectant ENT2 L-NAME ENT2END was administered topically to 12/27 animals
0	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of ENT1 aminoglycoside  ENT1END induced ENT2 sensorineural hearing loss ENT2END
0	The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against ENT1 high-frequency hearing loss ENT1END caused by ENT2 gentamicin ENT2END , but further studies are needed to confirm this
0	The nitric oxide ( ENT1 NO  ENT1END  inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against ENT2 high-frequency hearing loss ENT2END caused by gentamicin, but further studies are needed to confirm this
0	The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester ( ENT1 L-NAME  ENT1END  may act as an otoprotectant against ENT2 high-frequency hearing loss ENT2END caused by gentamicin, but further studies are needed to confirm this
0	The nitric oxide (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against ENT1 high-frequency hearing loss  ENT1END  caused by gentamicin, but further studies are needed to confirm this. ENT2 Aminoglycoside ENT2END antibiotics are still widely used by virtue of their efficacy and low cost
0	Nitro-L-arginine methyl ester: a potential protector against ENT1 gentamicin ENT1END ENT2 ototoxicity ENT2END
0	Nitro-L-arginine methyl ester: a potential protector against gentamicin ENT1 ototoxicity ENT1END .The ENT2 nitric oxide ENT2END (NO) inhibitor nitro-L-arginine methyl ester (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this
0	Nitro-L-arginine methyl ester: a potential protector against gentamicin ENT1 ototoxicity ENT1END .The nitric oxide (NO) inhibitor ENT2 nitro-L-arginine methyl ester ENT2END (L-NAME) may act as an otoprotectant against high-frequency hearing loss caused by gentamicin, but further studies are needed to confirm this
0	ENT1 Aminoglycoside ENT1END  antibiotics are still widely used by virtue of their efficacy and low cost. Their ENT2 ototoxicity ENT2END is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss
1	L-NAME reduced ENT1 gentamicin ENT1END induced ENT2 hearing loss ENT2END in the high-frequency range, but gave no protection in the middle or low frequencies
0	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of ENT1 NO ENT1END  inhibitors for the prevention of aminoglycoside-induced sensorineural hearing loss. In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear. The otoprotectant L-NAME was administered topically to 12/27 animals. Its effect was determined in terms of attenuation of ENT2 hearing loss ENT2END , measured by shifts in the auditory brainstem response threshold
0	ENT1 L-NAME  ENT1END reduced gentamicin-induced ENT2 hearing loss ENT2END in the high-frequency range, but gave no protection in the middle or low frequencies
0	Their ototoxicity is a serious health problem and, as their ototoxic mechanism involves the production of NO, we need to assess the use of NO inhibitors for the prevention of ENT1 aminoglycoside  ENT1END -induced sensorineural hearing loss. In this experimental study we used 30 Sprague-Dawley rats, 27 of which had gentamicin instilled into the middle ear. The otoprotectant L-NAME was administered topically to 12/27 animals. Its effect was determined in terms of attenuation of ENT2 hearing loss ENT2END , measured by shifts in the auditory brainstem response threshold
0	ENT1 Oxytocin ENT1END induced hypotension at cesarean delivery may be incorrectly attributed to ENT2 blood loss ENT2END
1	ENT1 Oxytocin ENT1END -induced ENT2 hypotension ENT2END at cesarean delivery may be incorrectly attributed to blood loss
0	Parturients with normal volume status, heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and ENT1 stroke  ENT1END volume. ENT2 Oxytocin ENT2END -induced hypotension at cesarean delivery may be incorrectly attributed to blood loss
0	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat ENT1 cancer ENT1END pain and chronic non malignant pain. This drug was initiated in association with paroxetine and ENT2 dosulepine hydrochloride ENT2END in a tetraparetic patient with chronic pain
0	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat ENT1 cancer ENT1END  pain and chronic non malignant pain. This drug was initiated in association with ENT2 paroxetine ENT2END and dosulepine hydrochloride in a tetraparetic patient with chronic pain
0	ENT1 Tramadol  ENT1END is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat ENT2 cancer ENT2END pain and chronic non malignant pain
0	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant ENT1 pain  ENT1END  This drug was initiated in association with paroxetine and ENT2 dosulepine hydrochloride ENT2END in a tetraparetic patient with chronic pain
0	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant ENT1 pain  ENT1END . This drug was initiated in association with ENT2 paroxetine ENT2END and dosulepine hydrochloride in a tetraparetic patient with chronic pain
0	Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and ENT1 tramadol ENT1END  The case report questions the long term use of ENT2 pain ENT2END killers combined with psycho-active drugs in chronic non malignant pain, especially if pain is under control
1	This drug was initiated in association with paroxetine and ENT1 dosulepine hydrochloride ENT1END  in a tetraparetic patient with chronic pain. Fifty-six days after initiation of the treatment the patient presented ENT2 hallucinations ENT2END that only stopped after the withdrawal of psycho-active drugs and tramadol
1	This drug was initiated in association with ENT1 paroxetine  ENT1END  and dosulepine hydrochloride in a tetraparetic patient with chronic pain. Fifty-six days after initiation of the treatment the patient presented ENT2 hallucinations ENT2END that only stopped after the withdrawal of psycho-active drugs and tramadol
1	Nightmares and ENT1 hallucinations  ENT1END  after long-term intake of ENT2 tramadol ENT2END combined with antidepressants
0	This drug was initiated in association with paroxetine and ENT1 dosulepine hydrochloride ENT1END  in a tetraparetic patient with ENT2 chronic pain ENT2END
0	This drug was initiated in association with ENT1 paroxetine  ENT1END  and dosulepine hydrochloride in a tetraparetic patient with ENT2 chronic pain ENT2END
0	This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with ENT1 chronic pain  ENT1END . Fifty-six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho-active drugs and ENT2 tramadol ENT2END
1	Dup 753 prevents the development of ENT1 puromycin aminonucleoside ENT1END -induced nephrosis.The appearance of ENT2 nephrotic syndromes ENT2END such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of ENT1 nephrotic syndromes  ENT1END  such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day. The results suggest a possible involvement of the renin- ENT2 angiotensin ENT2END system in the development of puromycin aminonucleoside-induced nephrosis
0	ENT1 Dup 753  ENT1END  prevents the development of puromycin aminonucleoside-induced nephrosis.The appearance of ENT2 nephrotic syndromes ENT2END such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of ENT1 nephrotic syndromes ENT1END  such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in ENT2 blood nitrogen urea ENT2END , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of ENT1 nephrotic syndromes ENT1END  such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel ENT2 angiotensin II ENT2END receptor antagonist, at a dose of 1 or 2 mg/kg per day
1	Dup 753 prevents the development of ENT1 puromycin aminonucleoside ENT1END -induced nephrosis.The appearance of nephrotic syndromes such as proteinuria, ENT2 hypoalbuminemia ENT2END , hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as proteinuria, ENT1 hypoalbuminemia  ENT1END , hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day. The results suggest a possible involvement of the renin ENT2 angiotensin ENT2END system in the development of puromycin aminonucleoside-induced nephrosis
0	ENT1 Dup 753  ENT1END  prevents the development of puromycin aminonucleoside-induced nephrosis.The appearance of nephrotic syndromes such as proteinuria, ENT2 hypoalbuminemia ENT2END , hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as proteinuria, ENT1 hypoalbuminemia  ENT1END , hypercholesterolemia and increase in ENT2 blood nitrogen urea ENT2END , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as proteinuria, ENT1 hypoalbuminemia  ENT1END , hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel ENT2 angiotensin II ENT2END receptor antagonist, at a dose of 1 or 2 mg/kg per day
1	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, ENT1 hypercholesterolemia ENT1END and increase in blood nitrogen urea, induced in rats by injection of ENT2 puromycin aminonucleoside ENT2END was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, ENT1 hypercholesterolemia  ENT1END  and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day. The results suggest a possible involvement of the renin ENT2 angiotensin ENT2END system in the development of puromycin aminonucleoside-induced nephrosis
0	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, ENT1 hypercholesterolemia ENT1END  and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of ENT2 Dup 753 ENT2END (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, ENT1 hypercholesterolemia  ENT1END  and increase in ENT2 blood nitrogen urea ENT2END , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, ENT1 hypercholesterolemia  ENT1END  and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel ENT2 angiotensin II ENT2END receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	Dup 753 prevents the development of ENT1 puromycin aminonucleoside  ENT1END -induced ENT2 nephrosis ENT2END
0	The results suggest a possible involvement of the renin- ENT1 angiotensin ENT1END  system in the development of puromycin aminonucleoside-induced ENT2 nephrosis ENT2END
0	ENT1 Dup 753  ENT1END  prevents the development of puromycin aminonucleoside-induced ENT2 nephrosis ENT2END
0	Dup 753 prevents the development of puromycin aminonucleoside-induced ENT1 nephrosis  ENT1END .The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in ENT2 blood nitrogen urea ENT2END , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as proteinuria, hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel ENT1 angiotensin II  ENT1END  receptor antagonist, at a dose of 1 or 2 mg/kg per day. The results suggest a possible involvement of the renin-angiotensin system in the development of puromycin aminonucleoside-induced ENT2 nephrosis ENT2END
1	Dup 753 prevents the development of ENT1 puromycin aminonucleoside ENT1END -induced nephrosis.The appearance of nephrotic syndromes such as ENT2 proteinuria ENT2END , hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as ENT1 proteinuria  ENT1END , hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day. The results suggest a possible involvement of the renin ENT2 angiotensin ENT2END system in the development of puromycin aminonucleoside-induced nephrosis
0	ENT1 Dup 753  ENT1END  prevents the development of puromycin aminonucleoside-induced nephrosis.The appearance of nephrotic syndromes such as ENT2 proteinuria ENT2END , hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as ENT1 proteinuria  ENT1END , hypoalbuminemia, hypercholesterolemia and increase in ENT2 blood nitrogen urea ENT2END , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel angiotensin II receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	The appearance of nephrotic syndromes such as ENT1 proteinuria  ENT1END , hypoalbuminemia, hypercholesterolemia and increase in blood nitrogen urea, induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 (losartan), a novel ENT2 angiotensin II ENT2END receptor antagonist, at a dose of 1 or 2 mg/kg per day
0	Phenylpropanolamine (PPA) is a sympathetic ENT1 amine ENT1END used in over-the-counter cold remedies and weight-control preparations worldwide. Its use has been associated with ENT2 hypertensive ENT2END episodes and hemorrhagic strokes in younger women
0	Its use has been associated with ENT1 hypertensive ENT1END  episodes and hemorrhagic strokes in younger women. Several reports have linked the abuse of ENT2 PPA ENT2END with myocardial injury, especially when overdose is involved
0	Phenylpropanolamine (PPA) is a sympathetic ENT1 amine ENT1END  used in over-the-counter cold remedies and weight-control preparations worldwide. Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women. Several reports have linked the abuse of PPA with ENT2 myocardial injury ENT2END , especially when overdose is involved
0	Several reports have linked the abuse of ENT1 PPA  ENT1END  with ENT2 myocardial injury ENT2END , especially when overdose is involved
0	Case report: Dexatrim (Phenylpropanolamine) as a cause of ENT1 myocardial infarction  ENT1END .Phenylpropanolamine (PPA) is a sympathetic ENT2 amine ENT2END used in over-the-counter cold remedies and weight-control preparations worldwide
1	Case report: Dexatrim (Phenylpropanolamine) as a cause of ENT1 myocardial infarction  ENT1END . ENT2 Phenylpropanolamine ENT2END (PPA) is a sympathetic amine used in over-the-counter cold remedies and weight-control preparations worldwide
0	Phenylpropanolamine (PPA) is a sympathetic ENT1 amine ENT1END  used in over-the-counter cold remedies and weight-control preparations worldwide. Its use has been associated with hypertensive episodes and ENT2 hemorrhagic strokes ENT2END in younger women
0	Its use has been associated with hypertensive episodes and ENT1 hemorrhagic strokes  ENT1END  in younger women. Several reports have linked the abuse of ENT2 PPA ENT2END with myocardial injury, especially when overdose is involved
0	Phenylpropanolamine (PPA) is a sympathetic ENT1 amine ENT1END  used in over-the-counter cold remedies and weight-control preparations worldwide. Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women. Several reports have linked the abuse of PPA with myocardial injury, especially when ENT2 overdose ENT2END is involved
0	Several reports have linked the abuse of ENT1 PPA  ENT1END  with myocardial injury, especially when ENT2 overdose ENT2END is involved
0	Phenylpropanolamine (PPA) is a sympathetic ENT1 amine ENT1END  used in over-the-counter cold remedies and weight-control preparations worldwide. Its use has been associated with hypertensive episodes and ENT2 hemorrhagic strokes ENT2END in younger women
0	Its use has been associated with hypertensive episodes and ENT1 hemorrhagic strokes  ENT1END  in younger women. Several reports have linked the abuse of ENT2 PPA ENT2END with myocardial injury, especially when overdose is involved
1	ENT1 Leg and back pain  ENT1END  after spinal anaesthesia involving hyperbaric 5% ENT2 lignocaine ENT2END
0	8% ENT1 glucose ENT1END solution for spinal anaesthesia were studied. Thirteen of these patients experienced ENT2 pain in the legs and/or back ENT2END after recovery from anaesthesia
0	Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without pain admitted to a high ENT1 alcohol ENT1END intake, which might be a contributing factor. ENT2 Leg and/or back pain ENT2END is associated with the intrathecal use of hyperbaric 5% lignocaine
0	Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without ENT1 pain ENT1END admitted to a high alcohol intake, which might be a contributing factor. Leg and/or back pain is associated with the intrathecal use of hyperbaric 5% ENT2 lignocaine ENT2END
0	8% ENT1 glucose ENT1END  solution for spinal anaesthesia were studied. Thirteen of these patients experienced pain in the legs and/or back after recovery from anaesthesia. The patients affected were younger (p < 0.05) and the site of the dural puncture was higher (p < 0.01) than those individuals without ENT2 pain ENT2END
0	Five of the 13 patients (38%) with pain and seven of the 41 patients (17%) without ENT1 pain  ENT1END  admitted to a high ENT2 alcohol ENT2END intake, which might be a contributing factor
1	The most common drug-related adverse events were diarrhea, flatulence, and ENT1 nausea ENT1END  most adverse events were mild to moderate in severity. CONCLUSION: The results of this study indicate that ENT2 levofloxacin ENT2END 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis
0	Open-label assessment of ENT1 levofloxacin  ENT1END  for the treatment of acute bacterial ENT2 sinusitis ENT2END in adults
1	Adverse events considered to be related to ENT1 levofloxacin ENT1END administration were reported by 29 patients (9%). The most common drug-related adverse events were ENT2 diarrhea ENT2END , flatulence, and nausea; most adverse events were mild to moderate in severity
1	Adverse events considered to be related to ENT1 levofloxacin ENT1END  administration were reported by 29 patients (9%). The most common drug-related adverse events were diarrhea, ENT2 flatulence ENT2END , and nausea; most adverse events were mild to moderate in severity
0	Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome (AIDS), but has resulted in an increase in ENT1 cardiac and skeletal myopathies ENT1END  METHODS AND RESULTS: In order to investigate whether the HAART component ENT2 zidovudine ENT2END (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0
1	In contrast, ENT1 AZT ENT1END treated FasL Tg mice developed ENT2 cardiac dilation ENT2END and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles
1	Myocardial Fas ligand expression increases susceptibility to ENT1 AZT  ENT1END -induced ENT2 cardiomyopathy ENT2END
0	Myocardial Fas ligand expression increases susceptibility to ENT1 AZT ENT1END -induced cardiomyopathy.BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many ENT2 HIV-infected ENT2END individuals, resulting in symptomatic heart failure in up to 5% of patients
0	Myocardial Fas ligand expression increases susceptibility to ENT1 AZT ENT1END -induced cardiomyopathy.BACKGROUND: Dilated cardiomyopathy (DCM) and ENT2 myocarditis ENT2END occur in many HIV-infected individuals, resulting in symptomatic heart failure in up to 5% of patients
0	Myocardial Fas ligand expression increases susceptibility to ENT1 AZT ENT1END -induced cardiomyopathy.BACKGROUND: Dilated cardiomyopathy (DCM) and myocarditis occur in many HIV-infected individuals, resulting in symptomatic ENT2 heart failure ENT2END in up to 5% of patients
0	In contrast, ENT1 AZT ENT1END -treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose-dependent manner, with concomitant inflammatory infiltration of both ventricles. These changes were associated with an increased sarcolemmal expression of Fas and FasL, as well as increased activation of caspase 3, translocation of calpain 1 to the sarcolemma and sarcomere, and increased numbers of cells undergoing apoptosis. These were associated with changes in dystrophin and cardiac troponin I localization, as well as loss of sarcolemmal integrity. CONCLUSIONS: The expression of Fas ligand in the myocardium, as identified in HIV-positive patients, might increase the susceptibility to HAART-induced cardiomyopathy due to activation of apoptotic pathways, resulting in ENT2 cardiac dilation and dysfunction ENT2END
0	Highly active antiretroviral therapy (HAART) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( ENT1 AIDS  ENT1END , but has resulted in an increase in cardiac and skeletal myopathies. METHODS AND RESULTS: In order to investigate whether the HAART component ENT2 zidovudine ENT2END (3'-azido-2',3'-deoxythymidine; AZT) triggers the Fas-dependent cell-death pathway and cause cytoskeletal disruption in a murine model of DCM, 8-week-old transgenic (expressing Fas ligand in the myocardium: FasL Tg) and non-transgenic (NTg) mice received water ad libitum containing different concentrations of AZT (0, 0
0	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and ENT1 cor pulmonale ENT1END after indomethacin therapy. Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria. Our case supports the hypothesis that endogenous renal ENT2 prostaglandins ENT2END play a role in the maintenance of renal blood flow when circulating plasma volume is diminished
1	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ascites, and ENT1 cor pulmonale ENT1END  after ENT2 indomethacin ENT2END therapy
0	We have reported a case of acute oliguric renal failure with ENT1 hyperkalemia  ENT1END in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy. Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria. Our case supports the hypothesis that endogenous renal ENT2 prostaglandins ENT2END play a role in the maintenance of renal blood flow when circulating plasma volume is diminished
1	We have reported a case of acute oliguric renal failure with ENT1 hyperkalemia  ENT1END  in a patient with cirrhosis, ascites, and cor pulmonale after ENT2 indomethacin ENT2END therapy
0	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with ENT1 cirrhosis  ENT1END  ascites, and cor pulmonale after indomethacin therapy. Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria. Our case supports the hypothesis that endogenous renal ENT2 prostaglandins ENT2END play a role in the maintenance of renal blood flow when circulating plasma volume is diminished
1	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with ENT1 cirrhosis  ENT1END , ascites, and cor pulmonale after ENT2 indomethacin ENT2END therapy
0	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ENT1 ascites  ENT1END  and cor pulmonale after indomethacin therapy. Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria. Our case supports the hypothesis that endogenous renal ENT2 prostaglandins ENT2END play a role in the maintenance of renal blood flow when circulating plasma volume is diminished
1	We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis, ENT1 ascites  ENT1END , and cor pulmonale after ENT2 indomethacin ENT2END therapy
0	We have reported a case of acute oliguric ENT1 renal failure  ENT1END with hyperkalemia in a patient with cirrhosis, ascites, and cor pulmonale after indomethacin therapy. Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria. Our case supports the hypothesis that endogenous renal ENT2 prostaglandins ENT2END play a role in the maintenance of renal blood flow when circulating plasma volume is diminished
0	ENT1 Indomethacin  ENT1END -induced ENT2 renal insufficiency ENT2END : recurrence on rechallenge
0	Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of indomethacin caused recurrence of acute reversible ENT1 oliguria  ENT1END  Our case supports the hypothesis that endogenous renal ENT2 prostaglandins ENT2END play a role in the maintenance of renal blood flow when circulating plasma volume is diminished
1	Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of ENT1 indomethacin  ENT1END caused recurrence of acute reversible ENT2 oliguria ENT2END
0	Our case supports the hypothesis that endogenous renal ENT1 prostaglandins ENT1END  play a role in the maintenance of renal blood flow when circulating plasma volume is diminished. Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause ENT2 acute renal failure ENT2END , they should be used with caution in such patients
1	Prompt restoration of renal function followed drug withdrawal, while re-exposure to a single dose of ENT1 indomethacin  ENT1END  caused recurrence of acute reversible oliguria. Our case supports the hypothesis that endogenous renal prostaglandins play a role in the maintenance of renal blood flow when circulating plasma volume is diminished. Since nonsteroidal anti-inflammatory agents interfere with this compensatory mechanism and may cause ENT2 acute renal failure ENT2END , they should be used with caution in such patients
0	In patients that were free of recurrence during the first year, 80% remained ENT1 tumor ENT1END free during the 2- to 3-year follow-up period. Of the patients developing one or more recurrences during the first year, only 50% presented with further recurrence once the instillations were stopped. The beneficial effect of ENT2 Adriamycin ENT2END appears obvious and might be related to the drug itself, the early and repeated instillations after TUR, or both
0	A multicenter study was performed in 110 patients with superficial transitional cell ENT1 carcinoma of the bladder ENT1END  ENT2 Adriamycin ENT2END (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors
0	A multicenter study was performed in 110 patients with superficial transitional cell ENT1 carcinoma of the bladder ENT1END ENT2 Adriamycin ENT2END (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors
1	ENT1 Adriamycin ENT1END  (50 mg/50 ml) was administered intravesically within 24 h after transurethral resection of TA-T1 (O-A) bladder tumors. Instillation was repeated twice during the first week, then weekly during the first month and afterwards monthly for 1 year. The tolerance was evaluated in these 110 patients, and 29 patients presented with local side-effects. In 24 of these patients chemical ENT2 cystitis ENT2END was severe enough for them to drop out of the study
1	The clinical and autopsy findings in a premature baby who died of ENT1 acute renal failure ENT1END after therapy with ENT2 gentamicin ENT2END (5 mg/kg/day) and penicillin are presented
0	The clinical and autopsy findings in a premature baby who died of ENT1 acute renal failure ENT1END  after therapy with gentamicin (5 mg/kg/day) and ENT2 penicillin ENT2END are presented
0	The clinical and autopsy findings in a premature baby who died of ENT1 acute renal failure ENT1END  after therapy with gentamicin (5 mg/kg/day) and penicillin are presented. The serum gentamicin concentration had reached toxic levels when anuria developed. Numerous ENT2 periodic acid ENT2END Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules
0	The serum ENT1 gentamicin ENT1END concentration had reached toxic levels when ENT2 anuria ENT2END developed
0	The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and ENT1 penicillin  ENT1END  are presented. The serum gentamicin concentration had reached toxic levels when ENT2 anuria ENT2END developed
0	The serum gentamicin concentration had reached toxic levels when ENT1 anuria  ENT1END  developed. Numerous ENT2 periodic acid ENT2END Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules
0	ENT1 Gentamicin ENT1END ENT2 nephropathy ENT2END in a neonate
0	Gentamicin ENT1 nephropathy  ENT1END  in a neonate.The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and ENT2 penicillin ENT2END are presented
0	Gentamicin ENT1 nephropathy  ENT1END  in a neonate.The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin (5 mg/kg/day) and penicillin are presented. The serum gentamicin concentration had reached toxic levels when anuria developed. Numerous ENT2 periodic acid ENT2END Schiff (PAS) positive, diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules
0	Bupropion is a monocyclic ENT1 antidepressant ENT1END structurally related to amphetamine. Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, hallucinations and convulsions. Two patients developed severe ENT2 cardiac arrhythmias ENT2END , including one patient who was resuscitated following a cardiac arrest
0	Two patients developed severe ENT1 cardiac arrhythmias ENT1END , including one patient who was resuscitated following a cardiac arrest. All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with ENT2 adenosine ENT2END
0	Two patients developed severe ENT1 cardiac arrhythmias ENT1END , including one patient who was resuscitated following a cardiac arrest. All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with ENT2 diazepam ENT2END and broad complex tachycardia was successfully treated with adenosine
1	Two patients developed severe ENT1 cardiac arrhythmias ENT1END , including one patient who was resuscitated following a cardiac arrest. All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g ENT2 bupropion ENT2END
0	Bupropion is a monocyclic antidepressant structurally related to ENT1 amphetamine  ENT1END  Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, hallucinations and convulsions. Two patients developed severe ENT2 cardiac arrhythmias ENT2END , including one patient who was resuscitated following a cardiac arrest
0	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with ENT1 adenosine ENT1END . Zyban caused significant ENT2 neurological and cardiovascular toxicity ENT2END in overdose
0	Recurrent seizures were treated with ENT1 diazepam  ENT1END  and broad complex tachycardia was successfully treated with adenosine. Zyban caused significant ENT2 neurological and cardiovascular toxicity ENT2END in overdose
0	ENT1 Zyban  ENT1END caused significant ENT2 neurological and cardiovascular toxicity ENT2END in overdose
0	Bupropion is a monocyclic ENT1 antidepressant ENT1END  structurally related to amphetamine. Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, hallucinations and convulsions. Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a ENT2 cardiac arrest ENT2END
0	Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a ENT1 cardiac arrest  ENT1END . All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with ENT2 adenosine ENT2END
0	Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a ENT1 cardiac arrest  ENT1END . All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with ENT2 diazepam ENT2END and broad complex tachycardia was successfully treated with adenosine
1	Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a ENT1 cardiac arrest  ENT1END . All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g ENT2 bupropion ENT2END
0	Bupropion is a monocyclic antidepressant structurally related to ENT1 amphetamine  ENT1END . Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, hallucinations and convulsions. Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a ENT2 cardiac arrest ENT2END
0	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with ENT1 adenosine ENT1END . Zyban caused significant ENT2 neurological and cardiovascular toxicity ENT2END in overdose
0	Recurrent seizures were treated with ENT1 diazepam  ENT1END  and broad complex tachycardia was successfully treated with adenosine. Zyban caused significant ENT2 neurological and cardiovascular toxicity ENT2END in overdose
0	ENT1 Zyban  ENT1END  caused significant ENT2 neurological and cardiovascular toxicity ENT2END in overdose
0	Bupropion (Zyban) ENT1 toxicity  ENT1END .Bupropion is a monocyclic ENT2 antidepressant ENT2END structurally related to amphetamine
0	8 patients developed symptoms of ENT1 toxicity  ENT1END  Common features included tachycardia, drowsiness, hallucinations and convulsions. Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest. All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with ENT2 adenosine ENT2END
0	8 patients developed symptoms of ENT1 toxicity  ENT1END . Common features included tachycardia, drowsiness, hallucinations and convulsions. Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest. All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with ENT2 diazepam ENT2END and broad complex tachycardia was successfully treated with adenosine
0	Bupropion ( ENT1 Zyban  ENT1END ) ENT2 toxicity ENT2END
0	Bupropion (Zyban) ENT1 toxicity  ENT1END .Bupropion is a monocyclic antidepressant structurally related to ENT2 amphetamine ENT2END
0	Bupropion is a monocyclic ENT1 antidepressant ENT1END  structurally related to amphetamine. Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, hallucinations and ENT2 convulsions ENT2END
0	Recurrent ENT1 seizures  ENT1END were treated with diazepam and broad complex tachycardia was successfully treated with ENT2 adenosine ENT2END
0	Recurrent ENT1 seizures  ENT1END  were treated with ENT2 diazepam ENT2END and broad complex tachycardia was successfully treated with adenosine
1	5g ENT1 bupropion  ENT1END . Recurrent ENT2 seizures ENT2END were treated with diazepam and broad complex tachycardia was successfully treated with adenosine
0	Bupropion is a monocyclic antidepressant structurally related to ENT1 amphetamine  ENT1END . Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, hallucinations and ENT2 convulsions ENT2END
0	Bupropion is a monocyclic ENT1 antidepressant ENT1END  structurally related to amphetamine. Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included ENT2 tachycardia ENT2END , drowsiness, hallucinations and convulsions
0	Recurrent seizures were treated with diazepam and broad complex ENT1 tachycardia  ENT1END was successfully treated with ENT2 adenosine ENT2END
0	Recurrent seizures were treated with ENT1 diazepam  ENT1END  and broad complex ENT2 tachycardia ENT2END was successfully treated with adenosine
1	Recurrent seizures were treated with diazepam and broad complex ENT1 tachycardia  ENT1END  was successfully treated with adenosine. ENT2 Zyban ENT2END caused significant neurological and cardiovascular toxicity in overdose
0	Bupropion is a monocyclic antidepressant structurally related to ENT1 amphetamine  ENT1END . Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included ENT2 tachycardia ENT2END , drowsiness, hallucinations and convulsions
0	Bupropion is a monocyclic ENT1 antidepressant ENT1END  structurally related to amphetamine. Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, ENT2 hallucinations ENT2END and convulsions
0	Common features included tachycardia, drowsiness, ENT1 hallucinations  ENT1END  and convulsions. Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest. All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with ENT2 adenosine ENT2END
0	Common features included tachycardia, drowsiness, ENT1 hallucinations  ENT1END  and convulsions. Two patients developed severe cardiac arrhythmias, including one patient who was resuscitated following a cardiac arrest. All patients recovered without sequelae. We report a case of a 31 year old female who required admission to the Intensive Care Unit for ventilation and full supportive therapy, following ingestion of 13.5g bupropion. Recurrent seizures were treated with ENT2 diazepam ENT2END and broad complex tachycardia was successfully treated with adenosine
1	Zyban, a sustained-release formulation of ENT1 bupropion hydrochloride  ENT1END  was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, ENT2 hallucinations ENT2END and convulsions
0	Bupropion is a monocyclic antidepressant structurally related to ENT1 amphetamine  ENT1END . Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 overdose cases have been reported to The National Poisons Information Centre. 8 patients developed symptoms of toxicity. Common features included tachycardia, drowsiness, ENT2 hallucinations ENT2END and convulsions
0	Bupropion is a monocyclic ENT1 antidepressant ENT1END  structurally related to amphetamine. Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 ENT2 overdose ENT2END cases have been reported to The National Poisons Information Centre
0	Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with ENT1 adenosine ENT1END . Zyban caused significant neurological and cardiovascular toxicity in ENT2 overdose ENT2END
0	Recurrent seizures were treated with ENT1 diazepam  ENT1END  and broad complex tachycardia was successfully treated with adenosine. Zyban caused significant neurological and cardiovascular toxicity in ENT2 overdose ENT2END
0	ENT1 Zyban  ENT1END  caused significant neurological and cardiovascular toxicity in ENT2 overdose ENT2END
0	Bupropion is a monocyclic antidepressant structurally related to ENT1 amphetamine  ENT1END . Zyban, a sustained-release formulation of bupropion hydrochloride, was recently released in Ireland, as a smoking cessation aid. In the initial 6 months since it's introduction, 12 ENT2 overdose ENT2END cases have been reported to The National Poisons Information Centre
0	A series of ENT1 N-pyrimidinyl-2-phenoxyacetamide ENT1END adenosine A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for ENT2 Parkinson's disease ENT2END
0	A series of N-pyrimidinyl-2-phenoxyacetamide ENT1 adenosine  ENT1END A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced catalepsy model for ENT2 Parkinson's disease ENT2END
0	) in the rat ENT1 haloperidol  ENT1END induced catalepsy model for ENT2 Parkinson's disease ENT2END
0	A series of ENT1 N-pyrimidinyl-2-phenoxyacetamide ENT1END  adenosine A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced ENT2 catalepsy ENT2END model for Parkinson's disease
0	A series of N-pyrimidinyl-2-phenoxyacetamide ENT1 adenosine  ENT1END  A(2A) antagonists is described. SAR studies led to compound 14 with excellent potency (K(i) = 0.4 nM), selectivity (A(1)/A(2A) > 100), and efficacy (MED 10 mg/kg p.o.) in the rat haloperidol-induced ENT2 catalepsy ENT2END model for Parkinson's disease
1	) in the rat ENT1 haloperidol  ENT1END -induced ENT2 catalepsy ENT2END model for Parkinson's disease
0	In order to investigate the effects of ENT1 daidzein ENT1END from Pueraria thunbergiana on scopolamine-induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ENT1 ACh  ENT1END , is an important factor in the treatment of Alzheimer's disease (AD). Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro. Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone). In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	In order to investigate the effects of daidzein from Pueraria thunbergiana on ENT1 scopolamine  ENT1END induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	The ENT1 choline  ENT1END acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD). Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro. Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone). In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	In order to investigate the effects of ENT1 daidzein ENT1END  from Pueraria thunbergiana on scopolamine-induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ENT1 ACh  ENT1END ), is an important factor in the treatment of Alzheimer's disease (AD). Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro. Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone). In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	In order to investigate the effects of daidzein from Pueraria thunbergiana on ENT1 scopolamine  ENT1END -induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	The ENT1 choline  ENT1END  acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD). Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro. Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone). In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine-induced ENT2 impairments of learning and memory ENT2END , we conducted a series of in vivo tests
0	The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease ( ENT1 AD ENT1END . Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro. Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as ENT2 daidzein ENT2END (4',7-dihydroxy-isoflavone)
0	The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ENT1 ACh ENT1END ), is an important factor in the treatment of ENT2 Alzheimer's disease ENT2END (AD)
0	The choline acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease ( ENT1 AD  ENT1END ). Methanolic extracts from Pueraria thunbergiana exhibited an activation effect (46%) on ChAT in vitro. Via the sequential isolation of Pueraria thunbergiana, the active component was ultimately identified as daidzein (4',7-dihydroxy-isoflavone). In order to investigate the effects of daidzein from Pueraria thunbergiana on ENT2 scopolamine ENT2END -induced impairments of learning and memory, we conducted a series of in vivo tests
0	The ENT1 choline  ENT1END  acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of ENT2 Alzheimer's disease ENT2END (AD)
0	ENT1 Daidzein  ENT1END  activates choline acetyltransferase from MC-IXC cells and improves drug-induced ENT2 amnesia ENT2END
0	These results indicate that daidzein might play a role in ENT1 acetylcholine ENT1END biosynthesis as a ChAT activator, and that it also ameliorates scopolamine-induced ENT2 amnesia ENT2END
1	5 mg/kg body weight) to mice was shown significantly to reverse ENT1 scopolamine ENT1END induced ENT2 amnesia ENT2END , according to the results of a Y-maze test
0	Daidzein activates choline acetyltransferase from MC-IXC cells and improves drug-induced ENT1 amnesia  ENT1END .The ENT2 choline ENT2END acetyltransferase (ChAT) activator, which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine (ACh), is an important factor in the treatment of Alzheimer's disease (AD)
1	CONCLUSION: This work shows that ENT1 confusion ENT1END with ENT2 valproic acid ENT2END is a serious, rather frequent but reversible adverse drug reaction
0	Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to ENT1 seizures  ENT1END  in mice lacking sodium channel beta 2-subunits.Sodium channel beta-subunits modulate channel gating, assembly, and cell surface expression in heterologous cell systems. We generated beta2(-/-) mice to investigate the role of beta2 in control of sodium channel density, localization, and function in neurons in vivo. Measurements of [(3)H] ENT2 saxitoxin ENT2END (STX) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2(-/-) neurons
1	beta2(-/-) mice displayed increased susceptibility to seizures, as indicated by reduced latency and threshold for ENT1 pilocarpine ENT1END induced ENT2 seizures ENT2END , but seemed normal in other neurological tests
0	Reduced sodium channel density, altered voltage dependence of inactivation, and increased susceptibility to ENT1 seizures  ENT1END  in mice lacking ENT2 sodium ENT2END channel beta 2-subunits
0	The development of ENT1 cardiac hypertrophy ENT1END was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0.3 mg/kg body weight). A time course was established for the change in tissue mass, RNA and DNA content, as well as ENT2 hydroxyproline ENT2END content
1	Development of ENT1 isoproterenol  ENT1END -induced ENT2 cardiac hypertrophy ENT2END
0	The total content of ENT1 hydroxyproline ENT1END remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy. Ventricular DNA content was unchanged during the early stage (1-4 days) of hypertrophic growth but increased to a new steady-state level 19% above the controls after 8 days of treatment. Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy. However, dP/dt in the ISO-treated hearts was slightly but significantly (P less than 0.05) elevated. These data indicate that the adaptive response to ISO shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA. However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and ENT2 hyperplasia ENT2END within the heart
1	These data indicate that the adaptive response to ENT1 ISO  ENT1END shows an early hypertrophic phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA. However, prolonged stimulation (8-12 days) appears to represent a complex integration of both cellular hypertrophy and ENT2 hyperplasia ENT2END within the heart
0	The total content of ENT1 hydroxyproline ENT1END  remained stable during the first 2 days of treatment but increased 46% after 4 days of therapy. Ventricular DNA content was unchanged during the early stage (1-4 days) of ENT2 hypertrophic ENT2END growth but increased to a new steady-state level 19% above the controls after 8 days of treatment
0	These data indicate that the adaptive response to ENT1 ISO ENT1END  shows an early ENT2 hypertrophic ENT2END phase (1-4 days) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA
0	We report 4 patients with late-onset LV probably due to ENT1 warfarin ENT1END  All 4 patients presented with ENT2 skin eruptions ENT2END that developed after receiving warfarin for several years
0	Skin reactions associated with oral ENT1 coumarin  ENT1END derived anticoagulants are an uncommon occurrence. Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered. We report 4 patients with late-onset LV probably due to warfarin. All 4 patients presented with ENT2 skin eruptions ENT2END that developed after receiving warfarin for several years
0	We report 4 patients with late-onset ENT1 LV  ENT1END probably due to ENT2 warfarin ENT2END
0	Warfarin-induced ENT1 leukocytoclastic vasculitis  ENT1END .Skin reactions associated with oral ENT2 coumarin ENT2END -derived anticoagulants are an uncommon occurrence
0	Leukocytoclastic vasculitis (LV) is primarily a ENT1 cutaneous small vessel vasculitis  ENT1END  though systemic involvement may be encountered. We report 4 patients with late-onset LV probably due to ENT2 warfarin ENT2END
0	Skin reactions associated with oral ENT1 coumarin  ENT1END -derived anticoagulants are an uncommon occurrence. Leukocytoclastic vasculitis (LV) is primarily a ENT2 cutaneous small vessel vasculitis ENT2END , though systemic involvement may be encountered
1	The results of skin lesion biopsies were available in 3 patients, confirming ENT1 LV Cutaneous lesions ENT1END resolved in all patients after ENT2 warfarin ENT2END was discontinued
0	Skin reactions associated with oral ENT1 coumarin  ENT1END -derived anticoagulants are an uncommon occurrence. Leukocytoclastic vasculitis (LV) is primarily a cutaneous small vessel vasculitis, though systemic involvement may be encountered. We report 4 patients with late-onset LV probably due to warfarin. All 4 patients presented with skin eruptions that developed after receiving warfarin for several years. The results of skin lesion biopsies were available in 3 patients, confirming ENT2 LV Cutaneous lesions ENT2END resolved in all patients after warfarin was discontinued
1	One patient had focal seizures and ENT1 transient hemiparesis ENT1END but recovered completely. High-dose intravenous ENT2 methotrexate ENT2END is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia
0	The most common toxicities encountered were transient serum transaminase and ENT1 bilirubin  ENT1END elevations, neutropenia, and mucositis. One patient had focal seizures and ENT2 transient hemiparesis ENT2END but recovered completely
0	ENT1 Leucovorin  ENT1END rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively. All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission. The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis. One patient had focal seizures and ENT2 transient hemiparesis ENT2END but recovered completely
0	The most common ENT1 toxicities  ENT1END encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis. One patient had focal seizures and transient hemiparesis but recovered completely. High-dose intravenous ENT2 methotrexate ENT2END is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia
0	The most common ENT1 toxicities  ENT1END  encountered were transient serum transaminase and ENT2 bilirubin ENT2END elevations, neutropenia, and mucositis
0	ENT1 Leucovorin  ENT1END  rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively. All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission. The most common ENT2 toxicities ENT2END encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis
0	Twenty children with acute lymphoblastic leukemia who developed ENT1 meningeal disease ENT1END were treated with a high-dose intravenous ENT2 methotrexate ENT2END regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing
0	Twenty children with acute lymphoblastic leukemia who developed ENT1 meningeal disease  ENT1END  were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing. The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours. Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively. All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission. The most common toxicities encountered were transient serum transaminase and ENT2 bilirubin ENT2END elevations, neutropenia, and mucositis
0	Twenty children with acute lymphoblastic leukemia who developed ENT1 meningeal disease  ENT1END  were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing. The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours. ENT2 Leucovorin ENT2END rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L
0	Remission induction of meningeal leukemia with high-dose intravenous ENT1 methotrexate ENT1END .Twenty children with ENT2 acute lymphoblastic leukemia ENT2END who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing
0	The most common toxicities encountered were transient serum transaminase and ENT1 bilirubin ENT1END  elevations, neutropenia, and mucositis. One patient had focal seizures and transient hemiparesis but recovered completely. High-dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in ENT2 acute lymphoblastic leukemia ENT2END
0	Twenty children with ENT1 acute lymphoblastic leukemia  ENT1END  who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing. The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours. ENT2 Leucovorin ENT2END rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L
1	One patient had focal ENT1 seizures  ENT1END and transient hemiparesis but recovered completely. High-dose intravenous ENT2 methotrexate ENT2END is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia
0	The most common toxicities encountered were transient serum transaminase and ENT1 bilirubin  ENT1END  elevations, neutropenia, and mucositis. One patient had focal ENT2 seizures ENT2END and transient hemiparesis but recovered completely
0	ENT1 Leucovorin  ENT1END  rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively. All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission. The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and mucositis. One patient had focal ENT2 seizures ENT2END and transient hemiparesis but recovered completely
0	Remission induction of ENT1 meningeal leukemia  ENT1END  with high-dose intravenous ENT2 methotrexate ENT2END
0	Remission induction of ENT1 meningeal leukemia  ENT1END  with high-dose intravenous methotrexate.Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing. The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours. Leucovorin rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively. All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission. The most common toxicities encountered were transient serum transaminase and ENT2 bilirubin ENT2END elevations, neutropenia, and mucositis
0	Remission induction of ENT1 meningeal leukemia  ENT1END  with high-dose intravenous methotrexate.Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high-dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10(-5) mol/L without the need for concomitant intrathecal dosing. The methotrexate was administered as a loading dose of 6,000 mg/m2 for a period of one hour followed by an infusion of 1,200 mg/m2/h for 23 hours. ENT2 Leucovorin ENT2END rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L
1	The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and ENT1 mucositis  ENT1END  One patient had focal seizures and transient hemiparesis but recovered completely. High-dose intravenous ENT2 methotrexate ENT2END is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia
0	The most common toxicities encountered were transient serum transaminase and ENT1 bilirubin  ENT1END  elevations, neutropenia, and ENT2 mucositis ENT2END
0	ENT1 Leucovorin  ENT1END  rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively. All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission. The most common toxicities encountered were transient serum transaminase and bilirubin elevations, neutropenia, and ENT2 mucositis ENT2END
1	The most common toxicities encountered were transient serum transaminase and bilirubin elevations, ENT1 neutropenia  ENT1END  and mucositis. One patient had focal seizures and transient hemiparesis but recovered completely. High-dose intravenous ENT2 methotrexate ENT2END is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia
0	The most common toxicities encountered were transient serum transaminase and ENT1 bilirubin  ENT1END  elevations, ENT2 neutropenia ENT2END , and mucositis
0	ENT1 Leucovorin  ENT1END  rescue was initiated 12 hours after the end of the infusion with a loading dose of 200 mg/m2 followed by 12 mg/m2 every three hours for six doses and then every six hours until the plasma methotrexate level decreased to less than 1 X 10(-7) mol/L. The mean steady-state plasma and CSF methotrexate concentrations achieved were 1.1 X 10(-3) mol/L and 3.6 X 10(-5) mol/L, respectively. All 20 patients responded to this regimen, 16/20 (80%) achieved a complete remission, and 20% obtained a partial remission. The most common toxicities encountered were transient serum transaminase and bilirubin elevations, ENT2 neutropenia ENT2END , and mucositis
0	Second- and third-generation ENT1 cephalosporins ENT1END  especially cefotetan, are increasingly associated with severe, sometimes fatal immune ENT2 hemolytic anemia ENT2END
1	We noticed that 10 of our 35 cases of ENT1 cefotetan ENT1END induced ENT2 hemolytic anemias ENT2END were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures
0	Fever and subsequent multiple ENT1 painful ENT1END erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy. The skin biopsy taken from each patient was consistent with erythema nodosum. All patients received short course of ENT2 steroids ENT2END
0	We describe four patients with classic APL who developed erythema nodosum during ENT1 ATRA  ENT1END therapy. Fever and subsequent multiple ENT2 painful ENT2END erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy
0	All patients received short course of ENT1 steroids ENT1END . ENT2 Fever ENT2END subsided rapidly and the skin lesions regressed completely
1	We describe four patients with classic APL who developed erythema nodosum during ENT1 ATRA ENT1END  therapy. ENT2 Fever ENT2END and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy
0	We describe four patients with classic ENT1 APL  ENT1END who developed erythema nodosum during ATRA therapy. Fever and subsequent multiple painful erythematous nodules over extremities developed on D11, D16, D17, and D19, respectively, after ATRA therapy. The skin biopsy taken from each patient was consistent with erythema nodosum. All patients received short course of ENT2 steroids ENT2END
0	Erythema nodosum associated with all- trans-retinoic acid ( ENT1 ATRA ENT1END  for ENT2 acute promyelocytic leukemia ENT2END (APL) is very rare
0	ATRA seemed to be the most possible etiology of ENT1 erythema nodosum ENT1END in our patients. Short-term use of ENT2 steroid ENT2END is very effective in ATRA-induced erythema nodosum
1	We describe four patients with classic APL who developed ENT1 erythema nodosum  ENT1END during ENT2 ATRA ENT2END therapy
0	The aggravated risk on intracerebral hemorrhage (ICH) with drugs used for ENT1 stroke ENT1END patients should be estimated carefully. We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration. In ICH intrastriatally induced by 0.014-unit, 0.070-unit, and 0.350-unit collagenase, the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume. The blood amounts and hematoma volumes were significantly correlated, and the hematoma induced by 0.014-unit collagenase was adequate to detect ICH deterioration. In ICH induction using 0.014-unit collagenase, ENT2 heparin ENT2END enhanced the hematoma volume 3
1	014-unit collagenase, ENT1 heparin ENT1END  enhanced the ENT2 hematoma ENT2END volume 3
0	014-unit collagenase, ENT1 heparin ENT1END  enhanced the hematoma volume 3.4-fold over that seen in control ICH animals and the ENT2 bleeding ENT2END 7
0	In ENT1 ICH  ENT1END induction using 0.014-unit collagenase, ENT2 heparin ENT2END enhanced the hematoma volume 3
0	In our experience and according to the literature, FK506 does not seem to cross-react with cyclosporin A ( ENT1 CyA ENT1END , an immuno-suppressive drug already known to induce ENT2 MAHA ENT2END
1	In one patient, reintroduction of FK506 led to rapid recurrence of ENT1 MAHA ENT1END  ENT2 FK506 ENT2END -associated MAHA is probably rare but physicians must be aware of this severe complication
0	In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, ENT1 corticosteroids ENT1END  aspirin, and dipyridamole led to resolution of ENT2 MAHA ENT2END
0	In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, aspirin, and ENT1 dipyridamole  ENT1END led to resolution of ENT2 MAHA ENT2END
0	In both cases, discontinuation of FK506 and treatment with plasma exchange, fresh frozen plasma replacement, corticosteroids, ENT1 aspirin  ENT1END  and dipyridamole led to resolution of ENT2 MAHA ENT2END
0	Protection against amphetamine-induced ENT1 neurotoxicity ENT1END  toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in iprindole-treated rats is reported. A single 18.4 mg/kg (i.p.) dose of (+/-)-amphetamine hemisulfate, given to rats pretreated with iprindole, resulted in persistent depletion of dopamine in the striatum 1 week later. This prolonged depletion of dopamine in the striatum was antagonized by ENT2 dizocilpine ENT2END (MK-801, a non-competitive antagonist of NMDA receptors) or by LY274614 (a competitive antagonist of NMDA receptors)
0	The data strengthen the evidence that the ENT1 neurotoxic ENT1END effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves ENT2 NMDA ENT2END receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats
0	The prolonged depletion of dopamine in the striatum in mice, given multiple injections of ENT1 methamphetamine  ENT1END  was also antagonized dose-dependently and completely by LY274614. The data strengthen the evidence that the ENT2 neurotoxic ENT2END effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats
1	Protection against ENT1 amphetamine  ENT1END -induced ENT2 neurotoxicity ENT2END toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist
0	The prolonged depletion of dopamine in the striatum in mice, given multiple injections of methamphetamine, was also antagonized dose-dependently and completely by ENT1 LY274614  ENT1END  The data strengthen the evidence that the ENT2 neurotoxic ENT2END effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long-lasting in vivo effects in rats
0	Protection against amphetamine-induced ENT1 neurotoxicity  ENT1END  toward striatal ENT2 dopamine ENT2END neurons in rodents by LY274614, an excitatory amino acid antagonist
0	Protection against amphetamine-induced ENT1 neurotoxicity  ENT1END  toward striatal dopamine neurons in rodents by LY274614, an excitatory ENT2 amino acid ENT2END antagonist
0	Protection against amphetamine-induced ENT1 neurotoxicity ENT1END  toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor. Here its ability to antagonize the prolonged depletion of dopamine in the striatum by amphetamine in ENT2 iprindole ENT2END -treated rats is reported
0	Protection against amphetamine-induced ENT1 neurotoxicity ENT1END  toward striatal dopamine neurons in rodents by LY274614, an excitatory amino acid antagonist.LY274614, 3SR,4aRS,6SR,8aRS-6-[phosphonomethyl]decahydr oisoquinoline-3- carboxylic acid, has been described as a potent antagonist of the N-methyl-D-aspartate (NMDA) subtype of ENT2 glutamate ENT2END receptor
0	A forty-six year-old premenopausal woman developed headache, ENT1 nausea ENT1END and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and ENT2 estradiol ENT2END
0	A forty-six year-old premenopausal woman developed headache, ENT1 nausea ENT1END  and vomiting, left hemiparesis and seizure two days after parenteral use of ENT2 progesterone ENT2END and estradiol
0	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and ENT1 estradiol ENT1END . Diabetes mellitus (DM) was found during admission. Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS). Left carotid angiography found ENT2 occlusion of the left internal carotid artery ENT2END (ICA)
0	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of ENT1 progesterone  ENT1END  and estradiol. Diabetes mellitus (DM) was found during admission. Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus (SSS). Left carotid angiography found ENT2 occlusion of the left internal carotid artery ENT2END (ICA)
0	A forty-six year-old premenopausal woman developed headache, nausea and ENT1 vomiting  ENT1END  left hemiparesis and seizure two days after parenteral use of progesterone and ENT2 estradiol ENT2END
0	A forty-six year-old premenopausal woman developed headache, nausea and ENT1 vomiting  ENT1END , left hemiparesis and seizure two days after parenteral use of ENT2 progesterone ENT2END and estradiol
0	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left ENT1 hemiparesis  ENT1END and seizure two days after parenteral use of progesterone and ENT2 estradiol ENT2END
0	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left ENT1 hemiparesis  ENT1END  and seizure two days after parenteral use of ENT2 progesterone ENT2END and estradiol
0	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and ENT1 estradiol ENT1END . ENT2 Diabetes mellitus ENT2END (DM) was found during admission
0	In this case, the authors postulate that the use of estradiol and ENT1 progesterone ENT1END and the underlying ENT2 DM ENT2END increased vascular thrombogenicity, which provided a common denominator for thrombosis of both the ICA and the venous sinus
0	A forty-six year-old premenopausal woman developed ENT1 headache  ENT1END  nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and ENT2 estradiol ENT2END
0	A forty-six year-old premenopausal woman developed ENT1 headache  ENT1END , nausea and vomiting, left hemiparesis and seizure two days after parenteral use of ENT2 progesterone ENT2END and estradiol
0	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and ENT1 seizure  ENT1END two days after parenteral use of progesterone and ENT2 estradiol ENT2END
0	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and ENT1 seizure  ENT1END  two days after parenteral use of ENT2 progesterone ENT2END and estradiol
1	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and ENT1 estradiol ENT1END . Diabetes mellitus (DM) was found during admission. Computed tomography showed a ENT2 hemorrhagic infarct ENT2END in the right frontal lobe and increased density in the superior sagittal sinus (SSS)
1	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of ENT1 progesterone  ENT1END  and estradiol. Diabetes mellitus (DM) was found during admission. Computed tomography showed a ENT2 hemorrhagic infarct ENT2END in the right frontal lobe and increased density in the superior sagittal sinus (SSS)
1	In this case, the authors postulate that the use of ENT1 estradiol ENT1END and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for ENT2 thrombosis of both the ICA and the venous sinus ENT2END
1	In this case, the authors postulate that the use of estradiol and ENT1 progesterone  ENT1END  and the underlying DM increased vascular thrombogenicity, which provided a common denominator for ENT2 thrombosis of both the ICA and the venous sinus ENT2END
1	In this case, the authors postulate that the use of ENT1 estradiol ENT1END  and progesterone and the underlying DM increased vascular thrombogenicity, which provided a common denominator for ENT2 thrombosis of both the ICA and the venous sinus ENT2END
1	In this case, the authors postulate that the use of estradiol and ENT1 progesterone  ENT1END  and the underlying DM increased vascular thrombogenicity, which provided a common denominator for ENT2 thrombosis of both the ICA and the venous sinus ENT2END
1	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of progesterone and ENT1 estradiol ENT1END . Diabetes mellitus (DM) was found during admission. Computed tomography showed a ENT2 hemorrhagic infarct ENT2END in the right frontal lobe and increased density in the superior sagittal sinus (SSS)
1	A forty-six year-old premenopausal woman developed headache, nausea and vomiting, left hemiparesis and seizure two days after parenteral use of ENT1 progesterone  ENT1END  and estradiol. Diabetes mellitus (DM) was found during admission. Computed tomography showed a ENT2 hemorrhagic infarct ENT2END in the right frontal lobe and increased density in the superior sagittal sinus (SSS)
1	Dose-dependent ENT1 bradycardia ENT1END induced by ENT2 verapamil ENT2END was potentiated by LNa, LCa, and HCa
0	Dose-dependent ENT1 bradycardia ENT1END  induced by verapamil was potentiated by LNa, LCa, and HCa. Independent but not additive effects of Na and ENT2 Ca ENT2END are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa
0	Dose-dependent ENT1 bradycardia ENT1END  induced by verapamil was potentiated by LNa, LCa, and HCa. Independent but not additive effects of ENT2 Na ENT2END and Ca are shown by decreases in the values of [verapamil]o needed to reduce BF by 30% (IC30) with the following order of inhibitory potency: LNa > LCa > HCa > N, resulting LNa+HCa similar to LNa
0	Acute analgesic and antiinflammatory activities were ascertained using ENT1 acetic acid ENT1END induced ENT2 writhing ENT2END model (mice) and carrageenan-induced rat paw edema model, respectively
1	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced ENT1 writhing ENT1END  model (mice) and ENT2 carrageenan ENT2END -induced rat paw edema model, respectively
0	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced ENT1 writhing ENT1END  model (mice) and carrageenan-induced rat paw edema model, respectively. In comparison to control, ENT2 E ENT2END D1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0
0	Acute analgesic and antiinflammatory activities were ascertained using ENT1 acetic acid ENT1END  induced writhing model (mice) and carrageenan-induced rat paw ENT2 edema ENT2END model, respectively
1	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and ENT1 carrageenan  ENT1END -induced rat paw ENT2 edema ENT2END model, respectively
0	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model (mice) and carrageenan-induced rat paw ENT1 edema  ENT1END  model, respectively. In comparison to control, E and ENT2 E ENT2END D1-ED4 showed highly significant analgesic and antiinflammatory activities (p <0
1	Ophthalmological assessment revealed features of ENT1 chloroquine ENT1END ENT2 retinopathy ENT2END , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern
1	A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, dizziness progressing to ENT1 syncopal attacks  ENT1END  Ophthalmological assessment revealed features of ENT2 chloroquine ENT2END retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern
1	A 27-year old African woman with history of regular ENT1 chloroquine ENT1END ingestion presented with progressive deterioration of vision, easy ENT2 fatiguability ENT2END , dyspnoea, dizziness progressing to syncopal attacks
1	ENT1 Chloroquine  ENT1END  related complete heart block with ENT2 blindness ENT2END : case report
0	A 27-year old African woman with history of regular ENT1 chloroquine ENT1END  ingestion presented with progressive ENT2 deterioration of vision ENT2END , easy fatiguability, dyspnoea, dizziness progressing to syncopal attacks
1	Ophthalmological assessment revealed features of ENT1 chloroquine ENT1END  retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with ENT2 right bundle branch block ENT2END pattern
1	The heart block was treated by pacemaker insertion and the ENT1 heart failure ENT1END resolved spontaneously following ENT2 chloroquine ENT2END discontinuation
0	ENT1 Chloroquine  ENT1END  related complete ENT2 heart block ENT2END with blindness: case report
1	A 27-year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision, easy fatiguability, dyspnoea, ENT1 dizziness  ENT1END progressing to syncopal attacks. Ophthalmological assessment revealed features of ENT2 chloroquine ENT2END retinopathy, cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern
1	A 27-year old African woman with history of regular ENT1 chloroquine ENT1END  ingestion presented with progressive deterioration of vision, easy fatiguability, ENT2 dyspnoea ENT2END , dizziness progressing to syncopal attacks
0	Frequencies of ENT1 ventricular fibrillation ENT1END were significantly lower (p less than 0.05) after ENT2 iopentol ENT2END (0%) and iohexol (3%) than after metrizoate (22%)
1	Thirty-six iopentol injections, 35 iohexol injections and 37 ENT1 metrizoate  ENT1END injections were made. Frequencies of ENT2 ventricular fibrillation ENT2END were significantly lower (p less than 0
0	Thirty-six iopentol injections, 35 ENT1 iohexol  ENT1END injections and 37 metrizoate injections were made. Frequencies of ENT2 ventricular fibrillation ENT2END were significantly lower (p less than 0
0	There was mutual potentiation between sub-effective doses of ketamine and morphine, but sub-effective doses of ketamine partly antagonized fully-effective doses of ENT1 morphine ENT1END  Latency to the loss of righting reflex, ENT2 rigidity ENT2END and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination
0	Latency to the loss of righting reflex, ENT1 rigidity ENT1END  and behavior on recovery, reflected the relative predominance of ENT2 ketamine ENT2END or morphine in each combination
0	While the mutual potentiation, antagonism and tolerance suggest common mechanisms for the induced catalepsy, differences in latency, ENT1 rigidity ENT1END and behavior, asymmetry of cross-tolerance and a widely-different ID50 for ENT2 naloxone ENT2END would argue against an action at a single opioid site
0	Previous studies demonstrated that both ketamine and ENT1 morphine ENT1END induced ENT2 analgesia ENT2END and catalepsy in the rat
0	Previous studies demonstrated that both ENT1 ketamine  ENT1END and morphine induced ENT2 analgesia ENT2END and catalepsy in the rat
0	Previous studies demonstrated that both ketamine and morphine induced ENT1 analgesia ENT1END  and catalepsy in the rat. Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ketamine but rather augmented the cataleptic response; this augmentation was attributed to residual morphine in the brain. The present studies explored the duration of the loss of righting reflex induced by sub-effective doses of ketamine and morphine, administered simultaneously. There was mutual potentiation between sub-effective doses of ketamine and morphine, but sub-effective doses of ketamine partly antagonized fully-effective doses of morphine. Latency to the loss of righting reflex, rigidity and behavior on recovery, reflected the relative predominance of ketamine or morphine in each combination. ENT2 Naloxone ENT2END inhibited the induced cataleptic effects
1	Previous studies demonstrated that both ketamine and ENT1 morphine ENT1END  induced analgesia and ENT2 catalepsy ENT2END in the rat
1	Pre-treatment with ketamine produced cross-tolerance to morphine, whereas pretreatment with morphine did not induce cross-tolerance to ENT1 ketamine ENT1END but rather augmented the ENT2 cataleptic ENT2END response; this augmentation was attributed to residual morphine in the brain
0	ENT1 Naloxone ENT1END  inhibited the induced ENT2 cataleptic ENT2END effects
0	RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model ENT1 anxiety ENT1END  because of the non-specific cue and the long-term effect. In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear. However, the pharmacological profiles of these two paradigms are very similar. The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms. METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist ENT2 yohimbine ENT2END (0
0	RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model ENT1 anxiety ENT1END , because of the non-specific cue and the long-term effect. In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear. However, the pharmacological profiles of these two paradigms are very similar. The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms. METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist ENT2 m-chlorophenylpiperazine ENT2END (mCPP, 0
0	RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model ENT1 anxiety ENT1END , because of the non-specific cue and the long-term effect. In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear. However, the pharmacological profiles of these two paradigms are very similar. The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms. METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the ENT2 GABA ENT2END (A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS
0	RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model ENT1 anxiety ENT1END , because of the non-specific cue and the long-term effect. In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear. However, the pharmacological profiles of these two paradigms are very similar. The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms. METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the 5-HT(2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist ENT2 pentylenetetrazole ENT2END (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS
0	RATIONALE AND OBJECTIVES: The light-enhanced startle paradigm (LES) is suggested to model ENT1 anxiety ENT1END , because of the non-specific cue and the long-term effect. In contrast, the fear-potentiated startle (FPS) is suggested to model conditioned fear. However, the pharmacological profiles of these two paradigms are very similar. The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms. METHODS: Male Wistar rats received each dose of the alpha(2)-adrenoceptor antagonist yohimbine (0.25-1.0mg/kg), the ENT2 5-HT ENT2END (2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0
1	Furthermore, ENT1 yohimbine ENT1END increased baseline ENT2 startle ENT2END amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS
1	Furthermore, yohimbine increased baseline startle amplitude in the LES, while ENT1 mCPP ENT1END suppressed baseline ENT2 startle ENT2END in both the LES and FPS and PTZ suppressed baseline startle in the FPS
0	0mg/kg) or the ENT1 GABA  ENT1END (A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS. RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values. Furthermore, yohimbine increased baseline ENT2 startle ENT2END amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS
1	Furthermore, yohimbine increased baseline startle amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and ENT1 PTZ ENT1END suppressed baseline ENT2 startle ENT2END in the FPS
0	0mg/kg), the ENT1 5-HT  ENT1END (2C) receptor agonist m-chlorophenylpiperazine (mCPP, 0.5-2.0mg/kg) or the GABA(A) inverse receptor agonist pentylenetetrazole (PTZ, 3-30mg/kg) and were subsequently tested in either LES or FPS. RESULTS: None of the drugs enhanced LES, whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values. Furthermore, yohimbine increased baseline ENT2 startle ENT2END amplitude in the LES, while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS
0	Injections of ENT1 ketamine ENT1END in doses from 100 microgram to 3 mg into the artery produced a ENT2 depression ENT2END of the SA nodal activity by a direct action
1	Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ENT1 ketamine ENT1END induced ENT2 tachycardia ENT2END , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta-blocking agent into the SA node artery
0	in 6 increments of 100 mg/kg each over 30 hr, on mouse motility and whole brain content of selected biogenic ENT1 amines ENT1END and major metabolites was studied in 4 strains of mice. These were the albino Sprague-Dawley ICR and BALB/C, the black C57BL/6 and the brown CDF-I mouse strains. Amantadine treatment produced a biphasic effect on mouse motility. The initial dose of amantadine ENT2 depressed ENT2END locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive
0	The initial dose of amantadine ENT1 depressed ENT1END  locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive. Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive. The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment. Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred. Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of ENT2 3,4-dihydroxyphenylacetic acid ENT2END in the BALB/C mice compared to saline control
0	The initial dose of ENT1 amantadine ENT1END ENT2 depressed ENT2END locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive
0	The initial dose of amantadine ENT1 depressed ENT1END  locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive. Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive. The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment. Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred. Treatment with amantadine did not alter whole brain ENT2 dopamine ENT2END levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control
0	The initial dose of amantadine ENT1 depressed ENT1END  locomotor activity in all mouse strains studied with the BALB/C mice being the most sensitive. Subsequent amantadine treatments produced enhancement of motility from corresponding control in all mouse strains with the BALB/C mice being the least sensitive. The locomotor activity was decreased from corresponding controls in all strains studied, except for the ICR mice, during an overnight drug-free period following the fourth amantadine treatment. Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where suppression of motility occurred. Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control. Conversely, brain ENT2 normetanephrine ENT2END concentration was increased from saline control by amantadine in the BALB/C mice
0	The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of ENT1 norepinephrine ENT1END which may account for a ENT2 behavioral depression ENT2END caused by amantadine in the BALB/C mice
0	The biochemical results of brain biogenic ENT1 amines  ENT1END of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a ENT2 behavioral depression ENT2END caused by amantadine in the BALB/C mice
0	Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where ENT1 suppression of motility  ENT1END occurred. Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of ENT2 3,4-dihydroxyphenylacetic acid ENT2END in the BALB/C mice compared to saline control
0	The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of ENT1 catecholamine  ENT1END turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a ENT2 behavioral depression ENT2END caused by amantadine in the BALB/C mice
1	The biochemical results of brain biogenic amines of BALB/C mouse strain suggest a probable decrease of catecholamine turnover rate and/or metabolism by monoamine oxidase and a resulting increase in O-methylation of norepinephrine which may account for a ENT1 behavioral depression ENT1END  caused by ENT2 amantadine ENT2END in the BALB/C mice
0	Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where ENT1 suppression of motility  ENT1END  occurred. Treatment with amantadine did not alter whole brain ENT2 dopamine ENT2END levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control
0	Readministration of amantadine, after a drug-free overnight period, increased motility from respective saline control in all strains with exception of the BALB/C mice where ENT1 suppression of motility  ENT1END  occurred. Treatment with amantadine did not alter whole brain dopamine levels but decreased the amounts of 3,4-dihydroxyphenylacetic acid in the BALB/C mice compared to saline control. Conversely, brain ENT2 normetanephrine ENT2END concentration was increased from saline control by amantadine in the BALB/C mice
1	Metformin treatment fully blocked ENT1 gentamicin ENT1END mediated ENT2 acute renal failure ENT2END
0	ENT1 Metformin  ENT1END treatment fully blocked gentamicin-mediated ENT2 acute renal failure ENT2END
0	Mitochondrial analysis, respiration intensity, levels of reactive ENT1 oxygen  ENT1END species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration. Metformin treatment fully blocked gentamicin-mediated ENT2 acute renal failure ENT2END
0	Here we tested whether it has a beneficial effect in a rat model of ENT1 gentamicin ENT1END ENT2 toxicity ENT2END
0	Here we tested whether it has a beneficial effect in a rat model of gentamicin ENT1 toxicity  ENT1END . Mitochondrial analysis, respiration intensity, levels of reactive oxygen species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration. ENT2 Metformin ENT2END treatment fully blocked gentamicin-mediated acute renal failure
0	Here we tested whether it has a beneficial effect in a rat model of gentamicin ENT1 toxicity  ENT1END . Mitochondrial analysis, respiration intensity, levels of reactive ENT2 oxygen ENT2END species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration
0	Thus, our study suggests that pleiotropic effects of metformin can lessen ENT1 gentamicin ENT1END ENT2 nephrotoxicity ENT2END and improve mitochondrial homeostasis
0	Thus, our study suggests that pleiotropic effects of ENT1 metformin  ENT1END can lessen gentamicin ENT2 nephrotoxicity ENT2END and improve mitochondrial homeostasis
0	These injuries, partly mediated by a rise in reactive ENT1 oxygen  ENT1END species from the electron transfer chain, were significantly decreased by metformin. Thus, our study suggests that pleiotropic effects of metformin can lessen gentamicin ENT2 nephrotoxicity ENT2END and improve mitochondrial homeostasis
0	The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent ENT1 vascular dysfunction  ENT1END even in nondiabetic patients. Here we tested whether it has a beneficial effect in a rat model of ENT2 gentamicin ENT2END toxicity
0	The antidiabetic drug ENT1 metformin  ENT1END can diminish apoptosis induced by oxidative stress in endothelial cells and prevent ENT2 vascular dysfunction ENT2END even in nondiabetic patients
0	The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent ENT1 vascular dysfunction  ENT1END  even in nondiabetic patients. Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity. Mitochondrial analysis, respiration intensity, levels of reactive ENT2 oxygen ENT2END species, permeability transition, and cytochrome c release were assessed 3 and 6 days after gentamicin administration
1	Enhanced stimulus-induced neurotransmitter overflow in ENT1 epinephrine  ENT1END -induced ENT2 hypertensive ENT2END rats is not mediated by prejunctional beta-adrenoceptor activation
0	Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced ENT1 hypertensive ENT1END  rats is not mediated by prejunctional beta-adrenoceptor activation.The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats. Renal ENT2 catecholamine ENT2END stores and stimulus-induced overflow in the vehicle-treated group consisted of norepinephrine only
0	Enhanced stimulus-induced neurotransmitter overflow in epinephrine-induced ENT1 hypertensive ENT1END  rats is not mediated by prejunctional beta-adrenoceptor activation.The present study examines the effect of 6-day epinephrine treatment (100 micrograms/kg per h, s.c.) on stimulus-induced (1 Hz) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle- and epinephrine-treated rats. Renal catecholamine stores and stimulus-induced overflow in the vehicle-treated group consisted of ENT2 norepinephrine ENT2END only
0	Conventional LW rats, implanted with testosterone at age 4 months, developed a higher incidence of prostate cancer after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic ENT1 tumors ENT1END  Preliminary results indicate that ENT2 testosterone ENT2END -treated LW rats that were fed the same diet, which was supplemented with corn oil up to 20% fat, developed prostate cancer after intervals of 6-12 months
1	Conventional LW rats, implanted with ENT1 testosterone ENT1END at age 4 months, developed a higher incidence of ENT2 prostate cancer ENT2END after an average interval of 14 months: 24% had developed gross tumors, and 40% when it included microscopic tumors
1	Conventional SD rats fed diet L-485 and treated with ENT1 testosterone ENT1END developed only ENT2 prostatitis ENT2END
0	Promotional effects of ENT1 testosterone  ENT1END  and dietary fat on prostate ENT2 carcinogenesis ENT2END in genetically susceptible rats
1	Recurrent reversible ENT1 acute renal failure  ENT1END  from ENT2 amphotericin ENT2END
0	Recurrent reversible acute renal failure from ENT1 amphotericin ENT1END .A patient with cryptogenic cirrhosis and disseminated ENT2 sporotrichosis ENT2END developed acute renal failure immediately following the administration of amphotericin B on four separate occasions
0	The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the ENT1 renal dysfunction ENT1END  We propose that ENT2 amphotericin ENT2END , in the setting of reduced effective arterial volume, may activate tubuloglomerular feedback, thereby contributing to acute renal failure
0	Recurrent reversible acute renal failure from ENT1 amphotericin ENT1END .A patient with cryptogenic ENT2 cirrhosis ENT2END and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions
0	A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of ENT1 amphotericin B ENT1END on four separate occasions. The abruptness of the ENT2 renal failure ENT2END and its reversibility within days suggests that there was a functional component to the renal dysfunction
0	Accumulation of ENT1 atracurium ENT1END in the intravenous line led to recurarization after flushing the line in the recovery room. A respiratory arrest with severe desaturation and bradycardia occurred. Circumstances leading to this event and the mechanisms enabling a ENT2 neuromuscular blockade ENT2END to occur, following the administration of a small dose of relaxant, are discussed
1	Accumulation of ENT1 atracurium ENT1END  in the intravenous line led to recurarization after flushing the line in the recovery room. A respiratory arrest with severe desaturation and ENT2 bradycardia ENT2END occurred
1	Accumulation of ENT1 atracurium ENT1END  in the intravenous line led to recurarization after flushing the line in the recovery room. A ENT2 respiratory arrest ENT2END with severe desaturation and bradycardia occurred
1	Accumulation of ENT1 atracurium ENT1END  in the intravenous line led to recurarization after flushing the line in the recovery room. A respiratory arrest with severe ENT2 desaturation ENT2END and bradycardia occurred
0	Postpartum psychosis induced by ENT1 bromocriptine ENT1END .Two multigravida patients with no prior ENT2 psychiatric ENT2END history were seen with postpartum psychosis, having received bromocriptine for inhibition of lactation
0	Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for ENT1 Parkinson's disease ENT1END  These cases demonstrate that ENT2 bromocriptine ENT2END may cause psychosis even when given in low doses
0	Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis, having received bromocriptine for ENT1 inhibition of lactation ENT1END  ENT2 Bromocriptine ENT2END given in high doses has been associated with psychosis in patients receiving the drug for Parkinson's disease
1	These cases demonstrate that ENT1 bromocriptine ENT1END  may cause ENT2 psychosis ENT2END even when given in low doses
0	Regional localization of the antagonism of amphetamine-induced ENT1 hyperactivity  ENT1END  by intracerebral ENT2 calcitonin ENT2END injections
1	Regional localization of the antagonism of ENT1 amphetamine  ENT1END -induced ENT2 hyperactivity ENT2END by intracerebral calcitonin injections
1	Recurrent ENT1 dysphonia  ENT1END  and ENT2 acitretin ENT2END
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ENT1 ocular pain ENT1END  decreased visual acuity, or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used ENT2 chloroquine ENT2END or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ENT1 ocular pain ENT1END , decreased visual acuity, or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with ENT2 corticosteroids ENT2END and mydriatics
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ENT1 ocular pain ENT1END , decreased visual acuity, or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used chloroquine or ENT2 hydroxychloroquine ENT2END in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Cataract and ENT1 band keratopathy  ENT1END occurred in only 22 and 13% of our group, respectively. We used ENT2 chloroquine ENT2END or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with ENT1 corticosteroids  ENT1END  and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and ENT2 band keratopathy ENT2END occurred in only 22 and 13% of our group, respectively
0	Cataract and ENT1 band keratopathy  ENT1END  occurred in only 22 and 13% of our group, respectively. We used chloroquine or ENT2 hydroxychloroquine ENT2END in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	We used ENT1 chloroquine ENT1END  or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs. Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found. Typical keratoconjunctivitis sicca developed in three of the uveitis cases. This association with uveitis and JRA was not noted previously. Surgical treatment of cataracts, band keratopathy, and ENT2 glaucoma ENT2END achieved uniformly discouraging results
0	Systemically administered ENT1 corticosteroids  ENT1END were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found. Typical keratoconjunctivitis sicca developed in three of the uveitis cases. This association with uveitis and JRA was not noted previously. Surgical treatment of cataracts, band keratopathy, and ENT2 glaucoma ENT2END achieved uniformly discouraging results
0	We used chloroquine or ENT1 hydroxychloroquine  ENT1END  in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs. Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found. Typical keratoconjunctivitis sicca developed in three of the uveitis cases. This association with uveitis and JRA was not noted previously. Surgical treatment of cataracts, band keratopathy, and ENT2 glaucoma ENT2END achieved uniformly discouraging results
0	ENT1 Iridocyclitis  ENT1END was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the arthritis. However, 30% of the patients developed uveitis after 16 years of age. Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry. Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases. Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with ENT2 corticosteroids ENT2END and mydriatics
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or ENT1 photophobia  ENT1END  in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used ENT2 chloroquine ENT2END or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or ENT1 photophobia  ENT1END , in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with ENT2 corticosteroids ENT2END and mydriatics
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or ENT1 photophobia  ENT1END , in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used chloroquine or ENT2 hydroxychloroquine ENT2END in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	We used ENT1 chloroquine ENT1END  or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs. Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found. Typical ENT2 keratoconjunctivitis ENT2END sicca developed in three of the uveitis cases
0	Systemically administered ENT1 corticosteroids  ENT1END  were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found. Typical ENT2 keratoconjunctivitis ENT2END sicca developed in three of the uveitis cases
0	We used chloroquine or ENT1 hydroxychloroquine  ENT1END  in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs. Systemically administered corticosteroids were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found. Typical ENT2 keratoconjunctivitis ENT2END sicca developed in three of the uveitis cases
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, ENT1 decreased visual acuity  ENT1END  or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used ENT2 chloroquine ENT2END or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, ENT1 decreased visual acuity  ENT1END , or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with ENT2 corticosteroids ENT2END and mydriatics
0	Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, ENT1 decreased visual acuity  ENT1END , or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics. Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of uveitis cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used chloroquine or ENT2 hydroxychloroquine ENT2END in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Iridocyclitis was seen most frequently in young female patients (0 to 4 years) with the monoarticular or pauciatricular form of the ENT1 arthritis  ENT1END  However, 30% of the patients developed uveitis after 16 years of age. Although 61% of patients had a noncontributory ocular history on entry, 42% had active uveitis on entry. Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases. Forty-four percent of patients with uveitis had one or more identifiable signs or symptoms, such as red eye, ocular pain, decreased visual acuity, or photophobia, in order of decreasing frequency. Even after early detection and prompt treatment, 41% of cases of uveitis did not respond to more than six months of intensive topical treatment with ENT2 corticosteroids ENT2END and mydriatics
0	ENT1 Cataract  ENT1END and band keratopathy occurred in only 22 and 13% of our group, respectively. We used ENT2 chloroquine ENT2END or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Systemically administered ENT1 corticosteroids ENT1END  were used in 75 of 210 cases; a significant number of posterior subcapsular ENT2 cataracts ENT2END was found
0	ENT1 Cataract  ENT1END  and band keratopathy occurred in only 22 and 13% of our group, respectively. We used chloroquine or ENT2 hydroxychloroquine ENT2END in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of ENT1 uveitis  ENT1END cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used ENT2 chloroquine ENT2END or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	Even after early detection and prompt treatment, 41% of cases of ENT1 uveitis  ENT1END did not respond to more than six months of intensive topical treatment with ENT2 corticosteroids ENT2END and mydriatics
0	Despite this, there was a dramatic decrease in the 50% incidence of blinding complications of ENT1 uveitis  ENT1END  cited in earlier studies. Cataract and band keratopathy occurred in only 22 and 13% of our group, respectively. We used chloroquine or ENT2 hydroxychloroquine ENT2END in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs
0	We used ENT1 chloroquine ENT1END  or hydroxychloroquine in 173 of 210 cases and found only one case of ENT2 chorioretinopathy ENT2END attributable to these drugs
0	We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of ENT1 chorioretinopathy  ENT1END  attributable to these drugs. Systemically administered ENT2 corticosteroids ENT2END were used in 75 of 210 cases; a significant number of posterior subcapsular cataracts was found
1	We used chloroquine or ENT1 hydroxychloroquine  ENT1END  in 173 of 210 cases and found only one case of ENT2 chorioretinopathy ENT2END attributable to these drugs
1	Does hormone therapy for the treatment of breast cancer have a ENT1 detrimental effect on memory and cognition ENT1END ? A pilot study.This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of ENT2 anastrozole ENT2END , tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures
1	Does hormone therapy for the treatment of breast cancer have a ENT1 detrimental effect on memory and cognition ENT1END ? A pilot study.This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of anastrozole, ENT2 tamoxifen ENT2END alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures
0	Does hormone therapy for the treatment of breast cancer have a ENT1 detrimental effect on memory and cognition ENT1END ? A pilot study.This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures. Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups. Patient group performance was not significantly related to length of treatment or measures of psychological morbidity. The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer. Verbal memory may be especially sensitive to changes in ENT2 oestrogen ENT2END levels, a finding commonly reported in studies of hormone replacement therapy in healthy women
1	Does hormone therapy for the treatment of breast cancer have a ENT1 detrimental effect on memory and cognition  ENT1END ? A pilot study.This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of ENT2 anastrozole ENT2END , tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures
1	Does hormone therapy for the treatment of breast cancer have a ENT1 detrimental effect on memory and cognition  ENT1END ? A pilot study.This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of anastrozole, ENT2 tamoxifen ENT2END alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures
0	Does hormone therapy for the treatment of breast cancer have a ENT1 detrimental effect on memory and cognition  ENT1END ? A pilot study.This pilot study examines whether hormone therapy for breast cancer affects cognition. Patients participating in a randomised trial of anastrozole, tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures. Compared with the control group, the patients were impaired on a processing speed task (p=0.032) and on a measure of immediate verbal memory (p=0.026) after controlling for the use of hormone replacement therapy in both groups. Patient group performance was not significantly related to length of treatment or measures of psychological morbidity. The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer. Verbal memory may be especially sensitive to changes in ENT2 oestrogen ENT2END levels, a finding commonly reported in studies of hormone replacement therapy in healthy women
0	This pilot study examines whether hormone therapy for ENT1 breast cancer  ENT1END affects cognition. Patients participating in a randomised trial of ENT2 anastrozole ENT2END , tamoxifen alone or combined (ATAC) (n=94) and a group of women without breast cancer (n=35) completed a battery of neuropsychological measures
0	Patients participating in a randomised trial of anastrozole, ENT1 tamoxifen ENT1END  alone or combined (ATAC) (n=94) and a group of women without ENT2 breast cancer ENT2END (n=35) completed a battery of neuropsychological measures
0	The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of ENT1 breast cancer  ENT1END  Verbal memory may be especially sensitive to changes in ENT2 oestrogen ENT2END levels, a finding commonly reported in studies of hormone replacement therapy in healthy women
0	The reaction was specific to ENT1 trihexyphenidyl ENT1END and not to other anticholinergic drugs. This antidyskinetic drug is widely used in clinical ENT2 psychiatric ENT2END practice and physicians should be aware of this side effect
0	Bradycardia due to ENT1 trihexyphenidyl hydrochloride ENT1END .A chronic ENT2 schizophrenic ENT2END patient was treated with an anticholinergic drug, trihexyphenidyl hydrochloride
1	ENT1 Bradycardia  ENT1END  due to ENT2 trihexyphenidyl hydrochloride ENT2END
0	ENT1 Liver disease  ENT1END  caused by ENT2 propylthiouracil ENT2END
1	This report presents the clinical, laboratory, and light and electron microscopic observations on a patient with ENT1 chronic active (aggressive) hepatitis ENT1END caused by the administration of ENT2 propylthiouracil ENT2END
0	ENT1 Apamin ENT1END (10 ng) had a tendency to decrease the ENT2 convulsive ENT2END threshold (21
1	The effects of sevoflurane on ENT1 lidocaine  ENT1END -induced ENT2 convulsions ENT2END
0	Apamin, a selective blocker of ENT1 calcium  ENT1END dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the ENT2 convulsive ENT2END threshold (21
0	Apamin, a selective blocker of calcium-dependent ENT1 potassium  ENT1END channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the ENT2 convulsive ENT2END threshold (21
0	It is suggested that ENT1 sevoflurane ENT1END reduces the ENT2 convulsive ENT2END effect of lidocaine toxicity but carries some risk due to circulatory depression
0	There was no significant difference in the ENT1 convulsive ENT1END threshold between sevoflurane and ENT2 enflurane ENT2END
0	ENT1 Apamin ENT1END  (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine ENT2 toxicity ENT2END but carries some risk due to circulatory depression
0	It is suggested that sevoflurane reduces the convulsive effect of ENT1 lidocaine ENT1END ENT2 toxicity ENT2END but carries some risk due to circulatory depression
0	Apamin, a selective blocker of ENT1 calcium  ENT1END -dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine ENT2 toxicity ENT2END but carries some risk due to circulatory depression
0	Apamin, a selective blocker of calcium-dependent ENT1 potassium  ENT1END  channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine ENT2 toxicity ENT2END but carries some risk due to circulatory depression
0	It is suggested that ENT1 sevoflurane  ENT1END  reduces the convulsive effect of lidocaine ENT2 toxicity ENT2END but carries some risk due to circulatory depression
0	6% ENT1 enflurane  ENT1END  However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg. Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine ENT2 toxicity ENT2END but carries some risk due to circulatory depression
0	ENT1 Apamin ENT1END  (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory ENT2 depression ENT2END
0	It is suggested that sevoflurane reduces the convulsive effect of ENT1 lidocaine  ENT1END  toxicity but carries some risk due to circulatory ENT2 depression ENT2END
0	Apamin, a selective blocker of ENT1 calcium  ENT1END -dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory ENT2 depression ENT2END
0	Apamin, a selective blocker of calcium-dependent ENT1 potassium  ENT1END  channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory ENT2 depression ENT2END
0	It is suggested that ENT1 sevoflurane  ENT1END  reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory ENT2 depression ENT2END
0	6% ENT1 enflurane  ENT1END . However, there was no significant difference in the lidocaine concentrations measured when the systolic blood pressure became 70 mmHg. Apamin, a selective blocker of calcium-dependent potassium channels, was administered intracerebroventricularly in rats anesthetized with 0.8% sevoflurane to investigate the mechanism of the anticonvulsive effects. Apamin (10 ng) had a tendency to decrease the convulsive threshold (21.6 +/- 2.2 to 19.9 +/- 2.5 mg. l(-1)) but this was not statistically significant. It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory ENT2 depression ENT2END
0	Ketamine reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked ENT1 pain ENT1END  ENT2 Lidocaine ENT2END reduced the area of punctate-evoked hyperalgesia significantly
0	It tended to reduce VAS scores of spontaneous pain but had no effect on evoked ENT1 pain ENT1END  The differential effects of ENT2 ketamine ENT2END and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology
1	Infusion started 15 min after injection of ENT1 capsaicin ENT1END  The following were measured: spontaneous ENT2 pain ENT2END evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked hyperalgesia
0	Differential effects of systemically administered ketamine and ENT1 lidocaine  ENT1END  on dynamic and static ENT2 hyperalgesia ENT2END induced by intradermal capsaicin in humans
0	The following were measured: spontaneous pain, pain evoked by punctate and brush stimuli (VAS), and areas of brush-evoked and punctate-evoked ENT1 hyperalgesia ENT1END  ENT2 Ketamine ENT2END reduced both the area of brush-evoked and punctate-evoked hyperalgesia significantly and it tended to reduce brush-evoked pain
1	We have examined the effect of systemic administration of ketamine and lidocaine on brush-evoked (dynamic) pain and punctate-evoked (static) ENT1 hyperalgesia ENT1END induced by ENT2 capsaicin ENT2END
0	The number of deaths related to ENT1 cardiac toxicity ENT1END is low. However, caution is required when ENT2 cyclophosphamide ENT2END or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients
0	The number of deaths related to ENT1 cardiac toxicity ENT1END  is low. However, caution is required when cyclophosphamide or ENT2 anthracyclines ENT2END such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients
0	The number of deaths related to ENT1 cardiac toxicity ENT1END  is low. However, caution is required when cyclophosphamide or anthracyclines such as ENT2 mitoxantrone ENT2END are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients
0	However, caution is required when cyclophosphamide or ENT1 anthracyclines ENT1END  such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients. In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine. The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation ENT2 autoimmune disease ENT2END database, and to propose a safe approach to such patients
0	However, caution is required when cyclophosphamide or anthracyclines such as ENT1 mitoxantrone  ENT1END  are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients. In November 2002, a meeting was held in Florence, bringing together a number of experts in various fields, including rheumatology, cardiology, neurology, pharmacology and transplantation medicine. The object of the meeting was to analyse existing data, both published or available, in the European Group for Blood and Marrow Transplantation ENT2 autoimmune disease ENT2END database, and to propose a safe approach to such patients
0	However, caution is required when ENT1 cyclophosphamide ENT1END  or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, ENT2 systemic sclerosis ENT2END patients
0	However, caution is required when cyclophosphamide or ENT1 anthracyclines  ENT1END  such as mitoxantrone are used in patients with a possible underlying heart damage, for example, ENT2 systemic sclerosis ENT2END patients
0	However, caution is required when cyclophosphamide or anthracyclines such as ENT1 mitoxantrone  ENT1END  are used in patients with a possible underlying heart damage, for example, ENT2 systemic sclerosis ENT2END patients
0	This is primarily due to complications related to either the stage of the disease at transplant or due to ENT1 infections  ENT1END  The number of deaths related to cardiac toxicity is low. However, caution is required when ENT2 cyclophosphamide ENT2END or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients
0	This is primarily due to complications related to either the stage of the disease at transplant or due to ENT1 infections  ENT1END . The number of deaths related to cardiac toxicity is low. However, caution is required when cyclophosphamide or ENT2 anthracyclines ENT2END such as mitoxantrone are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients
0	This is primarily due to complications related to either the stage of the disease at transplant or due to ENT1 infections  ENT1END . The number of deaths related to cardiac toxicity is low. However, caution is required when cyclophosphamide or anthracyclines such as ENT2 mitoxantrone ENT2END are used in patients with a possible underlying heart damage, for example, systemic sclerosis patients
1	However, caution is required when ENT1 cyclophosphamide ENT1END  or anthracyclines such as mitoxantrone are used in patients with a possible underlying ENT2 heart damage ENT2END , for example, systemic sclerosis patients
0	However, caution is required when cyclophosphamide or ENT1 anthracyclines  ENT1END  such as mitoxantrone are used in patients with a possible underlying ENT2 heart damage ENT2END , for example, systemic sclerosis patients
1	However, caution is required when cyclophosphamide or anthracyclines such as ENT1 mitoxantrone  ENT1END  are used in patients with a possible underlying ENT2 heart damage ENT2END , for example, systemic sclerosis patients
1	Drugs were ceased in six patients because of adverse reactions; in three of these ENT1 vancomycin ENT1END was considered the likely cause. Reactions included thrombophlebitis (20 of 54 patients), ENT2 rash ENT2END (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry)
0	Reactions included thrombophlebitis (20 of 54 patients), ENT1 rash ENT1END  (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry). Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an ENT2 aminoglycoside ENT2END plus vancomycin
1	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ENT1 ototoxicity ENT1END were confined to patients receiving an aminoglycoside plus ENT2 vancomycin ENT2END
0	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ENT1 ototoxicity  ENT1END  were confined to patients receiving an ENT2 aminoglycoside ENT2END plus vancomycin
1	Drugs were ceased in six patients because of adverse reactions; in three of these ENT1 vancomycin ENT1END  was considered the likely cause. Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), ENT2 proteinuria ENT2END (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry)
0	Reactions included thrombophlebitis (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), ENT1 proteinuria  ENT1END  (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry). Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an ENT2 aminoglycoside ENT2END plus vancomycin
1	Drugs were ceased in six patients because of adverse reactions; in three of these ENT1 vancomycin ENT1END  was considered the likely cause. Reactions included ENT2 thrombophlebitis ENT2END (20 of 54 patients), rash (4 of 54), nephrotoxicity (4 of 50), proteinuria (1 of 50) and ototoxicity (1 of 11 patients tested by audiometry)
0	ENT1 Thrombophlebitis  ENT1END occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an ENT2 aminoglycoside ENT2END plus vancomycin
0	ENT1 Vancomycin ENT1END was curative in 95% of 43 patients with proven ENT2 infection ENT2END
0	Thrombophlebitis occurred only with infusion through peripheral cannulae; nephrotoxicity and ototoxicity were confined to patients receiving an ENT1 aminoglycoside ENT1END  plus vancomycin. We conclude that vancomycin, administered appropriately, constitutes safe, effective therapy for ENT2 infections ENT2END caused by susceptible bacteria
0	Thrombophlebitis occurred only with infusion through peripheral cannulae; ENT1 nephrotoxicity  ENT1END and ototoxicity were confined to patients receiving an aminoglycoside plus ENT2 vancomycin ENT2END
0	Thrombophlebitis occurred only with infusion through peripheral cannulae; ENT1 nephrotoxicity  ENT1END  and ototoxicity were confined to patients receiving an ENT2 aminoglycoside ENT2END plus vancomycin
1	In four subacute toxicity studies, the intravenous administration of ENT1 cefonicid ENT1END or cefazedone to beagle dogs caused a dose-dependent incidence of ENT2 anemia ENT2END , neutropenia, and thrombocytopenia after 1-3 months of treatment
0	ENT1 Cephalosporin  ENT1END antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized. There is a need for a well-defined animal model in which these blood dyscrasias can be studied. In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of ENT2 anemia ENT2END , neutropenia, and thrombocytopenia after 1-3 months of treatment
1	In four subacute toxicity studies, the intravenous administration of cefonicid or ENT1 cefazedone  ENT1END to beagle dogs caused a dose-dependent incidence of ENT2 anemia ENT2END , neutropenia, and thrombocytopenia after 1-3 months of treatment
1	In four subacute toxicity studies, the intravenous administration of ENT1 cefonicid ENT1END  or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and ENT2 thrombocytopenia ENT2END after 1-3 months of treatment
0	ENT1 Cephalosporin  ENT1END  antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized. There is a need for a well-defined animal model in which these blood dyscrasias can be studied. In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and ENT2 thrombocytopenia ENT2END after 1-3 months of treatment
1	In four subacute toxicity studies, the intravenous administration of cefonicid or ENT1 cefazedone  ENT1END  to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and ENT2 thrombocytopenia ENT2END after 1-3 months of treatment
0	In four subacute ENT1 toxicity  ENT1END studies, the intravenous administration of ENT2 cefonicid ENT2END or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment
0	ENT1 Cephalosporin  ENT1END  antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized. There is a need for a well-defined animal model in which these blood dyscrasias can be studied. In four subacute ENT2 toxicity ENT2END studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment
0	In four subacute ENT1 toxicity  ENT1END  studies, the intravenous administration of cefonicid or ENT2 cefazedone ENT2END to beagle dogs caused a dose-dependent incidence of anemia, neutropenia, and thrombocytopenia after 1-3 months of treatment
0	We conclude that the administration of high doses of ENT1 cefonicid ENT1END or cefazedone to dogs can induce ENT2 hematotoxicity ENT2END similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders
0	The hematologic effects of cefonicid and cefazedone in the dog: a potential model of ENT1 cephalosporin ENT1END ENT2 hematotoxicity ENT2END in man
0	A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50% of dogs receiving 400-500 mg/kg cefonicid or 540-840 mg/kg ENT1 cefazedone ENT1END  All three ENT2 cytopenias ENT2END were completely reversible following cessation of treatment; the time required for recovery of the erythron (approximately 1 month) was considerably longer than that of the granulocytes and platelets (hours to a few days)
1	In four subacute toxicity studies, the intravenous administration of ENT1 cefonicid ENT1END  or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, ENT2 neutropenia ENT2END , and thrombocytopenia after 1-3 months of treatment
0	ENT1 Cephalosporin  ENT1END  antibiotics cause a variety of hematologic disturbances in man, the pathogeneses and hematopathology of which remain poorly characterized. There is a need for a well-defined animal model in which these blood dyscrasias can be studied. In four subacute toxicity studies, the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose-dependent incidence of anemia, ENT2 neutropenia ENT2END , and thrombocytopenia after 1-3 months of treatment
1	In four subacute toxicity studies, the intravenous administration of cefonicid or ENT1 cefazedone  ENT1END  to beagle dogs caused a dose-dependent incidence of anemia, ENT2 neutropenia ENT2END , and thrombocytopenia after 1-3 months of treatment
0	This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a ENT1 hemolytic  ENT1END component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia. We conclude that the administration of high doses of ENT2 cefonicid ENT2END or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders
0	This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a ENT1 hemolytic ENT1END  component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia. We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the ENT2 cephalosporin ENT2END -induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders
0	This observation, along with the rapid rate of decline in red cell mass parameters of affected dogs, suggests that a ENT1 hemolytic ENT1END  component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia. We conclude that the administration of high doses of cefonicid or ENT2 cefazedone ENT2END to dogs can induce hematotoxicity similar to the cephalosporin-induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders
0	5 microl diminished the haloperidol-induced ENT1 muscle rigidity ENT1END  In contrast, ENT2 2R,4R-APDC ENT2END injections were ineffective
0	ENT1 AIDA  ENT1END in doses of 7.5-15 microg/0.5 microl diminished the haloperidol-induced ENT2 muscle rigidity ENT2END
1	5 microl diminished the ENT1 haloperidol  ENT1END induced ENT2 muscle rigidity ENT2END
0	The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic ENT1 glutamate ENT1END  receptors.The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats. Haloperidol (1 mg/kg ip) induced parkinsonian-like ENT2 muscle rigidity ENT2END , measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint
0	In contrast, ENT1 2R,4R-APDC ENT1END  injections were ineffective. The present results may suggest that the blockade of striatal mGluR1, but not the stimulation of group II mGluRs, may ameliorate ENT2 parkinsonian ENT2END muscle rigidity
0	Haloperidol (1 mg/kg ip) induced ENT1 parkinsonian ENT1END like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint. ENT2 (RS)-1-aminoindan-1,5-dicarboxylic acid ENT2END (AIDA; 0
0	ENT1 Haloperidol  ENT1END (1 mg/kg ip) induced ENT2 parkinsonian ENT2END -like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint
0	The striatum as a target for anti-rigor effects of an antagonist of mGluR1, but not an agonist of group II metabotropic ENT1 glutamate  ENT1END  receptors.The aim of the present study was to find out whether the metabotropic receptor 1 (mGluR1) and group II mGluRs, localized in the striatum, are involved in antiparkinsonian-like effects in rats. Haloperidol (1 mg/kg ip) induced ENT2 parkinsonian ENT2END -like muscle rigidity, measured as an increased resistance of a rat's hind foot to passive flexion and extension at the ankle joint
1	Central ENT1 vein thrombosis  ENT1END  and topical ENT2 dipivalyl epinephrine ENT2END
0	A report is given on an 83-year-old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with ENT1 dipivalyl epinephrine ENT1END for advanced ENT2 glaucoma ENT2END discovered in the other eye
0	He was hospitalized for a myocardial infarction with ENT1 pulmonary edema ENT1END  treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT2 furosemide ENT2END and amine infusion
0	We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after ENT1 losartan  ENT1END administration. He was hospitalized for a myocardial infarction with ENT2 pulmonary edema ENT2END , treated with high-dose diuretics
0	He was hospitalized for a myocardial infarction with ENT1 pulmonary edema ENT1END , treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT2 amine ENT2END infusion
0	We report the case of a 70-year-old ENT1 hypertensive  ENT1END man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration. He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT2 furosemide ENT2END and amine infusion
0	Repeated transient anuria following ENT1 losartan  ENT1END  administration in a patient with a solitary kidney.We report the case of a 70-year-old ENT2 hypertensive ENT2END man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration
0	We report the case of a 70-year-old ENT1 hypertensive  ENT1END  man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration. He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT2 amine ENT2END infusion
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT1 furosemide ENT1END  and amine infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe ENT2 hypotension ENT2END was noted
0	During these two episodes, his blood pressure diminished but no severe ENT1 hypotension  ENT1END  was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin- ENT2 angiotensin ENT2END system (RAS)
0	One week later, by mistake, ENT1 losartan  ENT1END was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe ENT2 hypotension ENT2END was noted
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT1 amine  ENT1END  infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe ENT2 hypotension ENT2END was noted
0	During these two episodes, his blood pressure diminished but no severe ENT1 hypotension ENT1END  was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS). Under such conditions, ENT2 angiotensin II ENT2END receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure
0	We report the case of a 70-year-old hypertensive man with a solitary kidney and ENT1 chronic renal insufficiency  ENT1END who developed two episodes of transient anuria after losartan administration. He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT2 furosemide ENT2END and amine infusion
0	We report the case of a 70-year-old hypertensive man with a solitary kidney and ENT1 chronic renal insufficiency  ENT1END  who developed two episodes of transient anuria after ENT2 losartan ENT2END administration
0	We report the case of a 70-year-old hypertensive man with a solitary kidney and ENT1 chronic renal insufficiency  ENT1END  who developed two episodes of transient anuria after losartan administration. He was hospitalized for a myocardial infarction with pulmonary edema, treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT2 amine ENT2END infusion
0	He was hospitalized for a ENT1 myocardial infarction  ENT1END with pulmonary edema, treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT2 furosemide ENT2END and amine infusion
0	We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after ENT1 losartan  ENT1END  administration. He was hospitalized for a ENT2 myocardial infarction ENT2END with pulmonary edema, treated with high-dose diuretics
0	He was hospitalized for a ENT1 myocardial infarction  ENT1END  with pulmonary edema, treated with high-dose diuretics. Due to severe systolic dysfunction losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT2 amine ENT2END infusion
0	In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin- ENT1 angiotensin ENT1END  system (RAS). Under such conditions, angiotensin II receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure. This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with ENT2 renovascular disease ENT2END and should be used with extreme caution in this setting
0	This case report highlights the fact that the angiotensin II receptor antagonist ENT1 losartan  ENT1END can cause serious unexpected complications in patients with ENT2 renovascular disease ENT2END and should be used with extreme caution in this setting
0	This case report highlights the fact that the ENT1 angiotensin II  ENT1END receptor antagonist losartan can cause serious unexpected complications in patients with ENT2 renovascular disease ENT2END and should be used with extreme caution in this setting
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT1 furosemide ENT1END  and amine infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with ENT2 heart failure ENT2END and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS)
0	In this patient, renal artery stenosis combined with ENT1 heart failure  ENT1END  and diuretic therapy certainly resulted in a strong activation of the renin ENT2 angiotensin ENT2END system (RAS)
0	In this patient, renal artery stenosis combined with ENT1 heart failure ENT1END  and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS). Under such conditions, angiotensin II receptor blockade by ENT2 losartan ENT2END probably induced a critical fall in glomerular filtration pressure
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT1 amine  ENT1END  infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with ENT2 heart failure ENT2END and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS)
0	In this patient, renal artery stenosis combined with ENT1 heart failure  ENT1END  and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS). Under such conditions, ENT2 angiotensin II ENT2END receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT1 furosemide ENT1END  and amine infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% ENT2 renal artery stenosis ENT2END
0	In this patient, ENT1 renal artery stenosis  ENT1END combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin ENT2 angiotensin ENT2END system (RAS)
0	In this patient, ENT1 renal artery stenosis  ENT1END  combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS). Under such conditions, angiotensin II receptor blockade by ENT2 losartan ENT2END probably induced a critical fall in glomerular filtration pressure
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT1 amine  ENT1END  infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% ENT2 renal artery stenosis ENT2END
0	In this patient, ENT1 renal artery stenosis  ENT1END  combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS). Under such conditions, ENT2 angiotensin II ENT2END receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden ENT1 anuria  ENT1END  which lasted eight hours despite high-dose ENT2 furosemide ENT2END and amine infusion
0	One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient ENT1 anuria  ENT1END lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin ENT2 angiotensin ENT2END system (RAS)
1	We report the case of a 70-year-old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient ENT1 anuria  ENT1END after ENT2 losartan ENT2END administration
0	Surprisingly, the first dose of 50 mg of losartan resulted in a sudden ENT1 anuria  ENT1END , which lasted eight hours despite high-dose furosemide and ENT2 amine ENT2END infusion
0	One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient ENT1 anuria  ENT1END  lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin-angiotensin system (RAS). Under such conditions, ENT2 angiotensin II ENT2END receptor blockade by losartan probably induced a critical fall in glomerular filtration pressure
0	Due to severe ENT1 systolic dysfunction  ENT1END losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose ENT2 furosemide ENT2END and amine infusion
0	Due to severe ENT1 systolic dysfunction  ENT1END  losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and amine infusion. One week later, by mistake, losartan was prescribed again and after the second dose of 50 mg, the patient developed a second episode of transient anuria lasting 10 hours. During these two episodes, his blood pressure diminished but no severe hypotension was noted. Ultimately, an arteriography showed a 70-80% renal artery stenosis. In this patient, renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin ENT2 angiotensin ENT2END system (RAS)
0	Due to severe ENT1 systolic dysfunction ENT1END  ENT2 losartan ENT2END was prescribed
0	Due to severe ENT1 systolic dysfunction  ENT1END  losartan was prescribed. Surprisingly, the first dose of 50 mg of losartan resulted in a sudden anuria, which lasted eight hours despite high-dose furosemide and ENT2 amine ENT2END infusion
1	ENT1 Lithium carbonate ENT1END may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes neurologic depression, cyanosis, and ENT2 cardiac arrhythmia ENT2END when consumed prior to delivery
0	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to ENT1 lithium  ENT1END compounds in the first trimester of pregnancy. Sixty-three percent of these infants had tricuspid valve involvement. Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes neurologic depression, cyanosis, and ENT2 cardiac arrhythmia ENT2END when consumed prior to delivery
0	ENT1 Tricuspid valve regurgitation  ENT1END  and ENT2 lithium carbonate ENT2END toxicity in a newborn infant
0	A newborn with massive ENT1 tricuspid regurgitation ENT1END  atrial flutter, congestive heart failure, and a high serum ENT2 lithium ENT2END level is described
0	Tricuspid valve regurgitation and ENT1 lithium carbonate ENT1END ENT2 toxicity ENT2END in a newborn infant
0	Tricuspid valve regurgitation and lithium carbonate ENT1 toxicity  ENT1END  in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, congestive heart failure, and a high serum ENT2 lithium ENT2END level is described
0	Tricuspid valve regurgitation and ENT1 lithium carbonate ENT1END  toxicity in a newborn infant.A newborn with massive tricuspid regurgitation, ENT2 atrial flutter ENT2END , congestive heart failure, and a high serum lithium level is described
0	A newborn with massive tricuspid regurgitation, ENT1 atrial flutter  ENT1END , congestive heart failure, and a high serum ENT2 lithium ENT2END level is described
1	ENT1 Lithium carbonate ENT1END  may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes neurologic depression, ENT2 cyanosis ENT2END , and cardiac arrhythmia when consumed prior to delivery
0	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to ENT1 lithium  ENT1END  compounds in the first trimester of pregnancy. Sixty-three percent of these infants had tricuspid valve involvement. Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes neurologic depression, ENT2 cyanosis ENT2END , and cardiac arrhythmia when consumed prior to delivery
0	Tricuspid valve regurgitation and ENT1 lithium carbonate ENT1END  toxicity in a newborn infant.A newborn with massive tricuspid regurgitation, atrial flutter, ENT2 congestive heart failure ENT2END , and a high serum lithium level is described
0	A newborn with massive tricuspid regurgitation, atrial flutter, ENT1 congestive heart failure  ENT1END , and a high serum ENT2 lithium ENT2END level is described
0	ENT1 Lithium carbonate ENT1END  may be a factor in the increasing incidence of ENT2 congenital heart disease ENT2END when taken during early pregnancy
0	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with ENT1 cardiac disease  ENT1END among infants exposed to ENT2 lithium ENT2END compounds in the first trimester of pregnancy
1	ENT1 Lithium carbonate ENT1END  may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes ENT2 neurologic depression ENT2END , cyanosis, and cardiac arrhythmia when consumed prior to delivery
0	This is the first patient to initially manifest tricuspid regurgitation and atrial flutter, and the 11th described patient with cardiac disease among infants exposed to ENT1 lithium  ENT1END  compounds in the first trimester of pregnancy. Sixty-three percent of these infants had tricuspid valve involvement. Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy. It also causes ENT2 neurologic depression ENT2END , cyanosis, and cardiac arrhythmia when consumed prior to delivery
0	In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of ENT1 PD ENT1END treated with saline, L-DOPA or ENT2 bromocriptine ENT2END using two-dimensional difference gel electrophoresis and mass spectrometry (MS)
0	In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally ENT1 6-hydroxydopamine  ENT1END lesion rat model of ENT2 PD ENT2END treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS)
0	In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of ENT1 PD ENT1END  treated with saline, ENT2 L-DOPA ENT2END or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS)
0	In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6-hydroxydopamine-lesion rat model of PD treated with saline, L-DOPA or ENT1 bromocriptine ENT1END  using two-dimensional difference gel electrophoresis and mass spectrometry (MS). Rats treated with L-DOPA were allocated to two groups based on the presence or absence of ENT2 LID ENT2END
0	To this day, transcriptome analysis has been performed in a rat model of ENT1 LID  ENT1END [Neurobiol. Dis., 17 (2004), 219] but information regarding the proteome is still lacking. In the present study, we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally ENT2 6-hydroxydopamine ENT2END -lesion rat model of PD treated with saline, L-DOPA or bromocriptine using two-dimensional difference gel electrophoresis and mass spectrometry (MS)
1	Proteomic analysis of striatal proteins in the rat model of L-DOPA-induced ENT1 dyskinesia  ENT1END . ENT2 L-DOPA ENT2END -induced dyskinesia (LID) is among the motor complications that arise in Parkinson's disease (PD) patients after a prolonged treatment with L-DOPA
0	A dystonia-like syndrome after neuropeptide ( ENT1 MSH ENT1END /ACTH) stimulation of the rat locus ceruleus.The movement disorder investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit. The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE-mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo-cerebellar pathway. However, it is not certain as to the following: (a) what receptors were stimulated by the ACTH N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term ENT2 depression ENT2END at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder
0	However, it is not certain as to the following: (a) what receptors were stimulated by the ENT1 ACTH  ENT1END N-terminal fragments at the LC that resulted in this disorder; (b) whether NE, released onto Purkinje cell synapses located at terminals of the ceruleo-cerebellar pathway, did indeed cause the long-term ENT2 depression ENT2END at Purkinje cell synapses (previously described by others) that resulted in the long duration of the movement disorder; (c) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei, the output targets of the Purkinje cell axons, that may have been an important contributing factor to this disorder
1	A ENT1 dystonia ENT1END -like syndrome after neuropeptide ENT2 MSH ENT2END /ACTH) stimulation of the rat locus ceruleus
1	A ENT1 dystonia  ENT1END -like syndrome after neuropeptide (MSH ENT2 ACTH ENT2END ) stimulation of the rat locus ceruleus
0	A dystonia-like syndrome after neuropeptide ( ENT1 MSH ENT1END /ACTH) stimulation of the rat locus ceruleus.The ENT2 movement disorder ENT2END investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit
0	A dystonia-like syndrome after neuropeptide (MSH/ ENT1 ACTH  ENT1END ) stimulation of the rat locus ceruleus.The ENT2 movement disorder ENT2END investigated in these studies has some features in common with human idiopathic dystonia, and information obtained in these studies may be of potential clinical benefit
0	Vitamin E supplementation ameliorated ENT1 hypertension ENT1END  lowered plasma ENT2 MDA ENT2END concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression
0	This study was designed to discern whether the reduction in urinary NOx in lead-induced ENT1 hypertension ENT1END is, in part, due to depressed ENT2 NO ENT2END synthase (NOS) expression
0	ENT1 Vitamin E  ENT1END supplementation ameliorated ENT2 hypertension ENT2END , lowered plasma MDA concentration, and raised urinary NOx excretion while significantly lowering vascular, but not renal, tissue eNOS and iNOS expression
0	Nitric oxide synthase expression in the course of lead-induced ENT1 hypertension ENT1END .We recently showed elevated reactive ENT2 oxygen ENT2END species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as nitrotyrosine in various tissues in rats with lead-induced hypertension
0	This study was designed to discern whether the reduction in urinary NOx in lead-induced ENT1 hypertension ENT1END  is, in part, due to depressed NO synthase (NOS) expression. Male Sprague-Dawley rats were randomly assigned to a lead-treated group (given ENT2 lead acetate ENT2END , 100 ppm, in drinking water and regular rat chow), a group given lead and vitamin E-fortified chow, or a normal control group given either regular food and water or vitamin E-fortified food for 12 weeks
0	We recently showed elevated reactive oxygen species (ROS), reduced urinary excretion of NO metabolites (NOx), and increased NO sequestration as ENT1 nitrotyrosine ENT1END in various tissues in rats with lead-induced ENT2 hypertension ENT2END
1	Nitric oxide synthase expression in the course of ENT1 lead  ENT1END -induced ENT2 hypertension ENT2END
0	CASE SUMMARY: A 40-year-old woman with ENT1 major depression ENT1END took an overdose of ENT2 venlafaxine ENT2END in an apparent suicide attempt
1	ENT1 Seizure  ENT1END  resulting from a ENT2 venlafaxine ENT2END overdose
1	Seizure resulting from a ENT1 venlafaxine ENT1END ENT2 overdose ENT2END
1	ENT1 Verapamil  ENT1END  withdrawal as a possible cause of ENT2 myocardial infarction ENT2END in a hypertensive woman with a normal coronary angiogram
0	We report a case in which ENT1 myocardial infarction ENT1END coincided with the introduction of ENT2 captopril ENT2END and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension
0	We report a case in which ENT1 myocardial infarction ENT1END  coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension. Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for ENT2 catecholamines ENT2END are discussed
0	We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe ENT1 hypertension ENT1END  Possible mechanisms that involve a ENT2 verapamil ENT2END -related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for catecholamines are discussed
0	We report a case in which myocardial infarction coincided with the introduction of ENT1 captopril  ENT1END  and the withdrawal of verapamil in a previously asymptomatic woman with severe ENT2 hypertension ENT2END
0	We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe ENT1 hypertension  ENT1END . Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for ENT2 catecholamines ENT2END are discussed
0	ENT1 Verapamil ENT1END is an effective and relatively-safe antihypertensive drug. Serious adverse effects are uncommon and mainly have been related to the ENT2 depression ENT2END of cardiac contractility and conduction, especially when the drug is combined with beta-blocking agents
0	Serious adverse effects are uncommon and mainly have been related to the ENT1 depression  ENT1END  of cardiac contractility and conduction, especially when the drug is combined with beta-blocking agents. We report a case in which myocardial infarction coincided with the introduction of ENT2 captopril ENT2END and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension
0	Serious adverse effects are uncommon and mainly have been related to the ENT1 depression  ENT1END  of cardiac contractility and conduction, especially when the drug is combined with beta-blocking agents. We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension. Possible mechanisms that involve a verapamil-related increase in platelet and/or vascular alpha 2-adrenoreceptor affinity for ENT2 catecholamines ENT2END are discussed
1	We report a patient with primary biliary cirrhosis, who developed ENT1 polymyositis ENT1END while receiving ENT2 D-penicillamine ENT2END therapy
0	Polymyositis/ ENT1 dermatomyositis ENT1END can develop as one of the autoimmune complications of ENT2 D-penicillamine ENT2END treatment, but its exact pathogenesis remains unclear
0	Although ENT1 D-penicillamine ENT1END has been used for many ENT2 rheumatologic diseases ENT2END , toxicity limits its usefulness in many patients
0	Although ENT1 D-penicillamine ENT1END  has been used for many rheumatologic diseases, ENT2 toxicity ENT2END limits its usefulness in many patients
0	A case of polymyositis in a patient with ENT1 primary biliary cirrhosis  ENT1END  treated with ENT2 D-penicillamine ENT2END
0	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with ENT1 nifedipine ENT1END  These data suggest that coronary spasm may be the cause of ENT2 cardiotoxicity ENT2END due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of ENT1 5-FU ENT1END ENT2 cardiotoxicity ENT2END
0	These data suggest that coronary spasm may be the cause of ENT1 cardiotoxicity ENT1END  due to 5-FU, and that ENT2 calcium ENT2END antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	We report a case of a patient with colon carcinoma and liver ENT1 metastasis  ENT1END who presented chest pain after 5-fluorouracil (5-FU) administration. Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with ENT2 nifedipine ENT2END
0	We report a case of a patient with colon carcinoma and liver ENT1 metastasis ENT1END  who presented chest pain after ENT2 5-fluorouracil ENT2END (5-FU) administration
0	We report a case of a patient with colon carcinoma and liver ENT1 metastasis  ENT1END  who presented chest pain after 5-fluorouracil (5-FU) administration. Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine. These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that ENT2 calcium ENT2END antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	We report a case of a patient with ENT1 colon carcinoma  ENT1END and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration. Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with ENT2 nifedipine ENT2END
0	We report a case of a patient with ENT1 colon carcinoma  ENT1END  and liver metastasis who presented chest pain after ENT2 5-fluorouracil ENT2END (5-FU) administration
0	We report a case of a patient with ENT1 colon carcinoma  ENT1END  and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration. Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine. These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that ENT2 calcium ENT2END antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	Clinical electrocardiographic evolution was similar to that observed in ENT1 Prinzmetal's angina  ENT1END  and chest pain promptly resolved with ENT2 nifedipine ENT2END
1	We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil ( ENT1 5-FU  ENT1END  administration. Clinical electrocardiographic evolution was similar to that observed in ENT2 Prinzmetal's angina ENT2END , and chest pain promptly resolved with nifedipine
0	Clinical electrocardiographic evolution was similar to that observed in ENT1 Prinzmetal's angina  ENT1END , and chest pain promptly resolved with nifedipine. These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that ENT2 calcium ENT2END antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	Report of a case of spontaneous ENT1 angina  ENT1END .We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration. Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with ENT2 nifedipine ENT2END
0	Cardiac toxicity of ENT1 5-fluorouracil  ENT1END . Report of a case of spontaneous ENT2 angina ENT2END
0	Report of a case of spontaneous ENT1 angina  ENT1END .We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5-fluorouracil (5-FU) administration. Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with nifedipine. These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that ENT2 calcium ENT2END antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and ENT1 chest pain  ENT1END promptly resolved with ENT2 nifedipine ENT2END
1	We report a case of a patient with colon carcinoma and liver metastasis who presented ENT1 chest pain  ENT1END after ENT2 5-fluorouracil ENT2END (5-FU) administration
0	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and ENT1 chest pain  ENT1END  promptly resolved with nifedipine. These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5-FU, and that ENT2 calcium ENT2END antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	Clinical electrocardiographic evolution was similar to that observed in Prinzmetal's angina, and chest pain promptly resolved with ENT1 nifedipine ENT1END . These data suggest that ENT2 coronary spasm ENT2END may be the cause of cardiotoxicity due to 5-FU, and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	These data suggest that ENT1 coronary spasm ENT1END  may be the cause of cardiotoxicity due to ENT2 5-FU ENT2END , and that calcium antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	These data suggest that ENT1 coronary spasm  ENT1END  may be the cause of cardiotoxicity due to 5-FU, and that ENT2 calcium ENT2END antagonists may probably be used in the prevention or treatment of 5-FU cardiotoxicity
0	During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating ENT1 oral contraceptives  ENT1END to changes in hematologic parameters. Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups. Severe complications developed in four patients. All four had an abnormal blood coagulation profile, suggesting " ENT2 hypercoagulability ENT2END " before initiation of therapy
0	ENT1 Thromboembolic  ENT1END  and other complications of ENT2 oral contraceptive ENT2END therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study
1	The fourth patient developed ENT1 thrombophlebitis ENT1END 14 days after initiation of contraceptive therapy. All four patients were of the A or AB blood group. Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen. It appears from these data that hematologic work-ups may be useful in women who are about to start long-term ENT2 oral contraceptive ENT2END therapy
1	During a ten-year period, 348 women were studied for a total of 5,877 patient months in four separate studies relating ENT1 oral contraceptives ENT1END  to changes in hematologic parameters. Significant increases in certain factors of the blood coagulation and fibrinolysin systems (factors I,II,VII,VIII,IX, and X and plasminogen) were observed in the treated groups. Severe complications developed in four patients. All four had an abnormal blood coagulation profile, suggesting "hypercoagulability" before initiation of therapy. Some of these findings represented the most extreme abnormalities seen in the entire group of patients; some increased further during therapy. One of these patients developed a ENT2 myocardial infarction ENT2END before receiving any medication, shortly after the base-line values were obtained
1	Progestational agents and ENT1 blood coagulation  ENT1END . VII. Thromboembolic and other complications of ENT2 oral contraceptive ENT2END therapy in relationship to pretreatment levels of blood coagulation factors: summary report of a ten-year study
1	One patient developed ENT1 retinopathy  ENT1END 19 months after she began therapy, and another developed thrombophlebitis after 27 months of therapy. The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy. All four patients were of the A or AB blood group. Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen. It appears from these data that hematologic work-ups may be useful in women who are about to start long-term ENT2 oral contraceptive ENT2END therapy
1	One case of acute ENT1 hypercalcaemia  ENT1END and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon-ate- ENT2 sodium bicarbonate ENT2END powders for more than 20 years
1	One case of acute ENT1 hypercalcaemia ENT1END  and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of ENT2 calcium carbon-ate ENT2END -sodium bicarbonate powders for more than 20 years
1	One case of acute hypercalcaemia and two of recurrent ENT1 nephrolithiasis  ENT1END are reported in patients who had regularly consumed large amounts of calcium carbon-ate ENT2 sodium bicarbonate ENT2END powders for more than 20 years
1	One case of acute hypercalcaemia and two of recurrent ENT1 nephrolithiasis  ENT1END  are reported in patients who had regularly consumed large amounts of ENT2 calcium carbon-ate ENT2END -sodium bicarbonate powders for more than 20 years
0	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a ENT1 psychiatric ENT1END emergency service with a diagnosis of amphetamine- or ENT2 cocaine ENT2END -induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels
0	To examine the relationship between quantitative stimulant drug levels, ENT1 catecholamines  ENT1END  and psychotic symptoms, nineteen patients in a ENT2 psychiatric ENT2END emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels
0	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a ENT1 psychiatric ENT1END  emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels. ENT2 Methamphetamine ENT2END or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating
0	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a ENT1 psychiatric ENT1END  emergency service with a diagnosis of ENT2 amphetamine ENT2END - or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels
1	Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and ENT1 hyperkinesia  ENT1END .To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or ENT2 cocaine ENT2END -induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels
0	Quantitative drug levels in stimulant psychosis: relationship to symptom severity, ENT1 catecholamines  ENT1END  and ENT2 hyperkinesia ENT2END
1	ENT1 Methamphetamine ENT1END  or amphetamine levels were related to several psychopathology scores and the global ENT2 hyperkinesia ENT2END rating
1	Methamphetamine or ENT1 amphetamine  ENT1END levels were related to several psychopathology scores and the global ENT2 hyperkinesia ENT2END rating
0	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or ENT1 cocaine ENT1END -induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels. Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating. HVA levels were related to global hyperkinesia but not to psychopathology ratings. Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and ENT2 stereotypies ENT2END appears to be at least in part dose-related
0	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and ENT1 catecholamine  ENT1END metabolite levels. Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating. HVA levels were related to global hyperkinesia but not to psychopathology ratings. Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and ENT2 stereotypies ENT2END appears to be at least in part dose-related
0	ENT1 Methamphetamine  ENT1END  or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating. HVA levels were related to global hyperkinesia but not to psychopathology ratings. Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and ENT2 stereotypies ENT2END appears to be at least in part dose-related
0	Methamphetamine or ENT1 amphetamine  ENT1END  levels were related to several psychopathology scores and the global hyperkinesia rating. HVA levels were related to global hyperkinesia but not to psychopathology ratings. Although many other factors such as sensitization may play a role, intensity of stimulant-induced psychotic symptoms and ENT2 stereotypies ENT2END appears to be at least in part dose-related
1	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or ENT1 cocaine ENT1END -induced ENT2 psychosis ENT2END were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels
0	To examine the relationship between quantitative stimulant drug levels, ENT1 catecholamines ENT1END , and ENT2 psychotic symptoms ENT2END , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced psychosis were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels
1	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine- or cocaine-induced ENT1 psychosis  ENT1END  were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels. ENT2 Methamphetamine ENT2END or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating
1	To examine the relationship between quantitative stimulant drug levels, catecholamines, and psychotic symptoms, nineteen patients in a psychiatric emergency service with a diagnosis of ENT1 amphetamine  ENT1END - or cocaine-induced ENT2 psychosis ENT2END were interviewed, and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels
0	NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin ( ENT1 5-HT ENT1END 2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor ENT2 hyperactivity ENT2END induced by methamphetamine (MAP) in mice
1	NRA0160 and clozapine antagonized locomotor ENT1 hyperactivity ENT1END  induced by ENT2 methamphetamine ENT2END (MAP) in mice
0	NRA0160 and clozapine antagonized locomotor ENT1 hyperactivity ENT1END  induced by methamphetamine (MAP) in mice. NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given. NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the ENT2 phencyclidine ENT2END (PCP)-induced prolonged swimming latency in rats in a water maze task
0	NRA0160 and ENT1 clozapine  ENT1END antagonized locomotor ENT2 hyperactivity ENT2END induced by methamphetamine (MAP) in mice
0	ENT1 NRA0160  ENT1END and clozapine antagonized locomotor ENT2 hyperactivity ENT2END induced by methamphetamine (MAP) in mice
0	NRA0160 has negligible affinity for the human cloned ENT1 dopamine  ENT1END D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor ENT2 hyperactivity ENT2END induced by methamphetamine (MAP) in mice
0	NRA0160 and clozapine antagonized locomotor ENT1 hyperactivity ENT1END  induced by methamphetamine (MAP) in mice. NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given. NRA0160 and clozapine significantly induced catalepsy in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by ENT2 apomorphine ENT2END
0	NRA0160 has negligible affinity for the human cloned dopamine D3 receptor (Ki=39 nM), rat serotonin ( ENT1 5-HT ENT1END )2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice. NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given. NRA0160 and clozapine significantly induced ENT2 catalepsy ENT2END in rats, although their effects did not exceed 50% induction even at the highest dose given
0	NRA0160 and clozapine antagonized ENT1 MAP  ENT1END induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given. NRA0160 and clozapine significantly induced ENT2 catalepsy ENT2END in rats, although their effects did not exceed 50% induction even at the highest dose given
0	NRA0160 and clozapine significantly induced ENT1 catalepsy  ENT1END  in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by apomorphine. NRA0160 and clozapine significantly shortened the ENT2 phencyclidine ENT2END (PCP)-induced prolonged swimming latency in rats in a water maze task
1	NRA0160 and ENT1 clozapine  ENT1END significantly induced ENT2 catalepsy ENT2END in rats, although their effects did not exceed 50% induction even at the highest dose given
1	ENT1 NRA0160  ENT1END and clozapine significantly induced ENT2 catalepsy ENT2END in rats, although their effects did not exceed 50% induction even at the highest dose given
0	NRA0160 has negligible affinity for the human cloned ENT1 dopamine  ENT1END  D3 receptor (Ki=39 nM), rat serotonin (5-HT)2A receptors (Ki=180 nM) and rat alpha1 adrenoceptor (Ki=237 nM). NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine (MAP) in mice. NRA0160 and clozapine antagonized MAP-induced stereotyped behavior in mice, although their effects did not exceed 50% inhibition, even at the highest dose given. NRA0160 and clozapine significantly induced ENT2 catalepsy ENT2END in rats, although their effects did not exceed 50% induction even at the highest dose given
0	NRA0160 and clozapine significantly induced ENT1 catalepsy  ENT1END  in rats, although their effects did not exceed 50% induction even at the highest dose given. NRA0160 and clozapine significantly reversed the disruption of prepulse inhibition (PPI) in rats produced by ENT2 apomorphine ENT2END
1	ENT1 D-Penicillamine ENT1END caused ENT2 nephrotic syndrome ENT2END in 1 patient and milder reversible proteinuria in 3 other patients; none developed renal insufficiency
0	D-Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients; none developed ENT1 renal insufficiency ENT1END  These data suggest that ENT2 D-penicillamine ENT2END may be effective in severe cases of localized scleroderma
0	Joint stiffness and ENT1 contractures ENT1END also improved. The dose of ENT2 D-penicillamine ENT2END associated with a favorable response was as low as 2 to 5 mg/kg per day given over a period ranging from 15 to 53 months
0	ENT1 D-penicillamine  ENT1END  in the treatment of ENT2 localized scleroderma ENT2END
1	ENT1 D-Penicillamine ENT1END  caused nephrotic syndrome in 1 patient and milder reversible ENT2 proteinuria ENT2END in 3 other patients; none developed renal insufficiency
0	To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential ENT1 hypertension ENT1END who had shown hypokalaemia under prior oral diuretic treatment. Chlorthalidone (50 mg daily) was given for 14 days. Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet. All patients had a normal initial total body potassium (40K). The electrolyte balances, weight, bromide space, plasma renin activity, and ENT2 aldosterone ENT2END secretion rate were measured
0	Initial potassium loss and hypokalaemia during ENT1 chlorthalidone  ENT1END  administration in patients with essential ENT2 hypertension ENT2END : the influence of dietary sodium restriction
0	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential ENT1 hypertension ENT1END : the influence of dietary sodium restriction.To investigate the initial ENT2 potassium ENT2END loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment
0	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential ENT1 hypertension  ENT1END : the influence of dietary ENT2 sodium ENT2END restriction
0	To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown ENT1 hypokalaemia  ENT1END under prior oral diuretic treatment. Chlorthalidone (50 mg daily) was given for 14 days. Six patients received a normal-sodium diet and four a low-sodium (17 mmol/day) diet. All patients had a normal initial total body potassium (40K). The electrolyte balances, weight, bromide space, plasma renin activity, and ENT2 aldosterone ENT2END secretion rate were measured
1	Initial potassium loss and ENT1 hypokalaemia  ENT1END  during ENT2 chlorthalidone ENT2END administration in patients with essential hypertension: the influence of dietary sodium restriction
0	Initial ENT1 potassium  ENT1END  loss and ENT2 hypokalaemia ENT2END during chlorthalidone administration in patients with essential hypertension: the influence of dietary sodium restriction
0	Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension: the influence of dietary ENT1 sodium ENT1END  restriction.To investigate the initial potassium loss and development of ENT2 hypokalaemia ENT2END during the administration of an oral diuretic, metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment
1	Low clearance values found in several patients could be accounted for by their age and their pre- ENT1 lithium ENT1END values. Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients. The concentration defect appeared reversible, at least in part. ENT2 Polyuria ENT2END above 3 litres/24 hours was found in 10% of patients
0	Response to treatment was estimated by the visual analog scale for severity of ENT1 pain ENT1END  RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0.05). ENT2 Potassium ENT2END (K) increment of 0
0	Response to treatment was estimated by the visual analog scale for severity of ENT1 pain ENT1END . RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. BUN and ENT2 creatinine ENT2END increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0
0	Addition of ENT1 misoprostol ENT1END can minimize this renal impairment without affecting ENT2 pain ENT2END control
0	CONCLUSION: Hospitalized elderly patients are at risk for developing ENT1 indomethacin  ENT1END related renal dysfunction. Addition of misoprostol can minimize this renal impairment without affecting ENT2 pain ENT2END control
0	Response to treatment was estimated by the visual analog scale for severity of ENT1 pain ENT1END . RESULTS: Forty-two patients completed the study, 22 in Group A and 20 in Group B. ENT2 BUN ENT2END and creatinine increased by > 50% of baseline levels in 54 and 45% of Group A patients, respectively, compared to only 20 and 10% of Group B patients (p < 0
0	The mean increments in BUN, creatinine, and ENT1 K ENT1END were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related ENT2 renal dysfunction ENT2END
0	The mean increments in BUN, ENT1 creatinine  ENT1END  and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related ENT2 renal dysfunction ENT2END
0	CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related ENT1 renal dysfunction  ENT1END . Addition of ENT2 misoprostol ENT2END can minimize this renal impairment without affecting pain control
1	Protective effect of misoprostol on ENT1 indomethacin  ENT1END  induced ENT2 renal dysfunction ENT2END in elderly patients
0	The mean increments in ENT1 BUN  ENT1END  creatinine, and K were reduced by 63, 80, and 42%, respectively, in Group B patients compared to Group A. Response to treatment did not differ significantly between the 2 groups. CONCLUSION: Hospitalized elderly patients are at risk for developing indomethacin related ENT2 renal dysfunction ENT2END
1	These are ENT1 nephrotoxic ENT1END  but ENT2 SRL ENT2END seems to act differently displaying only minor nephrotoxic effects, although this question is still open
1	CONCLUSION: This rat study demonstrated a synergistic ENT1 nephrotoxic ENT1END effect of ENT2 CsA ENT2END plus SRL, whereas FK506 plus SRL was better tolerated
1	CONCLUSION: This rat study demonstrated a synergistic ENT1 nephrotoxic ENT1END  effect of CsA plus SRL, whereas ENT2 FK506 ENT2END plus SRL was better tolerated
0	The FK506 plus ENT1 SRL ENT1END combination showed only a marginally higher degree of ENT2 fibrosis ENT2END as compared with controls (P=0
0	The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of ENT1 fibrosis ENT1END in the cortex stained with Sirius Red. RESULTS: ENT2 CsA ENT2END , FK506 and SRL all significantly decreased the GFR
0	The morphological analysis of the kidneys included a semi-quantitative scoring system analysing the degree of striped fibrosis, subcapsular fibrosis and the number of basophilic tubules, plus an additional stereological analysis of the total grade of ENT1 fibrosis ENT1END  in the cortex stained with Sirius Red. RESULTS: CsA, ENT2 FK506 ENT2END and SRL all significantly decreased the GFR
0	We report the case of a patient who developed acute ENT1 hepatitis ENT1END with extensive hepatocellular necrosis, 7 months after the onset of administration of clotiazepam, a ENT2 thienodiazepine ENT2END derivative
1	This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross ENT1 hepatotoxicity ENT1END between ENT2 clotiazepam ENT2END and several benzodiazepines
0	This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross ENT1 hepatotoxicity ENT1END  between clotiazepam and several ENT2 benzodiazepines ENT2END
0	We report the case of a patient who developed acute hepatitis with ENT1 extensive hepatocellular necrosis  ENT1END  7 months after the onset of administration of clotiazepam, a ENT2 thienodiazepine ENT2END derivative
0	We report the case of a patient who developed acute hepatitis with ENT1 extensive hepatocellular necrosis ENT1END , 7 months after the onset of administration of ENT2 clotiazepam ENT2END , a thienodiazepine derivative
0	We report the case of a patient who developed acute hepatitis with ENT1 extensive hepatocellular necrosis ENT1END , 7 months after the onset of administration of clotiazepam, a thienodiazepine derivative. Clotiazepam withdrawal was followed by prompt recovery. The administration of several ENT2 benzodiazepines ENT2END , chemically related to clotiazepam, did not interfere with recovery and did not induce any relapse of hepatitis
0	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced ENT1 toxicity ENT1END in the rat model. ENT2 Gentamicin ENT2END at toxic doses, however, increased CSA nephrotoxicity
0	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), ENT1 amphothericin B  ENT1END and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced ENT2 toxicity ENT2END in the rat model
0	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the ENT1 CSA  ENT1END induced ENT2 toxicity ENT2END in the rat model
0	The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential, such as gentamicin (at therapeutic doses), amphothericin B and ENT1 ketoconazole  ENT1END  which are frequently used in immunosuppressed patients, did not aggravate the CSA induced ENT2 toxicity ENT2END in the rat model
0	The combined administration of CSA and various chemotherapeutic drugs with a ENT1 nephrotoxic ENT1END potential, such as ENT2 gentamicin ENT2END (at therapeutic doses), amphothericin B and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model
0	The combined administration of CSA and various chemotherapeutic drugs with a ENT1 nephrotoxic  ENT1END  potential, such as gentamicin (at therapeutic doses), ENT2 amphothericin B ENT2END and ketoconazole, which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model
1	Gentamicin at toxic doses, however, increased ENT1 CSA ENT1END ENT2 nephrotoxicity ENT2END
0	The combined administration of CSA and various chemotherapeutic drugs with a ENT1 nephrotoxic  ENT1END  potential, such as gentamicin (at therapeutic doses), amphothericin B and ENT2 ketoconazole ENT2END , which are frequently used in immunosuppressed patients, did not aggravate the CSA induced toxicity in the rat model
0	The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ENT1 ND-NMBA ENT1END  and muscle (most likely due to corticosteroids). ENT2 Hepatic dysfunction ENT2END and acidosis are contributing risk factors
0	The serum ENT1 vecuronium  ENT1END level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments. The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids). ENT2 Hepatic dysfunction ENT2END and acidosis are contributing risk factors
0	The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to ENT1 corticosteroids  ENT1END . ENT2 Hepatic dysfunction ENT2END and acidosis are contributing risk factors
0	The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ENT1 ND-NMBA ENT1END ) and muscle (most likely due to corticosteroids). Hepatic dysfunction and ENT2 acidosis ENT2END are contributing risk factors
0	Renal function was normal but hepatic function was impaired in all patients, and all had ENT1 acidosis  ENT1END  Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations. Repetitive stimulation at 2 Hz showed a decremental response in 2 patients. The serum ENT2 vecuronium ENT2END level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL
0	The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to ENT1 corticosteroids  ENT1END ). Hepatic dysfunction and ENT2 acidosis ENT2END are contributing risk factors
1	We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged ENT1 weakness ENT1END following the discontinuation of ENT2 ND-NMBAs ENT2END
0	The serum ENT1 vecuronium ENT1END  level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments. The ENT2 weakness ENT2END in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids)
0	We report 3 patients (age 37-52 years) with acute respiratory insufficiency who developed prolonged ENT1 weakness ENT1END  following the discontinuation of ND-NMBAs. Two patients also received intravenous ENT2 corticosteroids ENT2END
0	We report 3 patients (age 37-52 years) with acute ENT1 respiratory insufficiency  ENT1END who developed prolonged weakness following the discontinuation of ENT2 ND-NMBAs ENT2END
0	We report 3 patients (age 37-52 years) with acute ENT1 respiratory insufficiency  ENT1END  who developed prolonged weakness following the discontinuation of ND-NMBAs. Two patients also received intravenous corticosteroids. Renal function was normal but hepatic function was impaired in all patients, and all had acidosis. Electrophysiologic studies revealed low amplitude compound motor action potentials, normal sensory studies, and fibrillations. Repetitive stimulation at 2 Hz showed a decremental response in 2 patients. The serum ENT2 vecuronium ENT2END level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL
0	We report 3 patients (age 37-52 years) with acute ENT1 respiratory insufficiency  ENT1END  who developed prolonged weakness following the discontinuation of ND-NMBAs. Two patients also received intravenous ENT2 corticosteroids ENT2END
0	A muscle biopsy in this patient showed ENT1 loss of thick, myosin filaments  ENT1END  The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ENT2 ND-NMBA ENT2END ) and muscle (most likely due to corticosteroids)
0	The serum ENT1 vecuronium  ENT1END  level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed ENT2 loss of thick, myosin filaments ENT2END
1	A muscle biopsy in this patient showed ENT1 loss of thick, myosin filaments  ENT1END . The weakness in these patients is due to pathology at both the neuromuscular junction (most likely due to ND-NMBA) and muscle (most likely due to ENT2 corticosteroids ENT2END )
1	The weakness in these patients is due to ENT1 pathology at both the neuromuscular junction  ENT1END (most likely due to ENT2 ND-NMBA ENT2END ) and muscle (most likely due to corticosteroids)
0	The serum ENT1 vecuronium  ENT1END  level measured in 1 patient 14 days after the drug had been discontinued was 172 ng/mL. A muscle biopsy in this patient showed loss of thick, myosin filaments. The weakness in these patients is due to ENT2 pathology at both the neuromuscular junction ENT2END (most likely due to ND-NMBA) and muscle (most likely due to corticosteroids)
0	The weakness in these patients is due to ENT1 pathology at both the neuromuscular junction  ENT1END  (most likely due to ND-NMBA) and muscle (most likely due to ENT2 corticosteroids ENT2END )
0	Prolonged ENT1 paralysis  ENT1END  due to ENT2 nondepolarizing neuromuscular blocking agents ENT2END and corticosteroids
0	Prolonged ENT1 paralysis  ENT1END  due to nondepolarizing neuromuscular blocking agents and ENT2 corticosteroids ENT2END
0	We report a case of combined levomepromazine-fluvoxamine treatment-induced ENT1 seizures ENT1END  It seems that combined treatment of fluvoxamine with ENT2 phenothiazines ENT2END may possess proconvulsive activity
1	We report a case of combined levomepromazine- ENT1 fluvoxamine  ENT1END treatment-induced ENT2 seizures ENT2END
1	ENT1 Seizures  ENT1END  induced by combined ENT2 levomepromazine ENT2END -fluvoxamine treatment
0	ENT1 Papillomas ENT1END of the transitional epithelium of the bladder developed in all ENT2 paracetamol ENT2END -treated groups, and three rats bore bladder carcinomas
1	Induction by ENT1 paracetamol  ENT1END  of ENT2 bladder and liver tumours ENT2END in the rat
0	A low yield of ENT1 tumours ENT1END at various other sites also arose following ENT2 paracetamol ENT2END feeding
1	Additionally, 20 to 25% of ENT1 paracetamol ENT1END treated rats developed ENT2 hyperplasia ENT2END of the bladder epithelium, which was not coincident with the presence of bladder calculi
0	Additionally, 20 to 25% of paracetamol-treated rats developed hyperplasia of the bladder epithelium, which was not coincident with the presence of ENT1 bladder calculi  ENT1END  A low yield of tumours at various other sites also arose following ENT2 paracetamol ENT2END feeding
1	Induction by ENT1 paracetamol  ENT1END  of ENT2 bladder and liver tumours ENT2END in the rat
1	However, regardless of the duration of recovery (and irrespective of either lesion volume, amphetamine dose, or post-lesion motor exercise), ENT1 amphetamine ENT1END induced ENT2 rotation ENT2END tended to become gradually more ipsilateral as the observation session progressed, and all rats circled ipsilaterally to the lesion in response to further amphetamine injections
0	Following unilateral ENT1 6-OHDA ENT1END induced SN lesion, a transient period of ENT2 contralateral rotation ENT2END has been reported to precede the predominant ipsilateral circling
0	A calcineurin inhibitor combined with ENT1 methotrexate ENT1END is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either ENT2 myelodysplastic syndrome ENT2END (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	We report on a combination of everolimus and ENT1 tacrolimus  ENT1END in 24 patients (median age, 62 years) with either ENT2 myelodysplastic syndrome ENT2END (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	Everolimus, a derivative of ENT1 sirolimus  ENT1END  seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either ENT2 myelodysplastic syndrome ENT2END (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	We report on a combination of ENT1 everolimus  ENT1END and tacrolimus in 24 patients (median age, 62 years) with either ENT2 myelodysplastic syndrome ENT2END (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of ENT1 sinusoidal obstruction syndrome  ENT1END  and microangiopathy: results of the EVTAC trial.A calcineurin inhibitor combined with ENT2 methotrexate ENT2END is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
1	Graft-versus-host disease prophylaxis with everolimus and ENT1 tacrolimus  ENT1END  is associated with a high incidence of ENT2 sinusoidal obstruction syndrome ENT2END and microangiopathy: results of the EVTAC trial
0	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of ENT1 sinusoidal obstruction syndrome  ENT1END  and microangiopathy: results of the EVTAC trial.A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of ENT2 sirolimus ENT2END , seems to mediate antileukemia effects
1	Graft-versus-host disease prophylaxis with ENT1 everolimus  ENT1END  and tacrolimus is associated with a high incidence of ENT2 sinusoidal obstruction syndrome ENT2END and microangiopathy: results of the EVTAC trial
0	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and ENT1 microangiopathy  ENT1END : results of the EVTAC trial.A calcineurin inhibitor combined with ENT2 methotrexate ENT2END is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
1	Graft-versus-host disease prophylaxis with everolimus and ENT1 tacrolimus  ENT1END  is associated with a high incidence of sinusoidal obstruction syndrome and ENT2 microangiopathy ENT2END : results of the EVTAC trial
0	Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and ENT1 microangiopathy  ENT1END : results of the EVTAC trial.A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of ENT2 sirolimus ENT2END , seems to mediate antileukemia effects
1	Graft-versus-host disease prophylaxis with ENT1 everolimus  ENT1END  and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and ENT2 microangiopathy ENT2END : results of the EVTAC trial
0	A calcineurin inhibitor combined with ENT1 methotrexate ENT1END  is the standard prophylaxis for ENT2 graft-versus-host disease ENT2END (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT)
0	ENT1 Graft-versus-host disease  ENT1END  prophylaxis with everolimus and ENT2 tacrolimus ENT2END is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial
0	A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease ( ENT1 GVHD  ENT1END  after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of ENT2 sirolimus ENT2END , seems to mediate antileukemia effects
0	ENT1 Graft-versus-host disease  ENT1END  prophylaxis with ENT2 everolimus ENT2END and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial
0	A calcineurin inhibitor combined with ENT1 methotrexate ENT1END  is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV ENT2 mucositis ENT2END
0	We report on a combination of everolimus and ENT1 tacrolimus  ENT1END  in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV ENT2 mucositis ENT2END
0	Everolimus, a derivative of ENT1 sirolimus  ENT1END , seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV ENT2 mucositis ENT2END
0	We report on a combination of ENT1 everolimus  ENT1END  and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV ENT2 mucositis ENT2END
0	A calcineurin inhibitor combined with ENT1 methotrexate ENT1END  is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or ENT2 acute myeloid leukemia ENT2END (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	We report on a combination of everolimus and ENT1 tacrolimus  ENT1END  in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or ENT2 acute myeloid leukemia ENT2END (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	Everolimus, a derivative of ENT1 sirolimus  ENT1END , seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or ENT2 acute myeloid leukemia ENT2END (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	We report on a combination of ENT1 everolimus  ENT1END  and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or ENT2 acute myeloid leukemia ENT2END (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors
0	A calcineurin inhibitor combined with ENT1 methotrexate ENT1END  is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD. Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of ENT2 acute renal failure ENT2END
1	We report on a combination of everolimus and ENT1 tacrolimus  ENT1END  in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD. Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of ENT2 acute renal failure ENT2END
0	Everolimus, a derivative of ENT1 sirolimus  ENT1END , seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD. Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of ENT2 acute renal failure ENT2END
1	We report on a combination of ENT1 everolimus  ENT1END  and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD. Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of ENT2 acute renal failure ENT2END
0	The results indicate that, in this model, a subpopulation of GAD mRNA-containing neurons within the dentate gyrus is selectively vulnerable to ENT1 seizure ENT1END induced damage. Such differential vulnerability appears to be another indication of the heterogeneity of ENT2 GABA ENT2END neurons
0	Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced ENT1 seizures ENT1END  In situ hybridization histochemistry, using a ENT2 digoxigenin ENT2END -labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals
0	Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced ENT1 seizures ENT1END . In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals. Additional neuronanatomical studies, including ENT2 cresyl violet ENT2END staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels
1	Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following ENT1 pilocarpine  ENT1END -induced ENT2 seizures ENT2END
0	Loss of glutamate decarboxylase mRNA-containing neurons in the rat dentate gyrus following pilocarpine-induced ENT1 seizures ENT1END .In situ hybridization methods were used to determine if ENT2 glutamic acid ENT2END decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures
0	Additional neuronanatomical studies, including cresyl violet staining, neuronal degeneration methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to ENT1 neuronal loss  ENT1END rather than to a decrease in GAD mRNA levels. The loss of GAD mRNA-containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer. Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA-containing neurons in the hilus of both groups of experimental animals. No significant differences were found in the molecular layer or the granule cell layer, which included labeled neurons along the lower margin of the granule cell layer. The results indicate that, in this model, a subpopulation of GAD mRNA-containing neurons within the dentate gyrus is selectively vulnerable to seizure-induced damage. Such differential vulnerability appears to be another indication of the heterogeneity of ENT2 GABA ENT2END neurons
0	In situ hybridization histochemistry, using a ENT1 digoxigenin ENT1END -labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals. Additional neuronanatomical studies, including cresyl violet staining, ENT2 neuronal degeneration ENT2END methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels
0	Additional neuronanatomical studies, including ENT1 cresyl violet  ENT1END  staining, ENT2 neuronal degeneration ENT2END methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels
1	In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the ENT1 pilocarpine  ENT1END treated rats as compared to controls at all time intervals. Additional neuronanatomical studies, including cresyl violet staining, ENT2 neuronal degeneration ENT2END methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels
0	In situ hybridization methods were used to determine if ENT1 glutamic acid  ENT1END  decarboxylase (GAD) mRNA-containing neurons within the hilus of the dentate gyrus are vulnerable to seizure-induced damage in a model of chronic seizures. Sprague-Dawley rats were injected intraperitoneally with pilocarpine, and the hippocampal formation was studied histologically at 1, 2, 4, and 8 week intervals after pilocarpine-induced seizures. In situ hybridization histochemistry, using a digoxigenin-labeled GAD cRNA probe, demonstrated a substantial decrease in the number of GAD mRNA-containing neurons in the hilus of the dentate gyrus in the pilocarpine-treated rats as compared to controls at all time intervals. Additional neuronanatomical studies, including cresyl violet staining, ENT2 neuronal degeneration ENT2END methods, and histochemical localization of glial fibrillary acidic protein, suggested that the decrease in the number of GAD mRNA-containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels
0	Levodopa is the most effective drug for the treatment of ENT1 Parkinson's disease ENT1END  However, the long-term use of this ENT2 dopamine ENT2END precursor is complicated by highly disabling fluctuations and dyskinesias
0	In recent years, evidence from animal models of ENT1 Parkinson's disease ENT1END has provided important information to understand the effect of specific receptor and post-receptor molecular mechanisms underlying the development of dyskinetic movements. Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic ENT2 glutamate ENT2END receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced dyskinesias
0	Levodopa-induced dyskinesias in patients with ENT1 Parkinson's disease  ENT1END : filling the bench-to-bedside gap. ENT2 Levodopa ENT2END is the most effective drug for the treatment of Parkinson's disease
0	However, the long-term use of this ENT1 dopamine ENT1END  precursor is complicated by highly disabling fluctuations and ENT2 dyskinesias ENT2END
0	Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms, dopamine receptor subtypes, ionotropic and metabotropic ENT1 glutamate ENT1END  receptors, and non-dopaminergic neurotransmitter systems in the pathophysiology of levodopa-induced ENT2 dyskinesias ENT2END
1	ENT1 Levodopa  ENT1END -induced ENT2 dyskinesias ENT2END in patients with Parkinson's disease: filling the bench-to-bedside gap
1	3%) withdrew from the present study due to a severe ENT1 dry mouth ENT1END  The SF-36 scores changed significantly in the domains of physical functioning, role function emotional, social function and mental heath. CONCLUSION: ENT2 Tolterodine ENT2END was well tolerated and its effects improved the quality of life in Thai women with OAB
0	OBJECTIVES: To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( ENT1 OAB ENT1END  after ENT2 tolterodine ENT2END treatment
1	ENT1 Ventricular fibrillation ENT1END  from diatrizoate with and without chelating agents.The toxicity of ENT2 Renografin 76% ENT2END was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs
1	Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains ENT1 calcium disodium edetate ENT1END and no sodium citrate. ENT2 Ventricular fibrillation ENT2END occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography
0	ENT1 Ventricular fibrillation ENT1END  occurred significantly more often with ENT2 Renografin ENT2END , suggesting that chelating agents contribute to toxicity in coronary angiography
0	ENT1 Ventricular fibrillation  ENT1END  from ENT2 diatrizoate ENT2END with and without chelating agents
1	Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no ENT1 sodium citrate ENT1END ENT2 Ventricular fibrillation ENT2END occurred significantly more often with Renografin, suggesting that chelating agents contribute to toxicity in coronary angiography
0	The ENT1 toxicity  ENT1END of ENT2 Renografin 76% ENT2END was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs
0	Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains ENT1 calcium disodium edetate ENT1END  and no sodium citrate. Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to ENT2 toxicity ENT2END in coronary angiography
0	Ventricular fibrillation occurred significantly more often with ENT1 Renografin  ENT1END , suggesting that chelating agents contribute to ENT2 toxicity ENT2END in coronary angiography
0	Ventricular fibrillation from ENT1 diatrizoate  ENT1END  with and without chelating agents.The ENT2 toxicity ENT2END of Renografin 76% was compared with that of Hypaque 76% by selective injection of each into the right coronary artery of dogs
0	Renografin contains the chelating agents sodium citrate and disodium edetate, while Hypaque contains calcium disodium edetate and no ENT1 sodium citrate  ENT1END . Ventricular fibrillation occurred significantly more often with Renografin, suggesting that chelating agents contribute to ENT2 toxicity ENT2END in coronary angiography
1	ENT1 D-penicillamine  ENT1END -induced ENT2 angiopathy ENT2END in rats
1	In the present paper the authors describe 2 female patients who developed ENT1 incontinence ENT1END secondary to the selective serotonin reuptake inhibitors ENT2 paroxetine ENT2END and sertraline, as well as a third who developed this side effect on venlafaxine
0	In the present paper the authors describe 2 female patients who developed ENT1 incontinence ENT1END  secondary to the selective ENT2 serotonin ENT2END reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine
1	ENT1 Serotonergic antidepressants  ENT1END  and ENT2 urinary incontinence ENT2END
1	In 2 of the 3 cases the patients were also taking ENT1 lithium carbonate ENT1END and beta-blockers, both of which could have contributed to the ENT2 incontinence ENT2END
1	This concerns 2 male patients who experienced ENT1 incontinence ENT1END while taking ENT2 venlafaxine ENT2END
1	In the present paper the authors describe 2 female patients who developed ENT1 incontinence ENT1END  secondary to the selective serotonin reuptake inhibitors paroxetine and ENT2 sertraline ENT2END , as well as a third who developed this side effect on venlafaxine
0	In addition to its use as a stabilizer/rigidifier of membranes, ENT1 cholesteryl hemisuccinate ENT1END  tris salt (CS) administration has also been shown to protect rats from the ENT2 hepatotoxic ENT2END effects of carbon tetrachloride (CCl4)
0	In addition to its use as a stabilizer/rigidifier of membranes, cholesteryl hemisuccinate, tris salt (CS) administration has also been shown to protect rats from the ENT1 hepatotoxic ENT1END  effects of carbon tetrachloride (CCl4). To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, ENT2 gamma-cholesteryloxybutyric acid ENT2END , tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity
1	), resulted in significant protection against the ENT1 hepatotoxic ENT1END effects of CCl4, CHCl3, ENT2 acetaminophen ENT2END and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration
1	), resulted in significant protection against the ENT1 hepatotoxic ENT1END  effects of CCl4, ENT2 CHCl3 ENT2END , acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration
0	), resulted in significant protection against the ENT1 hepatotoxic ENT1END  effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of ENT2 adriamycin ENT2END administration
1	), resulted in significant protection against the ENT1 hepatotoxic ENT1END  effects of ENT2 CCl4 ENT2END , CHCl3, acetaminophen and galactosamine and against the lethal (and presumably cardiotoxic) effect of adriamycin administration
1	The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate (in light of the protection observed against ENT1 galactosamine ENT1END ENT2 hepatotoxicity ENT2END )
0	In addition to its use as a stabilizer/rigidifier of membranes, ENT1 cholesteryl hemisuccinate ENT1END , tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4). To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced ENT2 toxicity ENT2END
0	To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, ENT1 gamma-cholesteryloxybutyric acid  ENT1END , tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced ENT2 toxicity ENT2END
0	To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against ENT1 acetaminophen  ENT1END , adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced ENT2 toxicity ENT2END
0	To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, ENT1 chloroform  ENT1END  and galactosamine-induced ENT2 toxicity ENT2END
0	To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, ENT1 adriamycin  ENT1END , carbon tetrachloride-, chloroform- and galactosamine-induced ENT2 toxicity ENT2END
0	To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, ENT1 carbon tetrachloride  ENT1END , chloroform- and galactosamine-induced ENT2 toxicity ENT2END
0	To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and ENT1 galactosamine  ENT1END induced ENT2 toxicity ENT2END
0	In addition to its use as a stabilizer/rigidifier of membranes, ENT1 cholesteryl hemisuccinate ENT1END , tris salt (CS) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride (CCl4). To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, gamma-cholesteryloxybutyric acid, tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity. The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical. A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably ENT2 cardiotoxic ENT2END ) effect of adriamycin administration
0	To further our understanding of the mechanism of CS cytoprotection, we examined in rats and mice the protective abilities of CS and the non-hydrolyzable ether form of CS, ENT1 gamma-cholesteryloxybutyric acid  ENT1END , tris salt (CSE) against acetaminophen-, adriamycin-, carbon tetrachloride-, chloroform- and galactosamine-induced toxicity. The results of these studies demonstrated that CS-mediated protection is not selective for a particular species, organ system or toxic chemical. A 24-h pretreatment of both rats and mice with a single dose of CS (100mg/kg, i.p.), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably ENT2 cardiotoxic ENT2END ) effect of adriamycin administration
0	), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, ENT1 acetaminophen  ENT1END  and galactosamine and against the lethal (and presumably ENT2 cardiotoxic ENT2END ) effect of adriamycin administration
0	), resulted in significant protection against the hepatotoxic effects of CCl4, ENT1 CHCl3  ENT1END , acetaminophen and galactosamine and against the lethal (and presumably ENT2 cardiotoxic ENT2END ) effect of adriamycin administration
1	), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and galactosamine and against the lethal (and presumably ENT1 cardiotoxic  ENT1END ) effect of ENT2 adriamycin ENT2END administration
0	), resulted in significant protection against the hepatotoxic effects of ENT1 CCl4  ENT1END , CHCl3, acetaminophen and galactosamine and against the lethal (and presumably ENT2 cardiotoxic ENT2END ) effect of adriamycin administration
0	), resulted in significant protection against the hepatotoxic effects of CCl4, CHCl3, acetaminophen and ENT1 galactosamine  ENT1END and against the lethal (and presumably ENT2 cardiotoxic ENT2END ) effect of adriamycin administration
1	ENT1 Hepatic veno-occlusive disease  ENT1END  caused by ENT2 6-thioguanine ENT2END
0	Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with ENT1 acute lymphocytic leukemia ENT1END after 10 months of maintenance therapy with ENT2 6-thioguanine ENT2END
0	Clinically reversible veno-occlusive disease of the liver developed in a 23-year-old man with acute lymphocytic leukemia after 10 months of maintenance therapy with ENT1 6-thioguanine ENT1END . Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement. Although this disease was clinically reversible, some subintimal ENT2 fibrosis ENT2END about the terminal hepatic veins persisted
1	) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, ENT1 MK-801 ENT1END and partially reversed spontaneous ENT2 hyperactivity ENT2END of NMDA Nr1(neo-/-) mice
0	) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous ENT1 hyperactivity ENT1END  of ENT2 NMDA ENT2END Nr1(neo-/-) mice
0	Importantly, both classical ( ENT1 haloperidol ENT1END  and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of ENT2 hyperactivity ENT2END
1	In contrast, SSR103800 failed to affect ENT1 hyperactivity ENT1END induced by ENT2 amphetamine ENT2END or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p
0	Importantly, both classical (haloperidol) and atypical (olanzapine, ENT1 clozapine  ENT1END and aripiprazole) antipsychotics were effective in all these models of ENT2 hyperactivity ENT2END
0	Importantly, both classical (haloperidol) and atypical ( ENT1 olanzapine  ENT1END  clozapine and aripiprazole) antipsychotics were effective in all these models of ENT2 hyperactivity ENT2END
0	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the ENT1 glycine ENT1END (a co-agonist for the NMDA receptor) levels in the synapse. This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of ENT2 hyperactivity ENT2END , involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))
0	In contrast, SSR103800 failed to affect ENT1 hyperactivity ENT1END  induced by amphetamine or naturally observed in ENT2 dopamine ENT2END transporter (DAT(-/-)) knockout mice (10-30 mg/kg p
0	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and ENT1 aripiprazole  ENT1END  antipsychotics were effective in all these models of ENT2 hyperactivity ENT2END
0	However, the observation that antagonists of the ENT1 glutamate  ENT1END N-methyl-D-aspartate (NMDA) receptor produce schizophrenic-like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor. As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor. Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse. This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of ENT2 hyperactivity ENT2END , involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))
0	) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, ENT1 MK-801 ENT1END  and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice. In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.). Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
0	) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of ENT1 NMDA  ENT1END  Nr1(neo-/-) mice. In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.). Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
1	Importantly, both classical ( ENT1 haloperidol  ENT1END ) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
0	In contrast, SSR103800 failed to affect hyperactivity induced by ENT1 amphetamine  ENT1END  or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.). Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
1	Importantly, both classical (haloperidol) and atypical (olanzapine, ENT1 clozapine  ENT1END  and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
1	Importantly, both classical (haloperidol) and atypical ( ENT1 olanzapine  ENT1END , clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
0	Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the ENT1 glycine  ENT1END  (a co-agonist for the NMDA receptor) levels in the synapse. This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-)). Results showed that SSR103800 (10-30 mg/kg p.o.) blocked hyperactivity induced by the non-competitive NMDA receptor antagonist, MK-801 and partially reversed spontaneous hyperactivity of NMDA Nr1(neo-/-) mice. In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.). Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
0	In contrast, SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in ENT1 dopamine  ENT1END  transporter (DAT(-/-)) knockout mice (10-30 mg/kg p.o.). Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and aripiprazole) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
1	Importantly, both classical (haloperidol) and atypical (olanzapine, clozapine and ENT1 aripiprazole  ENT1END ) antipsychotics were effective in all these models of hyperactivity. However, unlike these latter, SSR103800 did not produce ENT2 catalepsy ENT2END (retention on the bar test) up to 30 mg/kg p
0	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce ENT1 schizophrenic ENT1END like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor. As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor. Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse. This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, amphetamine and ENT2 MK-801 ENT2END ) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))
0	However, the observation that antagonists of the glutamate N-methyl-D-aspartate ( ENT1 NMDA  ENT1END  receptor produce ENT2 schizophrenic ENT2END -like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor
0	However, the observation that antagonists of the glutamate N-methyl-D-aspartate (NMDA) receptor produce ENT1 schizophrenic ENT1END -like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor. As a result, there is a growing interest in the development of pharmacological agents with potential antipsychotic properties that enhance the activity of the glutamatergic system via a modulation of the NMDA receptor. Among them are glycine transporter-1 (GlyT1) inhibitors such as SSR103800, which indirectly enhance NMDA receptor function by increasing the glycine (a co-agonist for the NMDA receptor) levels in the synapse. This study aimed at investigating the potential antipsychotic-like properties of SSR103800, with a particular focus on models of hyperactivity, involving either drug challenge (ie, ENT2 amphetamine ENT2END and MK-801) or transgenic mice (ie, NMDA Nr1(neo-/-) and DAT(-/-))
0	The ENT1 glycine  ENT1END  transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. ENT2 Schizophrenia ENT2END has been initially associated with dysfunction in dopamine neurotransmission
0	ENT1 Schizophrenia ENT1END  has been initially associated with dysfunction in ENT2 dopamine ENT2END neurotransmission
0	However, the observation that antagonists of the ENT1 glutamate  ENT1END  N-methyl-D-aspartate (NMDA) receptor produce ENT2 schizophrenic ENT2END -like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor
0	IT ENT1 MK-801 ENT1END significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group. These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation. We suggest that opioids may be neurotoxic in the setting of ENT2 spinal cord ischemia ENT2END via NMDA receptor activation
0	The activation of spinal N-methyl-D-aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial ENT1 morphine  ENT1END  after a noninjurious interval of ENT2 spinal cord ischemia ENT2END
0	We suggest that opioids may be neurotoxic in the setting of ENT1 spinal cord ischemia ENT1END  via ENT2 NMDA ENT2END receptor activation
0	These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF ENT1 glutamate  ENT1END  which is involved in NMDA receptor activation. We suggest that opioids may be neurotoxic in the setting of ENT2 spinal cord ischemia ENT2END via NMDA receptor activation
0	IT ENT1 MK-801 ENT1END  significantly reduced the number of dark-stained alpha-motoneurons after morphine-induced spastic paraparesis compared with the saline group. These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation. We suggest that opioids may be ENT2 neurotoxic ENT2END in the setting of spinal cord ischemia via NMDA receptor activation
0	These data indicate that IT ENT1 morphine  ENT1END induces spastic paraparesis with a concomitant increase in CSF glutamate, which is involved in NMDA receptor activation. We suggest that opioids may be ENT2 neurotoxic ENT2END in the setting of spinal cord ischemia via NMDA receptor activation
0	We suggest that opioids may be ENT1 neurotoxic  ENT1END  in the setting of spinal cord ischemia via ENT2 NMDA ENT2END receptor activation
0	These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF ENT1 glutamate  ENT1END , which is involved in NMDA receptor activation. We suggest that opioids may be ENT2 neurotoxic ENT2END in the setting of spinal cord ischemia via NMDA receptor activation
0	Spinal cord ischemia was induced by ENT1 aortic occlusion ENT1END for 6 min with a balloon catheter. In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation. Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection). Second, we investigated the effect of IT ENT2 MK-801 ENT2END (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis
0	We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate (NMDA) receptors after neuraxial ENT1 morphine ENT1END following a noninjurious interval of ENT2 aortic occlusion ENT2END in rats
0	We investigated the relationship between the degeneration of spinal motor neurons and activation of N-methyl-d-aspartate ( ENT1 NMDA  ENT1END  receptors after neuraxial morphine following a noninjurious interval of ENT2 aortic occlusion ENT2END in rats
0	Spinal cord ischemia was induced by ENT1 aortic occlusion ENT1END  for 6 min with a balloon catheter. In a microdialysis study, 10 muL of saline (group C; n = 8) or 30 mug of morphine (group M; n = 8) was injected intrathecally (IT) 0.5 h after reflow, and 30 mug of morphine (group SM; n = 8) or 10 muL of saline (group SC; n = 8) was injected IT 0.5 h after sham operation. Microdialysis samples were collected preischemia, before IT injection, and at 2, 4, 8, 24, and 48 h of reperfusion (after IT injection). Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after morphine-induced spastic paraparesis. After IT morphine, the cerebrospinal fluid (CSF) ENT2 glutamate ENT2END concentration was increased in group M relative to both baseline and group C (P < 0
0	Second, we investigated the effect of IT ENT1 MK-801 ENT1END  (30 mug) on the histopathologic changes in the spinal cord after morphine-induced ENT2 spastic paraparesis ENT2END
1	Second, we investigated the effect of IT MK-801 (30 mug) on the histopathologic changes in the spinal cord after ENT1 morphine  ENT1END induced ENT2 spastic paraparesis ENT2END
0	These data indicate that IT morphine induces ENT1 spastic paraparesis ENT1END with a concomitant increase in CSF glutamate, which is involved in ENT2 NMDA ENT2END receptor activation
0	These data indicate that IT morphine induces ENT1 spastic paraparesis  ENT1END  with a concomitant increase in CSF ENT2 glutamate ENT2END , which is involved in NMDA receptor activation
1	The site of common side effects of ENT1 sumatriptan  ENT1END . ENT2 Atypical sensations ENT2END following the use of subcutaneous sumatriptan are common, but of uncertain origin
0	Atypical sensations following the use of subcutaneous ENT1 sumatriptan ENT1END are common, but of uncertain origin. They are almost always benign, but can be mistaken for a serious adverse event by the patient. Two patients are presented with tingling or burning sensations limited to areas of heat exposure or ENT2 sunburn ENT2END
0	ENT1 Doxorubicin  ENT1END is an anti- ENT2 tumor ENT2END agent that represses cardiac-specific gene expression and induces myocardial cell apoptosis
1	These findings demonstrate that overexpression of p300 protects cardiac myocytes from ENT1 doxorubicin ENT1END induced apoptosis and reduces the extent of acute ENT2 heart failure ENT2END in adult mice in vivo
0	twice-daily) of ENT1 tobramicyn ENT1END on steady-state serum concentrations and ENT2 toxicity ENT2END
0	Increased serum ENT1 creatinine ENT1END was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of ENT2 nephrotoxicity ENT2END
0	Increased serum creatinine was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of ENT1 nephrotoxicity ENT1END . In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function. CONCLUSION: This small study suggests that a once-daily dosing regimen of ENT2 tobramycin ENT2END is at least as effective as and is no more and possibly less toxic than the twice-daily regimen
0	Increased serum ENT1 creatinine ENT1END  was observed in 73% of patients in OD versus 57% of patients in TD, without evidence of nephrotoxicity. In TD group, three patients developed ENT2 decreased auditory function ENT2END , of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented decreased auditory function
1	In TD group, three patients developed decreased auditory function, of which one presented with an auditory loss of -30 dB, whereas in the OD group only one patient presented ENT1 decreased auditory function  ENT1END  CONCLUSION: This small study suggests that a once-daily dosing regimen of ENT2 tobramycin ENT2END is at least as effective as and is no more and possibly less toxic than the twice-daily regimen
1	A deficient L-arginine-nitric oxide system is implicated in cortisol-induced ENT1 hypertension ENT1END  We investigate whether abnormalities in L-arginine uptake contribute to this deficiency. Eight healthy men were recruited. ENT2 Hydrocortisone acetate ENT2END (50 mg) was given orally every 6 hours for 24 hours after a 5-day fixed-salt diet (150 mmol/d)
0	L-arginine transport in humans with cortisol-induced ENT1 hypertension  ENT1END .A deficient L-arginine- ENT2 nitric oxide ENT2END system is implicated in cortisol-induced hypertension
0	L-arginine transport in humans with ENT1 cortisol  ENT1END -induced ENT2 hypertension ENT2END
0	L-arginine transport in humans with cortisol-induced ENT1 hypertension ENT1END .A deficient ENT2 L-arginine ENT2END -nitric oxide system is implicated in cortisol-induced hypertension
1	The drug effect studied was the antagonism by metoprolol of ENT1 terbutaline ENT1END induced ENT2 hypokalemia ENT2END
0	The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the debrisoquine/ ENT1 sparteine  ENT1END type. The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs. We investigated if the latter also applies to the beta-2 adrenoceptor antagonism by metoprolol. The drug effect studied was the antagonism by metoprolol of terbutaline-induced ENT2 hypokalemia ENT2END
0	The metabolism of the cardioselective beta-blocker metoprolol is under genetic control of the ENT1 debrisoquine  ENT1END sparteine type. The two metabolic phenotypes, extensive (EM) and poor metabolizers (PM), show different stereoselective metabolism, resulting in apparently higher beta-1 adrenoceptor antagonistic potency of racemic metoprolol in EMs. We investigated if the latter also applies to the beta-2 adrenoceptor antagonism by metoprolol. The drug effect studied was the antagonism by metoprolol of terbutaline-induced ENT2 hypokalemia ENT2END
0	The drug effect studied was the antagonism by metoprolol of terbutaline-induced ENT1 hypokalemia ENT1END . By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy. Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o. Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2. Blood samples for the analysis of plasma ENT2 potassium ENT2END , terbutaline, metoprolol (racemic, R- and S-isomer), and alpha-hydroxymetoprolol concentrations were taken at regular time intervals, during 8 hr after metoprolol
0	The drug effect studied was the antagonism by metoprolol of terbutaline-induced ENT1 hypokalemia ENT1END . By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S-isomer, were quantitated in EMs and PMs in terms of IC50 values, representing metoprolol plasma concentrations resulting in half-maximum receptor occupancy. Six EMs received 0.5 mg of terbutaline s.c. on two different occasions: 1) 1 hr after administration of a placebo and 2) 1 hr after 150 mg of metoprolol p.o. Five PMs were studied according to the same protocol, except for a higher terbutaline dose (0.75 mg) on day 2. Blood samples for the analysis of plasma potassium, terbutaline, metoprolol (racemic, R- and S-isomer), and ENT2 alpha-hydroxymetoprolol ENT2END concentrations were taken at regular time intervals, during 8 hr after metoprolol
0	The drug effect studied was the antagonism by ENT1 metoprolol  ENT1END of terbutaline-induced ENT2 hypokalemia ENT2END
0	Improvement of levodopa-induced dyskinesia by ENT1 propranolol  ENT1END  in ENT2 Parkinson's disease ENT2END
0	This study suggests that administration of low doses of beta-blockers may improve ENT1 levodopa ENT1END induced ballistic and choreic dyskinesia in ENT2 PD ENT2END
0	Improvement of levodopa-induced ENT1 dyskinesia  ENT1END  by ENT2 propranolol ENT2END in Parkinson's disease
1	Improvement of ENT1 levodopa  ENT1END -induced ENT2 dyskinesia ENT2END by propranolol in Parkinson's disease
0	Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose ENT1 propranolol ENT1END as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian motor disability. Ballistic and choreic dyskinesia were markedly ameliorated, whereas ENT2 dystonia ENT2END was not
0	Ballistic and choreic dyskinesia were markedly ameliorated, whereas ENT1 dystonia  ENT1END  was not. This study suggests that administration of low doses of beta-blockers may improve ENT2 levodopa ENT2END -induced ballistic and choreic dyskinesia in PD
0	Seven patients suffering from Parkinson's disease (PD) with severely disabling dyskinesia received low-dose ENT1 propranolol ENT1END  as an adjunct to the currently used medical treatment. There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian ENT2 motor disability ENT2END
0	There was a significant 40% improvement in the dyskinesia score without increase of parkinsonian ENT1 motor disability  ENT1END . Ballistic and choreic dyskinesia were markedly ameliorated, whereas dystonia was not. This study suggests that administration of low doses of beta-blockers may improve ENT2 levodopa ENT2END -induced ballistic and choreic dyskinesia in PD
0	Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced ENT1 pain ENT1END sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain. Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization. The aim of this study was to assess the effects of ENT2 gabapentin ENT2END , a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states
0	Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced ENT1 pain ENT1END  sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain. Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization. The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states. Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and ENT2 capsaicin ENT2END -induced secondary hyperalgesia
0	Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding ENT1 tissue injury  ENT1END (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain. Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization. The aim of this study was to assess the effects of ENT2 gabapentin ENT2END , a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states
0	Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding ENT1 tissue injury  ENT1END  (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain. Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization. The aim of this study was to assess the effects of gabapentin, a drug effective in neuropathic pain patients, on brain processing of nociceptive information in normal and central sensitization states. Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and ENT2 capsaicin ENT2END -induced secondary hyperalgesia
0	Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin-induced ENT1 secondary hyperalgesia ENT1END  The dose of ENT2 gabapentin ENT2END was 1,800 mg per os, in a single administration
1	Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and ENT1 capsaicin  ENT1END -induced ENT2 secondary hyperalgesia ENT2END
0	The aim of this study was to assess the effects of ENT1 gabapentin ENT1END , a drug effective in ENT2 neuropathic pain ENT2END patients, on brain processing of nociceptive information in normal and central sensitization states
0	The aim of this study was to assess the effects of gabapentin, a drug effective in ENT1 neuropathic pain  ENT1END  patients, on brain processing of nociceptive information in normal and central sensitization states. Using functional magnetic resonance imaging (fMRI) in normal volunteers, we studied the gabapentin-induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and ENT2 capsaicin ENT2END -induced secondary hyperalgesia
1	There was ENT1 pain ENT1END on i.m. injection of ENT2 flunitrazepam ENT2END significantly more often than with isotonic saline
1	ENT1 Dizziness  ENT1END was less marked than sedation, but increased with the dose. There was pain on i.m. injection of ENT2 flunitrazepam ENT2END significantly more often than with isotonic saline
0	We interpret this as episodes of ENT1 cardiac arrest ENT1END caused by metoclopramide. The rapid injection via the central venous route and the concomitant tapering of ENT2 dopamine ENT2END infusion might have contributed in precipitating the adverse drug reaction
1	We interpret this as episodes of ENT1 cardiac arrest ENT1END  caused by ENT2 metoclopramide ENT2END
0	The ENT1 asystole ENT1END lasted 15-30 s on four occasions, on one occasion it lasted 2 min. The patient received ENT2 atropine ENT2END 0
0	Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ENT1 ischaemic stroke ENT1END has been reported after ENT2 methylphenidate ENT2END intake in children
0	Methylphenidate is structurally and functionally similar to ENT1 amphetamine  ENT1END  Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ENT2 ischaemic stroke ENT2END has been reported after methylphenidate intake in children
0	We report the case of a 63-year-old female who was treated with ENT1 methylphenidate ENT1END due to ENT2 hyperactivity ENT2END and suffered from multiple ischaemic strokes
0	Methylphenidate is structurally and functionally similar to ENT1 amphetamine  ENT1END . Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children. We report the case of a 63-year-old female who was treated with methylphenidate due to ENT2 hyperactivity ENT2END and suffered from multiple ischaemic strokes
1	ENT1 Cerebral vasculitis  ENT1END  following oral ENT2 methylphenidate ENT2END intake in an adult: a case report
0	Methylphenidate is structurally and functionally similar to ENT1 amphetamine ENT1END . ENT2 Cerebral vasculitis ENT2END associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children
0	Cerebral vasculitis associated with ENT1 amphetamine abuse  ENT1END is well documented, and in rare cases ischaemic stroke has been reported after ENT2 methylphenidate ENT2END intake in children
0	Methylphenidate is structurally and functionally similar to ENT1 amphetamine  ENT1END . Cerebral vasculitis associated with ENT2 amphetamine abuse ENT2END is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children
0	We conclude that ENT1 methylphenidate ENT1END mediated ENT2 vasculitis ENT2END should be considered in patients with neurological symptoms and a history of methylphenidate therapy
0	Methylphenidate is structurally and functionally similar to ENT1 amphetamine  ENT1END . Cerebral vasculitis associated with amphetamine abuse is well documented, and in rare cases ischaemic stroke has been reported after methylphenidate intake in children. We report the case of a 63-year-old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes. We consider drug-induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work-up. We conclude that methylphenidate mediated ENT2 vasculitis ENT2END should be considered in patients with neurological symptoms and a history of methylphenidate therapy
0	Possible contributing factors may have been concomitant ENT1 antidepressant ENT1END use and unaccustomed physical activity. CONCLUSIONS: Myocarditis is an increasingly recognized complication associated with the use of clozapine. It can be fatal if not recognized and treated early. Considering that clozapine remains the gold standard in treatment of resistant ENT2 psychosis ENT2END , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients
0	Considering that ENT1 clozapine  ENT1END remains the gold standard in treatment of resistant ENT2 psychosis ENT2END , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients
0	RESULTS: A 20-year-old male with ENT1 schizophrenia  ENT1END developed a sudden onset of myocarditis after commencement of clozapine. The patient recovered with intensive medical support. The symptoms occurred around 2 weeks after starting clozapine in an inpatient setting. Possible contributing factors may have been concomitant ENT2 antidepressant ENT2END use and unaccustomed physical activity
0	There is an urgent need to raise awareness about this potentially fatal complication of ENT1 clozapine  ENT1END use. RESULTS: A 20-year-old male with ENT2 schizophrenia ENT2END developed a sudden onset of myocarditis after commencement of clozapine
1	Possible contributing factors may have been concomitant ENT1 antidepressant ENT1END  use and unaccustomed physical activity. CONCLUSIONS: ENT2 Myocarditis ENT2END is an increasingly recognized complication associated with the use of clozapine
1	Acute ENT1 myocarditis  ENT1END  associated with ENT2 clozapine ENT2END
1	Three patients with ischaemic heart disease developed profound ENT1 cardiac failure ENT1END  hypotension and bradycardia during combined therapy with ENT2 verapamil ENT2END and beta-adrenergic blocking drugs
1	Three patients with ischaemic heart disease developed profound ENT1 cardiac failure ENT1END , hypotension and bradycardia during combined therapy with verapamil and ENT2 beta-adrenergic blocking drugs ENT2END
1	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and ENT1 bradycardia  ENT1END during combined therapy with ENT2 verapamil ENT2END and beta-adrenergic blocking drugs
1	Three patients with ischaemic heart disease developed profound cardiac failure, hypotension and ENT1 bradycardia  ENT1END  during combined therapy with verapamil and ENT2 beta-adrenergic blocking drugs ENT2END
1	Three patients with ischaemic heart disease developed profound cardiac failure, ENT1 hypotension  ENT1END and bradycardia during combined therapy with ENT2 verapamil ENT2END and beta-adrenergic blocking drugs
1	Three patients with ischaemic heart disease developed profound cardiac failure, ENT1 hypotension  ENT1END  and bradycardia during combined therapy with verapamil and ENT2 beta-adrenergic blocking drugs ENT2END
0	Adverse interaction between beta-adrenergic blocking drugs and ENT1 verapamil ENT1END --report of three cases.Three patients with ENT2 ischaemic heart disease ENT2END developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs
0	Adverse interaction between ENT1 beta-adrenergic blocking drugs  ENT1END  and verapamil--report of three cases.Three patients with ENT2 ischaemic heart disease ENT2END developed profound cardiac failure, hypotension and bradycardia during combined therapy with verapamil and beta-adrenergic blocking drugs
0	) or ENT1 rauwolscine ENT1END (3 mg kg-1 i.v.). ENT2 Orthostatic hypotension ENT2END was determined by the average decrease (%) in mean arterial pressure (MAP femoral) over the 60-s tilt period
0	Head-up tilts in these rats did not produce ENT1 orthostatic hypotension ENT1END when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.). Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats. 4. The pressor responses and bradycardia to the alpha 1-agonist ENT2 cirazoline ENT2END (0
0	Head-up tilts in these rats did not produce ENT1 orthostatic hypotension ENT1END  when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.). Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats. 4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist Abbott-53693 (1 and 3 micrograms kg-1 i.v.), and ENT2 noradrenaline ENT2END (0
1	However, the head-up tilt induced ENT1 orthostatic hypotension ENT1END in the SHR treated with ENT2 prazosin ENT2END (-16% MAP, n = 6), but not in the SHR treated with rauwolscine (less than +2% MAP, n = 6)
0	Head-up tilts in these rats did not produce ENT1 orthostatic hypotension ENT1END  when performed either prior to or after acute dosing of prazosin (0.1 mg kg-1 i.p.). Conversely, administration of rauwolscine (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats. 4. The pressor responses and bradycardia to the alpha 1-agonist cirazoline (0.6 and 2 micrograms kg-1 i.v.), the alpha 2-agonist ENT2 Abbott-53693 ENT2END (1 and 3 micrograms kg-1 i
0	Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2-adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously ENT1 hypertensive  ENT1END rats (SHR). 2. Conscious SHR (male 300-350 g) were subjected to 90 degrees head-up tilts for 60 s following acute administration of prazosin (0.1 mg kg-1 i.p.) or ENT2 rauwolscine ENT2END (3 mg kg-1 i
0	Orthostatic hypotension occurs following alpha 2-adrenoceptor blockade in chronic ENT1 prazosin  ENT1END -pretreated conscious spontaneously ENT2 hypertensive ENT2END rats
0	Conversely, administration of ENT1 rauwolscine ENT1END (3 mg kg-1 i.v.) in chronic prazosin treated SHR decreased the basal MAP by 12-31% (n = 4), and subsequent tilts induced further drops of MAP by 19-23% in these rats. 4. The pressor responses and ENT2 bradycardia ENT2END to the alpha 1-agonist cirazoline (0
1	Both the pressor and ENT1 bradycardia ENT1END effects of ENT2 cirazoline ENT2END were abolished in chronic prazosin treated SHR (n = 4) as compared to the untreated SHR (n = 4)
1	Furthermore, the ENT1 bradycardia ENT1END that accompanied the ENT2 noradrenaline ENT2END -induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47-71% reduction of the pressor effect in chronic alpha 1-receptor blocked SHR
0	On the other hand, the pressor effects of Abbott-53693 were similar in both groups of SHR, but the accompanying ENT1 bradycardia ENT1END was greater in SHR with chronic ENT2 prazosin ENT2END treatment than without such treatment
1	On the other hand, the pressor effects of ENT1 Abbott-53693  ENT1END were similar in both groups of SHR, but the accompanying ENT2 bradycardia ENT2END was greater in SHR with chronic prazosin treatment than without such treatment
0	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or ENT1 organic psychotic ENT1END patients using concomitantly haloperidol, ENT2 chlorpromazine ENT2END or clozapine
0	ENT1 Carbamazepine  ENT1END was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or ENT2 organic psychotic ENT2END patients using concomitantly haloperidol, chlorpromazine or clozapine
0	Carbamazepine was switched to its 10-keto analogue ENT1 oxcarbazepine  ENT1END among six difficult-to-treat schizophrenic or ENT2 organic psychotic ENT2END patients using concomitantly haloperidol, chlorpromazine or clozapine
0	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or ENT1 organic psychotic ENT1END  patients using concomitantly haloperidol, chlorpromazine or ENT2 clozapine ENT2END
0	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or ENT1 organic psychotic ENT1END  patients using concomitantly ENT2 haloperidol ENT2END , chlorpromazine or clozapine
1	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, ENT1 chlorpromazine ENT1END  or clozapine. This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of ENT2 extrapyramidal symptoms ENT2END
0	This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of ENT1 extrapyramidal symptoms ENT1END . None of the patients showed any clinical deteriotation during the following 3-6 months. The results of this case report support the idea that in contrast with ENT2 carbamazepine ENT2END oxcarbazepine does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs
1	This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of ENT1 extrapyramidal symptoms ENT1END . None of the patients showed any clinical deteriotation during the following 3-6 months. The results of this case report support the idea that in contrast with carbamazepine ENT2 oxcarbazepine ENT2END does not induce the hepatic microsomal enzyme systems regulating the inactivation of antipsychotic drugs
1	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly haloperidol, chlorpromazine or ENT1 clozapine  ENT1END . This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of ENT2 extrapyramidal symptoms ENT2END
1	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat schizophrenic or organic psychotic patients using concomitantly ENT1 haloperidol  ENT1END , chlorpromazine or clozapine. This change resulted within 2-4 weeks in the 50-200% increase in the plasma levels of these neuroleptics and the appearance of ENT2 extrapyramidal symptoms ENT2END
0	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat ENT1 schizophrenic  ENT1END or organic psychotic patients using concomitantly haloperidol, ENT2 chlorpromazine ENT2END or clozapine
0	ENT1 Carbamazepine  ENT1END  was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat ENT2 schizophrenic ENT2END or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine
0	Carbamazepine was switched to its 10-keto analogue ENT1 oxcarbazepine  ENT1END  among six difficult-to-treat ENT2 schizophrenic ENT2END or organic psychotic patients using concomitantly haloperidol, chlorpromazine or clozapine
0	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat ENT1 schizophrenic  ENT1END  or organic psychotic patients using concomitantly haloperidol, chlorpromazine or ENT2 clozapine ENT2END
0	Carbamazepine was switched to its 10-keto analogue oxcarbazepine among six difficult-to-treat ENT1 schizophrenic  ENT1END  or organic psychotic patients using concomitantly ENT2 haloperidol ENT2END , chlorpromazine or clozapine
1	A case of a ENT1 busulfan ENT1END induced ENT2 hemorrhage cystitis ENT2END is reported
0	A case of a busulfan-induced ENT1 hemorrhage cystitis ENT1END  is reported. Spontaneous resolution occurred following cessation of the drug. The similarity between the histologic appearances of busulfan cystitis and both radiation and ENT2 cyclophosphamide ENT2END -induced cystitis is discussed and the world literature reviewed
0	In view of the known tendency of ENT1 busulfan ENT1END to induce cellular atypia and ENT2 carcinoma ENT2END in other sites, periodic urinary cytology is suggested in patients on long-term therapy
0	The similarity between the histologic appearances of busulfan cystitis and both radiation and ENT1 cyclophosphamide  ENT1END -induced cystitis is discussed and the world literature reviewed. In view of the known tendency of busulfan to induce cellular atypia and ENT2 carcinoma ENT2END in other sites, periodic urinary cytology is suggested in patients on long-term therapy
1	The similarity between the histologic appearances of ENT1 busulfan ENT1END ENT2 cystitis ENT2END and both radiation and cyclophosphamide-induced cystitis is discussed and the world literature reviewed
0	The similarity between the histologic appearances of busulfan cystitis and both radiation and ENT1 cyclophosphamide ENT1END -induced ENT2 cystitis ENT2END is discussed and the world literature reviewed
0	ENT1 Drowsiness ENT1END was common on clonidine, but generally resolved by 6 to 8 weeks. CONCLUSIONS: Clonidine, used alone or with ENT2 methylphenidate ENT2END , appears safe and well tolerated in childhood ADHD
0	ENT1 Drowsiness ENT1END  was common on ENT2 clonidine ENT2END , but generally resolved by 6 to 8 weeks
0	OBJECTIVE: To examine the safety and tolerability of clonidine used alone or with ENT1 methylphenidate ENT1END in children with ENT2 attention-deficit/hyperactivity disorder ENT2END (ADHD)
0	ENT1 Clonidine  ENT1END  for ENT2 attention-deficit/hyperactivity disorder ENT2END : II
0	CONCLUSIONS: Clonidine, used alone or with ENT1 methylphenidate ENT1END , appears safe and well tolerated in childhood ADHD. Physicians prescribing clonidine should monitor for ENT2 bradycardia ENT2END and advise patients about the high likelihood of initial drowsiness
1	Physicians prescribing ENT1 clonidine  ENT1END should monitor for ENT2 bradycardia ENT2END and advise patients about the high likelihood of initial drowsiness
0	Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and ENT1 adrenaline ENT1END  The cardiac depressant actions of phenytoin and ENT2 hypothermia ENT2END can be additive
0	Following phenytoin administration, the patient developed acute severe bradycardia, refractory to ENT1 atropine  ENT1END and adrenaline. The cardiac depressant actions of phenytoin and ENT2 hypothermia ENT2END can be additive
0	The cardiac depressant actions of ENT1 phenytoin  ENT1END and ENT2 hypothermia ENT2END can be additive
0	Intravenous phenytoin was administered during the later part of the surgery for ENT1 seizure  ENT1END prophylaxis. Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and ENT2 adrenaline ENT2END
0	Intravenous phenytoin was administered during the later part of the surgery for ENT1 seizure  ENT1END  prophylaxis. Following phenytoin administration, the patient developed acute severe bradycardia, refractory to ENT2 atropine ENT2END and adrenaline
0	Intravenous phenytoin was administered during the later part of the surgery for ENT1 seizure ENT1END  prophylaxis. Following ENT2 phenytoin ENT2END administration, the patient developed acute severe bradycardia, refractory to atropine and adrenaline
0	Is phenytoin administration safe in a hypothermic child?A male neonate with a ENT1 Chiari malformation  ENT1END and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele. During anaesthesia and surgery, he inadvertently became moderately hypothermic. Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis. Following phenytoin administration, the patient developed acute severe bradycardia, refractory to atropine and ENT2 adrenaline ENT2END
0	Is phenytoin administration safe in a hypothermic child?A male neonate with a ENT1 Chiari malformation  ENT1END  and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele. During anaesthesia and surgery, he inadvertently became moderately hypothermic. Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis. Following phenytoin administration, the patient developed acute severe bradycardia, refractory to ENT2 atropine ENT2END and adrenaline
0	Is ENT1 phenytoin  ENT1END  administration safe in a hypothermic child?A male neonate with a ENT2 Chiari malformation ENT2END and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele
0	Following phenytoin administration, the patient developed acute severe ENT1 bradycardia  ENT1END  refractory to atropine and ENT2 adrenaline ENT2END
0	Following phenytoin administration, the patient developed acute severe ENT1 bradycardia  ENT1END , refractory to ENT2 atropine ENT2END and adrenaline
1	Following ENT1 phenytoin  ENT1END  administration, the patient developed acute severe ENT2 bradycardia ENT2END , refractory to atropine and adrenaline
0	Two prodrugs of potent and selective GluR5 ENT1 kainate  ENT1END  receptor antagonists actives in three animal models of ENT2 pain ENT2END
0	Their ester prodrugs 6 and 8 were orally active in three models of ENT1 pain ENT1END  reversal of formalin-induced paw licking, ENT2 carrageenan ENT2END -induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia
0	Their ester prodrugs 6 and 8 were orally active in three models of ENT1 pain ENT1END : reversal of ENT2 formalin ENT2END -induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia
0	Their ester prodrugs 6 and 8 were orally active in three models of ENT1 pain ENT1END : reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and ENT2 capsaicin ENT2END -induced mechanical hyperalgesia
0	Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other ENT1 glutamate  ENT1END receptors. Their ester prodrugs 6 and 8 were orally active in three models of ENT2 pain ENT2END : reversal of formalin-induced paw licking, carrageenan-induced thermal hyperalgesia, and capsaicin-induced mechanical hyperalgesia
0	Amino acids 5 and 7, two potent and selective competitive GluR5 ENT1 KA ENT1END receptor antagonists, exhibited high GluR5 receptor affinity over other glutamate receptors. Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced ENT2 thermal hyperalgesia ENT2END , and capsaicin-induced mechanical hyperalgesia
1	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, ENT1 carrageenan  ENT1END -induced ENT2 thermal hyperalgesia ENT2END , and capsaicin-induced mechanical hyperalgesia
0	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of ENT1 formalin  ENT1END -induced paw licking, carrageenan-induced ENT2 thermal hyperalgesia ENT2END , and capsaicin-induced mechanical hyperalgesia
1	Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced ENT1 thermal hyperalgesia  ENT1END , and ENT2 capsaicin ENT2END -induced mechanical hyperalgesia
0	Amino acids 5 and 7, two potent and selective competitive GluR5 KA receptor antagonists, exhibited high GluR5 receptor affinity over other ENT1 glutamate  ENT1END  receptors. Their ester prodrugs 6 and 8 were orally active in three models of pain: reversal of formalin-induced paw licking, carrageenan-induced ENT2 thermal hyperalgesia ENT2END , and capsaicin-induced mechanical hyperalgesia
0	once daily to rats for 1, 3, 6, 9 and 12 months revealed ENT1 neurological disorders  ENT1END indicating cerebellum damage (" ENT2 valproate ENT2END encephalopathy")
0	once daily to rats for 1, 3, 6, 9 and 12 months revealed ENT1 neurological disorders ENT1END  indicating cerebellum damage ("valproate encephalopathy"). The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment. They became more severe in the later months of the experiment, and were most severe after 12 months, located mainly in the molecular layer of the cerebellar cortex. Lesions of the capillary included necrosis of endothelial cells. Organelles of these cells, in particular the mitochondria (increased number and size, distinct degeneration of their matrix and cristae) and Golgi apparatus were altered. Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had ENT2 luminal ENT2END protrusions and swollen microvilli
0	once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating ENT1 cerebellum damage  ENT1END ( ENT2 valproate ENT2END encephalopathy")
0	once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating ENT1 cerebellum damage  ENT1END  ("valproate encephalopathy"). The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment. They became more severe in the later months of the experiment, and were most severe after 12 months, located mainly in the molecular layer of the cerebellar cortex. Lesions of the capillary included necrosis of endothelial cells. Organelles of these cells, in particular the mitochondria (increased number and size, distinct degeneration of their matrix and cristae) and Golgi apparatus were altered. Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had ENT2 luminal ENT2END protrusions and swollen microvilli
0	The possible influence of the hepatic damage, mainly ENT1 hyperammonemia ENT1END  upon the development of ENT2 valproate ENT2END encephalopathy is discussed
0	In electron micrographs both ENT1 luminal  ENT1END and antiluminal sides of the BBB of the cerebellar cortex had similar lesions. The possible influence of the hepatic damage, mainly ENT2 hyperammonemia ENT2END , upon the development of valproate encephalopathy is discussed
0	once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (" ENT1 valproate ENT1END  encephalopathy"). The first ultrastructural changes in structural elements of the blood-brain-barrier (BBB) in the cerebellar cortex were detectable after 3 months of the experiment. They became more severe in the later months of the experiment, and were most severe after 12 months, located mainly in the molecular layer of the cerebellar cortex. Lesions of the capillary included ENT2 necrosis ENT2END of endothelial cells
0	Reduced size of capillary lumen and occlusion were caused by swollen endothelial cells which had ENT1 luminal ENT1END  protrusions and swollen microvilli. Pressure on the vessel wall was produced by enlarged perivascular astrocytic processes. Fragments of ENT2 necrotic ENT2END endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions
1	once daily to rats for 1, 3, 6, 9 and 12 months revealed neurological disorders indicating cerebellum damage (" ENT1 valproate ENT1END  ENT2 encephalopathy ENT2END ")
0	In electron micrographs both ENT1 luminal ENT1END  and antiluminal sides of the BBB of the cerebellar cortex had similar lesions. The possible influence of the hepatic damage, mainly hyperammonemia, upon the development of valproate ENT2 encephalopathy ENT2END is discussed
0	The possible influence of the ENT1 hepatic damage  ENT1END  mainly hyperammonemia, upon the development of ENT2 valproate ENT2END encephalopathy is discussed
0	In electron micrographs both ENT1 luminal  ENT1END  and antiluminal sides of the BBB of the cerebellar cortex had similar lesions. The possible influence of the ENT2 hepatic damage ENT2END , mainly hyperammonemia, upon the development of valproate encephalopathy is discussed
0	We present a case of a 5-year-old child with ENT1 cerebral palsy ENT1END and seizure disorder, receiving ENT2 clonidine ENT2END for restlessness, who presented for placement of a baclofen pump
0	Cardiac arrest in a child with ENT1 cerebral palsy  ENT1END  undergoing ENT2 sevoflurane ENT2END induction of anesthesia after preoperative clonidine
0	We present a case of a 5-year-old child with ENT1 cerebral palsy ENT1END  and seizure disorder, receiving clonidine for restlessness, who presented for placement of a ENT2 baclofen ENT2END pump
1	During induction of anesthesia, the patient developed bradycardia and ENT1 hypotension ENT1END requiring cardiac resuscitation. There are no previous reports of ENT2 clonidine ENT2END -associated cardiac arrest in a child undergoing induction of anesthesia
0	Cardiac arrest in a child with cerebral palsy undergoing ENT1 sevoflurane  ENT1END  induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure. We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety. During induction of anesthesia, the patient developed bradycardia and ENT2 hypotension ENT2END requiring cardiac resuscitation
0	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a ENT1 baclofen  ENT1END  pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety. During induction of anesthesia, the patient developed bradycardia and ENT2 hypotension ENT2END requiring cardiac resuscitation
0	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving ENT1 clonidine ENT1END  for ENT2 restlessness ENT2END , who presented for placement of a baclofen pump
0	Cardiac arrest in a child with cerebral palsy undergoing ENT1 sevoflurane  ENT1END  induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure. We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for ENT2 restlessness ENT2END , who presented for placement of a baclofen pump
0	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for ENT1 restlessness  ENT1END , who presented for placement of a ENT2 baclofen ENT2END pump
1	During induction of anesthesia, the patient developed ENT1 bradycardia  ENT1END and hypotension requiring cardiac resuscitation. There are no previous reports of ENT2 clonidine ENT2END -associated cardiac arrest in a child undergoing induction of anesthesia
0	Cardiac arrest in a child with cerebral palsy undergoing ENT1 sevoflurane  ENT1END  induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure. We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety. During induction of anesthesia, the patient developed ENT2 bradycardia ENT2END and hypotension requiring cardiac resuscitation
0	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a ENT1 baclofen  ENT1END  pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety. During induction of anesthesia, the patient developed ENT2 bradycardia ENT2END and hypotension requiring cardiac resuscitation
0	Without the knowledge of the medical personnel, the patient's mother administered three doses of ENT1 clonidine ENT1END during the evening before and morning of surgery to reduce ENT2 anxiety ENT2END
0	Cardiac arrest in a child with cerebral palsy undergoing ENT1 sevoflurane  ENT1END  induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure. We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a baclofen pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce ENT2 anxiety ENT2END
0	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a ENT1 baclofen  ENT1END  pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce ENT2 anxiety ENT2END
0	We present a case of a 5-year-old child with cerebral palsy and ENT1 seizure disorder  ENT1END  receiving ENT2 clonidine ENT2END for restlessness, who presented for placement of a baclofen pump
0	Cardiac arrest in a child with cerebral palsy undergoing ENT1 sevoflurane  ENT1END  induction of anesthesia after preoperative clonidine.Clonidine is a frequently administered alpha2-adrenergic agonist which can decrease heart rate and blood pressure. We present a case of a 5-year-old child with cerebral palsy and ENT2 seizure disorder ENT2END , receiving clonidine for restlessness, who presented for placement of a baclofen pump
0	We present a case of a 5-year-old child with cerebral palsy and ENT1 seizure disorder  ENT1END , receiving clonidine for restlessness, who presented for placement of a ENT2 baclofen ENT2END pump
1	There are no previous reports of ENT1 clonidine ENT1END -associated ENT2 cardiac arrest ENT2END in a child undergoing induction of anesthesia
0	ENT1 Cardiac arrest  ENT1END  in a child with cerebral palsy undergoing ENT2 sevoflurane ENT2END induction of anesthesia after preoperative clonidine
0	We present a case of a 5-year-old child with cerebral palsy and seizure disorder, receiving clonidine for restlessness, who presented for placement of a ENT1 baclofen  ENT1END  pump. Without the knowledge of the medical personnel, the patient's mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety. During induction of anesthesia, the patient developed bradycardia and hypotension requiring cardiac resuscitation. There are no previous reports of clonidine-associated ENT2 cardiac arrest ENT2END in a child undergoing induction of anesthesia
0	Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/cisplatin combination has been used successfully and has significantly improved median response duration in ENT1 ovarian cancer ENT1END patients. We initiated a phase I/II trial to determine the response and toxicity of escalating ENT2 paclitaxel ENT2END doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma
0	Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with head and neck cancer, and the paclitaxel/ ENT1 cisplatin  ENT1END combination has been used successfully and has significantly improved median response duration in ENT2 ovarian cancer ENT2END patients
1	ENT1 Alopecia ENT1END  paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. ENT2 Paclitaxel ENT2END /cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
1	ENT1 Alopecia  ENT1END , paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. Paclitaxel/ ENT2 cisplatin ENT2END is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
0	We initiated a phase I/II trial to determine the response and toxicity of escalating ENT1 paclitaxel ENT1END  doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma. To date, 23 men with a median age of 50 years and good performance status have entered the trial. Primary ENT2 tumor ENT2END sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each
0	We initiated a phase I/II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed-dose ENT1 cisplatin  ENT1END with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma. To date, 23 men with a median age of 50 years and good performance status have entered the trial. Primary ENT2 tumor ENT2END sites were oropharynx, 10 patients; hypopharynx, four; larynx, two; oral cavity, three; unknown primary, two; and nasal cavity and parotid gland, one each
1	Alopecia, ENT1 paresthesias  ENT1END  and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. ENT2 Paclitaxel ENT2END /cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
1	Alopecia, ENT1 paresthesias  ENT1END , and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. Paclitaxel ENT2 cisplatin ENT2END is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
0	We initiated a phase I/II trial to determine the response and ENT1 toxicity  ENT1END of escalating ENT2 paclitaxel ENT2END doses combined with fixed-dose cisplatin with granulocyte colony-stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma
0	No dose-limiting hematologic ENT1 toxicity  ENT1END has been seen. Paclitaxel ENT2 cisplatin ENT2END is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
1	Alopecia, paresthesias, and ENT1 arthralgias  ENT1END myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. ENT2 Paclitaxel ENT2END /cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
1	Alopecia, paresthesias, and ENT1 arthralgias  ENT1END /myalgias have occurred frequently, but with one exception (a grade 3 myalgia) they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. Paclitaxel ENT2 cisplatin ENT2END is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
0	Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with ENT1 head and neck cancer ENT1END  and the ENT2 paclitaxel ENT2END /cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients
0	Preliminary results of an Eastern Cooperative Oncology Group study of single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) reported a 37% response rate in patients with ENT1 head and neck cancer  ENT1END , and the paclitaxel ENT2 cisplatin ENT2END combination has been used successfully and has significantly improved median response duration in ovarian cancer patients
0	Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 ENT1 myalgia  ENT1END  they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. ENT2 Paclitaxel ENT2END /cisplatin is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
0	Alopecia, paresthesias, and arthralgias/myalgias have occurred frequently, but with one exception (a grade 3 ENT1 myalgia  ENT1END ) they have been grade 1 or 2. No dose-limiting hematologic toxicity has been seen. Paclitaxel ENT2 cisplatin ENT2END is an effective first-line regimen for locoregionally advanced head and neck cancer and continued study is warranted
0	This was most frequently found in children, many of whom had received ENT1 clioquinol ENT1END as treatment for ENT2 acrodermatitis enteropathica ENT2END
0	An analysis is presented of 220 cases of possible neurotoxic reactions to ENT1 halogenated hydroxyquinolines  ENT1END reported from outside Japan. In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded. Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases. In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period. The most common manifestation, observed in 15 further cases, was isolated optic atrophy. This was most frequently found in children, many of whom had received clioquinol as treatment for ENT2 acrodermatitis enteropathica ENT2END
0	An analysis is presented of 220 cases of possible ENT1 neurotoxic ENT1END reactions to halogenated hydroxyquinolines reported from outside Japan. In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of ENT2 clioquinol ENT2END could be excluded
0	ENT1 Neurotoxicity  ENT1END  of ENT2 halogenated hydroxyquinolines ENT2END : clinical analysis of cases reported outside Japan
1	This was most frequently found in children, many of whom had received ENT1 clioquinol ENT1END  as treatment for acrodermatitis enteropathica. In the remaining cases, a combination of ENT2 myelopathy ENT2END , visual disturbance, and peripheral neuropathy was the most common manifestation
1	This was most frequently found in children, many of whom had received ENT1 clioquinol ENT1END  as treatment for acrodermatitis enteropathica. In the remaining cases, a combination of myelopathy, visual disturbance, and ENT2 peripheral neuropathy ENT2END was the most common manifestation
0	Of the remainder, a relationship to ENT1 clioquinol ENT1END was considered probable in 42 and possible in 69 cases. In six of the probable cases the ENT2 neurological disturbance ENT2END consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period
0	An analysis is presented of 220 cases of possible neurotoxic reactions to ENT1 halogenated hydroxyquinolines  ENT1END  reported from outside Japan. In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded. Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases. In six of the probable cases the ENT2 neurological disturbance ENT2END consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period
1	This was most frequently found in children, many of whom had received ENT1 clioquinol ENT1END  as treatment for acrodermatitis enteropathica. In the remaining cases, a combination of myelopathy, ENT2 visual disturbance ENT2END , and peripheral neuropathy was the most common manifestation
0	This was most frequently found in children, many of whom had received ENT1 clioquinol ENT1END  as treatment for acrodermatitis enteropathica. In the remaining cases, a combination of myelopathy, visual disturbance, and peripheral neuropathy was the most common manifestation. Isolated myelopathy or peripheral neuropathy, or these manifestations occurring together, were infrequent. The onset of all manifestations (except toxic encephalopathy) was usually subacute, with subsequent partial recovery. Older subjects tended to display more side effects. The full syndrome of subacute ENT2 myelo-optic neuropathy ENT2END was more frequent in women, but they tended to have taken greater quantities of the drug
1	The most common manifestation, observed in 15 further cases, was isolated ENT1 optic atrophy  ENT1END  This was most frequently found in children, many of whom had received ENT2 clioquinol ENT2END as treatment for acrodermatitis enteropathica
0	An analysis is presented of 220 cases of possible neurotoxic reactions to ENT1 halogenated hydroxyquinolines  ENT1END  reported from outside Japan. In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded. Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases. In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period. The most common manifestation, observed in 15 further cases, was isolated ENT2 optic atrophy ENT2END
1	In six of the probable cases the neurological disturbance consisted of an acute reversible ENT1 encephalopathy ENT1END usually related to the ingestion of a high dose of ENT2 clioquinol ENT2END over a short period
0	An analysis is presented of 220 cases of possible neurotoxic reactions to ENT1 halogenated hydroxyquinolines  ENT1END  reported from outside Japan. In 80 cases insufficient information was available for adequate comment and in 29 a relationship to the administration of clioquinol could be excluded. Of the remainder, a relationship to clioquinol was considered probable in 42 and possible in 69 cases. In six of the probable cases the neurological disturbance consisted of an acute reversible ENT2 encephalopathy ENT2END usually related to the ingestion of a high dose of clioquinol over a short period
1	Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now ENT1 seizure ENT1END free. Previous exposures to ENT2 enflurane ENT2END have to be disclosed to avoid mistakes in clinical interpretation of the EEG
0	ENT1 Epileptic ENT1END foci delineated and activated by ENT2 enflurane ENT2END were surgically ablated and the patients are now seizure-free
0	We report a case of variant ventricular tachycardia induced by ENT1 desipramine ENT1END toxicity. Unusual features of the ENT2 arrhythmia ENT2END are repetitive group beating, progressive shortening of the R-R interval, progressive widening of the QRS complex with eventual failure of intraventricular conduction, and changes in direction of the QRS axis
0	Variant ventricular tachycardia in ENT1 desipramine ENT1END ENT2 toxicity ENT2END
1	Variant ENT1 ventricular tachycardia  ENT1END  in ENT2 desipramine ENT2END toxicity
0	CONCLUSION: Therefore, these results demonstrate the effectiveness of ENT1 crocin ENT1END (30 mg/kg) in antagonizing the cognitive deficits caused by STZ-icv in rats and its potential in the treatment of ENT2 neurodegenerative diseases ENT2END such as Alzheimer's disease
0	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the cognitive deficits caused by ENT1 STZ  ENT1END icv in rats and its potential in the treatment of ENT2 neurodegenerative diseases ENT2END such as Alzheimer's disease
0	In addition, ENT1 crocin ENT1END in the mentioned dose could significantly attenuated ENT2 learning and memory impairment ENT2END in treated STZ-injected group in passive avoidance test
0	In addition, crocin in the mentioned dose could significantly attenuated ENT1 learning and memory impairment ENT1END  in treated ENT2 STZ ENT2END -injected group in passive avoidance test
0	In addition, ENT1 crocin ENT1END  in the mentioned dose could significantly attenuated ENT2 learning and memory impairment ENT2END in treated STZ-injected group in passive avoidance test
0	In addition, crocin in the mentioned dose could significantly attenuated ENT1 learning and memory impairment  ENT1END  in treated ENT2 STZ ENT2END -injected group in passive avoidance test
0	CONCLUSION: Therefore, these results demonstrate the effectiveness of ENT1 crocin ENT1END  (30 mg/kg) in antagonizing the ENT2 cognitive deficits ENT2END caused by STZ-icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease
1	CONCLUSION: Therefore, these results demonstrate the effectiveness of crocin (30 mg/kg) in antagonizing the ENT1 cognitive deficits  ENT1END  caused by ENT2 STZ ENT2END -icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer's disease
0	In the present study, the effect of ENT1 crocins ENT1END on sporadic ENT2 Alzheimer's disease ENT2END induced by intracerebroventricular (icv) streptozocin (STZ) in male rats was investigated
1	, crocin on ENT1 streptozocin  ENT1END -induced model of sporadic ENT2 Alzheimer's disease ENT2END in male rats
0	, crocin on streptozocin-induced model of sporadic ENT1 Alzheimer's disease ENT1END  in male rats.BACKGROUND: The involvement of water-soluble ENT2 carotenoids ENT2END , crocins, as the main and active components of Crocus sativus L
1	This increase in ENT1 aggressiveness ENT1END was not secondary to ENT2 METH ENT2END -induced hyperactivity
0	This increase in aggressiveness was not secondary to ENT1 METH ENT1END -induced ENT2 hyperactivity ENT2END
1	ENT1 Perhexiline maleate  ENT1END  and ENT2 peripheral neuropathy ENT2END
0	Peripheral neuropathy has been noted as a complication of therapy with ENT1 perhexiline maleate ENT1END  a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of ENT2 angina pectoris ENT2END
0	Peripheral neuropathy has been noted as a complication of therapy with ENT1 perhexiline maleate ENT1END , a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris. In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder. Improvement was noted with cessation of therapy. In a few cases the presence of active denervation signified a poor prognosis, with only slight improvement. The underlying mechanism causing the ENT2 neuropathy ENT2END is not yet fully known, although some evidence indicates that it may be a lipid storage process
1	Peripheral neuropathy has been noted as a complication of therapy with ENT1 perhexiline maleate ENT1END , a drug widely used in France (and in clinical trials in the United States) for the prophylactic treatment of angina pectoris. In 24 patients with this complication, the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a ENT2 demyelinating disorder ENT2END
1	BACKGROUND: It is not known if there is a relationship between input rate and incidence of ENT1 bupropion ENT1END induced ENT2 seizures ENT2END
0	Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children's Hospital of Eastern Ontario ENT1 Pain ENT1END Scale (CHEOPS). RESULTS: The average time from intravenous administration of ENT2 ketamine ENT2END to manipulation of the fracture or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes)
1	Minor side effects included nausea (thirteen patients), ENT1 emesis ENT1END (eight of the thirteen patients with nausea), clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient). No long-term sequelae were noted, and no patients had hallucinations or nightmares. CONCLUSIONS: ENT2 Ketamine ENT2END reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution
0	RESULTS: The average time from intravenous administration of ENT1 ketamine ENT1END  to manipulation of the fracture or ENT2 dislocation ENT2END was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes)
1	Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with ENT1 nausea  ENT1END , clumsiness (evident as ataxic movements in ten patients), and dysphoric reaction (one patient). No long-term sequelae were noted, and no patients had hallucinations or nightmares. CONCLUSIONS: ENT2 Ketamine ENT2END reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution
0	3 years; range, twelve months to ten years and ten months) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level-I ENT1 trauma ENT1END center were prospectively evaluated. ENT2 Ketamine hydrochloride ENT2END was administered intravenously (at a dose of two milligrams per kilogram of body weight) in ninety-nine of the patients and intramuscularly (at a dose of four milligrams per kilogram of body weight) in the other fifteen
1	Minor side effects included nausea (thirteen patients), emesis (eight of the thirteen patients with nausea), clumsiness (evident as ENT1 ataxic movements  ENT1END in ten patients), and dysphoric reaction (one patient). No long-term sequelae were noted, and no patients had hallucinations or nightmares. CONCLUSIONS: ENT2 Ketamine ENT2END reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution
0	No long-term sequelae were noted, and no patients had ENT1 hallucinations  ENT1END or nightmares. CONCLUSIONS: ENT2 Ketamine ENT2END reliably, safely, and quickly provided adequate sedation to effectively facilitate the reduction of children's fractures in the emergency department at our institution
0	RESULTS: The average time from intravenous administration of ENT1 ketamine ENT1END  to manipulation of the ENT2 fracture ENT2END or dislocation was one minute and thirty-six seconds (range, twenty seconds to five minutes), and the average time from intramuscular administration to manipulation was four minutes and forty-two seconds (range, sixty seconds to fifteen minutes)
0	RESULTS: During the time frame of the study, 330 women were found to have had ENT1 VTE ENT1END while on COCs. Of these women, 67 were on ENT2 levonorgestrel ENT2END -containing COCs
1	1 million Danish women, ages 15 to 44 years, were searched for evidence of ENT1 VTE ENT1END  ENT2 COC ENT2END use was ascertained through mailed questionnaires
0	Eleven were on CPA/ ENT1 EE ENT1END  The corresponding absolute risk of ENT2 VTE ENT2END was 3
0	OBJECTIVE: To achieve absolute risk estimates of venous thromboembolism ( ENT1 VTE ENT1END  among women on ENT2 cyproterone acetate ENT2END plus ethinylestradiol (CPA/EE), and among women on combined oral contraceptives (COCs)
0	They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed ENT1 hyperthermia ENT1END  and to have died in summer months. EDDs had concentrations of cocaine and ENT2 benzoylecgonine ENT2END in autopsy blood that were similar to those for controls
0	They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed ENT1 hyperthermia ENT1END , and to have died in summer months. EDDs had concentrations of ENT2 cocaine ENT2END and benzoylecgonine in autopsy blood that were similar to those for controls
0	Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of cocaine ENT1 toxicity  ENT1END .We describe an outbreak of deaths from cocaine-induced excited delirium (EDDs) in Dade County, Florida between 1979 and 1990. From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium. Compared with controls, EDDs were more frequently black, male, and younger. They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed hyperthermia, and to have died in summer months. EDDs had concentrations of cocaine and ENT2 benzoylecgonine ENT2END in autopsy blood that were similar to those for controls
0	Fatal excited delirium following cocaine use: epidemiologic findings provide new evidence for mechanisms of ENT1 cocaine ENT1END ENT2 toxicity ENT2END
0	EDDs had concentrations of cocaine and ENT1 benzoylecgonine ENT1END  in autopsy blood that were similar to those for controls. The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, ENT2 rhabdomyolysis ENT2END , and sudden death
1	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent ENT1 cocaine  ENT1END use, may precipitate agitation, delirium, aberrant thermoregulation, ENT2 rhabdomyolysis ENT2END , and sudden death
0	EDDs had concentrations of cocaine and ENT1 benzoylecgonine ENT1END  in autopsy blood that were similar to those for controls. The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and ENT2 sudden death ENT2END
1	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent ENT1 cocaine  ENT1END  use, may precipitate agitation, delirium, aberrant thermoregulation, rhabdomyolysis, and ENT2 sudden death ENT2END
0	EDDs had concentrations of cocaine and ENT1 benzoylecgonine ENT1END  in autopsy blood that were similar to those for controls. The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent cocaine use, may precipitate ENT2 agitation ENT2END , delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death
0	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and, when coupled with recent ENT1 cocaine  ENT1END  use, may precipitate ENT2 agitation ENT2END , delirium, aberrant thermoregulation, rhabdomyolysis, and sudden death
0	From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental cocaine ENT1 overdose  ENT1END without excited delirium. Compared with controls, EDDs were more frequently black, male, and younger. They were less likely to have a low body mass index, and more likely to have died in police custody, to have received medical treatment immediately before death, to have survived for a longer period, to have developed hyperthermia, and to have died in summer months. EDDs had concentrations of cocaine and ENT2 benzoylecgonine ENT2END in autopsy blood that were similar to those for controls
0	From a registry of all cocaine-related deaths in Dade County, Florida, from 1969-1990, 58 EDDs were compared with 125 victims of accidental ENT1 cocaine ENT1END ENT2 overdose ENT2END without excited delirium
0	ENT1 EDDs  ENT1END had concentrations of cocaine and ENT2 benzoylecgonine ENT2END in autopsy blood that were similar to those for controls
1	Fatal excited ENT1 delirium  ENT1END  following ENT2 cocaine ENT2END use: epidemiologic findings provide new evidence for mechanisms of cocaine toxicity
0	Estrogens protect ovariectomized rats from hippocampal injury induced by ENT1 kainic acid ENT1END induced ENT2 status epilepticus ENT2END (SE)
0	The extent of ENT1 silver ENT1END stained CA3 and CA1 hippocampal neurons was evaluated 2 days after ENT2 SE ENT2END
1	We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to ENT1 lithium ENT1END pilocarpine-induced ENT2 SE ENT2END
0	The extent of silver-stained CA3 and CA1 hippocampal neurons was evaluated 2 days after ENT1 SE ENT1END . ENT2 17beta-Estradiol ENT2END did not alter the onset of first clonus in ovariectomized rats but accelerated it in males
1	We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium- ENT1 pilocarpine  ENT1END induced ENT2 SE ENT2END
0	Estradiol reduces ENT1 seizure  ENT1END -induced hippocampal injury in ovariectomized female but not in male rats.Estrogens protect ovariectomized rats from hippocampal injury induced by ENT2 kainic acid ENT2END -induced status epilepticus (SE)
0	The extent of ENT1 silver ENT1END -stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE. 17beta-Estradiol did not alter the onset of first clonus in ovariectomized rats but accelerated it in males. 17beta-Estradiol reduced the argyrophilic neurons in the CA1 and CA3-C sectors of ovariectomized rats. In males, estradiol increased the total damage score. These findings suggest that the effects of estradiol on ENT2 seizure ENT2END threshold and damage may be altered by sex-related differences in the hormonal environment
0	Estradiol reduces ENT1 seizure  ENT1END -induced hippocampal injury in ovariectomized female but not in male rats.Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE). We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to ENT2 lithium ENT2END -pilocarpine-induced SE
0	These findings suggest that the effects of ENT1 estradiol  ENT1END on ENT2 seizure ENT2END threshold and damage may be altered by sex-related differences in the hormonal environment
0	Estradiol reduces ENT1 seizure  ENT1END -induced hippocampal injury in ovariectomized female but not in male rats.Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid-induced status epilepticus (SE). We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium ENT2 pilocarpine ENT2END -induced SE
0	Estrogens protect ovariectomized rats from ENT1 hippocampal injury  ENT1END induced by ENT2 kainic acid ENT2END -induced status epilepticus (SE)
0	Estrogens protect ovariectomized rats from ENT1 hippocampal injury  ENT1END  induced by kainic acid-induced status epilepticus (SE). We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium-pilocarpine-induced SE. Rats received subcutaneous injections of 17beta-estradiol (2 microg/rat) or oil once daily for four consecutive days. SE was induced 20 h following the second injection and terminated 3 h later. The extent of ENT2 silver ENT2END -stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE
1	Estrogens protect ovariectomized rats from ENT1 hippocampal injury  ENT1END  induced by kainic acid-induced status epilepticus (SE). We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to ENT2 lithium ENT2END -pilocarpine-induced SE
0	ENT1 Estradiol  ENT1END  reduces seizure-induced ENT2 hippocampal injury ENT2END in ovariectomized female but not in male rats
1	Estrogens protect ovariectomized rats from ENT1 hippocampal injury  ENT1END  induced by kainic acid-induced status epilepticus (SE). We compared the effects of 17beta-estradiol in adult male and ovariectomized female rats subjected to lithium ENT2 pilocarpine ENT2END -induced SE
0	Levofloxacin, a ENT1 fluoroquinolone ENT1END  is one of the most commonly prescribed antibiotics in clinical practice and is effective against Gram-positive, Gram-negative, and atypical bacteria. While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of warfarin. We report 3 cases of serious ENT2 bleeding ENT2END complications that appear to be the result of the interaction between warfarin and levofloxacin
1	We report 3 cases of serious ENT1 bleeding ENT1END  complications that appear to be the result of the interaction between warfarin and ENT2 levofloxacin ENT2END
1	While small prospective studies have not revealed any significant drug-drug interaction between warfarin and levofloxacin, several case reports have indicated that levofloxacin may significantly potentiate the anticoagulation effect of ENT1 warfarin  ENT1END  We report 3 cases of serious ENT2 bleeding ENT2END complications that appear to be the result of the interaction between warfarin and levofloxacin
0	Reversible cholestasis with bile duct injury following ENT1 azathioprine ENT1END  therapy. A case report.A 67-year-old patient, with primary ENT2 polymyositis ENT2END and without previous evidence of liver disease, developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy
0	A 67-year-old patient, with primary polymyositis and without previous evidence of ENT1 liver disease ENT1END  developed clinical and biochemical features of severe cholestasis 3 months after initiation of ENT2 azathioprine ENT2END therapy
1	It is believed that this is the first reported case of reversible ENT1 azathioprine ENT1END induced ENT2 cholestasis ENT2END associated with histological evidence of bile duct injury
1	None of the subjects/patients developed ENT1 UFH ENT1END related ENT2 HIT ENT2END
0	Heparin-induced ENT1 thrombocytopenia ENT1END  after liver transplantation.BACKGROUND: Unfractionated heparin sodium (UFH) or ENT2 low-molecular weight heparin ENT2END (LMWH) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation
0	The ENT1 heparin ENT1END induced ENT2 platelet aggregation ENT2END test was negative in these patients
0	BACKGROUND: Unfractionated heparin sodium (UFH) or low-molecular weight heparin (LMWH) is used in anticoagulant protocols at several institutions to prevent ENT1 thrombosis ENT1END after liver transplantation. ENT2 Heparin ENT2END -induced thrombocytopenia (HIT) is an adverse immune-mediated reaction to heparin, resulting in platelet count decreases of more than 50%
0	BACKGROUND: Unfractionated heparin sodium (UFH) or ENT1 low-molecular weight heparin  ENT1END  (LMWH) is used in anticoagulant protocols at several institutions to prevent ENT2 thrombosis ENT2END after liver transplantation
1	The number of patients with suppression of HIV p24 antigenemia in the combination and ENT1 zidovudine ENT1END groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, abdominal pain, and ENT2 weight loss ENT2END were common for combination recipients
1	The mean ENT1 SC-48334  ENT1END steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, abdominal pain, and ENT2 weight loss ENT2END were common for combination recipients
0	The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and ENT1 zidovudine  ENT1END  in patients with ENT2 HIV-1 infection ENT2END and 200-500 CD4 cells/mm3
0	The safety and efficacy of combination N-butyl-deoxynojirimycin ( ENT1 SC-48334  ENT1END ) and zidovudine in patients with ENT2 HIV-1 infection ENT2END and 200-500 CD4 cells/mm3
0	99 micrograms/ml) was below the in vitro inhibitory concentration for human ENT1 immunodeficiency ENT1END virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and ENT2 zidovudine ENT2END groups, respectively (p > 0
0	The mean ENT1 SC-48334  ENT1END  steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human ENT2 immunodeficiency ENT2END virus (HIV)
1	The number of patients with suppression of HIV p24 antigenemia in the combination and ENT1 zidovudine ENT1END  groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, ENT2 abdominal pain ENT2END , and weight loss were common for combination recipients
1	The mean ENT1 SC-48334  ENT1END  steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, flatulence, ENT2 abdominal pain ENT2END , and weight loss were common for combination recipients
1	The number of patients with suppression of HIV p24 antigenemia in the combination and ENT1 zidovudine ENT1END  groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, ENT2 flatulence ENT2END , abdominal pain, and weight loss were common for combination recipients
1	The mean ENT1 SC-48334  ENT1END  steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. Diarrhea, ENT2 flatulence ENT2END , abdominal pain, and weight loss were common for combination recipients
1	The number of patients with suppression of HIV p24 antigenemia in the combination and ENT1 zidovudine ENT1END  groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. ENT2 Diarrhea ENT2END , flatulence, abdominal pain, and weight loss were common for combination recipients
1	The mean ENT1 SC-48334  ENT1END  steady-state trough level (4.04 +/- 0.99 micrograms/ml) was below the in vitro inhibitory concentration for human immunodeficiency virus (HIV). The mean increase in CD4 cells at week 4 was 73.8 cells/mm3 and 52.4 cells/mm3 for the combination and zidovudine groups, respectively (p > 0.36). For patients with prior zidovudine therapy, the mean change in CD4 cells in the combination and zidovudine groups was 63.7 cells/mm3 and 4.9 cells/mm3 at week 8 and 6.8 cells/mm3 and -45.1 cells/mm3 at week 16, respectively. The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six (40%) and two (11%) at week 4 (p = 0.10) and five (45%) and two (14%) at week 24 (p = 0.08), respectively. ENT2 Diarrhea ENT2END , flatulence, abdominal pain, and weight loss were common for combination recipients
1	Tacrine, administered in ENT1 LiCl ENT1END pre-treated rats, induces electrocorticographic ENT2 seizures ENT2END and delayed hippocampal damage
1	Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic ENT1 seizures ENT1END  and delayed hippocampal damage. The toxic effects of ENT2 tacrine ENT2END -loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i
1	Tacrine, administered in ENT1 LiCl ENT1END  pre-treated rats, induces electrocorticographic seizures and delayed ENT2 hippocampal damage ENT2END
1	Tacrine, administered in LiCl pre-treated rats, induces electrocorticographic seizures and delayed ENT1 hippocampal damage  ENT1END . The toxic effects of ENT2 tacrine ENT2END -loaded poly-L-lactid acid nanoparticles (5mg/kg), a saline solution of tacrine (5mg/kg) and an empty colloidal nanoparticle suspension were compared following i
0	In addition, tacrine-loaded nanoparticles administration induced ENT1 damage of neuronal cells  ENT1END in CA1 field of the hippocampus in all treated animals, while the saline solution of tacrine only in 60% of animals. Empty nanoparticles provided similar results to control (saline-treated) group of animals. In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine- ENT2 lithium ENT2END model of epilepsy in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo
0	administration in ENT1 LiCl ENT1END pre-treated Wistar rats. All the animals treated with tacrine-loaded nanoparticles showed an earlier outcome of CNS adverse symptoms, i.e. ENT2 epileptic ENT2END onset, with respect to those animals treated with the free compound (10 min vs
0	In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the ENT1 tacrine ENT1END lithium model of ENT2 epilepsy ENT2END in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo
0	In conclusion, the evaluation of time-to-onset of symptoms and the severity of neurodegenerative processes induced by the tacrine- ENT1 lithium  ENT1END  model of ENT2 epilepsy ENT2END in the rat, could be used to evaluate preliminarily the capability of a drug delivery system to trespass (or not) the BBB in vivo
0	The high ENT1 tumor ENT1END angiogenic potential was associated with an elevated VEGF/VPF protein expression in the ENT2 E2 ENT2END exposed pituitary of ovariectomized (OVEX) rats
0	These findings suggest that over expression of VEGF and its receptor (VEGFR-2) may play an important role in the initial step of the regulation of ENT1 estrogen ENT1END induced ENT2 tumor ENT2END angiogenesis in the rat pituitary
1	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat ENT1 pituitary tumors ENT1END  may mediate estrogen-initiated tumor angiogenesis.Estrogens, which have been associated with several types of human and animal cancers, can induce tumor angiogenesis in the pituitary of Fischer 344 rats. The mechanistic details of tumor angiogenesis induction, during estrogen carcinogenesis, are still unknown. To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis. The expression of VEGF receptor (VEGFR-2/Flk-1/KDR) was also examined by immunohistochemistry. The results demonstrated that ENT2 17beta-estradiol ENT2END (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure
0	Over expression of vascular endothelial growth factor and its receptor during the development of ENT1 estrogen  ENT1END -induced rat ENT2 pituitary tumors ENT2END may mediate estrogen-initiated tumor angiogenesis
0	The mechanistic details of tumor angiogenesis induction, during estrogen ENT1 carcinogenesis  ENT1END  are still unknown. To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats, the density of blood vessels was analysed using factor VIII related antigen (FVIIIRAg) immunohistochemistry and the expression of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) was examined by Western blot and immunohistochemical analysis. The expression of VEGF receptor (VEGFR-2/Flk-1/KDR) was also examined by immunohistochemistry. The results demonstrated that ENT2 17beta-estradiol ENT2END (E2) induces neovascularization, as well as the growth and enlargement of blood vessels after 7 days of exposure
0	The mechanistic details of tumor angiogenesis induction, during ENT1 estrogen ENT1END ENT2 carcinogenesis ENT2END , are still unknown
0	In brain membranes from spontaneously ENT1 hypertensive ENT1END rats ENT2 clonidine ENT2END , 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM)
0	The hypotensive effect of 100 mg/kg ENT1 alpha-methyldopa  ENT1END was also partially reversed by naloxone. Naloxone alone did not affect either blood pressure or heart rate. In brain membranes from spontaneously ENT2 hypertensive ENT2END rats clonidine, 10(-8) to 10(-5) M, did not influence stereoselective binding of [3H]-naloxone (8 nM), and naloxone, 10(-8) to 10(-4) M, did not influence clonidine-suppressible binding of [3H]-dihydroergocryptine (1 nM)
0	ENT1 Naloxone ENT1END  reverses the antihypertensive effect of clonidine.In unanesthetized, spontaneously ENT2 hypertensive ENT2END rats the decrease in blood pressure and heart rate produced by intravenous clonidine, 5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0
0	In unanesthetized, spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous ENT1 clonidine ENT1END  5 to 20 micrograms/kg, was inhibited or reversed by nalozone, 0.2 to 2 mg/kg. The ENT2 hypotensive ENT2END effect of 100 mg/kg alpha-methyldopa was also partially reversed by naloxone
1	The ENT1 hypotensive  ENT1END  effect of 100 mg/kg ENT2 alpha-methyldopa ENT2END was also partially reversed by naloxone
0	The ENT1 hypotensive ENT1END  effect of 100 mg/kg alpha-methyldopa was also partially reversed by ENT2 naloxone ENT2END
0	The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with ENT1 dobutamine ENT1END infusion and other drugs while being assessed for heart transplantation. On transthoracic echocardiogram, she had moderate left ventricular dysfunction with regional variability and moderate ENT2 mitral regurgitation ENT2END
0	The 47-year-old female patient, known to have ENT1 hypertrophic cardiomyopathy  ENT1END  was admitted with biventricular failure and managed aggressively with ENT2 dobutamine ENT2END infusion and other drugs while being assessed for heart transplantation
0	The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with biventricular failure and managed aggressively with ENT1 dobutamine ENT1END  infusion and other drugs while being assessed for heart transplantation. On transthoracic echocardiogram, she had moderate ENT2 left ventricular dysfunction ENT2END with regional variability and moderate mitral regurgitation
1	It is likely that the hypersensitivity (eosinophilic) myocarditis was related to ENT1 dobutamine ENT1END infusion therapy. ENT2 Eosinophilic myocarditis ENT2END has been reported with an incidence of 2
1	It is likely that the hypersensitivity (eosinophilic) ENT1 myocarditis  ENT1END was related to ENT2 dobutamine ENT2END infusion therapy
1	It is likely that the ENT1 hypersensitivity  ENT1END (eosinophilic) myocarditis was related to ENT2 dobutamine ENT2END infusion therapy
0	The 47-year-old female patient, known to have hypertrophic cardiomyopathy, was admitted with ENT1 biventricular failure  ENT1END and managed aggressively with ENT2 dobutamine ENT2END infusion and other drugs while being assessed for heart transplantation
0	Three cases were related to cyclosporine, and 1 case was secondary to both ENT1 cyclosporine ENT1END and tacrolimus. The fifth case had features of thrombotic microangiopathy related to an ENT2 antiphospholipid syndrome ENT2END in a patient with systemic lupus erythematosus
0	Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and ENT1 tacrolimus  ENT1END  The fifth case had features of thrombotic microangiopathy related to an ENT2 antiphospholipid syndrome ENT2END in a patient with systemic lupus erythematosus
0	Three cases were related to cyclosporine, and 1 case was secondary to both ENT1 cyclosporine ENT1END  and tacrolimus. The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with ENT2 systemic lupus erythematosus ENT2END
0	Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and ENT1 tacrolimus  ENT1END . The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with ENT2 systemic lupus erythematosus ENT2END
0	Other causes include drug-related ( ENT1 cyclosporine ENT1END  tacrolimus) ENT2 toxicity ENT2END , procoagulant status, and antibody-mediated rejection
0	Other causes include drug-related (cyclosporine, ENT1 tacrolimus ENT1END ENT2 toxicity ENT2END , procoagulant status, and antibody-mediated rejection
0	CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the ENT1 hemolytic uremic syndrome ENT1END  Other causes include drug-related ENT2 cyclosporine ENT2END , tacrolimus) toxicity, procoagulant status, and antibody-mediated rejection
0	CONCLUSIONS: In the literature, the most-frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the ENT1 hemolytic uremic syndrome  ENT1END . Other causes include drug-related (cyclosporine, ENT2 tacrolimus ENT2END ) toxicity, procoagulant status, and antibody-mediated rejection
1	We found that the most-frequent cause of ENT1 thrombotic microangiopathy ENT1END was drug related, secondary mainly to ENT2 cyclosporine ENT2END
0	Three cases were related to cyclosporine, and 1 case was secondary to both cyclosporine and ENT1 tacrolimus ENT1END . The fifth case had features of ENT2 thrombotic microangiopathy ENT2END related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus
1	Brainstem dysgenesis in an infant prenatally exposed to ENT1 cocaine ENT1END .Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy. Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies. We report on an infant with ENT2 multiple cranial-nerve involvement ENT2END attributable to brainstem dysgenesis, born to a cocaine-addicted mother
0	Brainstem dysgenesis in an infant prenatally exposed to ENT1 cocaine ENT1END .Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy. Vasoconstriction appears to be the common mechanism of action leading to a wide range of ENT2 fetal anomalies ENT2END
0	Brainstem dysgenesis in an infant prenatally exposed to ENT1 cocaine ENT1END .Many authors described the effects on the fetus of maternal ENT2 cocaine abuse ENT2END during pregnancy
0	The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in ENT1 penicillin ENT1END induced ENT2 epilepsy ENT2END model
1	EEG recordings were obtained before and 15 minutes following ENT1 penicillin-G ENT1END injection, and at 10th minutes following each stimulus for analysis in terms of frequency, amplitude, and power spectrum. RESULTS: High frequency hippocampal DBS suppressed the acute penicillin-induced cortical ENT2 epileptic ENT2END activity independent from stimulus intensity
1	Higher optical density of an antigen assay predicts thrombosis in patients with ENT1 heparin  ENT1END -induced ENT2 thrombocytopenia ENT2END
1	Higher optical density of an antigen assay predicts ENT1 thrombosis  ENT1END  in patients with ENT2 heparin ENT2END -induced thrombocytopenia
1	In patients with ENT1 OAB ENT1END urinary ENT2 PGE2 ENT2END positively correlated with volume at first desire to void and maximum cystometric capacity (p <0
0	We investigated changes in urinary NGF and ENT1 PGs ENT1END in women with ENT2 OAB ENT2END
1	In addition, correlations between urinary NGF and PG, and urodynamic parameters in patients with ENT1 OAB ENT1END were examined. RESULTS: Urinary NGF, PGE2 and ENT2 PGF2alpha ENT2END were significantly increased in patients with OAB compared with controls (p <0
0	RESULTS: Urinary NGF, PGE2 and PGF2alpha were significantly increased in patients with ENT1 OAB ENT1END compared with controls (p <0.05). However, urinary ENT2 PGI2 ENT2END was not different between controls and patients with OAB
0	Flow and metabolism were measured 5-13 days after the ENT1 subarachnoid haemorrhage ENT1END by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired ENT2 isoflurane ENT2END concentration of 0
0	Cerebral blood flow and cerebral metabolic rate for ENT1 oxygen  ENT1END were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm. Flow and metabolism were measured 5-13 days after the ENT2 subarachnoid haemorrhage ENT2END by a modification of the classical Kety-Schmidt technique using xenon-133 i
0	Flow and metabolism were measured 5-13 days after the ENT1 subarachnoid haemorrhage ENT1END  by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM). Controlled hypotension to an average MAP of 50-55 mm ENT2 Hg ENT2END was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2
0	Flow and metabolism were measured 5-13 days after the ENT1 subarachnoid haemorrhage ENT1END  by a modification of the classical Kety-Schmidt technique using ENT2 xenon ENT2END -133 i
0	Flow and metabolism were measured 5-13 days after the ENT1 subarachnoid haemorrhage ENT1END  by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% ENT2 nitrous oxide ENT2END in oxygen), during which CBF and CMRO2 were 34
0	After the clipping of the ENT1 aneurysm ENT1END the ENT2 isoflurane ENT2END concentration was reduced to 0
0	75% (plus 67% nitrous oxide in ENT1 oxygen  ENT1END , during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM). Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%. This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged. After the clipping of the ENT2 aneurysm ENT2END the isoflurane concentration was reduced to 0
0	Controlled hypotension to an average MAP of 50-55 mm ENT1 Hg  ENT1END  was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%. This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged. After the clipping of the ENT2 aneurysm ENT2END the isoflurane concentration was reduced to 0
0	Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using ENT1 xenon  ENT1END -133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM). Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%. This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged. After the clipping of the ENT2 aneurysm ENT2END the isoflurane concentration was reduced to 0
0	75% (plus 67% ENT1 nitrous oxide  ENT1END  in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM). Controlled hypotension to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2.2 +/- 0.2%. This resulted in a significant decrease in CMRO2 (to 1.73 +/- 0.16 ml/100 g min-1), while CBF was unchanged. After the clipping of the ENT2 aneurysm ENT2END the isoflurane concentration was reduced to 0
1	Cerebral blood flow and metabolism during ENT1 isoflurane  ENT1END -induced ENT2 hypotension ENT2END in patients subjected to surgery for cerebral aneurysms
0	Cerebral blood flow and cerebral metabolic rate for ENT1 oxygen ENT1END  were measured during isoflurane-induced ENT2 hypotension ENT2END in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm
0	Controlled ENT1 hypotension  ENT1END to an average MAP of 50-55 mm ENT2 Hg ENT2END was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2
0	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced ENT1 hypotension  ENT1END  in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm. Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using ENT2 xenon ENT2END -133 i
0	75% (plus 67% ENT1 nitrous oxide  ENT1END  in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM). Controlled ENT2 hypotension ENT2END to an average MAP of 50-55 mm Hg was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2
0	Cerebral blood flow and metabolism during ENT1 isoflurane  ENT1END -induced hypotension in patients subjected to surgery for ENT2 cerebral aneurysms ENT2END
0	Cerebral blood flow and metabolism during isoflurane-induced hypotension in patients subjected to surgery for ENT1 cerebral aneurysms  ENT1END .Cerebral blood flow and cerebral metabolic rate for ENT2 oxygen ENT2END were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm
0	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a ENT1 cerebral aneurysm  ENT1END  Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% nitrous oxide in oxygen), during which CBF and CMRO2 were 34.3 +/- 2.1 ml/100 g min-1 and 2.32 +/- 0.16 ml/100 g min-1 at PaCO2 4.1 +/- 0.1 kPa (mean +/- SEM). Controlled hypotension to an average MAP of 50-55 mm ENT2 Hg ENT2END was induced by increasing the dose of isoflurane, and maintained at an inspired concentration of 2
0	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a ENT1 cerebral aneurysm  ENT1END . Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using ENT2 xenon ENT2END -133 i
0	Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane-induced hypotension in 10 patients subjected to craniotomy for clipping of a ENT1 cerebral aneurysm  ENT1END . Flow and metabolism were measured 5-13 days after the subarachnoid haemorrhage by a modification of the classical Kety-Schmidt technique using xenon-133 i.v. Anaesthesia was maintained with an inspired isoflurane concentration of 0.75% (plus 67% ENT2 nitrous oxide ENT2END in oxygen), during which CBF and CMRO2 were 34
0	Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase (SOD), catalase (CAT) and ENT1 glutathione ENT1END reductase (GSH), an index of oxidative stress process. Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels. The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial ENT2 dyskinesia ENT2END and oxidative stress
0	The results of the present study suggested that ENT1 Hibiscus rosa sinensis  ENT1END had a protective role against reserpine-induced orofacial ENT2 dyskinesia ENT2END and oxidative stress
0	Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of ENT1 superoxide  ENT1END dismutase (SOD), catalase (CAT) and glutathione reductase (GSH), an index of oxidative stress process. Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD, CAT and GSH levels. The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine-induced orofacial ENT2 dyskinesia ENT2END and oxidative stress
1	Effect of methanolic extract of Hibiscus rosa sinensis (100-300 mg/kg) was studied on ENT1 reserpine ENT1END induced orofacial ENT2 dyskinesia ENT2END and neurochemical alterations
0	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial ENT1 oxygen ENT1END demand associated with cocaine-induced increase in rate-pressure product. In other individuals with no underlying atherosclerotic obstruction, ENT2 coronary occlusion ENT2END may be due to spasm, thrombus, or both
0	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with ENT1 cocaine  ENT1END induced increase in rate-pressure product. In other individuals with no underlying atherosclerotic obstruction, ENT2 coronary occlusion ENT2END may be due to spasm, thrombus, or both
0	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial ENT1 oxygen ENT1END  demand associated with cocaine-induced increase in rate-pressure product. In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, thrombus, or both. With regard to spasm, the clinical findings are largely circumstantial, and the locus of cocaine-induced vasoconstriction remains speculative. Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial, medium-size vessels, other data suggest intramural vasoconstriction. Diffuse intramural vasoconstriction is not consistent with reports of segmental, discrete ENT2 infarction ENT2END
0	Diffuse intramural vasoconstriction is not consistent with reports of segmental, discrete ENT1 infarction ENT1END . Whereas certain in vivo data suggest that these effects are alpha-mediated, other in vitro data suggest the opposite. The finding of ENT2 cocaine ENT2END -induced vasoconstriction in segments of (noninnervated) human umbilical artery suggests that the presence or absence of intact innervation is not sufficient to explain the discrepant data involving the possibility of alpha-mediated effects
0	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial ENT1 oxygen ENT1END  demand associated with cocaine-induced increase in rate-pressure product. In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to spasm, ENT2 thrombus ENT2END , or both
0	Finally, the contribution of a primary, ENT1 thrombotic ENT1END effect of ENT2 cocaine ENT2END has not been excluded
0	In individuals with preexisting, high-grade coronary arterial narrowing, ENT1 acute myocardial infarction  ENT1END may result from an increase in myocardial ENT2 oxygen ENT2END demand associated with cocaine-induced increase in rate-pressure product
1	ENT1 Cocaine  ENT1END -induced ENT2 myocardial infarction ENT2END : clinical observations and pathogenetic considerations
0	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial ENT1 oxygen ENT1END  demand associated with cocaine-induced increase in rate-pressure product. In other individuals with no underlying ENT2 atherosclerotic obstruction ENT2END , coronary occlusion may be due to spasm, thrombus, or both
0	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial oxygen demand associated with ENT1 cocaine  ENT1END -induced increase in rate-pressure product. In other individuals with no underlying ENT2 atherosclerotic obstruction ENT2END , coronary occlusion may be due to spasm, thrombus, or both
0	In individuals with preexisting, high-grade coronary arterial narrowing, acute myocardial infarction may result from an increase in myocardial ENT1 oxygen ENT1END  demand associated with cocaine-induced increase in rate-pressure product. In other individuals with no underlying atherosclerotic obstruction, coronary occlusion may be due to ENT2 spasm ENT2END , thrombus, or both
0	With regard to ENT1 spasm ENT1END  the clinical findings are largely circumstantial, and the locus of ENT2 cocaine ENT2END -induced vasoconstriction remains speculative
0	The pilocarpine ( ENT1 PILO ENT1END  model of epilepsy is characterized by an acute period of ENT2 status epilepticus ENT2END followed by spontaneous recurrent seizures and related brain damage
0	This expression may represent an endogenous damping mechanism since NPY has been shown to block ENT1 seizure ENT1END like events following high-frequency stimulation in hippocampal slices. The ENT2 pilocarpine ENT2END (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage
0	The pilocarpine (PILO) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related ENT1 brain damage ENT1END  We report peroxidase-antiperoxidase immunostaining for NPY in several brain regions in this model. ENT2 PILO ENT2END -injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals, in the dentate gyrus inner molecular layer and, in a few cases, within presumed granule cells
1	The results demonstrate that changes in NPY expression, including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons, are present in the ENT1 PILO ENT1END model of ENT2 TLE ENT2END
0	The pilocarpine ( ENT1 PILO ENT1END ) model of ENT2 epilepsy ENT2END is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage
1	Severe thrombocytopenia and ENT1 haemolytic anaemia  ENT1END  associated with ENT2 ciprofloxacin ENT2END : a case report with fatal outcome
0	An accurate autopsy revealed most organs with diffuse petechial ENT1 haemorrhages ENT1END  No signs of bone marrow depression were found. No thrombi or signs of microangiopathies were observed in arterial vessels. Blood and urine cultures did not show any bacterial growth. This case report shows that ENT2 ciprofloxacin ENT2END may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures
1	This case report shows that ENT1 ciprofloxacin ENT1END  may precipitate life-threatening ENT2 thrombocytopenia ENT2END and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures
1	Haematological adverse reactions associated with fatal outcome are rare during treatment with ENT1 ciprofloxacin ENT1END  A 30-year old Caucasian man reported with ENT2 abdominal pain ENT2END and jaundice after 3-day administration of oral ciprofloxacin for a suspect of urinary tract infection
0	No ENT1 thrombi  ENT1END or signs of microangiopathies were observed in arterial vessels. Blood and urine cultures did not show any bacterial growth. This case report shows that ENT2 ciprofloxacin ENT2END may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures
1	A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ENT1 ciprofloxacin ENT1END for a suspect of urinary tract infection. Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis. The patient progressively developed ENT2 petechiae ENT2END and purpura on thorax and lower limbs
0	A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ENT1 ciprofloxacin ENT1END  for a suspect of urinary tract infection. Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and ENT2 haemolysis ENT2END
0	No signs of ENT1 bone marrow depression  ENT1END were found. No thrombi or signs of microangiopathies were observed in arterial vessels. Blood and urine cultures did not show any bacterial growth. This case report shows that ENT2 ciprofloxacin ENT2END may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures
1	A 30-year old Caucasian man reported with abdominal pain and ENT1 jaundice  ENT1END after 3-day administration of oral ENT2 ciprofloxacin ENT2END for a suspect of urinary tract infection
0	A 30-year old Caucasian man reported with abdominal pain and jaundice after 3-day administration of oral ENT1 ciprofloxacin ENT1END  for a suspect of ENT2 urinary tract infection ENT2END
0	No thrombi or signs of ENT1 microangiopathies  ENT1END were observed in arterial vessels. Blood and urine cultures did not show any bacterial growth. This case report shows that ENT2 ciprofloxacin ENT2END may precipitate life-threatening thrombocytopenia and haemolytic anaemia, even in the early phases of treatment and without apparent previous exposures
0	We observed sinoatrial block due to chronic ENT1 amiodarone ENT1END administration in a 5-year-old boy with ENT2 primary cardiomyopathy ENT2END , Wolff-Parkinson-White syndrome and supraventricular tachycardia
0	Reduction in the dosage of ENT1 amiodarone ENT1END resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic ENT2 sinus bradycardia ENT2END
1	ENT1 Amiodarone  ENT1END -induced ENT2 sinoatrial block ENT2END
0	We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, Wolff-Parkinson-White syndrome and ENT1 supraventricular tachycardia  ENT1END  Reduction in the dosage of ENT2 amiodarone ENT2END resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia
0	We observed sinoatrial block due to chronic amiodarone administration in a 5-year-old boy with primary cardiomyopathy, ENT1 Wolff-Parkinson-White syndrome  ENT1END and supraventricular tachycardia. Reduction in the dosage of ENT2 amiodarone ENT2END resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia
1	Why may epsilon-aminocaproic acid ( ENT1 EACA  ENT1END ) induce ENT2 myopathy ENT2END in man? Report of a case and literature review
1	A case of ENT1 necrotizing myopathy ENT1END due to a short ENT2 epsilon-aminocaproic acid ENT2END (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described
0	A case of necrotizing myopathy due to a short epsilon-aminocaproic acid ( ENT1 EACA ENT1END  treatment in a 72 year-old patient with ENT2 subarachnoid haemorrhage ENT2END (SAH) is described
0	ENT1 Adrenaline arrhythmia ENT1END  which is suppressed by Ca channel blockers, was induced by adrenaline infusion in ENT2 halothane ENT2END -anesthetized dogs
0	Digitalis ENT1 arrhythmia ENT1END  which is suppressed by ENT2 Na ENT2END channel blockers, was induced by intermittent intravenous (i
0	) injection of ouabain in ENT1 pentobarbital  ENT1END anesthetized dogs. ENT2 Adrenaline arrhythmia ENT2END , which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs
0	ENT1 Digitalis ENT1END ENT2 arrhythmia ENT2END , which is suppressed by Na channel blockers, was induced by intermittent intravenous (i
1	) injection of ENT1 ouabain  ENT1END in pentobarbital-anesthetized dogs. ENT2 Adrenaline arrhythmia ENT2END , which is suppressed by Ca channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs
0	Antiarrhythmic effects of optical isomers of ENT1 cibenzoline  ENT1END  on canine ENT2 ventricular arrhythmias ENT2END
0	ENT1 Adrenaline arrhythmia ENT1END , which is suppressed by ENT2 Ca ENT2END channel blockers, was induced by adrenaline infusion in halothane-anesthetized dogs
1	(+)-cibenzoline suppressed digitalis- and ENT1 adrenaline ENT1END induced ENT2 arrhythmias ENT2END , respectively
0	When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of ENT1 poisoning  ENT1END  Atropine- ENT2 MK801 ENT2END did not offer any additional protection against DFP toxicity
0	0 mg/kg BW), A(1)- ENT1 adenosine  ENT1END receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP. The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively. All rats were terminated either 24 h or 3 weeks after the DFP injection. The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs. When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of ENT2 poisoning ENT2END
0	In conclusion, CPA, diazepam and ENT1 2PAM ENT1END in combination with atropine prevented the occurrence of serious signs of ENT2 poisoning ENT2END and thus reduced the toxicity of DFP in rat
0	In conclusion, CPA, diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of ENT1 poisoning ENT1END  and thus reduced the toxicity of ENT2 DFP ENT2END in rat
0	In conclusion, CPA, ENT1 diazepam  ENT1END and 2PAM in combination with atropine prevented the occurrence of serious signs of ENT2 poisoning ENT2END and thus reduced the toxicity of DFP in rat
0	The rats treated with DFP-atropine showed severe typical ENT1 OP  ENT1END induced toxicity signs. When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of ENT2 poisoning ENT2END
0	When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of ENT1 poisoning ENT1END . ENT2 Atropine ENT2END -MK801 did not offer any additional protection against DFP toxicity
0	0 mg/kg BW), ENT1 NMDA  ENT1END receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP. The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively. All rats were terminated either 24 h or 3 weeks after the DFP injection. The rats treated with DFP-atropine showed severe typical OP-induced toxicity signs. When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of ENT2 poisoning ENT2END
0	When CPA, diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of ENT1 poisoning ENT1END . Atropine-MK801 did not offer any additional protection against DFP toxicity. In conclusion, ENT2 CPA ENT2END , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist ENT2 dizocilpine maleate ENT2END (+-MK801 hydrogen maleate) (2
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates ENT2 acetylcholine ENT2END (ACh) levels
0	Organophosphate-induced ENT1 convulsions  ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1) ENT2 adenosine ENT2END receptor agonist N(6)-cyclopentyl adenosine (CPA) (2
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and ENT2 soman ENT2END are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs)
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator ENT2 pralidoxime-2-chloride ENT2END (2PAM) (30
1	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as ENT2 diisopropylfluorophosphate ENT2END (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs)
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), ENT2 sarin ENT2END and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs)
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant ENT2 diazepam ENT2END (2
0	ENT1 Organophosphate  ENT1END -induced ENT2 convulsions ENT2END and prevention of neuropathological damages
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug ENT2 atropine sulfate ENT2END (50
0	Organophosphate-induced ENT1 convulsions  ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), ENT2 NMDA ENT2END -receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2
0	Organophosphate-induced ENT1 convulsions ENT1END  and prevention of neuropathological damages.Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist ENT2 N(6)-cyclopentyl adenosine ENT2END (CPA) (2
0	Atropine- ENT1 MK801 ENT1END  did not offer any additional protection against DFP ENT2 toxicity ENT2END
0	The acute ENT1 toxicity  ENT1END of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates ENT2 acetylcholine ENT2END (ACh) levels
0	The acute ENT1 toxicity  ENT1END  of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1) ENT2 adenosine ENT2END receptor agonist N(6)-cyclopentyl adenosine (CPA) (2
0	Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and ENT1 soman  ENT1END  are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute ENT2 toxicity ENT2END of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels
0	The rats treated with DFP-atropine showed severe typical OP-induced ENT1 toxicity ENT1END signs. When CPA, diazepam or ENT2 2PAM ENT2END was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning
0	Atropine-MK801 did not offer any additional protection against ENT1 DFP ENT1END ENT2 toxicity ENT2END
0	Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), ENT1 sarin  ENT1END  and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute ENT2 toxicity ENT2END of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels
0	The rats treated with DFP-atropine showed severe typical OP-induced ENT1 toxicity ENT1END  signs. When CPA, ENT2 diazepam ENT2END or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning
0	The acute ENT1 toxicity ENT1END  of ENT2 OPs ENT2END is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels
0	The rats treated with DFP- ENT1 atropine  ENT1END showed severe typical OP-induced ENT2 toxicity ENT2END signs
0	0 mg/kg BW), ENT1 NMDA  ENT1END -receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug atropine sulfate (50.0 mg/kg BW) immediately or 30 min after the single SC injection of DFP. The control rats received atropine sulfate, but also saline and olive oil instead of other antidotes and DFP, respectively. All rats were terminated either 24 h or 3 weeks after the DFP injection. The rats treated with DFP-atropine showed severe typical OP-induced ENT2 toxicity ENT2END signs
0	The rats treated with DFP-atropine showed severe typical OP-induced ENT1 toxicity ENT1END  signs. When ENT2 CPA ENT2END , diazepam or 2PAM was given immediately after DFP-atropine, these treatments prevented, delayed or shortened the occurrence of serious signs of poisoning
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist ENT2 dizocilpine maleate ENT2END (+-MK801 hydrogen maleate) (2
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates ENT2 acetylcholine ENT2END (ACh) levels
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1) ENT2 adenosine ENT2END receptor agonist N(6)-cyclopentyl adenosine (CPA) (2
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and ENT2 soman ENT2END are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs)
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator ENT2 pralidoxime-2-chloride ENT2END (2PAM) (30
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as ENT2 diisopropylfluorophosphate ENT2END (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs)
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), ENT2 sarin ENT2END and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs)
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant ENT2 diazepam ENT2END (2
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages ENT1END .Such ENT2 organophosphorus ENT2END (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs)
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), NMDA-receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2.0 mg/kg BW) or their combinations with cholinolytic drug ENT2 atropine sulfate ENT2END (50
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist N(6)-cyclopentyl adenosine (CPA) (2.0 mg/kg BW), ENT2 NMDA ENT2END -receptor antagonist dizocilpine maleate (+-MK801 hydrogen maleate) (2
0	Organophosphate-induced convulsions and prevention of ENT1 neuropathological damages  ENT1END .Such organophosphorus (OP) compounds as diisopropylfluorophosphate (DFP), sarin and soman are potent inhibitors of acetylcholinesterases (AChEs) and butyrylcholinesterases (BChEs). The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system (CNS), which elevates acetylcholine (ACh) levels. The protective action of subcutaneously (SC) administered antidotes or their combinations in DFP (2.0 mg/kg BW) intoxication was studied in 9-10-weeks-old Han-Wistar male rats. The rats received AChE reactivator pralidoxime-2-chloride (2PAM) (30.0 mg/kg BW), anticonvulsant diazepam (2.0 mg/kg BW), A(1)-adenosine receptor agonist ENT2 N(6)-cyclopentyl adenosine ENT2END (CPA) (2
1	PURPOSE: We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug-drug interactions related to the inhibition of cytochrome P450 (CYP) 1A2 in this case, as well as in other cases, of ENT1 levofloxacin ENT1END induced ENT2 seizures ENT2END
0	A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of ENT1 methysergide ENT1END by a 48-year-old woman. A brief review of the literature on similar cases is presented. A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of ENT2 migraine headache ENT2END
1	Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ENT1 ergot ENT1END preparations continue to play a major role in ENT2 migraine ENT2END therapy, so that the danger of St
0	A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of ENT1 migraine headache ENT1END . Despite the advent of ENT2 calcium ENT2END channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St
0	A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of ENT1 methysergide ENT1END  by a 48-year-old woman. A brief review of the literature on similar cases is presented. A discussion of the history of ergot includes its original discovery, the epidemics of ENT2 gangrene ENT2END that it has caused through the ages and its past and present role in the management of migraine headache
0	A discussion of the history of ENT1 ergot  ENT1END includes its original discovery, the epidemics of ENT2 gangrene ENT2END that it has caused through the ages and its past and present role in the management of migraine headache
0	A discussion of the history of ergot includes its original discovery, the epidemics of ENT1 gangrene  ENT1END  that it has caused through the ages and its past and present role in the management of migraine headache. Despite the advent of ENT2 calcium ENT2END channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St
1	A rare case of morbid ENT1 vasospasm  ENT1END  together with striking angiographic findings, is described secondary to the ingestion of ENT2 methysergide ENT2END by a 48-year-old woman
0	A rare case of morbid ENT1 vasospasm  ENT1END , together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman. A brief review of the literature on similar cases is presented. A discussion of the history of ENT2 ergot ENT2END includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache
0	A rare case of morbid ENT1 vasospasm  ENT1END , together with striking angiographic findings, is described secondary to the ingestion of methysergide by a 48-year-old woman. A brief review of the literature on similar cases is presented. A discussion of the history of ergot includes its original discovery, the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache. Despite the advent of ENT2 calcium ENT2END channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of St
0	ENT1 St. Anthony's fire  ENT1END , then and now: a case report and historical review.A rare case of morbid vasospasm, together with striking angiographic findings, is described secondary to the ingestion of ENT2 methysergide ENT2END by a 48-year-old woman
0	Despite the advent of calcium channel blockers and beta-adrenergic antagonists, ENT1 ergot ENT1END  preparations continue to play a major role in migraine therapy, so that the danger of ENT2 St. Anthony's fire ENT2END persists
0	Despite the advent of ENT1 calcium  ENT1END  channel blockers and beta-adrenergic antagonists, ergot preparations continue to play a major role in migraine therapy, so that the danger of ENT2 St. Anthony's fire ENT2END persists
0	This type of lesion broadens the spectrum of ENT1 liver injury ENT1END due to this drug combination, mainly represented by a benign cholestatic syndrome. The association of granulomas and eosinophilia favor an immunoallergic mechanism. As ENT2 penicillin ENT2END derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	This type of lesion broadens the spectrum of ENT1 liver injury ENT1END  due to this drug combination, mainly represented by a benign cholestatic syndrome. The association of granulomas and eosinophilia favor an immunoallergic mechanism. As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of ENT2 clavulanic acid ENT2END , might have a major role
1	We report the case of a patient with ENT1 amoxicillin-clavulanic acid ENT1END induced ENT2 hepatitis ENT2END with histologic multiple granulomas
0	This type of lesion broadens the spectrum of ENT1 liver injury ENT1END  due to this drug combination, mainly represented by a benign cholestatic syndrome. The association of granulomas and eosinophilia favor an immunoallergic mechanism. As penicillin derivatives and ENT2 amoxicillin ENT2END alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	The association of granulomas and ENT1 eosinophilia  ENT1END favor an immunoallergic mechanism. As ENT2 penicillin ENT2END derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	The association of granulomas and ENT1 eosinophilia  ENT1END  favor an immunoallergic mechanism. As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of ENT2 clavulanic acid ENT2END , might have a major role
0	We report the case of a patient with ENT1 amoxicillin-clavulanic acid  ENT1END -induced hepatitis with histologic multiple granulomas. This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign cholestatic syndrome. The association of granulomas and ENT2 eosinophilia ENT2END favor an immunoallergic mechanism
0	The association of granulomas and ENT1 eosinophilia  ENT1END  favor an immunoallergic mechanism. As penicillin derivatives and ENT2 amoxicillin ENT2END alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign ENT1 cholestatic syndrome  ENT1END  The association of granulomas and eosinophilia favor an immunoallergic mechanism. As ENT2 penicillin ENT2END derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign ENT1 cholestatic syndrome  ENT1END . The association of granulomas and eosinophilia favor an immunoallergic mechanism. As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of ENT2 clavulanic acid ENT2END , might have a major role
1	We report the case of a patient with ENT1 amoxicillin-clavulanic acid  ENT1END -induced hepatitis with histologic multiple granulomas. This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign ENT2 cholestatic syndrome ENT2END
0	This type of lesion broadens the spectrum of liver injury due to this drug combination, mainly represented by a benign ENT1 cholestatic syndrome  ENT1END . The association of granulomas and eosinophilia favor an immunoallergic mechanism. As penicillin derivatives and ENT2 amoxicillin ENT2END alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	The association of ENT1 granulomas  ENT1END and eosinophilia favor an immunoallergic mechanism. As ENT2 penicillin ENT2END derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	The association of ENT1 granulomas  ENT1END  and eosinophilia favor an immunoallergic mechanism. As penicillin derivatives and amoxicillin alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of ENT2 clavulanic acid ENT2END , might have a major role
1	ENT1 Granulomatous hepatitis  ENT1END  due to ENT2 combination of amoxicillin and clavulanic acid ENT2END
0	The association of ENT1 granulomas  ENT1END  and eosinophilia favor an immunoallergic mechanism. As penicillin derivatives and ENT2 amoxicillin ENT2END alone are known to induce such types of lesions, the amoxicillin component, with or without a potentiating effect of clavulanic acid, might have a major role
0	In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total ENT1 bilirubin ENT1END showed significant increases after operation. The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate ENT2 haemodilution ENT2END would cause impairment of hepatic function
0	ENT1 Haemodilution ENT1END in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of ENT2 dextran ENT2END solution, and final haematocrit values were 21 or 22%
0	ENT1 Haemodilution  ENT1END  in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%. Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min. Measurements included arterial ketone body ratio (AKBR, aceto-acetate/ ENT2 3-hydroxybutyrate ENT2END ) and clinical hepatic function parameters
0	Combined effects of prolonged prostaglandin E1 ( ENT1 PGE1 ENT1END -induced hypotension and ENT2 haemodilution ENT2END on hepatic function were studied in 30 patients undergoing hip surgery
0	ENT1 Haemodilution ENT1END  in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution, and final haematocrit values were 21 or 22%. Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min. Measurements included arterial ketone body ratio (AKBR, ENT2 aceto-acetate ENT2END /3-hydroxybutyrate) and clinical hepatic function parameters
0	In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of ENT1 hypotension  ENT1END and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total ENT2 bilirubin ENT2END showed significant increases after operation
0	Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of ENT1 dextran ENT1END  solution, and final haematocrit values were 21 or 22%. Controlled ENT2 hypotension ENT2END in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min
0	Controlled ENT1 hypotension  ENT1END  in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min. Measurements included arterial ketone body ratio (AKBR, aceto-acetate ENT2 3-hydroxybutyrate ENT2END ) and clinical hepatic function parameters
1	The results suggest that a prolonged combination of more than 120 min of ENT1 PGE1 ENT1END induced ENT2 hypotension ENT2END and moderate haemodilution would cause impairment of hepatic function
0	Controlled ENT1 hypotension  ENT1END  in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min. Measurements included arterial ketone body ratio (AKBR, ENT2 aceto-acetate ENT2END /3-hydroxybutyrate) and clinical hepatic function parameters
0	In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total ENT1 bilirubin ENT1END  showed significant increases after operation. The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause ENT2 impairment of hepatic function ENT2END
0	Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of ENT1 dextran  ENT1END  solution, and final haematocrit values were 21 or 22%. Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min. Measurements included arterial ketone body ratio (AKBR, aceto-acetate/3-hydroxybutyrate) and clinical hepatic function parameters. AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation. The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause ENT2 impairment of hepatic function ENT2END
0	Measurements included arterial ketone body ratio (AKBR, aceto-acetate/ ENT1 3-hydroxybutyrate  ENT1END ) and clinical hepatic function parameters. AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation. The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause ENT2 impairment of hepatic function ENT2END
1	The results suggest that a prolonged combination of more than 120 min of ENT1 PGE1  ENT1END -induced hypotension and moderate haemodilution would cause ENT2 impairment of hepatic function ENT2END
0	Measurements included arterial ketone body ratio (AKBR, ENT1 aceto-acetate  ENT1END /3-hydroxybutyrate) and clinical hepatic function parameters. AKBR and biological hepatic function tests showed no change throughout the time course in groups A and B. In group C, AKBR showed a significant decrease at 120 min (-40%) and at 180 min (-49%) after the start of hypotension and at 60 min (-32%) after recovery of normotension, and SGOT, SGPT, LDH and total bilirubin showed significant increases after operation. The results suggest that a prolonged combination of more than 120 min of PGE1-induced hypotension and moderate haemodilution would cause ENT2 impairment of hepatic function ENT2END
0	The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of ENT1 numbness ENT1END in his right foot. Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves. This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to ENT2 methylprednisolone ENT2END
0	The first course of high-dose ENT1 cytosine arabinoside  ENT1END resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of ENT2 numbness ENT2END in his right foot
0	This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to ENT1 methylprednisolone ENT1END . Although the mechanisms of ENT2 peripheral neuropathy ENT2END are still unclear, high-dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms
1	ENT1 Peripheral neuropathy  ENT1END  caused by high-dose ENT2 cytosine arabinoside ENT2END treatment in a patient with acute myeloid leukemia
0	The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the ENT1 toxicity  ENT1END of cytosine arabinoside in the peripheral nervous system has been infrequently reported. A 49-year-old Japanese man was diagnosed with acute myeloid leukemia. After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy. The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot. Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves. This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to ENT2 methylprednisolone ENT2END
0	The central nervous system toxicity of high-dose cytosine arabinoside is well recognized, but the ENT1 toxicity ENT1END  of ENT2 cytosine arabinoside ENT2END in the peripheral nervous system has been infrequently reported
0	This ENT1 neuropathy  ENT1END was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to ENT2 methylprednisolone ENT2END
0	The first course of high-dose ENT1 cytosine arabinoside  ENT1END  resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot. Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves. This ENT2 neuropathy ENT2END was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to methylprednisolone
0	This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of ENT1 graft-versus-host disease  ENT1END  and the symptoms subsequently responded to ENT2 methylprednisolone ENT2END
0	This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of ENT1 graft-versus-host disease ENT1END , and the symptoms subsequently responded to methylprednisolone. Although the mechanisms of peripheral neuropathy are still unclear, high-dose ENT2 cytosine arabinoside ENT2END is a therapy that is potentially toxic to the peripheral nervous system, and auto/alloimmunity may play an important role in these mechanisms
0	A 49-year-old Japanese man was diagnosed with ENT1 acute myeloid leukemia  ENT1END  After he achieved complete remission, he received high-dose cytosine arabinoside treatment (2 g/m2 twice a day for 5 days; total, 20 g/m2) as consolidation therapy. The first course of high-dose cytosine arabinoside resulted in no unusual symptoms, but on day 21 of the second course of treatment, the patient complained of numbness in his right foot. Electromyogram and nerve-conduction studies showed peripheral neuropathy in both peroneal nerves. This neuropathy was gradually resolving; however, after the patient received allogeneic bone marrow transplantation, the symptoms worsened, with the development of graft-versus-host disease, and the symptoms subsequently responded to ENT2 methylprednisolone ENT2END
0	Peripheral neuropathy caused by high-dose ENT1 cytosine arabinoside  ENT1END  treatment in a patient with ENT2 acute myeloid leukemia ENT2END
0	Intracerebroventricular injection of atropine, hexamethonium, and ENT1 naloxone ENT1END also decreased ENT2 catalepsy ENT2END induced by morphine plus nicotine
1	It was concluded that ENT1 morphine ENT1END ENT2 catalepsy ENT2END can be elicited by opioid and cholinergic receptors, and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms
0	Intraperitoneal administration of atropine, naloxone, mecamylamine, and ENT1 hexamethonium ENT1END to mice reduced ENT2 catalepsy ENT2END induced by a combination of morphine with nicotine
0	Intracerebroventricular injection of ENT1 atropine  ENT1END  hexamethonium, and naloxone also decreased ENT2 catalepsy ENT2END induced by morphine plus nicotine
1	In the present study, effects of ENT1 nicotine ENT1END on ENT2 catalepsy ENT2END induced by morphine in mice have been investigated
0	Intraperitoneal administration of atropine, naloxone, ENT1 mecamylamine  ENT1END  and hexamethonium to mice reduced ENT2 catalepsy ENT2END induced by a combination of morphine with nicotine
0	A transient ENT1 neurological deficit  ENT1END  following intrathecal injection of 1% hyperbaric ENT2 bupivacaine ENT2END for unilateral spinal anaesthesia
1	We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1% hyperbaric ENT1 bupivacaine  ENT1END slowly injected through a 25-gauge pencil-point spinal needle. The surgery and anaesthesia were uneventful, but 3 days after surgery, the patient reported an area of hypoaesthesia over L3-L4 dermatomes of the leg which had been operated on ( ENT2 loss of pinprick sensation ENT2END ) without reduction in muscular strength
0	Cocaine-induced mood disorder: prevalence rates and ENT1 psychiatric  ENT1END  symptoms in an outpatient ENT2 cocaine ENT2END -dependent sample
0	243 cocaine-dependent outpatients with ENT1 cocaine ENT1END induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms. The prevalence rate for CIMD was 12% at baseline. Introduction of the DSM-IV diagnosis of CIMD did not substantially affect rates of the other ENT2 depressive disorders ENT2END
0	243 cocaine-dependent outpatients with ENT1 cocaine  ENT1END -induced mood disorder ( ENT2 CIMD ENT2END ), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms
1	This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance-induced and other ENT1 mood disorders ENT1END  243 ENT2 cocaine ENT2END -dependent outpatients with cocaine-induced mood disorder (CIMD), other mood disorders, or no mood disorder were compared on measures of psychiatric symptoms
0	The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of ENT1 bupivacaine ENT1END  This patient had hearing threshold changes (15-20 dB) at 6-10 kHz on the opposite side also. IBPB may cause transient ENT2 auditory dysfunction ENT2END in the ipsilateral ear, possibly via an effect on sympathetic innervation
1	75% with ENT1 adrenaline ENT1END was given followed by a 24-hr continuous infusion of 0.25% bupivacaine. Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation. In four patients ENT2 hearing impairment ENT2END on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day
1	25% ENT1 bupivacaine  ENT1END  Three audiometric threshold measurements (0.25-18 kHz) were made: the first before IBPB, the second 2-6 h after surgery and the third on the first day after operation. In four patients ENT2 hearing impairment ENT2END on the side of the block was demonstrated after operation, in three measurements on the day of surgery and in one on the following day
1	Fatal ENT1 aplastic anemia  ENT1END  due to ENT2 indomethacin ENT2END --lymphocyte transformation tests in vitro
0	A case of fatal ENT1 aplastic anemia ENT1END is described in which no drugs other than ENT2 allopurinol ENT2END and indomethacin were given
0	Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat ENT1 cerebral infarction ENT1END  Streptomycin was administered to the inner ear by osmotic pump for 24 h, and ENT2 edaravone ENT2END (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days
0	Edaravone, a free radical scavenger, has potent free radical quenching action and is used in clinical practice to treat ENT1 cerebral infarction ENT1END . ENT2 Streptomycin ENT2END was administered to the inner ear by osmotic pump for 24 h, and edaravone (n=8) or saline (n=6) was intraperitoneally injected once a day for 7 days
0	This study investigated alleviation of streptomycin-induced ENT1 vestibulotoxicity ENT1END by ENT2 edaravone ENT2END in guinea pigs
1	Protective effect of edaravone against ENT1 streptomycin  ENT1END -induced ENT2 vestibulotoxicity ENT2END in the guinea pig
0	75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for ENT1 anemia ENT1END by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB). Hb, PSA and ENT2 Testosterone ENT2END measurements were recorded
1	All patients received CAB [leuprolide acetate ( ENT1 LHRH-A  ENT1END  3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for ENT2 anemia ENT2END by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB)
1	75 mg, intramuscularly, every 28 days plus 250 mg ENT1 flutamide  ENT1END  tid, per Os] and were evaluated for ENT2 anemia ENT2END by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB)
0	BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in ENT1 prostate cancer  ENT1END patients without bone involvement. PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study. All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB). Hb, PSA and ENT2 Testosterone ENT2END measurements were recorded
0	BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in ENT1 prostate cancer  ENT1END  patients without bone involvement. PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study. All patients received CAB [ ENT2 leuprolide acetate ENT2END (LHRH-A) 3
0	BACKGROUND: To determine the onset and extent of combined androgen blockade (CAB)-induced anemia in ENT1 prostate cancer  ENT1END  patients without bone involvement. PATIENTS AND METHODS: Forty-two patients with biopsy-proven prostatic adenocarcinoma [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study. All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg ENT2 flutamide ENT2END , tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB)
0	PATIENTS AND METHODS: Forty-two patients with biopsy-proven ENT1 prostatic adenocarcinoma  ENT1END [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study. All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg flutamide, tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB). Hb, PSA and ENT2 Testosterone ENT2END measurements were recorded
0	PATIENTS AND METHODS: Forty-two patients with biopsy-proven ENT1 prostatic adenocarcinoma ENT1END  [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study. All patients received CAB ENT2 leuprolide acetate ENT2END (LHRH-A) 3
0	PATIENTS AND METHODS: Forty-two patients with biopsy-proven ENT1 prostatic adenocarcinoma  ENT1END  [26 with stage C (T3N0M0) and 16 with stage D1 (T3N1M0)] were included in this study. All patients received CAB [leuprolide acetate (LHRH-A) 3.75 mg, intramuscularly, every 28 days plus 250 mg ENT2 flutamide ENT2END , tid, per Os] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals (1, 2, 3 and 6 months post-CAB)
0	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced ENT1 diabetes insipidus ENT1END  rat.The expression of ENT2 arginine vasopressin ENT2END (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay
0	Upregulation of the expression of ENT1 vasopressin  ENT1END  gene in the paraventricular and supraoptic nuclei of the lithium-induced ENT2 diabetes insipidus ENT2END rat
0	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced ENT1 diabetes insipidus ENT1END  rat.The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay. The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria. The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations. Plasma ENT2 sodium ENT2END concentrations were found to be slightly increased in the Li-treated rats compared with those in controls
0	These results suggest that dehydration and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the ENT1 Li ENT1END induced ENT2 diabetes insipidus ENT2END rat
0	Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced ENT1 diabetes insipidus ENT1END  rat.The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay. The male Wistar rats consuming a diet that contained ENT2 LiCl ENT2END (60 mmol/kg) for 4 weeks developed marked polyuria
0	These results suggest that ENT1 dehydration ENT1END and/or the activation of visceral afferent inputs may contribute to the elevation of plasma ENT2 AVP ENT2END and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat
0	Upregulation of the expression of ENT1 vasopressin  ENT1END  gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced polyuria, using in situ hybridization histochemistry and radioimmunoassay. The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked polyuria. The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations. Plasma sodium concentrations were found to be slightly increased in the Li-treated rats compared with those in controls. Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls. These results suggest that ENT2 dehydration ENT2END and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat
0	Plasma ENT1 sodium  ENT1END  concentrations were found to be slightly increased in the Li-treated rats compared with those in controls. Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls. These results suggest that ENT2 dehydration ENT2END and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat
0	Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the ENT1 Li  ENT1END treated rats compared with controls. These results suggest that ENT2 dehydration ENT2END and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat
0	The male Wistar rats consuming a diet that contained ENT1 LiCl  ENT1END  (60 mmol/kg) for 4 weeks developed marked polyuria. The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations. Plasma sodium concentrations were found to be slightly increased in the Li-treated rats compared with those in controls. Plasma concentration of AVP and transcripts of AVP gene in the PVN and SON were significantly increased in the Li-treated rats compared with controls. These results suggest that ENT2 dehydration ENT2END and/or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li-induced diabetes insipidus rat
0	The expression of arginine vasopressin ( ENT1 AVP ENT1END  gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced ENT2 polyuria ENT2END , using in situ hybridization histochemistry and radioimmunoassay
0	Upregulation of the expression of ENT1 vasopressin  ENT1END  gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat.The expression of arginine vasopressin (AVP) gene in the paraventricular (PVN) and supraoptic nuclei (SON) was investigated in rats with lithium (Li)-induced ENT2 polyuria ENT2END , using in situ hybridization histochemistry and radioimmunoassay
0	The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked ENT1 polyuria  ENT1END  The Li-treated rats produced a large volume of hypotonic urine with low ionic concentrations. Plasma ENT2 sodium ENT2END concentrations were found to be slightly increased in the Li-treated rats compared with those in controls
0	The male Wistar rats consuming a diet that contained LiCl (60 mmol/kg) for 4 weeks developed marked ENT1 polyuria ENT1END . The ENT2 Li ENT2END -treated rats produced a large volume of hypotonic urine with low ionic concentrations
1	The male Wistar rats consuming a diet that contained ENT1 LiCl  ENT1END  (60 mmol/kg) for 4 weeks developed marked ENT2 polyuria ENT2END
1	ENT1 Hallucinations  ENT1END  and ENT2 ifosfamide ENT2END -induced neurotoxicity
0	"Eyes-closed" ENT1 hallucinatory ENT1END experiences appear to be an unusual feature of this presentation. Patients anxious about this experience respond well to support and education about this occurrence. Optimal pharmacologic management of disturbed patients is unclear. If agitation becomes marked, high-potency neuroleptics (i.e., ENT2 haloperidol ENT2END ) may be effective
0	Hallucinations and ENT1 ifosfamide  ENT1END -induced ENT2 neurotoxicity ENT2END
0	The clinician should be alerted for possible ifosfamide-induced hallucinations, which may occur without other signs of ENT1 neurotoxicity  ENT1END  "Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation. Patients anxious about this experience respond well to support and education about this occurrence. Optimal pharmacologic management of disturbed patients is unclear. If agitation becomes marked, high-potency neuroleptics (i.e., ENT2 haloperidol ENT2END ) may be effective
0	The clinician should be alerted for possible ENT1 ifosfamide ENT1END induced hallucinations, which may occur without other signs of neurotoxicity. "Eyes-closed" hallucinatory experiences appear to be an unusual feature of this presentation. Patients anxious about this experience respond well to support and education about this occurrence. Optimal pharmacologic management of disturbed patients is unclear. If ENT2 agitation ENT2END becomes marked, high-potency neuroleptics (i
0	If ENT1 agitation  ENT1END  becomes marked, high-potency neuroleptics (i.e., ENT2 haloperidol ENT2END ) may be effective
1	We report the case of a patient in whom ENT1 troleandomycin ENT1END induced ENT2 hepatitis ENT2END was followed by prolonged anicteric cholestasis
1	ENT1 Jaundice ENT1END occurred after administration of ENT2 troleandomycin ENT2END for 7 days and was associated with hypereosinophilia
1	Jaundice occurred after administration of ENT1 troleandomycin ENT1END  for 7 days and was associated with ENT2 hypereosinophilia ENT2END
1	Prolonged ENT1 cholestasis  ENT1END  after ENT2 troleandomycin ENT2END -induced acute hepatitis
1	Jaundice occurred after administration of ENT1 troleandomycin ENT1END  for 7 days and was associated with hypereosinophilia. Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by ENT2 pruritus ENT2END and high levels of alkaline phosphatase and gammaglutamyltransferase activities
1	ENT1 Doxorubicin ENT1END ENT2 cardiomyopathy ENT2END in children with left-sided Wilms tumor
0	Two children with Wilms tumor of the left kidney experienced severe ENT1 anthracycline ENT1END ENT2 cardiomyopathy ENT2END after irradiation to the tumor bed and conventional dosage of doxorubicin
0	Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the ENT1 tumor ENT1END bed and conventional dosage of ENT2 doxorubicin ENT2END
0	Two children with Wilms tumor of the left kidney experienced severe ENT1 anthracycline  ENT1END  cardiomyopathy after irradiation to the ENT2 tumor ENT2END bed and conventional dosage of doxorubicin
0	ENT1 Doxorubicin  ENT1END  cardiomyopathy in children with left-sided ENT2 Wilms tumor ENT2END
0	Two children with ENT1 Wilms tumor  ENT1END of the left kidney experienced severe ENT2 anthracycline ENT2END cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin
0	8 mm Hg in the HEM and ENT1 SNP ENT1END groups, respectively, during hypotension (P less than 0.02). It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload. They are thus more important during absolute ENT2 hypovolemia ENT2END than during deliberate hypotension
0	8 mm Hg in the ENT1 HEM  ENT1END and ENT2 SNP ENT2END groups, respectively, during hypotension (P less than 0
1	Systolic pressure variation is greater during hemorrhage than during ENT1 sodium nitroprusside  ENT1END -induced ENT2 hypotension ENT2END in ventilated dogs
0	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent ENT1 anemia ENT1END who were receiving ENT2 iron ENT2END chelation therapy with daily subcutaneous deferoxamine
0	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent ENT1 anemia ENT1END  who were receiving iron chelation therapy with daily subcutaneous ENT2 deferoxamine ENT2END
0	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving ENT1 iron ENT1END  chelation therapy with daily subcutaneous deferoxamine. Twenty-two patients in the affected group had ENT2 abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz ENT2END and in the hearing threshold levels of 30 to 100 decibels
1	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous ENT1 deferoxamine  ENT1END . Twenty-two patients in the affected group had ENT2 abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz ENT2END and in the hearing threshold levels of 30 to 100 decibels
0	ENT1 Visual and auditory neurotoxicity  ENT1END was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving ENT2 iron ENT2END chelation therapy with daily subcutaneous deferoxamine
0	Auditory deterioration and improvement, demonstrated serially in individual patients receiving and not receiving deferoxamine, respectively, provided convincing evidence for a cause-and-effect relation between ENT1 deferoxamine ENT1END administration and ENT2 ototoxicity ENT2END
0	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving ENT1 iron ENT1END  chelation therapy with daily subcutaneous deferoxamine. Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels. When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic. Audiograms from 15 patients remained abnormal and four patients required hearing aids because of ENT2 permanent disability ENT2END
0	Audiograms from 15 patients remained abnormal and four patients required hearing aids because of ENT1 permanent disability ENT1END . Since 18 of the 22 patients were initially receiving ENT2 deferoxamine ENT2END doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further toxicity was demonstrated
0	Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving ENT1 iron ENT1END  chelation therapy with daily subcutaneous deferoxamine. Twenty-two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4,000 to 8,000 Hz and in the hearing threshold levels of 30 to 100 decibels. When deferoxamine therapy was discontinued and serial studies were performed, audiograms in seven cases reverted to normal or near normal within two to three weeks, and nine of 13 patients with symptoms became asymptomatic. Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability. Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg/kg per dose, therapy was restarted with lower doses, usually 50 mg/kg per dose or less depending on the degree of auditory abnormality, and with the exception of two cases no further ENT2 toxicity ENT2END was demonstrated
0	Based on these data, a plan of management was developed that allows effective yet safe administration of ENT1 deferoxamine ENT1END  A dose of 50 mg/kg is recommended in those without audiogram abnormalities. With mild ENT2 toxicity ENT2END , a reduction to 30 or 40 mg/kg per dose should result in a reversal of the abnormal results to normal within four weeks
0	Moderate abnormalities require a reduction of ENT1 deferoxamine ENT1END to 25 mg/kg per dose with careful monitoring. In those with symptoms of ENT2 hearing loss ENT2END , the drug should be stopped for four weeks, and when the audiogram is stable or improved, therapy should be restarted at 10 to 25 mg/kg per dose
0	ENT1 Visual and auditory neurotoxicity  ENT1END was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving ENT2 iron ENT2END chelation therapy with daily subcutaneous deferoxamine
1	Serial studies of auditory neurotoxicity in patients receiving ENT1 deferoxamine  ENT1END  therapy ENT2 Visual and auditory neurotoxicity ENT2END was previously documented in 42 of 89 patients with transfusion-dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine
0	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo ENT1 dementia ENT1END  models.To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in ENT2 amyloid beta peptide(1-42) ENT2END -infused rats
0	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo ENT1 dementia ENT1END  models.To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and ENT2 p-coumaric acid ENT2END
0	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo ENT1 dementia ENT1END  models.To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of ENT2 maltol ENT2END and p-coumaric acid
0	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo ENT1 dementia ENT1END  models.To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in ENT2 scopolamine ENT2END -injected rats and in amyloid beta peptide(1-42)-infused rats
0	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo ENT1 dementia ENT1END  models.To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or ENT2 H2O2 ENT2END
0	A novel compound, ENT1 maltolyl p-coumarate  ENT1END , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo ENT2 dementia ENT2END models
0	A novel compound, maltolyl p-coumarate, attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo ENT1 dementia ENT1END  models.To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), ENT2 glutamate ENT2END or H2O2
0	In the present study, we investigated whether maltolyl p-coumarate could improve ENT1 cognitive decline  ENT1END in scopolamine-injected rats and in ENT2 amyloid beta peptide(1-42) ENT2END -infused rats
0	To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of maltol and ENT1 p-coumaric acid  ENT1END . In the present study, we investigated whether maltolyl p-coumarate could improve ENT2 cognitive decline ENT2END in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats
0	To develop a novel and effective drug that could enhance cognitive function and neuroprotection, we newly synthesized maltolyl p-coumarate by the esterification of ENT1 maltol  ENT1END  and p-coumaric acid. In the present study, we investigated whether maltolyl p-coumarate could improve ENT2 cognitive decline ENT2END in scopolamine-injected rats and in amyloid beta peptide(1-42)-infused rats
1	In the present study, we investigated whether maltolyl p-coumarate could improve ENT1 cognitive decline  ENT1END  in ENT2 scopolamine ENT2END -injected rats and in amyloid beta peptide(1-42)-infused rats
0	Maltolyl p-coumarate was found to attenuate ENT1 cognitive deficits  ENT1END in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or ENT2 H2O2 ENT2END
0	A novel compound, ENT1 maltolyl p-coumarate  ENT1END , attenuates ENT2 cognitive deficits ENT2END and shows neuroprotective effects in vitro and in vivo dementia models
0	Maltolyl p-coumarate was found to attenuate ENT1 cognitive deficits  ENT1END  in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), ENT2 glutamate ENT2END or H2O2
0	Cells were pretreated with maltolyl p-coumarate, before exposed to ENT1 amyloid beta peptide(1-42) ENT1END  glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against ENT2 Alzheimer's disease ENT2END that is characterized by wide spread neuronal death and progressive decline of cognitive function
0	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in ENT1 scopolamine  ENT1END -injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against ENT2 Alzheimer's disease ENT2END that is characterized by wide spread neuronal death and progressive decline of cognitive function
0	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or ENT1 H2O2  ENT1END . We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against ENT2 Alzheimer's disease ENT2END that is characterized by wide spread neuronal death and progressive decline of cognitive function
0	Taking these in vitro and in vivo results together, our study suggests that ENT1 maltolyl p-coumarate  ENT1END is a potentially effective candidate against ENT2 Alzheimer's disease ENT2END that is characterized by wide spread neuronal death and progressive decline of cognitive function
0	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), ENT1 glutamate  ENT1END  or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against ENT2 Alzheimer's disease ENT2END that is characterized by wide spread neuronal death and progressive decline of cognitive function
0	Cells were pretreated with maltolyl p-coumarate, before exposed to ENT1 amyloid beta peptide(1-42) ENT1END , glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread ENT2 neuronal death ENT2END and progressive decline of cognitive function
0	In the present study, we investigated whether maltolyl p-coumarate could improve cognitive decline in ENT1 scopolamine  ENT1END -injected rats and in amyloid beta peptide(1-42)-infused rats. Maltolyl p-coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide(1-42)-infused rats. We also examined the neuroprotective effects of maltolyl p-coumarate in vitro using SH-SY5Y cells. Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread ENT2 neuronal death ENT2END and progressive decline of cognitive function
0	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), glutamate or ENT1 H2O2  ENT1END . We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread ENT2 neuronal death ENT2END and progressive decline of cognitive function
0	Taking these in vitro and in vivo results together, our study suggests that ENT1 maltolyl p-coumarate  ENT1END  is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread ENT2 neuronal death ENT2END and progressive decline of cognitive function
0	Cells were pretreated with maltolyl p-coumarate, before exposed to amyloid beta peptide(1-42), ENT1 glutamate  ENT1END  or H2O2. We found that maltolyl p-coumarate significantly decreased apoptotic cell death and reduced reactive oxygen species, cytochrome c release, and caspase 3 activation. Taking these in vitro and in vivo results together, our study suggests that maltolyl p-coumarate is a potentially effective candidate against Alzheimer's disease that is characterized by wide spread ENT2 neuronal death ENT2END and progressive decline of cognitive function
1	Sixty percent of the males developed breast changes or ENT1 impotence ENT1END while taking ENT2 cimetidine ENT2END and in all cases these changes disappeared when cimetidine was replaced by ranitidine
0	Sixty percent of the males developed breast changes or ENT1 impotence ENT1END  while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine. Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum ENT2 creatinine ENT2END level than seen with cimetidine therapy
0	2 g per day for ENT1 ranitidine  ENT1END and 3.6 g per day for cimetidine). Sixty percent of the males developed breast changes or ENT2 impotence ENT2END while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine
0	The H2- ENT1 histamine  ENT1END receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states. Nineteen patients had Zollinger-Ellison syndrome, one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion. The rates of onset of the action of cimetidine and ranitidine were the same. The actions of both drugs were increased by anticholinergic agents, and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion. However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine). Sixty percent of the males developed breast changes or ENT2 impotence ENT2END while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine
0	Treatment with high doses of ENT1 cimetidine ENT1END (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with ENT2 hepatic or hematologic toxicity ENT2END or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy
0	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with ENT1 hepatic or hematologic toxicity  ENT1END  or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum ENT2 creatinine ENT2END level than seen with cimetidine therapy
0	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with ENT1 hepatic or hematologic toxicity ENT1END  or alterations of serum gastrin concentrations, but ENT2 ranitidine ENT2END therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy
0	Nineteen patients had Zollinger-Ellison syndrome, one patient had ENT1 systemic mastocytosis ENT1END  and two patients had idiopathic hypersecretion. The rates of onset of the action of ENT2 cimetidine ENT2END and ranitidine were the same
0	Nineteen patients had Zollinger-Ellison syndrome, one patient had ENT1 systemic mastocytosis  ENT1END , and two patients had idiopathic hypersecretion. The rates of onset of the action of cimetidine and ranitidine were the same. The actions of both drugs were increased by anticholinergic agents, and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion. However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine). Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine. Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum ENT2 creatinine ENT2END level than seen with cimetidine therapy
0	Nineteen patients had Zollinger-Ellison syndrome, one patient had ENT1 systemic mastocytosis ENT1END , and two patients had idiopathic hypersecretion. The rates of onset of the action of cimetidine and ENT2 ranitidine ENT2END were the same
0	The H2- ENT1 histamine  ENT1END  receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states. Nineteen patients had Zollinger-Ellison syndrome, one patient had ENT2 systemic mastocytosis ENT2END , and two patients had idiopathic hypersecretion
0	Nineteen patients had ENT1 Zollinger-Ellison syndrome  ENT1END  one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion. The rates of onset of the action of ENT2 cimetidine ENT2END and ranitidine were the same
0	Nineteen patients had ENT1 Zollinger-Ellison syndrome  ENT1END , one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion. The rates of onset of the action of cimetidine and ranitidine were the same. The actions of both drugs were increased by anticholinergic agents, and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion. However, ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed (1.2 g per day for ranitidine and 3.6 g per day for cimetidine). Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine. Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum ENT2 creatinine ENT2END level than seen with cimetidine therapy
0	Nineteen patients had ENT1 Zollinger-Ellison syndrome  ENT1END , one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion. The rates of onset of the action of cimetidine and ENT2 ranitidine ENT2END were the same
0	The H2- ENT1 histamine  ENT1END  receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short- and long-term basis in 22 patients with gastric acid hypersecretory states. Nineteen patients had ENT2 Zollinger-Ellison syndrome ENT2END , one patient had systemic mastocytosis, and two patients had idiopathic hypersecretion
0	Treatment with high doses of ENT1 cimetidine ENT1END  (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with ENT2 hepatic or hematologic toxicity ENT2END or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy
0	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with ENT1 hepatic or hematologic toxicity  ENT1END  or alterations of serum gastrin concentrations, but ranitidine therapy was associated with a significantly lower serum ENT2 creatinine ENT2END level than seen with cimetidine therapy
0	Treatment with high doses of cimetidine (one to 60 months; median, 11 months) or ranitidine (two to 31 months; median, 14 months) was not associated with ENT1 hepatic or hematologic toxicity  ENT1END  or alterations of serum gastrin concentrations, but ENT2 ranitidine ENT2END therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy
0	The aim of this study was to investigate the effect of Rg1 on ENT1 learning impairment ENT1END by chronic morphine administration and the mechanism responsible for this effect. Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days. Spatial learning capacity was assessed in the Morris water maze. The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency. By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats. The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by N-methyl-D-aspartate (NMDA) receptor antagonist ENT2 MK801 ENT2END
1	The aim of this study was to investigate the effect of Rg1 on ENT1 learning impairment ENT1END  by chronic ENT2 morphine ENT2END administration and the mechanism responsible for this effect
0	The aim of this study was to investigate the effect of ENT1 Rg1  ENT1END on ENT2 learning impairment ENT2END by chronic morphine administration and the mechanism responsible for this effect
0	The aim of this study was to investigate the effect of Rg1 on ENT1 learning impairment ENT1END  by chronic morphine administration and the mechanism responsible for this effect. Male rats were subcutaneously injected with morphine (10 mg/kg) twice a day at 12 hour intervals for 10 days, and Rg1 (30 mg/kg) was intraperitoneally injected 2 hours after the second injection of morphine once a day for 10 days. Spatial learning capacity was assessed in the Morris water maze. The results showed that rats treated with Morphine/Rg1 decreased escape latency and increased the time spent in platform quadrant and entering frequency. By implantation of electrodes and electrophysiological recording in vivo, the results showed that Rg1 restored the long-term potentiation (LTP) impaired by morphine in both freely moving and anaesthetised rats. The electrophysiological recording in vitro showed that Rg1 restored the LTP in slices from the rats treated with morphine, but not changed LTP in the slices from normal saline- or morphine/Rg1-treated rats; this restoration could be inhibited by ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor antagonist MK801
0	Rg1, as a ENT1 ginsenoside ENT1END extracted from Panax ginseng, could ameliorate spatial ENT2 learning impairment ENT2END
1	Antagonism of ENT1 diazepam ENT1END induced effects by Ro15-1788 was investigated postoperatively in a double-blind placebo-controlled trial. The patient's subjective assessment of mood rating, an objective test of performance, a test for ENT2 amnesia ENT2END , and vital signs were recorded for up to 300 min after administration of the trial drug
0	No significant differences between the two groups were observed for mood rating, ENT1 amnesia ENT1END  or vital signs. The ENT2 Ro15-1788 ENT2END group showed a significant improvement in the performance test up to 120 min after administration of the drug
1	Thiopentone pretreatment for ENT1 propofol  ENT1END  injection ENT2 pain ENT2END in ambulatory patients
0	We conclude that lidocaine reduces the incidence and severity of propofol injection ENT1 pain ENT1END in ambulatory patients whereas ENT2 thiopentone ENT2END only reduces its severity
0	We conclude that ENT1 lidocaine  ENT1END reduces the incidence and severity of propofol injection ENT2 pain ENT2END in ambulatory patients whereas thiopentone only reduces its severity
0	Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing ENT1 propofol ENT1END administration using an infusion pump (rate 1000 micrograms.kg-1.min-1). ENT2 Loss of consciousness ENT2END occurred in 60-90 sec
0	Patients in Group C received 2 ml normal saline, Group L, 2 ml, lidocaine 2% (40 mg) and Group T, 2 ml ENT1 thiopentone  ENT1END 2.5% (50 mg). Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1). ENT2 Loss of consciousness ENT2END occurred in 60-90 sec
0	Patients in Group C received 2 ml normal saline, Group L, 2 ml, ENT1 lidocaine  ENT1END 2% (40 mg) and Group T, 2 ml thiopentone 2.5% (50 mg). Venous discomfort was assessed with a visual analogue scale (VAS) 5-15 sec after commencing propofol administration using an infusion pump (rate 1000 micrograms.kg-1.min-1). ENT2 Loss of consciousness ENT2END occurred in 60-90 sec
0	Effect of captopril on pre-existing and ENT1 aminonucleoside  ENT1END -induced proteinuria in spontaneously ENT2 hypertensive ENT2END rats
0	Proteinuria is a side effect of captopril treatment in ENT1 hypertensive ENT1END patients. The possibility of reproducing the same renal abnormality with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, ENT2 sodium ENT2END and potassium, endogenous creatinine clearance, body weight, and food and water consumption
0	Proteinuria is a side effect of ENT1 captopril  ENT1END treatment in ENT2 hypertensive ENT2END patients
0	Proteinuria is a side effect of captopril treatment in ENT1 hypertensive ENT1END  patients. The possibility of reproducing the same renal abnormality with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous ENT2 creatinine ENT2END clearance, body weight, and food and water consumption
0	Proteinuria is a side effect of captopril treatment in ENT1 hypertensive ENT1END  patients. The possibility of reproducing the same renal abnormality with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and ENT2 potassium ENT2END , endogenous creatinine clearance, body weight, and food and water consumption
0	Proteinuria is a side effect of captopril treatment in ENT1 hypertensive ENT1END  patients. The possibility of reproducing the same renal abnormality with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption. However, ENT2 ketone ENT2END bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR
0	Effect of captopril on pre-existing and ENT1 aminonucleoside ENT1END -induced proteinuria in spontaneously hypertensive rats.Proteinuria is a side effect of captopril treatment in hypertensive patients. The possibility of reproducing the same ENT2 renal abnormality ENT2END with captopril was examined in SHR
0	The possibility of reproducing the same ENT1 renal abnormality  ENT1END  with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, ENT2 sodium ENT2END and potassium, endogenous creatinine clearance, body weight, and food and water consumption
0	The possibility of reproducing the same ENT1 renal abnormality ENT1END  with ENT2 captopril ENT2END was examined in SHR
0	The possibility of reproducing the same ENT1 renal abnormality  ENT1END  with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous ENT2 creatinine ENT2END clearance, body weight, and food and water consumption
0	The possibility of reproducing the same ENT1 renal abnormality  ENT1END  with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and ENT2 potassium ENT2END , endogenous creatinine clearance, body weight, and food and water consumption
0	The possibility of reproducing the same ENT1 renal abnormality  ENT1END  with captopril was examined in SHR. Oral administration of captopril at 100 mg/kg for 14 days failed to aggravate proteinuria pre-existing in SHR. Also, captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption. However, ENT2 ketone ENT2END bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR
1	Effect of captopril on pre-existing and ENT1 aminonucleoside  ENT1END -induced ENT2 proteinuria ENT2END in spontaneously hypertensive rats
0	Also, captopril treatment failed to potentiate or facilitate development of massive ENT1 proteinuria  ENT1END invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, ENT2 sodium ENT2END and potassium, endogenous creatinine clearance, body weight, and food and water consumption
0	ENT1 Proteinuria  ENT1END is a side effect of ENT2 captopril ENT2END treatment in hypertensive patients
0	Also, captopril treatment failed to potentiate or facilitate development of massive ENT1 proteinuria  ENT1END  invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous ENT2 creatinine ENT2END clearance, body weight, and food and water consumption
0	Also, captopril treatment failed to potentiate or facilitate development of massive ENT1 proteinuria  ENT1END  invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and ENT2 potassium ENT2END , endogenous creatinine clearance, body weight, and food and water consumption
0	Also, captopril treatment failed to potentiate or facilitate development of massive ENT1 proteinuria  ENT1END  invoked by puromycin aminonucleoside in SHR. Captopril had little or no demonstrable effects on serum electrolyte concentrations, excretion of urine, sodium and potassium, endogenous creatinine clearance, body weight, and food and water consumption. However, ENT2 ketone ENT2END bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR
0	Administered to healthy volunteers, a subanesthetic dose of the non-competitive ENT1 NMDA ENT1END receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia. In patients with schizophrenia, ketamine exacerbates the core symptoms of illness, supporting the hypothesis of a ENT2 glutamatergic dysfunction ENT2END
0	In patients with schizophrenia, ENT1 ketamine  ENT1END exacerbates the core symptoms of illness, supporting the hypothesis of a ENT2 glutamatergic dysfunction ENT2END
0	Neural correlates of S-ketamine induced ENT1 psychosis ENT1END  during overt continuous verbal fluency.The glutamatergic ENT2 N-methyl-D-aspartate ENT2END (NMDA) receptor has been implicated in the pathophysiology of schizophrenia
1	ENT1 Ketamine ENT1END elicited ENT2 psychosis ENT2END like psychopathology
0	Our results provide further support for the hypothesis of an ENT1 NMDA ENT1END receptor dysfunction in the pathophysiology of ENT2 schizophrenia ENT2END
0	In patients with ENT1 schizophrenia ENT1END ENT2 ketamine ENT2END exacerbates the core symptoms of illness, supporting the hypothesis of a glutamatergic dysfunction
1	Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with ENT1 aplastic anaemia ENT1END  Preparations containing ENT2 lindane ENT2END continue to be sold over the counter and may represent a hazard to poorly informed patients
0	Is the treatment of scabies hazardous?Treatment for ENT1 scabies ENT1END is usually initiated by general practitioners; most consider ENT2 lindane ENT2END (gamma benzene hexachloride) the treatment of choice
0	Preparations containing ENT1 lindane ENT1END  continue to be sold over the counter and may represent a hazard to poorly informed patients. This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at-risk groups, and give adequate warnings regarding potential ENT2 toxicity ENT2END
1	Evidence is accumulating that ENT1 lindane ENT1END can be ENT2 toxic to the central nervous system ENT2END and may be associated with aplastic anaemia
1	The concomitant administration of etoposide and ENT1 cyclosporin A ENT1END resulted in eradication of hitherto refractory leukemic infiltration of bone marrow. Severe side effects in terms of mental ENT2 confusion ENT2END and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues
1	The concomitant administration of ENT1 etoposide  ENT1END and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow. Severe side effects in terms of mental ENT2 confusion ENT2END and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues
0	The concomitant administration of etoposide and ENT1 cyclosporin A ENT1END  resulted in eradication of hitherto refractory ENT2 leukemic infiltration ENT2END of bone marrow
0	The concomitant administration of ENT1 etoposide  ENT1END  and cyclosporin A resulted in eradication of hitherto refractory ENT2 leukemic infiltration ENT2END of bone marrow
0	A synergistic effect of etoposide and ENT1 cyclosporin A ENT1END was observed in a patient with ENT2 acute T-lymphocytic leukemia ENT2END in relapse
0	A synergistic effect of etoposide and cyclosporin A was observed in a patient with ENT1 acute T-lymphocytic leukemia  ENT1END  in relapse. The concomitant administration of ENT2 etoposide ENT2END and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow
0	Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of ENT1 toxicity ENT1END in normal tissues. This report demonstrates for the first time that the pharmacodynamic properties of ENT2 cyclosporin A ENT2END may not be confined strictly to suppression of normal T-cell functions
0	The concomitant administration of ENT1 etoposide  ENT1END  and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow. Severe side effects in terms of mental confusion and progressive hyperbilirubinemia, however, point to an enhancement not only of antineoplastic effects but also of ENT2 toxicity ENT2END in normal tissues
1	The concomitant administration of etoposide and ENT1 cyclosporin A ENT1END  resulted in eradication of hitherto refractory leukemic infiltration of bone marrow. Severe side effects in terms of mental confusion and progressive ENT2 hyperbilirubinemia ENT2END , however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues
1	The concomitant administration of ENT1 etoposide  ENT1END  and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow. Severe side effects in terms of mental confusion and progressive ENT2 hyperbilirubinemia ENT2END , however, point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues
1	Fatal haemorrhagic myocarditis secondary to ENT1 cyclophosphamide  ENT1END  therapy. ENT2 Haemorrhagic myocarditis ENT2END is a rare but important complication of cyclophosphamide therapy
1	Fatal haemorrhagic myocarditis secondary to ENT1 cyclophosphamide  ENT1END  therapy. ENT2 Haemorrhagic myocarditis ENT2END is a rare but important complication of cyclophosphamide therapy
0	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of ENT1 bacterial infections ENT1END in patients with acute liver failure (ALF). In the present study, oxygen radical production in patients with ALF due to ENT2 paracetamol ENT2END overdose was compared with that of healthy volunteers
0	Defects in superoxide and ENT1 hydrogen peroxide  ENT1END production may be implicated in the high incidence of ENT2 bacterial infections ENT2END in patients with acute liver failure (ALF)
0	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of ENT1 bacterial infections ENT1END  in patients with acute liver failure (ALF). In the present study, ENT2 oxygen ENT2END radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers
0	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of ENT1 bacterial infections ENT1END  in patients with acute liver failure (ALF). In the present study, oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers. Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum. Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0.01). This defect persisted when zymosan opsonized by control serum was used (P < 0.05). Superoxide and hydrogen peroxide production in neutrophils stimulated with ENT2 formyl-methionyl-leucyl-phenylalanine ENT2END (fMLP) from a further 18 ALF patients was unaffected compared with control neutrophils
0	Defects in ENT1 superoxide  ENT1END and hydrogen peroxide production may be implicated in the high incidence of ENT2 bacterial infections ENT2END in patients with acute liver failure (ALF)
0	In the present study, oxygen radical production in patients with ALF due to ENT1 paracetamol ENT1END  ENT2 overdose ENT2END was compared with that of healthy volunteers
0	In the present study, oxygen radical production in patients with ALF due to paracetamol ENT1 overdose ENT1END  was compared with that of healthy volunteers. Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum. Superoxide and ENT2 hydrogen peroxide ENT2END production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0
0	In the present study, ENT1 oxygen  ENT1END  radical production in patients with ALF due to paracetamol ENT2 overdose ENT2END was compared with that of healthy volunteers
0	Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine ( ENT1 fMLP ENT1END  from a further 18 ALF patients was unaffected compared with control neutrophils. Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects (P < 0.0005). These results demonstrate a neutrophil defect in ALF due to paracetamol ENT2 overdose ENT2END , that is complement dependent but independent of serum complement, possibly connected to the complement receptor
0	In the present study, oxygen radical production in patients with ALF due to paracetamol ENT1 overdose ENT1END  was compared with that of healthy volunteers. Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum. ENT2 Superoxide ENT2END and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0
1	In the present study, oxygen radical production in patients with ENT1 ALF  ENT1END due to ENT2 paracetamol ENT2END overdose was compared with that of healthy volunteers
0	Superoxide and ENT1 hydrogen peroxide ENT1END  production by ENT2 ALF ENT2END neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0
0	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ENT1 ALF  ENT1END . In the present study, ENT2 oxygen ENT2END radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers
0	Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl-methionyl-leucyl-phenylalanine ( ENT1 fMLP ENT1END ) from a further 18 ENT2 ALF ENT2END patients was unaffected compared with control neutrophils
0	Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ENT1 ALF  ENT1END or control serum. ENT2 Superoxide ENT2END and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects (P < 0
1	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in ENT1 nephrotic syndrome ENT1END induced by ENT2 puromycin aminonucleoside ENT2END were due to nephrotic syndrome per se, or, at least in part, to the aminonucleoside
0	In pre- ENT1 nephrotic ENT1END stage the plasma level of ENT2 fatty acids ENT2END , triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant
0	In pre- ENT1 nephrotic ENT1END  stage the plasma level of fatty acids, ENT2 triacylglycerol ENT2END and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant
0	In pre- ENT1 nephrotic ENT1END  stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, ENT2 cholesteryl esters ENT2END and HDL remained constant
0	The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of ENT1 puromycin aminonucleoside ENT1END (20 mg/kg for 7 days) and the subsequent development of nephrotic syndrome. Since massive ENT2 albuminuria ENT2END occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11)
0	Since massive ENT1 albuminuria  ENT1END  occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11). In pre-nephrotic stage the plasma level of ENT2 fatty acids ENT2END , triacylglycerol and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant
0	Since massive ENT1 albuminuria  ENT1END  occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11). In pre-nephrotic stage the plasma level of fatty acids, ENT2 triacylglycerol ENT2END and VLDL decreased while that of phospholipid, cholesteryl esters and HDL remained constant
0	Since massive ENT1 albuminuria  ENT1END  occurred after 6 days of treatment, the time-course study was divided into two stages: pre-nephrotic stage (day 1-5) and nephrotic stage (day 6-11). In pre-nephrotic stage the plasma level of fatty acids, triacylglycerol and VLDL decreased while that of phospholipid, ENT2 cholesteryl esters ENT2END and HDL remained constant
0	Pharmacological evidence for the potential of Daucus carota in the management of ENT1 cognitive dysfunctions ENT1END .The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice. The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice. Elevated plus maze and passive avoidance apparatus served as the exteroceptive behavioral models for testing memory. ENT2 Diazepam ENT2END -, scopolamine- and ageing-induced amnesia served as the interoceptive behavioral models
0	Therefore, ENT1 DCE ENT1END may prove to be a useful remedy for the management of ENT2 cognitive dysfunctions ENT2END on account of its multifarious beneficial effects such as, memory improving property, cholesterol lowering property and anticholinesterase activity
0	Therefore, DCE may prove to be a useful remedy for the management of ENT1 cognitive dysfunctions ENT1END  on account of its multifarious beneficial effects such as, memory improving property, ENT2 cholesterol ENT2END lowering property and anticholinesterase activity
0	Pharmacological evidence for the potential of Daucus carota in the management of ENT1 cognitive dysfunctions ENT1END .The present study was aimed at investigating the effects of Daucus carota seeds on cognitive functions, total serum cholesterol levels and brain cholinesterase activity in mice. The ethanolic extract of Daucus carota seeds (DCE) was administered orally in three doses (100, 200, 400 mg/kg) for seven successive days to different groups of young and aged mice. Elevated plus maze and passive avoidance apparatus served as the exteroceptive behavioral models for testing memory. Diazepam-, ENT2 scopolamine ENT2END - and ageing-induced amnesia served as the interoceptive behavioral models
1	ENT1 Diazepam ENT1END -, scopolamine- and ageing-induced ENT2 amnesia ENT2END served as the interoceptive behavioral models
0	Furthermore, ENT1 DCE ENT1END reversed the ENT2 amnesia ENT2END induced by scopolamine (0
0	Furthermore, DCE reversed the ENT1 amnesia ENT1END  induced by scopolamine (0.4 mg/kg, i.p.) and diazepam (1 mg/kg, i.p.). Daucus carota extract (200, 400 mg/kg, p.o.) reduced significantly the brain acetylcholinesterase activity and ENT2 cholesterol ENT2END levels in young and aged mice
1	Furthermore, DCE reversed the ENT1 amnesia ENT1END  induced by ENT2 scopolamine ENT2END (0
0	The present study aimed to investigate the effects of pallidal ENT1 neurotensin ENT1END on haloperidol-induced ENT2 parkinsonian symptoms ENT2END
0	The present study aimed to investigate the effects of pallidal neurotensin on ENT1 haloperidol  ENT1END induced ENT2 parkinsonian symptoms ENT2END
0	The present study aimed to investigate the effects of pallidal neurotensin on haloperidol-induced ENT1 parkinsonian symptoms ENT1END . METHODS: Behavioral experiments and electrophysiological recordings were performed in the present study. RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced parkinsonian catalepsy in rats. Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration. The ENT2 neurotensin type-1 receptor antagonist ENT2END SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin
0	Effects of pallidal ENT1 neurotensin  ENT1END  on haloperidol-induced ENT2 parkinsonian catalepsy ENT2END : behavioral and electrophysiological studies
1	Effects of pallidal neurotensin on ENT1 haloperidol  ENT1END -induced ENT2 parkinsonian catalepsy ENT2END : behavioral and electrophysiological studies
0	RESULTS: Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol-induced ENT1 parkinsonian catalepsy  ENT1END in rats. Electrophysiological recordings showed that microinjection of neurotensin induced excitation of pallidal neurons in the presence of systemic haloperidol administration. The ENT2 neurotensin type-1 receptor antagonist ENT2END SR48692 blocked both the behavioral and the electrophysiological effects induced by neurotensin
0	We describe 4 patients in whom ENT1 hyperkalemia ENT1END ranging from 6.1 to 6.9 mEq/l developed within 3 to 8 days of sulindac administration. In all of them normal serum ENT2 potassium ENT2END levels reached within 2 to 4 days of stopping sulindac
1	As no other medications known to effect serum potassium had been given concomitantly, this course of events is suggestive of a cause-and-effect relationship between ENT1 sulindac ENT1END and ENT2 hyperkalemia ENT2END
1	ENT1 Hyperkalemia ENT1END has recently been recognized as a complication of nonsteroidal antiinflammatory agents (NSAID) such as ENT2 indomethacin ENT2END
0	Several recent studies have stressed the renal sparing features of sulindac, owing to its lack of interference with renal ENT1 prostacyclin  ENT1END synthesis. We describe 4 patients in whom ENT2 hyperkalemia ENT2END ranging from 6
0	Two groups of patients receiving tacrolimus were compared over a period of 1 year, one group comprising ENT1 hypertensive ENT1END patients who were receiving ENT2 nifedipine ENT2END , and the other comprising nonhypertensive patients not receiving nifedipine
1	Two groups of patients receiving ENT1 tacrolimus  ENT1END were compared over a period of 1 year, one group comprising ENT2 hypertensive ENT2END patients who were receiving nifedipine, and the other comprising nonhypertensive patients not receiving nifedipine
0	Nifedipine significantly improved kidney function as indicated by a significant lowering of serum ENT1 creatinine ENT1END levels at 6 and 12 months. The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat ENT2 hypertension ENT2END in this population
0	The observed positive impact of ENT1 nifedipine ENT1END on reducing the ENT2 nephrotoxicity ENT2END associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population
0	The observed positive impact of nifedipine on reducing the ENT1 nephrotoxicity ENT1END  associated with ENT2 tacrolimus ENT2END in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population
0	Nifedipine significantly improved kidney function as indicated by a significant lowering of serum ENT1 creatinine  ENT1END  levels at 6 and 12 months. The observed positive impact of nifedipine on reducing the ENT2 nephrotoxicity ENT2END associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population
1	ENT1 Verapamil  ENT1END -induced carbamazepine ENT2 neurotoxicity ENT2END
0	Two patients with signs of carbamazepine ENT1 neurotoxicity ENT1END after combined treatment with verapamil showed complete recovery after discontinuation of the ENT2 calcium ENT2END entry blocker
1	Verapamil-induced ENT1 carbamazepine ENT1END ENT2 neurotoxicity ENT2END
1	A patient who received antithymocyte globulin therapy for ENT1 aplastic anemia ENT1END due to ENT2 D-penicillamine ENT2END therapy is described
0	A patient who received ENT1 antithymocyte globulin  ENT1END therapy for ENT2 aplastic anemia ENT2END due to D-penicillamine therapy is described
1	ENT1 Encephalopathy  ENT1END  induced by levetiracetam added to ENT2 valproate ENT2END
1	BACKGROUND: We report on the manifestation of a levetiracetam ( ENT1 LEV ENT1END -induced ENT2 encephalopathy ENT2END
1	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate ( ENT1 VPA ENT1END  (2000 mg). Frequency of generalized tonic-clonic seizures increased from one per 6 months to two per month. Neuropsychological testing showed ENT2 impaired word fluency, psychomotor speed and working memory ENT2END
1	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with ENT1 LEV  ENT1END (3000 mg) added to valproate (VPA) (2000 mg). Frequency of generalized tonic-clonic seizures increased from one per 6 months to two per month. Neuropsychological testing showed ENT2 impaired word fluency, psychomotor speed and working memory ENT2END
0	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized ENT1 seizures ENT1END was treated with LEV (3000 mg) added to ENT2 valproate ENT2END (VPA) (2000 mg)
0	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized ENT1 seizures  ENT1END  was treated with ENT2 LEV ENT2END (3000 mg) added to valproate (VPA) (2000 mg)
1	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV (3000 mg) added to valproate ( ENT1 VPA ENT1END ) (2000 mg). Frequency of generalized ENT2 tonic-clonic seizures ENT2END increased from one per 6 months to two per month
1	FINDINGS: A 28-year-old man suffering from idiopathic epilepsy with generalized seizures was treated with ENT1 LEV  ENT1END  (3000 mg) added to valproate (VPA) (2000 mg). Frequency of generalized ENT2 tonic-clonic seizures ENT2END increased from one per 6 months to two per month
0	FINDINGS: A 28-year-old man suffering from ENT1 idiopathic epilepsy  ENT1END with generalized seizures was treated with LEV (3000 mg) added to ENT2 valproate ENT2END (VPA) (2000 mg)
0	FINDINGS: A 28-year-old man suffering from ENT1 idiopathic epilepsy  ENT1END  with generalized seizures was treated with ENT2 LEV ENT2END (3000 mg) added to valproate (VPA) (2000 mg)
0	A percutaneous liver biopsy was obtained showing marked cholestasis, with portal edema, ductular proliferation, and acute ENT1 inflammation ENT1END  ENT2 Metformin hydrochloride ENT2END was discontinued, and the patient's jaundice resolved slowly over a period of several months
1	ENT1 Cholestatic jaundice  ENT1END  associated with the use of ENT2 metformin ENT2END
1	A percutaneous liver biopsy was obtained showing marked ENT1 cholestasis  ENT1END  with portal edema, ductular proliferation, and acute inflammation. ENT2 Metformin hydrochloride ENT2END was discontinued, and the patient's jaundice resolved slowly over a period of several months
0	A percutaneous liver biopsy was obtained showing marked cholestasis, with portal ENT1 edema  ENT1END  ductular proliferation, and acute inflammation. ENT2 Metformin hydrochloride ENT2END was discontinued, and the patient's jaundice resolved slowly over a period of several months
0	Given the onset of his jaundice 2 wk after the initiation of metformin, we believe that this case represents an example of ENT1 metformin ENT1END associated ENT2 hepatotoxicity ENT2END , the first such case reported
0	Given the onset of his ENT1 jaundice ENT1END 2 wk after the initiation of ENT2 metformin ENT2END , we believe that this case represents an example of metformin-associated hepatotoxicity, the first such case reported
1	However, asymptomatic ST changes (greater than or equal to 1 mm ST deviation) were common: six of 25 patients (24%) had ST changes before 5-FU infusion v 17 (68%) during ENT1 5-FU ENT1END infusion (P less than .002). The incidence of ENT2 ischemic ENT2END episodes per patient per hour was 0
0	Although there have been anecdotal reports of ENT1 cardiac toxicity ENT1END associated with ENT2 fluorouracil ENT2END (5-FU) therapy, this phenomenon has not been studied in a systematic fashion
1	Anginal episodes were rare: only one patient had ENT1 angina ENT1END (during ENT2 5-FU ENT2END infusion)
0	We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing ENT1 5-FU ENT1END infusion for treatment of solid ENT2 tumors ENT2END in order to assess the incidence of ischemic ST changes
0	There were two cases of ENT1 sudden death ENT1END  both of which occurred at the end of the chemotherapy course. We conclude that ENT2 5-FU ENT2END infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia, particularly among patients with coronary artery disease
0	5 minutes per patient per hour during ENT1 5-FU ENT1END (P less than .01). ECG changes were more common among patients with known ENT2 coronary artery disease ENT2END
1	ENT1 Sulfonamides ENT1END were associated with ENT2 anencephaly ENT2END (adjusted OR [AOR] = 3
0	Sulfonamides were associated with ENT1 anencephaly ENT1END  (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). ENT2 Nitrofurantoins ENT2END were associated with anophthalmia or microphthalmos (AOR = 3
0	Sulfonamides were associated with ENT1 anencephaly ENT1END  (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	Sulfonamides were associated with ENT1 anencephaly ENT1END  (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	Sulfonamides were associated with ENT1 anencephaly ENT1END  (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	Sulfonamides were associated with ENT1 anencephaly ENT1END  (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
1	ENT1 Sulfonamides ENT1END  were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), ENT2 choanal atresia ENT2END (AOR = 8
0	6), ENT1 choanal atresia  ENT1END  (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). ENT2 Nitrofurantoins ENT2END were associated with anophthalmia or microphthalmos (AOR = 3
0	6), ENT1 choanal atresia  ENT1END  (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	6), ENT1 choanal atresia  ENT1END  (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	6), ENT1 choanal atresia  ENT1END  (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	6), ENT1 choanal atresia  ENT1END  (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
0	ENT1 Sulfonamides ENT1END  were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with ENT2 anophthalmia ENT2END or microphthalmos (AOR = 3
1	ENT1 Nitrofurantoins  ENT1END  were associated with ENT2 anophthalmia ENT2END or microphthalmos (AOR = 3
0	Nitrofurantoins were associated with ENT1 anophthalmia  ENT1END  or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	Nitrofurantoins were associated with ENT1 anophthalmia  ENT1END  or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	Nitrofurantoins were associated with ENT1 anophthalmia  ENT1END  or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	Nitrofurantoins were associated with ENT1 anophthalmia  ENT1END  or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
0	ENT1 Sulfonamides ENT1END  were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or ENT2 microphthalmos ENT2END (AOR = 3
1	ENT1 Nitrofurantoins  ENT1END  were associated with anophthalmia or ENT2 microphthalmos ENT2END (AOR = 3
0	Nitrofurantoins were associated with anophthalmia or ENT1 microphthalmos  ENT1END  (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	Nitrofurantoins were associated with anophthalmia or ENT1 microphthalmos  ENT1END  (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	Nitrofurantoins were associated with anophthalmia or ENT1 microphthalmos  ENT1END  (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	Nitrofurantoins were associated with anophthalmia or ENT1 microphthalmos  ENT1END  (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
0	4), and ENT1 cleft lip ENT1END with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect). CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects. ENT2 Sulfonamides ENT2END and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny
1	ENT1 Nitrofurantoins  ENT1END  were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and ENT2 cleft lip ENT2END with cleft palate (AOR = 2
0	4), and ENT1 cleft lip  ENT1END  with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	4), and ENT1 cleft lip  ENT1END  with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	4), and ENT1 cleft lip  ENT1END  with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	4), and ENT1 cleft lip  ENT1END  with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
1	ENT1 Sulfonamides ENT1END  were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), ENT2 transverse limb deficiency ENT2END (AOR = 2
0	5), ENT1 transverse limb deficiency  ENT1END  (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). ENT2 Nitrofurantoins ENT2END were associated with anophthalmia or microphthalmos (AOR = 3
0	5), ENT1 transverse limb deficiency  ENT1END  (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	5), ENT1 transverse limb deficiency  ENT1END  (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	5), ENT1 transverse limb deficiency  ENT1END  (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	5), ENT1 transverse limb deficiency  ENT1END  (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
1	ENT1 Sulfonamides ENT1END  were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), coarctation of the aorta (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and ENT2 diaphragmatic hernia ENT2END (AOR = 2
0	9), and ENT1 diaphragmatic hernia  ENT1END  (AOR = 2.4; 95% CI, 1.1-5.4). ENT2 Nitrofurantoins ENT2END were associated with anophthalmia or microphthalmos (AOR = 3
0	9), and ENT1 diaphragmatic hernia  ENT1END  (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	9), and ENT1 diaphragmatic hernia  ENT1END  (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	9), and ENT1 diaphragmatic hernia  ENT1END  (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	9), and ENT1 diaphragmatic hernia  ENT1END  (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
0	4), and cleft lip with ENT1 cleft palate  ENT1END (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect). CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects. ENT2 Sulfonamides ENT2END and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny
1	ENT1 Nitrofurantoins  ENT1END  were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with ENT2 cleft palate ENT2END (AOR = 2
0	4), and cleft lip with ENT1 cleft palate  ENT1END  (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	4), and cleft lip with ENT1 cleft palate  ENT1END  (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	4), and cleft lip with ENT1 cleft palate  ENT1END  (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	4), and cleft lip with ENT1 cleft palate  ENT1END  (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
1	CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many ENT1 birth defects ENT1END ENT2 Sulfonamides ENT2END and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny
1	CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many ENT1 birth defects ENT1END . Sulfonamides and ENT2 nitrofurantoins ENT2END were associated with several birth defects, indicating a need for additional scrutiny
0	CONCLUSIONS: Reassuringly, penicillins, erythromycins, and ENT1 cephalosporins  ENT1END  although used commonly by pregnant women, were not associated with many ENT2 birth defects ENT2END
0	CONCLUSIONS: Reassuringly, ENT1 penicillins  ENT1END  erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many ENT2 birth defects ENT2END
0	CONCLUSIONS: Reassuringly, penicillins, ENT1 erythromycins  ENT1END  and cephalosporins, although used commonly by pregnant women, were not associated with many ENT2 birth defects ENT2END
0	Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT1 quinolones  ENT1END  (1 defect). CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many ENT2 birth defects ENT2END
0	1), ENT1 atrial septal defects  ENT1END (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect). CONCLUSIONS: Reassuringly, penicillins, erythromycins, and cephalosporins, although used commonly by pregnant women, were not associated with many birth defects. ENT2 Sulfonamides ENT2END and nitrofurantoins were associated with several birth defects, indicating a need for additional scrutiny
1	ENT1 Nitrofurantoins  ENT1END  were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), ENT2 atrial septal defects ENT2END (AOR = 1
0	1), ENT1 atrial septal defects  ENT1END  (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	1), ENT1 atrial septal defects  ENT1END  (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	1), ENT1 atrial septal defects  ENT1END  (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	1), ENT1 atrial septal defects  ENT1END  (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
1	ENT1 Sulfonamides ENT1END  were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), ENT2 hypoplastic left heart syndrome ENT2END (AOR = 3
1	ENT1 Nitrofurantoins ENT1END  were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), ENT2 hypoplastic left heart syndrome ENT2END (AOR = 4
0	2), ENT1 hypoplastic left heart syndrome  ENT1END  (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	2), ENT1 hypoplastic left heart syndrome  ENT1END  (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	2), ENT1 hypoplastic left heart syndrome  ENT1END  (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	2), ENT1 hypoplastic left heart syndrome  ENT1END  (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
1	ENT1 Sulfonamides ENT1END  were associated with anencephaly (adjusted OR [AOR] = 3.4; 95% confidence interval [CI], 1.3-8.8), hypoplastic left heart syndrome (AOR = 3.2; 95% CI, 1.3-7.6), ENT2 coarctation of the aorta ENT2END (AOR = 2
0	6), ENT1 coarctation of the aorta  ENT1END  (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). ENT2 Nitrofurantoins ENT2END were associated with anophthalmia or microphthalmos (AOR = 3
0	6), ENT1 coarctation of the aorta  ENT1END  (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), ENT2 cephalosporins ENT2END (1 defect), and quinolones (1 defect)
0	6), ENT1 coarctation of the aorta  ENT1END  (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), ENT2 penicillins ENT2END (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	6), ENT1 coarctation of the aorta  ENT1END  (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included ENT2 erythromycins ENT2END (2 defects), penicillins (1 defect), cephalosporins (1 defect), and quinolones (1 defect)
0	6), ENT1 coarctation of the aorta  ENT1END  (AOR = 2.7; 95% CI, 1.3-5.6), choanal atresia (AOR = 8.0; 95% CI, 2.7-23.5), transverse limb deficiency (AOR = 2.5; 95% CI, 1.0-5.9), and diaphragmatic hernia (AOR = 2.4; 95% CI, 1.1-5.4). Nitrofurantoins were associated with anophthalmia or microphthalmos (AOR = 3.7; 95% CI, 1.1-12.2), hypoplastic left heart syndrome (AOR = 4.2; 95% CI, 1.9-9.1), atrial septal defects (AOR = 1.9; 95% CI, 1.1-3.4), and cleft lip with cleft palate (AOR = 2.1; 95% CI, 1.2-3.9). Other antibacterial agents that showed associations included erythromycins (2 defects), penicillins (1 defect), cephalosporins (1 defect), and ENT2 quinolones ENT2END (1 defect)
0	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by ENT1 benzodiazepines ENT1END  Seizures and ENT2 cardiac arrhythmias ENT2END have complicated its use in adult patients
0	ENT1 Flumazenil  ENT1END is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines. Seizures and ENT2 cardiac arrhythmias ENT2END have complicated its use in adult patients
0	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by ENT1 benzodiazepines ENT1END . ENT2 Seizures ENT2END and cardiac arrhythmias have complicated its use in adult patients
1	ENT1 Seizure  ENT1END  after ENT2 flumazenil ENT2END administration in a pediatric patient
0	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by ENT1 benzodiazepines ENT1END . Seizures and cardiac arrhythmias have complicated its use in adult patients. ENT2 Overdose ENT2END patients who have coingested tricyclic antidepressants have a higher risk of these complications
0	ENT1 Overdose ENT1END  patients who have coingested tricyclic antidepressants have a higher risk of these complications. Little information exists concerning adverse effects of ENT2 flumazenil ENT2END in children
0	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and ENT1 respiratory depression  ENT1END induced by ENT2 benzodiazepines ENT2END
0	ENT1 Flumazenil  ENT1END  is a benzodiazepine receptor antagonist used to reverse sedation and ENT2 respiratory depression ENT2END induced by benzodiazepines
0	ENT1 Galanthamine hydrobromide ENT1END  an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) ENT2 overdosage ENT2END
0	Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine (hyoscine) ENT1 overdosage ENT1END . It is longer acting than ENT2 physostigmine ENT2END and is used in anaesthesia to reverse the non-depolarizing neuromuscular block
1	Galanthamine hydrobromide, an anticholinesterase drug capable of penetrating the blood-brain barrier, was used in a patient demonstrating central effects of scopolamine ( ENT1 hyoscine ENT1END ENT2 overdosage ENT2END
1	ENT1 Neuromuscular blockade  ENT1END  with ENT2 magnesium sulfate ENT2END and nifedipine
1	A patient who received tocolysis with ENT1 nifedipine ENT1END developed ENT2 neuromuscular blockade ENT2END after 500 mg of magnesium sulfate was administered
0	A patient who received tocolysis with nifedipine developed ENT1 neuromuscular blockade ENT1END  after 500 mg of magnesium sulfate was administered. This reaction demonstrates that nifedipine can seriously potentiate the toxicity of ENT2 magnesium ENT2END
0	A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of ENT1 magnesium sulfate ENT1END was administered. This reaction demonstrates that nifedipine can seriously potentiate the ENT2 toxicity ENT2END of magnesium
0	This reaction demonstrates that ENT1 nifedipine  ENT1END can seriously potentiate the ENT2 toxicity ENT2END of magnesium
0	This reaction demonstrates that nifedipine can seriously potentiate the ENT1 toxicity  ENT1END  of ENT2 magnesium ENT2END
1	ENT1 Valproate  ENT1END -induced ENT2 chorea ENT2END and encephalopathy in atypical nonketotic hyperglycinemia
0	Valproate-induced ENT1 chorea ENT1END  and encephalopathy in atypical nonketotic hyperglycinemia.Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the ENT2 glycine ENT2END cleavage system leads to an accumulation of glycine in the brain and other body compartments
0	In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant ENT1 psychomotor retardation ENT1END  An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner. This report describes a patient with mild language delay and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of ENT2 valproate ENT2END therapy
0	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of ENT1 glycine  ENT1END in the brain and other body compartments. In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant ENT2 psychomotor retardation ENT2END
0	ENT1 Valproate  ENT1END -induced chorea and encephalopathy in atypical ENT2 nonketotic hyperglycinemia ENT2END
0	ENT1 Nonketotic hyperglycinemia  ENT1END is a disorder of amino acid metabolism in which a defect in the ENT2 glycine ENT2END cleavage system leads to an accumulation of glycine in the brain and other body compartments
0	ENT1 Valproate ENT1END -induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments. In the classical form it presents as neonatal apnea, intractable ENT2 seizures ENT2END , and hypotonia, followed by significant psychomotor retardation
0	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of ENT1 glycine  ENT1END  in the brain and other body compartments. In the classical form it presents as neonatal apnea, intractable ENT2 seizures ENT2END , and hypotonia, followed by significant psychomotor retardation
0	This report describes a patient with mild ENT1 language delay  ENT1END and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of ENT2 valproate ENT2END therapy
0	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of ENT1 glycine  ENT1END  in the brain and other body compartments. In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation. An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner. This report describes a patient with mild ENT2 language delay ENT2END and mental retardation, who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy
1	ENT1 Valproate  ENT1END -induced chorea and ENT2 encephalopathy ENT2END in atypical nonketotic hyperglycinemia
0	Valproate-induced chorea and ENT1 encephalopathy  ENT1END  in atypical nonketotic hyperglycinemia.Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the ENT2 glycine ENT2END cleavage system leads to an accumulation of glycine in the brain and other body compartments
0	This report describes a patient with mild language delay and ENT1 mental retardation  ENT1END  who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of ENT2 valproate ENT2END therapy
0	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of ENT1 glycine  ENT1END  in the brain and other body compartments. In the classical form it presents as neonatal apnea, intractable seizures, and hypotonia, followed by significant psychomotor retardation. An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner. This report describes a patient with mild language delay and ENT2 mental retardation ENT2END , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy
0	ENT1 Valproate ENT1END -induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.Nonketotic hyperglycinemia is a ENT2 disorder of amino acid metabolism ENT2END in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments
0	Nonketotic hyperglycinemia is a ENT1 disorder of amino acid metabolism  ENT1END  in which a defect in the ENT2 glycine ENT2END cleavage system leads to an accumulation of glycine in the brain and other body compartments
0	ENT1 Valproate ENT1END -induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments. In the classical form it presents as neonatal apnea, intractable seizures, and ENT2 hypotonia ENT2END , followed by significant psychomotor retardation
0	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of ENT1 glycine  ENT1END  in the brain and other body compartments. In the classical form it presents as neonatal apnea, intractable seizures, and ENT2 hypotonia ENT2END , followed by significant psychomotor retardation
0	ENT1 Valproate ENT1END -induced chorea and encephalopathy in atypical nonketotic hyperglycinemia.Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments. In the classical form it presents as neonatal ENT2 apnea ENT2END , intractable seizures, and hypotonia, followed by significant psychomotor retardation
0	Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of ENT1 glycine  ENT1END  in the brain and other body compartments. In the classical form it presents as neonatal ENT2 apnea ENT2END , intractable seizures, and hypotonia, followed by significant psychomotor retardation
1	The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% ENT1 apraclonidine ENT1END  Decreases in systolic blood pressure were statistically, but not clinically, significant. No significant changes in diastolic blood pressure, pulse rate and basal tear secretion were noted. Conjunctival blanching and ENT2 mydriasis ENT2END were commonly found
1	The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% ENT1 apraclonidine ENT1END . Decreases in systolic blood pressure were statistically, but not clinically, significant. No significant changes in diastolic blood pressure, pulse rate and basal tear secretion were noted. Conjunctival blanching and mydriasis were commonly found. Upper lid retraction was frequently noted. While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical entropion and marked ENT2 corneal abrasion ENT2END 3 hours after instillation of the medication
1	The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% ENT1 apraclonidine ENT1END . Decreases in systolic blood pressure were statistically, but not clinically, significant. No significant changes in diastolic blood pressure, pulse rate and basal tear secretion were noted. ENT2 Conjunctival blanching ENT2END and mydriasis were commonly found
0	The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% ENT1 apraclonidine ENT1END . ENT2 Decreases in systolic blood pressure ENT2END were statistically, but not clinically, significant
1	The ENT1 ocular hypotensive ENT1END effects were statistically significant for ENT2 apraclonidine ENT2END -treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% apraclonidine
1	The ocular hypotensive effects were statistically significant for apraclonidine-treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1% ENT1 apraclonidine ENT1END . Decreases in systolic blood pressure were statistically, but not clinically, significant. No significant changes in diastolic blood pressure, pulse rate and basal tear secretion were noted. Conjunctival blanching and mydriasis were commonly found. Upper lid retraction was frequently noted. While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance, one subject suffered from mechanical ENT2 entropion ENT2END and marked corneal abrasion 3 hours after instillation of the medication
0	Prostaglandin F2 alpha had little effect on ENT1 pain ENT1END responses. These results demonstrate that both prostaglandin D2 and ENT2 prostaglandin E2 ENT2END exert hyperalgesia in the spinal cord, but in different ways
0	The effects of intrathecal administration of prostaglandins on ENT1 pain ENT1END responses in conscious mice were evaluated by using hot plate and ENT2 acetic acid ENT2END writhing tests
0	Prostaglandin F2 alpha had little effect on ENT1 pain ENT1END  responses. These results demonstrate that both ENT2 prostaglandin D2 ENT2END and prostaglandin E2 exert hyperalgesia in the spinal cord, but in different ways
0	ENT1 Prostaglandin F2 alpha  ENT1END had little effect on ENT2 pain ENT2END responses
0	The effects of intrathecal administration of ENT1 prostaglandins  ENT1END on ENT2 pain ENT2END responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests
0	Conversely, prostaglandin E2-induced hyperalgesia was blocked by ENT1 AH6809  ENT1END (greater than or equal to 500 ng) but not by the substance P antagonist. Prostaglandin F2 alpha had little effect on ENT2 pain ENT2END responses
1	These results demonstrate that both prostaglandin D2 and ENT1 prostaglandin E2 ENT1END  exert ENT2 hyperalgesia ENT2END in the spinal cord, but in different ways
0	Similar results were obtained by ENT1 acetic acid ENT1END writhing tests. The ENT2 hyperalgesic ENT2END effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist
1	The ENT1 hyperalgesic ENT1END  effect of ENT2 prostaglandin D2 ENT2END was blocked by simultaneous injection of a substance P antagonist (greater than or equal to 100 ng) but not by AH6809, a prostanoid EP1-receptor antagonist
0	Conversely, prostaglandin E2-induced ENT1 hyperalgesia  ENT1END was blocked by AH6809 (greater than or equal to 500 ng) but not by the substance P antagonist. ENT2 Prostaglandin F2 alpha ENT2END had little effect on pain responses
0	Prostaglandin E2 showed a ENT1 hyperalgesic ENT1END effect at doses of 1 ENT2 pg ENT2END to 10 ng/mouse, but the effect lasted shorter (3-30 min) than that of prostaglandin D2
0	Conversely, prostaglandin E2-induced ENT1 hyperalgesia  ENT1END  was blocked by ENT2 AH6809 ENT2END (greater than or equal to 500 ng) but not by the substance P antagonist
0	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced penile erection and climbing behavior, and stress-induced plasma ENT1 corticosterone ENT1END level. Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse. These data suggest that U-II may be involved in some aspects of ENT2 psychiatric disorders ENT2END
0	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, ENT1 apomorphine  ENT1END induced penile erection and climbing behavior, and stress-induced plasma corticosterone level. Taken together, the present study demonstrates that the central injection of U-II at doses of 1-10,000 ng/mouse induces anxiogenic- and depressant-like effects in mouse. These data suggest that U-II may be involved in some aspects of ENT2 psychiatric disorders ENT2END
0	These data suggest that ENT1 U-II  ENT1END may be involved in some aspects of ENT2 psychiatric disorders ENT2END
0	) injection of ENT1 U-II ENT1END causes ENT2 hypertension ENT2END and bradycardia and stimulates prolactin and thyrotropin secretion
0	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, apomorphine-induced ENT1 penile erection  ENT1END and climbing behavior, and stress-induced plasma ENT2 corticosterone ENT2END level
1	Whatever was the dose, the central administration of U-II had no effect on body temperature, nociception, ENT1 apomorphine  ENT1END -induced ENT2 penile erection ENT2END and climbing behavior, and stress-induced plasma corticosterone level
0	Whatever was the dose, the central administration of ENT1 U-II  ENT1END had no effect on body temperature, nociception, apomorphine-induced ENT2 penile erection ENT2END and climbing behavior, and stress-induced plasma corticosterone level
0	) injection of ENT1 U-II ENT1END  causes hypertension and ENT2 bradycardia ENT2END and stimulates prolactin and thyrotropin secretion
1	ENT1 Acetazolamide  ENT1END -induced ENT2 Gerstmann syndrome ENT2END
0	Acute ENT1 confusion ENT1END induced by ENT2 acetazolamide ENT2END is a well known adverse drug reaction in patients with renal impairment
0	Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with ENT1 renal impairment ENT1END  We report a case of ENT2 acetazolamide ENT2END -induced Gerstmann syndrome in a patient with normal renal function, to highlight predisposing factors that are frequently overlooked
0	Refractory ENT1 cardiogenic shock ENT1END  and complete heart block after verapamil SR and metoprolol treatment. A case report.A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol. The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine. However, shortly after the use of intravenous ENT2 calcium chloride ENT2END , the refractory hypotension and complete heart block resolved
0	Refractory ENT1 cardiogenic shock  ENT1END  and complete heart block after ENT2 verapamil ENT2END SR and metoprolol treatment
0	Refractory ENT1 cardiogenic shock ENT1END  and complete heart block after verapamil SR and metoprolol treatment. A case report.A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol. The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and ENT2 dobutamine ENT2END
0	Refractory ENT1 cardiogenic shock ENT1END  and complete heart block after verapamil SR and metoprolol treatment. A case report.A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol. The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous ENT2 atropine ENT2END as well as high doses of pressor agents such as dopamine and dobutamine
0	Refractory ENT1 cardiogenic shock ENT1END  and complete heart block after verapamil SR and metoprolol treatment. A case report.A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of metoprolol. The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as ENT2 dopamine ENT2END and dobutamine
0	Refractory ENT1 cardiogenic shock  ENT1END  and complete heart block after verapamil SR and ENT2 metoprolol ENT2END treatment
0	However, shortly after the use of intravenous ENT1 calcium chloride ENT1END , the refractory ENT2 hypotension ENT2END and complete heart block resolved
1	A seventy-eight-year-old woman presented with complete heart block and refractory ENT1 hypotension ENT1END two days after a therapeutic dose of sustained-release ENT2 verapamil ENT2END with concomitant use of metoprolol
0	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and ENT1 dobutamine  ENT1END . However, shortly after the use of intravenous calcium chloride, the refractory ENT2 hypotension ENT2END and complete heart block resolved
0	The patient continued to remain ENT1 hypotensive  ENT1END with complete heart block, even with multiple uses of intravenous ENT2 atropine ENT2END as well as high doses of pressor agents such as dopamine and dobutamine
0	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as ENT1 dopamine  ENT1END  and dobutamine. However, shortly after the use of intravenous calcium chloride, the refractory ENT2 hypotension ENT2END and complete heart block resolved
1	A seventy-eight-year-old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained-release verapamil with concomitant use of ENT1 metoprolol  ENT1END  The patient continued to remain ENT2 hypotensive ENT2END with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine
0	However, shortly after the use of intravenous ENT1 calcium chloride ENT1END , the refractory hypotension and complete ENT2 heart block ENT2END resolved
1	Refractory cardiogenic shock and complete ENT1 heart block  ENT1END  after ENT2 verapamil ENT2END SR and metoprolol treatment
0	The patient continued to remain hypotensive with complete heart block, even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and ENT1 dobutamine  ENT1END . However, shortly after the use of intravenous calcium chloride, the refractory hypotension and complete ENT2 heart block ENT2END resolved
0	The patient continued to remain hypotensive with complete ENT1 heart block  ENT1END  even with multiple uses of intravenous ENT2 atropine ENT2END as well as high doses of pressor agents such as dopamine and dobutamine
0	The patient continued to remain hypotensive with complete ENT1 heart block  ENT1END , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as ENT2 dopamine ENT2END and dobutamine
1	Refractory cardiogenic shock and complete ENT1 heart block  ENT1END  after verapamil SR and ENT2 metoprolol ENT2END treatment
0	Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of ENT1 hemorrhagic cystitis ENT1END  The data demonstrate that CAA after i.v. administration does not contribute to bladder damage. When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with ENT2 mesna ENT2END
0	Chloroacetaldehyde and its contribution to urotoxicity during treatment with ENT1 cyclophosphamide  ENT1END  or ifosfamide. An experimental study/short communication.Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of ENT2 hemorrhagic cystitis ENT2END
1	Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of ENT1 CAA  ENT1END in the development of ENT2 hemorrhagic cystitis ENT2END
0	Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ENT1 ifosfamide  ENT1END . An experimental study/short communication.Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of ENT2 hemorrhagic cystitis ENT2END
0	administration does not contribute to ENT1 bladder damage  ENT1END  When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with ENT2 mesna ENT2END
0	Chloroacetaldehyde and its contribution to urotoxicity during treatment with ENT1 cyclophosphamide  ENT1END  or ifosfamide. An experimental study/short communication.Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis. The data demonstrate that CAA after i.v. administration does not contribute to ENT2 bladder damage ENT2END
0	administration does not contribute to ENT1 bladder damage ENT1END . When instilled directly into the bladder, ENT2 CAA ENT2END exerts urotoxic effects, it is, however, susceptible to detoxification with mesna
0	Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ENT1 ifosfamide  ENT1END . An experimental study/short communication.Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis. The data demonstrate that CAA after i.v. administration does not contribute to ENT2 bladder damage ENT2END
0	Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of ENT1 hemorrhagic cystitis  ENT1END  The data demonstrate that CAA after i.v. administration does not contribute to bladder damage. When instilled directly into the bladder, CAA exerts urotoxic effects, it is, however, susceptible to detoxification with ENT2 mesna ENT2END
0	Chloroacetaldehyde and its contribution to urotoxicity during treatment with ENT1 cyclophosphamide  ENT1END  or ifosfamide. An experimental study/short communication.Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of ENT2 hemorrhagic cystitis ENT2END
1	Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of ENT1 CAA  ENT1END  in the development of ENT2 hemorrhagic cystitis ENT2END
0	Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ENT1 ifosfamide  ENT1END . An experimental study/short communication.Based on clinical data, indicating that chloroacetaldehyde (CAA) is an important metabolite of oxazaphosphorine cytostatics, an experimental study was carried out in order to elucidate the role of CAA in the development of ENT2 hemorrhagic cystitis ENT2END
0	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide ( ENT1 CPM ENT1END  and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma. The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and ENT2 musculoskeletal pain ENT2END
0	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide ( ENT1 VP  ENT1END  and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma. The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and ENT2 musculoskeletal pain ENT2END
1	The most common side effects attributable to the ENT1 AraG  ENT1END included Grade 2 and 3 sensory and motor neuropathy and ENT2 musculoskeletal pain ENT2END
0	Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and ENT1 cyclophosphamide ENT1END  although ENT2 neurological toxicity ENT2END must be closely monitored
0	Our experience supports the safety of giving AraG as salvage therapy in synchrony with ENT1 etoposide  ENT1END and cyclophosphamide, although ENT2 neurological toxicity ENT2END must be closely monitored
1	The most common side effects attributable to the ENT1 AraG ENT1END  included Grade 2 and 3 sensory and motor ENT2 neuropathy ENT2END and musculoskeletal pain
0	Salvage therapy with nelarabine, etoposide, and ENT1 cyclophosphamide  ENT1END  in relapsed/refractory paediatric ENT2 T-cell lymphoblastic leukaemia and lymphoma ENT2END
0	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric ENT1 T-cell lymphoblastic leukaemia and lymphoma ENT1END .A combination of 5 d of nelarabine (AraG) with 5 d of ENT2 etoposide ENT2END (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma
0	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric ENT1 T-cell lymphoblastic leukaemia and lymphoma ENT1END .A combination of 5 d of ENT2 nelarabine ENT2END (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma
0	Salvage therapy with nelarabine, etoposide, and ENT1 cyclophosphamide  ENT1END  in relapsed/refractory paediatric ENT2 T-cell lymphoblastic leukaemia and lymphoma ENT2END
0	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric ENT1 T-cell lymphoblastic leukaemia and lymphoma  ENT1END .A combination of 5 d of nelarabine (AraG) with 5 d of ENT2 etoposide ENT2END (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma
0	Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric ENT1 T-cell lymphoblastic leukaemia and lymphoma  ENT1END .A combination of 5 d of ENT2 nelarabine ENT2END (AraG) with 5 d of etoposide (VP) and cyclophosphamide (CPM) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma
0	A combination of 5 d of nelarabine (AraG) with 5 d of etoposide (VP) and cyclophosphamide ( ENT1 CPM ENT1END ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T-cell leukaemia or lymphoma. The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain. ENT2 Haematological toxicity ENT2END was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies
0	ENT1 Haematological toxicity  ENT1END  was greater for the combination than AraG alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies. All patients had some response to the combined therapy and five of the seven went into complete remission after one or two courses of AraG/ ENT2 VP ENT2END /CPM
1	ENT1 Haematological toxicity ENT1END  was greater for the combination than ENT2 AraG ENT2END alone, although median time to neutrophil and platelet recovery was consistent with other salvage therapies
1	Assessment of the onset and persistence of ENT1 amnesia  ENT1END  during procedural sedation with ENT2 propofol ENT2END
0	During the infusion of aminophylline, the ENT1 ventricular fibrillation  ENT1END threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( ENT2 PO2 ENT2END ) and carbon dioxide (CO2) were kept within normal limits
1	During the infusion of ENT1 aminophylline  ENT1END  the ENT2 ventricular fibrillation ENT2END threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide (CO2) were kept within normal limits
0	During the infusion of aminophylline, the ENT1 ventricular fibrillation ENT1END  threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and ENT2 carbon dioxide ENT2END (CO2) were kept within normal limits
0	During the infusion of aminophylline, the ENT1 ventricular fibrillation ENT1END  threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of ENT2 oxygen ENT2END (PO2) and carbon dioxide (CO2) were kept within normal limits
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( ENT1 PO2 ENT1END ) and carbon dioxide (CO2) were kept within normal limits. When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. These experiments suggest that although many factors may contribute to the increased incidence of ENT2 ventricular arrhythmias ENT2END in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role
0	These experiments suggest that although many factors may contribute to the increased incidence of ENT1 ventricular arrhythmias ENT1END  in respiratory failure, pharmacologic agents, particularly ENT2 aminophylline ENT2END , may play a significant role
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide ( ENT1 CO2  ENT1END  were kept within normal limits. When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. These experiments suggest that although many factors may contribute to the increased incidence of ENT2 ventricular arrhythmias ENT2END in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of ENT1 oxygen  ENT1END  (PO2) and carbon dioxide (CO2) were kept within normal limits. When respiratory failure was produced by hypoventilation (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level. These experiments suggest that although many factors may contribute to the increased incidence of ENT2 ventricular arrhythmias ENT2END in respiratory failure, pharmacologic agents, particularly aminophylline, may play a significant role
0	The possible additive role of pharmacologic agents in precipitating ENT1 cardiac disturbances ENT1END in patients with respiratory failure has only recently been emphasized. The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs. The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle. During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ENT2 PO2 ENT2END ) and carbon dioxide (CO2) were kept within normal limits
0	The possible additive role of pharmacologic agents in precipitating ENT1 cardiac disturbances ENT1END  in patients with respiratory failure has only recently been emphasized. The effects of ENT2 aminophylline ENT2END on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs
0	The possible additive role of pharmacologic agents in precipitating ENT1 cardiac disturbances  ENT1END  in patients with respiratory failure has only recently been emphasized. The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs. The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle. During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and ENT2 carbon dioxide ENT2END (CO2) were kept within normal limits
0	The possible additive role of pharmacologic agents in precipitating ENT1 cardiac disturbances  ENT1END  in patients with respiratory failure has only recently been emphasized. The effects of aminophylline on the ventricular fibrillation threshold during normal acid-base conditions and during respiratory failure were studied in anesthetized open chest dogs. The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle. During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of ENT2 oxygen ENT2END (PO2) and carbon dioxide (CO2) were kept within normal limits
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( ENT1 PO2 ENT1END ) and carbon dioxide (CO2) were kept within normal limits. When ENT2 respiratory failure ENT2END was produced by hypoventilation (pH 7
0	These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in ENT1 respiratory failure  ENT1END  pharmacologic agents, particularly ENT2 aminophylline ENT2END , may play a significant role
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide ( ENT1 CO2  ENT1END ) were kept within normal limits. When ENT2 respiratory failure ENT2END was produced by hypoventilation (pH 7
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of ENT1 oxygen  ENT1END  (PO2) and carbon dioxide (CO2) were kept within normal limits. When ENT2 respiratory failure ENT2END was produced by hypoventilation (pH 7
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( ENT1 PO2 ENT1END ) and carbon dioxide (CO2) were kept within normal limits. When respiratory failure was produced by ENT2 hypoventilation ENT2END (pH 7
0	When respiratory failure was produced by ENT1 hypoventilation ENT1END  (pH 7.05 to 7.25; PC02 70 to 100 mm Hg: P02 20 to 40 mm Hg), infusion of ENT2 aminophylline ENT2END resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen (PO2) and carbon dioxide ( ENT1 CO2  ENT1END ) were kept within normal limits. When respiratory failure was produced by ENT2 hypoventilation ENT2END (pH 7
0	During the infusion of aminophylline, the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of ENT1 oxygen  ENT1END  (PO2) and carbon dioxide (CO2) were kept within normal limits. When respiratory failure was produced by ENT2 hypoventilation ENT2END (pH 7
0	ENT1 Amnesia ENT1END produced by scopolamine and cycloheximide were reversed by ENT2 morphine ENT2END given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial
1	Similarly, pre-test scopolamine partially reversed the scopolamine-induced amnesia, but not significantly; and pre-test cycloheximide failed to reverse the ENT1 cycloheximide ENT1END induced ENT2 amnesia ENT2END
0	Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial (pre-test), and pre-test morphine also facilitated the memory retrieval in the animals administered ENT1 naloxone ENT1END during the training trial. Similarly, pre-test scopolamine partially reversed the scopolamine-induced ENT2 amnesia ENT2END , but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia
1	Similarly, pre-test scopolamine partially reversed the ENT1 scopolamine  ENT1END induced ENT2 amnesia ENT2END , but not significantly; and pre-test cycloheximide failed to reverse the cycloheximide-induced amnesia
0	This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish ENT1 bromocriptine ENT1END induced tachycardia in conscious rats. Isoproterenol pretreatment for 15 days caused ENT2 cardiac hypertrophy ENT2END without affecting baseline blood pressure and heart rate
1	ENT1 Isoproterenol  ENT1END pretreatment for 15 days caused ENT2 cardiac hypertrophy ENT2END without affecting baseline blood pressure and heart rate
0	It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central ENT1 dopamine  ENT1END D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart. This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats. Isoproterenol pretreatment for 15 days caused ENT2 cardiac hypertrophy ENT2END without affecting baseline blood pressure and heart rate
0	Isoproterenol pretreatment for 15 days caused ENT1 cardiac hypertrophy ENT1END  without affecting baseline blood pressure and heart rate. In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and tachycardia. Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. ENT2 domperidone ENT2END (0
1	In control rats, intravenous bromocriptine (150 microg/kg) induced significant hypotension and ENT1 tachycardia ENT1END  ENT2 Bromocriptine ENT2END -induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i
0	This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced ENT1 tachycardia  ENT1END in conscious rats. ENT2 Isoproterenol ENT2END pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate
0	It has been shown that bromocriptine-induced ENT1 tachycardia  ENT1END  which persisted after adrenalectomy, is (i) mediated by central ENT2 dopamine ENT2END D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart
0	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while ENT1 tachycardia  ENT1END was reversed to significant bradycardia, an effect that was partly reduced by i.v. ENT2 domperidone ENT2END (0
1	ENT1 Bromocriptine ENT1END -induced ENT2 hypotension ENT2END was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i
0	Bromocriptine-induced ENT1 hypotension ENT1END  was unaffected by ENT2 isoproterenol ENT2END pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i
0	It has been shown that bromocriptine-induced tachycardia, which persisted after adrenalectomy, is (i) mediated by central ENT1 dopamine ENT1END  D2 receptor activation and (ii) reduced by 5-day isoproterenol pretreatment, supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart. This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine-induced tachycardia in conscious rats. Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate. In control rats, intravenous bromocriptine (150 microg/kg) induced significant ENT2 hypotension ENT2END and tachycardia
0	Bromocriptine-induced ENT1 hypotension  ENT1END  was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant bradycardia, an effect that was partly reduced by i.v. ENT2 domperidone ENT2END (0
0	These results show that 15-day isoproterenol pretreatment not only abolished but reversed ENT1 bromocriptine ENT1END induced tachycardia to ENT2 bradycardia ENT2END , an effect that is mainly related to further cardiac beta-adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart
1	Bromocriptine-induced hypotension was unaffected by ENT1 isoproterenol ENT1END  pretreatment, while tachycardia was reversed to significant ENT2 bradycardia ENT2END , an effect that was partly reduced by i
0	They suggest that, in normal conscious rats, the central tachycardia of bromocriptine appears to predominate and to mask the ENT1 bradycardia ENT1END of this agonist at peripheral ENT2 dopamine ENT2END D2 receptors
1	Bromocriptine-induced hypotension was unaffected by isoproterenol pretreatment, while tachycardia was reversed to significant ENT1 bradycardia  ENT1END , an effect that was partly reduced by i.v. ENT2 domperidone ENT2END (0
1	Multiple side effects of ENT1 penicillamine  ENT1END  therapy in one patient with rheumatoid arthritis. ENT2 Skin rashes ENT2END , proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis
1	Multiple side effects of ENT1 penicillamine ENT1END  therapy in one patient with rheumatoid arthritis.Skin rashes, ENT2 proteinuria ENT2END , systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis
1	Multiple side effects of ENT1 penicillamine ENT1END  therapy in one patient with rheumatoid arthritis.Skin rashes, proteinuria, ENT2 systemic lupus erythematosus ENT2END , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis
1	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and ENT1 myasthenia gravis ENT1END have all been recorded as complications of ENT2 penicillamine ENT2END therapy in patients with rheumatoid arthritis
1	Skin rashes, proteinuria, systemic lupus erythematosus, ENT1 polymyositis  ENT1END and myasthenia gravis have all been recorded as complications of ENT2 penicillamine ENT2END therapy in patients with rheumatoid arthritis
0	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of ENT1 penicillamine ENT1END  therapy in patients with rheumatoid arthritis. A patient who had developed all 5 is now described. The skin lesion resembled ENT2 elastosis perforans serpiginosa ENT2END , which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine
0	Skin rashes, proteinuria, systemic lupus erythematosus, polymyositis and myasthenia gravis have all been recorded as complications of ENT1 penicillamine ENT1END  therapy in patients with rheumatoid arthritis. A patient who had developed all 5 is now described. The ENT2 skin lesion ENT2END resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with rheumatoid arthritis treated with penicillamine
0	The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with ENT1 Wilson's disease ENT1END but not in patients with rheumatoid arthritis treated with ENT2 penicillamine ENT2END
0	The skin lesion resembled elastosis perforans serpiginosa, which has been reported as a rare side effect in patients with Wilson's disease but not in patients with ENT1 rheumatoid arthritis  ENT1END treated with ENT2 penicillamine ENT2END
0	This hypothesis stems from findings that PREGS is a potent positive modulator of ENT1 N-methyl-d-aspartate ENT1END receptors (NMDARs) and a negative modulator of gamma-aminobutyric acid(A) receptors (GABA(A)Rs). Moreover, PREGS is able to reverse the ENT2 amnesic ENT2END -like effects of NMDAR and GABA(A)R ligands
0	Moreover, PREGS is able to reverse the ENT1 amnesic ENT1END -like effects of NMDAR and ENT2 GABA ENT2END (A)R ligands
0	The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine-induced ENT1 amnesia ENT1END  Both ENT2 PREGS ENT2END and its (-) enantiomer blocked the effects of scopolamine
0	ENT1 Steroid  ENT1END  structure and pharmacological properties determine the anti ENT2 amnesic ENT2END effects of pregnenolone sulphate in the passive avoidance task in rats
1	The memory-enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of ENT1 scopolamine  ENT1END induced ENT2 amnesia ENT2END
0	This study measured the objective and subjective neurocognitive effects of a single 10-mg dose of immediate-release oxycodone in healthy, older (> 65 years), and middle-aged (35 to 55 years) adults who were not suffering from chronic or significant daily ENT1 pain ENT1END  Seventy-one participants completed 2 separate study days and were blind to medication condition (placebo, 10-mg ENT2 oxycodone ENT2END )
0	This study suggests that for healthy older adults who are not suffering from ENT1 chronic pain ENT1END  neurocognitive and pharmacodynamic changes in response to a 10-mg dose of immediate-release ENT2 oxycodone ENT2END are similar to those observed for middle-aged adults
1	Plasma ENT1 oxycodone ENT1END concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01). Significant ENT2 declines in simple and sustained attention, working memory, and verbal memory ENT2END were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose
1	Plasma ENT1 oxycodone ENT1END  concentration peaked between 60 and 90 minutes postdose (P < .01) and pupil size, an indication of physiological effects of the medication, peaked at approximately 90 to 120 minutes postdose (P < .01). Significant ENT2 declines in simple and sustained attention, working memory, and verbal memory ENT2END were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose
0	Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received ENT1 sirolimus ENT1END de novo. Podocyte injury and focal segmental ENT2 glomerulosclerosis ENT2END have been related to mToR inhibition in some patients, but the pathways underlying these lesions remain hypothetic
0	Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin (mToR) inhibitors, especially ENT1 sirolimus ENT1END  in renal transplant recipients with ENT2 chronic allograft nephropathy ENT2END
1	Whether ENT1 proteinuria ENT1END was due to ENT2 sirolimus ENT2END or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo
0	There is a growing list of drugs implicated in acquired ENT1 long QT syndrome ENT1END and torsade de pointes. However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to ENT2 procainamide ENT2END
0	There is a growing list of drugs implicated in acquired ENT1 long QT syndrome ENT1END  and torsade de pointes. However, the torsadogenic potential of ENT2 metoclopramide ENT2END , a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide
0	There is a growing list of drugs implicated in acquired ENT1 long QT syndrome ENT1END  and torsade de pointes. However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide. We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide. This patient also developed torsade de pointes when ENT2 cisapride ENT2END and erythromycin were given simultaneously
0	There is a growing list of drugs implicated in acquired ENT1 long QT syndrome ENT1END  and torsade de pointes. However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to procainamide. We report on a 92-year-old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide. This patient also developed torsade de pointes when cisapride and ENT2 erythromycin ENT2END were given simultaneously
0	However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to ENT1 procainamide ENT1END . We report on a 92-year-old woman with preexisting complete left bundle branch block who developed ENT2 torsade de pointes ENT2END after intravenous and oral administration of metoclopramide
1	This is the first documentation that ENT1 metoclopramide ENT1END provokes ENT2 torsade de pointes ENT2END clinically
1	This patient also developed ENT1 torsade de pointes  ENT1END when ENT2 cisapride ENT2END and erythromycin were given simultaneously
1	This patient also developed ENT1 torsade de pointes  ENT1END  when cisapride and ENT2 erythromycin ENT2END were given simultaneously
0	However, the torsadogenic potential of metoclopramide, a commonly used antiemetic and prokinetic drug, has not been reported in the literature, despite its chemical similarity to ENT1 procainamide ENT1END . We report on a 92-year-old woman with preexisting complete ENT2 left bundle branch block ENT2END who developed torsade de pointes after intravenous and oral administration of metoclopramide
0	Torsade de pointes induced by ENT1 metoclopramide  ENT1END  in an elderly woman with preexisting complete ENT2 left bundle branch block ENT2END
0	We report on a 92-year-old woman with preexisting complete ENT1 left bundle branch block  ENT1END  who developed torsade de pointes after intravenous and oral administration of metoclopramide. This patient also developed torsade de pointes when ENT2 cisapride ENT2END and erythromycin were given simultaneously
0	We report on a 92-year-old woman with preexisting complete ENT1 left bundle branch block  ENT1END  who developed torsade de pointes after intravenous and oral administration of metoclopramide. This patient also developed torsade de pointes when cisapride and ENT2 erythromycin ENT2END were given simultaneously
1	Permeability, ultrastructural changes, and distribution of novel proteins in the glomerular barrier in early ENT1 puromycin aminonucleoside ENT1END ENT2 nephrosis ENT2END
1	BACKGROUND/AIMS: It is still unclear what happens in the glomerulus when ENT1 proteinuria ENT1END starts. Using ENT2 puromycin aminonucleoside ENT2END nephrosis (PAN) rats, we studied early ultrastructural and permeability changes in relation to the expression of the podocyte-associated molecules nephrin, a-actinin, dendrin, and plekhh2, the last two of which were only recently discovered in podocytes
1	The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to ENT1 propofol ENT1END at all doses used in this study. However, marked ENT2 tachycardia ENT2END associated with the use of ephedrine in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients
1	However, marked ENT1 tachycardia ENT1END  associated with the use of ENT2 ephedrine ENT2END in combination with propofol occurred in the majority of patients, occasionally reaching high levels in individual patients
1	The addition of ephedrine to propofol appears to be an effective method of obtunding the ENT1 hypotensive  ENT1END response to ENT2 propofol ENT2END at all doses used in this study
0	We investigated the safety and efficacy of adding different doses of ENT1 ephedrine ENT1END to propofol in order to obtund the ENT2 hypotensive ENT2END response
0	Due to the risk of this tachycardia inducing ENT1 myocardial ischemia  ENT1END  we would not recommend the use in elderly patients of any of the ephedrine/ ENT2 propofol ENT2END /mixtures studied
0	Due to the risk of this tachycardia inducing ENT1 myocardial ischemia ENT1END , we would not recommend the use in elderly patients of any of the ENT2 ephedrine ENT2END /propofol/mixtures studied
0	Thirty days after amiodarone discontinuation, His bundle electrograms showed ENT1 atrial flutter ENT1END without intra-Hisian or infra-Hisian delay. ENT2 Amiodarone ENT2END should be used with caution during long-term oral therapy in patients with or without clear intraventricular conduction defects
0	A case is presented of a reversible intra-Hisian block occurring under ENT1 amiodarone ENT1END treatment for atrial tachycardia in a patient without clear ENT2 intraventricular conduction abnormalities ENT2END
0	A case is presented of a reversible intra-Hisian block occurring under ENT1 amiodarone ENT1END  treatment for ENT2 atrial tachycardia ENT2END in a patient without clear intraventricular conduction abnormalities
1	A case is presented of a reversible ENT1 intra-Hisian block  ENT1END occurring under ENT2 amiodarone ENT2END treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities
0	In the same experimental conditions, ENT1 PG-9 ENT1END (5-20 microg per mouse, i.c.v.) was also able to prevent antimuscarine-induced ENT2 amnesia ENT2END , demonstrating a central localization of the activity
0	The effects of PG-9 (3alpha-tropyl 2-(p-bromophenyl)propionate), the ENT1 acetylcholine ENT1END releaser, on memory processes and nerve growth factor (NGF) synthesis were evaluated. In the mouse passive-avoidance test, PG-9 (10-30 mg/kg, i.p.), administered 20 min before the training session, prevented ENT2 amnesia ENT2END induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist S-(-)-ET-126
1	), administered 20 min before the training session, prevented ENT1 amnesia ENT1END  induced by both the non selective antimuscarinic drug scopolamine and the M1-selective antagonist ENT2 S-(-)-ET-126 ENT2END
1	), administered 20 min before the training session, prevented ENT1 amnesia ENT1END  induced by both the non selective antimuscarinic drug ENT2 scopolamine ENT2END and the M1-selective antagonist S-(-)-ET-126
0	We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of ENT1 clarithromycin ENT1END  The ENT2 dysrhythmias ENT2END resolved after discontinuation of the drug
0	Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer ENT1 macrolides ENT1END  We report a case of ENT2 ventricular dysrhythmias ENT2END that occurred after six therapeutic doses of clarithromycin
0	Cardiotoxicity has been demonstrated after both intravenous and oral administration of ENT1 erythromycin  ENT1END but has never been reported with the newer macrolides. We report a case of ENT2 ventricular dysrhythmias ENT2END that occurred after six therapeutic doses of clarithromycin
0	ENT1 Cardiotoxicity  ENT1END has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides. We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of ENT2 clarithromycin ENT2END
0	Although the side-effect profile of erythromycin is established, including gastroenteritis and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer ENT1 macrolides  ENT1END is still being recorded. ENT2 Cardiotoxicity ENT2END has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides
0	ENT1 Cardiotoxicity  ENT1END  has been demonstrated after both intravenous and oral administration of ENT2 erythromycin ENT2END but has never been reported with the newer macrolides
0	ENT1 Clarithromycin ENT1END is a relatively new macrolide antibiotic that offers twice-daily dosing. It differs from erythromycin only in the methylation of the hydroxyl group at position 6. Although the side-effect profile of erythromycin is established, including ENT2 gastroenteritis ENT2END and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded
0	Although the side-effect profile of erythromycin is established, including ENT1 gastroenteritis  ENT1END  and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer ENT2 macrolides ENT2END is still being recorded
1	Although the side-effect profile of ENT1 erythromycin  ENT1END is established, including ENT2 gastroenteritis ENT2END and interactions with other drugs subject to hepatic mixed-function oxidase metabolism, experience with the newer macrolides is still being recorded
1	Clarithromycin-induced ENT1 ventricular tachycardia ENT1END ENT2 Clarithromycin ENT2END is a relatively new macrolide antibiotic that offers twice-daily dosing
0	Clarithromycin-induced ENT1 ventricular tachycardia ENT1END .Clarithromycin is a relatively new ENT2 macrolide ENT2END antibiotic that offers twice-daily dosing
0	Clarithromycin-induced ENT1 ventricular tachycardia ENT1END .Clarithromycin is a relatively new macrolide antibiotic that offers twice-daily dosing. It differs from ENT2 erythromycin ENT2END only in the methylation of the hydroxyl group at position 6
0	Ten patients who had ENT1 Parkinson's disease ENT1END with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of ENT2 apomorphine ENT2END
0	Worsening of ENT1 levodopa  ENT1END -induced dyskinesias by motor and mental tasks.Ten patients who had ENT2 Parkinson's disease ENT2END with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose dyskinesia following administration of an effective single dose of apomorphine
1	Ten patients who had Parkinson's disease with disabling dyskinesia were included in this study to evaluate the role of mental (mental calculation) and motor (flexion/extension of right fingers, flexion/extension of left fingers, flexion/extension of the neck, speaking aloud) tasks on the worsening of peak-dose ENT1 dyskinesia  ENT1END following administration of an effective single dose of ENT2 apomorphine ENT2END
1	Worsening of ENT1 levodopa  ENT1END -induced ENT2 dyskinesias ENT2END by motor and mental tasks
1	ENT1 Selegiline  ENT1END -induced ENT2 postural hypotension ENT2END in Parkinson's disease: a longitudinal study on the effects of drug withdrawal
0	CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective ENT1 orthostatic hypotension ENT1END  The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and ENT2 metamphetamine ENT2END are discussed
0	CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective ENT1 orthostatic hypotension ENT1END . The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of ENT2 amphetamine ENT2END and metamphetamine are discussed
0	CONCLUSION: This study confirms our previous finding that selegiline in combination with ENT1 L-dopa  ENT1END is associated with selective ENT2 orthostatic hypotension ENT2END
0	RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 ENT1 PD ENT1END patients on ENT2 selegiline ENT2END , one of whom lost consciousness with unrecordable blood pressures
0	RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 ENT1 PD  ENT1END  patients on selegiline, one of whom lost consciousness with unrecordable blood pressures. A lesser degree of orthostatic hypotension occurred with standing. Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug. Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action. CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension. The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of amphetamine and ENT2 metamphetamine ENT2END are discussed
0	RESULTS: Head-up tilt caused systolic orthostatic hypotension which was marked in six of 20 ENT1 PD  ENT1END  patients on selegiline, one of whom lost consciousness with unrecordable blood pressures. A lesser degree of orthostatic hypotension occurred with standing. Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug. Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action. CONCLUSION: This study confirms our previous finding that selegiline in combination with L-dopa is associated with selective orthostatic hypotension. The possibilities that these cardiovascular findings might be the result of non-selective inhibition of monoamine oxidase or of ENT2 amphetamine ENT2END and metamphetamine are discussed
0	OBJECTIVES: The United Kingdom Parkinson's Disease Research Group (UKPDRG) trial found an increased mortality in patients with Parkinson's disease ( ENT1 PD ENT1END  randomized to receive 10 mg selegiline per day and ENT2 L-dopa ENT2END compared with those taking L-dopa alone
1	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( ENT1 VFD ENT1END  associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose ENT2 GVG ENT2END on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA)
0	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( ENT1 VFD ENT1END ) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) ENT2 dopamine ENT2END (DA)
0	OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( ENT1 VFD ENT1END ) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on ENT2 cocaine ENT2END -induced increases in nucleus accumbens (NAcc) dopamine (DA)
0	This non-receptor mediated inhibition requires de novo synthesis for restoration of functional ENT1 GABA ENT1END catabolism. OBJECTIVES: Given its preclinical success for treating substance abuse and the increased risk of ENT2 visual field defects ENT2END (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA)
0	OBJECTIVES: Given its preclinical success for treating ENT1 substance abuse  ENT1END and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose ENT2 GVG ENT2END on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA)
0	OBJECTIVES: Given its preclinical success for treating ENT1 substance abuse  ENT1END  and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) ENT2 dopamine ENT2END (DA)
0	OBJECTIVES: Given its preclinical success for treating ENT1 substance abuse  ENT1END  and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on ENT2 cocaine ENT2END -induced increases in nucleus accumbens (NAcc) dopamine (DA)
0	This non-receptor mediated inhibition requires de novo synthesis for restoration of functional ENT1 GABA  ENT1END  catabolism. OBJECTIVES: Given its preclinical success for treating ENT2 substance abuse ENT2END and the increased risk of visual field defects (VFD) associated with cumulative lifetime exposure, we explored the effects of sub-chronic low dose GVG on cocaine-induced increases in nucleus accumbens (NAcc) dopamine (DA)
1	ENT1 PTU  ENT1END -associated ENT2 vasculitis ENT2END in a girl with Turner Syndrome and Graves' disease
0	The diagnosis of propylthiouracil (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of ENT1 PTU ENT1END  Subsequent treatment of persistent ENT2 hyperthyroidism ENT2END with radioablation did not result in an exacerbation of the vasculitis, a complication described in prior case reports
0	ENT1 PTU  ENT1END -associated vasculitis in a girl with Turner Syndrome and ENT2 Graves' disease ENT2END
0	We report a girl with Turner syndrome and Graves' disease who presented with palpable ENT1 purpuric lesions ENT1END  The diagnosis of ENT2 propylthiouracil ENT2END (PTU)-associated vasculitis was made by observation of consistent clinical features, the detection of elevated ANA and ANCA in the blood, and the observed clinical resolution of symptoms following withdrawal of PTU
0	ENT1 PTU  ENT1END -associated vasculitis in a girl with ENT2 Turner Syndrome ENT2END and Graves' disease
1	We report a woman with coronary artery disease who developed a markedly ENT1 prolonged QT interval ENT1END and torsades de pointes (TdP) after taking ENT2 ketoconazole ENT2END for treatment of fungal infection
0	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ENT1 ketoconazole ENT1END  for treatment of ENT2 fungal infection ENT2END
0	We report a woman with ENT1 coronary artery disease  ENT1END who developed a markedly prolonged QT interval and torsades de pointes (TdP) after taking ENT2 ketoconazole ENT2END for treatment of fungal infection
1	We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( ENT1 TdP  ENT1END  after taking ENT2 ketoconazole ENT2END for treatment of fungal infection
0	The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked ENT1 anxiety ENT1END were indistinguishable from those of neuroleptic-induced akathisia. Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder. Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both. The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic ENT2 antidepressant ENT2END -induced "jitteriness" may be identical
0	The typical ENT1 fluoxetine  ENT1END induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked ENT2 anxiety ENT2END were indistinguishable from those of neuroleptic-induced akathisia
0	The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked ENT1 anxiety ENT1END  were indistinguishable from those of neuroleptic-induced akathisia. Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder. Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist ENT2 propranolol ENT2END , dose reduction, or both
0	Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or ENT1 major depression  ENT1END developed akathisia. The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia. Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder. Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both. The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic ENT2 antidepressant ENT2END -induced "jitteriness" may be identical
0	Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or ENT1 major depression  ENT1END  developed akathisia. The typical ENT2 fluoxetine ENT2END -induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia
0	Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or ENT1 major depression  ENT1END  developed akathisia. The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia. Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder. Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist ENT2 propranolol ENT2END , dose reduction, or both
0	Five patients receiving fluoxetine for the treatment of ENT1 obsessive compulsive disorder  ENT1END or major depression developed akathisia. The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia. Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder. Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist propranolol, dose reduction, or both. The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic ENT2 antidepressant ENT2END -induced "jitteriness" may be identical
0	Five patients receiving ENT1 fluoxetine  ENT1END for the treatment of ENT2 obsessive compulsive disorder ENT2END or major depression developed akathisia
0	Five patients receiving fluoxetine for the treatment of ENT1 obsessive compulsive disorder  ENT1END  or major depression developed akathisia. The typical fluoxetine-induced symptoms of restlessness, constant pacing, purposeless movements of the feet and legs, and marked anxiety were indistinguishable from those of neuroleptic-induced akathisia. Three patients who had experienced neuroleptic-induced akathisia in the past reported that the symptoms of fluoxetine-induced akathisia were identical, although somewhat milder. Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist ENT2 propranolol ENT2END , dose reduction, or both
0	The authors suggest that fluoxetine-induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced ENT1 akathisia  ENT1END and tricyclic ENT2 antidepressant ENT2END -induced "jitteriness" may be identical
1	ENT1 Fluoxetine  ENT1END -induced ENT2 akathisia ENT2END : clinical and theoretical implications
0	Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta-adrenergic antagonist ENT1 propranolol ENT1END , dose reduction, or both. The authors suggest that fluoxetine-induced ENT2 akathisia ENT2END may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine-induced akathisia and tricyclic antidepressant-induced "jitteriness" may be identical
0	These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by ENT1 adenosine ENT1END A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of ENT2 parkinsonism ENT2END
0	KF17837 also reduced the catalepsy induced by ENT1 haloperidol  ENT1END (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of ENT2 parkinsonism ENT2END
0	) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine ( ENT1 L-DOPA  ENT1END  25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of ENT2 parkinsonism ENT2END
0	Furthermore, ENT1 KF17837  ENT1END may be a useful drug in the treatment of ENT2 parkinsonism ENT2END
0	0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, ENT1 CGS 21680  ENT1END (10 micrograms), in a dose-dependent manner. KF17837 also reduced the catalepsy induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of ENT2 parkinsonism ENT2END
0	) and by ENT1 reserpine  ENT1END (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus benserazide (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of ENT2 parkinsonism ENT2END
0	) plus ENT1 benserazide  ENT1END (6.25 mg/kg i.p.). These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists. Furthermore, KF17837 may be a useful drug in the treatment of ENT2 parkinsonism ENT2END
0	0 mg/kg) significantly ameliorated the ENT1 cataleptic ENT1END responses induced by intracerebroventricular administration of an ENT2 adenosine ENT2END A2A receptor agonist, CGS 21680 (10 micrograms), in a dose-dependent manner
1	KF17837 also reduced the ENT1 catalepsy  ENT1END induced by ENT2 haloperidol ENT2END (1 mg/kg i
0	KF17837 also reduced the ENT1 catalepsy ENT1END  induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of ENT2 L-3,4-dihydroxyphenylalanine ENT2END (L-DOPA; 25 mg/kg i
0	ENT1 KF17837  ENT1END also reduced the ENT2 catalepsy ENT2END induced by haloperidol (1 mg/kg i
1	0 mg/kg) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, ENT1 CGS 21680  ENT1END  (10 micrograms), in a dose-dependent manner. KF17837 also reduced the ENT2 catalepsy ENT2END induced by haloperidol (1 mg/kg i
1	KF17837 also reduced the ENT1 catalepsy  ENT1END  induced by haloperidol (1 mg/kg i.p.) and by ENT2 reserpine ENT2END (5 mg/kg i
0	KF17837 also reduced the ENT1 catalepsy  ENT1END  induced by haloperidol (1 mg/kg i.p.) and by reserpine (5 mg/kg i.p.). These anticataleptic effects were exhibited dose dependently at doses from 0.625 and 2.5 mg/kg p.o., respectively. Moreover, KF17837 (0.625 mg/kg p.o.) potentiated the anticataleptic effects of a subthreshold dose of L-3,4-dihydroxyphenylalanine (L-DOPA; 25 mg/kg i.p.) plus ENT2 benserazide ENT2END (6
0	Massive proteinuria and acute renal failure after oral bisphosphonate ( ENT1 alendronate  ENT1END ) administration in a patient with ENT2 focal segmental glomerulosclerosis ENT2END
0	A 61-year-old Japanese man with nephrotic syndrome due to ENT1 focal segmental glomerulosclerosis ENT1END was initially responding well to ENT2 steroid ENT2END therapy
0	A 61-year-old Japanese man with nephrotic syndrome due to ENT1 focal segmental glomerulosclerosis ENT1END  was initially responding well to steroid therapy. The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure. After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis. Urinary volume and serum ENT2 creatinine ENT2END levels recovered to the normal range, with urinary protein disappearing completely within 40 days
0	Massive proteinuria and acute renal failure after oral ENT1 bisphosphonate  ENT1END  (alendronate) administration in a patient with ENT2 focal segmental glomerulosclerosis ENT2END
1	Massive proteinuria and ENT1 acute renal failure ENT1END  after oral bisphosphonate ENT2 alendronate ENT2END ) administration in a patient with focal segmental glomerulosclerosis
0	A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to ENT1 steroid ENT1END  therapy. The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with ENT2 acute renal failure ENT2END
0	8 g with ENT1 acute renal failure  ENT1END . After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis. Urinary volume and serum ENT2 creatinine ENT2END levels recovered to the normal range, with urinary protein disappearing completely within 40 days
0	Massive proteinuria and ENT1 acute renal failure  ENT1END  after oral ENT2 bisphosphonate ENT2END (alendronate) administration in a patient with focal segmental glomerulosclerosis
0	Massive proteinuria and acute renal failure after oral bisphosphonate ( ENT1 alendronate ENT1END ) administration in a patient with focal segmental glomerulosclerosis.A 61-year-old Japanese man with ENT2 nephrotic syndrome ENT2END due to focal segmental glomerulosclerosis was initially responding well to steroid therapy
0	A 61-year-old Japanese man with ENT1 nephrotic syndrome  ENT1END  due to focal segmental glomerulosclerosis was initially responding well to ENT2 steroid ENT2END therapy
0	A 61-year-old Japanese man with ENT1 nephrotic syndrome  ENT1END  due to focal segmental glomerulosclerosis was initially responding well to steroid therapy. The amount of daily urinary protein decreased from 15.6 to 2.8 g. Within 14 days of the oral bisphosphonate (alendronate sodium) administration, the amount of daily urinary protein increased rapidly up to 12.8 g with acute renal failure. After discontinuing the oral alendronate, the patient underwent six cycles of hemodialysis and four cycles of LDL apheresis. Urinary volume and serum ENT2 creatinine ENT2END levels recovered to the normal range, with urinary protein disappearing completely within 40 days
0	Massive proteinuria and acute renal failure after oral ENT1 bisphosphonate  ENT1END  (alendronate) administration in a patient with focal segmental glomerulosclerosis.A 61-year-old Japanese man with ENT2 nephrotic syndrome ENT2END due to focal segmental glomerulosclerosis was initially responding well to steroid therapy
1	Massive ENT1 proteinuria ENT1END  and acute renal failure after oral bisphosphonate ENT2 alendronate ENT2END ) administration in a patient with focal segmental glomerulosclerosis
0	Massive ENT1 proteinuria  ENT1END  and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis.A 61-year-old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to ENT2 steroid ENT2END therapy
0	Urinary volume and serum ENT1 creatinine ENT1END  levels recovered to the normal range, with urinary protein disappearing completely within 40 days. This report demonstrates that not only intravenous, but also oral bisphosphonates can aggravate ENT2 proteinuria ENT2END and acute renal failure
0	This report demonstrates that not only intravenous, but also oral ENT1 bisphosphonates  ENT1END can aggravate ENT2 proteinuria ENT2END and acute renal failure
0	Despite therapy with ursodeoxycholic acid, ENT1 prednisone ENT1END  and then tacrolimus, her cholestatic disease was unrelenting, with ENT2 cirrhosis ENT2END shown by biopsy 6 months after presentation
0	Despite therapy with ENT1 ursodeoxycholic acid  ENT1END  prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with ENT2 cirrhosis ENT2END shown by biopsy 6 months after presentation
0	Despite therapy with ursodeoxycholic acid, prednisone, and then ENT1 tacrolimus  ENT1END  her cholestatic disease was unrelenting, with ENT2 cirrhosis ENT2END shown by biopsy 6 months after presentation
0	A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ENT1 ibuprofen  ENT1END use. Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with ENT2 cirrhosis ENT2END shown by biopsy 6 months after presentation
0	Despite therapy with ursodeoxycholic acid, ENT1 prednisone ENT1END , and then tacrolimus, her ENT2 cholestatic disease ENT2END was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Despite therapy with ENT1 ursodeoxycholic acid  ENT1END , prednisone, and then tacrolimus, her ENT2 cholestatic disease ENT2END was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Despite therapy with ursodeoxycholic acid, prednisone, and then ENT1 tacrolimus  ENT1END , her ENT2 cholestatic disease ENT2END was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
1	A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ENT1 ibuprofen  ENT1END  use. Despite therapy with ursodeoxycholic acid, prednisone, and then tacrolimus, her ENT2 cholestatic disease ENT2END was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or ENT1 infection  ENT1END induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, ENT2 prednisone ENT2END , and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or ENT1 infection  ENT1END  induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ENT2 ursodeoxycholic acid ENT2END , prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or ENT1 infection  ENT1END  induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, prednisone, and then ENT2 tacrolimus ENT2END , her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated hypersensitivity reaction that affects all age groups, is drug or ENT1 infection  ENT1END  induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ENT2 ibuprofen ENT2END use
0	A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after ENT1 Stevens-Johnson syndrome  ENT1END is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, ENT2 prednisone ENT2END , and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after ENT1 Stevens-Johnson syndrome  ENT1END  is described; this was temporally associated with ibuprofen use. Despite therapy with ENT2 ursodeoxycholic acid ENT2END , prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after ENT1 Stevens-Johnson syndrome  ENT1END  is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, prednisone, and then ENT2 tacrolimus ENT2END , her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
1	A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after ENT1 Stevens-Johnson syndrome  ENT1END  is described; this was temporally associated with ENT2 ibuprofen ENT2END use
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated ENT1 hypersensitivity  ENT1END reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, ENT2 prednisone ENT2END , and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated ENT1 hypersensitivity  ENT1END  reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ENT2 ursodeoxycholic acid ENT2END , prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated ENT1 hypersensitivity  ENT1END  reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, prednisone, and then ENT2 tacrolimus ENT2END , her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Stevens-Johnson syndrome is a well-recognized immune complex-mediated ENT1 hypersensitivity  ENT1END  reaction that affects all age groups, is drug or infection induced, and has classic systemic, mucosal, and dermatologic manifestations. A previously healthy child who developed acute, severe, rapidly progressive vanishing bile duct syndrome shortly after Stevens-Johnson syndrome is described; this was temporally associated with ENT2 ibuprofen ENT2END use
0	A previously healthy child who developed acute, severe, rapidly progressive ENT1 vanishing bile duct syndrome  ENT1END shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ursodeoxycholic acid, ENT2 prednisone ENT2END , and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	A previously healthy child who developed acute, severe, rapidly progressive ENT1 vanishing bile duct syndrome  ENT1END  shortly after Stevens-Johnson syndrome is described; this was temporally associated with ibuprofen use. Despite therapy with ENT2 ursodeoxycholic acid ENT2END , prednisone, and then tacrolimus, her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation
0	Despite therapy with ursodeoxycholic acid, prednisone, and then ENT1 tacrolimus ENT1END , her cholestatic disease was unrelenting, with cirrhosis shown by biopsy 6 months after presentation. This case documents acute drug-related ENT2 vanishing bile duct syndrome ENT2END in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens-Johnson syndrome and vanishing bile duct syndrome
0	A previously healthy child who developed acute, severe, rapidly progressive ENT1 vanishing bile duct syndrome  ENT1END  shortly after Stevens-Johnson syndrome is described; this was temporally associated with ENT2 ibuprofen ENT2END use
0	Measures of ENT1 pupillary oscillation ENT1END were able to significantly distinguish a group of abstinent ENT2 crack cocaine ENT2END abusers endorsing past CIP (n = 32) from another group of crack addicts who denied past CIP (n = 29)
1	A measure of ENT1 pupillary oscillation  ENT1END  as a marker of ENT2 cocaine ENT2END -induced paranoia
0	Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP (n = 32) from another group of ENT1 crack ENT1END addicts who denied past ENT2 CIP ENT2END (n = 29)
1	A measure of pupillary oscillation as a marker of cocaine-induced ENT1 paranoia  ENT1END . ENT2 Cocaine ENT2END -induced paranoia (CIP) remains an important drug-induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged
0	Among women with ENT1 cardiovascular disease ENT1END  long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking ENT2 oestrogen ENT2END -only HT, versus similar-sized placebo groups
0	OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, ENT1 cancer ENT1END  gallbladder disease, cognition, fractures and quality of life. SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts. Also relevant non-indexed journals and conference abstracts. SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women. HT included oestrogens, with or without ENT2 progestogens ENT2END , via oral, transdermal, subcutaneous or transnasal routes
0	OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, ENT1 cancer ENT1END , gallbladder disease, cognition, fractures and quality of life. SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts. Also relevant non-indexed journals and conference abstracts. SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women. HT included ENT2 oestrogens ENT2END , with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes
0	HT included oestrogens, with or without ENT1 progestogens ENT1END , via oral, transdermal, subcutaneous or transnasal routes. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: Nineteen trials involving 41,904 women were included. In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), ENT2 breast cancer ENT2END and gallbladder disease
0	In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), ENT1 breast cancer ENT1END  and gallbladder disease. Long-term ENT2 oestrogen ENT2END -only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer
0	HT included oestrogens, with or without ENT1 progestogens ENT1END , via oral, transdermal, subcutaneous or transnasal routes. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: Nineteen trials involving 41,904 women were included. In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease. Long-term oestrogen-only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer. The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) ENT2 colon cancer ENT2END , with long-term use
0	Long-term ENT1 oestrogen  ENT1END -only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer. The only statistically significant benefits of HT were a decreased incidence of fractures and (for combined HT) ENT2 colon cancer ENT2END , with long-term use
1	HT included oestrogens, with or without ENT1 progestogens ENT1END , via oral, transdermal, subcutaneous or transnasal routes. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: Nineteen trials involving 41,904 women were included. In relatively healthy women, combined continuous HT significantly increased the risk of ENT2 venous thrombo-embolism ENT2END or coronary event (after one year's use), stroke (after three years), breast cancer and gallbladder disease
1	Long-term ENT1 oestrogen ENT1END -only HT significantly increased the risk of ENT2 venous thrombo-embolism ENT2END , stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer
0	HT included oestrogens, with or without ENT1 progestogens ENT1END , via oral, transdermal, subcutaneous or transnasal routes. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: Nineteen trials involving 41,904 women were included. In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), ENT2 stroke ENT2END (after three years), breast cancer and gallbladder disease
1	In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), ENT1 stroke  ENT1END  (after three years), breast cancer and gallbladder disease. Long-term ENT2 oestrogen ENT2END -only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer
0	SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane ENT1 Menstrual Disorders  ENT1END and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts. Also relevant non-indexed journals and conference abstracts. SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women. HT included oestrogens, with or without ENT2 progestogens ENT2END , via oral, transdermal, subcutaneous or transnasal routes
0	SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane ENT1 Menstrual Disorders  ENT1END  and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts. Also relevant non-indexed journals and conference abstracts. SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women. HT included ENT2 oestrogens ENT2END , with or without progestogens, via oral, transdermal, subcutaneous or transnasal routes
1	generally fit, without overt disease) and taking continuous combined HT, there was a statistically significant increase in the incidence of ENT1 dementia  ENT1END  Among women with cardiovascular disease, long-term use of combined continuous HT significantly increased the risk of venous thrombo-embolism.One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking ENT2 oestrogen ENT2END -only HT, versus similar-sized placebo groups
0	OBJECTIVES: To assess the effect of long-term HT on mortality, cardiovascular outcomes, cancer, gallbladder disease, cognition, ENT1 fractures  ENT1END and quality of life. SEARCH STRATEGY: We searched the following databases to November 2007: Trials Register of the Cochrane Menstrual Disorders and Subfertility Group, Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Biological Abstracts. Also relevant non-indexed journals and conference abstracts. SELECTION CRITERIA: Randomised double-blind trials of HT versus placebo, taken for at least one year by perimenopausal or postmenopausal women. HT included oestrogens, with or without ENT2 progestogens ENT2END , via oral, transdermal, subcutaneous or transnasal routes
0	Long-term ENT1 oestrogen ENT1END -only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer. The only statistically significant benefits of HT were a decreased incidence of ENT2 fractures ENT2END and (for combined HT) colon cancer, with long-term use
0	HT included oestrogens, with or without ENT1 progestogens ENT1END , via oral, transdermal, subcutaneous or transnasal routes. DATA COLLECTION AND ANALYSIS: Two authors independently assessed trial quality and extracted data. MAIN RESULTS: Nineteen trials involving 41,904 women were included. In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and ENT2 gallbladder disease ENT2END
1	In relatively healthy women, combined continuous HT significantly increased the risk of venous thrombo-embolism or coronary event (after one year's use), stroke (after three years), breast cancer and ENT1 gallbladder disease  ENT1END . Long-term ENT2 oestrogen ENT2END -only HT significantly increased the risk of venous thrombo-embolism, stroke and gallbladder disease (after one to two years, three years and seven years' use respectively), but did not significantly increase the risk of breast cancer
0	On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, ENT1 pain ENT1END induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit. Simultaneous administration of ENT2 morphine ENT2END with metamizol resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs
0	On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, ENT1 pain ENT1END -induced functional impairment model, and the charcoal meal test was used to evaluate the intestinal transit. Simultaneous administration of morphine with ENT2 metamizol ENT2END resulted in a markedly antinociceptive potentiation and an increasing of the duration of action after a single (298+/-7 vs
0	On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, ENT1 pain ENT1END -induced functional impairment model, and the ENT2 charcoal ENT2END meal test was used to evaluate the intestinal transit
1	The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate ENT1 morphine ENT1END induced ENT2 constipation ENT2END
0	The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that ENT1 metamizol  ENT1END did not potentiate morphine-induced ENT2 constipation ENT2END
0	This work evaluates the antinociceptive and ENT1 constipating  ENT1END effects of the combination of 3.2 mg/kg s.c. morphine with 177.8 mg/kg s.c. metamizol in acutely and chronically treated (once a day for 12 days) rats. On the 13th day, antinociceptive effects were assessed using a model of inflammatory nociception, pain-induced functional impairment model, and the ENT2 charcoal ENT2END meal test was used to evaluate the intestinal transit
0	2 mg/kg ENT1 naloxone ENT1END s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed. In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the ENT2 constipating ENT2END effects
0	These findings show a significant interaction between ENT1 morphine ENT1END and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of ENT2 chronic pain ENT2END
0	These findings show a significant interaction between morphine and ENT1 metamizol  ENT1END in chronically treated rats, suggesting that this combination could be useful for the treatment of ENT2 chronic pain ENT2END
0	2 mg/kg ENT1 naloxone  ENT1END  s.c. (P<0.05), suggesting the partial involvement of the opioidergic system in the synergism observed. In independent groups, morphine inhibited the intestinal transit in 48+/-4% and 38+/-4% after acute and chronic treatment, respectively, suggesting that tolerance did not develop to the constipating effects. The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment, suggesting that metamizol did not potentiate morphine-induced constipation. These findings show a significant interaction between morphine and metamizol in chronically treated rats, suggesting that this combination could be useful for the treatment of ENT2 chronic pain ENT2END
1	ENT1 Ventricular tachyarrhythmias  ENT1END  during cesarean section after ENT2 ritodrine ENT2END therapy: interaction with anesthetics
0	ENT1 Ventricular tachyarrhythmias ENT1END  during cesarean section after ritodrine therapy: interaction with anesthetics.This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section. Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum ENT2 potassium ENT2END level
0	ENT1 Ventricular tachyarrhythmias ENT1END  during cesarean section after ritodrine therapy: interaction with anesthetics.This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section. Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ephedrine are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as ENT2 phenylephrine ENT2END to treat hypotensive patients with tachycardia
0	ENT1 Ventricular tachyarrhythmias ENT1END  during cesarean section after ritodrine therapy: interaction with anesthetics.This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section. Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ENT2 ephedrine ENT2END are advised
0	This case illustrates that patients receiving ENT1 ritodrine ENT1END for ENT2 preterm labor ENT2END may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section
0	This case illustrates that patients receiving ritodrine for ENT1 preterm labor  ENT1END  may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section. Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum ENT2 potassium ENT2END level
0	This case illustrates that patients receiving ritodrine for ENT1 preterm labor  ENT1END  may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section. Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ephedrine are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as ENT2 phenylephrine ENT2END to treat hypotensive patients with tachycardia
0	This case illustrates that patients receiving ritodrine for ENT1 preterm labor  ENT1END  may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section. Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ENT2 ephedrine ENT2END are advised
0	Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ENT1 ritodrine ENT1END  Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ephedrine are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with ENT2 tachycardia ENT2END
0	Preoperative assessment should focus on cardiovascular status and serum ENT1 potassium  ENT1END  level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ephedrine are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with ENT2 tachycardia ENT2END
0	After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as ENT1 phenylephrine  ENT1END  to treat hypotensive patients with ENT2 tachycardia ENT2END
0	Careful fluid administration and cautious use of titrated doses of ENT1 ephedrine  ENT1END  are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat hypotensive patients with ENT2 tachycardia ENT2END
0	Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ENT1 ritodrine ENT1END . Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ephedrine are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat ENT2 hypotensive ENT2END patients with tachycardia
0	Preoperative assessment should focus on cardiovascular status and serum ENT1 potassium  ENT1END  level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ephedrine are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat ENT2 hypotensive ENT2END patients with tachycardia
0	After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as ENT1 phenylephrine  ENT1END  to treat ENT2 hypotensive ENT2END patients with tachycardia
0	Careful fluid administration and cautious use of titrated doses of ENT1 ephedrine  ENT1END  are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as phenylephrine to treat ENT2 hypotensive ENT2END patients with tachycardia
0	Such interactions may result in serious ENT1 cardiovascular complications  ENT1END even after cessation of an infusion of ENT2 ritodrine ENT2END
0	Such interactions may result in serious ENT1 cardiovascular complications  ENT1END  even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum ENT2 potassium ENT2END level
0	Such interactions may result in serious ENT1 cardiovascular complications  ENT1END  even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ephedrine are advised. After delivery of the infant, there should be no contraindication to the use of an alpha-adrenergic vasopressor such as ENT2 phenylephrine ENT2END to treat hypotensive patients with tachycardia
0	Such interactions may result in serious ENT1 cardiovascular complications  ENT1END  even after cessation of an infusion of ritodrine. Preoperative assessment should focus on cardiovascular status and serum potassium level. Delaying induction of anesthesia should be considered whenever possible. Careful fluid administration and cautious use of titrated doses of ENT2 ephedrine ENT2END are advised
0	Taken together, our results confirm the good tolerability of nimesulide and ENT1 paracetamol ENT1END in patients who experienced ENT2 urticaria ENT2END /angioedema caused by NSAIDs
0	Taken together, our results confirm the good tolerability of ENT1 nimesulide  ENT1END and paracetamol in patients who experienced ENT2 urticaria ENT2END /angioedema caused by NSAIDs
0	Tolerability of nimesulide and paracetamol in patients with ENT1 NSAID  ENT1END -induced ENT2 urticaria ENT2END /angioedema
1	Taken together, our results confirm the good tolerability of nimesulide and ENT1 paracetamol  ENT1END  in patients who experienced urticaria/ ENT2 angioedema ENT2END caused by NSAIDs
1	Tolerability of nimesulide and paracetamol in patients with NSAID-induced urticaria/ ENT1 angioedema ENT1END .Previous studies evaluated the tolerance of ENT2 nimesulide ENT2END and paracetamol in subjects with cutaneous, respiratory and anaphylactoid reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs)
1	However, the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and, above all, by a history of ENT1 NSAID ENT1END induced ENT2 angioedema ENT2END
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist ENT1 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine ENT1END hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	2 that might be responsible for the antinociception and the anti- ENT1 amnesic ENT1END effect induced by (+/-)-PG-9 through an increase in ENT2 acetylcholine ENT2END extracellular levels
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor ENT1 hemicholinium-3  ENT1END  but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the ENT1 5-hydroxytryptamin1A  ENT1END antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist ENT1 naloxone  ENT1END  the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist ENT1 R-(alpha)-methylhistamine  ENT1END  the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
1	) was able to prevent ENT1 amnesia ENT1END  induced by ENT2 scopolamine ENT2END (1 mg kg-1 i
0	2 that might be responsible for the antinociception and the anti- ENT1 amnesic  ENT1END  effect induced by (+/-)- ENT2 PG-9 ENT2END through an increase in acetylcholine extracellular levels
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist ENT1 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester  ENT1END hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists ENT1 pirenzepine  ENT1END and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist ENT1 atropine  ENT1END  the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the ENT1 gamma-aminobutyric acidB  ENT1END antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist ENT1 quinpirole  ENT1END  the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
1	) was able to prevent ENT1 amnesia ENT1END  induced by scopolamine (1 mg kg-1 i.p.) and ENT2 dicyclomine ENT2END (2 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist 3-aminopropyl-diethoxy-methyl-phosphinic acid, the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor ENT1 reserpine  ENT1END  Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	The antinociception produced by (+/-)-PG-9 was prevented by the unselective muscarinic antagonist atropine, the M1-selective antagonists pirenzepine and dicyclomine and the acetylcholine depletor hemicholinium-3, but not by the opioid antagonist naloxone, the gamma-aminobutyric acidB antagonist ENT1 3-aminopropyl-diethoxy-methyl-phosphinic acid  ENT1END  the H3 agonist R-(alpha)-methylhistamine, the D2 antagonist quinpirole, the 5-hydroxytryptamine4 antagonist 2-methoxy-4-amino-5-chlorobenzoic acid 2-(diethylamino)ethyl ester hydrochloride, the 5-hydroxytryptamin1A antagonist 1-(2-methoxyphenyl)-4-[4-(2-phthalimido)butyl]piperazine hydrobromide and the polyamines depletor reserpine. Based on these data, it can be postulated that (+/-)-PG-9 exerted an antinociceptive effect mediated by a central potentiation of cholinergic transmission. (+/-)-PG-9 (10-40 mg kg-1 i.p.) was able to prevent ENT2 amnesia ENT2END induced by scopolamine (1 mg kg-1 i
0	Reserpine also produced tremor and catalepsy, which are signs suggestive of ENT1 Parkinson's disease ENT1END  ENT2 MK-801 ENT2END (0
0	The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on ENT1 dopamine ENT1END related behaviors induced by reserpine treatments. This study focuses on behavioral syndromes that may used as models for ENT2 Parkinson's disease ENT2END , or tardive dyskinesia, and its response after glutamatergic blockage
0	These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as ENT1 parkinsonian ENT1END like and tardive dsykinesia signs. The glutamatergic blockage produced by ENT2 NMDA ENT2END can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model
0	ENT1 Reserpine  ENT1END also produced tremor and catalepsy, which are signs suggestive of ENT2 Parkinson's disease ENT2END
0	Reserpine also produced tremor and catalepsy, which are signs suggestive of ENT1 Parkinson's disease ENT1END . MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine. However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice. Reserpine (1 mg/kg), administered 90 min before the test and followed by ENT2 apomophine ENT2END injection (0
0	Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of ENT1 tardive dyskinesia  ENT1END  Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease. ENT2 MK-801 ENT2END (0
0	The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on ENT1 dopamine ENT1END -related behaviors induced by reserpine treatments. This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or ENT2 tardive dyskinesia ENT2END , and its response after glutamatergic blockage
0	These results show that reserpine produces different and abnormal movements, which are related to dose and schedule employed and can be considered as parkinsonian-like and ENT1 tardive dsykinesia  ENT1END signs. The glutamatergic blockage produced by ENT2 NMDA ENT2END can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and tremor according to the employed model
1	Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of ENT1 tardive dyskinesia  ENT1END . ENT2 Reserpine ENT2END also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease
0	Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of ENT1 tardive dyskinesia  ENT1END . Reserpine also produced tremor and catalepsy, which are signs suggestive of Parkinson's disease. MK-801 (0.1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and catalepsy induced by reserpine. However, MK-801 injection produced a significant increase of tremor in reserpine-treated mice. Reserpine (1 mg/kg), administered 90 min before the test and followed by ENT2 apomophine ENT2END injection (0
0	Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in tremor and ENT1 catalepsy ENT1END  whereas ENT2 MK-801 ENT2END (0
0	The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on ENT1 dopamine ENT1END -related behaviors induced by reserpine treatments. This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage. Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia. Reserpine also produced tremor and ENT2 catalepsy ENT2END , which are signs suggestive of Parkinson's disease
0	The glutamatergic blockage produced by ENT1 NMDA ENT1END  can restore these signs, such as vacuous chewing movements, tongue protrusions, ENT2 catalepsy ENT2END and tremor according to the employed model
1	1 mg/kg), administered 30 min before the observation test, prevented the vacuous chewing movements, tongue protrusions and ENT1 catalepsy ENT1END induced by ENT2 reserpine ENT2END
0	Reserpine (1 mg/kg), administered 90 min before the test and followed by ENT1 apomophine ENT1END  injection (0.1 mg/kg) 5 min before the test, did not produce oral dyskinesia in mice. On the other hand, reserpine induced increases in tremor and ENT2 catalepsy ENT2END compared to control mice
0	Pretreatment with reserpine (1 mg/kg) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion, as well as increases in ENT1 tremor  ENT1END and catalepsy, whereas ENT2 MK-801 ENT2END (0
0	The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on ENT1 dopamine ENT1END -related behaviors induced by reserpine treatments. This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage. Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in orofacial dyskinesia, tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia. Reserpine also produced ENT2 tremor ENT2END and catalepsy, which are signs suggestive of Parkinson's disease
0	The glutamatergic blockage produced by ENT1 NMDA ENT1END  can restore these signs, such as vacuous chewing movements, tongue protrusions, catalepsy and ENT2 tremor ENT2END according to the employed model
1	However, MK-801 injection produced a significant increase of ENT1 tremor ENT1END in ENT2 reserpine ENT2END -treated mice
0	However, MK-801 injection produced a significant increase of ENT1 tremor  ENT1END  in reserpine-treated mice. Reserpine (1 mg/kg), administered 90 min before the test and followed by ENT2 apomophine ENT2END injection (0
0	1 mg/kg) 5 min before the test, did not produce ENT1 oral dyskinesia ENT1END in mice. On the other hand, reserpine induced increases in tremor and catalepsy compared to control mice. ENT2 MK-801 ENT2END (0
0	The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, were studied on ENT1 dopamine ENT1END -related behaviors induced by reserpine treatments. This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage. Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in ENT2 orofacial dyskinesia ENT2END , tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia
0	The effects of dizocilpine (MK-801), a noncompetitive N-methyl-D-aspartate ( ENT1 NMDA  ENT1END  receptor antagonist, were studied on dopamine-related behaviors induced by reserpine treatments. This study focuses on behavioral syndromes that may used as models for Parkinson's disease, or tardive dyskinesia, and its response after glutamatergic blockage. Reserpine (1 mg/kg), administered once every other day for 4 days, produced increases in ENT2 orofacial dyskinesia ENT2END , tongue protrusion and vacuous chewing in mice, which are signs indicative of tardive dyskinesia
0	1 mg/kg) 5 min before the test, did not produce ENT1 oral dyskinesia ENT1END  in mice. On the other hand, ENT2 reserpine ENT2END induced increases in tremor and catalepsy compared to control mice
0	Reserpine (1 mg/kg), administered 90 min before the test and followed by ENT1 apomophine  ENT1END  injection (0.1 mg/kg) 5 min before the test, did not produce ENT2 oral dyskinesia ENT2END in mice
0	To determine sensitivity we assessed tremor in 44 patients with ENT1 obstructive lung disease ENT1END after administration of cumulative doses of ENT2 salbutamol ENT2END
1	ENT1 Tremor  ENT1END  side effects of ENT2 salbutamol ENT2END , quantified by a laser pointer technique
0	It is suggested that the patient had ENT1 sulfasalazine ENT1END induced lupus, which manifested with ENT2 serositis ENT2END and pulmonary parenchymal involvement in the absence of joint symptoms
1	It is suggested that the patient had ENT1 sulfasalazine ENT1END -induced ENT2 lupus ENT2END , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms
1	ENT1 Sulfasalazine ENT1END -induced lupus erythematosus.Pneumonitis, bilateral ENT2 pleural effusions ENT2END , echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis
1	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of ENT1 cardiac tamponade ENT1END  and positive autoantibodies developed in a 43-year-old man, who was receiving long-term ENT2 sulfasalazine ENT2END therapy for chronic ulcerative colitis
0	Pneumonitis, bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term ENT1 sulfasalazine ENT1END  therapy for chronic ENT2 ulcerative colitis ENT2END
0	Physicians who use ENT1 sulfasalazine ENT1END to treat patients with ENT2 inflammatory bowel disease ENT2END should be aware of the signs of sulfasalazine-induced lupus syndrome
1	ENT1 Sulfasalazine  ENT1END -induced lupus erythematosus. ENT2 Pneumonitis ENT2END , bilateral pleural effusions, echocardiographic evidence of cardiac tamponade, and positive autoantibodies developed in a 43-year-old man, who was receiving long-term sulfasalazine therapy for chronic ulcerative colitis
0	Naloxone reversal of hypotension due to ENT1 captopril ENT1END ENT2 overdose ENT2END
1	Naloxone reversal of hypotension due to captopril ENT1 overdose ENT1END .The hemodynamic effects of captopril and other ENT2 angiotensin-converting enzyme inhibitors ENT2END may be mediated by the endogenous opioid system
0	ENT1 Naloxone  ENT1END  reversal of hypotension due to captopril ENT2 overdose ENT2END
0	Naloxone reversal of ENT1 hypotension  ENT1END  due to ENT2 captopril ENT2END overdose
1	Naloxone reversal of ENT1 hypotension  ENT1END  due to captopril overdose.The hemodynamic effects of captopril and other ENT2 angiotensin-converting enzyme inhibitors ENT2END may be mediated by the endogenous opioid system
0	ENT1 Naloxone  ENT1END  reversal of ENT2 hypotension ENT2END due to captopril overdose
1	Compared with the placebo group, there was a significantly increased risk of vascular events and ENT1 hypertriglyceridaemia ENT1END among women on ENT2 tamoxifen ENT2END
0	BACKGROUND: Tamoxifen is a candidate chemopreventive agent in breast cancer, although the drug may be associated with the development of ENT1 endometrial cancer ENT1END  Therefore we did a trial in hysterectomised women of ENT2 tamoxifen ENT2END as a chemopreventive
0	Prevention of ENT1 breast cancer  ENT1END  with ENT2 tamoxifen ENT2END : preliminary findings from the Italian randomised trial among hysterectomised women
1	Compared with the placebo group, there was a significantly increased risk of ENT1 vascular events  ENT1END and hypertriglyceridaemia among women on ENT2 tamoxifen ENT2END
0	Iatrogenically induced intractable atrioventricular reentrant tachycardia after ENT1 verapamil  ENT1END  and catheter ablation in a patient with Wolff-Parkinson-White syndrome and ENT2 idiopathic dilated cardiomyopathy ENT2END
1	Iatrogenically induced intractable ENT1 atrioventricular reentrant tachycardia  ENT1END  after ENT2 verapamil ENT2END and catheter ablation in a patient with Wolff-Parkinson-White syndrome and idiopathic dilated cardiomyopathy
0	Iatrogenically induced intractable atrioventricular reentrant tachycardia after ENT1 verapamil  ENT1END  and catheter ablation in a patient with ENT2 Wolff-Parkinson-White syndrome ENT2END and idiopathic dilated cardiomyopathy
1	A 49-year-old woman was transferred to our department because of quadriparesis, lancinating ENT1 pain ENT1END  sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of ENT2 disulfiram ENT2END (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm
0	A 49-year-old woman was transferred to our department because of quadriparesis, lancinating ENT1 pain ENT1END , sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT2 ALCOHOL ENT2END STOP TAB, Shin-Poong Pharm
0	One month previously, she had taken a single high dose of ENT1 disulfiram ENT1END  (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness. She noticed ENT2 hoarseness ENT2END and distally accentuated motor and sensory dysfunction after she had recovered from this state
0	One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT1 ALCOHOL  ENT1END  STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness. She noticed ENT2 hoarseness ENT2END and distally accentuated motor and sensory dysfunction after she had recovered from this state
0	A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, ENT1 sensory loss  ENT1END  and paresthesia of the distal limbs. One month previously, she had taken a single high dose of ENT2 disulfiram ENT2END (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm
0	A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, ENT1 sensory loss  ENT1END , and paresthesia of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT2 ALCOHOL ENT2END STOP TAB, Shin-Poong Pharm
1	A 49-year-old woman was transferred to our department because of ENT1 quadriparesis  ENT1END  lancinating pain, sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of ENT2 disulfiram ENT2END (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm
0	A 49-year-old woman was transferred to our department because of ENT1 quadriparesis  ENT1END , lancinating pain, sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT2 ALCOHOL ENT2END STOP TAB, Shin-Poong Pharm
1	A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and ENT1 paresthesia  ENT1END of the distal limbs. One month previously, she had taken a single high dose of ENT2 disulfiram ENT2END (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm
0	A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and ENT1 paresthesia  ENT1END  of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT2 ALCOHOL ENT2END STOP TAB, Shin-Poong Pharm
1	Acute ENT1 vocal fold palsy  ENT1END  after acute ENT2 disulfiram ENT2END intoxication
0	Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to ENT1 vocal fold palsy  ENT1END  A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT2 ALCOHOL ENT2END STOP TAB, Shin-Poong Pharm
0	This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal ENT1 polyneuropathy ENT1END caused by high-dose ENT2 disulfiram ENT2END intoxication
0	One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT1 ALCOHOL ENT1END  STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and giddiness. She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state. A nerve conduction study was consistent with severe sensorimotor axonal ENT2 polyneuropathy ENT2END
0	One month previously, she had taken a single high dose of ENT1 disulfiram ENT1END  (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and ENT2 giddiness ENT2END
0	One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT1 ALCOHOL  ENT1END  STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ataxia and ENT2 giddiness ENT2END
1	One month previously, she had taken a single high dose of ENT1 disulfiram ENT1END  (130 tablets of ALCOHOL STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ENT2 ataxia ENT2END and giddiness
0	One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT1 ALCOHOL  ENT1END  STOP TAB, Shin-Poong Pharm. Co., Ansan, Korea) in a suicide attempt. She was not an alcoholic. For the first few days after ingestion, she was in a confused state and had mild to moderate ENT2 ataxia ENT2END and giddiness
0	Acute peripheral neuropathy caused by a ENT1 disulfiram ENT1END ENT2 overdose ENT2END is very rare and there is no report of it leading to vocal fold palsy
0	Acute peripheral neuropathy caused by a disulfiram ENT1 overdose  ENT1END  is very rare and there is no report of it leading to vocal fold palsy. A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT2 ALCOHOL ENT2END STOP TAB, Shin-Poong Pharm
1	Acute ENT1 peripheral neuropathy  ENT1END caused by a ENT2 disulfiram ENT2END overdose is very rare and there is no report of it leading to vocal fold palsy
0	Acute ENT1 peripheral neuropathy  ENT1END  caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy. A 49-year-old woman was transferred to our department because of quadriparesis, lancinating pain, sensory loss, and paresthesia of the distal limbs. One month previously, she had taken a single high dose of disulfiram (130 tablets of ENT2 ALCOHOL ENT2END STOP TAB, Shin-Poong Pharm
0	This was a case of acute ENT1 palsy  ENT1END of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high-dose ENT2 disulfiram ENT2END intoxication
0	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as ENT1 cardiac dysrhythmias ENT1END  hypertension, hallucinations, and violent behavior. Dental patients abusing ENT2 methamphetamine ENT2END can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear
0	Oral rehabilitation of patients using ENT1 methamphetamine ENT1END can be challenging. CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental ENT2 pain ENT2END , bad breath, and self-reported poor esthetics
0	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, ENT1 hypertension  ENT1END  hallucinations, and violent behavior. Dental patients abusing ENT2 methamphetamine ENT2END can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear
0	Dental patients abusing methamphetamine can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive ENT1 tooth wear  ENT1END  Oral rehabilitation of patients using ENT2 methamphetamine ENT2END can be challenging
0	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, hallucinations, and ENT1 violent behavior  ENT1END  Dental patients abusing ENT2 methamphetamine ENT2END can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear
0	Dental patients abusing ENT1 methamphetamine ENT1END  can present with poor oral hygiene, ENT2 xerostomia ENT2END , rampant caries ("meth mouth"), and excessive tooth wear
1	She reported her use of ENT1 methamphetamine ENT1END for five years and had not experienced any major ENT2 carious episodes ENT2END before she started using the drug
0	Oral rehabilitation of patients using ENT1 methamphetamine ENT1END  can be challenging. CASE DESCRIPTION: A 30-year-old Caucasian woman presented with dental pain, ENT2 bad breath ENT2END , and self-reported poor esthetics
0	BACKGROUND: Methamphetamine is a very addictive, powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias, hypertension, ENT1 hallucinations  ENT1END  and violent behavior. Dental patients abusing ENT2 methamphetamine ENT2END can present with poor oral hygiene, xerostomia, rampant caries ("meth mouth"), and excessive tooth wear
0	Nitroprusside-induced ENT1 hypotension ENT1END evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation. Portal plasma concentrations of neither ENT2 arginine vasopressin ENT2END nor oxytocin are significantly altered in this paradigm
0	Suppression of irCRF secretion in response to nitroprusside-induced ENT1 hypotension ENT1END is observed and occurs at a plasma ENT2 corticosterone ENT2END level between 8-12 micrograms/dl
1	ENT1 Nitroprusside  ENT1END induced ENT2 hypotension ENT2END evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation
0	Nitroprusside-induced ENT1 hypotension ENT1END  evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation. Portal plasma concentrations of neither arginine vasopressin nor ENT2 oxytocin ENT2END are significantly altered in this paradigm
0	Nitroprusside-induced ENT1 hypotension ENT1END  evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin-releasing factor (irCRF) into the hypophysial-portal circulation. Portal plasma concentrations of neither arginine vasopressin nor oxytocin are significantly altered in this paradigm. Application of a delayed feedback signal, in the form of a 2-h systemic corticosterone infusion in ENT2 urethane ENT2END -anesthetized rats with pharmacological blockade of glucocorticoid synthesis, is without effect on the resting secretion of arginine vasopressin and oxytocin at any corticosterone feedback dose tested
1	This study supports the role of lipid peroxidation in mediating the proteinuric injury in ENT1 PAN ENT1END ENT2 nephropathy ENT2END
0	Time course of lipid peroxidation in puromycin aminonucleoside-induced ENT1 nephropathy ENT1END .Reactive ENT2 oxygen ENT2END species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the proteinuria
0	Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as ENT1 thiobarbituric acid  ENT1END reactive substances. Proteinuria was evident at day 5, peaked at day 7 and persisted to day 27. Lipid peroxidation in homogenates was maximal at day 3 and declined rapidly to control levels by day 17. This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN ENT2 nephropathy ENT2END
1	This study supports the role of lipid peroxidation in mediating the ENT1 proteinuric injury  ENT1END in ENT2 PAN ENT2END nephropathy
0	Reactive ENT1 oxygen ENT1END  species have been implicated in the pathogenesis of acute puromycin aminonucleoside (PAN)-induced nephropathy, with antioxidants significantly reducing the ENT2 proteinuria ENT2END
0	Tissue lipid peroxidation was measured in whole homogenates as well as in lipid extracts from homogenates as ENT1 thiobarbituric acid ENT1END  reactive substances. ENT2 Proteinuria ENT2END was evident at day 5, peaked at day 7 and persisted to day 27
0	Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm ENT1 alpha-benzene hexachloride ENT1END were examined histochemically and electron microscopically. Although most of the hepatomas were well-differentiated ENT2 tumors ENT2END and contained a considerable number of peroxisomes, the tumor cells did not respond to ethyl-alpha-p-chlorophenoxyisobutyrate with proliferation of peroxisomes
0	Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the ENT1 tumor ENT1END cells did not respond to ENT2 ethyl-alpha-p-chlorophenoxyisobutyrate ENT2END with proliferation of peroxisomes
1	Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by ENT1 alpha-benzene hexachloride ENT1END .Peroxisomes in ENT2 hepatomas ENT2END and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically
0	Although most of the ENT1 hepatomas  ENT1END were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ENT2 ethyl-alpha-p-chlorophenoxyisobutyrate ENT2END with proliferation of peroxisomes
0	Peroxisomes in hepatomas and hyperplastic preneoplastic ENT1 liver lesions  ENT1END induced in mice by 500 ppm ENT2 alpha-benzene hexachloride ENT2END were examined histochemically and electron microscopically
0	Peroxisomes in hepatomas and hyperplastic preneoplastic ENT1 liver lesions  ENT1END  induced in mice by 500 ppm alpha-benzene hexachloride were examined histochemically and electron microscopically. Although most of the hepatomas were well-differentiated tumors and contained a considerable number of peroxisomes, the tumor cells did not respond to ENT2 ethyl-alpha-p-chlorophenoxyisobutyrate ENT2END with proliferation of peroxisomes
1	This paper presents the results of treating IST by intratympanic instillation of lignocaine ( ENT1 lidocaine ENT1END  2 per cent through a grommet, for five weekly courses. Fifty-two patients suffering from intractable tinnitus entered this therapeutic trial, but only nine finished all five courses. In one patient, the tinnitus was almost completely abolished, but in all the nine patients the decompensated tinnitus changed to a compensated one. We suggest this mode of treatment for patients that were previously treated by drugs, acupuncture and biofeedback, with disappointing results. Patients should be warned about the side effects of ENT2 vertigo ENT2END and vomiting, which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life
0	This paper presents the results of treating ENT1 IST ENT1END by intratympanic instillation of ENT2 lignocaine ENT2END (lidocaine) 2 per cent through a grommet, for five weekly courses
1	This paper presents the results of treating IST by intratympanic instillation of lignocaine ( ENT1 lidocaine ENT1END ) 2 per cent through a grommet, for five weekly courses. Fifty-two patients suffering from intractable tinnitus entered this therapeutic trial, but only nine finished all five courses. In one patient, the tinnitus was almost completely abolished, but in all the nine patients the decompensated tinnitus changed to a compensated one. We suggest this mode of treatment for patients that were previously treated by drugs, acupuncture and biofeedback, with disappointing results. Patients should be warned about the side effects of vertigo and ENT2 vomiting ENT2END , which subsides gradually with every new instillation, and that the tinnitus may not disappear but will be alleviated, enabling them to cope more easily with the disease and lead a more normal life
0	Sodium nitroprusside is a non-selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced ENT1 hypotension ENT1END  Fenoldopam is a selective ENT2 dopamine ENT2END -1 (DA1) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension
1	Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium ENT1 nitroprusside ENT1END induced ENT2 hypotension ENT2END (P less than 0
1	Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively, in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under ENT1 halothane ENT1END general anaesthesia. Mean arterial pressure was decreased 30 +/- 8 per cent from control with infusion of fenoldopam (3.4 +/- 2.0 micrograms.kg-1.min-1) and 34 +/- 4 per cent with infusion of sodium nitroprusside (5.9 micrograms.kg-1.min-1) (NS). Renal blood flow (RBF) increased during fenoldopam-induced ENT2 hypotension ENT2END 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0
1	Renal blood flow (RBF) increased during ENT1 fenoldopam  ENT1END induced ENT2 hypotension ENT2END 11 +/- 7 per cent and decreased 21 +/- 8 per cent during sodium nitroprusside-induced hypotension (P less than 0
0	Renal blood flow (RBF) increased during fenoldopam-induced hypotension 11 +/- 7 per cent and decreased 21 +/- 8 per cent during ENT1 sodium  ENT1END nitroprusside-induced ENT2 hypotension ENT2END (P less than 0
0	A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered ENT1 veratridine ENT1END (100 microM). Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced ENT2 hyperthermia ENT2END and reduced basal body temperature
0	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in ENT1 dopamine  ENT1END  outflow and inhibition of ENT2 hyperthermia ENT2END in rats
0	Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced ENT1 hyperthermia ENT1END  and reduced basal body temperature. ENT2 MPEP ENT2END administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect
1	Moreover, it transiently diminished the ENT1 methamphetamine  ENT1END (10 mg/kg sc)-induced ENT2 hyperthermia ENT2END and reduced basal body temperature
0	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of ENT1 hyperthermia ENT1END  in rats.The aim of this study was to examine the role of metabotropic ENT2 glutamate ENT2END receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats
0	A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered ENT1 veratridine ENT1END  (100 microM). Moreover, it transiently diminished the methamphetamine (10 mg/kg sc)-induced hyperthermia and reduced basal body temperature. MPEP administered into the striatum at high concentrations (500 microM) increased extracellular dopamine levels, while lower concentrations (50-100 microM) were devoid of any effect. The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced ENT2 toxicity ENT2END
0	The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced ENT1 toxicity ENT1END . Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine-induced ENT2 dopamine ENT2END efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia
0	The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine-induced ENT1 toxicity ENT1END . Neuroprotection rendered by ENT2 MPEP ENT2END may be associated with the reduction of the methamphetamine-induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5, and with a decrease in hyperthermia
0	The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against ENT1 methamphetamine  ENT1END induced ENT2 toxicity ENT2END
0	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic ENT1 neurotoxicity  ENT1END  is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.The aim of this study was to examine the role of metabotropic glutamate receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats. Methamphetamine (10 mg/kg sc), administered five times, reduced the levels of dopamine and its metabolites in striatal tissue when measured 72 h after the last injection. A selective antagonist of mGluR5, 2-methyl-6-(phenylethynyl)pyridine (MPEP; 5 mg/kg ip), when administered five times immediately before each methamphetamine injection reversed the above-mentioned methamphetamine effects. A single MPEP (5 mg/kg ip) injection reduced the basal extracellular dopamine level in the striatum, as well as dopamine release stimulated either by methamphetamine (10 mg/kg sc) or by intrastriatally administered ENT2 veratridine ENT2END (100 microM)
0	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic ENT1 neurotoxicity  ENT1END  is associated with a decrease in ENT2 dopamine ENT2END outflow and inhibition of hyperthermia in rats
0	Neuroprotective action of ENT1 MPEP  ENT1END , a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic ENT2 neurotoxicity ENT2END is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats
0	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in ENT1 methamphetamine  ENT1END -induced dopaminergic ENT2 neurotoxicity ENT2END is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats
0	Neuroprotective action of MPEP, a selective mGluR5 antagonist, in methamphetamine-induced dopaminergic ENT1 neurotoxicity  ENT1END  is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats.The aim of this study was to examine the role of metabotropic ENT2 glutamate ENT2END receptor 5 (mGluR5) in the toxic action of methamphetamine on dopaminergic neurones in rats
0	Risperidone is an antipsychotic drug with high affinity at ENT1 dopamine ENT1END D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative ENT2 psychotic symptoms ENT2END and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics
0	Risperidone is an antipsychotic drug with high affinity at dopamine D2 and ENT1 serotonin 5-HT2  ENT1END receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative ENT2 psychotic symptoms ENT2END and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics
0	Extrapyramidal side effects with risperidone and ENT1 haloperidol  ENT1END  at comparable D2 receptor occupancy levels.Risperidone is an antipsychotic drug with high affinity at dopamine D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative ENT2 psychotic symptoms ENT2END and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics
0	Previous clinical studies have proposed that ENT1 risperidone  ENT1END s pharmacologic profile may produce improved efficacy for negative ENT2 psychotic symptoms ENT2END and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics
0	Risperidone is an antipsychotic drug with high affinity at ENT1 dopamine ENT1END  D2 and serotonin 5-HT2 receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics. To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7). Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses. There was no significant difference between occupancy levels obtained with haloperidol or risperidone. ENT2 Drug-induced parkinsonism ENT2END was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%
0	Risperidone is an antipsychotic drug with high affinity at dopamine D2 and ENT1 serotonin 5-HT2  ENT1END  receptors. Previous clinical studies have proposed that risperidone's pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects; features shared by so-called 'atypical' neuroleptics. To determine if routine risperidone treatment is associated with a unique degree of D2 receptor occupancy and pattern of clinical effects, we used [123I]IBZM SPECT to determine D2 occupancy in subjects treated with routine clinical doses of risperidone (n = 12) or haloperidol (n = 7). Both risperidone and haloperidol produced D2 occupancy levels between approximately 60 and 90% at standard clinical doses. There was no significant difference between occupancy levels obtained with haloperidol or risperidone. ENT2 Drug-induced parkinsonism ENT2END was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%
1	There was no significant difference between occupancy levels obtained with ENT1 haloperidol  ENT1END or risperidone. ENT2 Drug-induced parkinsonism ENT2END was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%
1	There was no significant difference between occupancy levels obtained with haloperidol or ENT1 risperidone ENT1END ENT2 Drug-induced parkinsonism ENT2END was observed in subjects treated with risperidone (42%) and haloperidol (29%) and was observed at occupancy levels above 60%
0	Patients who develop ESRD have a higher preoperative and 1-year serum ENT1 creatinine ENT1END and are more likely to have ENT2 hepatorenal syndrome ENT2END
1	BACKGROUND: The calcineurin inhibitors ENT1 cyclosporine ENT1END and tacrolimus are both known to be ENT2 nephrotoxic ENT2END
1	BACKGROUND: The calcineurin inhibitors cyclosporine and ENT1 tacrolimus  ENT1END are both known to be ENT2 nephrotoxic ENT2END
0	RESULTS: At 13 years after OLTX, the incidence of severe ENT1 renal dysfunction ENT1END was 18.1% (CRF 8.6% and ESRD 9.5%). Compared with control patients, CRF and ESRD patients had higher preoperative serum ENT2 creatinine ENT2END levels, a greater percentage of patients with hepatorenal syndrome, higher percentage requirement for dialysis in the first 3 months postoperatively, and a higher 1-year serum creatinine
0	End-stage renal disease ( ENT1 ESRD  ENT1END ) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.BACKGROUND: The calcineurin inhibitors ENT2 cyclosporine ENT2END and tacrolimus are both known to be nephrotoxic
0	End-stage renal disease ( ENT1 ESRD  ENT1END ) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment.BACKGROUND: The calcineurin inhibitors cyclosporine and ENT2 tacrolimus ENT2END are both known to be nephrotoxic
0	Patients were divided into three groups: Controls, no CRF or ESRD, n=748; ENT1 CRF ENT1END  sustained serum ENT2 creatinine ENT2END >2
0	Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and ENT1 hyperlocomotion ENT1END in rats. Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats. In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats. Finally, carteolol did not inhibit ENT2 physostigmine ENT2END -induced lethality in rats
0	Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and ENT1 hyperlocomotion ENT1END  in rats. Carteolol did not antagonize the inhibitory effects of ENT2 haloperidol ENT2END on apomorphine-induced stereotypy and locomotor activity in rats
0	The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of ENT1 biperiden  ENT1END  Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and ENT2 hyperlocomotion ENT2END in rats
0	Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and ENT1 hyperlocomotion ENT1END  in rats. Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats. In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit ENT2 5-hydroxytryptophan ENT2END -induced head twitch in rats
0	Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and ENT1 hyperlocomotion ENT1END  in rats. ENT2 Carteolol ENT2END did not antagonize the inhibitory effects of haloperidol on apomorphine-induced stereotypy and locomotor activity in rats
0	Carteolol did not evoke postsynaptic ENT1 dopamine  ENT1END receptor-stimulating behavioral signs such as stereotypy and ENT2 hyperlocomotion ENT2END in rats
0	The inhibitory effect of carteolol was almost comparable to that of ENT1 propranolol  ENT1END  but was weaker than that of biperiden. Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and ENT2 hyperlocomotion ENT2END in rats
0	Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and ENT1 hyperlocomotion ENT1END  in rats. Carteolol did not antagonize the inhibitory effects of haloperidol on ENT2 apomorphine ENT2END -induced stereotypy and locomotor activity in rats
0	Finally, carteolol did not inhibit ENT1 physostigmine ENT1END -induced lethality in rats. These results strongly suggest that carteolol improves haloperidol-induced ENT2 catalepsy ENT2END via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity
1	Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on ENT1 haloperidol ENT1END induced ENT2 catalepsy ENT2END in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist
0	Carteolol, as well as propranolol and ENT1 biperiden ENT1END  inhibited the haloperidol-induced ENT2 catalepsy ENT2END
0	In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit ENT1 5-hydroxytryptophan  ENT1END -induced head twitch in rats. Finally, carteolol did not inhibit physostigmine-induced lethality in rats. These results strongly suggest that carteolol improves haloperidol-induced ENT2 catalepsy ENT2END via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity
0	Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced ENT1 catalepsy ENT1END . The inhibitory effect of ENT2 carteolol ENT2END was almost comparable to that of propranolol, but was weaker than that of biperiden
0	Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced ENT1 catalepsy  ENT1END . The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden. Carteolol did not evoke postsynaptic ENT2 dopamine ENT2END receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats
0	Carteolol, as well as ENT1 propranolol  ENT1END and biperiden, inhibited the haloperidol-induced ENT2 catalepsy ENT2END
0	Carteolol, as well as propranolol and biperiden, inhibited the haloperidol-induced ENT1 catalepsy  ENT1END . The inhibitory effect of carteolol was almost comparable to that of propranolol, but was weaker than that of biperiden. Carteolol did not evoke postsynaptic dopamine receptor-stimulating behavioral signs such as stereotypy and hyperlocomotion in rats. Carteolol did not antagonize the inhibitory effects of haloperidol on ENT2 apomorphine ENT2END -induced stereotypy and locomotor activity in rats
0	Finally, carteolol did not inhibit ENT1 physostigmine ENT1END -induced lethality in rats. These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of ENT2 akathisia ENT2END without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity
0	Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced ENT1 akathisia  ENT1END  Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on ENT2 haloperidol ENT2END -induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist
0	Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced ENT1 akathisia ENT1END . Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and ENT2 biperiden ENT2END , a muscarinic receptor antagonist
0	In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit ENT1 5-hydroxytryptophan  ENT1END -induced head twitch in rats. Finally, carteolol did not inhibit physostigmine-induced lethality in rats. These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of ENT2 akathisia ENT2END without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity
0	Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced ENT1 akathisia ENT1END . Therefore, the effects of ENT2 carteolol ENT2END , a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden, a muscarinic receptor antagonist
0	These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of ENT1 akathisia ENT1END  without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic ENT2 dopamine ENT2END receptor antagonistic activity
0	Neuroleptic-induced catalepsy, a model of neuroleptic-induced extrapyramidal side effects, was considered suitable as a model for predicting neuroleptic-induced akathisia in humans, although neuroleptic-induced catalepsy was not considered a specific test for neuroleptic-induced ENT1 akathisia ENT1END . Therefore, the effects of carteolol, a beta-adrenoceptor antagonist, on haloperidol-induced catalepsy in rats were behaviorally studied and compared with those of ENT2 propranolol ENT2END and biperiden, a muscarinic receptor antagonist
0	Carteolol did not antagonize the inhibitory effects of haloperidol on ENT1 apomorphine  ENT1END -induced stereotypy and locomotor activity in rats. In addition, carteolol did not evoke 5-HT1A receptor-stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5-hydroxytryptophan-induced head twitch in rats. Finally, carteolol did not inhibit physostigmine-induced lethality in rats. These results strongly suggest that carteolol improves haloperidol-induced catalepsy via its beta-adrenoceptor antagonistic activity and is expected to be effective in the treatment of ENT2 akathisia ENT2END without attenuating neuroleptic-induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity
0	This apparent difference in risk may not be due to differences in ENT1 nephrotoxic ENT1END potential of the drugs themselves. A lower relative risk would be expected for ENT2 acetaminophen ENT2END if the risk of both drugs in combination with other analgesics was higher than the risk of either agent alone
0	These studies suggest that both ENT1 phenacetin  ENT1END and acetaminophen may contribute to the burden of ESRD, with the risk of the latter being somewhat less than that of the former. This apparent difference in risk may not be due to differences in ENT2 nephrotoxic ENT2END potential of the drugs themselves
0	The possibility that habitual use of ENT1 acetaminophen ENT1END alone increases the risk of ENT2 ESRD ENT2END has not been clearly demonstrated, but cannot be dismissed
1	Habitual use of acetaminophen as a risk factor for ENT1 chronic renal failure  ENT1END : a comparison with ENT2 phenacetin ENT2END
0	We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with ENT1 mitomycin C ENT1END and died in ENT2 pulmonary edema ENT2END
0	Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi, expanded subendothelial zones in glomerular capillary walls, ENT1 ischemic ENT1END wrinkling of glomerular basement membranes and mesangiolysis. The mechanism of action is postulated as ENT2 mitomycin C ENT2END -induced endothelial cell damage
0	It consists of microangiopathic ENT1 hemolytic anemia ENT1END  thrombocytopenia and progressive renal failure associated with ENT2 mitomycin C ENT2END treatment and affects about 10% of patients treated with this agent
0	We describe the clinical course and pathological findings in a 65 yr-old man with gastric adenocarcinoma who developed renal failure and ENT1 thrombocytopenia  ENT1END while on treatment with ENT2 mitomycin C ENT2END and died in pulmonary edema
0	Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin ENT1 thrombi  ENT1END  expanded subendothelial zones in glomerular capillary walls, ischemic wrinkling of glomerular basement membranes and mesangiolysis. The mechanism of action is postulated as ENT2 mitomycin C ENT2END -induced endothelial cell damage
1	It consists of microangiopathic hemolytic anemia, thrombocytopenia and progressive ENT1 renal failure  ENT1END associated with ENT2 mitomycin C ENT2END treatment and affects about 10% of patients treated with this agent
1	Mitomycin C associated ENT1 hemolytic uremic syndrome  ENT1END . ENT2 Mitomycin C ENT2END associated Hemolytic Uremic Syndrome (HUS) is a potentially fatal but uncommon condition that is not yet widely recognised
0	We describe the clinical course and pathological findings in a 65 yr-old man with ENT1 gastric adenocarcinoma  ENT1END who developed renal failure and thrombocytopenia while on treatment with ENT2 mitomycin C ENT2END and died in pulmonary edema
0	, nephrotoxicity, ototoxicity, and ENT1 neurotoxicity ENT1END  have limited its use as a treatment for breast carcinoma. ENT2 WR-2721 ENT2END or amifostine initially was developed to protect military personnel in the event of nuclear war
0	Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with ENT1 cisplatin  ENT1END (e.g., nephrotoxicity, ototoxicity, and ENT2 neurotoxicity ENT2END ) have limited its use as a treatment for breast carcinoma
0	, nephrotoxicity, ototoxicity, and ENT1 neurotoxicity ENT1END ) have limited its use as a treatment for breast carcinoma. WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war. Amifostine subsequently was shown to protect normal tissues from the toxic effects of ENT2 alkylating agents ENT2END and cisplatin without decreasing the antitumor effect of the chemotherapy
0	CONCLUSIONS: The combination of cisplatin and ENT1 amifostine ENT1END in this study resulted in an overall response rate of 16%. Neither a ENT2 tumor ENT2END -protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial
0	CONCLUSIONS: The combination of ENT1 cisplatin  ENT1END and amifostine in this study resulted in an overall response rate of 16%. Neither a ENT2 tumor ENT2END -protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial
0	Neither a tumor-protective effect nor reduced ENT1 toxicity ENT1END to normal tissues was observed with the addition of ENT2 amifostine ENT2END to cisplatin in this trial
0	Although a dose-response effect has been observed with cisplatin, the dose-limiting ENT1 toxicities  ENT1END associated with ENT2 cisplatin ENT2END (e
0	Although a dose-response effect has been observed with cisplatin, the dose-limiting ENT1 toxicities  ENT1END  associated with cisplatin (e.g., nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma. WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war. Amifostine subsequently was shown to protect normal tissues from the toxic effects of ENT2 alkylating agents ENT2END and cisplatin without decreasing the antitumor effect of the chemotherapy
0	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and ENT1 neuropathy ENT1END were reduced. METHODS: A Phase II study of the combination of cisplatin plus ENT2 amifostine ENT2END was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease
0	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and ENT1 neuropathy ENT1END  were reduced. METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease. Patients received amifostine, 910 mg/m2 intravenously over 15 minutes. After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes. Intravenous hydration and ENT2 mannitol ENT2END was administered before and after cisplatin
1	Early trials of cisplatin and amifostine also suggested that the incidence and severity of ENT1 cisplatin  ENT1END induced nephrotoxicity, ototoxicity, and ENT2 neuropathy ENT2END were reduced
0	Amifostine subsequently was shown to protect normal tissues from the toxic effects of ENT1 alkylating agents  ENT1END  and cisplatin without decreasing the antitumor effect of the chemotherapy. Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ototoxicity, and ENT2 neuropathy ENT2END were reduced
0	, nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for ENT1 breast carcinoma ENT1END ENT2 WR-2721 ENT2END or amifostine initially was developed to protect military personnel in the event of nuclear war
0	METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic ENT1 breast carcinoma  ENT1END who had received one, but not more than one, chemotherapy regimen for metastatic disease. Patients received amifostine, 910 mg/m2 intravenously over 15 minutes. After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes. Intravenous hydration and ENT2 mannitol ENT2END was administered before and after cisplatin
0	A Phase II trial of ENT1 cisplatin  ENT1END  plus WR-2721 (amifostine) for metastatic ENT2 breast carcinoma ENT2END : an Eastern Cooperative Oncology Group Study (E8188)
0	, nephrotoxicity, ototoxicity, and neurotoxicity) have limited its use as a treatment for ENT1 breast carcinoma  ENT1END . WR-2721 or amifostine initially was developed to protect military personnel in the event of nuclear war. Amifostine subsequently was shown to protect normal tissues from the toxic effects of ENT2 alkylating agents ENT2END and cisplatin without decreasing the antitumor effect of the chemotherapy
0	Early trials of cisplatin and ENT1 amifostine ENT1END also suggested that the incidence and severity of cisplatin-induced ENT2 nephrotoxicity ENT2END , ototoxicity, and neuropathy were reduced
0	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced ENT1 nephrotoxicity  ENT1END , ototoxicity, and neuropathy were reduced. METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease. Patients received amifostine, 910 mg/m2 intravenously over 15 minutes. After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes. Intravenous hydration and ENT2 mannitol ENT2END was administered before and after cisplatin
1	Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with ENT1 cisplatin ENT1END  (e.g., ENT2 nephrotoxicity ENT2END , ototoxicity, and neurotoxicity) have limited its use as a treatment for breast carcinoma
0	Amifostine subsequently was shown to protect normal tissues from the toxic effects of ENT1 alkylating agents  ENT1END  and cisplatin without decreasing the antitumor effect of the chemotherapy. Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced ENT2 nephrotoxicity ENT2END , ototoxicity, and neuropathy were reduced
0	, nephrotoxicity, ENT1 ototoxicity  ENT1END  and neurotoxicity) have limited its use as a treatment for breast carcinoma. ENT2 WR-2721 ENT2END or amifostine initially was developed to protect military personnel in the event of nuclear war
0	Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ENT1 ototoxicity  ENT1END  and neuropathy were reduced. METHODS: A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one, but not more than one, chemotherapy regimen for metastatic disease. Patients received amifostine, 910 mg/m2 intravenously over 15 minutes. After completion of the amifostine infusion, cisplatin 120 mg/m2 was administered over 30 minutes. Intravenous hydration and ENT2 mannitol ENT2END was administered before and after cisplatin
1	Although a dose-response effect has been observed with cisplatin, the dose-limiting toxicities associated with ENT1 cisplatin  ENT1END  (e.g., nephrotoxicity, ENT2 ototoxicity ENT2END , and neurotoxicity) have limited its use as a treatment for breast carcinoma
0	Amifostine subsequently was shown to protect normal tissues from the toxic effects of ENT1 alkylating agents  ENT1END  and cisplatin without decreasing the antitumor effect of the chemotherapy. Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin-induced nephrotoxicity, ENT2 ototoxicity ENT2END , and neuropathy were reduced
0	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil ( ENT1 5-FU ENT1END , have been the mainstay of treatment for several solid tumors, including ENT2 colorectal, breast and head and neck cancers ENT2END , for > 40 years
0	It has shown promising results alone or in combination with other chemotherapeutic agents in ENT1 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers ENT1END  The most commonly reported toxic effects of ENT2 capecitabine ENT2END are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in ENT2 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers ENT2END
0	It has shown promising results alone or in combination with other chemotherapeutic agents in ENT1 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers  ENT1END . The most commonly reported toxic effects of ENT2 capecitabine ENT2END are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers. The most commonly reported toxic effects of capecitabine are diarrhea, nausea, ENT2 vomiting ENT2END , stomatitis and hand-foot syndrome
1	The most commonly reported toxic effects of ENT1 capecitabine  ENT1END  are diarrhea, nausea, ENT2 vomiting ENT2END , stomatitis and hand-foot syndrome
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers. The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and ENT2 hand-foot syndrome ENT2END
1	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and ENT1 hand-foot syndrome ENT1END . ENT2 Capecitabine ENT2END has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions
0	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil ( ENT1 5-FU ENT1END ), have been the mainstay of treatment for several solid ENT2 tumors ENT2END , including colorectal, breast and head and neck cancers, for > 40 years
0	Safety of ENT1 capecitabine  ENT1END : a review.IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil (5-FU), have been the mainstay of treatment for several solid ENT2 tumors ENT2END , including colorectal, breast and head and neck cancers, for > 40 years
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in ENT2 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers ENT2END
0	It has shown promising results alone or in combination with other chemotherapeutic agents in ENT1 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers  ENT1END . The most commonly reported toxic effects of ENT2 capecitabine ENT2END are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome
0	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil ( ENT1 5-FU ENT1END ), have been the mainstay of treatment for several solid tumors, including ENT2 colorectal, breast and head and neck cancers ENT2END , for > 40 years
0	It has shown promising results alone or in combination with other chemotherapeutic agents in ENT1 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers  ENT1END  The most commonly reported toxic effects of ENT2 capecitabine ENT2END are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers. The most commonly reported toxic effects of capecitabine are diarrhea, ENT2 nausea ENT2END , vomiting, stomatitis and hand-foot syndrome
1	The most commonly reported toxic effects of ENT1 capecitabine  ENT1END  are diarrhea, ENT2 nausea ENT2END , vomiting, stomatitis and hand-foot syndrome
0	WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, ENT1 renal and kidney disease  ENT1END  We also explore different dosing and schedules of capecitabine administration. TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT2 5-FU ENT2END and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile
0	WHAT THE READER WILL GAIN: The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age, ENT1 renal and kidney disease ENT1END . We also explore different dosing and schedules of ENT2 capecitabine ENT2END administration
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in ENT2 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers ENT2END
0	It has shown promising results alone or in combination with other chemotherapeutic agents in ENT1 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers  ENT1END . The most commonly reported toxic effects of ENT2 capecitabine ENT2END are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers. The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, ENT2 stomatitis ENT2END and hand-foot syndrome
1	The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, ENT1 stomatitis  ENT1END  and hand-foot syndrome. ENT2 Capecitabine ENT2END has a well-established safety profile and can be given safely to patients with advanced age, hepatic and renal dysfunctions
0	IMPORTANCE OF THE FIELD: Fluoropyrimidines, in particular 5-fluorouracil ( ENT1 5-FU ENT1END ), have been the mainstay of treatment for several solid tumors, including ENT2 colorectal, breast and head and neck cancers ENT2END , for > 40 years
0	It has shown promising results alone or in combination with other chemotherapeutic agents in ENT1 colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers  ENT1END  The most commonly reported toxic effects of ENT2 capecitabine ENT2END are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers. The most commonly reported toxic effects of capecitabine are ENT2 diarrhea ENT2END , nausea, vomiting, stomatitis and hand-foot syndrome
1	The most commonly reported toxic effects of ENT1 capecitabine  ENT1END  are ENT2 diarrhea ENT2END , nausea, vomiting, stomatitis and hand-foot syndrome
0	TAKE HOME MESSAGE: Capecitabine is an oral prodrug of ENT1 5-FU ENT1END  and was developed to fulfill the need for a more convenient therapy and provide an improved safety/efficacy profile. It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal, breast, pancreaticobiliary, gastric, renal cell and head and neck cancers. The most commonly reported toxic effects of capecitabine are diarrhea, nausea, vomiting, stomatitis and hand-foot syndrome. Capecitabine has a well-established safety profile and can be given safely to patients with advanced age, ENT2 hepatic and renal dysfunctions ENT2END
0	ENT1 Capecitabine  ENT1END  has a well-established safety profile and can be given safely to patients with advanced age, ENT2 hepatic and renal dysfunctions ENT2END
0	Pretreatment with the D2 agonist PHNO enhanced nicotine-induced ENT1 hyperactivity ENT1END  whereas the D1 agonist ENT2 SKF 38393 ENT2END had no effect
0	Nicotine-induced hyperactivity was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist ENT1 fluphenazine  ENT1END  Pretreatment with the D2 agonist PHNO enhanced nicotine-induced ENT2 hyperactivity ENT2END , whereas the D1 agonist SKF 38393 had no effect
0	The stimulant action of nicotine was blocked by the central nicotinic antagonist mecamylamine but not by the peripheral nicotinic blocker ENT1 hexamethonium ENT1END  indicating that the response is probably mediated by central nicotinic receptors. Nicotine-induced ENT2 hyperactivity ENT2END was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine
0	Nicotine-induced ENT1 hyperactivity ENT1END  was blocked by the selective D1 antagonist ENT2 SCH 23390 ENT2END , the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine
1	Evidence for an involvement of D1 and D2 dopamine receptors in mediating ENT1 nicotine  ENT1END -induced ENT2 hyperactivity ENT2END in rats
0	The stimulant action of nicotine was blocked by the central nicotinic antagonist ENT1 mecamylamine  ENT1END but not by the peripheral nicotinic blocker hexamethonium, indicating that the response is probably mediated by central nicotinic receptors. Nicotine-induced ENT2 hyperactivity ENT2END was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist raclopride and the D1/D2 antagonist fluphenazine
0	Evidence for an involvement of D1 and D2 ENT1 dopamine  ENT1END  receptors in mediating nicotine-induced ENT2 hyperactivity ENT2END in rats
0	Nicotine-induced ENT1 hyperactivity ENT1END  was blocked by the selective D1 antagonist SCH 23390, the selective D2 antagonist ENT2 raclopride ENT2END and the D1/D2 antagonist fluphenazine
0	METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the ENT1 nephrotoxic ENT1END effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol. The study involved 129 patients with diabetes with serum ENT2 creatinine ENT2END concentrations of 1
0	METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the ENT1 nephrotoxic ENT1END  effects of an iso-osmolar, dimeric, nonionic contrast medium, ENT2 iodixanol ENT2END , with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol
1	003; value in the iodixanol group minus the value in the ENT1 iohexol ENT1END group, -0.17 mg per deciliter [95 percent confidence interval, -0.34 to -0.07]). CONCLUSIONS: ENT2 Nephropathy ENT2END induced by contrast medium may be less likely to develop in high-risk patients when iodixanol is used rather than a low-osmolar, nonionic contrast medium
0	The study involved 129 patients with ENT1 diabetes  ENT1END with serum ENT2 creatinine ENT2END concentrations of 1
0	METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, ENT1 iodixanol  ENT1END , with those of a low-osmolar, nonionic, monomeric contrast medium, iohexol. The study involved 129 patients with ENT2 diabetes ENT2END with serum creatinine concentrations of 1
0	METHODS: We conducted a randomized, double-blind, prospective, multicenter study comparing the nephrotoxic effects of an iso-osmolar, dimeric, nonionic contrast medium, iodixanol, with those of a low-osmolar, nonionic, monomeric contrast medium, ENT1 iohexol  ENT1END  The study involved 129 patients with ENT2 diabetes ENT2END with serum creatinine concentrations of 1
0	The incidence rate of ENT1 thromboembolism ENT1END was 0.9% for all the studies and 0.5, 0, 20, and 0% in groups a, b, c, and d, respectively; for hemorrhage, the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups). CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with ENT2 UH ENT2END
1	METHODS: For this paper, the current medical literature on ENT1 LMWH ENT1END in patients with mechanical heart valves was extensively reviewed. RESULTS: There were eight series and six case reports. None of the studies was randomized, and only one was prospective. Data to establish the ENT2 thromboembolic ENT2END risk were incomplete
0	5, 0, 20, and 0% in groups a, b, c, and d, respectively; for ENT1 hemorrhage  ENT1END  the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups). CONCLUSIONS: In patients with mechanical heart valves, short-term LMWH therapy compares favorably with ENT2 UH ENT2END
1	5, 0, 20, and 0% in groups a, b, c, and d, respectively; for ENT1 hemorrhage ENT1END , the overall rate was 3.4% (3.8, 2.6, 10, and 0% for the respective groups). CONCLUSIONS: In patients with mechanical heart valves, short-term ENT2 LMWH ENT2END therapy compares favorably with UH
0	QTLs for susceptibility to ENT1 pilocarpine ENT1END induced ENT2 seizures ENT2END , a model of temporal lobe epilepsy, have not been reported, and CSS have not previously been used to localize seizure susceptibility genes
1	QTLs for susceptibility to ENT1 pilocarpine ENT1END -induced seizures, a model of ENT2 temporal lobe epilepsy ENT2END , have not been reported, and CSS have not previously been used to localize seizure susceptibility genes
0	However, these medications were more effective in both young and old patients when given after ENT1 parkinsonism ENT1END developed. Akathisia was controlled by the benzodiazepine ENT2 lorazepam ENT2END in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective
1	The incidence of extrapyramidal side effects (EPS) was evaluated in 98 patients treated with ENT1 haloperidol ENT1END  The incidence of ENT2 parkinsonism ENT2END was higher at higher doses of haloperidol and in younger patients
0	However, these medications were more effective in both young and old patients when given after ENT1 parkinsonism ENT1END  developed. Akathisia was controlled by the ENT2 benzodiazepine ENT2END lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective
0	ENT1 Akathisia  ENT1END was controlled by the benzodiazepine ENT2 lorazepam ENT2END in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective
0	The incidence of parkinsonism was higher at higher doses of ENT1 haloperidol  ENT1END and in younger patients. Prophylactic antiparkinsonian medication was effective in younger but not in older patients. However, these medications were more effective in both young and old patients when given after parkinsonism developed. ENT2 Akathisia ENT2END was controlled by the benzodiazepine lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective
0	ENT1 Akathisia  ENT1END  was controlled by the ENT2 benzodiazepine ENT2END lorazepam in 14 out of 16 patients, while prophylactic antiparkinsonians were ineffective
1	A second echocardiography was performed (median interval: 13 months) after ENT1 pergolide ENT1END withdrawal (n=10 patients). Controls were age- and sex-matched non-PD patients referred to the cardiology department. RESULTS: Compared to controls, ENT2 aortic regurgitation ENT2END (OR: 3
0	RESULTS: Compared to controls, ENT1 aortic regurgitation ENT1END  (OR: 3.1; 95% IC: 1.1-8.8) and mitral regurgitation (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS). The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group. Severity of regurgitation was not correlated with pergolide cumulative dose. A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure. Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination. This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot ENT2 dopamine ENT2END agonists
0	Valvular heart abnormalities have been reported in patients with Parkinson's disease ( ENT1 PD ENT1END  treated with ENT2 pergolide ENT2END
0	This study supports the high frequency of restrictive valve regurgitation in ENT1 PD  ENT1END patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot ENT2 dopamine ENT2END agonists
1	A second echocardiography was performed (median interval: 13 months) after ENT1 pergolide ENT1END  withdrawal (n=10 patients). Controls were age- and sex-matched non-PD patients referred to the cardiology department. RESULTS: Compared to controls, aortic regurgitation (OR: 3.1; 95% IC: 1.1-8.8) and ENT2 mitral regurgitation ENT2END (OR: 10
0	8) and ENT1 mitral regurgitation  ENT1END  (OR: 10.7; 95% IC: 2.1-53) were more frequent in PD patients (tricuspid: NS). The number of affected valves (n=2.4+/-0.7) and the sum of regurgitation grades (n=2.8+/-1.09) were higher (p=0.008 and p=0.006, respectively) in the pergolide group. Severity of regurgitation was not correlated with pergolide cumulative dose. A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with heart failure. Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination. This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot ENT2 dopamine ENT2END agonists
0	A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40%) patients including two with ENT1 heart failure ENT1END  ENT2 Pergolide ENT2END was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p=0
0	01) at the second transthoracic echocardiography and the two patients with ENT1 heart failure  ENT1END returned to nearly normal clinical examination. This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot ENT2 dopamine ENT2END agonists
0	A restrictive pattern of ENT1 valvular regurgitation ENT1END  suggestive of the role of ENT2 pergolide ENT2END , was observed in 12/30 (40%) patients including two with heart failure
0	This study supports the high frequency of restrictive ENT1 valve regurgitation  ENT1END in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot ENT2 dopamine ENT2END agonists
1	ENT1 Ticlopidine  ENT1END -induced ENT2 cholestatic hepatitis ENT2END
0	CONCLUSIONS: ENT1 Cholestatic hepatitis ENT1END is a rare adverse effect of ticlopidine that may be immune mediated. Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts. This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent ENT2 clopidogrel ENT2END
1	Our patients developed ENT1 jaundice ENT1END following treatment with ENT2 ticlopidine ENT2END and showed the clinical and laboratory characteristics of cholestatic hepatitis, which resolved after discontinuation of the drug
1	The mechanisms of this ENT1 ticlopidine ENT1END induced ENT2 cholestasis ENT2END are unclear
0	CONCLUSIONS: ENT1 Cholestatic hepatitis  ENT1END is a rare adverse effect of ticlopidine that may be immune mediated. Patients receiving the drug should be monitored with liver function tests along with complete blood cell counts. This complication will be observed even less often in the future as ticlopidine is being replaced by the newer antiplatelet agent ENT2 clopidogrel ENT2END
0	Intravenous administration of a single 50-mg bolus of ENT1 lidocaine ENT1END in a 67-year-old man resulted in profound ENT2 depression ENT2END of the activity of the sinoatrial and atrioventricular nodal pacemakers
1	ENT1 Lidocaine  ENT1END -induced ENT2 cardiac asystole ENT2END
0	The patient had no apparent associated conditions which might have predisposed him to the development of ENT1 bradyarrhythmias ENT1END  and, thus, this probably represented a true idiosyncrasy to ENT2 lidocaine ENT2END
0	ENT1 Glyceryl trinitrate ENT1END  induces attacks of migraine without aura in sufferers of migraine with aura.Migraine with aura and migraine without aura have the same ENT2 pain ENT2END phase, thus indicating that migraine with aura and migraine without aura share a common pathway of nociception
0	In recent years, increasing evidence has suggested that the messenger molecule nitric oxide ( ENT1 NO ENT1END  is involved in ENT2 pain ENT2END mechanisms of migraine without aura
0	Headache was more severe in ENT1 migraineurs ENT1END than in the controls during and immediately after ENT2 GTN ENT2END infusion (p=0
0	At this time the induced headache in 6 of 12 ENT1 migraineurs ENT1END fulfilled the diagnostic criteria for migraine without aura of the International Headache Society. The results therefore suggest that ENT2 NO ENT2END is involved in the pain mechanisms of migraine with aura
0	In the controls, the ENT1 GTN ENT1END induced ENT2 headache ENT2END gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion
0	At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International ENT1 Headache  ENT1END Society. The results therefore suggest that ENT2 NO ENT2END is involved in the pain mechanisms of migraine with aura
0	In order to clarify whether the same is true for migraine with aura, in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( ENT1 GTN ENT1END  (0.5 microg/kg/min for 20 min) in 12 sufferers of ENT2 migraine with aura ENT2END
0	The results therefore suggest that ENT1 NO ENT1END  is involved in the pain mechanisms of ENT2 migraine with aura ENT2END
1	ENT1 Glyceryl trinitrate  ENT1END  induces attacks of ENT2 migraine without aura ENT2END in sufferers of migraine with aura
1	In recent years, increasing evidence has suggested that the messenger molecule nitric oxide ( ENT1 NO ENT1END ) is involved in pain mechanisms of ENT2 migraine without aura ENT2END
0	In the controls, the ENT1 GTN ENT1END -induced headache gradually disappeared, whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post-infusion. At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society. The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura. Since cortical spreading ENT2 depression ENT2END has been shown to liberate NO in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura
0	Since cortical spreading ENT1 depression ENT1END  has been shown to liberate ENT2 NO ENT2END in animals, this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura
0	We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside (PAN)-induced ENT1 nephrotic syndrome ENT1END  The time courses of urinary sodium excretion, plasma ENT2 aldosterone ENT2END concentration and proteinuria were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle
1	In conclusion, ENaC mRNA expression, especially alphaENaC, is increased in the very early phase of the experimental model of ENT1 PAN ENT1END induced ENT2 nephrotic syndrome ENT2END in rats, but appears to escape from the regulation by aldosterone after day 3
0	In experimental ENT1 nephrotic syndrome ENT1END  urinary ENT2 sodium ENT2END excretion is decreased during the early phase of the disease
0	The time courses of urinary sodium excretion, plasma ENT1 aldosterone ENT1END  concentration and ENT2 proteinuria ENT2END were studied in male Sprague-Dawley rats treated with a single dose of either PAN or vehicle
1	The time courses of urinary sodium excretion, plasma aldosterone concentration and ENT1 proteinuria ENT1END  were studied in male Sprague-Dawley rats treated with a single dose of either ENT2 PAN ENT2END or vehicle
0	The kinetics of urinary ENT1 sodium ENT1END excretion and the appearance of ENT2 proteinuria ENT2END were comparable with those reported previously
0	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with ENT1 renovascular hypertension ENT1END .The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the ENT2 angiotensin ENT2END converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
0	Adverse effect of the calcium channel blocker ENT1 nitrendipine  ENT1END  on nephrosclerosis in rats with ENT2 renovascular hypertension ENT2END
0	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with ENT1 renovascular hypertension ENT1END .The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor ENT2 enalapril ENT2END on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
0	Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with ENT1 renovascular hypertension ENT1END .The effect of a 6-week treatment with the ENT2 calcium ENT2END channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
0	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the ENT1 angiotensin ENT1END  converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension. Six weeks after clipping of one renal artery, ENT2 hypertensive ENT2END rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10)
0	Furthermore, glomerulosclerosis index was significantly increased in the ENT1 nitrendipine ENT1END treated group compared with the ENT2 hypertensive ENT2END controls (0
0	Six weeks after clipping of one renal artery, hypertensive rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated ENT1 hypertensive ENT1END controls (n = 8), ENT2 enalapril ENT2END -treated (n = 8), or nitrendipine-treated (n = 10)
0	The effect of a 6-week treatment with the ENT1 calcium  ENT1END  channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension. Six weeks after clipping of one renal artery, ENT2 hypertensive ENT2END rats (178 +/- 4 mm Hg) were randomly assigned to three groups: untreated hypertensive controls (n = 8), enalapril-treated (n = 8), or nitrendipine-treated (n = 10)
0	Furthermore, ENT1 glomerulosclerosis  ENT1END index was significantly increased in the ENT2 nitrendipine ENT2END -treated group compared with the hypertensive controls (0
0	Renal plasma flow increased, but albumin excretion and ENT1 glomerulosclerosis ENT1END did not change after ENT2 enalapril ENT2END treatment
0	Adverse effect of the calcium channel blocker nitrendipine on ENT1 nephrosclerosis  ENT1END  in rats with renovascular hypertension.The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the ENT2 angiotensin ENT2END converting enzyme inhibitor enalapril on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
1	Adverse effect of the calcium channel blocker ENT1 nitrendipine  ENT1END  on ENT2 nephrosclerosis ENT2END in rats with renovascular hypertension
0	Adverse effect of the calcium channel blocker nitrendipine on ENT1 nephrosclerosis  ENT1END  in rats with renovascular hypertension.The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor ENT2 enalapril ENT2END on blood pressure, albuminuria, renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
0	Adverse effect of the ENT1 calcium  ENT1END  channel blocker nitrendipine on ENT2 nephrosclerosis ENT2END in rats with renovascular hypertension
0	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the ENT1 angiotensin ENT1END  converting enzyme inhibitor enalapril on blood pressure, ENT2 albuminuria ENT2END , renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
1	In contrast, in the ENT1 nitrendipine ENT1END treated group ENT2 albuminuria ENT2END increased from 12
0	The effect of a 6-week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor ENT1 enalapril  ENT1END  on blood pressure, ENT2 albuminuria ENT2END , renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
0	The effect of a 6-week treatment with the ENT1 calcium  ENT1END  channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure, ENT2 albuminuria ENT2END , renal hemodynamics, and morphology of the nonclipped kidney was studied in rats with two-kidney, one clip renovascular hypertension
1	The disease occurred subsequent to the initiation of ENT1 heparin ENT1END therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation. The rate of resolution of the radiographic findings may be helpful in distinguishing between true ENT2 pyeloureteritis cystica ENT2END and submucosal hemorrhage
0	There is no evidence of antecedent or concurrent ENT1 infection  ENT1END in this patient. The disease occurred subsequent to the initiation of ENT2 heparin ENT2END therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation
0	The disease occurred subsequent to the initiation of ENT1 heparin ENT1END  therapy for suspected pelvic ENT2 thrombophlebitis ENT2END and cleared rapidly subsequent to its discontinuation
0	The disease occurred subsequent to the initiation of ENT1 heparin ENT1END  therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation. The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and ENT2 submucosal hemorrhage ENT2END
0	The etiology of pyeloureteritis cystica has long been attributed to chronic infection and ENT1 inflammation  ENT1END  A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography. There is no evidence of antecedent or concurrent infection in this patient. The disease occurred subsequent to the initiation of ENT2 heparin ENT2END therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation
0	ENT1 Ocular and auditory toxicity  ENT1END  in hemodialyzed patients receiving ENT2 desferrioxamine ENT2END
0	This ENT1 toxicity ENT1END appeared in patients receiving the higher doses of ENT2 desferrioxamine ENT2END or coincided with the normalization of ferritin or aluminium serum levels
1	Auditory toxicity was characterized by a mid- to high-frequency ENT1 neurosensorial hearing loss ENT1END and the lesion was of the cochlear type. ENT2 Desferrioxamine ENT2END withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3
0	Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of ENT1 hearing loss  ENT1END in 3 patients and partial recovery in 3. This toxicity appeared in patients receiving the higher doses of ENT2 desferrioxamine ENT2END or coincided with the normalization of ferritin or aluminium serum levels
1	ENT1 Ocular and auditory toxicity  ENT1END  in hemodialyzed patients receiving ENT2 desferrioxamine ENT2END
1	Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and ENT1 pigmentary retinal deposits  ENT1END  Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type. ENT2 Desferrioxamine ENT2END withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3
1	One of the patients developed cardiac failure after 30 mg m-2 MMC and only 150 mg m-2 ENT1 doxorubicin ENT1END  The ENT2 cardiac failure ENT2END was predicted by a drop in EF determined during a cold pressor test
1	One of the patients developed ENT1 cardiac failure ENT1END after 30 mg m-2 ENT2 MMC ENT2END and only 150 mg m-2 doxorubicin
0	Since 1975 mitomycin C (MMC) has been suggested to be ENT1 cardiotoxic ENT1END  especially when combined with or given following ENT2 doxorubicin ENT2END
0	Based on the combined data from the present study and the literature, we suggest that ENT1 MMC ENT1END related ENT2 cardiotoxicity ENT2END is dose dependent, occurring at cumulative dose levels of 30 mg m-2 or more, mainly in patients also (previously or simultaneously) treated with doxorubicin
1	The ENT1 timolol ENT1END related increase in heart size was observed only in patients with normal and borderline heart size. In patients with ENT2 cardiomegaly ENT2END , the increase in heart size was similar in both groups
0	Changes in heart size during long-term ENT1 timolol  ENT1END  treatment after ENT2 myocardial infarction ENT2END
0	After re- ENT1 infarction ENT1END  heart size increased in the placebo group and remained unchanged in the ENT2 timolol ENT2END group
0	These differences may be caused by ENT1 timolol ENT1END induced ENT2 bradycardia ENT2END and a compensatory increase in end-diastolic volume
1	Renal papillary necrosis ( ENT1 RPN ENT1END  and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and ENT2 paracetamol ENT2END in female Fischer 344 rats
1	Renal papillary necrosis ( ENT1 RPN ENT1END ) and a decreased urinary concentrating ability developed during continuous long-term treatment with ENT2 aspirin ENT2END and paracetamol in female Fischer 344 rats
0	Irreversible damage to the medullary interstitium in experimental analgesic ENT1 nephropathy  ENT1END  in F344 rats.Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with aspirin and ENT2 paracetamol ENT2END in female Fischer 344 rats
0	Irreversible damage to the medullary interstitium in experimental analgesic ENT1 nephropathy  ENT1END  in F344 rats.Renal papillary necrosis (RPN) and a decreased urinary concentrating ability developed during continuous long-term treatment with ENT2 aspirin ENT2END and paracetamol in female Fischer 344 rats
0	Drug-induced arterial spasm relieved by ENT1 lidocaine ENT1END . Case report.Following major intracranial surgery in a 35-year-old man, sodium pentothal was intravenously infused to minimize ENT2 cerebral ischaemia ENT2END
0	Following major intracranial surgery in a 35-year-old man, ENT1 sodium pentothal  ENT1END was intravenously infused to minimize ENT2 cerebral ischaemia ENT2END
0	Since the cranial condition precluded use of more usual methods, ENT1 lidocaine ENT1END was given intra-arterially, with careful cardiovascular monitoring, to counteract the ENT2 vasospasm ENT2END
0	Following major intracranial surgery in a 35-year-old man, ENT1 sodium pentothal ENT1END  was intravenously infused to minimize cerebral ischaemia. Intense ENT2 vasospasm ENT2END with threatened gangrene arose in the arm used for the infusion
0	Intense vasospasm with threatened ENT1 gangrene  ENT1END arose in the arm used for the infusion. Since the cranial condition precluded use of more usual methods, ENT2 lidocaine ENT2END was given intra-arterially, with careful cardiovascular monitoring, to counteract the vasospasm
0	Following major intracranial surgery in a 35-year-old man, ENT1 sodium pentothal  ENT1END  was intravenously infused to minimize cerebral ischaemia. Intense vasospasm with threatened ENT2 gangrene ENT2END arose in the arm used for the infusion
0	Drug-induced arterial ENT1 spasm  ENT1END  relieved by ENT2 lidocaine ENT2END
1	Drug-induced arterial ENT1 spasm  ENT1END  relieved by lidocaine. Case report.Following major intracranial surgery in a 35-year-old man, ENT2 sodium pentothal ENT2END was intravenously infused to minimize cerebral ischaemia
0	ENT1 99mTc-glucarate  ENT1END  for detection of isoproterenol-induced ENT2 myocardial infarction ENT2END in rats
1	99mTc-glucarate for detection of ENT1 isoproterenol  ENT1END -induced ENT2 myocardial infarction ENT2END in rats
0	Infarct-avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute ENT1 myocardial infarction ENT1END  The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol. A new infarct-avid radiopharmaceutical based on ENT2 glucaric acid ENT2END was prepared in the hospital radiopharmacy of the INCMNSZ
0	ENT1 99mTc-glucarate  ENT1END  for detection of isoproterenol-induced myocardial infarction in rats. ENT2 Infarct ENT2END -avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction
0	The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with ENT1 isoproterenol ENT1END  A new ENT2 infarct ENT2END -avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ
0	A new ENT1 infarct  ENT1END -avid radiopharmaceutical based on ENT2 glucaric acid ENT2END was prepared in the hospital radiopharmacy of the INCMNSZ
1	A murine model of adenomyosis: the effects of ENT1 hyperprolactinemia  ENT1END  induced by ENT2 fluoxetine hydrochloride ENT2END , a selective serotonin reuptake inhibitor, on adenomyosis induction in Wistar albino rats
0	A murine model of adenomyosis: the effects of ENT1 hyperprolactinemia  ENT1END  induced by fluoxetine hydrochloride, a selective ENT2 serotonin ENT2END reuptake inhibitor, on adenomyosis induction in Wistar albino rats
1	OBJECTIVE: The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to ENT1 adenomyosis ENT1END  DESIGN: ENT2 Fluoxetine ENT2END , a serotonin reuptake inhibitor, was given to Wistar Albino rats for 98 days to produce hyperprolactinemia
0	CONCLUSION: It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian ENT1 steroids ENT1END that results in a myometrial invasion by endometrial stroma. This invasion eventually progresses to ENT2 adenomyosis ENT2END
0	A murine model of adenomyosis: the effects of hyperprolactinemia induced by fluoxetine hydrochloride, a selective ENT1 serotonin  ENT1END  reuptake inhibitor, on ENT2 adenomyosis ENT2END induction in Wistar albino rats
0	In this study, we investigated whether increased generation of FR during ENT1 status epilepticus ENT1END would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the ENT2 pilocarpine ENT2END model of temporal lobe epilepsy
0	Investigation of mitochondrial involvement in the experimental model of epilepsy induced by ENT1 pilocarpine ENT1END .Mitochondrial abnormalities have been associated with several aspects of epileptogenesis, such as energy generation, control of cell ENT2 death ENT2END , neurotransmitter synthesis, and free radical (FR) production
0	Investigation of mitochondrial involvement in the experimental model of epilepsy induced by ENT1 pilocarpine  ENT1END . ENT2 Mitochondrial abnormalities ENT2END have been associated with several aspects of epileptogenesis, such as energy generation, control of cell death, neurotransmitter synthesis, and free radical (FR) production
0	Investigation of mitochondrial involvement in the experimental model of ENT1 epilepsy  ENT1END  induced by ENT2 pilocarpine ENT2END
1	In this study, we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase (CCO), complex IV of the respiratory chain, in the chronic phase of the ENT1 pilocarpine ENT1END  model of ENT2 temporal lobe epilepsy ENT2END
0	Data from 60 patients treated with amikacin were analyzed for factors associated with ENT1 nephrotoxicity ENT1END  In 42 of these patients, data were examined for factors associated with clinical outcome. Variables evaluated included patient weight, age, sex, serum ENT2 creatinine ENT2END level, creatinine clearance, duration of therapy, total dose, mean daily dose, organism minimum inhibitory concentration (MIC), mean peak levels, mean trough levels, mean area under the serum concentration-time curve (AUC), total AUC, mean AUC greater than MIC, total AUC greater than MIC, mean Schumacher's intensity factor (IF), total IF, In (mean maximum concentration [Cmax]/MIC)
1	Data from 60 patients treated with ENT1 amikacin  ENT1END were analyzed for factors associated with ENT2 nephrotoxicity ENT2END
1	Explicit episodic memory for sensory-discriminative components of ENT1 capsaicin  ENT1END -induced ENT2 pain ENT2END : immediate and delayed ratings
0	ENT1 Dexamethasone ENT1END was started between the 7th and the 28th day of life over 7 days with a total dose of 2.35 mg/kg/day. Exclusion criteria were ENT2 asphyxia ENT2END , malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation
1	After ENT1 dexamethasone ENT1END treatment, children showed a higher rate of minor ENT2 neurological dysfunctions ENT2END
0	ENT1 Dexamethasone ENT1END  was started between the 7th and the 28th day of life over 7 days with a total dose of 2.35 mg/kg/day. Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe ENT2 psychomotor retardation ENT2END
0	ENT1 Dexamethasone ENT1END  was started between the 7th and the 28th day of life over 7 days with a total dose of 2.35 mg/kg/day. Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, ENT2 periventricular leukomalacia ENT2END , and severe psychomotor retardation
0	ENT1 Dexamethasone ENT1END  was started between the 7th and the 28th day of life over 7 days with a total dose of 2.35 mg/kg/day. Exclusion criteria were asphyxia, ENT2 malformations ENT2END , major surgical interventions, small for gestational age, intraventricular haemorrhage grades III and IV, periventricular leukomalacia, and severe psychomotor retardation
0	ENT1 Dexamethasone ENT1END  was started between the 7th and the 28th day of life over 7 days with a total dose of 2.35 mg/kg/day. Exclusion criteria were asphyxia, malformations, major surgical interventions, small for gestational age, intraventricular ENT2 haemorrhage ENT2END grades III and IV, periventricular leukomalacia, and severe psychomotor retardation
0	ENT1 Myopathy ENT1END  associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin. Lovastatin and ENT2 simvastatin ENT2END are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol
0	ENT1 Myopathy ENT1END , associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with ENT2 lovastatin ENT2END , especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin
0	ENT1 Myopathy ENT1END , associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin. Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum ENT2 cholesterol ENT2END
1	ENT1 Myopathy ENT1END , associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with ENT2 cyclosporin ENT2END , gemfibrozil or niacin
1	ENT1 Myopathy ENT1END , associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or ENT2 niacin ENT2END
0	Minor elevations of ENT1 creatine  ENT1END kinase levels are reported in about 5% of patients. ENT2 Myopathy ENT2END , associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin
1	ENT1 Myopathy ENT1END , associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, ENT2 gemfibrozil ENT2END or niacin
0	Lovastatin and ENT1 simvastatin ENT1END  are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol. As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to ENT2 hypercholesterolaemia ENT2END and its consequences
0	ENT1 Lovastatin  ENT1END and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol. As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to ENT2 hypercholesterolaemia ENT2END and its consequences
0	Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum ENT1 cholesterol  ENT1END . As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to ENT2 hypercholesterolaemia ENT2END and its consequences
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with ENT1 cyclosporin  ENT1END , gemfibrozil or niacin. Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol. As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to ENT2 hypercholesterolaemia ENT2END and its consequences
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or ENT1 niacin  ENT1END . Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol. As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to ENT2 hypercholesterolaemia ENT2END and its consequences
0	Minor elevations of ENT1 creatine  ENT1END  kinase levels are reported in about 5% of patients. Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin. Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol. As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to ENT2 hypercholesterolaemia ENT2END and its consequences
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, ENT1 gemfibrozil  ENT1END  or niacin. Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol. As wider use confirms their safety profile, they will gain increasing importance in the therapeutic approach to ENT2 hypercholesterolaemia ENT2END and its consequences
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient ENT1 renal failure  ENT1END  has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin. Lovastatin and ENT2 simvastatin ENT2END are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol
1	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient ENT1 renal failure  ENT1END , has been rarely reported with ENT2 lovastatin ENT2END , especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient ENT1 renal failure  ENT1END , has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin. Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum ENT2 cholesterol ENT2END
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient ENT1 renal failure  ENT1END , has been rarely reported with lovastatin, especially in patients concomitantly treated with ENT2 cyclosporin ENT2END , gemfibrozil or niacin
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient ENT1 renal failure  ENT1END , has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or ENT2 niacin ENT2END
0	Minor elevations of ENT1 creatine  ENT1END  kinase levels are reported in about 5% of patients. Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient ENT2 renal failure ENT2END , has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin
0	Myopathy, associated in some cases with myoglobinuria, and in 2 cases with transient ENT1 renal failure  ENT1END , has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, ENT2 gemfibrozil ENT2END or niacin
0	Myopathy, associated in some cases with ENT1 myoglobinuria  ENT1END  and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin. Lovastatin and ENT2 simvastatin ENT2END are both effective and well-tolerated agents for lowering elevated levels of serum cholesterol
1	Myopathy, associated in some cases with ENT1 myoglobinuria  ENT1END , and in 2 cases with transient renal failure, has been rarely reported with ENT2 lovastatin ENT2END , especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin
0	Myopathy, associated in some cases with ENT1 myoglobinuria  ENT1END , and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin. Lovastatin and simvastatin are both effective and well-tolerated agents for lowering elevated levels of serum ENT2 cholesterol ENT2END
0	Myopathy, associated in some cases with ENT1 myoglobinuria  ENT1END , and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with ENT2 cyclosporin ENT2END , gemfibrozil or niacin
0	Myopathy, associated in some cases with ENT1 myoglobinuria  ENT1END , and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or ENT2 niacin ENT2END
0	Minor elevations of ENT1 creatine  ENT1END  kinase levels are reported in about 5% of patients. Myopathy, associated in some cases with ENT2 myoglobinuria ENT2END , and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, gemfibrozil or niacin
0	Myopathy, associated in some cases with ENT1 myoglobinuria  ENT1END , and in 2 cases with transient renal failure, has been rarely reported with lovastatin, especially in patients concomitantly treated with cyclosporin, ENT2 gemfibrozil ENT2END or niacin
1	Age-related changes in ultrasound production corresponded with changes in cardiovascular variables, including baseline cardiac rate and ENT1 clonidine ENT1END induced ENT2 bradycardia ENT2END
0	Although generally consisted safe when given intramuscularly, intravenous administration is known to cause ENT1 respiratory and cardiovascular depression ENT1END  This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of ENT2 midazolam ENT2END
1	Possible intramuscular ENT1 midazolam  ENT1END -associated ENT2 cardiorespiratory arrest ENT2END and death
0	Possible intramuscular midazolam-associated cardiorespiratory arrest and ENT1 death  ENT1END . ENT2 Midazolam hydrochloride ENT2END is commonly used for dental or endoscopic procedures
1	Although generally consisted safe when given intramuscularly, intravenous administration is known to cause ENT1 respiratory and cardiovascular depression  ENT1END  This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of ENT2 midazolam ENT2END
1	In conclusion, ENT1 octreotide ENT1END induced ENT2 gall stones ENT2END are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium
0	Composition of ENT1 gall bladder stones  ENT1END  associated with octreotide: response to oral ENT2 ursodeoxycholic acid ENT2END
0	In conclusion, octreotide induced ENT1 gall stones ENT1END  are generally small, multiple, and ENT2 cholesterol ENT2END rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some gall stones containing calcium
0	In conclusion, octreotide induced gall stones are generally small, multiple, and cholesterol rich although, in common with spontaneous gall stone disease, at presentation some patients will have a blocked cystic duct and some ENT1 gall stones ENT1END containing ENT2 calcium ENT2END
0	Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 ENT1 octreotide ENT1END treated ENT2 acromegalic ENT2END patients with gall stones
0	Composition of gall bladder stones associated with octreotide: response to oral ENT1 ursodeoxycholic acid ENT1END .Octreotide, an effective treatment for ENT2 acromegaly ENT2END , induces gall bladder stones in 13-60% of patients
0	Because knowledge of stone composition is essential for studies of their pathogenesis, treatment, and prevention, this was investigated by direct and indirect methods in 14 octreotide treated ENT1 acromegalic ENT1END  patients with gall stones. Chemical analysis of gall stones retrieved at cholecystectomy from two patients, showed that they contained 71% and 87% ENT2 cholesterol ENT2END by weight
0	The results have shown that the degradation product ENT1 p-choloroaniline ENT1END is not a significant factor in chlorhexidine-digluconate associated erosive ENT2 cystitis ENT2END
1	A high percentage of kanamycin-colistin and ENT1 povidone-iodine ENT1END irrigations were associated with erosive ENT2 cystitis ENT2END and suggested a possible complication with human usage
1	The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive ENT1 cystitis  ENT1END . A high percentage of kanamycin- ENT2 colistin ENT2END and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage
1	The results have shown that the degradation product p-choloroaniline is not a significant factor in ENT1 chlorhexidine-digluconate  ENT1END associated erosive ENT2 cystitis ENT2END
1	The results have shown that the degradation product p-choloroaniline is not a significant factor in chlorhexidine-digluconate associated erosive ENT1 cystitis ENT1END . A high percentage of ENT2 kanamycin ENT2END -colistin and povidone-iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage
0	A high percentage of kanamycin-colistin and povidone-iodine irrigations were associated with erosive ENT1 cystitis ENT1END  and suggested a possible complication with human usage. ENT2 Picloxydine ENT2END irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures
0	General safety was also assessed, including adjudicated ENT1 thrombotic cardiovascular ENT1END event data. Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale). RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the ENT2 etoricoxib ENT2END and diclofenac groups, respectively
0	Use of gastroprotective agents and low-dose ENT1 aspirin  ENT1END was allowed. The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs). General safety was also assessed, including adjudicated ENT2 thrombotic cardiovascular ENT2END event data
0	General safety was also assessed, including adjudicated ENT1 thrombotic cardiovascular ENT1END  event data. Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale). RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and ENT2 diclofenac ENT2END groups, respectively
0	Gastrointestinal tolerability of ENT1 etoricoxib  ENT1END  in ENT2 rheumatoid arthritis ENT2END patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II)
0	8 years) diagnosed with ENT1 RA  ENT1END were enrolled and received etoricoxib 90 mg daily (n = 2032) or diclofenac 75 mg twice daily (n = 2054). Use of gastroprotective agents and low-dose ENT2 aspirin ENT2END was allowed
0	OBJECTIVE: A randomised, double-blind study to compare the gastrointestinal (GI) tolerability, safety and efficacy of etoricoxib and ENT1 diclofenac ENT1END in patients with ENT2 rheumatoid arthritis ENT2END (RA)
1	01 for ENT1 oedema ENT1END . ENT2 Etoricoxib ENT2END and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0
0	01 for ENT1 oedema ENT1END ). Etoricoxib and ENT2 diclofenac ENT2END treatment resulted in similar efficacy (PGADS mean changes from baseline -0
1	001 for ENT1 hypertension  ENT1END and p<0.01 for oedema). ENT2 Etoricoxib ENT2END and diclofenac treatment resulted in similar efficacy (PGADS mean changes from baseline -0
0	001 for ENT1 hypertension  ENT1END  and p<0.01 for oedema). Etoricoxib and ENT2 diclofenac ENT2END treatment resulted in similar efficacy (PGADS mean changes from baseline -0
0	The cumulative discontinuation rate due to ENT1 GI AEs ENT1END was significantly lower with ENT2 etoricoxib ENT2END than diclofenac (5
0	Use of gastroprotective agents and low-dose ENT1 aspirin  ENT1END  was allowed. The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences (AEs). General safety was also assessed, including adjudicated thrombotic cardiovascular event data. Efficacy was evaluated using the Patient Global Assessment of Disease Status (PGADS; 0-4 point scale). RESULTS: Mean (SD; maximum) duration of treatment was 19.3 (10.3; 32.9) and 19.1 (10.4; 33.1) months in the etoricoxib and diclofenac groups, respectively. The cumulative discontinuation rate due to ENT2 GI AEs ENT2END was significantly lower with etoricoxib than diclofenac (5
1	CONCLUSIONS: Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to ENT1 GI AEs ENT1END compared with ENT2 diclofenac ENT2END 150 mg
1	ENT1 Ifosfamide ENT1END ENT2 encephalopathy ENT2END presenting with asterixis
0	We report a case of a 51-year-old man who developed severe, disabling negative myoclonus of the upper and lower extremities after the infusion of ENT1 ifosfamide ENT1END for ENT2 plasmacytoma ENT2END
0	Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and ENT1 metabolic abnormalities ENT1END  An electroencephalogram showed continuous, generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy. The administration of ENT2 ifosfamide ENT2END was discontinued and within 12 h the asterixis resolved completely
1	In the patient described, the presence of asterixis during infusion of ifosfamide, normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative ENT1 myoclonus ENT1END is associated with the use of ENT2 IFX ENT2END
0	In the patient described, the presence of ENT1 asterixis ENT1END during infusion of ENT2 ifosfamide ENT2END , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX
0	In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma ENT1 aldosterone ENT1END values were raised, with a concomitant suppression of renin levels. Our findings show that long-term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid-related ENT2 hypertension ENT2END
0	In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated ENT1 hypertension ENT1END 31 (patient 1) and 52 weeks (patient 2) after treatment. In patient 1, plasma levels of deoxycorticosterone and ENT2 11-deoxycortisol ENT2END were elevated
1	Two of 14 patients with Cushing's syndrome treated on a long-term basis with ENT1 ketoconazole ENT1END developed sustained ENT2 hypertension ENT2END
0	In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated ENT1 hypertension ENT1END  31 (patient 1) and 52 weeks (patient 2) after treatment. In patient 1, plasma levels of ENT2 deoxycorticosterone ENT2END and 11-deoxycortisol were elevated
0	Two of 14 patients with Cushing's syndrome treated on a long-term basis with ketoconazole developed sustained ENT1 hypertension ENT1END . In both cases normal plasma and urinary free ENT2 cortisol ENT2END levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment
0	Two of 14 patients with ENT1 Cushing's syndrome  ENT1END treated on a long-term basis with ketoconazole developed sustained hypertension. In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment. In patient 1, plasma levels of deoxycorticosterone and 11-deoxycortisol were elevated. In patient 2, in addition to an increase in both deoxycorticosterone and 11-deoxycortisol levels, plasma ENT2 aldosterone ENT2END values were raised, with a concomitant suppression of renin levels
0	Two of 14 patients with ENT1 Cushing's syndrome  ENT1END  treated on a long-term basis with ketoconazole developed sustained hypertension. In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment. In patient 1, plasma levels of deoxycorticosterone and ENT2 11-deoxycortisol ENT2END were elevated
0	Two of 14 patients with ENT1 Cushing's syndrome  ENT1END  treated on a long-term basis with ENT2 ketoconazole ENT2END developed sustained hypertension
0	Two of 14 patients with ENT1 Cushing's syndrome  ENT1END  treated on a long-term basis with ketoconazole developed sustained hypertension. In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment. In patient 1, plasma levels of ENT2 deoxycorticosterone ENT2END and 11-deoxycortisol were elevated
0	Two of 14 patients with ENT1 Cushing's syndrome  ENT1END  treated on a long-term basis with ketoconazole developed sustained hypertension. In both cases normal plasma and urinary free ENT2 cortisol ENT2END levels had been achieved following ketoconazole therapy, yet continuous blood pressure monitoring demonstrated hypertension 31 (patient 1) and 52 weeks (patient 2) after treatment
1	A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated ENT1 primary pulmonary hypertension ENT1END  Intake of ENT2 appetite suppressants ENT2END may accelerate the progression of the disease
1	Twenty-three of the patients had previously taken appetite suppressants, mainly ENT1 fenfluramines ENT1END  as compared with only 5 of the controls (66 versus 6%, p<0.0001). Five patients died before the interview, all of them had taken appetite suppressants. In 8 patients the diagnosis of ENT2 primary pulmonary hypertension ENT2END was uncertain, 5 of them had taken appetite suppressants
1	Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence ENT1 malformations ENT1END with ENT2 ASA ENT2END when a multiple dosing paradigm is used
0	, 2003); hence, the present study focused on these malformations, even though ENT1 ASA ENT1END induces several other low-incidence malformations. In single dose studies, DH, ENT2 MD ENT2END , and VSD were induced on GDs 9 and 10
1	, 2003); hence, the present study focused on these malformations, even though ENT1 ASA ENT1END  induces several other low-incidence malformations. In single dose studies, ENT2 DH ENT2END , MD, and VSD were induced on GDs 9 and 10
0	Objectives of the current study were to compare results between Sprague-Dawley (SD) and Wistar strains when ASA is administered on GD 9, 10, or 11; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats; and to test the hypothesis that maternal ENT1 gastrointestinal toxicity  ENT1END confounds the detection of low incidence malformations with ENT2 ASA ENT2END when a multiple dosing paradigm is used
1	, 2003); hence, the present study focused on these malformations, even though ENT1 ASA ENT1END  induces several other low-incidence malformations. In single dose studies, DH, MD, and ENT2 VSD ENT2END were induced on GDs 9 and 10
0	CONCLUSIONS: High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and ENT1 hydrocephalus ENT1END in the Wistar rats. Variations and malformations were similar when ENT2 ASA ENT2END was administered as a single dose or during the period of organogenesis (GDs 6 to 17)
0	We evaluated cardiovascular event data for ENT1 valdecoxib ENT1END  a new COX-2-specific inhibitor in approximately 8000 patients with ENT2 osteoarthritis ENT2END and rheumatoid arthritis treated with this agent in randomized clinical trials
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ENT1 ibuprofen ENT1END 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized ENT2 osteoarthritis ENT2END and rheumatoid arthritis trials that were 6-52 weeks in duration
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized ENT1 osteoarthritis ENT1END  and rheumatoid arthritis trials that were 6-52 weeks in duration. The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) ENT2 aspirin ENT2END (n = 1051) and nonusers of aspirin (n = 6883)
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or ENT1 naproxen  ENT1END 500 mg bid) and placebo data from 10 randomized ENT2 osteoarthritis ENT2END and rheumatoid arthritis trials that were 6-52 weeks in duration
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID ( ENT1 diclofenac  ENT1END 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized ENT2 osteoarthritis ENT2END and rheumatoid arthritis trials that were 6-52 weeks in duration
0	We evaluated cardiovascular event data for ENT1 valdecoxib ENT1END , a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and ENT2 rheumatoid arthritis ENT2END treated with this agent in randomized clinical trials
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ENT1 ibuprofen ENT1END  800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and ENT2 rheumatoid arthritis ENT2END trials that were 6-52 weeks in duration
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and ENT1 rheumatoid arthritis  ENT1END  trials that were 6-52 weeks in duration. The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) ENT2 aspirin ENT2END (n = 1051) and nonusers of aspirin (n = 6883)
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or ENT1 naproxen  ENT1END  500 mg bid) and placebo data from 10 randomized osteoarthritis and ENT2 rheumatoid arthritis ENT2END trials that were 6-52 weeks in duration
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID ( ENT1 diclofenac  ENT1END  75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and ENT2 rheumatoid arthritis ENT2END trials that were 6-52 weeks in duration
0	Effects of the cyclooxygenase-2 specific inhibitor ENT1 valdecoxib  ENT1END  versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with ENT2 arthritis ENT2END
0	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with ENT1 arthritis  ENT1END .There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials. The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ENT2 ibuprofen ENT2END 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration
0	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with ENT1 arthritis  ENT1END .There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials. The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration. The incidence rates of events were determined in all patients (n = 7934) and in users of low-dose (< or =325 mg daily) ENT2 aspirin ENT2END (n = 1051) and nonusers of aspirin (n = 6883)
0	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with ENT1 arthritis  ENT1END .There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials. The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or ENT2 naproxen ENT2END 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration
0	Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with ENT1 arthritis ENT1END .There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase (COX)-2-specific inhibitors than nonselective nonsteroidal antiinflammatory drugs (NSAIDs). We evaluated cardiovascular event data for valdecoxib, a new COX-2-specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials. The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial thrombotic) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID ENT2 diclofenac ENT2END 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration
0	The risk of serious thrombotic events was also similar for each ENT1 valdecoxib ENT1END dose. ENT2 Thrombotic ENT2END risk was consistently higher for users of aspirin users than nonusers of aspirin (placebo, 1
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial ENT1 thrombotic  ENT1END  was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ENT2 ibuprofen ENT2END 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration
1	ENT1 Thrombotic ENT1END  risk was consistently higher for users of ENT2 aspirin ENT2END users than nonusers of aspirin (placebo, 1
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial ENT1 thrombotic  ENT1END ) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID (diclofenac 75 mg bid, ibuprofen 800 mg tid, or ENT2 naproxen ENT2END 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration
0	The incidence of cardiovascular thrombotic events (cardiac, cerebrovascular and peripheral vascular, or arterial ENT1 thrombotic ENT1END ) was determined by analyzing pooled valdecoxib (10-80 mg daily), nonselective NSAID ENT2 diclofenac ENT2END 75 mg bid, ibuprofen 800 mg tid, or naproxen 500 mg bid) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6-52 weeks in duration
1	From these results, we conclude that ENT1 ribavirin ENT1END has an antiviral effect in advanced cases of AHF, and that ENT2 anemia ENT2END , the only secondary reaction observed, can be easily managed
0	Administration of ENT1 ribavirin ENT1END resulted in a neutralization of viremia and a drop of endogenous interferon titers. The average time of ENT2 death ENT2END was delayed
0	The possible beneficial effect of ENT1 ribavirin ENT1END during the initial days of ENT2 AHF ENT2END is discussed
0	Administration of ENT1 ribavirin ENT1END  resulted in a neutralization of ENT2 viremia ENT2END and a drop of endogenous interferon titers
0	Effects of an inhibitor of ENT1 angiotensin  ENT1END  converting enzyme (Captopril) on ENT2 pulmonary and renal insufficiency ENT2END due to intravascular coagulation in the rat
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( ENT1 AMCA ENT1END  in the rat gives rise to ENT2 pulmonary and renal insufficiency ENT2END resembling that occurring after trauma or sepsis in man
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency ENT1END in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril. The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone. It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in ENT2 prostacyclin ENT2END (secondary to an increase in bradykinin)
0	Effects of an inhibitor of angiotensin converting enzyme ( ENT1 Captopril  ENT1END ) on ENT2 pulmonary and renal insufficiency ENT2END due to intravascular coagulation in the rat
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency ENT1END  in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum ENT2 urea ENT2END and in kidney weight was prevented by Captopril
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency ENT1END  in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril. The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone. It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of ENT2 Angiotension II ENT2END and an increase in prostacyclin (secondary to an increase in bradykinin)
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency ENT1END  in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril. The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone. It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in ENT2 bradykinin ENT2END )
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or ENT1 sepsis ENT1END in man. Injection of Captopril (1 mg/kg), an inhibitor of ENT2 angiotensin ENT2END converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( ENT1 AMCA  ENT1END ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or ENT2 sepsis ENT2END in man
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or ENT1 sepsis ENT1END  in man. Injection of ENT2 Captopril ENT2END (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or ENT1 sepsis  ENT1END  in man. Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum ENT2 urea ENT2END and in kidney weight was prevented by Captopril
0	Effects of an inhibitor of ENT1 angiotensin  ENT1END  converting enzyme (Captopril) on pulmonary and renal insufficiency due to ENT2 intravascular coagulation ENT2END in the rat
1	Induction of ENT1 intravascular coagulation ENT1END and inhibition of fibrinolysis by injection of thrombin and ENT2 tranexamic acid ENT2END (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man
0	Effects of an inhibitor of angiotensin converting enzyme ( ENT1 Captopril  ENT1END ) on pulmonary and renal insufficiency due to ENT2 intravascular coagulation ENT2END in the rat
0	Induction of ENT1 intravascular coagulation  ENT1END  and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man. Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum ENT2 urea ENT2END and in kidney weight was prevented by Captopril
0	Effects of an inhibitor of ENT1 angiotensin  ENT1END  converting enzyme (Captopril) on ENT2 pulmonary and renal insufficiency ENT2END due to intravascular coagulation in the rat
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( ENT1 AMCA ENT1END ) in the rat gives rise to ENT2 pulmonary and renal insufficiency ENT2END resembling that occurring after trauma or sepsis in man
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency  ENT1END in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril. The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone. It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in ENT2 prostacyclin ENT2END (secondary to an increase in bradykinin)
0	Effects of an inhibitor of angiotensin converting enzyme ( ENT1 Captopril  ENT1END ) on ENT2 pulmonary and renal insufficiency ENT2END due to intravascular coagulation in the rat
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency  ENT1END  in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum ENT2 urea ENT2END and in kidney weight was prevented by Captopril
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency  ENT1END  in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril. The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone. It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of ENT2 Angiotension II ENT2END and an increase in prostacyclin (secondary to an increase in bradykinin)
0	Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both ENT1 pulmonary and renal insufficiency  ENT1END  in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril. The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and AMCA alone. It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in ENT2 bradykinin ENT2END )
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after ENT1 trauma  ENT1END or sepsis in man. Injection of Captopril (1 mg/kg), an inhibitor of ENT2 angiotensin ENT2END converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( ENT1 AMCA  ENT1END ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after ENT2 trauma ENT2END or sepsis in man
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after ENT1 trauma  ENT1END  or sepsis in man. Injection of ENT2 Captopril ENT2END (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model
0	Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid (AMCA) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after ENT1 trauma  ENT1END  or sepsis in man. Injection of Captopril (1 mg/kg), an inhibitor of angiotensin converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. Renal damage as reflected by an increase in serum ENT2 urea ENT2END and in kidney weight was prevented by Captopril
0	Injection of Captopril (1 mg/kg), an inhibitor of ENT1 angiotensin ENT1END  converting enzyme (ACE), reduced both pulmonary and renal insufficiency in this rat model. The lung weights were lower and PaO2 was improved in rats given this enzyme-blocking agent. The contents of albumin in the lungs were not changed, indicating that Captopril did not influence the extravasation of protein. ENT2 Renal damage ENT2END as reflected by an increase in serum urea and in kidney weight was prevented by Captopril
0	ENT1 Renal damage ENT1END  as reflected by an increase in serum urea and in kidney weight was prevented by Captopril. The amount of fibrin in the kidneys was also considerably lower than in animals which received thrombin and ENT2 AMCA ENT2END alone
0	It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in ENT1 prostacyclin ENT1END  (secondary to an increase in bradykinin). Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less ENT2 kidney damage ENT2END will be produced
0	The contents of albumin in the lungs were not changed, indicating that ENT1 Captopril  ENT1END did not influence the extravasation of protein. ENT2 Renal damage ENT2END as reflected by an increase in serum urea and in kidney weight was prevented by Captopril
0	ENT1 Renal damage  ENT1END  as reflected by an increase in serum ENT2 urea ENT2END and in kidney weight was prevented by Captopril
0	It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of ENT1 Angiotension II  ENT1END  and an increase in prostacyclin (secondary to an increase in bradykinin). Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less ENT2 kidney damage ENT2END will be produced
0	It is suggested that the effects of Captopril on the lungs may be attributable to a vasodilatory effect due to a reduction in the circulating level of Angiotension II and an increase in prostacyclin (secondary to an increase in ENT1 bradykinin  ENT1END ). Captopril may, by the same mechanism, reduce the increase in glomerular filtration that is known to occur after an injection of thrombin, thereby diminishing the aggregation of fibrin monomers in the glomeruli, with the result that less fibrin will be deposited and thus less ENT2 kidney damage ENT2END will be produced
1	Adverse effects forced a reduction in the dose of amiodarone in 41% and discontinuation of ENT1 amiodarone ENT1END in 10% of patients. The most common symptomatic adverse reactions were tremor or ENT2 ataxia ENT2END (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%)
1	Adverse effects forced a reduction in the dose of amiodarone in 41% and discontinuation of ENT1 amiodarone ENT1END  in 10% of patients. The most common symptomatic adverse reactions were tremor or ataxia (35%), ENT2 nausea ENT2END and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%)
1	Adverse effects forced a reduction in the dose of amiodarone in 41% and discontinuation of ENT1 amiodarone ENT1END  in 10% of patients. The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and ENT2 anorexia ENT2END (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%)
1	The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), ENT1 thyroid function abnormalities ENT1END (6%) and pulmonary interstitial infiltrates (5%). Although large-dose ENT2 amiodarone ENT2END is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients
0	Long-term efficacy and ENT1 toxicity  ENT1END  of high-dose ENT2 amiodarone ENT2END therapy for ventricular tachycardia or ventricular fibrillation
0	Long-term efficacy and toxicity of high-dose ENT1 amiodarone  ENT1END  therapy for ENT2 ventricular tachycardia ENT2END or ventricular fibrillation
1	The most common symptomatic adverse reactions were tremor or ataxia (35%), nausea and anorexia (8%), ENT1 visual halos or blurring  ENT1END (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%). Although large-dose ENT2 amiodarone ENT2END is highly effective in the long-term treatment of VT or VF refractory to conventional antiarrhythmic drugs, it causes significant toxicity in approximately 50% of patients
0	Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ENT1 ventricular fibrillation  ENT1END . ENT2 Amiodarone ENT2END was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a cardiac arrest (n = 36) and who were refractory to conventional antiarrhythmic drugs
0	ENT1 Amiodarone ENT1END  was administered to 154 patients who had sustained, symptomatic ventricular tachycardia (VT) (n = 118) or a ENT2 cardiac arrest ENT2END (n = 36) and who were refractory to conventional antiarrhythmic drugs
0	Adverse effects forced a reduction in the dose of amiodarone in 41% and discontinuation of ENT1 amiodarone ENT1END  in 10% of patients. The most common symptomatic adverse reactions were ENT2 tremor ENT2END or ataxia (35%), nausea and anorexia (8%), visual halos or blurring (6%), thyroid function abnormalities (6%) and pulmonary interstitial infiltrates (5%)
0	Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, ENT1 chlorpheniramine  ENT1END , and placebo in the treatment of ENT2 spring allergic rhinitis ENT2END
0	Multicenter, double-blind, multiple-dose, parallel-groups efficacy and safety trial of azelastine, chlorpheniramine, and placebo in the treatment of ENT1 spring allergic rhinitis  ENT1END . ENT2 Azelastine ENT2END , a novel antiallergic medication, was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter, double-blind, multiple-dose, parallel-groups study
0	In contrast, although the ENT1 chlorpheniramine ENT1END group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study. There were no serious side effects in any of the treatment groups. Drowsiness and ENT2 altered taste perception ENT2END were increased significantly over placebo only in the high-dose azelastine group
1	Drowsiness and ENT1 altered taste perception ENT1END  were increased significantly over placebo only in the high-dose ENT2 azelastine ENT2END group
0	In contrast, although the ENT1 chlorpheniramine ENT1END  group did have fewer symptoms than the placebo group during the study, the difference never reached statistical significance during any week of the study. There were no serious side effects in any of the treatment groups. ENT2 Drowsiness ENT2END and altered taste perception were increased significantly over placebo only in the high-dose azelastine group
1	ENT1 Drowsiness  ENT1END  and altered taste perception were increased significantly over placebo only in the high-dose ENT2 azelastine ENT2END group
1	BACKGROUND: The possible role of alcohol in the development of ENT1 hepatotoxicity ENT1END associated with therapeutic doses of ENT2 paracetamol ENT2END (acetaminophen) is currently debated
0	BACKGROUND: The possible role of ENT1 alcohol  ENT1END in the development of ENT2 hepatotoxicity ENT2END associated with therapeutic doses of paracetamol (acetaminophen) is currently debated
0	ENT1 Acute liver failure  ENT1END  in two patients with regular alcohol consumption ingesting ENT2 paracetamol ENT2END at therapeutic dosage
0	ENT1 Acute liver failure  ENT1END  in two patients with regular ENT2 alcohol ENT2END consumption ingesting paracetamol at therapeutic dosage
1	regular consumption of alcohol, ENT1 liver failure ENT1END is possible when therapeutic doses are ingested. We propose that the ENT2 paracetamol ENT2END dose should not exceed 2 g/day in such patients and that their liver function should be monitored closely while being treated with paracetamol
0	regular consumption of ENT1 alcohol ENT1END ENT2 liver failure ENT2END is possible when therapeutic doses are ingested
0	Although increased risk of ENT1 thromboembolic disease ENT1END has been reported during treatment with ENT2 epsilon-aminocaproic acid ENT2END , cerebral sinus thrombosis has not been previously described
0	We describe a 42-year-old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged ENT1 epsilon-aminocaproic acid ENT1END therapy for ENT2 menorrhagia ENT2END
1	We describe a 42-year-old woman who developed superior ENT1 sagittal and left transverse sinus thrombosis  ENT1END associated with prolonged ENT2 epsilon-aminocaproic acid ENT2END therapy for menorrhagia
0	We describe a 42-year-old woman who developed superior ENT1 sagittal and left transverse sinus thrombosis  ENT1END associated with prolonged ENT2 epsilon-aminocaproic acid ENT2END therapy for menorrhagia
0	Although increased risk of thromboembolic disease has been reported during treatment with ENT1 epsilon-aminocaproic acid ENT1END , ENT2 cerebral sinus thrombosis ENT2END has not been previously described
0	This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce ENT1 blood loss  ENT1END  Although increased risk of thromboembolic disease has been reported during treatment with ENT2 epsilon-aminocaproic acid ENT2END , cerebral sinus thrombosis has not been previously described
0	The residual serum concentrations of ENT1 oxazepam ENT1END  temazepam and zopiclone were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed ENT2 dementia ENT2END
0	The residual serum concentrations of oxazepam, temazepam and ENT1 zopiclone  ENT1END were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed ENT2 dementia ENT2END
0	Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed ENT1 dementia ENT1END . After adjustment for these variables as confounders, use of ENT2 BZDs ENT2END /RDs was not associated with cognitive function as measured by the MMSE
0	The residual serum concentrations of oxazepam, ENT1 temazepam  ENT1END and zopiclone were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed ENT2 dementia ENT2END
0	The residual serum concentrations of ENT1 oxazepam ENT1END , temazepam and zopiclone were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger ENT2 depressive symptoms ENT2END measured at the beginning of the hospital stay
0	The residual serum concentrations of oxazepam, temazepam and ENT1 zopiclone  ENT1END  were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger ENT2 depressive symptoms ENT2END measured at the beginning of the hospital stay
1	However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger ENT1 depressive symptoms ENT1END  measured at the beginning of the hospital stay. Use of ENT2 BZDs ENT2END /RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission
0	However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger ENT1 depressive symptoms ENT1END  measured at the beginning of the hospital stay. Use of BZDs/RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission. A higher residual serum concentration of ENT2 temazepam ENT2END correlated with a lower MMSE sum score after adjustment for confounding variables
0	The residual serum concentrations of ENT1 oxazepam ENT1END , temazepam and zopiclone were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with dizziness, ENT2 inability to sleep ENT2END after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
0	The residual serum concentrations of oxazepam, temazepam and ENT1 zopiclone  ENT1END  were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with dizziness, ENT2 inability to sleep ENT2END after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
1	However, use of ENT1 BZDs  ENT1END RDs was associated with dizziness, ENT2 inability to sleep ENT2END after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
0	However, use of BZDs/RDs was associated with dizziness, ENT1 inability to sleep  ENT1END  after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay. Use of BZDs/RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission. A higher residual serum concentration of ENT2 temazepam ENT2END correlated with a lower MMSE sum score after adjustment for confounding variables
0	The residual serum concentrations of ENT1 oxazepam ENT1END , temazepam and zopiclone were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with ENT2 dizziness ENT2END , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
0	The residual serum concentrations of oxazepam, temazepam and ENT1 zopiclone  ENT1END  were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with ENT2 dizziness ENT2END , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
1	However, use of ENT1 BZDs  ENT1END /RDs was associated with ENT2 dizziness ENT2END , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
0	However, use of BZDs/RDs was associated with ENT1 dizziness  ENT1END , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay. Use of BZDs/RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission. A higher residual serum concentration of ENT2 temazepam ENT2END correlated with a lower MMSE sum score after adjustment for confounding variables
0	The residual serum concentrations of ENT1 oxazepam ENT1END , temazepam and zopiclone were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and ENT2 tiredness ENT2END in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
0	The residual serum concentrations of oxazepam, temazepam and ENT1 zopiclone  ENT1END  were analysed. RESULTS: The mean +/- SD duration of BZD/RD use was 7 +/- 7 years (range 1-31). Two or three BZDs/RDs were concomitantly taken by 26% of users (n = 20). Long-term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS, which tended to be related to diagnosed dementia. After adjustment for these variables as confounders, use of BZDs/RDs was not associated with cognitive function as measured by the MMSE. However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and ENT2 tiredness ENT2END in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
1	However, use of ENT1 BZDs  ENT1END /RDs was associated with dizziness, inability to sleep after awaking at night and ENT2 tiredness ENT2END in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay
0	However, use of BZDs/RDs was associated with dizziness, inability to sleep after awaking at night and ENT1 tiredness  ENT1END  in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay. Use of BZDs/RDs tended to be associated with a reduced ability to walk and shorter night-time sleep during the week prior to admission. A higher residual serum concentration of ENT2 temazepam ENT2END correlated with a lower MMSE sum score after adjustment for confounding variables
0	Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of ENT1 phenylacetic acid ENT1END  Although generally well-tolerated, asymptomatic ENT2 abnormalities of liver function ENT2END have been recorded and, less commonly, severe hepatitis induced by diclofenac
1	Although generally well-tolerated, asymptomatic abnormalities of liver function have been recorded and, less commonly, severe ENT1 hepatitis ENT1END induced by ENT2 diclofenac ENT2END
0	ENT1 Chronic active hepatitis  ENT1END  associated with diclofenac sodium therapy.Diclofenac sodium (Voltarol, Geigy Pharmaceuticals) is a non-steroidal anti-inflammatory derivative of ENT2 phenylacetic acid ENT2END
0	ENT1 Chronic active hepatitis  ENT1END  associated with ENT2 diclofenac sodium ENT2END therapy
0	We measured diazepam-induced anxiolysis with the elevated plus-maze test, ENT1 diazepam ENT1END induced sedation by recording the vigilance states, and picrotoxin- and pentylenetetrazol-induced ENT2 seizures ENT2END after i
1	Two mouse lines selected for differential sensitivities to ENT1 beta-carboline  ENT1END -induced ENT2 seizures ENT2END are also differentially sensitive to various pharmacological effects of other GABA(A) receptor ligands
1	We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and picrotoxin- and ENT1 pentylenetetrazol  ENT1END induced ENT2 seizures ENT2END after i
0	Two mouse lines were selectively bred according to their sensitivity (BS line) or resistance (BR line) to ENT1 seizures ENT1END induced by a single i.p. injection of methyl beta-carboline-3-carboxylate (beta-CCM), an inverse agonist of the GABA(A) receptor ENT2 benzodiazepine ENT2END site
0	Two mouse lines selected for differential sensitivities to beta-carboline-induced ENT1 seizures  ENT1END  are also differentially sensitive to various pharmacological effects of other ENT2 GABA ENT2END (A) receptor ligands
1	We measured diazepam-induced anxiolysis with the elevated plus-maze test, diazepam-induced sedation by recording the vigilance states, and ENT1 picrotoxin  ENT1END  and pentylenetetrazol-induced ENT2 seizures ENT2END after i
1	In this article, we report an interesting case of a young woman who presented with this rare type of reverse ENT1 apical ballooning syndrome ENT1END occurring after ENT2 amphetamine ENT2END use
0	One of the rarest is the reverse type of this syndrome, with hyperdynamic apex and complete ENT1 akinesia  ENT1END of the base (as opposed to the classic apical ballooning). In this article, we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after ENT2 amphetamine ENT2END use
1	This new case of ENT1 RPGN ENT1END in the course of ENT2 D-penicillamine ENT2END treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients
0	The patient was treated with steroid pulse, plasmapheresis, ENT1 cyclophosphamide  ENT1END and antiplatelet agents. A complete recovery of renal function was achieved in a few weeks. This new case of ENT2 RPGN ENT2END in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients
0	The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and ENT1 antiplatelet agents  ENT1END  A complete recovery of renal function was achieved in a few weeks. This new case of ENT2 RPGN ENT2END in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients
0	The patient was treated with ENT1 steroid  ENT1END pulse, plasmapheresis, cyclophosphamide and antiplatelet agents. A complete recovery of renal function was achieved in a few weeks. This new case of ENT2 RPGN ENT2END in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients
0	ENT1 Penicillamine  ENT1END -induced rapidly progressive glomerulonephritis in a patient with ENT2 rheumatoid arthritis ENT2END
0	A 67-year-old woman with ENT1 rheumatoid arthritis  ENT1END presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment. Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole. Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium. The patient was treated with steroid pulse, plasmapheresis, ENT2 cyclophosphamide ENT2END and antiplatelet agents
0	A 67-year-old woman with ENT1 rheumatoid arthritis  ENT1END  presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment. Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole. Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium. The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and ENT2 antiplatelet agents ENT2END
0	A 67-year-old woman with ENT1 rheumatoid arthritis  ENT1END  presented rapidly progressive glomerulonephritis (RPGN) after 5 months of D-penicillamine (250 mg/day) treatment. Light microscopy study showed severe glomerulonephritis with crescent formation in 60% of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole. Immunofluorescence revealed scanty granular IgG, IgA and C3 deposits along the capillary walls and mesangium. The patient was treated with ENT2 steroid ENT2END pulse, plasmapheresis, cyclophosphamide and antiplatelet agents
0	This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and ENT1 proteinuria ENT1END in these patients. The prompt discontinuation of ENT2 D-penicillamine ENT2END and vigorous treatment measures could allow for a good prognosis as in this case
0	The patient was treated with steroid pulse, plasmapheresis, ENT1 cyclophosphamide  ENT1END  and antiplatelet agents. A complete recovery of renal function was achieved in a few weeks. This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and ENT2 proteinuria ENT2END in these patients
0	The patient was treated with steroid pulse, plasmapheresis, cyclophosphamide and ENT1 antiplatelet agents  ENT1END . A complete recovery of renal function was achieved in a few weeks. This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and ENT2 proteinuria ENT2END in these patients
0	The patient was treated with ENT1 steroid  ENT1END  pulse, plasmapheresis, cyclophosphamide and antiplatelet agents. A complete recovery of renal function was achieved in a few weeks. This new case of RPGN in the course of D-penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and ENT2 proteinuria ENT2END in these patients
1	In Group II, P did not prevent ENT1 gentamicin ENT1END ENT2 ARF ENT2END (maximal decrease in CCr at day 9
0	In Group II, ENT1 P  ENT1END did not prevent gentamicin ENT2 ARF ENT2END (maximal decrease in CCr at day 9
0	Because rats with ENT1 streptozotocin ENT1END induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced ENT2 acute renal failure ENT2END (ARF)
0	Because rats with streptozotocin-induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure ( ENT1 ARF ENT1END . The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular ENT2 glucose ENT2END reabsorption with phlorizin (P)
0	1 ml/min, undetectable lysozymuria) or damage ( ENT1 tubular necrosis  ENT1END score [maximum 4], zero). In Group II, P did not prevent ENT2 gentamicin ENT2END -ARF (maximal decrease in CCr at day 9
0	1 ml/min, undetectable lysozymuria) or damage ( ENT1 tubular necrosis  ENT1END  score [maximum 4], zero). In Group II, ENT2 P ENT2END did not prevent gentamicin-ARF (maximal decrease in CCr at day 9
0	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular ENT1 glucose ENT1END  reabsorption with phlorizin (P). DM rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied. Unanesthetized adult female, Sprague-Dawley rats were divided in four groups and studied for 15 days. Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild DM + gentamicin). Nephrotoxic doses (40 mg/kg body wt/day) of gentamicin were injected during the last nine days of study to the animals of groups II to IV. In Group I, P induced a moderate and stable glycosuria (3.9 +/- 0.1 g/day, SE), and no functional or morphologic evidence of renal dysfunction (baseline CCr 2.1 +/- 0.1 ml/min, undetectable lysozymuria) or damage ENT2 tubular necrosis ENT2END score [maximum 4], zero)
0	Phlorizin-induced glycosuria does not prevent ENT1 gentamicin ENT1END ENT2 nephrotoxicity ENT2END in rats
0	ENT1 Phlorizin  ENT1END -induced glycosuria does not prevent gentamicin ENT2 nephrotoxicity ENT2END in rats
0	Phlorizin-induced glycosuria does not prevent gentamicin ENT1 nephrotoxicity  ENT1END  in rats.Because rats with ENT2 streptozotocin ENT2END -induced diabetes mellitus (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF)
0	The protection from gentamicin ENT1 nephrotoxicity  ENT1END was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular ENT2 glucose ENT2END reabsorption with phlorizin (P)
0	Phlorizin-induced ENT1 glycosuria  ENT1END  does not prevent ENT2 gentamicin ENT2END nephrotoxicity in rats
0	ENT1 Phlorizin  ENT1END -induced ENT2 glycosuria ENT2END does not prevent gentamicin nephrotoxicity in rats
0	Because rats with ENT1 streptozotocin  ENT1END -induced diabetes mellitus (DM) have a high solute diuresis ( ENT2 glycosuria ENT2END of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF)
0	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular ENT1 glucose ENT1END  reabsorption with phlorizin (P). DM rats with mild ENT2 glycosuria ENT2END (similar in degree to that of the P treated animals) were also studied
0	Group 1 (P alone) received P, 360 mg/day, for 15 days; Group II (P + gentamicin); Group III (gentamicin alone) and Group IV (mild ENT1 DM ENT1END + ENT2 gentamicin ENT2END )
0	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( ENT1 P ENT1END . ENT2 DM ENT2END rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied
1	Because rats with ENT1 streptozotocin ENT1END -induced ENT2 diabetes mellitus ENT2END (DM) have a high solute diuresis (glycosuria of 10 to 12 g/day), we have suggested that this may in part be responsible for their resistance to gentamicin-induced acute renal failure (ARF)
0	The protection from gentamicin nephrotoxicity was studied in non-diabetic rats with chronic solute diuresis induced by blockage of tubular ENT1 glucose  ENT1END  reabsorption with phlorizin (P). ENT2 DM ENT2END rats with mild glycosuria (similar in degree to that of the P treated animals) were also studied
0	ENT1 FLA-63 ENT1END  a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT2 hypotension ENT2END , bradycardia or reflex-enhancing effect of L-dopa
0	In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to ENT1 norepinephrine  ENT1END  FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT2 hypotension ENT2END , bradycardia or reflex-enhancing effect of L-dopa
0	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT1 hypotension ENT1END , bradycardia or reflex-enhancing effect of L-dopa. Pimozide did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes. Removal of the carotid sinuses caused an elevation blood pressure and heart rate and abolished the negative chronotropic effect of norepinephrine. However, L-dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate. ENT2 5-HTP ENT2END (5 mg/kg i
0	) in anesthetize ENT1 MAO  ENT1END inhibited dogs. In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine. FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT2 hypotension ENT2END , bradycardia or reflex-enhancing effect of L-dopa
0	In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, ENT1 DL-Threo-dihydroxyphenylserine  ENT1END had no effect on blood pressure, heart rate or reflex responses to norepinephrine. FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT2 hypotension ENT2END , bradycardia or reflex-enhancing effect of L-dopa
0	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT1 hypotension ENT1END , bradycardia or reflex-enhancing effect of L-dopa. ENT2 Pimozide ENT2END did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes
0	) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with ENT1 MK-486  ENT1END (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs. In addition, reflex bradycardia caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine. FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT2 hypotension ENT2END , bradycardia or reflex-enhancing effect of L-dopa
0	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the ENT1 hypotension ENT1END , bradycardia or reflex-enhancing effect of ENT2 L-dopa ENT2END
0	FLA-63, a ENT1 dopamine  ENT1END beta-oxidase inhibitor, did not have any effect on the ENT2 hypotension ENT2END , bradycardia or reflex-enhancing effect of L-dopa
0	ENT1 FLA-63 ENT1END , a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, ENT2 bradycardia ENT2END or reflex-enhancing effect of L-dopa
1	) decreased blood pressure and heart rate and decreased the reflex ENT1 bradycardia ENT1END to ENT2 norepinephrine ENT2END
0	ENT1 5-HTP  ENT1END  (5 mg/kg i.v.) decreased blood pressure and heart rate and decreased the reflex ENT2 bradycardia ENT2END to norepinephrine
0	) in anesthetize ENT1 MAO ENT1END -inhibited dogs. In addition, reflex ENT2 bradycardia ENT2END caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine
0	In addition, reflex ENT1 bradycardia  ENT1END  caused by injected norepinephrine was significantly enhanced by L-dopa, ENT2 DL-Threo-dihydroxyphenylserine ENT2END had no effect on blood pressure, heart rate or reflex responses to norepinephrine
0	FLA-63, a dopamine-beta-oxidase inhibitor, did not have any effect on the hypotension, ENT1 bradycardia  ENT1END  or reflex-enhancing effect of L-dopa. ENT2 Pimozide ENT2END did not affect the actions of L-dopa on blood pressure and heart rate but completely blocked the enhancement of reflexes
0	) decreased blood pressure and heart rate after extracerebral decarboxylase inhibition with ENT1 MK-486  ENT1END  (25 mg/kg i.v.) in anesthetize MAO-inhibited dogs. In addition, reflex ENT2 bradycardia ENT2END caused by injected norepinephrine was significantly enhanced by L-dopa, DL-Threo-dihydroxyphenylserine had no effect on blood pressure, heart rate or reflex responses to norepinephrine
0	Mediation of enhanced reflex vagal ENT1 bradycardia  ENT1END  by ENT2 L-dopa ENT2END via central dopamine formation in dogs
0	Mediation of enhanced reflex vagal ENT1 bradycardia  ENT1END  by L-dopa via central ENT2 dopamine ENT2END formation in dogs
1	The clinical and radiographic features of cerebral ENT1 deep venous thrombosis ENT1END in a 21-year-old white woman are presented. This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes. The only known risk factor was "low-dose" ENT2 oral contraceptive ENT2END pills
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or ENT1 tamoxifen ENT1END  METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with ENT2 osteoporosis ENT2END
0	METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with ENT1 osteoporosis ENT1END . Women were randomly assigned to ENT2 raloxifene ENT2END 60 mg/d or 120 mg/d or placebo
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal ENT1 estrogen  ENT1END therapy or tamoxifen. METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with ENT2 osteoporosis ENT2END
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or ENT1 tamoxifen ENT1END . METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included ENT2 venous thromboembolism ENT2END , cataracts, gallbladder disease, and endometrial hyperplasia or cancer
1	3 years, ENT1 raloxifene ENT1END was associated with an increased risk for ENT2 venous thromboembolism ENT2END (relative risk [RR] 2
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal ENT1 estrogen  ENT1END  therapy or tamoxifen. METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included ENT2 venous thromboembolism ENT2END , cataracts, gallbladder disease, and endometrial hyperplasia or cancer
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or ENT1 tamoxifen ENT1END . METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, cataracts, gallbladder disease, and ENT2 endometrial hyperplasia or cancer ENT2END
0	Outcomes included venous thromboembolism, cataracts, gallbladder disease, and ENT1 endometrial hyperplasia or cancer  ENT1END . RESULTS: During a mean follow-up of 3.3 years, ENT2 raloxifene ENT2END was associated with an increased risk for venous thromboembolism (relative risk [RR] 2
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal ENT1 estrogen  ENT1END  therapy or tamoxifen. METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, cataracts, gallbladder disease, and ENT2 endometrial hyperplasia or cancer ENT2END
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or ENT1 tamoxifen ENT1END . METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, ENT2 cataracts ENT2END , gallbladder disease, and endometrial hyperplasia or cancer
0	ENT1 Raloxifene ENT1END did not increase risk for ENT2 cataracts ENT2END (RR 0
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal ENT1 estrogen  ENT1END  therapy or tamoxifen. METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, ENT2 cataracts ENT2END , gallbladder disease, and endometrial hyperplasia or cancer
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or ENT1 tamoxifen ENT1END . METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, cataracts, gallbladder disease, and ENT2 endometrial hyperplasia or cancer ENT2END
0	1), or ENT1 endometrial cancer ENT1END (RR 0.9; 95% CI 0.3-2.7). CONCLUSION: ENT2 Raloxifene ENT2END was associated with an increased risk for venous thromboembolism, but there was no increased risk for cataracts, gallbladder disease, endometrial hyperplasia, or endometrial cancer
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal ENT1 estrogen  ENT1END  therapy or tamoxifen. METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, cataracts, gallbladder disease, and ENT2 endometrial hyperplasia or cancer ENT2END
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or ENT1 tamoxifen ENT1END . METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, cataracts, ENT2 gallbladder disease ENT2END , and endometrial hyperplasia or cancer
0	ENT1 Raloxifene ENT1END  did not increase risk for cataracts (RR 0.9; 95% CI 0.8-1.1), ENT2 gallbladder disease ENT2END (RR 1
0	OBJECTIVE: To examine the effect of raloxifene on major adverse events that occur with postmenopausal ENT1 estrogen  ENT1END  therapy or tamoxifen. METHODS: The Multiple Outcomes of Raloxifene Evaluation, a multicenter, randomized, double-blind trial, enrolled 7,705 postmenopausal women with osteoporosis. Women were randomly assigned to raloxifene 60 mg/d or 120 mg/d or placebo. Outcomes included venous thromboembolism, cataracts, ENT2 gallbladder disease ENT2END , and endometrial hyperplasia or cancer
0	Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics-induced ENT1 convulsions ENT1END  and the counteraction by co-administration with local anesthetics.Alterations of ENT2 norepinephrine ENT2END transporter (NET) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice
0	Co-administration of lidocaine, ENT1 bupivacaine ENT1END or tricaine with desipramine reversed this effect. Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus. Daily administration of desipramine increased the incidence of appearance of lidocaine-induced ENT2 convulsions ENT2END and decreased that of cocaine-induced convulsions
1	Desipramine-induced sensitization of ENT1 lidocaine ENT1END ENT2 seizures ENT2END may have a mechanism distinct from kindling resulting from repeated administration of cocaine
0	These results suggest that down-regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine-induced sensitization of lidocaine ENT1 convulsions ENT1END  Inhibition of ENT2 Na ENT2END (+) channels by local anesthetics may regulate desipramine-induced down-regulation of NET function
1	Alterations of norepinephrine transporter (NET) function by chronic inhibition of NET in relation to sensitization to ENT1 seizures ENT1END induce by ENT2 cocaine ENT2END and local anesthetics were studied in mice
0	Co-administration of lidocaine with ENT1 desipramine ENT1END reversed the changes of ENT2 convulsive ENT2END activity of lidocaine and cocaine induced by repeated administration of desipramine
0	Co-administration of lidocaine, bupivacaine or ENT1 tricaine  ENT1END with desipramine reversed this effect. Daily treatment of cocaine increased [(3)H]norepinephrine uptake into the hippocampus. Daily administration of desipramine increased the incidence of appearance of lidocaine-induced ENT2 convulsions ENT2END and decreased that of cocaine-induced convulsions
0	009), reducing the requirement for adjuvant ENT1 pentobarbital ENT1END in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min (P < 0.001). Although dexmedetomidine sedation was associated with a 16% incidence of ENT2 bradycardia ENT2END , all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher
0	Although dexmedetomidine sedation was associated with a 16% incidence of ENT1 bradycardia ENT1END , all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and ENT2 oxygen ENT2END saturations were 95% or higher
1	Although ENT1 dexmedetomidine  ENT1END sedation was associated with a 16% incidence of ENT2 bradycardia ENT2END , all concomitant mean arterial blood pressures were within 20% of age-adjusted normal range and oxygen saturations were 95% or higher
0	International ENT1 mexiletine  ENT1END  and placebo antiarrhythmic coronary trial: I. Report on ENT2 arrhythmia ENT2END and other findings
0	The antiarrhythmic effects of the sustained release form of mexiletine ( ENT1 Mexitil-Perlongets ENT1END  were evaluated in a double-blind placebo trial in 630 patients with recent documented ENT2 myocardial infarction ENT2END
0	There were more ENT1 deaths ENT1END in the ENT2 mexiletine ENT2END group (7
1	Previously recognized side effects, particularly tremor and ENT1 gastrointestinal problems ENT1END  were more frequent in the ENT2 mexiletine ENT2END group than in the placebo group
1	Previously recognized side effects, particularly ENT1 tremor  ENT1END and gastrointestinal problems, were more frequent in the ENT2 mexiletine ENT2END group than in the placebo group
1	Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with kanamycin and ENT1 gentamicin ENT1END  Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing ENT2 impairment of renal reabsorption ENT2END and accumulation of proteins
0	ENT1 Nephrotoxic ENT1END  effects of aminoglycoside treatment on renal protein reabsorption and accumulation.To quantify the effects of gentamicin, kanamycin and ENT2 netilmicin ENT2END on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days
0	ENT1 Nephrotoxic ENT1END  effects of aminoglycoside treatment on renal protein reabsorption and accumulation.To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days. Scanning electron microscopy of the glomerular endothelia, urinary measurements of ENT2 sodium ENT2END , potassium, endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i
0	ENT1 Nephrotoxic ENT1END  effects of aminoglycoside treatment on renal protein reabsorption and accumulation.To quantify the effects of gentamicin, kanamycin and netilmicin on renal protein reabsorption and accumulation, these drugs were administered to rats intraperitoneally (30 mg/kg/day) for 7, 14 or 21 days. Scanning electron microscopy of the glomerular endothelia, urinary measurements of sodium, ENT2 potassium ENT2END , endogenous lysozyme, N-acetyl-beta-D-glucosaminidase (NAG) as well as clearance and accumulation experiments after i
0	ENT1 Nephrotoxic  ENT1END  effects of ENT2 aminoglycoside ENT2END treatment on renal protein reabsorption and accumulation
1	Daily excretion of total protein, endogenous lysozyme and NAG increased only after treatment with ENT1 kanamycin  ENT1END and gentamicin. Thus, aminoglycosides may act as nephrotoxicants at glomerular and/or tubular level inducing ENT2 impairment of renal reabsorption ENT2END and accumulation of proteins
0	Cross-sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate, noninvasive assessment of the presence or absence of ENT1 lithium ENT1END induced ENT2 cardiac malformations ENT2END
1	Maternal ENT1 lithium  ENT1END  and neonatal ENT2 Ebstein's anomaly ENT2END : evaluation with cross-sectional echocardiography
0	In vivo characterization of a dual ENT1 adenosine A2A/A1 receptor antagonist  ENT1END  in animal models of ENT2 Parkinson's disease ENT2END
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of ENT1 Parkinson's disease ENT1END including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and ENT2 MPTP ENT2END -treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of ENT1 Parkinson's disease ENT1END  including mouse and rat models of ENT2 haloperidol ENT2END -induced catalepsy, mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of ENT1 Parkinson's disease ENT1END  including mouse and rat models of haloperidol-induced catalepsy, mouse model of ENT2 reserpine ENT2END -induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of ENT1 Parkinson's disease ENT1END  including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced akinesia, rat ENT2 6-hydroxydopamine ENT2END (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	The in vivo characterization of a dual ENT1 adenosine A(2A)/A(1) receptor antagonist ENT1END in several animal models of Parkinson's disease is described. Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%. Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced ENT2 akinesia ENT2END , rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced ENT1 akinesia  ENT1END , rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and ENT2 MPTP ENT2END -treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of ENT1 haloperidol  ENT1END -induced catalepsy, mouse model of reserpine-induced ENT2 akinesia ENT2END , rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
1	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of ENT1 reserpine  ENT1END -induced ENT2 akinesia ENT2END , rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced catalepsy, mouse model of reserpine-induced ENT1 akinesia  ENT1END , rat ENT2 6-hydroxydopamine ENT2END (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	The in vivo characterization of a dual ENT1 adenosine A(2A)/A(1) receptor antagonist ENT1END  in several animal models of Parkinson's disease is described. Discovery and scale-up syntheses of compound 1 are described in detail, highlighting optimization steps that increased the overall yield of 1 from 10.0% to 30.5%. Compound 1 is a potent A(2A)/A(1) receptor antagonist in vitro (A(2A) K(i) = 4.1 nM; A(1) K(i) = 17.0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced ENT2 catalepsy ENT2END , mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced ENT1 catalepsy  ENT1END , mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and ENT2 MPTP ENT2END -treated non-human primate model
1	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of ENT1 haloperidol  ENT1END -induced ENT2 catalepsy ENT2END , mouse model of reserpine-induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced ENT1 catalepsy  ENT1END , mouse model of ENT2 reserpine ENT2END -induced akinesia, rat 6-hydroxydopamine (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	0 nM) that has excellent activity, after oral administration, across a number of animal models of Parkinson's disease including mouse and rat models of haloperidol-induced ENT1 catalepsy  ENT1END , mouse model of reserpine-induced akinesia, rat ENT2 6-hydroxydopamine ENT2END (6-OHDA) lesion model of drug-induced rotation, and MPTP-treated non-human primate model
0	ENT1 VNB ENT1END was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred. At least one episode of grade 3 or 4 granulocytopenia was seen in 59% of patients. A grade 2 or 3 ENT2 infection ENT2END occurred in 16% of patients, but no toxic deaths occurred
0	A grade 2 or 3 infection occurred in 16% of patients, but no toxic ENT1 deaths ENT1END occurred. Other side effects were rare, and peripheral neurotoxicity has been minor (26% grade 1). CONCLUSION: These data indicate that ENT2 VNB ENT2END is an active agent in metastatic esophageal squamous cell carcinoma
0	Phase II trial of ENT1 vinorelbine  ENT1END  in metastatic ENT2 squamous cell esophageal carcinoma ENT2END
0	PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic ENT1 squamous cell esophageal carcinoma ENT1END  PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy. Thirty patients without prior chemotherapy and 16 pretreated with ENT2 cisplatin ENT2END -based chemotherapy were assessable for toxicity and response
0	European Organization for Research and Treatment of Cancer Gastrointestinal Treat ENT1 Cancer ENT1END  Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of ENT2 vinorelbine ENT2END (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma
0	European Organization for Research and Treatment of Cancer Gastrointestinal Treat ENT1 Cancer  ENT1END  Cooperative Group.PURPOSE: To evaluate the response rate and toxic effects of vinorelbine (VNB) administered as a single agent in metastatic squamous cell esophageal carcinoma. PATIENTS AND METHODS: Forty-six eligible patients with measurable lesions were included and were stratified according to previous chemotherapy. Thirty patients without prior chemotherapy and 16 pretreated with ENT2 cisplatin ENT2END -based chemotherapy were assessable for toxicity and response
1	Other side effects were rare, and ENT1 peripheral neurotoxicity  ENT1END has been minor (26% grade 1). CONCLUSION: These data indicate that ENT2 VNB ENT2END is an active agent in metastatic esophageal squamous cell carcinoma
0	Thirty patients without prior chemotherapy and 16 pretreated with cisplatin-based chemotherapy were assessable for ENT1 toxicity ENT1END and response. ENT2 VNB ENT2END was administered weekly as a 25-mg/m2 short intravenous (i
0	Thirty patients without prior chemotherapy and 16 pretreated with ENT1 cisplatin  ENT1END -based chemotherapy were assessable for ENT2 toxicity ENT2END and response
1	ENT1 VNB ENT1END  was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred. At least one episode of grade 3 or 4 ENT2 granulocytopenia ENT2END was seen in 59% of patients
0	Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with ENT1 acute myocardial infarction  ENT1END . ENT2 Nitroglycerin ENT2END has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced hypotension
0	Our study was designed to determine the effects of combined nitroglycerin and ENT1 phenylephrine ENT1END therapy. Ten patients with acute transmural ENT2 myocardial infarctions ENT2END received intravenous nitroglycerin, sufficient to reduce mean arterial pressure from 107 +/- 6 to 85 +/- 6 mm Hg (P less than 0
1	Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse ENT1 nitroglycerin ENT1END induced ENT2 hypotension ENT2END
0	Nitroglycerin has been shown to reduce ST-segment elevation during acute myocardial infarction, an effect potentiated in the dog by agents that reverse nitroglycerin-induced ENT1 hypotension  ENT1END . Our study was designed to determine the effects of combined nitroglycerin and ENT2 phenylephrine ENT2END therapy
0	The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease ( ENT1 PD ENT1END  is still unclear. The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance). We therefore conducted the present acute dose-response study in four ENT2 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ENT2END (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0
0	The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease ( ENT1 PD ENT1END ) is still unclear. The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and ENT2 A-77636 ENT2END ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance)
0	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either ENT1 LY-171555 ENT1END or subsequent challenge of levodopa. Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist. Potent DA D1 receptor agents with an intermediate duration of efficacy such as A-86929 (approximately 4 hr at higher doses tested) are potential therapeutic tools in ENT2 PD ENT2END and merit further attention
0	The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease ( ENT1 PD ENT1END ) is still unclear. The therapeutic use of selective DA D1 receptor agonists such as ENT2 SKF-82958 ENT2END (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance)
0	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian ENT1 levodopa ENT1END -primed monkeys.The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of ENT2 Parkinson's disease ENT2END (PD) is still unclear
0	The clinical utility of dopamine ( ENT1 DA  ENT1END  D1 receptor agonists in the treatment of ENT2 Parkinson's disease ENT2END (PD) is still unclear
0	Potent DA D1 receptor agents with an intermediate duration of efficacy such as ENT1 A-86929  ENT1END (approximately 4 hr at higher doses tested) are potential therapeutic tools in ENT2 PD ENT2END and merit further attention
0	We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ( ENT1 MPTP ENT1END -exposed cynomolgus monkeys primed to exhibit levodopa-induced ENT2 dyskinesias ENT2END to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0
0	The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for ENT1 A-77636  ENT1END (> 20 hr, leading to behavioral tolerance). We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced ENT2 dyskinesias ENT2END to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0
0	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced ENT1 dyskinesias  ENT1END in these animals than with either ENT2 LY-171555 ENT2END or subsequent challenge of levodopa
0	The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for ENT1 SKF-82958  ENT1END (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance). We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced ENT2 dyskinesias ENT2END to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0
1	We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit ENT1 levodopa  ENT1END induced ENT2 dyskinesias ENT2END to evaluate the locomotor and dyskinetic effects on challenge with four doses (from 0
0	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced parkinsonism as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced ENT1 dyskinesias ENT1END  in these animals than with either LY-171555 or subsequent challenge of levodopa. Selective stimulation of the ENT2 DA ENT2END D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus (referred to as the basal ganglia output) compared with levodopa and selective DA D2 receptor agonist
0	We therefore conducted the present acute dose-response study in four 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed cynomolgus monkeys primed to exhibit levodopa-induced dyskinesias to evaluate the locomotor and ENT1 dyskinetic ENT1END effects on challenge with four doses (from 0.03 to 1.0 mg/kg) of ENT2 A-86929 ENT2END ([-]-[5aR,11bS]-4,5,5a,6,7,11b-hexahydro-2-propyl-3-thia-5-+ ++azacyclopent-1- ena[c]phenathrene-9-10-diol), a selective and full DA D1-like receptor agonist with an intermediate duration of action
1	Acute administration of A-86929 was as efficacious in alleviating ENT1 MPTP ENT1END induced ENT2 parkinsonism ENT2END as levodopa and LY-171555, but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa
0	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in ENT1 parkinsonian  ENT1END  levodopa-primed monkeys.The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear. The therapeutic use of selective DA D1 receptor agonists such as SKF-82958 (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and ENT2 A-77636 ENT2END ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance)
0	Acute administration of A-86929 was as efficacious in alleviating MPTP-induced ENT1 parkinsonism ENT1END  as levodopa and ENT2 LY-171555 ENT2END , but was less likely to reproduce the levodopa-induced dyskinesias in these animals than with either LY-171555 or subsequent challenge of levodopa
0	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in ENT1 parkinsonian  ENT1END  levodopa-primed monkeys.The clinical utility of dopamine (DA) D1 receptor agonists in the treatment of Parkinson's disease (PD) is still unclear. The therapeutic use of selective DA D1 receptor agonists such as ENT2 SKF-82958 ENT2END (6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzaze pine hydrobromide) and A-77636 ([1R, 3S] 3-[1'-admantyl]-1-aminomethyl-3,4-dihydro-5,6-dihydroxy-1H-2-benzo pyran hydrochloride) seems limited because of their duration of action, which is too short for SKF-82958 (< 1 hr) and too long for A-77636 (> 20 hr, leading to behavioral tolerance)
0	Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in ENT1 parkinsonian ENT1END ENT2 levodopa ENT2END -primed monkeys
0	Potential therapeutic use of the selective ENT1 dopamine  ENT1END  D1 receptor agonist, A-86929: an acute study in ENT2 parkinsonian ENT2END levodopa-primed monkeys
0	Potential therapeutic use of the selective dopamine D1 receptor agonist, ENT1 A-86929  ENT1END : an acute study in ENT2 parkinsonian ENT2END levodopa-primed monkeys
0	Past medical history was remarkable for ENT1 hypertension ENT1END  hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and ENT2 paroxetine ENT2END
0	Past medical history was remarkable for ENT1 hypertension ENT1END , hyperlipidemia, and depression. Reported medications included bumetanide, ENT2 pravastatin ENT2END , and paroxetine
0	Past medical history was remarkable for ENT1 hypertension ENT1END , hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous ENT2 calcium gluconate ENT2END was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes
0	Past medical history was remarkable for ENT1 hypertension ENT1END , hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to ENT2 calcium ENT2END chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia
0	Past medical history was remarkable for ENT1 hypertension ENT1END , hyperlipidemia, and depression. Reported medications included ENT2 bumetanide ENT2END , pravastatin, and paroxetine
0	We report a case of severe ENT1 citrate  ENT1END toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for ENT2 hypertension ENT2END , hyperlipidemia, and depression
0	Reported medications included bumetanide, pravastatin, and ENT1 paroxetine ENT1END . Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic ENT2 hypocalcemia ENT2END
0	Reported medications included bumetanide, ENT1 pravastatin  ENT1END , and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic ENT2 hypocalcemia ENT2END
0	Empirical treatment with intravenous ENT1 calcium gluconate  ENT1END  was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic ENT2 hypocalcemia ENT2END
0	The events are consistent with a severe reaction to ENT1 calcium  ENT1END  chelation by sodium citrate anticoagulant resulting in symptomatic systemic ENT2 hypocalcemia ENT2END
0	Upon additional retrospective analysis, it was noted that ENT1 bumetanide ENT1END is a loop diuretic that may cause significant ENT2 hypocalcemia ENT2END
1	The events are consistent with a severe reaction to calcium chelation by ENT1 sodium citrate  ENT1END anticoagulant resulting in symptomatic systemic ENT2 hypocalcemia ENT2END
0	Upon additional retrospective analysis, it was noted that bumetanide is a ENT1 loop diuretic  ENT1END that may cause significant ENT2 hypocalcemia ENT2END
0	Reported medications included bumetanide, pravastatin, and ENT1 paroxetine ENT1END . Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity ENT2 tetany ENT2END
0	Reported medications included bumetanide, ENT1 pravastatin  ENT1END , and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity ENT2 tetany ENT2END
0	She then very rapidly developed acute onset of severe facial and extremity ENT1 tetany  ENT1END . Empirical treatment with intravenous ENT2 calcium gluconate ENT2END was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes
0	She then very rapidly developed acute onset of severe facial and extremity ENT1 tetany  ENT1END . Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to ENT2 calcium ENT2END chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia
0	Reported medications included ENT1 bumetanide  ENT1END , pravastatin, and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity ENT2 tetany ENT2END
0	She then very rapidly developed acute onset of severe facial and extremity ENT1 tetany  ENT1END . Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by ENT2 sodium citrate ENT2END anticoagulant resulting in symptomatic systemic hypocalcemia
0	She then very rapidly developed acute onset of severe facial and extremity ENT1 tetany  ENT1END . Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia. Upon additional retrospective analysis, it was noted that bumetanide is a ENT2 loop diuretic ENT2END that may cause significant hypocalcemia
0	We report a case of severe citrate ENT1 toxicity  ENT1END during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and ENT2 paroxetine ENT2END
0	We report a case of severe citrate ENT1 toxicity  ENT1END  during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, ENT2 pravastatin ENT2END , and paroxetine
0	We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate ENT1 toxicity ENT1END  Laboratory measurement of pre-procedure serum ENT2 calcium ENT2END levels in selected donors may identify cases requiring heightened vigilance
0	Upon additional retrospective analysis, it was noted that ENT1 bumetanide  ENT1END  is a loop diuretic that may cause significant hypocalcemia. We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate ENT2 toxicity ENT2END
0	Severe ENT1 citrate ENT1END ENT2 toxicity ENT2END complicating volunteer apheresis platelet donation
0	Upon additional retrospective analysis, it was noted that bumetanide is a ENT1 loop diuretic  ENT1END  that may cause significant hypocalcemia. We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate ENT2 toxicity ENT2END
0	Past medical history was remarkable for hypertension, ENT1 hyperlipidemia  ENT1END  and depression. Reported medications included bumetanide, pravastatin, and ENT2 paroxetine ENT2END
0	Past medical history was remarkable for hypertension, ENT1 hyperlipidemia  ENT1END , and depression. Reported medications included bumetanide, ENT2 pravastatin ENT2END , and paroxetine
0	Past medical history was remarkable for hypertension, ENT1 hyperlipidemia  ENT1END , and depression. Reported medications included bumetanide, pravastatin, and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous ENT2 calcium gluconate ENT2END was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes
0	Past medical history was remarkable for hypertension, ENT1 hyperlipidemia  ENT1END , and depression. Reported medications included bumetanide, pravastatin, and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to ENT2 calcium ENT2END chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia
0	Past medical history was remarkable for hypertension, ENT1 hyperlipidemia  ENT1END , and depression. Reported medications included ENT2 bumetanide ENT2END , pravastatin, and paroxetine
0	We report a case of severe ENT1 citrate  ENT1END  toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, ENT2 hyperlipidemia ENT2END , and depression
0	Reported medications included bumetanide, pravastatin, and ENT1 paroxetine ENT1END . Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous calcium gluconate was initiated, and ENT2 muscle contractions ENT2END slowly subsided over approximately 10 to 15 minutes
0	Reported medications included bumetanide, ENT1 pravastatin  ENT1END , and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous calcium gluconate was initiated, and ENT2 muscle contractions ENT2END slowly subsided over approximately 10 to 15 minutes
0	Empirical treatment with intravenous ENT1 calcium gluconate  ENT1END  was initiated, and ENT2 muscle contractions ENT2END slowly subsided over approximately 10 to 15 minutes
0	Empirical treatment with intravenous calcium gluconate was initiated, and ENT1 muscle contractions  ENT1END  slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to ENT2 calcium ENT2END chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia
0	Empirical treatment with intravenous calcium gluconate was initiated, and ENT1 muscle contractions  ENT1END  slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia. Upon additional retrospective analysis, it was noted that ENT2 bumetanide ENT2END is a loop diuretic that may cause significant hypocalcemia
0	Empirical treatment with intravenous calcium gluconate was initiated, and ENT1 muscle contractions  ENT1END  slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by ENT2 sodium citrate ENT2END anticoagulant resulting in symptomatic systemic hypocalcemia
0	Empirical treatment with intravenous calcium gluconate was initiated, and ENT1 muscle contractions  ENT1END  slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia. Upon additional retrospective analysis, it was noted that bumetanide is a ENT2 loop diuretic ENT2END that may cause significant hypocalcemia
0	Past medical history was remarkable for hypertension, hyperlipidemia, and ENT1 depression  ENT1END  Reported medications included bumetanide, pravastatin, and ENT2 paroxetine ENT2END
0	Past medical history was remarkable for hypertension, hyperlipidemia, and ENT1 depression  ENT1END . Reported medications included bumetanide, ENT2 pravastatin ENT2END , and paroxetine
0	Past medical history was remarkable for hypertension, hyperlipidemia, and ENT1 depression  ENT1END . Reported medications included bumetanide, pravastatin, and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous ENT2 calcium gluconate ENT2END was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes
0	Past medical history was remarkable for hypertension, hyperlipidemia, and ENT1 depression  ENT1END . Reported medications included bumetanide, pravastatin, and paroxetine. Thirty minutes from the start of the procedure, the donor noted tingling around the mouth, hands, and feet. She then very rapidly developed acute onset of severe facial and extremity tetany. Empirical treatment with intravenous calcium gluconate was initiated, and muscle contractions slowly subsided over approximately 10 to 15 minutes. The events are consistent with a severe reaction to ENT2 calcium ENT2END chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia
0	Past medical history was remarkable for hypertension, hyperlipidemia, and ENT1 depression  ENT1END . Reported medications included ENT2 bumetanide ENT2END , pravastatin, and paroxetine
0	We report a case of severe ENT1 citrate  ENT1END  toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and ENT2 depression ENT2END
1	Acute ENT1 cholestatic hepatitis  ENT1END  after exposure to ENT2 isoflurane ENT2END
0	There was no evidence for viral, autoimmune, or metabolic causes of ENT1 hepatitis ENT1END  No other medications were involved except for dipyrone for analgesia. The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum ENT2 bilirubin ENT2END reached a peak of 17
0	There was no evidence for viral, autoimmune, or metabolic causes of ENT1 hepatitis ENT1END . No other medications were involved except for ENT2 dipyrone ENT2END for analgesia
0	There was no evidence for viral, autoimmune, or metabolic causes of ENT1 hepatitis ENT1END . No other medications were involved except for dipyrone for analgesia. The ENT2 alanine ENT2END aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17
0	OBJECTIVE: To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic ENT1 isoflurane ENT1END  CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia. There was no evidence for viral, autoimmune, or metabolic causes of hepatitis. No other medications were involved except for dipyrone for ENT2 analgesia ENT2END
0	No other medications were involved except for dipyrone for ENT1 analgesia  ENT1END . The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum ENT2 bilirubin ENT2END reached a peak of 17
0	No other medications were involved except for ENT1 dipyrone  ENT1END  for ENT2 analgesia ENT2END
0	No other medications were involved except for dipyrone for ENT1 analgesia  ENT1END . The ENT2 alanine ENT2END aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17
0	DISCUSSION: The clinical and histologic picture of this case resembles ENT1 halothane hepatitis ENT1END  which has a significant mortality rate. CONCLUSIONS: ENT2 Isoflurane ENT2END , a common anesthetic agent, can cause severe cholestatic hepatitis
0	The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum ENT1 bilirubin  ENT1END  reached a peak of 17.0 mg/dL. There was slow improvement over 4 months. Accidental reexposure by the patient to dipyrone was uneventful. DISCUSSION: The clinical and histologic picture of this case resembles ENT2 halothane hepatitis ENT2END , which has a significant mortality rate
0	Accidental reexposure by the patient to ENT1 dipyrone  ENT1END was uneventful. DISCUSSION: The clinical and histologic picture of this case resembles ENT2 halothane hepatitis ENT2END , which has a significant mortality rate
0	The ENT1 alanine  ENT1END  aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17.0 mg/dL. There was slow improvement over 4 months. Accidental reexposure by the patient to dipyrone was uneventful. DISCUSSION: The clinical and histologic picture of this case resembles ENT2 halothane hepatitis ENT2END , which has a significant mortality rate
1	Acute ENT1 cholestatic hepatitis  ENT1END  after exposure to ENT2 isoflurane ENT2END
0	CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute ENT1 cholestatic hepatitis  ENT1END 3 weeks following repair of the right rotator cuff under general anesthesia. There was no evidence for viral, autoimmune, or metabolic causes of hepatitis. No other medications were involved except for dipyrone for analgesia. The alanine aminotransferase was elevated to a peak concentration of 1533 U/L and the serum ENT2 bilirubin ENT2END reached a peak of 17
0	CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute ENT1 cholestatic hepatitis  ENT1END  3 weeks following repair of the right rotator cuff under general anesthesia. There was no evidence for viral, autoimmune, or metabolic causes of hepatitis. No other medications were involved except for ENT2 dipyrone ENT2END for analgesia
0	CASE SUMMARY: A 70-year-old healthy woman from Iraq developed acute ENT1 cholestatic hepatitis  ENT1END  3 weeks following repair of the right rotator cuff under general anesthesia. There was no evidence for viral, autoimmune, or metabolic causes of hepatitis. No other medications were involved except for dipyrone for analgesia. The ENT2 alanine ENT2END aminotransferase was elevated to a peak concentration of 1533 U/L and the serum bilirubin reached a peak of 17
0	Hypotension following the initiation of tizanidine in a patient treated with an ENT1 angiotensin  ENT1END  converting enzyme inhibitor for chronic ENT2 hypertension ENT2END
0	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control ENT1 hypertension ENT1END who developed hypotension following the addition of ENT2 tizanidine ENT2END , an alpha-2 agonist, for the treatment of spasticity
0	The authors present a 10-year-old boy chronically treated with ENT1 lisinopril  ENT1END  an angiotensin converting enzyme inhibitor, to control ENT2 hypertension ENT2END who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity
0	Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to ENT1 disorders of the central nervous system ENT1END  In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported. Adults chronically treated with ENT2 angiotensin ENT2END converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked
0	Hypotension following the initiation of ENT1 tizanidine  ENT1END  in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension.Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to ENT2 disorders of the central nervous system ENT2END
0	Centrally acting alpha-2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to ENT1 disorders of the central nervous system  ENT1END . In addition to their effects on spasticity, certain adverse cardiorespiratory effects have been reported. Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked. The authors present a 10-year-old boy chronically treated with ENT2 lisinopril ENT2END , an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity
0	The authors present a 10-year-old boy chronically treated with lisinopril, an ENT1 angiotensin ENT1END converting enzyme inhibitor, to control hypertension who developed ENT2 hypotension ENT2END following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity
1	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed ENT1 hypotension  ENT1END  following the addition of ENT2 tizanidine ENT2END , an alpha-2 agonist, for the treatment of spasticity
1	The authors present a 10-year-old boy chronically treated with ENT1 lisinopril  ENT1END , an angiotensin converting enzyme inhibitor, to control hypertension who developed ENT2 hypotension ENT2END following the addition of tizanidine, an alpha-2 agonist, for the treatment of spasticity
0	In addition to their effects on ENT1 spasticity  ENT1END  certain adverse cardiorespiratory effects have been reported. Adults chronically treated with ENT2 angiotensin ENT2END converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked
0	The authors present a 10-year-old boy chronically treated with lisinopril, an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of ENT1 spasticity ENT1END  The possible interaction of ENT2 tizanidine ENT2END and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients
0	The authors present a 10-year-old boy chronically treated with ENT1 lisinopril  ENT1END , an angiotensin converting enzyme inhibitor, to control hypertension who developed hypotension following the addition of tizanidine, an alpha-2 agonist, for the treatment of ENT2 spasticity ENT2END
0	To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 ENT1 suprofen ENT1END exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting ENT2 renal disease ENT2END , a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	Possible risk factors included young age, concurrent use of other analgesic agents (especially ENT1 ibuprofen  ENT1END , preexisting ENT2 renal disease ENT2END , a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting ENT1 renal disease ENT1END , a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt. These were findings that were suggestive but did not reach conventional statistical significance. These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of ENT2 uric acid ENT2END in renal tubules
0	02); and to use ENT1 alcohol  ENT1END (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting ENT2 renal disease ENT2END , a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 ENT1 suprofen ENT1END -exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and ENT2 asthma ENT2END (odds ratio, 3
0	1), suffer from hay fever and ENT1 asthma  ENT1END  (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ENT2 ibuprofen ENT2END ), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	1), suffer from hay fever and ENT1 asthma  ENT1END  (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt. These were findings that were suggestive but did not reach conventional statistical significance. These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of ENT2 uric acid ENT2END in renal tubules
0	1), suffer from hay fever and ENT1 asthma  ENT1END  (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use ENT2 alcohol ENT2END (odds ratio, 4
0	To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 ENT1 suprofen ENT1END -exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from ENT2 hay fever ENT2END and asthma (odds ratio, 3
0	1), suffer from ENT1 hay fever  ENT1END  and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ENT2 ibuprofen ENT2END ), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	1), suffer from ENT1 hay fever  ENT1END  and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt. These were findings that were suggestive but did not reach conventional statistical significance. These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of ENT2 uric acid ENT2END in renal tubules
0	1), suffer from ENT1 hay fever  ENT1END  and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use ENT2 alcohol ENT2END (odds ratio, 4
0	To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 ENT1 suprofen ENT1END -exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of ENT2 gout ENT2END , a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	Possible risk factors included young age, concurrent use of other analgesic agents (especially ENT1 ibuprofen  ENT1END ), preexisting renal disease, a history of kidney stones, a history of ENT2 gout ENT2END , a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of ENT1 gout  ENT1END , a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt. These were findings that were suggestive but did not reach conventional statistical significance. These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of ENT2 uric acid ENT2END in renal tubules
0	02); and to use ENT1 alcohol  ENT1END  (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of kidney stones, a history of ENT2 gout ENT2END , a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 ENT1 suprofen ENT1END -exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of ENT2 kidney stones ENT2END , a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	Possible risk factors included young age, concurrent use of other analgesic agents (especially ENT1 ibuprofen  ENT1END ), preexisting renal disease, a history of ENT2 kidney stones ENT2END , a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of ENT1 kidney stones  ENT1END , a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt. These were findings that were suggestive but did not reach conventional statistical significance. These findings are consistent with the postulated mechanism for this unusual syndrome: acute diffuse crystallization of ENT2 uric acid ENT2END in renal tubules
0	02); and to use ENT1 alcohol  ENT1END  (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ibuprofen), preexisting renal disease, a history of ENT2 kidney stones ENT2END , a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
1	The epidemiology of the acute ENT1 flank pain  ENT1END  syndrome from ENT2 suprofen ENT2END
0	Until physicians began reporting an unusual acute ENT1 flank pain  ENT1END syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported. To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use alcohol (odds ratio, 4.4; 95% confidence interval, 1.1-17.5). Possible risk factors included young age, concurrent use of other analgesic agents (especially ENT2 ibuprofen ENT2END ), preexisting renal disease, a history of kidney stones, a history of gout, a recent increase in activity, a recent increase in sun exposure, and residence in the Sunbelt
0	Until physicians began reporting an unusual acute ENT1 flank pain  ENT1END  syndrome to the spontaneous reporting system, 700,000 persons used the drug in the United States. Through August 1986, a total of 163 cases of this syndrome were reported. To elucidate the epidemiology of the syndrome, a case-control study was performed, comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen-exposed control subjects who did not have the syndrome. Case patients were more likely to be men (odds ratio, 3.8; 95% confidence interval, 1.2-12.1), suffer from hay fever and asthma (odds ratio, 3.4; 95% confidence interval, 1.0-11.9); to participate in regular exercise (odds ratio, 5.9; 95% confidence interval, 1.1-30.7), especially in the use of Nautilus equipment (p = 0.02); and to use ENT2 alcohol ENT2END (odds ratio, 4
0	ENT1 Liver injuries  ENT1END were quantified as serum activities of glutamate-oxaloacetate transaminase (GOT) and glutamate- ENT2 pyruvate ENT2END transaminase (GPT)
1	The present study investigates the effects of a diet free of precursors of NAD, the substrate on which PARP acts, in female NMRI mice with ENT1 AAP ENT1END ENT2 hepatitis ENT2END and evaluates the influence of simultaneous ethanol consumption in these animals
0	Recently, we demonstrated the hepatoprotective effects of nicotinic acid amide, a selective inhibitor of ENT1 poly(ADP-ribose)  ENT1END polymerase (PARP; EC 2.4.2.30) on mice suffering from acetaminophen (AAP)- ENT2 hepatitis ENT2END , suggesting that the AAP-induced liver injury involves a step which depends on adenoribosylation
0	Influence of diet free of ENT1 NAD  ENT1END -precursors on acetaminophen ENT2 hepatotoxicity ENT2END in mice
1	Our results provide evidence that the AAP-induced ENT1 hepatitis ENT1END and its exacerbation by ENT2 ethanol ENT2END can either be reduced by end-product inhibition of PARP by NAA or by dietary depletion of the enzyme's substrate NAD
0	ENT1 Liver injuries  ENT1END  were quantified as serum activities of glutamate- ENT2 oxaloacetate ENT2END transaminase (GOT) and glutamate-pyruvate transaminase (GPT)
0	A further 64% reduction of ENT1 hepatitis ENT1END was observed, when ENT2 NAA ENT2END was given to ethanol/AAP-mice
0	ENT1 Liver injuries ENT1END  were quantified as serum activities of ENT2 glutamate ENT2END -oxaloacetate transaminase (GOT) and glutamate-pyruvate transaminase (GPT)
0	Experimental cranial pain elicited by ENT1 capsaicin ENT1END : a PET study.Using a positron emission tomography (PET) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the ENT2 headache ENT2END state, but not in the headache free interval
1	Experimental cranial ENT1 pain  ENT1END  elicited by ENT2 capsaicin ENT2END : a PET study
0	To test this hypothesis we performed an experimental pain study in seven healthy volunteers, using the same positioning in the PET scanner as in the ENT1 migraine ENT1END patients. A small amount of ENT2 capsaicin ENT2END was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve
0	A small amount of ENT1 capsaicin ENT1END  was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve. Increases of regional cerebral blood flow (rCBF) were found bilaterally in the insula, in the anterior cingulate cortex, the cavernous sinus and the cerebellum. Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state. The increase of activation in the region of the cavernous sinus however, suggests that this structure is more likely to be involved in trigeminal transmitted pain as such, rather than in a specific type of headache as was suggested for ENT2 cluster headache ENT2END
0	We conclude that mPGES-1-derived ENT1 PGE(2) ENT1END mediates lithium-induced ENT2 polyuria ENT2END likely via inhibition of AQP2 and NKCC2 expression
0	The present study was undertaken to assess lithium-induced ENT1 polyuria ENT1END in mice deficient in microsomal ENT2 prostaglandin E ENT2END synthase-1 (mPGES-1)
0	Mice lacking mPGES-1 are resistant to ENT1 lithium  ENT1END -induced ENT2 polyuria ENT2END
0	Similarly, the total protein abundance of the ENT1 Na  ENT1END K-2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment. In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice. We conclude that mPGES-1-derived PGE(2) mediates lithium-induced ENT2 polyuria ENT2END likely via inhibition of AQP2 and NKCC2 expression
0	Cyclooxygenase-2 activity is required for the development of lithium-induced ENT1 polyuria ENT1END  However, the involvement of a specific, terminal ENT2 prostaglandin ENT2END (PG) isomerase has not been evaluated
1	A 2-wk administration of ENT1 LiCl ENT1END (4 mmol.kg(-1).day(-1) ip) in mPGES-1 +/+ mice led to a marked ENT2 polyuria ENT2END with hyposmotic urine
0	Similarly, the total protein abundance of the Na- ENT1 K  ENT1END 2Cl cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment. In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice. We conclude that mPGES-1-derived PGE(2) mediates lithium-induced ENT2 polyuria ENT2END likely via inhibition of AQP2 and NKCC2 expression
0	Similarly, the total protein abundance of the Na-K-2 ENT1 Cl  ENT1END cotransporter (NKCC2) in the medulla but not in the cortex of the +/+ mice was significantly reduced by lithium treatment. In contrast, the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the -/- mice. We conclude that mPGES-1-derived PGE(2) mediates lithium-induced ENT2 polyuria ENT2END likely via inhibition of AQP2 and NKCC2 expression
0	We have studied the role of ENT1 NO ENT1END and its association with apoptosis in an experimental model of ENT2 nephrotic syndrome ENT2END induced by a single injection of adriamycin (ADR)
0	We have studied the role of NO and its association with apoptosis in an experimental model of ENT1 nephrotic syndrome ENT1END  induced by a single injection of adriamycin (ADR). METHODS: The alteration in the NO pathway was assessed by measuring nitrite levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system. Rats were stratified into control groups and ADR-induced nephropathy groups. These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving ENT2 aminoguanidine ENT2END (AG) which is a specific inhibitor of inducible-NO synthase
0	We have studied the role of NO and its association with apoptosis in an experimental model of ENT1 nephrotic syndrome ENT1END  induced by a single injection of adriamycin (ADR). METHODS: The alteration in the NO pathway was assessed by measuring ENT2 nitrite ENT2END levels in serum/urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney (IPRK) system
1	We have studied the role of NO and its association with apoptosis in an experimental model of ENT1 nephrotic syndrome ENT1END  induced by a single injection of ENT2 adriamycin ENT2END (ADR)
0	In the IPRK phenylephrine and ENT1 acetylcholine ENT1END related responses were significantly impaired in the ADR-nephropathy group. Apoptosis was not detected in controls. However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas. Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages. Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels. CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced ENT2 nephrosis ENT2END
0	CONCLUSION: We suggest that interactions between ENT1 NO  ENT1END and apoptosis are important in the pathogenesis of the ADR-induced ENT2 nephrosis ENT2END
0	Treatment with ENT1 AG  ENT1END prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels. CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced ENT2 nephrosis ENT2END
0	In the IPRK ENT1 phenylephrine  ENT1END and acetylcholine related responses were significantly impaired in the ADR-nephropathy group. Apoptosis was not detected in controls. However, in the ADR-nephropathy group, numerous apoptotic cells were identified in the tubulointerstitial areas. Double staining revealed numerous interstitial apoptotic cells to stain for ED1, a marker for monocytes/macrophages. Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels. CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced ENT2 nephrosis ENT2END
0	Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine ENT1 nitrite  ENT1END levels and apoptosis to control levels. CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR-induced ENT2 nephrosis ENT2END
0	CONCLUSION: We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ENT1 ADR  ENT1END induced ENT2 nephrosis ENT2END
0	They also had significantly higher levels of ENT1 proteinuria  ENT1END compared with control and treatment groups (P < 0.05). Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05). In the IPRK phenylephrine and ENT2 acetylcholine ENT2END related responses were significantly impaired in the ADR-nephropathy group
0	These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible- ENT1 NO  ENT1END synthase. On day 21, rats were sacrificed after obtaining material for biochemical analysis. RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation. They also had significantly higher levels of ENT2 proteinuria ENT2END compared with control and treatment groups (P < 0
0	These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine ( ENT1 AG  ENT1END  which is a specific inhibitor of inducible-NO synthase. On day 21, rats were sacrificed after obtaining material for biochemical analysis. RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation. They also had significantly higher levels of ENT2 proteinuria ENT2END compared with control and treatment groups (P < 0
0	They also had significantly higher levels of ENT1 proteinuria  ENT1END  compared with control and treatment groups (P < 0.05). Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05). In the IPRK ENT2 phenylephrine ENT2END and acetylcholine related responses were significantly impaired in the ADR-nephropathy group
0	They also had significantly higher levels of ENT1 proteinuria ENT1END  compared with control and treatment groups (P < 0.05). Urine ENT2 nitrite ENT2END levels were significantly increased in the ADR-nephropathy group (P < 0
1	They also had significantly higher levels of ENT1 proteinuria ENT1END  compared with control and treatment groups (P < 0.05). Urine nitrite levels were significantly increased in the ENT2 ADR ENT2END -nephropathy group (P < 0
0	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of ENT1 mesangial proliferation  ENT1END and mild tubulointerstitial inflammation. They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05). Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05). In the IPRK phenylephrine and ENT2 acetylcholine ENT2END related responses were significantly impaired in the ADR-nephropathy group
0	These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible- ENT1 NO  ENT1END  synthase. On day 21, rats were sacrificed after obtaining material for biochemical analysis. RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of ENT2 mesangial proliferation ENT2END and mild tubulointerstitial inflammation
0	These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine ( ENT1 AG  ENT1END ) which is a specific inhibitor of inducible-NO synthase. On day 21, rats were sacrificed after obtaining material for biochemical analysis. RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of ENT2 mesangial proliferation ENT2END and mild tubulointerstitial inflammation
0	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of ENT1 mesangial proliferation  ENT1END  and mild tubulointerstitial inflammation. They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05). Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05). In the IPRK ENT2 phenylephrine ENT2END and acetylcholine related responses were significantly impaired in the ADR-nephropathy group
0	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of ENT1 mesangial proliferation  ENT1END  and mild tubulointerstitial inflammation. They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05). Urine ENT2 nitrite ENT2END levels were significantly increased in the ADR-nephropathy group (P < 0
0	RESULTS: Histopathological examination of the kidneys of rats treated with ENT1 ADR  ENT1END revealed focal areas of ENT2 mesangial proliferation ENT2END and mild tubulointerstitial inflammation
0	Urine nitrite levels were significantly increased in the ADR- ENT1 nephropathy  ENT1END group (P < 0.05). In the IPRK phenylephrine and ENT2 acetylcholine ENT2END related responses were significantly impaired in the ADR-nephropathy group
0	Association of ENT1 nitric oxide  ENT1END  production and apoptosis in a model of experimental ENT2 nephropathy ENT2END
0	Rats were stratified into control groups and ADR-induced ENT1 nephropathy  ENT1END groups. These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving ENT2 aminoguanidine ENT2END (AG) which is a specific inhibitor of inducible-NO synthase
0	Urine nitrite levels were significantly increased in the ADR- ENT1 nephropathy  ENT1END  group (P < 0.05). In the IPRK ENT2 phenylephrine ENT2END and acetylcholine related responses were significantly impaired in the ADR-nephropathy group
0	Urine ENT1 nitrite  ENT1END  levels were significantly increased in the ADR ENT2 nephropathy ENT2END group (P < 0
0	Urine nitrite levels were significantly increased in the ENT1 ADR ENT1END ENT2 nephropathy ENT2END group (P < 0
0	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild ENT1 tubulointerstitial inflammation  ENT1END  They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05). Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05). In the IPRK phenylephrine and ENT2 acetylcholine ENT2END related responses were significantly impaired in the ADR-nephropathy group
0	These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine (AG) which is a specific inhibitor of inducible- ENT1 NO  ENT1END  synthase. On day 21, rats were sacrificed after obtaining material for biochemical analysis. RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild ENT2 tubulointerstitial inflammation ENT2END
0	These two groups were then divided into: group 1, animals receiving saline; and group 2, animals receiving aminoguanidine ( ENT1 AG  ENT1END ) which is a specific inhibitor of inducible-NO synthase. On day 21, rats were sacrificed after obtaining material for biochemical analysis. RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild ENT2 tubulointerstitial inflammation ENT2END
0	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild ENT1 tubulointerstitial inflammation  ENT1END . They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05). Urine nitrite levels were significantly increased in the ADR-nephropathy group (P < 0.05). In the IPRK ENT2 phenylephrine ENT2END and acetylcholine related responses were significantly impaired in the ADR-nephropathy group
0	RESULTS: Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild ENT1 tubulointerstitial inflammation  ENT1END . They also had significantly higher levels of proteinuria compared with control and treatment groups (P < 0.05). Urine ENT2 nitrite ENT2END levels were significantly increased in the ADR-nephropathy group (P < 0
0	RESULTS: Histopathological examination of the kidneys of rats treated with ENT1 ADR  ENT1END  revealed focal areas of mesangial proliferation and mild ENT2 tubulointerstitial inflammation ENT2END
0	Pneumonitis with pleural and pericardial effusion and neuropathy during ENT1 amiodarone ENT1END  therapy.A patient with ENT2 sinuatrial disease ENT2END and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias
0	A patient with ENT1 sinuatrial disease ENT1END  and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias. He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone. Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued ENT2 steroid ENT2END therapy to ensure full recovery
0	A patient with ENT1 sinuatrial disease ENT1END  and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias. He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with ENT2 prednisolone ENT2END
0	Pneumonitis with pleural and pericardial effusion and ENT1 neuropathy  ENT1END  during ENT2 amiodarone ENT2END therapy
0	Pneumonitis with pleural and pericardial effusion and ENT1 neuropathy  ENT1END  during amiodarone therapy.A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias. He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone. Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued ENT2 steroid ENT2END therapy to ensure full recovery
0	Pneumonitis with pleural and pericardial effusion and ENT1 neuropathy  ENT1END  during amiodarone therapy.A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of supraventricular tachyarrhythmias. He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with ENT2 prednisolone ENT2END
1	Pneumonitis with ENT1 pleural and pericardial effusion  ENT1END  and neuropathy during ENT2 amiodarone ENT2END therapy
0	He developed pneumonitis, ENT1 pleural and pericardial effusions  ENT1END  and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone. Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued ENT2 steroid ENT2END therapy to ensure full recovery
0	He developed pneumonitis, ENT1 pleural and pericardial effusions  ENT1END , and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with ENT2 prednisolone ENT2END
1	Pneumonitis with ENT1 pleural and pericardial effusion  ENT1END  and neuropathy during ENT2 amiodarone ENT2END therapy
0	He developed pneumonitis, ENT1 pleural and pericardial effusions  ENT1END  and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone. Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued ENT2 steroid ENT2END therapy to ensure full recovery
0	He developed pneumonitis, ENT1 pleural and pericardial effusions  ENT1END , and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with ENT2 prednisolone ENT2END
0	A patient with sinuatrial disease and implanted pacemaker was treated with ENT1 amiodarone ENT1END (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of ENT2 supraventricular tachyarrhythmias ENT2END
0	A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of ENT1 supraventricular tachyarrhythmias  ENT1END . He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone. Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued ENT2 steroid ENT2END therapy to ensure full recovery
0	A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone (maximum dose 1000 mg, maintenance dose 800 mg daily) for 10 months, for control of ENT1 supraventricular tachyarrhythmias  ENT1END . He developed pneumonitis, pleural and pericardial effusions, and a predominantly proximal motor neuropathy. Immediate but gradual improvement followed withdrawal of amiodarone and treatment with ENT2 prednisolone ENT2END
1	He developed pneumonitis, pleural and pericardial effusions, and a predominantly ENT1 proximal motor neuropathy ENT1END  Immediate but gradual improvement followed withdrawal of ENT2 amiodarone ENT2END and treatment with prednisolone
0	He developed pneumonitis, pleural and pericardial effusions, and a predominantly ENT1 proximal motor neuropathy  ENT1END . Immediate but gradual improvement followed withdrawal of amiodarone and treatment with prednisolone. Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis, immediate withdrawal of amiodarone, and prompt but continued ENT2 steroid ENT2END therapy to ensure full recovery
0	He developed pneumonitis, pleural and pericardial effusions, and a predominantly ENT1 proximal motor neuropathy  ENT1END . Immediate but gradual improvement followed withdrawal of amiodarone and treatment with ENT2 prednisolone ENT2END
1	Review of this and previously reported cases indicates the need for early diagnosis of ENT1 amiodarone ENT1END ENT2 pneumonitis ENT2END , immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery
0	Review of this and previously reported cases indicates the need for early diagnosis of amiodarone ENT1 pneumonitis  ENT1END , immediate withdrawal of amiodarone, and prompt but continued ENT2 steroid ENT2END therapy to ensure full recovery
0	Immediate but gradual improvement followed withdrawal of amiodarone and treatment with ENT1 prednisolone  ENT1END . Review of this and previously reported cases indicates the need for early diagnosis of amiodarone ENT2 pneumonitis ENT2END , immediate withdrawal of amiodarone, and prompt but continued steroid therapy to ensure full recovery
0	In Nx dogs, ENT1 OCT ENT1END reversed abnormal bone formation, such as woven osteoid and ENT2 fibrosis ENT2END , but did not significantly alter the level of bone turnover
1	BACKGROUND: ENT1 Calcitriol ENT1END therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including ENT2 hypercalcemia ENT2END and/or marked suppression of bone turnover, which may lead to adynamic bone disease
0	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including ENT1 hypercalcemia ENT1END  and/or marked suppression of bone turnover, which may lead to adynamic bone disease. A new ENT2 vitamin D ENT2END analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics
0	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including ENT1 hypercalcemia ENT1END  and/or marked suppression of bone turnover, which may lead to adynamic bone disease. A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics. This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function. METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22). The animals received supplemental ENT2 phosphate ENT2END to enhance PTH secretion
1	CONCLUSIONS: These results indicate that even though ENT1 OCT ENT1END does not completely prevent the occurrence of ENT2 hypercalcemia ENT2END in experimental dogs with renal insufficiency, it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and, therefore, does not increase the risk of adynamic bone disease
0	Biochemical and hormonal indices of ENT1 calcium ENT1END and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period. RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency. In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months. Serum PTH levels rose thereafter, but the rise was less pronounced compared with baseline than the rise seen in Nx control. These effects were accompanied by episodes of ENT2 hypercalcemia ENT2END and hyperphosphatemia
0	22-oxacalcitriol suppresses ENT1 secondary hyperparathyroidism  ENT1END  without inducing low bone turnover in dogs with renal failure.BACKGROUND: ENT2 Calcitriol ENT2END therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease
0	22-oxacalcitriol suppresses ENT1 secondary hyperparathyroidism  ENT1END  without inducing low bone turnover in dogs with renal failure.BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease. A new ENT2 vitamin D ENT2END analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics
0	Fourteen weeks after the start of ENT1 phosphate ENT1END supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks. Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months. Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period. RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency. In long-standing ENT2 secondary hyperparathyroidism ENT2END , OCT (0
0	In long-standing ENT1 secondary hyperparathyroidism ENT1END , ENT2 OCT ENT2END (0
0	Biochemical and hormonal indices of ENT1 calcium  ENT1END  and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period. RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency. In long-standing ENT2 secondary hyperparathyroidism ENT2END , OCT (0
0	22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with ENT1 renal failure  ENT1END .BACKGROUND: ENT2 Calcitriol ENT2END therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease
0	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with ENT1 renal failure  ENT1END but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease. A new ENT2 vitamin D ENT2END analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics
0	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with ENT1 renal failure  ENT1END  but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease. A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics. This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function. METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22). The animals received supplemental ENT2 phosphate ENT2END to enhance PTH secretion
0	RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of ENT1 renal insufficiency  ENT1END  In long-standing secondary hyperparathyroidism, ENT2 OCT ENT2END (0
0	Biochemical and hormonal indices of ENT1 calcium  ENT1END  and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period. RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of ENT2 renal insufficiency ENT2END
1	These effects were accompanied by episodes of hypercalcemia and ENT1 hyperphosphatemia ENT1END  In animals with normal renal function, ENT2 OCT ENT2END induced a transient decrease in serum PTH levels at a dose of 0
0	Biochemical and hormonal indices of ENT1 calcium  ENT1END  and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period. RESULTS: In Nx dogs, OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency. In long-standing secondary hyperparathyroidism, OCT (0.03 microg/kg) stabilized serum PTH levels during the first months. Serum PTH levels rose thereafter, but the rise was less pronounced compared with baseline than the rise seen in Nx control. These effects were accompanied by episodes of hypercalcemia and ENT2 hyperphosphatemia ENT2END
0	BACKGROUND: ENT1 Calcitriol ENT1END  therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease. A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics. This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or ENT2 impaired renal function ENT2END
0	A new ENT1 vitamin D  ENT1END  analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics. This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or ENT2 impaired renal function ENT2END
0	This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or ENT1 impaired renal function  ENT1END . METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22). The animals received supplemental ENT2 phosphate ENT2END to enhance PTH secretion
0	This study was undertaken to determine the effects of ENT1 OCT  ENT1END on serum PTH levels and bone turnover in states of normal or ENT2 impaired renal function ENT2END
0	This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or ENT1 impaired renal function  ENT1END . METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22). The animals received supplemental phosphate to enhance PTH secretion. Fourteen weeks after the start of phosphate supplementation, half of the Nx and Sham dogs received doses of OCT (three times per week); the other half were given vehicle for 60 weeks. Thereafter, the treatment modalities for a subset of animals were crossed over for an additional eight months. Biochemical and hormonal indices of ENT2 calcium ENT2END and bone metabolism were measured throughout the study, and bone biopsies were done at baseline, 60 weeks after OCT or vehicle treatment, and at the end of the crossover period
1	22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing ENT1 low bone turnover  ENT1END  in dogs with renal failure.BACKGROUND: ENT2 Calcitriol ENT2END therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to adynamic bone disease
0	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to ENT1 adynamic bone disease  ENT1END  A new ENT2 vitamin D ENT2END analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics
0	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to ENT1 adynamic bone disease  ENT1END . A new vitamin D analogue, 22-oxacalcitriol (OCT), has been shown to have promising characteristics. This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function. METHODS: Sixty dogs were either nephrectomized (Nx, N = 38) or sham-operated (Sham, N = 22). The animals received supplemental ENT2 phosphate ENT2END to enhance PTH secretion
0	BACKGROUND: Calcitriol therapy suppresses serum levels of parathyroid hormone (PTH) in patients with renal failure but has several drawbacks, including hypercalcemia and/or marked suppression of bone turnover, which may lead to ENT1 adynamic bone disease ENT1END . A new vitamin D analogue, ENT2 22-oxacalcitriol ENT2END (OCT), has been shown to have promising characteristics
0	ENT1 Cerebral infarction ENT1END  with a single oral dose of phenylpropanolamine.Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to ENT2 amphetamine ENT2END , is available over the counter in anorectics, nasal congestants, and cold preparations
1	ENT1 Cerebral infarction  ENT1END  with a single oral dose of ENT2 phenylpropanolamine ENT2END
0	Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to ENT1 amphetamine ENT1END , is available over the counter in anorectics, nasal congestants, and cold preparations. Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, ENT2 neuropsychiatric symptoms ENT2END , and nonhemorrhagic cerebral infarction
1	Its prolonged use or overuse has been associated with seizures, intracerebral hemorrhage, ENT1 neuropsychiatric symptoms ENT1END , and nonhemorrhagic cerebral infarction. We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of ENT2 PPA ENT2END
0	Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to ENT1 amphetamine ENT1END , is available over the counter in anorectics, nasal congestants, and cold preparations. Its prolonged use or overuse has been associated with ENT2 seizures ENT2END , intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction
1	Its prolonged use or overuse has been associated with ENT1 seizures  ENT1END , intracerebral hemorrhage, neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction. We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of ENT2 PPA ENT2END
0	Phenylpropanolamine (PPA), a synthetic sympathomimetic that is structurally similar to ENT1 amphetamine ENT1END , is available over the counter in anorectics, nasal congestants, and cold preparations. Its prolonged use or overuse has been associated with seizures, ENT2 intracerebral hemorrhage ENT2END , neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction
1	Its prolonged use or overuse has been associated with seizures, ENT1 intracerebral hemorrhage  ENT1END , neuropsychiatric symptoms, and nonhemorrhagic cerebral infarction. We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of ENT2 PPA ENT2END
1	The renal pathology in a case of ENT1 lithium  ENT1END -induced ENT2 diabetes insipidus ENT2END
1	The role of nitrergic system in ENT1 lidocaine  ENT1END -induced ENT2 convulsion ENT2END in the mouse
0	) and ENT1 diazepam ENT1END (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced ENT2 convulsions ENT2END
0	)-induced ENT1 convulsions ENT1END significantly. These results may suggest that ENT2 NO ENT2END is a proconvulsant mediator in lidocaine-induced convulsions
0	The role of nitrergic system in lidocaine-induced ENT1 convulsion ENT1END  in the mouse.The effects of ENT2 N-nitro-L-arginine-methyl ester ENT2END (L-NAME) a nitric oxide (NO) synthase inhibitor and L-arginine, a NO precursor, were investigated on lidocaine-induced convulsions
0	) and diazepam (2 mg/kg) significantly decreased the incidence of lidocaine (50 mg/kg)-induced ENT1 convulsions ENT1END . In contrast, the ENT2 L-arginine ENT2END treatment increased the incidence of lidocaine (80 mg/kg, i
1	ENT1 Hypomania  ENT1END -like syndrome induced by ENT2 olanzapine ENT2END
0	We report a female patient with a diagnosis of a not otherwise specified ENT1 psychotic disorder ENT1END (DSM-IV) who developed hypomania shortly after the introduction of ENT2 olanzapine ENT2END treatment
0	Light chain proteinuria and cellular mediated immunity in ENT1 rifampin  ENT1END  treated patients with ENT2 tuberculosis ENT2END
1	Light chain ENT1 proteinuria  ENT1END  and cellular mediated immunity in ENT2 rifampin ENT2END treated patients with tuberculosis
1	For compounds that have shown ENT1 TDP ENT1END in the clinic (terfenadine, terodiline, ENT2 cisapride ENT2END ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins
0	Four compounds known to increase QT interval and cause ENT1 TDP ENT1END were investigated: terfenadine, terodiline, cisapride and ENT2 E4031 ENT2END
1	For compounds that have shown ENT1 TDP  ENT1END  in the clinic ( ENT2 terfenadine ENT2END , terodiline, cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins
1	For compounds that have shown ENT1 TDP ENT1END  in the clinic (terfenadine, ENT2 terodiline ENT2END , cisapride) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man (< 10-fold) reflecting their limited safety margins
0	Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, ENT1 cisapride ENT1END , terfenadine and terodiline on monophasic action potential duration in dog.1. Torsades de pointes (TDP) is a potentially fatal ENT2 ventricular tachycardia ENT2END associated with increases in QT interval and monophasic action potential duration (MAPD)
0	Pharmacokinetic/pharmacodynamic assessment of the effects of ENT1 E4031  ENT1END , cisapride, terfenadine and terodiline on monophasic action potential duration in dog.1. Torsades de pointes (TDP) is a potentially fatal ENT2 ventricular tachycardia ENT2END associated with increases in QT interval and monophasic action potential duration (MAPD)
0	Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, ENT1 terfenadine  ENT1END  and terodiline on monophasic action potential duration in dog.1. Torsades de pointes (TDP) is a potentially fatal ENT2 ventricular tachycardia ENT2END associated with increases in QT interval and monophasic action potential duration (MAPD)
0	Pharmacokinetic/pharmacodynamic assessment of the effects of E4031, cisapride, terfenadine and ENT1 terodiline  ENT1END  on monophasic action potential duration in dog.1. Torsades de pointes (TDP) is a potentially fatal ENT2 ventricular tachycardia ENT2END associated with increases in QT interval and monophasic action potential duration (MAPD)
0	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after ENT1 nitroglycerin ENT1END were similar in the normal and diabetic subjects without ENT2 autonomic neuropathy ENT2END , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy
0	Provocation of postural hypotension by ENT1 nitroglycerin  ENT1END  in ENT2 diabetic autonomic neuropathy ENT2END ?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy
0	The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after ENT1 nitroglycerin ENT1END  were similar in the normal and ENT2 diabetic ENT2END subjects without autonomic neuropathy, whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy
1	Provocation of postural ENT1 hypotension  ENT1END  by ENT2 nitroglycerin ENT2END in diabetic autonomic neuropathy?The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects, 12 diabetic subjects without autonomic neuropathy, and 5 diabetic subjects with autonomic neuropathy
1	The case of a 40-year-old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and ENT1 isoniazid ENT1END is reported. A ENT2 bilateral retrobulbar neuropathy ENT2END with an unusual central bitemporal hemianopic scotoma was found
1	ENT1 Bilateral optic neuropathy  ENT1END  due to combined ENT2 ethambutol ENT2END and isoniazid treatment
1	A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic ENT1 scotoma ENT1END was found. Ethambutol was stopped and only small improvement of the visual acuity followed. ENT2 Isoniazid ENT2END was discontinued later, followed by a dramatic improvement in the visual acuity
1	A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic ENT1 scotoma ENT1END  was found. ENT2 Ethambutol ENT2END was stopped and only small improvement of the visual acuity followed
0	The hazards of optic nerve ENT1 toxicity ENT1END due to ethambutol are known. We emphasize the potential danger in the use of ethambutol and ENT2 isoniazid ENT2END
0	The hazards of optic nerve ENT1 toxicity ENT1END  due to ENT2 ethambutol ENT2END are known
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, ENT1 amiodarone  ENT1END -induced lung toxicity and doxorubicin-induced ENT2 cardiotoxicity ENT2END by a novel IH636 grape seed proanthocyanidin extract
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during ENT1 acetaminophen  ENT1END -induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced ENT2 cardiotoxicity ENT2END by a novel IH636 grape seed proanthocyanidin extract
1	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone (AMI)-induced lung toxicity, and doxorubicin ( ENT1 DOX ENT1END -induced ENT2 cardiotoxicity ENT2END in mice
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced ENT1 cardiotoxicity  ENT1END  by a novel ENT2 IH636 grape seed proanthocyanidin extract ENT2END
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced ENT1 cardiotoxicity ENT1END  by a novel IH636 grape seed proanthocyanidin extract.Grape seed extract, primarily a mixture of ENT2 proanthocyanidins ENT2END , has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective
0	Results indicate that GSPE preexposure prior to AAP, ENT1 AMI ENT1END and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation. Histopathological examination of kidney, heart and lung sections revealed moderate to massive ENT2 tissue damage ENT2END with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence
0	Results indicate that GSPE preexposure prior to ENT1 AAP  ENT1END  AMI and DOX, provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation. Histopathological examination of kidney, heart and lung sections revealed moderate to massive ENT2 tissue damage ENT2END with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence
0	Results indicate that GSPE preexposure prior to AAP, AMI and ENT1 DOX  ENT1END  provided near complete protection in terms of serum chemistry changes (ALT, BUN and CPK), and significantly reduced DNA fragmentation. Histopathological examination of kidney, heart and lung sections revealed moderate to massive ENT2 tissue damage ENT2END with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence
0	Histopathological examination of kidney, heart and lung sections revealed moderate to massive ENT1 tissue damage ENT1END  with a variety of morphological aberrations by all the three drugs in the absence of ENT2 GSPE ENT2END preexposure than in its presence
1	Interestingly, all the drugs, such as, AAP, ENT1 AMI ENT1END and DOX induced apoptotic death in addition to ENT2 necrosis ENT2END in the respective organs which was very effectively blocked by GSPE
1	In vivo protection of dna damage associated apoptotic and ENT1 necrotic  ENT1END  cell deaths during ENT2 acetaminophen ENT2END -induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract
1	Interestingly, all the drugs, such as, AAP, AMI and ENT1 DOX  ENT1END induced apoptotic death in addition to ENT2 necrosis ENT2END in the respective organs which was very effectively blocked by GSPE
0	Interestingly, all the drugs, such as, AAP, AMI and DOX induced apoptotic death in addition to ENT1 necrosis ENT1END  in the respective organs which was very effectively blocked by ENT2 GSPE ENT2END
0	In vivo protection of dna damage associated apoptotic and ENT1 necrotic  ENT1END  cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.Grape seed extract, primarily a mixture of ENT2 proanthocyanidins ENT2END , has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced ENT1 nephrotoxicity  ENT1END , ENT2 amiodarone ENT2END -induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract
1	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen ( ENT1 AAP ENT1END -induced ENT2 nephrotoxicity ENT2END , amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced ENT1 nephrotoxicity  ENT1END , amiodarone-induced lung toxicity and ENT2 doxorubicin ENT2END -induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract
0	This study assessed the ability of IH636 grape seed proanthocyanidin extract ( ENT1 GSPE  ENT1END  to prevent acetaminophen (AAP)-induced ENT2 nephrotoxicity ENT2END , amiodarone (AMI)-induced lung toxicity, and doxorubicin (DOX)-induced cardiotoxicity in mice
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced ENT1 nephrotoxicity  ENT1END , amiodarone-induced lung toxicity and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.Grape seed extract, primarily a mixture of ENT2 proanthocyanidins ENT2END , has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective
1	This study assessed the ability of IH636 grape seed proanthocyanidin extract (GSPE) to prevent acetaminophen (AAP)-induced nephrotoxicity, amiodarone ( ENT1 AMI ENT1END -induced ENT2 lung toxicity ENT2END , and doxorubicin (DOX)-induced cardiotoxicity in mice
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during ENT1 acetaminophen  ENT1END -induced nephrotoxicity, amiodarone-induced ENT2 lung toxicity ENT2END and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced ENT1 lung toxicity  ENT1END  and ENT2 doxorubicin ENT2END -induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced ENT1 lung toxicity  ENT1END  and doxorubicin-induced cardiotoxicity by a novel ENT2 IH636 grape seed proanthocyanidin extract ENT2END
0	In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen-induced nephrotoxicity, amiodarone-induced ENT1 lung toxicity  ENT1END  and doxorubicin-induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract.Grape seed extract, primarily a mixture of ENT2 proanthocyanidins ENT2END , has been shown to modulate a wide-range of biological, pharmacological and toxicological effects which are mainly cytoprotective
0	Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge, gallstones, and ENT1 cholecystitis ENT1END during ENT2 octreotide ENT2END therapy in Chinese acromegalic patients
0	In 8 patients followed for 24 weeks, gallbladder contractility remained ENT1 depressed ENT1END throughout therapy. After withdrawal of ENT2 octreotide ENT2END in 10 patients without gallstones, 8 patients assessed had return of normal gallbladder contractility within 1 month
1	After withdrawal of ENT1 octreotide ENT1END  in 10 patients without ENT2 gallstones ENT2END , 8 patients assessed had return of normal gallbladder contractility within 1 month
0	It is therefore very important to follow the changes of gallbladder function during long-term ENT1 octreotide ENT1END therapy of ENT2 acromegalic ENT2END patients
1	During treatment with ENT1 octreotide ENT1END  17 patients developed sludge, 10 had gallstones, and 1 developed ENT2 acute cholecystitis ENT2END requiring surgery
0	Angiotensin-converting enzyme inhibitor (ACEI)-induced angioedema was suspected, and anti- ENT1 hypertensive ENT1END medications were discontinued. Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites. The recognition of ENT2 angiotensin ENT2END -converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons
0	This is a case report on a 45-year old African-American female with newly diagnosed ENT1 hypertension ENT1END  who was started on a combination pill of ENT2 amlodipine ENT2END /benazapril 10/5 mg
0	This is a case report on a 45-year old African-American female with newly diagnosed ENT1 hypertension  ENT1END , who was started on a combination pill of amlodipine/ ENT2 benazapril ENT2END 10/5 mg
0	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of ENT1 amlodipine ENT1END /benazapril 10/5 mg. The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and ENT2 vomiting ENT2END
0	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/ ENT1 benazapril  ENT1END  10/5 mg. The very next day, she presented at the emergency room (ER) with abdominal pain, nausea and ENT2 vomiting ENT2END
0	Her symptoms improved within the next 24 hours, and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ENT1 ascites  ENT1END  The recognition of ENT2 angiotensin ENT2END -converting enzyme (ACE) and angiotensin receptor blocker (ARB) intestinal angioedema constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons
0	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of ENT1 amlodipine ENT1END /benazapril 10/5 mg. The very next day, she presented at the emergency room (ER) with ENT2 abdominal pain ENT2END , nausea and vomiting
0	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/ ENT1 benazapril  ENT1END  10/5 mg. The very next day, she presented at the emergency room (ER) with ENT2 abdominal pain ENT2END , nausea and vomiting
0	The recognition of angiotensin-converting enzyme (ACE) and ENT1 angiotensin ENT1END receptor blocker (ARB) ENT2 intestinal angioedema ENT2END constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons
0	The recognition of angiotensin-converting enzyme (ACE) and ENT1 angiotensin ENT1END  receptor blocker (ARB) ENT2 intestinal angioedema ENT2END constitutes a challenge to primary care physicians, internists, emergency room personal and surgeons
1	Angiotensin-converting enzyme (ACE) inhibitor-associated ENT1 angioedema  ENT1END  of the stomach and small intestine: a case report.This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of ENT2 amlodipine ENT2END /benazapril 10/5 mg
1	Angiotensin-converting enzyme (ACE) inhibitor-associated ENT1 angioedema  ENT1END  of the stomach and small intestine: a case report.This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine ENT2 benazapril ENT2END 10/5 mg
0	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of ENT1 amlodipine ENT1END /benazapril 10/5 mg. The very next day, she presented at the emergency room (ER) with abdominal pain, ENT2 nausea ENT2END and vomiting
0	This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/ ENT1 benazapril  ENT1END  10/5 mg. The very next day, she presented at the emergency room (ER) with abdominal pain, ENT2 nausea ENT2END and vomiting
0	We report a favorable response to treatment with ENT1 citalopram ENT1END by a 15-year-old boy with ENT2 major depression ENT2END who exhibited palpebral twitching during his first 2 weeks of treatment
1	ENT1 Palpebral twitching  ENT1END  in a depressed adolescent on ENT2 citalopram ENT2END
0	Palpebral twitching in a ENT1 depressed  ENT1END  adolescent on ENT2 citalopram ENT2END
1	ENT1 Agranulocytosis ENT1END occurred 3-20 weeks after initiation of ENT2 ticlopidine ENT2END , so frequent examination of white cell count during treatment is recommended
0	ENT1 Agranulocytosis ENT1END  occurred 3-20 weeks after initiation of ticlopidine, so frequent examination of white cell count during treatment is recommended. There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression. Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect. The fact that 5 of the 6 patients who received concurrent ENT2 calcium ENT2END channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously
1	ENT1 Ticlopidine  ENT1END -induced ENT2 aplastic anemia ENT2END : report of three Chinese patients and review of the literature
0	Treatment for ticlopidine-induced ENT1 aplastic anemia  ENT1END with colony-stimulating factors seemed to have little effect. The fact that 5 of the 6 patients who received concurrent ENT2 calcium ENT2END channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously
0	There seemed to be no direct correlation between the dose or duration used and the severity of ENT1 bone marrow suppression ENT1END  Treatment for ENT2 ticlopidine ENT2END -induced aplastic anemia with colony-stimulating factors seemed to have little effect
0	There seemed to be no direct correlation between the dose or duration used and the severity of ENT1 bone marrow suppression  ENT1END . Treatment for ticlopidine-induced aplastic anemia with colony-stimulating factors seemed to have little effect. The fact that 5 of the 6 patients who received concurrent ENT2 calcium ENT2END channel blockers died, should alert clinicians to be more cautious when using these two drugs simultaneously
0	Although the United States Food and Drug Administration banned its use for ENT1 nocturnal leg cramps ENT1END due to lack of safety and efficacy, ENT2 quinine ENT2END is widely available in beverages including tonic water and bitter lemon
1	Numerous anecdotal reports suggest that products containing ENT1 quinine ENT1END may produce neurological complications, including confusion, altered mental status, ENT2 seizures ENT2END , and coma, particularly in older women
1	Numerous anecdotal reports suggest that products containing ENT1 quinine ENT1END  may produce neurological complications, including ENT2 confusion ENT2END , altered mental status, seizures, and coma, particularly in older women
0	Numerous anecdotal reports suggest that products containing ENT1 quinine ENT1END  may produce ENT2 neurological complications ENT2END , including confusion, altered mental status, seizures, and coma, particularly in older women
1	Numerous anecdotal reports suggest that products containing quinine may produce neurological complications, including confusion, altered mental status, seizures, and ENT1 coma ENT1END  particularly in older women. Psychologists need to inquire about consumption of ENT2 quinine ENT2END -containing beverages as part of an evaluation process
0	It has been proposed that modest changes in plasma potassium can alter the tendency towards ENT1 cardiac arrhythmias  ENT1END  If this were so, patients with coronary artery disease might be especially susceptible. Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic ( ENT2 amiloride ENT2END ) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study
0	It has been proposed that modest changes in plasma potassium can alter the tendency towards ENT1 cardiac arrhythmias  ENT1END . If this were so, patients with coronary artery disease might be especially susceptible. Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic ( ENT2 chlorthalidone ENT2END ) in a randomised study
0	Diuretics, ENT1 potassium  ENT1END  and ENT2 arrhythmias ENT2END in hypertensive coronary disease
0	It has been proposed that modest changes in plasma potassium can alter the tendency towards ENT1 cardiac arrhythmias ENT1END . If this were so, patients with coronary artery disease might be especially susceptible. Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study. Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy. Blood pressure and volume states as assessed by bodyweight, plasma renin and ENT2 noradrenaline ENT2END (norepinephrine) concentrations were similar on the 2 regimens
0	Thus, myocardial electrical excitability was measured in patients with mild essential ENT1 hypertension ENT1END and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic ENT2 amiloride ENT2END ) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study
0	Thus, myocardial electrical excitability was measured in patients with mild essential ENT1 hypertension ENT1END  and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic ENT2 chlorthalidone ENT2END ) in a randomised study
0	Diuretics, ENT1 potassium  ENT1END  and arrhythmias in ENT2 hypertensive ENT2END coronary disease
0	Thus, myocardial electrical excitability was measured in patients with mild essential ENT1 hypertension  ENT1END  and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study. Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy. Blood pressure and volume states as assessed by bodyweight, plasma renin and ENT2 noradrenaline ENT2END (norepinephrine) concentrations were similar on the 2 regimens
0	Compared to ENT1 amiloride ENT1END treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation. The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ENT2 ischaemic heart disease ENT2END , even minor falls in plasma potassium concentrations are probably best avoided in such patients
0	Compared to amiloride treatment, the ENT1 chlorthalidone  ENT1END phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation. The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ENT2 ischaemic heart disease ENT2END , even minor falls in plasma potassium concentrations are probably best avoided in such patients
0	The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ENT1 ischaemic heart disease ENT1END , even minor falls in plasma ENT2 potassium ENT2END concentrations are probably best avoided in such patients
0	Blood pressure and volume states as assessed by bodyweight, plasma renin and noradrenaline ( ENT1 norepinephrine  ENT1END  concentrations were similar on the 2 regimens. Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation. The above results indicate that because potassium-losing diuretic therapy can increase myocardial electrical excitability in patients with ENT2 ischaemic heart disease ENT2END , even minor falls in plasma potassium concentrations are probably best avoided in such patients
0	Diuretics, potassium and arrhythmias in hypertensive ENT1 coronary disease ENT1END .It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias. If this were so, patients with coronary artery disease might be especially susceptible. Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic ENT2 amiloride ENT2END ) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study
0	Diuretics, potassium and arrhythmias in hypertensive ENT1 coronary disease ENT1END .It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias. If this were so, patients with coronary artery disease might be especially susceptible. Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic ENT2 chlorthalidone ENT2END ) in a randomised study
0	Diuretics, ENT1 potassium  ENT1END  and arrhythmias in hypertensive ENT2 coronary disease ENT2END
0	Diuretics, potassium and arrhythmias in hypertensive ENT1 coronary disease  ENT1END .It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias. If this were so, patients with coronary artery disease might be especially susceptible. Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study. Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy. Blood pressure and volume states as assessed by bodyweight, plasma renin and ENT2 noradrenaline ENT2END (norepinephrine) concentrations were similar on the 2 regimens
0	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known ENT1 coronary artery disease ENT1END after 8 weeks of treatment with a potassium-conserving diuretic ENT2 amiloride ENT2END ) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study
0	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known ENT1 coronary artery disease ENT1END  after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic ENT2 chlorthalidone ENT2END ) in a randomised study
0	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known ENT1 coronary artery disease ENT1END  after 8 weeks of treatment with a ENT2 potassium ENT2END -conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study
0	Thus, myocardial electrical excitability was measured in patients with mild essential hypertension and known ENT1 coronary artery disease  ENT1END  after 8 weeks of treatment with a potassium-conserving diuretic (amiloride) and a similar period on a potassium-losing diuretic (chlorthalidone) in a randomised study. Plasma potassium concentrations were on average 1 mmol/L lower during the chlorthalidone phase compared to amiloride therapy. Blood pressure and volume states as assessed by bodyweight, plasma renin and ENT2 noradrenaline ENT2END (norepinephrine) concentrations were similar on the 2 regimens
0	Compared to ENT1 amiloride ENT1END  treatment, the chlorthalidone phase was associated with an increased frequency of ENT2 ventricular ectopic beats ENT2END (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation
1	Compared to amiloride treatment, the ENT1 chlorthalidone  ENT1END  phase was associated with an increased frequency of ENT2 ventricular ectopic beats ENT2END (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation
0	Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ENT1 ventricular ectopic beats ENT1END  (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation. The above results indicate that because ENT2 potassium ENT2END -losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease, even minor falls in plasma potassium concentrations are probably best avoided in such patients
0	Blood pressure and volume states as assessed by bodyweight, plasma renin and noradrenaline ( ENT1 norepinephrine  ENT1END ) concentrations were similar on the 2 regimens. Compared to amiloride treatment, the chlorthalidone phase was associated with an increased frequency of ENT2 ventricular ectopic beats ENT2END (24-hour Holter monitoring) and a higher Lown grading, increased upslope and duration of the monophasic action potential, prolonged ventricular effective refractory period, and increased electrical instability during programmed ventricular stimulation
0	Importantly, GNC92H2 prevented ENT1 death  ENT1END even post- ENT2 cocaine ENT2END injection
1	Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, ENT1 seizures  ENT1END up to 77% and death by 72%. Importantly, GNC92H2 prevented death even post ENT2 cocaine ENT2END injection
0	Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for ENT1 cocaine overdose ENT1END .The illicit use of ENT2 cocaine ENT2END continues in epidemic proportions and treatment for cocaine overdose remains elusive
0	Significant blockade of ENT1 cocaine ENT1END ENT2 toxicity ENT2END was observed with the higher dose of GNC92H2 (190 mg/kg), where premorbid behaviors were reduced up to 40%, seizures up to 77% and death by 72%
0	CASE SUMMARY: A 41-year-old Chinese man with a history of ENT1 hyperthyroidism ENT1END had been treated with carbimazole and ENT2 propranolol ENT2END for the past 5 years
0	OBJECTIVE: To report a case of fatal liver failure possibly associated with concurrent use of ENT1 bupropion  ENT1END and carbimazole. CASE SUMMARY: A 41-year-old Chinese man with a history of ENT2 hyperthyroidism ENT2END had been treated with carbimazole and propranolol for the past 5 years
0	CASE SUMMARY: A 41-year-old Chinese man with a history of ENT1 hyperthyroidism ENT1END  had been treated with ENT2 carbimazole ENT2END and propranolol for the past 5 years
0	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and ENT1 propranolol ENT1END  for the past 5 years. He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation. He developed acute liver failure with rapid deterioration of renal function. Liver biopsy showed evidence of nonspecific drug-induced acute liver injury. His condition was further complicated by ENT2 sepsis ENT2END and coagulopathy
0	His condition was further complicated by ENT1 sepsis ENT1END  and coagulopathy. Death resulted 19 days after the onset of symptoms. The likelihood that ENT2 bupropion ENT2END induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale
0	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with ENT1 carbimazole  ENT1END  and propranolol for the past 5 years. He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation. He developed acute liver failure with rapid deterioration of renal function. Liver biopsy showed evidence of nonspecific drug-induced acute liver injury. His condition was further complicated by ENT2 sepsis ENT2END and coagulopathy
0	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and ENT1 propranolol ENT1END  for the past 5 years. He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation. He developed acute liver failure with rapid deterioration of renal function. Liver biopsy showed evidence of nonspecific drug-induced acute liver injury. His condition was further complicated by sepsis and ENT2 coagulopathy ENT2END
0	His condition was further complicated by sepsis and ENT1 coagulopathy  ENT1END . Death resulted 19 days after the onset of symptoms. The likelihood that ENT2 bupropion ENT2END induced hepatotoxicity in our patient was possible, based on the Naranjo probability scale
0	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with ENT1 carbimazole  ENT1END  and propranolol for the past 5 years. He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation. He developed acute liver failure with rapid deterioration of renal function. Liver biopsy showed evidence of nonspecific drug-induced acute liver injury. His condition was further complicated by sepsis and ENT2 coagulopathy ENT2END
0	OBJECTIVE: To report a case of fatal ENT1 liver failure  ENT1END possibly associated with concurrent use of bupropion and carbimazole. CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and ENT2 propranolol ENT2END for the past 5 years
0	OBJECTIVE: To report a case of fatal ENT1 liver failure  ENT1END  possibly associated with concurrent use of ENT2 bupropion ENT2END and carbimazole
0	Acute liver failure with concurrent bupropion and ENT1 carbimazole  ENT1END  therapy.OBJECTIVE: To report a case of fatal ENT2 liver failure ENT2END possibly associated with concurrent use of bupropion and carbimazole
0	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and ENT1 propranolol ENT1END  for the past 5 years. He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation. He developed acute liver failure with rapid deterioration of renal function. Liver biopsy showed evidence of nonspecific ENT2 drug-induced acute liver injury ENT2END
1	The likelihood that ENT1 bupropion ENT1END  induced ENT2 hepatotoxicity ENT2END in our patient was possible, based on the Naranjo probability scale
1	DISCUSSION: Although there is increasing evidence of hepatotoxicity induced by bupropion, this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with ENT1 carbimazole ENT1END  CONCLUSIONS: Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other ENT2 hepatotoxic ENT2END drugs
0	CASE SUMMARY: A 41-year-old Chinese man with a history of hyperthyroidism had been treated with carbimazole and ENT1 propranolol ENT1END  for the past 5 years. He received a 10-day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation. He developed ENT2 acute liver failure ENT2END with rapid deterioration of renal function
1	CONCLUSIONS: Clinicians should be aware of the possibility of ENT1 acute liver insult ENT1END induced by ENT2 bupropion ENT2END given concurrently with other hepatotoxic drugs
1	ENT1 Acute liver failure  ENT1END  with concurrent bupropion and ENT2 carbimazole ENT2END therapy
0	Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor ( ENT1 statin ENT1END  therapy. However, ENT2 hepatotoxic ENT2END events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe
0	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of ENT1 simvastatin hydroxy acid ENT1END  resulting in increased simvastatin exposure and subsequent ENT2 hepatotoxicity ENT2END
0	Ezetimibe undergoes extensive glucuronidation by ENT1 uridine diphosphate  ENT1END glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent ENT2 hepatotoxicity ENT2END
0	Simvastatinezetimibe and ENT1 escitalopram ENT1END (which she was taking for depression) were discontinued, and other potential causes of ENT2 hepatotoxicity ENT2END were excluded
0	We postulate that the mechanism of the simvastatinezetimibe-induced ENT1 hepatotoxicity ENT1END is the increased simvastatin exposure by ENT2 ezetimibe ENT2END inhibition of UGT enzymes
1	Clinicians should be aware of potential ENT1 hepatotoxicity ENT1END with ENT2 simvastatin-ezetimibe ENT2END especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage
0	A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe ENT1 drug toxicity ENT1END  She underwent liver transplantation with an uneventful postoperative course. Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events. Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased ENT2 simvastatin ENT2END exposure and subsequent hepatotoxicity
0	A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe ENT1 drug toxicity  ENT1END . She underwent liver transplantation with an uneventful postoperative course. Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events. Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of ENT2 simvastatin hydroxy acid ENT2END , resulting in increased simvastatin exposure and subsequent hepatotoxicity
0	A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe ENT1 drug toxicity  ENT1END . She underwent liver transplantation with an uneventful postoperative course. Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events. Ezetimibe undergoes extensive glucuronidation by ENT2 uridine diphosphate ENT2END glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity
0	Simvastatinezetimibe and ENT1 escitalopram  ENT1END  (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded. A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe ENT2 drug toxicity ENT2END
0	A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe ENT1 drug toxicity ENT1END . She underwent liver transplantation with an uneventful postoperative course. Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events. ENT2 Ezetimibe ENT2END undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity
0	ENT1 Simvastatinezetimibe  ENT1END and escitalopram (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded. A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe ENT2 drug toxicity ENT2END
0	We describe a 70-year-old Hispanic woman who developed ENT1 fulminant hepatic failure ENT1END necessitating liver transplantation 10 weeks after conversion from ENT2 simvastatin ENT2END 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day
0	We describe a 70-year-old Hispanic woman who developed ENT1 fulminant hepatic failure  ENT1END  necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day. The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity. A routine laboratory work-up 10 weeks after conversion revealed elevated serum aminotransferase levels. Simvastatinezetimibe and ENT2 escitalopram ENT2END (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded
0	However, hepatotoxic events have not been widely published with ENT1 ezetimibe  ENT1END or the combination agent simvastatin-ezetimibe. We describe a 70-year-old Hispanic woman who developed ENT2 fulminant hepatic failure ENT2END necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day
1	However, hepatotoxic events have not been widely published with ezetimibe or the combination agent ENT1 simvastatin-ezetimibe  ENT1END  We describe a 70-year-old Hispanic woman who developed ENT2 fulminant hepatic failure ENT2END necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day
0	The patient's lipid panel had been maintained with ENT1 simvastatin ENT1END for 18 months before the conversion without evidence of hepatotoxicity. A routine laboratory work-up 10 weeks after conversion revealed elevated serum aminotransferase levels. Simvastatinezetimibe and escitalopram (which she was taking for ENT2 depression ENT2END ) were discontinued, and other potential causes of hepatotoxicity were excluded
0	Simvastatinezetimibe and escitalopram (which she was taking for ENT1 depression  ENT1END ) were discontinued, and other potential causes of hepatotoxicity were excluded. A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity. She underwent liver transplantation with an uneventful postoperative course. Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events. Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of ENT2 simvastatin hydroxy acid ENT2END , resulting in increased simvastatin exposure and subsequent hepatotoxicity
0	Simvastatinezetimibe and escitalopram (which she was taking for ENT1 depression  ENT1END ) were discontinued, and other potential causes of hepatotoxicity were excluded. A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity. She underwent liver transplantation with an uneventful postoperative course. Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events. Ezetimibe undergoes extensive glucuronidation by ENT2 uridine diphosphate ENT2END glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity
0	Simvastatinezetimibe and ENT1 escitalopram  ENT1END  (which she was taking for ENT2 depression ENT2END ) were discontinued, and other potential causes of hepatotoxicity were excluded
0	Simvastatinezetimibe and escitalopram (which she was taking for ENT1 depression  ENT1END ) were discontinued, and other potential causes of hepatotoxicity were excluded. A repeat work-up revealed further elevations in aminotransferase levels, and liver biopsy revealed evidence of moderate-to-severe drug toxicity. She underwent liver transplantation with an uneventful postoperative course. Her aminotransferase levels returned to normal by postoperative day 23, and her 2-year follow-up showed no adverse events. ENT2 Ezetimibe ENT2END undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity
0	ENT1 Simvastatinezetimibe  ENT1END  and escitalopram (which she was taking for ENT2 depression ENT2END ) were discontinued, and other potential causes of hepatotoxicity were excluded
0	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased ENT1 simvastatin ENT1END  exposure and subsequent hepatotoxicity. To our knowledge, this is the first case report of simvastatin-ezetimibe-induced ENT2 liver failure ENT2END that resulted in liver transplantation
0	Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of ENT1 simvastatin hydroxy acid  ENT1END , resulting in increased simvastatin exposure and subsequent hepatotoxicity. To our knowledge, this is the first case report of simvastatin-ezetimibe-induced ENT2 liver failure ENT2END that resulted in liver transplantation
0	Ezetimibe undergoes extensive glucuronidation by ENT1 uridine diphosphate  ENT1END  glucoronosyltransferases (UGT) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid, resulting in increased simvastatin exposure and subsequent hepatotoxicity. To our knowledge, this is the first case report of simvastatin-ezetimibe-induced ENT2 liver failure ENT2END that resulted in liver transplantation
0	Simvastatin-ezetimibe-induced ENT1 hepatic failure  ENT1END  necessitating liver transplantation.Abstract Serum aminotransferase elevations are a commonly known adverse effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy. However, hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin-ezetimibe. We describe a 70-year-old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg/day to simvastatin 10 mg-ezetimibe 40 mg/day. The patient's lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity. A routine laboratory work-up 10 weeks after conversion revealed elevated serum aminotransferase levels. Simvastatinezetimibe and ENT2 escitalopram ENT2END (which she was taking for depression) were discontinued, and other potential causes of hepatotoxicity were excluded
0	To our knowledge, this is the first case report of simvastatin-ezetimibe-induced ENT1 liver failure  ENT1END  that resulted in liver transplantation. We postulate that the mechanism of the simvastatinezetimibe-induced hepatotoxicity is the increased simvastatin exposure by ENT2 ezetimibe ENT2END inhibition of UGT enzymes
0	To our knowledge, this is the first case report of ENT1 simvastatin-ezetimibe  ENT1END induced ENT2 liver failure ENT2END that resulted in liver transplantation
0	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and ENT1 status epilepticus ENT1END  in mice.Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and ENT2 deoxycorticosterone ENT2END (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice
0	However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and ENT1 status epilepticus ENT1END was obtained. The steroids also caused a dose-dependent delay in ENT2 NMDA ENT2END (257 mg/kg, s
0	)-induced limbic motor seizures and ENT1 status epilepticus ENT1END (ED50 values, 7.0-18.7 mg/kg, i.p.). The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.). Although the neuroactive steroids were considerably less potent than the ENT2 benzodiazepine ENT2END clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity
0	)-induced limbic motor seizures and ENT1 status epilepticus ENT1END  (ED50 values, 7.0-18.7 mg/kg, i.p.). The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.). Although the neuroactive steroids were considerably less potent than the benzodiazepine ENT2 clonazepam ENT2END in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity
1	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and ENT1 kainic acid ENT1END induced seizures and ENT2 status epilepticus ENT2END in mice, and may be of utility in the treatment of some forms of status epilepticus in humans
0	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and ENT1 status epilepticus ENT1END  in mice.Several structurally related metabolites of ENT2 progesterone ENT2END (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice
0	However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and ENT1 status epilepticus ENT1END  was obtained. The ENT2 steroids ENT2END also caused a dose-dependent delay in NMDA (257 mg/kg, s
1	We conclude that neuroactive steroids are highly effective in protecting against ENT1 pilocarpine  ENT1END  and kainic acid-induced seizures and ENT2 status epilepticus ENT2END in mice, and may be of utility in the treatment of some forms of status epilepticus in humans
0	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic ENT1 seizures  ENT1END  and status epilepticus in mice.Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and ENT2 deoxycorticosterone ENT2END (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice
0	)-induced lethality, but did not completely protect against ENT1 NMDA ENT1END ENT2 seizures ENT2END or lethality
0	Although the neuroactive steroids were considerably less potent than the ENT1 benzodiazepine ENT1END  clonazepam in protecting against pilocarpine ENT2 seizures ENT2END , steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity
0	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for ENT1 seizure ENT1END protection) than ENT2 clonazepam ENT2END , indicating that some neuroactive steroids may have lower relative toxicity
1	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine- and ENT1 kainic acid ENT1END -induced ENT2 seizures ENT2END and status epilepticus in mice, and may be of utility in the treatment of some forms of status epilepticus in humans
0	Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic ENT1 seizures  ENT1END  and status epilepticus in mice.Several structurally related metabolites of ENT2 progesterone ENT2END (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice
0	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine ENT1 seizures ENT1END , ENT2 steroids ENT2END with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity
1	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against ENT1 pilocarpine ENT1END ENT2 seizures ENT2END , steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative toxicity
0	Several structurally related metabolites of progesterone (3 alpha-hydroxy pregnane-20-ones) and deoxycorticosterone ( ENT1 3 alpha-hydroxy pregnane-21-diol-20-ones ENT1END  and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice. Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.). The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.). Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative ENT2 toxicity ENT2END
0	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative ENT1 toxicity  ENT1END . Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s.c.), but did not completely protect against the seizures. However, when a second dose of the steroid was administered 1 hr after the first dose, complete protection from the kainic acid-induced limbic seizures and status epilepticus was obtained. The steroids also caused a dose-dependent delay in ENT2 NMDA ENT2END (257 mg/kg, s
0	Although the neuroactive steroids were considerably less potent than the ENT1 benzodiazepine  ENT1END  clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative ENT2 toxicity ENT2END
0	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than ENT1 clonazepam  ENT1END , indicating that some neuroactive steroids may have lower relative ENT2 toxicity ENT2END
0	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative ENT1 toxicity ENT1END . Steroids with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by ENT2 kainic acid ENT2END (32 mg/kg, s
0	Several structurally related metabolites of progesterone ( ENT1 3 alpha-hydroxy pregnane-20-ones  ENT1END  and deoxycorticosterone (3 alpha-hydroxy pregnane-21-diol-20-ones) and their 3 beta-epimers were evaluated for protective activity against pilocarpine-, kainic acid- and N-methyl-D-aspartate (NMDA)-induced seizures in mice. Steroids with the 3-hydroxy group in the alpha-position and 5-H in the alpha- or beta-configurations were highly effective in protecting against pilocarpine (416 mg/kg, s.c.)-induced limbic motor seizures and status epilepticus (ED50 values, 7.0-18.7 mg/kg, i.p.). The corresponding epimers with the 3-hydroxy group in the beta-position were also effective but less potent (ED50 values, 33.8-63.5, i.p.). Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative ENT2 toxicity ENT2END
0	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative ENT1 toxicity ENT1END . ENT2 Steroids ENT2END with the 5 alpha,3 alpha- or 5 beta,3 alpha-configurations also produced a dose-dependent delay in the onset of limbic seizures induced by kainic acid (32 mg/kg, s
0	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against ENT1 pilocarpine  ENT1END  seizures, steroids with the 5 alpha,3 alpha-configuration had comparable or higher protective index values (TD50 for motor impairment divided by ED50 for seizure protection) than clonazepam, indicating that some neuroactive steroids may have lower relative ENT2 toxicity ENT2END
1	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and ENT1 weight loss ENT1END from ENT2 daunorubicin ENT2END and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin
0	RESULTS: Nontoxic doses of ENT1 dexrazoxane  ENT1END reduced myelosuppression and ENT2 weight loss ENT2END from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin
1	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, ENT1 weight loss ENT1END  nor the in vitro cytotoxicity from ENT2 doxorubicin ENT2END
0	Dexrazoxane (ICRF-187) is recommended for protection against ENT1 anthracycline  ENT1END induced cardiotoxicity. EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays. Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done. RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and ENT2 weight loss ENT2END from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the ENT1 epipodophyllotoxin  ENT1END etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity. EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays. Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done. RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and ENT2 weight loss ENT2END from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin
1	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and ENT1 weight loss ENT1END  from daunorubicin and ENT2 etoposide ENT2END in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin
0	PURPOSE: The anthracyclines ENT1 daunorubicin ENT1END and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and ENT2 cardiac toxicity ENT2END limit their use
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and ENT1 cardiac toxicity ENT1END  limit their use. ENT2 Dexrazoxane ENT2END (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity
0	PURPOSE: The anthracyclines daunorubicin and ENT1 doxorubicin  ENT1END and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and ENT2 cardiac toxicity ENT2END limit their use
0	Dexrazoxane (ICRF-187) is recommended for protection against ENT1 anthracycline ENT1END -induced ENT2 cardiotoxicity ENT2END
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the ENT1 epipodophyllotoxin  ENT1END  etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and ENT2 cardiac toxicity ENT2END limit their use
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin ENT1 etoposide  ENT1END are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and ENT2 cardiac toxicity ENT2END limit their use
0	CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically, the potent antagonism of ENT1 daunorubicin ENT1END activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention. Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane. Clinical trials in patients with brain ENT2 metastases ENT2END combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity
0	Clinical trials in patients with brain ENT1 metastases ENT1END  combining ENT2 dexrazoxane ENT2END and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity
0	CONCLUSION: Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from ENT1 doxorubicin  ENT1END clinically, the potent antagonism of daunorubicin activity raises concern; a possible interference with anticancer efficacy certainly would call for renewed attention. Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane. Clinical trials in patients with brain ENT2 metastases ENT2END combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity
0	Clinical trials in patients with brain ENT1 metastases ENT1END  combining dexrazoxane and high doses of ENT2 etoposide ENT2END is ongoing with the aim of improving efficacy without aggravating hematologic toxicity
0	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from ENT1 daunorubicin ENT1END  and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro ENT2 cytotoxicity ENT2END from doxorubicin
0	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, ENT1 dexrazoxane  ENT1END neither reduced myelosuppression, weight loss, nor the in vitro ENT2 cytotoxicity ENT2END from doxorubicin
0	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro ENT1 cytotoxicity  ENT1END  from ENT2 doxorubicin ENT2END
0	Dexrazoxane (ICRF-187) is recommended for protection against ENT1 anthracycline  ENT1END -induced cardiotoxicity. EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays. Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done. RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro ENT2 cytotoxicity ENT2END from doxorubicin
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the ENT1 epipodophyllotoxin  ENT1END  etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity. EXPERIMENTAL DESIGN: Because of their widespread use, the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays. Likewise, in vivo, B6D2F1 mice were treated with etoposide, daunorubicin, and doxorubicin, with or without dexrazoxane over a wide range of doses: posttreatment, a full hematologic evaluation was done. RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro ENT2 cytotoxicity ENT2END from doxorubicin
0	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and ENT1 etoposide  ENT1END  in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro ENT2 cytotoxicity ENT2END from doxorubicin
1	EXPERIMENTAL DESIGN: Because of their widespread use, the ENT1 hematologic toxicity ENT1END following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, ENT2 daunorubicin ENT2END , and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays
0	EXPERIMENTAL DESIGN: Because of their widespread use, the ENT1 hematologic toxicity ENT1END  following coadministration of ENT2 dexrazoxane ENT2END and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays
1	EXPERIMENTAL DESIGN: Because of their widespread use, the ENT1 hematologic toxicity ENT1END  following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and ENT2 doxorubicin ENT2END +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays
0	Dexrazoxane (ICRF-187) is recommended for protection against ENT1 anthracycline  ENT1END -induced cardiotoxicity. EXPERIMENTAL DESIGN: Because of their widespread use, the ENT2 hematologic toxicity ENT2END following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the ENT1 epipodophyllotoxin  ENT1END  etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, myelosuppression and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against anthracycline-induced cardiotoxicity. EXPERIMENTAL DESIGN: Because of their widespread use, the ENT2 hematologic toxicity ENT2END following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated: Sensitivity of human and murine blood progenitor cells to etoposide, daunorubicin, and doxorubicin +/- dexrazoxane was determined in granulocyte-macrophage colony forming assays
1	Clinical trials in patients with brain metastases combining dexrazoxane and high doses of ENT1 etoposide ENT1END  is ongoing with the aim of improving efficacy without aggravating ENT2 hematologic toxicity ENT2END
0	RESULTS: Nontoxic doses of dexrazoxane reduced ENT1 myelosuppression  ENT1END and weight loss from ENT2 daunorubicin ENT2END and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin
0	RESULTS: Nontoxic doses of ENT1 dexrazoxane  ENT1END  reduced ENT2 myelosuppression ENT2END and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced myelosuppression, weight loss, nor the in vitro cytotoxicity from doxorubicin
0	RESULTS: Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay; however, dexrazoxane neither reduced ENT1 myelosuppression  ENT1END  weight loss, nor the in vitro cytotoxicity from ENT2 doxorubicin ENT2END
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, ENT1 myelosuppression  ENT1END and cardiac toxicity limit their use. Dexrazoxane (ICRF-187) is recommended for protection against ENT2 anthracycline ENT2END -induced cardiotoxicity
0	PURPOSE: The anthracyclines daunorubicin and doxorubicin and the ENT1 epipodophyllotoxin  ENT1END  etoposide are potent DNA cleavage-enhancing drugs that are widely used in clinical oncology; however, ENT2 myelosuppression ENT2END and cardiac toxicity limit their use
0	Dexrazoxane protects against ENT1 myelosuppression  ENT1END  from the DNA cleavage-enhancing drugs ENT2 etoposide ENT2END and daunorubicin but not doxorubicin
0	8 nmol/min/g heart in ENT1 OB  ENT1END , (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ ENT2 ADP ENT2END ratio after doxorubicin administration
1	High ENT1 fat  ENT1END  diet-fed ENT2 obese ENT2END rats are highly sensitive to doxorubicin-induced cardiotoxicity
0	This cardioprotection is accompanied by decreased cardiac oxidative stress and ENT1 triglycerides ENT1END and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces ENT2 obesity ENT2END in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity
0	8 nmol/min/g heart in ENT1 OB ENT1END ), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ENT2 ATP ENT2END levels accompanied by decreased ATP/ADP ratio after doxorubicin administration
0	8 nmol/min/g heart in ENT1 OB ENT1END ), (5) decreased mitochondrial ENT2 AMP ENT2END -alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration
0	High fat diet-fed ENT1 obese  ENT1END  rats are highly sensitive to ENT2 doxorubicin ENT2END -induced cardiotoxicity
0	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and ENT1 doxorubicinol ENT1END (toxic metabolite) in the normal diet-fed (ND) and ENT2 OB ENT2END hearts
0	8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ ENT1 ADP ENT1END  ratio after doxorubicin administration. Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway. In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced ENT2 cardiotoxicity ENT2END by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway
0	High ENT1 fat  ENT1END  diet-fed obese rats are highly sensitive to doxorubicin-induced ENT2 cardiotoxicity ENT2END
0	Recently, we have shown that moderate diet restriction remarkably protects against doxorubicin-induced ENT1 cardiotoxicity  ENT1END  This cardioprotection is accompanied by decreased cardiac oxidative stress and ENT2 triglycerides ENT2END and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway
0	In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced ENT1 cardiotoxicity ENT1END  by substantially downregulating cardiac mitochondrial ENT2 ATP ENT2END generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway
0	8 nmol/min/g heart in OB), (5) decreased mitochondrial ENT1 AMP  ENT1END -alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration. Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK/STAT3 pathway. In conclusion, HFD-induced obese rats are highly sensitized to doxorubicin-induced ENT2 cardiotoxicity ENT2END by substantially downregulating cardiac mitochondrial ATP generation, increasing oxidative stress and downregulating the JAK/STAT3 pathway
0	High fat diet-fed obese rats are highly sensitive to ENT1 doxorubicin  ENT1END -induced ENT2 cardiotoxicity ENT2END
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher ENT1 cardiotoxicity  ENT1END  cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity. Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and ENT2 doxorubicinol ENT2END (toxic metabolite) in the normal diet-fed (ND) and OB hearts
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity  ENT1END  Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts. Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP ENT2 ADP ENT2END ratio after doxorubicin administration
0	In the current study, we investigated whether a physiological intervention by feeding 40% high ENT1 fat  ENT1END diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT2 renal or hepatic toxicity ENT2END
0	This cardioprotection is accompanied by decreased cardiac oxidative stress and ENT1 triglycerides  ENT1END  and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT2 renal or hepatic toxicity ENT2END
0	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ENT1 ATP  ENT1END synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT2 renal or hepatic toxicity ENT2END
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity  ENT1END . Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts. Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial ENT2 AMP ENT2END -alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity ENT1END . ENT2 Doxorubicin ENT2END toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity  ENT1END . Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and ENT2 doxorubicinol ENT2END (toxic metabolite) in the normal diet-fed (ND) and OB hearts
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, ENT1 cardiac dysfunction  ENT1END  lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity. Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts. Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP ENT2 ADP ENT2END ratio after doxorubicin administration
0	In the current study, we investigated whether a physiological intervention by feeding 40% high ENT1 fat  ENT1END  diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, ENT2 cardiac dysfunction ENT2END , lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity
0	This cardioprotection is accompanied by decreased cardiac oxidative stress and ENT1 triglycerides  ENT1END  and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, ENT2 cardiac dysfunction ENT2END , lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity
0	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ENT1 ATP  ENT1END  synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, ENT2 cardiac dysfunction ENT2END , lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, ENT1 cardiac dysfunction  ENT1END , lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity. Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts. Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial ENT2 AMP ENT2END -alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration
1	A LD(10) dose (8 mg ENT1 doxorubicin  ENT1END kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, ENT2 cardiac dysfunction ENT2END , lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, ENT1 cardiac dysfunction  ENT1END , lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity. Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and ENT2 doxorubicinol ENT2END (toxic metabolite) in the normal diet-fed (ND) and OB hearts
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity  ENT1END  Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts. Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial AMP-alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP ENT2 ADP ENT2END ratio after doxorubicin administration
0	In the current study, we investigated whether a physiological intervention by feeding 40% high ENT1 fat  ENT1END  diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT2 renal or hepatic toxicity ENT2END
0	This cardioprotection is accompanied by decreased cardiac oxidative stress and ENT1 triglycerides  ENT1END  and increased cardiac fatty-acid oxidation, ATP synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT2 renal or hepatic toxicity ENT2END
0	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty-acid oxidation, ENT1 ATP  ENT1END  synthesis, and upregulated JAK/STAT3 pathway. In the current study, we investigated whether a physiological intervention by feeding 40% high fat diet (HFD), which induces obesity in male Sprague-Dawley rats (250-275 g), sensitizes to doxorubicin-induced cardiotoxicity. A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT2 renal or hepatic toxicity ENT2END
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity  ENT1END . Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts. Mechanistic studies revealed that OB rats are sensitized due to: (1) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3, (2) downregulation of cardiac peroxisome proliferators activated receptor-alpha, (3) decreased plasma adiponectin levels, (4) decreased cardiac fatty-acid oxidation (666.9+/-14.0 nmol/min/g heart in ND versus 400.2+/-11.8 nmol/min/g heart in OB), (5) decreased mitochondrial ENT2 AMP ENT2END -alpha2 protein kinase, and (6) 86% drop in cardiac ATP levels accompanied by decreased ATP/ADP ratio after doxorubicin administration
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity  ENT1END . ENT2 Doxorubicin ENT2END toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol (toxic metabolite) in the normal diet-fed (ND) and OB hearts
0	A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant ENT1 renal or hepatic toxicity  ENT1END . Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and ENT2 doxorubicinol ENT2END (toxic metabolite) in the normal diet-fed (ND) and OB hearts
0	Torsade de pointes can be treated when recognized early, possibly without discontinuation of ENT1 pentamidine ENT1END  When ENT2 QTc interval prolongation ENT2END is observed, early magnesium supplementation is advocated
0	When ENT1 QTc interval prolongation ENT1END  is observed, early ENT2 magnesium ENT2END supplementation is advocated
0	ENT1 Pentamidine ENT1END induced torsade de pointes may be related to serum magnesium levels and ENT2 hypomagnesemia ENT2END may synergistically induce torsade
0	Pentamidine-induced torsade de pointes may be related to serum ENT1 magnesium  ENT1END levels and ENT2 hypomagnesemia ENT2END may synergistically induce torsade
1	ENT1 Pentamidine ENT1END -induced ENT2 torsade de pointes ENT2END may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade
0	Pentamidine-induced ENT1 torsade de pointes  ENT1END  may be related to serum ENT2 magnesium ENT2END levels and hypomagnesemia may synergistically induce torsade
0	Case report: ENT1 pentamidine  ENT1END  and polymorphic ENT2 ventricular tachycardia ENT2END revisited
0	Pentamidine isethionate has been associated with ENT1 ventricular tachyarrhythmias  ENT1END  including torsade de pointes. This article reports two cases of this complication and reviews all reported cases to date. Pentamidine-induced torsade de pointes may be related to serum ENT2 magnesium ENT2END levels and hypomagnesemia may synergistically induce torsade
0	ENT1 Delirium ENT1END  which may be induced by tricyclic drug therapy in the elderly, can be caused by tricyclics with low anticholinergic potency. Therapeutic ranges for ENT2 antidepressants ENT2END that have been derived from general adult population studies may not be appropriate for the elderly
1	ENT1 Desipramine  ENT1END -induced ENT2 delirium ENT2END at "subtherapeutic" concentrations: a case report
1	ENT1 Triazolam  ENT1END -induced brief episodes of secondary ENT2 mania ENT2END in a depressed patient
0	Triazolam-induced brief episodes of secondary mania in a ENT1 depressed ENT1END  patient.Large doses of ENT2 triazolam ENT2END repeatedly induced brief episodes of mania in a depressed elderly woman
0	Features of organic mental disorder ( ENT1 delirium ENT1END  were not present. Manic excitement was coincident with the duration of action of ENT2 triazolam ENT2END
0	Large doses of ENT1 triazolam ENT1END  repeatedly induced brief episodes of mania in a depressed elderly woman. Features of ENT2 organic mental disorder ENT2END (delirium) were not present
0	Twenty-three h postoperatively he developed a brief self-limited ENT1 seizure ENT1END  Both plasma pethidine and ENT2 norpethidine ENT2END were elevated in the range associated with clinical manifestations of central nervous system excitation
1	ENT1 Pethidine  ENT1END -associated ENT2 seizure ENT2END in a healthy adolescent receiving pethidine for postoperative pain control
0	Both plasma pethidine and ENT1 norpethidine ENT1END  were elevated in the range associated with clinical manifestations of central nervous system excitation. No other risk factors for CNS ENT2 toxicity ENT2END were identified
0	No other risk factors for CNS ENT1 toxicity ENT1END  were identified. This method allowed frequent self-dosing of ENT2 pethidine ENT2END at short time intervals and rapid accumulation of pethidine and norpethidine
0	A healthy 17-year-old male received standard intermittent doses of pethidine via a patient-controlled analgesia (PCA) pump for management of ENT1 postoperative pain  ENT1END control. Twenty-three h postoperatively he developed a brief self-limited seizure. Both plasma pethidine and ENT2 norpethidine ENT2END were elevated in the range associated with clinical manifestations of central nervous system excitation
0	Pethidine-associated seizure in a healthy adolescent receiving ENT1 pethidine  ENT1END  for ENT2 postoperative pain ENT2END control
0	METHODS: We performed a case control study of ENT1 heart failure  ENT1END patients treated with spironolactone in our clinical practice. Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency ( ENT2 Cr ENT2END >or=2
0	METHODS: We performed a case control study of ENT1 heart failure ENT1END  patients treated with spironolactone in our clinical practice. Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case. Clinical characteristics, medications, and serum chemistries at baseline and follow-up time periods were compared. RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34). Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134). Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum ENT2 creatinine ENT2END , required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls
0	METHODS: We performed a case control study of ENT1 heart failure  ENT1END  patients treated with spironolactone in our clinical practice. Cases were patients who developed hyperkalemia ( ENT2 K ENT2END (+) >5
0	METHODS: We performed a case control study of ENT1 heart failure ENT1END  patients treated with spironolactone in our clinical practice. Cases were patients who developed hyperkalemia (K(+) >5.0 mEq/L) or renal insufficiency (Cr >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case. Clinical characteristics, medications, and serum chemistries at baseline and follow-up time periods were compared. RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34). Patients who developed hyperkalemia were older and more likely to have diabetes, had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134). Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with ENT2 thiazide ENT2END diuretics than controls
0	BACKGROUND: A previous randomized controlled trial evaluating the use of ENT1 spironolactone ENT1END in ENT2 heart failure ENT2END patients reported a low risk of hyperkalemia (2%) and renal insufficiency (0%)
0	Cases were patients who developed ENT1 hyperkalemia ENT1END (K(+) >5.0 mEq/L) or renal insufficiency ENT2 Cr ENT2END >or=2
0	Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum ENT1 creatinine ENT1END , required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls. CONCLUSIONS: Spironolactone-induced ENT2 hyperkalemia ENT2END and renal insufficiency are more common in our clinical experience than reported previously
0	Cases were patients who developed ENT1 hyperkalemia ENT1END  ENT2 K ENT2END (+) >5
0	Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with ENT1 thiazide  ENT1END  diuretics than controls. CONCLUSIONS: Spironolactone-induced ENT2 hyperkalemia ENT2END and renal insufficiency are more common in our clinical experience than reported previously
1	2%) required discontinuation of ENT1 spironolactone ENT1END due to ENT2 hyperkalemia ENT2END (n = 33) or renal failure (n = 34)
0	0 mEq/L) or renal insufficiency ( ENT1 Cr ENT1END  >or=2.5 mg/dL), and they were compared to 2 randomly selected controls per case. Clinical characteristics, medications, and serum chemistries at baseline and follow-up time periods were compared. RESULTS: Sixty-seven of 926 patients (7.2%) required discontinuation of spironolactone due to hyperkalemia (n = 33) or renal failure (n = 34). Patients who developed hyperkalemia were older and more likely to have ENT2 diabetes ENT2END , had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134)
0	Patients who developed hyperkalemia were older and more likely to have ENT1 diabetes  ENT1END , had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134). Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum ENT2 creatinine ENT2END , required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls
0	Patients who developed hyperkalemia were older and more likely to have ENT1 diabetes ENT1END , had higher baseline serum ENT2 potassium ENT2END levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134)
0	Patients who developed hyperkalemia were older and more likely to have ENT1 diabetes  ENT1END , had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134). Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with ENT2 thiazide ENT2END diuretics than controls
0	2%) required discontinuation of ENT1 spironolactone  ENT1END  due to hyperkalemia (n = 33) or renal failure (n = 34). Patients who developed hyperkalemia were older and more likely to have ENT2 diabetes ENT2END , had higher baseline serum potassium levels and lower baseline potassium supplement doses, and were more likely to be treated with beta-blockers than controls (n = 134)
0	0 mEq/L) or ENT1 renal insufficiency ENT1END ENT2 Cr ENT2END >or=2
0	Patients who developed ENT1 renal insufficiency  ENT1END had lower baseline body weight and higher baseline serum ENT2 creatinine ENT2END , required higher doses of loop diuretics, and were more likely to be treated with thiazide diuretics than controls
0	Cases were patients who developed hyperkalemia ( ENT1 K  ENT1END (+) >5.0 mEq/L) or ENT2 renal insufficiency ENT2END (Cr >or=2
0	Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine, required higher doses of loop diuretics, and were more likely to be treated with ENT1 thiazide ENT1END  diuretics than controls. CONCLUSIONS: Spironolactone-induced hyperkalemia and ENT2 renal insufficiency ENT2END are more common in our clinical experience than reported previously
1	ENT1 Spironolactone  ENT1END -induced ENT2 renal insufficiency ENT2END and hyperkalemia in patients with heart failure
0	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of ENT1 difluoromethylornithine  ENT1END  and sulindac for prevention of sporadic ENT2 colorectal adenomas ENT2END
0	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and ENT1 sulindac  ENT1END  for prevention of sporadic ENT2 colorectal adenomas ENT2END
0	A phase III clinical trial assessed the recurrence of ENT1 adenomatous polyps ENT1END after treatment for 36 months with ENT2 difluoromethylornithine ENT2END (DFMO) plus sulindac or matched placebos
0	A phase III clinical trial assessed the recurrence of ENT1 adenomatous polyps ENT1END  after treatment for 36 months with difluoromethylornithine (DFMO) plus ENT2 sulindac ENT2END or matched placebos
0	Temporary hearing loss is a known ENT1 toxicity ENT1END of treatment with ENT2 DFMO ENT2END , thus a comprehensive approach was developed to analyze serial air conduction audiograms
0	A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus ENT1 sulindac  ENT1END  or matched placebos. Temporary hearing loss is a known ENT2 toxicity ENT2END of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms
0	There was no significant difference in the proportion of subjects in the ENT1 DFMO ENT1END plus sulindac group who experienced clinically significant hearing loss compared with the placebo group. The estimated attributable risk of ENT2 ototoxicity ENT2END from exposure to the drug is 8
0	There was no significant difference in the proportion of subjects in the DFMO plus ENT1 sulindac  ENT1END group who experienced clinically significant hearing loss compared with the placebo group. The estimated attributable risk of ENT2 ototoxicity ENT2END from exposure to the drug is 8
0	Temporary ENT1 hearing loss  ENT1END is a known toxicity of treatment with ENT2 DFMO ENT2END , thus a comprehensive approach was developed to analyze serial air conduction audiograms
1	A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine (DFMO) plus ENT1 sulindac  ENT1END  or matched placebos. Temporary ENT2 hearing loss ENT2END is a known toxicity of treatment with DFMO, thus a comprehensive approach was developed to analyze serial air conduction audiograms
0	Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and ENT1 benzylthiouracil ENT1END .OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs. METHODS: Retrospective review of medical records of 236 patients with ENT2 hyperthyroidism ENT2END admitted in our department (in- or out-patients) from 1986 to 1992
0	Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between ENT1 carbimazole  ENT1END  and benzylthiouracil.OBJECTIVE: This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs. METHODS: Retrospective review of medical records of 236 patients with ENT2 hyperthyroidism ENT2END admitted in our department (in- or out-patients) from 1986 to 1992
0	One of the latter two patients further experienced a cytolytic ENT1 hepatitis ENT1END which appeared after ENT2 Benzylthiouracil ENT2END (Basd  ne) had replaced carbimazole
1	Two others had a mixed (cholestatic and cytolytic) ENT1 hepatitis ENT1END following ENT2 carbimazole ENT2END
0	One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil ( ENT1 Basd  ne ENT1END  had replaced carbimazole. Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug, while biliary, viral and immunological searches were negative. Only 2 patients of our retrospective study experienced a mild or severe ENT2 neutropenia ENT2END
0	One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil (Basd  ne) had replaced ENT1 carbimazole  ENT1END  Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug, while biliary, viral and immunological searches were negative. Only 2 patients of our retrospective study experienced a mild or severe ENT2 neutropenia ENT2END
0	Two others had a mixed ( ENT1 cholestatic  ENT1END and cytolytic) hepatitis following carbimazole. One of the latter two patients further experienced a cytolytic hepatitis which appeared after ENT2 Benzylthiouracil ENT2END (Basd  ne) had replaced carbimazole
1	Two patients had a ENT1 cholestatic hepatitis ENT1END induced by ENT2 carbimazole ENT2END (N  omercazole)
1	Seven out of 12 subjects experienced ENT1 headache ENT1END of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of ENT2 CLZ ENT2END
1	Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; ENT1 BPT  ENT1END  40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14. At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed. Throughout the observation period, no significant alteration in vital signs was observed. Seven out of 12 subjects experienced ENT2 headache ENT2END of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ
0	At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet ENT1 cAMP  ENT1END were performed. Throughout the observation period, no significant alteration in vital signs was observed. Seven out of 12 subjects experienced ENT2 headache ENT2END of a short duration accompanying facial flush in one and nausea in one, especially after ingestion of CLZ
1	Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and ENT1 nausea  ENT1END in one, especially after ingestion of ENT2 CLZ ENT2END
1	Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; ENT1 BPT  ENT1END : 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14. At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed. Throughout the observation period, no significant alteration in vital signs was observed. Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and ENT2 nausea ENT2END in one, especially after ingestion of CLZ
0	Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and ENT1 nausea ENT1END  in one, especially after ingestion of CLZ. All of these symptoms, probably caused by the vasodilating effect of the two agents, were of mild degree and no special treatment was required. Intraplatelet ENT2 cAMP ENT2END content was gradually but significantly increased to 9
1	Seven out of 12 subjects experienced headache of a short duration accompanying ENT1 facial flush  ENT1END in one and nausea in one, especially after ingestion of ENT2 CLZ ENT2END
1	Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; ENT1 BPT  ENT1END : 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14. At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed. Throughout the observation period, no significant alteration in vital signs was observed. Seven out of 12 subjects experienced headache of a short duration accompanying ENT2 facial flush ENT2END in one and nausea in one, especially after ingestion of CLZ
0	At various time intervals, physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet ENT1 cAMP  ENT1END  were performed. Throughout the observation period, no significant alteration in vital signs was observed. Seven out of 12 subjects experienced headache of a short duration accompanying ENT2 facial flush ENT2END in one and nausea in one, especially after ingestion of CLZ
0	from day 7 to 14, ENT1 CLZ ENT1END  200 mg t.i.d. from day 3 to 14. At various time intervals, physical examination and blood collection for ex vivo ENT2 platelet aggregation ENT2END and determination of intraplatelet cAMP were performed
0	Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; ENT1 BPT  ENT1END : 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14. At various time intervals, physical examination and blood collection for ex vivo ENT2 platelet aggregation ENT2END and determination of intraplatelet cAMP were performed
0	At various time intervals, physical examination and blood collection for ex vivo ENT1 platelet aggregation  ENT1END  and determination of intraplatelet ENT2 cAMP ENT2END were performed
0	Among various oral antiplatelets, a combination of a novel ENT1 prostacyclin  ENT1END analogue beraprost (BPT) and a potent phosphodiesterase inhibitor cilostazol (CLZ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP (cyclic adenosine 3',5'-monophosphate). Thereby, a clinical study of the combined administration of the two agents was attempted. Twelve healthy volunteers were assigned to take BPT/CLZ in the following schedule; BPT: 40 micrograms at day 1 and 120 micrograms t.i.d. from day 7 to 14, CLZ: 200 mg t.i.d. from day 3 to 14. At various time intervals, physical examination and blood collection for ex vivo ENT2 platelet aggregation ENT2END and determination of intraplatelet cAMP were performed
0	BACKGROUND: Current animal models of obsessive-compulsive disorder (OCD) typically involve acute, drug-induced symptom provocation or a genetic association with stereotypies or ENT1 anxiety ENT1END  None of these current models demonstrate multiple OCD-like behaviors. METHODS: Neonatal rats were treated with the tricyclic ENT2 antidepressant ENT2END clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood
1	RESULTS: ENT1 Clomipramine ENT1END exposure in immature rats produced significant behavioral and biochemical changes that include enhanced ENT2 anxiety ENT2END (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e
0	RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced ENT1 anxiety ENT1END  (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction. ENT2 Dopamine ENT2END D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex
0	RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced ENT1 anxiety ENT1END  (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction. Dopamine D2 receptors were elevated in the striatum, whereas ENT2 serotonin ENT2END 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex
0	METHODS: Neonatal rats were treated with the tricyclic ENT1 antidepressant ENT1END  clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood. RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working ENT2 memory impairment ENT2END (e
1	RESULTS: ENT1 Clomipramine  ENT1END  exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working ENT2 memory impairment ENT2END (e
0	RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working ENT1 memory impairment  ENT1END  (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction. ENT2 Dopamine ENT2END D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex
0	RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working ENT1 memory impairment  ENT1END  (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction. Dopamine D2 receptors were elevated in the striatum, whereas ENT2 serotonin ENT2END 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex
0	METHODS: Neonatal rats were treated with the tricyclic ENT1 antidepressant ENT1END  clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood. RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction. Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex. CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals. Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD. This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other ENT2 psychiatric disorders ENT2END
0	RESULTS: ENT1 Clomipramine  ENT1END  exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), hoarding, and corticostriatal dysfunction. Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex. CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals. Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD. This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other ENT2 psychiatric disorders ENT2END
0	ENT1 Dopamine  ENT1END  D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex. CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals. Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD. This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other ENT2 psychiatric disorders ENT2END
0	Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not ENT1 serotonin  ENT1END 1A, receptors were elevated in the orbital frontal cortex. CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an OCD-like profile in animals. Moreover, these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD. This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease-like systems permanently, which could have implications for current and future therapeutic strategies for this and other ENT2 psychiatric disorders ENT2END
0	None of these current models demonstrate multiple ENT1 OCD  ENT1END like behaviors. METHODS: Neonatal rats were treated with the tricyclic ENT2 antidepressant ENT2END clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood
0	None of these current models demonstrate multiple ENT1 OCD ENT1END -like behaviors. METHODS: Neonatal rats were treated with the tricyclic antidepressant ENT2 clomipramine ENT2END or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood
0	ENT1 Dopamine ENT1END  D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex. CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an ENT2 OCD ENT2END -like profile in animals
0	Dopamine D2 receptors were elevated in the striatum, whereas serotonin 2C, but not ENT1 serotonin  ENT1END  1A, receptors were elevated in the orbital frontal cortex. CONCLUSIONS: This is the first demonstration of multiple symptoms consistent with an ENT2 OCD ENT2END -like profile in animals
0	METHODS: Neonatal rats were treated with the tricyclic ENT1 antidepressant ENT1END  clomipramine or vehicle between days 9 and 16 twice daily and behaviorally tested in adulthood. RESULTS: Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), ENT2 hoarding ENT2END , and corticostriatal dysfunction
1	RESULTS: ENT1 Clomipramine  ENT1END  exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety (elevated plus maze and marble burying), behavioral inflexibility (perseveration in the spontaneous alternation task and impaired reversal learning), working memory impairment (e.g., win-shift paradigm), ENT2 hoarding ENT2END , and corticostriatal dysfunction
0	, win-shift paradigm), ENT1 hoarding  ENT1END , and corticostriatal dysfunction. ENT2 Dopamine ENT2END D2 receptors were elevated in the striatum, whereas serotonin 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex
0	, win-shift paradigm), ENT1 hoarding  ENT1END , and corticostriatal dysfunction. Dopamine D2 receptors were elevated in the striatum, whereas ENT2 serotonin ENT2END 2C, but not serotonin 1A, receptors were elevated in the orbital frontal cortex
0	During the SNP infusion the control animals demonstrated a progressive ENT1 increase in blood pressure ENT1END to 61 torr, whereas the ENT2 saralasin ENT2END -treated animals showed no change
0	Rebound ENT1 hypertensive  ENT1END  after sodium nitroprusside prevented by saralasin in rats.The role of the renin-- ENT2 angiotensin ENT2END system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated
0	Rebound ENT1 hypertensive  ENT1END  after ENT2 sodium nitroprusside ENT2END prevented by saralasin in rats
0	Rebound ENT1 hypertensive ENT1END  after sodium nitroprusside prevented by saralasin in rats.The role of the renin--angiotensin system in the maintenance of blood pressure during ENT2 halothane ENT2END anesthesia and sodium nitroprusside (SNP)-induced hypotension was evaluated
0	A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of ENT1 angiotensin II  ENT1END  throughout the experimental period. In each group, SNP infusion resulted in an initial decrease in blood pressure from 86 torr and 83 torr, respectively, to 48 torr. During the SNP infusion the control animals demonstrated a progressive ENT2 increase in blood pressure ENT2END to 61 torr, whereas the saralasin-treated animals showed no change
0	This study indicates that with stable halothane anesthesia, the partial recovery of blood pressure during SNP infusion and the post-SNP rebound of blood pressure can be completely blocked by ENT1 saralasin ENT1END  This demonstrates the participation of the renin--angiotensin system in antagonizing the combined ENT2 hypotensive ENT2END effects of halothane and SNP
0	This demonstrates the participation of the renin-- ENT1 angiotensin  ENT1END system in antagonizing the combined ENT2 hypotensive ENT2END effects of halothane and SNP
1	The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( ENT1 SNP ENT1END -induced ENT2 hypotension ENT2END was evaluated
1	This demonstrates the participation of the renin--angiotensin system in antagonizing the combined ENT1 hypotensive ENT1END  effects of ENT2 halothane ENT2END and SNP
0	The role of the renin--angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside (SNP)-induced ENT1 hypotension  ENT1END  was evaluated. Control rats received halothane anesthesia (1 MAC) for one hour, followed by SNP infusion, 40 microgram/kg/min, for 30 min, followed by a 30-min recovery period. A second group of rats was treated identically and, in addition, received an infusion of saralasin (a competitive inhibitor of ENT2 angiotensin II ENT2END ) throughout the experimental period
0	This article describes two ENT1 critically ill ENT1END patients in whom transient episodes of hypotension reproducibly developed after administration of ENT2 acetaminophen ENT2END
0	The potential for ENT1 acetaminophen ENT1END to produce ENT2 cardiovascular toxicities ENT2END is very low
0	This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of ENT1 acetaminophen ENT1END . Other symptoms of ENT2 allergic reactions ENT2END were not clinically detectable
0	However, ENT1 acetaminophen ENT1END has been demonstrated to produce symptoms of ENT2 anaphylaxis ENT2END , including hypotension, in sensitive individuals
1	ENT1 Acetaminophen  ENT1END -induced ENT2 hypotension ENT2END
1	Two cases of postinfarction ENT1 ventricular septal rupture ENT1END in patients on long-term ENT2 steroid ENT2END therapy are presented and the favourable outcome in both cases described
1	In the NASCIS, there was no mention regarding the possibility of acute corticosteroid ENT1 myopathy ENT1END that high-dose ENT2 methylprednisolone ENT2END may cause
0	Further, ENT1 steroid ENT1END ENT2 myopathy ENT2END recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury
0	In the NASCIS, there was no mention regarding the possibility of acute ENT1 corticosteroid ENT1END ENT2 myopathy ENT2END that high-dose methylprednisolone may cause
0	Further, steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that ENT1 methylprednisolone ENT1END offers to the ENT2 spinal cord injury ENT2END
0	We hypothesize that it may cause some damage to the muscle of ENT1 spinal cord injury  ENT1END patients. Further, ENT2 steroid ENT2END myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy, instead of any protection that methylprednisolone offers to the spinal cord injury
0	Because of the National Acute Spinal Cord Injury Studies (NASCIS), high-dose methylprednisolone became the standard of care for the acute ENT1 spinal cord injury  ENT1END  In the NASCIS, there was no mention regarding the possibility of acute ENT2 corticosteroid ENT2END myopathy that high-dose methylprednisolone may cause
1	Hepatic adenomas and focal nodular hyperplasia of the liver in young women on ENT1 oral contraceptives ENT1END : case reports.Two cases of hepatic ENT2 adenoma ENT2END and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives, are reported
1	Hepatic adenomas and ENT1 focal nodular hyperplasia  ENT1END  of the liver in young women on ENT2 oral contraceptives ENT2END : case reports
1	Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced ENT1 nephrotic syndrome  ENT1END . ENT2 Doxorubicin ENT2END -induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis
0	Plasma ENT1 aldosterone ENT1END levels increased in ENT2 nephrotic ENT2END mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice
0	During the course of ENT1 nephrotic syndrome ENT1END  serum ENT2 urea ENT2END concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs
0	Serum- and glucocorticoid-inducible kinase 1 in doxorubicin-induced ENT1 nephrotic syndrome ENT1END .Doxorubicin-induced nephropathy leads to epithelial ENT2 sodium ENT2END channel (ENaC)-dependent volume retention and renal fibrosis
0	ENT1 Doxorubicin ENT1END treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body ENT2 weight gain ENT2END in sgk1(+/+) compared with sgk1(-/-) mice (+6
0	Plasma ENT1 aldosterone  ENT1END  levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body ENT2 weight gain ENT2END in sgk1(+/+) compared with sgk1(-/-) mice (+6
0	Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body ENT1 weight gain  ENT1END  in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum ENT2 urea ENT2END concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs
0	Urinary ENT1 sodium  ENT1END excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body ENT2 weight gain ENT2END in sgk1(+/+) compared with sgk1(-/-) mice (+6
0	The present study was performed to elucidate the role of SGK1 in the volume retention and ENT1 fibrosis ENT1END during nephrotic syndrome. To this end, ENT2 doxorubicin ENT2END (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))
0	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent volume retention and renal ENT1 fibrosis ENT1END  The ENT2 aldosterone ENT2END -sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess
0	During the course of nephrotic syndrome, serum ENT1 urea ENT1END  concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice). In conclusion, gene-targeted mice lacking SGK1 showed blunted volume retention, yet were not protected against renal ENT2 fibrosis ENT2END during experimental nephrotic syndrome
0	Doxorubicin-induced nephropathy leads to epithelial ENT1 sodium  ENT1END  channel (ENaC)-dependent volume retention and renal ENT2 fibrosis ENT2END
1	ENT1 Doxorubicin ENT1END  treatment resulted in heavy ENT2 proteinuria ENT2END (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes
0	Doxorubicin treatment resulted in heavy ENT1 proteinuria  ENT1END  (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes. Plasma ENT2 aldosterone ENT2END levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice
0	Doxorubicin treatment resulted in heavy ENT1 proteinuria  ENT1END  (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum ENT2 urea ENT2END concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs
0	Doxorubicin treatment resulted in heavy ENT1 proteinuria  ENT1END  (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary ENT2 sodium ENT2END excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6
1	ENT1 Doxorubicin ENT1END  treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ENT2 ascites ENT2END , lipidemia, and hypoalbuminemia in both genotypes
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ENT1 ascites  ENT1END , lipidemia, and hypoalbuminemia in both genotypes. Plasma ENT2 aldosterone ENT2END levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ENT1 ascites  ENT1END , lipidemia, and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum ENT2 urea ENT2END concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ENT1 ascites  ENT1END , lipidemia, and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary ENT2 sodium ENT2END excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6
1	ENT1 Doxorubicin ENT1END  treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, ENT2 lipidemia ENT2END , and hypoalbuminemia in both genotypes
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, ENT1 lipidemia  ENT1END , and hypoalbuminemia in both genotypes. Plasma ENT2 aldosterone ENT2END levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, ENT1 lipidemia  ENT1END , and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum ENT2 urea ENT2END concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, ENT1 lipidemia  ENT1END , and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary ENT2 sodium ENT2END excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6
1	ENT1 Doxorubicin ENT1END  treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and ENT2 hypoalbuminemia ENT2END in both genotypes
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and ENT1 hypoalbuminemia  ENT1END  in both genotypes. Plasma ENT2 aldosterone ENT2END levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and ENT1 hypoalbuminemia  ENT1END  in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum ENT2 urea ENT2END concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs
0	Doxorubicin treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and ENT1 hypoalbuminemia  ENT1END  in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary ENT2 sodium ENT2END excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6
0	ENT1 Doxorubicin ENT1END -induced ENT2 nephropathy ENT2END leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis
0	Doxorubicin-induced ENT1 nephropathy  ENT1END  leads to epithelial sodium channel (ENaC)-dependent volume retention and renal fibrosis. The ENT2 aldosterone ENT2END -sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess
0	Doxorubicin-induced ENT1 nephropathy  ENT1END  leads to epithelial ENT2 sodium ENT2END channel (ENaC)-dependent volume retention and renal fibrosis
0	ENT1 Doxorubicin ENT1END  treatment resulted in heavy proteinuria (>100 mg protein/mg crea) in 15/44 of sgk1(+/+) and 15/44 of sgk1(-/-) mice leading to severe nephrotic syndrome with ascites, lipidemia, and hypoalbuminemia in both genotypes. Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to ENT2 uremia ENT2END and a reduced median survival in sgk1(-/-) mice (29 vs
0	Plasma ENT1 aldosterone  ENT1END  levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1(+/+) mice. Urinary sodium excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to ENT2 uremia ENT2END and a reduced median survival in sgk1(-/-) mice (29 vs
0	During the course of nephrotic syndrome, serum ENT1 urea  ENT1END  concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to ENT2 uremia ENT2END and a reduced median survival in sgk1(-/-) mice (29 vs
0	Urinary ENT1 sodium  ENT1END  excretion reached signficantly lower values in sgk1(+/+) mice (15 +/- 5 mumol/mg crea) than in sgk1(-/-) mice (35 +/- 5 mumol/mg crea) and was associated with a significantly higher body weight gain in sgk1(+/+) compared with sgk1(-/-) mice (+6.6 +/- 0.7 vs. +4.1 +/- 0.8 g). During the course of nephrotic syndrome, serum urea concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to ENT2 uremia ENT2END and a reduced median survival in sgk1(-/-) mice (29 vs
0	The present study was performed to elucidate the role of SGK1 in the ENT1 volume retention  ENT1END and fibrosis during nephrotic syndrome. To this end, ENT2 doxorubicin ENT2END (15 mug/g body wt) was injected intravenously into gene-targeted mice lacking SGK1 (sgk1(-/-)) and their wild-type littermates (sgk1(+/+))
0	Doxorubicin-induced nephropathy leads to epithelial sodium channel (ENaC)-dependent ENT1 volume retention  ENT1END and renal fibrosis. The ENT2 aldosterone ENT2END -sensitive serum- and glucocorticoid-inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess
0	During the course of nephrotic syndrome, serum ENT1 urea ENT1END  concentrations increased significantly faster in sgk1(-/-) mice than in sgk1(+/+) mice leading to uremia and a reduced median survival in sgk1(-/-) mice (29 vs. 40 days in sgk1(+/+) mice). In conclusion, gene-targeted mice lacking SGK1 showed blunted ENT2 volume retention ENT2END , yet were not protected against renal fibrosis during experimental nephrotic syndrome
0	Doxorubicin-induced nephropathy leads to epithelial ENT1 sodium  ENT1END  channel (ENaC)-dependent ENT2 volume retention ENT2END and renal fibrosis
1	The Calcineurin-inhibitor Induced ENT1 Pain ENT1END Syndrome (CIPS) is a rare but severe side effect of ENT2 cyclosporine ENT2END or tacrolimus and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans
1	The Calcineurin-inhibitor Induced ENT1 Pain ENT1END  Syndrome (CIPS) is a rare but severe side effect of cyclosporine or ENT2 tacrolimus ENT2END and is accurately diagnosed by its typical presentation, magnetic resonance imaging and bone scans
0	The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT1 calcium ENT1END channel blockers led to relief of ENT2 pain ENT2END
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, ENT1 polyneuropathy ENT1END  Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, ENT1 polyneuropathy ENT1END , Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, ENT1 polyneuropathy  ENT1END , Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, ENT1 stress fractures  ENT1END  and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, ENT1 stress fractures  ENT1END , and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, ENT1 stress fractures  ENT1END , and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, ENT1 Morton's neuralgia  ENT1END  gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, ENT1 Morton's neuralgia  ENT1END , gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, ENT1 Morton's neuralgia  ENT1END , gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, ENT1 avascular necrosis  ENT1END  intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, ENT1 avascular necrosis  ENT1END , intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, ENT1 avascular necrosis  ENT1END , intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic ENT1 foot deformities  ENT1END  stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic ENT1 foot deformities  ENT1END , stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic ENT1 foot deformities  ENT1END , stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, ENT1 osteoporosis  ENT1END  avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, ENT1 osteoporosis  ENT1END , avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, ENT1 osteoporosis  ENT1END , avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, ENT1 intermittent claudication  ENT1END  orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, ENT1 intermittent claudication  ENT1END , orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, ENT1 intermittent claudication  ENT1END , orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and ENT1 hyperparathyroidism  ENT1END  The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and ENT1 hyperparathyroidism  ENT1END . The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and ENT1 hyperparathyroidism  ENT1END . The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like ENT1 reflex sympathetic dystrophy  ENT1END  polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like ENT1 reflex sympathetic dystrophy  ENT1END , polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like ENT1 reflex sympathetic dystrophy  ENT1END , polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, ENT1 gout  ENT1END  osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, ENT1 gout  ENT1END , osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, ENT1 gout  ENT1END , osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
1	Magnetic resonance imaging demonstrated ENT1 bone marrow oedema  ENT1END in the painful bones. Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
1	Magnetic resonance imaging demonstrated ENT1 bone marrow oedema  ENT1END  in the painful bones. Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Magnetic resonance imaging demonstrated ENT1 bone marrow oedema  ENT1END  in the painful bones. Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
1	Magnetic resonance imaging demonstrated ENT1 bone marrow oedema  ENT1END in the painful bones. Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of ENT2 cyclosporine ENT2END - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain
1	Magnetic resonance imaging demonstrated ENT1 bone marrow oedema  ENT1END  in the painful bones. Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or ENT2 tacrolimus ENT2END trough levels and the administration of calcium channel blockers led to relief of pain
0	Magnetic resonance imaging demonstrated ENT1 bone marrow oedema  ENT1END  in the painful bones. Pain was not explained by other diseases causing foot pain, like reflex sympathetic dystrophy, polyneuropathy, Morton's neuralgia, gout, osteoporosis, avascular necrosis, intermittent claudication, orthopaedic foot deformities, stress fractures, and hyperparathyroidism. The reduction of cyclosporine- or tacrolimus trough levels and the administration of ENT2 calcium ENT2END channel blockers led to relief of pain
0	Predictors of decreased renal function in patients with ENT1 heart failure  ENT1END  during ENT2 angiotensin ENT2END -converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function
0	METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of ENT1 enalapril ENT1END for the treatment of ENT2 CHF ENT2END
0	METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of ENT1 CHF ENT1END . There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days. Decreased renal function was defined as a rise in serum ENT2 creatinine ENT2END >/=0
0	CONCLUSIONS: Enalapril use caused a 33% increase in the risk of decreased renal function in patients with ENT1 CHF ENT1END  ENT2 Diuretic ENT2END use and advanced age increased this risk
0	Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of ENT1 left ventricular dysfunction ENT1END  (SOLVD)BACKGROUND: Although ENT2 angiotensin ENT2END -converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function
0	METHOD: We analyzed data from the Studies of ENT1 Left Ventricular Dysfunction  ENT1END (SOLVD), a randomized, double-blind, placebo-controlled trial of ENT2 enalapril ENT2END for the treatment of CHF
0	METHOD: We analyzed data from the Studies of ENT1 Left Ventricular Dysfunction  ENT1END  (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF. There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days. Decreased renal function was defined as a rise in serum ENT2 creatinine ENT2END >/=0
0	METHOD: We analyzed data from the Studies of ENT1 Left Ventricular Dysfunction ENT1END  (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF. There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days. Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline. We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, diabetes, and use of antiplatelet, ENT2 diuretic ENT2END , and beta-blocker therapy
0	OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed ENT1 angiotensin ENT1END converting enzyme inhibitor therapy. METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF. There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days. Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline. We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of ENT2 hypertension ENT2END , diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy
0	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of ENT1 hypertension ENT1END , diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy. RESULTS: Patients randomly assigned to ENT2 enalapril ENT2END had a 33% greater likelihood of decreased renal function than controls (P =
0	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline ENT1 creatinine  ENT1END  low systolic blood pressure (<100 mm Hg), history of ENT2 hypertension ENT2END , diabetes, and use of antiplatelet, diuretic, and beta-blocker therapy
0	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of ENT1 hypertension  ENT1END , diabetes, and use of antiplatelet, ENT2 diuretic ENT2END , and beta-blocker therapy
0	OBJECTIVE: To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed ENT1 angiotensin ENT1END -converting enzyme inhibitor therapy. METHOD: We analyzed data from the Studies of Left Ventricular Dysfunction (SOLVD), a randomized, double-blind, placebo-controlled trial of enalapril for the treatment of CHF. There were 3379 patients randomly assigned to enalapril with a median follow-up of 974 days and 3379 patients randomly assigned to placebo with a mean follow-up of 967 days. Decreased renal function was defined as a rise in serum creatinine >/=0.5 mg/dL (44 micromol/L) from baseline. We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline creatinine, low systolic blood pressure (<100 mm Hg), history of hypertension, ENT2 diabetes ENT2END , and use of antiplatelet, diuretic, and beta-blocker therapy
0	By multivariate analysis, in both the placebo and ENT1 enalapril ENT1END groups older age, diuretic therapy, and ENT2 diabetes ENT2END were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective
0	We used time-to-event analysis to identify potential predictors of decrease in renal function including age, baseline ejection fraction, baseline ENT1 creatinine  ENT1END , low systolic blood pressure (<100 mm Hg), history of hypertension, ENT2 diabetes ENT2END , and use of antiplatelet, diuretic, and beta-blocker therapy
0	By multivariate analysis, in both the placebo and enalapril groups older age, ENT1 diuretic  ENT1END therapy, and ENT2 diabetes ENT2END were associated with decreased renal function, whereas beta-blocker therapy and higher ejection fraction were renoprotective
0	Predictors of ENT1 decreased renal function  ENT1END  in patients with heart failure during ENT2 angiotensin ENT2END -converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)BACKGROUND: Although angiotensin-converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure (CHF), it may also cause decreased renal function
1	Diuretic therapy was likewise associated with a greater risk of ENT1 decreased renal function ENT1END in the ENT2 enalapril ENT2END group (RR 1
0	ENT1 Decreased renal function  ENT1END was defined as a rise in serum ENT2 creatinine ENT2END >/=0
1	CONCLUSIONS: Enalapril use caused a 33% increase in the risk of ENT1 decreased renal function  ENT1END in patients with CHF. ENT2 Diuretic ENT2END use and advanced age increased this risk
0	Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced ENT1 increase in MAP ENT1END in both groups. Infusion of the central nervous system ENT2 alpha2-adrenergic receptor agonist ENT2END clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet
0	OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the ENT1 hypertensive ENT1END effect of dietary sodium chloride supplementation. METHODS: Male SHR (aged 6 weeks) that had been treated from conception onward with either captopril or vehicle remained on a basal ENT2 sodium chloride ENT2END diet or were fed a high sodium chloride diet
0	Contribution of the sympathetic nervous system to salt-sensitivity in lifetime ENT1 captopril  ENT1END -treated spontaneously ENT2 hypertensive ENT2END rats
0	Intravenous infusion of the ganglionic blocker ENT1 hexamethonium  ENT1END resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced ENT2 increase in MAP ENT2END in both groups
0	Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride-induced ENT1 increase in MAP ENT1END  in both groups. Infusion of the central nervous system alpha2-adrenergic receptor agonist ENT2 clonidine ENT2END also resulted in a greater reduction in MAP in both groups of SHR that were fed the high (compared with the basal) sodium chloride diet
1	OBJECTIVE: To test the hypothesis that, in lifetime captopril-treated spontaneously hypertensive rats (SHR), the sympathetic nervous system contributes importantly to the ENT1 hypertensive ENT1END  effect of ENT2 dietary sodium chloride ENT2END supplementation
0	ENT1 Cardiotoxic  ENT1END  and possible leukemogenic effects of ENT2 adriamycin ENT2END in nonhuman primates
0	ENT1 Cardiotoxic ENT1END  and possible leukemogenic effects of adriamycin in nonhuman primates.10 monkeys (macaques) received adriamycin by monthly intravenous injections at 12 mg/m2 (1 mg/kg). 8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man. Histologically, the myocardial lesions resembled those found in human ENT2 anthracycline ENT2END -induced cardiomyopathy
0	Histologically, the myocardial lesions resembled those found in human anthracycline-induced ENT1 cardiomyopathy ENT1END  1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of ENT2 adriamycin ENT2END ; the 10th monkey is alive and well 26 months after the last dose of drug
0	Histologically, the myocardial lesions resembled those found in human ENT1 anthracycline  ENT1END -induced ENT2 cardiomyopathy ENT2END
1	8 of the 10 monkeys developed ENT1 congestive heart failure ENT1END at an average cumulative ENT2 adriamycin ENT2END dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man
0	8 of the 10 monkeys developed ENT1 congestive heart failure  ENT1END  at an average cumulative adriamycin dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man. Histologically, the myocardial lesions resembled those found in human ENT2 anthracycline ENT2END -induced cardiomyopathy
1	1 of the 10 monkeys developed ENT1 acute myeloblastic leukemia  ENT1END after receiving 324 mg/m2 of ENT2 adriamycin ENT2END ; the 10th monkey is alive and well 26 months after the last dose of drug
0	Histologically, the myocardial lesions resembled those found in human ENT1 anthracycline  ENT1END -induced cardiomyopathy. 1 of the 10 monkeys developed ENT2 acute myeloblastic leukemia ENT2END after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug
0	8 of the 10 monkeys developed congestive heart failure at an average cumulative ENT1 adriamycin ENT1END  dose (310 mg/m2) well below that considered the safe upper limit (550 mg/m2) in man. Histologically, the ENT2 myocardial lesions ENT2END resembled those found in human anthracycline-induced cardiomyopathy
0	Histologically, the ENT1 myocardial lesions  ENT1END  resembled those found in human ENT2 anthracycline ENT2END -induced cardiomyopathy
0	Our results suggest that ENT1 adriamycin ENT1END is a more potent cardiotoxin in monkeys than in man, and that ENT2 leukemia ENT2END may be a consequence of prolonged treatment with this drug
0	Histologically, the myocardial lesions resembled those found in human ENT1 anthracycline  ENT1END -induced cardiomyopathy. 1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg/m2 of adriamycin; the 10th monkey is alive and well 26 months after the last dose of drug. Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man, and that ENT2 leukemia ENT2END may be a consequence of prolonged treatment with this drug
1	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END  ENT2 5-azacytidine ENT2END (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg)
1	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END , 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, ENT2 benzo[a]-pyrene ENT2END (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg)
1	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END , 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and ENT2 1,2-dimethylhydrazine ENT2END (1,2-DMH) (100 mg/kg)
1	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END , 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg). The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of ENT2 CCl4 ENT2END
0	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END , 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg). The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4. The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only. Administration of [3H]-5-azadeoxycytidine during the repair synthesis induced by 1,2-DMH further showed that 0.019 mol % of ENT2 cytosine ENT2END residues in DNA were substituted by the analogue, indicating that incorporation of 5-AzC occurs during repair synthesis
1	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END , 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg). The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% ENT2 2-acetylaminofluorene ENT2END coupled with a necrogenic dose of CCl4
1	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END , 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), ENT2 N-methyl-N-nitrosourea ENT2END (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg)
0	To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the ENT1 initiation of carcinogenic process ENT1END , 5-azacytidine (5-AzC) (10 mg/kg), an inhibitor of DNA methylation, was given to rats during the phase of repair synthesis induced by the three carcinogens, benzo[a]-pyrene (200 mg/kg), N-methyl-N-nitrosourea (60 mg/kg) and 1,2-dimethylhydrazine (1,2-DMH) (100 mg/kg). The initiated hepatocytes in the liver were assayed as the gamma-glutamyltransferase (gamma-GT) positive foci formed following a 2-week selection regimen consisting of dietary 0.02% 2-acetylaminofluorene coupled with a necrogenic dose of CCl4. The results obtained indicate that with all three carcinogens, administration of 5-AzC during repair synthesis increased the incidence of initiated hepatocytes, for example 10-20 foci/cm2 in 5-AzC and carcinogen-treated rats compared with 3-5 foci/cm2 in rats treated with carcinogen only. Administration of ENT2 [3H]-5-azadeoxycytidine ENT2END during the repair synthesis induced by 1,2-DMH further showed that 0
0	ENT1 Suxamethonium ENT1END causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons. Here, we present a similar incident in a severely ENT2 depressed ENT2END patient who received electroconvulsive therapy (ECT)
0	Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by ENT1 organophosphorus (OP) poisons  ENT1END  Here, we present a similar incident in a severely ENT2 depressed ENT2END patient who received electroconvulsive therapy (ECT)
1	ENT1 Suxamethonium ENT1END  causes prolonged ENT2 apnea ENT2END in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus (OP) poisons
1	Prolonged ENT1 apnea ENT1END in our case ensued because the information about suicidal attempt by ENT2 OP compound ENT2END was concealed from the treating team
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and ENT1 beta-carotene ENT1END  the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements. Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of ENT2 stroke ENT2END were 1
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of ENT1 folate  ENT1END  vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements. Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of ENT2 stroke ENT2END were 1
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, ENT1 vitamin E  ENT1END  and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1.0, 0.97, 1.11, 1.47, and 1.84 (P for trend < 0.01) across quintiles of total vitamin C intake from food and supplements. Adjusted relative risks of coronary artery disease were 1.0, 0.81, 0.99, 1.26, and 1.91 (P for trend = 0.01) and of ENT2 stroke ENT2END were 1
0	01) and of ENT1 stroke ENT1END  were 1.0, 0.52, 1.23, 2.22, and 2.57 (P for trend < 0.01). When dietary and supplemental ENT2 vitamin C ENT2END were analyzed separately, only supplemental vitamin C showed a positive association with mortality endpoints
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and ENT1 beta-carotene ENT1END , the adjusted relative risks of total ENT2 cardiovascular disease ENT2END mortality were 1
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of ENT1 folate  ENT1END , vitamin E, and beta-carotene, the adjusted relative risks of total ENT2 cardiovascular disease ENT2END mortality were 1
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, ENT1 vitamin E  ENT1END , and beta-carotene, the adjusted relative risks of total ENT2 cardiovascular disease ENT2END mortality were 1
1	Does supplemental ENT1 vitamin C  ENT1END  increase ENT2 cardiovascular disease ENT2END risk in women with diabetes?BACKGROUND: Vitamin C acts as a potent antioxidant; however, it can also be a prooxidant and glycate protein under certain circumstances in vitro
0	These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote ENT1 atherosclerosis  ENT1END  OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease. DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline. Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and ENT2 beta-carotene ENT2END , the adjusted relative risks of total cardiovascular disease mortality were 1
0	These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote ENT1 atherosclerosis  ENT1END . OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease. DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline. Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of ENT2 folate ENT2END , vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1
0	These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote ENT1 atherosclerosis  ENT1END . OBJECTIVE: The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease. DESIGN: We studied the relation between vitamin C intake and mortality from total cardiovascular disease (n = 281), coronary artery disease (n = 175), and stroke (n = 57) in 1923 postmenopausal women who reported being diabetic at baseline. Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of coronary artery disease were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, ENT2 vitamin E ENT2END , and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1
0	These observations led us to hypothesize that a high intake of ENT1 vitamin C  ENT1END in diabetic persons might promote ENT2 atherosclerosis ENT2END
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of ENT1 diabetes  ENT1END  and intakes of folate, vitamin E, and ENT2 beta-carotene ENT2END , the adjusted relative risks of total cardiovascular disease mortality were 1
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of ENT1 diabetes  ENT1END , and intakes of ENT2 folate ENT2END , vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1
0	RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of ENT1 diabetes  ENT1END , and intakes of folate, ENT2 vitamin E ENT2END , and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1
0	These observations led us to hypothesize that a high intake of ENT1 vitamin C ENT1END  in ENT2 diabetic ENT2END persons might promote atherosclerosis
0	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of ENT1 coronary artery disease  ENT1END were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, vitamin E, and ENT2 beta-carotene ENT2END , the adjusted relative risks of total cardiovascular disease mortality were 1
0	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of ENT1 coronary artery disease  ENT1END  were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of ENT2 folate ENT2END , vitamin E, and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1
0	Diet was assessed with a food-frequency questionnaire at baseline, and subjects initially free of ENT1 coronary artery disease  ENT1END  were prospectively followed for 15 y. RESULTS: After adjustment for cardiovascular disease risk factors, type of diabetes medication used, duration of diabetes, and intakes of folate, ENT2 vitamin E ENT2END , and beta-carotene, the adjusted relative risks of total cardiovascular disease mortality were 1
0	01) across quintiles of total ENT1 vitamin C ENT1END intake from food and supplements. Adjusted relative risks of ENT2 coronary artery disease ENT2END were 1
1	Nine patients exhibited mild to moderate ENT1 extrapyramidal concomitant symptoms ENT1END  no other side effects were observed. The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects. In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group. Certain clues, including the onset of action, seem to be indicative of the superiority of ENT2 bromperidol ENT2END
1	Nine patients exhibited mild to moderate ENT1 extrapyramidal concomitant symptoms ENT1END ; no other side effects were observed. The results of detailed laboratory tests and evaluations of various quantitative and qualitative tolerability parameters were not indicative of toxic effects. In the double blind study with ENT2 haloperidol ENT2END , both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group
0	In the double blind study with haloperidol, both substances were found to be highly effective in the treatment of ENT1 psychotic syndromes belonging predominantly to the schizophrenia group  ENT1END  Certain clues, including the onset of action, seem to be indicative of the superiority of ENT2 bromperidol ENT2END
0	In the double blind study with ENT1 haloperidol  ENT1END , both substances were found to be highly effective in the treatment of ENT2 psychotic syndromes belonging predominantly to the schizophrenia group ENT2END
0	Fatal intracranial bleeding associated with prehospital use of ENT1 epinephrine ENT1END .We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of ENT2 pulmonary edema ENT2END with wheezing
0	ENT1 Epinephrine ENT1END has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe ENT2 hypertension ENT2END should be viewed with caution
0	The sudden onset of respiratory distress, ENT1 rash ENT1END  and a history of a new medicine led the two paramedics on the scene to administer subcutaneous ENT2 epinephrine ENT2END
0	We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with ENT1 wheezing  ENT1END  The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous ENT2 epinephrine ENT2END
1	Subsequently, acute cardiac arrest and fatal ENT1 subarachnoid hemorrhage  ENT1END occurred. ENT2 Epinephrine ENT2END has a proven role in cardiac arrest in prehospital care; however, use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution
0	Fatal intracranial bleeding associated with prehospital use of ENT1 epinephrine ENT1END .We present a case of paramedic misjudgment in the execution of a protocol for the treatment of ENT2 allergic reaction ENT2END in a case of pulmonary edema with wheezing
1	The sudden onset of respiratory distress, rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous ENT1 epinephrine ENT1END . Subsequently, acute ENT2 cardiac arrest ENT2END and fatal subarachnoid hemorrhage occurred
0	The sudden onset of ENT1 respiratory distress  ENT1END  rash, and a history of a new medicine led the two paramedics on the scene to administer subcutaneous ENT2 epinephrine ENT2END
0	It is assumed that patients with some ENT1 cerebral damage ENT1END are liable to manifest ENT2 DPH ENT2END toxicity as focal neurological signs
1	Among the common side effects of diphenylhydantoin ( ENT1 DPH ENT1END  overdose, the most frequently encountered neurological signs are those of ENT2 cerebellar dysfunction ENT2END
1	Two patients are presented who suffered progressive ENT1 hemiparesis ENT1END due to ENT2 DPH ENT2END overdose
0	It is assumed that patients with some cerebral damage are liable to manifest ENT1 DPH ENT1END  ENT2 toxicity ENT2END as focal neurological signs
1	Two patients are presented who suffered progressive hemiparesis due to ENT1 DPH ENT1END  ENT2 overdose ENT2END
0	Electrocardiographic evidence of ENT1 myocardial injury  ENT1END  in psychiatrically hospitalized ENT2 cocaine ENT2END abusers
1	Eleven of the ENT1 cocaine ENT1END abusers and none of the controls had ECG evidence of significant myocardial injury defined as ENT2 myocardial infarction ENT2END , ischemia, and bundle branch block
0	Eleven of the ENT1 cocaine ENT1END  abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ENT2 ischemia ENT2END , and bundle branch block
1	Eleven of the ENT1 cocaine ENT1END  abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and ENT2 bundle branch block ENT2END
0	The electrocardiograms (ECG) of 99 cocaine-abusing patients were compared with the ECGs of 50 ENT1 schizophrenic  ENT1END controls. Eleven of the ENT2 cocaine ENT2END abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction, ischemia, and bundle branch block
0	A randomized, placebo-controlled dose-comparison trial of ENT1 haloperidol  ENT1END  for ENT2 psychosis ENT2END and disruptive behaviors in Alzheimer's disease
0	A randomized, placebo-controlled dose-comparison trial of ENT1 haloperidol  ENT1END  for psychosis and ENT2 disruptive behaviors ENT2END in Alzheimer's disease
1	CONCLUSIONS: The results indicated a favorable therapeutic profile for ENT1 haloperidol ENT1END in doses of 2-3 mg/day, although a subgroup developed moderate to severe ENT2 extrapyramidal signs ENT2END
0	RESULTS: For the 60 patients who completed phase A, standard-dose haloperidol was efficacious and superior to both low-dose ENT1 haloperidol ENT1END and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on ENT2 psychomotor agitation ENT2END
0	A randomized, placebo-controlled dose-comparison trial of ENT1 haloperidol  ENT1END  for psychosis and disruptive behaviors in ENT2 Alzheimer's disease ENT2END
0	ENT1 Dexmedetomidine ENT1END was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal ENT2 myocardial infarction ENT2END (OR 0
1	An anticholinergic did not reduce the incidence of ENT1 bradycardia ENT1END (p = 0.43). A randomised placebo-controlled trial of ENT2 dexmedetomidine ENT2END is warranted
1	Peri-operative ENT1 hypotension  ENT1END (26%, OR 3.80, 95% CI 1.91-7.54, p = 0.0001) and bradycardia (17%, OR 5.45, 95% CI 2.98-9.95, p < 0.00001) were significantly increased. An anticholinergic did not reduce the incidence of bradycardia (p = 0.43). A randomised placebo-controlled trial of ENT2 dexmedetomidine ENT2END is warranted
0	ENT1 Dexmedetomidine ENT1END  was associated with a trend towards improved cardiac outcomes; all-cause mortality (OR 0.27, 95% CI 0.01-7.13, p = 0.44), non-fatal myocardial infarction (OR 0.26, 95% CI 0.04-1.60, p = 0.14), and ENT2 myocardial ischaemia ENT2END (OR 0
0	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine-induced ENT1 amnesia ENT1END  in adult male rats.The effect of ENT2 ritanserin ENT2END (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced amnesia in Morris water maze (MWM) was investigated
0	The effect of ritanserin (5-HT2 antagonist) on scopolamine (muscarinic cholinergic antagonist)-induced ENT1 amnesia ENT1END in Morris water maze (MWM) was investigated. Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus. One week later, they received repeatedly vehicles (saline, ENT2 DMSO ENT2END , saline+DMSO), scopolamine (2 microg/0
1	Microinjection of ritanserin into the CA1 region of hippocampus improves ENT1 scopolamine  ENT1END -induced ENT2 amnesia ENT2END in adult male rats
0	Following short exposure to oral ENT1 prednisone ENT1END  both boys developed lethargy, increasing ENT2 somnolence ENT2END , polydipsia, polyphagia, and polyuria
0	Following short exposure to oral prednisone, both boys developed lethargy, increasing ENT1 somnolence ENT1END , polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
0	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and ENT2 acidosis ENT2END
0	Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and ENT1 acidosis  ENT1END . Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
1	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound coma, ENT2 hypotension ENT2END , severe hyperglycemia, and acidosis
0	Both presented in the emergency room with profound coma, ENT1 hypotension  ENT1END , severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
1	ENT1 Hyperglycemic acidotic coma  ENT1END  and death in Kearns-Sayre syndrome.This paper presents the clinical and metabolic findings in two young boys with long-standing Kearns-Sayre syndrome. Following short exposure to oral ENT2 prednisone ENT2END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria
0	Nonketotic ENT1 lactic acidosis  ENT1END was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
0	This paper presents the clinical and metabolic findings in two young boys with long-standing ENT1 Kearns-Sayre syndrome  ENT1END  Following short exposure to oral ENT2 prednisone ENT2END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria
0	Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT1 lactate ENT1END  level was present in the other. Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation. We believe these two cases represent a newly described and catastrophic metabolic-endocrine failure in the ENT2 Kearns-Sayre syndrome ENT2END
0	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and ENT2 polyuria ENT2END
0	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and ENT1 polyuria  ENT1END . Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
1	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound coma, hypotension, severe ENT2 hyperglycemia ENT2END , and acidosis
0	Both presented in the emergency room with profound coma, hypotension, severe ENT1 hyperglycemia  ENT1END , and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
0	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, ENT2 polyphagia ENT2END , and polyuria
0	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, polydipsia, ENT1 polyphagia  ENT1END , and polyuria. Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
0	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other. ENT2 Respiratory failure ENT2END rapidly ensued and both patients expired in spite of efforts at resuscitation
0	Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT1 lactate  ENT1END  level was present in the other. ENT2 Respiratory failure ENT2END rapidly ensued and both patients expired in spite of efforts at resuscitation
0	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed ENT2 lethargy ENT2END , increasing somnolence, polydipsia, polyphagia, and polyuria
0	Following short exposure to oral prednisone, both boys developed ENT1 lethargy  ENT1END , increasing somnolence, polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
0	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, ENT2 polydipsia ENT2END , polyphagia, and polyuria
0	Following short exposure to oral prednisone, both boys developed lethargy, increasing somnolence, ENT1 polydipsia  ENT1END , polyphagia, and polyuria. Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
1	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound coma, hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ENT2 ketosis ENT2END without a known serum lactate level was present in the other
0	Nonketotic lactic acidosis was present in one and ENT1 ketosis  ENT1END  without a known serum ENT2 lactate ENT2END level was present in the other
1	Following short exposure to oral ENT1 prednisone ENT1END , both boys developed lethargy, increasing somnolence, polydipsia, polyphagia, and polyuria. Both presented in the emergency room with profound ENT2 coma ENT2END , hypotension, severe hyperglycemia, and acidosis
0	Both presented in the emergency room with profound ENT1 coma  ENT1END , hypotension, severe hyperglycemia, and acidosis. Nonketotic lactic acidosis was present in one and ketosis without a known serum ENT2 lactate ENT2END level was present in the other
0	AIM: To report a case of optic and peripheral neuropathy after chronic use of ENT1 disulfiram ENT1END for alcohol dependence management. MATERIALS AND METHODS: A case report. RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent ENT2 headaches ENT2END for 2 months
0	He also complained of paraesthesia with ENT1 numbness ENT1END in both feet. His vision was 6/15 and 2/60 in the right and left eyes, respectively. Fundoscopy revealed bilaterally swollen optic nerve heads. Visual field testing confirmed bilateral central-caecal scotomata. He had been taking ENT2 disulfiram ENT2END for alcohol dependence for the preceding 3 years
0	AIM: To report a case of optic and peripheral neuropathy after chronic use of ENT1 disulfiram ENT1END  for ENT2 alcohol dependence ENT2END management
0	ENT1 Disulfiram  ENT1END -induced transient ENT2 optic and peripheral neuropathy ENT2END : a case report
0	AIM: To report a case of optic and peripheral neuropathy after chronic use of ENT1 disulfiram ENT1END  for alcohol dependence management. MATERIALS AND METHODS: A case report. RESULTS: A 57-year-old male presented with gradual ENT2 loss of vision ENT2END in both eyes with intermittent headaches for 2 months
1	ENT1 Disulfiram  ENT1END -induced transient ENT2 optic and peripheral neuropathy ENT2END : a case report
1	AIM: To report a case of optic and peripheral neuropathy after chronic use of ENT1 disulfiram ENT1END  for alcohol dependence management. MATERIALS AND METHODS: A case report. RESULTS: A 57-year-old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months. He also complained of ENT2 paraesthesia ENT2END with numbness in both feet
1	Visual field testing confirmed bilateral central-caecal ENT1 scotomata  ENT1END  He had been taking ENT2 disulfiram ENT2END for alcohol dependence for the preceding 3 years
0	CONCLUSIONS: Severe adverse effects of ENT1 sirolimus ENT1END include fever, ENT2 anemia ENT2END , and capillary leak syndrome
0	Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or ENT1 dexamethasone  ENT1END induced apoptosis than did normal T cells, particularly in the presence of sirolimus. CONCLUSIONS: Severe adverse effects of sirolimus include fever, ENT2 anemia ENT2END , and capillary leak syndrome
0	CONCLUSIONS: Severe adverse effects of ENT1 sirolimus ENT1END  include ENT2 fever ENT2END , anemia, and capillary leak syndrome
0	Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or ENT1 dexamethasone  ENT1END -induced apoptosis than did normal T cells, particularly in the presence of sirolimus. CONCLUSIONS: Severe adverse effects of sirolimus include ENT2 fever ENT2END , anemia, and capillary leak syndrome
0	Systemic toxicity following administration of sirolimus (formerly ENT1 rapamycin  ENT1END ) for ENT2 psoriasis ENT2END : association of capillary leak syndrome with apoptosis of lesional lymphocytes
0	Activated peripheral blood T cells from patients with ENT1 psoriasis  ENT1END tended to exhibit greater spontaneous or ENT2 dexamethasone ENT2END -induced apoptosis than did normal T cells, particularly in the presence of sirolimus
0	CONCLUSIONS: Severe adverse effects of ENT1 sirolimus ENT1END  include fever, anemia, and capillary leak syndrome. These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators. Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with ENT2 inflammatory diseases ENT2END who are treated with immune modulators
0	Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or ENT1 dexamethasone  ENT1END -induced apoptosis than did normal T cells, particularly in the presence of sirolimus. CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and capillary leak syndrome. These symptoms may be the result of drug-induced apoptosis of lesional leukocytes, especially activated T lymphocytes, and possibly release of inflammatory mediators. Because patients with severe psoriasis may develop capillary leak from various systemic therapies, clinical monitoring is advisable for patients with ENT2 inflammatory diseases ENT2END who are treated with immune modulators
0	Systemic ENT1 toxicity  ENT1END  following administration of ENT2 sirolimus ENT2END (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes
0	Systemic ENT1 toxicity  ENT1END  following administration of sirolimus (formerly rapamycin) for psoriasis: association of capillary leak syndrome with apoptosis of lesional lymphocytes.BACKGROUND: Sirolimus (formerly rapamycin) is an immunosuppressive agent that interferes with T-cell activation. After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis. OBSERVATIONS: A keratome skin specimen from 1 patient with sirolimus-induced capillary leak syndrome had a 2.3-fold increase in percentage of apoptotic cells (to 48%) compared with an unaffected sirolimus-treated patient with psoriasis (21%). Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or ENT2 dexamethasone ENT2END -induced apoptosis than did normal T cells, particularly in the presence of sirolimus
1	OBSERVATIONS: A keratome skin specimen from 1 patient with ENT1 sirolimus ENT1END induced ENT2 capillary leak syndrome ENT2END had a 2
0	Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or ENT1 dexamethasone ENT1END -induced apoptosis than did normal T cells, particularly in the presence of sirolimus. CONCLUSIONS: Severe adverse effects of sirolimus include fever, anemia, and ENT2 capillary leak syndrome ENT2END
0	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant ENT1 rapamycin ENT1END (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days. The molecular mechanisms of CsA and FK506 ENT2 toxicity ENT2END were investigated
0	The molecular mechanisms of ENT1 CsA  ENT1END and FK506 ENT2 toxicity ENT2END were investigated
0	The molecular mechanisms of CsA and ENT1 FK506 ENT1END ENT2 toxicity ENT2END were investigated
0	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related ENT1 macrolide  ENT1END immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days. The molecular mechanisms of CsA and FK506 ENT2 toxicity ENT2END were investigated
0	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant ENT1 rapamycin ENT1END  (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and ENT2 hypertrophy ENT2END of the juxtaglomerular apparatus in male Wistar rats when given for 10 days
0	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and ENT1 hypertrophy  ENT1END  of the juxtaglomerular apparatus in male Wistar rats when given for 10 days. The molecular mechanisms of ENT2 CsA ENT2END and FK506 toxicity were investigated
0	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related macrolide immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and ENT1 hypertrophy  ENT1END  of the juxtaglomerular apparatus in male Wistar rats when given for 10 days. The molecular mechanisms of CsA and ENT2 FK506 ENT2END toxicity were investigated
0	Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related ENT1 macrolide  ENT1END  immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and ENT2 hypertrophy ENT2END of the juxtaglomerular apparatus in male Wistar rats when given for 10 days
0	Finally, specific immunophilin-drug-calcineurin complexes formed only in the presence of CsA and FK506, but not ENT1 rapamycin ENT1END  These results suggest that the ENT2 nephrotoxic ENT2END effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase
1	ENT1 Nephrotoxicity  ENT1END  of ENT2 cyclosporin A ENT2END and FK506: inhibition of calcineurin phosphatase
1	These results suggest that the ENT1 nephrotoxic ENT1END  effects of CsA and ENT2 FK506 ENT2END is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase
0	ENT1 Nephrotoxicity  ENT1END  of cyclosporin A and FK506: inhibition of calcineurin phosphatase.Cyclosporin A (CsA; 50 mg/kg) and Fujimycine (FK506; 5 mg/kg), but not the related ENT2 macrolide ENT2END immunosuppressant rapamycin (5 mg/kg), caused a reduction of glomerular filtration rate, degenerative changes of proximal tubular epithelium, and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and ENT1 heart failure ENT1END during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by ENT2 prostaglandin ENT2END -independent effects
1	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and ENT1 heart failure ENT1END  during treatment with ENT2 cyclooxygenase inhibitors ENT2END
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, hypertension and ENT1 heart failure ENT1END  during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects. Diagnostic markers such as ENT2 N-terminal pro brain natriuretic peptide ENT2END (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of ENT1 myocardial infarction  ENT1END  stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by ENT2 prostaglandin ENT2END -independent effects
1	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of ENT1 myocardial infarction  ENT1END , stroke, hypertension and heart failure during treatment with ENT2 cyclooxygenase inhibitors ENT2END
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of ENT1 myocardial infarction  ENT1END , stroke, hypertension and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects. Diagnostic markers such as ENT2 N-terminal pro brain natriuretic peptide ENT2END (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, ENT1 hypertension  ENT1END and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by ENT2 prostaglandin ENT2END -independent effects
1	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, ENT1 hypertension  ENT1END  and heart failure during treatment with ENT2 cyclooxygenase inhibitors ENT2END
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, stroke, ENT1 hypertension  ENT1END  and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects. Diagnostic markers such as ENT2 N-terminal pro brain natriuretic peptide ENT2END (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity
0	A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by ENT1 prostaglandin ENT1END -independent effects. Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious ENT2 cardiovascular toxicity ENT2END
0	A comparison of individual selective and unselective ENT1 cyclooxygenase inhibitors  ENT1END suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects. Diagnostic markers such as N-terminal pro brain natriuretic peptide (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious ENT2 cardiovascular toxicity ENT2END
0	Diagnostic markers such as N-terminal pro brain natriuretic peptide ( ENT1 NT-proBNP  ENT1END  or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious ENT2 cardiovascular toxicity ENT2END
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, ENT1 stroke  ENT1END  hypertension and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by ENT2 prostaglandin ENT2END -independent effects
1	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, ENT1 stroke  ENT1END , hypertension and heart failure during treatment with ENT2 cyclooxygenase inhibitors ENT2END
0	Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction, ENT1 stroke  ENT1END , hypertension and heart failure during treatment with cyclooxygenase inhibitors. Adverse cardiovascular effects occurred mainly, but not exclusively, in patients with concomitant risk factors. Cyclooxygenase inhibitors cause complex changes in renal, vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention. The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time. A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance-specific differences, which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin-independent effects. Diagnostic markers such as ENT2 N-terminal pro brain natriuretic peptide ENT2END (NT-proBNP) or high-sensitive C-reactive protein might help in the early identification of patients at risk, thus avoiding the occurrence of serious cardiovascular toxicity
1	We strongly suspect that this lethal ENT1 anuria ENT1END was mainly due to ENT2 ifosfamide ENT2END , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension
0	A sixty-year-old woman with advanced breast cancer, previously treated with ENT1 cisplatin ENT1END  developed an irreversible lethal renal failure with ENT2 anuria ENT2END , the day after 5 g/m2 bolus ifosfamide
0	We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient ENT1 hypotension ENT1END  We recommend careful use of ENT2 ifosfamide ENT2END in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion
0	We strongly suspect that this lethal anuria was mainly due to ifosfamide, occurring in a patient having received previous ENT1 cisplatin  ENT1END chemotherapy and with poor kidney perfusion due to transient ENT2 hypotension ENT2END
1	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ENT1 ifosfamide ENT1END  ENT2 Postrenal failure ENT2END was excluded by echography
0	Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an ENT1 impaired renal function  ENT1END .A sixty-year-old woman with advanced breast cancer, previously treated with ENT2 cisplatin ENT2END , developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide
0	Lethal anuria complicating high dose ENT1 ifosfamide  ENT1END  chemotherapy in a ENT2 breast cancer ENT2END patient with an impaired renal function
0	A sixty-year-old woman with advanced ENT1 breast cancer  ENT1END  previously treated with ENT2 cisplatin ENT2END , developed an irreversible lethal renal failure with anuria, the day after 5 g/m2 bolus ifosfamide
0	A sixty-year-old woman with advanced breast cancer, previously treated with cisplatin, developed an irreversible lethal ENT1 renal failure  ENT1END with anuria, the day after 5 g/m2 bolus ENT2 ifosfamide ENT2END
0	A sixty-year-old woman with advanced breast cancer, previously treated with ENT1 cisplatin  ENT1END , developed an irreversible lethal ENT2 renal failure ENT2END with anuria, the day after 5 g/m2 bolus ifosfamide
0	She was treated with ENT1 heparin ENT1END  dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained. Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe ENT2 hypertension ENT2END and microangiopathic hemolytic anemia, should be performed with caution
0	She was treated with heparin, ENT1 dipyridamole  ENT1END and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained. Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe ENT2 hypertension ENT2END and microangiopathic hemolytic anemia, should be performed with caution
0	A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking ENT1 oral contraceptives  ENT1END  She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained. Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe ENT2 hypertension ENT2END and microangiopathic hemolytic anemia, should be performed with caution
0	She was treated with ENT1 heparin ENT1END , dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of ENT2 anuria ENT2END , dialysis treatment was stopped
0	She was treated with heparin, ENT1 dipyridamole  ENT1END  and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of ENT2 anuria ENT2END , dialysis treatment was stopped
0	A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking ENT1 oral contraceptives  ENT1END . She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of ENT2 anuria ENT2END , dialysis treatment was stopped
0	She was treated with ENT1 heparin ENT1END , dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained. Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and ENT2 microangiopathic hemolytic anemia ENT2END , should be performed with caution
0	She was treated with heparin, ENT1 dipyridamole  ENT1END  and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained. Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and ENT2 microangiopathic hemolytic anemia ENT2END , should be performed with caution
0	A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking ENT1 oral contraceptives  ENT1END . She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged oliguria, recovery of renal function can be obtained. Therefore, in adult patients affected by HUS, dialysis should not be discontinued prematurely; moreover, bilateral nephrectomy, for treatment of severe hypertension and ENT2 microangiopathic hemolytic anemia ENT2END , should be performed with caution
0	A case is reported of the hemolytic uremic syndrome ( ENT1 HUS  ENT1END  in a woman taking oral contraceptives. She was treated with ENT2 heparin ENT2END , dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped
0	A case is reported of the hemolytic uremic syndrome ( ENT1 HUS  ENT1END ) in a woman taking oral contraceptives. She was treated with heparin, ENT2 dipyridamole ENT2END and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped
1	A case is reported of the hemolytic uremic syndrome ( ENT1 HUS  ENT1END ) in a woman taking ENT2 oral contraceptives ENT2END
0	She was treated with ENT1 heparin ENT1END , dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged ENT2 oliguria ENT2END , recovery of renal function can be obtained
0	She was treated with heparin, ENT1 dipyridamole  ENT1END  and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged ENT2 oliguria ENT2END , recovery of renal function can be obtained
0	A case is reported of the hemolytic uremic syndrome (HUS) in a woman taking ENT1 oral contraceptives  ENT1END . She was treated with heparin, dipyridamole and hemodialysis; and after more than three months, her urinary output rose above 500 ml; and six months after the onset of anuria, dialysis treatment was stopped. This case emphasizes the possibility that HUS in adults is not invariably irreversible and that, despite prolonged ENT2 oliguria ENT2END , recovery of renal function can be obtained
0	In addition to ENT1 muscle damage ENT1END  severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus ENT2 epinephrine ENT2END
1	In addition to ENT1 muscle damage ENT1END , severe damage was also seen in harderian glands, especially after exposure to mepivacaine and ENT2 lidocaine ENT2END plus epinephrine
1	In addition to ENT1 muscle damage ENT1END , severe damage was also seen in harderian glands, especially after exposure to ENT2 mepivacaine ENT2END and lidocaine plus epinephrine
1	75% ENT1 bupivacaine hydrochloride ENT1END  2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes. Controls were injected with physiological saline. All three anesthetics produced massive degeneration of the extraocular muscles. ENT2 Muscle degeneration ENT2END is followed by regeneration of the damaged muscle fibers
0	In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus ENT1 epinephrine ENT1END . With these findings in rats, it is hypothesized that the temporary ENT2 diplopia ENT2END sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles
0	In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and ENT1 lidocaine  ENT1END  plus epinephrine. With these findings in rats, it is hypothesized that the temporary ENT2 diplopia ENT2END sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles
0	In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to ENT1 mepivacaine  ENT1END  and lidocaine plus epinephrine. With these findings in rats, it is hypothesized that the temporary ENT2 diplopia ENT2END sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles
0	75% ENT1 bupivacaine hydrochloride  ENT1END , 2.0% mepivacaine hydrochloride, and 2.0% lidocaine hydrochloride plus 1:100,000 epinephrine) were injected into the retrobulbar area of rat eyes. Controls were injected with physiological saline. All three anesthetics produced massive degeneration of the extraocular muscles. Muscle degeneration is followed by regeneration of the damaged muscle fibers. In addition to muscle damage, severe damage was also seen in harderian glands, especially after exposure to mepivacaine and lidocaine plus epinephrine. With these findings in rats, it is hypothesized that the temporary ENT2 diplopia ENT2END sometimes seen in patients after ophthalmic surgery might be due to anesthetic-induced damage to the extraocular muscles
0	Hypothalamic prolactin receptor messenger ENT1 ribonucleic acid  ENT1END  levels, prolactin signaling, and ENT2 hyperprolactinemic ENT2END inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol
0	These data show that GnRH pulse frequency is inhibited by chronic ENT1 hyperprolactinemia ENT1END in a ENT2 steroid ENT2END -dependent manner
0	Hypothalamic prolactin receptor messenger ribonucleic acid levels, prolactin signaling, and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on ENT1 estradiol  ENT1END . ENT2 Hyperprolactinemia ENT2END can reduce fertility and libido
0	Chronic ENT1 hyperprolactinemia ENT1END induced by the ENT2 dopamine ENT2END antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol
1	Chronic ENT1 hyperprolactinemia ENT1END  induced by the dopamine antagonist ENT2 sulpiride ENT2END caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol
0	We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility: pulsatile LH secretion and the ENT1 estrogen  ENT1END induced LH surge. Chronic ENT2 hyperprolactinemia ENT2END induced by the dopamine antagonist sulpiride caused a 40% reduction LH pulse frequency in ovariectomized rats, but only in the presence of chronic low levels of estradiol
0	Reversibility of ENT1 captopril  ENT1END -induced renal insufficiency after prolonged use in an unusual case of ENT2 renovascular hypertension ENT2END
0	Reversibility of ENT1 captopril ENT1END -induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension.We report a case of severe ENT2 hypertension ENT2END with an occluded renal artery to a solitary kidney, who developed sudden deterioration of renal function following treatment with captopril
1	We report a case of severe hypertension with an occluded renal artery to a solitary kidney, who developed ENT1 sudden deterioration of renal function ENT1END following treatment with ENT2 captopril ENT2END
0	This indicates reversibility in ENT1 captopril ENT1END induced ENT2 renal failure ENT2END even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition
1	In contrast, D-MED prevented ENT1 alfentanil ENT1END induced ENT2 muscle rigidity ENT2END in a dose-dependent fashion
0	Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist ENT1 DG-5128  ENT1END [10 mg/kg], or; 6) saline. Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment. Each rat was then injected with alfentanil (ALF, 0.5 mg/kg sc). ALF injection resulted in a marked increase in hindlimb EMG activity in the L-MED treatment group which was indistinguishable from that seen in animals treated with saline. In contrast, D-MED prevented alfentanil-induced ENT2 muscle rigidity ENT2END in a dose-dependent fashion
0	In the present study, the authors determined if treatment with D-MED prevents the ENT1 muscle rigidity ENT1END caused by high-dose alfentanil anesthesia in the rat. Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of ENT2 medetomidine ENT2END ), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline
0	In the present study, the authors determined if treatment with ENT1 D-MED  ENT1END prevents the ENT2 muscle rigidity ENT2END caused by high-dose alfentanil anesthesia in the rat
0	In the present study, the authors determined if treatment with D-MED prevents the ENT1 muscle rigidity ENT1END  caused by high-dose alfentanil anesthesia in the rat. Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, ENT2 idazoxan ENT2END [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline
0	In contrast, D-MED prevented ENT1 alfentanil ENT1END -induced muscle rigidity in a dose-dependent fashion. The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate. The high-dose D-MED animals were flaccid, akinetic, and lacked a ENT2 startle ENT2END response during the entire experimental period
0	The high-dose ENT1 D-MED  ENT1END animals were flaccid, akinetic, and lacked a ENT2 startle ENT2END response during the entire experimental period
0	The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing ENT1 muscle flaccidity ENT1END and anesthesia in rats and dogs. Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists. Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism. In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose ENT2 alfentanil ENT2END anesthesia in the rat
0	The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing ENT1 muscle flaccidity  ENT1END  and anesthesia in rats and dogs. Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists. Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism. In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat. Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist ENT2 DG-5128 ENT2END [10 mg/kg], or; 6) saline
0	The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing ENT1 muscle flaccidity  ENT1END  and anesthesia in rats and dogs. Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists. Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism. In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat. Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of ENT2 medetomidine ENT2END ), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, idazoxan [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline
0	The highly-selective alpha-2 adrenergic agonist dexmedetomidine ( ENT1 D-MED  ENT1END  is capable of inducing ENT2 muscle flaccidity ENT2END and anesthesia in rats and dogs
0	The highly-selective alpha-2 adrenergic agonist dexmedetomidine (D-MED) is capable of inducing ENT1 muscle flaccidity  ENT1END  and anesthesia in rats and dogs. Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists. Although the neurochemistry of opiate-induced rigidity has yet to be fully elucidated, recent work suggests a role for a central adrenergic mechanism. In the present study, the authors determined if treatment with D-MED prevents the muscle rigidity caused by high-dose alfentanil anesthesia in the rat. Animals (n = 42) were treated intraperitoneally with one of the following six regimens: 1) L-MED (the inactive L-isomer of medetomidine), 30 micrograms/kg; 2) D-MED, 10 micrograms/kg; 3) D-MED, 30 micrograms/kg; 4) D-MED [30 micrograms/kg] and the central-acting alpha-2 antagonist, ENT2 idazoxan ENT2END [10 mg/kg]; 5) D-MED [30 micrograms/kg] and the peripheral-acting alpha-2 antagonist DG-5128 [10 mg/kg], or; 6) saline
0	In contrast, D-MED prevented ENT1 alfentanil ENT1END -induced muscle rigidity in a dose-dependent fashion. The small EMG values obtained in the high-dose D-MED group were comparable with those recorded in earlier studies from control animals not given any opiate. The high-dose D-MED animals were flaccid, ENT2 akinetic ENT2END , and lacked a startle response during the entire experimental period
0	The high-dose ENT1 D-MED  ENT1END  animals were flaccid, ENT2 akinetic ENT2END , and lacked a startle response during the entire experimental period
1	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, ENT1 seizure ENT1END activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), ENT2 methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate ENT2END (DMCM), or strychnine (STR) was not different from control
1	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, ENT1 seizure ENT1END  activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or ENT2 strychnine ENT2END (STR) was not different from control
0	Differential effects of gamma-hexachlorocyclohexane (lindane) on pharmacologically-induced ENT1 seizures  ENT1END . ENT2 Gamma-hexachlorocyclohexane ENT2END (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to PTZ-induced seizures 24 h after exposure to gamma-HCH (Vohland et al
1	Gamma-hexachlorocyclohexane (gamma-HCH), the active ingredient of the insecticide lindane, has been shown to decrease seizure threshold to pentylenetrazol (PTZ) 3 h after exposure to gamma-HCH and conversely increase threshold to ENT1 PTZ ENT1END induced ENT2 seizures ENT2END 24 h after exposure to gamma-HCH (Vohland et al
0	MPA, BCC, DMCM, and STR showed no inhibition of 3H-TBOB ( ENT1 t-butyl bicyclo-orthobenzoate ENT1END  binding at concentrations of 100 micron. The pharmacological challenge data suggest that tolerance may occur to ENT2 seizure ENT2END activity induced by PTZ and PTX 24 h after gamma-HCH, since the response to only these two seizure-inducing agents is decreased
1	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, ENT1 seizure ENT1END  activity due to 3-mercaptopropionic acid (MPA), ENT2 bicuculline ENT2END (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control
1	Seizure activity due to PTZ and picrotoxin (PTX) was significantly decreased; however, ENT1 seizure ENT1END  activity due to ENT2 3-mercaptopropionic acid ENT2END (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control
0	The in vitro data suggest that the site responsible for the decrease in ENT1 seizure ENT1END activity 24 h after gamma-HCH may be the ENT2 GABA ENT2END -A receptor-linked chloride channel
1	ENT1 Seizure ENT1END activity due to PTZ and ENT2 picrotoxin ENT2END (PTX) was significantly decreased; however, seizure activity due to 3-mercaptopropionic acid (MPA), bicuculline (BCC), methyl 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate (DMCM), or strychnine (STR) was not different from control
1	On the first day of the schedule, moderate high doses of ENT1 Methotrexate ENT1END  Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive ENT2 pulmonary obstruction ENT2END due to choriocarcinomic tissue plugs, probably originating from the uterus
1	On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and ENT1 Cyclophosphamide  ENT1END were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive ENT2 pulmonary obstruction ENT2END due to choriocarcinomic tissue plugs, probably originating from the uterus
0	213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT1 Cisplatin  ENT1END  On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive ENT2 pulmonary obstruction ENT2END due to choriocarcinomic tissue plugs, probably originating from the uterus
0	213, Methotrexate, Cyclophosphamide, ENT1 Actomycin-D  ENT1END  and Cisplatin. On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive ENT2 pulmonary obstruction ENT2END due to choriocarcinomic tissue plugs, probably originating from the uterus
1	On the first day of the schedule, moderate high doses of Methotrexate, ENT1 Etoposide  ENT1END and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive ENT2 pulmonary obstruction ENT2END due to choriocarcinomic tissue plugs, probably originating from the uterus
0	On the first day of the schedule, moderate high doses of ENT1 Methotrexate ENT1END , Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely. Patients with large ENT2 pelvic tumor ENT2END loads are, according to existing classifications, at high risk to die and to develop drug resistance
0	On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and ENT1 Cyclophosphamide  ENT1END  were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely. Patients with large ENT2 pelvic tumor ENT2END loads are, according to existing classifications, at high risk to die and to develop drug resistance
0	213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT1 Cisplatin  ENT1END . On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely. Patients with large ENT2 pelvic tumor ENT2END loads are, according to existing classifications, at high risk to die and to develop drug resistance
0	213, Methotrexate, Cyclophosphamide, ENT1 Actomycin-D  ENT1END , and Cisplatin. On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely. Patients with large ENT2 pelvic tumor ENT2END loads are, according to existing classifications, at high risk to die and to develop drug resistance
0	On the first day of the schedule, moderate high doses of Methotrexate, ENT1 Etoposide  ENT1END  and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations, such as spontaneous necrosis, must be considered less likely. Patients with large ENT2 pelvic tumor ENT2END loads are, according to existing classifications, at high risk to die and to develop drug resistance
0	On the first day of the schedule, moderate high doses of ENT1 Methotrexate ENT1END , Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive ENT2 tumor ENT2END necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and ENT1 Cyclophosphamide  ENT1END  were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive ENT2 tumor ENT2END necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT1 Cisplatin  ENT1END . On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive ENT2 tumor ENT2END necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	213, Methotrexate, Cyclophosphamide, ENT1 Actomycin-D  ENT1END , and Cisplatin. On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive ENT2 tumor ENT2END necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	On the first day of the schedule, moderate high doses of Methotrexate, ENT1 Etoposide  ENT1END  and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive ENT2 tumor ENT2END necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of ENT1 choriocarcinoma ENT1END  Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, ENT2 Methotrexate ENT2END , Cyclophosphamide, Actomycin-D, and Cisplatin
0	Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of ENT1 choriocarcinoma ENT1END . Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, ENT2 Cyclophosphamide ENT2END , Actomycin-D, and Cisplatin
0	Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of ENT1 choriocarcinoma  ENT1END . Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT2 Cisplatin ENT2END
0	Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of ENT1 choriocarcinoma  ENT1END . Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, ENT2 Actomycin-D ENT2END , and Cisplatin
0	Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of ENT1 choriocarcinoma ENT1END . Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: ENT2 Etoposide ENT2END 16
0	ENT1 Death  ENT1END  from chemotherapy in gestational trophoblastic disease.Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, ENT2 Methotrexate ENT2END , Cyclophosphamide, Actomycin-D, and Cisplatin
0	ENT1 Death  ENT1END  from chemotherapy in gestational trophoblastic disease.Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, ENT2 Cyclophosphamide ENT2END , Actomycin-D, and Cisplatin
0	ENT1 Death  ENT1END  from chemotherapy in gestational trophoblastic disease.Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT2 Cisplatin ENT2END
0	ENT1 Death  ENT1END  from chemotherapy in gestational trophoblastic disease.Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, ENT2 Actomycin-D ENT2END , and Cisplatin
0	ENT1 Death  ENT1END  from chemotherapy in gestational trophoblastic disease.Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: ENT2 Etoposide ENT2END 16
0	On the first day of the schedule, moderate high doses of ENT1 Methotrexate ENT1END , Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive ENT2 embolism ENT2END other explanations, such as spontaneous necrosis, must be considered less likely
0	On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and ENT1 Cyclophosphamide  ENT1END  were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive ENT2 embolism ENT2END other explanations, such as spontaneous necrosis, must be considered less likely
0	213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT1 Cisplatin  ENT1END . On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive ENT2 embolism ENT2END other explanations, such as spontaneous necrosis, must be considered less likely
0	213, Methotrexate, Cyclophosphamide, ENT1 Actomycin-D  ENT1END , and Cisplatin. On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive ENT2 embolism ENT2END other explanations, such as spontaneous necrosis, must be considered less likely
0	On the first day of the schedule, moderate high doses of Methotrexate, ENT1 Etoposide  ENT1END  and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli. In view of the close time association between the start of chemotherapy and the acute onset of massive ENT2 embolism ENT2END other explanations, such as spontaneous necrosis, must be considered less likely
0	On the first day of the schedule, moderate high doses of ENT1 Methotrexate ENT1END , Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor ENT2 necrosis ENT2END at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and ENT1 Cyclophosphamide  ENT1END  were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor ENT2 necrosis ENT2END at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT1 Cisplatin  ENT1END . On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor ENT2 necrosis ENT2END at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	213, Methotrexate, Cyclophosphamide, ENT1 Actomycin-D  ENT1END , and Cisplatin. On the first day of the schedule, moderate high doses of Methotrexate, Etoposide and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor ENT2 necrosis ENT2END at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	On the first day of the schedule, moderate high doses of Methotrexate, ENT1 Etoposide  ENT1END  and Cyclophosphamide were administered. Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs, probably originating from the uterus. Formation of these plugs was probably due to extensive tumor ENT2 necrosis ENT2END at the level of the walls of the major uterine veins, which resulted in an open exchange of tumor plugs to the vascular spaces; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli
0	Death from chemotherapy in ENT1 gestational trophoblastic disease  ENT1END .Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, ENT2 Methotrexate ENT2END , Cyclophosphamide, Actomycin-D, and Cisplatin
0	Death from chemotherapy in ENT1 gestational trophoblastic disease  ENT1END .Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, ENT2 Cyclophosphamide ENT2END , Actomycin-D, and Cisplatin
0	Death from chemotherapy in ENT1 gestational trophoblastic disease  ENT1END .Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, Actomycin-D, and ENT2 Cisplatin ENT2END
0	Death from chemotherapy in ENT1 gestational trophoblastic disease  ENT1END .Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: Etoposide 16.213, Methotrexate, Cyclophosphamide, ENT2 Actomycin-D ENT2END , and Cisplatin
0	Death from chemotherapy in ENT1 gestational trophoblastic disease  ENT1END .Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high-risk stage of choriocarcinoma. Based on this principle a 27-year old woman, classified as being in the high-risk group (Goldstein and Berkowitz score: 11), was treated with multiple cytotoxic drugs. The multiple drug schema consisted of: ENT2 Etoposide ENT2END 16
0	In Mg(2+)-free bathing medium containing ENT1 bicuculline ENT1END  conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience ENT2 SE ENT2END
0	In ENT1 Mg  ENT1END 2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience ENT2 SE ENT2END
1	Similar to rats, systemic ENT1 pilocarpine ENT1END injection causes ENT2 status epilepticus ENT2END (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice
0	Focal ENT1 glutamate ENT1END photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from ENT2 SE ENT2END survivors but not other groups
0	Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous ENT1 seizures  ENT1END and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice. Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice. In Mg(2+)-free bathing medium containing ENT2 bicuculline ENT2END , conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE
0	Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous ENT1 seizures  ENT1END  and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice. Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice. In ENT2 Mg ENT2END (2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE
1	Similar to rats, systemic ENT1 pilocarpine  ENT1END  injection causes status epilepticus (SE) and the eventual development of spontaneous ENT2 seizures ENT2END and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice
0	Focal ENT1 glutamate ENT1END  photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups. These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of ENT2 seizure ENT2END development in these murine strains, resembling rat models of human temporal lobe epilepsy
0	Recurrent excitation in the dentate gyrus of a murine model of ENT1 temporal lobe epilepsy  ENT1END .Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice. Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice. In Mg(2+)-free bathing medium containing ENT2 bicuculline ENT2END , conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE
0	Recurrent excitation in the dentate gyrus of a murine model of ENT1 temporal lobe epilepsy  ENT1END .Similar to rats, systemic pilocarpine injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice. Population responses in granule cells of the dentate gyrus were examined in transverse slices of the ventral hippocampus from pilocarpine-treated and untreated mice. In ENT2 Mg ENT2END (2+)-free bathing medium containing bicuculline, conditions designed to increase excitability in the slices, electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine-treated mice that did not experience SE
0	Recurrent excitation in the dentate gyrus of a murine model of ENT1 temporal lobe epilepsy  ENT1END .Similar to rats, systemic ENT2 pilocarpine ENT2END injection causes status epilepticus (SE) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL/6 and CD1 mice, but the physiological correlates of these events have not been identified in mice
0	Focal ENT1 glutamate ENT1END  photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1-30 s duration in slices from SE survivors but not other groups. These data support the hypothesis that SE-induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains, resembling rat models of human ENT2 temporal lobe epilepsy ENT2END
0	Lithium also caused proteinuria and systolic ENT1 hypertension ENT1END in absence of glomerulosclerosis. HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma ENT2 creatinine ENT2END levels in lithium pretreated rats
1	ENT1 Lithium  ENT1END also caused proteinuria and systolic ENT2 hypertension ENT2END in absence of glomerulosclerosis
0	Lithium also caused ENT1 proteinuria  ENT1END and systolic hypertension in absence of glomerulosclerosis. HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma ENT2 creatinine ENT2END levels in lithium pretreated rats
1	ENT1 Lithium  ENT1END  also caused ENT2 proteinuria ENT2END and systolic hypertension in absence of glomerulosclerosis
0	HP failed to accentuante progression of ENT1 renal failure  ENT1END and in fact tended to increase GFR and decrease plasma ENT2 creatinine ENT2END levels in lithium pretreated rats
0	Rats with lithium-induced nephropathy were subjected to high protein (HP) feeding, uninephrectomy (NX) or a combination of these, in an attempt to induce glomerular hyperfiltration and further progression of ENT1 renal failure ENT1END  Newborn female Wistar rats were fed a ENT2 lithium ENT2END -containing diet (50 mmol/kg) for 8 weeks and then randomized to normal diet, HP diet (40 vs
0	HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma ENT1 creatinine ENT1END  levels in lithium pretreated rats. NX caused an additive deterioration in GFR which, however, was ameliorated by HP. NX+HP caused a further rise in blood pressure in Li-pretreated rats. The results indicate that Li-induced ENT2 nephropathy ENT2END , even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension
0	The results indicate that ENT1 Li  ENT1END induced ENT2 nephropathy ENT2END , even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension
0	HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma ENT1 creatinine ENT1END  levels in lithium pretreated rats. NX caused an additive deterioration in GFR which, however, was ameliorated by HP. NX+HP caused a further rise in blood pressure in Li-pretreated rats. The results indicate that Li-induced nephropathy, even when the GFR is only modestly reduced, is associated with proteinuria and arterial systolic hypertension. In this model of ENT2 chronic renal failure ENT2END the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow, which may be the functional expression of the formation of nonfiltrating atubular glomeruli
1	Effects of uninephrectomy and high protein feeding on ENT1 lithium  ENT1END -induced ENT2 chronic renal failure ENT2END in rats
0	Lithium also caused proteinuria and systolic hypertension in absence of ENT1 glomerulosclerosis  ENT1END  HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma ENT2 creatinine ENT2END levels in lithium pretreated rats
0	ENT1 Lithium  ENT1END  also caused proteinuria and systolic hypertension in absence of ENT2 glomerulosclerosis ENT2END
0	Phenylephrine but not ephedrine ENT1 reduces frontal lobe oxygenation ENT1END  following anesthesia-induced hypotension.BACKGROUND: Vasopressor agents are used to correct anesthesia-induced hypotension. We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension. METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and ENT2 propofol ENT2END (2
1	ENT1 Phenylephrine  ENT1END  but not ephedrine ENT2 reduces frontal lobe oxygenation ENT2END following anesthesia-induced hypotension
0	Phenylephrine but not ENT1 ephedrine ENT1END ENT2 reduces frontal lobe oxygenation ENT2END following anesthesia-induced hypotension
0	Phenylephrine but not ephedrine ENT1 reduces frontal lobe oxygenation ENT1END  following anesthesia-induced hypotension.BACKGROUND: Vasopressor agents are used to correct anesthesia-induced hypotension. We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension. METHODS: Following induction of anesthesia by ENT2 fentanyl ENT2END (0
1	15 mg kg(-1)) and ENT1 propofol ENT1END  (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered. RESULTS: Induction of anesthesia was followed by ENT2 a decrease in MAP, HR, SV, and CO ENT2END concomitant with an elevation in S(c)O(2)
0	RESULTS: Induction of anesthesia was followed by ENT1 a decrease in MAP, HR, SV, and CO ENT1END  concomitant with an elevation in S(c)O(2). After administration of ENT2 phenylephrine ENT2END , MAP increased (51 +/- 12 to 81 +/- 13 mmHg; P < 0
0	1 mg iv) and 12 patients received ENT1 ephedrine  ENT1END (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered. RESULTS: Induction of anesthesia was followed by ENT2 a decrease in MAP, HR, SV, and CO ENT2END concomitant with an elevation in S(c)O(2)
1	METHODS: Following induction of anesthesia by ENT1 fentanyl  ENT1END  (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, stroke volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered. RESULTS: Induction of anesthesia was followed by ENT2 a decrease in MAP, HR, SV, and CO ENT2END concomitant with an elevation in S(c)O(2)
1	We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced ENT1 hypotension  ENT1END  METHODS: Following induction of anesthesia by fentanyl (0.15 mg kg(-1)) and ENT2 propofol ENT2END (2
0	CONCLUSIONS: The utilization of ENT1 phenylephrine ENT1END to correct ENT2 hypotension ENT2END induced by anesthesia has a negative impact on S(c)O(2) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO
0	BACKGROUND: Vasopressor agents are used to correct anesthesia-induced ENT1 hypotension ENT1END  We describe the effect of phenylephrine and ENT2 ephedrine ENT2END on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced hypotension
1	We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation (S(c)O(2)) following anesthesia-induced ENT1 hypotension  ENT1END . METHODS: Following induction of anesthesia by ENT2 fentanyl ENT2END (0
0	15 mg kg(-1)) and ENT1 propofol ENT1END  (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, ENT2 stroke ENT2END volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered
0	0 mg kg(-1)), 13 patients received ENT1 phenylephrine  ENT1END (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, ENT2 stroke ENT2END volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered
0	1 mg iv) and 12 patients received ENT1 ephedrine  ENT1END  (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, ENT2 stroke ENT2END volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered
0	METHODS: Following induction of anesthesia by ENT1 fentanyl  ENT1END  (0.15 mg kg(-1)) and propofol (2.0 mg kg(-1)), 13 patients received phenylephrine (0.1 mg iv) and 12 patients received ephedrine (10 mg iv) to restore mean arterial pressure (MAP). Heart rate (HR), MAP, ENT2 stroke ENT2END volume (SV), cardiac output (CO), and frontal lobe oxygenation (S(c)O(2)) were registered
0	High doses of the ENT1 vitamin K ENT1END antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week. In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of ENT2 calcification ENT2END in the media of vitamin D-treated rats at 3 and 4 days
0	Because Warfarin treatment had no effect on the elevation in serum ENT1 calcium ENT1END produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a ENT2 calcification ENT2END inhibitor
0	In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of ENT1 calcification ENT1END  in the media of ENT2 vitamin D ENT2END -treated rats at 3 and 4 days
0	Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D, the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that ENT1 Warfarin  ENT1END inhibits the activity of matrix Gla protein as a ENT2 calcification ENT2END inhibitor
0	This observation suggests that increased susceptibility to Warfarin-induced artery calcification could be related to higher serum ENT1 phosphate  ENT1END levels. The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification. High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days. High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media, but at treatment times of 2 weeks or longer yet not at 1 week. In the current study, we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of ENT2 calcification ENT2END in the media of vitamin D-treated rats at 3 and 4 days
0	These observations indicate that although the ENT1 gamma-carboxyglutamate ENT1END residues of matrix Gla protein are apparently required for its function as a ENT2 calcification ENT2END inhibitor, they are not required for its accumulation at calcification sites
0	High doses of the ENT1 vitamin K ENT1END  antagonist Warfarin are also known to cause ENT2 calcification of the artery ENT2END media, but at treatment times of 2 weeks or longer yet not at 1 week
0	There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce ENT1 artery calcification ENT1END through its effect on serum ENT2 calcium ENT2END
0	There was a close parallel between the effect of ENT1 vitamin D ENT1END dose on ENT2 artery calcification ENT2END and the effect of vitamin D dose on the elevation of serum calcium, which suggests that vitamin D may induce artery calcification through its effect on serum calcium
1	The first series of experiments examined the influence of age and growth status on ENT1 artery calcification ENT1END in ENT2 Warfarin ENT2END -treated rats
0	Although the explanation for the association between artery calcification and growth status cannot be determined from the present study, there was a relationship between higher serum ENT1 phosphate ENT1END and susceptibility to ENT2 artery calcification ENT2END , with 30% higher levels of serum phosphate in young, ad libitum-fed rats compared with either of the groups that was resistant to Warfarin-induced artery calcification, ie, the 10-month-old rats and the restricted-diet, growth-inhibited young rats
0	High levels of matrix Gla protein are found at sites of ENT1 artery calcification ENT1END in rats treated with vitamin D plus Warfarin, and chemical analysis showed that the protein that accumulated was indeed not ENT2 gamma-carboxylated ENT2END
0	The data suggest that in VIP(-/-) mice with bladder inflammation, inflammatory mediators are increased above that observed in WT with ENT1 CYP ENT1END  This shift in balance may contribute to increased ENT2 bladder dysfunction ENT2END in VIP(-/-) mice with bladder inflammation and altered neurochemical expression in micturition pathways
1	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type (WT) and VIP(-/-) mice with or without ENT1 CYP ENT1END induced ENT2 cystitis ENT2END (150 mg/kg; i
0	A 3-year-old girl had behavioral deterioration, with hyperkinesis, ENT1 irritability ENT1END  and sleeping difficulties after the therapeutic administration of ENT2 isoniazid ENT2END
0	A 3-year-old girl had behavioral deterioration, with hyperkinesis, ENT1 irritability ENT1END , and sleeping difficulties after the therapeutic administration of isoniazid. The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms. After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine. A placebo had no effect, but niacinamide was as effective as pyridoxine. Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis. The level of ENT2 pyridoxal ENT2END in the blood was normal during the periods of relapse
0	A ENT1 pyridoxine  ENT1END -dependent behavioral disorder unmasked by isoniazid.A 3-year-old girl had behavioral deterioration, with hyperkinesis, ENT2 irritability ENT2END , and sleeping difficulties after the therapeutic administration of isoniazid
0	A 3-year-old girl had behavioral deterioration, with hyperkinesis, ENT1 irritability ENT1END , and sleeping difficulties after the therapeutic administration of isoniazid. The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms. After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine. A placebo had no effect, but ENT2 niacinamide ENT2END was as effective as pyridoxine
0	A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and ENT1 sleeping difficulties  ENT1END after the therapeutic administration of ENT2 isoniazid ENT2END
0	A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and ENT1 sleeping difficulties  ENT1END  after the therapeutic administration of isoniazid. The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms. After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine. A placebo had no effect, but niacinamide was as effective as pyridoxine. Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis. The level of ENT2 pyridoxal ENT2END in the blood was normal during the periods of relapse
0	A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and ENT1 sleeping difficulties ENT1END  after the therapeutic administration of isoniazid. The administration of pharmacologic doses of ENT2 pyridoxine hydrochloride ENT2END led to a disappearance of symptoms
0	A 3-year-old girl had behavioral deterioration, with hyperkinesis, irritability, and ENT1 sleeping difficulties  ENT1END  after the therapeutic administration of isoniazid. The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms. After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine. A placebo had no effect, but ENT2 niacinamide ENT2END was as effective as pyridoxine
1	A pyridoxine-dependent behavioral disorder unmasked by ENT1 isoniazid ENT1END .A 3-year-old girl had behavioral deterioration, with ENT2 hyperkinesis ENT2END , irritability, and sleeping difficulties after the therapeutic administration of isoniazid
0	Periodic withdrawal of pyridoxine was associated with return of the ENT1 hyperkinesis ENT1END  The level of pyridoxal in the blood was normal during the periods of relapse. Metabolic studies suggested a block in the kynurenine pathway of ENT2 tryptophan ENT2END metabolism
0	Periodic withdrawal of pyridoxine was associated with return of the ENT1 hyperkinesis  ENT1END . The level of ENT2 pyridoxal ENT2END in the blood was normal during the periods of relapse
0	Periodic withdrawal of ENT1 pyridoxine  ENT1END was associated with return of the ENT2 hyperkinesis ENT2END
0	Periodic withdrawal of pyridoxine was associated with return of the ENT1 hyperkinesis ENT1END . The level of pyridoxal in the blood was normal during the periods of relapse. Metabolic studies suggested a block in the ENT2 kynurenine ENT2END pathway of tryptophan metabolism
0	A placebo had no effect, but ENT1 niacinamide  ENT1END  was as effective as pyridoxine. Periodic withdrawal of pyridoxine was associated with return of the ENT2 hyperkinesis ENT2END
1	A pyridoxine-dependent ENT1 behavioral disorder  ENT1END  unmasked by ENT2 isoniazid ENT2END
0	A 3-year-old girl had ENT1 behavioral deterioration  ENT1END  with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid. The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms. After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine. A placebo had no effect, but niacinamide was as effective as pyridoxine. Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis. The level of ENT2 pyridoxal ENT2END in the blood was normal during the periods of relapse
0	A ENT1 pyridoxine  ENT1END -dependent ENT2 behavioral disorder ENT2END unmasked by isoniazid
0	A 3-year-old girl had ENT1 behavioral deterioration  ENT1END , with hyperkinesis, irritability, and sleeping difficulties after the therapeutic administration of isoniazid. The administration of pharmacologic doses of pyridoxine hydrochloride led to a disappearance of symptoms. After discontinuing isoniazid therapy a similar pattern of behavior was noted that was controlled by pyridoxine. A placebo had no effect, but ENT2 niacinamide ENT2END was as effective as pyridoxine
0	These responses were blocked by systemic pre-administration of ENT1 hexamethonium chloride ENT1END (20 mg/kg). The evoked increases in dural blood flow were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater. We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino-parasympathetic reflex. The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges. Similar mechanisms may be involved in the pathogenesis of ENT2 cluster headache ENT2END
0	The blood flow responses seem to be mediated by the release of ENT1 acetylcholine  ENT1END and VIP within the meninges. Similar mechanisms may be involved in the pathogenesis of ENT2 cluster headache ENT2END
0	ENT1 Cluster headache ENT1END is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances. Both the trigeminal and the cranial parasympathetic systems may be involved in mediating these dysfunctions. An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa. Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry. ENT2 Capsaicin ENT2END (0
0	The evoked increases in dural blood flow were also abolished by topical pre-administration of ENT1 atropine  ENT1END (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater. We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino-parasympathetic reflex. The blood flow responses seem to be mediated by the release of acetylcholine and VIP within the meninges. Similar mechanisms may be involved in the pathogenesis of ENT2 cluster headache ENT2END
0	These responses were blocked by systemic pre-administration of ENT1 hexamethonium chloride ENT1END  (20 mg/kg). The evoked ENT2 increases in dural blood flow ENT2END were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0
0	The evoked ENT1 increases in dural blood flow  ENT1END  were also abolished by topical pre-administration of atropine (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0.1 mm), a vasoactive intestinal polypeptide (VIP) antagonist, onto the exposed dura mater. We conclude that noxious stimulation of facial mucosa increases intracranial blood flow and lacrimation via a trigemino-parasympathetic reflex. The blood flow responses seem to be mediated by the release of ENT2 acetylcholine ENT2END and VIP within the meninges
1	ENT1 Capsaicin ENT1END  (0.01-1 mm) applied to oral or nasal mucosa induced ENT2 increases in dural and cortical blood flow ENT2END and provoked lacrimation
0	The evoked ENT1 increases in dural blood flow  ENT1END  were also abolished by topical pre-administration of ENT2 atropine ENT2END (1 mm) and [Lys1, Pro2,5, Arg3,4, Tyr6]-VIP (0
0	Cluster headache is characterized by typical autonomic dysfunctions including facial and ENT1 intracranial vascular disturbances  ENT1END  Both the trigeminal and the cranial parasympathetic systems may be involved in mediating these dysfunctions. An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa. Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry. Capsaicin (0.01-1 mm) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation. These responses were blocked by systemic pre-administration of ENT2 hexamethonium chloride ENT2END (20 mg/kg)
1	Cluster headache is characterized by typical autonomic dysfunctions including facial and ENT1 intracranial vascular disturbances  ENT1END . Both the trigeminal and the cranial parasympathetic systems may be involved in mediating these dysfunctions. An experimental model was developed in the rat to measure changes in lacrimation and intracranial blood flow following noxious chemical stimulation of facial mucosa. Blood flow was monitored in arteries of the exposed cranial dura mater and the parietal cortex using laser Doppler flowmetry. ENT2 Capsaicin ENT2END (0
1	Reversible ENT1 dilated cardiomyopathy  ENT1END  related to ENT2 amphotericin B ENT2END therapy
0	We describe a patient who developed ENT1 dilated cardiomyopathy ENT1END and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated coccidioidomycosis. His echocardiographic abnormalities and heart failure resolved after ENT2 posaconazole ENT2END was substituted for AmB
1	We describe a patient who developed dilated cardiomyopathy and clinical congestive ENT1 heart failure ENT1END after 2 months of therapy with ENT2 amphotericin B ENT2END (AmB) for disseminated coccidioidomycosis
0	His echocardiographic abnormalities and ENT1 heart failure  ENT1END resolved after ENT2 posaconazole ENT2END was substituted for AmB
0	It is important to recognize the rare and potentially reversible ENT1 toxicity ENT1END of ENT2 AmB ENT2END
0	His echocardiographic abnormalities and heart failure resolved after ENT1 posaconazole  ENT1END  was substituted for AmB. It is important to recognize the rare and potentially reversible ENT2 toxicity ENT2END of AmB
0	We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( ENT1 AmB ENT1END  for disseminated ENT2 coccidioidomycosis ENT2END
0	We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B (AmB) for disseminated ENT1 coccidioidomycosis  ENT1END . His echocardiographic abnormalities and heart failure resolved after ENT2 posaconazole ENT2END was substituted for AmB
1	The current study investigated the visual fields and visual electrophysiology of eight patients with known ENT1 vigabatrin ENT1END attributed ENT2 visual field loss ENT2END , three of whom were reported previously
0	ENT1 Coenzyme Q10 ENT1END significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT2 tumor ENT2END necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT1 tumor ENT1END  necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from ENT2 cisplatin ENT2END administration
0	Coenzyme Q10 significantly reduced ENT1 blood urea nitrogen  ENT1END and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT2 tumor ENT2END necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT1 tumor ENT1END  necrosis factor-alpha, ENT2 nitric oxide ENT2END and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT1 tumor ENT1END  necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and ENT2 zinc ENT2END ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT1 tumor ENT1END  necrosis factor-alpha, nitric oxide and ENT2 platinum ENT2END ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT1 tumor ENT1END  necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of ENT2 selenium ENT2END and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly reduced blood urea nitrogen and serum ENT1 creatinine  ENT1END levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT2 tumor ENT2END necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( ENT1 reduced glutathione  ENT1END level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT2 tumor ENT2END necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and ENT1 superoxide  ENT1END dismutase activity), suppressed lipid peroxidation, decreased the elevations of ENT2 tumor ENT2END necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	The nephroprotective effect of ENT1 coenzyme Q10 ENT1END was investigated in mice with ENT2 acute renal injury ENT2END induced by a single i
1	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury ENT1END  induced by a single i.p. injection of ENT2 cisplatin ENT2END (5 mg/kg)
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury  ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced ENT2 blood urea nitrogen ENT2END and serum creatinine levels which were increased by cisplatin
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury  ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, ENT2 nitric oxide ENT2END and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury  ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and ENT2 zinc ENT2END ions in renal tissue resulted from cisplatin administration
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury  ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and ENT2 platinum ENT2END ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury  ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of ENT2 selenium ENT2END and zinc ions in renal tissue resulted from cisplatin administration
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury  ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum ENT2 creatinine ENT2END levels which were increased by cisplatin
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ENT2 reduced glutathione ENT2END level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	The nephroprotective effect of coenzyme Q10 was investigated in mice with ENT1 acute renal injury  ENT1END  induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and ENT2 superoxide ENT2END dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	ENT1 Coenzyme Q10 ENT1END  significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT2 necrosis ENT2END factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT1 necrosis  ENT1END  factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from ENT2 cisplatin ENT2END administration
0	Coenzyme Q10 significantly reduced ENT1 blood urea nitrogen  ENT1END  and serum creatinine levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT2 necrosis ENT2END factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT1 necrosis  ENT1END  factor-alpha, ENT2 nitric oxide ENT2END and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT1 necrosis  ENT1END  factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and ENT2 zinc ENT2END ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT1 necrosis  ENT1END  factor-alpha, nitric oxide and ENT2 platinum ENT2END ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT1 necrosis  ENT1END  factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of ENT2 selenium ENT2END and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly reduced blood urea nitrogen and serum ENT1 creatinine  ENT1END  levels which were increased by cisplatin. Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT2 necrosis ENT2END factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( ENT1 reduced glutathione  ENT1END  level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT2 necrosis ENT2END factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and ENT1 superoxide  ENT1END  dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor ENT2 necrosis ENT2END factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration
0	ENT1 Coenzyme Q10  ENT1END  treatment ameliorates acute cisplatin ENT2 nephrotoxicity ENT2END in mice
0	Coenzyme Q10 treatment ameliorates acute ENT1 cisplatin ENT1END ENT2 nephrotoxicity ENT2END in mice
0	Coenzyme Q10 treatment ameliorates acute cisplatin ENT1 nephrotoxicity  ENT1END  in mice.The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced ENT2 blood urea nitrogen ENT2END and serum creatinine levels which were increased by cisplatin
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, ENT1 nitric oxide ENT1END  and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration. Also, histopathological ENT2 renal tissue damage ENT2END mediated by cisplatin was ameliorated by coenzyme Q10 treatment
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and ENT1 zinc  ENT1END  ions in renal tissue resulted from cisplatin administration. Also, histopathological ENT2 renal tissue damage ENT2END mediated by cisplatin was ameliorated by coenzyme Q10 treatment
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and ENT1 platinum  ENT1END  ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration. Also, histopathological ENT2 renal tissue damage ENT2END mediated by cisplatin was ameliorated by coenzyme Q10 treatment
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of ENT1 selenium  ENT1END  and zinc ions in renal tissue resulted from cisplatin administration. Also, histopathological ENT2 renal tissue damage ENT2END mediated by cisplatin was ameliorated by coenzyme Q10 treatment
0	Coenzyme Q10 treatment ameliorates acute cisplatin ENT1 nephrotoxicity  ENT1END  in mice.The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i.p. injection of cisplatin (5 mg/kg). Coenzyme Q10 treatment (10 mg/kg/day, i.p.) was applied for 6 consecutive days, starting 1 day before cisplatin administration. Coenzyme Q10 significantly reduced blood urea nitrogen and serum ENT2 creatinine ENT2END levels which were increased by cisplatin
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( ENT1 reduced glutathione  ENT1END  level and superoxide dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration. Also, histopathological ENT2 renal tissue damage ENT2END mediated by cisplatin was ameliorated by coenzyme Q10 treatment
0	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms (reduced glutathione level and ENT1 superoxide  ENT1END  dismutase activity), suppressed lipid peroxidation, decreased the elevations of tumor necrosis factor-alpha, nitric oxide and platinum ion concentration, and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration. Also, histopathological ENT2 renal tissue damage ENT2END mediated by cisplatin was ameliorated by coenzyme Q10 treatment
1	A case of tardive dyskinesia caused by ENT1 metoclopramide  ENT1END . ENT2 Abnormal involuntary movements ENT2END appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days
0	Abnormal involuntary movements appeared in the mouth, tongue, neck and abdomen of a 64-year-old male patient after he took ENT1 metoclopramide ENT1END for ENT2 gastrointestinal disorder ENT2END in a regimen of 30 mg per day for a total of about 260 days
0	Urine N-acetyl-beta-D-glucosaminidase--a marker of tubular damage?BACKGROUND: Although an indicator of ENT1 renal tubular dysfunction ENT1END  an increased urinary N-acetyl-beta-D-glucosaminidase (NAG) activity might reflect increased lysosomal activity in renal tubular cells. METHODS: ENT2 Puromycin aminonucleoside ENT2END (PAN) was administered to Sprague Dawley rats to induce proteinuria
1	METHODS: Puromycin aminonucleoside ( ENT1 PAN ENT1END  was administered to Sprague Dawley rats to induce ENT2 proteinuria ENT2END
1	On repeat challenge with ENT1 phenobarbital ENT1END  the ENT2 dyskinesia ENT2END recurred
0	ENT1 Phenobarbital  ENT1END -induced dyskinesia in a ENT2 neurologically-impaired ENT2END child
0	A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting ENT1 phenobarbital ENT1END therapy for ENT2 seizures ENT2END
0	A 2-year-old child with known neurologic impairment developed a dyskinesia soon after starting ENT1 phenobarbital ENT1END  therapy for seizures. Known causes of ENT2 movement disorders ENT2END were eliminated after evaluation
1	RESULTS: Maternal toxicity, ENT1 intrauterine growth retardation ENT1END  and increase of external and skeletal variations were found in rats treated with the highest dose of ENT2 piroxicam ENT2END
1	RESULTS: Maternal toxicity, ENT1 intrauterine growth retardation ENT1END , and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam. Decrease of fetal length was the only signs of the ENT2 DFU ENT2END developmental toxicity observed in pups exposed to the highest compound dose
0	The pooled statistical analysis for ENT1 ventricular septal (VSD) and midline (MD) defects ENT1END was performed for rat fetuses exposed to ENT2 piroxicam ENT2END , selective and non-selective COX-2 inhibitor based on present and historic data
0	Unlike ENT1 DFU ENT1END  piroxicam was also highly toxic to the dams. Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ENT2 ventricular septal and midline defects ENT2END in rat when compared to non-selective drugs and historic control
0	The aim of the experiment was to evaluate the developmental ENT1 toxicity  ENT1END of the non-selective ( ENT2 piroxicam ENT2END ) and selective (DFU; 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl) phenyl-2(5H)-furanon) COX-2 inhibitors
0	Decrease of fetal length was the only signs of the ENT1 DFU ENT1END  developmental ENT2 toxicity ENT2END observed in pups exposed to the highest compound dose
1	RESULTS: Maternal toxicity, intrauterine growth retardation, and ENT1 increase of external and skeletal variations  ENT1END were found in rats treated with the highest dose of ENT2 piroxicam ENT2END
0	RESULTS: Maternal toxicity, intrauterine growth retardation, and ENT1 increase of external and skeletal variations  ENT1END  were found in rats treated with the highest dose of piroxicam. Decrease of fetal length was the only signs of the ENT2 DFU ENT2END developmental toxicity observed in pups exposed to the highest compound dose
0	The pooled statistical analysis for ENT1 ventricular septal (VSD) and midline (MD) defects  ENT1END was performed for rat fetuses exposed to ENT2 piroxicam ENT2END , selective and non-selective COX-2 inhibitor based on present and historic data
0	Unlike ENT1 DFU ENT1END , piroxicam was also highly toxic to the dams. Prenatal exposure to selective COX-2 inhibitors does not increase the risk of ENT2 ventricular septal and midline defects ENT2END in rat when compared to non-selective drugs and historic control
0	Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and ENT1 Erectile Dysfunction ENT1END Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures). Participants were followed biweekly during study period. RESULTS: After 12 weeks of treatment, the mean (sd) scores for CGI-SF were significantly lower, i.e. better, in patients on ENT2 bupropion ENT2END SR, at 2
1	PATIENTS AND METHODS: The randomized sample consisted of 234 euthymic men who were receiving some type of ENT1 SSRI  ENT1END  The men were randomly assigned to bupropion SR (150 mg twice daily, 117) or placebo (twice daily, 117) for 12 weeks. Efficacy was evaluated using the Clinical Global Impression-Sexual Function (CGI-SF; the primary outcome measure), the International Index of Erectile Function (IIEF), Arizona Sexual Experience Scale (ASEX), and ENT2 Erectile Dysfunction ENT2END Inventory of Treatment Satisfaction (EDITS) (secondary outcome measures)
0	The effects of the adjunctive ENT1 bupropion  ENT1END  on male ENT2 sexual dysfunction ENT2END induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study
0	OBJECTIVE: To determine the safety and efficacy of adjunctive bupropion sustained-release (SR) on male sexual dysfunction (SD) induced by a selective serotonin reuptake inhibitor ( ENT1 SSRI ENT1END , as ENT2 SD ENT2END is a common side-effect of SSRIs and the most effective treatments have yet to be determined
0	ENT1 Amiodarone ENT1END represents an effective antiarrhythmic drug for cardioversion of recent-onset ENT2 atrial fibrillation ENT2END (AF) and maintenance of sinus rhythm
1	Acute ENT1 low back pain  ENT1END  during intravenous administration of ENT2 amiodarone ENT2END : a report of two cases
1	ENT1 Visual hallucinations  ENT1END  associated with ENT2 zonisamide ENT2END
0	ENT1 Zonisamide ENT1END is a broad-spectrum antiepileptic drug used to treat various types of ENT2 seizures ENT2END
0	Although visual hallucinations have not been reported as an adverse effect of this agent, we describe three patients who experienced complex visual hallucinations and altered mental status after ENT1 zonisamide ENT1END treatment was begun or its dosage increased. All three had been diagnosed earlier with ENT2 epilepsy ENT2END , and their electroencephalogram (EEG) findings were abnormal
0	These results suggest that ENT1 betaxolol ENT1END could be less of a ENT2 depression ENT2END -inducer than timolol in predisposed patients
1	These results suggest that betaxolol could be less of a ENT1 depression ENT1END -inducer than ENT2 timolol ENT2END in predisposed patients
0	Depression and ENT1 sexual dysfunction  ENT1END have been related to side effects of topical beta-blockers. We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker ( ENT2 betaxolol ENT2END ) regarding CNS side effects
0	Depression and ENT1 sexual dysfunction  ENT1END  have been related to side effects of topical beta-blockers. We performed a preliminary study in order to determine any difference between a non selective beta-blocker ( ENT2 timolol ENT2END ) and a selective beta-blocker (betaxolol) regarding CNS side effects
0	We performed a preliminary study in order to determine any difference between a non selective beta-blocker (timolol) and a selective beta-blocker ( ENT1 betaxolol ENT1END ) regarding CNS side effects. Eight ENT2 glaucomatous ENT2END patients chronically treated with timolol 0
0	Eight ENT1 glaucomatous ENT1END  patients chronically treated with ENT2 timolol ENT2END 0
0	METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected ENT1 fungal infection ENT1END  RESULTS: Patients receiving concomitant ENT2 AmB ENT2END and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone (P = 0
0	METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected ENT1 fungal infection ENT1END . RESULTS: Patients receiving concomitant AmB and spironolactone had significantly higher plasma ENT2 potassium ENT2END levels than those receiving AmB alone (P = 0
0	METHODS: In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected ENT1 fungal infection ENT1END . RESULTS: Patients receiving concomitant AmB and ENT2 spironolactone ENT2END had significantly higher plasma potassium levels than those receiving AmB alone (P = 0
1	Spironolactone: is it a novel drug for the prevention of ENT1 amphotericin B  ENT1END -related ENT2 hypokalemia ENT2END in cancer patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage
0	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent ENT1 hypokalemia ENT1END by reducing urinary ENT2 potassium ENT2END loss in neutropenic patients on AmB treatment
0	CONCLUSION: This study showed that ENT1 spironolactone  ENT1END can reduce potassium requirements and prevent ENT2 hypokalemia ENT2END by reducing urinary potassium loss in neutropenic patients on AmB treatment
0	Spironolactone: is it a novel drug for the prevention of ENT1 amphotericin B  ENT1END -related hypokalemia in ENT2 cancer ENT2END patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage
0	Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in ENT1 cancer ENT1END  patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage. Selective distal tubular epithelial toxicity seems to be responsible for the profound ENT2 potassium ENT2END wasting that is a major clinical side effect of treatment with AmB
0	ENT1 Spironolactone  ENT1END : is it a novel drug for the prevention of amphotericin B-related hypokalemia in ENT2 cancer ENT2END patients?OBJECTIVE: Nephrotoxicity is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage
0	Potassium depletion also potentiates the tubular ENT1 toxicity ENT1END of ENT2 AmB ENT2END
0	ENT1 Potassium  ENT1END depletion also potentiates the tubular ENT2 toxicity ENT2END of AmB
0	Potassium depletion also potentiates the tubular ENT1 toxicity ENT1END  of AmB. This study was designed to assess the ability of ENT2 spironolactone ENT2END to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment
0	METHODS: In this study 26 patients with various ENT1 hematological disorders ENT1END were randomized to receive either intravenous ENT2 AmB ENT2END alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection
0	This study was designed to assess the ability of spironolactone to reduce ENT1 potassium  ENT1END requirements and to prevent hypokalemia in neutropenic patients on AmB treatment. METHODS: In this study 26 patients with various ENT2 hematological disorders ENT2END were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection
0	METHODS: In this study 26 patients with various ENT1 hematological disorders ENT1END  were randomized to receive either intravenous AmB alone or AmB and oral ENT2 spironolactone ENT2END 100 mg twice daily when developing a proven or suspected fungal infection
0	Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: ENT1 Nephrotoxicity ENT1END is the major adverse effect of ENT2 amphotericin B ENT2END (AmB), often limiting administration of full dosage
0	Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: ENT1 Nephrotoxicity  ENT1END  is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage. Selective distal tubular epithelial toxicity seems to be responsible for the profound ENT2 potassium ENT2END wasting that is a major clinical side effect of treatment with AmB
0	ENT1 Spironolactone  ENT1END : is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?OBJECTIVE: ENT2 Nephrotoxicity ENT2END is the major adverse effect of amphotericin B (AmB), often limiting administration of full dosage
0	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in ENT1 neutropenic ENT1END patients on ENT2 AmB ENT2END treatment
0	CONCLUSION: This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary ENT1 potassium ENT1END  loss in ENT2 neutropenic ENT2END patients on AmB treatment
0	This study was designed to assess the ability of ENT1 spironolactone  ENT1END  to reduce potassium requirements and to prevent hypokalemia in ENT2 neutropenic ENT2END patients on AmB treatment
1	Thiazide diuretics, hypokalemia and ENT1 cardiac arrhythmias ENT1END .Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs. Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy. We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with ENT2 hydrochlorothiazide ENT2END (HCTC) administered on a twice daily schedule
0	Thiazide diuretics, hypokalemia and ENT1 cardiac arrhythmias ENT1END .Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs. Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy. We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with hydrochlorothiazide (HCTC) administered on a twice daily schedule. Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized. The serum ENT2 K ENT2END during the control period was 4
0	Thiazide diuretics, hypokalemia and ENT1 cardiac arrhythmias  ENT1END . ENT2 Thiazide ENT2END diuretics are widely accepted as the cornerstone of antihypertensive treatment programs
0	We treated 38 patients (22 low renin, 16 normal renin) with moderate ENT1 diastolic hypertension  ENT1END with ENT2 hydrochlorothiazide ENT2END (HCTC) administered on a twice daily schedule
0	We treated 38 patients (22 low renin, 16 normal renin) with moderate ENT1 diastolic hypertension  ENT1END  with hydrochlorothiazide (HCTC) administered on a twice daily schedule. Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg, 150 mg and 200 mg daily until blood pressure normalized. The serum ENT2 K ENT2END during the control period was 4
0	Hypokalemia is a commonly encountered metabolic consequence of chronic ENT1 thiazide  ENT1END therapy. We treated 38 patients (22 low renin, 16 normal renin) with moderate ENT2 diastolic hypertension ENT2END with hydrochlorothiazide (HCTC) administered on a twice daily schedule
1	ENT1 Hypokalemia  ENT1END is a commonly encountered metabolic consequence of chronic thiazide therapy. We treated 38 patients (22 low renin, 16 normal renin) with moderate diastolic hypertension with ENT2 hydrochlorothiazide ENT2END (HCTC) administered on a twice daily schedule
0	In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body ENT1 potassium ENT1END  The more profound ENT2 hypokalemia ENT2END , the greater the propensity for the occurrence of PVC's
0	ENT1 Thiazide  ENT1END  diuretics, ENT2 hypokalemia ENT2END and cardiac arrhythmias
0	The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and ENT1 NMDA ENT1END receptors. In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced ENT2 convulsions ENT2END and lethality
0	In behavioral studies, pre-treatment of mice with BD1018, ENT1 BD1063  ENT1END  or LR132 significantly attenuated cocaine-induced ENT2 convulsions ENT2END and lethality
1	In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated ENT1 cocaine  ENT1END induced ENT2 convulsions ENT2END and lethality
0	To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense ENT1 oligodeoxynucleotide ENT1END against sigma1 receptors was also shown to significantly attenuate the ENT2 convulsive ENT2END and locomotor stimulatory effects of cocaine
0	In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced ENT1 convulsions ENT1END  and lethality. Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals. In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist ENT2 di-o-tolylguanidine ENT2END (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4
0	Conformationally restricted analogs of ENT1 BD1008  ENT1END  and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice.Cocaine's ability to interact with sigma receptors suggests that these proteins mediate some of its behavioral effects. Therefore, three novel sigma receptor ligands with antagonist activity were evaluated in Swiss Webster mice: BD1018 (3S-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane), BD1063 (1-[2-(3,4-dichlorophenyl)ethyl]-4-methylpiperazine), and LR132 (1R,2S-(+)-cis-N-[2-(3,4-dichlorophenyl)ethyl]-2-(1-pyrrolidinyl)cyclohexylamine). Competition binding assays demonstrated that all three compounds have high affinities for sigma1 receptors. The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and NMDA receptors. In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced ENT2 convulsions ENT2END and lethality
0	The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, ENT1 GABA  ENT1END A) and NMDA receptors. In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced ENT2 convulsions ENT2END and lethality
0	The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for ENT1 dopamine  ENT1END  opioid, GABA(A) and NMDA receptors. In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced ENT2 convulsions ENT2END and lethality
0	The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, GABA(A) and ENT1 NMDA ENT1END  receptors. In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality. Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals. In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral ENT2 toxicity ENT2END of cocaine
0	0]nonane) each worsened the behavioral ENT1 toxicity ENT1END  of cocaine. At doses where alone, they produced no significant effects on locomotion, BD1018, ENT2 BD1063 ENT2END and LR132 significantly attenuated the locomotor stimulatory effects of cocaine
0	0]nonane) each worsened the behavioral ENT1 toxicity ENT1END  of ENT2 cocaine ENT2END
0	0]nonane) each worsened the behavioral ENT1 toxicity  ENT1END  of cocaine. At doses where alone, they produced no significant effects on locomotion, BD1018, BD1063 and LR132 significantly attenuated the locomotor stimulatory effects of cocaine. To further validate the hypothesis that the anti-cocaine effects of the novel ligands involved antagonism of sigma receptors, an antisense ENT2 oligodeoxynucleotide ENT2END against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine
0	In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine ( ENT1 DTG  ENT1END  and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral ENT2 toxicity ENT2END of cocaine
0	The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for dopamine, opioid, ENT1 GABA  ENT1END (A) and NMDA receptors. In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality. Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals. In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral ENT2 toxicity ENT2END of cocaine
0	The three compounds vary in their affinities for sigma2 receptors and exhibit negligible affinities for ENT1 dopamine  ENT1END , opioid, GABA(A) and NMDA receptors. In behavioral studies, pre-treatment of mice with BD1018, BD1063, or LR132 significantly attenuated cocaine-induced convulsions and lethality. Moreover, post-treatment with LR132 prevented cocaine-induced lethality in a significant proportion of animals. In contrast to the protection provided by the putative antagonists, the well-characterized sigma receptor agonist di-o-tolylguanidine (DTG) and the novel sigma receptor agonist BD1031 (3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane) each worsened the behavioral ENT2 toxicity ENT2END of cocaine
0	Diarrhoea-predominant IBS patients had a higher ENT1 pain ENT1END score after ENT2 cisapride ENT2END therapy [score, 55 +/- 15 versus 34 +/- 12 mm, cisapride versus placebo (P < 0
1	Effects of ENT1 cisapride ENT1END  on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome.BACKGROUND: Irritable bowel syndrome is a common cause of ENT2 abdominal pain ENT2END and discomfort and may be related to disordered gastrointestinal motility
0	Symptom scores relating to the severity of constipation were lower in ENT1 cisapride ENT1END treated constipation-predominant ENT2 IBS ENT2END patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0
0	BACKGROUND: Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to ENT1 disordered gastrointestinal motility ENT1END  Our aim was to assess the effects of long-term treatment with a prokinetic agent, ENT2 cisapride ENT2END , on postprandial jejunal motility and symptoms in the irritable bowel syndrome (IBS)
0	Symptom scores relating to the severity of constipation were lower in ENT1 cisapride ENT1END -treated ENT2 constipation ENT2END -predominant IBS patients [score, 54 +/- 5 versus 67 +/- 14 mm, cisapride versus placebo (P < 0
0	In ENT1 cisapride ENT1END treated ENT2 diarrhoea ENT2END -predominant patients the mean contraction amplitude was higher (29
0	OUTCOME MEASURES: Laboratory analyses of calcium, ENT1 magnesium ENT1END and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up. RESULTS: Hypothyroidism developed in 40 patients, excluding 8 patients who were hypothyroid at baseline. All patients having first-degree relatives affected by ENT2 thyroid illness ENT2END had accelerated onset of hypothyroidism (3
0	CONCLUSIONS: Familial ENT1 thyroid illness ENT1END is a risk factor for hypothyroidism and hypercalcemia during ENT2 lithium ENT2END therapy
0	Thus, lithium treatment counteracted the decrease in plasma ENT1 calcium  ENT1END levels associated with aging. CONCLUSIONS: Familial ENT2 thyroid illness ENT2END is a risk factor for hypothyroidism and hypercalcemia during lithium therapy
0	PATIENTS: One hundred and one patients (28 men and 73 women) with ENT1 bipolar disorder  ENT1END receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration. The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics. OUTCOME MEASURES: Laboratory analyses of calcium, ENT2 magnesium ENT2END and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up
0	PATIENTS: One hundred and one patients (28 men and 73 women) with ENT1 bipolar disorder ENT1END  receiving ENT2 lithium ENT2END maintenance therapy ranging from 1 year's to 32 years' duration
0	PATIENTS: One hundred and one patients (28 men and 73 women) with ENT1 bipolar disorder ENT1END  receiving lithium maintenance therapy ranging from 1 year's to 32 years' duration. The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital's out-patient clinics. OUTCOME MEASURES: Laboratory analyses of ENT2 calcium ENT2END , magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up
0	The control group consisted of 82 patients with no ENT1 psychiatric  ENT1END or endocrinological diagnoses from the hospital's out-patient clinics. OUTCOME MEASURES: Laboratory analyses of calcium, ENT2 magnesium ENT2END and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up
0	PATIENTS: One hundred and one patients (28 men and 73 women) with bipolar disorder receiving ENT1 lithium  ENT1END  maintenance therapy ranging from 1 year's to 32 years' duration. The control group consisted of 82 patients with no ENT2 psychiatric ENT2END or endocrinological diagnoses from the hospital's out-patient clinics
0	The control group consisted of 82 patients with no ENT1 psychiatric  ENT1END  or endocrinological diagnoses from the hospital's out-patient clinics. OUTCOME MEASURES: Laboratory analyses of ENT2 calcium ENT2END , magnesium and thyroid-stimulating hormone levels performed before beginning lithium therapy and at biannual follow-up
0	Women over 60 years of age were more often affected by ENT1 hypothyroidism ENT1END than women under 60 years of age (34.6% versus 31.9%). ENT2 Magnesium ENT2END levels in patients on lithium treatment were unchanged from baseline levels
1	CONCLUSIONS: Familial thyroid illness is a risk factor for ENT1 hypothyroidism  ENT1END and hypercalcemia during ENT2 lithium ENT2END therapy
0	Thus, lithium treatment counteracted the decrease in plasma ENT1 calcium  ENT1END  levels associated with aging. CONCLUSIONS: Familial thyroid illness is a risk factor for ENT2 hypothyroidism ENT2END and hypercalcemia during lithium therapy
0	ENT1 Magnesium ENT1END  levels in patients on lithium treatment were unchanged from baseline levels. After lithium treatment, calcium levels were higher than either baseline levels or control levels. Thus, lithium treatment counteracted the decrease in plasma calcium levels associated with aging. CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and ENT2 hypercalcemia ENT2END during lithium therapy
0	CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and ENT1 hypercalcemia  ENT1END  during ENT2 lithium ENT2END therapy
0	Thus, lithium treatment counteracted the decrease in plasma ENT1 calcium  ENT1END  levels associated with aging. CONCLUSIONS: Familial thyroid illness is a risk factor for hypothyroidism and ENT2 hypercalcemia ENT2END during lithium therapy
1	The epidemiological studies that assessed the risk of venous thromboembolism ( ENT1 VTE ENT1END  associated with newer ENT2 oral contraceptives ENT2END (OC) did not distinguish between patterns of OC use, namely first-time users, repeaters and switchers
0	METHODS: This double-blind study examined the incidence and severity of postoperative nausea and vomiting and ENT1 pain ENT1END in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients. Patients were randomly allocated to either receive or not receive 1 1 fentanyl, while a third group received ENT2 dexamethasone ENT2END in addition to fentanyl
0	Omitting ENT1 fentanyl  ENT1END  reduces nausea and vomiting, without increasing ENT2 pain ENT2END , after sevoflurane for day surgery
0	Omitting fentanyl reduces nausea and vomiting, without increasing ENT1 pain  ENT1END , after ENT2 sevoflurane ENT2END for day surgery
0	ENT1 Dexamethasone ENT1END had no significant effect on the incidence or severity of postoperative nausea and vomiting. Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034). Pain severity and analgesic requirements were unaffected by the omission of fentanyl. Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, ENT2 hypotension ENT2END and bradycardia
1	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, ENT1 hypotension ENT1END  and bradycardia. CONCLUSION: As ENT2 fentanyl ENT2END exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery
0	Fentanyl did reduce minor intraoperative movement but had no ENT1 sevoflurane  ENT1END sparing effect and increased respiratory depression, ENT2 hypotension ENT2END and bradycardia
0	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of ENT1 vomiting  ENT1END and/or moderate to severe nausea prior to discharge from 20% and 17% with fentanyl and fentanyl- ENT2 dexamethasone ENT2END , respectively, to 5% (P = 0
0	Omitting ENT1 fentanyl  ENT1END  reduces nausea and ENT2 vomiting ENT2END , without increasing pain, after sevoflurane for day surgery
0	Omitting fentanyl reduces nausea and ENT1 vomiting  ENT1END , without increasing pain, after ENT2 sevoflurane ENT2END for day surgery
0	ENT1 Dexamethasone ENT1END  had no significant effect on the incidence or severity of ENT2 postoperative nausea and vomiting ENT2END
1	CONCLUSION: As ENT1 fentanyl ENT1END  exacerbated ENT2 postoperative nausea and vomiting ENT2END without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery
0	BACKGROUND AND OBJECTIVE: Despite advantages of induction and maintenance of anaesthesia with ENT1 sevoflurane ENT1END  ENT2 postoperative nausea and vomiting ENT2END occurs frequently
0	ENT1 Dexamethasone ENT1END  had no significant effect on the incidence or severity of postoperative nausea and vomiting. Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034). Pain severity and analgesic requirements were unaffected by the omission of fentanyl. Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and bradycardia. CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in ENT2 postoperative pain ENT2END and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery
0	CONCLUSION: As ENT1 fentanyl  ENT1END  exacerbated postoperative nausea and vomiting without an improvement in ENT2 postoperative pain ENT2END and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery
0	CONCLUSION: As fentanyl exacerbated postoperative nausea and vomiting without an improvement in ENT1 postoperative pain ENT1END  and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to ENT2 sevoflurane ENT2END in day surgery
0	ENT1 Dexamethasone ENT1END  had no significant effect on the incidence or severity of postoperative nausea and vomiting. Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034). Pain severity and analgesic requirements were unaffected by the omission of fentanyl. Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and ENT2 bradycardia ENT2END
1	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased respiratory depression, hypotension and ENT1 bradycardia  ENT1END . CONCLUSION: As ENT2 fentanyl ENT2END exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery
0	Fentanyl did reduce minor intraoperative movement but had no ENT1 sevoflurane  ENT1END -sparing effect and increased respiratory depression, hypotension and ENT2 bradycardia ENT2END
0	RESULTS: Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting, but did reduce the incidence of vomiting and/or moderate to severe ENT1 nausea  ENT1END prior to discharge from 20% and 17% with fentanyl and fentanyl ENT2 dexamethasone ENT2END , respectively, to 5% (P = 0
0	Omitting ENT1 fentanyl  ENT1END  reduces ENT2 nausea ENT2END and vomiting, without increasing pain, after sevoflurane for day surgery
0	Omitting fentanyl reduces ENT1 nausea  ENT1END  and vomiting, without increasing pain, after ENT2 sevoflurane ENT2END for day surgery
0	ENT1 Dexamethasone ENT1END  had no significant effect on the incidence or severity of postoperative nausea and vomiting. Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids, reducing postoperative nausea and vomiting and nausea prior to discharge from 35% and 33% to 22% and 19% (P = 0.049 and P = 0.035), respectively, while nausea in the first 24 h was decreased from 42% to 27% (P = 0.034). Pain severity and analgesic requirements were unaffected by the omission of fentanyl. Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased ENT2 respiratory depression ENT2END , hypotension and bradycardia
1	Fentanyl did reduce minor intraoperative movement but had no sevoflurane-sparing effect and increased ENT1 respiratory depression  ENT1END , hypotension and bradycardia. CONCLUSION: As ENT2 fentanyl ENT2END exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects, it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery
0	Fentanyl did reduce minor intraoperative movement but had no ENT1 sevoflurane  ENT1END -sparing effect and increased ENT2 respiratory depression ENT2END , hypotension and bradycardia
0	However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to ENT1 KA ENT1END  Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine. Moreover, the dopaminergic control of epilepsy-induced ENT2 neurodegeneration ENT2END seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters
0	Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and ENT1 acetylcholine  ENT1END  Moreover, the dopaminergic control of epilepsy-induced ENT2 neurodegeneration ENT2END seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters
0	However, ENT1 pilocarpine  ENT1END induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA. Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine. Moreover, the dopaminergic control of epilepsy-induced ENT2 neurodegeneration ENT2END seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters
0	Thus, the absence of D2R lowers the threshold for seizures induced by both ENT1 glutamate  ENT1END and acetylcholine. Moreover, the dopaminergic control of epilepsy-induced ENT2 neurodegeneration ENT2END seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters
1	However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to ENT1 KA ENT1END . Thus, the absence of D2R lowers the threshold for ENT2 seizures ENT2END induced by both glutamate and acetylcholine
0	Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of ENT1 seizures ENT1END at the cellular level. In this respect, little is known about the role of ENT2 DA ENT2END receptors in the occurrence of epilepsy-induced neuronal cell death
0	Thus, the absence of D2R lowers the threshold for ENT1 seizures  ENT1END  induced by both glutamate and ENT2 acetylcholine ENT2END
1	However, ENT1 pilocarpine ENT1END -induced ENT2 seizures ENT2END result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA
0	Thus, the absence of D2R lowers the threshold for ENT1 seizures  ENT1END  induced by both ENT2 glutamate ENT2END and acetylcholine
0	Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater ENT1 neurotoxicity  ENT1END  However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to ENT2 KA ENT2END
0	In this respect, little is known about the role of ENT1 DA ENT1END  receptors in the occurrence of epilepsy-induced neuronal cell death. Here we analyze the occurrence of seizures and ENT2 neurotoxicity ENT2END in D2R -/- mice treated with the cholinergic agonist pilocarpine
0	Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater ENT1 neurotoxicity  ENT1END . However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA. Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and ENT2 acetylcholine ENT2END
0	Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater ENT1 neurotoxicity  ENT1END . However, ENT2 pilocarpine ENT2END -induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to KA
0	We compared these results with those previously obtained with kainic acid (KA), a potent ENT1 glutamate  ENT1END agonist. Importantly, D2R -/- mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater ENT2 neurotoxicity ENT2END
0	However, pilocarpine-induced seizures result in a more widespread neuronal death in both WT and D2R -/- brains in comparison to ENT1 KA ENT1END . Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine. Moreover, the dopaminergic control of ENT2 epilepsy ENT2END -induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters
0	In this respect, little is known about the role of ENT1 DA ENT1END  receptors in the occurrence of ENT2 epilepsy ENT2END -induced neuronal cell death
0	Thus, the absence of D2R lowers the threshold for seizures induced by both glutamate and ENT1 acetylcholine  ENT1END . Moreover, the dopaminergic control of ENT2 epilepsy ENT2END -induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters
0	In this respect, little is known about the role of DA receptors in the occurrence of ENT1 epilepsy ENT1END -induced neuronal cell death. Here we analyze the occurrence of seizures and neurotoxicity in D2R -/- mice treated with the cholinergic agonist ENT2 pilocarpine ENT2END
0	Thus, the absence of D2R lowers the threshold for seizures induced by both ENT1 glutamate  ENT1END  and acetylcholine. Moreover, the dopaminergic control of ENT2 epilepsy ENT2END -induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters
0	The dosing schedule, duration of lithium treatment, and daily dose of lithium did not affect maximum osmolality or ENT1 creatinine ENT1END clearance. CONCLUSIONS: Urine volume can be reduced by giving lithium once daily and/or by lowering the total daily dose. Lithium-induced ENT2 polyuria ENT2END seems to be related to extrarenal as well as to renal effects
1	ENT1 Lithium  ENT1END induced ENT2 polyuria ENT2END seems to be related to extrarenal as well as to renal effects
0	An elderly woman developed an Alzheimer-like subacute ENT1 dementia ENT1END as a result of ENT2 propranolol ENT2END toxicity
0	Amnestic syndrome associated with ENT1 propranolol ENT1END ENT2 toxicity ENT2END : a case report
0	An elderly woman developed an ENT1 Alzheimer  ENT1END like subacute dementia as a result of ENT2 propranolol ENT2END toxicity
1	ENT1 Amnestic syndrome  ENT1END  associated with ENT2 propranolol ENT2END toxicity: a case report
1	ENT1 Pilocarpine ENT1END on either day induced ENT2 status epilepticus ENT2END ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures, whereas P20 rats had no cell loss or spontaneous seizures
0	ENT1 Pilocarpine ENT1END ENT2 seizures ENT2END cause age-dependent impairment in auditory location discrimination
1	ENT1 Pilocarpine  ENT1END  seizures cause age-dependent ENT2 impairment in auditory location discrimination ENT2END
0	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine ( ENT1 BAU ENT1END  to effect, in vivo, AZT-induced ENT2 anemia ENT2END and leukopenia was assessed
0	This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without ENT1 Urd ENT1END related toxicity. In mice rendered ENT2 anemic ENT2END and leukopenic by the administration of AZT for 28 days in drinking water (1
1	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, ENT1 AZT  ENT1END induced ENT2 anemia ENT2END and leukopenia was assessed
0	When coadministered with AZT from the onset of drug administration, ENT1 BAU ENT1END reduced AZT-induced ENT2 marrow toxicity ENT2END
0	Benzylacyclouridine reverses azidothymidine-induced ENT1 marrow suppression ENT1END  without impairment of anti-human immunodeficiency virus activity.Increased extracellular concentrations of ENT2 uridine ENT2END (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity
1	When coadministered with AZT from the onset of drug administration, BAU reduced ENT1 AZT  ENT1END induced ENT2 marrow toxicity ENT2END
0	ENT1 Benzylacyclouridine  ENT1END  reverses azidothymidine-induced marrow suppression without impairment of anti-human ENT2 immunodeficiency ENT2END virus activity
0	Benzylacyclouridine reverses azidothymidine-induced marrow suppression without impairment of anti-human ENT1 immunodeficiency  ENT1END  virus activity.Increased extracellular concentrations of ENT2 uridine ENT2END (Urd) have been reported to reduce, in vitro, azidothymidine (AZT)-induced inhibition of human granulocyte-macrophage progenitor cells without impairment of its antihuman immunodeficiency virus (HIV) activity
0	Benzylacyclouridine reverses ENT1 azidothymidine  ENT1END -induced marrow suppression without impairment of anti-human ENT2 immunodeficiency ENT2END virus activity
0	Because of the clinical ENT1 toxicities ENT1END associated with chronic Urd administration, the ability of ENT2 benzylacyclouridine ENT2END (BAU) to effect, in vivo, AZT-induced anemia and leukopenia was assessed
0	This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without ENT1 Urd ENT1END -related ENT2 toxicity ENT2END
0	This agent inhibits Urd catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related ENT1 toxicity ENT1END . In mice rendered anemic and leukopenic by the administration of ENT2 AZT ENT2END for 28 days in drinking water (1
0	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine ( ENT1 BAU ENT1END ) to effect, in vivo, AZT-induced anemia and ENT2 leukopenia ENT2END was assessed
0	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, AZT-induced anemia and ENT1 leukopenia ENT1END  was assessed. This agent inhibits ENT2 Urd ENT2END catabolism and, in vivo, increases the plasma concentration of Urd in a dose-dependent manner, without Urd-related toxicity
1	Because of the clinical toxicities associated with chronic Urd administration, the ability of benzylacyclouridine (BAU) to effect, in vivo, ENT1 AZT  ENT1END -induced anemia and ENT2 leukopenia ENT2END was assessed
0	The most common adverse effect of intravenous ribavirin is reversible mild ENT1 anemia ENT1END  The use of ENT2 cidofovir ENT2END in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity
0	The most common adverse effect of intravenous ENT1 ribavirin  ENT1END is reversible mild ENT2 anemia ENT2END
0	Ribavirin, a ENT1 guanosine  ENT1END analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro. Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses. The most common adverse effect of intravenous ribavirin is reversible mild ENT2 anemia ENT2END
0	Use of ENT1 cidofovir ENT1END in 1 child was associated with progressive renal failure and neutropenia. DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with ENT2 immunodeficiency ENT2END
0	DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with ENT1 immunodeficiency ENT1END . Although intravenous ENT2 ribavirin ENT2END was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the infection
0	The use of ENT1 cidofovir ENT1END  in severe ENT2 adenovirus infection ENT2END has been limited by adverse effects, the most significant of which is nephrotoxicity
0	The remaining 3 children died of ENT1 adenovirus disease ENT1END  Intravenous ENT2 ribavirin ENT2END therapy was well tolerated
0	Apparent clinical success in the treatment of severe ENT1 adenovirus disease  ENT1END is limited to a few case reports and small series. Experience is greatest with intravenous ribavirin and cidofovir. Ribavirin, a ENT2 guanosine ENT2END analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro
0	The bone marrow transplant patient also received intravenous ENT1 cidofovir ENT1END for progressive disseminated disease. An additional 3 children developed ENT2 adenovirus pneumonia ENT2END ; 2 were neonates, 1 of whom had partial DiGeorge syndrome
0	RESULTS: Complete clinical recovery followed later by viral clearance was observed in 2 children: the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with ENT1 adenovirus pneumonia  ENT1END  The remaining 3 children died of adenovirus disease. Intravenous ENT2 ribavirin ENT2END therapy was well tolerated
0	The bone marrow transplant patient also received intravenous ENT1 cidofovir ENT1END  for progressive disseminated disease. An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial ENT2 DiGeorge syndrome ENT2END
0	An additional 3 children developed adenovirus pneumonia; 2 were neonates, 1 of whom had partial ENT1 DiGeorge syndrome ENT1END . The remaining infant had recently undergone a cardiac transplant. Intravenous ENT2 ribavirin ENT2END was administered on a compassionate-use protocol
0	Use of ENT1 cidofovir ENT1END  in 1 child was associated with progressive renal failure and neutropenia. DISCUSSION: Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease, namely solid-organ and bone marrow transplant recipients, neonates, and children with immunodeficiency. Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the ENT2 infection ENT2END
0	Although intravenous ENT1 ribavirin  ENT1END  was not effective for all children with severe adenovirus disease in this series or in the literature, therapy is unlikely to be of benefit if begun late in the course of the ENT2 infection ENT2END
0	The use of ENT1 cidofovir ENT1END  in severe adenovirus infection has been limited by adverse effects, the most significant of which is ENT2 nephrotoxicity ENT2END
0	The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is ENT1 nephrotoxicity ENT1END . OBJECTIVE: We report our experience with intravenous ENT2 ribavirin ENT2END therapy for severe adenovirus disease in a series of immunocompromised children and review the literature
0	Ribavirin, a ENT1 guanosine  ENT1END  analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro. Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses. The most common adverse effect of intravenous ribavirin is reversible mild anemia. The use of cidofovir in severe adenovirus infection has been limited by adverse effects, the most significant of which is ENT2 nephrotoxicity ENT2END
0	Two patients developed adenovirus ENT1 hemorrhagic cystitis  ENT1END after cardiac and bone marrow transplants, respectively. The bone marrow transplant patient also received intravenous ENT2 cidofovir ENT2END for progressive disseminated disease
0	DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ENT1 ribavirin  ENT1END for documented severe adenovirus disease. Two patients developed adenovirus ENT2 hemorrhagic cystitis ENT2END after cardiac and bone marrow transplants, respectively
0	Intravenous ribavirin is the treatment of choice for ENT1 infection with hemorrhagic fever viruses  ENT1END  The most common adverse effect of intravenous ribavirin is reversible mild anemia. The use of ENT2 cidofovir ENT2END in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity
0	Intravenous ENT1 ribavirin  ENT1END is the treatment of choice for ENT2 infection with hemorrhagic fever viruses ENT2END
0	Ribavirin, a ENT1 guanosine  ENT1END  analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro. Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat hepatitis C. Intravenous ribavirin is the treatment of choice for ENT2 infection with hemorrhagic fever viruses ENT2END
0	Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat ENT1 hepatitis C  ENT1END  Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses. The most common adverse effect of intravenous ribavirin is reversible mild anemia. The use of ENT2 cidofovir ENT2END in severe adenovirus infection has been limited by adverse effects, the most significant of which is nephrotoxicity
0	Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat ENT1 hepatitis C  ENT1END . Intravenous ENT2 ribavirin ENT2END is the treatment of choice for infection with hemorrhagic fever viruses
0	Ribavirin, a ENT1 guanosine  ENT1END  analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro. Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection, and orally in combination with interferon to treat ENT2 hepatitis C ENT2END
1	Use of ENT1 cidofovir ENT1END  in 1 child was associated with ENT2 progressive renal failure ENT2END and neutropenia
0	Intravenous ENT1 ribavirin  ENT1END  therapy was well tolerated. Use of cidofovir in 1 child was associated with ENT2 progressive renal failure ENT2END and neutropenia
0	Two patients developed adenovirus ENT1 hemorrhagic cystitis  ENT1END after cardiac and bone marrow transplants, respectively. The bone marrow transplant patient also received intravenous ENT2 cidofovir ENT2END for progressive disseminated disease
0	DESIGN/METHODS: We retrospectively reviewed the medical records of 5 children treated with intravenous ENT1 ribavirin  ENT1END  for documented severe adenovirus disease. Two patients developed adenovirus ENT2 hemorrhagic cystitis ENT2END after cardiac and bone marrow transplants, respectively
1	Use of ENT1 cidofovir ENT1END  in 1 child was associated with progressive renal failure and ENT2 neutropenia ENT2END
0	Intravenous ENT1 ribavirin  ENT1END  therapy was well tolerated. Use of cidofovir in 1 child was associated with progressive renal failure and ENT2 neutropenia ENT2END
0	Experience is greatest with intravenous ribavirin and ENT1 cidofovir ENT1END  Ribavirin, a guanosine analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro. Ribavirin is licensed in aerosol form for the treatment of ENT2 respiratory syncytial virus infection ENT2END , and orally in combination with interferon to treat hepatitis C
0	ENT1 Ribavirin  ENT1END is licensed in aerosol form for the treatment of ENT2 respiratory syncytial virus infection ENT2END , and orally in combination with interferon to treat hepatitis C
0	Ribavirin, a ENT1 guanosine  ENT1END  analogue, has broad antiviral activity against both RNA and DNA viruses, including documented activity against adenovirus in vitro. Ribavirin is licensed in aerosol form for the treatment of ENT2 respiratory syncytial virus infection ENT2END , and orally in combination with interferon to treat hepatitis C
0	We report a case of bile duct hamartoma which developed in a patient who had been on long-term ENT1 danazol ENT1END treatment. Such patients should be under close follow-up, preferably with periodic ultrasound examination of the liver. If the patient develops a ENT2 liver mass ENT2END , because of non-specific clinical features and imaging appearances, biopsy may be the only way to achieve a definitive diagnosis
1	Bile duct hamartoma occurring in association with long-term treatment with ENT1 danazol ENT1END .We report a case of ENT2 bile duct hamartoma ENT2END which developed in a patient who had been on long-term danazol treatment
1	Bile duct hamartoma occurring in association with long-term treatment with ENT1 danazol ENT1END .We report a case of ENT2 bile duct hamartoma ENT2END which developed in a patient who had been on long-term danazol treatment
0	Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced ENT1 hyperactivity ENT1END  Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal ENT2 DA ENT2END and DOPAC concentration or GAD activity
0	Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of apomorphine-induced ENT1 hyperactivity ENT1END . Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and ENT2 DOPAC ENT2END concentration or GAD activity
0	Calcitonin injection resulted in a potentiation of ENT1 haloperidol  ENT1END induced catalepsy and a partial prevention of apomorphine-induced ENT2 hyperactivity ENT2END
1	Calcitonin injection resulted in a potentiation of haloperidol-induced catalepsy and a partial prevention of ENT1 apomorphine  ENT1END induced ENT2 hyperactivity ENT2END
0	Calcitonin injection resulted in a potentiation of haloperidol-induced ENT1 catalepsy  ENT1END and a partial prevention of apomorphine-induced hyperactivity. Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal ENT2 DA ENT2END and DOPAC concentration or GAD activity
0	Calcitonin injection resulted in a potentiation of haloperidol-induced ENT1 catalepsy  ENT1END  and a partial prevention of apomorphine-induced hyperactivity. Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and ENT2 DOPAC ENT2END concentration or GAD activity
1	Calcitonin injection resulted in a potentiation of ENT1 haloperidol  ENT1END -induced ENT2 catalepsy ENT2END and a partial prevention of apomorphine-induced hyperactivity
0	Calcitonin injection resulted in a potentiation of haloperidol-induced ENT1 catalepsy  ENT1END  and a partial prevention of ENT2 apomorphine ENT2END -induced hyperactivity
0	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of ENT1 alpha-methyl-para-tyrosine ENT1END on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature. Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved. In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced ENT2 dopaminergic deficits ENT2END that are of comparable magnitude on both sides of the brain
0	In addition, we demonstrate that mice genetically engineered to have unilateral brain ENT1 DA  ENT1END deficits develop METH-induced ENT2 dopaminergic deficits ENT2END that are of comparable magnitude on both sides of the brain
0	In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop ENT1 METH  ENT1END induced ENT2 dopaminergic deficits ENT2END that are of comparable magnitude on both sides of the brain
0	Here we show that the recently reported ability of ENT1 L-dihydroxyphenylalanine  ENT1END to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature. Further, we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity, as long as the thermic effects of METH are preserved. In addition, we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH-induced ENT2 dopaminergic deficits ENT2END that are of comparable magnitude on both sides of the brain
0	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance ENT1 toxicity  ENT1END  However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data. Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of ENT2 alpha-methyl-para-tyrosine ENT2END on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature
0	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase ENT1 DA  ENT1END neurotransmission enhance ENT2 toxicity ENT2END
0	It is widely believed that dopamine (DA) mediates methamphetamine ( ENT1 METH ENT1END -induced ENT2 toxicity ENT2END to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance toxicity
0	It is widely believed that dopamine (DA) mediates methamphetamine (METH)-induced toxicity to brain dopaminergic neurons, because drugs that interfere with DA neurotransmission decrease toxicity, whereas drugs that increase DA neurotransmission enhance ENT1 toxicity  ENT1END . However, temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data. Here we show that the recently reported ability of ENT2 L-dihydroxyphenylalanine ENT2END to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA neurotoxicity is also confounded by drug effects on body temperature
0	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of ENT1 alpha-methyl-para-tyrosine ENT1END  on METH-induced DA ENT2 neurotoxicity ENT2END is also confounded by drug effects on body temperature
0	Here we show that the recently reported ability of L-dihydroxyphenylalanine to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced ENT1 DA ENT1END ENT2 neurotoxicity ENT2END is also confounded by drug effects on body temperature
1	Further, we show that mice genetically engineered to be deficient in brain DA develop ENT1 METH ENT1END ENT2 neurotoxicity ENT2END , as long as the thermic effects of METH are preserved
0	Here we show that the recently reported ability of ENT1 L-dihydroxyphenylalanine  ENT1END  to reverse the protective effect of alpha-methyl-para-tyrosine on METH-induced DA ENT2 neurotoxicity ENT2END is also confounded by drug effects on body temperature
0	Behavioral effects of diazepam and propranolol in patients with panic disorder and ENT1 agoraphobia ENT1END .The effects of oral doses of ENT2 diazepam ENT2END (single dose of 10 mg and a median dose of 30 mg/day for 2 weeks) and propranolol (single dose of 80 mg and a median dose of 240 mg/day for 2 weeks) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double-blind, randomized and crossover design
0	Behavioral effects of diazepam and ENT1 propranolol  ENT1END  in patients with panic disorder and ENT2 agoraphobia ENT2END
1	Both drugs impaired immediate free recall but the decrease was greater for ENT1 diazepam ENT1END than propranolol. ENT2 Delayed free recall was also impaired ENT2END but the two drugs did not differ
1	Both drugs impaired immediate free recall but the decrease was greater for diazepam than ENT1 propranolol ENT1END ENT2 Delayed free recall was also impaired ENT2END but the two drugs did not differ
0	Patients tapped faster after propranolol than diazepam and they were more sedated after ENT1 diazepam ENT1END than propranolol. After 2 weeks of treatment, patients tested 5-8 h after the last dose of medication did not show any decrement of performance. These results are similar to those previously found in healthy subjects. Accumulation of drugs was not reflected in prolonged ENT2 behavioral impairment ENT2END
0	Patients tapped faster after propranolol than diazepam and they were more sedated after diazepam than ENT1 propranolol  ENT1END  After 2 weeks of treatment, patients tested 5-8 h after the last dose of medication did not show any decrement of performance. These results are similar to those previously found in healthy subjects. Accumulation of drugs was not reflected in prolonged ENT2 behavioral impairment ENT2END
0	Behavioral effects of ENT1 diazepam  ENT1END  and propranolol in patients with ENT2 panic disorder ENT2END and agoraphobia
0	Behavioral effects of diazepam and ENT1 propranolol  ENT1END  in patients with ENT2 panic disorder ENT2END and agoraphobia
0	Five hours after exposure, he developed ENT1 disulfiram ENT1END like syndrome with flushing, ENT2 tachycardia ENT2END , and arterial hypotension after consuming three glasses of wine
1	In less than 1 hour after the ingestion of ENT1 alcohol ENT1END  he developed malaise with flushing of the face, ENT2 tachycardia ENT2END , and dyspnea
1	The second case occurred in a 55-year-old farmer following cutaneous contact with ENT1 Dormex  ENT1END  Five hours after exposure, he developed disulfiram-like syndrome with flushing, ENT2 tachycardia ENT2END , and arterial hypotension after consuming three glasses of wine
0	Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce ENT1 acetaldehyde  ENT1END syndrome in case of alcohol use. The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide. The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal. In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, ENT2 tachycardia ENT2END , and dyspnea
0	Five hours after exposure, he developed ENT1 disulfiram ENT1END -like syndrome with ENT2 flushing ENT2END , tachycardia, and arterial hypotension after consuming three glasses of wine
1	In less than 1 hour after the ingestion of ENT1 alcohol ENT1END , he developed malaise with ENT2 flushing of the face ENT2END , tachycardia, and dyspnea
1	The second case occurred in a 55-year-old farmer following cutaneous contact with ENT1 Dormex  ENT1END . Five hours after exposure, he developed disulfiram-like syndrome with ENT2 flushing ENT2END , tachycardia, and arterial hypotension after consuming three glasses of wine
0	Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce ENT1 acetaldehyde  ENT1END  syndrome in case of alcohol use. The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide. The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal. In less than 1 hour after the ingestion of alcohol, he developed malaise with ENT2 flushing of the face ENT2END , tachycardia, and dyspnea
0	Five hours after exposure, he developed ENT1 disulfiram ENT1END -like syndrome with flushing, tachycardia, and ENT2 arterial hypotension ENT2END after consuming three glasses of wine
1	Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and ENT1 arterial hypotension ENT1END  after consuming three glasses of wine. The patient recovered spontaneously in 3 hours under surveillance in the hospital. These cases confirm the necessity of avoiding ENT2 alcohol ENT2END consumption as recommended in the instructions for use of Dormex and of preventing cutaneous contact during use
1	The second case occurred in a 55-year-old farmer following cutaneous contact with ENT1 Dormex  ENT1END . Five hours after exposure, he developed disulfiram-like syndrome with flushing, tachycardia, and ENT2 arterial hypotension ENT2END after consuming three glasses of wine
0	In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and ENT1 dyspnea  ENT1END  Manifestations regressed spontaneously under surveillance in the hospital. The second case occurred in a 55-year-old farmer following cutaneous contact with Dormex. Five hours after exposure, he developed ENT2 disulfiram ENT2END -like syndrome with flushing, tachycardia, and arterial hypotension after consuming three glasses of wine
1	In less than 1 hour after the ingestion of ENT1 alcohol  ENT1END , he developed malaise with flushing of the face, tachycardia, and ENT2 dyspnea ENT2END
1	In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and ENT1 dyspnea  ENT1END . Manifestations regressed spontaneously under surveillance in the hospital. The second case occurred in a 55-year-old farmer following cutaneous contact with ENT2 Dormex ENT2END
0	Contact with the skin can result in percutaneous absorption of the substance that inhibits aldehyde dehydrogenase and can induce ENT1 acetaldehyde  ENT1END  syndrome in case of alcohol use. The purpose of this report is to describe two cases of a disulfiram-like syndrome following occupational exposure to hydrogen cyanamide. The first case involved a 59-year-old man who used Dormex, which contains hydrogen cyanamide, without protection after consuming a large amount of alcohol during a meal. In less than 1 hour after the ingestion of alcohol, he developed malaise with flushing of the face, tachycardia, and ENT2 dyspnea ENT2END
1	An unusual toxic reaction to axillary block by mepivacaine with ENT1 adrenaline ENT1END .An ENT2 increase in blood pressure ENT2END , accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An ENT1 increase in blood pressure ENT1END , accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, metoprolol and ENT2 midazolam ENT2END the patient's condition improved, and 15 min later he woke up
1	An unusual toxic reaction to axillary block by ENT1 mepivacaine  ENT1END  with adrenaline.An ENT2 increase in blood pressure ENT2END , accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An ENT1 increase in blood pressure ENT1END , accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of ENT2 labetalol ENT2END , metoprolol and midazolam the patient's condition improved, and 15 min later he woke up
0	An ENT1 increase in blood pressure ENT1END , accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, ENT2 metoprolol ENT2END and midazolam the patient's condition improved, and 15 min later he woke up
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing ENT1 adrenaline ENT1END 0.225 mg, for correction of ENT2 Dupuytren's contracture ENT2END
0	225 mg, for correction of ENT1 Dupuytren's contracture  ENT1END . After intravenous administration of labetalol, metoprolol and ENT2 midazolam ENT2END the patient's condition improved, and 15 min later he woke up
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with ENT1 mepivacaine  ENT1END 850 mg containing adrenaline 0.225 mg, for correction of ENT2 Dupuytren's contracture ENT2END
0	225 mg, for correction of ENT1 Dupuytren's contracture  ENT1END . After intravenous administration of ENT2 labetalol ENT2END , metoprolol and midazolam the patient's condition improved, and 15 min later he woke up
0	225 mg, for correction of ENT1 Dupuytren's contracture  ENT1END . After intravenous administration of labetalol, ENT2 metoprolol ENT2END and midazolam the patient's condition improved, and 15 min later he woke up
0	An unusual toxic reaction to axillary block by mepivacaine with ENT1 adrenaline ENT1END .An increase in blood pressure, accompanied by atrial fibrillation, ENT2 agitation ENT2END , incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An increase in blood pressure, accompanied by atrial fibrillation, ENT1 agitation  ENT1END , incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, metoprolol and ENT2 midazolam ENT2END the patient's condition improved, and 15 min later he woke up
0	An unusual toxic reaction to axillary block by ENT1 mepivacaine  ENT1END  with adrenaline.An increase in blood pressure, accompanied by atrial fibrillation, ENT2 agitation ENT2END , incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An increase in blood pressure, accompanied by atrial fibrillation, ENT1 agitation  ENT1END , incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of ENT2 labetalol ENT2END , metoprolol and midazolam the patient's condition improved, and 15 min later he woke up
0	An increase in blood pressure, accompanied by atrial fibrillation, ENT1 agitation  ENT1END , incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, ENT2 metoprolol ENT2END and midazolam the patient's condition improved, and 15 min later he woke up
1	An unusual toxic reaction to axillary block by mepivacaine with ENT1 adrenaline ENT1END .An increase in blood pressure, accompanied by ENT2 atrial fibrillation ENT2END , agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	After intravenous administration of labetalol, metoprolol and ENT1 midazolam ENT1END  the patient's condition improved, and 15 min later he woke up. The block was successful and surgery was conducted as scheduled despite persisting ENT2 atrial fibrillation ENT2END
1	An unusual toxic reaction to axillary block by ENT1 mepivacaine  ENT1END  with adrenaline.An increase in blood pressure, accompanied by ENT2 atrial fibrillation ENT2END , agitation, incomprehensible shouts and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	After intravenous administration of ENT1 labetalol  ENT1END , metoprolol and midazolam the patient's condition improved, and 15 min later he woke up. The block was successful and surgery was conducted as scheduled despite persisting ENT2 atrial fibrillation ENT2END
0	After intravenous administration of labetalol, ENT1 metoprolol  ENT1END  and midazolam the patient's condition improved, and 15 min later he woke up. The block was successful and surgery was conducted as scheduled despite persisting ENT2 atrial fibrillation ENT2END
0	An unusual toxic reaction to axillary block by mepivacaine with ENT1 adrenaline ENT1END .An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and ENT2 loss of consciousness ENT2END , was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and ENT1 loss of consciousness  ENT1END , was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, metoprolol and ENT2 midazolam ENT2END the patient's condition improved, and 15 min later he woke up
0	An unusual toxic reaction to axillary block by ENT1 mepivacaine  ENT1END  with adrenaline.An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and ENT2 loss of consciousness ENT2END , was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and ENT1 loss of consciousness  ENT1END , was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of ENT2 labetalol ENT2END , metoprolol and midazolam the patient's condition improved, and 15 min later he woke up
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, incomprehensible shouts and ENT1 loss of consciousness  ENT1END , was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, ENT2 metoprolol ENT2END and midazolam the patient's condition improved, and 15 min later he woke up
0	An unusual toxic reaction to axillary block by mepivacaine with ENT1 adrenaline ENT1END .An increase in blood pressure, accompanied by atrial fibrillation, agitation, ENT2 incomprehensible shouts ENT2END and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, ENT1 incomprehensible shouts  ENT1END  and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, metoprolol and ENT2 midazolam ENT2END the patient's condition improved, and 15 min later he woke up
0	An unusual toxic reaction to axillary block by ENT1 mepivacaine  ENT1END  with adrenaline.An increase in blood pressure, accompanied by atrial fibrillation, agitation, ENT2 incomprehensible shouts ENT2END and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, ENT1 incomprehensible shouts  ENT1END  and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of ENT2 labetalol ENT2END , metoprolol and midazolam the patient's condition improved, and 15 min later he woke up
0	An increase in blood pressure, accompanied by atrial fibrillation, agitation, ENT1 incomprehensible shouts  ENT1END  and loss of consciousness, was observed in an elderly, ASA classification group II, cardiovascularly medicated male, 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0.225 mg, for correction of Dupuytren's contracture. After intravenous administration of labetalol, ENT2 metoprolol ENT2END and midazolam the patient's condition improved, and 15 min later he woke up
0	Attentional modulation of perceived ENT1 pain  ENT1END  intensity in ENT2 capsaicin ENT2END -induced secondary hyperalgesia
1	Attentional modulation of perceived pain intensity in ENT1 capsaicin  ENT1END -induced secondary ENT2 hyperalgesia ENT2END
0	Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative ENT1 hallucinations ENT1END  Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia. An antisialogue was usually unnecessary in operations lasting up to 2 h, ENT2 glycopyrrolate ENT2END being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate
0	ENT1 Diazepam  ENT1END  unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative ENT2 hallucinations ENT2END
0	Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/ ENT1 oxygen  ENT1END only. After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective. Emphasis was placed on bedside clinical monitoring, relying heavily on the heart rate. Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative ENT2 hallucinations ENT2END
1	Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ENT1 ketamine  ENT1END as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative ENT2 hallucinations ENT2END
0	Local anaesthetic blocks were useful in decreasing the requirement for postoperative ENT1 analgesia  ENT1END  An antisialogue was usually unnecessary in operations lasting up to 2 h, ENT2 glycopyrrolate ENT2END being the best choice for its lowest psychotropic and chronotropic effects, especially in a hot climate
0	ENT1 Diazepam  ENT1END , unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations. Local anaesthetic blocks were useful in decreasing the requirement for postoperative ENT2 analgesia ENT2END
0	Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air/ ENT1 oxygen  ENT1END  only. After premedication with diazepam, glycopyrrolate and local anaesthesia, and induction with standard doses of ketamine, a maintenance dose of 10-20 microg/kg/min of ketamine proved safe and effective. Emphasis was placed on bedside clinical monitoring, relying heavily on the heart rate. Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations. Local anaesthetic blocks were useful in decreasing the requirement for postoperative ENT2 analgesia ENT2END
0	Diazepam, unless contraindicated or risky, remains the only necessary complementary drug to ENT1 ketamine  ENT1END  as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations. Local anaesthetic blocks were useful in decreasing the requirement for postoperative ENT2 analgesia ENT2END
0	PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces ENT1 doxorubicin ENT1END ENT2 cardiotoxicity ENT2END while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC)
0	PURPOSE: To determine whether Myocet (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with ENT1 cyclophosphamide  ENT1END significantly reduces doxorubicin ENT2 cardiotoxicity ENT2END while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC)
0	Antitumor efficacy was assessed by objective ENT1 tumor ENT1END response rates (World Health Organization criteria), time to progression, and survival. RESULTS: Six percent of MC patients versus 21% (including five cases of CHF) of AC patients developed cardiotoxicity (P =.0002). Median cumulative ENT2 doxorubicin ENT2END dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =
0	PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of ENT1 cyclophosphamide  ENT1END (C), every 3 weeks until disease progression or unacceptable toxicity. Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or congestive heart failure (CHF). Antitumor efficacy was assessed by objective ENT2 tumor ENT2END response rates (World Health Organization criteria), time to progression, and survival
0	PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional ENT1 doxorubicin ENT1END (A), in combination with 600 mg/m(2) of cyclophosphamide (C), every 3 weeks until disease progression or unacceptable ENT2 toxicity ENT2END
0	PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of ENT1 cyclophosphamide  ENT1END  (C), every 3 weeks until disease progression or unacceptable ENT2 toxicity ENT2END
0	Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic ENT1 breast cancer ENT1END .PURPOSE: To determine whether ENT2 Myocet ENT2END (liposome-encapsulated doxorubicin; The Liposome Company, Elan Corporation, Princeton, NJ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first-line treatment of metastatic breast cancer (MBC)
0	CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy, when used in combination with ENT1 cyclophosphamide ENT1END as first-line therapy for ENT2 MBC ENT2END
1	RESULTS: Six percent of MC patients versus 21% (including five cases of ENT1 CHF  ENT1END  of AC patients developed cardiotoxicity (P =.0002). Median cumulative ENT2 doxorubicin ENT2END dose at onset was more than 2,220 mg/m(2) for MC versus 480 mg/m(2) for AC (P =
1	PATIENTS AND METHODS: Two hundred ninety-seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg/m(2) of Myocet (M) or conventional doxorubicin (A), in combination with 600 mg/m(2) of ENT1 cyclophosphamide ENT1END  (C), every 3 weeks until disease progression or unacceptable toxicity. Cardiotoxicity was defined by reductions in left-ventricular ejection fraction, assessed by serial multigated radionuclide angiography scans, or ENT2 congestive heart failure ENT2END (CHF)
1	CONCLUSION: Myocet improves the therapeutic index of ENT1 doxorubicin ENT1END by significantly reducing cardiotoxicity and grade 4 ENT2 neutropenia ENT2END and provides comparable antitumor efficacy, when used in combination with cyclophosphamide as first-line therapy for MBC
1	CONCLUSION: Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 ENT1 neutropenia  ENT1END  and provides comparable antitumor efficacy, when used in combination with ENT2 cyclophosphamide ENT2END as first-line therapy for MBC
0	A significant correlation was found between baseline TAFI antigen concentrations and the duration of ENT1 amenorrhea ENT1END (P < 0.05; r = 0.33). CONCLUSION: We suggest that the increased risk of venous thromboembolism due to ENT2 raloxifene ENT2END treatment may be related to increased tPA levels, but not TAFI levels
0	Age-matched controls (n = 14) were given only ENT1 calcium  ENT1END  Plasma TAFI, tPA, and PAI-1 antigen levels were measured at baseline and after 3 months of treatment by commercially available ELISA kits. Variations of individuals were assessed by Wilcoxon's test. Relationship between those markers and demographic characteristics were investigated. RESULTS: Three months of raloxifene treatment was associated with a significant decrease in the plasma TAFI antigen concentrations (16% change, P < 0.01), and a significant increase in tPA antigen concentrations (25% change, P < 0.05). A significant correlation was found between baseline TAFI antigen concentrations and the duration of ENT2 amenorrhea ENT2END (P < 0
0	METHODS: Thirty-nine postmenopausal women with osteopenia or ENT1 osteoporosis ENT1END were included in this prospective, controlled clinical study. Twenty-five women were given ENT2 raloxifene hydrochloride ENT2END (60 mg/day) plus calcium (500 mg/day)
0	METHODS: Thirty-nine postmenopausal women with osteopenia or ENT1 osteoporosis ENT1END  were included in this prospective, controlled clinical study. Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus ENT2 calcium ENT2END (500 mg/day)
1	CONCLUSION: We suggest that the increased risk of ENT1 venous thromboembolism  ENT1END due to ENT2 raloxifene ENT2END treatment may be related to increased tPA levels, but not TAFI levels
0	BACKGROUND: Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of ENT1 raloxifene ENT1END administration in postmenopausal women. METHODS: Thirty-nine postmenopausal women with ENT2 osteopenia ENT2END or osteoporosis were included in this prospective, controlled clinical study
0	METHODS: Thirty-nine postmenopausal women with ENT1 osteopenia  ENT1END  or osteoporosis were included in this prospective, controlled clinical study. Twenty-five women were given raloxifene hydrochloride (60 mg/day) plus ENT2 calcium ENT2END (500 mg/day)
1	While side effects were rare, those experienced after ENT1 theophylline ENT1END use did involve the ENT2 cardiovascular and gastrointestinal systems ENT2END
0	While side effects were rare, those experienced after theophylline use did involve the ENT1 cardiovascular and gastrointestinal systems ENT1END . These results show that ENT2 ipratropium ENT2END is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction
0	Acute bronchodilating effects of ipratropium bromide and ENT1 theophylline  ENT1END  in ENT2 chronic obstructive pulmonary disease ENT2END
0	Acute bronchodilating effects of ENT1 ipratropium bromide  ENT1END  and theophylline in ENT2 chronic obstructive pulmonary disease ENT2END
1	While side effects were rare, those experienced after ENT1 theophylline ENT1END  use did involve the ENT2 cardiovascular and gastrointestinal systems ENT2END
0	While side effects were rare, those experienced after theophylline use did involve the ENT1 cardiovascular and gastrointestinal systems  ENT1END . These results show that ENT2 ipratropium ENT2END is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction
0	25% showed a dose-dependent enhancing effect on the development of the ENT1 BHA ENT1END induced epithelial hyperplasia. Tumors, all ENT2 papillomas ENT2END , were induced in 3 rats (17%) with 0
0	Tumors, all ENT1 papillomas ENT1END , were induced in 3 rats (17%) with 0.25% ENT2 RA ENT2END and in one rat (10%) with 0
0	25% showed a dose-dependent enhancing effect on the development of the ENT1 BHA ENT1END -induced epithelial hyperplasia. ENT2 Tumors ENT2END , all papillomas, were induced in 3 rats (17%) with 0
0	ENT1 Tumors  ENT1END , all papillomas, were induced in 3 rats (17%) with 0.25% ENT2 RA ENT2END and in one rat (10%) with 0
0	Co- ENT1 carcinogenic  ENT1END  effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with ENT2 butylated hydroxyanisole ENT2END
0	Co- ENT1 carcinogenic  ENT1END  effect of ENT2 retinyl acetate ENT2END on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole
0	25% showed a dose-dependent enhancing effect on the development of the ENT1 BHA ENT1END -induced ENT2 epithelial hyperplasia ENT2END
0	25% showed a dose-dependent enhancing effect on the development of the BHA-induced ENT1 epithelial hyperplasia  ENT1END . Tumors, all papillomas, were induced in 3 rats (17%) with 0.25% ENT2 RA ENT2END and in one rat (10%) with 0
1	These findings indicate that RA acted as a co-carcinogen in the ENT1 BHA ENT1END ENT2 forestomach carcinogenesis ENT2END of the rat
0	Co-carcinogenic effect of ENT1 retinyl acetate  ENT1END  on ENT2 forestomach carcinogenesis ENT2END of male F344 rats induced with butylated hydroxyanisole
0	05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with ENT1 carcinoma ENT1END  in the group given RA-free water. In rats given 1% ENT2 BHA ENT2END , RA co-administered at a dose of 0
0	05) increased the incidence of forestomach tumors (squamous cell papilloma and carcinoma) to 60% (9/15, 2 rats with carcinoma) from 15% (3/20, one rat with ENT1 carcinoma ENT1END ) in the group given ENT2 RA ENT2END -free water
1	Nineteen ENT1 sexually dysfunctional ENT1END women receiving either fluoxetine, sertraline, or ENT2 paroxetine ENT2END participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction
1	Nineteen ENT1 sexually dysfunctional ENT1END  women receiving either ENT2 fluoxetine ENT2END , sertraline, or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction
1	Nineteen ENT1 sexually dysfunctional ENT1END  women receiving either fluoxetine, ENT2 sertraline ENT2END , or paroxetine participated in an eight-week, double-blind, placebo-controlled, cross-over study of the effects of ephedrine (50 mg) on self-report measures of sexual desire, arousal, orgasm, and sexual satisfaction
0	A randomized, placebo-controlled, crossover study of ENT1 ephedrine  ENT1END  for SSRI-induced female ENT2 sexual dysfunction ENT2END
1	This case is the earliest (second day of treatment) ENT1 NMS ENT1END due to ENT2 ziprasidone ENT2END reported in the literature
0	Although conventional neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs like ENT1 ziprasidone ENT1END may also be a cause. The patient is a 24-year-old male with a history of ENT2 schizophrenia ENT2END who developed signs and symptoms of NMS after 2 days of treatment with an 80-mg/day dose of orally administrated ziprasidone
0	Neuroleptic malignant syndrome (NMS) is the rarest and most serious of the neuroleptic-induced ENT1 movement disorders ENT1END  We describe a case of neuroleptic malignant syndrome (NMS) associated with the use of ENT2 ziprasidone ENT2END
0	Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a ENT1 carbidopa/levodopa ENT1END preparation; and both had the onset of ENT2 hallucinosis ENT2END and recurrent seizures, which were refractory to anticonvulsants
0	Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of ENT1 hallucinosis ENT1END  and recurrent seizures, which were refractory to anticonvulsants. The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of ENT2 vitamin B6 ENT2END
0	Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a ENT1 carbidopa/levodopa ENT1END  preparation; and both had the onset of hallucinosis and recurrent ENT2 seizures ENT2END , which were refractory to anticonvulsants
0	Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent ENT1 seizures  ENT1END , which were refractory to anticonvulsants. The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of ENT2 vitamin B6 ENT2END
1	Serial ENT1 epilepsy  ENT1END  caused by ENT2 levodopa/carbidopa ENT2END administration in two patients on hemodialysis
0	Serial ENT1 epilepsy  ENT1END  caused by levodopa/carbidopa administration in two patients on hemodialysis.Two patients with similar clinical features are presented: both patients had chronic renal failure, on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants. The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of ENT2 vitamin B6 ENT2END
0	Two patients with similar clinical features are presented: both patients had ENT1 chronic renal failure  ENT1END  on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a ENT2 carbidopa/levodopa ENT2END preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants
0	Two patients with similar clinical features are presented: both patients had ENT1 chronic renal failure  ENT1END , on hemodialysis for many years but recently begun on a high-flux dialyzer; both had been receiving a carbidopa/levodopa preparation; and both had the onset of hallucinosis and recurrent seizures, which were refractory to anticonvulsants. The first patient died without a diagnosis; the second patient had a dramatic recovery following the administration of ENT2 vitamin B6 ENT2END
1	UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ENT1 ouabain ENT1END induced ENT2 ventricular tachycardias ENT2END
0	Sublingual absorption of the ENT1 quaternary ammonium  ENT1END  antiarrhythmic agent, UM-272.UM-272 (N,N-dimethylpropranolol), a quaternary antiarrhythmic agent, was administered sublingually to dogs with ouabain-induced ENT2 ventricular tachycardias ENT2END
0	Sublingual ENT1 UM-272 ENT1END converted ENT2 ventricular tachycardia ENT2END to sinus rhythm in all 5 dogs
1	Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and ENT1 eserine ENT1END  On the other hand, ENT2 mydriasis ENT2END , tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as ENT1 mydriasis ENT1END  tremor and clonic-tonic convulsions caused by carbachol and eserine. Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that calcium ions in excess have an ENT2 atropine ENT2END -like action also in the central nervous system
1	Calcium chloride depressed or almost completely abolished the vocalization and fighting due to ENT1 carbachol  ENT1END and eserine. On the other hand, ENT2 mydriasis ENT2END , tremor and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as ENT1 mydriasis ENT1END , tremor and clonic-tonic convulsions caused by carbachol and eserine. ENT2 Calcium chloride ENT2END inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as ENT1 mydriasis ENT1END , tremor and clonic-tonic convulsions caused by carbachol and eserine. Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that ENT2 calcium ENT2END ions in excess have an atropine-like action also in the central nervous system
1	On the other hand, mydriasis, tremor and ENT1 clonic-tonic convulsions ENT1END evoked by carbachol and ENT2 eserine ENT2END were not significantly changed by calcium chloride
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and ENT1 clonic-tonic convulsions  ENT1END caused by carbachol and eserine. Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that calcium ions in excess have an ENT2 atropine ENT2END -like action also in the central nervous system
1	On the other hand, mydriasis, tremor and ENT1 clonic-tonic convulsions ENT1END  evoked by ENT2 carbachol ENT2END and eserine were not significantly changed by calcium chloride
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and ENT1 clonic-tonic convulsions  ENT1END  caused by carbachol and eserine. ENT2 Calcium chloride ENT2END inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, tremor and ENT1 clonic-tonic convulsions  ENT1END  caused by carbachol and eserine. Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that ENT2 calcium ENT2END ions in excess have an atropine-like action also in the central nervous system
1	Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and ENT1 eserine ENT1END . On the other hand, mydriasis, ENT2 tremor ENT2END and clonic-tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, ENT1 tremor  ENT1END and clonic-tonic convulsions caused by carbachol and eserine. Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that calcium ions in excess have an ENT2 atropine ENT2END -like action also in the central nervous system
1	On the other hand, mydriasis, ENT1 tremor  ENT1END  and clonic-tonic convulsions evoked by ENT2 carbachol ENT2END and eserine were not significantly changed by calcium chloride
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, ENT1 tremor  ENT1END  and clonic-tonic convulsions caused by carbachol and eserine. ENT2 Calcium chloride ENT2END inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites
0	It is apparent that calcium chloride can "dissociate" vocalization and fighting from autonomic and motor phenomena such as mydriasis, ENT1 tremor  ENT1END  and clonic-tonic convulsions caused by carbachol and eserine. Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites. These results further support the view that ENT2 calcium ENT2END ions in excess have an atropine-like action also in the central nervous system
0	Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative ENT1 sensorineural hearing loss ENT1END  The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss. Two groups of 22 similar patients were studied: one group received 6 mL ENT2 prilocaine ENT2END 2%; and the other received 3 mL bupivacaine 0
0	Up until now, the only factor studied has been the effect of the diameter of the spinal needle on post-operative ENT1 sensorineural hearing loss ENT1END . The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss. Two groups of 22 similar patients were studied: one group received 6 mL prilocaine 2%; and the other received 3 mL ENT2 bupivacaine ENT2END 0
1	Patients given ENT1 prilocaine ENT1END were more likely to develop ENT2 hearing loss ENT2END (10 out of 22) than those given bupivacaine (4 out of 22) (P < 0
1	Patients given prilocaine were more likely to develop ENT1 hearing loss ENT1END  (10 out of 22) than those given ENT2 bupivacaine ENT2END (4 out of 22) (P < 0
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma ENT2 iron ENT2END binding capacity
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum ENT2 lactate ENT2END dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of ENT2 mangiferin ENT2END was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium
0	The current study dealt with the protective role of mangiferin, a ENT1 polyphenol  ENT1END from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism. Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT2 myocardial damage ENT2END in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased ENT2 uric acid ENT2END level and reduced plasma iron binding capacity
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by ENT2 triphenyl tetrazolium chloride ENT2END (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, ENT2 Vitamin C ENT2END , Vitamin E and glutathione levels were altered in MI rats
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and ENT2 creatine ENT2END phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity
0	Subcutaneous injection of ENT1 ISPH  ENT1END (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT2 myocardial damage ENT2END in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, ENT2 Vitamin E ENT2END and glutathione levels were altered in MI rats
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, ENT2 glutathione ENT2END peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of ENT2 dimethyl sulphoxide ENT2END ) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused ENT1 myocardial damage ENT1END  in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as ENT2 superoxide ENT2END dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats
0	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction ( ENT1 MI  ENT1END  in rats through its antioxidative mechanism. Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma ENT2 iron ENT2END binding capacity
0	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction ( ENT1 MI  ENT1END ) in rats through its antioxidative mechanism. Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum ENT2 lactate ENT2END dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity
0	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in ENT1 MI ENT1END rats. Upon pretreatment with ENT2 mangiferin ENT2END (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels
0	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol-induced ENT1 myocardial infarction  ENT1END  in rats.The current study dealt with the protective role of mangiferin, a ENT2 polyphenol ENT2END from Mangifera indica Linn
0	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction ( ENT1 MI  ENT1END ) in rats through its antioxidative mechanism. Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased ENT2 uric acid ENT2END level and reduced plasma iron binding capacity
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( ENT1 TTC  ENT1END  test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in ENT2 MI ENT2END rats
0	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, ENT1 Vitamin C  ENT1END , Vitamin E and glutathione levels were altered in ENT2 MI ENT2END rats
0	(Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction ( ENT1 MI  ENT1END ) in rats through its antioxidative mechanism. Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and ENT2 creatine ENT2END phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity
1	Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ENT1 ISPH ENT1END induced ENT2 MI ENT2END rats
0	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, ENT1 Vitamin E  ENT1END  and glutathione levels were altered in ENT2 MI ENT2END rats
0	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and ENT1 glutathione  ENT1END levels were altered in ENT2 MI ENT2END rats
0	Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of ENT1 dimethyl sulphoxide ENT1END ) given intraperitoneally for 28 days to ENT2 MI ENT2END rats protected the above-mentioned parameters to fall from the normal levels
0	The heart tissue antioxidant enzymes such as ENT1 superoxide  ENT1END  dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in ENT2 MI ENT2END rats
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma ENT1 iron ENT1END  binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum ENT1 lactate  ENT1END  dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	From the present study it is concluded that ENT1 mangiferin  ENT1END exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased ENT1 uric acid  ENT1END  level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( ENT1 TTC  ENT1END ) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, ENT1 Vitamin C  ENT1END , Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and ENT1 creatine  ENT1END  phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ischemic myocardium. The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	From the present study it is concluded that mangiferin exerts a beneficial effect against ENT1 ISPH  ENT1END induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, ENT1 Vitamin E  ENT1END  and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and ENT1 glutathione  ENT1END  levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of ENT1 dimethyl sulphoxide  ENT1END ) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	The heart tissue antioxidant enzymes such as ENT1 superoxide  ENT1END  dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of dimethyl sulphoxide) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels. Activities of heart tissue enzymic antioxidants and serum non-enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH-induced MI rats. From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH-induced MI due to its antioxidant potential, which regulated the tissues defense system against ENT2 cardiac damage ENT2END
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma ENT1 iron ENT1END  binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum ENT1 lactate  ENT1END  dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	The protective role of ENT1 mangiferin  ENT1END  was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	The current study dealt with the protective role of mangiferin, a ENT1 polyphenol  ENT1END  from Mangifera indica Linn. (Anacardiaceae), on isoproterenol (ISPH)-induced myocardial infarction (MI) in rats through its antioxidative mechanism. Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased ENT1 uric acid  ENT1END  level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( ENT1 TTC  ENT1END ) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT1 ischemic myocardium  ENT1END . The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, ENT2 Vitamin C ENT2END , Vitamin E and glutathione levels were altered in MI rats
0	Subcutaneous injection of ISPH (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and ENT1 creatine  ENT1END  phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	Subcutaneous injection of ENT1 ISPH  ENT1END  (200 mg/kg body weight in 1 ml saline) to rats for 2 consecutive days caused myocardial damage in rat heart, which was determined by the increased activity of serum lactate dehydrogenase (LDH) and creatine phosphokinase isoenzymes (CK-MB), increased uric acid level and reduced plasma iron binding capacity. The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT2 ischemic myocardium ENT2END
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT1 ischemic myocardium  ENT1END . The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, ENT2 Vitamin E ENT2END and glutathione levels were altered in MI rats
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT1 ischemic myocardium  ENT1END . The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, ENT2 glutathione ENT2END peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT1 ischemic myocardium  ENT1END . The heart tissue antioxidant enzymes such as superoxide dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats. Upon pretreatment with mangiferin (100 mg/kg body weight suspended in 2 ml of ENT2 dimethyl sulphoxide ENT2END ) given intraperitoneally for 28 days to MI rats protected the above-mentioned parameters to fall from the normal levels
0	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride (TTC) test used for macroscopic enzyme mapping assay of the ENT1 ischemic myocardium  ENT1END . The heart tissue antioxidant enzymes such as ENT2 superoxide ENT2END dismutase, catalase, glutathione peroxidase, glutathione transferase and glutathione reductase activities, non-enzymic antioxidants such as cerruloplasmin, Vitamin C, Vitamin E and glutathione levels were altered in MI rats
0	Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and ENT1 drug abuse ENT1END  RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies. When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non-alcohol-exposed group, regardless of prior drinking patterns. Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers. ENT2 Amphetamine ENT2END abuse was predictive of larger cranial to body growth ratios
0	Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and ENT1 drug abuse  ENT1END . RESULTS: Nearly half of the pregnant drinkers abstained after learning of their pregnancies. When women reportedly quit drinking early in their pregnancies, fetal growth measures were not significantly different from a non- ENT2 alcohol ENT2END -exposed group, regardless of prior drinking patterns
1	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as ENT1 decreased cranial to body growth  ENT1END in comparison with women who either quit drinking or who were nondrinkers. ENT2 Amphetamine ENT2END abuse was predictive of larger cranial to body growth ratios
1	This study examined the utility of biometry for detecting ENT1 alcohol ENT1END related fetal ENT2 growth impairment ENT2END
0	In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)- ENT1 SM 21 ENT1END significantly attenuated cocaine-induced ENT2 convulsions ENT2END and locomotor activity, but not lethality
1	In behavioral studies, pretreatment of Swiss Webster mice with UMB24 or (+/-)-SM 21 significantly attenuated ENT1 cocaine  ENT1END induced ENT2 convulsions ENT2END and locomotor activity, but not lethality
0	In behavioral studies, pretreatment of Swiss Webster mice with ENT1 UMB24  ENT1END or (+/-)-SM 21 significantly attenuated cocaine-induced ENT2 convulsions ENT2END and locomotor activity, but not lethality
0	We report the increased amount of motor disability in four patients with ENT1 idiopathic Parkinson's disease ENT1END after exposure to the ENT2 antidepressant ENT2END fluoxetine
0	The possibility of a clinically relevant dopamine-antagonistic capacity of ENT1 fluoxetine ENT1END in ENT2 Parkinson's disease ENT2END patients must be considered
0	The possibility of a clinically relevant ENT1 dopamine  ENT1END antagonistic capacity of fluoxetine in ENT2 Parkinson's disease ENT2END patients must be considered
0	ENT1 Depression  ENT1END is a major clinical feature of Parkinson's disease. We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the ENT2 antidepressant ENT2END fluoxetine
0	Increase of Parkinson disability after ENT1 fluoxetine  ENT1END  medication ENT2 Depression ENT2END is a major clinical feature of Parkinson's disease
0	ENT1 Depression  ENT1END  is a major clinical feature of Parkinson's disease. We report the increased amount of motor disability in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine. The possibility of a clinically relevant ENT2 dopamine ENT2END -antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered
0	We report the increased amount of ENT1 motor disability  ENT1END in four patients with idiopathic Parkinson's disease after exposure to the ENT2 antidepressant ENT2END fluoxetine
1	Increase of ENT1 Parkinson disability  ENT1END  after ENT2 fluoxetine ENT2END medication
0	We report the increased amount of ENT1 motor disability  ENT1END  in four patients with idiopathic Parkinson's disease after exposure to the antidepressant fluoxetine. The possibility of a clinically relevant ENT2 dopamine ENT2END -antagonistic capacity of fluoxetine in Parkinson's disease patients must be considered
0	The most common adverse effects were nausea and vomiting in the flumazenil group and ENT1 nausea ENT1END and injection-site pain in the placebo group. Flumazenil was found to promptly reverse sedation induced by ENT2 diazepam ENT2END in the presence of opioids
1	The most common adverse effects were nausea and vomiting in the ENT1 flumazenil  ENT1END group and ENT2 nausea ENT2END and injection-site pain in the placebo group
0	The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site ENT1 pain  ENT1END in the placebo group. Flumazenil was found to promptly reverse sedation induced by ENT2 diazepam ENT2END in the presence of opioids
0	The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection-site ENT1 pain ENT1END  in the placebo group. ENT2 Flumazenil ENT2END was found to promptly reverse sedation induced by diazepam in the presence of opioids
0	The most common adverse effects were nausea and ENT1 vomiting  ENT1END in the flumazenil group and nausea and injection-site pain in the placebo group. Flumazenil was found to promptly reverse sedation induced by ENT2 diazepam ENT2END in the presence of opioids
1	The most common adverse effects were nausea and ENT1 vomiting  ENT1END  in the ENT2 flumazenil ENT2END group and nausea and injection-site pain in the placebo group
0	The case of a nonepileptic patient who developed psychosis following ENT1 phenytoin ENT1END treatment for ENT2 trigeminal neuralgia ENT2END is described
0	This case suggests that the psychotic symptoms that occur following ENT1 phenytoin ENT1END treatment in some epileptic patients may be the direct result of medication, unrelated to ENT2 seizures ENT2END
0	This case suggests that the psychotic symptoms that occur following ENT1 phenytoin ENT1END  treatment in some ENT2 epileptic ENT2END patients may be the direct result of medication, unrelated to seizures
0	The case of a nonepileptic patient who developed ENT1 psychosis  ENT1END following ENT2 phenytoin ENT2END treatment for trigeminal neuralgia is described
0	We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant ENT1 tongue swelling ENT1END and protrusion developed within 10 minutes of the administration of a single IV dose of ENT2 droperidol ENT2END
0	We report the case of a previously healthy 19-year-old man with no known ENT1 drug allergies  ENT1END in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of ENT2 droperidol ENT2END
0	We report the case of a previously healthy 19-year-old man with no known drug allergies in whom angioedema with significant ENT1 tongue swelling  ENT1END and protrusion developed within 10 minutes of the administration of a single IV dose of ENT2 droperidol ENT2END
0	Angioedema associated with ENT1 droperidol ENT1END  administration.Angioedema, also known as angioneurotic edema or Quincke's disease, is a well-demarcated, localized edema involving the subcutaneous tissues that may cause ENT2 upper-airway obstruction ENT2END
1	ENT1 Angioedema  ENT1END  associated with ENT2 droperidol ENT2END administration
0	Induction studies have further shown that while pretreatment of 3-methylcholanthrene ( ENT1 MC ENT1END , an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced ENT2 convulsions ENT2END , pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
0	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced ENT1 convulsions ENT1END , pretreatment with ENT2 phenobarbital ENT2END (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
1	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of ENT1 lindane  ENT1END induced ENT2 convulsions ENT2END , pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
0	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced ENT1 convulsions ENT1END , pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ENT2 ethanol ENT2END , an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
0	In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and ENT1 NDMA  ENT1END d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively. Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced ENT2 convulsions ENT2END , pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
0	Similarly, when the P450-mediated metabolism of lindane was blocked by ENT1 cobalt chloride ENT1END incidence of ENT2 convulsions ENT2END was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity
0	Induction studies have further shown that while pretreatment of 3-methylcholanthrene ( ENT1 MC ENT1END ), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions. Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral ENT2 toxicity ENT2END
0	Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with ENT1 phenobarbital  ENT1END  (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions. Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral ENT2 toxicity ENT2END
0	Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that ENT1 lindane  ENT1END per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral ENT2 toxicity ENT2END
0	Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ENT1 ethanol  ENT1END inducible P450 isoenzymes are involved in its neurobehavioral ENT2 toxicity ENT2END
0	In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and ENT1 NDMA  ENT1END -d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively. Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions. Similarly, when the P450-mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral ENT2 toxicity ENT2END
0	Similarly, when the P450-mediated metabolism of lindane was blocked by ENT1 cobalt chloride  ENT1END  incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral ENT2 toxicity ENT2END
0	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced ENT1 neurotoxicity ENT1END .Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver. A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days. As observed with different doses, the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain. Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes. In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively. Induction studies have further shown that while pretreatment of ENT2 3-methylcholanthrene ENT2END (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
0	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced ENT1 neurotoxicity  ENT1END .Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver. A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days. As observed with different doses, the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain. Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes. In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively. Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with ENT2 phenobarbital ENT2END (PB), an inducer of P450 2B1/2B2 or ethanol, an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
0	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in ENT1 lindane  ENT1END  induced ENT2 neurotoxicity ENT2END
0	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced ENT1 neurotoxicity  ENT1END .Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and N-nitrosodimethylamine demethylase (NDMA-d) in rat brain and liver. A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose (2.5 mg/kg) of lindane was increased from 5 days to 15 or 21 days. As observed with different doses, the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain. Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1/1A2, 2B1/2B2 and 2E1 isoenzymes. In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD, EROD and NDMA-d are due to the increase in the levels of P450 2B1/2B2, 1A1/1A2 and 2E1 isoenzymes, respectively. Induction studies have further shown that while pretreatment of 3-methylcholanthrene (MC), an inducer of P4501A1/1A2, did not produce any significant effect in the incidence of lindane induced convulsions, pretreatment with phenobarbital (PB), an inducer of P450 2B1/2B2 or ENT2 ethanol ENT2END , an inducer of P450 2E1 catalysed reactions, significantly increased the incidence of lindane induced convulsions
0	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced ENT1 neurotoxicity ENT1END .Oral administration of lindane (2.5, 5, 10 and 15 mg/kg, body weight) for 5 days was found to produce a dose-dependent increase in the activity of P450 dependent 7-ethoxyresorufin-O-deethylase (EROD), 7-pentoxyresorufin-O-dealkylase (PROD) and ENT2 N-nitrosodimethylamine ENT2END demethylase (NDMA-d) in rat brain and liver
0	When the ENT1 carbamazepine ENT1END was discontinued, two of the children returned to their former state very quickly, two had the minor motor ENT2 seizures ENT2END resolve in 3 and 6 months, and one had the seizures persist
0	When the ENT1 carbamazepine ENT1END  was discontinued, two of the children returned to their former state very quickly, two had the minor motor seizures resolve in 3 and 6 months, and one had the seizures persist. The child in whom the seizures persisted was later found to have ENT2 ceroid lipofuscinosis ENT2END
1	ENT1 Myoclonic, atonic, and absence seizures  ENT1END  following institution of ENT2 carbamazepine ENT2END therapy in children
0	Five children, aged 3 to 11 years, treated with ENT1 carbamazepine ENT1END for ENT2 epilepsy ENT2END , had an acute aberrant reaction characterized by the onset of myoclonic, atypical absence and/or atonic (minor motor) seizures within a few days
1	ENT1 Myoclonic, atonic, and absence seizures  ENT1END  following institution of ENT2 carbamazepine ENT2END therapy in children
0	The authors present three patients with de novo absence epilepsy after administration of ENT1 carbamazepine ENT1END and vigabatrin. Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs. The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy. Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor. The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure. The possibility of drug-induced aggravation should be considered whenever an unexpected increase in ENT2 seizure ENT2END frequency and/or new seizure types appear following a change in drug treatment
0	The ENT1 gamma-aminobutyric acid  ENT1END transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy. Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor. The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure. The possibility of drug-induced aggravation should be considered whenever an unexpected increase in ENT2 seizure ENT2END frequency and/or new seizure types appear following a change in drug treatment
0	The authors present three patients with de novo absence epilepsy after administration of carbamazepine and ENT1 vigabatrin  ENT1END  Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs. The gamma-aminobutyric acid-transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy. Because drug-induced de novo absence seizure is rare, pro-absence drugs can only be considered a promoting factor. The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure. The possibility of drug-induced aggravation should be considered whenever an unexpected increase in ENT2 seizure ENT2END frequency and/or new seizure types appear following a change in drug treatment
1	The authors present three patients with de novo ENT1 absence epilepsy  ENT1END after administration of ENT2 carbamazepine ENT2END and vigabatrin
0	Despite the underlying diseases, the prognosis for drug-induced de novo ENT1 absence seizure  ENT1END is good because it subsides rapidly after discontinuing the use of the offending drugs. The ENT2 gamma-aminobutyric acid ENT2END -transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy
1	The authors present three patients with de novo ENT1 absence epilepsy  ENT1END  after administration of carbamazepine and ENT2 vigabatrin ENT2END
0	Anti- ENT1 epileptic  ENT1END  drugs-induced de novo absence seizures.The authors present three patients with de novo absence epilepsy after administration of ENT2 carbamazepine ENT2END and vigabatrin
0	Anti- ENT1 epileptic  ENT1END  drugs-induced de novo absence seizures.The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin. Despite the underlying diseases, the prognosis for drug-induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs. The ENT2 gamma-aminobutyric acid ENT2END -transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy
0	Anti- ENT1 epileptic  ENT1END  drugs-induced de novo absence seizures.The authors present three patients with de novo absence epilepsy after administration of carbamazepine and ENT2 vigabatrin ENT2END
1	Delayed-onset ENT1 heparin  ENT1END -induced ENT2 thrombocytopenia ENT2END
0	Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, ENT1 warfarin ENT1END (11 patients). Three patients died. CONCLUSIONS: Delayed-onset heparin-induced ENT2 thrombocytopenia ENT2END is increasingly being recognized
0	MEASUREMENTS: Platelet counts, onset of objectively determined ENT1 thromboembolism ENT1END  results of ENT2 heparin ENT2END -induced platelet factor 4 antibody tests, and outcomes
0	Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, ENT1 warfarin ENT1END  (11 patients). Three patients died. CONCLUSIONS: Delayed-onset heparin-induced thrombocytopenia is increasingly being recognized. To avoid disastrous outcomes, physicians must consider heparin-induced thrombocytopenia whenever a recently hospitalized patient returns with ENT2 thromboembolism ENT2END ; therapy with alternative anticoagulants, not heparin, should be initiated
1	BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after ENT1 heparin ENT1END exposure, with or without ENT2 arterial or venous thromboemboli ENT2END
1	BACKGROUND: Heparin-induced thrombocytopenia presents 5 to 12 days after ENT1 heparin ENT1END  exposure, with or without ENT2 arterial or venous thromboemboli ENT2END
1	Thromboemboli were venous (12 patients, 7 with ENT1 pulmonary emboli ENT1END  or arterial (4 patients) or both. Platelet counts were mildly decreased in all but 2 patients on second presentation. On readmission, 11 patients received therapeutic ENT2 heparin ENT2END , which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L)
0	Thromboemboli were venous (12 patients, 7 with ENT1 pulmonary emboli  ENT1END ) or arterial (4 patients) or both. Platelet counts were mildly decreased in all but 2 patients on second presentation. On readmission, 11 patients received therapeutic heparin, which worsened the patients' clinical condition and, in all 11 cases, decreased the platelet count (mean at readmission, 143 x 10(9) cells/L; mean nadir after heparin re-exposure, 39 x 10(9) cells/L). Results of serologic tests for heparin-induced antibodies were positive in all patients. Subsequent treatments included alternative anticoagulants (11 patients), thrombolytic drugs (3 patients), inferior vena cava filters (3 patients) and, eventually, ENT2 warfarin ENT2END (11 patients)
0	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after ENT1 paracetamol ENT1END ENT2 overdose ENT2END , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived
0	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol ENT1 overdose ENT1END , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived. A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with ENT2 aspartate ENT2END aminotransferase, which showed a sharp early peak and then a fall
1	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived ENT1 fulminant hepatic failure  ENT1END after ENT2 paracetamol ENT2END overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived
0	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with ENT1 fulminant hepatic failure  ENT1END due to viral hepatitis whether or not they survived. A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with ENT2 aspartate ENT2END aminotransferase, which showed a sharp early peak and then a fall
0	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after ENT1 paracetamol ENT1END  overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to ENT2 viral hepatitis ENT2END whether or not they survived
0	Acid protease (cathepsin D) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose, whereas activities were increased equally in patients with fulminant hepatic failure due to ENT1 viral hepatitis  ENT1END  whether or not they survived. A correlation was found between serum acid protease activity and prothrombin time, and the increase in cathepsin D activity was sustained over several days compared with ENT2 aspartate ENT2END aminotransferase, which showed a sharp early peak and then a fall
0	The diagnosis depends on exclusion of other entities, such as heart failure, ENT1 infection ENT1END  and malignancy. While withdrawal of ENT2 amiodarone ENT2END leads to clinical improvement in majority of cases, this is not always possible or advisable
0	The diagnosis depends on exclusion of other entities, such as heart failure, ENT1 infection ENT1END , and malignancy. While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant ENT2 steroid ENT2END therapy may have a role in selected patients
0	ENT1 Amiodarone ENT1END ENT2 pulmonary toxicity ENT2END
0	The clinical and radiographic features of amiodarone-induced ENT1 pulmonary toxicity  ENT1END are characteristic but nonspecific. The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy. While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant ENT2 steroid ENT2END therapy may have a role in selected patients
0	The diagnosis depends on exclusion of other entities, such as heart failure, infection, and ENT1 malignancy  ENT1END  While withdrawal of ENT2 amiodarone ENT2END leads to clinical improvement in majority of cases, this is not always possible or advisable
0	The diagnosis depends on exclusion of other entities, such as heart failure, infection, and ENT1 malignancy  ENT1END . While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant ENT2 steroid ENT2END therapy may have a role in selected patients
0	The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated ENT1 hypersensitivity pneumonitis ENT1END  The clinical and radiographic features of ENT2 amiodarone ENT2END -induced pulmonary toxicity are characteristic but nonspecific
0	The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated ENT1 hypersensitivity pneumonitis  ENT1END . The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific. The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy. While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant ENT2 steroid ENT2END therapy may have a role in selected patients
0	The diagnosis depends on exclusion of other entities, such as ENT1 heart failure  ENT1END  infection, and malignancy. While withdrawal of ENT2 amiodarone ENT2END leads to clinical improvement in majority of cases, this is not always possible or advisable
0	The diagnosis depends on exclusion of other entities, such as ENT1 heart failure  ENT1END , infection, and malignancy. While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant ENT2 steroid ENT2END therapy may have a role in selected patients
1	The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated ENT1 hypersensitivity pneumonitis  ENT1END  The clinical and radiographic features of ENT2 amiodarone ENT2END -induced pulmonary toxicity are characteristic but nonspecific
0	The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated ENT1 hypersensitivity pneumonitis  ENT1END . The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific. The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy. While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant ENT2 steroid ENT2END therapy may have a role in selected patients
1	Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being ENT1 pneumonitis ENT1END  The pulmonary toxicity of ENT2 amiodarone ENT2END is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis
0	Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side-effects, the most problematic being ENT1 pneumonitis  ENT1END . The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell-mediated hypersensitivity pneumonitis. The clinical and radiographic features of amiodarone-induced pulmonary toxicity are characteristic but nonspecific. The diagnosis depends on exclusion of other entities, such as heart failure, infection, and malignancy. While withdrawal of amiodarone leads to clinical improvement in majority of cases, this is not always possible or advisable. Dose reduction or concomitant ENT2 steroid ENT2END therapy may have a role in selected patients
0	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of ENT1 cyanosis ENT1END  The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40). Serum ENT2 sodium ENT2END (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use
0	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of ENT1 CM  ENT1END and the presence of ENT2 cyanosis ENT2END
0	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of ENT1 cyanosis ENT1END . The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40). Serum sodium (Na), potassium (K), and ENT2 creatinine ENT2END (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use
0	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of ENT1 cyanosis ENT1END . The 80 patients in the study consecutively received either iopromide (group A, n = 40) or iohexol (group B, n = 40). Serum sodium (Na), ENT2 potassium ENT2END (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use
0	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of ENT1 cyanosis ENT1END . The 80 patients in the study consecutively received either ENT2 iopromide ENT2END (group A, n = 40) or iohexol (group B, n = 40)
0	This prospective study determined the incidence of CIN for two nonionic contrast media (CM), iopromide and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of ENT1 cyanosis ENT1END . The 80 patients in the study consecutively received either iopromide (group A, n = 40) or ENT2 iohexol ENT2END (group B, n = 40)
0	Urine samples for ENT1 Na ENT1END and Cr also were checked at the same intervals. Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population. Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury. Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014). Among the 15 patients with CIN, 6 had cyanotic ENT2 congenital heart diseases ENT2END , but the incidence did not differ significantly from that for the noncyanotic patients (p = 0
0	6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of ENT1 CM  ENT1END (p = 0.014). Among the 15 patients with CIN, 6 had cyanotic ENT2 congenital heart diseases ENT2END , but the incidence did not differ significantly from that for the noncyanotic patients (p = 0
0	Urine samples for Na and ENT1 Cr  ENT1END also were checked at the same intervals. Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population. Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury. Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014). Among the 15 patients with CIN, 6 had cyanotic ENT2 congenital heart diseases ENT2END , but the incidence did not differ significantly from that for the noncyanotic patients (p = 0
0	Serum sodium (Na), potassium ( ENT1 K  ENT1END , and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population. Accordingly, among the 15 CIN patients (18.75%), 7.5% of the patients in group A had increased risk and 3.75% had renal injury, whereas 5% of group B had increased risk and 2.5% had renal injury. Whereas 33.3% of the patients with CIN were among those who received the proper dosage of CM, the percentage increased to 66.6% among those who received larger doses, with a significant difference in the incidence of CIN related to the different dosages of CM (p = 0.014). Among the 15 patients with CIN, 6 had cyanotic ENT2 congenital heart diseases ENT2END , but the incidence did not differ significantly from that for the noncyanotic patients (p = 0
0	Urine samples for ENT1 Na ENT1END  and Cr also were checked at the same intervals. Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage ENT2 renal damage ENT2END (RIFLE criteria) were used to define CIN and its incidence in the study population
1	Despite increasing reports on nonionic ENT1 contrast media ENT1END induced ENT2 nephropathy ENT2END (CIN) in hospitalized adult patients during cardiac procedures, the studies in pediatrics are limited, with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography
0	Urine samples for Na and ENT1 Cr  ENT1END  also were checked at the same intervals. Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage ENT2 renal damage ENT2END (RIFLE criteria) were used to define CIN and its incidence in the study population
0	Serum sodium (Na), potassium ( ENT1 K  ENT1END ), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage ENT2 renal damage ENT2END (RIFLE criteria) were used to define CIN and its incidence in the study population
1	This prospective study determined the incidence of ENT1 CIN ENT1END for two nonionic contrast media (CM), ENT2 iopromide ENT2END and iohexol, among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis
1	This prospective study determined the incidence of ENT1 CIN ENT1END  for two nonionic contrast media (CM), iopromide and ENT2 iohexol ENT2END , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis
0	Urine samples for ENT1 Na ENT1END  and Cr also were checked at the same intervals. Risk of renal failure, ENT2 Injury to the kidney ENT2END , Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	5% had ENT1 renal injury ENT1END  Whereas 33.3% of the patients with CIN were among those who received the proper dosage of ENT2 CM ENT2END , the percentage increased to 66
0	Urine samples for Na and ENT1 Cr  ENT1END  also were checked at the same intervals. Risk of renal failure, ENT2 Injury to the kidney ENT2END , Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	Serum sodium (Na), potassium ( ENT1 K  ENT1END ), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of renal failure, ENT2 Injury to the kidney ENT2END , Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	The 80 patients in the study consecutively received either ENT1 iopromide  ENT1END  (group A, n = 40) or iohexol (group B, n = 40). Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of renal failure, ENT2 Injury to the kidney ENT2END , Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	The 80 patients in the study consecutively received either iopromide (group A, n = 40) or ENT1 iohexol  ENT1END  (group B, n = 40). Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of renal failure, ENT2 Injury to the kidney ENT2END , Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	Urine samples for ENT1 Na ENT1END  and Cr also were checked at the same intervals. Risk of ENT2 renal failure ENT2END , Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after ENT1 CM  ENT1END use. Urine samples for Na and Cr also were checked at the same intervals. Risk of ENT2 renal failure ENT2END , Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	Urine samples for Na and ENT1 Cr  ENT1END  also were checked at the same intervals. Risk of ENT2 renal failure ENT2END , Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	Serum sodium (Na), potassium ( ENT1 K  ENT1END ), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of ENT2 renal failure ENT2END , Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	The 80 patients in the study consecutively received either ENT1 iopromide  ENT1END  (group A, n = 40) or iohexol (group B, n = 40). Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of ENT2 renal failure ENT2END , Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	The 80 patients in the study consecutively received either iopromide (group A, n = 40) or ENT1 iohexol  ENT1END  (group B, n = 40). Serum sodium (Na), potassium (K), and creatinine (Cr) were measured 24 h before angiography as baseline values, then measured again at 12-, 24-, and 48-h intervals after CM use. Urine samples for Na and Cr also were checked at the same intervals. Risk of ENT2 renal failure ENT2END , Injury to the kidney, Failure of kidney function, Loss of kidney function, and End-stage renal damage (RIFLE criteria) were used to define CIN and its incidence in the study population
0	The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable ENT1 lung cancer ENT1END under treatment with ENT2 IF ENT2END (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle
0	Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable ENT1 lung cancer ENT1END .The protective effect of oral administration of the ENT2 thiol ENT2END compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle
0	Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate ( ENT1 MESNA  ENT1END ) to patients with inoperable ENT2 lung cancer ENT2END
0	There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic ENT1 toxicity ENT1END of the cytostatic treatment. Our results support the view that MESNA, given orally in conjunction with combined cytostatic regimens which include ENT2 IF ENT2END , simplifies the treatment and provides optimum protection for the urinary epithelium
0	There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic ENT1 toxicity ENT1END  of the cytostatic treatment. Our results support the view that ENT2 MESNA ENT2END , given orally in conjunction with combined cytostatic regimens which include IF, simplifies the treatment and provides optimum protection for the urinary epithelium
0	MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of ENT1 IF ENT1END , 4 hr and 8 hr p.i. Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic ENT2 haematuria ENT2END and no episodes of gross haematuria
0	The protective effect of oral administration of the ENT1 thiol  ENT1END  compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle. MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i. Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic ENT2 haematuria ENT2END and no episodes of gross haematuria
0	Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross ENT1 haematuria ENT1END  In this group of 45 patients under protection with ENT2 MESNA ENT2END there were 5 complete remissions and 9 partial remissions (total 31%)
1	Treatment of ENT1 ifosfamide  ENT1END -induced ENT2 urothelial toxicity ENT2END by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancer
0	The protective effect of oral administration of the ENT1 thiol ENT1END  compound sodium 2-mercaptoethane sulphonate (MESNA) against ENT2 urothelial toxicity ENT2END induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle
0	The protective effect of oral administration of the thiol compound sodium 2-mercaptoethane sulphonate ( ENT1 MESNA  ENT1END  against ENT2 urothelial toxicity ENT2END induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle
0	A further group of 25 patients under polychemotherapy with ENT1 IF  ENT1END were treated by conventional prophylactic measures (raised fluid intake and forced diuresis). In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation ( ENT2 cystitis ENT2END and pollakisuria)
0	The protective effect of oral administration of the ENT1 thiol ENT1END  compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle. MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i. Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria. In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%). A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures (raised fluid intake and forced diuresis). In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation ENT2 cystitis ENT2END and pollakisuria)
0	In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation ( ENT1 cystitis ENT1END  and pollakisuria). There were no appreciable differences between the ENT2 MESNA ENT2END series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment
0	A further group of 25 patients under polychemotherapy with ENT1 IF ENT1END  were treated by conventional prophylactic measures (raised fluid intake and forced diuresis). In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and ENT2 pollakisuria ENT2END )
0	The protective effect of oral administration of the ENT1 thiol  ENT1END  compound sodium 2-mercaptoethane sulphonate (MESNA) against urothelial toxicity induced by ifosfamide (IF) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF (2250 mg/m2 on days 2-5) as part of a polychemotherapy regimen repeated in a 4-week cycle. MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg/m2, each administered at 0 hr (= injection of IF), 4 hr and 8 hr p.i. Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria. In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions (total 31%). A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures (raised fluid intake and forced diuresis). In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and ENT2 pollakisuria ENT2END )
0	In this group there were 1 complete and 5 partial remissions (total 24%), but nearly all patients developed either gross haematuria and/or symptoms of bladder irritation (cystitis and ENT1 pollakisuria  ENT1END ). There were no appreciable differences between the ENT2 MESNA ENT2END series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment
0	The anti- ENT1 dementia ENT1END effects of s-limonene and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH). These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH. Analysis of neurotransmitter concentration in some brain regions on the test day showed that ENT2 dopamine ENT2END concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine
0	The anti- ENT1 dementia ENT1END  effects of ENT2 s-limonene ENT2END and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH)
0	The anti- ENT1 dementia ENT1END  effects of s-limonene and ENT2 s-perillyl alcohol ENT2END were observed using the passive avoidance test (PA) and the open field habituation test (OFH)
0	Components of lemon essential oil attenuate ENT1 dementia  ENT1END  induced by ENT2 scopolamine ENT2END
0	These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, s-perillyl alcohol relieved the ENT1 deficit of associative memory  ENT1END in PA only, and did not improve non-associative memory significantly in OFH. Analysis of neurotransmitter concentration in some brain regions on the test day showed that ENT2 dopamine ENT2END concentration of the vehicle/scopolamine group was significantly lower than that of the vehicle/vehicle group, but this phenomenon was reversed when s-limonene or s-perillyl alcohol were administered before the injection of scopolamine
0	The anti-dementia effects of ENT1 s-limonene ENT1END  and s-perillyl alcohol were observed using the passive avoidance test (PA) and the open field habituation test (OFH). These lemon essential oils showed strong ability to improve ENT2 memory impaired ENT2END by scopolamine; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH
0	These lemon essential oils showed strong ability to improve memory impaired by scopolamine; however, ENT1 s-perillyl alcohol  ENT1END relieved the ENT2 deficit of associative memory ENT2END in PA only, and did not improve non-associative memory significantly in OFH
1	These lemon essential oils showed strong ability to improve ENT1 memory impaired ENT1END  by ENT2 scopolamine ENT2END ; however, s-perillyl alcohol relieved the deficit of associative memory in PA only, and did not improve non-associative memory significantly in OFH
0	Treatment with hydration, furosemide, and discontinuation of the calcium and ENT1 vitamin D ENT1END source is adequate. Pamidronate treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe ENT2 hypercalcemia ENT2END
0	ENT1 Pamidronate  ENT1END treatment is associated with considerable risk for hypocalcemia, even in cases of initially severe ENT2 hypercalcemia ENT2END
1	OBJECTIVE: To describe 3 patients with ENT1 calcium carbonate ENT1END induced ENT2 hypercalcemia ENT2END and gain insights into the cause and management of the milk-alkali syndrome
0	METHODS: We report the clinical and laboratory data in 3 patients who presented with severe ENT1 hypercalcemia ENT1END (corrected serum ENT2 calcium ENT2END > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome
0	METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on ENT1 milk-alkali syndrome ENT1END  RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and ENT2 1,25-dihydroxyvitamin D ENT2END concentrations
0	CONCLUSION: Milk-alkali syndrome may be a common cause of unexplained ENT1 hypercalcemia ENT1END and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons. Treatment with hydration, ENT2 furosemide ENT2END , and discontinuation of the calcium and vitamin D source is adequate
0	Calcium carbonate ENT1 toxicity ENT1END : the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of furosemide. The 2 patients with the higher serum calcium concentrations received ENT2 pamidronate ENT2END intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia
0	ENT1 Calcium carbonate ENT1END ENT2 toxicity ENT2END : the updated milk-alkali syndrome; report of 3 cases and review of the literature
0	Calcium carbonate ENT1 toxicity  ENT1END : the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum ENT2 calcium ENT2END > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome
0	Calcium carbonate ENT1 toxicity  ENT1END : the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and ENT2 1,25-dihydroxyvitamin D ENT2END concentrations
0	Calcium carbonate ENT1 toxicity ENT1END : the updated milk-alkali syndrome; report of 3 cases and review of the literature.OBJECTIVE: To describe 3 patients with calcium carbonate-induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of ENT2 furosemide ENT2END
0	RESULTS: The 3 patients had acute renal insufficiency, relative ENT1 metabolic alkalosis  ENT1END  and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of furosemide. The 2 patients with the higher serum calcium concentrations received ENT2 pamidronate ENT2END intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia
0	OBJECTIVE: To describe 3 patients with ENT1 calcium carbonate  ENT1END -induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative ENT2 metabolic alkalosis ENT2END , and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations
0	METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum ENT1 calcium  ENT1END  > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had acute renal insufficiency, relative ENT2 metabolic alkalosis ENT2END , and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations
0	RESULTS: The 3 patients had acute renal insufficiency, relative ENT1 metabolic alkalosis  ENT1END , and low parathyroid hormone (PTH), PTH-related peptide, and ENT2 1,25-dihydroxyvitamin D ENT2END concentrations
0	RESULTS: The 3 patients had acute renal insufficiency, relative ENT1 metabolic alkalosis  ENT1END , and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of ENT2 furosemide ENT2END
0	Treatment with hydration, furosemide, and discontinuation of the calcium and ENT1 vitamin D ENT1END  source is adequate. Pamidronate treatment is associated with considerable risk for ENT2 hypocalcemia ENT2END , even in cases of initially severe hypercalcemia
1	ENT1 Pamidronate  ENT1END  treatment is associated with considerable risk for ENT2 hypocalcemia ENT2END , even in cases of initially severe hypercalcemia
0	The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe ENT1 hypocalcemia ENT1END  Of the 3 patients, 2 were ingesting acceptable doses of elemental calcium (1 g and 2 g daily, respectively) in the form of ENT2 calcium carbonate ENT2END
0	The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe ENT1 hypocalcemia ENT1END . Of the 3 patients, 2 were ingesting acceptable doses of elemental ENT2 calcium ENT2END (1 g and 2 g daily, respectively) in the form of calcium carbonate
0	RESULTS: The 3 patients had acute renal insufficiency, relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and ENT1 1,25-dihydroxyvitamin D  ENT1END  concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of furosemide. The 2 patients with the higher serum calcium concentrations received pamidronate intravenously (60 and 30 mg, respectively), which caused severe ENT2 hypocalcemia ENT2END
0	Treatment with hydration, ENT1 furosemide  ENT1END , and discontinuation of the calcium and vitamin D source is adequate. Pamidronate treatment is associated with considerable risk for ENT2 hypocalcemia ENT2END , even in cases of initially severe hypercalcemia
0	RESULTS: The 3 patients had ENT1 acute renal insufficiency  ENT1END  relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of furosemide. The 2 patients with the higher serum calcium concentrations received ENT2 pamidronate ENT2END intravenously (60 and 30 mg, respectively), which caused severe hypocalcemia
0	OBJECTIVE: To describe 3 patients with ENT1 calcium carbonate  ENT1END -induced hypercalcemia and gain insights into the cause and management of the milk-alkali syndrome. METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum calcium > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had ENT2 acute renal insufficiency ENT2END , relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations
0	METHODS: We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia (corrected serum ENT1 calcium  ENT1END  > or = 14 mg/dL) and review the pertinent literature on milk-alkali syndrome. RESULTS: The 3 patients had ENT2 acute renal insufficiency ENT2END , relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations
0	RESULTS: The 3 patients had ENT1 acute renal insufficiency  ENT1END , relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and ENT2 1,25-dihydroxyvitamin D ENT2END concentrations
0	RESULTS: The 3 patients had ENT1 acute renal insufficiency  ENT1END , relative metabolic alkalosis, and low parathyroid hormone (PTH), PTH-related peptide, and 1,25-dihydroxyvitamin D concentrations. No malignant lesion was found. Treatment included aggressive hydration and varied amounts of ENT2 furosemide ENT2END
0	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with ENT1 bipolar mania ENT1END  METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies. Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or haloperidol monotherapy as respective active controls. Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or ENT2 divalproex ENT2END , QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/DVP) (n = 203)
0	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with ENT1 bipolar mania ENT1END . METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies. Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with ENT2 lithium ENT2END or haloperidol monotherapy as respective active controls
0	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with ENT1 quetiapine  ENT1END in patients with ENT2 bipolar mania ENT2END
0	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including akathisia, with quetiapine in patients with ENT1 bipolar mania ENT1END . METHODS: Data were analyzed from four similarly designed, randomized, double-blind, 3- to 12-week studies. Two studies evaluated quetiapine monotherapy (up to 800 mg/day) (n = 209) versus placebo (n = 198), with lithium or ENT2 haloperidol ENT2END monotherapy as respective active controls
0	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + Li/ ENT1 DVP ENT1END  (n = 203). ENT2 Extrapyramidal symptoms ENT2END were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage
1	Two studies evaluated quetiapine (up to 800 mg/day) in combination with a mood stabilizer (lithium or divalproex, QTP + Li/DVP) (n = 196) compared to placebo and mood stabilizer (PBO + ENT1 Li  ENT1END DVP) (n = 203). ENT2 Extrapyramidal symptoms ENT2END were evaluated using the Simpson-Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), adverse event reports and anticholinergic drug usage
0	Placebo-level incidence of extrapyramidal symptoms ( ENT1 EPS  ENT1END ) with ENT2 quetiapine ENT2END in controlled studies of patients with bipolar mania
1	Adverse events related to ENT1 EPS ENT1END occurred in 59.6% of patients treated with ENT2 haloperidol ENT2END (n = 99) monotherapy, whereas 26
0	6%) and PBO + Li/ ENT1 DVP ENT1END (4.9%). Lithium was associated with a significantly higher incidence (p < 0.05) of ENT2 tremor ENT2END (18
1	6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of ENT1 tremor ENT1END in patients receiving ENT2 lithium ENT2END therapy
0	05) of ENT1 tremor ENT1END  (18.4%) than ENT2 quetiapine ENT2END (5
1	6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of ENT1 tremor ENT1END  in patients receiving lithium therapy. ENT2 Haloperidol ENT2END induced a significantly higher incidence (p < 0
0	The incidence of ENT1 akathisia  ENT1END was low and similar with quetiapine monotherapy (3.3%) and placebo (6.1%), and with QTP + Li/ ENT2 DVP ENT2END (3
0	6%); cerebellar tremor, which is a known adverse effect of lithium, may have contributed to the elevated rate of tremor in patients receiving ENT1 lithium ENT1END  therapy. Haloperidol induced a significantly higher incidence (p < 0.001) of ENT2 akathisia ENT2END (33
0	OBJECTIVES: To evaluate extrapyramidal symptoms (EPS), including ENT1 akathisia  ENT1END  with ENT2 quetiapine ENT2END in patients with bipolar mania
1	ENT1 Haloperidol  ENT1END  induced a significantly higher incidence (p < 0.001) of ENT2 akathisia ENT2END (33
0	We investigated the effect of repeated treatment with fluvoxamine, a selective ENT1 serotonin ENT1END uptake inhibitor, on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the "behavioral despair" test. A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the amphetamine-induced ENT2 hyperactivity ENT2END
1	A repeated treatment with fluvoxamine (twice daily for 14 days) potentiated in mice and in rats (weaker) the ENT1 amphetamine  ENT1END induced ENT2 hyperactivity ENT2END
1	The ENT1 hyperactivity ENT1END induced by nomifensine in mice remained unaffected by fluvoxamine. The stimulation of locomotor activity by intracerebroventricularly administered ENT2 methoxamine ENT2END was not affected by repeated treatment with fluvoxamine
1	The ENT1 hyperactivity ENT1END  induced by ENT2 nomifensine ENT2END in mice remained unaffected by fluvoxamine
0	The ENT1 hyperactivity ENT1END  induced by nomifensine in mice remained unaffected by fluvoxamine. The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine. Given three times fluvoxamine had no effect on the immobilization time in the "behavioral despair" test in rats. The results indicate that fluvoxamine given repeatedly acts differently than ENT2 citalopram ENT2END , another selective serotonin uptake inhibitor, and differs also from other antidepressant drugs
1	The ENT1 hyperactivity ENT1END  induced by nomifensine in mice remained unaffected by ENT2 fluvoxamine ENT2END
0	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with ENT2 valproate ENT2END , clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test
1	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate. On the other hand, bicuculline, ENT2 aminophylline ENT2END and BAY k-8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam
0	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of ENT2 loreclezole ENT2END (2
0	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type ENT2 calcium ENT2END channels) reversed the protective activity of loreclezole alone and its combination with valproate
0	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or ENT2 carbamazepine ENT2END (applied at their subprotective doses) also exhibited antiseizure effect in this test
0	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, ENT2 clonazepam ENT2END , or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test
1	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, ENT2 bicuculline ENT2END , N-methyl-D-aspartic acid and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate
0	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, bicuculline, ENT2 N-methyl-D-aspartic acid ENT2END and BAY k-8644 (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate
1	Loreclezole (5 mg/kg) exerted a significant protective action in amygdala-kindled rats, reducing both ENT1 seizure ENT1END  and afterdischarge durations. The combinations of loreclezole (2.5 mg/kg) with valproate, clonazepam, or carbamazepine (applied at their subprotective doses) also exhibited antiseizure effect in this test. However, only two first combinations occurred to be of pharmacodynamic nature. Among several chemoconvulsants, bicuculline, N-methyl-D-aspartic acid and ENT2 BAY k-8644 ENT2END (the opener of L-type calcium channels) reversed the protective activity of loreclezole alone and its combination with valproate
1	We report an undiagnosed case of myotonia congenita in a 24-year-old previously healthy primigravida, who developed life threatening ENT1 masseter spasm ENT1END following a standard dose of intravenous ENT2 suxamethonium ENT2END for induction of anaesthesia
0	We report an undiagnosed case of ENT1 myotonia congenita  ENT1END in a 24-year-old previously healthy primigravida, who developed life threatening masseter spasm following a standard dose of intravenous ENT2 suxamethonium ENT2END for induction of anaesthesia
0	The results showed that intracollicular microinjection of ENT1 MK-801 ENT1END and AP7 previous to systemic injections of haloperidol significantly attenuated the ENT2 catalepsy ENT2END , as indicated by a reduced latency to step down from a horizontal bar
0	Glutamatergic neurotransmission mediated by ENT1 NMDA  ENT1END  receptors in the inferior colliculus can modulate haloperidol-induced ENT2 catalepsy ENT2END
1	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate ENT1 haloperidol  ENT1END -induced ENT2 catalepsy ENT2END
0	The present study examined the influence of excitatory amino acid-mediated mechanisms in the IC on the ENT1 catalepsy ENT1END induced by the ENT2 dopamine ENT2END receptor blocker haloperidol administered systemically (1 or 0
0	The present study examined the influence of excitatory ENT1 amino acid  ENT1END mediated mechanisms in the IC on the ENT2 catalepsy ENT2END induced by the dopamine receptor blocker haloperidol administered systemically (1 or 0
0	The results showed that intracollicular microinjection of MK-801 and ENT1 AP7  ENT1END previous to systemic injections of haloperidol significantly attenuated the ENT2 catalepsy ENT2END , as indicated by a reduced latency to step down from a horizontal bar
0	Haloperidol-induced ENT1 catalepsy ENT1END was challenged with prior intracollicular microinjections of ENT2 glutamate ENT2END NMDA receptor antagonists, MK-801 (15 or 30 mmol/0
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af ENT1 embolic events ENT1END  Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. ENT2 Angiotensin ENT2END -converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af ENT1 embolic events ENT1END . Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling. Preliminary studies suggest that ENT2 statins ENT2END could interfere with the risk of recurrence after electrical cardioversion
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus ENT1 aspirin  ENT1END  in the prevention af ENT2 embolic events ENT2END
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as ENT1 vitamin K ENT1END antagonist drugs in the prevention of ENT2 embolic events ENT2END , but has been recently withdrawn because of abnormal liver function tests
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of ENT1 embolic events ENT1END , but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with ENT2 Irbesartan ENT2END for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af ENT1 embolic events ENT1END . Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and ENT2 angiotensin II ENT2END receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy ( ENT1 clopidogrel  ENT1END plus aspirin) in the prevention af ENT2 embolic events ENT2END
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that ENT1 warfarin  ENT1END is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af ENT2 embolic events ENT2END
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af ENT1 embolic events ENT1END . ENT2 Idraparinux ENT2END , a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation
0	ENT1 Ximelagatran  ENT1END  an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of ENT2 embolic events ENT2END , but has been recently withdrawn because of abnormal liver function tests
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function  ENT1END tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. ENT2 Angiotensin ENT2END -converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function  ENT1END  tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling. Preliminary studies suggest that ENT2 statins ENT2END could interfere with the risk of recurrence after electrical cardioversion
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function  ENT1END  tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus ENT2 aspirin ENT2END ) in the prevention af embolic events
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as ENT1 vitamin K  ENT1END  antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT2 abnormal liver function ENT2END tests
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function  ENT1END  tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with ENT2 Irbesartan ENT2END for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function  ENT1END  tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and ENT2 angiotensin II ENT2END receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function ENT1END  tests. The ACTIVE-W (Atrial Fibrillation ENT2 Clopidogrel ENT2END Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function  ENT1END  tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that ENT2 warfarin ENT2END is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT1 abnormal liver function  ENT1END  tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. ENT2 Idraparinux ENT2END , a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation
1	ENT1 Ximelagatran  ENT1END , an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of ENT2 abnormal liver function ENT2END tests
0	Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with ENT1 atrial fibrillation ENT1END ENT2 Angiotensin ENT2END -converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling
0	Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in ENT1 atrial fibrillation  ENT1END through cardiac remodelling. Preliminary studies suggest that ENT2 statins ENT2END could interfere with the risk of recurrence after electrical cardioversion
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus ENT1 aspirin  ENT1END ) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with ENT2 atrial fibrillation ENT2END
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as ENT1 vitamin K  ENT1END  antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W ( ENT2 Atrial Fibrillation ENT2END Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	The ACTIVE-W ( ENT1 Atrial Fibrillation  ENT1END  Clopidogrel Trial with ENT2 Irbesartan ENT2END for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	Angiotensin-converting enzyme inhibitors and ENT1 angiotensin II  ENT1END  receptor-blocking drugs hold promise in ENT2 atrial fibrillation ENT2END through cardiac remodelling
0	The ACTIVE-W ( ENT1 Atrial Fibrillation ENT1END ENT2 Clopidogrel ENT2END Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	The ACTIVE-W ( ENT1 Atrial Fibrillation  ENT1END  Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that ENT2 warfarin ENT2END is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	ENT1 Idraparinux  ENT1END , a Factor Xa inhibitor, is being evaluated in patients with ENT2 atrial fibrillation ENT2END
0	ENT1 Ximelagatran ENT1END , an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W ENT2 Atrial Fibrillation ENT2END Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	ENT1 Angiotensin ENT1END -converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT1 cardiac remodelling  ENT1END . Preliminary studies suggest that ENT2 statins ENT2END could interfere with the risk of recurrence after electrical cardioversion
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus ENT1 aspirin  ENT1END ) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as ENT1 vitamin K  ENT1END  antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with ENT1 Irbesartan  ENT1END  for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	Angiotensin-converting enzyme inhibitors and ENT1 angiotensin II  ENT1END  receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy ( ENT1 clopidogrel  ENT1END  plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that ENT1 warfarin  ENT1END  is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	ENT1 Idraparinux  ENT1END , a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	ENT1 Ximelagatran  ENT1END , an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through ENT2 cardiac remodelling ENT2END
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END  with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. ENT2 Angiotensin ENT2END -converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END , with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and angiotensin II receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling. Preliminary studies suggest that ENT2 statins ENT2END could interfere with the risk of recurrence after electrical cardioversion
0	Overall, in high-risk patients, warfarin is superior to ENT1 aspirin  ENT1END in preventing ENT2 strokes ENT2END , with a relative risk reduction of 36%
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END , with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as ENT2 vitamin K ENT2END antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END , with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with ENT2 Irbesartan ENT2END for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END , with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. Idraparinux, a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation. Angiotensin-converting enzyme inhibitors and ENT2 angiotensin II ENT2END receptor-blocking drugs hold promise in atrial fibrillation through cardiac remodelling
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END , with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation ENT2 Clopidogrel ENT2END Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events
0	Pooled data from trials comparing antithrombotic treatment with placebo have shown that ENT1 warfarin ENT1END reduces the risk of ENT2 stroke ENT2END by 62%, and that aspirin alone reduces the risk by 22%
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END , with a relative risk reduction of 36%. Ximelagatran, an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests. The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) study has demonstrated that warfarin is superior to platelet therapy (clopidogrel plus aspirin) in the prevention af embolic events. ENT2 Idraparinux ENT2END , a Factor Xa inhibitor, is being evaluated in patients with atrial fibrillation
0	Overall, in high-risk patients, warfarin is superior to aspirin in preventing ENT1 strokes  ENT1END , with a relative risk reduction of 36%. ENT2 Ximelagatran ENT2END , an oral direct thrombin inhibitor, was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events, but has been recently withdrawn because of abnormal liver function tests
0	In the animal study, Nrf2 was demonstrated to be crucial in ameliorating ENT1 streptozotocin ENT1END induced ENT2 renal damage ENT2END
0	OBJECTIVE: Diabetic nephropathy is one of the major causes of renal failure, which is accompanied by the production of reactive ENT1 oxygen  ENT1END species (ROS). Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis. Here, we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy. RESEARCH DESIGN AND METHODS: We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients, a streptozotocin-induced diabetic nephropathy model in Nrf2(-/-) mice, and cultured human mesangial cells. RESULTS: The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels. In the animal study, Nrf2 was demonstrated to be crucial in ameliorating streptozotocin-induced ENT2 renal damage ENT2END
0	This is evident by Nrf2(-/-) mice having higher ROS production and suffering from greater oxidative DNA damage and ENT1 renal injury ENT1END compared with Nrf2(+/+) mice. Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against diabetic nephropathy is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production. In human renal mesangial cells, high ENT2 glucose ENT2END induced ROS production and activated expression of Nrf2 and its downstream genes
1	The protective role of Nrf2 in ENT1 streptozotocin  ENT1END -induced ENT2 diabetic nephropathy ENT2END
0	OBJECTIVE: ENT1 Diabetic nephropathy  ENT1END is one of the major causes of renal failure, which is accompanied by the production of reactive ENT2 oxygen ENT2END species (ROS)
0	Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2-mediated protection against ENT1 diabetic nephropathy  ENT1END is, at least, partially through inhibition of transforming growth factor-beta1 (TGF-beta1) and reduction of extracellular matrix production. In human renal mesangial cells, high ENT2 glucose ENT2END induced ROS production and activated expression of Nrf2 and its downstream genes
0	The protective role of Nrf2 in ENT1 streptozotocin ENT1END -induced diabetic nephropathy.OBJECTIVE: Diabetic nephropathy is one of the major causes of ENT2 renal failure ENT2END , which is accompanied by the production of reactive oxygen species (ROS)
0	OBJECTIVE: Diabetic nephropathy is one of the major causes of ENT1 renal failure  ENT1END , which is accompanied by the production of reactive ENT2 oxygen ENT2END species (ROS)
1	Reversible ENT1 cerebral lesions  ENT1END  associated with ENT2 tiazofurin ENT2END usage: MR demonstration
0	Review of the literature reveals an association between ENT1 tamoxifen ENT1END use and gynecologic ENT2 tumors ENT2END
0	Review of the literature reveals an association between tamoxifen use and gynecologic ENT1 tumors ENT1END . CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma. Her ENT2 aspartate ENT2END transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use
0	Review of the literature reveals an association between tamoxifen use and gynecologic ENT1 tumors ENT1END . CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive breast carcinoma. Her aspartate transaminase and ENT2 alanine ENT2END transaminase levels increase markedly after 6 months of tamoxifen use
0	Review of the literature reveals an association between tamoxifen use and gynecologic ENT1 tumors ENT1END . CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II ENT2 estrogen ENT2END receptor-positive breast carcinoma
0	CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for ENT1 granulosa cell tumors ENT1END because of alterations in ENT2 tamoxifen ENT2END metabolism
0	Her ENT1 aspartate  ENT1END  transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary. CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for ENT2 granulosa cell tumors ENT2END because of alterations in tamoxifen metabolism
0	Her aspartate transaminase and ENT1 alanine  ENT1END  transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary. CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for ENT2 granulosa cell tumors ENT2END because of alterations in tamoxifen metabolism
0	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II ENT1 estrogen  ENT1END  receptor-positive breast carcinoma. Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary. CONCLUSION: Patients with tamoxifen-induced liver dysfunction may be at increased risk for ENT2 granulosa cell tumors ENT2END because of alterations in tamoxifen metabolism
0	CASE: A 52-year-old postmenopausal woman was treated with ENT1 tamoxifen ENT1END for stage II estrogen receptor-positive ENT2 breast carcinoma ENT2END
0	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive ENT1 breast carcinoma  ENT1END . Her ENT2 aspartate ENT2END transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use
0	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor-positive ENT1 breast carcinoma  ENT1END . Her aspartate transaminase and ENT2 alanine ENT2END transaminase levels increase markedly after 6 months of tamoxifen use
0	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II ENT1 estrogen  ENT1END  receptor-positive ENT2 breast carcinoma ENT2END
1	ENT1 Granulosa cell tumor of the ovary  ENT1END  associated with antecedent ENT2 tamoxifen ENT2END use
0	Her ENT1 aspartate ENT1END  transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic ENT2 granulosa cell tumor of the ovary ENT2END
0	Her aspartate transaminase and ENT1 alanine  ENT1END  transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic ENT2 granulosa cell tumor of the ovary ENT2END
0	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II ENT1 estrogen  ENT1END  receptor-positive breast carcinoma. Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic ENT2 granulosa cell tumor of the ovary ENT2END
1	CONCLUSION: Patients with ENT1 tamoxifen ENT1END induced ENT2 liver dysfunction ENT2END may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism
0	Her ENT1 aspartate  ENT1END  transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary. CONCLUSION: Patients with tamoxifen-induced ENT2 liver dysfunction ENT2END may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism
0	Her aspartate transaminase and ENT1 alanine  ENT1END  transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary. CONCLUSION: Patients with tamoxifen-induced ENT2 liver dysfunction ENT2END may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism
0	CASE: A 52-year-old postmenopausal woman was treated with tamoxifen for stage II ENT1 estrogen  ENT1END  receptor-positive breast carcinoma. Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use. After an additional 17 months of elevated serum transaminases, the patient was found to have a stage Ic granulosa cell tumor of the ovary. CONCLUSION: Patients with tamoxifen-induced ENT2 liver dysfunction ENT2END may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism
0	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in ENT1 FANFT ENT1END ENT2 carcinogenesis ENT2END in the bladder and forestomach, and that aspirin's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation
0	The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT ENT1 carcinogenesis ENT1END  in the bladder and forestomach, and that ENT2 aspirin ENT2END 's effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation
1	The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of ENT1 FANFT ENT1END induced ENT2 bladder carcinomas ENT2END but a concomitant induction of forestomach tumors
0	The co-administration of ENT1 aspirin  ENT1END with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced ENT2 bladder carcinomas ENT2END but a concomitant induction of forestomach tumors
1	The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of ENT1 FANFT ENT1END -induced bladder carcinomas but a concomitant induction of ENT2 forestomach tumors ENT2END
0	The co-administration of aspirin with N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide (FANFT) to rats resulted in a reduced incidence of FANFT-induced bladder carcinomas but a concomitant induction of ENT1 forestomach tumors ENT1END . An autoradiographic study was performed on male F-344 rats fed diet containing FANFT at a level of 0.2% and/or ENT2 aspirin ENT2END at a level of 0
1	Nimodipine prevents ENT1 memory impairment  ENT1END  caused by ENT2 nitroglycerin ENT2END -induced hypotension in adult mice
0	ENT1 Nimodipine  ENT1END  prevents ENT2 memory impairment ENT2END caused by nitroglycerin-induced hypotension in adult mice
0	BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of ENT1 cognitive dysfunction ENT1END  We tested the hypothesis that nimodipine (NIMO) administered at the onset of ENT2 nitroglycerin ENT2END (NTG)-induced hypotension would preserve long-term associative memory
0	BACKGROUND: Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of ENT1 cognitive dysfunction ENT1END . We tested the hypothesis that ENT2 nimodipine ENT2END (NIMO) administered at the onset of nitroglycerin (NTG)-induced hypotension would preserve long-term associative memory
1	We tested the hypothesis that nimodipine (NIMO) administered at the onset of nitroglycerin ( ENT1 NTG ENT1END -induced ENT2 hypotension ENT2END would preserve long-term associative memory
0	CONCLUSION: In a PA retention paradigm, the injection of NTG immediately after learning produced a significant impairment of long-term associative memory in mice, whereas delayed induced ENT1 hypotension ENT1END had no effect. ENT2 NIMO ENT2END attenuated the disruption in consolidation of long-term memory caused by NTG but did not improve latency in the absence of hypotension
0	The observed effect of NIMO may have been attributable to the preservation of ENT1 calcium ENT1END homeostasis during ENT2 hypotension ENT2END , because there were no differences in the PbtO(2) indices among groups
0	ENT1 Vasopressin  ENT1END  in the treatment of milrinone-induced hypotension in severe ENT2 heart failure ENT2END
0	The use of phosphodiesterase inhibitors such as ENT1 milrinone ENT1END in the treatment of severe ENT2 heart failure ENT2END is frequently restricted because they cause vasodilation and hypotension
1	ENT1 Vasopressin  ENT1END  in the treatment of milrinone-induced ENT2 hypotension ENT2END in severe heart failure
1	Vasopressin in the treatment of ENT1 milrinone  ENT1END -induced ENT2 hypotension ENT2END in severe heart failure
0	Physiological dose (<1 mg) of ENT1 folic acid ENT1END both in healthy and 60 epileptic women, all without any ENT2 autoimmune disease ENT2END , did not increase the risk for epileptic seizures
0	This 22-year-old epileptic woman was treated continuously by ENT1 carbamazepine ENT1END and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation. She developed status epilepticus and later symptoms of systemic lupus erythematodes. Her pregnancy ended with stillbirth. CONCLUSIONS: The epileptic pregnant patient's ENT2 autoimmune disease ENT2END (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of folic acid triggered a cluster of seizures
0	Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of ENT1 folic acid ENT1END containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural ENT2 birth defects ENT2END and epilepsy-related side effects
0	Epileptogenic activity of folic acid after drug induces SLE (folic acid and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural ENT1 birth defects  ENT1END  and epilepsy-related side effects. STUDY DESIGN: First a randomised trial, later periconception care including in total 12225 females. RESULTS: Of 60 epileptic women with periconceptional folic acid (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period. One epileptic woman delivered a newborn with cleft lip and palate. Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin. This 22-year-old epileptic woman was treated continuously by ENT2 carbamazepine ENT2END and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation
1	Epileptogenic activity of folic acid after drug induces ENT1 SLE ENT1END  ENT2 folic acid ENT2END and epilepsy)OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects
0	This 22-year-old epileptic woman was treated continuously by ENT1 carbamazepine ENT1END  and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation. She developed status epilepticus and later symptoms of ENT2 systemic lupus erythematodes ENT2END
0	RESULTS: Of 60 epileptic women with periconceptional ENT1 folic acid ENT1END (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period. One epileptic woman delivered a newborn with ENT2 cleft lip and palate ENT2END
0	One epileptic woman delivered a newborn with ENT1 cleft lip and palate  ENT1END . Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin. This 22-year-old epileptic woman was treated continuously by ENT2 carbamazepine ENT2END and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation
0	RESULTS: Of 60 epileptic women with periconceptional ENT1 folic acid ENT1END  (0.8 mg)-containing multivitamin supplementation, no one developed epilepsy-related side effects during the periconception period. One epileptic woman delivered a newborn with ENT2 cleft lip and palate ENT2END
0	One epileptic woman delivered a newborn with ENT1 cleft lip and palate  ENT1END . Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin. This 22-year-old epileptic woman was treated continuously by ENT2 carbamazepine ENT2END and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation
0	This 22-year-old epileptic woman was treated continuously by carbamazepine and a ENT1 folic acid ENT1END (1 mg)-containing multivitamin from the 20th week of gestation. She developed ENT2 status epilepticus ENT2END and later symptoms of systemic lupus erythematodes
0	This 22-year-old epileptic woman was treated continuously by ENT1 carbamazepine  ENT1END  and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation. She developed ENT2 status epilepticus ENT2END and later symptoms of systemic lupus erythematodes
1	CONCLUSIONS: The epileptic pregnant patient's autoimmune disease (probably drug-induced lupus) could damage the blood-brain barrier, therefore the therapeutic dose (> or =1 mg) of ENT1 folic acid ENT1END triggered a cluster of ENT2 seizures ENT2END
0	Another patient exhibited with a cluster of ENT1 seizures  ENT1END after the periconception period using another multivitamin. This 22-year-old epileptic woman was treated continuously by ENT2 carbamazepine ENT2END and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation
0	Epileptogenic activity of folic acid after drug induces SLE ( ENT1 folic acid  ENT1END  and ENT2 epilepsy ENT2END )OBJECTIVE: To study the effect of folic acid-containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy-related side effects
0	This 22-year-old ENT1 epileptic  ENT1END woman was treated continuously by ENT2 carbamazepine ENT2END and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation
0	This 22-year-old epileptic woman was treated continuously by carbamazepine and a ENT1 folic acid ENT1END  (1 mg)-containing multivitamin from the 20th week of gestation. She developed status epilepticus and later symptoms of systemic lupus erythematodes. Her pregnancy ended with ENT2 stillbirth ENT2END
0	This 22-year-old epileptic woman was treated continuously by ENT1 carbamazepine  ENT1END  and a folic acid (1 mg)-containing multivitamin from the 20th week of gestation. She developed status epilepticus and later symptoms of systemic lupus erythematodes. Her pregnancy ended with ENT2 stillbirth ENT2END
0	ENT1 Caffeine  ENT1END -induced ENT2 cardiac arrhythmia ENT2END : an unrecognised danger of healthfood products
1	We describe a 25-year-old woman with pre-existing mitral valve prolapse who developed intractable ENT1 ventricular fibrillation ENT1END after consuming a "natural energy" guarana health drink containing a high concentration of ENT2 caffeine ENT2END
0	ENT1 Caffeine ENT1END -induced cardiac arrhythmia: an unrecognised danger of healthfood products.We describe a 25-year-old woman with pre-existing ENT2 mitral valve prolapse ENT2END who developed intractable ventricular fibrillation after consuming a "natural energy" guarana health drink containing a high concentration of caffeine
0	The serotonin-1A receptor agonist, ENT1 8-OH-DPAT ENT1END  induced a significant disruption of PPI in all groups. Amphetamine-induced ENT2 locomotor hyperactivity ENT2END was similar in all groups
1	ENT1 Amphetamine  ENT1END induced ENT2 locomotor hyperactivity ENT2END was similar in all groups
0	The ENT1 serotonin  ENT1END 1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups. Amphetamine-induced ENT2 locomotor hyperactivity ENT2END was similar in all groups
0	Amphetamine-induced ENT1 locomotor hyperactivity ENT1END  was similar in all groups. These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by ENT2 corticosterone ENT2END treatment, on dopaminergic regulation of PPI
0	Amphetamine-induced ENT1 locomotor hyperactivity ENT1END  was similar in all groups. These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI. The altered effects of apomorphine and amphetamine could indicate differential changes in ENT2 dopamine ENT2END receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus
0	Amphetamine-induced ENT1 locomotor hyperactivity ENT1END  was similar in all groups. These results show an inhibitory interaction of early stress, caused by maternal deprivation, combined with 'adolescent' stress, simulated by corticosterone treatment, on dopaminergic regulation of PPI. The altered effects of ENT2 apomorphine ENT2END and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation, or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus
0	The development of ENT1 schizophrenia  ENT1END may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease. We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats. Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress. Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups. The serotonin-1A receptor agonist, ENT2 8-OH-DPAT ENT2END , induced a significant disruption of PPI in all groups
0	The development of ENT1 schizophrenia ENT1END  may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease. We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats. Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress. ENT2 Amphetamine ENT2END treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups
0	The development of ENT1 schizophrenia  ENT1END  may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease. We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats. Acute treatment with apomorphine caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress. Amphetamine treatment significantly disrupted PPI in both non-deprived groups, but was absent in both maternally deprived groups. The ENT2 serotonin ENT2END -1A receptor agonist, 8-OH-DPAT, induced a significant disruption of PPI in all groups
0	Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent ENT1 corticosterone  ENT1END  treatment in rats.The development of ENT2 schizophrenia ENT2END may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease
0	The development of ENT1 schizophrenia ENT1END  may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events, in combination leading to overt disease. We investigated the effect of an early stress, in the form of maternal deprivation, combined with a later stress, simulated by chronic periadolescent corticosterone treatment, on behaviour in rats. Acute treatment with ENT2 apomorphine ENT2END caused disruption of prepulse inhibition (PPI) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment, but was surprisingly absent in rats that had undergone the combined early and late stress
0	A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of ENT1 isosorbide dinitrate ENT1END 5 mg sublingually. After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of ENT2 acute coronary insufficiency ENT2END
0	A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of ENT1 isosorbide dinitrate ENT1END  5 mg sublingually. After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated myocardial ischemia occurring downstream to significant ENT2 coronary arterial stenosis ENT2END in the pathophysiology of acute coronary insufficiency
0	A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of ENT1 isosorbide dinitrate ENT1END  5 mg sublingually. After detailing the course of events, we discuss the role of paradoxical coronary spasm and ENT2 hypotension ENT2END -mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency
0	A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of ENT1 isosorbide dinitrate ENT1END  5 mg sublingually. After detailing the course of events, we discuss the role of paradoxical coronary spasm and hypotension-mediated ENT2 myocardial ischemia ENT2END occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency
1	ENT1 Myocardial infarction  ENT1END  following sublingual administration of ENT2 isosorbide dinitrate ENT2END
0	Myocardial infarction following sublingual administration of ENT1 isosorbide dinitrate ENT1END .A 78-year-old with healed septal ENT2 necrosis ENT2END suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually
0	A 78-year-old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of ENT1 isosorbide dinitrate ENT1END  5 mg sublingually. After detailing the course of events, we discuss the role of paradoxical coronary ENT2 spasm ENT2END and hypotension-mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency
0	Detailed spectral profile analysis of ENT1 penicillin  ENT1END -induced ENT2 epileptiform activity ENT2END in anesthetized rats
0	ENT1 urethane ENT1END and connected to an electrocorticogram setup. After a short period of basal activity recording, ENT2 epileptic ENT2END focus was induced by injecting 400IU/2 microl penicillin-G potassium into the left lateral ventricle while the cortical activity was continuously recorded
1	After a short period of basal activity recording, ENT1 epileptic ENT1END  focus was induced by injecting 400IU/2 microl ENT2 penicillin-G potassium ENT2END into the left lateral ventricle while the cortical activity was continuously recorded
0	Immunopathology of ENT1 penicillamine ENT1END -induced glomerular disease.Four patients with ENT2 rheumatoid arthritis ENT2END developed heavy proteinuria after five to 12 months of treatment with D-penicillamine
0	Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with ENT1 D-penicillamine ENT1END  Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase, or no departure from normal. Electron microscopy, however, revealed subepithelial electron-dense deposits, fusion of epithelial cell foot processes, and evidence of mesangial cell hyperactivity. Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3. The findings were similar to those in early ENT2 membranous glomerulonephritis ENT2END , differences being observed however in the results of staining for the early-acting complement components C1q and C4
1	Immunopathology of ENT1 penicillamine  ENT1END -induced ENT2 glomerular disease ENT2END
1	Four patients with rheumatoid arthritis developed heavy ENT1 proteinuria  ENT1END after five to 12 months of treatment with ENT2 D-penicillamine ENT2END
0	This is a case report of euphoria and ENT1 choreoathetoid movements ENT1END both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing ENT2 heroine ENT2END and cocaine
1	Choreoathetoid movements associated with rapid adjustment to ENT1 methadone  ENT1END . ENT2 Choreatiform hyperkinesias ENT2END are known to be occasional movement abnormalities during intoxications with cocaine but not opiates
1	Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with ENT1 cocaine  ENT1END but not opiates. This is a case report of euphoria and ENT2 choreoathetoid movements ENT2END both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine
0	ENT1 Choreatiform hyperkinesias  ENT1END are known to be occasional movement abnormalities during intoxications with cocaine but not opiates. This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing ENT2 heroine ENT2END and cocaine
0	Choreoathetoid movements associated with rapid adjustment to ENT1 methadone ENT1END ENT2 Choreatiform hyperkinesias ENT2END are known to be occasional movement abnormalities during intoxications with cocaine but not opiates
1	ENT1 Choreatiform hyperkinesias  ENT1END  are known to be occasional movement abnormalities during intoxications with ENT2 cocaine ENT2END but not opiates
0	Choreatiform hyperkinesias are known to be occasional ENT1 movement abnormalities  ENT1END during intoxications with cocaine but not opiates. This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu-opioid receptor agonist methadone in an inpatient previously abusing ENT2 heroine ENT2END and cocaine
0	Choreoathetoid movements associated with rapid adjustment to ENT1 methadone  ENT1END .Choreatiform hyperkinesias are known to be occasional ENT2 movement abnormalities ENT2END during intoxications with cocaine but not opiates
0	Choreatiform hyperkinesias are known to be occasional ENT1 movement abnormalities  ENT1END  during intoxications with ENT2 cocaine ENT2END but not opiates
0	Although there was a discrepancy between the amount of cTnI and cTnT after DOX, probably due to heterogeneity in cross-reactivities of mAbs to various cTnI and cTnT forms, it is likely that cTnT in rats after ENT1 DOX ENT1END indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced ENT2 cardiotoxicity ENT2END and possibly for cardioprotective experiments
0	Only five of the controls exhibited evidence of very slight perivascular ENT1 fibrosis ENT1END  A significant rise in cTnT was found in ENT2 DOX ENT2END rats after cumulative doses of 7
0	RESULTS: Eighteen of the ENT1 DOX ENT1END rats died prematurely of general ENT2 toxicity ENT2END during the 9-week period
0	CONCLUSIONS: Among markers of ENT1 ischemic injury ENT1END after ENT2 DOX ENT2END in rats, cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes
1	Evaluation of cardiac troponin I and T levels as markers of ENT1 myocardial damage  ENT1END  in ENT2 doxorubicin ENT2END -induced cardiomyopathy rats, and their relationship with echocardiographic and histological findings
0	We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( ENT1 DOX ENT1END -induced cardiomyopathy, and we examined the relationship between serial cTnI and cTnT with the development of ENT2 cardiac disorders ENT2END monitored by echocardiography and histological examinations in this model
0	She underwent recent chemotherapy with ENT1 fluorouracil ENT1END for metastatic ENT2 colorectal cancer ENT2END
0	A 79-year-old woman presented with typical ENT1 ischemic  ENT1END chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram. She underwent recent chemotherapy with ENT2 fluorouracil ENT2END for metastatic colorectal cancer
0	ENT1 5 flourouracil ENT1END -induced apical ballooning syndrome: a case report.The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease. ENT2 Cardiotoxicity ENT2END is not an uncommon adverse effect of chemotherapeutic agents
0	We describe the case of a woman who developed the syndrome after chemotherapy for metastatic ENT1 cancer  ENT1END  A 79-year-old woman presented with typical ischemic chest pain, elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram. She underwent recent chemotherapy with ENT2 fluorouracil ENT2END for metastatic colorectal cancer
0	In our patient, both supraphysiologic levels of plasma ENT1 catecholamines ENT1END and stress related neuropeptides caused by ENT2 cancer ENT2END diagnosis as well as chemotherapy may have contributed the development of ABS
0	ENT1 5 flourouracil ENT1END -induced apical ballooning syndrome: a case report.The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with ENT2 hyperkinesis ENT2END of the basal left ventricular (LV) segments without obstructive epicardial coronary disease
0	Pathogenetic mechanisms of ENT1 cardiac complications  ENT1END in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation. In our patient, both supraphysiologic levels of plasma ENT2 catecholamines ENT2END and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS
0	Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent ENT1 thrombus  ENT1END formation. In our patient, both supraphysiologic levels of plasma ENT2 catecholamines ENT2END and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS
1	ENT1 5 flourouracil  ENT1END -induced ENT2 apical ballooning syndrome ENT2END : a case report
0	In our patient, both supraphysiologic levels of plasma ENT1 catecholamines ENT1END  and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ENT2 ABS ENT2END
1	A 79-year-old woman presented with typical ischemic ENT1 chest pain  ENT1END  elevated cardiac enzymes with significant ST-segment abnormalities on her electrocardiogram. She underwent recent chemotherapy with ENT2 fluorouracil ENT2END for metastatic colorectal cancer
0	Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include ENT1 coronary vasospasm  ENT1END  endothelial damage and consequent thrombus formation. In our patient, both supraphysiologic levels of plasma ENT2 catecholamines ENT2END and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS
0	ENT1 5 flourouracil ENT1END -induced apical ballooning syndrome: a case report.The apical ballooning syndrome (ABS) is a recently described stress-mediated acute cardiac syndrome characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive ENT2 epicardial coronary disease ENT2END
0	ENT1 5 flourouracil ENT1END -induced apical ballooning syndrome: a case report.The apical ballooning syndrome (ABS) is a recently described stress-mediated ENT2 acute cardiac syndrome ENT2END characterized by transient wall-motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular (LV) segments without obstructive epicardial coronary disease
0	She underwent recent chemotherapy with ENT1 fluorouracil ENT1END  for metastatic colorectal cancer. Echocardiography revealed a wall-motion abnormality involving the apical and periapical segments which appeared ENT2 akinetic ENT2END
0	Echocardiogram revealed a normal ejection fraction and a resolution of the apical ENT1 akinesis  ENT1END  Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm, endothelial damage and consequent thrombus formation. In our patient, both supraphysiologic levels of plasma ENT2 catecholamines ENT2END and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS
0	001), respectively, but no ENT1 tachycardia ENT1END and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin. The release rate of ENT2 epinephrine ENT2END (control, 6
0	001), respectively, but no ENT1 tachycardia ENT1END  and no augmentation of the ENT2 norepinephrine ENT2END release rate (up to 0
0	001), respectively, but no ENT1 tachycardia ENT1END  and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by ENT2 hydralazine ENT2END or nitroglycerin
0	001), respectively, but no ENT1 tachycardia ENT1END  and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable hypotension induced by hydralazine or ENT2 nitroglycerin ENT2END
0	In six conscious, trained dogs, maintained on a normal ENT1 sodium  ENT1END intake of 2 to 4 mEq/kg/day, sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15-minute i.v. infusions of human alpha-atrial natriuretic factor. Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no ENT2 tachycardia ENT2END and no augmentation of the norepinephrine release rate (up to 0
0	3 microgram/kg/min) were observed, which is in contrast to comparable ENT1 hypotension  ENT1END induced by hydralazine or nitroglycerin. The release rate of ENT2 epinephrine ENT2END (control, 6
0	001), respectively, but no tachycardia and no augmentation of the ENT1 norepinephrine  ENT1END  release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable ENT2 hypotension ENT2END induced by hydralazine or nitroglycerin
1	3 microgram/kg/min) were observed, which is in contrast to comparable ENT1 hypotension  ENT1END  induced by ENT2 hydralazine ENT2END or nitroglycerin
1	3 microgram/kg/min) were observed, which is in contrast to comparable ENT1 hypotension  ENT1END  induced by hydralazine or ENT2 nitroglycerin ENT2END
0	In six conscious, trained dogs, maintained on a normal ENT1 sodium  ENT1END  intake of 2 to 4 mEq/kg/day, sympathetic activity was assessed as the release rate of norepinephrine and epinephrine during 15-minute i.v. infusions of human alpha-atrial natriuretic factor. Mean arterial pressure (as a percentage of control +/- SEM) during randomized infusions of 0.03, 0.1, 0.3, or 1.0 microgram/kg/min was 99 +/- 1, 95 +/- 1 (p less than 0.05), 93 +/- 1 (p less than 0.01), or 79 +/- 6% (p less than 0.001), respectively, but no tachycardia and no augmentation of the norepinephrine release rate (up to 0.3 microgram/kg/min) were observed, which is in contrast to comparable ENT2 hypotension ENT2END induced by hydralazine or nitroglycerin
1	ENT1 Heparin  ENT1END -induced ENT2 thrombocytopenia ENT2END , thrombosis, and hemorrhage
1	Clinical manifestations of this disorder include hemorrhage or, more frequently, ENT1 thromboembolic ENT1END events in patients receiving ENT2 heparin ENT2END
1	Heparin-induced thrombocytopenia, thrombosis, and ENT1 hemorrhage ENT1END .Sixty-two patients with a ENT2 heparin ENT2END -induced thrombocytopenia are reported
0	If the platelet count falls to less than 100,000/mm3, while the patient is receiving ENT1 heparin ENT1END  ENT2 platelet aggregation ENT2END testing, using the patient's plasma, is indicated
0	ENT1 Heparin  ENT1END -induced thrombocytopenia, ENT2 thrombosis ENT2END , and hemorrhage
0	Anticoagulant-induced femoral nerve palsy represents the most common form of ENT1 warfarin ENT1END induced peripheral neuropathy; it is characterized by severe ENT2 pain ENT2END in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity
0	Anticoagulant-induced femoral nerve palsy represents the most common form of ENT1 warfarin ENT1END -induced ENT2 peripheral neuropathy ENT2END ; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity
1	We present the case of a 28-year-old man on chronic ENT1 warfarin ENT1END therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip. Surgical exploration revealed an iliopsoas ENT2 hematoma ENT2END and femoral nerve entrapment, resulting in a femoral nerve palsy and partial loss of quadriceps functions
1	Surgical exploration revealed an iliopsoas hematoma and femoral ENT1 nerve entrapment  ENT1END  resulting in a femoral nerve palsy and partial loss of quadriceps functions. Anticoagulant-induced femoral nerve palsy represents the most common form of ENT2 warfarin ENT2END -induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity
0	Anticoagulant-induced femoral nerve palsy represents the most common form of ENT1 warfarin ENT1END -induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of ENT2 motor and sensory impairment ENT2END , and flexure contracture of the involved extremity
0	We present the case of a 28-year-old man on chronic ENT1 warfarin ENT1END  therapy who sustained a minor muscle tear and developed increasing pain and a flexure ENT2 contracture ENT2END of the right hip
1	Anticoagulant-induced ENT1 femoral nerve palsy  ENT1END represents the most common form of ENT2 warfarin ENT2END -induced peripheral neuropathy; it is characterized by severe pain in the inguinal region, varying degrees of motor and sensory impairment, and flexure contracture of the involved extremity
1	We present the case of a 28-year-old man on chronic ENT1 warfarin ENT1END  therapy who sustained a minor ENT2 muscle tear ENT2END and developed increasing pain and a flexure contracture of the right hip
0	ENT1 Warfarin  ENT1END -induced iliopsoas ENT2 hemorrhage ENT2END with subsequent femoral nerve palsy
0	It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and ENT1 hypothyroidism ENT1END during lithium treatment. We measured serum ENT2 thyroxine ENT2END and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium
1	We measured serum thyroxine and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving ENT1 lithium ENT1END  ENT2 Hypothyroidism ENT2END developed in eight patients while they were taking lithium
0	It has been suggested that adenylate cyclase inhibition may be important in the development of both ENT1 nephrogenic diabetes insipidus  ENT1END and hypothyroidism during lithium treatment. We measured serum ENT2 thyroxine ENT2END and urine-concentrating ability (Umax) in response to desmopressin (DDAVP) in 85 patients receiving lithium
0	It has been suggested that adenylate cyclase inhibition may be important in the development of both ENT1 nephrogenic diabetes insipidus ENT1END  and hypothyroidism during ENT2 lithium ENT2END treatment
0	Protective efficacy of neuroactive steroids against ENT1 cocaine ENT1END  kindled-seizures in mice.Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT2 neurological and psychiatric disorders ENT2END
0	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT1 neurological and psychiatric disorders ENT1END . They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the ENT2 gamma-aminobutyric acid ENT2END (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling)
0	Neuroactive ENT1 steroids  ENT1END demonstrate pharmacological actions that have relevance for a host of ENT2 neurological and psychiatric disorders ENT2END
0	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT1 neurological and psychiatric disorders ENT1END . They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling). Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ENT2 ganaxolone ENT2END (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice
0	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT1 neurological and psychiatric disorders ENT1END . They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling). ENT2 Allopregnanolone ENT2END (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice
0	Protective efficacy of neuroactive steroids against ENT1 cocaine ENT1END  kindled-seizures in mice.Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders. They offer protection against seizures in a range of models and seem to inhibit certain stages of ENT2 drug dependence ENT2END in preclinical assessments
0	They offer protection against seizures in a range of models and seem to inhibit certain stages of ENT1 drug dependence  ENT1END  in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the ENT2 gamma-aminobutyric acid ENT2END (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling)
0	They offer protection against seizures in a range of models and seem to inhibit certain stages of ENT1 drug dependence ENT1END  in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive ENT2 steroid ENT2END that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling)
0	They offer protection against seizures in a range of models and seem to inhibit certain stages of ENT1 drug dependence  ENT1END  in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling). Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ENT2 ganaxolone ENT2END (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice
0	They offer protection against seizures in a range of models and seem to inhibit certain stages of ENT1 drug dependence  ENT1END  in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling). ENT2 Allopregnanolone ENT2END (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice
1	Protective efficacy of neuroactive steroids against ENT1 cocaine  ENT1END  kindled ENT2 seizures ENT2END in mice
0	All of these positive ENT1 GABA ENT1END A) modulators suppressed the expression of kindled ENT2 seizures ENT2END , whereas only allopregnanolone and ganaxolone inhibited the development of kindling
0	Protective efficacy of neuroactive steroids against cocaine kindled- ENT1 seizures  ENT1END  in mice.Neuroactive ENT2 steroids ENT2END demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders
0	All of these positive GABA(A) modulators suppressed the expression of kindled ENT1 seizures ENT1END , whereas only allopregnanolone and ENT2 ganaxolone ENT2END inhibited the development of kindling
0	The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( ENT1 seizure  ENT1END kindling). ENT2 Allopregnanolone ENT2END (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice
0	Protective efficacy of neuroactive steroids against ENT1 cocaine ENT1END  kindled-seizures in mice.Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT2 neurological and psychiatric disorders ENT2END
0	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT1 neurological and psychiatric disorders  ENT1END . They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the ENT2 gamma-aminobutyric acid ENT2END (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling)
0	Neuroactive ENT1 steroids  ENT1END  demonstrate pharmacological actions that have relevance for a host of ENT2 neurological and psychiatric disorders ENT2END
0	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT1 neurological and psychiatric disorders  ENT1END . They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling). Allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ENT2 ganaxolone ENT2END (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice
0	Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of ENT1 neurological and psychiatric disorders  ENT1END . They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments. The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma-aminobutyric acid (GABA(A)) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration (seizure kindling). ENT2 Allopregnanolone ENT2END (3alpha-hydroxy-5alpha-pregnan-20-one), pregnanolone (3alpha-hydroxy-5beta-pregnan-20-one) and ganaxolone (a synthetic derivative of allopregnanolone 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one) were tested for their ability to suppress the expression (anticonvulsant effect) and development (antiepileptogenic effect) of cocaine-kindled seizures in male, Swiss-Webster mice
0	CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate ENT1 hypertension ENT1END  The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, ENT2 dihydropyridine ENT2END calcium antagonists
0	CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate ENT1 hypertension ENT1END . The results also show ENT2 valsartan ENT2END to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine calcium antagonists
0	CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate ENT1 hypertension ENT1END . The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine ENT2 calcium ENT2END antagonists
0	CONCLUSIONS: The data show that valsartan is at least as effective as ENT1 amlodipine  ENT1END in the treatment of mild to moderate ENT2 hypertension ENT2END
0	Valsartan, a new ENT1 angiotensin II  ENT1END  antagonist for the treatment of essential ENT2 hypertension ENT2END : a comparative study of the efficacy and safety against amlodipine
0	The incidence of drug-related dependent ENT1 edema  ENT1END was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine). CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension. The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, ENT2 dihydropyridine ENT2END calcium antagonists
1	The incidence of drug-related dependent ENT1 edema ENT1END  was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg ENT2 valsartan ENT2END ; 3
0	The incidence of drug-related dependent ENT1 edema  ENT1END  was somewhat higher in the amlodipine group, particularly at a dose of 10 mg per day (2.4% for 80 mg valsartan; 3.6% for 5 mg amlodipine; 0% for valsartan plus 5 mg amlodipine; 14.3% for 10 mg amlodipine). CONCLUSIONS: The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension. The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class, dihydropyridine ENT2 calcium ENT2END antagonists
1	The incidence of drug-related dependent ENT1 edema ENT1END  was somewhat higher in the ENT2 amlodipine ENT2END group, particularly at a dose of 10 mg per day (2
1	The annual incidence of ENT1 warfarin ENT1END related bleeding at Brigham and Women's Hospital increased from 0.97/1,000 patient admissions in the first time period (January 1995 to October 1998) to 1.19/1,000 patient admissions in the second time period (November 1998 to August 2002) of this study. The proportion of patients with major and ENT2 intracranial bleeding ENT2END increased from 20
1	The annual incidence of ENT1 warfarin ENT1END -related ENT2 bleeding ENT2END at Brigham and Women's Hospital increased from 0
0	For this reason, each clinician should recognize this entity in the differential diagnosis of ENT1 PB ENT1END related asymptomatic ENT2 chronic hepatic enzyme dysfunction ENT2END
1	Hepatonecrosis and ENT1 cholangitis  ENT1END  related to long-term ENT2 phenobarbital ENT2END therapy: an autopsy report of two patients
0	Here we report of two adult patients with a long history of epilepsy treated with ENT1 PB ENT1END who died suddenly: one as consequence of cardiac arrest, the other of acute ENT2 bronchopneumonia ENT2END
0	At autopsy, analysis of liver parenchyma revealed rich portal inflammatory infiltrate, which consisted of mixed eosinophil and monocyte cells, associated with several foci of ENT1 necrosis ENT1END surrounded by a hard ring of non-specific granulomatous tissue. Inflammatory reactions of internal and external hepatic biliary ducts were also seen. Our findings illustrate that ENT2 PB ENT2END may be associated with chronic liver damage, which may lead to more serious and deleterious consequences
1	Our findings illustrate that ENT1 PB ENT1END  may be associated with chronic ENT2 liver damage ENT2END , which may lead to more serious and deleterious consequences
0	Here we report of two adult patients with a long history of ENT1 epilepsy  ENT1END treated with ENT2 PB ENT2END who died suddenly: one as consequence of cardiac arrest, the other of acute bronchopneumonia
0	Here we report of two adult patients with a long history of epilepsy treated with ENT1 PB ENT1END  who died suddenly: one as consequence of ENT2 cardiac arrest ENT2END , the other of acute bronchopneumonia
0	He had been prescribed telithromycin 400 mg/d PO to treat an ENT1 upper respiratory tract infection ENT1END 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); ENT2 aspartate ENT2END aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	He had been prescribed telithromycin 400 mg/d PO to treat an ENT1 upper respiratory tract infection ENT1END  7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total ENT2 bilirubin ENT2END , 20
0	He had been prescribed ENT1 telithromycin  ENT1END 400 mg/d PO to treat an ENT2 upper respiratory tract infection ENT2END 7 days prior
0	He had been prescribed telithromycin 400 mg/d PO to treat an ENT1 upper respiratory tract infection ENT1END  7 days prior. Admission laboratory tests were as follows: ENT2 alanine ENT2END aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	He had been prescribed telithromycin 400 mg/d PO to treat an ENT1 upper respiratory tract infection ENT1END  7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, ENT2 alcohol ENT2END , or other drugs were reported
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and ENT1 vomiting  ENT1END  He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); ENT2 aspartate ENT2END aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and ENT1 vomiting  ENT1END . He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total ENT2 bilirubin ENT2END , 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and ENT1 vomiting  ENT1END . He had been prescribed ENT2 telithromycin ENT2END 400 mg/d PO to treat an upper respiratory tract infection 7 days prior
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and ENT1 vomiting  ENT1END . He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: ENT2 alanine ENT2END aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and ENT1 vomiting  ENT1END . He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, ENT2 alcohol ENT2END , or other drugs were reported
0	With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among ENT1 adverse drug reactions  ENT1END  idiosyncratic reactions are the most serious. CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); ENT2 aspartate ENT2END aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	Based on a score of 8 on the Naranjo ENT1 adverse drug reaction ENT1END probability scale, ENT2 telithromycin ENT2END was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis
0	With widespread use of antimicrobial agents, however, hepatic injury occurs frequently, and among ENT1 adverse drug reactions  ENT1END , idiosyncratic reactions are the most serious. CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, nausea, and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: ENT2 alanine ENT2END aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	No toxin, ENT1 alcohol  ENT1END , or other drugs were reported. The patient had suffered a previous episode of "acute hepatitis of unknown origin," that occurred after telithromycin usage. Both incidents occurred within a year. DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use. It has been associated with infrequent and usually reversible severe hepatic dysfunction. Based on a score of 8 on the Naranjo ENT2 adverse drug reaction ENT2END probability scale, telithromycin was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, ENT1 nausea  ENT1END  and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); ENT2 aspartate ENT2END aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, ENT1 nausea  ENT1END , and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total ENT2 bilirubin ENT2END , 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, ENT1 nausea  ENT1END , and vomiting. He had been prescribed ENT2 telithromycin ENT2END 400 mg/d PO to treat an upper respiratory tract infection 7 days prior
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, ENT1 nausea  ENT1END , and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: ENT2 alanine ENT2END aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of jaundice, malaise, ENT1 nausea  ENT1END , and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, ENT2 alcohol ENT2END , or other drugs were reported
0	Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); ENT1 aspartate ENT1END  aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, alcohol, or other drugs were reported. The patient had suffered a previous episode of "acute hepatitis of unknown origin," that occurred after telithromycin usage. Both incidents occurred within a year. DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use. It has been associated with infrequent and usually reversible severe ENT2 hepatic dysfunction ENT2END
0	0 mg/dL); direct ENT1 bilirubin  ENT1END  14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, alcohol, or other drugs were reported. The patient had suffered a previous episode of "acute hepatitis of unknown origin," that occurred after telithromycin usage. Both incidents occurred within a year. DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use. It has been associated with infrequent and usually reversible severe ENT2 hepatic dysfunction ENT2END
0	It has been associated with infrequent and usually reversible severe ENT1 hepatic dysfunction  ENT1END . Based on a score of 8 on the Naranjo adverse drug reaction probability scale, ENT2 telithromycin ENT2END was the probable cause of acute hepatitis in this patient, and pathological findings suggested drug-induced toxic hepatitis
0	Admission laboratory tests were as follows: ENT1 alanine  ENT1END  aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, alcohol, or other drugs were reported. The patient had suffered a previous episode of "acute hepatitis of unknown origin," that occurred after telithromycin usage. Both incidents occurred within a year. DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use. It has been associated with infrequent and usually reversible severe ENT2 hepatic dysfunction ENT2END
0	No toxin, ENT1 alcohol  ENT1END , or other drugs were reported. The patient had suffered a previous episode of "acute hepatitis of unknown origin," that occurred after telithromycin usage. Both incidents occurred within a year. DISCUSSION: Telithromycin is the first of the ketolide antibacterials to receive US Food and Drug Administration approval for clinical use. It has been associated with infrequent and usually reversible severe ENT2 hepatic dysfunction ENT2END
0	Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); ENT1 aspartate ENT1END  aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, alcohol, or other drugs were reported. The patient had suffered a previous episode of "acute ENT2 hepatitis ENT2END of unknown origin," that occurred after telithromycin usage
0	0 mg/dL); direct ENT1 bilirubin  ENT1END , 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, alcohol, or other drugs were reported. The patient had suffered a previous episode of "acute ENT2 hepatitis ENT2END of unknown origin," that occurred after telithromycin usage
1	Acute ENT1 hepatitis  ENT1END  attack after exposure to ENT2 telithromycin ENT2END
0	Admission laboratory tests were as follows: ENT1 alanine  ENT1END  aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, alcohol, or other drugs were reported. The patient had suffered a previous episode of "acute ENT2 hepatitis ENT2END of unknown origin," that occurred after telithromycin usage
0	No toxin, ENT1 alcohol  ENT1END , or other drugs were reported. The patient had suffered a previous episode of "acute ENT2 hepatitis ENT2END of unknown origin," that occurred after telithromycin usage
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of ENT1 jaundice  ENT1END  malaise, nausea, and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); ENT2 aspartate ENT2END aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of ENT1 jaundice  ENT1END , malaise, nausea, and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total ENT2 bilirubin ENT2END , 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of ENT1 jaundice  ENT1END , malaise, nausea, and vomiting. He had been prescribed ENT2 telithromycin ENT2END 400 mg/d PO to treat an upper respiratory tract infection 7 days prior
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of ENT1 jaundice  ENT1END , malaise, nausea, and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: ENT2 alanine ENT2END aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20
0	CASE SUMMARY: A 25-year-old male patient, with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department, Istanbul, Turkey, with 5 days' history of ENT1 jaundice  ENT1END , malaise, nausea, and vomiting. He had been prescribed telithromycin 400 mg/d PO to treat an upper respiratory tract infection 7 days prior. Admission laboratory tests were as follows: alanine aminotransferase, 67 U/L (reference range, 10-37 U/L); aspartate aminotransferase, 98 U/L (10-40 U/L); alkaline phosphatase, 513 U/L (0-270 U/L); gamma-glutamyltransferase, 32 U/L (7-49 U/L); amylase, 46 U/L (0-220 U/L); total bilirubin, 20.1 mg/dL (0.2-1.0 mg/dL); direct bilirubin, 14.8 mg/dL (0-0.3 mg/dL); and albumin, 4.7 mg/dL (3.5-5.4 mg/dL). No toxin, ENT2 alcohol ENT2END , or other drugs were reported
0	An extremely rare case of delusional parasitosis in a ENT1 chronic hepatitis C  ENT1END  patient during ENT2 pegylated interferon alpha-2b ENT2END and ribavirin treatment
0	During treatment of ENT1 chronic hepatitis C ENT1END patients with interferon and ENT2 ribavirin ENT2END , a lot of side effects are described
0	An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during ENT1 pegylated interferon alpha-2b ENT1END  and ribavirin treatment.During treatment of chronic hepatitis C patients with interferon and ribavirin, a lot of side effects are described. Twenty-three percent to 44% of patients develop ENT2 depression ENT2END
0	During treatment of chronic hepatitis C patients with interferon and ENT1 ribavirin  ENT1END , a lot of side effects are described. Twenty-three percent to 44% of patients develop ENT2 depression ENT2END
0	A minority of patients evolve to ENT1 psychosis ENT1END  To the best of our knowledge, no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature. We present a 49-year-old woman who developed a delusional parasitosis during treatment with ENT2 pegylated interferon alpha-2b ENT2END weekly and ribavirin
0	During treatment of chronic hepatitis C patients with interferon and ENT1 ribavirin  ENT1END , a lot of side effects are described. Twenty-three percent to 44% of patients develop depression. A minority of patients evolve to ENT2 psychosis ENT2END
1	We present a 49-year-old woman who developed a ENT1 delusional parasitosis  ENT1END during treatment with ENT2 pegylated interferon alpha-2b ENT2END weekly and ribavirin
1	We present a 49-year-old woman who developed a ENT1 delusional parasitosis ENT1END  during treatment with pegylated interferon alpha-2b weekly and ENT2 ribavirin ENT2END
0	The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ENT1 ataxia ENT1END  slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989). There have also been two reported fatalities from ENT2 DM ENT2END overdoses (Fleming 1986)
0	Dextromethorphan (DM), the dextrorotatory isomer of ENT1 3-hydroxy-N-methylmorphinan  ENT1END  is the main ingredient in a number of widely available, over-the-counter antitussives. Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability. Subsequently, however, several articles reporting abuse of this drug have appeared in the literature. The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ENT2 ataxia ENT2END , slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989)
1	ENT1 Cognitive deterioration  ENT1END  from long-term abuse of ENT2 dextromethorphan ENT2END : a case report
0	ENT1 Cognitive deterioration  ENT1END  from long-term abuse of dextromethorphan: a case report.Dextromethorphan (DM), the dextrorotatory isomer of ENT2 3-hydroxy-N-methylmorphinan ENT2END , is the main ingredient in a number of widely available, over-the-counter antitussives
0	The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and ENT1 nystagmus  ENT1END to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989). There have also been two reported fatalities from ENT2 DM ENT2END overdoses (Fleming 1986)
0	Dextromethorphan (DM), the dextrorotatory isomer of ENT1 3-hydroxy-N-methylmorphinan  ENT1END , is the main ingredient in a number of widely available, over-the-counter antitussives. Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability. Subsequently, however, several articles reporting abuse of this drug have appeared in the literature. The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and ENT2 nystagmus ENT2END to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989)
0	The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and ENT1 aggressive behavior  ENT1END (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989). There have also been two reported fatalities from ENT2 DM ENT2END overdoses (Fleming 1986)
0	Dextromethorphan (DM), the dextrorotatory isomer of ENT1 3-hydroxy-N-methylmorphinan  ENT1END , is the main ingredient in a number of widely available, over-the-counter antitussives. Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability. Subsequently, however, several articles reporting abuse of this drug have appeared in the literature. The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and ENT2 aggressive behavior ENT2END (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989)
0	The drug is known to cause a variety of acute toxic effects, ranging from nausea, ENT1 restlessness  ENT1END  insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989). There have also been two reported fatalities from ENT2 DM ENT2END overdoses (Fleming 1986)
0	Dextromethorphan (DM), the dextrorotatory isomer of ENT1 3-hydroxy-N-methylmorphinan  ENT1END , is the main ingredient in a number of widely available, over-the-counter antitussives. Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability. Subsequently, however, several articles reporting abuse of this drug have appeared in the literature. The drug is known to cause a variety of acute toxic effects, ranging from nausea, ENT2 restlessness ENT2END , insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989)
0	The drug is known to cause a variety of acute toxic effects, ranging from ENT1 nausea  ENT1END  restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989). There have also been two reported fatalities from ENT2 DM ENT2END overdoses (Fleming 1986)
0	Dextromethorphan (DM), the dextrorotatory isomer of ENT1 3-hydroxy-N-methylmorphinan  ENT1END , is the main ingredient in a number of widely available, over-the-counter antitussives. Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability. Subsequently, however, several articles reporting abuse of this drug have appeared in the literature. The drug is known to cause a variety of acute toxic effects, ranging from ENT2 nausea ENT2END , restlessness, insomnia, ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989)
0	The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, ENT1 insomnia  ENT1END  ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989). There have also been two reported fatalities from ENT2 DM ENT2END overdoses (Fleming 1986)
0	Dextromethorphan (DM), the dextrorotatory isomer of ENT1 3-hydroxy-N-methylmorphinan  ENT1END , is the main ingredient in a number of widely available, over-the-counter antitussives. Initial studies (Bornstein 1968) showed that it possessed no respiratory suppressant effects and no addiction liability. Subsequently, however, several articles reporting abuse of this drug have appeared in the literature. The drug is known to cause a variety of acute toxic effects, ranging from nausea, restlessness, ENT2 insomnia ENT2END , ataxia, slurred speech and nystagmus to mood changes, perceptual alterations, inattention, disorientation and aggressive behavior (Rammer et al 1988; Katona and Watson 1986; Isbell and Fraser 1953; Devlin et al 1985; McCarthy 1971; Dodds and Revai 1967; Degkwitz 1964; Hildebrand et al 1989)
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with ENT1 bendrofluazide ENT1END treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No ENT2 corneal disease ENT2END is known to have occurred in the propranolol group
0	No ENT1 corneal disease ENT1END  is known to have occurred in the propranolol group. Mean serum potassium level fell, and urea and ENT2 uric acid ENT2END levels rose, in men and women taking bendrofluazide
0	No ENT1 corneal disease ENT1END  is known to have occurred in the propranolol group. Mean serum potassium level fell, and ENT2 urea ENT2END and uric acid levels rose, in men and women taking bendrofluazide
0	No ENT1 corneal disease ENT1END  is known to have occurred in the propranolol group. Mean serum ENT2 potassium ENT2END level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking ENT1 propranolol  ENT1END  No ENT2 corneal disease ENT2END is known to have occurred in the propranolol group
0	Adverse reactions to ENT1 bendrofluazide  ENT1END  and propranolol for the treatment of mild ENT2 hypertension ENT2END
0	Adverse reactions to bendrofluazide and ENT1 propranolol  ENT1END  for the treatment of mild ENT2 hypertension ENT2END
1	Other adverse reactions significantly linked with active drugs include ENT1 impaired glucose tolerance  ENT1END in men and women and gout in men, associated with ENT2 bendrofluazide ENT2END treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol
0	Other adverse reactions significantly linked with active drugs include ENT1 impaired glucose tolerance  ENT1END  in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and urea and ENT2 uric acid ENT2END levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include ENT1 impaired glucose tolerance  ENT1END  in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and ENT2 urea ENT2END and uric acid levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include ENT1 impaired glucose tolerance  ENT1END  in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum ENT2 potassium ENT2END level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide
0	The results show an association between bendrofluazide treatment and impotence, and impotence also occurred more frequently in patients taking ENT1 propranolol  ENT1END than in those taking placebos. Other adverse reactions significantly linked with active drugs include ENT2 impaired glucose tolerance ENT2END in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with ENT1 bendrofluazide ENT1END  treatment, and ENT2 Raynaud's phenomenon ENT2END and dyspnoea in men and women taking propranolol
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and ENT1 Raynaud's phenomenon  ENT1END  and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and urea and ENT2 uric acid ENT2END levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and ENT1 Raynaud's phenomenon  ENT1END  and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and ENT2 urea ENT2END and uric acid levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and ENT1 Raynaud's phenomenon  ENT1END  and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum ENT2 potassium ENT2END level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide
1	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and ENT1 Raynaud's phenomenon  ENT1END  and dyspnoea in men and women taking ENT2 propranolol ENT2END
1	The results show an association between ENT1 bendrofluazide ENT1END treatment and ENT2 impotence ENT2END , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos
0	The results show an association between bendrofluazide treatment and impotence, and ENT1 impotence  ENT1END also occurred more frequently in patients taking propranolol than in those taking placebos. Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and urea and ENT2 uric acid ENT2END levels rose, in men and women taking bendrofluazide
0	The results show an association between bendrofluazide treatment and impotence, and ENT1 impotence  ENT1END  also occurred more frequently in patients taking propranolol than in those taking placebos. Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and ENT2 urea ENT2END and uric acid levels rose, in men and women taking bendrofluazide
0	The results show an association between bendrofluazide treatment and impotence, and ENT1 impotence  ENT1END  also occurred more frequently in patients taking propranolol than in those taking placebos. Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum ENT2 potassium ENT2END level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide
1	The results show an association between bendrofluazide treatment and impotence, and ENT1 impotence  ENT1END  also occurred more frequently in patients taking ENT2 propranolol ENT2END than in those taking placebos
1	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and ENT1 gout  ENT1END in men, associated with ENT2 bendrofluazide ENT2END treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and ENT1 gout  ENT1END  in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and urea and ENT2 uric acid ENT2END levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and ENT1 gout  ENT1END  in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and ENT2 urea ENT2END and uric acid levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and ENT1 gout  ENT1END  in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum ENT2 potassium ENT2END level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and ENT1 gout  ENT1END  in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and dyspnoea in men and women taking ENT2 propranolol ENT2END
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with ENT1 bendrofluazide ENT1END  treatment, and Raynaud's phenomenon and ENT2 dyspnoea ENT2END in men and women taking propranolol
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and ENT1 dyspnoea  ENT1END  in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and urea and ENT2 uric acid ENT2END levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and ENT1 dyspnoea  ENT1END  in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum potassium level fell, and ENT2 urea ENT2END and uric acid levels rose, in men and women taking bendrofluazide
0	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and ENT1 dyspnoea  ENT1END  in men and women taking propranolol. No corneal disease is known to have occurred in the propranolol group. Mean serum ENT2 potassium ENT2END level fell, and urea and uric acid levels rose, in men and women taking bendrofluazide
1	Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men, associated with bendrofluazide treatment, and Raynaud's phenomenon and ENT1 dyspnoea  ENT1END  in men and women taking ENT2 propranolol ENT2END
1	Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and ENT1 isoflurane ENT1END  ENT2 Hypotension ENT2END was induced for 236
0	Anesthesia was maintained with fentanyl, ENT1 nitrous oxide  ENT1END  oxygen, and isoflurane. ENT2 Hypotension ENT2END was induced for 236
0	Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured by inulin and para-aminohippurate ( ENT1 PAH  ENT1END  clearance, respectively. Anesthesia was maintained with fentanyl, nitrous oxide, oxygen, and isoflurane. ENT2 Hypotension ENT2END was induced for 236
0	Anesthesia was maintained with fentanyl, nitrous oxide, ENT1 oxygen  ENT1END  and isoflurane. ENT2 Hypotension ENT2END was induced for 236
0	Anesthesia was maintained with ENT1 fentanyl  ENT1END  nitrous oxide, oxygen, and isoflurane. ENT2 Hypotension ENT2END was induced for 236
1	ENT1 Cocaine  ENT1END -induced brainstem ENT2 seizures ENT2END and behavior
0	ENT1 Cocaine ENT1END generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects. The abnormal behaviors were yawning, retrocollis, ENT2 hyperactivity ENT2END , hypersensitivity, "beating drum" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching
0	ENT1 Cocaine ENT1END  generated more abnormal behaviors in the brainstem perturbation group, especially the electrically perturbated subjects. The abnormal behaviors were yawning, retrocollis, hyperactivity, ENT2 hypersensitivity ENT2END , "beating drum" behavior, squealing, head bobbing, circling, sniffing, abnormal posturing, and facial twitching
0	Using linear regression we found that no correlation exists between ENT1 seizure ENT1END duration, elevation of ENT2 phenytoin ENT2END serum levels and cerebellar volume
1	Magnetic resonance volumetry of the cerebellum in epileptic patients after ENT1 phenytoin ENT1END ENT2 overdosages ENT2END
0	The aim of this study was to evaluate the relationship between ENT1 phenytoin ENT1END medication and ENT2 cerebellar atrophy ENT2END in patients who had experienced clinical intoxication
0	Magnetic resonance volumetry of the cerebellum in ENT1 epileptic  ENT1END  patients after ENT2 phenytoin ENT2END overdosages
0	A 67-year-old man who was treated with ENT1 oxacillin ENT1END for one week because of Staphylococcus aureus bacteremia, developed renal failure and diffuse, symmetric, palpable ENT2 purpuric lesions ENT2END on his feet
0	Oxacillin was discontinued and patient was treated with ENT1 corticosteroids ENT1END  The rash disappeared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable ENT2 purpura ENT2END of the lower extremities often accompanied by abdominal pain, arthralgia, and renal involvement
0	Etiologic factors or associated disorders include infections, medications, ENT1 collagen vascular disease ENT1END and neoplasia. However, in half of the cases no etiologic factor is identified. Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications. ENT2 Oxacillin ENT2END should be included among the drugs that can cause leucocytoclastic vasculitis
0	Etiologic factors or associated disorders include infections, medications, ENT1 collagen vascular disease ENT1END  and neoplasia. However, in half of the cases no etiologic factor is identified. Usually it is a self-limited disorder, but ENT2 corticosteroid ENT2END therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications
0	A 67-year-old man who was treated with ENT1 oxacillin ENT1END  for one week because of ENT2 Staphylococcus aureus bacteremia ENT2END , developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet
0	A 67-year-old man who was treated with oxacillin for one week because of ENT1 Staphylococcus aureus bacteremia  ENT1END , developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet. Necrotic blisters were noted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. Oxacillin was discontinued and patient was treated with ENT2 corticosteroids ENT2END
0	ENT1 Oxacillin ENT1END was discontinued and patient was treated with corticosteroids. The rash disappeared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by ENT2 abdominal pain ENT2END , arthralgia, and renal involvement
0	Oxacillin was discontinued and patient was treated with ENT1 corticosteroids  ENT1END . The rash disappeared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by ENT2 abdominal pain ENT2END , arthralgia, and renal involvement
1	Skin biopsies showed findings diagnostic of ENT1 leucocytoclastic vasculitis ENT1END ENT2 Oxacillin ENT2END was discontinued and patient was treated with corticosteroids
1	Skin biopsies showed findings diagnostic of ENT1 leucocytoclastic vasculitis  ENT1END . Oxacillin was discontinued and patient was treated with ENT2 corticosteroids ENT2END
1	A 67-year-old man who was treated with ENT1 oxacillin ENT1END  for one week because of Staphylococcus aureus bacteremia, developed ENT2 renal failure ENT2END and diffuse, symmetric, palpable purpuric lesions on his feet
1	A 67-year-old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia, developed ENT1 renal failure  ENT1END  and diffuse, symmetric, palpable purpuric lesions on his feet. Necrotic blisters were noted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. Oxacillin was discontinued and patient was treated with ENT2 corticosteroids ENT2END
0	Etiologic factors or associated disorders include ENT1 infections  ENT1END  medications, collagen vascular disease and neoplasia. However, in half of the cases no etiologic factor is identified. Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications. ENT2 Oxacillin ENT2END should be included among the drugs that can cause leucocytoclastic vasculitis
0	Etiologic factors or associated disorders include ENT1 infections  ENT1END , medications, collagen vascular disease and neoplasia. However, in half of the cases no etiologic factor is identified. Usually it is a self-limited disorder, but ENT2 corticosteroid ENT2END therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications
0	Etiologic factors or associated disorders include infections, medications, collagen vascular disease and ENT1 neoplasia  ENT1END  However, in half of the cases no etiologic factor is identified. Usually it is a self-limited disorder, but corticosteroid therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications. ENT2 Oxacillin ENT2END should be included among the drugs that can cause leucocytoclastic vasculitis
0	Etiologic factors or associated disorders include infections, medications, collagen vascular disease and ENT1 neoplasia  ENT1END . However, in half of the cases no etiologic factor is identified. Usually it is a self-limited disorder, but ENT2 corticosteroid ENT2END therapy may be needed in life-threatening cases since early treatment with corticosteroids in severe cases can prevent complications
0	A 67-year-old man who was treated with ENT1 oxacillin ENT1END  for one week because of ENT2 Staphylococcus aureus bacteremia ENT2END , developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet
0	A 67-year-old man who was treated with oxacillin for one week because of ENT1 Staphylococcus aureus bacteremia  ENT1END , developed renal failure and diffuse, symmetric, palpable purpuric lesions on his feet. Necrotic blisters were noted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. Oxacillin was discontinued and patient was treated with ENT2 corticosteroids ENT2END
0	ENT1 Oxacillin ENT1END  was discontinued and patient was treated with corticosteroids. The ENT2 rash ENT2END disappeared after three weeks and renal function returned to normal
0	Oxacillin was discontinued and patient was treated with ENT1 corticosteroids  ENT1END . The ENT2 rash ENT2END disappeared after three weeks and renal function returned to normal
0	ENT1 Necrotic blisters  ENT1END were noted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. ENT2 Oxacillin ENT2END was discontinued and patient was treated with corticosteroids
0	ENT1 Necrotic blisters  ENT1END  were noted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. Oxacillin was discontinued and patient was treated with ENT2 corticosteroids ENT2END
0	ENT1 Oxacillin ENT1END  was discontinued and patient was treated with corticosteroids. The rash disappeared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, ENT2 arthralgia ENT2END , and renal involvement
0	Oxacillin was discontinued and patient was treated with ENT1 corticosteroids  ENT1END . The rash disappeared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, ENT2 arthralgia ENT2END , and renal involvement
0	ENT1 Necrotic blisters  ENT1END were noted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. ENT2 Oxacillin ENT2END was discontinued and patient was treated with corticosteroids
0	ENT1 Necrotic blisters  ENT1END  were noted on his fingers. Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis. Oxacillin was discontinued and patient was treated with ENT2 corticosteroids ENT2END
0	ENT1 Oxacillin ENT1END  was discontinued and patient was treated with corticosteroids. The rash disappeared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and ENT2 renal involvement ENT2END
0	Oxacillin was discontinued and patient was treated with ENT1 corticosteroids  ENT1END . The rash disappeared after three weeks and renal function returned to normal. Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain, arthralgia, and ENT2 renal involvement ENT2END
0	A previously unknown ENT1 hypothyroidism ENT1END  probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While lovastatin and ENT2 simvastatin ENT2END have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	He was admitted with acute myopathy of the lower limbs which resolved in a few days after ENT1 pravastatin  ENT1END discontinuation. A previously unknown ENT2 hypothyroidism ENT2END , probably due to chronic autoimmune thyroiditis, was evidenced
0	A previously unknown ENT1 hypothyroidism ENT1END , probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While ENT2 lovastatin ENT2END and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and ENT1 hypertension  ENT1END  He assumed pravastatin (20 mg/day) because of hypercholesterolemia. He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation. A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While lovastatin and ENT2 simvastatin ENT2END have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and ENT1 hypertension ENT1END . He assumed ENT2 pravastatin ENT2END (20 mg/day) because of hypercholesterolemia
0	The patient, a 69-year-old man was affected by non-insulin-dependent diabetes mellitus and ENT1 hypertension  ENT1END . He assumed pravastatin (20 mg/day) because of hypercholesterolemia. He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation. A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While ENT2 lovastatin ENT2END and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	A previously unknown hypothyroidism, probably due to chronic ENT1 autoimmune thyroiditis  ENT1END  was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While lovastatin and ENT2 simvastatin ENT2END have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	He was admitted with acute myopathy of the lower limbs which resolved in a few days after ENT1 pravastatin  ENT1END  discontinuation. A previously unknown hypothyroidism, probably due to chronic ENT2 autoimmune thyroiditis ENT2END , was evidenced
0	A previously unknown hypothyroidism, probably due to chronic ENT1 autoimmune thyroiditis  ENT1END , was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While ENT2 lovastatin ENT2END and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
1	A case of acute ENT1 inflammatory myopathy ENT1END associated with the use of ENT2 pravastatin ENT2END , a new hydrophilic 3-hydroxy-3 methylglutaril coenzyme A reductase inhibitor, is reported
0	The patient, a 69-year-old man was affected by ENT1 non-insulin-dependent diabetes mellitus  ENT1END and hypertension. He assumed pravastatin (20 mg/day) because of hypercholesterolemia. He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation. A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While lovastatin and ENT2 simvastatin ENT2END have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	The patient, a 69-year-old man was affected by ENT1 non-insulin-dependent diabetes mellitus  ENT1END  and hypertension. He assumed ENT2 pravastatin ENT2END (20 mg/day) because of hypercholesterolemia
0	The patient, a 69-year-old man was affected by ENT1 non-insulin-dependent diabetes mellitus  ENT1END  and hypertension. He assumed pravastatin (20 mg/day) because of hypercholesterolemia. He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation. A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While ENT2 lovastatin ENT2END and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	He assumed pravastatin (20 mg/day) because of ENT1 hypercholesterolemia  ENT1END  He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation. A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While lovastatin and ENT2 simvastatin ENT2END have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	He assumed ENT1 pravastatin  ENT1END  (20 mg/day) because of ENT2 hypercholesterolemia ENT2END
0	He assumed pravastatin (20 mg/day) because of ENT1 hypercholesterolemia  ENT1END . He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation. A previously unknown hypothyroidism, probably due to chronic autoimmune thyroiditis, was evidenced. Muscle biopsy (left gastrocnemius) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4+ lymphocytes. While ENT2 lovastatin ENT2END and simvastatin have been associated with toxic myopathy, pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	While lovastatin and ENT1 simvastatin ENT1END  have been associated with toxic ENT2 myopathy ENT2END , pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	While lovastatin and simvastatin have been associated with toxic ENT1 myopathy ENT1END , ENT2 pravastatin ENT2END -associated myopathy could represent a distinct, inflammatory entity
0	While ENT1 lovastatin  ENT1END  and simvastatin have been associated with toxic ENT2 myopathy ENT2END , pravastatin-associated myopathy could represent a distinct, inflammatory entity
0	Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with ENT1 heparin ENT1END induced ENT2 platelet aggregation ENT2END who require brief reexposure to heparin, but its success in patients who have developed the thrombosis syndrome is not well defined
1	The morbidity and mortality associated with ENT1 heparin ENT1END induced ENT2 thrombosis ENT2END remain high despite numerous empirical therapies
0	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on ENT1 rilmenidine ENT1END hypotension. The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and ENT2 a reduced locomotor activity ENT2END
0	The enhanced ENT1 alpha-methyldopa  ENT1END hypotension in Ovx rats was paralleled with further reduction in SDRR and ENT2 a reduced locomotor activity ENT2END
0	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and ENT1 a reduced locomotor activity  ENT1END . Estrogen replacement ( ENT2 17beta-estradiol ENT2END subcutaneous pellet, 14
0	The enhanced alpha-methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and ENT1 a reduced locomotor activity ENT1END . Estrogen replacement (17beta-estradiol subcutaneous pellet, 14.2 microg/day, 12 wk) of Ovx rats restored the hemodynamic and locomotor effects of alpha-methyldopa to sham-operated levels. These findings suggest that ENT2 estrogen ENT2END downregulates alpha2- but not I1-receptor-mediated hypotension and highlight a role for the cardiac autonomic control in alpha-methyldopa-estrogen interaction
1	Ovx significantly enhanced the hypotensive response to alpha-methyldopa, in contrast to no effect on ENT1 rilmenidine ENT1END  ENT2 hypotension ENT2END
1	The enhanced ENT1 alpha-methyldopa ENT1END  ENT2 hypotension ENT2END in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity
0	The enhanced alpha-methyldopa ENT1 hypotension ENT1END  in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity. Estrogen replacement ENT2 17beta-estradiol ENT2END subcutaneous pellet, 14
0	We have recently shown that estrogen negatively modulates the ENT1 hypotensive ENT1END effect of ENT2 clonidine ENT2END (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction
0	Differential modulation by estrogen of alpha2-adrenergic and I1- ENT1 imidazoline  ENT1END  receptor-mediated ENT2 hypotension ENT2END in female rats
0	We have recently shown that ENT1 estrogen  ENT1END negatively modulates the ENT2 hypotensive ENT2END effect of clonidine (mixed alpha2-/I1-receptor agonist) in female rats and implicates the cardiovascular autonomic control in this interaction
0	All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to ENT1 MDM ENT1END  and 44 of 46 (96%) to ENT2 PG ENT2END
0	A total of 177 patients were diagnosed as allergic to ENT1 beta-lactam  ENT1END antibiotics. We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG. Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema. All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to ENT2 MDM ENT2END , and 44 of 46 (96%) to PG
0	All the patients were skin test negative to BPO; 49 of 51 (96%) were also negative to ENT1 MDM ENT1END , and 44 of 46 (96%) to PG. Skin tests with ENT2 AX ENT2END were positive in 34 (63%) patients
0	A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate ENT1 allergic ENT1END responses to amoxicillin (AX) or were cross-reacting with other ENT2 penicillin ENT2END derivatives
0	5%) cases of immediate AX ENT1 allergy ENT1END with good tolerance of ENT2 PG ENT2END
0	A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients ENT1 allergic ENT1END to ENT2 beta-lactam ENT2END antibiotics had selective immediate allergic responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives
1	5%) cases of immediate ENT1 AX ENT1END ENT2 allergy ENT2END with good tolerance of PG
0	A detailed clinical history, together with skin tests, RAST (radioallergosorbent test), and controlled challenge tests, was used to establish whether patients allergic to beta-lactam antibiotics had selective immediate ENT1 allergic ENT1END  responses to amoxicillin (AX) or were cross-reacting with other penicillin derivatives. Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ENT2 ampicillin ENT2END (AMP), and AX
0	5%) cases of immediate AX allergy with good tolerance of ENT1 PG ENT1END . ENT2 Anaphylaxis ENT2END was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema
0	A total of 177 patients were diagnosed as allergic to ENT1 beta-lactam  ENT1END  antibiotics. We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG. ENT2 Anaphylaxis ENT2END was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema
1	5%) cases of immediate ENT1 AX  ENT1END  allergy with good tolerance of PG. ENT2 Anaphylaxis ENT2END was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema
0	Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin ( ENT1 AMP  ENT1END , and AX. RAST for BPO-PLL and AX-PLL was done. When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX. A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics. We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG. ENT2 Anaphylaxis ENT2END was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or angioedema
0	5%) cases of immediate AX allergy with good tolerance of ENT1 PG ENT1END . Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having ENT2 urticaria ENT2END and/or angioedema
0	A total of 177 patients were diagnosed as allergic to ENT1 beta-lactam  ENT1END  antibiotics. We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG. Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having ENT2 urticaria ENT2END and/or angioedema
0	5%) cases of immediate ENT1 AX  ENT1END  allergy with good tolerance of PG. Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having ENT2 urticaria ENT2END and/or angioedema
0	Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin ( ENT1 AMP  ENT1END ), and AX. RAST for BPO-PLL and AX-PLL was done. When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX. A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics. We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG. Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having ENT2 urticaria ENT2END and/or angioedema
0	5%) cases of immediate AX allergy with good tolerance of ENT1 PG ENT1END . Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or ENT2 angioedema ENT2END
0	A total of 177 patients were diagnosed as allergic to ENT1 beta-lactam  ENT1END  antibiotics. We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG. Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or ENT2 angioedema ENT2END
1	5%) cases of immediate ENT1 AX  ENT1END  allergy with good tolerance of PG. Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or ENT2 angioedema ENT2END
0	Skin tests were performed with benzylpenicilloyl-poly-L-lysine (BPO-PLL), benzylpenicilloate, benzylpenicillin (PG), ampicillin ( ENT1 AMP  ENT1END ), and AX. RAST for BPO-PLL and AX-PLL was done. When both skin test and RAST for BPO were negative, single-blind, placebo-controlled challenge tests were done to ensure tolerance of PG or sensitivity to AX. A total of 177 patients were diagnosed as allergic to beta-lactam antibiotics. We selected the 54 (30.5%) cases of immediate AX allergy with good tolerance of PG. Anaphylaxis was seen in 37 patients (69%), the other 17 (31%) having urticaria and/or ENT2 angioedema ENT2END
0	A strong association has been found between nephritis and dermatitis due to Tiopronin (a ENT1 D-Penicillamine ENT1END like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35. Compared to healthy controls a lower DR5 frequency was observed in patients with ENT2 RA ENT2END except for the Tiopronin related nephritis group
0	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to ENT1 gold  ENT1END thiosulphate and B35. Compared to healthy controls a lower DR5 frequency was observed in patients with ENT2 RA ENT2END except for the Tiopronin related nephritis group
0	Compared to healthy controls a lower DR5 frequency was observed in patients with ENT1 RA ENT1END  except for the ENT2 Tiopronin ENT2END related nephritis group
0	Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without ENT1 toxicity  ENT1END were studied for possible associations with class I and II HLA antigens. A strong association has been found between nephritis and dermatitis due to Tiopronin (a ENT2 D-Penicillamine ENT2END like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35
0	Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without ENT1 toxicity  ENT1END  were studied for possible associations with class I and II HLA antigens. A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to ENT2 gold ENT2END thiosulphate and B35
0	Twenty-five patients with rheumatoid arthritis (RA) who developed toxicity while taking remission inducing drugs and 30 without ENT1 toxicity ENT1END  were studied for possible associations with class I and II HLA antigens. A strong association has been found between nephritis and dermatitis due to ENT2 Tiopronin ENT2END (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35
0	A strong association has been found between nephritis and ENT1 dermatitis  ENT1END due to Tiopronin (a ENT2 D-Penicillamine ENT2END like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35
1	A strong association has been found between nephritis and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between ENT1 dermatitis  ENT1END due to ENT2 gold ENT2END thiosulphate and B35
1	A strong association has been found between nephritis and ENT1 dermatitis  ENT1END  due to ENT2 Tiopronin ENT2END (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35
0	A strong association has been found between ENT1 nephritis  ENT1END and dermatitis due to Tiopronin (a ENT2 D-Penicillamine ENT2END like compound) and class I antigens B35-Cw4, and between dermatitis due to gold thiosulphate and B35
0	A strong association has been found between ENT1 nephritis  ENT1END  and dermatitis due to Tiopronin (a D-Penicillamine like compound) and class I antigens B35-Cw4, and between dermatitis due to ENT2 gold ENT2END thiosulphate and B35
1	Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the ENT1 Tiopronin ENT1END  related ENT2 nephritis ENT2END group
0	A 73-year-old woman died of aplastic anemia less than two months after undergoing ENT1 cataract ENT1END extraction and beginning topical therapy with ENT2 chloramphenicol ENT2END
1	Fatal aplastic anemia following topical administration of ophthalmic ENT1 chloramphenicol ENT1END .A 73-year-old woman died of ENT2 aplastic anemia ENT2END less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol
0	A 73-year-old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with ENT1 chloramphenicol ENT1END . The first signs of ENT2 pancytopenia ENT2END began within one month of the surgery
0	Any other suspected cases of ENT1 ocular toxicity ENT1END associated with topically applied ENT2 chloramphenicol ENT2END should be reported to the National Registry of Drug-Induced Ocular Side Effects, Oregon Health Sciences University, Portland, OR 97201
0	This was the second report of fatal aplastic anemia after topical treatment with ENT1 chloramphenicol ENT1END for ocular conditions, although two cases of reversible ENT2 bone marrow hypoplasia ENT2END have also been reported
0	ENT1 Neurotoxicity ENT1END is a potentially serious toxic effect. It is characterized by encephalopathy, headaches, seizures, or neurological deficits. Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN. MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis. Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of ENT2 methylprednisolone ENT2END pulse therapy
0	ENT1 TAC  ENT1END has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. ENT2 Neurotoxicity ENT2END is a potentially serious toxic effect
0	Recovery of tacrolimus-associated brachial neuritis after conversion to ENT1 everolimus  ENT1END  in a pediatric renal transplant recipient--case report and review of the literature.TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. ENT2 Neurotoxicity ENT2END is a potentially serious toxic effect
0	MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both ENT1 myelitis  ENT1END and right brachial plexitis. Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of ENT2 methylprednisolone ENT2END pulse therapy
0	MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both ENT1 myelitis ENT1END  and right brachial plexitis. Symptoms persisted for three months despite ENT2 TAC ENT2END dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy
0	MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both ENT1 myelitis ENT1END  and right brachial plexitis. Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of methylprednisolone pulse therapy. Improvement and eventually full recovery only occurred after TAC was completely discontinued and successfully replaced by ENT2 everolimus ENT2END
0	It is characterized by encephalopathy, ENT1 headaches  ENT1END  seizures, or neurological deficits. Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN. MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis. Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of ENT2 methylprednisolone ENT2END pulse therapy
0	ENT1 TAC  ENT1END  has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by encephalopathy, ENT2 headaches ENT2END , seizures, or neurological deficits
0	Recovery of tacrolimus-associated brachial neuritis after conversion to ENT1 everolimus  ENT1END  in a pediatric renal transplant recipient--case report and review of the literature.TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by encephalopathy, ENT2 headaches ENT2END , seizures, or neurological deficits
0	It is characterized by encephalopathy, headaches, ENT1 seizures  ENT1END  or neurological deficits. Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN. MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis. Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of ENT2 methylprednisolone ENT2END pulse therapy
0	ENT1 TAC  ENT1END  has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by encephalopathy, headaches, ENT2 seizures ENT2END , or neurological deficits
0	Recovery of tacrolimus-associated brachial neuritis after conversion to ENT1 everolimus  ENT1END  in a pediatric renal transplant recipient--case report and review of the literature.TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by encephalopathy, headaches, ENT2 seizures ENT2END , or neurological deficits
0	It is characterized by encephalopathy, headaches, seizures, or ENT1 neurological deficits  ENT1END  Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN. MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis. Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of ENT2 methylprednisolone ENT2END pulse therapy
0	ENT1 TAC  ENT1END  has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by encephalopathy, headaches, seizures, or ENT2 neurological deficits ENT2END
0	Recovery of tacrolimus-associated brachial neuritis after conversion to ENT1 everolimus  ENT1END  in a pediatric renal transplant recipient--case report and review of the literature.TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by encephalopathy, headaches, seizures, or ENT2 neurological deficits ENT2END
0	It is characterized by ENT1 encephalopathy  ENT1END  headaches, seizures, or neurological deficits. Here, we describe an eight-and-a-half-yr-old male renal transplant recipient with right BN. MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis. Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of ENT2 methylprednisolone ENT2END pulse therapy
0	ENT1 TAC  ENT1END  has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by ENT2 encephalopathy ENT2END , headaches, seizures, or neurological deficits
0	Recovery of tacrolimus-associated brachial neuritis after conversion to ENT1 everolimus  ENT1END  in a pediatric renal transplant recipient--case report and review of the literature.TAC has been shown to be a potent immunosuppressive agent for solid organ transplantation in pediatrics. Neurotoxicity is a potentially serious toxic effect. It is characterized by ENT2 encephalopathy ENT2END , headaches, seizures, or neurological deficits
0	MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right ENT1 brachial plexitis  ENT1END  Symptoms persisted for three months despite TAC dose reduction, administration of IVIG and four doses of ENT2 methylprednisolone ENT2END pulse therapy
1	Recovery of ENT1 tacrolimus  ENT1END -associated ENT2 brachial neuritis ENT2END after conversion to everolimus in a pediatric renal transplant recipient--case report and review of the literature
0	Recovery of tacrolimus-associated ENT1 brachial neuritis  ENT1END  after conversion to ENT2 everolimus ENT2END in a pediatric renal transplant recipient--case report and review of the literature
0	Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), tardive dyskinesia, sedation, and possible impairment of some cognitive measures, as well as cardiac effects, ENT1 orthostatic hypotension ENT1END  hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain. The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily ENT2 clozapine ENT2END ), and agranulocytosis (clozapine only)
0	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, ENT1 weight gain  ENT1END  sexual dysfunction, hepatic effects, lowered seizure threshold (primarily ENT2 clozapine ENT2END ), and agranulocytosis (clozapine only)
0	The newer atypical agents have a lower risk of ENT1 EPS  ENT1END  but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily ENT2 clozapine ENT2END ), and agranulocytosis (clozapine only)
0	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, ENT1 sexual dysfunction  ENT1END  hepatic effects, lowered seizure threshold (primarily ENT2 clozapine ENT2END ), and agranulocytosis (clozapine only)
0	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered ENT1 seizure  ENT1END threshold (primarily ENT2 clozapine ENT2END ), and agranulocytosis (clozapine only)
1	The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and ENT1 agranulocytosis  ENT1END ( ENT2 clozapine ENT2END only)
0	Conventional agents are associated with unwanted central nervous system effects, including extrapyramidal symptoms (EPS), ENT1 tardive dyskinesia  ENT1END  sedation, and possible impairment of some cognitive measures, as well as cardiac effects, orthostatic hypotension, hepatic changes, anticholinergic side effects, sexual dysfunction, and weight gain. The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily ENT2 clozapine ENT2END ), and agranulocytosis (clozapine only)
0	1-mg ENT1 FA ENT1END intravitreal implant or standard therapy were analyzed. RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively. Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes. Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year. The rate of ENT2 hypotony ENT2END (IOP </= 5 mm Hg) following IOP-lowering surgery (42
1	OBJECTIVE: To report the incidence and management of ENT1 elevated intraocular pressure ENT1END (IOP) in patients with uveitis treated with the ENT2 fluocinolone acetonide ENT2END (FA) intravitreal implant
0	Intraocular pressure in patients with ENT1 uveitis  ENT1END  treated with ENT2 fluocinolone acetonide ENT2END implants
0	The patient with ENT1 nitrazepam ENT1END overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG. The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without neurological sequelae following the withdrawal of the offending agents. The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed. It is suggested that in both situations disturbed reticulo-thalamic interactions are important in the pathogenesis of alpha coma. It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant ENT2 hypoxaemia ENT2END , a favourable outcome may be anticipated
0	The fourth patient who was unconscious after ENT1 chlormethiazole  ENT1END administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without neurological sequelae following the withdrawal of the offending agents. The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed. It is suggested that in both situations disturbed reticulo-thalamic interactions are important in the pathogenesis of alpha coma. It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication, in the absence of significant ENT2 hypoxaemia ENT2END , a favourable outcome may be anticipated
0	Alpha and beta coma in drug intoxication uncomplicated by ENT1 cerebral hypoxia ENT1END .Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described. Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of ENT2 nitrazepam ENT2END
0	Alpha and beta coma in drug intoxication uncomplicated by ENT1 cerebral hypoxia ENT1END .Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described. Three patients received high doses of ENT2 chlormethiazole ENT2END for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam
0	Alpha and beta coma in drug intoxication uncomplicated by ENT1 cerebral hypoxia ENT1END .Four patients who were rendered comatose or stuporous by drug intoxication, but who were not hypoxic, are described. Three patients received high doses of chlormethiazole for ENT2 alcohol ENT2END withdrawal symptoms, and one took a suicidal overdose of nitrazepam
0	The patient with ENT1 nitrazepam ENT1END  overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG. The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without ENT2 neurological sequelae ENT2END following the withdrawal of the offending agents
0	The fourth patient who was unconscious after ENT1 chlormethiazole  ENT1END  administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without ENT2 neurological sequelae ENT2END following the withdrawal of the offending agents
0	Three patients received high doses of chlormethiazole for ENT1 alcohol  ENT1END  withdrawal symptoms, and one took a suicidal overdose of nitrazepam. The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG. The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without ENT2 neurological sequelae ENT2END following the withdrawal of the offending agents
0	Three patients received high doses of chlormethiazole for alcohol ENT1 withdrawal symptoms  ENT1END  and one took a suicidal overdose of ENT2 nitrazepam ENT2END
0	Three patients received high doses of ENT1 chlormethiazole  ENT1END  for alcohol ENT2 withdrawal symptoms ENT2END , and one took a suicidal overdose of nitrazepam
0	Three patients received high doses of chlormethiazole for ENT1 alcohol ENT1END ENT2 withdrawal symptoms ENT2END , and one took a suicidal overdose of nitrazepam
0	Four patients who were rendered comatose or ENT1 stuporous  ENT1END by drug intoxication, but who were not hypoxic, are described. Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms, and one took a suicidal overdose of ENT2 nitrazepam ENT2END
1	Four patients who were rendered comatose or ENT1 stuporous  ENT1END  by drug intoxication, but who were not hypoxic, are described. Three patients received high doses of ENT2 chlormethiazole ENT2END for alcohol withdrawal symptoms, and one took a suicidal overdose of nitrazepam
0	Four patients who were rendered comatose or ENT1 stuporous  ENT1END  by drug intoxication, but who were not hypoxic, are described. Three patients received high doses of chlormethiazole for ENT2 alcohol ENT2END withdrawal symptoms, and one took a suicidal overdose of nitrazepam
0	The patient with ENT1 nitrazepam ENT1END  overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG. The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without neurological sequelae following the withdrawal of the offending agents. The similarities between the effects of structural lesions and pharmacological ENT2 depression ENT2END of the brain stem reticular formation are discussed
0	The fourth patient who was unconscious after ENT1 chlormethiazole  ENT1END  administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without neurological sequelae following the withdrawal of the offending agents. The similarities between the effects of structural lesions and pharmacological ENT2 depression ENT2END of the brain stem reticular formation are discussed
0	Three patients received high doses of chlormethiazole for ENT1 alcohol  ENT1END  withdrawal symptoms, and one took a suicidal overdose of nitrazepam. The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG. The fourth patient who was unconscious after chlormethiazole administration exhibite generalized non-reactive activity in the slow beta range. All four recovered completely without neurological sequelae following the withdrawal of the offending agents. The similarities between the effects of structural lesions and pharmacological ENT2 depression ENT2END of the brain stem reticular formation are discussed
1	The patient with ENT1 nitrazepam ENT1END  ENT2 overdose ENT2END and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG
0	The patient with nitrazepam ENT1 overdose ENT1END  and two of those with ENT2 chlormethiazole ENT2END intoxication conformed to the criteria of 'alpha coma', showing non-reactive generalized or frontally predominant alpha activity in the EEG
0	Three patients received high doses of chlormethiazole for ENT1 alcohol ENT1END  withdrawal symptoms, and one took a suicidal ENT2 overdose ENT2END of nitrazepam
1	The patient with ENT1 nitrazepam ENT1END  overdose and two of those with chlormethiazole intoxication conformed to the criteria of 'alpha ENT2 coma ENT2END ', showing non-reactive generalized or frontally predominant alpha activity in the EEG
1	The patient with nitrazepam overdose and two of those with ENT1 chlormethiazole  ENT1END  intoxication conformed to the criteria of 'alpha ENT2 coma ENT2END ', showing non-reactive generalized or frontally predominant alpha activity in the EEG
0	Four patients who were rendered ENT1 comatose  ENT1END or stuporous by drug intoxication, but who were not hypoxic, are described. Three patients received high doses of chlormethiazole for ENT2 alcohol ENT2END withdrawal symptoms, and one took a suicidal overdose of nitrazepam
0	Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and ENT1 decreased cardiac output ENT1END and QS/QT. ENT2 Nitroprusside ENT2END caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate, but did not change cardiac output or QS/QT
0	During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm ENT1 H2O ENT1END , while decreasing QS/QT, produce marked ENT2 decreases in arterial blood pressure and cardiac output ENT2END
1	Pulmonary shunt and cardiovascular responses to CPAP during ENT1 nitroprusside  ENT1END -induced ENT2 hypotension ENT2END
0	During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics, but high levels of CPAP (10 cm ENT1 H2O ENT1END ), while decreasing QS/QT, produce marked ENT2 decreases in arterial blood pressure and cardiac output ENT2END
1	Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in ENT1 M ENT1END and T, respectively). This was associated with a similar ENT2 loss in body weight ENT2END
0	Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the ENT1 steroid  ENT1END treated groups (-50 and -79% in M and T, respectively). This was associated with a similar ENT2 loss in body weight ENT2END
0	Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of ENT1 corticosteroids  ENT1END  The mechanism of this myopathy is poorly understood. Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and T, respectively). This was associated with a similar ENT2 loss in body weight ENT2END
1	Nutritional intake, measured daily in 15 animals, showed a significant reduction of food intake in the steroid-treated groups (-50 and -79% in M and ENT1 T  ENT1END  respectively). This was associated with a similar ENT2 loss in body weight ENT2END
0	Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with ENT1 M ENT1END  whereas ENT2 tetanic ENT2END tensions were similar
0	Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas ENT1 tetanic ENT1END  tensions were similar. ENT2 Steroid ENT2END treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0
0	05) and the ENT1 T  ENT1END group (765 +/- 145 g/cm(2), NS). Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with M, whereas ENT2 tetanic ENT2END tensions were similar
1	Nutritional intake, measured daily in 15 animals, showed a significant ENT1 reduction of food intake  ENT1END in the steroid-treated groups (-50 and -79% in ENT2 M ENT2END and T, respectively)
0	Nutritional intake, measured daily in 15 animals, showed a significant ENT1 reduction of food intake  ENT1END  in the ENT2 steroid ENT2END -treated groups (-50 and -79% in M and T, respectively)
0	Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of ENT1 corticosteroids  ENT1END . The mechanism of this myopathy is poorly understood. Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or triamcinolone (T) 80 mg/kg/d for 5 d. Nutritional intake, measured daily in 15 animals, showed a significant ENT2 reduction of food intake ENT2END in the steroid-treated groups (-50 and -79% in M and T, respectively)
1	Nutritional intake, measured daily in 15 animals, showed a significant ENT1 reduction of food intake  ENT1END  in the steroid-treated groups (-50 and -79% in M and ENT2 T ENT2END , respectively)
0	Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with ENT1 M ENT1END , whereas tetanic tensions were similar. Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05). ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of ENT2 necrosis ENT2END
0	We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb atrophy, resulting in the expected alterations in diaphragm contractile properties; (3) neither ENT1 steroid ENT1END caused muscle ENT2 necrosis ENT2END ; (4) type IIb atrophy was not caused by acute nutritional deprivation alone
0	ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of ENT1 necrosis ENT1END . Finally, a pair-fed (PF) study, performed in 18 rats (C, ENT2 T ENT2END , and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals
0	Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with ENT1 M ENT1END , whereas tetanic tensions were similar. Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05). ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis. Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in T-treated animals. We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb ENT2 atrophy ENT2END , resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone
0	We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of ENT1 steroids  ENT1END induced predominantly type IIb ENT2 atrophy ENT2END , resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone
0	Finally, a pair-fed (PF) study, performed in 18 rats (C, T, and PF), showed that muscle atrophy was considerably less pronounced in PF animals than in ENT1 T  ENT1END treated animals. We conclude that (1) short-term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting; (2) both types of steroids induced predominantly type IIb ENT2 atrophy ENT2END , resulting in the expected alterations in diaphragm contractile properties; (3) neither steroid caused muscle necrosis; (4) type IIb atrophy was not caused by acute nutritional deprivation alone
0	The mechanism of this ENT1 myopathy ENT1END is poorly understood. Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), ENT2 methylprednisolone ENT2END (M), or triamcinolone (T) 80 mg/kg/d for 5 d
0	Effects of acute ENT1 steroid ENT1END  administration on ventilatory and peripheral muscles in rats.Occasional case reports have shown that acute ENT2 myopathy ENT2END may occur in patients treated with massive doses of corticosteroids
0	Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of ENT1 corticosteroids  ENT1END . The mechanism of this ENT2 myopathy ENT2END is poorly understood
0	The mechanism of this ENT1 myopathy ENT1END  is poorly understood. Therefore, 60 male rats were randomly assigned to receive daily injection of saline (C), methylprednisolone (M), or ENT2 triamcinolone ENT2END (T) 80 mg/kg/d for 5 d
1	Half-relaxation time was prolonged in both steroid groups, and time to peak tension was longer with ENT1 M ENT1END , whereas tetanic tensions were similar. Steroid treatment also induced a leftward shift of the force-frequency curve at 25 and 50 Hz when compared with saline treatment (p < 0.05). ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber ENT2 atrophy ENT2END in the steroid groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis
0	ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber ENT1 atrophy ENT1END  in the ENT2 steroid ENT2END groups and also diaphragmatic type IIa atrophy with T, whereas histologic examinations revealed a normal muscular pattern with absence of necrosis
1	ATPase staining of the diaphragm, scalenus medius, and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa ENT1 atrophy ENT1END with ENT2 T ENT2END , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis
0	In the saline group, 45% of the mice developed large ENT1 hematomas ENT1END (i.e., >15 microL). In contrast, such extensive lesions were never found in the ENT2 PCC ENT2END group
0	ENT1 Warfarin ENT1END associated intracerebral hemorrhage (W-ICH) is a severe type of ENT2 stroke ENT2END
0	Warfarin-associated intracerebral hemorrhage (W-ICH) is a severe type of ENT1 stroke ENT1END . There is no consensus on the optimal treatment for W-ICH. Using a mouse model, we tested whether the rapid reversal of anticoagulation using human ENT2 prothrombin complex concentrate ENT2END (PCC) can reduce hemorrhagic blood volume
0	Rapid reversal of anticoagulation reduces ENT1 hemorrhage  ENT1END  volume in a mouse model of ENT2 warfarin ENT2END -associated intracerebral hemorrhage
0	Forty-five minutes later, the animals were randomly treated with ENT1 PCC ENT1END (100 U/kg) or saline i.v. (n=12 per group). Twenty-four hours after ENT2 hemorrhage ENT2END induction, hemorrhagic blood volume was quantified using a photometric hemoglobin assay
1	Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin-associated ENT1 intracerebral hemorrhage ENT1END ENT2 Warfarin ENT2END -associated intracerebral hemorrhage (W-ICH) is a severe type of stroke
0	We provide experimental data suggesting ENT1 PCC  ENT1END to be an effective acute treatment for W- ENT2 ICH ENT2END in terms of reducing hemorrhagic blood volume
0	The transient ENT1 steroid ENT1END induced ENT2 IOP rise ENT2END did not seem to cause functional impairment
1	During the follow-up, 3 patients (12%) developed steroid-induced ENT1 elevated intraocular pressure ENT1END (IOP) that resolved after ENT2 corticosteroid ENT2END therapy was discontinued
1	Reversible ENT1 inferior colliculus lesion  ENT1END  in ENT2 metronidazole ENT2END -induced encephalopathy: magnetic resonance findings on diffusion-weighted and fluid attenuated inversion recovery imaging
0	They had been taking ENT1 metronidazole ENT1END (total dosage, 45-120 g; duration, 30 days to 2 months) to treat the ENT2 infection ENT2END in various organs
0	Treatment has included use of plasma exchange, ENT1 prednisone ENT1END  aspirin, and dipyridamole. The patients have all regained some degree of renal function. However, it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement. Quinine-associated ENT2 hemolytic-uremic syndrome ENT2END probably occurs more often than is recognized
0	Treatment has included use of plasma exchange, prednisone, aspirin, and ENT1 dipyridamole  ENT1END  The patients have all regained some degree of renal function. However, it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement. Quinine-associated ENT2 hemolytic-uremic syndrome ENT2END probably occurs more often than is recognized
1	Hemolytic-uremic syndrome associated with ingestion of ENT1 quinine  ENT1END . ENT2 Hemolytic-uremic syndrome ENT2END following quinine ingestion is a newly described phenomenon, with just two previous descriptions of 4 cases in the literature
0	Treatment has included use of plasma exchange, prednisone, ENT1 aspirin  ENT1END  and dipyridamole. The patients have all regained some degree of renal function. However, it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement. Quinine-associated ENT2 hemolytic-uremic syndrome ENT2END probably occurs more often than is recognized
0	Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after ENT1 PAN ENT1END injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with ENT2 glomerulosclerosis ENT2END (days 45-126)
0	Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein ENT1 tyrosine  ENT1END phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes. This receptor plays a role in regulating the structure and function of podocyte foot process. To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat. Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW). Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with ENT2 glomerulosclerosis ENT2END (days 45-126)
1	Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after ENT1 PAN ENT1END  injection so as to include both the acute phase of ENT2 proteinuria ENT2END associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126)
0	Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein ENT1 tyrosine  ENT1END  phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes. This receptor plays a role in regulating the structure and function of podocyte foot process. To better understand the utility of GLEPP1 as a marker of glomerular injury, the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat. Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW). Tissues were analyzed at 0, 5, 7, 11, 21, 45, 80 and 126 days after PAN injection so as to include both the acute phase of ENT2 proteinuria ENT2END associated with foot process effacement (days 5-11) and the chronic phase of proteinuria associated with glomerulosclerosis (days 45-126)
1	GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat ENT1 PAN ENT1END ENT2 nephrosis ENT2END
0	GLEPP1 receptor ENT1 tyrosine  ENT1END  phosphatase (Ptpro) in rat PAN ENT2 nephrosis ENT2END
0	To better understand the utility of GLEPP1 as a marker of ENT1 glomerular injury ENT1END  the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat. ENT2 Puromycin aminonucleoside ENT2END nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside (PAN, 20 mg/100g BW)
0	Glomerular epithelial protein 1 (GLEPP1) is a podocyte receptor membrane protein ENT1 tyrosine  ENT1END  phosphatase located on the apical cell membrane of visceral glomerular epithelial cell and foot processes. This receptor plays a role in regulating the structure and function of podocyte foot process. To better understand the utility of GLEPP1 as a marker of ENT2 glomerular injury ENT2END , the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry, Western blot and RNase protection assay in a model of podocyte injury in the rat
1	In ENT1 DXR ENT1END ENT2 CM ENT2END myocardial damage is proportional to the degree of cytotoxic insult (DXR dose) while myocardial function is preserved until a critical dose or degree of damage is reached, after which myocardial performance deteriorates rapidly
0	The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous ENT1 amiodarone ENT1END for rate and rhythm control. When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion. Exogenous creatine is used by athletes to theoretically improve exercise performance. Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products. Previous anecdotal reports have linked creatine to the development of ENT2 arrhythmia ENT2END
0	Therefore, when the ENT1 arrhythmia ENT1END is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, ENT2 magnesium ENT2END , and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	When discharged less than 24 hours later, he was receiving metoprolol and ENT1 aspirin  ENT1END  with follow-up plans for echocardiography and nuclear imaging to assess perfusion. Exogenous creatine is used by athletes to theoretically improve exercise performance. Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products. Previous anecdotal reports have linked creatine to the development of ENT2 arrhythmia ENT2END
0	Therefore, when the ENT1 arrhythmia ENT1END  is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and ENT2 alcohol ENT2END use was denied
0	The patient was admitted to the hospital, anticoagulated with unfractionated ENT1 heparin  ENT1END  and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control. When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion. Exogenous creatine is used by athletes to theoretically improve exercise performance. Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products. Previous anecdotal reports have linked creatine to the development of ENT2 arrhythmia ENT2END
0	Therefore, when the ENT1 arrhythmia ENT1END  is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and ENT2 potassium ENT2END levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	Previous anecdotal reports have linked ENT1 creatine  ENT1END to the development of ENT2 arrhythmia ENT2END
0	The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous ENT1 diltiazem  ENT1END for rate control and intravenous amiodarone for rate and rhythm control. When discharged less than 24 hours later, he was receiving metoprolol and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion. Exogenous creatine is used by athletes to theoretically improve exercise performance. Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products. Previous anecdotal reports have linked creatine to the development of ENT2 arrhythmia ENT2END
0	When discharged less than 24 hours later, he was receiving ENT1 metoprolol  ENT1END and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion. Exogenous creatine is used by athletes to theoretically improve exercise performance. Vegetarians may also take creatine to replace what they are not consuming from meat, fish, and other animal products. Previous anecdotal reports have linked creatine to the development of ENT2 arrhythmia ENT2END
0	ENT1 Thyroid disorders  ENT1END  illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous ENT2 amiodarone ENT2END for rate and rhythm control
0	ENT1 Thyroid disorders  ENT1END , illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, ENT2 magnesium ENT2END , and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	ENT1 Thyroid disorders  ENT1END , illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and ENT2 alcohol ENT2END use was denied
0	ENT1 Thyroid disorders  ENT1END , illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated ENT2 heparin ENT2END , and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control
0	ENT1 Thyroid disorders  ENT1END , illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and ENT2 potassium ENT2END levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	Lone atrial fibrillation associated with ENT1 creatine  ENT1END  monohydrate supplementation.Atrial fibrillation in young patients without structural heart disease is rare. Therefore, when the arrhythmia is present in this population, reversible causes must be identified and resolved. ENT2 Thyroid disorders ENT2END , illicit drug or stimulant use, and acute alcohol intoxication are among these causes
0	ENT1 Thyroid disorders  ENT1END , illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous ENT2 diltiazem ENT2END for rate control and intravenous amiodarone for rate and rhythm control
0	Thyroid disorders, illicit drug or stimulant use, and ENT1 acute alcohol intoxication  ENT1END are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous ENT2 amiodarone ENT2END for rate and rhythm control
0	Thyroid disorders, illicit drug or stimulant use, and ENT1 acute alcohol intoxication  ENT1END  are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, ENT2 magnesium ENT2END , and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	Thyroid disorders, illicit drug or stimulant use, and ENT1 acute alcohol intoxication  ENT1END  are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and ENT2 alcohol ENT2END use was denied
0	Thyroid disorders, illicit drug or stimulant use, and ENT1 acute alcohol intoxication  ENT1END  are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated ENT2 heparin ENT2END , and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control
0	Thyroid disorders, illicit drug or stimulant use, and ENT1 acute alcohol intoxication  ENT1END  are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and ENT2 potassium ENT2END levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	Lone atrial fibrillation associated with ENT1 creatine  ENT1END  monohydrate supplementation.Atrial fibrillation in young patients without structural heart disease is rare. Therefore, when the arrhythmia is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and ENT2 acute alcohol intoxication ENT2END are among these causes
0	Thyroid disorders, illicit drug or stimulant use, and ENT1 acute alcohol intoxication  ENT1END  are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous ENT2 diltiazem ENT2END for rate control and intravenous amiodarone for rate and rhythm control
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous ENT2 amiodarone ENT2END for rate and rhythm control
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END  with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, ENT2 magnesium ENT2END , and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END  with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control. When discharged less than 24 hours later, he was receiving metoprolol and ENT2 aspirin ENT2END , with follow-up plans for echocardiography and nuclear imaging to assess perfusion
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END  with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and ENT2 alcohol ENT2END use was denied
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END  with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated ENT2 heparin ENT2END , and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END  with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and ENT2 potassium ENT2END levels were within normal limits, urine drug screen was negative, and alcohol use was denied
1	Lone ENT1 atrial fibrillation  ENT1END  associated with ENT2 creatine ENT2END monohydrate supplementation
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END  with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous ENT2 diltiazem ENT2END for rate control and intravenous amiodarone for rate and rhythm control
0	We report the case of a 30-year-old Caucasian man who came to the emergency department in ENT1 atrial fibrillation  ENT1END  with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control. When discharged less than 24 hours later, he was receiving ENT2 metoprolol ENT2END and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion
0	Atrial fibrillation in young patients without structural ENT1 heart disease  ENT1END is rare. Therefore, when the arrhythmia is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, ENT2 magnesium ENT2END , and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	Atrial fibrillation in young patients without structural ENT1 heart disease  ENT1END  is rare. Therefore, when the arrhythmia is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and ENT2 alcohol ENT2END use was denied
0	Atrial fibrillation in young patients without structural ENT1 heart disease  ENT1END  is rare. Therefore, when the arrhythmia is present in this population, reversible causes must be identified and resolved. Thyroid disorders, illicit drug or stimulant use, and acute alcohol intoxication are among these causes. We report the case of a 30-year-old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response. His medical history was unremarkable, except for minor fractures of the fingers and foot. Thyroid-stimulating hormone, magnesium, and ENT2 potassium ENT2END levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	Lone atrial fibrillation associated with ENT1 creatine  ENT1END  monohydrate supplementation.Atrial fibrillation in young patients without structural ENT2 heart disease ENT2END is rare
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous ENT2 amiodarone ENT2END for rate and rhythm control
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END  of the fingers and foot. Thyroid-stimulating hormone, ENT2 magnesium ENT2END , and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END  of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control. When discharged less than 24 hours later, he was receiving metoprolol and ENT2 aspirin ENT2END , with follow-up plans for echocardiography and nuclear imaging to assess perfusion
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END  of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and ENT2 alcohol ENT2END use was denied
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END  of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated ENT2 heparin ENT2END , and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END  of the fingers and foot. Thyroid-stimulating hormone, magnesium, and ENT2 potassium ENT2END levels were within normal limits, urine drug screen was negative, and alcohol use was denied
0	His medical history was unremarkable, except for minor ENT1 fractures ENT1END  of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of ENT2 creatine ENT2END monohydrate was revealed
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END  of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous ENT2 diltiazem ENT2END for rate control and intravenous amiodarone for rate and rhythm control
0	His medical history was unremarkable, except for minor ENT1 fractures  ENT1END  of the fingers and foot. Thyroid-stimulating hormone, magnesium, and potassium levels were within normal limits, urine drug screen was negative, and alcohol use was denied. However, when the patient was questioned about use of herbal products and supplements, the use of creatine monohydrate was revealed. The patient was admitted to the hospital, anticoagulated with unfractionated heparin, and given intravenous diltiazem for rate control and intravenous amiodarone for rate and rhythm control. When discharged less than 24 hours later, he was receiving ENT2 metoprolol ENT2END and aspirin, with follow-up plans for echocardiography and nuclear imaging to assess perfusion
1	Azidothymidine ( ENT1 AZT ENT1END -induced ENT2 anemia ENT2END in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3)
0	Azidothymidine (AZT)-induced ENT1 anemia ENT1END  in mice can be reversed by the administration of IGF-IL-3 (fusion protein of insulin-like growth factor II (IGF II) and interleukin 3). Although interleukin 3 (IL-3) and erythropoietin (EPO) are known to act synergistically on hematopoietic cell proliferation in vitro, injection of IGF-IL-3 and EPO in AZT-treated mice resulted in a reduction of red cells and an increase of plasma EPO levels as compared to animals treated with IGF-IL-3 or EPO alone. We tested the hypothesis that the antagonistic effect of IL-3 and EPO on erythroid cells may be mediated by endothelial cells. Bovine liver erythroid cells were cultured on monolayers of human bone marrow endothelial cells previously treated with EPO and IGF-IL-3. There was a significant reduction of ENT2 thymidine ENT2END incorporation into both erythroid and endothelial cells in cultures pre-treated with IGF-IL-3 and EPO
1	We used rat models of ENT1 intrahepatic cholestasis ENT1END by ENT2 ethinyl estradiol ENT2END (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage
0	We used rat models of intrahepatic cholestasis by ethinyl estradiol ( ENT1 EE ENT1END  treatment and ENT2 extrahepatic cholestasis ENT2END by bile duct ligation (BDL) to precisely determine the site of TJ damage
0	Although hepatocyte TJs are impaired in ENT1 cholestasis  ENT1END  attempts to localize the precise site of hepatocyte TJ damage by freeze-fracture electron microscopy have produced limited information. Recently, several TJ-associated proteins like ZO-1 and 7H6 have been identified and characterized. Immunolocalization of 7H6 appears to closely correlate with paracellular permeability. We used rat models of intrahepatic cholestasis by ENT2 ethinyl estradiol ENT2END (EE) treatment and extrahepatic cholestasis by bile duct ligation (BDL) to precisely determine the site of TJ damage
0	The overall incidence of side effects and the frequency and severity of blurred vision, ENT1 dry mouth ENT1END  and drowsiness were significantly less with dothiepin than with amitriptyline. Dothiepin also produced fewer CNS and cardiovascular effects. There were no clinically important changes in laboratory parameters. Dothiepin thus was found to be an effective ENT2 antidepressant ENT2END drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients
1	The overall incidence of side effects and the frequency and severity of blurred vision, ENT1 dry mouth ENT1END , and drowsiness were significantly less with dothiepin than with ENT2 amitriptyline ENT2END
0	The overall incidence of side effects and the frequency and severity of blurred vision, ENT1 dry mouth ENT1END , and drowsiness were significantly less with ENT2 dothiepin ENT2END than with amitriptyline
0	Dothiepin thus was found to be an effective ENT1 antidepressant ENT1END  drug associated with fewer side effects than amitriptyline in the treatment of ENT2 depressed ENT2END outpatients
0	Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than ENT1 amitriptyline  ENT1END in the treatment of ENT2 depressed ENT2END outpatients
0	In a 6-week double-blind parallel treatment study, dothiepin and amitriptyline were compared to placebo in the treatment of 33 ENT1 depressed ENT1END outpatients. ENT2 Dothiepin ENT2END and amitriptyline were equally effective in alleviating the symptoms of depressive illness, and both were significantly superior to placebo
0	The overall incidence of side effects and the frequency and severity of ENT1 blurred vision  ENT1END  dry mouth, and drowsiness were significantly less with dothiepin than with amitriptyline. Dothiepin also produced fewer CNS and cardiovascular effects. There were no clinically important changes in laboratory parameters. Dothiepin thus was found to be an effective ENT2 antidepressant ENT2END drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients
1	The overall incidence of side effects and the frequency and severity of ENT1 blurred vision  ENT1END , dry mouth, and drowsiness were significantly less with dothiepin than with ENT2 amitriptyline ENT2END
0	The overall incidence of side effects and the frequency and severity of ENT1 blurred vision  ENT1END , dry mouth, and drowsiness were significantly less with ENT2 dothiepin ENT2END than with amitriptyline
0	ENT1 PEG 400 ENT1END impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality. Light microscopic analysis showed a significant protection against ADR-induced ENT2 cardiac morphological alterations ENT2END
1	Light microscopic analysis showed a significant protection against ENT1 ADR  ENT1END induced ENT2 cardiac morphological alterations ENT2END
0	ENT1 PEG 400 ENT1END  impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality. Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations. Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in ENT2 Ehrlich ascites tumor ENT2END
0	Such treatment did not diminish the ENT1 ADR  ENT1END antitumor activity in L1210 leukemia and in ENT2 Ehrlich ascites tumor ENT2END
0	Effect of ENT1 polyethylene glycol 400  ENT1END  on adriamycin ENT2 toxicity ENT2END in mice
0	Effect of polyethylene glycol 400 on ENT1 adriamycin ENT1END ENT2 toxicity ENT2END in mice
0	ENT1 PEG 400 ENT1END  impressively decreased both acute high-dose and chronic low-dose-ADR-associated lethality. Light microscopic analysis showed a significant protection against ADR-induced cardiac morphological alterations. Such treatment did not diminish the ADR antitumor activity in ENT2 L1210 leukemia ENT2END and in Ehrlich ascites tumor
0	Such treatment did not diminish the ENT1 ADR  ENT1END  antitumor activity in ENT2 L1210 leukemia ENT2END and in Ehrlich ascites tumor
0	We report a case of intractable hemorrhagic cystitis due to ENT1 cyclophosphamide ENT1END therapy for ENT2 Wegener's granulomatosis ENT2END
0	Hyperbaric ENT1 oxygen  ENT1END  therapy for control of intractable cyclophosphamide-induced hemorrhagic cystitis.We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for ENT2 Wegener's granulomatosis ENT2END
0	We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for ENT1 Wegener's granulomatosis ENT1END . Conservative treatment, including bladder irrigation with physiological saline and instillation of ENT2 prostaglandin F2 alpha ENT2END , failed to totally control hemorrhage
1	We report a case of intractable ENT1 hemorrhagic cystitis  ENT1END due to ENT2 cyclophosphamide ENT2END therapy for Wegener's granulomatosis
0	Conservative treatment, including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha, failed to totally control ENT1 hemorrhage ENT1END  We then used hyperbaric ENT2 oxygen ENT2END at an absolute pressure of 2 atm, 5 days a week for 8 consecutive weeks
0	Conservative treatment, including bladder irrigation with physiological saline and instillation of ENT1 prostaglandin F2 alpha  ENT1END , failed to totally control ENT2 hemorrhage ENT2END
1	The bleeding ceased completely by the end of treatment and the patient remained free of ENT1 hematuria ENT1END thereafter. No side effect was noted during the course of therapy. In future, this form of therapy can offer a safe alternative in the treatment of ENT2 cyclophosphamide ENT2END -induced hemorrhagic cystitis
0	We then used hyperbaric ENT1 oxygen  ENT1END  at an absolute pressure of 2 atm, 5 days a week for 8 consecutive weeks. The bleeding ceased completely by the end of treatment and the patient remained free of ENT2 hematuria ENT2END thereafter
0	Conservative treatment, including bladder irrigation with physiological saline and instillation of ENT1 prostaglandin F2 alpha  ENT1END , failed to totally control hemorrhage. We then used hyperbaric oxygen at an absolute pressure of 2 atm, 5 days a week for 8 consecutive weeks. The bleeding ceased completely by the end of treatment and the patient remained free of ENT2 hematuria ENT2END thereafter
1	We report a case of intractable ENT1 hemorrhagic cystitis  ENT1END due to ENT2 cyclophosphamide ENT2END therapy for Wegener's granulomatosis
0	Hyperbaric ENT1 oxygen  ENT1END  therapy for control of intractable cyclophosphamide-induced ENT2 hemorrhagic cystitis ENT2END
0	We report a case of intractable ENT1 hemorrhagic cystitis  ENT1END  due to cyclophosphamide therapy for Wegener's granulomatosis. Conservative treatment, including bladder irrigation with physiological saline and instillation of ENT2 prostaglandin F2 alpha ENT2END , failed to totally control hemorrhage
0	Although low concentrations (less than or equal to 50 ppm) of ENT1 corticosterone ENT1END had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP. ENT2 Neurotoxic ENT2END esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds
0	Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or ENT1 DFP ENT1END ENT2 Neurotoxic ENT2END esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds
0	ENT1 Neurotoxic ENT1END  esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given ENT2 organophosphorous ENT2END compounds
0	Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on TOTP-induced neuropathy, greater than or equal to 200 ppm exacerbated clinical signs in chickens given either ENT1 TOTP  ENT1END or DFP. ENT2 Neurotoxic ENT2END esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given organophosphorous compounds
0	Dose-related beneficial and adverse effects of dietary ENT1 corticosterone  ENT1END  on organophosphorus-induced delayed ENT2 neuropathy ENT2END in chickens
1	Dose-related beneficial and adverse effects of dietary corticosterone on organophosphorus-induced delayed ENT1 neuropathy ENT1END  in chickens.Tri-ortho-tolyl phosphate (TOTP), 360 mg/kg, po, and ENT2 0,0'-diisopropyl phosphorofluoridate ENT2END (DFP), 1 mg/kg sc, were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone
0	Dose-related beneficial and adverse effects of dietary corticosterone on ENT1 organophosphorus  ENT1END -induced delayed ENT2 neuropathy ENT2END in chickens
1	Although low concentrations (less than or equal to 50 ppm) of corticosterone had beneficial effects on ENT1 TOTP ENT1END induced ENT2 neuropathy ENT2END , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP
0	Chickens given 200 ppm ENT1 corticosterone ENT1END without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase. ENT2 Degenerating myelinated fibers ENT2END were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP
1	ENT1 Degenerating myelinated fibers ENT1END  were also evident in distal levels of the peripheral nerves of chickens given TOTP or ENT2 DFP ENT2END
0	Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20% of values measured in chickens not given ENT1 organophosphorous  ENT1END  compounds. Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase. ENT2 Degenerating myelinated fibers ENT2END were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP
1	ENT1 Degenerating myelinated fibers ENT1END  were also evident in distal levels of the peripheral nerves of chickens given ENT2 TOTP ENT2END or DFP
0	He remained thirsty and ENT1 polyuric ENT1END despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and ENT2 vasopressin ENT2END secretion, with clear evidence of nephrogenic diabetes insipidus
1	He remained thirsty and ENT1 polyuric ENT1END  despite cessation of ENT2 lithium ENT2END and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of nephrogenic diabetes insipidus
0	We report the case of a patient who developed severe hypernatraemic dehydration following a ENT1 head injury  ENT1END  Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued. He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and ENT2 vasopressin ENT2END secretion, with clear evidence of nephrogenic diabetes insipidus
0	We report the case of a patient who developed severe hypernatraemic dehydration following a ENT1 head injury ENT1END . Ten years previously he had been diagnosed to have ENT2 lithium ENT2END -induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued
0	We report the case of a patient who developed severe hypernatraemic ENT1 dehydration  ENT1END following a head injury. Ten years previously he had been diagnosed to have lithium-induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued. He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and ENT2 vasopressin ENT2END secretion, with clear evidence of nephrogenic diabetes insipidus
0	We report the case of a patient who developed severe hypernatraemic ENT1 dehydration  ENT1END  following a head injury. Ten years previously he had been diagnosed to have ENT2 lithium ENT2END -induced nephrogenic diabetes insipidus, and lithium therapy had been discontinued
0	He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and ENT1 vasopressin ENT1END  secretion, with clear evidence of ENT2 nephrogenic diabetes insipidus ENT2END
1	He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion, with clear evidence of ENT1 nephrogenic diabetes insipidus ENT1END . ENT2 Lithium ENT2END induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped
1	ENT1 Simvastatin  ENT1END -induced bilateral leg ENT2 compartment syndrome ENT2END and myonecrosis associated with hypothyroidism
0	A 54-year-old hypothyroid male taking ENT1 thyroxine ENT1END and simvastatin presented with bilateral leg ENT2 compartment syndrome ENT2END and myonecrosis
0	ENT1 Simvastatin  ENT1END -induced bilateral leg compartment syndrome and ENT2 myonecrosis ENT2END associated with hypothyroidism
0	Simvastatin-induced bilateral leg compartment syndrome and ENT1 myonecrosis  ENT1END  associated with hypothyroidism.A 54-year-old hypothyroid male taking ENT2 thyroxine ENT2END and simvastatin presented with bilateral leg compartment syndrome and myonecrosis
0	A 54-year-old ENT1 hypothyroid ENT1END male taking thyroxine and ENT2 simvastatin ENT2END presented with bilateral leg compartment syndrome and myonecrosis
0	A 54-year-old ENT1 hypothyroid  ENT1END  male taking ENT2 thyroxine ENT2END and simvastatin presented with bilateral leg compartment syndrome and myonecrosis
0	Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of ENT1 simvastatin ENT1END  It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all ENT2 arteriopathic ENT2END patients
0	A 54-year-old hypothyroid male taking ENT1 thyroxine  ENT1END  and simvastatin presented with bilateral leg compartment syndrome and myonecrosis. Urgent fasciotomies were performed and the patient made an uneventful recovery with the withdrawal of simvastatin. It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all ENT2 arteriopathic ENT2END patients
0	The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual-perfusion technique and with ENT1 thallium ENT1END 201 single-photon emission tomography (SPECT). During a transient (20-s) ENT2 coronary occlusion ENT2END , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced
0	During a transient (20-s) ENT1 coronary occlusion ENT1END , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced. The perfusion defect correlated significantly with the anatomic area at risk (r = 0.74; p less than 0.002). During ENT2 dipyridamole ENT2END -induced hyperemia, 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography
0	Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of ENT1 coronary stenosis  ENT1END : correlation with ENT2 thallium ENT2END -201 single-photon emission tomography
0	During ENT1 dipyridamole ENT1END -induced hyperemia, 12 of the 16 dogs with a partial ENT2 coronary stenosis ENT2END had a visible area of hypoperfusion by contrast echocardiography
0	ENT1 Thallium ENT1END 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole-induced ENT2 hyperemia ENT2END ; the size of the perfusion defect correlated with the anatomic area at risk (r = 0
1	During ENT1 dipyridamole ENT1END -induced ENT2 hyperemia ENT2END , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography
1	In three patients, ENT1 LTG ENT1END exacerbated ENT2 MJ ENT2END in a dose-dependent manner with early aggravation during titration
0	Five patients with idiopathic generalized epilepsies ( ENT1 IGE ENT1END  treated with ENT2 lamotrigine ENT2END (LTG) experienced exacerbation or de novo appearance of myoclonic jerks (MJ)
0	We studied a patient with no prior history of neuromuscular disease who became virtually ENT1 quadriplegic ENT1END after parenteral magnesium administration for preeclampsia. The serum magnesium concentration was 3.0 mEq/L, which is usually well tolerated. The magnesium was stopped and she recovered over a few days. While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade. After her strength returned, repetitive stimulation was normal, but single fiber EMG revealed increased jitter and blocking. Her ENT2 acetylcholine ENT2END receptor antibody level was markedly elevated
0	We studied a patient with no prior history of neuromuscular disease who became virtually ENT1 quadriplegic ENT1END  after parenteral ENT2 magnesium ENT2END administration for preeclampsia
0	We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for ENT1 preeclampsia  ENT1END  The serum magnesium concentration was 3.0 mEq/L, which is usually well tolerated. The magnesium was stopped and she recovered over a few days. While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting postsynaptic neuromuscular blockade. After her strength returned, repetitive stimulation was normal, but single fiber EMG revealed increased jitter and blocking. Her ENT2 acetylcholine ENT2END receptor antibody level was markedly elevated
0	We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for ENT1 preeclampsia ENT1END . The serum ENT2 magnesium ENT2END concentration was 3
0	Her ENT1 acetylcholine ENT1END  receptor antibody level was markedly elevated. Although paralysis after magnesium administration has been described in patients with known ENT2 myasthenia gravis ENT2END , it has not previously been reported to be the initial or only manifestation of the disease
1	ENT1 Myasthenia gravis  ENT1END  presenting as weakness after ENT2 magnesium ENT2END administration
0	Her ENT1 acetylcholine ENT1END  receptor antibody level was markedly elevated. Although paralysis after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease. Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying ENT2 disorder of neuromuscular transmission ENT2END
0	Patients who are unusually sensitive to the neuromuscular effects of ENT1 magnesium  ENT1END should be suspected of having an underlying ENT2 disorder of neuromuscular transmission ENT2END
0	While she was weak, 2-Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise, suggesting ENT1 postsynaptic neuromuscular blockade  ENT1END  After her strength returned, repetitive stimulation was normal, but single fiber EMG revealed increased jitter and blocking. Her ENT2 acetylcholine ENT2END receptor antibody level was markedly elevated
0	We studied a patient with no prior history of ENT1 neuromuscular disease  ENT1END who became virtually quadriplegic after parenteral ENT2 magnesium ENT2END administration for preeclampsia
0	Her ENT1 acetylcholine ENT1END  receptor antibody level was markedly elevated. Although ENT2 paralysis ENT2END after magnesium administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease
0	Although ENT1 paralysis ENT1END  after ENT2 magnesium ENT2END administration has been described in patients with known myasthenia gravis, it has not previously been reported to be the initial or only manifestation of the disease
0	CONCLUSION: The addition of ENT1 thalidomide ENT1END to docetaxel in the treatment of ENT2 prostate cancer ENT2END significantly increases the frequency of VTE
0	CONCLUSION: The addition of thalidomide to ENT1 docetaxel  ENT1END in the treatment of ENT2 prostate cancer ENT2END significantly increases the frequency of VTE
0	INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral ENT1 thalidomide ENT1END 200 mg every evening plus the same docetaxel regimen. This 4-week cycle was repeated until there was evidence of excessive ENT2 toxicity ENT2END or disease progression
0	INTERVENTION: Each patient received either intravenous docetaxel 30 mg/m2/week for 3 consecutive weeks, followed by 1 week off, or the combination of continuous oral thalidomide 200 mg every evening plus the same ENT1 docetaxel  ENT1END regimen. This 4-week cycle was repeated until there was evidence of excessive ENT2 toxicity ENT2END or disease progression
1	MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received docetaxel alone developed VTE, whereas 9 of 47 patients (19%) who received docetaxel plus ENT1 thalidomide ENT1END developed ENT2 VTE ENT2END (p=0
1	MEASUREMENTS AND MAIN RESULTS: None of 23 patients who received ENT1 docetaxel ENT1END alone developed ENT2 VTE ENT2END , whereas 9 of 47 patients (19%) who received docetaxel plus thalidomide developed VTE (p=0
1	The cumulative doses of ENT1 levobupivacaine ENT1END that produced ENT2 dysrhythmias ENT2END and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine
1	The cumulative doses of levobupivacaine that produced ENT1 dysrhythmias ENT1END  and asystole were smaller than the corresponding doses of ENT2 ropivacaine ENT2END , but they were larger than those of bupivacaine
0	The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of ENT1 bupivacaine  ENT1END  The cumulative doses of levobupivacaine that produced ENT2 dysrhythmias ENT2END and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine
0	The cumulative doses of levobupivacaine that produced ENT1 dysrhythmias ENT1END  and asystole were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine. The number of successful resuscitations did not differ among groups. However, a smaller dose of ENT2 epinephrine ENT2END was required in the Ropivacaine group than in the other groups
1	The cumulative doses of ENT1 levobupivacaine ENT1END and ropivacaine that produced ENT2 seizures ENT2END were similar and were larger than those of bupivacaine
1	The cumulative doses of levobupivacaine and ENT1 ropivacaine  ENT1END that produced ENT2 seizures ENT2END were similar and were larger than those of bupivacaine
0	The cumulative doses of levobupivacaine and ropivacaine that produced ENT1 seizures  ENT1END  were similar and were larger than those of ENT2 bupivacaine ENT2END
0	ENT1 Epinephrine  ENT1END 0.01 mg/kg was administered at 1-min intervals while external cardiac compressions were applied. Resuscitation was considered successful when a systolic arterial pressure > or =100 mm Hg was achieved within 5 min. The cumulative doses of levobupivacaine and ropivacaine that produced ENT2 seizures ENT2END were similar and were larger than those of bupivacaine
0	We conclude that the systemic ENT1 toxicity ENT1END of ENT2 levobupivacaine ENT2END is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine
0	We compared the systemic ENT1 toxicity ENT1END of bupivacaine, levobupivacaine, and ENT2 ropivacaine ENT2END in anesthetized rats
0	We compared the systemic ENT1 toxicity ENT1END  of ENT2 bupivacaine ENT2END , levobupivacaine, and ropivacaine in anesthetized rats
0	However, a smaller dose of ENT1 epinephrine  ENT1END  was required in the Ropivacaine group than in the other groups. We conclude that the systemic ENT2 toxicity ENT2END of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine-induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine
1	The cumulative doses of ENT1 levobupivacaine ENT1END  that produced dysrhythmias and ENT2 asystole ENT2END were smaller than the corresponding doses of ropivacaine, but they were larger than those of bupivacaine
1	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ENT1 ropivacaine ENT1END induced ENT2 cardiac arrest ENT2END appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine
0	We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and ENT1 bupivacaine  ENT1END when administered at the same rate and that ropivacaine-induced ENT2 cardiac arrest ENT2END appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine
0	When ENT1 asystole  ENT1END was recorded, drug infusion was stopped and a resuscitation sequence was begun. ENT2 Epinephrine ENT2END 0
0	Prolongation of the QT interval related to cisapride- ENT1 diltiazem ENT1END  interaction.Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of ENT2 gastrointestinal motility disorders ENT2END
0	Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of ENT1 gastrointestinal motility disorders ENT1END . Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or ENT2 azole ENT2END antifungal agents, but not with other CYP3A4 inhibitors
0	ENT1 Cisapride  ENT1END  a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of ENT2 gastrointestinal motility disorders ENT2END
0	Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of ENT1 gastrointestinal motility disorders ENT1END . Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with ENT2 erythromycin ENT2END or azole antifungal agents, but not with other CYP3A4 inhibitors
0	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and ENT1 diltiazem ENT1END  an agent that has inhibitory effect on CYP3A4, for ENT2 hypertension ENT2END
0	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or ENT1 azole  ENT1END  antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for ENT2 hypertension ENT2END
0	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for ENT1 hypertension ENT1END . The patient was in near syncope and had QT-interval prolongation. After discontinuing ENT2 cisapride ENT2END , the QT interval returned to normal and symptoms did not recur
0	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with ENT1 erythromycin  ENT1END  or azole antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for ENT2 hypertension ENT2END
1	ENT1 Prolongation of the QT interval  ENT1END  related to cisapride ENT2 diltiazem ENT2END interaction
1	ENT1 Prolongation of QT interval  ENT1END  torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or ENT2 azole ENT2END antifungal agents, but not with other CYP3A4 inhibitors
1	ENT1 Prolongation of the QT interval  ENT1END  related to ENT2 cisapride ENT2END -diltiazem interaction
1	ENT1 Prolongation of QT interval  ENT1END , torsades de pointes, and sudden cardiac death have been reported after concomitant administration with ENT2 erythromycin ENT2END or azole antifungal agents, but not with other CYP3A4 inhibitors
0	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and ENT1 diltiazem ENT1END , an agent that has inhibitory effect on CYP3A4, for hypertension. The patient was in near ENT2 syncope ENT2END and had QT-interval prolongation
0	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or ENT1 azole  ENT1END  antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension. The patient was in near ENT2 syncope ENT2END and had QT-interval prolongation
0	The patient was in near ENT1 syncope  ENT1END  and had QT-interval prolongation. After discontinuing ENT2 cisapride ENT2END , the QT interval returned to normal and symptoms did not recur
0	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with ENT1 erythromycin  ENT1END  or azole antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension. The patient was in near ENT2 syncope ENT2END and had QT-interval prolongation
0	Prolongation of the QT interval related to cisapride- ENT1 diltiazem ENT1END  interaction.Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders. Prolongation of QT interval, torsades de pointes, and ENT2 sudden cardiac death ENT2END have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors
1	Prolongation of QT interval, torsades de pointes, and ENT1 sudden cardiac death  ENT1END  have been reported after concomitant administration with erythromycin or ENT2 azole ENT2END antifungal agents, but not with other CYP3A4 inhibitors
1	ENT1 Cisapride  ENT1END , a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders. Prolongation of QT interval, torsades de pointes, and ENT2 sudden cardiac death ENT2END have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors
1	Prolongation of QT interval, torsades de pointes, and ENT1 sudden cardiac death  ENT1END  have been reported after concomitant administration with ENT2 erythromycin ENT2END or azole antifungal agents, but not with other CYP3A4 inhibitors
0	A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for ENT1 gastroesophageal reflux disorder  ENT1END and ENT2 diltiazem ENT2END , an agent that has inhibitory effect on CYP3A4, for hypertension
0	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with erythromycin or ENT1 azole  ENT1END  antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for ENT2 gastroesophageal reflux disorder ENT2END and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension
0	A possible drug interaction occurred in a 45-year-old woman who was taking ENT1 cisapride  ENT1END for ENT2 gastroesophageal reflux disorder ENT2END and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension
0	Prolongation of QT interval, torsades de pointes, and sudden cardiac death have been reported after concomitant administration with ENT1 erythromycin  ENT1END  or azole antifungal agents, but not with other CYP3A4 inhibitors. A possible drug interaction occurred in a 45-year-old woman who was taking cisapride for ENT2 gastroesophageal reflux disorder ENT2END and diltiazem, an agent that has inhibitory effect on CYP3A4, for hypertension
0	Prolongation of the QT interval related to cisapride- ENT1 diltiazem ENT1END  interaction.Cisapride, a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders. Prolongation of QT interval, ENT2 torsades de pointes ENT2END , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors
1	Prolongation of QT interval, ENT1 torsades de pointes  ENT1END , and sudden cardiac death have been reported after concomitant administration with erythromycin or ENT2 azole ENT2END antifungal agents, but not with other CYP3A4 inhibitors
1	ENT1 Cisapride  ENT1END , a cytochrome P450 3A4 (CYP3A4) substrate, is widely prescribed for the treatment of gastrointestinal motility disorders. Prolongation of QT interval, ENT2 torsades de pointes ENT2END , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents, but not with other CYP3A4 inhibitors
1	Prolongation of QT interval, ENT1 torsades de pointes  ENT1END , and sudden cardiac death have been reported after concomitant administration with ENT2 erythromycin ENT2END or azole antifungal agents, but not with other CYP3A4 inhibitors
0	RESULTS: 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary ENT1 metastases ENT1END (4%), one minor response, and 2 patients stable for over 6 months. Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level. Systemic plasma VEGF165 levels did not change with therapy. CONCLUSION: These results are consistent with a low level of activity of ENT2 thalidomide ENT2END in renal cell carcinoma
0	OBJECTIVES: To evaluate the ENT1 toxicity ENT1END and activity of ENT2 thalidomide ENT2END in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor, vascular endothelial growth factor (VEGF)165, with therapy
1	Somnolence and ENT1 constipation  ENT1END were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level. Systemic plasma VEGF165 levels did not change with therapy. CONCLUSION: These results are consistent with a low level of activity of ENT2 thalidomide ENT2END in renal cell carcinoma
0	CONCLUSION: These results are consistent with a low level of activity of ENT1 thalidomide ENT1END  in ENT2 renal cell carcinoma ENT2END
1	ENT1 Somnolence  ENT1END and constipation were prominent toxicities and most patients could not tolerate the 1200 mg/day dose level. Systemic plasma VEGF165 levels did not change with therapy. CONCLUSION: These results are consistent with a low level of activity of ENT2 thalidomide ENT2END in renal cell carcinoma
0	05) ENT1 increase in heart rate and cardiac output ENT1END  rebound hypertension was observed in three patients after discontinuation of nitroprusside. Labetalol administration was not associated with any of these findings. Arterial ENT2 PO2 ENT2END decreased in both groups
1	05) ENT1 increase in heart rate and cardiac output ENT1END ; rebound hypertension was observed in three patients after discontinuation of ENT2 nitroprusside ENT2END
0	05) ENT1 increase in heart rate and cardiac output ENT1END ; rebound hypertension was observed in three patients after discontinuation of nitroprusside. ENT2 Labetalol ENT2END administration was not associated with any of these findings
0	05) increase in heart rate and cardiac output; rebound ENT1 hypertension  ENT1END was observed in three patients after discontinuation of nitroprusside. Labetalol administration was not associated with any of these findings. Arterial ENT2 PO2 ENT2END decreased in both groups
0	05) increase in heart rate and cardiac output; rebound ENT1 hypertension  ENT1END  was observed in three patients after discontinuation of ENT2 nitroprusside ENT2END
0	05) increase in heart rate and cardiac output; rebound ENT1 hypertension  ENT1END  was observed in three patients after discontinuation of nitroprusside. ENT2 Labetalol ENT2END administration was not associated with any of these findings
0	Each patient was subjected to an identical anesthetic protocol and similar drug-induced ENT1 reductions in mean arterial blood pressure  ENT1END (BP) (50 to 55 mmHg). Nitroprusside infusion was associated with a significant (p less than 0.05) increase in heart rate and cardiac output; rebound hypertension was observed in three patients after discontinuation of nitroprusside. Labetalol administration was not associated with any of these findings. Arterial ENT2 PO2 ENT2END decreased in both groups
1	In a randomized study, labetalol-induced ENT1 hypotension ENT1END and ENT2 nitroprusside ENT2END -induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures
1	In a randomized study, ENT1 labetalol  ENT1END induced ENT2 hypotension ENT2END and nitroprusside-induced hypotension were compared in 20 patients (10 in each group) scheduled for major orthopedic procedures
0	The present study was done to investigate the protective effect of TCR on experimentally induced ENT1 myocardial infarction ENT1END in rats. Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h). TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ENT2 ADP ENT2END -stimulated oxygen uptake and respiratory coupling ratio
1	Cardioprotective effect of tincture of Crataegus on ENT1 isoproterenol  ENT1END -induced ENT2 myocardial infarction ENT2END in rats
0	The present study was done to investigate the protective effect of TCR on experimentally induced ENT1 myocardial infarction ENT1END  in rats. Pretreatment of TCR, at a dose of 0.5 mL/100 g bodyweight per day, orally for 30 days, prevented the increase in lipid peroxidation and activity of marker enzymes observed in isoproterenol-induced rats (85 mg kg(-1) s. c. for 2 days at an interval of 24 h). TCR prevented the isoproterenol-induced decrease in antioxidant enzymes in the heart and increased the rate of ADP-stimulated ENT2 oxygen ENT2END uptake and respiratory coupling ratio
0	Cardioprotective effect of tincture of Crataegus on isoproterenol-induced ENT1 myocardial infarction  ENT1END  in rats. ENT2 Tincture of Crataegus ENT2END (TCR), an alcoholic extract of the berries of hawthorn (Crataegus oxycantha), is used in herbal and homeopathic medicine
1	ENT1 Antidepressant  ENT1END -induced ENT2 mania ENT2END in bipolar patients: identification of risk factors
0	In contrast, mood switches were less frequent in patients receiving lithium (15%, 4/26) than in patients not treated with ENT1 lithium ENT1END (44%, 8/18; p = .04). The number of previous ENT2 manic ENT2END episodes did not affect the probability of switching, whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching (p =
1	RESULTS: Switches to hypomania or mania occurred in 27% of all patients (N = 12) (and in 24% of the subgroup of patients treated with ENT1 SSRIs ENT1END [8/33]); 16% (N = 7) experienced ENT2 manic ENT2END episodes, and 11% (N = 5) experienced hypomanic episodes
1	This study describes neuropsychiatric side effects in patients after treatment with ENT1 mefloquine ENT1END  Reactions consisted mainly of seizures, acute psychoses, ENT2 anxiety neurosis ENT2END , and major disturbances of sleep-wake rhythm
1	This study describes neuropsychiatric side effects in patients after treatment with ENT1 mefloquine ENT1END . Reactions consisted mainly of seizures, acute psychoses, anxiety neurosis, and major ENT2 disturbances of sleep-wake rhythm ENT2END
1	This study describes neuropsychiatric side effects in patients after treatment with ENT1 mefloquine ENT1END . Reactions consisted mainly of ENT2 seizures ENT2END , acute psychoses, anxiety neurosis, and major disturbances of sleep-wake rhythm
1	This study describes neuropsychiatric side effects in patients after treatment with ENT1 mefloquine ENT1END . Reactions consisted mainly of seizures, acute ENT2 psychoses ENT2END , anxiety neurosis, and major disturbances of sleep-wake rhythm
0	Therefore, certain limitations for ENT1 malaria ENT1END prophylaxis and treatment with ENT2 mefloquine ENT2END are recommended
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT1 pain ENT1END  fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); ENT2 amiodarone ENT2END at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and ENT1 atazanavir  ENT1END resulting in rhabdomyolysis and acute renal failure. BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT2 pain ENT2END , fatigue, and dark orange urine for 3 days
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT1 pain ENT1END , fatigue, and dark orange urine for 3 days. The patient was taking 80 mg ENT2 simvastatin ENT2END at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT1 pain ENT1END , fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L ENT2 aspartate ENT2END aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT1 pain ENT1END , fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT2 blood urea nitrogen ENT2END , 4
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT1 pain ENT1END , fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT2 alanine ENT2END aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT1 pain ENT1END , fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL ENT2 creatinine ENT2END , 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized ENT1 pain ENT1END , fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L ENT2 creatine ENT2END kinase, 93 mg/dL blood urea nitrogen, 4
0	Simvastatin, ENT1 amiodarone ENT1END  and the patient's ENT2 human immunodeficiency virus ENT2END medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and ENT1 atazanavir ENT1END  resulting in rhabdomyolysis and acute renal failure. BACKGROUND: A 72-year-old white man with underlying ENT2 human immunodeficiency virus ENT2END , atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days
0	ENT1 Simvastatin  ENT1END  amiodarone, and the patient's ENT2 human immunodeficiency virus ENT2END medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis
0	6 mg/dL creatinine, 1579 U/L ENT1 aspartate  ENT1END  aminotransferase, and 738 U/L alanine aminotransferase. Simvastatin, amiodarone, and the patient's ENT2 human immunodeficiency virus ENT2END medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis
0	Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT1 blood urea nitrogen  ENT1END , 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase. Simvastatin, amiodarone, and the patient's ENT2 human immunodeficiency virus ENT2END medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis
0	6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT1 alanine  ENT1END  aminotransferase. Simvastatin, amiodarone, and the patient's ENT2 human immunodeficiency virus ENT2END medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis
0	6 mg/dL ENT1 creatinine  ENT1END , 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase. Simvastatin, amiodarone, and the patient's ENT2 human immunodeficiency virus ENT2END medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis
0	Simvastatin, amiodarone, and the patient's ENT1 human immunodeficiency virus ENT1END  medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis. Nine days later the patient's ENT2 creatine ENT2END kinase had dropped to 1695 U/L and creatinine was 3
1	OBJECTIVE: To report a case of a severe interaction between simvastatin, ENT1 amiodarone ENT1END  and atazanavir resulting in ENT2 rhabdomyolysis ENT2END and acute renal failure
1	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and ENT1 atazanavir  ENT1END  resulting in ENT2 rhabdomyolysis ENT2END and acute renal failure
1	OBJECTIVE: To report a case of a severe interaction between ENT1 simvastatin  ENT1END  amiodarone, and atazanavir resulting in ENT2 rhabdomyolysis ENT2END and acute renal failure
0	DISCUSSION: The risk of ENT1 rhabdomyolysis ENT1END is increased in the presence of concomitant drugs that inhibit simvastatin metabolism. Simvastatin is metabolized by CYP3A4. Amiodarone and atazanavir are recognized CYP3A4 inhibitors. CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions. In patients requiring the concurrent use of statins and CYP3A4 inhibitors, ENT2 pravastatin ENT2END , fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors
0	6 mg/dL creatinine, 1579 U/L ENT1 aspartate  ENT1END  aminotransferase, and 738 U/L alanine aminotransferase. Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis. Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered. DISCUSSION: The risk of ENT2 rhabdomyolysis ENT2END is increased in the presence of concomitant drugs that inhibit simvastatin metabolism
0	DISCUSSION: The risk of ENT1 rhabdomyolysis ENT1END  is increased in the presence of concomitant drugs that inhibit simvastatin metabolism. Simvastatin is metabolized by CYP3A4. Amiodarone and atazanavir are recognized CYP3A4 inhibitors. CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions. In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and ENT2 lovastatin ENT2END have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors
0	Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT1 blood urea nitrogen  ENT1END , 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase. Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis. Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered. DISCUSSION: The risk of ENT2 rhabdomyolysis ENT2END is increased in the presence of concomitant drugs that inhibit simvastatin metabolism
0	DISCUSSION: The risk of ENT1 rhabdomyolysis ENT1END  is increased in the presence of concomitant drugs that inhibit simvastatin metabolism. Simvastatin is metabolized by CYP3A4. Amiodarone and atazanavir are recognized CYP3A4 inhibitors. CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions. In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and rosuvastatin carry the lowest risk of drug interactions; ENT2 atorvastatin ENT2END carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors
0	DISCUSSION: The risk of ENT1 rhabdomyolysis ENT1END  is increased in the presence of concomitant drugs that inhibit simvastatin metabolism. Simvastatin is metabolized by CYP3A4. Amiodarone and atazanavir are recognized CYP3A4 inhibitors. CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions. In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, ENT2 fluvastatin ENT2END , and rosuvastatin carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors
0	6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT1 alanine  ENT1END  aminotransferase. Simvastatin, amiodarone, and the patient's human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis. Nine days later the patient's creatine kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered. DISCUSSION: The risk of ENT2 rhabdomyolysis ENT2END is increased in the presence of concomitant drugs that inhibit simvastatin metabolism
0	Nine days later the patient's creatine kinase had dropped to 1695 U/L and ENT1 creatinine  ENT1END was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered. DISCUSSION: The risk of ENT2 rhabdomyolysis ENT2END is increased in the presence of concomitant drugs that inhibit simvastatin metabolism
0	Nine days later the patient's ENT1 creatine  ENT1END  kinase had dropped to 1695 U/L and creatinine was 3.3 mg/dL. The patient was discharged and continued outpatient dialysis for 1 month until his renal function recovered. DISCUSSION: The risk of ENT2 rhabdomyolysis ENT2END is increased in the presence of concomitant drugs that inhibit simvastatin metabolism
0	DISCUSSION: The risk of ENT1 rhabdomyolysis ENT1END  is increased in the presence of concomitant drugs that inhibit simvastatin metabolism. Simvastatin is metabolized by CYP3A4. Amiodarone and atazanavir are recognized CYP3A4 inhibitors. CONCLUSIONS: Pharmacokinetic differences in statins are an important consideration for assessing the risk of potential drug interactions. In patients requiring the concurrent use of statins and CYP3A4 inhibitors, pravastatin, fluvastatin, and ENT2 rosuvastatin ENT2END carry the lowest risk of drug interactions; atorvastatin carries moderate risk, whereas simvastatin and lovastatin have the highest risk and should be avoided in patients taking concomitant CYP3A4 inhibitors
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT1 hyperlipidemia  ENT1END presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); ENT2 amiodarone ENT2END at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and ENT1 atazanavir  ENT1END  resulting in rhabdomyolysis and acute renal failure. BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT2 hyperlipidemia ENT2END presented with generalized pain, fatigue, and dark orange urine for 3 days
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT1 hyperlipidemia  ENT1END  presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg ENT2 simvastatin ENT2END at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT1 hyperlipidemia  ENT1END  presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L ENT2 aspartate ENT2END aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT1 hyperlipidemia  ENT1END  presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT2 blood urea nitrogen ENT2END , 4
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT1 hyperlipidemia  ENT1END  presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT2 alanine ENT2END aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT1 hyperlipidemia  ENT1END  presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL ENT2 creatinine ENT2END , 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and ENT1 hyperlipidemia  ENT1END  presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L ENT2 creatine ENT2END kinase, 93 mg/dL blood urea nitrogen, 4
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, ENT1 amiodarone ENT1END , and atazanavir resulting in rhabdomyolysis and acute renal failure. BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT2 atrial fibrillation ENT2END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and ENT1 atazanavir  ENT1END  resulting in rhabdomyolysis and acute renal failure. BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT2 atrial fibrillation ENT2END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT1 atrial fibrillation  ENT1END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg ENT2 simvastatin ENT2END at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT1 atrial fibrillation  ENT1END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L ENT2 aspartate ENT2END aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT1 atrial fibrillation  ENT1END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT2 blood urea nitrogen ENT2END , 4
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT1 atrial fibrillation  ENT1END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT2 alanine ENT2END aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT1 atrial fibrillation  ENT1END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL ENT2 creatinine ENT2END , 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, ENT1 atrial fibrillation  ENT1END , coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L ENT2 creatine ENT2END kinase, 93 mg/dL blood urea nitrogen, 4
1	Severe rhabdomyolysis and ENT1 acute renal failure  ENT1END  secondary to concomitant use of simvastatin, ENT2 amiodarone ENT2END , and atazanavir
1	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and ENT1 atazanavir ENT1END  resulting in rhabdomyolysis and ENT2 acute renal failure ENT2END
1	Severe rhabdomyolysis and ENT1 acute renal failure  ENT1END  secondary to concomitant use of ENT2 simvastatin ENT2END , amiodarone, and atazanavir
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and ENT1 acute renal failure  ENT1END . BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L ENT2 aspartate ENT2END aminotransferase, and 738 U/L alanine aminotransferase
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and ENT1 acute renal failure  ENT1END . BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT2 blood urea nitrogen ENT2END , 4
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and ENT1 acute renal failure  ENT1END . BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT2 alanine ENT2END aminotransferase
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and ENT1 acute renal failure  ENT1END . BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL ENT2 creatinine ENT2END , 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and atazanavir resulting in rhabdomyolysis and ENT1 acute renal failure  ENT1END . BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L ENT2 creatine ENT2END kinase, 93 mg/dL blood urea nitrogen, 4
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, ENT1 amiodarone ENT1END , and atazanavir resulting in rhabdomyolysis and acute renal failure. BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT2 coronary artery disease ENT2END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days
0	OBJECTIVE: To report a case of a severe interaction between simvastatin, amiodarone, and ENT1 atazanavir  ENT1END  resulting in rhabdomyolysis and acute renal failure. BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT2 coronary artery disease ENT2END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT1 coronary artery disease  ENT1END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg ENT2 simvastatin ENT2END at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT1 coronary artery disease  ENT1END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L ENT2 aspartate ENT2END aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT1 coronary artery disease  ENT1END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT2 blood urea nitrogen ENT2END , 4
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT1 coronary artery disease  ENT1END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT2 alanine ENT2END aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT1 coronary artery disease  ENT1END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL ENT2 creatinine ENT2END , 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, ENT1 coronary artery disease  ENT1END , and hyperlipidemia presented with generalized pain, fatigue, and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L ENT2 creatine ENT2END kinase, 93 mg/dL blood urea nitrogen, 4
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue  ENT1END  and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); ENT2 amiodarone ENT2END at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue ENT1END , and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg ENT2 atazanavir ENT2END daily (initiated at least 2 years previously)
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue  ENT1END , and dark orange urine for 3 days. The patient was taking 80 mg ENT2 simvastatin ENT2END at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously)
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue  ENT1END , and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L ENT2 aspartate ENT2END aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue  ENT1END , and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL ENT2 blood urea nitrogen ENT2END , 4
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue  ENT1END , and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL creatinine, 1579 U/L aspartate aminotransferase, and 738 U/L ENT2 alanine ENT2END aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue  ENT1END , and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L creatine kinase, 93 mg/dL blood urea nitrogen, 4.6 mg/dL ENT2 creatinine ENT2END , 1579 U/L aspartate aminotransferase, and 738 U/L alanine aminotransferase
0	BACKGROUND: A 72-year-old white man with underlying human immunodeficiency virus, atrial fibrillation, coronary artery disease, and hyperlipidemia presented with generalized pain, ENT1 fatigue  ENT1END , and dark orange urine for 3 days. The patient was taking 80 mg simvastatin at bedtime (initiated 27 days earlier); amiodarone at a dose of 400 mg daily for 7 days, then 200 mg daily (initiated 19 days earlier); and 400 mg atazanavir daily (initiated at least 2 years previously). Laboratory evaluation revealed 66,680 U/L ENT2 creatine ENT2END kinase, 93 mg/dL blood urea nitrogen, 4
1	Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 ENT1 neurotoxicity ENT1END  Three patients with severe neutropenia (6%) died of sepsis. The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of ENT2 GEM ENT2END and VNB is moderately active and well tolerated except in patients age >/= 75 years
1	Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 thrombocytopenia, and 2 patients (4%) had Grade 3 ENT1 neurotoxicity ENT1END . Three patients with severe neutropenia (6%) died of sepsis. The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of GEM and ENT2 VNB ENT2END is moderately active and well tolerated except in patients age >/= 75 years
0	Three patients with severe neutropenia (6%) died of ENT1 sepsis  ENT1END  The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of ENT2 GEM ENT2END and VNB is moderately active and well tolerated except in patients age >/= 75 years
0	Three patients with severe neutropenia (6%) died of ENT1 sepsis  ENT1END . The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of GEM and ENT2 VNB ENT2END is moderately active and well tolerated except in patients age >/= 75 years
1	Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 ENT1 thrombocytopenia  ENT1END  and 2 patients (4%) had Grade 3 neurotoxicity. Three patients with severe neutropenia (6%) died of sepsis. The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of ENT2 GEM ENT2END and VNB is moderately active and well tolerated except in patients age >/= 75 years
1	Six patients (12%) had World Health Organization Grade 3-4 neutropenia, 2 patients (4%) had Grade 3-4 ENT1 thrombocytopenia  ENT1END , and 2 patients (4%) had Grade 3 neurotoxicity. Three patients with severe neutropenia (6%) died of sepsis. The median age of those patients developing Grade 3-4 neutropenia was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of GEM and ENT2 VNB ENT2END is moderately active and well tolerated except in patients age >/= 75 years
0	In the current study the efficacy and ENT1 toxicity ENT1END of the combination of ENT2 GEM ENT2END and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed
0	All patients were evaluable for response and ENT1 toxicity ENT1END  Treatment was comprised of ENT2 VNB ENT2END , 25 mg/m(2), plus GEM, 1000 mg/m(2), both on Days 1, 8, and 15 every 28 days
0	METHODS: Forty-nine patients with advanced NSCLC were included, 38 of whom were age >/= 70 years and 11 were age < 70 years but who had some contraindication to receiving ENT1 cisplatin  ENT1END  All patients were evaluable for response and ENT2 toxicity ENT2END
0	ENT1 Gemcitabine  ENT1END  plus vinorelbine in ENT2 nonsmall cell lung carcinoma ENT2END patients age 70 years or older or patients who cannot receive cisplatin
0	Gemcitabine plus ENT1 vinorelbine  ENT1END  in ENT2 nonsmall cell lung carcinoma ENT2END patients age 70 years or older or patients who cannot receive cisplatin
0	In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced ENT1 NSCLC ENT1END or those with some contraindication to receiving ENT2 cisplatin ENT2END were assessed
0	CONCLUSIONS: The combination of ENT1 GEM ENT1END  and VNB is moderately active and well tolerated except in patients age >/= 75 years. This age group had an increased risk of ENT2 myelosuppression ENT2END
0	CONCLUSIONS: The combination of GEM and ENT1 VNB  ENT1END  is moderately active and well tolerated except in patients age >/= 75 years. This age group had an increased risk of ENT2 myelosuppression ENT2END
1	The median age of those patients developing Grade 3-4 ENT1 neutropenia  ENT1END was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of ENT2 GEM ENT2END and VNB is moderately active and well tolerated except in patients age >/= 75 years
1	The median age of those patients developing Grade 3-4 ENT1 neutropenia  ENT1END  was significantly higher than that of the remaining patients (75 years vs. 72 years; P = 0.047). CONCLUSIONS: The combination of GEM and ENT2 VNB ENT2END is moderately active and well tolerated except in patients age >/= 75 years
0	Our present study indicated the possible value of ENT1 MK-212 ENT1END and (-)-baclofen in the management of clinical ENT2 myoclonus ENT2END
0	3 mg/kg) was found to be several fold more potent than ENT1 diazepam ENT1END (0.3-3 mg/kg) in blocking the ENT2 myoclonic jerks ENT2END
0	In male Swiss mice, muscimol produced ENT1 myoclonic jerks ENT1END  A 3 mg/kg (i.p.) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min. Increasing the brain ENT2 serotonin ENT2END levels by the administration of 5-hydroxytryptophan (80-160 mg/kg) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect
0	3-3 mg/kg) in blocking the ENT1 myoclonic jerks  ENT1END . While (-)- ENT2 baclofen ENT2END (1-3 mg/kg) proved to be an effective antagonist of muscimol, its (+)-isomer (5-20 mg/kg) lacked this property
0	Considering the fact that ENT1 5-HTP ENT1END and the benzodiazepines have been found to be beneficial in the management of clinical ENT2 myoclonus ENT2END , the muscimol-induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition
1	Considering the fact that 5-HTP and the benzodiazepines have been found to be beneficial in the management of clinical ENT1 myoclonus ENT1END , the ENT2 muscimol ENT2END -induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition
0	Of the benzodiazepines, ENT1 clonazepam  ENT1END (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the ENT2 myoclonic jerks ENT2END
0	Serotonergic drugs, ENT1 benzodiazepines  ENT1END  and baclofen block muscimol-induced ENT2 myoclonic jerks ENT2END in a strain of mice
0	However, in a similar experiment ENT1 l-dopa  ENT1END (80-160 mg/kg) was without effect. In doses of 3-10 mg/kg, the serotonin receptor agonist MK-212 caused a dose-dependent blockade of the response of muscimol. Of the benzodiazepines, clonazepam (0.1-0.3 mg/kg) was found to be several fold more potent than diazepam (0.3-3 mg/kg) in blocking the ENT2 myoclonic jerks ENT2END
0	It was shown that ENT1 memory dissociation ENT1END occurred in both groups. Differences in the parameters of training under the influence of ENT2 pentobarbital ENT2END between Groups 1 and 2 were revealed
1	Learning of rats under ENT1 amnesia  ENT1END  caused by ENT2 pentobarbital ENT2END
0	Two patients with ENT1 type II diabetes mellitus ENT1END developed an acute hepatitis-like syndrome soon after initiation of ENT2 glyburide ENT2END therapy
0	For glyburide, a second-generation ENT1 sulfonylurea  ENT1END  only two brief reports of hepatotoxicity exist. Two patients with ENT2 type II diabetes mellitus ENT2END developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy
1	ENT1 Glyburide  ENT1END -induced ENT2 hepatitis ENT2END
0	For glyburide, a second-generation ENT1 sulfonylurea ENT1END , only two brief reports of ENT2 hepatotoxicity ENT2END exist
0	Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of ENT1 glyburide ENT1END  therapy. There was no serologic evidence of ENT2 viral infection ENT2END , and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis
0	For glyburide, a second-generation ENT1 sulfonylurea  ENT1END , only two brief reports of hepatotoxicity exist. Two patients with type II diabetes mellitus developed an acute hepatitis-like syndrome soon after initiation of glyburide therapy. There was no serologic evidence of ENT2 viral infection ENT2END , and a liver biopsy sample showed a histologic pattern consistent with drug-induced hepatitis
0	In the study presented here, we investigated the use of dexamethasone in combination with ENT1 mesna ENT1END for the prevention of IFS-induced ENT2 HC ENT2END
0	However, the replacement of last two doses of mesna with saline or all of the mesna doses with ENT1 dexamethasone ENT1END did not prevent ENT2 HC ENT2END
1	In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of ENT1 IFS  ENT1END induced ENT2 HC ENT2END
0	One, two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus ENT1 mesna ENT1END  ENT2 Cystitis ENT2END was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis
0	One, two or three doses of mesna were replaced with dexamethasone alone or with ENT1 dexamethasone  ENT1END plus mesna. ENT2 Cystitis ENT2END was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis
1	In the study presented here, we investigated the use of dexamethasone in combination with mesna for the prevention of ENT1 IFS ENT1END -induced ENT2 HC ENT2END
0	After recovery from ENT1 hypertension ENT1END  the activity of (Na,K)-ATPase increased, due to higher affinity of the ENT2 ATP ENT2END -binding site, as revealed from the lowered Km value for ATP
0	After recovery from ENT1 hypertension  ENT1END , the activity of (Na, ENT2 K ENT2END )-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP
0	To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to NO-deficient ENT1 hypertension ENT1END induced in rats by NO-synthase inhibition with 40 mg/kg/day ENT2 N(G)-nitro-L-arginine methyl ester ENT2END (L-NAME) for 4 four weeks
1	To assess the molecular basis of disturbances in transmembraneous transport of Na+, we studied the response of cardiac (Na,K)-ATPase to ENT1 NO  ENT1END deficient ENT2 hypertension ENT2END induced in rats by NO-synthase inhibition with 40 mg/kg/day N(G)-nitro-L-arginine methyl ester (L-NAME) for 4 four weeks
0	After recovery from ENT1 hypertension  ENT1END , the activity of ( ENT2 Na ENT2END ,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ATP
0	After recovery from hypertension, the activity of (Na,K)-ATPase increased, due to higher affinity of the ATP-binding site, as revealed from the lowered Km value for ENT1 ATP ENT1END  The K(Na) value for Na+ returned to control value. Inhibition of NO-synthase induced a reversible hypertension accompanied by ENT2 depressed ENT2END Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase
0	Inhibition of NO-synthase induced a reversible hypertension accompanied by ENT1 depressed  ENT1END  Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na, ENT2 K ENT2END )-ATPase
0	Inhibition of ENT1 NO  ENT1END synthase induced a reversible hypertension accompanied by ENT2 depressed ENT2END Na+-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase
0	Inhibition of NO-synthase induced a reversible hypertension accompanied by ENT1 depressed ENT1END  ENT2 Na ENT2END +-extrusion from cardiac cells as a consequence of deteriorated Na+-binding properties of the (Na,K)-ATPase
1	We hypothesized that ENT1 propofol ENT1END infusion ENT2 pain ENT2END might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target-controlled infusions (TCI) of both drugs were used
0	Reduction of pain during induction with target-controlled propofol and ENT1 remifentanil ENT1END .BACKGROUND: ENT2 Pain ENT2END on injection of propofol is unpleasant
0	Intracavernous ENT1 epinephrine  ENT1END : a minimally invasive treatment for ENT2 priapism ENT2END in the emergency department
1	A 45-year-old man, an admitted frequent cocaine user, presented to the Emergency Department (ED) on two separate occasions with a history of ENT1 priapism ENT1END after ENT2 cocaine ENT2END use
0	METHODS: The changes in ENT1 pain ENT1END thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto. RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia. Pretreatment with L-NOArg and L-NIL but not 7-NI, significantly increases antihyperalgesic activity both HOE 140 and des Arg10 HOE 140. It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by ENT2 vincristine ENT2END
0	METHODS: The changes in ENT1 pain ENT1END  thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto. RESULTS: The results of this paper confirm that inhibition of bradykinin receptors and inducible ENT2 NO ENT2END synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia
0	1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin ( ENT1 HOE 140  ENT1END  70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated. METHODS: The changes in ENT2 pain ENT2END thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto
0	1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or ENT1 des Arg10 HOE 140  ENT1END (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated. METHODS: The changes in ENT2 pain ENT2END thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto
0	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and ENT1 streptozotocin  ENT1END  induced hyperalgesia in chemotherapy and diabetic neuropathy rat model.PURPOSE: The influence of an irreversible inhibitor of constitutive NO synthase (L-NOArg; 1.0 mg/kg ip), a relatively selective inhibitor of inducible NO synthase (L-NIL; 1.0 mg/kg ip) and a relatively specific inhibitor of neuronal NO synthase (7-NI; 0.1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy was investigated. METHODS: The changes in ENT2 pain ENT2END thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto
0	METHODS: The changes in ENT1 pain ENT1END  thresholds were determined using mechanical stimuli--the modification of the classic paw withdrawal test described by Randall-Selitto. RESULTS: The results of this paper confirm that inhibition of ENT2 bradykinin ENT2END receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia
1	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by ENT1 vincristine ENT1END . Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or des-Arg10HOE 140 in ENT2 toxic neuropathy ENT2END
0	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both ENT1 diabetic and toxic neuropathy ENT1END  In streptozotocin-induced hyperalgesia, inducible ENT2 NO ENT2END synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway
0	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of ENT1 HOE 140  ENT1END or des-Arg10HOE 140 in ENT2 toxic neuropathy ENT2END
0	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or ENT1 des-Arg10HOE 140  ENT1END in ENT2 toxic neuropathy ENT2END
0	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both ENT1 diabetic and toxic neuropathy ENT1END . In ENT2 streptozotocin ENT2END -induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway
0	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both ENT1 diabetic and toxic neuropathy ENT1END . In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of ENT2 bradykinin ENT2END , whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway
0	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in ENT1 vincristine  ENT1END  and streptozotocin induced hyperalgesia in chemotherapy and ENT2 diabetic neuropathy ENT2END rat model
0	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both ENT1 diabetic and toxic neuropathy  ENT1END  In streptozotocin-induced hyperalgesia, inducible ENT2 NO ENT2END synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway
0	1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin ( ENT1 HOE 140 ENT1END ; 70 nmol/kg ip) or des Arg10 HOE 140 (70 nmol/kg ip) respectively, in model of ENT2 diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy ENT2END was investigated
0	1 mg/kg ip), on antihyperalgesic action of selective antagonists of B2 and B1 receptors: D-Arg-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin (HOE 140; 70 nmol/kg ip) or ENT1 des Arg10 HOE 140  ENT1END  (70 nmol/kg ip) respectively, in model of ENT2 diabetic (streptozotocin-induced) and toxic (vincristine-induced) neuropathy ENT2END was investigated
1	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both ENT1 diabetic and toxic neuropathy  ENT1END . In ENT2 streptozotocin ENT2END -induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway
0	CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both ENT1 diabetic and toxic neuropathy  ENT1END . In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of ENT2 bradykinin ENT2END , whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway
1	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in ENT1 vincristine ENT1END induced ENT2 hyperalgesia ENT2END bradykinin seemed to activate neuronal NO synthase pathway
0	In streptozotocin-induced ENT1 hyperalgesia  ENT1END  inducible ENT2 NO ENT2END synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway
0	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in ENT1 hyperalgesia  ENT1END produced by vincristine. Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of ENT2 HOE 140 ENT2END or des-Arg10HOE 140 in toxic neuropathy
0	It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in ENT1 hyperalgesia  ENT1END  produced by vincristine. Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or ENT2 des-Arg10HOE 140 ENT2END in toxic neuropathy
1	Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and ENT1 streptozotocin  ENT1END  induced ENT2 hyperalgesia ENT2END in chemotherapy and diabetic neuropathy rat model
0	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced ENT1 hyperalgesia ENT1END  ENT2 bradykinin ENT2END seemed to activate neuronal NO synthase pathway
0	In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in ENT1 vincristine ENT1END -induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway. Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of ENT2 neuropathic pain ENT2END , even in hospital care
0	Therefore, concomitant administration of small doses of bradykinin receptor antagonists and ENT1 NO  ENT1END synthase inhibitors can be effective in alleviation of ENT2 neuropathic pain ENT2END , even in hospital care
0	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of ENT1 HOE 140  ENT1END  or des-Arg10HOE 140 in toxic neuropathy. CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy. In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway. Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of ENT2 neuropathic pain ENT2END , even in hospital care
0	Moreover, L-NOArg and 7-NI but not L-NIL intensify antihyperalgesic activity of HOE 140 or ENT1 des-Arg10HOE 140  ENT1END  in toxic neuropathy. CONCLUSIONS: Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy. In streptozotocin-induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway. Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of ENT2 neuropathic pain ENT2END , even in hospital care
0	In ENT1 streptozotocin  ENT1END -induced hyperalgesia, inducible NO synthase participates in pronociceptive activity of bradykinin, whereas in vincristine-induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway. Therefore, concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of ENT2 neuropathic pain ENT2END , even in hospital care
0	Therefore, concomitant administration of small doses of ENT1 bradykinin  ENT1END receptor antagonists and NO synthase inhibitors can be effective in alleviation of ENT2 neuropathic pain ENT2END , even in hospital care
1	The girl died seven days, the man four weeks after intrathecal injection of ENT1 vincristine ENT1END  Clinically, the onset was characterized by the signs of ENT2 opistothonus, sensory and motor dysfunction ENT2END and ascending paralysis
1	Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed ENT1 degeneration of myelin and axons ENT1END as well as pseudocystic transformation in areas exposed to ENT2 vincristine ENT2END , accompanied by secondary changes with numerous prominent macrophages
0	We report on two fatal cases of accidental intrathecal ENT1 vincristine ENT1END instillation in a 5-year old girl with recurrent ENT2 acute lymphoblastic leucemia ENT2END and a 57-year old man with lymphoblastic lymphoma
0	Fatal ENT1 myeloencephalopathy  ENT1END  due to accidental intrathecal ENT2 vincristin ENT2END administration: a report of two cases
1	Histological and immunohistochemical investigations (HE-LFB, CD-68, Neurofilament) revealed ENT1 degeneration of myelin and axons  ENT1END as well as pseudocystic transformation in areas exposed to ENT2 vincristine ENT2END , accompanied by secondary changes with numerous prominent macrophages
0	The girl died seven days, the man four weeks after intrathecal injection of ENT1 vincristine ENT1END . Clinically, the onset was characterized by the signs of opistothonus, sensory and motor dysfunction and ascending ENT2 paralysis ENT2END
0	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and ENT1 bupivacaine ENT1END  CLINICAL FEATURES: A 50-year-old woman with ENT2 low back and right leg pain ENT2END was scheduled for epidural steroid injection
0	CLINICAL FEATURES: A 50-year-old woman with ENT1 low back and right leg pain ENT1END  was scheduled for epidural ENT2 steroid ENT2END injection
0	CLINICAL FEATURES: A 50-year-old woman with ENT1 low back and right leg pain ENT1END  was scheduled for epidural steroid injection. INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level. Spread of the contrast medium within the epidural space was determined by radiographic imaging. After verifying the epidural space, bupivacaine and ENT2 triamcinolone diacetate ENT2END were injected
0	The following case is a report of cauda equina syndrome possibly caused by epidural injection of ENT1 triamcinolone  ENT1END and bupivacaine. CLINICAL FEATURES: A 50-year-old woman with ENT2 low back and right leg pain ENT2END was scheduled for epidural steroid injection
0	OBJECTIVE: Conventional treatment methods of lumbusacral ENT1 radiculopathy  ENT1END are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy. Cauda equina syndrome is a rare complication of epidural anesthesia. The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and ENT2 bupivacaine ENT2END
0	OBJECTIVE: Conventional treatment methods of lumbusacral ENT1 radiculopathy ENT1END  are physical therapy, epidural ENT2 steroid ENT2END injections, oral medications, and spinal manipulative therapy
0	OBJECTIVE: Conventional treatment methods of lumbusacral ENT1 radiculopathy  ENT1END  are physical therapy, epidural steroid injections, oral medications, and spinal manipulative therapy. Cauda equina syndrome is a rare complication of epidural anesthesia. The following case is a report of cauda equina syndrome possibly caused by epidural injection of ENT2 triamcinolone ENT2END and bupivacaine
1	The following case is a report of ENT1 cauda equina syndrome  ENT1END possibly caused by epidural injection of triamcinolone and ENT2 bupivacaine ENT2END
0	ENT1 Cauda equina syndrome  ENT1END  after epidural ENT2 steroid ENT2END injection: a case report
1	The following case is a report of ENT1 cauda equina syndrome  ENT1END  possibly caused by epidural injection of triamcinolone and bupivacaine. CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural steroid injection. INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level. Spread of the contrast medium within the epidural space was determined by radiographic imaging. After verifying the epidural space, bupivacaine and ENT2 triamcinolone diacetate ENT2END were injected
0	The following case is a report of ENT1 cauda equina syndrome  ENT1END  possibly caused by epidural injection of ENT2 triamcinolone ENT2END and bupivacaine
0	After verifying the epidural space, ENT1 bupivacaine ENT1END and triamcinolone diacetate were injected. After the injection, there was a reduction in radicular symptoms. Three hours later, she complained of perineal ENT2 numbness ENT2END and lower extremity weakness
0	CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural ENT1 steroid  ENT1END  injection. INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level. Spread of the contrast medium within the epidural space was determined by radiographic imaging. After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected. After the injection, there was a reduction in radicular symptoms. Three hours later, she complained of perineal ENT2 numbness ENT2END and lower extremity weakness
0	After verifying the epidural space, bupivacaine and ENT1 triamcinolone diacetate  ENT1END  were injected. After the injection, there was a reduction in radicular symptoms. Three hours later, she complained of perineal ENT2 numbness ENT2END and lower extremity weakness
0	Clinical examination and continued vigilance for ENT1 neurologic deterioration ENT1END after epidural ENT2 steroid ENT2END injections is important
0	After verifying the epidural space, ENT1 bupivacaine ENT1END  and triamcinolone diacetate were injected. After the injection, there was a reduction in radicular symptoms. Three hours later, she complained of perineal numbness and ENT2 lower extremity weakness ENT2END
0	CLINICAL FEATURES: A 50-year-old woman with low back and right leg pain was scheduled for epidural ENT1 steroid  ENT1END  injection. INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level. Spread of the contrast medium within the epidural space was determined by radiographic imaging. After verifying the epidural space, bupivacaine and triamcinolone diacetate were injected. After the injection, there was a reduction in radicular symptoms. Three hours later, she complained of perineal numbness and ENT2 lower extremity weakness ENT2END
0	After verifying the epidural space, bupivacaine and ENT1 triamcinolone diacetate  ENT1END  were injected. After the injection, there was a reduction in radicular symptoms. Three hours later, she complained of perineal numbness and ENT2 lower extremity weakness ENT2END
0	The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and ENT1 bupivacaine ENT1END . CLINICAL FEATURES: A 50-year-old woman with ENT2 low back and right leg pain ENT2END was scheduled for epidural steroid injection
0	CLINICAL FEATURES: A 50-year-old woman with ENT1 low back and right leg pain  ENT1END  was scheduled for epidural ENT2 steroid ENT2END injection
0	CLINICAL FEATURES: A 50-year-old woman with ENT1 low back and right leg pain  ENT1END  was scheduled for epidural steroid injection. INTERVENTION AND OUTCOME: An 18-gauge Touhy needle was inserted until loss of resistance occurred at the L4-5 level. Spread of the contrast medium within the epidural space was determined by radiographic imaging. After verifying the epidural space, bupivacaine and ENT2 triamcinolone diacetate ENT2END were injected
0	The following case is a report of cauda equina syndrome possibly caused by epidural injection of ENT1 triamcinolone  ENT1END  and bupivacaine. CLINICAL FEATURES: A 50-year-old woman with ENT2 low back and right leg pain ENT2END was scheduled for epidural steroid injection
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and ENT1 cyclophosphamide ENT1END  Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. ENT2 Myositis ENT2END was suspected, and the patient was treated with steroids
0	Additional therapy with chloroquine ( ENT1 CQ  ENT1END  was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. ENT2 Myositis ENT2END was suspected, and the patient was treated with steroids
0	ENT1 Myositis ENT1END  was suspected, and the patient was treated with ENT2 steroids ENT2END
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with ENT1 azathioprine  ENT1END and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. ENT2 Myositis ENT2END was suspected, and the patient was treated with steroids
0	At the same time, slightly increased ENT1 creatine  ENT1END kinase (CK) levels were noted. ENT2 Myositis ENT2END was suspected, and the patient was treated with steroids
0	Since 1989, she had been suffering from systemic lupus erythematosus ( ENT1 SLE  ENT1END  with renal involvement and undergone periods of treatment with azathioprine and ENT2 cyclophosphamide ENT2END
0	We report the clinical and bioptic findings for a 57-year-old woman with severe ENT1 chloroquine ENT1END induced myopathy. Since 1989, she had been suffering from ENT2 systemic lupus erythematosus ENT2END (SLE) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide
0	Since 1989, she had been suffering from systemic lupus erythematosus ( ENT1 SLE  ENT1END ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with ENT2 steroids ENT2END
0	Since 1989, she had been suffering from systemic lupus erythematosus ( ENT1 SLE  ENT1END ) with renal involvement and undergone periods of treatment with ENT2 azathioprine ENT2END and cyclophosphamide
0	Differential diagnosis of high serum ENT1 creatine  ENT1END  kinase levels in ENT2 systemic lupus erythematosus ENT2END
0	As it revealed ENT1 chloroquine ENT1END induced myopathy, medication was stopped. Discriminating between primary SLE-induced ENT2 affection of the musculoskeletal system ENT2END and drug-induced side effects is important for appropriate treatment of SLE patients
0	Thus, muscle biopsy of the deltoid muscle was performed in order to exclude ENT1 polymyositis  ENT1END or toxic myopathy. As it revealed ENT2 chloroquine ENT2END -induced myopathy, medication was stopped
0	Myositis was suspected, and the patient was treated with ENT1 steroids  ENT1END . The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy. Routine controls revealed markedly elevated CK levels of 1,700 U/l. The neurological and electrophysiological findings were not typical of myositis. Thus, muscle biopsy of the deltoid muscle was performed in order to exclude ENT2 polymyositis ENT2END or toxic myopathy
0	At the same time, slightly increased ENT1 creatine  ENT1END  kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy. Routine controls revealed markedly elevated CK levels of 1,700 U/l. The neurological and electrophysiological findings were not typical of myositis. Thus, muscle biopsy of the deltoid muscle was performed in order to exclude ENT2 polymyositis ENT2END or toxic myopathy
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and ENT1 cyclophosphamide ENT1END . Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive ENT2 muscular weakness ENT2END and muscular atrophy
1	Additional therapy with chloroquine ( ENT1 CQ  ENT1END ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive ENT2 muscular weakness ENT2END and muscular atrophy
0	Myositis was suspected, and the patient was treated with ENT1 steroids  ENT1END . The CK increase persisted, however, and she developed progressive ENT2 muscular weakness ENT2END and muscular atrophy
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with ENT1 azathioprine  ENT1END  and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive ENT2 muscular weakness ENT2END and muscular atrophy
0	At the same time, slightly increased ENT1 creatine  ENT1END  kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive ENT2 muscular weakness ENT2END and muscular atrophy
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with ENT1 renal involvement  ENT1END and undergone periods of treatment with azathioprine and ENT2 cyclophosphamide ENT2END
0	We report the clinical and bioptic findings for a 57-year-old woman with severe ENT1 chloroquine  ENT1END -induced myopathy. Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with ENT2 renal involvement ENT2END and undergone periods of treatment with azathioprine and cyclophosphamide
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with ENT1 renal involvement  ENT1END  and undergone periods of treatment with azathioprine and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with ENT2 steroids ENT2END
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with ENT1 renal involvement  ENT1END  and undergone periods of treatment with ENT2 azathioprine ENT2END and cyclophosphamide
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with ENT1 renal involvement  ENT1END  and undergone periods of treatment with azathioprine and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased ENT2 creatine ENT2END kinase (CK) levels were noted
0	We report the clinical and bioptic findings for a 57-year-old woman with severe chloroquine-induced ENT1 myopathy  ENT1END  Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and ENT2 cyclophosphamide ENT2END
0	We report the clinical and bioptic findings for a 57-year-old woman with severe ENT1 chloroquine  ENT1END -induced ENT2 myopathy ENT2END
0	Myositis was suspected, and the patient was treated with ENT1 steroids ENT1END . The CK increase persisted, however, and she developed progressive muscular weakness and muscular atrophy. Routine controls revealed markedly elevated CK levels of 1,700 U/l. The neurological and electrophysiological findings were not typical of myositis. Thus, muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic ENT2 myopathy ENT2END
0	We report the clinical and bioptic findings for a 57-year-old woman with severe chloroquine-induced ENT1 myopathy  ENT1END . Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with ENT2 azathioprine ENT2END and cyclophosphamide
0	Differential diagnosis of high serum ENT1 creatine  ENT1END  kinase levels in systemic lupus erythematosus.We report the clinical and bioptic findings for a 57-year-old woman with severe chloroquine-induced ENT2 myopathy ENT2END
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and ENT1 cyclophosphamide ENT1END . Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive muscular weakness and ENT2 muscular atrophy ENT2END
1	Additional therapy with chloroquine ( ENT1 CQ  ENT1END ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive muscular weakness and ENT2 muscular atrophy ENT2END
0	Myositis was suspected, and the patient was treated with ENT1 steroids  ENT1END . The CK increase persisted, however, and she developed progressive muscular weakness and ENT2 muscular atrophy ENT2END
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with ENT1 azathioprine  ENT1END  and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of arthralgia. At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive muscular weakness and ENT2 muscular atrophy ENT2END
0	At the same time, slightly increased ENT1 creatine  ENT1END  kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with steroids. The CK increase persisted, however, and she developed progressive muscular weakness and ENT2 muscular atrophy ENT2END
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with azathioprine and ENT1 cyclophosphamide ENT1END . Additional therapy with chloroquine (CQ) was started because of ENT2 arthralgia ENT2END
0	Additional therapy with chloroquine ( ENT1 CQ  ENT1END ) was started because of ENT2 arthralgia ENT2END
0	Additional therapy with chloroquine (CQ) was started because of ENT1 arthralgia  ENT1END . At the same time, slightly increased creatine kinase (CK) levels were noted. Myositis was suspected, and the patient was treated with ENT2 steroids ENT2END
0	Since 1989, she had been suffering from systemic lupus erythematosus (SLE) with renal involvement and undergone periods of treatment with ENT1 azathioprine  ENT1END  and cyclophosphamide. Additional therapy with chloroquine (CQ) was started because of ENT2 arthralgia ENT2END
0	Additional therapy with chloroquine (CQ) was started because of ENT1 arthralgia  ENT1END . At the same time, slightly increased ENT2 creatine ENT2END kinase (CK) levels were noted
1	ENT1 Learning and memory deficits  ENT1END  in ENT2 ecstasy ENT2END users and their neural correlates during a face-learning task
0	To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested ENT1 cannabis ENT1END users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008. ENT2 Deficits in learning and memory ENT2END : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users
0	These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the ENT1 neurotoxic ENT1END effects of ENT2 ecstasy ENT2END
0	These results elucidated ecstasy-related deficits, only some of which might be attributed to ENT1 cannabis  ENT1END use. These ecstasy-specific effects may be related to the vulnerability of isocortical and allocortical regions to the ENT2 neurotoxic ENT2END effects of ecstasy
0	A conjunction analysis of the encode and recall phases of the task revealed ENT1 ecstasy ENT1END specific ENT2 hyperactivity ENT2END in bilateral frontal regions, left temporal, right parietal, bilateral temporal, and bilateral occipital brain regions
0	Deficits in learning and memory: parahippocampal ENT1 hyperactivity ENT1END and frontocortical hypoactivity in ENT2 cannabis ENT2END users
1	ENT1 Learning and memory deficits  ENT1END  in ENT2 ecstasy ENT2END users and their neural correlates during a face-learning task
0	To address the potential confounding effects of the cannabis use of the ecstasy using group, a second analysis included 14 previously tested ENT1 cannabis ENT1END  users (Nestor, L., Roberts, G., Garavan, H., Hester, R., 2008. ENT2 Deficits in learning and memory ENT2END : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users
0	On average, age-specific mortality rates were slightly higher for the 101 patients whose ENT1 paracetamol ENT1END induced ENT2 liver injury ENT2END had caused an acute liver failure (adjusted mortality rate ratio = 1
0	CONCLUSIONS: ENT1 Paracetamol ENT1END induced acute liver failure did not affect long-term mortality. Clinical follow-up may be justified by the cause of the ENT2 liver failure ENT2END , but not by the liver failure itself
0	More likely, the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of ENT1 substance abuse  ENT1END among survivors of acute liver failure. CONCLUSIONS: ENT2 Paracetamol ENT2END -induced acute liver failure did not affect long-term mortality
1	Long-term prognosis for transplant-free survivors of ENT1 paracetamol  ENT1END -induced ENT2 acute liver failure ENT2END
0	On average, age-specific mortality rates were slightly higher for the 101 patients whose ENT1 paracetamol ENT1END -induced liver injury had caused an acute liver failure (adjusted mortality rate ratio = 1.70, 95% CI 1.02-2.85), but the association was age-dependent, and no survivors of acute liver failure died of ENT2 liver disease ENT2END , whereas suicides were frequent in both groups
1	On the other hand, BNP did not increase in the patients without ENT1 heart failure ENT1END given ENT2 DNR ENT2END , even at more than 700 mg/m(2)
0	The plasma level of ANP did not always increase in all the patients with clinical and subclinical ENT1 heart failure ENT1END  These preliminary results suggest that BNP may be useful as an early and sensitive indicator of ENT2 anthracycline ENT2END -induced cardiotoxicity
0	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced ENT1 cardiotoxicity ENT1END in patients with acute leukemia treated with a ENT2 daunorubicin ENT2END (DNR)-containing regimen
0	Brain natriuretic peptide is a predictor of anthracycline-induced ENT1 cardiotoxicity  ENT1END . ENT2 Anthracyclines ENT2END are effective antineoplastic drugs, but they frequently cause dose-related cardiotoxicity
0	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with ENT1 acute leukemia  ENT1END treated with a ENT2 daunorubicin ENT2END (DNR)-containing regimen
0	We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of ENT1 anthracycline  ENT1END induced cardiotoxicity in patients with ENT2 acute leukemia ENT2END treated with a daunorubicin (DNR)-containing regimen
0	The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting ENT1 cardiac dysfunction  ENT1END  We measured the plasma level of brain natriuretic peptide (BNP) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline-induced cardiotoxicity in patients with acute leukemia treated with a ENT2 daunorubicin ENT2END (DNR)-containing regimen
0	The cardiotoxicity of conventional ENT1 anthracycline  ENT1END therapy highlights a need to search for methods that are highly sensitive and capable of predicting ENT2 cardiac dysfunction ENT2END
0	OBJECTIVES: The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of ENT1 trihexyphenidyl ENT1END on measures reflecting sedation and ENT2 confusion ENT2END and to investigate the relationship between trihexyphenidyl-induced subjective effects and objective memory performance
1	CONCLUSION: The epsilon4 allele in healthy elderly was associated with increased subjective ENT1 mental slowing ENT1END after ENT2 trihexyphenidyl ENT2END anticholinergic challenge
0	We investigated the potential role of ENT1 mitochondrial injury ENT1END in the onset of these lesions. METHODS: Rats were treated with intravenous ENT2 doxorubicin ENT2END (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose
0	We investigated the potential role of ENT1 mitochondrial injury ENT1END  in the onset of these lesions. METHODS: Rats were treated with intravenous doxorubicin (1 mg kg(-1) week(-1)) for 7 weeks and were sacrificed either 1 week ('short-term') or 30 weeks ('long-term') following the last dose. Additional rats received a single dose either 6 days or 2 h prior to euthanasia. All rats were killed at 48 weeks of age. Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components. Finally, we quantified both nuclear and mitochondrial DNA (mtDNA) as well as ENT2 superoxide ENT2END production and the 4834 base pair 'common' mtDNA deletion
1	Mitochondrial DNA and its respiratory chain products are defective in ENT1 doxorubicin ENT1END ENT2 nephrosis ENT2END
0	CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of superoxide in ENT1 doxorubicin ENT1END induced ENT2 renal lesions ENT2END
0	CONCLUSIONS: These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA-encoded respiratory chain function and induction of ENT1 superoxide  ENT1END in doxorubicin-induced ENT2 renal lesions ENT2END
0	RESULTS: The 'long-term' group had significant ENT1 glomerular and tubular lesions ENT1END  depressed activities of mtDNA-encoded NADH dehydrogenase and cytochrome-c oxidase (COX) and increased ENT2 citrate ENT2END synthase activity
0	Progressive improvement occurred in 7 cases after commencement of prednisolone and ENT1 methotrexate ENT1END  and in one case spontaneously. These observations suggest that statins may initiate an immune-mediated ENT2 myopathy ENT2END that persists after withdrawal of the drug and responds to immunosuppressive therapy
1	What is less well known is a phenomenon whereby ENT1 statins ENT1END may induce a ENT2 myopathy ENT2END , which persists or may progress after stopping the drug
0	Progressive improvement occurred in 7 cases after commencement of ENT1 prednisolone  ENT1END and methotrexate, and in one case spontaneously. These observations suggest that statins may initiate an immune-mediated ENT2 myopathy ENT2END that persists after withdrawal of the drug and responds to immunosuppressive therapy
0	In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non- ENT1 necrotic  ENT1END fibres. Progressive improvement occurred in 7 cases after commencement of prednisolone and ENT2 methotrexate ENT2END , and in one case spontaneously
1	What is less well known is a phenomenon whereby ENT1 statins ENT1END  may induce a myopathy, which persists or may progress after stopping the drug. We investigated the muscle pathology in 8 such cases. All had myofibre ENT2 necrosis ENT2END but only 3 had an inflammatory infiltrate
0	In all cases there was diffuse or multifocal up-regulation of MHC-I expression even in non- ENT1 necrotic  ENT1END  fibres. Progressive improvement occurred in 7 cases after commencement of ENT2 prednisolone ENT2END and methotrexate, and in one case spontaneously
1	Central ENT1 retinal vein occlusion  ENT1END  associated with ENT2 clomiphene ENT2END -induced ovulation
1	A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication, although mild ENT1 visual disturbance ENT1END after ENT2 CC ENT2END intake is not uncommon
0	A search of the literature on the ENT1 thromboembolic ENT1END complications of ENT2 CC ENT2END does not include this severe ophthalmic complication, although mild visual disturbance after CC intake is not uncommon
0	Extra caution is warranted in treating ENT1 infertility ENT1END patients with ENT2 CC ENT2END , and patients should be well informed of this side effect before commencement of therapy
0	Arteritis induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and ENT1 tumor ENT1END growth factor-beta1 (TGF-beta1). Rats were administered ENT2 fenoldopam ENT2END for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline
0	Immunohistochemical study on inducible type of ENT1 nitric oxide  ENT1END  (iNOS), basic fibroblast growth factor (bFGF) and ENT2 tumor ENT2END growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and theophylline, vasodilators
0	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and ENT1 tumor  ENT1END  growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and ENT2 theophylline ENT2END , vasodilators
1	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in ENT1 arteritis  ENT1END  induced in rats by ENT2 fenoldopam ENT2END and theophylline, vasodilators
0	Immunohistochemical study on inducible type of ENT1 nitric oxide  ENT1END  (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in ENT2 arteritis ENT2END induced in rats by fenoldopam and theophylline, vasodilators
1	Immunohistochemical study on inducible type of nitric oxide (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1) in arteritis induced in rats by fenoldopam and ENT1 theophylline  ENT1END , vasodilators. ENT2 Arteritis ENT2END induced in rats by vasodilators, fenoldopam and theophylline, was examined immunohistochemically for expressions of inducible type of nitric oxide synthase (iNOS), basic fibroblast growth factor (bFGF) and tumor growth factor-beta1 (TGF-beta1)
0	We describe a patient who developed tetany with sudden ENT1 respiratory arrest ENT1END after the infusion of intravenous ENT2 diltiazem ENT2END
0	Rapid reversal of life-threatening diltiazem-induced tetany with ENT1 calcium chloride  ENT1END .We describe a patient who developed tetany with sudden ENT2 respiratory arrest ENT2END after the infusion of intravenous diltiazem
1	Rapid reversal of life-threatening ENT1 diltiazem  ENT1END -induced ENT2 tetany ENT2END with calcium chloride
0	Rapid reversal of life-threatening diltiazem-induced ENT1 tetany  ENT1END  with ENT2 calcium chloride ENT2END
0	Immunological activation has been proposed to play a role in methamphetamine-induced ENT1 dopaminergic terminal damage ENT1END  In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal ENT2 dopamine ENT2END neurotoxicity
0	Immunological activation has been proposed to play a role in methamphetamine-induced ENT1 dopaminergic terminal damage ENT1END . In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity. Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later. Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and ENT2 3,4-dihydroxyphenylacetic acid ENT2END depletions in a dose-dependent manner
0	Immunological activation has been proposed to play a role in methamphetamine-induced ENT1 dopaminergic terminal damage ENT1END . In this study, we examined the roles of ENT2 lipopolysaccharide ENT2END , a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine neurotoxicity
0	Immunological activation has been proposed to play a role in ENT1 methamphetamine  ENT1END induced ENT2 dopaminergic terminal damage ENT2END
0	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited ENT1 hyperthermia ENT1END three days later. Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal ENT2 dopamine ENT2END and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner
0	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited ENT1 hyperthermia  ENT1END  three days later. Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and ENT2 3,4-dihydroxyphenylacetic acid ENT2END depletions in a dose-dependent manner
0	Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited ENT1 hyperthermia ENT1END  three days later. Such systemic ENT2 lipopolysaccharide ENT2END treatment mitigated methamphetamine-induced striatal dopamine and 3,4-dihydroxyphenylacetic acid depletions in a dose-dependent manner
1	Lipopolysaccharide pretreatment did not affect the basal body temperature or ENT1 methamphetamine  ENT1END elicited ENT2 hyperthermia ENT2END three days later
0	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal ENT1 dopamine ENT1END  ENT2 neurotoxicity ENT2END
0	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine ENT1 neurotoxicity  ENT1END . Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later. Such systemic lipopolysaccharide treatment mitigated methamphetamine-induced striatal dopamine and ENT2 3,4-dihydroxyphenylacetic acid ENT2END depletions in a dose-dependent manner
0	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the methamphetamine-induced nigrostriatal dopamine ENT1 neurotoxicity ENT1END . ENT2 Lipopolysaccharide ENT2END pretreatment did not affect the basal body temperature or methamphetamine-elicited hyperthermia three days later
0	In this study, we examined the roles of lipopolysaccharide, a pro-inflammatory and inflammatory factor, treatment in modulating the ENT1 methamphetamine  ENT1END induced nigrostriatal dopamine ENT2 neurotoxicity ENT2END
0	Clinicians should be aware that ENT1 tenofovir ENT1END may raise the risk of ENT2 renal failure ENT2END during prolonged administration of vancomycin
0	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged ENT1 vancomycin  ENT1END  course for osteomyelitis. ENT2 Renal failure ENT2END developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen
0	ENT1 Renal failure ENT1END  developed after a prolonged course of vancomycin therapy in 2 patients who were receiving ENT2 tenofovir disoproxil fumarate ENT2END as part of an antiretroviral regimen
0	Vancomycin nephrotoxicity is infrequent but may result from coadministration with a ENT1 nephrotoxic  ENT1END agent. Clinicians should be aware that ENT2 tenofovir ENT2END may raise the risk of renal failure during prolonged administration of vancomycin
0	ENT1 Vancomycin ENT1END ENT2 nephrotoxicity ENT2END is infrequent but may result from coadministration with a nephrotoxic agent
0	Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving ENT1 tenofovir disoproxil fumarate  ENT1END  as part of an antiretroviral regimen. Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule. Vancomycin ENT2 nephrotoxicity ENT2END is infrequent but may result from coadministration with a nephrotoxic agent
0	ENT1 Acute renal failure  ENT1END  in patients with AIDS on ENT2 tenofovir ENT2END while receiving prolonged vancomycin course for osteomyelitis
1	ENT1 Acute renal failure  ENT1END  in patients with AIDS on tenofovir while receiving prolonged ENT2 vancomycin ENT2END course for osteomyelitis
1	ENT1 Acute renal failure  ENT1END  in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving ENT2 tenofovir disoproxil fumarate ENT2END as part of an antiretroviral regimen
0	ENT1 Tenofovir ENT1END has been implicated in the development of ENT2 Fanconi syndrome ENT2END and renal insufficiency because of its effects on the proximal renal tubule
0	Tenofovir has been implicated in the development of ENT1 Fanconi syndrome  ENT1END  and renal insufficiency because of its effects on the proximal renal tubule. ENT2 Vancomycin ENT2END nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent
0	Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving ENT1 tenofovir disoproxil fumarate  ENT1END  as part of an antiretroviral regimen. Tenofovir has been implicated in the development of ENT2 Fanconi syndrome ENT2END and renal insufficiency because of its effects on the proximal renal tubule
0	Acute renal failure in patients with AIDS on ENT1 tenofovir  ENT1END  while receiving prolonged vancomycin course for ENT2 osteomyelitis ENT2END
0	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged ENT1 vancomycin  ENT1END  course for ENT2 osteomyelitis ENT2END
0	Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for ENT1 osteomyelitis  ENT1END .Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving ENT2 tenofovir disoproxil fumarate ENT2END as part of an antiretroviral regimen
0	Acute renal failure in patients with ENT1 AIDS  ENT1END  on ENT2 tenofovir ENT2END while receiving prolonged vancomycin course for osteomyelitis
0	Acute renal failure in patients with ENT1 AIDS  ENT1END  on tenofovir while receiving prolonged ENT2 vancomycin ENT2END course for osteomyelitis
0	Acute renal failure in patients with ENT1 AIDS  ENT1END  on tenofovir while receiving prolonged vancomycin course for osteomyelitis.Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving ENT2 tenofovir disoproxil fumarate ENT2END as part of an antiretroviral regimen
0	Fatal ENT1 haemopericardium ENT1END  and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin. We propose that naturally occurring compounds such as ENT2 flavonoids ENT2END , which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin
0	Fatal ENT1 haemopericardium  ENT1END  and gastrointestinal haemorrhage due to possible interaction of cranberry juice with ENT2 warfarin ENT2END
0	We report a case of fatal internal ENT1 haemorrhage  ENT1END in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin. We propose that naturally occurring compounds such as ENT2 flavonoids ENT2END , which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin
0	Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with ENT1 warfarin  ENT1END .We report a case of fatal internal ENT2 haemorrhage ENT2END in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin
1	Fatal haemopericardium and ENT1 gastrointestinal haemorrhage  ENT1END  due to possible interaction of cranberry juice with warfarin.We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin. We propose that naturally occurring compounds such as ENT2 flavonoids ENT2END , which are present in fruit juices, may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin
1	Fatal haemopericardium and ENT1 gastrointestinal haemorrhage  ENT1END  due to possible interaction of cranberry juice with ENT2 warfarin ENT2END
1	On the mechanisms of the development of tolerance to the ENT1 muscular rigidity  ENT1END  produced by ENT2 morphine ENT2END in rats
1	ENT1 Haloperidol ENT1END enhanced the ENT2 rigidity ENT2END in the A group
1	Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of ENT1 morphine ENT1END that was not significantly less than in the controls and were akinetic (A group). The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or ENT2 hyperkinetic ENT2END (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation
0	The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of akinetic or ENT1 hyperkinetic ENT1END  (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation. The rigidity was considerably decreased in both groups after 20 days' treatment. In a further series of experiments, ENT2 haloperidol ENT2END (0
1	Rats treated for 11 days with morphine and withdrawn for 36-40 h showed differences in the development of tolerance: about half of the animals showed a rigidity after the test dose of ENT1 morphine ENT1END  that was not significantly less than in the controls and were ENT2 akinetic ENT2END (A group)
0	The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped (S) licking and/or gnawing in presence of ENT1 akinetic  ENT1END or hyperkinetic (K) behaviour (AS/KS group), suggesting signs of dopaminergic activation. The rigidity was considerably decreased in both groups after 20 days' treatment. In a further series of experiments, ENT2 haloperidol ENT2END (0
0	Our study suggests that prophylactic ENT1 lamivudine ENT1END significantly decreases the incidence of HBV reactivation and overall morbidity in ENT2 cancer ENT2END patients during and after immunosuppressive therapy
0	Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in ENT1 cancer ENT1END  patients during and after immunosuppressive therapy. Further studies are needed to determine the most appropriate ENT2 nucleoside ENT2END or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT
0	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen ( ENT1 HBSAG  ENT1END ) seropositive ENT2 cancer ENT2END patients undergoing cytotoxic chemotherapy
0	Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in ENT1 cancer ENT1END  patients during and after immunosuppressive therapy. Further studies are needed to determine the most appropriate nucleoside or ENT2 nucleotide ENT2END analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT
0	Comparison of the mean ALT values revealed significantly higher mean ENT1 alanine  ENT1END aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32). Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in ENT2 cancer ENT2END patients during and after immunosuppressive therapy
0	In this study, cancer patients who have solid and ENT1 hematological malignancies ENT1END with chronic HBV infection received the antiviral agent ENT2 lamivudine ENT2END prior and during CT compared with historical control group who did not receive lamivudine
0	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen ( ENT1 HBSAG  ENT1END ) seropositive cancer patients undergoing cytotoxic chemotherapy.Hepatitis B virus (HBV) is one of the major causes of chronic liver disease worldwide. Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy (CT) and this has mainly been attributed to HBV reactivation. In this study, cancer patients who have solid and ENT2 hematological malignancies ENT2END with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine
0	In the prophylactic ENT1 lamivudine ENT1END group severe ENT2 hepatitis ENT2END were observed only in 1 patient (2
0	In the prophylactic lamivudine group severe ENT1 hepatitis  ENT1END  were observed only in 1 patient (2.7%) of 37 patients (p < 0.006). Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32). Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy. Further studies are needed to determine the most appropriate ENT2 nucleoside ENT2END or nucleotide analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT
0	In the prophylactic lamivudine group severe ENT1 hepatitis  ENT1END  were observed only in 1 patient (2.7%) of 37 patients (p < 0.006). Comparison of the mean ALT values revealed significantly higher mean alanine aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0.32). Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy. Further studies are needed to determine the most appropriate nucleoside or ENT2 nucleotide ENT2END analogue for antiviral prophylaxis during CT and the optimal duration of administration after completion of CT
0	In the prophylactic lamivudine group severe ENT1 hepatitis  ENT1END  were observed only in 1 patient (2.7%) of 37 patients (p < 0.006). Comparison of the mean ALT values revealed significantly higher mean ENT2 alanine ENT2END aminotransferase (ALT) values in the control group than the prophylactic lamivudine group; 154:64 (p < 0
0	ENT1 Lamivudine  ENT1END  for the prevention of ENT2 hepatitis B ENT2END virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy
1	Lamivudine for the prevention of ENT1 hepatitis B  ENT1END  virus reactivation in ENT2 hepatitis-B surface antigen ENT2END (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy
0	ENT1 Lamivudine ENT1END  for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy.Hepatitis B virus (HBV) is one of the major causes of chronic ENT2 liver disease ENT2END worldwide
0	Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen ( ENT1 HBSAG  ENT1END ) seropositive cancer patients undergoing cytotoxic chemotherapy.Hepatitis B virus (HBV) is one of the major causes of chronic ENT2 liver disease ENT2END worldwide
0	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more ENT1 anxiety ENT1END and depression than ENT2 ethopropazine ENT2END treated patients
0	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during ENT1 procyclindine  ENT1END treatment, and significantly more ENT2 anxiety ENT2END and depression than ethopropazine treated patients
1	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more ENT1 anxiety ENT1END  and depression than ethopropazine treated patients. This suggests that ENT2 benztropine ENT2END is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect
0	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by ENT1 fluphenazine enanthate  ENT1END in 60 schizophrenic outpatients. Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug. However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more ENT2 anxiety ENT2END and depression than ethopropazine treated patients
0	However, benztropine treated patients had a significant increase in ENT1 tardive dyskinesia  ENT1END compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ENT2 ethopropazine ENT2END treated patients
0	However, benztropine treated patients had a significant increase in ENT1 tardive dyskinesia  ENT1END  compared to their condition during ENT2 procyclindine ENT2END treatment, and significantly more anxiety and depression than ethopropazine treated patients
1	However, ENT1 benztropine  ENT1END treated patients had a significant increase in ENT2 tardive dyskinesia ENT2END compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients
0	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by ENT1 fluphenazine enanthate  ENT1END  in 60 schizophrenic outpatients. Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug. However, benztropine treated patients had a significant increase in ENT2 tardive dyskinesia ENT2END compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients
0	Ethopropazine and benztropine in neuroleptic-induced ENT1 parkinsonism ENT1END .In a 12-week controlled study ENT2 ethopropazine ENT2END was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients
0	Ethopropazine and benztropine were found to be equally effective in controlling ENT1 parkinsonian symptoms ENT1END and were as efficacious as ENT2 procyclidine ENT2END , their previous antiparkinsonian drug
0	In a 12-week controlled study ethopropazine was compared to ENT1 benztropine ENT1END in the treatment of ENT2 parkinsonism ENT2END induced by fluphenazine enanthate in 60 schizophrenic outpatients
1	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of ENT1 parkinsonism  ENT1END  induced by ENT2 fluphenazine enanthate ENT2END in 60 schizophrenic outpatients
0	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and ENT1 depression  ENT1END than ENT2 ethopropazine ENT2END treated patients
0	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during ENT1 procyclindine  ENT1END  treatment, and significantly more anxiety and ENT2 depression ENT2END than ethopropazine treated patients
1	However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and ENT1 depression  ENT1END  than ethopropazine treated patients. This suggests that ENT2 benztropine ENT2END is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect
0	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by ENT1 fluphenazine enanthate  ENT1END  in 60 schizophrenic outpatients. Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug. However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and ENT2 depression ENT2END than ethopropazine treated patients
0	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 ENT1 schizophrenic ENT1END outpatients. ENT2 Ethopropazine ENT2END and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug
0	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 ENT1 schizophrenic  ENT1END  outpatients. Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as ENT2 procyclidine ENT2END , their previous antiparkinsonian drug
0	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 ENT1 schizophrenic ENT1END  outpatients. Ethopropazine and ENT2 benztropine ENT2END were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug
0	In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by ENT1 fluphenazine enanthate  ENT1END  in 60 ENT2 schizophrenic ENT2END outpatients
0	ENT1 Asenapine ENT1END is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of ENT2 manic ENT2END or mixed episodes associated with bipolar I disorder with or without psychotic features
0	Efficacy and safety of asenapine in a placebo- and ENT1 haloperidol  ENT1END -controlled trial in patients with acute exacerbation of schizophrenia.Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of ENT2 manic ENT2END or mixed episodes associated with bipolar I disorder with or without psychotic features
0	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without ENT1 psychotic ENT1END features. In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with ENT2 asenapine ENT2END at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or haloperidol at 4 mg BID (to verify assay sensitivity)
0	Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without ENT1 psychotic ENT1END  features. In a double-blind 6-week trial, 458 patients with acute schizophrenia were randomly assigned to fixed-dose treatment with asenapine at 5 mg twice daily (BID), asenapine at 10 mg BID, placebo, or ENT2 haloperidol ENT2END at 4 mg BID (to verify assay sensitivity)
1	ENT1 Extrapyramidal symptoms ENT1END reported as AEs occurred in 15% and 18%, 34%, and 10% of the ENT2 asenapine ENT2END at 5 and 10 mg BID, haloperidol, and placebo groups, respectively
1	Treatment-related adverse events (AEs) occurred in 44% and 52%, 57%, and 41% of the asenapine at 5 and 10 mg BID, ENT1 haloperidol  ENT1END  and placebo groups, respectively. ENT2 Extrapyramidal symptoms ENT2END reported as AEs occurred in 15% and 18%, 34%, and 10% of the asenapine at 5 and 10 mg BID, haloperidol, and placebo groups, respectively
0	Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of ENT1 schizophrenia ENT1END ENT2 Asenapine ENT2END is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features
0	Efficacy and safety of asenapine in a placebo- and ENT1 haloperidol  ENT1END -controlled trial in patients with acute exacerbation of ENT2 schizophrenia ENT2END
1	The use of serum cholinesterase in ENT1 succinylcholine ENT1END ENT2 apnoea ENT2END
0	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on ENT1 convulsions ENT1END induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated. Ibuprofen, sulindac, ENT2 mefenamic acid ENT2END , and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents
0	To investigate the relationship of prostaglandins ( ENT1 PGs ENT1END  to ENT2 seizure ENT2END induction, the effects of six PG synthetase inhibitors on convulsions induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated
1	These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and ENT1 PTZ ENT1END induced ENT2 convulsions ENT2END , but not picrotoxin-, electroshock-, or bicuculline-induced convulsions
0	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on ENT1 convulsions ENT1END  induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated. Ibuprofen, ENT2 sulindac ENT2END , mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents
1	These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced convulsions, but not picrotoxin-, electroshock-, or ENT1 bicuculline ENT1END induced ENT2 convulsions ENT2END
0	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on ENT1 convulsions ENT1END  induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated. Ibuprofen, sulindac, mefenamic acid, and low dose ENT2 meclofenamic acid ENT2END increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents
0	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on ENT1 convulsions ENT1END  induced by flurothyl, picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated. ENT2 Ibuprofen ENT2END , sulindac, mefenamic acid, and low dose meclofenamic acid increased the latency-to-onset in the flurothyl and/or PTZ models; the electroshock, picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents
1	To investigate the relationship of prostaglandins (PGs) to seizure induction, the effects of six PG synthetase inhibitors on ENT1 convulsions ENT1END  induced by ENT2 flurothyl ENT2END , picrotoxin, pentetrazol (PTZ), electroshock or bicuculline were evaluated
1	These results suggest that PGs are involved in the mechanism(s) underlying fluorthyl- and PTZ-induced ENT1 convulsions ENT1END , but not ENT2 picrotoxin ENT2END -, electroshock-, or bicuculline-induced convulsions
1	ENT1 Acute renal failure  ENT1END  in high dose ENT2 carboplatin ENT2END chemotherapy
0	We report a 4 1/2-year-old girl who was treated with high-dose ENT1 carboplatin ENT1END for metastatic parameningeal ENT2 embryonal rhabdomyosarcoma ENT2END
1	Both patients and controls developed significantly stronger immediate ENT1 headache ENT1END on the ENT2 GTN ENT2END day than on the placebo day and the headache was significantly more pronounced in patients than in controls
1	It has been proposed that nitric oxide ( ENT1 NO ENT1END  induced ENT2 headache ENT2END in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP)
0	In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( ENT1 GTN ENT1END  in 16 patients with chronic ENT2 tension-type headache ENT2END and 16 healthy controls
0	Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic ENT1 tension-type headache ENT1END .It has been proposed that ENT2 nitric oxide ENT2END (NO) induced headache in primary headaches may be associated with release of calcitonin gene-related peptide (CGRP)
0	It has been proposed that nitric oxide (NO) induced headache in ENT1 primary headaches ENT1END may be associated with release of calcitonin gene-related peptide (CGRP). In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor ENT2 glyceryl trinitrate ENT2END (GTN) in 16 patients with chronic tension-type headache and 16 healthy controls
0	It has been proposed that nitric oxide ( ENT1 NO  ENT1END ) induced headache in ENT2 primary headaches ENT2END may be associated with release of calcitonin gene-related peptide (CGRP)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or ENT1 hypercapnia ENT1END applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another ENT2 pyrrolidinone ENT2END derivative was used for comparison
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or ENT1 hypercapnia ENT1END  applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral ENT2 aniracetam ENT2END doses of 10-100 mg/kg
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal ENT1 hypercapnia ENT1END immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the ENT2 scopolamine ENT2END -induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by ENT1 cycloheximide  ENT1END injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or ENT2 hypercapnia ENT2END applied immediately before retrieval testing (24 h after acquisition)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by ENT1 chloramphenicol  ENT1END or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or ENT2 hypercapnia ENT2END applied immediately before retrieval testing (24 h after acquisition)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or ENT1 hypercapnia ENT1END  applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. ENT2 Piracetam ENT2END , another pyrrolidinone derivative was used for comparison
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another ENT2 pyrrolidinone ENT2END derivative was used for comparison
0	Effects of the novel compound aniracetam ( ENT1 Ro 13-5057  ENT1END ) upon ENT2 impaired learning and memory ENT2END in rodents
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the ENT2 scopolamine ENT2END -induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
1	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or ENT2 cycloheximide ENT2END administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
1	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by ENT2 chloramphenicol ENT2END or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. ENT2 Piracetam ENT2END , another pyrrolidinone derivative was used for comparison
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another ENT2 pyrrolidinone ENT2END derivative was used for comparison
0	Effects of the novel compound aniracetam ( ENT1 Ro 13-5057  ENT1END ) upon ENT2 impaired learning and memory ENT2END in rodents
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the ENT2 scopolamine ENT2END -induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or ENT2 cycloheximide ENT2END administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by ENT2 chloramphenicol ENT2END or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	Effects of the novel compound aniracetam (Ro 13-5057) upon ENT1 impaired learning and memory  ENT1END  in rodents.The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. ENT2 Piracetam ENT2END , another pyrrolidinone derivative was used for comparison
0	These improvements or normalizations of ENT1 impaired cognitive functions  ENT1END were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another ENT2 pyrrolidinone ENT2END derivative was used for comparison
0	These improvements or normalizations of ENT1 impaired cognitive functions  ENT1END  were seen at oral ENT2 aniracetam ENT2END doses of 10-100 mg/kg
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally ENT1 impaired cognitive functions  ENT1END (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the ENT2 scopolamine ENT2END -induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by ENT1 cycloheximide  ENT1END  injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of ENT2 impaired cognitive functions ENT2END were seen at oral aniracetam doses of 10-100 mg/kg
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by ENT1 chloramphenicol  ENT1END  or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of ENT2 impaired cognitive functions ENT2END were seen at oral aniracetam doses of 10-100 mg/kg
0	These improvements or normalizations of ENT1 impaired cognitive functions  ENT1END  were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. ENT2 Piracetam ENT2END , another pyrrolidinone derivative was used for comparison
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against ENT1 amnesia  ENT1END for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. Piracetam, another ENT2 pyrrolidinone ENT2END derivative was used for comparison
0	The effect of aniracetam (Ro 13-5057, ENT1 1-anisoyl-2-pyrrolidinone ENT1END  was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term ENT2 amnesia ENT2END for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
1	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the ENT1 scopolamine  ENT1END -induced short-term ENT2 amnesia ENT2END for a passive avoidance task; (3) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against ENT1 amnesia  ENT1END  for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or ENT2 cycloheximide ENT2END administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against ENT1 amnesia  ENT1END  for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by ENT2 chloramphenicol ENT2END or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition)
0	The effect of aniracetam (Ro 13-5057, 1-anisoyl-2-pyrrolidinone) was studied on various forms of experimentally impaired cognitive functions (learning and memory) in rodents and produced the following effects: (1) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session; (2) partial (rats) or complete (mice) prevention of the scopolamine-induced short-term amnesia for a passive avoidance task; (3) complete protection against ENT1 amnesia  ENT1END  for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition; (4) prevention of the long-term retention- or retrieval-deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition; (5) reversal, when administered as late as 1 h before the retention test, of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously; (6) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing (24 h after acquisition). These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10-100 mg/kg. Generally, the dose-response curves were bell-shaped. The mechanisms underlying the activity of aniracetam and its 'therapeutic window' are unknown. ENT2 Piracetam ENT2END , another pyrrolidinone derivative was used for comparison
0	ENT1 Octreotide  ENT1END -induced ENT2 hypoxemia ENT2END and pulmonary hypertension in premature neonates
0	Pulmonary hypertension developed after administration of a somatostatin analogue, ENT1 octreotide ENT1END  to enhance resolution of the ENT2 fistula ENT2END
0	The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating ENT1 necrotizing enterocolitis  ENT1END  Pulmonary hypertension developed after administration of a somatostatin analogue, ENT2 octreotide ENT2END , to enhance resolution of the fistula
1	ENT1 Octreotide  ENT1END -induced hypoxemia and ENT2 pulmonary hypertension ENT2END in premature neonates
0	The patient noticed that before these episodes he had been using an inhalator of ENT1 salbutamol ENT1END  After stopping the beta-agonist, and after a week with the atenolol, the ENT2 arrhythmia ENT2END disappeared
0	After stopping the beta-agonist, and after a week with the ENT1 atenolol  ENT1END  the ENT2 arrhythmia ENT2END disappeared
0	Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like ENT1 salbutamol ENT1END (known to induce ENT2 tachycardia ENT2END ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as atenolol (that blocks the adrenergic activity) may relieve it
0	Although it is difficult to define causality in a case report, it is logical to think that a beta-agonist like salbutamol (known to induce ENT1 tachycardia ENT1END ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta-blocker such as ENT2 atenolol ENT2END (that blocks the adrenergic activity) may relieve it
1	Swallowing-induced ENT1 atrial tachyarrhythmia  ENT1END  triggered by ENT2 salbutamol ENT2END : case report and review of the literature
0	After stopping the beta-agonist, and after a week with the ENT1 atenolol ENT1END , the arrhythmia disappeared. DISCUSSION: Swallowing-induced ENT2 atrial tachyarrhythmia ENT2END (SIAT) is a rare phenomenon
0	The correlation between neuropathic damage and inhibition of neurotoxic esterase or ENT1 neuropathy ENT1END target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic ENT2 organophosphate ENT2END
0	The correlation between neurotoxic esterase inhibition and ENT1 mipafox  ENT1END -induced ENT2 neuropathic damage ENT2END in rats
0	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a ENT1 neurotoxic ENT1END ENT2 organophosphate ENT2END
0	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox ( ENT1 N, N'-diisopropylphosphorodiamidofluoridate  ENT1END , a ENT2 neurotoxic ENT2END organophosphate
0	The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme (NTE) was examined in rats acutely exposed to Mipafox (N, N'-diisopropylphosphorodiamidofluoridate), a neurotoxic ENT1 organophosphate ENT1END . Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of Mipafox (ip, 1-15 mg/kg). These data were correlated with histologically scored cervical ENT2 cord damage ENT2END in a separate group of similarly dosed rats sampled 14-21 days post-exposure
1	Brain and spinal cord NTE activities were measured in Long-Evans male rats 1 hr post-exposure to various dosages of ENT1 Mipafox  ENT1END (ip, 1-15 mg/kg). These data were correlated with histologically scored cervical ENT2 cord damage ENT2END in a separate group of similarly dosed rats sampled 14-21 days post-exposure
0	To evaluate the effect of prostaglandin E1 (PGE1) or trimethaphan (TMP) induced ENT1 hypotension ENT1END on epidural blood flow (EBF) during spinal surgery, EBF was measured using the heat clearance method in 30 patients who underwent postero-lateral interbody fusion under ENT2 isoflurane ENT2END anaesthesia
1	01), and the degree of ENT1 hypotension ENT1END due to ENT2 PGE1 ENT2END remained constant until 60 min after its discontinuation
1	These results suggest that PGE1 may be preferable to ENT1 TMP ENT1END for ENT2 hypotensive ENT2END anaesthesia in spinal surgery because TMP decreased EBF
0	Liver biopsies should be undertaken at regular intervals if ENT1 azathioprine ENT1END therapy is continued so that structural ENT2 liver damage ENT2END may be detected at an early and reversible stage
0	Treatment of ENT1 psoriasis  ENT1END  with ENT2 azathioprine ENT2END
1	Minimal cholestasis was seen in two cases and portal ENT1 fibrosis  ENT1END of a reversible degree in eight. Liver biopsies should be undertaken at regular intervals if ENT2 azathioprine ENT2END therapy is continued so that structural liver damage may be detected at an early and reversible stage
1	Minimal ENT1 cholestasis  ENT1END was seen in two cases and portal fibrosis of a reversible degree in eight. Liver biopsies should be undertaken at regular intervals if ENT2 azathioprine ENT2END therapy is continued so that structural liver damage may be detected at an early and reversible stage
1	5 x 10(6) IU ENT1 vitamin D3 ENT1END  were associated with prolonged ENT2 hypercalcemia ENT2END , hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows
0	5 x 10(6) IU vitamin D3) were associated with prolonged ENT1 hypercalcemia ENT1END , hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows. ENT2 Calcium ENT2END concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8
0	ENT1 Vitamin D3 ENT1END ENT2 toxicity ENT2END in dairy cows
0	Vitamin D3 ENT1 toxicity  ENT1END  in dairy cows.Large parenteral doses of vitamin D3 (15 to 17.5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, hyperphosphatemia, and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows. ENT2 Calcium ENT2END concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8
0	Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of ENT1 vitamin D3 ENT1END that prevent ENT2 milk fever ENT2END and doses that induce milk fever, we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum
0	ENT1 Calcium ENT1END  concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8.8 mg/100 ml) than in control cows (5.5 mg/100 ml). None of the cows treated with vitamin D3 showed signs of ENT2 milk fever ENT2END during the peripartal period; however, 22% of the control cows developed clinical signs of milk fever during this period
1	5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, ENT1 hyperphosphatemia ENT1END  and large increases of ENT2 vitamin D3 ENT2END and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows
0	5 x 10(6) IU vitamin D3) were associated with prolonged hypercalcemia, ENT1 hyperphosphatemia  ENT1END , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows. ENT2 Calcium ENT2END concentrations 1 day postpartum were higher in cows treated with vitamin D3 about 32 days prepartum (8
0	Hemorrhagic cystitis is a major potential ENT1 toxicity ENT1END of ifosfamide that can be prevented by administering ENT2 mesna ENT2END along with the cytotoxic agent
0	Hemorrhagic cystitis is a major potential ENT1 toxicity ENT1END  of ENT2 ifosfamide ENT2END that can be prevented by administering mesna along with the cytotoxic agent
1	Continuous subcutaneous administration of ENT1 mesna  ENT1END  to prevent ifosfamide-induced ENT2 hemorrhagic cystitis ENT2END
1	Continuous subcutaneous administration of mesna to prevent ENT1 ifosfamide  ENT1END -induced ENT2 hemorrhagic cystitis ENT2END
0	In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral ENT1 mesna ENT1END who experiences severe ifosfamide-induced ENT2 emesis ENT2END and is unable to absorb the drug
0	In addition, subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations, such as in a patient taking oral mesna who experiences severe ENT1 ifosfamide  ENT1END induced ENT2 emesis ENT2END and is unable to absorb the drug
1	Continuous subcutaneous administration of ENT1 mesna  ENT1END  to prevent ifosfamide-induced ENT2 hemorrhagic cystitis ENT2END
1	Continuous subcutaneous administration of mesna to prevent ENT1 ifosfamide  ENT1END -induced ENT2 hemorrhagic cystitis ENT2END
1	Rats were given a single dose of ENT1 adriamycin ENT1END and one month later divided into four groups matched for ENT2 albuminuria ENT2END , blood pressure, and plasma albumin concentration
0	Chronic ENT1 enalapril ENT1END treatment reduced blood pressure without reducing ENT2 albuminuria ENT2END in group 4
0	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of ENT1 renal injury ENT1END in ENT2 adriamycin ENT2END nephrosis
0	Groups 3 and 4 were studied at four and at six months to assess the effect of ENT1 enalapril  ENT1END on progression of ENT2 renal injury ENT2END in adriamycin nephrosis
1	The effect of the converting enzyme inhibitor (CEI) enalapril was assessed in Munich-Wistar rats with established ENT1 adriamycin ENT1END ENT2 nephrosis ENT2END
0	Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin ENT1 nephrosis  ENT1END  Chronic ENT2 enalapril ENT2END treatment reduced blood pressure without reducing albuminuria in group 4
0	The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine ( ENT1 L-alpha-GFC ENT1END  on ENT2 memory impairment ENT2END induced by scopolamine in man
1	The present study was carried out to test the effects of L-alpha-glycerylphosphorylcholine (L-alpha-GFC) on ENT1 memory impairment ENT1END  induced by ENT2 scopolamine ENT2END in man
0	Effect of ENT1 L-alpha-glyceryl-phosphorylcholine  ENT1END  on ENT2 amnesia ENT2END caused by scopolamine
0	Effect of L-alpha-glyceryl-phosphorylcholine on ENT1 amnesia  ENT1END  caused by ENT2 scopolamine ENT2END
1	Receptor mechanisms of ENT1 nicotine  ENT1END -induced ENT2 locomotor hyperactivity ENT2END in chronic nicotine-treated rats
0	However, this response was correlated with an elevated number of striatal [3H]spiperone binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal ENT1 DA ENT1END level were normal. These results suggest that chronic nicotine-treated rats develop ENT2 locomotor hyperactivity ENT2END in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum
0	However, this response was correlated with an elevated number of striatal [3H] ENT1 spiperone  ENT1END binding sites, whereas the number of striatal L-[3H]nicotine binding sites and the striatal DA level were normal. These results suggest that chronic nicotine-treated rats develop ENT2 locomotor hyperactivity ENT2END in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration, followed by inducing DA receptor supersensitivity in the striatum
1	Liver enlargement and ENT1 muscle wastage ENT1END occurred in Wistar rats following the subcutaneous administration of ENT2 prednisolone ENT2END
1	On two paradoxical side-effects of ENT1 prednisolone  ENT1END  in rats, ribosomal RNA biosyntheses, and a mechanism of action. ENT2 Liver enlargement ENT2END and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone
0	ENT1 Testosterone  ENT1END -dependent ENT2 hypertension ENT2END and upregulation of intrarenal angiotensinogen in Dahl salt-sensitive rats
0	Testosterone contributes to the development of ENT1 hypertension  ENT1END and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin- ENT2 angiotensin ENT2END system
0	Testosterone-dependent ENT1 hypertension  ENT1END  and upregulation of intrarenal angiotensinogen in Dahl ENT2 salt ENT2END -sensitive rats
0	In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by ENT1 testosterone ENT1END that also causes increases in BP and ENT2 renal injury ENT2END
0	Testosterone contributes to the development of hypertension and ENT1 renal injury  ENT1END in male DS rats on HS diet possibly through upregulation of the intrarenal renin ENT2 angiotensin ENT2END system
1	In this study, the hypothesis was tested that there is a sexual dimorphism in HS-induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and ENT1 renal injury  ENT1END . On a low- ENT2 salt ENT2END (LS) diet, male DS had higher levels of intrarenal angiotensinogen mRNA than females
0	Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo ENT1 purine ENT1END synthesis. Extensive experimental and limited clinical data have shown that lometrexol has activity against ENT2 tumours ENT2END which are refractory to other drugs, notably methotrexate
0	A phase I clinical study of the ENT1 antipurine  ENT1END  antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis. Extensive experimental and limited clinical data have shown that lometrexol has activity against ENT2 tumours ENT2END which are refractory to other drugs, notably methotrexate
0	Lometrexol is an antifolate which inhibits ENT1 glycinamide ribonucleotide  ENT1END formyltransferase (GARFT), an enzyme essential for de novo purine synthesis. Extensive experimental and limited clinical data have shown that lometrexol has activity against ENT2 tumours ENT2END which are refractory to other drugs, notably methotrexate
0	Extensive experimental and limited clinical data have shown that lometrexol has activity against ENT1 tumours ENT1END  which are refractory to other drugs, notably ENT2 methotrexate ENT2END
0	Extensive experimental and limited clinical data have shown that ENT1 lometrexol  ENT1END has activity against ENT2 tumours ENT2END which are refractory to other drugs, notably methotrexate
0	A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral ENT1 folic acid  ENT1END .Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis. Extensive experimental and limited clinical data have shown that lometrexol has activity against ENT2 tumours ENT2END which are refractory to other drugs, notably methotrexate
0	Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably ENT1 methotrexate ENT1END . However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities. Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose. This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation. ENT2 Thrombocytopenia ENT2END and mucositis were the major toxicities
1	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of ENT1 lometrexol  ENT1END can be markedly reduced by folic acid supplementation. ENT2 Thrombocytopenia ENT2END and mucositis were the major toxicities
0	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by ENT1 folic acid  ENT1END supplementation. ENT2 Thrombocytopenia ENT2END and mucositis were the major toxicities
0	Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo ENT1 purine ENT1END  synthesis. Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate. However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative ENT2 toxicities ENT2END
0	A phase I clinical study of the ENT1 antipurine  ENT1END  antifolate lometrexol (DDATHF) given with oral folic acid.Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase (GARFT), an enzyme essential for de novo purine synthesis. Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate. However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative ENT2 toxicities ENT2END
0	Lometrexol is an antifolate which inhibits ENT1 glycinamide ribonucleotide  ENT1END  formyltransferase (GARFT), an enzyme essential for de novo purine synthesis. Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably methotrexate. However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative ENT2 toxicities ENT2END
0	Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably ENT1 methotrexate  ENT1END . However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative ENT2 toxicities ENT2END
0	Preclinical murine studies demonstrated that the ENT1 toxicity ENT1END of ENT2 lometrexol ENT2END can be prevented by low dose folic acid administration, i
0	There was no clear relationship between clinical ENT1 toxicity ENT1END and the extent of plasma ENT2 folate ENT2END elevation
0	Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs, notably ENT1 methotrexate ENT1END . However, the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities. Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration, i.e. for 7 days prior to and 7 days following a single bolus dose. This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation. Thrombocytopenia and ENT2 mucositis ENT2END were the major toxicities
1	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of ENT1 lometrexol  ENT1END  can be markedly reduced by folic acid supplementation. Thrombocytopenia and ENT2 mucositis ENT2END were the major toxicities
0	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by ENT1 folic acid  ENT1END  supplementation. Thrombocytopenia and ENT2 mucositis ENT2END were the major toxicities
0	In addition, the effect of the specific endothelin type A receptor antagonist ENT1 FR 139317 ENT1END on FK 506-induced ENT2 hypertension ENT2END in rats was studied
1	Mechanisms of ENT1 FK 506  ENT1END -induced ENT2 hypertension ENT2END in the rat
0	d-1) prevented FK 506-induced ENT1 hypertension ENT1END in rats. These results indicate that FK 506 may increase blood pressure not only by increasing ET-1 production but also by decreasing ENT2 NO ENT2END synthesis in the vasculature
0	The clinical utility of FK 506 is complicated by substantial hypertension and ENT1 nephrotoxicity  ENT1END  To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels. In addition, the effect of the specific endothelin type A receptor antagonist ENT2 FR 139317 ENT2END on FK 506-induced hypertension in rats was studied
0	The clinical utility of FK 506 is complicated by substantial hypertension and ENT1 nephrotoxicity ENT1END . To clarify the mechanisms of ENT2 FK 506 ENT2END -induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial nitric oxide synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels
0	The clinical utility of FK 506 is complicated by substantial hypertension and ENT1 nephrotoxicity ENT1END . To clarify the mechanisms of FK 506-induced hypertension, we studied the chronic effects of FK 506 on the synthesis of endothelin-1 (ET-1), the expression of mRNA of ET-1 and endothelin-converting enzyme-1 (ECE-1), the endothelial ENT2 nitric oxide ENT2END synthase (eNOS) activity, and the expression of mRNA of eNOS and C-type natriuretic peptide (CNP) in rat blood vessels
1	Valproate-induced ENT1 encephalopathy  ENT1END . ENT2 Valproate ENT2END -induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals
0	It is usually but not necessarily associated with ENT1 hyperammonemia ENT1END  The EEG shows characteristic triphasic waves in most patients with this complication. A case of ENT2 valproate ENT2END -induced encephalopathy is presented
0	ENT1 Valproate ENT1END -induced encephalopathy is a rare syndrome that may manifest in otherwise normal ENT2 epileptic ENT2END individuals
0	Differential impact of immune escape mutations G145R and P120T on the replication of ENT1 lamivudine ENT1END -resistant hepatitis B virus e antigen-positive and -negative strains.Immune escape variants of the ENT2 hepatitis B ENT2END virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests
1	Immune escape variants of the ENT1 hepatitis B ENT1END  virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests. Recent data suggest a preferential selection of immune escape mutants in distinct peripheral blood leukocyte compartments of infected individuals. We therefore systematically analyzed the functional impact of the most prevalent immune escape variants, the sG145R and sP120T mutants, on the viral replication efficacy and antiviral drug susceptibility of common treatment-associated mutants with resistance to lamivudine (LAM) and/or HBeAg negativity. Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants. The sG145R mutation strongly reduced ENT2 HBsAg ENT2END levels and was able to fully restore the impaired replication of LAM-resistant HBV mutants to the levels of wild-type HBV, and PC or BCP mutations further enhanced viral replication
1	Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant ENT1 hepatitis B virus e antigen  ENT1END -positive and -negative strains.Immune escape variants of the ENT2 hepatitis B ENT2END virus (HBV) represent an emerging clinical challenge, because they can be associated with vaccine escape, HBV reactivation, and failure of diagnostic tests
0	Exclusion criteria included CNS ENT1 leukemic infiltration ENT1END at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term neurocognitive defects. During a 9-year period, we retrospectively collected 27 neurological events (11%) in as many patients, from 253 children enrolled in the ALL front-line protocol. CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related ENT1 peripheral neuropathy  ENT1END  late-onset encephalopathy, or long-term neurocognitive defects. During a 9-year period, we retrospectively collected 27 neurological events (11%) in as many patients, from 253 children enrolled in the ALL front-line protocol. CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT1 methotrexate ENT1END  ENT2 toxicity ENT2END (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
1	Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset encephalopathy, or long-term ENT1 neurocognitive defects  ENT1END  During a 9-year period, we retrospectively collected 27 neurological events (11%) in as many patients, from 253 children enrolled in the ALL front-line protocol. CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	During a 9-year period, we retrospectively collected 27 neurological events (11%) in as many patients, from 253 children enrolled in the ENT1 ALL  ENT1END front-line protocol. CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	CNS complications included posterior reversible ENT1 leukoencephalopathy  ENT1END syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT1 methotrexate ENT1END  toxicity (n = 2), syndrome of ENT2 inappropriate antidiuretic hormone secretion ENT2END (n = 1), and other unclassified events (n = 7)
0	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), ENT1 stroke  ENT1END (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	Exclusion criteria included CNS leukemic infiltration at diagnosis, therapy-related peripheral neuropathy, late-onset ENT1 encephalopathy  ENT1END  or long-term neurocognitive defects. During a 9-year period, we retrospectively collected 27 neurological events (11%) in as many patients, from 253 children enrolled in the ALL front-line protocol. CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), temporal lobe epilepsy (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	CNS complications included posterior reversible leukoencephalopathy syndrome (n = 10), stroke (n = 5), ENT1 temporal lobe epilepsy  ENT1END (n = 2), high-dose ENT2 methotrexate ENT2END toxicity (n = 2), syndrome of inappropriate antidiuretic hormone secretion (n = 1), and other unclassified events (n = 7)
0	PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with ENT1 propofol ENT1END sedation. Sedation depth was titrated using processed electroencephalography with the bispectral index (BIS), and patients were randomized to receive either deep (BIS, approximately 50) or light (BIS, >or=80) sedation. Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of ENT2 Mental Disorders ENT2END (Third Edition Revised) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery
0	PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe dementia who underwent ENT1 hip fracture  ENT1END repair under spinal anesthesia with ENT2 propofol ENT2END sedation
0	PATIENTS AND METHODS: We performed a double-blind, randomized controlled trial at an academic medical center of elderly patients (>or=65 years) without preoperative delirium or severe ENT1 dementia  ENT1END who underwent hip fracture repair under spinal anesthesia with ENT2 propofol ENT2END sedation
1	CONCLUSION: The use of light ENT1 propofol ENT1END sedation decreased the prevalence of ENT2 postoperative delirium ENT2END by 50% compared with deep sedation
1	CONCLUSION: The use of light ENT1 propofol ENT1END  sedation decreased the prevalence of ENT2 postoperative delirium ENT2END by 50% compared with deep sedation
1	Prenatal exposure to ENT1 fluoxetine  ENT1END  induces ENT2 fetal pulmonary hypertension ENT2END in the rat
0	As compared with controls, fluoxetine exposure resulted in ENT1 fetal pulmonary hypertension ENT1END as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01). Postnatal mortality was increased among experimental animals, and arterial ENT2 oxygen ENT2END saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0
0	Prenatal exposure to fluoxetine induces ENT1 fetal pulmonary hypertension ENT1END  in the rat.RATIONALE: Fluoxetine is a selective ENT2 serotonin ENT2END reuptake inhibitor antidepressant widely used by pregnant women
1	Prenatal exposure to ENT1 fluoxetine  ENT1END  induces ENT2 fetal pulmonary hypertension ENT2END in the rat
0	As compared with controls, fluoxetine exposure resulted in ENT1 fetal pulmonary hypertension  ENT1END as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum (P = 0.02) and by an increase in pulmonary arterial medial thickness (P < 0.01). Postnatal mortality was increased among experimental animals, and arterial ENT2 oxygen ENT2END saturation was 96 +/- 1% in 1-day-old control animals and significantly lower (P < 0
0	Prenatal exposure to fluoxetine induces ENT1 fetal pulmonary hypertension  ENT1END  in the rat.RATIONALE: Fluoxetine is a selective ENT2 serotonin ENT2END reuptake inhibitor antidepressant widely used by pregnant women
0	Serum ENT1 testosterone ENT1END concentration increased with pubertal status but was not affected by ENT2 hyperprolactinemia ENT2END
0	A cross-sectional evaluation of the effect of risperidone and selective ENT1 serotonin ENT1END  reuptake inhibitors on bone mineral density in boys.OBJECTIVE: The aim of the present study was to investigate the effect of risperidone-induced ENT2 hyperprolactinemia ENT2END on trabecular bone mineral density (BMD) in children and adolescents
1	OBJECTIVE: The aim of the present study was to investigate the effect of ENT1 risperidone  ENT1END induced ENT2 hyperprolactinemia ENT2END on trabecular bone mineral density (BMD) in children and adolescents
0	Serum ENT1 testosterone ENT1END  concentration increased with pubertal status but was not affected by hyperprolactinemia. As expected, bone mineral content and BMD increased with sexual maturity. After adjusting for the stage of sexual development and height and BMI z scores, serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius (P < .03). Controlling for relevant covariates, we also found treatment with selective serotonin reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05). These findings became more marked when the analysis was restricted to non-Hispanic white patients. Of 13 documented ENT2 fractures ENT2END , 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia
0	Controlling for relevant covariates, we also found treatment with selective ENT1 serotonin  ENT1END reuptake inhibitors (SSRIs) to be associated with lower trabecular BMD at the radius (P = .03) and BMD z score at the lumbar spine (P < .05). These findings became more marked when the analysis was restricted to non-Hispanic white patients. Of 13 documented ENT2 fractures ENT2END , 3 occurred after risperidone and SSRIs were started, and none occurred in patients with hyperprolactinemia
0	Of 13 documented ENT1 fractures ENT1END , 3 occurred after ENT2 risperidone ENT2END and SSRIs were started, and none occurred in patients with hyperprolactinemia
0	Coronary spasm was induced by intracoronary injection of ENT1 acetylcholine ENT1END  and no fixed ENT2 coronary artery stenosis ENT2END was documented on angiograms in all patients
0	Coronary spasm was induced by intracoronary injection of acetylcholine, and no fixed ENT1 coronary artery stenosis ENT1END  was documented on angiograms in all patients. DSE was performed with intravenous ENT2 dobutamine ENT2END infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes
0	All patients had ENT1 anginal  ENT1END attacks at rest with ST elevation on the electrocardiogram (variant angina). Coronary spasm was induced by intracoronary injection of ENT2 acetylcholine ENT2END , and no fixed coronary artery stenosis was documented on angiograms in all patients
0	The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by ENT1 dobutamine  ENT1END  We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis. All patients had ENT2 anginal ENT2END attacks at rest with ST elevation on the electrocardiogram (variant angina)
0	All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( ENT1 variant angina  ENT1END . Coronary spasm was induced by intracoronary injection of ENT2 acetylcholine ENT2END , and no fixed coronary artery stenosis was documented on angiograms in all patients
1	The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by ENT1 dobutamine ENT1END . We performed DSE on 51 patients with ENT2 coronary spastic angina ENT2END but without significant fixed coronary artery stenosis
0	The aim of the present study is to examine whether ENT1 myocardial ischemia  ENT1END due to coronary spasm is induced by dobutamine. We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis. All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina). Coronary spasm was induced by intracoronary injection of ENT2 acetylcholine ENT2END , and no fixed coronary artery stenosis was documented on angiograms in all patients
0	ENT1 Myocardial ischemia  ENT1END  due to coronary artery spasm during ENT2 dobutamine ENT2END stress echocardiography
0	Coronary spasm was induced by intracoronary injection of ENT1 acetylcholine ENT1END , and no fixed coronary artery stenosis was documented on angiograms in all patients. DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes. Of the 51 patients, 7 patients showed asynergy with ST elevation. All 7 patients (13.7%) had ENT2 chest pain ENT2END during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy
0	7%) had chest pain during asynergy, and both ENT1 chest pain ENT1END and electrocardiographic changes were preceded by asynergy. These findings indicate that ENT2 dobutamine ENT2END can provoke coronary spasm in some patients with coronary spastic angina
0	The aim of the present study is to examine whether myocardial ischemia due to ENT1 coronary spasm  ENT1END is induced by dobutamine. We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis. All patients had anginal attacks at rest with ST elevation on the electrocardiogram (variant angina). Coronary spasm was induced by intracoronary injection of ENT2 acetylcholine ENT2END , and no fixed coronary artery stenosis was documented on angiograms in all patients
1	Myocardial ischemia due to ENT1 coronary artery spasm  ENT1END  during ENT2 dobutamine ENT2END stress echocardiography
0	Coronary spasm was induced by intracoronary injection of ENT1 acetylcholine ENT1END , and no fixed coronary artery stenosis was documented on angiograms in all patients. DSE was performed with intravenous dobutamine infusion with an incremental doses of 5, 10, 20, 30, and 40 microg/kg/min every 5 minutes. Of the 51 patients, 7 patients showed asynergy with ST elevation. All 7 patients (13.7%) had chest pain during asynergy, and both chest pain and electrocardiographic changes were preceded by asynergy. These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina. When DSE is performed to evaluate ENT2 coronary artery disease ENT2END , not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy
0	These findings indicate that ENT1 dobutamine  ENT1END  can provoke coronary spasm in some patients with coronary spastic angina. When DSE is performed to evaluate ENT2 coronary artery disease ENT2END , not only fixed coronary stenosis, but also coronary spasm should be considered as a genesis of asynergy
0	Thus, the reduction in blood and brain ammonia and the prevention of ENT1 ammonia ENT1END coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action. These results provide a reasonable explanation for the beneficial effects observed in some ENT2 encephalopathic ENT2END patients receiving L-dopa
0	The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and ENT1 urea  ENT1END  Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations. Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented. Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action. These results provide a reasonable explanation for the beneficial effects observed in some ENT2 encephalopathic ENT2END patients receiving L-dopa
0	68 mmol L-dopa given by gastric intubation 15 minutes before the ENT1 ammonium salt  ENT1END injection. The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and urea. Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations. Bilateral nephrectomy eliminated the beneficial effect of L-dopa on blood and brain ammonia and the ammonia coma was not prevented. Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of dopamine on renal function rather than its central action. These results provide a reasonable explanation for the beneficial effects observed in some ENT2 encephalopathic ENT2END patients receiving L-dopa
0	These results provide a reasonable explanation for the beneficial effects observed in some ENT1 encephalopathic ENT1END  patients receiving ENT2 L-dopa ENT2END
0	Thus, the reduction in blood and brain ammonia and the prevention of ammonia coma after L-dopa, can be accounted for by the peripheral effect of ENT1 dopamine  ENT1END on renal function rather than its central action. These results provide a reasonable explanation for the beneficial effects observed in some ENT2 encephalopathic ENT2END patients receiving L-dopa
0	Reversal of ENT1 ammonia ENT1END ENT2 coma ENT2END in rats by L-dopa: a peripheral effect
1	7 mmol ENT1 NH4CL ENT1END  This ENT2 coma ENT2END was prevented with 1
0	The effect of L-dopa was correlated with a decrease in blood and brain ammonia, an increase in brain dopamine, and an increase in renal excretion of ammonia and ENT1 urea ENT1END . Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia ENT2 coma ENT2END nor affect the blood and brain ammonia concentrations
0	This ENT1 coma  ENT1END  was prevented with 1.68 mmol L-dopa given by gastric intubation 15 minutes before the ENT2 ammonium salt ENT2END injection
0	Thus, the reduction in blood and brain ammonia and the prevention of ammonia ENT1 coma ENT1END after ENT2 L-dopa ENT2END , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action
0	Intraventricular infusion of dopamine sufficient to raise the brain ENT1 dopamine  ENT1END to the same extent did not prevent the ammonia ENT2 coma ENT2END nor affect the blood and brain ammonia concentrations
1	To elucidate the possible role of the kinin B1 receptor (B1R) during the development of ENT1 DOX ENT1END ENT2 cardiomyopathy ENT2END , we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy
0	Doxorubicin ENT1 cardiomyopathy ENT1END -induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor.Clinical use of the ENT2 anthracycline ENT2END doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis
0	ENT1 Doxorubicin  ENT1END  cardiomyopathy-induced ENT2 inflammation ENT2END and apoptosis are attenuated by gene deletion of the kinin B1 receptor
0	Doxorubicin cardiomyopathy-induced ENT1 inflammation  ENT1END  and apoptosis are attenuated by gene deletion of the kinin B1 receptor.Clinical use of the ENT2 anthracycline ENT2END doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis
0	Clinical use of the anthracycline doxorubicin ( ENT1 DOX ENT1END  is limited by its ENT2 cardiotoxic ENT2END effects, which are attributed to the induction of apoptosis
0	Clinical use of the ENT1 anthracycline  ENT1END  doxorubicin (DOX) is limited by its ENT2 cardiotoxic ENT2END effects, which are attributed to the induction of apoptosis
0	In ENT1 DOX ENT1END B1R(-/-) mice, ENT2 cardiac dysfunction ENT2END was improved compared to DOX control mice, which was associated with normalization of the bax/bcl-2 ratio and interleukin 6, as well as AKT activation state
0	Clinical use of the ENT1 anthracycline ENT1END  doxorubicin (DOX) is limited by its cardiotoxic effects, which are attributed to the induction of apoptosis. To elucidate the possible role of the kinin B1 receptor (B1R) during the development of DOX cardiomyopathy, we studied B1R knockout mice (B1R(-/-)) by investigating cardiac inflammation and apoptosis after induction of DOX-induced cardiomyopathy. DOX control mice showed ENT2 cardiac dysfunction ENT2END measured by pressure-volume loops in vivo
0	In the pinealectomized chick, pretreatment with dopamine increased the duration of ENT1 catatonia ENT1END (DOC) after ketamine, but pretreatment with norepinephrine did not. The pineal indolamines exhibited mixed actions. Serotonin and ENT2 N-acetyl serotonin ENT2END which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick
1	In the pinealectomized chick, pretreatment with dopamine increased the duration of ENT1 catatonia ENT1END  (DOC) after ketamine, but pretreatment with norepinephrine did not. The pineal indolamines exhibited mixed actions. ENT2 Serotonin ENT2END and N-acetyl serotonin which augmented ketamine DOC, did not do so in the absence of the pineal gland, whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick
0	In the pinealectomized chick, pretreatment with dopamine increased the duration of ENT1 catatonia ENT1END  (DOC) after ketamine, but pretreatment with ENT2 norepinephrine ENT2END did not
0	Effects of ENT1 amine  ENT1END  pretreatment on ketamine ENT2 catatonia ENT2END in pinealectomized or hypophysectomized animals
1	In addition, these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by ENT1 melatonin ENT1END  Furthermore, dopamine appeared to act on systems more closely involved with the induction of ketamine ENT2 catatonia ENT2END rather than directly on the pituitary
0	The present studies were designed to clarify the role of ENT1 catecholamines ENT1END and pineal idolamines on ketamine-induced ENT2 catatonia ENT2END in the intact, pinealectomized or hypophysectomized chick and rat
1	In the pinealectomized chick, pretreatment with ENT1 dopamine  ENT1END increased the duration of ENT2 catatonia ENT2END (DOC) after ketamine, but pretreatment with norepinephrine did not
1	Effects of amine pretreatment on ENT1 ketamine ENT1END ENT2 catatonia ENT2END in pinealectomized or hypophysectomized animals
0	We describe a patient with no previous history of cardiac disease or ENT1 arrhythmia ENT1END who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after ENT2 caffeine ENT2END administration
0	We describe a patient with no previous history of ENT1 cardiac disease  ENT1END or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after ENT2 caffeine ENT2END administration
1	A case of ventricular tachycardia related to ENT1 caffeine ENT1END  pretreatment.Suboptimal ENT2 seizure ENT2END duration is commonly encountered in electroconvulsive therapy practice, especially in older patients with higher seizure thresholds
1	Intravenous ENT1 caffeine ENT1END is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ENT2 ventricular ectopy ENT2END
1	We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ENT1 ventricular tachycardia  ENT1END after ENT2 caffeine ENT2END administration
0	A 72-year-old woman was admitted to the hospital with "flash" ENT1 pulmonary edema ENT1END  preceded by chest pain, requiring intubation. Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include ENT2 angiotensin ENT2END -converting enzyme inhibitors or beta-blockers
0	A 72-year-old woman was admitted to the hospital with "flash" ENT1 pulmonary edema ENT1END , preceded by chest pain, requiring intubation. Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to ENT2 lisinopril ENT2END therapy was elicited
0	Angioedema following the intravenous administration of ENT1 metoprolol  ENT1END .A 72-year-old woman was admitted to the hospital with "flash" ENT2 pulmonary edema ENT2END , preceded by chest pain, requiring intubation
0	Her medical history included coronary artery disease with previous myocardial infarctions, ENT1 hypertension ENT1END  and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous steroids and ENT2 diphenhydramine ENT2END hydrochloride
0	Her medical history included coronary artery disease with previous myocardial infarctions, ENT1 hypertension  ENT1END , and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include ENT2 angiotensin ENT2END -converting enzyme inhibitors or beta-blockers
0	Her medical history included coronary artery disease with previous myocardial infarctions, ENT1 hypertension ENT1END , and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous ENT2 steroids ENT2END and diphenhydramine hydrochloride
0	Her medical history included coronary artery disease with previous myocardial infarctions, ENT1 hypertension  ENT1END , and diabetes mellitus. A history of angioedema secondary to ENT2 lisinopril ENT2END therapy was elicited
0	Angioedema following the intravenous administration of ENT1 metoprolol  ENT1END .A 72-year-old woman was admitted to the hospital with "flash" pulmonary edema, preceded by chest pain, requiring intubation. Her medical history included coronary artery disease with previous myocardial infarctions, ENT2 hypertension ENT2END , and diabetes mellitus
0	Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and ENT1 diabetes mellitus  ENT1END  A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous steroids and ENT2 diphenhydramine ENT2END hydrochloride
0	Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and ENT1 diabetes mellitus  ENT1END . A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include ENT2 angiotensin ENT2END -converting enzyme inhibitors or beta-blockers
0	Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and ENT1 diabetes mellitus  ENT1END . A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous ENT2 steroids ENT2END and diphenhydramine hydrochloride
0	Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and ENT1 diabetes mellitus  ENT1END . A history of angioedema secondary to ENT2 lisinopril ENT2END therapy was elicited
0	Angioedema following the intravenous administration of ENT1 metoprolol  ENT1END .A 72-year-old woman was admitted to the hospital with "flash" pulmonary edema, preceded by chest pain, requiring intubation. Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and ENT2 diabetes mellitus ENT2END
0	The ENT1 angioedema  ENT1END resolved after therapy with intravenous steroids and ENT2 diphenhydramine ENT2END hydrochloride
0	A history of ENT1 angioedema  ENT1END secondary to lisinopril therapy was elicited. Current medications did not include ENT2 angiotensin ENT2END -converting enzyme inhibitors or beta-blockers
0	The ENT1 angioedema  ENT1END  resolved after therapy with intravenous ENT2 steroids ENT2END and diphenhydramine hydrochloride
1	A history of ENT1 angioedema  ENT1END  secondary to ENT2 lisinopril ENT2END therapy was elicited
1	During the first day of hospitalization (while intubated), intravenous ENT1 metoprolol ENT1END was given, resulting in severe ENT2 angioedema ENT2END
0	Her medical history included coronary artery disease with previous ENT1 myocardial infarctions  ENT1END  hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous steroids and ENT2 diphenhydramine ENT2END hydrochloride
0	Her medical history included coronary artery disease with previous ENT1 myocardial infarctions  ENT1END , hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include ENT2 angiotensin ENT2END -converting enzyme inhibitors or beta-blockers
0	Her medical history included coronary artery disease with previous ENT1 myocardial infarctions  ENT1END , hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous ENT2 steroids ENT2END and diphenhydramine hydrochloride
0	Her medical history included coronary artery disease with previous ENT1 myocardial infarctions  ENT1END , hypertension, and diabetes mellitus. A history of angioedema secondary to ENT2 lisinopril ENT2END therapy was elicited
0	Angioedema following the intravenous administration of ENT1 metoprolol  ENT1END .A 72-year-old woman was admitted to the hospital with "flash" pulmonary edema, preceded by chest pain, requiring intubation. Her medical history included coronary artery disease with previous ENT2 myocardial infarctions ENT2END , hypertension, and diabetes mellitus
0	A 72-year-old woman was admitted to the hospital with "flash" pulmonary edema, preceded by ENT1 chest pain  ENT1END  requiring intubation. Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include ENT2 angiotensin ENT2END -converting enzyme inhibitors or beta-blockers
0	A 72-year-old woman was admitted to the hospital with "flash" pulmonary edema, preceded by ENT1 chest pain  ENT1END , requiring intubation. Her medical history included coronary artery disease with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to ENT2 lisinopril ENT2END therapy was elicited
0	Angioedema following the intravenous administration of ENT1 metoprolol  ENT1END .A 72-year-old woman was admitted to the hospital with "flash" pulmonary edema, preceded by ENT2 chest pain ENT2END , requiring intubation
0	Her medical history included ENT1 coronary artery disease  ENT1END with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous steroids and ENT2 diphenhydramine ENT2END hydrochloride
0	Her medical history included ENT1 coronary artery disease  ENT1END  with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include ENT2 angiotensin ENT2END -converting enzyme inhibitors or beta-blockers
0	Her medical history included ENT1 coronary artery disease  ENT1END  with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to lisinopril therapy was elicited. Current medications did not include angiotensin-converting enzyme inhibitors or beta-blockers. She had no previous beta-blocking drug exposure. During the first day of hospitalization (while intubated), intravenous metoprolol was given, resulting in severe angioedema. The angioedema resolved after therapy with intravenous ENT2 steroids ENT2END and diphenhydramine hydrochloride
0	Her medical history included ENT1 coronary artery disease  ENT1END  with previous myocardial infarctions, hypertension, and diabetes mellitus. A history of angioedema secondary to ENT2 lisinopril ENT2END therapy was elicited
0	Angioedema following the intravenous administration of ENT1 metoprolol  ENT1END .A 72-year-old woman was admitted to the hospital with "flash" pulmonary edema, preceded by chest pain, requiring intubation. Her medical history included ENT2 coronary artery disease ENT2END with previous myocardial infarctions, hypertension, and diabetes mellitus
0	Our results indicated that 1) treatment of mice with ENT1 ADR ENT1END caused ENT2 cardiovascular arrhythmias ENT2END characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment
0	The use of adriamycin (ADR) in cancer chemotherapy has been limited due to its cumulative ENT1 cardiovascular toxicity ENT1END  Earlier observations that ENT2 ADR ENT2END interacts with mitochondrial cytochrome c oxidase (COX) and suppresses its enzyme activity led us to investigate ADR's action on the cardiovascular functions and heart mitochondrial morphology in Balb-c mice i
1	ENT1 Structural and functional impairment of mitochondria  ENT1END  in ENT2 adriamycin ENT2END -induced cardiomyopathy in mice: suppression of cytochrome c oxidase II gene expression
0	The use of adriamycin ( ENT1 ADR ENT1END  in ENT2 cancer ENT2END chemotherapy has been limited due to its cumulative cardiovascular toxicity
1	Our results indicated that 1) treatment of mice with ENT1 ADR ENT1END  caused cardiovascular arrhythmias characterized by ENT2 bradycardia ENT2END , extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent swelling, fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment
0	Structural and functional impairment of mitochondria in ENT1 adriamycin  ENT1END -induced ENT2 cardiomyopathy ENT2END in mice: suppression of cytochrome c oxidase II gene expression
0	Our results indicated that 1) treatment of mice with ENT1 ADR ENT1END  caused cardiovascular arrhythmias characterized by bradycardia, extension of ventricular depolarization time (tQRS), and failure of QRS at high concentrations (10-14 mg/kg body weight cumulative dose); 2) the heart mitochondria underwent ENT2 swelling ENT2END , fusion, dissolution, and/or disruption of mitochondrial cristae after several weeks of treatment
1	Post-operative ENT1 rigidity  ENT1END  after ENT2 fentanyl ENT2END administration
0	A case of thoraco-abdominal ENT1 rigidity ENT1END leading to respiratory failure is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl. This was successfully reversed by ENT2 naloxone ENT2END
0	Post-operative rigidity after ENT1 fentanyl ENT1END  administration.A case of thoraco-abdominal rigidity leading to ENT2 respiratory failure ENT2END is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl
0	A case of thoraco-abdominal rigidity leading to ENT1 respiratory failure  ENT1END  is described in the post-operative period in an elderly patient who received a moderate dose of fentanyl. This was successfully reversed by ENT2 naloxone ENT2END
1	OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed modafinil on sleep and ENT1 daytime sleepiness ENT1END in chronic ENT2 cocaine ENT2END users
0	OBJECTIVE: The purpose of the present study was to determine the effect of morning-dosed ENT1 modafinil  ENT1END on sleep and ENT2 daytime sleepiness ENT2END in chronic cocaine users
1	This is a case report of myxedema coma secondary to ENT1 amiodarone ENT1END induced ENT2 hypothyroidism ENT2END in a patient with severe congestive heart failure (CHF)
0	The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine ( ENT1 T3 ENT1END . Patients with CHF on amiodarone may suffer serious morbidity and mortality from ENT2 hypothyroidism ENT2END , and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels
0	The condition is treated with intravenous thyroxine ( ENT1 T4  ENT1END  or intravenous tri-iodo-thyronine (T3). Patients with CHF on amiodarone may suffer serious morbidity and mortality from ENT2 hypothyroidism ENT2END , and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels
0	This case report carries an important clinical application given the frequent usage of ENT1 amiodarone ENT1END among CHF patients. The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with ENT2 hypotension ENT2END , weakness or other unexplained symptoms
0	The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine ( ENT1 T3  ENT1END ). Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels. This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients. The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with ENT2 hypotension ENT2END , weakness or other unexplained symptoms
0	The condition is treated with intravenous thyroxine ( ENT1 T4  ENT1END ) or intravenous tri-iodo-thyronine (T3). Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels. This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients. The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with ENT2 hypotension ENT2END , weakness or other unexplained symptoms
1	To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term ENT1 amiodarone ENT1END therapy. ENT2 Myxedema coma ENT2END is a life threatening condition that carries a mortality reaching as high as 20% with treatment
0	ENT1 Myxedema coma ENT1END  is a life threatening condition that carries a mortality reaching as high as 20% with treatment. The condition is treated with intravenous thyroxine (T4) or intravenous ENT2 tri-iodo-thyronine ENT2END (T3)
0	ENT1 Myxedema coma ENT1END  is a life threatening condition that carries a mortality reaching as high as 20% with treatment. The condition is treated with intravenous ENT2 thyroxine ENT2END (T4) or intravenous tri-iodo-thyronine (T3)
0	This case report carries an important clinical application given the frequent usage of ENT1 amiodarone ENT1END  among CHF patients. The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, ENT2 weakness ENT2END or other unexplained symptoms
0	The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine ( ENT1 T3  ENT1END ). Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels. This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients. The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, ENT2 weakness ENT2END or other unexplained symptoms
0	The condition is treated with intravenous thyroxine ( ENT1 T4  ENT1END ) or intravenous tri-iodo-thyronine (T3). Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels. This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients. The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension, ENT2 weakness ENT2END or other unexplained symptoms
0	Patients with ENT1 CHF ENT1END on ENT2 amiodarone ENT2END may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels
0	The condition is treated with intravenous thyroxine (T4) or intravenous tri-iodo-thyronine ( ENT1 T3  ENT1END ). Patients with ENT2 CHF ENT2END on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels
0	The condition is treated with intravenous thyroxine ( ENT1 T4  ENT1END ) or intravenous tri-iodo-thyronine (T3). Patients with ENT2 CHF ENT2END on amiodarone may suffer serious morbidity and mortality from hypothyroidism, and thus may deserve closer follow up for thyroid stimulating hormone (TSH) levels
1	To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term ENT1 amiodarone ENT1END  therapy. ENT2 Myxedema coma ENT2END is a life threatening condition that carries a mortality reaching as high as 20% with treatment
0	ENT1 Myxedema coma  ENT1END  is a life threatening condition that carries a mortality reaching as high as 20% with treatment. The condition is treated with intravenous thyroxine (T4) or intravenous ENT2 tri-iodo-thyronine ENT2END (T3)
0	ENT1 Myxedema coma  ENT1END  is a life threatening condition that carries a mortality reaching as high as 20% with treatment. The condition is treated with intravenous ENT2 thyroxine ENT2END (T4) or intravenous tri-iodo-thyronine (T3)
0	ENT1 decreased thymus (P < 0.001) and bodyweights ENT1END (P" < 0.01). Allopurinol decreased serum ENT2 urate ENT2END from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0
1	ENT1 Dex  ENT1END increased SBP (110 +/- 2-126 +/- 3 mmHg; P < 0.001) and ENT2 decreased thymus (P < 0.001) and bodyweights ENT2END (P" < 0
0	ENT1 decreased thymus (P < 0.001) and bodyweights ENT1END  (P" < 0.01). ENT2 Allopurinol ENT2END decreased serum urate from 76 +/- 5 to 30 +/- 3 micromol/L (P < 0
0	Thymus weight was used as a marker of glucocorticoid activity, and serum ENT1 urate ENT1END to assess XO inhibition. 5. Dex ENT2 increased SBP ENT2END (110 +/- 2-126 +/- 3 mmHg; P < 0
0	Role of ENT1 xanthine  ENT1END  oxidase in dexamethasone-induced ENT2 hypertension ENT2END in rats
1	We studied the role of xanthine oxidase (XO), which is implicated in the production of reactive oxygen species, in dexamethasone-induced hypertension ( ENT1 dex ENT1END ENT2 HT ENT2END )
0	Glucocorticoid-induced hypertension (GC- ENT1 HT ENT1END  in the rat is associated with ENT2 nitric oxide ENT2END -redox imbalance
0	ENT1 Allopurinol  ENT1END did not prevent dex- ENT2 HT ENT2END
0	A reproducible model for producing diffuse ENT1 myocardial injury ENT1END (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction. Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased ENT2 radiocalcium ENT2END uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs
0	Effects of acetylsalicylic acid, ENT1 dipyridamole  ENT1END , and hydrocortisone on epinephrine-induced ENT2 myocardial injury ENT2END in dogs
0	Effects of ENT1 acetylsalicylic acid  ENT1END , dipyridamole, and hydrocortisone on epinephrine-induced ENT2 myocardial injury ENT2END in dogs
0	A reproducible model for producing diffuse ENT1 myocardial injury ENT1END  (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction. Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction). Myocardial concentrations of ENT2 calcium ENT2END also increased significantly (12
0	Effects of acetylsalicylic acid, dipyridamole, and ENT1 hydrocortisone  ENT1END  on epinephrine-induced ENT2 myocardial injury ENT2END in dogs
1	A reproducible model for producing diffuse ENT1 myocardial injury  ENT1END  ( ENT2 epinephrine ENT2END infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction
0	A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute ENT1 myocardial infarction  ENT1END  Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased ENT2 radiocalcium ENT2END uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs
0	Effects of acetylsalicylic acid, ENT1 dipyridamole  ENT1END , and hydrocortisone on epinephrine-induced myocardial injury in dogs.A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute ENT2 myocardial infarction ENT2END
0	Effects of ENT1 acetylsalicylic acid  ENT1END , dipyridamole, and hydrocortisone on epinephrine-induced myocardial injury in dogs.A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute ENT2 myocardial infarction ENT2END
0	A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute ENT1 myocardial infarction  ENT1END . Infusions of epinephrine (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs. 827 counts per minute per gram of dried tissue or fraction). Myocardial concentrations of ENT2 calcium ENT2END also increased significantly (12
0	Effects of acetylsalicylic acid, dipyridamole, and ENT1 hydrocortisone  ENT1END  on epinephrine-induced myocardial injury in dogs.A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute ENT2 myocardial infarction ENT2END
0	A reproducible model for producing diffuse myocardial injury (epinephrine infusion) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute ENT1 myocardial infarction ENT1END . Infusions of ENT2 epinephrine ENT2END (4 mug per kilogram per minute for 6 hours) increased radiocalcium uptakes into intact myocardium and each of its subcellular components with the mitochondrial fraction showing the most consistent changes when compared to saline-infused control animals (4,957 vs
0	The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the ENT1 serotonin ENT1END system in the development of ENT2 RS ENT2END
0	The underlying mechanism of withdrawal-emergent RS in the present case may have been related to the pharmacological profile of risperidone, a serotonin- ENT1 dopamine  ENT1END antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of ENT2 RS ENT2END
0	The symptom was treated successfully with ENT1 trihexyphenidyl ENT1END anticholinergic therapy. The underlying mechanism of ENT2 withdrawal-emergent RS ENT2END in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS
1	Withdrawal-emergent rabbit syndrome during dose reduction of ENT1 risperidone  ENT1END . ENT2 Rabbit syndrome ENT2END (RS) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication
0	The underlying mechanism of ENT1 withdrawal-emergent RS ENT1END in the present case may have been related to the pharmacological profile of risperidone, a ENT2 serotonin ENT2END -dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS
0	The underlying mechanism of ENT1 withdrawal-emergent RS  ENT1END  in the present case may have been related to the pharmacological profile of risperidone, a serotonin ENT2 dopamine ENT2END antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS
0	The symptom was treated successfully with ENT1 trihexyphenidyl  ENT1END  anticholinergic therapy. The underlying mechanism of ENT2 withdrawal-emergent RS ENT2END in the present case may have been related to the pharmacological profile of risperidone, a serotonin-dopamine antagonist, suggesting the pathophysiologic influence of the serotonin system in the development of RS
1	ENT1 Withdrawal-emergent rabbit syndrome  ENT1END  during dose reduction of ENT2 risperidone ENT2END
0	Plasma concentration and urine excretion of the renin- ENT1 angiotensin ENT1END system proteins are altered in rats with ENT2 nephrotic syndrome ENT2END (NS)
1	These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute ENT1 NS ENT1END induced by ENT2 PAN ENT2END
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, ENT2 infections ENT2END with recovery in 3, and grand mal seizures in 1 patient
1	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END  is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, ENT2 infections ENT2END with recovery in 3, and grand mal seizures in 1 patient
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 nausea and ENT2 vomiting ENT2END occurred in 66% courses and phlebitis in the infusion arm in 37%
1	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 nausea and ENT2 vomiting ENT2END occurred in 66% courses and phlebitis in the infusion arm in 37%
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 ENT2 nausea ENT2END and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%
1	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 ENT2 nausea ENT2END and vomiting occurred in 66% courses and phlebitis in the infusion arm in 37%
0	Phase II study of the ENT1 amsacrine  ENT1END  analogue CI-921 (NSC 343499) in ENT2 non-small cell lung cancer ENT2END
0	Phase II study of the amsacrine analogue CI-921 (NSC 343499) in ENT1 non-small cell lung cancer  ENT1END . ENT2 CI-921 ENT2END (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised ENT2 squamous carcinoma ENT2END (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1)
0	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised ENT2 squamous carcinoma ENT2END (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1)
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal ENT2 seizures ENT2END in 1 patient
1	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal ENT2 seizures ENT2END in 1 patient
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), ENT2 adenocarcinoma ENT2END (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1)
0	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), ENT2 adenocarcinoma ENT2END (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1)
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), ENT2 bronchio-alveolar carcinoma ENT2END (1) and large cell undifferentiated carcinoma (1)
0	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), ENT2 bronchio-alveolar carcinoma ENT2END (1) and large cell undifferentiated carcinoma (1)
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell ENT2 undifferentiated carcinoma ENT2END (1)
0	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell ENT2 undifferentiated carcinoma ENT2END (1)
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). ENT2 Neutropenia ENT2END grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient
1	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). ENT2 Neutropenia ENT2END grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient
0	Phase II study of the ENT1 amsacrine ENT1END  analogue CI-921 (NSC 343499) in non-small cell lung cancer.CI-921 (NSC 343499; 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and ENT2 phlebitis ENT2END in the infusion arm in 37%
1	CI-921 (NSC 343499; ENT1 9-[[2-methoxy-4-[(methylsulphonyl)amino]phenyl]amino] -N,5-dimethyl- 4-acridinecarboxamide  ENT1END ) is a topoisomerase II poison with high experimental antitumour activity. It was administered by 15 min infusion to 16 evaluable patients with non-small cell lung cancer (NSCLC) (7 with no prior treatment, 9 patients in relapse following surgery/radiotherapy) at a dose (648 mg/m2 divided over 3 days, repeated every 3 weeks) determined by phase I trial. Patients had a median performance status of 1 (WHO), and median age of 61 years. The histology comprised squamous carcinoma (11), adenocarcinoma (1), mixed histology (2), bronchio-alveolar carcinoma (1) and large cell undifferentiated carcinoma (1). Neutropenia grade greater than or equal to 3 was seen in 15 patients, infections with recovery in 3, and grand mal seizures in 1 patient. Grade less than or equal to 2 nausea and vomiting occurred in 66% courses and ENT2 phlebitis ENT2END in the infusion arm in 37%
0	An 80-yr-old man developed acute ENT1 hepatitis ENT1END shortly after ingesting oral ceftriaxone. Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum ENT2 bilirubin ENT2END and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia
0	An 80-yr-old man developed acute ENT1 hepatitis ENT1END  shortly after ingesting oral ceftriaxone. Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia. These responded to systemic ENT2 steroids ENT2END and immunoglobulins
0	An 80-yr-old man developed acute ENT1 hepatitis ENT1END  shortly after ingesting oral ceftriaxone. Although the transaminases gradually returned to baseline after withholding the ENT2 beta lactam ENT2END antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia
1	An 80-yr-old man developed acute ENT1 hepatitis ENT1END  shortly after ingesting oral ENT2 ceftriaxone ENT2END
0	Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum ENT1 bilirubin ENT1END  and a decrease in hemoglobin concentration caused by an ENT2 autoimmune hemolytic anemia ENT2END and erythroblastocytopenia
0	Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an ENT1 autoimmune hemolytic anemia  ENT1END  and erythroblastocytopenia. These responded to systemic ENT2 steroids ENT2END and immunoglobulins
0	Although the transaminases gradually returned to baseline after withholding the ENT1 beta lactam  ENT1END  antibiotic, there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an ENT2 autoimmune hemolytic anemia ENT2END and erythroblastocytopenia
1	Acute hepatitis, ENT1 autoimmune hemolytic anemia  ENT1END , and erythroblastocytopenia induced by ENT2 ceftriaxone ENT2END
0	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ENT1 ovarian and breast carcinoma ENT1END  Two phase II trials of 24-hour ENT2 paclitaxel ENT2END infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%
1	Grade 1 or 2 polyneuropathy affected 56% of patients while only one (2%) experienced severe ENT1 polyneuropathy ENT1END  Similarly, grade 1 or 2 myalgia/arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4. Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4. ENT2 Paclitaxel ENT2END is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity
1	Similarly, grade 1 or 2 ENT1 myalgia  ENT1END arthralgia was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4. Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4. ENT2 Paclitaxel ENT2END is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity
1	Nausea and ENT1 vomiting  ENT1END were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4. ENT2 Paclitaxel ENT2END is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity
0	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different ENT1 tumor  ENT1END types, notably ovarian and breast carcinoma. Two phase II trials of 24-hour ENT2 paclitaxel ENT2END infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%
0	We investigated the efficacy and ENT1 toxicity ENT1END of a 3-hour ENT2 paclitaxel ENT2END infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC
0	Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) has demonstrated significant antineoplastic activity against different tumor types, notably ENT1 ovarian and breast carcinoma  ENT1END  Two phase II trials of 24-hour ENT2 paclitaxel ENT2END infusions in chemotherapy-naive patients with stage IIIB or IV non-small cell lung cancer (NSCLC) reported response rates of 21% and 24%
1	ENT1 Nausea  ENT1END and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4. ENT2 Paclitaxel ENT2END is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity
1	ENT1 Paclitaxel ENT1END 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication. Of 50 patients evaluable for response, 12 (24%) had partial remission, 26 (52%) had no change, and 12 had disease progression (24%). Hematologic toxicities were mild: only one patient (2%) developed grade 3 or 4 ENT2 neutropenia ENT2END , while 29% had grade 1 or 2
0	5% of patients experienced grade 4 ENT1 leukopenia  ENT1END  We investigated the efficacy and toxicity of a 3-hour ENT2 paclitaxel ENT2END infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC
0	4%) had stage IV ENT1 NSCLC ENT1END ENT2 Paclitaxel ENT2END 225 mg/m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication
1	Similarly, grade 1 or 2 myalgia/ ENT1 arthralgia  ENT1END was observed in 63.2% of patients, but only 14.3% experienced grade 3 or 4. Nausea and vomiting were infrequent, with 14% of patients experiencing grade 1 or 2 and only 2% experiencing grade 3 or 4. ENT2 Paclitaxel ENT2END is thus an active single agent in this patient population, with a 3-hour infusion proving comparably effective to a 24-hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity
1	Reports of persistent ENT1 paralysis ENT1END after the discontinuance of these drugs have most often involved aminosteroid-based NMBAs such as ENT2 vecuronium bromide ENT2END , especially when used in conjunction with corticosteroids
1	We report a case of ENT1 atracurium ENT1END related ENT2 paralysis ENT2END persisting for approximately 50 hours in a patient who was not treated with corticosteroids
0	thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on ENT1 aspartate ENT1END or glycine levels compared to controls in rat cortex and brain stem. Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced ENT2 respiratory arrest ENT2END with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain
0	thiopental produced ENT1 respiratory arrest ENT1END  with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain. ENT2 Naloxone ENT2END (2
0	ENT1 thiopental  ENT1END produced ENT2 respiratory arrest ENT2END with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain
0	Pretreatment of rats with ENT1 thiosemicarbazide  ENT1END for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced ENT2 respiratory arrest ENT2END with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain
0	thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or ENT1 glycine  ENT1END levels compared to controls in rat cortex and brain stem. Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental. 50 mg/kg, i.v. thiopental produced ENT2 respiratory arrest ENT2END with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain
0	thiopental produced ENT1 respiratory arrest ENT1END  with further increase in ENT2 GABA ENT2END and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain
0	thiopental produced ENT1 respiratory arrest ENT1END  with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the ENT2 amino acids ENT2END studied in four regions of rat brain
0	thiopental produced ENT1 respiratory arrest ENT1END  with further increase in GABA and decrease in ENT2 glutamate ENT2END again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain
0	In this study naloxone reversed ENT1 respiratory paralysis  ENT1END induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on ENT2 aspartate ENT2END or glycine levels compared to controls in rat cortex and brain stem
0	In this study ENT1 naloxone  ENT1END reversed ENT2 respiratory paralysis ENT2END induced by thiopental in rats
1	In this study naloxone reversed ENT1 respiratory paralysis ENT1END  induced by ENT2 thiopental ENT2END in rats
0	In this study naloxone reversed ENT1 respiratory paralysis  ENT1END  induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem. Pretreatment of rats with ENT2 thiosemicarbazide ENT2END for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental
0	In this study naloxone reversed ENT1 respiratory paralysis  ENT1END  induced by thiopental in rats. 25 mg/kg, i.v. thiopental produced anesthesia without altering respiratory rate, increased GABA, decreased glutamate, and had no effect on aspartate or ENT2 glycine ENT2END levels compared to controls in rat cortex and brain stem
0	) reversed ENT1 respiratory paralysis ENT1END  glutamate and ENT2 GABA ENT2END levels to control values in brain stem and cortex with no changes in caudate or cerebellum
0	thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the ENT1 amino acids  ENT1END  studied in four regions of rat brain. Naloxone (2.5 mg/kg, i.v.) reversed ENT2 respiratory paralysis ENT2END , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum
0	) reversed ENT1 respiratory paralysis ENT1END , ENT2 glutamate ENT2END and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum
1	Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, ENT1 edrophonium ENT1END induced ENT2 bradycardias ENT2END
0	Use of glycopyrronium 5 micrograms kg-1 provided greater cardiovascular stability and, given 1 min before the edrophonium, was sufficient to minimize early, edrophonium-induced ENT1 bradycardias ENT1END . This low dose of ENT2 glycopyrronium ENT2END provided good control of oropharyngeal secretions
1	Acute ENT1 cocaine  ENT1END -induced ENT2 seizures ENT2END : differential sensitivity of six inbred mouse strains
0	A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for ENT1 hypertension ENT1END  The stone passed spontaneously and was found to contain a triamterene metabolite admixed with ENT2 uric acid salts ENT2END
0	A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide-triamterene therapy for ENT1 hypertension ENT1END . The stone passed spontaneously and was found to contain a ENT2 triamterene ENT2END metabolite admixed with uric acid salts
0	A case of triamterene nephrolithiasis is reported in a man after 4 years of ENT1 hydrochlorothiazide-triamterene  ENT1END therapy for ENT2 hypertension ENT2END
0	The stone passed spontaneously and was found to contain a triamterene metabolite admixed with ENT1 uric acid salts ENT1END . Factors affecting triamterene ENT2 nephrolithiasis ENT2END are discussed and 2 previously reported cases are reviewed
1	ENT1 Triamterene ENT1END ENT2 nephrolithiasis ENT2END complicating dyazide therapy
0	Triamterene ENT1 nephrolithiasis  ENT1END  complicating ENT2 dyazide ENT2END therapy
1	Cardiac toxicity is a major complication which limits the use of ENT1 adriamycin ENT1END as a chemotherapeutic agent. ENT2 Cardiomyopathy ENT2END is frequent when the total dose exceeds 600 mg/m2 and occurs within one to six months after cessation of therapy
0	Late, late ENT1 doxorubicin ENT1END ENT2 cardiotoxicity ENT2END
1	Therefore, the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone- and ENT1 carbamazepine ENT1END induced ENT2 cognitive impairment ENT2END and oxidative stress in rats
0	At the end of study period, serum phenobarbitone and carbamazepine, whole brain malondialdehyde and reduced ENT1 glutathione ENT1END levels were estimated. The administration of phenobarbitone and carbamazepine for 21days caused a significant ENT2 impairment of learning and memory ENT2END as well as an increased oxidative stress
1	Curcumin ameliorates ENT1 cognitive dysfunction  ENT1END  and oxidative damage in ENT2 phenobarbitone ENT2END and carbamazepine administered rats
0	At the end of study period, serum phenobarbitone and carbamazepine, whole brain ENT1 malondialdehyde  ENT1END and reduced glutathione levels were estimated. The administration of phenobarbitone and carbamazepine for 21days caused a significant ENT2 impairment of learning and memory ENT2END as well as an increased oxidative stress
0	ENT1 Curcumin  ENT1END  ameliorates ENT2 cognitive dysfunction ENT2END and oxidative damage in phenobarbitone and carbamazepine administered rats
1	ENT1 Veno-occlusive liver disease  ENT1END  after ENT2 dacarbazine ENT2END therapy (DTIC) for melanoma
0	A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine ( ENT1 DTIC ENT1END  therapy for melanoma is reported. There was a fulminant clinical course from start of symptoms until ENT2 death ENT2END
0	A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine ( ENT1 DTIC ENT1END ) therapy for melanoma is reported. There was a fulminant clinical course from start of symptoms until death. At autopsy the liver was enlarged and firm with signs of ENT2 venous congestion ENT2END
0	A case of veno-occlusive disease of the liver with fatal outcome after dacarbazine ( ENT1 DTIC ENT1END ) therapy for melanoma is reported. There was a fulminant clinical course from start of symptoms until death. At autopsy the liver was enlarged and firm with signs of venous congestion. Small- and medium-sized hepatic veins were blocked by ENT2 thrombosis ENT2END
0	Veno-occlusive liver disease after dacarbazine therapy ( ENT1 DTIC  ENT1END ) for ENT2 melanoma ENT2END
0	Sulpiride is a selective D2-receptor antagonist with antipsychotic and ENT1 antidepressant ENT1END properties. Although initially thought to be free of extrapyramidal side effects, sulpiride-induced ENT2 tardive dyskinesia ENT2END and parkinsonism have been reported occasionally
0	Although initially thought to be free of extrapyramidal side effects, ENT1 sulpiride  ENT1END induced ENT2 tardive dyskinesia ENT2END and parkinsonism have been reported occasionally
0	Sulpiride is a selective D2-receptor antagonist with antipsychotic and ENT1 antidepressant ENT1END  properties. Although initially thought to be free of extrapyramidal side effects, sulpiride-induced tardive dyskinesia and ENT2 parkinsonism ENT2END have been reported occasionally
0	Although initially thought to be free of extrapyramidal side effects, ENT1 sulpiride  ENT1END -induced tardive dyskinesia and ENT2 parkinsonism ENT2END have been reported occasionally
0	Sulpiride-induced ENT1 tardive dystonia  ENT1END .Sulpiride is a selective D2-receptor antagonist with antipsychotic and ENT2 antidepressant ENT2END properties
1	Sulpiride-induced ENT1 tardive dystonia  ENT1END . ENT2 Sulpiride ENT2END is a selective D2-receptor antagonist with antipsychotic and antidepressant properties
1	Although cessation of ENT1 sulphasalazine ENT1END treatment resulted in improvements in ENT2 fever ENT2END , red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	Although cessation of sulphasalazine treatment resulted in improvements in ENT1 fever ENT1END , red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated ENT2 steroid ENT2END therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	Although cessation of ENT1 sulphasalazine ENT1END  treatment resulted in improvements in fever, ENT2 red eyes ENT2END , chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	Although cessation of sulphasalazine treatment resulted in improvements in fever, ENT1 red eyes  ENT1END , chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated ENT2 steroid ENT2END therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and ENT1 urinary abnormalities ENT1END after restarting of ENT2 sulphasalazine ENT2END treatment
0	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and ENT1 urinary abnormalities  ENT1END  after restarting of sulphasalazine treatment. Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement. Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative. PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively. Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated ENT2 steroid ENT2END therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	Although cessation of ENT1 sulphasalazine ENT1END  treatment resulted in improvements in fever, red eyes, ENT2 chest pain ENT2END , titer of C-reactive protein and volume of the pleural effusions, we initiated steroid therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, ENT1 chest pain  ENT1END , titer of C-reactive protein and volume of the pleural effusions, we initiated ENT2 steroid ENT2END therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
1	A 59-year-old woman with ulcerative colitis developed red eyes, ENT1 pleural effusion  ENT1END  eosinophilia and urinary abnormalities after restarting of ENT2 sulphasalazine ENT2END treatment
0	One month after ENT1 steroid ENT1END therapy, the ENT2 pleural effusion ENT2END disappeared, and PR3-ANCA titer normalized 3 months later
0	Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing glomerulonephritis after restarting ENT1 sulphasalazine ENT1END  treatment.A 59-year-old woman with ENT2 ulcerative colitis ENT2END developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment
0	A 59-year-old woman with ENT1 ulcerative colitis  ENT1END  developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment. Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement. Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative. PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively. Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated ENT2 steroid ENT2END therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
1	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, eosinophilia and urinary abnormalities after restarting of ENT1 sulphasalazine ENT1END  treatment. Light microscopy of a kidney biopsy revealed ENT2 segmental necrotizing glomerulonephritis ENT2END without deposition of immunoglobulin or complement
0	Light microscopy of a kidney biopsy revealed ENT1 segmental necrotizing glomerulonephritis  ENT1END  without deposition of immunoglobulin or complement. Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative. PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively. Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated ENT2 steroid ENT2END therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	Proteinase 3-antineutrophil cytoplasmic antibody-(PR3-ANCA) positive necrotizing ENT1 glomerulonephritis  ENT1END  after restarting ENT2 sulphasalazine ENT2END treatment
0	One month after ENT1 steroid ENT1END  therapy, the pleural effusion disappeared, and PR3-ANCA titer normalized 3 months later. This case suggests that sulphasalazine can induce PR3-ANCA-positive necrotizing ENT2 glomerulonephritis ENT2END
0	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, ENT1 eosinophilia  ENT1END and urinary abnormalities after restarting of ENT2 sulphasalazine ENT2END treatment
0	A 59-year-old woman with ulcerative colitis developed red eyes, pleural effusion, ENT1 eosinophilia  ENT1END  and urinary abnormalities after restarting of sulphasalazine treatment. Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement. Proteinase 3-antineutrophil cytoplasmic antibody (PR3-ANCA) titer was elevated at 183 ELISA units (EU) in sera (normal range less than 10 EU), myeloperoxidase-ANCA was negative. PR3-ANCA titer was 250 and 1,070 EU in pleural effusions on right and left side, respectively. Although cessation of sulphasalazine treatment resulted in improvements in fever, red eyes, chest pain, titer of C-reactive protein and volume of the pleural effusions, we initiated ENT2 steroid ENT2END therapy, because PR3-ANCA titer rose to 320 EU, eosinophil count increased to 1,100 cells/microl, and the pleural effusion remained
0	Within the last several years, previously rare liver tumors have been seen in young women using oral contraceptive ENT1 steroids ENT1END  The Registry for ENT2 Liver Tumors ENT2END Associated with Oral Contraceptives at the University of California, Irvine, has clearly identified 27 cases
1	Etiologic factors in the pathogenesis of ENT1 liver tumors  ENT1END  associated with ENT2 oral contraceptives ENT2END
0	Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, ENT1 hamartoma ENT1END  and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive ENT2 steroids ENT2END
0	Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, ENT1 hamartoma ENT1END , and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of ENT2 oral contraceptive ENT2END steroids
0	Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive ENT1 steroids ENT1END . Eight deaths and liver ENT2 rupture ENT2END in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon
0	Significant statistical etiologic factors include prolonged uninterrupted usage of ENT1 oral contraceptive  ENT1END  steroids. Eight deaths and liver ENT2 rupture ENT2END in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon
0	Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, ENT1 adenoma  ENT1END  hamartoma, and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive ENT2 steroids ENT2END
0	Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, ENT1 adenoma  ENT1END , hamartoma, and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of ENT2 oral contraceptive ENT2END steroids
0	Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and ENT1 hepatoma  ENT1END  Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive ENT2 steroids ENT2END
0	Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia, adenoma, hamartoma, and ENT1 hepatoma  ENT1END . Significant statistical etiologic factors include prolonged uninterrupted usage of ENT2 oral contraceptive ENT2END steroids
0	Common to these 71 cases has been a histopathologic diagnosis of ENT1 focal nodular hyperplasia  ENT1END  adenoma, hamartoma, and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive ENT2 steroids ENT2END
0	Common to these 71 cases has been a histopathologic diagnosis of ENT1 focal nodular hyperplasia  ENT1END , adenoma, hamartoma, and hepatoma. Significant statistical etiologic factors include prolonged uninterrupted usage of ENT2 oral contraceptive ENT2END steroids
0	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C ( ENT1 CHC ENT1END . Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs. A brain imaging study and repetitive nerve stimulation test indicated no abnormality. The ENT2 acetylcholine ENT2END receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal
0	The ocular myasthenia associated with combination therapy of ENT1 pegylated IFN alpha-2b ENT1END and ribavirin for ENT2 CHC ENT2END is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy
0	The ocular myasthenia associated with combination therapy of pegylated IFN alpha-2b and ENT1 ribavirin  ENT1END for ENT2 CHC ENT2END is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy
0	A 63-year-old male experienced sudden ENT1 diplopia  ENT1END after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs. A brain imaging study and repetitive nerve stimulation test indicated no abnormality. The ENT2 acetylcholine ENT2END receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal
0	A 63-year-old male experienced sudden ENT1 diplopia ENT1END  after 9 weeks of administration of ENT2 pegylated interferon (IFN) alpha-2b ENT2END and ribavirin for chronic hepatitis C (CHC)
0	Development of ocular myasthenia during pegylated interferon and ENT1 ribavirin  ENT1END  treatment for chronic hepatitis C.A 63-year-old male experienced sudden ENT2 diplopia ENT2END after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ribavirin for chronic hepatitis C (CHC)
0	The ENT1 acetylcholine ENT1END  receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal. The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ribavirin. The ENT2 ocular myasthenia ENT2END associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy
1	Development of ENT1 ocular myasthenia  ENT1END  during ENT2 pegylated interferon ENT2END and ribavirin treatment for chronic hepatitis C
1	The patient's ophthalmological symptoms improved rapidly 3 weeks after discontinuation of pegylated IFN alpha-2b and ENT1 ribavirin  ENT1END  The ENT2 ocular myasthenia ENT2END associated with combination therapy of pegylated IFN alpha-2b and ribavirin for CHC is very rarely reported; therefore, we present this case with a review of the various eye complications of IFN therapy
0	Ophthalmologic examinations showed ENT1 ptosis on the right upper lid  ENT1END and restricted right eye movement without any other neurological signs. A brain imaging study and repetitive nerve stimulation test indicated no abnormality. The ENT2 acetylcholine ENT2END receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal
1	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of ENT1 pegylated interferon (IFN) alpha-2b  ENT1END  and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ENT2 ptosis on the right upper lid ENT2END and restricted right eye movement without any other neurological signs
1	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ENT1 ribavirin  ENT1END for chronic hepatitis C (CHC). Ophthalmologic examinations showed ENT2 ptosis on the right upper lid ENT2END and restricted right eye movement without any other neurological signs
0	Ophthalmologic examinations showed ptosis on the right upper lid and ENT1 restricted right eye movement  ENT1END without any other neurological signs. A brain imaging study and repetitive nerve stimulation test indicated no abnormality. The ENT2 acetylcholine ENT2END receptor antibody titer and response to acetylcholinesterase inhibitors were negative, and the results of thyroid function tests were normal
1	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of ENT1 pegylated interferon (IFN) alpha-2b  ENT1END  and ribavirin for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right upper lid and ENT2 restricted right eye movement ENT2END without any other neurological signs
1	A 63-year-old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon (IFN) alpha-2b and ENT1 ribavirin  ENT1END  for chronic hepatitis C (CHC). Ophthalmologic examinations showed ptosis on the right upper lid and ENT2 restricted right eye movement ENT2END without any other neurological signs
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of ENT1 inflammation ENT1END of the liver capsule, necrosis, and steatosis throughout the study. The liver levels of beta-oxidation metabolites of ENT2 VPA ENT2END were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study
0	Liver ENT1 LPO  ENT1END levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05). Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05). Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of ENT2 inflammation ENT2END of the liver capsule, necrosis, and steatosis throughout the study
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of ENT1 inflammation ENT1END  of the liver capsule, necrosis, and steatosis throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of ENT2 4-ene-VPA ENT2END and (E)-2,4-diene-VPA were not elevated throughout the study
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of ENT1 inflammation ENT1END  of the liver capsule, necrosis, and steatosis throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study. Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of ENT2 15-F(2t)-IsoP ENT2END , which precedes the onset of necrosis, steatosis, and elevated levels of serum alpha-GST
0	Liver and plasma ENT1 TBARs  ENT1END were not increased until 14 days (2-fold vs. control, p < 0.05). Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of ENT2 inflammation ENT2END of the liver capsule, necrosis, and steatosis throughout the study
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of ENT1 inflammation  ENT1END  of the liver capsule, necrosis, and steatosis throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E)- ENT2 2,4-diene-VPA ENT2END were not elevated throughout the study
0	Liver toxicity was evaluated based on serum levels of alpha- ENT1 glutathione  ENT1END S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of ENT2 inflammation ENT2END of the liver capsule, necrosis, and steatosis throughout the study
1	Valproic acid I: time course of lipid peroxidation biomarkers, ENT1 liver toxicity  ENT1END , and ENT2 valproic acid ENT2END metabolite levels in rats
1	Liver ENT1 LPO ENT1END  levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05). Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05). ENT2 Liver toxicity ENT2END was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to ENT1 hepatotoxicity  ENT1END as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of ENT2 4-ene-VPA ENT2END and (E)-2,4-diene-VPA were not elevated throughout the study
1	A single dose of valproic acid (VPA), which is a widely used antiepileptic drug, is associated with oxidative stress in rats, as recently demonstrated by elevated levels of 15-F(2t)-isoprostane ( ENT1 15-F(2t)-IsoP ENT1END . To determine whether there was a temporal relationship between VPA-associated oxidative stress and ENT2 hepatotoxicity ENT2END , adult male Sprague-Dawley rats were treated ip with VPA (500 mg/kg) or 0
1	Liver and plasma ENT1 TBARs  ENT1END  were not increased until 14 days (2-fold vs. control, p < 0.05). ENT2 Liver toxicity ENT2END was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to ENT1 hepatotoxicity  ENT1END  as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and steatosis throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E) ENT2 2,4-diene-VPA ENT2END were not elevated throughout the study
0	ENT1 Liver toxicity  ENT1END  was evaluated based on serum levels of alpha ENT2 glutathione ENT2END S-transferase (alpha-GST) and by histology
1	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and ENT1 steatosis  ENT1END throughout the study. The liver levels of beta-oxidation metabolites of ENT2 VPA ENT2END were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study
0	Liver ENT1 LPO  ENT1END  levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05). Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05). Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and ENT2 steatosis ENT2END throughout the study
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and ENT1 steatosis  ENT1END  throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of ENT2 4-ene-VPA ENT2END and (E)-2,4-diene-VPA were not elevated throughout the study
0	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of ENT1 15-F(2t)-IsoP ENT1END , which precedes the onset of necrosis, ENT2 steatosis ENT2END , and elevated levels of serum alpha-GST
0	Liver and plasma ENT1 TBARs  ENT1END  were not increased until 14 days (2-fold vs. control, p < 0.05). Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and ENT2 steatosis ENT2END throughout the study
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and ENT1 steatosis  ENT1END  throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E) ENT2 2,4-diene-VPA ENT2END were not elevated throughout the study
0	Liver toxicity was evaluated based on serum levels of alpha- ENT1 glutathione  ENT1END  S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, necrosis, and ENT2 steatosis ENT2END throughout the study
1	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, ENT1 necrosis  ENT1END  and steatosis throughout the study. The liver levels of beta-oxidation metabolites of ENT2 VPA ENT2END were decreased by day 14, while the levels of 4-ene-VPA and (E)-2,4-diene-VPA were not elevated throughout the study
0	Liver ENT1 LPO  ENT1END  levels were not elevated until day 7 of treatment (1.8-fold versus control, p < 0.05). Liver and plasma TBARs were not increased until 14 days (2-fold vs. control, p < 0.05). Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, ENT2 necrosis ENT2END , and steatosis throughout the study
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, ENT1 necrosis  ENT1END , and steatosis throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of ENT2 4-ene-VPA ENT2END and (E)-2,4-diene-VPA were not elevated throughout the study
0	Overall, these findings indicate that VPA treatment results in oxidative stress, as measured by levels of ENT1 15-F(2t)-IsoP ENT1END , which precedes the onset of ENT2 necrosis ENT2END , steatosis, and elevated levels of serum alpha-GST
0	Liver and plasma ENT1 TBARs  ENT1END  were not increased until 14 days (2-fold vs. control, p < 0.05). Liver toxicity was evaluated based on serum levels of alpha-glutathione S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, ENT2 necrosis ENT2END , and steatosis throughout the study
0	Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, ENT1 necrosis  ENT1END , and steatosis throughout the study. The liver levels of beta-oxidation metabolites of VPA were decreased by day 14, while the levels of 4-ene-VPA and (E) ENT2 2,4-diene-VPA ENT2END were not elevated throughout the study
0	Liver toxicity was evaluated based on serum levels of alpha- ENT1 glutathione  ENT1END  S-transferase (alpha-GST) and by histology. Serum alpha-GST levels were significantly elevated by day 4, which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule, ENT2 necrosis ENT2END , and steatosis throughout the study
1	With this model, we were able to identify diffuse cortical hypoxia in the ENT1 puromycin aminonucleoside ENT1END induced ENT2 nephrotic syndrome ENT2END and focal and segmental hypoxia in the remnant kidney model
1	With this model, we were able to identify diffuse cortical ENT1 hypoxia  ENT1END in the ENT2 puromycin aminonucleoside ENT2END -induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model
0	Hypoxia in renal disease with proteinuria and/or glomerular ENT1 hypertension  ENT1END .Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available. In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat. We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney. With this model, we were able to identify diffuse cortical hypoxia in the ENT2 puromycin aminonucleoside ENT2END -induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model
0	We then applied this animal model to the detection of tubulointerstitial hypoxia in the ENT1 diseased kidney  ENT1END  With this model, we were able to identify diffuse cortical hypoxia in the ENT2 puromycin aminonucleoside ENT2END -induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model
0	Hypoxia in renal disease with ENT1 proteinuria  ENT1END  and/or glomerular hypertension.Despite the increasing need to identify and quantify tissue oxygenation at the cellular level, relatively few methods have been available. In this study, we developed a new hypoxia-responsive reporter vector using a hypoxia-responsive element of the 5' vascular endothelial growth factor untranslated region and generated a novel hypoxia-sensing transgenic rat. We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney. With this model, we were able to identify diffuse cortical hypoxia in the ENT2 puromycin aminonucleoside ENT2END -induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model
0	BACKGROUND: An association between the use of oral contraceptives and the risk of ENT1 myocardial infarction ENT1END has been found in some, but not all, studies. We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or gestodene) and second-generation (i.e., ENT2 levonorgestrel ENT2END ) oral contraceptives, the dose of estrogen, and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence
0	BACKGROUND: An association between the use of oral contraceptives and the risk of ENT1 myocardial infarction ENT1END  has been found in some, but not all, studies. We investigated this association, according to the type of progestagen included in third-generation (i.e., desogestrel or ENT2 gestodene ENT2END ) and second-generation (i
0	BACKGROUND: An association between the use of oral contraceptives and the risk of ENT1 myocardial infarction ENT1END  has been found in some, but not all, studies. We investigated this association, according to the type of ENT2 progestagen ENT2END included in third-generation (i
0	BACKGROUND: An association between the use of oral contraceptives and the risk of ENT1 myocardial infarction ENT1END  has been found in some, but not all, studies. We investigated this association, according to the type of progestagen included in third-generation (i.e., ENT2 desogestrel ENT2END or gestodene) and second-generation (i
1	The results with respect to the use of third-generation oral contraceptives were inconclusive but suggested that the risk was lower than the risk associated with second-generation ENT1 oral contraceptives ENT1END  The risk of ENT2 myocardial infarction ENT2END was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation
0	, levonorgestrel) oral contraceptives, the dose of ENT1 estrogen ENT1END  and the presence or absence of prothrombotic mutations METHODS: In a nationwide, population-based, case-control study, we identified and enrolled 248 women 18 through 49 years of age who had had a first ENT2 myocardial infarction ENT2END between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age, calendar year of the index event, and area of residence
1	ENT1 Subarachnoid and cerebral hemorrhage  ENT1END was noted in 18% of the hypertensive rats. A single PPA/ ENT2 caffeine ENT2END administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals
1	ENT1 Subarachnoid and cerebral hemorrhage ENT1END  was noted in 18% of the hypertensive rats. A single ENT2 PPA ENT2END /caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals
1	Subarachnoid and cerebral hemorrhage was noted in 18% of the ENT1 hypertensive  ENT1END rats. A single PPA ENT2 caffeine ENT2END administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals
1	Subarachnoid and cerebral hemorrhage was noted in 18% of the ENT1 hypertensive  ENT1END  rats. A single ENT2 PPA ENT2END /caffeine administration (same dose) lead to acute hypertension in both the normotensive and hypertensive animals
0	In order to determine if PPA/ ENT1 caffeine ENT1END can lead to ENT2 stroke ENT2END in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days
1	In order to determine if ENT1 PPA  ENT1END caffeine can lead to ENT2 stroke ENT2END in normotensive and/or hypertensive rats, we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days
1	These results suggest that PPA/ ENT1 caffeine ENT1END can lead to ENT2 cerebral hemorrhage ENT2END in previously hypertensive animals when administered in greater than the allowed dosage
1	These results suggest that ENT1 PPA  ENT1END caffeine can lead to ENT2 cerebral hemorrhage ENT2END in previously hypertensive animals when administered in greater than the allowed dosage
0	These infants are treated with two injections of ENT1 hepatitis B ENT1END immune globulin (HBIG) and at least three injections of plasma derived ENT2 hepatitis B vaccine ENT2END
1	This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( ENT1 HBsAg  ENT1END  and hepatitis B e antigen (HBeAg) positive mothers. These infants are treated with two injections of ENT2 hepatitis B ENT2END immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine
1	This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen (HBsAg) and hepatitis B e antigen ( ENT1 HBeAg  ENT1END  positive mothers. These infants are treated with two injections of ENT2 hepatitis B ENT2END immune globulin (HBIG) and at least three injections of plasma derived hepatitis B vaccine
0	These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and ENT1 morphine ENT1END in a persistent ENT2 pain ENT2END model that can be distinguished from those observed in acute pain models
0	These findings demonstrate a sexually-dimorphic interaction between ENT1 NMDA  ENT1END antagonists and morphine in a persistent ENT2 pain ENT2END model that can be distinguished from those observed in acute pain models
0	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a ENT1 capsaicin  ENT1END  model of persistent ENT2 pain ENT2END : comparisons to two models of acute pain
0	Enhancement of morphine antinociception by ENT1 dextromethorphan  ENT1END was seen in both males and females in the acute pain models, with the magnitude of this effect being greater in males. These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and morphine in a persistent ENT2 pain ENT2END model that can be distinguished from those observed in acute pain models
0	In acute pain models, N-methyl-D-aspartate (NMDA) antagonists enhance the antinociceptive effects of ENT1 morphine ENT1END to a greater extent in males than females. The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated, neurochemical substrates, and duration of the nociceptive stimulus. To this end, persistent ENT2 hyperalgesia ENT2END was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured
0	To this end, persistent ENT1 hyperalgesia ENT1END  was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured. For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures. In males, the non-competitive ENT2 NMDA ENT2END antagonist dextromethorphan enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner
1	To this end, persistent ENT1 hyperalgesia ENT1END  was induced by administration of ENT2 capsaicin ENT2END in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured
0	To this end, persistent ENT1 hyperalgesia ENT1END  was induced by administration of capsaicin in the tail of gonadally intact F344 rats, following which the tail was immersed in a mildly noxious thermal stimulus, and tail-withdrawal latencies measured. For comparison, tests were conducted in two acute pain models, the hotplate and warm water tail-withdrawal procedures. In males, the non-competitive NMDA antagonist ENT2 dextromethorphan ENT2END enhanced the antihyperalgesic effect of low to moderate doses of morphine in a dose-and time-dependent manner
0	These findings demonstrate a sexually-dimorphic interaction between NMDA antagonists and ENT1 morphine ENT1END  in a persistent pain model that can be distinguished from those observed in ENT2 acute pain ENT2END models
0	In ENT1 acute pain ENT1END models, ENT2 N-methyl-D-aspartate ENT2END (NMDA) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females
0	Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a ENT1 capsaicin  ENT1END  model of persistent pain: comparisons to two models of ENT2 acute pain ENT2END
0	Enhancement of morphine antinociception by ENT1 dextromethorphan ENT1END  was seen in both males and females in the ENT2 acute pain ENT2END models, with the magnitude of this effect being greater in males
1	A patient with ENT1 cholestatic hepatitis ENT1END due to ENT2 amiodarone ENT2END treatment is presented below and a review of the hepatotoxicity of amiodarone is given
1	It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment, including steatosis, alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular ENT1 cirrhosis of the liver ENT1END  Patients receiving ENT2 amiodarone ENT2END should be regularly screened with respect to hepatic enzyme levels
0	Amiodarone has proved very effective in the treatment of otherwise resistant cardiac ENT1 tachyarrhythmias ENT1END  The use of ENT2 amiodarone ENT2END has, however, been limited due to its serious side-effects
0	Patients receiving ENT1 amiodarone ENT1END  should be regularly screened with respect to hepatic enzyme levels. Therapy should be discontinued on the suspicion of cholestatic injury or ENT2 hepatomegaly ENT2END
1	ENT1 Hepatotoxicity  ENT1END  of ENT2 amiodarone ENT2END
1	It is concluded that solid evidence exists of hepatic injury due to ENT1 amiodarone ENT1END treatment, including ENT2 steatosis ENT2END , alterations resembling alcoholic hepatitis, cholestatic hepatitis and micronodular cirrhosis of the liver
0	It is concluded that solid evidence exists of hepatic injury due to ENT1 amiodarone ENT1END  treatment, including steatosis, alterations resembling ENT2 alcoholic hepatitis ENT2END , cholestatic hepatitis and micronodular cirrhosis of the liver
1	0 ml/kg of corn oil containing ENT1 vitamin D2 ENT1END and cholesterol to induce ENT2 atherosclerosis ENT2END
0	Moreover, a positive correlation of ENT1 histamine ENT1END to gastric hemorrhage and to ulcer was found in those ENT2 atherosclerotic ENT2END rats
0	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, ENT1 luminal ENT1END hemoglobin content and ulcer areas were determined. Elevated ENT2 atherosclerotic ENT2END parameters, such as serum calcium, total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats
1	0 ml/kg of corn oil containing vitamin D2 and ENT1 cholesterol  ENT1END to induce ENT2 atherosclerosis ENT2END
0	Elevated ENT1 atherosclerotic ENT1END  parameters, such as serum ENT2 calcium ENT2END , total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats
0	This hemorrhagic ulcer and various ulcerogenic parameters were dose-dependently ameliorated by daily intragastric ENT1 verapamil ENT1END  ENT2 Atherosclerosis ENT2END could produce gastric hemorrhagic ulcer via aggravation of gastric acid back-diffusion, LPO generation, histamine release and microvascular permeability that could be ameliorated by verapamil in rats
1	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating ENT1 gastric hemorrhage ENT1END and ulcer in rats with atherosclerosis induced by coadministration of ENT2 vitamin D2 ENT2END and cholesterol
0	Moreover, a positive correlation of ENT1 histamine ENT1END  to ENT2 gastric hemorrhage ENT2END and to ulcer was found in those atherosclerotic rats
0	Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and ENT1 luminal  ENT1END hemoglobin content were also observed in these rats. Moreover, a positive correlation of histamine to ENT2 gastric hemorrhage ENT2END and to ulcer was found in those atherosclerotic rats
1	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating ENT1 gastric hemorrhage ENT1END  and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and ENT2 cholesterol ENT2END
0	Elevated atherosclerotic parameters, such as serum ENT1 calcium  ENT1END , total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats. Severe gastric ulcers accompanied with increased ulcerogenic factors, including gastric acid back-diffusion, histamine release, LPO generation and luminal hemoglobin content were also observed in these rats. Moreover, a positive correlation of histamine to ENT2 gastric hemorrhage ENT2END and to ulcer was found in those atherosclerotic rats
0	Protective effect of ENT1 verapamil  ENT1END  on ENT2 gastric hemorrhagic ENT2END ulcers in severe atherosclerotic rats
1	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ENT1 ulcer  ENT1END in rats with atherosclerosis induced by coadministration of ENT2 vitamin D2 ENT2END and cholesterol
0	Moreover, a positive correlation of ENT1 histamine ENT1END  to gastric hemorrhage and to ENT2 ulcer ENT2END was found in those atherosclerotic rats
0	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, ENT1 luminal ENT1END  hemoglobin content and ENT2 ulcer ENT2END areas were determined
1	The aim of this study is to examine the role of gastric acid back-diffusion, mast cell histamine release, lipid peroxide (LPO) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and ENT1 cholesterol ENT1END . Additionally, the protective effect of verapamil on this ENT2 ulcer ENT2END model was evaluated
0	Gastric acid back-diffusion, mucosal LPO generation, histamine concentration, microvascular permeability, luminal hemoglobin content and ENT1 ulcer  ENT1END  areas were determined. Elevated atherosclerotic parameters, such as serum ENT2 calcium ENT2END , total cholesterol and low-density lipoprotein concentration were obtained in atherosclerotic rats
0	Additionally, the protective effect of ENT1 verapamil  ENT1END on this ENT2 ulcer ENT2END model was evaluated
0	Myasthenia gravis caused by ENT1 penicillamine  ENT1END  and chloroquine therapy for ENT2 rheumatoid arthritis ENT2END
0	We have described a unique patient who had reversible and dose-related myasthenia gravis after penicillamine and chloroquine therapy for ENT1 rheumatoid arthritis ENT1END  Although ENT2 acetylcholine ENT2END receptor antibodies were not detectable, the time course was consistent with an autoimmune process
0	Myasthenia gravis caused by penicillamine and ENT1 chloroquine  ENT1END  therapy for ENT2 rheumatoid arthritis ENT2END
1	We have described a unique patient who had reversible and dose-related ENT1 myasthenia gravis ENT1END after ENT2 penicillamine ENT2END and chloroquine therapy for rheumatoid arthritis
0	We have described a unique patient who had reversible and dose-related ENT1 myasthenia gravis  ENT1END  after penicillamine and chloroquine therapy for rheumatoid arthritis. Although ENT2 acetylcholine ENT2END receptor antibodies were not detectable, the time course was consistent with an autoimmune process
1	We have described a unique patient who had reversible and dose-related ENT1 myasthenia gravis ENT1END  after penicillamine and ENT2 chloroquine ENT2END therapy for rheumatoid arthritis
0	A palpable venous cord was present in 23% (14 of 62) of patients in the diazepam group, compared with 2% (1 of 60 patients) in the ENT1 midazolam ENT1END group (p < 0.002). ENT2 Pain ENT2END at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the midazolam group (p < 0
0	ENT1 Pain ENT1END  at the injection site occurred in 35% (22 of 62) of patients in the ENT2 diazepam ENT2END group compared with 7% (4 of 60 patients) in the midazolam group (p < 0
0	Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, ENT1 alcohol ENT1END use, and ENT2 pain ENT2END during the injection had no effect on the incidence of venous complications
0	Pain at the injection site occurred in 35% (22 of 62) of patients in the diazepam group compared with 7% (4 of 60 patients) in the ENT1 midazolam ENT1END group (p < 0.001). ENT2 Swelling ENT2END and warmth at the injection site were not significantly different between the two groups
0	Pain at the injection site occurred in 35% (22 of 62) of patients in the ENT1 diazepam  ENT1END  group compared with 7% (4 of 60 patients) in the midazolam group (p < 0.001). ENT2 Swelling ENT2END and warmth at the injection site were not significantly different between the two groups
0	ENT1 Swelling  ENT1END  and warmth at the injection site were not significantly different between the two groups. Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, ENT2 alcohol ENT2END use, and pain during the injection had no effect on the incidence of venous complications
1	ENT1 Venous complications  ENT1END  of ENT2 midazolam ENT2END versus diazepam
1	ENT1 Venous complications  ENT1END  of midazolam versus ENT2 diazepam ENT2END
0	Smoking, nonsteroidal anti-inflammatory drug use, intravenous catheter site, dwell time of the needle, ENT1 alcohol ENT1END  use, and pain during the injection had no effect on the incidence of ENT2 venous complications ENT2END
0	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced ENT1 hyperactivity ENT1END and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by RAMH indicating the involvement of ENT2 histamine ENT2END H(3)-receptors
0	THP exhibited an antipsychotic-like profile by potentiating ENT1 haloperidol  ENT1END induced catalepsy, reducing amphetamine-induced ENT2 hyperactivity ENT2END and reducing apomorphine-induced climbing in mice
1	On ENT1 amphetamine ENT1END induced ENT2 hyperactivity ENT2END , THP (3
0	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced ENT1 hyperactivity ENT1END  and reducing apomorphine-induced climbing in mice. Such effects of THP were reversed by ENT2 RAMH ENT2END indicating the involvement of histamine H(3)-receptors
0	On amphetamine-induced ENT1 hyperactivity ENT1END , ENT2 THP ENT2END (3
0	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced catalepsy, reducing amphetamine-induced ENT1 hyperactivity ENT1END  and reducing ENT2 apomorphine ENT2END -induced climbing in mice
0	The present study was designed to study the effect of ENT1 histamine ENT1END H(3)-receptor ligands on neuroleptic-induced ENT2 catalepsy ENT2END , apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice
1	THP exhibited an antipsychotic-like profile by potentiating ENT1 haloperidol ENT1END -induced ENT2 catalepsy ENT2END , reducing amphetamine-induced hyperactivity and reducing apomorphine-induced climbing in mice
0	THP exhibited an antipsychotic-like profile by potentiating haloperidol-induced ENT1 catalepsy ENT1END , reducing ENT2 amphetamine ENT2END -induced hyperactivity and reducing apomorphine-induced climbing in mice
0	) 1 h prior to haloperidol resulted in a dose-dependent increase in the ENT1 catalepsy ENT1END times (P < 0.05). However, pretreatment with ENT2 RAMH ENT2END significantly reversed such an effect of THP (15 mg/kg i
1	), per se did not cause ENT1 catalepsy ENT1END  Administration of ENT2 THP ENT2END (3
0	The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced ENT1 catalepsy ENT1END , ENT2 apomorphine ENT2END -induced climbing behavior and amphetamine-induced locomotor activities in mice
0	Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of ENT1 schizophrenia  ENT1END  The present study was designed to study the effect of ENT2 histamine ENT2END H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice
0	Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of ENT1 schizophrenia ENT1END . The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and amphetamine-induced locomotor activities in mice. Catalepsy was induced by ENT2 haloperidol ENT2END (2 mg/kg p
0	Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of ENT1 schizophrenia ENT1END . The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, apomorphine-induced climbing behavior and ENT2 amphetamine ENT2END -induced locomotor activities in mice
0	Such effects of THP were reversed by ENT1 RAMH ENT1END  indicating the involvement of histamine H(3)-receptors. Findings suggest a potential for H(3)-receptor antagonists in improving the refractory cases of ENT2 schizophrenia ENT2END
0	Antipsychotic-like profile of ENT1 thioperamide  ENT1END , a selective H3-receptor antagonist in mice.Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of ENT2 schizophrenia ENT2END
0	Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of ENT1 schizophrenia  ENT1END . The present study was designed to study the effect of histamine H(3)-receptor ligands on neuroleptic-induced catalepsy, ENT2 apomorphine ENT2END -induced climbing behavior and amphetamine-induced locomotor activities in mice
1	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that ENT1 NMS ENT1END like symptoms can occur after combined ENT2 paroxetine ENT2END and alprazolam treatment
0	The patient received bromocriptine and ENT1 diazepam ENT1END to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of ENT2 neuroleptic malignant syndrome ENT2END (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment
0	Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT1 aspartate  ENT1END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of ENT2 neuroleptic malignant syndrome ENT2END (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment
0	The patient received ENT1 bromocriptine  ENT1END and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of ENT2 neuroleptic malignant syndrome ENT2END (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment
0	Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT1 alanine  ENT1END aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of ENT2 neuroleptic malignant syndrome ENT2END (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment
0	Laboratory tests showed an elevation of ENT1 creatine  ENT1END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of ENT2 neuroleptic malignant syndrome ENT2END (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment
1	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that ENT1 NMS ENT1END -like symptoms can occur after combined paroxetine and ENT2 alprazolam ENT2END treatment
0	On the 10th day of ENT1 paroxetine ENT1END and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe ENT2 extrapyramidal symptoms ENT2END
0	2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe ENT1 extrapyramidal symptoms  ENT1END . Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe ENT1 extrapyramidal symptoms  ENT1END . Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe ENT1 extrapyramidal symptoms  ENT1END . Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe ENT1 extrapyramidal symptoms  ENT1END . Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe ENT1 extrapyramidal symptoms  ENT1END . Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and ENT1 alprazolam  ENT1END treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe ENT2 extrapyramidal symptoms ENT2END
0	On the 10th day of ENT1 paroxetine ENT1END  and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a ENT2 fever ENT2END (38
0	The patient received bromocriptine and ENT1 diazepam ENT1END  to treat his symptoms. 7 days later, the ENT2 fever ENT2END disappeared and the patient's serum CPK levels were normalized (175 IU/L)
0	Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT1 aspartate  ENT1END  aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the ENT2 fever ENT2END disappeared and the patient's serum CPK levels were normalized (175 IU/L)
0	The patient received ENT1 bromocriptine  ENT1END  and diazepam to treat his symptoms. 7 days later, the ENT2 fever ENT2END disappeared and the patient's serum CPK levels were normalized (175 IU/L)
0	Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT1 alanine  ENT1END  aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and diazepam to treat his symptoms. 7 days later, the ENT2 fever ENT2END disappeared and the patient's serum CPK levels were normalized (175 IU/L)
0	The patient had a ENT1 fever  ENT1END  (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and ENT1 alprazolam  ENT1END  treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a ENT2 fever ENT2END (38
0	Possible neuroleptic malignant syndrome related to concomitant treatment with ENT1 paroxetine ENT1END  and alprazolam.A 74-year-old man with depressive symptoms was admitted to a ENT2 psychiatric ENT2END hospital due to insomnia, loss of appetite, exhaustion, and agitation
0	A 74-year-old man with depressive symptoms was admitted to a ENT1 psychiatric  ENT1END  hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a ENT1 psychiatric  ENT1END  hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a ENT1 psychiatric  ENT1END  hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a ENT1 psychiatric  ENT1END  hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a ENT1 psychiatric  ENT1END  hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and ENT1 alprazolam  ENT1END .A 74-year-old man with depressive symptoms was admitted to a ENT2 psychiatric ENT2END hospital due to insomnia, loss of appetite, exhaustion, and agitation
0	On the 10th day of ENT1 paroxetine ENT1END  and alprazolam treatment, the patient exhibited marked ENT2 psychomotor retardation ENT2END , disorientation, and severe muscle rigidity with tremors
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked ENT1 psychomotor retardation  ENT1END , disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked ENT1 psychomotor retardation  ENT1END , disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked ENT1 psychomotor retardation  ENT1END , disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked ENT1 psychomotor retardation  ENT1END , disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked ENT1 psychomotor retardation  ENT1END , disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and ENT1 alprazolam  ENT1END  treatment, the patient exhibited marked ENT2 psychomotor retardation ENT2END , disorientation, and severe muscle rigidity with tremors
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and ENT1 agitation ENT1END  Medical treatment was initiated at a daily dose of 20 mg ENT2 paroxetine ENT2END and 1
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and ENT1 agitation  ENT1END . Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and ENT1 agitation  ENT1END . Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and ENT1 agitation  ENT1END . Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and ENT1 agitation  ENT1END . Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and ENT1 agitation  ENT1END . Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and ENT1 agitation ENT1END . Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg ENT2 alprazolam ENT2END
0	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined ENT1 paroxetine ENT1END  and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, ENT2 malnutrition ENT2END , and exhaustion
0	The patient received bromocriptine and ENT1 diazepam  ENT1END  to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, ENT2 malnutrition ENT2END , and exhaustion
0	The patient received ENT1 bromocriptine  ENT1END  and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, ENT2 malnutrition ENT2END , and exhaustion
0	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and ENT1 alprazolam  ENT1END  treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration, agitation, ENT2 malnutrition ENT2END , and exhaustion
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, ENT1 loss of appetite  ENT1END  exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg ENT2 paroxetine ENT2END and 1
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, ENT1 loss of appetite  ENT1END , exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, ENT1 loss of appetite  ENT1END , exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, ENT1 loss of appetite  ENT1END , exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, ENT1 loss of appetite  ENT1END , exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, ENT1 loss of appetite  ENT1END , exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and ENT1 alprazolam  ENT1END .A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia, ENT2 loss of appetite ENT2END , exhaustion, and agitation
0	On the 10th day of ENT1 paroxetine ENT1END  and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe ENT2 muscle rigidity ENT2END with tremors
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe ENT1 muscle rigidity  ENT1END  with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe ENT1 muscle rigidity  ENT1END  with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe ENT1 muscle rigidity  ENT1END  with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe ENT1 muscle rigidity  ENT1END  with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe ENT1 muscle rigidity  ENT1END  with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and ENT1 alprazolam  ENT1END  treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe ENT2 muscle rigidity ENT2END with tremors
0	Possible neuroleptic malignant syndrome related to concomitant treatment with ENT1 paroxetine ENT1END  and alprazolam.A 74-year-old man with ENT2 depressive symptoms ENT2END was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation
0	The patient received bromocriptine and ENT1 diazepam ENT1END  to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly ENT2 depressive ENT2END patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion
0	A 74-year-old man with ENT1 depressive symptoms  ENT1END  was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	The patient received ENT1 bromocriptine  ENT1END  and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly ENT2 depressive ENT2END patients whose symptoms often include dehydration, agitation, malnutrition, and exhaustion
0	A 74-year-old man with ENT1 depressive symptoms  ENT1END  was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with ENT1 depressive symptoms  ENT1END  was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and ENT1 alprazolam  ENT1END .A 74-year-old man with ENT2 depressive symptoms ENT2END was admitted to a psychiatric hospital due to insomnia, loss of appetite, exhaustion, and agitation
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to ENT1 insomnia  ENT1END  loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg ENT2 paroxetine ENT2END and 1
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to ENT1 insomnia  ENT1END , loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to ENT1 insomnia  ENT1END , loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to ENT1 insomnia  ENT1END , loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to ENT1 insomnia  ENT1END , loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to ENT1 insomnia  ENT1END , loss of appetite, exhaustion, and agitation. Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1.2 mg alprazolam. On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with tremors. The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and ENT1 alprazolam  ENT1END .A 74-year-old man with depressive symptoms was admitted to a psychiatric hospital due to ENT2 insomnia ENT2END , loss of appetite, exhaustion, and agitation
0	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined ENT1 paroxetine ENT1END  and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include ENT2 dehydration ENT2END , agitation, malnutrition, and exhaustion
0	The patient received bromocriptine and ENT1 diazepam  ENT1END  to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include ENT2 dehydration ENT2END , agitation, malnutrition, and exhaustion
0	The patient received ENT1 bromocriptine  ENT1END  and diazepam to treat his symptoms. 7 days later, the fever disappeared and the patient's serum CPK levels were normalized (175 IU/L). This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and alprazolam treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include ENT2 dehydration ENT2END , agitation, malnutrition, and exhaustion
0	This patient presented with symptoms of neuroleptic malignant syndrome (NMS), thus demonstrating that NMS-like symptoms can occur after combined paroxetine and ENT1 alprazolam  ENT1END  treatment. The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case, indicating a probable relationship between the patient's NMS-like adverse symptoms and the combined treatment used in this case. The involvement of physiologic and environmental aspects specific to this patient was suspected. Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include ENT2 dehydration ENT2END , agitation, malnutrition, and exhaustion
0	On the 10th day of ENT1 paroxetine ENT1END  and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with ENT2 tremors ENT2END
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with ENT1 tremors  ENT1END . The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received bromocriptine and ENT2 diazepam ENT2END to treat his symptoms
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with ENT1 tremors  ENT1END . The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), ENT2 aspartate ENT2END aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with ENT1 tremors  ENT1END . The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27.9 mg/ml) levels. The patient received ENT2 bromocriptine ENT2END and diazepam to treat his symptoms
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with ENT1 tremors  ENT1END . The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of creatine phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), ENT2 alanine ENT2END aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and alprazolam treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with ENT1 tremors  ENT1END . The patient had a fever (38.2 degrees C), fluctuating blood pressure (between 165/90 and 130/70 mg mm Hg), and severe extrapyramidal symptoms. Laboratory tests showed an elevation of ENT2 creatine ENT2END phosphokinase (2218 IU/L), aspartate aminotransferase (134 IU/L), alanine aminotransferase (78 IU/L), and BUN (27
0	On the 10th day of paroxetine and ENT1 alprazolam  ENT1END  treatment, the patient exhibited marked psychomotor retardation, disorientation, and severe muscle rigidity with ENT2 tremors ENT2END
0	To our knowledge, this has not previously been reported as a side effect of preoperative dipyridamole therapy, although ENT1 dipyridamole ENT1END induced myocardial ischemia has been demonstrated to occur in animals and humans with ENT2 coronary artery disease ENT2END
0	Epicardial coronary collateral vessels were demonstrated in all four patients; a coronary "steal" phenomenon may be the mechanism of the ENT1 dipyridamole ENT1END induced ENT2 ischemia ENT2END observed
1	ENT1 Dipyridamole  ENT1END -induced myocardial ischemia. ENT2 Angina ENT2END and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures
0	ENT1 Dipyridamole  ENT1END -induced ENT2 myocardial ischemia ENT2END
1	Topiramate-induced ENT1 nephrolithiasis  ENT1END . ENT2 Topiramate ENT2END is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures
0	These factors can lead to the development of ENT1 calcium phosphate ENT1END ENT2 nephrolithiasis ENT2END
0	ENT1 Topiramate ENT1END  is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures. Urologists should be aware that this medication can cause ENT2 metabolic acidosis ENT2END in patients secondary to inhibition of carbonic anhydrase
0	Urologists should be aware that this medication can cause ENT1 metabolic acidosis  ENT1END  in patients secondary to inhibition of carbonic anhydrase. In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of ENT2 calcium phosphate ENT2END nephrolithiasis
0	ENT1 Topiramate ENT1END  is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating ENT2 refractory seizures ENT2END
0	Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating ENT1 refractory seizures  ENT1END . Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase. In addition, a distal tubular acidification defect may result, thus impairing the normal compensatory drop in urine pH. These factors can lead to the development of ENT2 calcium phosphate ENT2END nephrolithiasis
0	Aventyl (nortriptyline) and Elavil ( ENT1 amitriptyline ENT1END  each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ENT2 ventricular arrhythmias ENT2END responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one
0	Electrocardiographic changes and ENT1 cardiac arrhythmias ENT1END  in patients receiving psychotropic drugs.Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either phenothiazines or tricyclic antidepressants. Although most patients were receiving several drugs, ENT2 Mellaril ENT2END (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman
0	Aventyl ( ENT1 nortriptyline  ENT1END  and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ENT2 ventricular arrhythmias ENT2END responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one
0	Electrocardiographic changes and ENT1 cardiac arrhythmias ENT1END  in patients receiving psychotropic drugs.Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either ENT2 phenothiazines ENT2END or tricyclic antidepressants
0	The ENT1 ventricular arrhythmias ENT1END  responded to intravenous administration of ENT2 lidocaine ENT2END and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one
0	Supraventricular tachycardia developed in one patient receiving Thorazine ( ENT1 chlorpromazine  ENT1END . Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ENT2 ventricular arrhythmias ENT2END responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one
0	The ENT1 ventricular arrhythmias ENT1END  responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of ENT2 propranolol ENT2END combined with ventricular pacing in one
0	A prospective clinical trial is suggested to quantify the risk of ENT1 cardiac complications ENT1END to patients receiving ENT2 phenothiazines ENT2END or tricyclic antidepressant drugs
0	The ventricular arrhythmias responded to intravenous administration of ENT1 lidocaine  ENT1END  and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease. Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs. A prospective clinical trial is suggested to quantify the risk of ENT2 cardiac complications ENT2END to patients receiving phenothiazines or tricyclic antidepressant drugs
0	The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of ENT1 propranolol  ENT1END  combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease. Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs. A prospective clinical trial is suggested to quantify the risk of ENT2 cardiac complications ENT2END to patients receiving phenothiazines or tricyclic antidepressant drugs
0	Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ENT1 ventricular tachycardia ENT1END  one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and ENT2 Elavil ENT2END (amitriptyline) each produced left bundle branch block in a 73 year old woman
1	Although most patients were receiving several drugs, Mellaril ( ENT1 thioridazine  ENT1END  appeared to be responsible for five cases of ENT2 ventricular tachycardia ENT2END , one of which was fatal in a 35 year old woman
0	Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ENT1 ventricular tachycardia ENT1END , one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). ENT2 Aventyl ENT2END (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman
0	Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either ENT1 phenothiazines  ENT1END  or tricyclic antidepressants. Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ENT2 ventricular tachycardia ENT2END , one of which was fatal in a 35 year old woman
0	Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ENT1 ventricular tachycardia  ENT1END , one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of ENT2 lidocaine ENT2END and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one
0	Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ENT1 ventricular tachycardia ENT1END , one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving ENT2 Thorazine ENT2END (chlorpromazine)
0	Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ENT1 ventricular tachycardia  ENT1END , one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of ENT2 propranolol ENT2END combined with ventricular pacing in one
0	Aventyl (nortriptyline) and Elavil ( ENT1 amitriptyline ENT1END ) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The ENT2 tachyarrhythmias ENT2END generally subsided within 48 hours after administration of the drugs was stopped
0	Although most patients were receiving several drugs, Mellaril ( ENT1 thioridazine  ENT1END ) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The ENT2 tachyarrhythmias ENT2END generally subsided within 48 hours after administration of the drugs was stopped
0	Aventyl ( ENT1 nortriptyline  ENT1END ) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The ENT2 tachyarrhythmias ENT2END generally subsided within 48 hours after administration of the drugs was stopped
0	The ENT1 tachyarrhythmias  ENT1END  generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent heart disease. Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs. A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving ENT2 phenothiazines ENT2END or tricyclic antidepressant drugs
0	The ventricular arrhythmias responded to intravenous administration of ENT1 lidocaine  ENT1END  and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The ENT2 tachyarrhythmias ENT2END generally subsided within 48 hours after administration of the drugs was stopped
0	Supraventricular tachycardia developed in one patient receiving Thorazine ( ENT1 chlorpromazine  ENT1END ). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The ENT2 tachyarrhythmias ENT2END generally subsided within 48 hours after administration of the drugs was stopped
0	The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of ENT1 propranolol  ENT1END  combined with ventricular pacing in one. The ENT2 tachyarrhythmias ENT2END generally subsided within 48 hours after administration of the drugs was stopped
0	ENT1 Supraventricular tachycardia  ENT1END developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and ENT2 Elavil ENT2END (amitriptyline) each produced left bundle branch block in a 73 year old woman
1	Although most patients were receiving several drugs, Mellaril ( ENT1 thioridazine  ENT1END ) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman. ENT2 Supraventricular tachycardia ENT2END developed in one patient receiving Thorazine (chlorpromazine)
0	ENT1 Supraventricular tachycardia  ENT1END  developed in one patient receiving Thorazine (chlorpromazine). ENT2 Aventyl ENT2END (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman
0	Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either ENT1 phenothiazines  ENT1END  or tricyclic antidepressants. Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman. ENT2 Supraventricular tachycardia ENT2END developed in one patient receiving Thorazine (chlorpromazine)
0	ENT1 Supraventricular tachycardia  ENT1END  developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of ENT2 lidocaine ENT2END and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one
0	ENT1 Supraventricular tachycardia  ENT1END  developed in one patient receiving ENT2 Thorazine ENT2END (chlorpromazine)
0	ENT1 Supraventricular tachycardia  ENT1END  developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of ENT2 propranolol ENT2END combined with ventricular pacing in one
1	Aventyl (nortriptyline) and Elavil ( ENT1 amitriptyline ENT1END ) each produced ENT2 left bundle branch block ENT2END in a 73 year old woman
0	Although most patients were receiving several drugs, Mellaril ( ENT1 thioridazine  ENT1END ) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced ENT2 left bundle branch block ENT2END in a 73 year old woman
1	Aventyl ( ENT1 nortriptyline  ENT1END ) and Elavil (amitriptyline) each produced ENT2 left bundle branch block ENT2END in a 73 year old woman
0	Eight patients had cardiac manifestations that were life-threatening in five while taking psychotropic drugs, either ENT1 phenothiazines  ENT1END  or tricyclic antidepressants. Although most patients were receiving several drugs, Mellaril (thioridazine) appeared to be responsible for five cases of ventricular tachycardia, one of which was fatal in a 35 year old woman. Supraventricular tachycardia developed in one patient receiving Thorazine (chlorpromazine). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced ENT2 left bundle branch block ENT2END in a 73 year old woman
0	Aventyl (nortriptyline) and Elavil (amitriptyline) each produced ENT1 left bundle branch block  ENT1END  in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of ENT2 lidocaine ENT2END and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one
0	Supraventricular tachycardia developed in one patient receiving Thorazine ( ENT1 chlorpromazine  ENT1END ). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced ENT2 left bundle branch block ENT2END in a 73 year old woman
0	Aventyl (nortriptyline) and Elavil (amitriptyline) each produced ENT1 left bundle branch block  ENT1END  in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of ENT2 propranolol ENT2END combined with ventricular pacing in one
0	Aventyl (nortriptyline) and Elavil ( ENT1 amitriptyline ENT1END ) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent ENT2 heart disease ENT2END
0	Aventyl ( ENT1 nortriptyline  ENT1END ) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent ENT2 heart disease ENT2END
0	Major cardiac arrhythmias are a potential hazard in patients without ENT1 heart disease  ENT1END who are receiving customary therapeutic doses of psychotropic drugs. A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving ENT2 phenothiazines ENT2END or tricyclic antidepressant drugs
0	The ventricular arrhythmias responded to intravenous administration of ENT1 lidocaine  ENT1END  and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent ENT2 heart disease ENT2END
0	Supraventricular tachycardia developed in one patient receiving Thorazine ( ENT1 chlorpromazine  ENT1END ). Aventyl (nortriptyline) and Elavil (amitriptyline) each produced left bundle branch block in a 73 year old woman. Electrocardiographic T and U wave abnormalities were present in most patients. The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent ENT2 heart disease ENT2END
0	The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock; ventricular pacing was required in some instances and intravenous administration of ENT1 propranolol  ENT1END  combined with ventricular pacing in one. The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped. Five of the eight patients were 50 years of age or younger; only one clearly had antecedent ENT2 heart disease ENT2END
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and ENT1 MK-801 ENT1END  markedly reduced the ENT2 dyskinetic ENT2END movements but at the cost of a return of parkinsonian symptomatology
0	However, ENT1 yohimbine ENT1END and meperidine reduced predominantly the ENT2 dyskinetic ENT2END movements
0	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the ENT1 dyskinetic ENT1END movements would be modified. Several drugs, including clonidine, ENT2 physostigmine ENT2END , methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology
0	Effect of nondopaminergic drugs on L-dopa-induced ENT1 dyskinesias  ENT1END  in ENT2 MPTP ENT2END -treated monkeys
0	However, yohimbine and meperidine reduced predominantly the ENT1 dyskinetic ENT1END  movements. ENT2 Baclofen ENT2END was also useful in one monkey against a more dystonic form of dyskinesia
1	They were then treated chronically with ENT1 L-DOPA/benserazide ENT1END 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested ENT2 dyskinesia ENT2END
0	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the ENT1 dyskinetic ENT1END  movements would be modified. Several drugs, including ENT2 clonidine ENT2END , physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology
0	Baclofen was also useful in one monkey against a more dystonic form of ENT1 dyskinesia ENT1END  ENT2 Atropine ENT2END converted the dystonic movements into chorea
0	Effect of nondopaminergic drugs on ENT1 L-dopa  ENT1END -induced ENT2 dyskinesias ENT2END in MPTP-treated monkeys
0	Several drugs, including clonidine, physostigmine, ENT1 methysergide  ENT1END  5-MDOT, propranolol, and MK-801, markedly reduced the ENT2 dyskinetic ENT2END movements but at the cost of a return of parkinsonian symptomatology
0	A series of agents acting primarily on neurotransmitters other than ENT1 dopamine  ENT1END were then tested in combination with L-DOPA to see if the ENT2 dyskinetic ENT2END movements would be modified
0	However, yohimbine and ENT1 meperidine  ENT1END reduced predominantly the ENT2 dyskinetic ENT2END movements
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, ENT1 propranolol  ENT1END  and MK-801, markedly reduced the ENT2 dyskinetic ENT2END movements but at the cost of a return of parkinsonian symptomatology
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and ENT1 MK-801 ENT1END , markedly reduced the dyskinetic movements but at the cost of a return of ENT2 parkinsonian ENT2END symptomatology
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT1 parkinsonian  ENT1END  symptomatology. However, ENT2 yohimbine ENT2END and meperidine reduced predominantly the dyskinetic movements
0	Several drugs, including clonidine, ENT1 physostigmine  ENT1END , methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT2 parkinsonian ENT2END symptomatology
1	A group of four monkeys was rendered ENT1 parkinsonian ENT1END with the toxin ENT2 MPTP ENT2END
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT1 parkinsonian  ENT1END  symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. ENT2 Baclofen ENT2END was also useful in one monkey against a more dystonic form of dyskinesia
0	A group of four monkeys was rendered ENT1 parkinsonian  ENT1END  with the toxin MPTP. They were then treated chronically with ENT2 L-DOPA/benserazide ENT2END 50/12
0	Several drugs, including ENT1 clonidine  ENT1END , physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT2 parkinsonian ENT2END symptomatology
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT1 parkinsonian  ENT1END  symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. ENT2 Atropine ENT2END converted the dystonic movements into chorea
0	Effect of nondopaminergic drugs on ENT1 L-dopa  ENT1END -induced dyskinesias in MPTP-treated monkeys.A group of four monkeys was rendered ENT2 parkinsonian ENT2END with the toxin MPTP
0	Several drugs, including clonidine, physostigmine, ENT1 methysergide  ENT1END , 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT2 parkinsonian ENT2END symptomatology
0	A series of agents acting primarily on neurotransmitters other than ENT1 dopamine  ENT1END  were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT2 parkinsonian ENT2END symptomatology
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT1 parkinsonian  ENT1END  symptomatology. However, yohimbine and ENT2 meperidine ENT2END reduced predominantly the dyskinetic movements
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, ENT1 propranolol  ENT1END , and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of ENT2 parkinsonian ENT2END symptomatology
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and ENT1 MK-801 ENT1END , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	However, ENT1 yohimbine  ENT1END  and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	Several drugs, including clonidine, ENT1 physostigmine  ENT1END , methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	ENT1 Baclofen  ENT1END  was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	Several drugs, including ENT1 clonidine  ENT1END , physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	ENT1 Atropine  ENT1END  converted the dystonic movements into ENT2 chorea ENT2END
0	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with ENT1 L-DOPA  ENT1END to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	Several drugs, including clonidine, physostigmine, ENT1 methysergide  ENT1END , 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	A series of agents acting primarily on neurotransmitters other than ENT1 dopamine  ENT1END  were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	However, yohimbine and ENT1 meperidine  ENT1END  reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, ENT1 propranolol  ENT1END , and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more dystonic form of dyskinesia. Atropine converted the dystonic movements into ENT2 chorea ENT2END
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and ENT1 MK-801 ENT1END , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	However, ENT1 yohimbine  ENT1END  and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	Several drugs, including clonidine, ENT1 physostigmine  ENT1END , methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	ENT1 Baclofen  ENT1END  was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	They were then treated chronically with ENT1 L-DOPA/benserazide  ENT1END  50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	Several drugs, including ENT1 clonidine  ENT1END , physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	ENT1 Atropine ENT1END  converted the ENT2 dystonic ENT2END movements into chorea
0	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with ENT1 L-DOPA  ENT1END  to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	Several drugs, including clonidine, physostigmine, ENT1 methysergide  ENT1END , 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	A series of agents acting primarily on neurotransmitters other than ENT1 dopamine  ENT1END  were then tested in combination with L-DOPA to see if the dyskinetic movements would be modified. Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, propranolol, and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	However, yohimbine and ENT1 meperidine  ENT1END  reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
0	Several drugs, including clonidine, physostigmine, methysergide, 5-MDOT, ENT1 propranolol  ENT1END , and MK-801, markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology. However, yohimbine and meperidine reduced predominantly the dyskinetic movements. Baclofen was also useful in one monkey against a more ENT2 dystonic ENT2END form of dyskinesia
1	This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on ENT1 TAM ENT1END induced ENT2 hemolytic anemia ENT2END and the involvement of biomembranes in its cytostatic action mechanisms
0	This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced ENT1 hemolytic anemia ENT1END  and the involvement of biomembranes in its cytostatic action mechanisms. TAM induces hemolysis of erythrocytes as a function of concentration. The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions. Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes. The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage. This was further evidenced by absence of ENT2 oxygen ENT2END consumption and hemoglobin oxidation both determined in parallel with TAM-induced hemolysis
0	Hemolysis caused by TAM was not preceded by the leakage of ENT1 K ENT1END +) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves. However, TAM induces release of peripheral proteins of membrane-cytoskeleton and cytosol proteins essentially bound to band 3. Either alpha-T or alpha-TAc increases membrane packing and prevents TAM partition into model membranes. These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided. Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane. These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in ENT2 hemolytic anemia ENT2END
0	This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced ENT1 hemolytic anemia ENT1END  and the involvement of biomembranes in its cytostatic action mechanisms. TAM induces hemolysis of erythrocytes as a function of concentration. The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions. Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes. The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional ENT2 hydroxyl ENT2END ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage
0	This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced ENT1 hemolytic anemia ENT1END  and the involvement of biomembranes in its cytostatic action mechanisms. TAM induces hemolysis of erythrocytes as a function of concentration. The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions. Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes. The hemolytic effect of TAM is prevented by low concentrations of ENT2 alpha-tocopherol ENT2END (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage
0	These effects suggest that the protection from hemolysis by ENT1 tocopherols  ENT1END is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided. Therefore, TAM-induced hemolysis results from a structural perturbation of red cell membrane, leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane. These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM, resulting in ENT2 hemolytic anemia ENT2END
0	Tamoxifen ( ENT1 TAM ENT1END , the antiestrogenic drug most widely prescribed in the chemotherapy of ENT2 breast cancer ENT2END , induces changes in normal discoid shape of erythrocytes and hemolytic anemia
0	Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of ENT1 breast cancer  ENT1END , induces changes in normal discoid shape of erythrocytes and hemolytic anemia. This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms. TAM induces hemolysis of erythrocytes as a function of concentration. The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions. Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes. The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional ENT2 hydroxyl ENT2END ) indicating that TAM-induced hemolysis is not related to oxidative membrane damage
0	Tamoxifen (TAM), the antiestrogenic drug most widely prescribed in the chemotherapy of ENT1 breast cancer  ENT1END , induces changes in normal discoid shape of erythrocytes and hemolytic anemia. This work evaluates the effects of TAM on isolated human erythrocytes, attempting to identify the underlying mechanisms on TAM-induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms. TAM induces hemolysis of erythrocytes as a function of concentration. The extension of hemolysis is variable with erythrocyte samples, but 12.5 microM TAM induces total hemolysis of all tested suspensions. Despite inducing extensive erythrocyte lysis, TAM does not shift the osmotic fragility curves of erythrocytes. The hemolytic effect of TAM is prevented by low concentrations of ENT2 alpha-tocopherol ENT2END (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage
1	ENT1 TAM ENT1END induces ENT2 hemolysis ENT2END of erythrocytes as a function of concentration
0	This was further evidenced by absence of ENT1 oxygen ENT1END  consumption and hemoglobin oxidation both determined in parallel with TAM-induced ENT2 hemolysis ENT2END
0	Furthermore, it was observed that TAM inhibits the peroxidation of human erythrocytes induced by ENT1 AAPH ENT1END  thus ruling out TAM-induced cell oxidative stress. ENT2 Hemolysis ENT2END caused by TAM was not preceded by the leakage of K(+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves
0	ENT1 Hemolysis  ENT1END  caused by TAM was not preceded by the leakage of ENT2 K ENT2END (+) from the cells, also excluding a colloid-osmotic type mechanism of hemolysis, according to the effects on osmotic fragility curves
0	The hemolytic effect of TAM is prevented by low concentrations of alpha-tocopherol (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional ENT1 hydroxyl ENT1END ) indicating that TAM-induced ENT2 hemolysis ENT2END is not related to oxidative membrane damage
0	The ENT1 hemolytic  ENT1END effect of TAM is prevented by low concentrations of ENT2 alpha-tocopherol ENT2END (alpha-T) and alpha-tocopherol acetate (alpha-TAc) (inactivated functional hydroxyl) indicating that TAM-induced hemolysis is not related to oxidative membrane damage
0	These effects suggest that the protection from ENT1 hemolysis  ENT1END by ENT2 tocopherols ENT2END is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided
0	The 50% effective dose of ENT1 d-tubocurarine ENT1END did not correlate with muscle mass or AChR expression. Our results suggest that the ENT2 neuromuscular dysfunction ENT2END after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression
0	Our results suggest that the ENT1 neuromuscular dysfunction ENT1END  after prednisolone is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression. IMPLICATIONS: The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear. We suggest that the observed effects are dose-dependent and derive primarily from muscle atrophy and derive less from changes in ENT2 acetylcholine ENT2END receptor expression
0	Our results suggest that the ENT1 neuromuscular dysfunction ENT1END  after ENT2 prednisolone ENT2END is dose-dependent, and derives primarily from muscle atrophy and derives less so from changes in AChR expression
0	Prednisolone-induced ENT1 muscle dysfunction ENT1END  is caused more by atrophy than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood. We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression. With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days. A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group). On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of ENT2 d-tubocurarine ENT2END in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs
0	Prednisolone-induced ENT1 muscle dysfunction  ENT1END  is caused more by atrophy than by altered ENT2 acetylcholine ENT2END receptor expression
1	ENT1 Prednisolone  ENT1END -induced ENT2 muscle dysfunction ENT2END is caused more by atrophy than by altered acetylcholine receptor expression
0	On Day 8, the nerve-evoked peak twitch tensions, ENT1 tetanic  ENT1END tensions, and fatigability, and the dose-response curves of ENT2 d-tubocurarine ENT2END in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs
0	We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and ENT1 acetylcholine  ENT1END receptor (AChR) expression. With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days. A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group). On Day 8, the nerve-evoked peak twitch tensions, ENT2 tetanic ENT2END tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs
0	With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg ENT1 prednisolone  ENT1END (P100 group), or an equal volume of saline (S group) for 7 days. A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group). On Day 8, the nerve-evoked peak twitch tensions, ENT2 tetanic ENT2END tensions, and fatigability, and the dose-response curves of d-tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs
0	Prednisolone-induced muscle dysfunction is caused more by ENT1 atrophy  ENT1END  than by altered acetylcholine receptor expression.Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood. We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology, and their relationship to changes in muscle size and acetylcholine receptor (AChR) expression. With institutional approval, 35 Sprague-Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg/kg prednisolone (P10 group), 100 mg/kg prednisolone (P100 group), or an equal volume of saline (S group) for 7 days. A fourth group of rats was pair fed (food restricted) with the P100 rats for 7 days (FR group). On Day 8, the nerve-evoked peak twitch tensions, tetanic tensions, and fatigability, and the dose-response curves of ENT2 d-tubocurarine ENT2END in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs
0	Prednisolone-induced muscle dysfunction is caused more by ENT1 atrophy  ENT1END  than by altered ENT2 acetylcholine ENT2END receptor expression
0	ENT1 Prednisolone  ENT1END -induced muscle dysfunction is caused more by ENT2 atrophy ENT2END than by altered acetylcholine receptor expression
0	The 50% effective dose of ENT1 d-tubocurarine ENT1END  did not correlate with muscle mass or AChR expression. Our results suggest that the neuromuscular dysfunction after prednisolone is dose-dependent, and derives primarily from ENT2 muscle atrophy ENT2END and derives less so from changes in AChR expression
0	We suggest that the observed effects are dose-dependent and derive primarily from ENT1 muscle atrophy  ENT1END and derive less from changes in ENT2 acetylcholine ENT2END receptor expression
1	Our results suggest that the neuromuscular dysfunction after ENT1 prednisolone  ENT1END  is dose-dependent, and derives primarily from ENT2 muscle atrophy ENT2END and derives less so from changes in AChR expression